<SEC-DOCUMENT>0001564590-22-020206.txt : 20220516
<SEC-HEADER>0001564590-22-020206.hdr.sgml : 20220516
<ACCEPTANCE-DATETIME>20220513185343
ACCESSION NUMBER:		0001564590-22-020206
CONFORMED SUBMISSION TYPE:	S-1/A
PUBLIC DOCUMENT COUNT:		26
FILED AS OF DATE:		20220516
DATE AS OF CHANGE:		20220513

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MAIA Biotechnology, Inc.
		CENTRAL INDEX KEY:			0001878313
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE

	FILING VALUES:
		FORM TYPE:		S-1/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-264225
		FILM NUMBER:		22924583

	BUSINESS ADDRESS:	
		STREET 1:		444 WEST LAKE STREET, SUITE 1700
		CITY:			CHICAGO
		STATE:			IL
		ZIP:			60606
		BUSINESS PHONE:		312-416-8592

	MAIL ADDRESS:	
		STREET 1:		444 WEST LAKE STREET, SUITE 1700
		CITY:			CHICAGO
		STATE:			IL
		ZIP:			60606
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-1/A
<SEQUENCE>1
<FILENAME>maia-s1a.htm
<DESCRIPTION>S-1/A
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
maia-s1a.htm
</title>
</head>
<!-- NG Converter v5.0.2.71 -->
<body>

<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As filed with the U.S. Securities and Exchange Commission on May 13, 2022. </p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:3pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk101936145"></a><a name="_Hlk101936145"></a>Registration No. 333-264225</p>
<p style="text-align:center;margin-bottom:0pt;border-bottom:Double 3pt;padding-bottom:1pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:3pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:3pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UNITED STATES<br />SECURITIES AND EXCHANGE COMMISSION<br />Washington, D.C. 20549</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:3pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FORM S-1</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:3pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Amendment No. 2)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:3pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:3pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">MAIA Biotechnology, Inc.<font style="font-weight:normal;"><br /></font><font style="font-size:8pt;font-weight:normal;">(Exact name of registrant as specified in its charter)</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:3pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:32.05%;"></td>
<td style="width:2.03%;"></td>
<td style="width:32.05%;"></td>
<td style="width:1.92%;"></td>
<td style="width:31.94%;"></td>
</tr>
<tr>
<td valign="top"  style=" border-bottom:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Delaware</p></td>
<td valign="top"  style=" border-bottom:solid 1.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style=" border-bottom:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2834</p></td>
<td valign="top"  style=" border-bottom:solid 1.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style=" border-bottom:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">83-1495913</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(State or other jurisdiction of<br />incorporation or organization)</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:7pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Primary Standard Industrial<br />Classification Code Number)</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:7pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(I.R.S. Employer<br />Identification No.)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:3pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">444 West Lake Street, Suite 1700<br />Chicago, IL 60606<br />(312) 416-8592</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Address, including zip code, and telephone number, including area code, of registrant&#8217;s principal executive offices)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:3pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Vlad Vitoc<br />Chief Executive Officer<br />c/o MAIA Biotechnology, Inc.<br />444 West Lake Street, Suite 1700<br />Chicago, IL 60606<br />(312) 416-8592</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:3pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Name, Address, Including Zip Code, and Telephone Number, Including Area Code, of Agent for Service)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:3pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Copies to:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:3pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:51.07%;"></td>
<td style="width:0.96%;"></td>
<td style="width:47.97%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Mitchell S. Nussbaum, Esq.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Janeane R. Ferrari, Esq.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Loeb &amp; Loeb LLP</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">345 Park Avenue</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">New York, NY 10154</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Phone: (212) 407-4000</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fax: (212) 407-4990</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:8pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">William N. Haddad, Esq.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Arif Soto, Esq.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Venable LLP</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1270 Avenue of the Americas, 24th Floor</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">New York, NY 10020</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Phone: (212) 503-9812 </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fax: (212) 307-5598</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:8pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:3pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Approximate date of commencement of proposed sale to public: <font style="font-weight:normal;">As soon as practicable after the effective date hereof.</font></p>
<p style="margin-bottom:0pt;margin-top:3pt;text-indent:0%;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box. <font style="font-family:Segoe UI Symbol;">&#9744;</font></p>
<p style="margin-bottom:0pt;margin-top:3pt;text-indent:0%;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. <font style="font-family:Segoe UI Symbol;">&#9744;</font></p>
<p style="margin-bottom:0pt;margin-top:3pt;text-indent:0%;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. <font style="font-family:Segoe UI Symbol;">&#9744;</font></p>
<p style="margin-bottom:0pt;margin-top:3pt;text-indent:0%;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. <font style="font-family:Segoe UI Symbol;">&#9744;</font></p>
<p style="margin-bottom:0pt;margin-top:3pt;text-indent:0%;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:3pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:30.42%;"></td>
<td style="width:2.91%;"></td>
<td style="width:0.16%;"></td>
<td style="width:0.16%;"></td>
<td style="width:26.28%;"></td>
<td style="width:0.16%;"></td>
<td style="width:37%;"></td>
<td style="width:2.92%;"></td>
</tr>
<tr>
<td valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Large accelerated filer</p></td>
<td valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6.5pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6.5pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6.5pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6.5pt;">&nbsp;</p></td>
<td valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accelerated filer</p></td>
<td valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
</tr>
<tr>
<td valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-accelerated filer</p></td>
<td valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9746;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6.5pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6.5pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6.5pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6.5pt;">&nbsp;</p></td>
<td valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Smaller reporting company</p></td>
<td valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9746;</p></td>
</tr>
<tr>
<td valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6.5pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6.5pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6.5pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6.5pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6.5pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6.5pt;">&nbsp;</p></td>
<td valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Emerging growth company</p></td>
<td valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9746;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:3pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. <font style="font-family:Segoe UI Symbol;">&#9744;</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6.5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933, as amended, or until the registration statement shall become effective on such date as the Commission, acting pursuant to Section 8(a), may determine.</p>
<p style="text-align:justify;margin-bottom:0pt;border-bottom:Double 3pt;padding-bottom:1pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:3pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:1pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:1pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p><a name="_AEIOULastRenderedPageBreakAEIOU1"></a>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#C00000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">The information contained in this preliminary prospectus is not complete and may be changed. These securities may not be sold until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any state where the offer or sale is not permitted.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:33.97%;"></td>
<td style="width:1.1%;"></td>
<td style="width:31.97%;"></td>
<td style="width:1.05%;"></td>
<td style="width:31.91%;"></td>
</tr>
<tr>
<td valign="bottom"  style="white-space:nowrap;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#C00000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">PRELIMINARY PROSPECTUS</p></td>
<td valign="bottom"  style="white-space:nowrap;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#C00000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SUBJECT TO COMPLETION</p></td>
<td valign="bottom"  style="white-space:nowrap;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#C00000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">DATED MAY 13, 2022</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:14pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shares</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:14pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Common Stock </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:24pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gyowp0iggm03000001.jpg" title="" alt="" style="width:290px;height:110px;"></p>
<p style="margin-bottom:0pt;margin-top:12pt;border-bottom:Solid 0.75pt;padding-bottom:1pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">MAIA Biotechnology, Inc. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:40.6%;margin-right:40.6%;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This is a firm commitment initial public offering of shares of common stock of MAIA Biotechnology, Inc. (the &#8220;Company&#8221;). Prior to this offering, there has been no public market for our common stock. We anticipate that the initial public offering price of our shares will be between $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; .</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have applied to have our common stock listed on the NASDAQ Capital Market LLC, or Nasdaq, under the symbol &#8220;MAIA.&#8221; </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Investing in our common stock involves a high degree of risk. See &#8220;<a href="#RISK_FACTORS"><font style="font-style:italic;text-decoration:underline;">Risk Factors</font></a><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8221; beginning on page 13. Neither the Securities and Exchange Commission (the &#8220;SEC&#8221;) nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Per Share</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Initial public offering price</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Underwriting discounts and commissions<sup style="font-size:85%;line-height:120%;vertical-align:top">(1)</sup></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds to us, before expenses</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(1)</sup></font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Underwriting discounts and commissions do not include a non-accountable expense allowance equal to 1.0% of the initial public offering price payable to the underwriters. We refer you to &#8220;Underwriting&#8221; beginning on page 146 for additional information regarding underwriters&#8217; compensation.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have granted a 45-day option to the representative of the underwriters to purchase up to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; additional shares of common stock solely to cover over-allotments, if any.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The underwriters expect to deliver the shares to purchasers on or about &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2022.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ThinkEquity</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The date of this prospectus is&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2022</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">TABLE OF CONTENTS</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:92.3%; border-bottom:solid 1.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"><a name="_Hlk84759654"></a>&nbsp;</p></td>
<td valign="bottom"  style="width:7.7%; border-bottom:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Page</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="width:92.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#PROSPECTUS_SUMMARY"><font style="text-decoration:underline;">PROSPECTUS SUMMARY</font></a></p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="width:7.7%; border-top:solid 1.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
</tr>
<tr>
<td valign="top"  style="width:92.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#RISK_FACTORS"><font style="text-decoration:underline;">RISK FACTORS</font></a></p></td>
<td valign="top"  style="width:7.7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="width:92.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CAUTIONARY_NOTE_REGARDING_FORWARDLOOKING"><font style="text-decoration:underline;">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</font></a></p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="width:7.7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59</p></td>
</tr>
<tr>
<td valign="top"  style="width:92.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#USE_PROCEEDS"><font style="text-decoration:underline;">USE OF PROCEEDS</font></a></p></td>
<td valign="top"  style="width:7.7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="width:92.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#DIVIDEND_POLICY"><font style="text-decoration:underline;">DIVIDEND POLICY</font></a></p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="width:7.7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61</p></td>
</tr>
<tr>
<td valign="top"  style="width:92.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CAPITALIZATION"><font style="text-decoration:underline;">CAPITALIZATION</font></a></p></td>
<td valign="top"  style="width:7.7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="width:92.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#DILUTION"><font style="text-decoration:underline;">DILUTION</font></a></p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="width:7.7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63</p></td>
</tr>
<tr>
<td valign="top"  style="width:92.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#MANAGEMENTS_DISCUSSION_ANALYSIS_FINANCIA"><font style="text-decoration:underline;">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</font></a></p></td>
<td valign="bottom"  style="width:7.7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="width:92.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#BUSINESS"><font style="text-decoration:underline;">BUSINESS</font></a></p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="width:7.7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76</p></td>
</tr>
<tr>
<td valign="top"  style="width:92.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#MANAGEMENT"><font style="text-decoration:underline;">MANAGEMENT</font></a></p></td>
<td valign="top"  style="width:7.7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">117</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="width:92.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#EXECUTIVE_DIRECTOR_COMPENSATION"><font style="text-decoration:underline;">EXECUTIVE AND DIRECTOR COMPENSATION</font></a></p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="width:7.7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">124</p></td>
</tr>
<tr>
<td valign="top"  style="width:92.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#PRINCIPAL_STOCKHOLDERS"><font style="text-decoration:underline;">PRINCIPAL STOCKHOLDERS</font></a></p></td>
<td valign="top"  style="width:7.7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">134</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="width:92.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CERTAIN_RELATIONSHIPS_RELATED_PARTY_TRAN"><font style="text-decoration:underline;">CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS</font></a></p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="width:7.7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">136</p></td>
</tr>
<tr>
<td valign="top"  style="width:92.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#DESCRIPTION_CAPITAL_STOCK"><font style="text-decoration:underline;">DESCRIPTION OF CAPITAL STOCK</font></a></p></td>
<td valign="top"  style="width:7.7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">138</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="width:92.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#SHARES_ELIGIBLE_FOR_FUTURE_SALE"><font style="text-decoration:underline;">SHARES ELIGIBLE FOR FUTURE SALE</font></a></p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="width:7.7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">141</p></td>
</tr>
<tr>
<td valign="top"  style="width:92.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#MATERIAL_US_FEDERAL_INCOME_TAX_CONSEQUEN"><font style="text-decoration:underline;">MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES FOR NON-U.S. HOLDERS</font></a></p></td>
<td valign="top"  style="width:7.7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">143</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="width:92.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#UNDERWRITING"><font style="text-decoration:underline;">UNDERWRITING</font></a></p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="width:7.7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">146</p></td>
</tr>
<tr>
<td valign="top"  style="width:92.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#EXPERTS"><font style="text-decoration:underline;">EXPERTS</font></a></p></td>
<td valign="top"  style="width:7.7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">153</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="width:92.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#LEGAL_MATTERS"><font style="text-decoration:underline;">LEGAL MATTERS</font></a></p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="width:7.7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">154</p></td>
</tr>
<tr>
<td valign="top"  style="width:92.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#WHERE_YOU_CAN_FIND_MORE_INFORMATION"><font style="text-decoration:underline;">WHERE YOU CAN FIND MORE INFORMATION</font></a></p></td>
<td valign="top"  style="width:7.7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">155</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="width:92.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#INDEX_TO_FINANCIAL_STATEMENTS"><font style="text-decoration:underline;">INDEX TO FINANCIAL STATEMENTS</font></a></p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="width:7.7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-1</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">You should rely only on the information contained in this prospectus. We have not authorized any other person to provide you with information different from or in addition to that contained in this prospectus, and we take no responsibility for any other information others may give you. If anyone provides you with different or inconsistent information, you should not rely on it. We are not making an offer to sell these securities in any jurisdiction where an offer or sale is not permitted. You should assume that the information appearing in this prospectus is accurate only as of the date on the front cover of this prospectus. Our business, financial condition, results of operations and prospects may have changed since that date.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">No action is being taken in any jurisdiction outside the United States to permit a public offering of our common stock or possession or distribution of this prospectus in that jurisdiction. Persons who come into possession of this prospectus in jurisdictions outside the United States are required to inform themselves about and to observe any restrictions as to this offering and the distribution of this prospectus applicable to that jurisdiction.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As used in this prospectus, unless the context indicates or otherwise requires, &#8220;the Company,&#8221; &#8220;our Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; refer to MAIA Biotechnology, Inc., a Delaware corporation, and its consolidated subsidiaries.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</a></p>
<hr style="page-break-after:always;width:100%;">
<div style="width:100%;border-top:Solid 0.75pt #000000;border-bottom:Solid 0.75pt #000000;border-left:Solid 0.75pt #000000;border-right:Solid 0.75pt #000000;">
<div style="padding-left:6.7%;padding-Right:6.7%;padding-Top:5.18%;padding-Bottom:5.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="PROSPECTUS_SUMMARY"></a><a name="PROSPECTUS_SUMMARY"></a>PROSPECTUS SUMMARY</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">This summary highlights certain information appearing elsewhere in this prospectus. Because it is only a summary, it does not contain all of the information that you should consider before investing in our common stock and it is qualified in its entirety by, and should be read in conjunction with, the more detailed information appearing elsewhere in this prospectus. Before you decide to invest in our common stock, you should read the entire prospectus carefully, including &#8220;Risk Factors&#8221; beginning on page 10 and the financial statements and related notes included in this prospectus.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">This prospectus includes trademarks, service marks and trade names owned by us or other companies. All trademarks, service marks and trade names included in this prospectus are the property of their respective owners.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Our Company</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO, our lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. THIO will enter Phase 2 human trials (THIO-101) in Australia and Europe in the first half of 2022. Patients with advanced Non-Small Cell Lung Cancer (NSCLC) will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo&#174; (cemiplimab) manufactured and commercialized by Regeneron. Cemiplimab is a fully human monoclonal antibody targeting the immune checkpoint receptor PD-1 on T-cells. Cemiplimab has been approved in the United States and the rest of the world for multiple cancer indications, including NSCLC. In February 2021, we signed a clinical supply agreement with Regeneron to receive cemiplimab at no cost, which represents a significant cost-savings for the study. In return, we have granted Regeneron exclusive development rights in combination with PD-1 inhibitors for NSCLC for the study period. Based on the clinical data generated by our THIO-101 trial, in late 2024 we plan to seek an accelerated approval of THIO in the United States for the treatment of patients with advanced NSCLC, but even if granted, accelerated approval status does not guarantee an accelerated review or marketing approval by the FDA. In addition, in the First Quarter of 2023, we plan to initiate a pivotal Phase 2 clinical trial of THIO in patients with advanced colorectal cancer administered in sequence with Anti-PD-1 or Anti-PD-L1. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Our Lead Product Candidate </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">THIO (6-thio-dG or 6-thio-2&#8217;-deoxyguanosine) is a telomere-targeting agent currently in clinical development to evaluate its activity in NSCLC. Telomeres, along with the enzyme telomerase, play a fundamental role in the survival of cancer cells and their resistance to current therapies. THIO is being developed as a second- or later line of treatment for NSCLC for patients that have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2019, our research team discovered that THIO produced telomere modifications and disruption, which ultimately induced cancer-specific innate and adaptive immune responses against immunologically &#8220;cold&#8221; or tumor types that were unresponsive to immune checkpoint inhibitors. This hypothesis was tested and demonstrated in syngeneic and humanized mouse models. THIO administered to mice in low doses and followed by an immune-checkpoint inhibiting agent, such as an anti-PD-1 or anti-PD-L1 compound, induced complete tumor regression with no tumor recurrence during the 14 weeks of observation. Further, no toxicities were reported in the tumor-free mice. These new findings were published in the peer-reviewed research scientific journal, <font style="text-decoration:underline;">Cancer Cell </font>in July 2020. Based on these recent discoveries, a new therapeutic approach has been designed to advance THIO into a Phase 2 clinical trial (THIO-101) in patients with advanced NSCLC.&nbsp;&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our regulatory strategy includes a planned filing of an Investigational New Drug application (IND) with the U.S. FDA. This would allow U.S. sites to participate in the THIO-101 NSCLC trial. The human safety data generated in the first part of 2022 in Australia and Europe would constitute the basis of the IND application. Although we plan to rely solely on the safety and efficacy data we generate in our own clinical trials in support of our planned NDA filing, and do not plan to rely on clinical data generated by unaffiliated third parties, we take added confidence in the potential tolerability of THIO in light of the fact that the THIO doses we plan to test represent a range 4 to 40 times </p></div></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</a></p>
<hr style="page-break-after:always;width:100%;">
<div style="width:100%;border-top:Solid 0.75pt #000000;border-bottom:Solid 0.75pt #000000;border-left:Solid 0.75pt #000000;border-right:Solid 0.75pt #000000;">
<div style="padding-left:6.7%;padding-Right:6.7%;padding-Top:5.18%;padding-Bottom:5.18%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">lower than the maximum tolerated dose tested in the earlier clinical trials sponsored by the National Cancer Institute in the 1970s. </font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A</font><font style="color:#000000;">s part of the existing data base of clinical experience with the drug, we expect to reference the older NCI studies in the public domain as well as reference NCI&#8217;s original IND filing in support of an IND filing, pursuant to FDA regulations, and we are currently working with experts to evaluate the extent and quality of the existing data supporting THIO. We expect to request a pre-IND meeting with the FDA for guidance in 2022. </font><font style="letter-spacing:0.2pt;">The planned THIO-101 phase 2 trial is intended to be a proof-of-concept study that may be modified depending on interim results to include both primary and secondary endpoints and be consistent with previously approved cancer treatments. Based on the clinical data generated in the </font><font style="letter-spacing:0.2pt;">THIO-101</font><font style="letter-spacing:0.2pt;"> study and assuming THIO achieves its intended clinical effect with a manageable safety profile</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> at one of the doses tested in the study, we expect to seek early FDA guidance </font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">on the possibility of utilizing one or more of FDA&#8217;s expedited programs for serious conditions, such as fast track designation, breakthrough therapy designation, priority review and/or accelerated approval designation.</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="color:#000000;">Even if granted, accelerated approval status does not guarantee an accelerated review or marketing approval by </font><font style="color:#000000;">the </font><font style="color:#000000;">FDA.</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The </font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">THIO-101</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> study protocol may need to be amended to increase the number of patients enrolled, undergo modification of the statistical analysis</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> or change in the trial design and/or primary endpoints. </font></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Our Science--Driven Telomere Targeting Approach</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Telomeres are regions of repetitive DNA nucleotide sequences that are associated with specialized proteins at the ends of linear chromosomes in cells. THIO&#8217;s mechanism of action comprises telomere targeting and induction of anti-cancer immunogenicity. The enzyme telomerase recognizes THIO&#8217;s metabolite formed <font style="font-style:italic;">in situ</font> and incorporates it into the structure of the cancer cell&#8217;s telomeres, creating a faulty structure, which breaks apart the telomere spatial structure. As a result, the telomeric structure unwinds and the cancer cells die. We believe THIO transforms &#8220;cold&#8221; tumors into &#8220;hot&#8221; tumors rendering them responsive to immunotherapy (checkpoint inhibitors) and this process takes place promptly within 24 to 72 hours. We believe we can improve the immunotherapy efficacy and we can restore the immunotherapy efficacy in patients who have progressed or developed resistance to prior immunotherapy.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Telomere maintenance is essential for cell proliferation and resilience in cancer cells, and thus represents one of the key therapeutic targets for cancer treatment. Telomerase is an enzyme that is present in a majority of human cancer cells (over 85% in the aggregate), across various tumor types. In contrast, its activity is detected in less than 1% of normal cells. THIO has only been shown to be active in cancer cells that are telomerase positive (TERT+). Cancer cells are constantly telomerase positive due to an uncontrolled division process, while a relatively small number of normal cells are telomerase positive only transiently. Therefore, THIO activity is expected to be highly specific to cancer cells versus normal cells. Cancer-specific disturbance of telomeric structure, mediated by telomerase, is likely to lead to disruption in the cell cycle, followed by a very rapid and telomere-length independent cell death. THIO was observed to induce cancer-specific telomere disruption, by using the enzyme telomerase, which differentiates THIO from all other available cancer therapies currently in clinical use. We are also currently developing potential next generation small molecule telomere modifying agents with the goal of identifying additional proprietary drug candidates, across multiple cancer types. We have generated 82 new telomere-targeting compounds of which 60 compounds have been evaluated in vitro. Currently, five molecules have been selected for further evaluation in additional in vitro and in vivo models.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Human clinical trials prior to approval are typically conducted in three sequential Phases that may overlap or be combined. In Phase 1, the drug or biologic is initially introduced into healthy human subjects and tested for safety, dosage tolerance, absorption, metabolism, distribution and excretion. In Phase 2, the drug or biologic is evaluated in a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance, optimal dosage and dosing schedule for patients having the specific disease. In Phase 3, larger-scale clinical trials are undertaken to evaluate clinical efficacy and safety and the overall risk/benefit ratio of the product. Post-approval studies, or Phase 4 clinical trials, may be conducted voluntarily, or as a condition of FDA&#8217;s approval of a drug. These studies may be used to confirm preliminary efficacy results, gain additional experience from the treatment of certain patient populations, or to support additional indications or labeling changes.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We completed our selection process for the clinical sites for our Phase 2 study in Australia and Europe and our application to start the Phase 2 study in Australia has been approved. We also plan to submit a similar application in the Second Quarter 2022, to conduct the same Phase 2 study in Europe.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</a></p>
<hr style="page-break-after:always;width:100%;">
<div style="width:100%;border-top:Solid 0.75pt #000000;border-bottom:Solid 0.75pt #000000;border-left:Solid 0.75pt #000000;border-right:Solid 0.75pt #000000;">
<div style="padding-left:6.7%;padding-Right:6.7%;padding-Top:5.18%;padding-Bottom:5.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2022, the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) to THIO for the treatment of hepatocellular carcinoma and in May 2022, the FDA granted ODD to THIO for the treatment of small cell lung cancer. The FDA&#8217;s Office of Orphan Products Development may grant orphan designation status to drugs and biologics that are intended for the treatment, diagnosis or prevention of rare diseases, or conditions that affect fewer than 200,000 people in the U.S. Orphan Drug Designation provides certain benefits, including financial incentives, to support clinical development and the potential for up to seven years of market exclusivity for the drug for the designated orphan indication in the U.S. if the drug is ultimately approved for its designated indication.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:5pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:5pt;"><a name="BigHand_Transcription"></a>&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;<img src="gyowp0iggm03000002.jpg" title="" alt="" style="width:594px;height:314px;"></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Our Second Generation Target Candidates</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our THIO program drives our development pipeline of second-generation telomere targeting agents. We have initiated an early-stage research and discovery program aimed at identifying new compounds capable of acting through similar mechanisms of activity as THIO, such as the targeting and modifying telomeric structures of cancer cells through cancer-cell intrinsic telomerase activity. The main objective for this program is to discover new compounds with potentially improved specificity towards cancer cells relative to normal cells and with potentially increased anticancer activity. This program may also allow us to strengthen our patent portfolio. Although the program is in early stages and we may not be able to identify suitable compounds, we believe we will be able to create a second generation of THIO-like compounds.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our current 2nd-generation pipeline of potential telomere-targeting agents includes five compounds that have successfully undergone <font style="font-style:italic;">in vitro</font> inhibitory testing in five cancer models. The data from those studies showed a significantly lower 50% inhibitory concentration (IC50) for those compounds compared to THIO. Based on those data, we have progressed those five compounds to <font style="font-style:italic;">in vivo</font> testing and with proceeds from the IPO, we plan to initiate pre-IND testing for two of them in mid-2022, with the goal of advancing them to clinical trials by the end of 2024.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</a></p>
<hr style="page-break-after:always;width:100%;">
<div style="width:100%;border-top:Solid 0.75pt #000000;border-bottom:Solid 0.75pt #000000;border-left:Solid 0.75pt #000000;border-right:Solid 0.75pt #000000;">
<div style="padding-left:6.7%;padding-Right:6.7%;padding-Top:5.18%;padding-Bottom:5.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p><a name="_AEIOULastRenderedPageBreakAEIOU3"></a>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">OUR PIPELINE</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Our robust pipeline includes several targeted immuno-oncology candidates for relapsed and refractory cancers.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;<img src="gyowp0iggm03000003.jpg" title="" alt="" style="width:608px;height:242px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*Basket study expected to evaluate: Small Cell Lung Cancer (SCLC), Hepatocellular Carcinoma (HCC), Glioblastoma (GBM), Melanoma, Ovarian, Pancreatic, Breast &amp; Prostate cancers.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pipeline products are under investigation and have not been proven to be safe or effective. There is no guarantee any product will be approved in the sought-after indication or will meet the developmental milestones set forth above.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Our Strategy </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our goal is to be the leader in the discovery, development and commercialization of cancer telomere targeting agents and other similar small molecules. Our initial focus is to efficiently advance our Phase 2 clinical program using THIO in sequential combination with cemiplimab. Ultimately, we envision positioning THIO as a patient anticancer immunity priming treatment for all immune-activating agents used in the treatment of cancer. To date, THIO has never been tested in clinical trials in combination with any check-point inhibitor. The key elements of our strategy are to: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Advance our existing clinical programs, including seeking accelerated approval for THIO in NSCLC as a tumor mass-reducing and simultaneously immune system priming agent administered in advance of the immune-activating agent, cemiplimab for treatment of advanced NSCLC, and ultimately, as a cancer treatment foundation in multiple indications and geographies. Even if granted, accelerated approval status does not guarantee an accelerated review or marketing approval by the FDA.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Broaden the clinical development of THIO by exploring synergistic administration prior to other standard-of care immune-therapies including cell therapy. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Develop a franchise of telomere-targeting cancer treatments not inclusive of checkpoint inhibitors.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Leverage our regulatory strategy to acquire additional human data faster outside U.S. for other cancer indications.&nbsp;&nbsp;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Selectively enter into strategic collaborations with pharmaceutical and biotechnology companies that have immune activating therapies.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Expand our existing intellectual property portfolio.</font></p></td></tr></table></div></div></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</a></p>
<hr style="page-break-after:always;width:100%;">
<div style="width:100%;border-top:Solid 0.75pt #000000;border-bottom:Solid 0.75pt #000000;border-left:Solid 0.75pt #000000;border-right:Solid 0.75pt #000000;">
<div style="padding-left:6.7%;padding-Right:6.7%;padding-Top:5.18%;padding-Bottom:5.18%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We will face certain challenges in implementing our business strategy including, among others, the fact that earlier development of THIO was not commercially pursued. Even if THIO successfully advances through clinical studies and towards approval for use, we may face early competition from generic alternatives to THIO after expiration of any applicable regulatory exclusivities. The FDA&#8217;s accelerated approval pathway, even if initially granted, does not guarantee an accelerated review or marketing approval by the FDA.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Our Intellectual Property</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our global patent and patent-pending estate covers several areas. Telomerase mediated telomere altering compounds and treatment of therapy-resistant cancers are part of our portfolio. Further, THIO&#8217;s immunogenic treatment strategy, which focuses on sequential combination with checkpoint inhibitors has been filed. We maintain four issued patents and have 16 pending applications.&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Our Leadership Team </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have assembled an experienced management team with deep research, development, and commercialization experience in the areas of cancer treatment, telomere-related science, immunotherapy, and spreading across a vast array of oncology indications. Members of our team bring experiences from multiple biotech and pharmaceutical companies including Pfizer Inc., Bayer Oncology, Novartis Oncology, Astellas Pharma Inc., Janssen - a Johnson &amp; Johnson pharmaceutical company, Incyte Corporation, Pharmacyclics Inc., Juno Therapeutics Inc., Celgene, Cephalon Inc., Geron Corporation, and AbbVie Bio Corp., among others. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc79562746"></a>Our Corporate Information</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We were incorporated in Delaware in August 2018, and we have operations in Chicago, Illinois, with some of our team members setup virtually and working remotely in California, Nevada and Florida. Our principal executive office is located at 444 West Lake Street, Suite 1700, Chicago, IL 60606, and our phone number is (312) 416-8592. In July 2021, we established a wholly owned Australian subsidiary, MAIA Biotechnology Australia Pty Ltd, to conduct various preclinical and clinical activities for the development of our product candidates. In April 2022, we established a wholly owned Romanian subsidiary, MAIA BIOTECHNOLOGY ROMANIA S.R.L. to conduct various preclinical and clinical activities for the development of our product candidates. Our website address is <font style="font-style:italic;text-decoration:underline;color:#0000FF;">www.MAIABiotech.com</font>. The information contained on our website is not incorporated by reference into this prospectus, and you should not consider any information contained on, or that can be accessed through, our website as part of this prospectus or in deciding whether to purchase our common stock.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Implications of Being an Emerging Growth Company</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are an &#8220;emerging growth company,&#8221; as defined in Section 2(a) of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), as modified by the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. As such, we are eligible to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, as amended, or the Sarbanes-Oxley Act;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">reduced disclosure obligations regarding executive compensation in our periodic reports, proxy statements, and registration statements; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">exemptions from the requirements of holding a non-binding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If some investors find our common stock less attractive as a result of these exemptions, there may be a less active trading market for our common stock and the price of our common stock may be more volatile.</p></div></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</a></p>
<hr style="page-break-after:always;width:100%;">
<div style="width:100%;border-top:Solid 0.75pt #000000;border-bottom:Solid 0.75pt #000000;border-left:Solid 0.75pt #000000;border-right:Solid 0.75pt #000000;">
<div style="padding-left:6.7%;padding-Right:6.7%;padding-Top:5.18%;padding-Bottom:5.18%;">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, Section 107 of the JOBS Act also provides that an emerging growth company can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. In other words, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We intend to take advantage of the benefits of this extended transition period.</font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We will remain an emerging growth company until the earlier of (1) the last day of the fiscal year (a) following the fifth anniversary of the completion of this offering, (b) in which we have total annual gross revenue of at least $1.07 billion, or (c) in which we are deemed to be a large accelerated filer, which means the market value of our common stock that is held by non-affiliates exceeds $700 million as of the prior June 30, and (2) the date on which we have issued more than $1.0 billion in non-convertible debt securities during the prior three-year period. References herein to emerging growth company will have the meaning associated with it in the JOBS Act.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Implications of Being a Smaller Reporting Company</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, we are a &#8220;smaller reporting company&#8221; as defined in Rule 10(f)(1) of Regulation S-K. Smaller reporting companies may take advantage of certain reduced disclosure obligations, including, among other things, providing only two years of audited financial statements. We will remain a smaller reporting company until the last day of the fiscal year in which (1) the market value of our common stock held by non-affiliates equals or exceeds $250 million as of the end of that year&#8217;s second fiscal quarter, or (2) our annual revenues equaled or exceeded $100 million during such completed fiscal year and the market value of our common stock held by non-affiliates equals or exceeds $700 million as of the end of that year&#8217;s second fiscal quarter.</p><a name="_AEIOULastRenderedPageBreakAEIOU4"></a></div></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</a></p>
<hr style="page-break-after:always;width:100%;">
<div style="width:100%;border-top:Solid 0.75pt #000000;border-bottom:Solid 0.75pt #000000;border-left:Solid 0.75pt #000000;border-right:Solid 0.75pt #000000;">
<div style="padding-left:6.7%;padding-Right:6.7%;padding-Top:5.18%;padding-Bottom:5.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="FERING"></a><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="FERING"></a>THE OF</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FERING</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:19%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuer</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MAIA Biotechnology, Inc.</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock offered</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock.</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock to </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">be outstanding </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">after this offering</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;  shares (or &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares if the underwriters&#8217; option to purchase additional shares is exercised in full) of common stock.</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Offering price</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share.</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Over-allotment option</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have granted the underwriters a 45-day option to purchase up to an additional &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock at the initial public offering price, less the underwriting discount, to cover over-allotments, if any.</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Use of proceeds</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We estimate that we will receive net proceeds of approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million from our sale of common stock in this offering, or approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million if the underwriters exercise their over-allotment option in full. We intend to use the net proceeds from this offering, along with our existing cash and cash equivalents, to fund the planned trials of THIO, pre-clinical development of second-generation of telomere targeting compounds and our other research and development activities, as well as for working capital and other general corporate purposes. See &#8220;Use of Proceeds&#8221; in this prospectus for a more complete description of the intended use of proceeds from this offering.</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Concentration of ownership</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon completion of this offering, our executive officers and directors will beneficially own, in the aggregate, approximately &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of the outstanding shares of our common stock.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proposed trading market and symbol</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have applied to list our common stock for trading on the Nasdaq under the symbol &#8220;MAIA.&#8221; No assurance can be given that our application will be approved. </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk factors</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investing in our common stock involves a high degree of risk. See &#8220;Risk Factors&#8221; beginning on page 13 and the other information in this prospectus for a discussion of the factors you should consider carefully before you decide to invest in our common stock.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lock-Up</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We, each of our officers, directors, and certain of our stockholders have agreed, subject to certain exceptions, not to offer, pledge, sell, contract to sell, grant, lend, or otherwise transfer or dispose of, directly or indirectly, or enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of any shares of our capital stock or any securities convertible into or exercisable or exchangeable for shares of our common stock, for a period of 12 months after the date of this prospectus, without the prior written consent of the representative. Certain of our other stockholders, who are not insiders, have agreed, subject to certain exceptions, not offer, pledge, sell, contract to sell, grant, lend, or otherwise transfer or dispose of, directly or indirectly, or enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of any shares of our capital stock or any securities convertible into or exercisable or exchangeable for shares of our common stock, for a period of 6 months (or in the case of options with a weighted average exercise price of $1.80 or $1.83, for a period of 12 months) after the date of this prospectus, without the prior written consent of the representative. Following the expiration of the applicable lock-up period, all of the issued and outstanding shares of our common stock will be eligible for future sale, subject to the applicable volume, manner of sale, holding period, and other limitations of Rule 144. See the section of this prospectus entitled &#8220;Underwriting&#8221; for additional information.</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</a></p>
<hr style="page-break-after:always;width:100%;">
<div style="width:100%;border-top:Solid 0.75pt #000000;border-bottom:Solid 0.75pt #000000;border-left:Solid 0.75pt #000000;border-right:Solid 0.75pt #000000;">
<div style="padding-left:6.7%;padding-Right:6.7%;padding-Top:5.18%;padding-Bottom:5.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:left;margin-top:2pt;margin-bottom:0pt;text-indent:3.85%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The number of shares of our common stock to be outstanding after this offering is based on 7,951,320 shares of our common stock outstanding as of April 26, 2022, and excludes the following: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">5,880,367  shares of common stock issuable upon exercise of options to purchase shares of common stock outstanding as of April 26, 2022, with a weighted-average exercise price of $2.37 per share; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">222,133 shares of common stock reserved for future issuance as of April 26, 2022, under our 2020 Plan; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock reserved for issuance under our 2021 Equity Incentive Plan that we intend to adopt in connection with this offering; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">warrants to purchase 1,235,006 shares of common stock, with a weighted average exercise price of $4.17 per share and of which warrants to purchase 553,021 shares must be exercised or they will expire at the closing of our initial public offering.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.85%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unless we indicate otherwise or unless the context otherwise requires, all information in this prospectus assumes the following:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">no exercise of outstanding options or warrants;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">no exercise by the underwriters of their option to purchase up to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; additional shares of our common stock from us to cover over-allotments, if any;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">no exercise of the representative&#8217;s warrants to be issued upon consummation of this offering at an exercise price equal to 125% of the initial offering price of the common stock;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">the filing and effectiveness of our amended and restated certificate of incorporation and the effectiveness of our amended and restated bylaws, each of which will be in effect immediately upon the consummation of this offering; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">an initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, the midpoint of the estimated initial public offering price range on the cover page of this prospectus. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">an initial public offering price greater than the per share price paid by investors in our Crossover Round and therefore no requirement to issue additional shares of our common stock to the investors in the Crossover Round. See &#8220;Description of Capital Stock&#8212;Crossover Round.&#8221;</font></p></td></tr></table></div><a name="_AEIOULastRenderedPageBreakAEIOU5"></a></div></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</a></p>
<hr style="page-break-after:always;width:100%;">
<div style="width:100%;border-top:Solid 0.75pt #000000;border-bottom:Solid 0.75pt #000000;border-left:Solid 0.75pt #000000;border-right:Solid 0.75pt #000000;">
<div style="padding-left:6.7%;padding-Right:6.7%;padding-Top:5.18%;padding-Bottom:5.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="SUMMARY_RISK_FACTORS"></a><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="SUMMARY_RISK_FACTORS"></a>SUMMARY OF R</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ISK FACTORS</font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our business is subject to a number of risks of which you should be aware of before making an investment decision. These risks are discussed more fully in the &#8220;<font style="font-style:italic;">Risk Factors</font>&#8221; section of this prospectus immediately following this prospectus summary. Some of these risks include the following:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">We have incurred losses since our inception and anticipate that we will continue to incur increasing losses for the foreseeable future.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">Even if this offering is successful, we will require additional capital to fund our operations, and if we fail to obtain necessary financing, we may not be able to complete the development and commercialization of THIO.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our product candidates on unfavorable terms to us.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">We have a limited operating history and no history of commercializing pharmaceutical products, which may make it difficult to evaluate the prospects for our future viability.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">We are heavily dependent on the success of THIO, our most advanced candidate, which is still under clinical development, and if this drug does not receive regulatory approval or is not successfully commercialized, our business may be harmed.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">Clinical trials are expensive, time consuming, difficult to design and implement, and involve uncertain outcomes. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">Our product candidates are based on novel technologies, which make it difficult to predict the timing, results and cost of product candidate development and likelihood of obtaining regulatory approval.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">We may find it difficult to enroll patients in our clinical trials given the limited number of patients who have the diseases for which our product candidates are being studied which could delay or prevent the start of clinical trials for our product candidates.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time consuming, expensive, and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for THIO or any other candidates, our business will be substantially harmed.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">Enrollment and retention of patients in clinical trials is an expensive and time-consuming process and could be made more difficult or rendered impossible by multiple factors outside our control.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">Results of preclinical studies, early clinical trials or analyses may not be indicative of results obtained in later trials.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">The market opportunities for THIO, if approved, may be smaller than we anticipate.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">Development of THIO could take longer, be more expensive, or become impractical if the FDA requires the use of an FDA-approved companion diagnostic test in conjunction with treatment with THIO.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">Even if we obtain FDA approval for THIO or any other candidates in the United States, we may never obtain approval for or commercialize THIO or any other development candidate in any other jurisdiction, which would limit our ability to realize their full global market potential.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">The successful commercialization of THIO and any other candidate we develop will depend in part on the extent to which governmental authorities and health insurers establish adequate coverage, reimbursement levels, and pricing policies. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">Even if THIO or any candidate we develop receives marketing approval, it may fail to achieve market acceptance by physicians, patients, third-party payors or others in the medical community necessary for commercial success.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">If we are unable to establish sales, marketing and distribution capabilities either on our own or in collaboration with third parties, we may not be successful in commercializing THIO, if approved.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">A variety of risks associated with operating internationally could materially adversely affect our business.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">Our employees and independent contractors, including principal investigators, clinical trial sites, contract research organizations (&#8220;CROs&#8221;), consultants, vendors, and any third parties we may engage in connection with development and commercialization, may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could have a material adverse effect on our business.</font></p></td></tr></table></div></div></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</a></p>
<hr style="page-break-after:always;width:100%;">
<div style="width:100%;border-top:Solid 0.75pt #000000;border-bottom:Solid 0.75pt #000000;border-left:Solid 0.75pt #000000;border-right:Solid 0.75pt #000000;">
<div style="padding-left:6.7%;padding-Right:6.7%;padding-Top:5.18%;padding-Bottom:5.18%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="text-decoration:none;Background-color:#auto;font-size:10pt;font-family:'Times New Roman';"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">We currently rely on third-party contract manufacturing organizations, or CMOs, for the production of clinical supply of THIO and intend to rely on CMOs for the production of commercial supply of THIO, if approved. Our dependence on CMOs may impair the development and commercialization of the drug, which would adversely impact our business and financial position.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">We intend to rely on third parties to conduct, supervise and monitor our clinical trials. If those third parties do not successfully carry out their contractual duties, or if they perform in an unsatisfactory manner, it may harm our business.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">We depend on license agreements with the University of Texas Southwestern, or UTSW, to permit us to use patents and patent applications, as well as to exploit specific technological know-how. Termination of these rights or the failure to comply with obligations under these agreements could materially harm our business and prevent us from developing or commercializing our product candidates.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">We have been granted licenses of use to patent applications. There can be no assurance that any of the patent applications that we have licenses to will result in issued patents. As a result, our ability to protect our proprietary technology in the marketplace may be limited.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">Our patents may be challenged in courts or in patent offices which could result in the invalidation, narrowing or unenforceability of our patents and our patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">Changes in patent laws or patent jurisprudence could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">Intellectual property rights do not address all potential threats to our competitive advantage.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">Our reliance on third parties requires us to share our trade secrets, which increases the possibility that our trade secrets will be misappropriated or disclosed, and confidentiality agreements with employees and third parties may not adequately prevent disclosure of trade secrets and protect other proprietary information.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">We may need to license certain intellectual property from third parties, and such licenses may not be available or may not be available on commercially reasonable terms.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of their former employers or other third parties.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">We expect to expand our development, regulatory, and sales and marketing capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">There is no existing market for our common stock and an active, liquid trading market for our common stock may not develop. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">The price of our common stock may be volatile and you could lose all or part of your investment. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">We do not intend to pay dividends for the foreseeable future, and our ability to pay dividends to our stockholders is restricted by applicable laws and regulations.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">We may, in the future, issue additional capital stock, which would reduce investors&#8217; percent of ownership and may dilute our share value.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">A potential failure to maintain effective internal control over financial reporting in accordance with Section 404 of the Sarbanes-Oxley Act could have a material adverse effect on our business, financial condition, and results of operations.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;">We identified material weaknesses in our internal control over financial reporting, and we may identify additional material weaknesses in the future that may cause us to fail to meet our reporting obligations or result in material misstatements of our financial statements. If we fail to remediate any material weaknesses or if we otherwise fail to establish and maintain effective control over financial reporting, our ability to accurately and timely report our financial results could be adversely affected.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">The lack of public company experience of our management team could adversely impact our ability to comply with the reporting requirements of U.S. securities laws, which could have a materially adverse effect on our business.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">We will incur increased costs as a result of being a publicly traded company. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:-3.85%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:-3.85%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="SUMMARY_FINANCIAL_INFORMATION"></a><a name="SUMMARY_FINANCIAL_INFORMATION"></a>SUMMARY FINANCIAL INFORMATION</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following tables present our summary consolidated financial and other data as of and for the periods indicated. The summary consolidated statements of operations data for the fiscal years ended December 31, 2021 and December 31, 2020 and the consolidated balance sheet data as of December 31, 2021 and 2020 are derived from our audited financial statements included elsewhere in this prospectus. The summary consolidated statements of operations data for the three months ended March 31, 2022 and March 31, 2021 and the consolidated balance sheet data as of March 31, 2022 are derived from our unaudited financial statements included elsewhere in this prospectus. The unaudited interim financial statements have been prepared on the same basis as the audited financial statements and reflect, in the opinion of management, all adjustments of a normal, recurring nature that are necessary for a fair presentation of the unaudited interim financial statements.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The summarized financial information presented below is derived from and should be read in conjunction with our consolidated financial statements including the notes to those financial statements, which are included elsewhere in this prospectus along with the sections entitled "Selected Financial Data," &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and &#8220;Capitalization.&#8221; Our historical results are not necessarily indicative of results that should be expected in any future period, and our results for any interim period are not necessarily indicative of results that should be expected for any full year.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.92%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.84%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.82%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.68%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.92%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.84%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.68%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.68%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.5%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating expenses</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,443,558</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,050,713</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,786,627</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,975,601</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,443,558</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,050,713</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7,786,627</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,975,601</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income (expense), net</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,713</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,194</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,791,584</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,353</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,413,845</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,021,519</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12,578,211</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,959,248</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to MAIA Biotechnology, Inc.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; shareholders</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,864,423</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(983,994</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12,503,880</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,636,660</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per common share - basic and diluted <sup style="font-size:85%;line-height:120%;vertical-align:top">(1)</sup></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.84%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.50</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.64%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.23</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.68%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.5%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.37</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.68%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.50</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average common shares outstanding - basic and</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; diluted<sup style="font-size:85%;line-height:120%;vertical-align:top">(1)</sup></p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.84%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,752,042</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.64%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 4,329,088</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.68%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.5%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,278,435</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.68%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,427,242</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(1)</sup> See Note 1 to our audited financial statements appearing at the end of this prospectus for further details on the calculation of basic and diluted net loss per common share.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance Sheet Data:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,293,460</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,574,292</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">663,457</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Working capital (deficit) <sup style="font-size:85%;line-height:120%;vertical-align:top">(</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">1</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">)</sup></p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,097,195</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,526,499</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(947,239</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,444,563</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,327,199</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">746,505</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,430,893</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,145,996</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,362,805</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stockholders' equity (deficit)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,013,670</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,181,203</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,616,300</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">1</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">)</sup> We define working capital (deficit) as current assets less current liabilities.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:1pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:1pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p><a name="_AEIOULastRenderedPageBreakAEIOU7"></a>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="RISK_FACTORS"></a><a name="RISK_FACTORS"></a>RISK FACTORS</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Any investment in our common stock involves a high degree of risk. You should carefully consider the risks described below, which we believe represent certain of the material risks to our business, together with the information contained elsewhere in this prospectus, before you make a decision to invest in our common stock. Please note that the risks highlighted here are not the only ones that we may face. For example, additional risks presently unknown to us or that we currently consider immaterial or unlikely to occur could also impair our operations. If any of the following events occur or any additional risks presently unknown to us actually occur, our business, financial condition and operating results may be materially adversely affected. In that event, the trading price of our common stock could decline and you could lose all or part of your investment.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:-0.2pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Our Financial Position and Need for Additional Capital</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:-0.2pt;text-transform:none;font-variant: normal;">We have incurred losses since inception and anticipate that we will continue to incur losses for the foreseeable future. We are not currently profitable, and we may never achieve or sustain profitability.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a clinical stage biopharmaceutical company with a limited operating history and have incurred losses since our formation. We incurred net losses of $12,578,211 and $6,959,248 for the years ended December 31, 2021 and 2020, respectively. We incurred net losses of $3,413,845 and $1,021,519 for the three months ended March 31, 2022 and March 31, 2021, respectively. As of March 31, 2022, we had an accumulated deficit of $31,851,838. We have not commercialized any products and have never generated revenue from the commercialization of any product. To date, we have devoted most of our financial resources to research and development, including our preclinical and clinical work, and to intellectual property.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect to incur significant additional operating losses for the next several years, at least, as we advance THIO and any other candidates through clinical development, complete clinical trials, seek regulatory approval and commercialize the drug or any other candidates, if approved. The costs of advancing candidates into each clinical phase tend to increase substantially over the duration of the clinical development process. Therefore, the total costs to advance any of our candidates to marketing approval in even a single jurisdiction will be substantial. Because of the numerous risks and uncertainties associated with pharmaceutical product development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to begin generating revenue from the commercialization of any products or achieve or maintain profitability. Our expenses will also increase substantially if and as we:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>commence our Phase 2 trial, or conduct clinical trials for any other indications or other candidates;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>establish sales, marketing, distribution, and compliance infrastructures to commercialize our drug, if approved, and for any other candidates for which we may obtain marketing approval;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>maintain, expand and protect our intellectual property portfolio;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>hire additional clinical, scientific and commercial personnel;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>add operational, financial and management information systems and personnel, including personnel to support our development and planned future commercialization efforts, as well as to support our transition to a public reporting company; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>acquire or in-license or invent other candidates or technologies.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8203;<font style="letter-spacing:0.2pt;">Furthermore, our ability to successfully develop, commercialize and license any candidates and generate product revenue is subject to substantial additional risks and uncertainties, as described under &#8220;&#8212; Risks Related to Development, Clinical Testing, Manufacturing and Regulatory Approval&#8221; and &#8220;&#8212; Risks Related to Commercialization.&#8221; As a result, we expect to continue to incur net losses and negative cash flows for the foreseeable future. These net losses and negative cash flows have had, and will continue to have, an adverse effect on our stockholders&#8217; equity and working capital. The amount of our future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenues. If we are unable to develop and commercialize one or more product candidates, either alone or through collaborations, or if revenues from any product that receives marketing approval are insufficient, we will not achieve profitability. Even if we do achieve profitability, we may not be able to sustain profitability or meet outside expectations for our profitability. If we are unable to achieve or sustain profitability or to meet outside expectations for our profitability, the value of our common stock will be materially and adversely affected.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:-0.2pt;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:-0.2pt;text-transform:none;font-variant: normal;">Even if this offering is successful, we will require additional capital to fund our operations, and if we fail to obtain necessary financing, we may not be able to complete the development and commercialization of THIO.</font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our operations have consumed substantial amounts of cash since inception. We expect to continue to spend substantial amounts to advance the clinical development of THIO and launch and commercialize THIO, if we receive regulatory approval. We will require additional capital for the further development and potential commercialization of THIO and may also need to raise additional funds sooner to pursue a more accelerated development of THIO. If we are unable to raise capital when needed or on attractive terms, we could be forced to delay, reduce or eliminate our research and development programs or any future commercialization efforts.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that the net proceeds from this offering together with our existing cash as of December 31, 2021, will enable us to fund our operating expenses and capital expenditure requirements for at least the next 36 months. We have based this estimate on assumptions that may prove to be wrong, and we could deploy our available capital resources sooner than we currently expect. Our future funding requirements, both near and long-term, will depend on many factors, including, but not limited to the:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>initiation, progress, timing, costs and results of preclinical studies and clinical trials, including patient enrollment in such trials, for THIO or any other future candidates;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>&#8203;clinical development plans we establish for THIO and any other future candidates;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>&#8203;obligation to make royalty and non-royalty sublicense receipt payments to third-party licensors, if any, under our licensing agreements;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>&#8203;number and characteristics of candidates that we discover or in-license and develop;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>&#8203;outcome, timing and cost of regulatory review by the FDA and comparable foreign regulatory authorities, including the potential for the FDA or comparable foreign regulatory authorities to require that we perform more studies than those that we currently expect;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>&#8203;costs of filing, prosecuting, defending and enforcing any patent claims and maintaining and enforcing other intellectual property rights;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>&#8203;effects of competing technological and market developments;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>&#8203;costs and timing of the implementation of commercial-scale manufacturing activities; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>&#8203;costs and timing of establishing sales, marketing and distribution capabilities for any product candidates for which we may receive regulatory approval.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8203;If we are unable to expand our operations or otherwise capitalize on our business opportunities due to a lack of capital, our ability to become profitable will be compromised.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;text-transform:none;font-variant: normal;">Raising additional capital may cause dilution to our stockholders, including purchasers of common stock in this offering, restrict our operations or require us to relinquish rights to our technologies or product candidates.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Until such time, if ever, as we can generate substantial revenue, we may finance our cash needs through a combination of equity offerings, debt financings, marketing and distribution arrangements and other collaborations, strategic alliances and licensing arrangements or other sources. We do not currently have any committed external source of funds. In addition, we may seek additional capital due to favorable market conditions or strategic considerations, even if we believe that we have sufficient funds for our current or future operating plans.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a common stockholder. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may be required to relinquish valuable rights to our technologies, intellectual property, future revenue streams or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate candidate development or future commercialization efforts.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:-0.2pt;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:-0.2pt;text-transform:none;font-variant: normal;">We have a limited operating history and no history of commercializing pharmaceutical products, which may make it difficult to evaluate the prospects for our future viability.</font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We were incorporated in Delaware and began our operations in August 2018. Our operations to date have been limited to financing and staffing our company, licensing candidates, conducting preclinical studies, manufacturing clinical supply, and preparing for clinical studies of THIO. We have not yet demonstrated the ability to successfully complete a large-scale, pivotal clinical trial, obtain marketing approval, manufacture a commercial scale product, arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for successful product commercialization. Consequently, predictions about our future success or viability may not be as accurate as they could be if we had a history of successfully developing and commercializing pharmaceutical products.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, as a business with a limited operating history, we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown factors. We will eventually need to transition from a company with a research focus to a company capable of supporting commercial activities. We may not be successful in such a transition and, as a result, our business may be adversely affected.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As we continue to build our business, we expect our financial condition and operating results may fluctuate significantly from quarter to quarter and year to year due to a variety of factors, many of which are beyond our control. Accordingly, you should not rely upon the results of any particular quarterly or annual period as indications of future operating performance.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Development, Clinical Testing, Manufacturing and Regulatory Approval</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:-0.2pt;text-transform:none;font-variant: normal;">We are heavily dependent on the success of THIO, which is still under clinical development, and if this drug does not receive regulatory approval or is not successfully commercialized, our business may be harmed.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not have any products that have gained regulatory approval. Currently, our lead clinical stage candidate is THIO. As a result, our business is dependent on our ability to successfully complete clinical development of, obtain regulatory approval for, and, if approved, successfully commercialize THIO in a timely manner. We cannot commercialize THIO in the United States without first obtaining regulatory approval from the FDA; similarly, we cannot commercialize THIO outside of the United States without obtaining regulatory approval from comparable foreign regulatory authorities. Before obtaining regulatory approvals for the commercial sale of THIO for a target indication, we must demonstrate with substantial evidence gathered in preclinical studies and clinical trials, generally including two adequate and well-controlled clinical trials, and, with respect to approval in the United States, to the satisfaction of the FDA, that THIO is safe and effective for use for that target indication and that the manufacturing facilities, processes and controls are adequate. Even if we were to successfully obtain approval of THIO from the FDA and comparable foreign regulatory authorities, any approval might contain significant limitations related to use restrictions for specified age groups, warnings, precautions or contraindications, or may be subject to burdensome post-approval study or risk management requirements. If we are unable to obtain regulatory approval for THIO in one or more jurisdictions, or any approval contains significant limitations, we may not be able to obtain sufficient funding or generate sufficient revenue to continue the development of any other candidate that we may in-license, develop or acquire in the future. Furthermore, even if we obtain regulatory approval for THIO, we will still need to develop a commercial organization, establish commercially viable pricing and obtain approval for adequate reimbursement from third-party and government payors. If we are unable to successfully commercialize THIO, we may not be able to earn sufficient revenue to continue our business.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:-0.2pt;text-transform:none;font-variant: normal;">We may face future business disruption and related risks resulting from the recent outbreak of the novel coronavirus 2019 (COVID-19) or from another pandemic, epidemic or outbreak of an infectious disease, any of which could have a material adverse effect on our business.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The development of our drug candidates could be disrupted and materially adversely affected in the future by a pandemic, epidemic or outbreak of an infectious disease like the recent outbreak of COVID-19. For example, as a result of measures imposed by the governments in regions affected by COVID-19 businesses and schools have been suspended due to quarantines or &#8220;stay at home&#8221; orders intended to contain this outbreak. The spread of COVID-19 from China to other countries has resulted in the Director General of the World Health </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:10pt;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Organization declaring the outbreak of COVID-19 as a Public Health Emergency of International Concern (PHEIC), based on the advice of the Emergency Committee under the International Health Regulations (2005). In March 2020, and subsequently, various international travel restrictions were imposed and modified between the US and foreign countries and such restrictions may continue, be reimposed, or be expanded or otherwise further modified for the foreseeable future. COVID-19 continues to spread globally, including with the advent of the new &#8220;Delta&#8221; variant throughout 2021. The COVID-19 outbreak has impacted international stock markets, which continue to reflect the uncertainty associated with the slow-down in global economies and the reduced levels of international travel experienced since the beginning of January 2020. We continue to assess our business plans and the impact COVID-19 may have on our ability to advance the development of our drug candidates, including delays in starting or completing clinical trials, or to raise financing to support the development of our drug candidates, but no assurances can be given that this analysis will enable us to avoid part or all of any impact from the spread of COVID-19 or its consequences, including downturns in business sentiment generally or in our sector in particular. One of our initial clinical studies is taking place in Australia, which has imposed one of the strictest COVID-19-related measures, including lock-downs. While we have not currently experienced any potential delays or increased costs as a result of these measures, we may do so in the future.&nbsp;&nbsp; </font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The spread of an infectious disease, including COVID-19, may also result in the inability of our suppliers to deliver components or raw materials on a timely basis or materially and adversely affect our collaborators and out-license partners&#8217; ability to perform preclinical studies and clinical trials. In addition, hospitals may reduce staffing and reduce or postpone certain treatments in response to the spread of an infectious disease. Such events may result in a period of business and manufacturing disruption, and in reduced operations, any of which could materially affect our business, financial condition and results of operations. The extent to which the coronavirus impacts our business will depend on future developments, which are highly uncertain and cannot be predicted, including new information which may emerge concerning the severity of the coronavirus and the actions to contain the coronavirus or treat its impact, among others.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:-0.2pt;text-transform:none;font-variant: normal;">Clinical trials are expensive, time-consuming and difficult to design and implement, and involve an uncertain outcome.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical trial process. Because the results of preclinical studies and early clinical trials are not necessarily predictive of future results, THIO and our other compounds may not have favorable results in later preclinical and clinical studies or receive regulatory approval. We may experience delays in initiating and completing any clinical trials that we intend to conduct, and we do not know whether planned clinical trials will begin on time, need to be redesigned, enroll patients on time or be completed on schedule, or at all. Clinical trials can be delayed for a variety of reasons, including delays related to:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="letter-spacing:0.2pt;">the FDA or comparable foreign regulatory authorities disagreeing as to the design or implementation of our clinical studies;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="letter-spacing:0.2pt;">obtaining regulatory approval to commence and continue to conduct a trial;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="letter-spacing:0.2pt;">reaching an agreement on acceptable terms with prospective contract research organizations, or CROs, and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="letter-spacing:0.2pt;">obtaining Institutional Review Board, or IRB, approval at each site, or Independent Ethics Committee, or IEC, approval at sites outside the United States;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="letter-spacing:0.2pt;">recruiting suitable patients to participate in a trial in a timely manner and in sufficient numbers;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="letter-spacing:0.2pt;">having patients complete a trial or return for post-treatment follow-up;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="letter-spacing:0.2pt;">imposition of a clinical hold by regulatory authorities, or IRBs, including as a result of unforeseen safety issues or side effects or failure of trial sites to adhere to regulatory requirements or follow trial protocols;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="letter-spacing:0.2pt;">clinical sites deviating from trial protocol, failing to adequately enroll study subjects, committing fraud or other violations of regulatory requirements, or dropping out of a trial, which can render data from that site unusable in support of regulatory approval;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="letter-spacing:0.2pt;">addressing patient safety concerns that arise during the course of a trial;</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</a></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="letter-spacing:0.2pt;">adding a sufficient number of clinical trial sites; or</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>manufacturing sufficient quantities of THIO for use in clinical trials.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8203;<font style="letter-spacing:0.2pt;">We could also encounter delays if a clinical trial is suspended or terminated by us, the IRBs or IECs of the institutions in which such trials are being conducted, the Data Safety Monitoring Board, or DSMB, for such trial or the FDA or other regulatory authorities. Such authorities may impose such a suspension or termination due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a drug, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. Furthermore, we rely on CROs and clinical trial sites to ensure the proper and timely conduct of our clinical trials and, while we have agreements governing their committed activities, we have limited influence over their actual performance, as described in &#8220;&#8212; Risks Related to Our Dependence on Third Parties.&#8221;</font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Treatment of cancer patients with our oncology product candidates may be used in combination with other cancer drugs, such as other immuno-oncology agents, monoclonal antibodies or other protein-based drugs or small molecule anti-cancer agent such as targeted agents or chemotherapy, which can cause side effects or adverse events that are unrelated to our product candidate but may still impact the success of our clinical trials. Additionally, our product candidates could potentially cause adverse events. The inclusion of critically ill patients in our clinical trials may result in deaths or other adverse medical events due to other therapies or medications that such patients may be using. As described above, any of these events could prevent us from obtaining regulatory approval or achieving or maintaining market acceptance of our product candidates and impair our ability to commercialize our products. Because all of our product candidates are derived from our platform technologies, a clinical failure of one of our product candidates may also increase the actual or perceived likelihood that our other product candidates will experience similar failures.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Of the large number of products in development, only a small percentage successfully complete the FDA or comparable foreign regulatory authorities&#8217; approval processes and are commercialized. The lengthy approval process as well as the unpredictability of future clinical trial results may result in our failing to obtain regulatory approval to market our product candidates, which would significantly harm our business, financial condition, results of operations and prospects.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if we eventually complete clinical testing and receive approval of a biologics license application (BLA) or foreign marketing application for our product candidates, the FDA or the comparable foreign regulatory authorities may grant approval contingent on the performance of costly additional clinical trials, including post-market clinical trials. The FDA or the comparable foreign regulatory authorities also may approve a product candidate for a more limited indication or patient population than we originally request, and the FDA or comparable foreign regulatory authorities may not approve the labeling that we believe is necessary or desirable for the successful commercialization of a product candidate. Any delay in obtaining, or inability to obtain, applicable regulatory approval would delay or prevent commercialization of that product candidate and would adversely impact our business and prospects.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the FDA or comparable foreign regulatory authorities may change their policies, adopt additional regulations or revise existing regulations or take other actions, which may prevent or delay approval of our future product candidates under development on a timely basis. Such policy or regulatory changes could impose additional requirements upon us that could delay our ability to obtain approvals, increase the costs of compliance or restrict our ability to maintain any marketing authorizations we may have obtained.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our product candidates are based on novel technologies, which make it difficult to predict the timing, results and cost of product candidate development and likelihood of obtaining regulatory approval.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have not yet succeeded and may not succeed in demonstrating efficacy and safety for any product candidates in clinical trials or in obtaining marketing approval thereafter and use of our platform technologies may not ever result in marketable products. We may also experience delays in developing a sustainable, reproducible, and scalable manufacturing process or transferring that process to commercial partners or establishing our own commercial manufacturing capabilities, which may prevent us from completing our clinical trials or commercializing any products on a timely or profitable basis, if at all.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Serious adverse events, undesirable side effects or other unexpected properties of our product candidates may be identified during development or after approval, which could lead to the discontinuation of our clinical development programs, refusal by regulatory authorities to approve our product candidates or, if discovered following marketing approval, revocation of marketing authorizations or limitations on the use of our product candidates thereby limiting the commercial potential of such product candidate.</font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As we develop our product candidates and initiate clinical trials of our additional product candidates, serious adverse events, or SAEs, undesirable side effects, relapse of disease or unexpected characteristics may emerge causing us to abandon these product candidates or limit their development to more narrow uses or subpopulations in which the SAEs or undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective or in which efficacy is more pronounced or durable. Should we observe SAEs in our clinical trials or identify other undesirable side effects or other unexpected findings depending on their severity, our trials could be delayed or even stopped and our development programs may be halted entirely.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if our product candidates initially show promise in early clinical trials, the side effects of biological products are frequently only detectable after they are tested in larger, longer and more extensive clinical trials or, in some cases, after they are made available to patients on a commercial scale after approval. Sometimes, it can be difficult to determine if the serious adverse or unexpected side effects were caused by the product candidate or another factor, especially in oncology subjects who may suffer from other medical conditions and be taking other medications. If serious adverse or unexpected side effects are identified during development or after approval and are determined to be attributed to our product candidate, we may be required to develop a REMS to ensure that the benefits of treatment with such product candidate outweigh the risks for each potential patient, which may include, among other things, a communication plan to health care practitioners, patient education, extensive patient monitoring or distribution systems and processes that are highly controlled, restrictive and more costly than what is typical for the industry. Product-related side effects could also result in potential product liability claims. Any of these occurrences may harm our business, financial condition and prospects significantly.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, if one or more of our product candidates receives marketing approval, and we or others later identify undesirable side effects or ADA caused by such products, a number of potentially significant negative consequences could result, including:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">regulatory authorities may suspend, withdraw or limit approvals of such product, or seek an injunction against its manufacture or distribution;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">regulatory authorities may require additional warnings on the label, including &#8220;boxed&#8221; warnings, or issue safety alerts, Dear Healthcare Provider letters, press releases or other communications containing warnings or other safety information about the product;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">we may be required to create a medication guide outlining the risks of such side effects for distribution to patients;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">we may be required to change the way a product is administered or conduct additional clinical trials;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the product may become less competitive, and our reputation may suffer;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">we may decide to remove the product from the marketplace; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">we may be subject to fines, injunctions or the imposition of civil or criminal penalties.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Interim, topline and preliminary data from our clinical trials may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, we may publicly disclose preliminary, interim or topline data from our preclinical studies and clinical trials, which is based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change as patient enrollment and treatment continues and more patient data become available. Adverse differences between previous preliminary or interim data and future interim or final data could significantly harm our business prospects. We may also announce topline data following the completion of a preclinical study or clinical trial, which may be subject to change following a more comprehensive review of the data related to the particular study or trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the interim, topline or preliminary results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:10pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and fully evaluated. Topline data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, interim, topline and preliminary data should be viewed with caution until the final data are available.</font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and our company in general. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine to be material or otherwise appropriate information to include in our disclosure, and any information we determine not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views, activities or otherwise regarding a particular product candidate or our business. If the interim, topline, or preliminary data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for and commercialize our product candidates, our business, operating results, prospects or financial condition may be harmed.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Disruptions at the FDA and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire, retain or deploy key leadership and other personnel, or otherwise prevent new or modified products from being developed, or approved or commercialized in a timely manner or at all, which could negatively impact our business.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, statutory, regulatory, and policy changes, the FDA&#8217;s ability to hire and retain key personnel and accept the payment of user fees, and other events that may otherwise affect the FDA&#8217;s ability to perform routine functions. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. Disruptions at the FDA and other agencies may also slow the time necessary for new biologics to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, including for 35 days beginning on December 22, 2018, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA employees and stop critical activities.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Separately, in response to the global COVID-19 pandemic, on March 10, 2020 the FDA announced its intention to postpone most foreign inspections of manufacturing facilities and products, and on March 18, 2020, the FDA announced its intention to temporarily postpone routine surveillance inspections of domestic manufacturing facilities. Subsequently, on July 10, 2020 the FDA announced its intention to resume certain on-site inspections of domestic manufacturing facilities subject to a risk-based prioritization system. The FDA intends to use this risk-based assessment system to identify the categories of regulatory activity that can occur within a given geographic area, ranging from mission critical inspections to resumption of all regulatory activities. Regulatory authorities outside the United States may adopt similar restrictions or other policy measures in response to the COVID-19 pandemic. If a prolonged government shutdown occurs, or if global health concerns continue to prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because we have limited financial and managerial resources, we must prioritize our research programs and will need to focus our discovery and development on select product candidates and indications. Correctly prioritizing our research and development activities is particularly important for us due to the breadth of potential product candidates and indications that we believe could be pursued using our platform technologies. As a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:10pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">products. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may also relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate.</font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may not be successful in our efforts to identify or discover additional product candidates in the future.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our research programs may initially show promise in identifying potential product candidates, yet fail to yield product candidates for clinical development for a number of reasons, including:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">our inability to design such product candidates with the properties that we desire; or</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">potential product candidates may, on further study, be shown to have harmful side effects or other characteristics that indicate that they are unlikely to be products that will receive marketing approval and achieve market acceptance.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research programs to identify new product candidates require substantial technical, financial and human resources. If we are unable to identify suitable additional candidates for preclinical and clinical development, our opportunities to successfully develop and commercialize therapeutic products will be limited.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:-0.2pt;text-transform:none;font-variant: normal;">The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time consuming, expensive, and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for THIO or any other candidates, our business will be substantially harmed.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The time required to obtain approval by the FDA and comparable foreign authorities is unpredictable but typically takes many years following the commencement of clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory authorities. In addition, approval policies, regulations or the type and amount of clinical data necessary to gain approval may change during the course of a candidate&#8217;s clinical development and may vary among jurisdictions. We have not obtained regulatory approval for any product candidate and it is possible that we will never obtain regulatory approval for THIO or any other candidates. We are not permitted to market any of our product candidates in the United States until we receive regulatory approval of a NDA from the FDA. Our ability to obtain approval by the FDA or other regulatory authorities can be adversely impacted for various reasons including:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="letter-spacing:0.2pt;">we may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that a candidate is safe and effective for its proposed indication;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="letter-spacing:0.2pt;">serious and unexpected drug-related side effects experienced by participants in our clinical trials or by individuals using drugs similar to our candidates, or other products containing the active ingredient in our candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="letter-spacing:0.2pt;">negative or ambiguous results from our clinical trials or results that may not meet the level of statistical significance required by the FDA or comparable foreign regulatory authorities for approval;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>we may be unable to demonstrate that a candidate&#8217;s clinical and other benefits outweigh its safety risks;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="letter-spacing:0.2pt;">the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="letter-spacing:0.2pt;">the data collected from clinical trials of our development candidates may not be acceptable or sufficient to support the submission of an NDA or other submission or to obtain regulatory approval in the United States or elsewhere, and we may be required to conduct additional clinical trials;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="letter-spacing:0.2pt;">the FDA or comparable foreign authorities may disagree regarding the formulation, labeling and/or the specifications of our candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="letter-spacing:0.2pt;">the FDA or comparable foreign regulatory authorities may fail to approve or find deficiencies with the manufacturing processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="letter-spacing:0.2pt;">the FDA or comparable foreign regulatory authorities may inspect and find deficiencies at the clinical trial sites we use to conduct our clinical studies; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval.</p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8203;</font><font style="letter-spacing:0.2pt;">Prior to obtaining approval to commercialize a candidate in the United States or abroad, we must demonstrate with substantial evidence from well-controlled clinical trials, and to the satisfaction of the FDA or foreign regulatory agencies, that such candidates are safe and effective for their intended uses. Results from preclinical studies and clinical trials can be interpreted in different ways. Even if we believe the preclinical or clinical data for our candidates are promising, such data may not be sufficient to support approval by the FDA and other regulatory authorities. The planned THIO-101 phase 2 trial is intended to be a proof-of-concept trial that may be expanded depending on interim results and includes both primary and secondary endpoints consistent with previously approved medicines. If THIO achieves its intended effects and does not exhibit unacceptable safety risks, we plan to seek accelerated approval of THIO based on positive results of the expanded phase 2 THIO-101 trial, followed by full approval based on the results of a single phase 3 clinical study, as opposed to the traditional approach of conducting two or more phase 3 studies. </font><font style="color:#000000;">Even if granted, accelerated approval status does not guarantee an accelerated review or marketing approval by</font><font style="color:#000000;"> the</font><font style="color:#000000;"> FDA.</font><font style="letter-spacing:0.2pt;"> </font><font style="letter-spacing:0.2pt;">A single-study approach is permissible in certain circumstances, particularly in oncology, but such circumstances are exceptional and FDA may not agree with that proposed approach, and thus we may be required to conduct two phase 3 trials.</font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA or any foreign regulatory bodies can delay, limit or deny approval of our candidates or require us to conduct additional preclinical or clinical testing or abandon a program for many reasons, including:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="letter-spacing:0.2pt;">the FDA or comparable foreign regulatory authorities may disagree with the adequacy of the design or implementation of our clinical trials;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="letter-spacing:0.2pt;">the FDA or comparable foreign regulatory authorities may disagree with our safety interpretation of our drug;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="letter-spacing:0.2pt;">the FDA or comparable foreign regulatory authorities may disagree with our efficacy interpretation of our drug; or</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="letter-spacing:0.2pt;">the FDA or comparable foreign regulatory authorities may regard our CMC package as inadequate, and more particularly:</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="letter-spacing:0.2pt;">if our NDA does not include adequate tests by all methods reasonably applicable to show whether or not such drug is safe for use under the conditions prescribed, recommended, or suggested in the proposed labeling thereof;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="letter-spacing:0.2pt;">if the results of such tests show that such drug is unsafe for use under such conditions or do not show that such drug is safe for use under such conditions;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="letter-spacing:0.2pt;">if the methods used in, and the facilities and controls used for, the manufacture, processing, and packing of such drug are inadequate to preserve its identity, strength, quality, and purity;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="letter-spacing:0.2pt;">if the FDA determines that it has insufficient information to determine whether such drug is safe for use under such conditions;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>if based on information we submit and any other information before the FDA, the FDA determines there is a lack of substantial evidence that the drug will have the effect it purports or is represented to have under the conditions of use prescribed, recommended, or suggested in the proposed labeling thereof; or</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="letter-spacing:0.2pt;">if the FDA determines that our labeling is false or misleading in any particular way.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Of the large number of drugs that enter clinical development, only a small percentage successfully complete the regulatory approval processes and are approved and commercialized. This lengthy approval process, as well as the unpredictability of future clinical trial results, may result in our failing to obtain regulatory approval to market THIO or any other candidates, which would significantly harm our business, results of operations and prospects.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the FDA or an applicable foreign regulatory agency also may approve a product candidate for a more limited indication or patient population than we originally requested, the FDA or foreign regulatory agency may approve a product candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate, or may require warnings, other safety-related labeling information, or impose post-market safety requirements, including distribution restrictions, that negatively impact the commercial potential of the drug. Any of the foregoing scenarios could materially harm the commercial prospects for our product candidates.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:-0.2pt;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:-0.2pt;text-transform:none;font-variant: normal;">Enrollment and retention of patients in clinical trials is an expensive and time-consuming process and could be made more difficult or rendered impossible by multiple factors outside our control.</font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The timely completion of clinical trials in accordance with their protocols depends, among other things, on our ability to enroll a sufficient number of patients who remain in the study until its conclusion. We may encounter delays in enrolling, or be unable to enroll, a sufficient number of patients to complete any of our clinical trials, and even once enrolled, we may be unable to retain a sufficient number of patients to complete any of our trials. Patient enrollment and retention in clinical trials depends on many factors, including:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="letter-spacing:0.2pt;">the patient eligibility criteria defined in the protocol;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="letter-spacing:0.2pt;">the size of the patient population required for analysis of the trial&#8217;s primary endpoints;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="letter-spacing:0.2pt;">the nature of the trial protocol;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="letter-spacing:0.2pt;">the existing body of safety and efficacy data with respect to the product candidate;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="letter-spacing:0.2pt;">the proximity of patients to clinical sites;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="letter-spacing:0.2pt;">our ability to recruit clinical trial investigators with the appropriate competencies and experience;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="letter-spacing:0.2pt;">clinicians&#8217; and patients&#8217; perceptions as to the potential advantages of the product candidate being studied in relation to other available therapies, including any new drugs that may be approved for the indications we are investigating;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="letter-spacing:0.2pt;">competing clinical trials being conducted by other companies or institutions;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="letter-spacing:0.2pt;">our ability to maintain patient consents;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="letter-spacing:0.2pt;">the risk that patients enrolled in clinical trials will drop out of the trials before completion; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>delays or difficulties in enrollment and completion of studies due to the COVID 19 pandemic.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:-0.2pt;text-transform:none;font-variant: normal;">Results of preclinical studies, early clinical trials or analyses may not be indicative of results obtained in later trials.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The results of preclinical studies, early clinical trials or analyses of our product candidates may not be predictive of the results of later-stage clinical trials. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy traits despite having progressed through preclinical studies and initial clinical trials. A number of companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or adverse safety profiles, notwithstanding promising results in earlier trials. In addition, conclusions based on promising data from analyses of clinical results may be shown to be incorrect when implemented in prospective clinical trials. Even if our clinical trials for THIO are completed as planned, we cannot be certain that their results will support the safety and efficacy sufficient to obtain regulatory approval.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Serious adverse events or undesirable side effects caused by THIO or any other candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or other comparable foreign authorities. Results of any clinical trial we conduct could reveal a high and unacceptable severity and prevalence of side effects or unexpected characteristics. <font style="color:#000000;">THIO has been previously evaluated in at least 19 clinical studies both as monotherapy and in combination with other therapies in multiple solid tumors and hematologic malignancies. A classic treatment strategy was used where patients were treated to maximum tolerated dose (MTD).</font> <font style="color:#000000;">Dose-limiting reversible toxicities were mainly hematologic (leukopenia, thrombocytopenia), gastrointestinal (nausea, vomiting) and generalized skin rashes; increases in blood urea nitrogen, creatinine, aspartate aminotransferase, alanine transaminase, and bilirubin were also recorded (Douglass, 1979; Gagliano, 1981; Higgins, 1985)</font><font style="color:#0000FF;">.</font> <font style="color:#000000;">The available data provides substantial information on the safety profile of THIO in over 600 subjects (adult and pediatric) at doses significantly higher than those intended for investigation in the current program.</font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If unacceptable side effects arise in the development of our candidates, we, the FDA or the IRBs at the institutions in which our studies are conducted, or the DSMB, if constituted for our clinical trials, could recommend a suspension or termination of our clinical trials, or the FDA or comparable foreign regulatory authorities could order us to cease further development of or deny approval of a product candidate for any or all targeted indications. In addition, drug-related side effects could affect patient recruitment or the ability of enrolled patients to complete a trial or result in potential product liability claims. In addition, these side effects may not be appropriately recognized or managed by the treating medical staff. We expect to have to train medical personnel using our development candidates to understand the side effect profiles for our clinical trials </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:10pt;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and upon any commercialization of any of our product candidates. Inadequate training in recognizing or managing the potential side effects of our product candidates could result in patient injury or death. Any of these occurrences may harm our business, financial condition and prospects significantly.</font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, if one or more of our product candidates receives marketing approval, and we or others later identify undesirable side effects caused by such products, a number of potentially significant negative consequences could result, including:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="letter-spacing:0.2pt;">regulatory authorities may withdraw approvals of such product;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="letter-spacing:0.2pt;">regulatory authorities may require additional warnings on the label, such as a &#8220;black box&#8221; warning or contraindication;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="letter-spacing:0.2pt;">additional restrictions may be imposed on the marketing of the particular product or the manufacturing processes for the product or any component thereof;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="letter-spacing:0.2pt;">we may be required to implement a Risk Evaluation and Mitigation Strategy, or REMS, or create a medication guide outlining the risks of such side effects for distribution to patients;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="letter-spacing:0.2pt;">we could be sued and held liable for harm caused to patients;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="letter-spacing:0.2pt;">the product may become less competitive; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>our reputation may suffer.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any of these events could prevent us from achieving or maintaining market acceptance of a product candidate, if approved, and could significantly harm our business, results of operations and prospects.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:-0.2pt;text-transform:none;font-variant: normal;">The market opportunities for THIO, if approved, may be smaller than we anticipate.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect to initially seek approval for THIO for use as a priming treatment in combination with the immune check point inhibitor cemiplimab in non-small cell lung cancer (&#8220;NSCLC&#8221;) in the United States. Our estimates of market potential have been derived from a variety of sources, including scientific literature, patient foundations and primary and secondary market research, and may prove to be incorrect. Even if we obtain significant market share for any product candidate, if approved, if the potential target populations are small, we may never achieve profitability without obtaining marketing approval for additional indications.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:-0.2pt;text-transform:none;font-variant: normal;">We have never obtained marketing approval for a development candidate and we may be unable to obtain, or may be delayed in obtaining, marketing approval for any of our development candidates.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have never obtained marketing approval for a product candidate. It is possible that the FDA may refuse to accept for substantive review any NDAs that we submit for our development candidates or may conclude after review of our data that our application is insufficient to obtain marketing approval of our development candidates. If the FDA does not accept or approve our NDAs for our development candidates, it may require that we conduct additional clinical, preclinical or manufacturing validation studies and submit that data before it will reconsider our applications. Depending on the extent of these or any other FDA-required studies, approval of any NDA that we submit may be delayed or may require us to expend more resources than we have available. It is also possible that additional studies, if performed and completed, may not be considered sufficient by the FDA to approve our NDAs.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any delay in obtaining, or an inability to obtain, marketing approvals would prevent us from commercializing our development candidates, generating revenues and achieving and sustaining profitability. If any of these outcomes occur, we may be forced to abandon our development efforts for our product candidates, which could significantly harm our business.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;text-transform:none;font-variant: normal;">Development of THIO could take longer, be more expensive, or become impractical if the FDA requires the use of an FDA-approved companion diagnostic test in conjunction with treatment with THIO.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">THIO is active in cells that are telomerase positive (TERT+). The status of a tumor as being TERT+ can only be established by use of an in vitro test of the tumor cells. While experimental versions of such tests currently exist, none to date have received FDA approval. Under current FDA Guidances, for drugs and therapeutic biologics where the use of a specific diagnostic test is essential for the safe and effective use of the therapeutic product, such as when the use of a product is limited to a specific patient subpopulation that can be identified by using the test, the FDA </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:10pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">generally will not approve the therapeutic product if a relevant &#8220;companion diagnostic&#8221; test is not also approved or cleared for the appropriate indication. As stated in its Guidances, the FDA may decide that it is appropriate to approve such a therapeutic product without an approved or cleared </font><font style="font-style:italic;">in vitro </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">companion diagnostic device when the drug or therapeutic biologic is intended to treat a serious or life-threatening condition for which no satisfactory alternative treatment exists and the FDA determines that the benefits from the use of a product with an unapproved or uncleared </font><font style="font-style:italic;">in vitro </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">companion diagnostic device are so pronounced as to outweigh the risks from the lack of an approved or cleared </font><font style="font-style:italic;">in vitro </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">companion diagnostic device. Although the vast majority of cancers are TERT+, the FDA may determine that THIO can only be approved (if at all) for patients whose cancer has been confirmed to be TERT+ through use of an FDA-approved companion diagnostic. If the FDA were to take such a position, the development and potential approval and commercialization of THIO would take longer, be more expensive, and could become impractical. </font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:-0.2pt;text-transform:none;font-variant: normal;">Even if we obtain FDA approval for THIO or any other candidates in the United States, we may never obtain approval for or commercialize THIO or any other development candidate in any other jurisdiction, which would limit our ability to realize their full global market potential.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In order to market any products in any particular jurisdiction, we must establish and comply with numerous and varying regulatory requirements on a country-by-country basis regarding safety and efficacy. Approval by the FDA in the United States does not ensure approval by regulatory authorities in other countries or jurisdictions. However, the failure to obtain approval in one jurisdiction may negatively impact our ability to obtain approval elsewhere. In addition, clinical trials conducted in one country may not be accepted by regulatory authorities in other countries, and regulatory approval in one country does not guarantee regulatory approval in any other country.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Approval processes vary among countries and can involve additional product testing and validation and additional administrative review periods. Seeking foreign regulatory approval could result in difficulties and increased costs for us and require additional preclinical studies or clinical trials which could be costly and time consuming. Regulatory requirements can vary widely from country to country and could delay or prevent the introduction of our products in those countries. We do not have any product candidates approved for sale in any jurisdiction, including in international markets, and we do not have experience in obtaining regulatory approval in international markets. If we fail to comply with regulatory requirements in international markets or to obtain and maintain required approvals, or if regulatory approvals in international markets are delayed, our target market will be reduced and our ability to realize the full market potential of any product we develop will be unrealized.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:-0.2pt;text-transform:none;font-variant: normal;">Even if we obtain regulatory approval for THIO or any development candidate, we will still face extensive and ongoing regulatory requirements and obligations and any development candidates, if approved, may face future development and regulatory difficulties.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any candidate for which we obtain marketing approval, along with the manufacturing processes, post-approval clinical data, labeling, packaging, distribution, adverse event reporting, storage, recordkeeping, export, import, advertising and promotional activities for such product, among other things, will be subject to extensive and ongoing requirements of and review by the FDA and other regulatory authorities. These requirements include submissions of safety and other post-marketing information and reports, establishment registration and drug listing requirements, continued compliance with current Good Manufacturing Practice, or cGMP, requirements relating to manufacturing, quality control, quality assurance and corresponding maintenance of records and documents, requirements regarding the distribution of samples to physicians and recordkeeping and Good Clinical Practice, or GCP, requirements for any clinical trials that we conduct post-approval.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if marketing approval of a product candidate is granted, the approval may be subject to limitations on the indicated uses for which the product candidate may be marketed or to the conditions of approval, including a requirement to implement a REMS. If any of our product candidates receive marketing approval, the accompanying label may limit the approved indicated use of the product candidate, which could limit sales of the product candidate. The FDA may also impose requirements for costly post-marketing studies or clinical trials and surveillance to monitor the safety or efficacy of a product. The FDA closely regulates the post-approval marketing and promotion of drugs to ensure drugs are marketed only for the approved indications and in accordance with the provisions of the approved labeling. The FDA imposes stringent restrictions on </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:10pt;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">manufacturers&#8217; communications regarding off-label use, and if we market our products for uses beyond their approved indications, we may be subject to enforcement action for off-label marketing. Violations of the Federal Food, Drug, and Cosmetic Act, or FDCA, relating to the promotion of prescription drugs may lead to FDA enforcement actions and investigations alleging violations of federal and state healthcare fraud and abuse laws, as well as state consumer protection laws.</font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, later discovery of previously unknown adverse events or other problems with our products, manufacturers or manufacturing processes or failure to comply with regulatory requirements, may yield various results, including:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="letter-spacing:0.2pt;">restrictions on manufacturing such products;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="letter-spacing:0.2pt;">restrictions on the labeling or marketing of products;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="letter-spacing:0.2pt;">restrictions on product distribution or use;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="letter-spacing:0.2pt;">requirements to conduct post-marketing studies or clinical trials;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="letter-spacing:0.2pt;">warning letters or untitled letters;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="letter-spacing:0.2pt;">withdrawal of the products from the market;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="letter-spacing:0.2pt;">refusal to approve pending applications or supplements to approved applications that we submit;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="letter-spacing:0.2pt;">recall of products;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="letter-spacing:0.2pt;">fines, restitution or disgorgement of profits or revenues;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="letter-spacing:0.2pt;">suspension or withdrawal of marketing approvals;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="letter-spacing:0.2pt;">refusal to permit the import or export of our products;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="letter-spacing:0.2pt;">product seizure; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>injunctions or the imposition of civil or criminal penalties.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, the FDA&#8217;s policies may change, and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained, which would adversely affect our business, prospects and ability to achieve or sustain profitability. We also cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:-0.2pt;text-transform:none;font-variant: normal;">We may seek a Breakthrough Therapy designation for THIO from the FDA. However, we might not seek such designation or be granted the designation by the FDA if sought, and even if we are granted the designation, it may not lead to a faster development or regulatory review or approval process.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:-0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may seek a Breakthrough Therapy designation for THIO or one or more of our other candidates. Breakthrough Therapy designation is a process designed to expedite the development and review of drugs that are intended to treat a serious condition and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over available therapy on a clinically significant endpoint(s). For purposes of Breakthrough Therapy designation, clinically significant endpoint generally refers to an endpoint that measures an effect on irreversible morbidity or mortality (IMM) or on symptoms that represent serious consequences of the disease. A clinically significant endpoint can also refer to findings that suggest an effect on IMM or serious symptoms. For drugs that have been designated as breakthrough therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. Drugs designated as breakthrough therapies by the FDA may also be eligible for fast track designation (under a separate request), priority review, or accelerated approval, if supported by clinical data at the time the NDA is submitted to the FDA. FDA encourages a Breakthrough Therapy designation request to be submitted, and received by FDA, no later than the end-of-phase-2 meetings. <font style="color:#000000;">Even if granted, accelerated approval status does not guarantee an accelerated review or marketing approval by the FDA.</font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:-0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Designation as a Breakthrough Therapy is within the discretion of the FDA both at the time of the submission of such a request, and during FDA&#8217;s review of the drug and supporting data. Even if we believe that one of our candidates meets the criteria for designation as a Breakthrough Therapy, the FDA may disagree and instead determine not to make such designation or may grant such a designation and subsequently rescind the designation prior to approval. Even if we receive and maintain Breakthrough Therapy designation, the receipt of such designation for a product candidate may not result in </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:10pt;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:-0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:-0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a faster development or regulatory review or approval process compared to drugs considered for approval under conventional FDA procedures and does not assure ultimate approval by the FDA. In addition, even if one or more of our product candidates qualify as breakthrough therapies, the FDA may later decide that the product candidates no longer meet the conditions for qualification or decide that the time period for FDA review or approval will not be shortened.</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:-0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Potential product liability lawsuits against us could cause us to incur substantial liabilities and limit commercialization of any products that we may develop.</font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The use of THIO or any other candidates we may develop in clinical trials and the sale of any products for which we obtain marketing approval exposes us to the risk of product liability claims. Product liability claims might be brought against us by patients, healthcare providers, pharmaceutical companies or others selling or otherwise coming into contact with our products. On occasion, large judgments have been awarded in class action lawsuits based on drugs that had unanticipated adverse effects. If we cannot successfully defend against product liability claims, we could incur substantial liability and costs. In addition, regardless of merit or eventual outcome, product liability claims may result in:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>impairment of our business reputation and significant negative media attention;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>withdrawal of participants from our clinical trials;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>significant costs to defend the litigation;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>distraction of management&#8217;s attention from our primary business;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>substantial monetary awards to patients or other claimants;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>inability to commercialize THIO or any other product candidate;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>product recalls, withdrawals or labeling, marketing or promotional restrictions;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>decreased market demand for any product; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>loss of revenue.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The product liability insurance coverage we plan to acquire in the future may not be sufficient to reimburse us for any expenses or losses we may suffer. We intend to acquire insurance coverage to include larger clinical studies, different countries and the potential sale of commercial products; however, we may be unable to obtain product liability insurance on commercially reasonable terms or in adequate amounts. A successful product liability claim, or series of claims, brought against us could cause our share price to decline and, if judgments exceed our insurance coverage, could adversely affect the results of our operations and business, including preventing or limiting the commercialization of any product candidates we develop.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Commercialization</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:-0.2pt;text-transform:none;font-variant: normal;">We face significant competition from other biotechnology and pharmaceutical companies and our operating results will suffer if we fail to compete effectively.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The biopharmaceutical and pharmaceutical industries are highly competitive and subject to significant and rapid technological change. Our success is highly dependent on our ability to acquire, develop, and obtain marketing approval for new products on a cost-effective basis and to market them successfully. If THIO is approved, we will face intense competition from a variety of businesses, including large, fully integrated pharmaceutical companies, specialty pharmaceutical companies and biopharmaceutical companies in the United States and other jurisdictions. These organizations may have significantly greater resources than we do and may conduct similar research; seek patent protection; and establish collaborative arrangements for research, development, manufacturing and marketing of products that may compete with us.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our competitors may, among other things:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="letter-spacing:0.2pt;">have significantly greater name recognition, financial, manufacturing, marketing, drug development, technical, and human resources than we do, and future mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even more resources being concentrated in our competitors;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="letter-spacing:0.2pt;">develop and commercialize products that are safer, more effective, less expensive, more convenient, or easier to administer, or have fewer or less severe effects;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>obtain quicker regulatory approval;</p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</a></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;"></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>implement more effective approaches to sales and marketing; or</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>form more advantageous strategic alliances.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Smaller and other early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These third parties compete with us in recruiting and retaining qualified scientific and management personnel; establishing clinical trial sites and patient registration; and in acquiring technologies complementary to, or necessary for, our programs. Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are more effective, have fewer or less severe side effects, or are more convenient or are less expensive than THIO. Our competitors may also obtain FDA or other regulatory approval for their product candidates more rapidly than we may obtain approval for THIO, which could result in our competitors establishing or strengthening their market position before we are able to enter the market.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:-0.2pt;text-transform:none;font-variant: normal;">We may face early generic competition for THIO or our other products.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pharmaceutical companies developing novel products face intense competition from generic drug manufacturers who aggressively seek to challenge patents and non-patent exclusivities for branded products, and who are able to use much less-onerous product development and FDA approval pathways for their generic products. The active ingredient of THIO was extensively tested as early as the 1970s and we intend to rely in part on the clinical data previously developed for the drug in support of an NDA for THIO. Generic drug applicants and other competitors may be able to similarly rely upon the prior clinical data in support of efforts to gain approval of competing products using the same active ingredient as THIO. If one or more such competitors complete development and seek and obtain regulatory approval before we do, our ability to obtain approval of and market THIO may be delayed. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the FDA&#8217;s generic drug approval processes, described in more detail in the section titled &#8220;Hatch-Waxman and Generic Competition,&#8221; we believe that THIO, if approved before any other application for a drug containing the same active ingredient, may be eligible for a five-year regulatory exclusivity period known as new chemical entity, or NCE Exclusivity, which would delay FDA review and approval of a competing product application that relies in whole or in part upon the FDA&#8217;s approval of THIO, but such exclusivity is only determined by the FDA after a drug is approved and the FDA may determine that THIO is not eligible for NCE Exclusivity, or that approval of THIO must be delayed due to another applicant&#8217;s relevant exclusivity. A new drug may, upon approval of its initial NDA or approval of supplemental NDAs, qualify for a three-year exclusivity period during which no generic version could be approved for the specific conditions of use covered by such exclusivity. Three-year exclusivity does not prevent FDA approval of another drug with the same active ingredient for a different indication or other conditions of use not protected by the exclusivity. Even if a competing version of THIO was approved with a different indication or condition of use, physicians would be free to prescribe such drug for uses that are covered by our regulatory exclusivity, if any. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:-0.2pt;text-transform:none;font-variant: normal;">The successful commercialization of THIO and any other candidate we develop will depend in part on the extent to which governmental authorities and health insurers establish adequate coverage, reimbursement levels, and pricing policies. Failure to obtain or maintain coverage and adequate reimbursement for our candidates, if approved, could limit our ability to market those products and decrease our ability to generate revenue.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The availability and adequacy of coverage and reimbursement by governmental healthcare programs such as Medicare and Medicaid, private health insurers and other third-party payors are essential for most patients to be able to afford prescription medications such as THIO, if approved. Our ability to achieve acceptable levels of coverage and reimbursement for products by governmental authorities, private health insurers and other organizations will have an effect on our ability to successfully commercialize our drug and any other product candidates we develop. Assuming we obtain coverage for our product candidates by a third-party payor, the resulting reimbursement payment rates may not be adequate or may require co-payments that patients find unacceptably high. We cannot be sure that coverage and reimbursement in the United States or elsewhere will be available for our product candidates or any product that we may develop, and any reimbursement that may become available may be decreased or eliminated in the future.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There is significant uncertainty related to the insurance coverage and reimbursement of newly approved products. In the United States, third-party payors, including private and governmental payors, such as the </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:10pt;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Medicare and Medicaid programs, play an important role in determining the extent to which new drugs and biologics will be covered. The Medicare and Medicaid programs increasingly are used as models in the United States for how private payors and other governmental payors develop their coverage and reimbursement policies for drugs and biologics. Some third-party payors may require pre-approval of coverage for new or innovative devices or drug therapies before they will reimburse healthcare providers who use such therapies. It is difficult to predict at this time what third-party payors will decide with respect to the coverage and reimbursement for our product candidates.</font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">No<font style="letter-spacing:0.2pt;"> uniform policy for coverage and reimbursement for products exists among third-party payors in the United States. Therefore, coverage and reimbursement for products can differ significantly from payor to payor. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our product candidates to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. Furthermore, rules and regulations regarding reimbursement change frequently, in some cases at short notice, and we believe that changes in these rules and regulations are likely.</font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Third-party payors increasingly are challenging prices charged for pharmaceutical products and services, and many third-party payors may refuse to provide coverage and reimbursement for particular drugs or biologics when a comparable alternative drug, an equivalent generic drug, a biosimilar, or a less expensive therapy is available. It is possible that a third-party payor may consider our product candidates as alternatives to less expensive drugs and offer to reimburse patients only for the less expensive product. Even if we show improved efficacy or improved convenience of administration with our product candidates, pricing of existing drugs may limit the amount we will be able to charge for our product candidates. These payors may deny or revoke the reimbursement status of a given product or establish prices for new or existing marketed products at levels that are too low to enable us to realize an appropriate return on our investment in our product candidates. If reimbursement is not available or is available only at limited levels, we may not be able to successfully commercialize our product candidates and may not be able to obtain a satisfactory financial return on our product candidates.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may also be subject to extensive governmental price controls and other market regulations outside of the United States, and we believe the increasing emphasis on cost-containment initiatives in other countries have and will continue to put pressure on the pricing and usage of medical products. In many countries, the prices of medical products are subject to varying price control mechanisms as part of national health systems. Other countries allow companies to fix their own prices for medical products but monitor and control company profits.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additional foreign price controls or other changes in pricing regulation could restrict the amount that we are able to charge for our product candidates. Accordingly, in markets outside the United States, the reimbursement for our product candidates may be reduced compared with the United States and may be insufficient to generate commercially reasonable revenue and profits.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, increasing efforts by governmental and third-party payors in the United States to cap or reduce healthcare costs may cause such organizations to limit both coverage and the level of reimbursement for newly approved products and, as a result, they may not cover or provide adequate payment for our product candidates. We expect to experience pricing pressures in connection with the sale of our product candidates due to the trend toward managed health care, the increasing influence of health maintenance organizations and additional legislative changes. The downward pressure on healthcare costs in general, particularly prescription drugs and biologics and surgical procedures and other treatments, has become intense. As a result, increasingly high barriers are being erected to the entry of new products.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:-0.2pt;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:-0.2pt;text-transform:none;font-variant: normal;">Even if THIO or any candidate we develop receives marketing approval, it may fail to achieve market acceptance by physicians, patients, third-party payors or others in the medical community necessary for commercial success.</font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If THIO or any candidate we develop receives marketing approval, it may nonetheless fail to gain sufficient market acceptance by physicians, patients, third-party payors and others in the medical community. If it does not achieve an adequate level of acceptance, we may not generate significant product revenues or become profitable. The degree of market acceptance of our product candidates, if approved, will depend on a number of factors, including but not limited to:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="letter-spacing:0.2pt;">the efficacy and potential advantages compared to alternative treatments;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="letter-spacing:0.2pt;">effectiveness of sales and marketing efforts;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="letter-spacing:0.2pt;">the cost of treatment in relation to alternative treatments, including any similar generic treatments;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="letter-spacing:0.2pt;">our ability to offer our products for sale at competitive prices;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="letter-spacing:0.2pt;">the convenience and ease of administration compared to alternative treatments;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="letter-spacing:0.2pt;">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="letter-spacing:0.2pt;">the strength of marketing and distribution support;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="letter-spacing:0.2pt;">the availability of third-party coverage and adequate reimbursement;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="letter-spacing:0.2pt;">the prevalence and severity of any side effects; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>any restrictions on the use of our product together with other medications.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because we expect sales of our product candidates, if approved, to generate substantially all of our revenues for the foreseeable future, the failure of our product candidates to find market acceptance would harm our business and could require us to seek additional financing.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:-0.2pt;text-transform:none;font-variant: normal;">If we are unable to establish sales, marketing and distribution capabilities either on our own or in collaboration with third parties, we may not be successful in commercializing THIO, if approved.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not have any infrastructure for the sales, marketing or distribution of THIO, or compliance functions related to such activities, and the cost of establishing and maintaining such an organization may exceed the cost-effectiveness of doing so. In order to market and successfully commercialize our drug or any product candidate we develop, if approved, we must build our sales, distribution, marketing, managerial, compliance, and other non-technical capabilities or make arrangements with third parties to perform these services. We expect to build a focused sales, distribution and marketing infrastructure to market THIO, if approved, in the United States, with expected licenses in other countries and regions, including large markets such as Japan and Europe. There are significant expenses and risks involved with establishing our own sales, marketing and distribution capabilities, including our ability to hire, retain and appropriately incentivize qualified individuals, generate sufficient sales leads, provide adequate training to sales and marketing personnel, oversee the compliance of sales and marketing functions, and effectively manage a geographically dispersed sales and marketing team. Any failure or delay in the development of our internal sales, marketing, distribution and compliance capabilities could delay any product launch, which would adversely impact the commercialization of that product. For example, if the commercial launch of THIO for which we recruit a sales force and establish marketing capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. This may be costly, and our investment would be lost if we cannot retain or reposition our sales and marketing personnel.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Factors that may inhibit our efforts to commercialize our product candidates on our own include, but are not limited to:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>our inability to recruit, train and retain adequate numbers of effective sales and marketing personnel;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>the inability of sales personnel to obtain access to physicians or attain adequate numbers of physicians to prescribe our products; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>unforeseen costs and expenses associated with creating an independent sales and marketing organization.</p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not anticipate having the resources in the foreseeable future to allocate to the sales and marketing of our product candidates, if approved, in certain markets overseas. Therefore, our future success will depend, in part, on our ability to enter into and maintain collaborative relationships for such capabilities, the collaborator&#8217;s strategic interest in a product and such collaborator&#8217;s ability to successfully market and sell the product. We intend to pursue collaborative arrangements regarding the sale and marketing of THIO, if approved, for certain markets overseas; however, we cannot assure you that we will be able to establish or maintain such collaborative arrangements, or if able to do so, that they will have effective sales forces. To the extent that we depend on third parties for marketing and distribution, any revenues we receive will depend upon the efforts of such third parties, and there can be no assurance that such efforts will be successful.</font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we are unable to build our own sales force or negotiate a collaborative relationship for the commercialization of THIO, we may be forced to delay the potential commercialization of the drug or reduce the scope of our sales or marketing activities. If we need to increase our expenditures to fund commercialization activities for THIO we will need to obtain additional capital, which may not be available to us on acceptable terms, or at all. We may also have to enter into collaborative arrangements for THIO at an earlier stage than otherwise would be ideal and we may be required to relinquish rights to it or otherwise agree to terms unfavorable to us. Any of these occurrences may have an adverse effect on our business, operating results and prospects.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we are unable to establish adequate sales, marketing and distribution capabilities, either on our own or in collaboration with third parties, we will not be successful in commercializing our product candidates and may never become profitable. We will be competing with many companies that currently have extensive and well-funded marketing and sales operations. Without an internal team or the support of a third party to perform marketing and sales functions, we may be unable to compete successfully against these more established companies.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:-0.2pt;text-transform:none;font-variant: normal;">A variety of risks associated with operating internationally could materially adversely affect our business.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2021, we established a wholly owned Australian subsidiary, MAIA Biotechnology Australia Pty Ltd, to conduct various pre-clinical and clinical activities for the development of our product candidates and in April 2022, we established a wholly owned Romanian subsidiary, MAIA BIOTECHNOLOGY ROMANIA S.R.L. to conduct various preclinical and clinical activities for the development of our product candidates. Additionally, our business strategy includes potentially expanding further internationally if any of our product candidates receive regulatory approval. Doing business internationally involves a number of risks, including but not limited to:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>multiple, conflicting and changing laws and regulations, such as privacy regulations, tax laws, export and import restrictions, employment laws, regulatory requirements and other governmental approvals, permits and licenses;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>failure by us to obtain and maintain regulatory approvals for the use of our products in various countries;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>additional potentially relevant third-party patent rights;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>complexities and difficulties in obtaining protection and enforcing our intellectual property;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>difficulties in staffing and managing foreign operations;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>complexities associated with managing multiple payor reimbursement regimes, government payors or patient self-pay systems;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>limits in our ability to penetrate international markets;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>financial risks, such as longer payment cycles, difficulty collecting accounts receivable, the impact of local and regional financial crises on demand and payment for our products and exposure to foreign currency exchange rate fluctuations;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>natural disasters, political and economic instability, including wars, terrorism and political unrest, outbreak of disease, boycotts, curtailment of trade and other business restrictions;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>the expansion of the Russian military invasion of Ukraine;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>certain expenses including, among others, expenses for travel, translation and insurance; and</p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</a></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;"></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>regulatory and compliance risks that relate to maintaining accurate information and control over sales and activities that may fall within the purview of the U.S. Foreign Corrupt Practices Act, its books and records provisions, or its anti-bribery provisions.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any of these factors could significantly harm any future international expansion and operations and, consequently, our results of operations.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Our Dependence on Third Parties</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:-0.2pt;text-transform:none;font-variant: normal;">Our employees and independent contractors, including principal investigators, clinical trial sites, contract research organizations (&#8220;CROs&#8221;), consultants, vendors, and any third parties we may engage in connection with development and commercialization, may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could have a material adverse effect on our business.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our employees and independent contractors, including principal investigators, clinical trial sites, consultants, vendors and any third parties we may engage in connection with development and commercialization of our product candidates, could engage in misconduct, including intentional, reckless or negligent conduct or unauthorized activities that violate: the laws and regulations of the FDA or other similar regulatory requirements of other authorities, including those laws that require the reporting of true, complete and accurate information to such authorities; manufacturing standards; data privacy, security, fraud and abuse and other healthcare laws and regulations; or laws that require the reporting of true, complete and accurate financial information and data. Specifically, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Activities subject to these laws could also involve the improper use or misrepresentation of information obtained in the course of clinical trials, creation of fraudulent data in preclinical studies or clinical trials or illegal misappropriation of drug product, which could result in regulatory sanctions and cause serious harm to our reputation. It is not always possible to identify and deter misconduct by employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with such laws or regulations. Additionally, we are subject to the risk that a person or government could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and results of operations, including the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, disgorgements, possible exclusion from participation in Medicare, Medicaid, other U.S. federal healthcare programs or healthcare programs in other jurisdictions, individual imprisonment, other sanctions, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:-0.2pt;text-transform:none;font-variant: normal;">We currently rely on third-party contract manufacturing organizations, or CMOs, for the production of clinical supply of THIO and intend to rely on CMOs for the production of commercial supply of THIO, if approved. Our dependence on CMOs may impair the development and commercialization of the drug, which would adversely impact our business and financial position.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have limited personnel with experience in manufacturing, and we do not own facilities for manufacturing. Instead, we rely on and expect to continue to rely on CMOs for the supply of cGMP grade clinical trial materials and commercial quantities of THIO and any candidates we develop, if approved. Reliance on CMOs may expose us to more risk than if we were to manufacture our product candidates ourselves. We intend to have manufactured a sufficient clinical supply of THIO drug substance to enable us to complete our clinical trials, and we have also engaged a CMO to provide clinical and commercial supply of the drug product.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The facilities used to manufacture our product candidates must be inspected by the FDA and comparable foreign authorities. While we provide oversight of manufacturing activities, we do not and will not control the execution of manufacturing activities by, and are or will be essentially dependent on, our CMOs for compliance with cGMP requirements for the manufacture of our product candidates. As a result, we are subject to the risk that our product candidates may have manufacturing defects that we have limited ability to prevent. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:10pt;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If a CMO cannot successfully manufacture material that conforms to our specifications and the regulatory requirements, we will not be able to secure or maintain regulatory approval for the use of our product candidates in clinical trials, or for commercial distribution of our product candidates, if approved. In addition, we have limited control over the ability of our CMOs to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or comparable foreign regulatory authority finds deficiencies with or does not approve these facilities for the manufacture of our product candidates or if it withdraws any such approval or finds deficiencies in the future, we may need to find alternative manufacturing facilities, which would delay our development program and significantly impact our ability to develop, obtain regulatory approval for or commercialize our product candidates, if approved. In addition, any failure to achieve and maintain compliance with these laws, regulations and standards could subject us to the risk that we may have to suspend the manufacture of our product candidates or that obtained approvals could be revoked. Furthermore, CMOs may breach existing agreements they have with us because of factors beyond our control. They may also terminate or refuse to renew their agreement at a time that is costly or otherwise inconvenient for us. If we were unable to find an adequate CMO or another acceptable solution in time, our clinical trials could be delayed, or our commercial activities could be harmed.</font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We rely on and will continue to rely on CMOs to purchase from third-party suppliers the raw materials necessary to produce our product candidates. We do not and will not have control over the process or timing of the acquisition of these raw materials by our CMOs. Moreover, we currently do not have any agreements for the production of these raw materials. Supplies of raw material could be interrupted from time to time and we cannot be certain that alternative supplies could be obtained within a reasonable timeframe, at an acceptable cost, or at all. In addition, a disruption in the supply of raw materials could delay the commercial launch of our product candidates, if approved, or result in a shortage in supply, which would impair our ability to generate revenues from the sale of our product candidates. Growth in the costs and expenses of raw materials may also impair our ability to cost effectively manufacture our product candidates. There are a limited number of suppliers for the raw materials that we may use to manufacture our product candidates and we may need to assess alternative suppliers to prevent a possible disruption of the manufacture of our product candidates.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finding new CMOs or third-party suppliers involves additional cost and requires our management&#8217;s time and focus. In addition, there is typically a transition period when a new CMO commences work. Although we generally have not, and do not intend to, begin a clinical trial unless we believe we have on hand, or will be able to obtain, a sufficient supply of our product candidates to complete the clinical trial, any significant delay in the supply of our product candidates or the raw materials needed to produce our product candidates, could considerably delay conducting our clinical trials and potential regulatory approval of our product candidates.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As part of their manufacture of our product candidates, our CMOs and third-party suppliers are expected to comply with and respect the proprietary rights of others. If a CMO or third-party supplier fails to acquire the proper licenses or otherwise infringes the proprietary rights of others in the course of providing services to us, we may have to find alternative CMOs or third-party suppliers or defend against claims of infringement, either of which would significantly impact our ability to develop, obtain regulatory approval for or commercialize our product candidates, if approved.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:-0.2pt;text-transform:none;font-variant: normal;">We intend to rely on third parties to conduct, supervise and monitor our clinical trials. If those third parties do not successfully carry out their contractual duties, or if they perform in an unsatisfactory manner, it may harm our business.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We rely, and will continue to rely, on CROs, CRO-contracted vendors and clinical trial sites to ensure the proper and timely conduct of our clinical trials, including our Phase 2 trials of THIO. Our reliance on CROs for clinical development activities limits our control over these activities, but we remain responsible for ensuring that each of our trials is conducted in accordance with the applicable protocol and legal, regulatory and scientific standards.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We and our CROs will be required to comply with the good laboratory practice requirements for our preclinical studies and GCP requirements for our clinical trials, which are regulations and guidelines enforced by the FDA and are also required by comparable foreign regulatory authorities. Regulatory authorities enforce GCP requirements through periodic inspections of trial sponsors, principal investigators and clinical trial sites. If we or our CROs fail to comply with GCP requirements, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that upon </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:10pt;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials comply with GCP requirements. In addition, our clinical trials must be conducted with product produced under cGMP requirements. Accordingly, if our CROs fail to comply with these requirements, we may be required to repeat clinical trials, which would delay the regulatory approval process.</font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our CROs are not our employees, and we do not control whether or not they devote sufficient time and resources to our clinical trials. Our CROs may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials, or other drug development activities, which could harm our competitive position. We face the risk of potential unauthorized disclosure or misappropriation of our intellectual property by CROs, which may reduce our trade secret protection and allow our potential competitors to access and exploit our proprietary technology. If our CROs do not successfully carry out their contractual duties or obligations, fail to meet expected deadlines, or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory requirements or for any other reason, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain regulatory approval for, or successfully commercialize any product candidate that we develop. As a result, our financial results and the commercial prospects for any product candidate that we develop would be harmed, our costs could increase, and our ability to generate revenue could be delayed.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If our relationship with any CROs terminate, we may not be able to enter into arrangements with alternative CROs or do so on commercially reasonable terms. Switching or adding additional CROs involves substantial cost and requires management&#8217;s time and focus. In addition, there is a natural transition period when a new CRO commences work. As a result, delays occur, which can materially impact our ability to meet our desired clinical development timelines. Though we intend to carefully manage our relationships with our CROs, there can be no assurance that we will not encounter challenges or delays in the future or that these delays or challenges will not have an adverse impact on our business, financial condition and prospects.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;text-transform:none;font-variant: normal;">The number and type of our collaborations could adversely affect our attractiveness to future collaborators or acquirers and the loss of, or a disruption in our relationship with, any one or more collaborators could harm our business.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8203;<font style="letter-spacing:0.2pt;">If any collaborations do not result in the successful development and commercialization of products or if one of our collaborators terminates its agreement with us, we may not receive any future research and development funding or milestone or royalty payments under such collaborations. If we do not receive the funding we expect under these agreements, our continued development of our product candidates could be delayed, and we may need additional resources to develop additional product candidates. All of the risks relating to product development, regulatory approval and commercialization described in this prospectus also apply to the activities of any collaborators and there can be no assurance that our collaborations will produce positive results or successful products on a timely basis or at all.</font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, subject to its contractual obligations to us, if one of our collaborators is involved in a business combination or otherwise changes its business priorities, the collaborator might deemphasize or terminate the development or commercialization of our product candidates. If a collaborator terminates its agreement with us, we may find it more difficult to attract new collaborators and the perception of our business and our stock price could be adversely affected.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may in the future collaborate with additional pharmaceutical and biotechnology companies for development and potential commercialization of therapeutic products. We face significant competition in seeking appropriate collaborators. Our ability to reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#8217;s evaluation of a number of factors. If we are unable to reach agreements with suitable collaborators on a timely basis, on acceptable terms, or at all, we may have to curtail the development of a product candidate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to fund and undertake development or commercialization activities on our own, we may need to obtain additional expertise and additional capital, which may not be available to us on acceptable terms or at all. If we fail to enter into collaborations and do not </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:10pt;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">have sufficient funds or expertise to undertake the necessary development and commercialization activities, we may not be able to further develop our product candidates or bring them to market or continue to develop our programs, and our business may be materially and adversely affected.</font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Healthcare Laws and Other Legal Compliance Matters</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:-0.2pt;text-transform:none;font-variant: normal;">Enacted and future healthcare legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our development candidates, if approved, and may affect the prices we may set.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the United States and other jurisdictions, there have been, and we expect there will continue to be, a number of legislative and regulatory changes and proposed changes to the healthcare system that could affect our future results of operations. In particular, there have been and continue to be a number of initiatives at the U.S. federal and state levels that seek to reduce healthcare costs and improve the quality of healthcare. For example, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively the ACA, has substantially changed the way healthcare is financed by both governmental and private insurers. Among the provisions of the ACA, those of greatest importance to the pharmaceutical and biotechnology industries include the following:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>an annual, non-deductible fee payable by any entity that manufactures or imports certain branded prescription drugs and biologic agents (other than those designated as orphan drugs), which is apportioned among these entities according to their market share in certain government healthcare programs;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>&#8203;<font style="letter-spacing:0.2pt;">a Medicare Part D coverage gap discount program, in which manufacturers must agree to offer point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs to be covered under Medicare Part D;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="letter-spacing:0.2pt;">requirements to report certain financial arrangements with physicians and teaching hospitals, including reporting &#8220;transfers of value&#8221; made or distributed to prescribers and other healthcare providers and reporting investment interests held by physicians and their immediate family members;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>&#8203;<font style="letter-spacing:0.2pt;">an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>&#8203;a methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs and biologics that are inhaled, infused, instilled, implanted, or injected;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>&#8203;extension of a manufacturer&#8217;s Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>expansion of eligibility criteria for Medicaid programs thereby potentially increasing a manufacturer&#8217;s Medicaid rebate liability;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>&#8203;a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>&#8203;establishment of a Center for Medicare Innovation at the Centers for Medicare &amp; Medicaid Services, or CMS, to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>&#8203;expansion of the entities eligible for discounts under the Public Health Service program; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>&#8203;a licensure framework for follow on biologic products.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8203;<font style="letter-spacing:0.2pt;">Since its enactment, there have been judicial and Congressional challenges to certain aspects of the ACA, and we expect there will be additional challenges and amendments to the ACA in the future. It is uncertain the extent to which any such changes may impact our business or financial condition.</font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other legislative changes have been proposed and adopted in the United States since the ACA was enacted. For example, the Budget Control Act of 2011, resulted in aggregate reductions of Medicare payments to providers of 2% per fiscal year. These reductions went into effect in April 2013 and, due to subsequent legislative amendments to the statute, will remain in effect through 2027 unless additional action is taken by Congress. In January 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, further reduced Medicare payments to several types of providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:10pt;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">recover overpayments to providers from three to five years. Additionally, the orphan drug tax credit was reduced as part of a broader tax reform. These new laws or any other similar laws introduced in the future may result in additional reductions in Medicare and other health care funding, which could negatively affect our customers and accordingly, our financial operations.</font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, there has been increasing legislative and enforcement interest in the United States with respect to specialty drug pricing practices. Specifically, there have been Congressional inquiries and proposed federal and state legislation designed to bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs and reform government program reimbursement methodologies for drugs. Moreover, payment methodologies may be subject to changes in healthcare legislation and regulatory initiatives. We expect that additional U.S. federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that the U.S. federal government will pay for healthcare products and services, which could result in reduced demand for our product candidates or additional pricing pressures.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Individual states in the United States have also become increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. Legally mandated price controls on payment amounts by third-party payors or other restrictions could harm our business, results of operations, financial condition and prospects. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. This could reduce the ultimate demand for our product candidates or put pressure on our product pricing.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In markets outside of the United States, reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted price ceilings on specific products and therapies. We cannot predict the likelihood, nature, or extent of government regulation that may arise from future legislation or administrative action in the United States or any other jurisdiction. If we or any third parties we may engage are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we or such third parties are not able to maintain regulatory compliance, our product candidates may lose any regulatory approval that may have been obtained and we may not achieve or sustain profitability.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:-0.2pt;text-transform:none;font-variant: normal;">Our business operations and current and future relationships with investigators, healthcare professionals, consultants, third-party payors, patient organizations, and customers will be subject to applicable healthcare regulatory laws, which could expose us to penalties.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our business operations and current and future arrangements with investigators, healthcare professionals, consultants, third-party payors, patient organizations, and customers, may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations. These laws may constrain the business or financial arrangements and relationships through which we conduct our operations, including how we research, market, sell and distribute our product candidates, if approved. Such laws include:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="letter-spacing:0.2pt;">the U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from knowingly and willfully soliciting, offering, receiving, or providing any remuneration (including any kickback, bribe, or certain rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, lease, order, or recommendation of, any good, facility, item, or service, for which payment may be made, in whole or in part, under U.S. federal and state healthcare programs such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. The U.S. federal Anti-Kickback Statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers and formulary managers on the other hand;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>the U.S. federal false claims and civil monetary penalties laws, including the civil False Claims Act, or FCA, which, among other things, impose criminal and civil penalties, including through civil whistleblower or <font style="font-style:italic;">qui tam</font> actions, against individuals or entities for knowingly presenting, or causing </p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</a></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to be presented, to the U.S. federal government, claims for payment or approval that are false or fraudulent, knowingly making, using or causing to be made or used, a false record or statement material to a false or fraudulent claim, or from knowingly making a false statement to avoid, decrease or conceal an obligation to pay money to the U.S. federal government. In addition, the government may assert that a claim including items and services resulting from a violation of the U.S. federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the FCA. A claim includes &#8220;any request or demand&#8221; for money or property presented to the federal government. In addition, manufacturers can be held liable under the FCA even when they do not submit claims directly to government payors if they are deemed to &#8220;cause&#8221; the submission of false or fraudulent claims;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="letter-spacing:0.2pt;">the U.S. federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which imposes criminal and civil liability for, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or property owned by, or</font> <font style="letter-spacing:0.2pt;">under the custody or control of, any healthcare benefit program, regardless of the payor (e.g., public or private) and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement, in connection with the delivery of, or payment for, healthcare benefits, items or services. Similar to the U.S. federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="letter-spacing:0.2pt;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, and their respective implementing regulations, which impose, among other things, specified requirements relating to the privacy, security and transmission of individually identifiable health information without appropriate authorization by covered entities subject to the rule, such as health plans, healthcare clearinghouses and healthcare providers as well as their business associates that perform certain services involving the use or disclosure of individually identifiable health information. HITECH also created new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys&#8217; fees and costs associated with pursuing federal civil actions;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="letter-spacing:0.2pt;">the FDCA, which prohibits, among other things, the adulteration or misbranding of drugs, biologics and medical devices;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="letter-spacing:0.2pt;">the U.S. federal legislation commonly referred to as the Physician Payments Sunshine Act and its implementing regulations, which requires certain manufacturers of drugs, devices, biologics, and medical supplies that are reimbursable under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program to report annually to the government information related to certain payments and other transfers of value to physicians and teaching hospitals, as well as ownership and investment interests held by the physicians described above and their immediate family members; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="letter-spacing:0.2pt;">analogous U.S. state laws and regulations, including: state anti-kickback and false claims laws, which may apply to our business practices, including but not limited to, research, distribution, sales, and marketing arrangements and claims involving healthcare items or services reimbursed by any third-party payor, including private insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the U.S. federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state laws and regulations that require drug manufacturers to file reports relating to pricing and marketing information, which requires tracking gifts and other remuneration and items of value provided to healthcare professionals and entities; and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because of the breadth of these laws and the narrowness of the statutory exceptions and regulatory safe harbors available under such laws, it is possible that some of our business activities, including our consulting agreements and other relationships with physicians and other healthcare providers, some of whom receive stock or stock options as compensation for their services, could be subject to challenge under one or more of such laws. Ensuring that our current and future internal operations and business arrangements with third parties </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:10pt;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices do not comply with current or future statutes, regulations, agency guidance or case law involving applicable fraud and abuse or other healthcare laws and regulations.</font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If our operations are found to be in violation of any of the laws described above or any other governmental laws and regulations that may apply to us, we may be subject to the imposition of civil, criminal and administrative penalties, damages, disgorgement, monetary fines, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, individual imprisonment, contractual damages, reputational harm, diminished profits and future earnings, additional reporting requirements or oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, and curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations. If any of the physicians or other providers or entities with whom we expect to do business are found to not be in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs and imprisonment, which could affect our ability to operate our business. Further, defending against any such actions can be costly, time-consuming and may require significant personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:-0.2pt;text-transform:none;font-variant: normal;">Any clinical trial programs we conduct or research collaborations we enter into in the European Economic Area may subject us to the General Data Protection Regulation.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we conduct clinical trial programs or enter into research collaborations in the European Economic Area, or EEA, we may be subject to the General Data Protection regulation, or GDPR. The GDPR applies extraterritorially and implements stringent operational requirements for processors and controllers of personal data, including, for example, high standards for obtaining consent from individuals to process their personal data, robust disclosures to individuals, a comprehensive individual data rights regime, data export restrictions governing transfers of data from the EEA/European Union, or EU, to other jurisdictions, short timelines for data breach notifications, limitations on retention of information, increased requirements pertaining to health data, other special categories of personal data and coded data and additional obligations if we contract third-party processors in connection with the processing of personal data. The United Kingdom has implemented its own version of the GDPR, which contains similar requirements. The GDPR provides that EU member states may establish their own laws and regulations limiting the processing of personal data, including genetic, biometric or health data, which could limit our ability to use and share personal data or could cause our costs to increase. If our or our partners&#8217; or service providers&#8217; privacy or data security measures fail to comply with the GDPR requirements, we may be subject to litigation, regulatory investigations, enforcement notices requiring us to change the way we use personal data and/or fines of up to 20 million Euros or up to 4% of the total worldwide annual turnover of the preceding financial year, whichever is higher, as well as compensation claims by affected individuals, negative publicity, reputational harm and a potential loss of business and goodwill.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:-0.2pt;text-transform:none;font-variant: normal;">We are subject to environmental, health and safety laws and regulations, and we may become exposed to liability and substantial expenses in connection with environmental compliance or remediation activities.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our operations, including our development, testing and manufacturing activities, are subject to numerous environmental, health and safety laws and regulations. These laws and regulations govern, among other things, the controlled use, handling, release and disposal of and the maintenance of a registry for, hazardous materials and biological materials, such as chemical solvents, human cells, carcinogenic compounds, mutagenic compounds and compounds that have a toxic effect on reproduction, laboratory procedures and exposure to blood-borne pathogens. If we fail to comply with such laws and regulations, we could be subject to fines or other sanctions.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As with other companies engaged in activities similar to ours, we face a risk of environmental liability inherent in our current and historical activities, including liability relating to releases of or exposure to hazardous or biological materials. Environmental, health and safety laws and regulations are becoming more stringent. We may be required to incur substantial expenses in connection with future environmental compliance or remediation activities, in which case, the production efforts of our third-party manufacturers or our development efforts may be interrupted or delayed.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:-0.2pt;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:-0.2pt;text-transform:none;font-variant: normal;">Recent legislation may materially adversely affect our financial condition, results of operations and cash flows.</font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Recently enacted U.S. tax legislation has significantly changed the U.S. federal income taxation of U.S. corporations, including by reducing the U.S. corporate income tax rate, limiting interest deductions, and revising the rules governing NOLs. Many of these changes are effective immediately, without any transition periods or grandfathering for existing transactions. The legislation is unclear in many respects and could be subject to potential amendments and technical corrections, as well as interpretations and implementing regulations by the Treasury and Internal Revenue Service, or the IRS, any of which could lessen or increase certain adverse impacts of the legislation. In addition, it is unclear how these U.S. federal income tax changes will affect state and local taxation, which often uses federal taxable income as a starting point for computing state and local tax liabilities.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The reduction of the corporate tax rate under the legislation may cause a reduction in the economic benefit of deferred tax assets available to us. Furthermore, under the legislation, although the treatment of tax losses generated before December 31, 2017, has generally not changed, tax losses generated in calendar year 2018 and beyond will only be able to offset 80% of taxable income. This change may require us to pay federal income taxes in future years despite generating a loss for federal income tax purposes in prior years.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While some of the changes made by the tax legislation may adversely affect us in one or more reporting periods and prospectively, other changes may be beneficial on a going-forward basis. We intend to work with our tax advisors and auditors to determine the full impact that the recent tax legislation as a whole will have on us. We urge our investors to consult with their legal and tax advisors with respect to such legislation.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Our Intellectual Property</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We depend on license agreements with the University of Texas Southwestern, or UTSW, to permit us to use patents and patent applications, as well as to exploit specific technological know-how. Termination of these rights or the failure to comply with obligations under these agreements could materially harm our business and prevent us from developing or commercializing our product candidates.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a party to license agreements with UTSW under which we were granted rights to patents and patent applications, as well as proprietary technologies, that are important and necessary to our business. Our rights to use these patents and patent applications and employ the inventions claimed in these licensed patents, as well as the exploitation of proprietary technology, are subject to the continuation of, and our compliance with, the terms of our license agreements.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our license agreements impose upon us various diligence, payment and other obligations, including the following:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">our obligation to pay UTSW various milestone payments;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">our obligation to pay UTSW royalties based on net sales; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">our obligation to pay UTSW fees associated with the prosecution, maintenance, or filing of the patents and patent applications we have licensed.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we fail to comply with any of our obligations under the license agreements, or we are subject to a bankruptcy or dissolution, UTSW may have the right to terminate their respective license agreements, in which event we would not be able to market any product candidates covered by the licenses.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not currently own any patents, and we are heavily reliant upon licenses from UTSW to certain patent rights that are important or necessary to the development of our technology and product candidates. As a result, we may be limited in our ability to prevent competitors from developing and commercializing competitive products.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not control the prosecution, maintenance, or filing of the patents and patent applications that are licensed to us under the license agreements. Thus, these patents and patent applications were not drafted by us or our attorneys, and we do not directly control the prosecution of these patents and patent applications. We cannot be certain that drafting or prosecution of the patents and patent applications licensed to us has been conducted in compliance with applicable laws and regulations or will result in valid and enforceable patents. UTSW directly controls the preparation, filing and prosecution of patent applications, and is responsible for maintaining the patents, covering technology that we license.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we fail to comply with the obligations under our license agreement, including as a result of COVID-19 impacting our operations or due to lack of funds, or if we use the licensed intellectual property in an unauthorized manner, we may be required to pay damages and our licensors may have the right to terminate the license. If our license agreement is terminated, we may not be able to develop, manufacture, market or sell the product candidates covered by our agreement. Such an occurrence could materially adversely affect the value of the product candidates being developed under any such agreement.</font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Disputes may arise regarding intellectual property subject to, and any of our rights and obligations under, any license or other strategic agreement, including:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the scope of rights granted under the license agreement and other interpretation-related issues;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the extent to which our technology and processes infringe, misappropriate or violate the intellectual property of the licensor that is not subject to the license agreement;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">our diligence obligations under the license agreement and what activities satisfy those diligence obligations;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the sublicensing of patent and other rights to third parties under any such agreement or collaborative relationships;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the inventorship and ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the priority of invention of patented technology.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the agreements under which we license intellectual property or technology to or from third parties are complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations and prospects. Moreover, if disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our business also would suffer if any current or future licensors fail to abide by the terms of the license, if the licensed patents or other rights are found to be invalid or unenforceable, or if we are unable to enter into necessary licenses on acceptable terms. Moreover, our licensors may own or control intellectual property that has not been licensed to us and, as a result, we may be subject to claims, regardless of their merit, that we are infringing, misappropriating or otherwise violating the licensor&#8217;s rights.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, if we are unable to successfully obtain rights to required third-party intellectual property rights or maintain the existing intellectual property rights we have, we may have to seek alternative options, such as developing new product candidates with design-around technologies, which may require more time and investment, or abandon development of the relevant research programs or product candidates and our business, financial condition, results of operations and prospects could suffer.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We have been granted licenses of use to patent applications. There can be no assurance that any of the patent applications that we have licenses to will result in issued patents. As a result, our ability to protect our proprietary technology in the marketplace may be limited.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have been granted licenses of use to patent applications in many countries worldwide. These applications cover a range of treatment methods. Unless and until the pending patent applications are issued, their protective scope is impossible to determine. It is also impossible to predict whether or how many of the patent applications will result in issued patents. Even if pending applications are issued, they may be issued with coverage significantly narrower than what is currently sought.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:-0.2pt;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:-0.2pt;text-transform:none;font-variant: normal;">Our proprietary position for our product candidates currently depends in part upon licenses to patents protecting methods of use, which may not prevent a competitor or other third party from using the same product candidate for another use.</font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:-0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Composition of matter patent claims on the active pharmaceutical ingredient, or API, in pharmaceutical drug products are generally considered to be the favored form of intellectual property protection for pharmaceutical products, as such patents generally provide protection without regard to any particular method of use, manufacture or formulation of the API used. Method of use patent claims protect the use of a product for the specified method. These types of patent claims do not prevent a competitor or other third party from making and marketing an identical API for an indication that is outside the scope of the method claims. Moreover, even if competitors or other third parties do not actively promote their product for our targeted indications or uses for which we may obtain patents, physicians may recommend that patients use these products off-label, or patients may do so themselves. Although off-label use may infringe or contribute to the infringement of method of use patents, the practice is common and such infringement is difficult to prevent or prosecute.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:-0.2pt;text-transform:none;font-variant: normal;">Our patents may be challenged in courts or in patent offices which could result in the invalidation, narrowing or unenforceability of our patents and our patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There is no assurance that all the potentially relevant prior art relating to our patents and patent applications has been found, which can invalidate a patent or prevent a patent from issuing from a pending patent application. Even if patents do successfully issue and even if such patents further cover THIO or any future product candidate, third parties may challenge their validity, enforceability or scope, which may result in such patents being narrowed, invalidated, or held unenforceable. Any successful challenge to any patents owned by or licensed to us could deprive us of rights necessary for the successful commercialization of any product candidates that we may develop. Further, if we encounter delays in regulatory approvals, the period during which we could market a product candidate under patent protection could be reduced.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has in recent years been the subject of much litigation. In addition, the laws of foreign countries may not protect our rights to the same extent as the laws of the United States. For example, European patent law restricts the patentability of methods of treatment of the human body more than U.S. law does. However, in certain instances, the laws of the United States are more restrictive than those of foreign countries. For example, a recent series of Supreme Court Cases has narrowed the types of subject matter considered eligible for patenting. Accordingly, certain diagnostic methods are considered ineligible for patenting because they are directed to a &#8220;law of nature.&#8221; Further, publications of discoveries in scientific literature often lag the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Therefore, we cannot know with certainty whether we were the first to make the inventions claimed in our owned or licensed patents or pending patent applications, or that we were the first to file for patent protection of such inventions. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Our pending and future patent applications may not result in patents being issued which protect our technology or products, in whole or in part, or which effectively prevent others from commercializing competitive technologies and products. Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our patents or narrow the scope of our patent protection.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our owned and licensed patents may be challenged in the courts or patent offices in the United States and abroad. Such challenges may result in patent claims being narrowed, invalidated, held unenforceable, in whole or in part, or reduced in term. Such a result could limit our ability to stop others from using or commercializing similar or identical technology and products. Moreover, patents have a limited lifespan. In the United States, the natural expiration of a patent is generally 20 years after it is filed. While various extensions may be available, the life of a patent is limited. Without patent protection for our current or future product candidates, we may be open to competition from generic versions of such products. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:-0.2pt;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:-0.2pt;text-transform:none;font-variant: normal;">We may become subject to third parties&#8217; claims alleging infringement of their patents and proprietary rights, or we may need to become involved in lawsuits to protect or enforce our patents, which could be costly and/or time consuming, delay or prevent the development and commercialization of our product candidates or put our patents and other proprietary rights at risk.</font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our commercial success depends, in part, upon our ability to develop, manufacture, market and sell our product candidates without alleged or actual infringement, misappropriation or other violation of the patents and proprietary rights of third parties. Litigation relating to infringement or misappropriation of patent and other intellectual property rights in the pharmaceutical and biotechnology industries is common, including patent infringement lawsuits, <font style="font-style:italic;">inter partes</font> review, interferences, oppositions and reexamination proceedings before the U.S. Patent and Trademark Office, or USPTO, and corresponding foreign patent offices. The various markets in which we plan to operate are subject to frequent and extensive litigation regarding patents and other intellectual property rights. In addition, many companies in intellectual property-dependent industries, including the biotechnology and pharmaceutical industries, have employed intellectual property litigation as a means to gain an advantage over their competitors. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Numerous U.S., EU and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are developing product candidates. Some claimants may have substantially greater resources than we do and may be able to sustain the costs of complex intellectual property litigation to a greater degree and for longer periods of time than we could. In addition, patent holding companies that focus solely on extracting royalties and settlements by enforcing patent rights may target us. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our product candidates may be subject to claims of infringement of the intellectual property rights of third parties.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may be subject to third-party claims including infringement, interference, or derivation proceedings before the USPTO or similar adversarial proceedings or litigation in other jurisdictions. Even if we believe third party infringement claims are without merit, a court of competent jurisdiction could hold that the third-party patents are valid, enforceable and infringed, and the holders of any such patents may be able to block our ability to commercialize the applicable product candidate unless we obtained a license under the applicable patents, or until such patents expire or are finally determined to be invalid or unenforceable. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceedings challenging our patents or those that we license may also result in our patent claims being invalidated or narrowed in scope. Similarly, if our patents or patent applications are challenged during interference or derivation proceedings, a court may hold that a third-party is entitled to certain patent ownership rights instead of us. Further, if any third-party patents were held by a court of competent jurisdiction to cover aspects of our compositions, formulations, methods of manufacture, or methods of treatment, prevention or use, the holders of any such patents may be able to block our ability to develop and commercialize the applicable product candidate unless we obtained a license or until such patent expires or is finally determined to be invalid or unenforceable. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Defending such claims would cause us to incur substantial expenses and, if unsuccessful, could cause us to pay substantial damages if we are found to be infringing a third party&#8217;s patent rights. If we are found to have infringed such rights willfully, the damages may be enhanced and may include attorneys&#8217; fees. Further, if a patent infringement suit is brought against us or our third-party service providers, our development, manufacturing or sales activities relating to the product or product candidate that is the subject of the suit may be delayed or terminated. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a result of patent infringement claims, or in order to avoid potential infringement claims, we may choose to seek, or be required to seek, a license from the third party, which may require us to pay license fees or royalties or both. These licenses may not be available on acceptable terms, or at all. Even if a license can be obtained on acceptable terms, the rights may be nonexclusive, which could give our competitors access to the same intellectual property rights. If we are unable to enter into a license on acceptable terms, we could be prevented from commercializing one or more of our product candidates, forced to modify such product candidates, or to cease some aspect of our business operations, which could harm our business significantly. Modifying our product candidates to design around third-party intellectual property rights may result in significant cost or delay to us and could prove to be technically infeasible. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any of these events, even if we were ultimately to prevail, could require us to divert substantial financial and management resources that we would otherwise be able to devote to our business. In addition, if the breadth or strength of protection provided the patents and patent applications we own or in-license is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates.</font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we were to initiate legal proceedings against a third party to enforce a patent covering one of our product candidates, the defendant could counterclaim that our patent is invalid or unenforceable. In patent litigation in the United States and in Europe, defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, for example, lack of eligibility, lack of novelty, obviousness or non-enablement. Third parties might allege unenforceability of our patents because someone connected with prosecution of the patent withheld relevant information, or made a misleading statement, during prosecution. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The outcome of proceedings involving assertions of invalidity and unenforceability during patent litigation is unpredictable. With respect to the validity of patents, for example, we cannot be certain that there is no invalidating prior art of which we and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of the patent protection on our product candidates. Furthermore, our patents and other intellectual property rights also will not protect our technology if competitors design around our protected technology without infringing on our patents or other intellectual property rights.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors view these announcements in a negative light, the price of our common stock could be adversely affected.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finally, even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors view these announcements in a negative light, the price of our common stock could be adversely affected. Such litigation or proceedings could substantially increase our operating losses and reduce our resources available for development activities. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their substantially greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have an adverse effect on our ability to compete in the marketplace.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:-0.2pt;text-transform:none;font-variant: normal;">We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent, which might adversely affect our ability to develop, manufacture and market our product candidates.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We cannot guarantee that any of our or our licensors&#8217; patent searches or analyses, including but not limited to the identification of relevant patents, the scope of patent claims or the expiration of relevant patents, are complete or thorough, nor can we be certain that we have identified each and every third-party patent and pending application in the United States, Europe and elsewhere that is relevant to or necessary for the commercialization of our product candidates in any jurisdiction. For example, in the United States, applications filed before November 29, 2000 and certain applications filed after that date that will not be filed outside the United States remain confidential until patents issue. Patent applications in the United States, EU and elsewhere are published approximately 18 months after the earliest filing for which priority is claimed, with such earliest filing date being commonly referred to as the priority date. Therefore, patent applications covering our future product candidates, or their manufacture or use may currently be unpublished. Additionally, pending patent applications that have been published can, subject to certain limitations, be later </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:10pt;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">amended in a manner that could cover our product candidates or the use of our product candidates. The scope of a patent claim is determined by an interpretation of the law, the written disclosure in a patent and the patent&#8217;s prosecution history. Our interpretation of the relevance or the scope of a patent or a pending application may be incorrect, which may negatively impact our ability to market our product candidates. We may incorrectly determine that our product candidates are not covered by a third-party patent or may incorrectly predict whether a third party&#8217;s pending application will issue with claims of relevant scope. Our determination of the expiration date of any patent in the United States, the EU or elsewhere that we consider relevant may be incorrect, which may negatively impact our ability to develop and market our product candidates. Our failure to identify and correctly interpret relevant patents may negatively impact our ability to develop and market our product candidates.</font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time we may identify patents or applications in the same general area as our products and product candidates. We may determine these third-party patents are irrelevant to our business based on various factors including our interpretation of the scope of the patent claims and our interpretation of when the patent expires. If the patents are asserted against us, however, a court may disagree with our determinations. Further, while we may determine that the scope of claims that will issue from a patent application does not present a risk, it is difficult to accurately predict the scope of claims that will issue from a patent application, our determination may be incorrect, and the issuing patent may be asserted against us. We cannot guarantee that we will be able to successfully settle or otherwise resolve such infringement claims. If we fail in any such dispute, in addition to being forced to pay monetary damages, we may be temporarily or permanently prohibited from commercializing our product candidates. We might, if possible, also be forced to redesign our product candidates so that we no longer infringe on the third-party intellectual property rights. Any of these events, even if we were ultimately to prevail, could require us to divert substantial financial and management resources that we would otherwise be able to devote to our business.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:-0.2pt;text-transform:none;font-variant: normal;">Changes in patent laws or patent jurisprudence could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As is the case with other biopharmaceutical and pharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical and pharmaceutical industries involve both technological complexity and legal complexity. Therefore, obtaining and enforcing biopharmaceutical and pharmaceutical patents is costly, time-consuming and inherently uncertain. In addition, the America Invents Act (AIA) which was passed in September 2011, resulted in significant changes to the U.S. patent system.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">An important change introduced by the AIA is that, as of March 16, 2013, the United States transitioned to a &#8220;first-to-file&#8221; system for deciding which party should be granted a patent when two or more patent applications are filed by different parties claiming the same invention. A third party that files a patent application in the USPTO after that date but before us could therefore be awarded a patent covering an invention of ours even if we made the invention before it was made by the third party. This will require us to be cognizant going forward of the time from invention to filing of a patent application, but circumstances could prevent us from promptly filing patent applications on our inventions.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Among some of the other changes introduced by the AIA are changes that limit where a patentee may file a patent infringement suit and provide opportunities for third parties to challenge any issued patent with the USPTO. This applies to all of our U.S. patents, even those issued before March 16, 2013. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in U.S. federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action. It is not clear what, if any, impact the AIA will have on the operation of our business. However, the AIA and its implementation could increase the uncertainties and costs surrounding the prosecution of our or our licensors&#8217; patent applications and the enforcement or defense of our or our licensors&#8217; issued patents.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, the U.S. Supreme Court has ruled on several patent cases in recent years either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by Congress, the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. Similarly, the complexity and uncertainty of European patent laws has also increased in recent years. In addition, the European patent system is relatively stringent in the type of amendments that are allowed during prosecution. Complying with these laws and regulations could limit our ability to obtain new patents in the future that may be important for our business.</font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:-0.2pt;text-transform:none;font-variant: normal;">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Periodic maintenance and annuity fees on any issued patent are due to be paid to the USPTO and European and other patent agencies over the lifetime of a patent. In addition, the USPTO and European and other patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. While an inadvertent failure to make payment of such fees or to comply with such provisions can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which such noncompliance will result in the abandonment or lapse of the patent or patent application, and the partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of a patent or patent application include failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents within prescribed time limits. If we or our licensors fail to maintain the patents and patent applications covering our product candidates or if we or our licensors otherwise allow our patents or patent applications to be abandoned or lapse, our competitors might be able to enter the market, which would hurt our competitive position and could impair our ability to successfully commercialize our product candidates in any indication for which they are approved.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:-0.2pt;text-transform:none;font-variant: normal;">We enjoy only limited geographical protection with respect to certain patents and we may not be able to protect our intellectual property rights throughout the world.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Filing, prosecuting and defending patents covering our product candidates in all countries throughout the world would be prohibitively expensive. Competitors may use our and our licensors&#8217; technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we and our licensors have patent protection, but enforcement is not as strong as that in the United States or the EU. These products may compete with our product candidates, and our and our licensors&#8217; patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, we may decide to abandon national and regional patent applications before grant. The grant proceeding of each national or regional patent is an independent proceeding which may lead to situations in which applications might in some jurisdictions be refused by the relevant patent offices, while granted by others. For example, unlike other countries, China has a heightened requirement for patentability, and specifically requires a detailed description of medical uses of a claimed drug. Furthermore, generic drug manufacturers or other competitors may challenge the scope, validity or enforceability of our or our licensors&#8217; patents, requiring us or our licensors to engage in complex, lengthy and costly litigation or other proceedings. Generic drug manufacturers may develop, seek approval for and launch generic versions of our products. It is also quite common that depending on the country, the scope of patent protection may vary for the same product candidate or technology.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The laws of some jurisdictions do not protect intellectual property rights to the same extent as the laws or rules and regulations in the United States and the EU, and many companies have encountered significant difficulties in protecting and defending such rights in such jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, which could make it difficult for us to stop the infringement of our patents or </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:10pt;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in other jurisdictions, whether or not successful, could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing, and could provoke third parties to assert claims against us. </font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. Furthermore, while we intend to protect our intellectual property rights in our expected significant markets, we cannot ensure that we will be able to initiate or maintain similar efforts in all jurisdictions in which we may wish to market our product candidates. Accordingly, our efforts to protect our intellectual property rights in such countries may be inadequate, which may have an adverse effect on our ability to successfully commercialize our product candidates in all of our expected significant foreign markets. If we or our licensors encounter difficulties in protecting, or are otherwise precluded from effectively protecting, the intellectual property rights important for our business in such jurisdictions, the value of these rights may be diminished, and we may face additional competition from others in those jurisdictions.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Some countries also have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, some countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we or any of our licensors is forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:-0.2pt;text-transform:none;font-variant: normal;">If we do not obtain patent term extension in the United States under the Hatch-Waxman Act and in foreign countries having similar legislation, thereby potentially extending the term of marketing exclusivity for our product candidates, our business may be materially harmed.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S. non-provisional filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates are obtained, once the patent life has expired for a product, we may be open to competition from competitive medications, including generic medications. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depending upon the timing, duration and conditions of FDA marketing approval of our product candidates, we may be able to extend the term of a patent covering each product candidate under the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as the Hatch-Waxman Amendments and similar legislation in the EU. The Hatch-Waxman Amendments permit a patent term extension of up to five years for a non-expired patent which claims a human drug product, a method of using the product, or a method of manufacturing the product, as compensation for effective patent term lost during product development and the FDA regulatory review process. Moreover, only one patent may be extended covering the drug product and the total patent term including the extension cannot exceed 14 years following regulatory approval. However, we may not receive an extension if we fail to apply within applicable deadlines, fail to apply prior to expiration of relevant patents or otherwise fail to satisfy applicable requirements. Moreover, the length of the extension could be less than we request. If we are unable to obtain patent term extension or the term of any such extension is less than we request, the period during which we can enforce our patent rights for that product will be shortened and our competitors may obtain approval to market competing products sooner. As a result, our revenue from applicable products could be reduced, possibly materially.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, under certain circumstances, patent terms covering our products or product candidates may be extended for time spent during the pendency of the patent application in the USPTO (referred to as Patent Term Adjustment, or PTA). The laws and regulations underlying how the USPTO calculates the PTA is subject to change and any such PTA granted by the USPTO could be challenged by a third-party. If we do not prevail </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:10pt;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">under such a challenge, the PTA may be reduced or eliminated, resulting in a shorter patent term, which may negatively impact our ability to exclude competitors. Because PTA added to the term of patents covering pharmaceutical products has particular value, our business may be adversely affected if the PTA is successfully challenged by a third party and our ability to exclude competitors is reduced or eliminated.</font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:-0.2pt;text-transform:none;font-variant: normal;">Intellectual property rights do not address all potential threats to our competitive advantage.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately protect our business, or permit us to maintain our competitive advantage. The following examples are illustrative:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>others may be able to make products that are similar to THIO or our future product candidates but that are not covered by the claims of the patents that we own or license from others;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>others may independently develop similar or alternative technologies or otherwise circumvent any of our technologies without infringing our intellectual property rights;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>we or any of our collaborators might not have been the first to conceive and reduce to practice the inventions covered by the patents or patent applications that we own, license or will own or license;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>we or any of our collaborators might not have been the first to file patent applications covering certain of the patents or patent applications that we or they own or have obtained a license, or will own or will have obtained a license;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>it is possible that our pending patent applications will not lead to issued patents;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>issued patents that we own may not provide us with any competitive advantage, or may be held invalid or unenforceable, as a result of legal challenges by our competitors;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>our competitors might conduct research and development activities in countries where we do not have patent rights, or in countries where research and development safe harbor laws exist, and then use the information learned from such activities to develop competitive products for sale in our major commercial markets;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>ownership of our patents or patent applications may be challenged by third parties; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="letter-spacing:0.2pt;">the patents of third parties or pending or future applications of third parties, if issued, may have an adverse effect on our business.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:-0.2pt;text-transform:none;font-variant: normal;">Our reliance on third parties requires us to share our trade secrets, which increases the possibility that our trade secrets will be misappropriated or disclosed, and confidentiality agreements with employees and third parties may not adequately prevent disclosure of trade secrets and protect other proprietary information.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We consider proprietary trade secrets or confidential know-how and unpatented know-how to be important to our business. We may rely on trade secrets or confidential know-how to protect our technology, especially where patent protection is believed by us to be of limited value. Because we expect to rely on third parties to manufacture THIO and any future product candidates, and we expect to collaborate with third parties on the development of THIO and any future product candidates, we must, at times, share trade secrets with them. We also conduct joint research and development programs that may require us to share trade secrets under the terms of our research and development partnerships or similar agreements. However, trade secrets or confidential know-how can be difficult to maintain as confidential.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To protect this type of information against disclosure or appropriation by competitors, our policy is to require our employees, consultants, contractors and advisors to enter into confidentiality agreements and, if applicable, material transfer agreements, consulting agreements or other similar agreements with us prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential information, including our trade secrets. However, current or former employees, consultants, contractors and advisers may unintentionally or willfully disclose our confidential information to competitors, and confidentiality agreements may not provide an adequate remedy in the event of unauthorized disclosure of confidential information. The need to share trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements. Given that our proprietary position is based, in part, on our know-how and trade secrets, a competitor&#8217;s discovery of our trade secrets or other unauthorized use or disclosure would impair our competitive position and may have an </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:10pt;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">adverse effect on our business and results of operations. Enforcing a claim that a third party obtained illegally and is using trade secrets or confidential know-how is expensive, time consuming and unpredictable. The enforceability of confidentiality agreements may vary from jurisdiction to jurisdiction.</font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, these agreements typically restrict the ability of our advisors, employees, third-party contractors and consultants to publish data potentially relating to our trade secrets, although our agreements may contain certain limited publication rights. Despite our efforts to protect our trade secrets, our competitors may discover our trade secrets, either through breach of our agreements with third parties, independent development or publication of information by any of our third-party collaborators. A competitor&#8217;s discovery of our trade secrets would impair our competitive position and have an adverse impact on our business.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:-0.2pt;text-transform:none;font-variant: normal;">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect to rely on trademarks as one means to distinguish any of our product candidates that are approved for marketing from the products of our competitors. We have not yet selected trademarks for our product candidates and have not yet begun the process of applying to register trademarks for any other of our product candidates. Once we select trademarks and apply to register them, our trademark applications may not be approved. Third parties may oppose our trademark applications, or otherwise challenge our use of the trademarks. In the event that our trademarks are successfully challenged, we could be forced to rebrand our products, which could result in loss of brand recognition and could require us to devote resources to advertising and marketing new brands. Our competitors may infringe our trademarks and we may not have adequate resources to enforce our trademarks.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, any proprietary name we propose to use with our clinical-stage product candidates or any other product candidate in the United States must be approved by the FDA, regardless of whether we have registered it, or applied to register it, as a trademark. The FDA typically conducts a review of proposed product names, including an evaluation of the potential for confusion with other product names. If the FDA objects to any of our proposed proprietary product names, we may be required to expend significant additional resources in an effort to identify a suitable proprietary product name that would qualify under applicable trademark laws, not infringe the existing rights of third parties and be acceptable to the FDA. The EMA may also object to our proposed proprietary product name that infringes the existing rights of third parties.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively, and our business may be adversely affected. Our efforts to enforce or protect our proprietary rights related to trademarks, trade secrets, domain names, copyrights or other intellectual property may be ineffective and could result in substantial costs and diversion of resources and could adversely affect our business, financial condition, results of operations and growth prospects.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:-0.2pt;text-transform:none;font-variant: normal;">We may need to license certain intellectual property from third parties, and such licenses may not be available or may not be available on commercially reasonable terms.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A third party may hold intellectual property, including patent rights that are important or necessary to the development or commercialization of THIO or our future product candidates. It may be necessary for us to use the patented or proprietary technology of third parties to commercialize THIO or our product candidates, in which case we would be required to obtain a license from these third parties. Such a license may not be available on commercially reasonable terms, or at all, which could materially harm our business. At this time, we are unaware of any intellectual property that interferes with ours or is complementary and needed to commercialize THIO.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:-0.2pt;text-transform:none;font-variant: normal;">We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of their former employers or other third parties.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We employ individuals who were previously employed at other biotechnology or pharmaceutical companies. Although we seek to protect our ownership of intellectual property rights by ensuring that our agreements with </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:10pt;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our employees, collaborators and other third parties with whom we do business include provisions requiring such parties to assign rights in inventions to us, we may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed confidential information of our employees&#8217; former employers or other third parties. We may also be subject to claims that former employers or other third parties have an ownership interest in our patents. Litigation may be necessary to defend against these claims. There is no guarantee of success in defending these claims, and if we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership or right to use. Even if we are successful, litigation could result in substantial cost and be a distraction to our management and other employees.</font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:-0.2pt;text-transform:none;font-variant: normal;">Our proprietary information may be lost, or we may suffer security breaches.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the ordinary course of our business, we collect and store sensitive data, including intellectual property, clinical trial data, proprietary business information, personal data and personally identifiable information of our clinical trial subjects and employees, in our data centers and on our networks. The secure processing, maintenance and transmission of this information is critical to our operations. Despite our security measures, our information technology and infrastructure may be vulnerable to attacks by hackers or breached due to employee error, malfeasance or other disruptions. Although, to our knowledge, we have not experienced any such material security breach to date, any such breach could compromise our networks and the information stored there could be accessed, publicly disclosed, lost or stolen. Any such access, disclosure or other loss of information could result in legal claims or proceedings, liability under laws that protect the privacy of personal information, significant regulatory penalties, disruption of our operations, damage to our reputation and cause a loss of confidence in us and our ability to conduct clinical trials, which could adversely affect our reputation and delay our clinical development of our product candidates.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Our Employees, Managing Our Growth and Our Operations</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:-0.2pt;text-transform:none;font-variant: normal;">Our future success depends on our ability to retain our key personnel and to attract, retain and motivate qualified personnel.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are highly dependent on the development, regulatory, commercialization and business development expertise of Vlad Vitoc and Mihail Obrocea, as well as the other principal members of our management, scientific and clinical teams. Although we have employment agreements, offer letters or consulting agreements with our executive officers, these agreements do not prevent them from terminating their services at any time.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we lose one or more of our executive officers or key employees, our ability to implement our business strategy successfully could be seriously harmed. Furthermore, replacing executive officers and key employees may be difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to successfully develop product candidates, gain regulatory approval, and commercialize new products. Competition to hire from this limited pool is intense, and we may be unable to hire, train, retain or motivate these additional key personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions. In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategy. Our consultants and advisors may be engaged by entities other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us. If we are unable to continue to attract and retain highly qualified personnel, our ability to develop and commercialize product candidates will be limited.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:-0.2pt;text-transform:none;font-variant: normal;">We expect to expand our development, regulatory, and sales and marketing capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect to experience significant growth in the number of our employees and the scope of our operations, particularly in the areas of development, regulatory affairs and sales and marketing. To manage our anticipated future growth, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities or acquire new facilities and continue to recruit and train additional qualified personnel. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:10pt;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Due to our limited financial resources and the limited experience of our management team in managing a company with such anticipated growth, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. The expansion of our operations may lead to significant costs and may divert our management and business development resources. Any inability to manage growth could delay the execution of our business plans or disrupt our operations.</font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:-0.2pt;text-transform:none;font-variant: normal;">We may engage in acquisitions that could disrupt our business, cause dilution to our stockholders or reduce our financial resources.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the future, we may enter into transactions to acquire other businesses, products or technologies. If we do identify suitable candidates, we may not be able to make such acquisitions on favorable terms, or at all. Any acquisitions we make may not strengthen our competitive position, and these transactions may be viewed negatively by customers or investors. We may decide to incur debt in connection with an acquisition or issue our common stock or other equity securities to the stockholders of the acquired company, which would reduce the percentage ownership of our existing stockholders. We could incur losses resulting from undiscovered liabilities of the acquired business that are not covered by the indemnification we may obtain from the seller. In addition, we may not be able to successfully integrate the acquired personnel, technologies and operations into our existing business in an effective, timely and non-disruptive manner. Acquisitions may also divert management attention from day-to-day responsibilities, increase our expenses and reduce our cash available for operations and other uses. We cannot predict the number, timing or size of future acquisitions or the effect that any such transactions might have on our operating results.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:-0.2pt;text-transform:none;font-variant: normal;">Our business and operations would suffer in the event of system failures.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our computer systems, as well as those of our CROs and other contractors and consultants, are vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. If such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our development programs. For example, the loss of preclinical or clinical trial data from completed, ongoing or planned trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach were to result in a loss of or damage to our data or applications, or inappropriate disclosure of personal, confidential or proprietary information, we could incur liability and the further development of THIO or any other product candidate could be delayed.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Relating to Our Initial Public Offering and Ownership of Our Common Stock </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">There is no existing market for our common stock and an active, liquid trading market for our common stock may not develop. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to this offering, there has been a limited market for our common stock. Although we have applied to list our common stock on the Nasdaq under the symbol &#8220;MAIA,&#8221; we cannot predict the extent to which investor interest in our Company will lead to the development of an active trading market or how liquid that market may become. If an active trading market does not develop, you may have difficulty selling any of our shares that you purchase. The initial public offering price of our common stock will be determined by negotiation between us and the underwriters, and may not be indicative of prices that will prevail after the completion of this offering. The market price of our common stock may decline below the initial public offering price, and you may not be able to resell your shares at, or above, the initial public offering price. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">The price of our common stock may be volatile and you could lose all or part of your investment. </font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Securities markets worldwide have experienced in the past, and are likely to experience in the future, significant price and volume fluctuations. This market volatility, as well as general economic, market, or political conditions could reduce the market price of our common stock regardless of our results of operations. The trading price of our common stock is likely to be highly volatile and could be subject to wide price fluctuations in response to various factors including, among other things, the risk factors described herein and other factors beyond our control. Factors affecting the trading price of our common stock could include, but are not limited to:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">market conditions in the broader stock market; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">actual or anticipated variations in our quarterly results of operations;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">developments in our industry in general; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">results from our ongoing clinical trials and future clinical trials with our current and future product candidates or of our competitors;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">adverse results or delays in clinical trials;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">failure to commercialize our product candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">unanticipated serious safety concerns related to the use of our product candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">changes in our projected operating results that we provide to the public, our failure to meet these projections or changes in recommendations by securities analysts that elect to follow our common stock;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">any delay in our regulatory filings for our product candidates and any adverse development or perceived adverse development with respect to the applicable regulatory authority&#8217;s review of such filings, including without limitation the FDA&#8217;s issuance of a &#8220;refusal to file&#8221; letter or a request for additional information;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">regulatory or legal developments in the United States and other countries;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the level of expenses related to future product candidates or clinical development programs;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">our failure to achieve product development goals in the timeframe we announce;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">issuance of new, negative or changed securities analysts' reports or recommendations or estimates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">sales, or anticipated sales, of our stock, including sales by our officers, directors and significant stockholders;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">additions or departures of key personnel;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">regulatory or political developments;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the public's response to press releases or other public announcements by us or third parties, including our filings with the SEC;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">announcements, media reports or other public forum comments related to litigation, claims or reputational charges against us;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">guidance, if any, that we provide to the public, any changes in this guidance, or our failure to meet this guidance;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the development and sustainability of an active trading market for our common stock; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">investor perceptions of the investment opportunity associated with our common stock relative to other investment alternatives;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">other events or factors, including those resulting from system failures and disruptions, earthquakes, hurricanes, war, acts of terrorism, global outbreaks or pandemic, other natural disasters or responses to these events;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">changes in accounting principles;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">litigation and governmental investigations; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">changing economic conditions. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These and other factors may cause the market price and demand for shares of our common stock to fluctuate substantially, which may limit or prevent investors from readily selling their shares of common stock and may otherwise negatively affect the liquidity of our common stock. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We could be subject to securities class action litigation.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the past, when the market price of a stock has been volatile, holders of that stock sometimes have instituted securities class action litigation against the company that issued the stock following a decline in the market price of their securities. This risk is especially relevant for us because biotechnology companies have experienced significant </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:10pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">share price volatility in recent years. Securities litigation against us, regardless of the merits or outcome, could result in substantial costs and divert the time and attention of our management from our business, which could have a material adverse effect on our business, financial condition, and results of operations. </font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Future sales of our common stock, or the perception in the public markets that these sales may occur, could cause the market price for our common stock to decline. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All shares of common stock sold in this offering will be freely transferable without restriction or further registration under the Securities Act. At the time of this offering, we also will have &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; registered shares of common stock reserved for issuance under our equity incentive plans of which restricted stock units representing &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock are outstanding, which shares may be issued upon issuance and once vested, subject to any applicable lock-up restrictions then in effect. We cannot predict the effect, if any, that market sales of shares of our common stock or the availability of shares of our common stock for sale will have on the market price of our common stock prevailing from time to time. Sales of substantial amounts of shares of our common stock in the public market, or the perception that those sales will occur, could cause the market price of our common stock to decline. Of the shares of common stock outstanding, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; will be restricted securities within the meaning of Rule 144 under the Securities Act and subject to certain restrictions on resale following the consummation of this offering. Restricted securities may be sold in the public market only if they are registered under the Securities Act, or are sold pursuant to an exemption from registration such as Rule 144 or Rule 701, as described in &#8220;Shares Eligible for Future Sale.&#8221; </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We, each of our officers, directors, and certain of our stockholders have agreed, subject to certain exceptions, not to offer, pledge, sell, contract to sell, grant, lend, or otherwise transfer or dispose of, directly or indirectly, or enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of any shares of our capital stock or any securities convertible into or exercisable or exchangeable for shares of our common stock, for a period of 12 months after the date of this prospectus, without the prior written consent of the representative. Certain of our other stockholders, who are not insiders, have agreed, subject to certain exceptions, not offer, pledge, sell, contract to sell, grant, lend, or otherwise transfer or dispose of, directly or indirectly, or enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of any shares of our capital stock or any securities convertible into or exercisable or exchangeable for shares of our common stock, for a period of 6 months (or in the case of options with a weighted average exercise price of $1.80 or $1.83, for a period of 12 months) after the date of this prospectus, without the prior written consent of the representative. Following the expiration of the applicable lock-up period, all of the issued and outstanding shares of our common stock will be eligible for future sale, subject to the applicable volume, manner of sale, holding period, and other limitations of Rule 144. See the section of this prospectus entitled &#8220;Underwriting&#8221; for additional information. See &#8220;Underwriting&#8221; for additional information. Following the expiration of the applicable lock-up period, all of the issued and outstanding shares of our common stock will be eligible for future sale, subject to the applicable volume, manner of sale, holding period, and other limitations of Rule 144. See &#8220;Shares Eligible for Future Sale&#8221; for a discussion of the shares of common stock that may be sold into the public market in the future. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If securities or industry analysts publish unfavorable research about our business, or if our competitors' stock performance decline, the price of our common stock and our trading volume could decline. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The trading market for our common stock will depend in part on the research and reports that securities or industry analysts may publish about us or our business. We do not have any control over these analysts. Securities and industry analysts do not currently publish research on our Company. Once securities or industry analysts initiate coverage, if one or more of the analysts who cover us downgrade our common stock or publish unfavorable research about our business, the price of our common stock likely would decline. Additionally, if one of our competitor's stock performance declines, the price of our common stock and our trading volume could decline as well. If one or more of these analysts cease coverage of our Company or fail to publish reports on us regularly, or if one of our competitor's stock performance declines, demand for our common stock could decrease, which might cause the price of our common stock and trading volume to decline. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We do not intend to pay dividends for the foreseeable future, and our ability to pay dividends to our stockholders is restricted by applicable laws and regulations.</font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may retain future earnings, if any, for future operations, expansion and debt repayment and have no current plans to pay any cash dividends for the foreseeable future. As a result of our current dividend policy, you may not receive any return on an investment in our common stock unless you sell our common stock for a price greater than that which you paid for it. Any future determination to declare and pay cash dividends will be at the discretion of our board of directors and will depend on, among other things, our financial condition, results of operations, cash requirements, contractual restrictions and such other factors as our board of directors deems relevant. Our ability to declare and pay dividends to our stockholders is subject to certain laws, regulations, and policies, including minimum capital requirements and, as a Delaware corporation, we are subject to certain restrictions on dividends under the Delaware General Corporation Law (the "DGCL"). Under the DGCL, our board of directors may not authorize payment of a dividend unless it is either paid out of our surplus, as calculated in accordance with the DGCL, or if we do not have a surplus, it is paid out of our net profits for the fiscal year in which the dividend is declared and/or the preceding fiscal year. Our ability to pay dividends depends on our receipt of cash dividends from our operating subsidiaries, which may further restrict our ability to pay dividends as a result of the laws of their jurisdiction of organization or agreements of our subsidiaries, including agreements governing our indebtedness. For more information, see "Dividend Policy."</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We will have broad discretion in the use of the net proceeds from this offering and may not use them effectively.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We will have broad discretion in the application of the net proceeds from this offering and our shareholders will not have the opportunity as part of their investment decision to assess whether the net proceeds are being used appropriately. You may not agree with our decisions, and our use of the proceeds may not yield any return on your investment. Because of the number and variability of factors that will determine our use of the net proceeds from this offering, their ultimate use may vary substantially from their currently intended use. Our failure to apply the net proceeds of this offering effectively could compromise our ability to pursue our growth strategy and we might not be able to yield a significant return, if any, on our investment of these net proceeds. See &#8220;Use of Proceeds&#8221; for a description of how we intend to use the proceeds of the offering.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If you purchase shares of our common stock in this offering, you will incur immediate dilution in the book value of your shares.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The initial public offering price of our common stock will be substantially higher than the as adjusted net tangible book value per share of our common stock. Therefore, if you purchase our common stock in this offering, you will pay a price per share of our common stock that substantially exceeds the book value of our tangible assets after subtracting our liabilities. Based on an initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, you will experience immediate dilution of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, representing the difference between our net tangible book value per share, after giving effect to this offering, and the initial public offering price. Further, the issuance of any Ratchet Shares to the Crossover Investors, and the future exercise of any outstanding options and/or warrants to purchase shares of our common stock will cause you to experience additional dilution. See &#8220;Description of Capital Stock&#8212;Crossover Round&#8221; and &#8220;Dilution.&#8221;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Claims for indemnification by our directors and officers may reduce our available funds to satisfy successful third-party claims against us and may reduce the amount of money available to us. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our amended and restated certificate of incorporation and amended and restated bylaws that will be in effect prior to the completion of this offering provide that we will indemnify our directors and officers, in each case, to the fullest extent permitted by Delaware law. Pursuant to our amended and restated bylaws and the DGCL, our directors will not be liable to the Company or any stockholders for damages for any breach of fiduciary duty, except (i) acts that breach his or her duty of loyalty to the Company or its stockholders; (ii) acts or omissions without good faith or involving intentional misconduct or knowing violation of the law; (iii) pursuant to Section 174 of the DGCL regarding director liability for unlawful payment of a dividend or unlawful stock purchase or redemption; or (iv) for any transaction from which the director derived an improper personal benefit. In addition, we intend to enter into indemnification agreements with each of our executive officers and directors that will be in effect upon the completion of this offering. The indemnification agreements will provide the executive officers and directors with contractual rights to indemnification, expense advancement and reimbursement, to the fullest extent permitted under the DGCL. The bylaws also require us, if so requested, to advance expenses that such director or officer incurred in </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:10pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">defending or investigating a threatened or pending action, suit or proceeding, provided that such person will return any such advance if it is ultimately determined that such person is not entitled to indemnification by us. Any claims for indemnification by our directors and officers may reduce our available funds to satisfy successful third-party claims against us and may reduce the amount of money available to us.</font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may, in the future, issue additional capital stock, which would reduce investors&#8217; percent of ownership and may dilute our share value.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have the right to raise additional capital or incur borrowings from third parties to finance our business. We may also implement public or private mergers, business combinations, business acquisitions and similar transactions pursuant to which it would issue substantial additional capital stock to outside parties, causing substantial dilution in the ownership of the Company by our existing stockholders. Our Board of Directors has the authority, without the consent of any of the stockholders, to cause us to issue more shares of common stock and/or preferred stock at such price and on such terms and conditions as are determined by the Board of Directors in its sole discretion. The issuance of additional shares of capital stock by us will dilute your ownership percentage in the Company and could impair our ability to raise capital in the future through the sale of equity securities.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Certain stockholders who are also officers and directors of the Company may have significant control over our management.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our directors and executive officers own as of March 31, 2022, an aggregate of 3,290,577 shares of our common stock, which currently constitutes 41.46 % of our issued and outstanding common stock and, upon closing of this offering, will own an aggregate of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock, which will constitute &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of our issued and outstanding common stock. As a result, our directors and executive officers may have a significant influence on our affairs and management, as well as on all matters requiring stockholder approval, including electing and removing members of our Board of Directors, causing us to engage in transactions with affiliated entities, causing or restricting our sale or merger, and certain other matters. Such concentration of ownership and control could have the effect of delaying, deferring or preventing a change in control of us even when such a change of control would be in the best interests of our stockholders.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Anti-takeover protections in our amended and restated certificate of incorporation and our amended and restated bylaws, each of which will be in effect prior to the completion of this offering, or our contractual obligations may discourage or prevent a takeover of our Company, even if an acquisition would be beneficial to our stockholders. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provisions contained in our amended and restated certificate of incorporation and our amended and restated bylaws, each as amended to be in effect upon completion of this offering, as well as provisions of the DGCL, could delay or make it more difficult to remove incumbent directors or could impede a merger, takeover or other business combination involving us or the replacement of our management, or discourage a potential investor from making a tender offer for our common stock, which, under certain circumstances, could reduce the market value of our common stock, even if it would benefit our stockholders. Among other things, these provisions: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">do not permit cumulative voting in the election of directors, which would otherwise allow less than a majority of stockholders to elect director candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">delegate the sole power of a majority of the board of directors to fix the number of directors;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">provide the power to our board of directors to fill any vacancy on our board of directors, whether such vacancy occurs as a result of an increase in the number of directors or otherwise;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">generally limit stockholders ability to call special meetings of stockholders and generally prohibit stockholder action to be taken by written consent; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">establish advance notice requirements for nominations for election to our board of directors or for proposing matters that can be acted on by stockholders at stockholder meetings. </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our amended and restated bylaws will designate the Court of Chancery of the State of Delaware as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could limit our stockholders' ability to obtain a favorable judicial forum for disputes with us or our directors, officers, employees, agents or other stockholders. </font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our amended and restated bylaws will provide that, unless we consent in writing to an alternative forum, the Court of Chancery of the State of Delaware shall, to the fullest extent permitted by law, be the sole and exclusive forum for any (i) derivative action or proceeding brought on our behalf, (ii) action asserting a claim of breach of a fiduciary duty or other wrongdoing by any current or former director, officer, employee, agent or stockholder to us or our stockholders, (iii) <font style="color:#000000;">any action or proceeding asserting a claim against us or any current or former director, officer or other employee of the company, arising out of or pursuant to </font>arising under any provision of the DGCL, our amended and restated certificate of incorporation, or our amended and restated bylaws or as to which the DGCL confers jurisdiction on the Court of Chancery of the State of Delaware, or (iv) action asserting a claim governed by the internal affairs doctrine of the law of the State of Delaware, except for, as to each of (i) through (iv) above, any action as to which the Court of Chancery of the State of Delaware determines that there is an indispensable party not subject to the personal jurisdiction of the Court of Chancery of the State of Delaware (and the indispensable party does not consent to the personal jurisdiction of the Court of Chancery of the State of Delaware within ten (10) days following such determination), in which case the United States District Court for the District of Delaware or other state courts of the State of Delaware, as applicable, shall, to the fullest extent permitted by law, be the sole and exclusive forum for any such claims. However, the exclusive forum provisions shall not apply to suits brought to enforce a duty or liability created by the Securities Act, the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction, for which the federal district courts of the District of Delaware shall be the sole and exclusive forum unless the Company consents in writing to the selection of an alternative forum. Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all suits brought to enforce any duty or liability created by the Securities Act or the rules and regulations thereunder. To the fullest extent permitted by law, any person or entity purchasing or otherwise acquiring or holding any interest in any shares of our capital stock shall be deemed to have notice of and consented to the forum provision in our amended and restated bylaws. This choice of forum provision may limit a stockholder's ability to bring a claim in a different judicial forum, including one that it may find favorable or convenient for a specified class of disputes with us or our directors, officers, other stockholders, or employees, which may discourage such lawsuits, make them more difficult or expensive to pursue, and result in outcomes that are less favorable to such stockholders than outcomes that may have been attainable in other jurisdictions. By agreeing to this provision, however, stockholders will not be deemed to have waived our compliance with the federal securities laws and the rules and regulations thereunder. The enforceability of similar choice of forum provisions in other companies' certificates of incorporation has been challenged in legal proceedings, and it is possible that a court could find these types of provisions to be inapplicable or unenforceable. If a court were to find the choice of forum provisions in our amended and restated bylaws to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could have a material adverse effect on our business, financial condition and results of operations.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We are considered a &#8220;smaller reporting company&#8221; and are exempt from certain disclosure requirements, which could make our stock less attractive to potential investors.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Rule 12b-2 of the Exchange Act defines a &#8220;smaller reporting company&#8221; as an issuer that is not an investment company, an asset-backed issuer, or a majority-owned subsidiary of a parent that is not a smaller reporting company and that:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Had a public float of less than $250 million as of the last business day of its most recently completed fiscal quarter, computed by multiplying the aggregate number of worldwide number of shares of its voting and non-voting common equity held by non-affiliates by the price at which the common equity was last sold, or the average of the bid and asked prices of common equity, in the principal market for the common equity; or</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">In the case of an initial registration statement under the Securities Act or the Exchange Act for shares of its common equity, had a public float of less than $250 million as of a date within 30 days of the date of the filing of the registration statement, computed by multiplying the aggregate worldwide number of such shares held by non-affiliates before the registration plus, in the case of a Securities Act registration statement, the number of such shares included in the registration statement by the estimated initial public offering price of the shares; or</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54</a></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></font><font style="color:#000000;"></font><font style="color:#000000;">In the case of an issuer who had annual revenue of less than $100 million during the most recently completed fiscal year for which audit financial statements are available, had a public float as calculated under paragraph (1) or (2) of this definition that was either zero or less than $700 million.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a &#8220;smaller reporting company&#8221; we are not required and may not include a Compensation Discussion and Analysis section in our proxy statements; we provide only 3 years of business development information; provide fewer years of selected data; and have other &#8220;scaled&#8221; disclosure requirements that are less comprehensive than issuers that are not &#8220;smaller reporting companies&#8221; which could make our stock less attractive to potential investors, which could make it more difficult for you to sell your shares.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We are considered an &#8220;emerging growth company,&#8221; and the reduced reporting requirements applicable to emerging growth companies may make our common stock less attractive to investors.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are an &#8220;emerging growth company,&#8221; as defined in the Jumpstart Our Business Startups Act, or JOBS Act. For as long as we continue to be an emerging growth company, we may take advantage of exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies, including exemption from compliance with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. We will remain an emerging growth company until the earlier of (1) the last day of the fiscal year (a) following the fifth anniversary of the closing of this offering, (b) in which we have total annual gross revenue of at least $1.07 billion or (c) in which we are deemed to be a large accelerated filer, which means the market value of our common stock held by non-affiliates exceeds $700 million as of the end of our prior second fiscal quarter, and (2) the date on which we have issued more than $1.0 billion in non-convertible debt during the prior three-year period.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards until such time as those standards apply to private companies. We intend to take advantage of the extended transition period for adopting new or revised accounting standards under the JOBS Act as an emerging growth company. As a result of this election, our financial statements may not be comparable to companies that comply with public company effective dates.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We cannot predict if investors will find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our share price may be more volatile.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">General Risk Factors </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Changes in accounting standards and subjective assumptions, estimates and judgments by management related to complex accounting matters may materially impact reporting of our financial condition and results of operations. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounting principles generally accepted in the United States and related accounting pronouncements, implementation guidelines, and interpretations we apply to a wide range of matters that are relevant to our business, such as accounting for long-lived asset impairment and share-based compensation, are complex and involve subjective assumptions, estimates and judgments by our management. Changes in these rules or their interpretation or changes in underlying assumptions, estimates or judgments by our management could significantly change or add significant volatility to our reported or expected financial performance.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">A potential failure to maintain effective internal control over financial reporting in accordance with Section 404 of the Sarbanes-Oxley Act could have a material adverse effect on our business, financial condition, and results of operations.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;). Under standards established by the Public Company Accounting Oversight Board (&#8220;PCAOB&#8221;), a deficiency in internal control over financial reporting exists when the design or </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:10pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">operation of a control does not allow management or personnel, in the normal course of performing their assigned functions, to prevent or detect misstatements on a timely basis. The PCAOB defines a material weakness as a deficiency, or combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of annual or interim financial statements will not be prevented, or detected and corrected, on a timely basis.</font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are required, pursuant to Section 404 of the Sarbanes-Oxley Act, to furnish a report by management on, among other things, the effectiveness of our internal control over financial reporting for the first fiscal year beginning after the effective date of our IPO and in each year thereafter. Our auditors will also need to attest to the effectiveness of our internal control over financial reporting. If we are unable to assert that our internal control over financial reporting is effective, or when required in the future, if our independent registered public accounting firm is unable to express an unqualified opinion as to the effectiveness of our internal control over financial reporting, investors may lose confidence in the accuracy and completeness of our financial reports, the market price of our common stock could be adversely affected, and we could become subject to litigation or investigations by the stock exchange on which our common stock are listed, the SEC or other regulatory authorities, which could require additional financial and management resources and could have a material adverse effect on our business, financial condition, and results of operations. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">The lack of public company experience of our management team could adversely impact our ability to comply with the reporting requirements of U.S. securities laws, which could have a materially adverse effect on our business.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our officers have limited public company experience, which could impair our ability to comply with legal and regulatory requirements such as those imposed by Sarbanes-Oxley Act. Such responsibilities include complying with federal securities laws and making required disclosures on a timely basis. Any such deficiencies, weaknesses or lack of compliance could have a materially adverse effect on our ability to comply with the reporting requirements of the Exchange Act, which is necessary to maintain our public company status. If we were to fail to fulfill those obligations, our ability to continue as a U.S. public company would be in jeopardy in which event you could lose your entire investment in our Company.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We identified material weaknesses in our internal control over financial reporting, and we may identify additional material weaknesses in the future that may cause us to fail to meet our reporting obligations or result in material misstatements of our financial statements. If we fail to remediate any material weaknesses or if we otherwise fail to establish and maintain effective control over financial reporting, our ability to accurately and timely report our financial results could be adversely affected.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon becoming a public company, we will be required to comply with the SEC&#8217;s rules implementing Sections 302 and 404 of the Sarbanes-Oxley Act, which will require management to certify financial and other information in our quarterly and annual reports and provide an annual management report on the effectiveness of our controls over financial reporting. Although we will be required to disclose changes made in our internal controls and procedures on a quarterly basis, we will not be required to make our first annual assessment of our internal controls over financial reporting pursuant to Section 404 until the later of (i) the year following our first annual report required to be filed with the SEC or (ii) the date we are no longer an emerging growth company. This assessment will need to include disclosure of any material weaknesses identified by our management in our internal control over financial reporting, as well as a statement that our independent registered public accounting firm has issued an opinion on the effectiveness of our internal control over financial reporting, provided that our independent registered public accounting firm will not be required to attest to the effectiveness of our internal control over financial reporting until our first annual report required to be filed with the Securities and Exchange Commission, or SEC, following the later of the date we are deemed to be an &#8220;accelerated filer&#8221; or a &#8220;large accelerated filer,&#8221; each as defined in the Exchange Act, or the date we are no longer an emerging growth company, as defined in the JOBS Act. We could be an emerging growth company for up to five years.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We identified deficiencies in our internal control that we consider to be material weaknesses in our internal control over financial reporting which existed as of December 31, 2021. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our consolidated financial statements will not be prevented or detected on a timely basis. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company did not maintain an effective control environment <font style="color:#000000;">as there was an insufficient complement of personnel within the finance and accounting function with appropriate degree of knowledge, experience and training in the application of U.S. generally accepted accounting principles (&#8220;U.S. GAAP).&nbsp;&nbsp;In addition, the Company did not </font>have an effective risk assessment process that defined clear financial reporting objectives and elevated risks, including fraud risks, at a sufficient level of detail to identify all relevant risks of material misstatement including the risks associated with the use of outsourced consultants in the preparation of schedules supporting balances within the consolidated financial statements.&nbsp;&nbsp;These factors contributed to the following additional material weaknesses.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We failed to design, implement and maintain effective controls regarding:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>the accounting for stock-based compensation and other stock-based financial instruments in accordance with U.S. GAAP. Specifically, we did not design and maintain controls to timely identify transactions requiring a valuation of our common stock and to review in sufficient detail, the valuation model assumptions used in determining the fair value of our common stock which is used as an input in accounting for stock-based compensation provided to employees and other stock-based financial instruments;&nbsp;&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the calculation of </font><font style="Background-color:#FFFFFF;color:#333333;">earnings per share in accordance with </font><font style="color:#000000;">U.S. GAAP; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>the reconciliation and review of significant account balances, authorization over cash disbursements, stock-based compensation calculations and related valuation models including inputs, period end financial reporting, risks associated with segregation of duties, and certain other entity level controls.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As we work towards remediating these&#160;material weaknesses, we will design and implement controls to properly identify transactions for which a valuation of our common stock is required and to review assumptions used in the valuation models to ensure our equity-based transactions are accounted for in accordance with U.S. generally accepted accounting principles. Additionally, we will design and implement controls to properly calculate basic and diluted weighted-average shares outstanding. Lastly, we will design, document, and consistently perform control activities in the identified areas which are currently lacking. To assist us in the remediation and performance of remediated controls we recently hired a Corporate Controller, and we will continue to utilize an accounting and financial reporting advisory firm with significant experience with publicly held companies to assist our management in evaluating transactions requiring the valuation of our common stock, in retaining and reviewing the work of valuation experts necessary to complete those valuations, and performing the calculation of basic and diluted weighted-average shares outstanding.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may identify future material weaknesses in our internal controls over financial reporting or fail to meet the demands that will be placed upon us as a public company, including the requirements of the Sarbanes-Oxley, and we may be unable to accurately report our financial results, or report them within the timeframes required by law or stock exchange regulations. We cannot assure that our existing material weakness will be remediated or that additional material weaknesses will not exist or otherwise be discovered, any of which could adversely affect our reputation, financial condition and results of operations.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We will incur increased costs as a result of being a publicly traded company. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a company with publicly traded securities, we will incur significant legal, accounting and other expenses not presently incurred as a private company. In addition, the Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Consumer Protection Act and the rules and regulations promulgated by the SEC and Nasdaq, will require us to adopt corporate governance practices applicable to U.S. public companies. These rules and regulations will increase our legal and financial compliance costs and may place a strain on our systems and resources. The Exchange Act requires that we file annual, quarterly and current reports with respect to our business and financial condition. The Sarbanes-Oxley Act requires that we maintain effective disclosure controls and procedures and internal controls over financial reporting. To maintain and improve the effectiveness of our disclosure controls and procedures, we will need to commit significant resources, hire additional staff and provide additional management oversight. We will be implementing additional procedures and processes for the purpose of addressing the standards and requirements applicable to public companies. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Unanticipated changes in the insurance market or factors affecting self-insurance reserve estimates could have a material adverse effect on our business, financial condition and results of operations. </font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We use a combination of insurance and self-insurance coverage to provide for potential liabilities for workers' compensation, general liability, property losses, auto liability, directors and officers liability, pharmacy liability and employee health care benefits. However, there are types of losses we may incur but against which we cannot be insured or which we believe are not economically reasonable to insure, such as losses due to acts of war, employee and certain other crime, certain wage and hour and other employment-related claims, including class actions, actions based on certain customer protection laws, certain cyber events and some natural and other disasters or similar events. If we incur these losses and they are material, our business could suffer. Liabilities associated with the risks that are retained by us are determined, based in part, by considering historical claims experience, severity factors, inflation, and other actuarial assumptions. Our determination of the risk we retain is subject to a high degree of variability related to, among other things, future interest and inflation rates, future economic conditions, litigation trends and benefit-level changes. Any deviation of actual claims and other expenses related to these and other risks in excess of our assumptions, estimates, and historical trends, may have a material adverse effect on our business, financial condition and results of operations.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We are currently operating in a period of economic uncertainty and capital markets disruption, which has been significantly impacted by geopolitical instability due to the ongoing military conflict between Russia and Ukraine.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. and global markets are experiencing volatility and disruption following the escalation of geopolitical tensions and the start of the military conflict between Russia and Ukraine. In February 2022, Russia launched a full-scale military invasion of Ukraine. Although the length and impact of the ongoing military conflict is highly unpredictable, the conflict in Ukraine could lead to market disruptions, including significant volatility in commodity prices, credit and capital markets. Additionally, Russia&#8217;s prior annexation of Crimea, recent recognition of two separatist republics in the Donetsk and Luhansk regions of Ukraine and subsequent military interventions in Ukraine have led to sanctions and other penalties being levied by the United States, European Union and other countries against Russia, Belarus, the Crimea Region of Ukraine, the so-called Donetsk People&#8217;s Republic, and the so-called Luhansk People&#8217;s Republic, including agreement to remove certain Russian financial institutions from the Society for Worldwide Interbank Financial Telecommunication (SWIFT) payment system. Additional potential sanctions and penalties have also been proposed and/or threatened. Russian military actions and the resulting sanctions could adversely affect the global economy and financial markets and lead to instability and lack of liquidity in capital markets, potentially making it more difficult for us to obtain additional funds. Any of the abovementioned factors could affect our business, prospects, financial condition, and operating results. The extent and duration of the military action, sanctions and resulting market disruptions are impossible to predict, but could be substantial. Any such disruptions may also magnify the impact of other risks described in this registration statement on Form S-1.</p><a name="_AEIOULastRenderedPageBreakAEIOU8"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="CAUTIONARY_NOTE_REGARDING_FORWARDLOOKING"></a><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="CAUTIONARY_NOTE_REGARDING_FORWARDLOOKING"></a>CAUTIONARY NOTE REGARDING </font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FORWARD-LOOKING STATEMENTS</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain statements contained in this prospectus, which reflect our current views with respect to future events and financial performance, and any other statements of a future or forward-looking nature constitute &#8220;forward-looking statements&#8221; within the meaning of the federal securities laws. We intend the forward-looking statements to be covered by the applicable safe harbor under the federal securities laws. In some cases, you can identify forward-looking statements by terms such as &#8220;may,&#8221; &#8220;should,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;predicts,&#8221; &#8220;potential,&#8221; &#8220;continue,&#8221; &#8220;expects,&#8221; &#8220;anticipates,&#8221; &#8220;future,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;believes,&#8221; &#8220;estimates,&#8221; or the negative of these terms or other similar expressions, as well as statements in future tense, identify forward-looking statements. Forward-looking statements should not be read as a guarantee of future performance or results and may not be accurate indications of when such performance or results will be achieved. Forward-looking statements are based on the information we have when the statements are made or management&#8217;s good faith belief as of that time with respect to future events and are subject to significant risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forward-looking statements necessarily involve risks and uncertainties, and our actual results could differ materially from those anticipated in the forward-looking statements due to a number of factors, including those set forth above under &#8220;Risk Factors&#8221; and elsewhere in this prospectus. The factors set forth above under &#8220;Risk Factors&#8221; and other cautionary statements made in this prospectus should be read and understood as being applicable to all related forward-looking statements wherever they appear in this prospectus. The forward-looking statements contained in this prospectus represent our judgment as of the date of this prospectus. We caution readers not to place undue reliance on such statements. We operate in an evolving environment where new risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties. Except as required by law, we undertake no obligation to update publicly any forward-looking statements for any reason, even if new information becomes available or other events occur in the future. All subsequent written and oral forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the cautionary statements contained above and throughout this prospectus.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">INDUSTRY AND OTHER DATA</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We obtained the industry, market and competitive position data in this prospectus from our own internal estimates and research as well as from industry and general publications and research, surveys and studies conducted by third parties. Information that is based on estimates, forecasts, market research or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances that are assumed in this information based on various factors, including those discussed in &#8220;Risk Factors.&#8221;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">TRADEMARKS, SERVICE MARKS AND TRADE NAMES</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We own or have rights to use a number of registered and common law trademarks, service marks and/or trade names in connection with our business in the United States and/or in certain foreign jurisdictions.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Solely for convenience, the trademarks, service marks, logos and trade names referred to in this prospectus are without the &#174; and &#8482; symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the rights of the applicable licensors to these trademarks, service marks and trade names. This prospectus contains additional trademarks, service marks and trade names of others, which are the property of their respective owners. All trademarks, service marks and trade names appearing in this prospectus are, to our knowledge, the property of their respective owners. We do not intend our use or display of other companies&#8217; trademarks, service marks, copyrights or trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies.</p><a name="_AEIOULastRenderedPageBreakAEIOU9"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="USE_PROCEEDS"></a><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="USE_PROCEEDS"></a>USE OF P</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ROCEEDS</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We estimate that the net proceeds from the sale of the common stock we are offering will be approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million. If the underwriters fully exercise the over-allotment option, the net proceeds of the common stock we sell will be approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;  million. These assume an initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;  per share, the midpoint of the estimated initial public offering price range set forth on the cover page of this prospectus. &#8220;Net proceeds&#8221; is what we expect to receive after deducting the underwriting discount and commission and estimated offering expenses payable by us. We intend to use the net proceeds from this offering, along with our existing cash and cash equivalents, as follows:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">approximately $10-15 million to fund the planned Phase 2 trial of THIO for NSCLC indication (THIO-101);</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">approximately $2-4 million to fund the planned Phase 2 trial of THIO for CRC indication (THIO-102);</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">approximately $3-5 million to fund pre-clinical to IND development for two second-generation telomere targeting compounds;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the remaining proceeds to fund our other research and development activities, as well as for working capital and other general corporate purposes.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A $1.00 increase (decrease) in the assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, the midpoint of the estimated initial public offering price range set forth on the cover page of this prospectus, would increase (decrease) the net proceeds to us from this offering by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million, assuming the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting the underwriting discount and commission and estimated offering expenses payable by us in connection with this offering.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The net proceeds from this offering, together with our cash, will not be sufficient for us to fund any of our product candidates through regulatory approval, and we will need to raise additional capital to complete the development and commercialization of our product candidates. We may satisfy our future cash needs through the sale of equity securities, debt financings, working capital lines of credit, corporate collaborations or license agreements, grant funding, interest income earned on invested cash balances or a combination of one or more of these sources. This expected use of the net proceeds from this offering represents our intentions based upon our current plans and business conditions. As of the date of this prospectus, we cannot predict with certainty all of the particular uses for the net proceeds to be received upon the closing of this offering or the amounts that we will actually spend. The amounts and timing of our actual expenditures and the extent of clinical development may vary significantly depending on numerous factors, including the progress of our development efforts, the clinical trials we may commence in the future, as well as any collaborations that we may enter into with third parties for our product candidates and any unforeseen cash needs. As a result, our management will have significant discretion in the use of any net proceeds and Investors will be relying on the judgment of our management regarding the application of the proceeds. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based on our planned use of the net proceeds from this offering and our existing cash, we estimate that such funds will be sufficient to enable us to fund our operating expenses and capital expenditure requirements for at least the next 36 months. In particular, we expect that these capital resources will allow us to fund:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">our planned Phase 2 trial of THIO through completion; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">our planned pre-clinical to IND development for two second-generation telomere targeting compounds.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have based this estimate on assumptions that may prove to be incorrect, and we could use our available capital resources sooner than we currently expect. Our existing cash and cash equivalents as of the date of this prospectus, together with the estimated net proceeds from this offering, may or may not be sufficient to fund development of our product candidates through regulatory approval and commercialization. To obtain the capital necessary to fund our product candidates through regulatory approval and commercialization, we expect to finance our cash needs through public or private equity offerings, debt financings and/or other capital sources which may include strategic collaborations, licensing arrangements or other arrangements with third parties.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending our use of the net proceeds from this offering, we intend to invest the net proceeds in a variety of capital preservation investments, including short-term, investment-grade, interest-bearing instruments and U.S. government securities.</p><a name="_AEIOULastRenderedPageBreakAEIOU10"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="DIVIDEND_POLICY"></a><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="DIVIDEND_POLICY"></a>DIVIDEND</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> POLICY</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have never declared or paid any cash dividends on our common stock and we do not anticipate paying any cash dividends in the foreseeable future. Investors should not purchase our common stock with the expectation of receiving cash dividends. The payment of dividends, if any, in the future is within the discretion of our Board of Directors and will depend on our earnings, capital requirements and financial condition and other relevant facts. We currently intend to retain all future earnings, if any, to finance the development and growth of our business.</p><a name="_AEIOULastRenderedPageBreakAEIOU11"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="CAPITALIZATION"></a><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="CAPITALIZATION"></a>CAPITAL</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">IZATION</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table sets forth our cash and capitalization as of March 31, 2022:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:10pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">on an actual basis;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:10pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">on a pro forma as adjusted basis to give effect to the sale of common stock in this offering, assuming no exercise of the underwriters&#8217; option to purchase additional shares, at an assumed initial public offering price of $ ____ per share, which is the midpoint of the estimated initial public offering price range set forth on the cover page of this prospectus, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us, and the application of the proceeds therefrom as described in &#8220;Use of Proceeds.&#8221;</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information below is illustrative only, and our capitalization following the completion of this offering will be adjusted based on the actual initial public offering price and other terms of this offering determined at pricing. You should read the information in this table together with our financial statements and accompanying notes appearing at the end of this prospectus and the &#8220;Selected Financial Data,&#8221; &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; and &#8220;Description of Capital Stock&#8221; sections of this prospectus.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of March 31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Actual</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Pro Forma</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As Adjusted </p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited)</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited)</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,293,460</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total debt</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stockholders' Equity:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preferred stock, $0.0001 par value, 70,000,000 shares authorized, 0 shares</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; issued and outstanding, actual; and 0 shares outstanding pro forma as</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; adjusted</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock, $0.0001 par value, 30,000,000 shares authorized, 7,936,320</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; shares issued and outstanding, actual; and [ ] shares outstanding pro forma</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; as adjusted</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">794</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additional paid-in capital</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40,862,993</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated deficit</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(31,851,838</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumlated other comprehensive income</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,721</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stockholders' equity:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,013,670</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total capitalization:</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,013,670</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The number of shares of common stock issued and outstanding and pro forma in the table above is based on 7,936,320 shares of our common stock outstanding as of March 31, 2022, and excludes the following:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:10pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">5,859,589 shares of common stock issuable upon exercise of  options to purchase shares of common stock outstanding as of March 31, 2022, with a weighted-average exercise price of $2.35 per share;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:10pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">242,911 shares of common stock reserved for future issuance as of March 31, 2022, under our 2020 Plan; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:10pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">warrants to purchase 1,250,006 shares of common stock with a weighted-average exercise price of $4.14 per share; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:10pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">29,168 shares of common stock issuable upon the settlement of outstanding restricted common stock awards, inclusive of restricted common stock awards which will vest upon the pricing of this offering.</p></td></tr></table></div><a name="_AEIOULastRenderedPageBreakAEIOU12"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="DILUTION"></a><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="DILUTION"></a>DILU</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">TION</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If you purchase common stock in this offering, your interest will be diluted immediately to the extent of the difference between the assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share and the net tangible book value per share of our common stock immediately upon the consummation of this offering.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our net tangible book value as of March 31, 2022, was $9.01 million, or $1.14 per share. Net tangible book value per share of our common stock represents our total tangible assets (total assets less intangible assets) less total liabilities divided by the number of shares of common stock outstanding as of that date.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net tangible book value dilution per share to new investors represents the difference between the amount per share paid by purchasers in this offering and the as adjusted net tangible book value per share of common stock immediately after completion of this offering. After giving effect to our sale of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock in this offering at an assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;  per share, which is the midpoint of the estimated initial public offering price range set forth on the cover page of this prospectus, and after deducting underwriters&#8217; commissions and estimated offering expenses, our as adjusted net tangible book value as of December 31, 2021, would have been $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;  million, or $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share. This represents an immediate increase in net tangible book value of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share to existing stockholders and an immediate dilution in net tangible book value of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share to purchasers of securities in this offering, as illustrated in the following table:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assumed initial public offering price per share</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net tangible book value per share as of March 31, 2022</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.14</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Increase in net tangible book value per share attributable to new investors</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As adjusted net tangible book value per share as of <font style="color:#000000;">March 31,</font> 2022, after</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; giving effect to the offering</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dilution per share to new investors in the offering</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A $1.00 increase (or decrease) in the assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, which is the midpoint of the estimated initial public offering price range set forth on the cover page of this prospectus, would increase (or decrease) the as adjusted net tangible book value per share after this offering by approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, and dilution in net tangible book value per share to new investors by approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the underwriters exercise their option in full to purchase &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;  additional shares of common stock in this offering at the assumed offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;  per unit, the net tangible book value per share after this offering would be $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, the increase in the net tangible book value per share to existing stockholders would be $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share and the dilution to new investors purchasing common stock in this offering would be $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To the extent that outstanding exercisable options or warrants are exercised, you may experience further dilution.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, we may choose to raise additional capital due to market conditions or strategic considerations, even if we believe we have sufficient funds for our current or future operating plans. To the extent that we raise additional capital by issuing equity securities or convertible debt, your ownership will be further diluted.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SELECTED FINANCIAL DATA</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">You should read the following selected financial data together with our financial statements and the related notes appearing at the end of this prospectus and the &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; section of this prospectus. We have derived the statement of operations data and balance sheet data for the years ended December 31, 2021 and 2020 from our audited financial statements appearing at the end of this prospectus. We have derived the statement of operations data for the three months ended March 31, 2022 and 2021 and the balance sheet data as of March 31, 2022, from our unaudited interim financial statements appearing at the end of this prospectus. The unaudited interim financial statements have been prepared on the same </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:10pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">basis as the audited financial statements and reflect, in the opinion of management, all adjustments of a normal, recurring nature that are necessary for a fair presentation of the unaudited interim financial statements. Our historical results are not necessarily indicative of results that should be expected in any future period, and our results for any interim period are not necessarily indicative of results that should be expected for any full year</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.32%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="5" valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.66%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December 31,</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited)</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance Sheet Data:</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,293,460</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,574,292</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">663,457</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Working capital (deficit) <sup style="font-size:85%;line-height:120%;vertical-align:top">(1)</sup></p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,097,195</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,526,499</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(947,239</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total assets</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,444,563</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,327,199</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">746,505</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued Interest</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,678</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued bonus</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">561,873</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">384,750</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">780,000</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred compensation</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">114,333</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">111,271</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">661,058</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Convertible note payable, current portion</p></td>
<td colspan="2" valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,586</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Convertible notes payable, net of current portion</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">332,841</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Derivative liability for embedded conversion features&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; on convertible notes payable and related parties</p></td>
<td colspan="2" valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">127,000</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Convertible notes payable, related parties</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">98,960</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrant liability</p></td>
<td colspan="2" valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85,260</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Simple agreement for future equity payable</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,000</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stockholders' equity (deficit)</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,013,670</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,181,203</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,616,300</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">1)</sup> We define working capital (deficit) as current assets less current liabilities.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="8" valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="7" valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48.76%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="8" valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.16%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="7" valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.7%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48.76%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="4" valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="3" valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="3" valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="3" valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="8" valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited)</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.5%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Statement of Operations Data:</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.64%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses:</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.64%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.64%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,077,329</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">262,758</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,496,796</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,412,409</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48.76%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.52%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,366,229</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">787,955</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,289,831</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,563,192</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48.76%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating expenses</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,443,558</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,050,713</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,786,627</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,975,601</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48.76%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,443,558</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,050,713</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7,786,627</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,975,601</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">) </p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Paycheck protection program loan forgiveness</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.52%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.14%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62,500</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.5%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62,500</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Austrailian research and development incentives</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.64%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,241</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43,666</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest expense</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.14%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(62,767</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(827,539</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(32,226</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">) </p></td>
</tr>
<tr>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.64%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">472</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">141</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,012</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">679</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value of embedded features</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.14%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(15,000</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(203,000</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,000</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value of warrant liability</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.14%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">106,820</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,546,280</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19,600</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">) </p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48.76%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss on extinguishment of convertible notes and</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.52%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.14%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,322,943)</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48.76%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; convertible notes, related parties</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.52%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.64%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.5%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,413,845</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.5%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,021,519</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12,578,211</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,959,248</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">) </p></td>
</tr>
<tr>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to noncontrolling interests</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.14%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(37,525</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(74,331</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(322,588</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">) </p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48.76%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deemed dividend on warrant modification</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.52%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(450,578</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48.76%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to MAIA Biotechnology, Inc.</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.52%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.64%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,864,423</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(983,994</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12,503,880</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.64%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,636,660</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48.76%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per common share - basic and diluted<sup style="font-size:85%;line-height:120%;vertical-align:top">(1)</sup></p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.52%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.64%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.5%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.50</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.5%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.23</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.37</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.64%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.5%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.50</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48.76%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average common shares outstanding - basic</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.52%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.14%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,752,042</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,329,088</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,278,435</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.64%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,427,242</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48.76%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; and diluted<sup style="font-size:85%;line-height:120%;vertical-align:top">(1)</sup></p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.52%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.14%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.64%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(1)</sup> See Note 1 to our audited financial statements appearing at the end of this prospectus for further details on the calculation of basic and diluted net loss per common share.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p><a name="_AEIOULastRenderedPageBreakAEIOU13"></a>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="Section1"></a><a name="MANAGEMENTS_DISCUSSION_ANALYSIS_FINANCIA"></a><a name="MANAGEMENTS_DISCUSSION_ANALYSIS_FINANCIA"></a>MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">You should read the following discussion together with our financial statements and the related notes included elsewhere in this prospectus. This discussion contains forward-looking statements that are based on our current expectations, estimates and projections about our business and operations. Our actual results may differ materially from those currently anticipated and expressed in such forward-looking statements as a result of a number of factors, including those which we discuss under &#8220;Risk Factors&#8221; and elsewhere in this prospectus. See &#8220;Cautionary Note Regarding Forward-Looking Statements.&#8221;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Overview</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a clinical stage biotechnology company engaged in the discovery, development and commercialization of therapies targeting cancer. Our initial disease target is lung cancer, a serious medical condition with an incidence of over 235,000 new cases in the US in 2021, representing 12.4% of all cancers, and over 131,000 deaths, or 21.7% of all cancers. Worldwide, lung cancer incidence is over 2,200,000 per year (ranking second only after breast cancer), and mortality over 1,800,000 (ranking first). Specifically, we are targeting Non-Small Cell Lung Cancer (NSCLC), which represents 85% of all lung cancers.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We accomplished the following key milestones:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">In November 2018, we in-licensed THIO from University of Texas Southwestern, in Dallas. The patent license is global and exclusive for the duration of the patients&#8217; lives.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">In 2019, we completed a common stock seed round in the amount of $2 million.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">In 2019, we generated the first data for THIO demonstrating complete regression with no recurrence when administered in advance of atezolizumab (TecentriQ&#174;; Genentech), in colorectal and lung cancer preclinical models.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">In the First Quarter 2020, we filed a provisional patent application for THIO in sequential combination with checkpoint inhibitors, covering all tumor types. The patent was allowed in the US in the First Quarter 2021 and expires in 2041.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">In the First Quarter 2021, we entered into a Drug Supply Agreement with Regeneron Pharmaceuticals, Inc. Under this agreement, Regeneron will provide cemiplimab (LIBTAYO; anti-PD-1 checkpoint inhibitor) at no charge for the THIO-101 trials, testing THIO administration for immune activation followed by cemiplimab in NSCLC. This drug supply agreement replaces direct drug purchase expense that we would be otherwise required to incur. In exchange, Regeneron received development exclusivity in NSCLC for the duration of the trial which is expected to be two years, meaning we cannot conduct trials in NSCLC with another checkpoint inhibitor during the time of the trial. All other areas of study and development in any other tumor types remain open.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">In the First Quarter 2021, we initiated our clinical supply manufacturing (CMC) under Good Manufacturing Practices (GMP) conditions to provide clinical supply for THIO-101 and other development needs.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">In the Second Quarter 2021, we completed a convertible note funding round in the amount of approximately $8 million.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">In the Third Quarter 2021 and Fourth Quarter 2021, we sold common shares of MAIA for total proceeds of approximately $6.2 million. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">In the First Quarter 2022, we completed the Crossover Round for total proceeds of approximately $2.4 million. After this round, we believe we have raised sufficient capital to fund the THIO-101 lead-in and preliminary efficacy of the phase 2 THIO-101 trial.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">In the First Quarter 2022, THIO received approval by the Bellberry Human Research Ethics Committee (HREC) in Australia to initiate the THIO-101 Phase 2 clinical study.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">In March 2022, the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) to THIO for the treatment of hepatocellular carcinoma, and in May 2022, the FDA granted ODD to THIO for the treatment of small cell lung cancer. The FDA&#8217;s Office of Orphan Products Development may grant orphan designation status to drugs and biologics that are intended for the treatment, diagnosis or prevention </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66</a></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">of rare diseases, or conditions that affect fewer than 200,000 people in the U.S. Orphan Drug Designation provides certain benefits, including financial incentives, to support clinical development and the potential for up to seven years of market exclusivity for the drug for the designated orphan indication in the U.S. if the drug is ultimately approved for its designated indication.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Impact of the COVID-19 Pandemic on Our Operations</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On January 30, 2020, the World Health Organization (&#8220;WHO&#8221;) announced a global health emergency because of a new strain of coronavirus originating in Wuhan, China (the &#8220;COVID-19 Outbreak&#8221;) and the risks to the international community as the virus spreads globally beyond its point of origin. In March 2020, the WHO classified the COVID-19 Outbreak as a pandemic, based on the rapid increase in exposure globally.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The full impact of the COVID-19 Outbreak continues to evolve as of the date of this report. As a result, we cannot estimate the full magnitude that the pandemic will have on our business. If the COVID-19 Outbreak continues, it may have a material adverse effect on our financial condition, liquidity, and future results of operations for the future. We are actively monitoring the impact of the global pandemic on our financial condition, liquidity, operations, industry, and workforce. Given the daily evolution of the COVID-19 Outbreak and the global responses to curb its spread, we are not able to estimate the effects of the COVID-19 Outbreak on our results of operations, financial condition, or liquidity for the future. While we have not currently experienced any potential delays or increased costs as a result of these measures, we may do so in the future.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><a name="_Hlk102495713"></a>Impact of the War in Ukraine on Our Operations</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#333333;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#333333;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The short and long-term implications of Russia&#8217;s invasion of Ukraine are difficult to predict at this time. The imposition of sanctions and counter sanctions may have an adverse effect on the economic markets generally and could impact our business, financial condition, and results of operations. Because of the highly uncertain and dynamic nature of these events, the Company terminated any planned research activities in Russia. </p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Financial Operations Overview and Analysis For the Years Ended December 31, 2021 and 2020</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Comparison of the Years Ended December 31, 2021 and 2020</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.84%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.52%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="5" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.02%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Change</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.84%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Dollars</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Percentage</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.86%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,496,796</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,412,409</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,084,387</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">148%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,289,831</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,563,192</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,273,361</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.86%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(23)%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating costs and expenses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,786,627</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,975,601</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">811,026</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7,786,627</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,975,601</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(811,026</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12)%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income (expense):</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.86%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Paycheck protection program loan forgiveness</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62,500</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62,500</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest expense</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(827,539</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(32,226</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(795,313</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2468)%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest Income</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,012</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">679</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,333</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">196%</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Australian research and development incentives</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43,666</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43,666</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value of embedded features</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(203,000</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,000</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(208,000</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4160)%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value of warrant liability</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,546,280</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19,600</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,526,680</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7789)%</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss on extinguishment of convertible notes</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; and convertible notes, related parties</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,322,943</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,322,943</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.86%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(100)%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income (expense), net</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,791,584</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,353</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,807,937</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(29401)%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12,578,211</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,959,248</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,618,963</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.86%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(81)%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to noncontrolling interests</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(74,331</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(322,588</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">248,257</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.86%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.84%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to MAIA Biotechnology,</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; Inc. shareholders</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12,503,880</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,636,660</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,867,220</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(88)%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Operating Expenses</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Research and development expenses</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses increased by approximately $2,084,000 or 148%, from approximately $1,412,000 for the year ended December 31, 2020 to approximately $3,497,000 for the year ended December 31, 2021. The increase was primarily related to the increase in clinical expenses related to the clinical preparation of THIO of approximately $802,000, an increase in stock based compensation costs of approximately $518,000 related to employee options granted during fiscal year 2021, an increase in payroll and bonus expenses of approximately $384,000 related to increased headcount of two employees during fiscal year 2021 and bonus accruals for certain executive members of management, an increase in professional fees of approximately $326,000, and an increase in other expenses related to research and development of approximately $56,000.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">General and administrative expenses</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses decreased by approximately $1,273,000 or 23% from approximately $5,563,000 for the year ended December 31, 2020 to approximately $4,290,000 for the year ended December 31, 2021. The decrease was primarily related to a decrease in stock based compensation expense of approximately $1,733,000 and a decrease in payroll and bonus expense of approximately $448,000, offset by an increase in professional fess of approximately $636,000, an increase in the state of Delaware business franchise tax of approximately $37,000, and an increase in other general and administrative expenses of approximately $188,000. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Other income (expense), net</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income (expense), net changed approximately $4,808,000 from other income of approximately $16,000 for the year ended December 31, 2020 to other expense of approximately $4,792,000 for the year ended December 31, 2021. The change in other income (expense), net was primarily the result of a loss on extinguishment of convertible notes and convertible notes of approximately $2,323,000, an increase in interest expense of approximately $795,000 related to the issuance of additional convertible notes payable issued during the year ended December 31, 2021, and approximately $44,000 related to a research and development incentive. Additionally, other income (expense), net </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:10pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">changed by approximately $208,000 and $1,527,000 for the embedded features and warrants related to the convertible notes payable, respectively, due to the increase of the fair value of the mark-to-market adjustments recorded.</font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Liquidity and Capital Resources</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table presents selected financial information and statistics as of and for the years ended December 31, 2021 and 2020:</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Years Ended December 31, 2021 and 2020</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance Sheet Data:</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,574,292</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">663,457</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Working Capital (Deficit)</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,526,499</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(947,239</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total assets</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,327,199</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">746,505</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Convertible notes payable - current portion</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,586</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loan payable to officer</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,367</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Convertible notes payable, net of current portion</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">332,841</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Convertible notes payable, related parties</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">98,960</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Derivative liability for embedded conversion features on convertible notes payable and convertible notes payable, related parties</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">127,000</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrant liability</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85,260</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Simple agreement for future equity payable</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,000</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stockholders' equity (deficit)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,181,203</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,616,300</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Statement of Cash Flow Data:</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash flows used in operating activities</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,122,896</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,844,163</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash flows provided by investing activities</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash flows provided by financing activities</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,033,731</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">798,055</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net increase (decrease) in cash and cash equivalents</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,910,835</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,046,108</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Capital Resources</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2021, our available cash totaled approximately $10,574,000 which represented an increase of approximately $9,911,000 compared to December&#160;31, 2020. As of December&#160;31, 2021, we had working capital of approximately $8,526,000 which represents an increase of approximately $9,473,000 compared to December&#160;31, 2020. We have generated no revenues as of December 31, 2021, and we expect to continue to incur operating losses for the foreseeable future, and may never become profitable. We are dependent on our ability to continue to raise equity and/or debt financing to continue operations, and the attainment of profitable operations. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk99538117"></a><a name="_Hlk99538117"></a>Management believes that the Company&#8217;s existing cash and cash equivalents will allow the Company to continue its operations at least into the Second Quarter 2023. As a result of recurring losses, the continued viability of the Company beyond the Second Quarter 2023 is dependent on its ability to continue to raise additional capital to finance its operations.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Paycheck Protection Program Loan </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On January 31, 2021, we received a second PPP loan with a bank in the amount of $62,500. Under the terms of the PPP loan, interest accrued on the outstanding principal at the rate of 1% per annum. The Company used the entire PPP Loan for qualifying expenses. The Company received full forgiveness of all outstanding principal and accrued and unpaid interest on the PPP Loan in November 2021 in the amount of $62,500.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><font style="font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Convertible Notes</font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Between August 2019 and June 2021, we issued unsecured convertible notes payable to investors for a total of $8,010,000. The notes bore simple interest at rates between 6% and 8% per annum and were to mature two years from issuance. The notes also contained an automatic conversion feature, such that in the event we consummate an equity financing, as defined in the agreement, prior to the notes&#8217; maturity, the outstanding principal and interest would be converted into shares of the Company which may be issued in connection with such equity financing. These notes were automatically converted into shares of the Company&#8217;s common stock on September 30, 2021 at $6.00 per share as a result of the sale of common stock which qualified as an equity financing in accordance with the terms of the convertible note agreements. As of December&#160;31, 2021 there were no convertible notes payable outstanding.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Sale of Common Stock</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Between July 18, 2021 and December&#160;31, 2021, the Company sold 772,563 shares of common stock at $8.00 per share for gross proceeds of approximately $6.2 million. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the sale of common stock, the Company converted all $8,010,000 of its outstanding principal and all accrued and unpaid interest of approximately $240,000 related to the Company&#8217;s 2019 Convertible Notes, 2020 Convertible Notes, and 2021 Convertible Notes into 1,375,228 shares of the Company&#8217;s common stock on September 30, 2021.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, during January and February 2022, the Company sold 263,729 shares of common stock at $9 per share for gross proceeds of $2,373,561 before transaction costs and expenses.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We will need to raise additional capital to fund our operations, to develop and commercialize THIO, and to develop, acquire or in-license other products. We may seek to fund our operations through public equity, private equity, or debt financings, as well as other sources. We cannot make any assurances that additional financings will be available to us and, if available, on acceptable terms or at all. This could negatively impact our business and operations and could also lead to the reduction of our operations. We believe that we currently have sufficient funds to support operations through the next 12 months from the date of this filing.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Cash Flows</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Operating Activities</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the year ended December 31, 2021, net cash used in operating activities was approximately $4,123,000, which consisted of a consolidated net loss of approximately $12,578,000 offset by non-cash charges of approximately $7,330,000 which primarily includes approximately $2,723,000 in stock-based compensation, a loss of approximately $203,000 related to the change in fair value of embedded features related to convertible notes, a loss of approximately $1,546,000 related to the changes in the fair value of the warrant liability, and amortization of debt discount on convertible notes of approximately $597,000, offset by a gain from forgiveness of Payroll Protection Plan loan of approximately $63,000. Total changes in operating assets and liabilities of approximately $1,126,000 were primarily driven by an approximate $806,000 increase in accounts payable, and an approximate $1,261,000 increase in accrued expenses, offset by an approximate $7,000 decrease in related party payables, an approximate $15,000 increase in prepaid expenses and other current assets, an approximate $264,000 increase in deferred compensation, and an approximate $652,000 increase in deferred offering costs.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the year ended December 31, 2020, net cash used in operating activities was approximately $1,844,000, which consisted of a net loss of approximately $6,959,000 offset by non-cash charges of approximately $3,861,000 which primarily includes approximately $3,889,000 in stock-based compensation offset by approximately $63,000 related to gain from forgiveness of Paycheck Protection Program loan and a loss of approximately $5,000 related to the change in fair value of embedded features related to convertible notes offset by changes in the fair value of the warrant liability of approximately $20,000 and amortization of debt discount on convertible notes of approximately $20,000. Total changes in operating assets and liabilities of approximately $1,254,000 were primarily driven by an approximately $824,000 increase in accrued expenses, an approximate $483,000 increase in deferred compensation, an approximate $5,000 increase in related party payables offset by an approximate $58,000 increase in prepaid expenses and other current assets. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><font style="font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Financing Activities</font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by financing activities for the year ended December 31, 2021 was approximately $14,034,000 which consisted primarily of proceeds from issuance of convertible notes totaling approximately $7,369,000, collections of subscriptions receivable of approximately $322,000 for MAIA, proceeds from issuance of common stock (net of transaction costs) of approximately $5,742,000, proceeds from the paycheck protection program loan totaling $63,000, proceeds from exercise of warrants of approximately $529,000 for MAIA, and proceeds from exercise of stock options of approximately $9,000 for MAIA.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by financing activities for the year ended December 31, 2020 was approximately $798,000 which consisted of proceeds from issuance of convertible notes totaling approximately $610,000, collections of subscriptions receivable of approximately $102,000 and approximately $35,000 for MAIA and DGD, respectively, proceeds from the paycheck protection program loan totaling approximately $63,000, and proceeds from the issuance of common stock of DGD totaling approximately $50,000, offset by return of capital - DGD Pharmaceuticals Corporation totaling approximately $58,000, and payment on loan payable to officer of approximately $4,000. </p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Financial Operations Overview and Analysis for the Three Months Ended March 31, 2022 and 2021 </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Comparison of the Three Months Ended March 31, 2022 and 2021</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.16%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.14%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Change</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.16%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Dollar</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Percentage</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,077,329</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">262,758</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.82%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,814,571</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.82%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">690.59</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,366,229</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">787,955</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.82%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.42%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">578,274</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.82%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73.39</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating costs and expenses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,443,558</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,050,713</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.82%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.42%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,392,845</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.82%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">227.74</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,443,558</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">) </p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,050,713</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.82%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.42%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,392,845</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.82%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-227.74</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income (expense):</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.82%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.82%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest expense</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(62,767</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.82%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62,767</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.82%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-100.00</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">472</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">141</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.82%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">331</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.82%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">234.75</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Austrailian research and development incentives</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,241</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.82%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.82%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100.00</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value of embedded features</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(15,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.82%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.82%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-100.00</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value of warranty liability</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">106,820</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.82%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.42%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(106,820</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.82%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-100.00</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income (expense), net</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,713</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,194</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.82%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.42%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">519</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.82%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.78</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,413,845</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,021,519</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.82%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,392,326</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.82%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">234.19</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to noncontrolling interests</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(37,525</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.82%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,525</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.82%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-100.00</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deemed dividend on warrant modification</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(450,578</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.82%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.42%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(450,578</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.82%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100.00</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable shareholder</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,864,423</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(983,994</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.82%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.42%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,880,429</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.82%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">292.73</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Operating Expenses</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Research and development expenses</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses increased by approximately $1,815,000 or 691%, from approximately $263,000 for the three months ended March 31, 2021 to approximately $2,077,000 for the three months ended March 31, 2022. The increase was primarily related to the increase in clinical expenses related to the clinical preparation and startup of THIO trials of approximately $1,088,000, an increase in payroll and bonus expenses of approximately $330,000 related to increased headcount of four additional research and development employees during the first three months of 2022, an increase in professional fees of approximately $135,000, an increase in stock based compensation costs of approximately $207,000 related to employee options granted during fiscal year 2021, and an increase in other expenses related to research and development of approximately $55,000.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><font style="font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">General and administrative expenses</font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses increased by approximately $578,000 or 131% from approximately $788,000 for the three months ended March 31, 2021 to approximately $1,366,000 for the three months ended March 31, 2022. The increase was primarily related to an increase in professional fees of approximately $349,000, an increase in payroll of approximately $118,000, and an increase in other general fees of $158,000 offset by a decrease in stock based compensation of approximately $47,000. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Other income (expense), net</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income (expense), net increased approximately $1,000 from other income of approximately $29,000 for the three months ended March 31, 2021 to other income of approximately $30,000 for the three months ended March 31, 2022. The change in other income (expense), net was primarily the result of a decrease in interest expense of approximately $63,000 related to the issuance of convertible notes payable issued during the three months ended March 31, 2021, a decrease of $15,000 related to a change in fair value of embedded features offset by a net change of approximately $106,000 for change in fair value of warrant liability.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Liquidity and Capital Resources</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Capital Resources</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March 31, 2022, our available cash totalled approximately $10,293,000 which represented a decrease of approximately $281,000 compared to December&#160;31, 2021. As of March 31, 2022, we had working capital of approximately $8,097,000 which represents a decrease of approximately $429,000 compared to December&#160;31, 2021. We have generated no revenues and we expect to continue to incur operating losses for the foreseeable future and may never become profitable. We are dependent on our ability to continue to raise equity and/or debt financing to continue operations, until the attainment of profitable operations. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We will need to raise additional capital to fund our operations, to develop and commercialize THIO, and to develop, acquire or in-license other products. We may seek to fund our operations through public equity, private equity, or debt financings, as well as other sources. We cannot make any assurances that additional financings will be available to us and, if available, on acceptable terms or at all. This could negatively impact our business and operations and could also lead to the reduction of our operations. We believe that we currently have sufficient funds to support operations through the next 12 months from the date of this filing. If the Company is unable to raise the necessary funding, management will undertake cost cutting measures, as done in the past, to reduce compensation and reduce the scope of or delay its clinical programs.&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Cash Flows<font style="font-weight:normal;font-style:normal;"> </font>Three Months Ended March 31, 2022 and March 31, 2021</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.9%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.48%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.9%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash flows used in operating activities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.36%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,545,718</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.5%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(253,315</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash flows provided by financing activities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.36%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,269,168</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,429,535</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.9%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effect of foreign currency exchange on cash</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,282</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.9%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net (decrease) increase in cash and cash equivalents</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.36%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(280,832</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,176,220</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Operating Activities</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the three months ended March 31, 2022, net cash used in operating activities was approximately $2,546,000, which consisted of a consolidated net loss of approximately $3,414,000 offset by non-cash charges of approximately $713,000 in stock-based compensation. Total changes in operating assets and liabilities of approximately $155,000 were driven by an approximate $134,000 increase in prepaid assets, an approximate $67,000 decrease in accounts payable offset by an approximate $353,000 increase in accrued expenses and $3,000 increase in deferred compensation.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the three months ended March 31, 2021, net cash used in operating activities was approximately $253,000, which consisted of a net loss of approximately $1,021,519 offset by non-cash charges of approximately $507,000 which primarily includes approximately $553,000 in stock-based compensation, $15,000 related to the change in fair value of embedded features, $45,000 amortization of debt discount on convertible notes offset by changes in the fair value of the warrant liability of approximately $107,000. Total changes in operating assets and liabilities of approximately $261,000 were primarily driven by an approximate$120,000 increase in accounts payable, an approximate $48,000 increase in accrued expenses, an approximate increase in deferred compensation of $125,000 and an approximate $44,000 decrease in prepaid expenses offset by an approximate $69,000 increase in other assets and an approximate $7,000 decrease in amounts due to related parties. </font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the three months ended March 31, 2022 the effect of foreign currency exchange on cash increased the cash balance as of March 31, 2022 approximately $4,000.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Financing Activities</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by financing activities was approximately $2,269,000 and $2,430,000 for the three months ended March 31, 2022 and 2021, respectively. Net cash provided by financing activities for the three months ended March 31, 2022 consisted primarily of proceeds from issuance of common stock with no transaction costs of approximately of $2,374,000 and net proceeds from issuance of common stock upon exercise of warrants of $110,000 and stock options of approximately $48,000 offset by an approximate $262,000 increase in deferred offering costs. Net cash provided by financing activities for the three months ended March 31, 2021 consisted of proceeds from issuance of convertible notes totaling approximately $2,360,000, collections of subscriptions receivable of approximately $2,000, proceeds from the paycheck protection program loan totaling approximately $63,000, and proceeds from exercise of stock options of approximately $5,000.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Critical Accounting Policies and Significant Judgments and Estimates</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Management&#8217;s discussion and analysis of our financial condition and results of our operations is based on our consolidated financial statements, which have been prepared in accordance with U.S. GAAP. The preparation of these financial statements requires us to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities as of the date of the balance sheet and the reported amounts of expenses during the reporting period. In accordance with U.S. GAAP, we evaluate estimates and judgments on an ongoing basis. The most significant estimates relate to the valuation of common stock, the valuation of stock options and warrants, embedded features in convertible notes, and the valuation allowance of deferred tax assets resulting from net operating losses. We base our estimates and assumptions on current facts, historical experiences, and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We define our critical accounting policies as those accounting principles that require it to make subjective estimates and judgments about matters that are uncertain and are likely to have a material impact on our financial condition and results of operations, as well as the specific manner in which we apply those principles. While our significant accounting policies are more fully described in Note 1 to our financial statements, we believe the following are the critical accounting policies used in the preparation of its financial statements that require significant estimates and judgments.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Fair value of common stock </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For all periods prior to this offering, there was no public market for our common stock. The Company sold shares of its common stock to third parties beginning in September 2018 through June 2019 at $1.80 per share. Subsequent to July 2019 the fair value of the shares of common stock underlying our stock-based awards was estimated by our board of directors based in part on valuations until we began selling shares of our common stock to third parties beginning on July 15, 2021 through October 15, 2021 at $8.00 per share and beginning on January 27, 2022 through February 27, 2022 at $9.00 per share. To determine the fair value of our common stock underlying annual option grants to officers and directors, our board of directors considered, among other things, input from management, valuations of our common stock valuation firms in accordance with the guidance provided by the American Institute of Certified Public Accountants 2013 Practice Aid, Valuation of Privately-Held-Company Equity Securities Issued as Compensation, and our board of directors&#8217; assessment of additional objective and subjective factors that it believed were relevant, and factors that may have changed from the date of the most recent valuation through the date of the grant. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These factors included, but were not limited to:</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">our results of operations and financial position, including our levels of available capital resources;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">our stage of development and material risks related to our business;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">our business conditions and projections;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">the valuation of publicly traded companies in the life sciences industry sectors, as well as recently completed mergers and acquisitions of peer companies;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">the lack of marketability of our common stock as a private company;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">the likelihood of achieving a liquidity event for our security holders, such as an initial public offering or a sale of our company, given prevailing market conditions;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">the hiring of key personnel and the experience and expertise of management;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">trends and developments in our industry; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">external market conditions affecting the life sciences industry sectors.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our valuation as of February 28, 2021 indicated a fair value of our common stock of $1.83 per share. For grants of stock awards and stock option awards during the period February 28, 2021 through July 12, 2021, management set the exercise prices for those awards based on the February 28, 2021 valuation until the Company initiated the sale of common stock at $8.00 per share which was first competed on July 18, 2021 and followed by additional sales through September 26, 2021. The Company set the exercise price of awards granted from July 18, 2021 through October 30, 2021 at $8.00 per share.  </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In evaluating the fair value of our common stock during the period March 2021 through May 2021, management evaluated events and their potential impact on the estimated fair value per share of the common stock. We considered events during this period which would have an effect on the fair value of our common stock such as milestones related to the clinical development and operations of our drug substances and advances in the production of drug substances and our drug product, however, there were no specific events that would indicate a definitive change in the value of the Company.&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Given that there were no specific events that caused the change in fair value of our common stock from the indicated value of $1.83 as of February 28, 2021 to the $8.00 per share realized from the sale of common stock initiated in mid July, we performed a retrospective valuation of our common stock as of April 30, 2021. The retrospective valuation as of April 30, 2021 also indicated a fair value of our common stock of $1.83. In estimating the fair value of stock and stock option awards, we used an estimated fair value of $1.83 for awards granted from February 28, 2021 through May 31, 2021, based on the February 28, 2021 and April 30, 2021 valuations. From June 1, 2021 through October 30, 2021, we used an estimated of fair value of our common stock of $8.00 in valuing our stock and stock option awards. We believe the fair values based on the valuations materially represents the fair value of our common stock during the period February 28, 2021 through May 31, 2021 since no single intervening specific event indicated a definitive change in the value of the Company.  </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk102561081"></a><a name="_Hlk102561081"></a>The February 28, 2021 and the April 30, 2021 valuations used the income approach and the market approach in estimating the fair value of our common stock. The market approach utilized guideline public companies in estimating fair value of our stock. The income approach estimates enterprise value based on the estimated present value of future cash flows the business is expected to generate over its remaining life. The estimated present value is calculated using a discount rate reflective of the risks associated with an investment in a similar company in a similar industry or having a similar history of revenue growth. The market approach measures the value of a business through an analysis of recent sales or offerings of comparable investments or assets, and in our case, focused on comparing us to a group of our peer companies. In applying this method, valuation multiples are derived from historical and projected operating data of the peer company group. We then apply the selected multiples to our operating data to arrive at a range of indicated enterprise values of the Company. We then subtracted the net debt to determine equity value. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During November 2021 and December 2021, the fair value of the Company&#8217;s common stock was determined to be $8.69 and $8.87, respectively. For our valuations of common stock performed November 2021 and December 2021, we used a hybrid method of the Option Pricing Method ("OPM&#8221;) and the Probability-Weighted Expected Return Method ("PWERM&#8221;). PWERM considers various potential liquidity outcomes. Our approach included the use of an initial public offering scenario, a scenario assuming continued operation as a private entity, and a dissolution </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">scenario. Under the hybrid OPM and PWERM, the per share value calculated under the OPM and PWERM are weighted based on expected exit outcomes and the quality of the information specific to each allocation methodology to arrive at a final estimated fair value per share of the common stock before a discount for lack of marketability is applied. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the First Quarter of 2022, the Company made further progress in its clinical programs, which included the approval of THIO by the Bellberry Human Research Ethics Committee (HREC) in Australia to initiate the THIO-101 Phase 2 clinical study. Additionally, the Company completed its selection process for the clinical sites for its Phase 2 study in Australia and Europe and its application to start the Phase 2 study in Australia was approved. The Company also plans to submit a similar application in the second quarter of 2022, to conduct the same Phase 2 study in Europe<font style="font-size:12pt;">.</font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The events above resulted in the Company being able to complete sales of its common stock to unrelated third-party investors beginning in January 27, 2022, through February 28, 2022, of 263,729 shares of common stock at a price of $9.00 per share resulting in aggregate proceeds of approximately $2.4 million. Due to the lack of any single specific event that would have indicated a definitive change in the value of the Company, the fair value of the </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Company&#8217;s common stock from January 27, 2022 through March 31, 2022, was determined based on sales of the Company&#8217;s shares at arm&#8217;s length to unrelated third parties at $9.00 per share.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Following this offering, it will not be necessary to determine the fair value of our common stock, as our shares will be traded in the public market.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our stock-based awards are classified as equity (restricted stock awards, stock options, and warrants). We recognize related stock-based compensation expense based on the grant date fair value of the awards. The fair value of restricted stock awards is based on our common stock price. We estimate the fair value of stock options and warrants using the Black-Scholes-Merton valuation model which requires the use of subjective assumptions that could materially impact the estimation of fair value and related compensation expense to be recognized. One of these assumptions include the expected volatility of our stock price. Developing this assumption requires the use of judgment. The Company lacks company-specific historical and implied volatility information. Therefore, we estimate our expected stock volatility based on the historical volatility of a publicly traded set of peer companies. These estimates are highly subjective and once this offering is completed these estimates will no longer be necessary since the fair value will be based on the trading value of the Company&#8217;s common stock.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Two of the assumptions used in the Black-Scholes-Merton valuation model are historical volatility and fair value of common stock, both of which are subject to uncertainty. Historical volatility is subject to uncertainty due to changes in the market over time. The fair value of our common stock is subject to uncertainty due to the possibility of changes in the results of our clinical trials, which could impact the fair value of our common stock. The total expense related to stock options is material to our financial statements on an annual basis, and significant fluctuations in the volatility assumption or the fair value of our common stock could result in material changes in related compensation expense to be recognized.</p><a name="_AEIOULastRenderedPageBreakAEIOU14"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="BUSINESS"></a><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="BUSINESS"></a>BUSI</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NESS</font></p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Our Company</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO, our lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. We completed our selection process for the clinical sites for our Phase 2 study in Australia and Europe and our application to start the Phase 2 study in Australia has been approved. We also plan to submit a similar application in the Second Quarter 2022, to conduct the same Phase 2 study in Europe. Patients with advanced Non-Small Cell Lung Cancer (NSCLC) will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo&#174; (cemiplimab) manufactured and commercialized by Regeneron. Cemiplimab is a fully human monoclonal antibody targeting the immune checkpoint receptor PD-1 on T-cells. Cemiplimab has been approved in the United States and the rest of the world for multiple cancer indications, including NSCLC. In February 2021, we signed a clinical supply agreement with Regeneron to receive cemiplimab at no cost, which represents a significant cost-savings for the study. In return, we have granted Regeneron exclusive development rights in combination with PD-1 inhibitors for NSCLC for the study period. Based on the clinical data generated by the THIO-101 trial, in late 2024 we plan to seek an accelerated approval of THIO in the United States for the treatment of patients with advanced NSCLC. Even if granted, accelerated approval status does not guarantee an accelerated review or marketing approval by the FDA. In addition, in the First Quarter of 2023, we plan to initiate a pivotal Phase 2 clinical trial of THIO in patients with advanced colorectal cancer administered in sequence with Anti-PD-1 or Anti-PD-L1.</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Our Lead Product Candidate </p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">THIO (6-thio-dG or 6-thio-2&#8217;-deoxyguanosine) is a telomere-targeting agent currently in clinical development to evaluate its activity in NSCLC. Telomeres, along with the enzyme telomerase, play a fundamental role in the survival of cancer cells and their resistance to current therapies. THIO is being developed as a second- or later line of treatment for NSCLC for patients that have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors.</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2019, our research team discovered that THIO produced telomere modifications and disruption, which ultimately induced cancer-specific innate and adaptive immune responses against immunologically &#8220;cold&#8221; tumors or tumor types that were unresponsive to immune checkpoint inhibitors. This hypothesis was tested and demonstrated in syngeneic and humanized mouse models. THIO administered to mice in low doses and followed by an immune-checkpoint inhibiting agent, such as an anti-PD-1 or anti-PD-L1 compound, induced complete tumor regression with no tumor recurrence during the 14 weeks of observation. Further, no toxicities were reported in the tumor-free mice. These new findings were published in the highly reputable, peer-reviewed research scientific journal, <font style="text-decoration:underline;">Cancer Cell </font>in July 2020. Based on these recent discoveries, a new therapeutic approach has been designed to advance THIO into a Phase 2 clinical trial (THIO-101) in patients with advanced NSCLC. </p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our regulatory strategy includes a planned filing of an Investigational New Drug application (IND) with the U.S. FDA in the near future. This would allow U.S. sites to participate in the THIO-101 NSCLC trial. The human safety data generated in the first part of 2022 in Australia and Europe would constitute the basis of the IND application. Although we plan to rely solely on the safety and efficacy data we generate in our own clinical trials in support of our planned NDA filing, we take added confidence in the potential tolerability of THIO in light of the fact that the THIO doses we plan to test represent a range of 4 to 40 times lower than the maximum tolerated dose tested in the earlier clinical trials sponsored by the National Cancer Institute in the 1970s. <font style="letter-spacing:0.2pt;">The planned THIO-101 phase 2 trial is intended to be a proof-of-concept study that may be modified depending on interim results to include both primary and secondary endpoints and be consistent with previously approved cancer treatments. Based on the clinical data generated in the THIO-101 study and assuming THIO achieves its intended clinical effect with a manageable safety profile</font> at one of the doses tested in the study, we expect to seek early FDA guidance and agreement for using this clinical trial as basis for requesting an accelerated approval. The FDA instituted its Accelerated Approval Program to allow for earlier approval of drugs that treat serious conditions, and that fill an unmet medical need based on a surrogate endpoint. A surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign or other measure that is thought to predict clinical benefit, but is not itself a measure of clinical benefit. The use of a surrogate endpoint can considerably shorten the time required prior to receiving FDA approval.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MAIA Biotechnology will still be required to conduct studies to confirm the anticipated clinical benefit. These studies are known as confirmatory trials. If the confirmatory trial shows that the drug actually provides a clinical benefit, then the FDA grants traditional approval for the drug. If the confirmatory trial does not show that the drug provides clinical benefit, FDA has regulatory procedures in place that could lead to removing the drug from the market. <font style="color:#000000;">The FDA&#8217;s accelerated approval pathway, even if initially granted, does not guarantee an accelerated review or marketing approval by the FDA. </font>The THIO-101 study protocol may need to be amended to increase the number of patients enrolled, undergo modification of the statistical analysis or change in the trial design and/or primary endpoints.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Our Science--Driven Telomere Targeting Approach</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Telomeres are regions of repetitive DNA nucleotide sequences that are associated with specialized proteins at the ends of linear chromosomes in cells. THIO&#8217;s mechanism of action comprises telomere targeting and induction of anti-cancer immunogenicity. The enzyme telomerase recognizes THIO&#8217;s metabolite formed <font style="font-style:italic;">in situ</font> and incorporates it into the structure of the cancer cell&#8217;s telomeres, creating a faulty structure, which breaks apart the telomere spatial structure. As a result, the telomeric structure unwinds and the cancer cells die. We believe THIO transforms &#8220;cold&#8221; tumors into &#8220;hot&#8221; tumors rendering them responsive to immunotherapy (checkpoint inhibitors) and this process takes place promptly within 24 to 72 hours. We believe we can improve the immunotherapy efficacy and we can restore the immunotherapy efficacy in patients who have progressed or developed resistance to prior immunotherapy.</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Telomere maintenance is essential for cell proliferation and resilience in cancer cells, and thus represents one of the key therapeutic targets for cancer treatment. Telomerase is an enzyme that is present in a majority of human cancer cells (over 85% in the aggregate), across various tumor types. In contrast, its activity is detected in less than 1% of normal cells. THIO has only been shown to be active in cancer cells that are telomerase positive (TERT+). Cancer cells are constantly telomerase positive due to an uncontrolled division process, while a relatively small number of normal cells are telomerase positive only transiently. Therefore, THIO activity is expected to be highly specific to cancer cells versus normal cells. Cancer-specific disturbance of telomeric structure, mediated by telomerase, is likely to lead to disruption in the cell cycle, followed by a very rapid and telomere-length independent cell death. THIO was observed to induce cancer-specific telomere disruption, by using the enzyme telomerase which differentiates THIO from all other available cancer therapies currently in clinical use. We are also currently developing potential next-generation small molecule telomere modifying agents with the goal of identifying additional proprietary drug candidates, across multiple cancer types. </p><a name="_AEIOULastRenderedPageBreakAEIOU15"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Our Second Generation Target Candidates</font></p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our THIO program drives our development pipeline of second-generation telomere targeting agents. We have initiated an early-stage research and discovery program aimed at identifying new compounds capable of acting through similar mechanisms of activity as THIO, such as the targeting and modifying telomeric structures of cancer cells through cancer-cell intrinsic telomerase activity. The main objective for this program is to discover new compounds with potentially improved specificity towards cancer cells relative to normal cells and with increased anticancer activity. This program may also allow us to strengthen our patent portfolio. Our current 2nd-generation pipeline of potential telomere-targeting agents includes five compounds that have successfully undergone <font style="font-style:italic;">in vitro</font> inhibitory testing in five cancer models. The data from those studies showed a significantly lower 50% inhibitory concentration (IC50) for those compounds compared to THIO, as reflected in the following figure:</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gyowp0iggm03000004.jpg" title="" alt="" style="width:474px;height:202px;"></p>
<p style="margin-bottom:8pt;margin-top:0pt;margin-left:15.38%;margin-right:15.38%;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">IC50 is <font style="Background-color:#FFFFFF;">the half maximal inhibitory concentration, and it is a measure of the potency of a substance in inhibiting a specific biological or biochemical function, such as cell proliferation. </font><font style="font-style:normal;color:#000000;">Cell lines: MC38, LLC, Hep55-1C, H2081, and HEK293 are Non-Small Cell Lung Carcinoma, Colorectal, Hepatocellular carcinoma, Small Cell Lung Carcinoma, and Immortalized Human Kidney cell line, respectively. *- Data unavailable</font></p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">The figures below represent dose-response curves from which IC50 values were derived for second generation compounds #5 (X97848), and #12 (X97855) in HEK293 cells:</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gyowp0iggm03000005.jpg" title="" alt="" style="width:307px;height:206px;"><img src="gyowp0iggm03000006.jpg" title="" alt="" style="width:307px;height:206px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The graph below demonstrates the dose response curves for our number five next generation compound, designated as 6S-dG-dimer, in ovarian cancer-derived cell line CoC1/DDP, in comparison with cisplatin (current standard of care in this setting). The corresponding IC50 values are shown next to the plot.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gyowp0iggm03000007.jpg" title="" alt="" style="width:624px;height:251px;"></p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based on the data presented, we have progressed five second-generation compounds to <font style="font-style:italic;">in vivo</font> testing, and with proceeds from the IPO, we plan to initiate pre-IND testing for two of them in mid-2022, with the goal of advancing them to clinical trials by the end of 2024.</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although the program is in early stages and we may not be able to identify suitable compounds, we believe we will be able to create a second generation of THIO-like compounds. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#3E677D;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">OUR PIPELINE</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#3E677D;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Our robust pipeline includes several targeted immuno-oncology candidates for relapsed and refractory cancers.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;<img src="gyowp0iggm03000008.jpg" title="" alt="" style="width:608px;height:242px;"></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*Basket study expected to evaluate: Small Cell Lung Cancer (SCLC), Hepatocellular Carcinoma (HCC), Glioblastoma (GBM), Melanoma, Ovarian, Pancreatic, Breast &amp; Prostate cancers.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pipeline products are under investigation and have not been proven to be safe or effective. There is no guarantee any product will be approved in the sought-after indication or will meet the developmental milestones set forth above.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Our Strategy </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our goal is to be the leader in the discovery, development and commercialization of cancer telomere targeting agents and other similar small molecules. Our initial focus is to efficiently advance our Phase 2 clinical program with THIO in sequential combination with cemiplimab. Ultimately, we envision positioning THIO as a patient anticancer immunity priming treatment for all immune-activating agents used in the treatment of cancer. To date, THIO has never been tested in clinical trials in combination with any check-point inhibitor. The key elements of our strategy are to: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Advance our existing clinical programs, including seeking accelerated approval for THIO in NSCLC as a tumor mass-reducing and simultaneously immune system priming agent administered in advance of the immune-activating agent, cemiplimab for treatment of advanced NSCLC, and ultimately, as a cancer treatment foundation in multiple indications and geographies. Even if granted, accelerated approval status does not guarantee an accelerated review or marketing approval by the FDA.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Broaden the clinical development of THIO by exploring synergistic administration prior to other standard-of care immune-therapies including cell therapy. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Develop a franchise of telomere-targeting cancer treatments.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Leverage our regulatory strategy to acquire additional human data faster outside U.S. for other cancer indications. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Selectively enter into strategic collaborations with pharmaceutical and biotechnology companies that have immune activating therapies.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Expand our existing intellectual property portfolio.</font></p></td></tr></table></div>
<p style="margin-top:8pt;margin-bottom:8pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We will face certain challenges in implementing our business strategy including, among others, the fact that earlier development of THIO was not commercially pursued. Even if THIO successfully advances through clinical studies and towards approval for use, we may face early competition from generic alternatives to THIO after expiration of any applicable regulatory exclusivities. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">THIO Market Opportunity and Unmet Medical Need</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Most cancer cells are telomerase positive (TERT+), including 73% to 100% of primary human cancers dependent upon tumor type, indicating a significant potential therapeutic utilization for THIO across most of the tumor types. Successful targeting of telomeres in TERT+ cancers represent a significant potential for broad therapeutic utilization. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#1D4258" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.9%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#F7F8F9;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Tumor Type</p></td>
<td valign="bottom"  BGCOLOR="#1D4258" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#F7F8F9;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#1D4258" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#F7F8F9;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">TERT(+)</p></td>
<td valign="bottom"  BGCOLOR="#1D4258" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#F7F8F9;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#1D4258" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#F7F8F9;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#1D4258" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.74%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#F7F8F9;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Tumor Type</p></td>
<td valign="bottom"  BGCOLOR="#1D4258" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#F7F8F9;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#1D4258" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#F7F8F9;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">TERT(+)</p></td>
<td valign="bottom"  BGCOLOR="#1D4258" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#F7F8F9;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#EBECEB" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-Small Cell Lung Cancer (NSCLC)</p></td>
<td valign="bottom"  BGCOLOR="#EBECEB" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#EBECEB" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78%</p></td>
<td valign="bottom"  BGCOLOR="#EBECEB" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#EBECEB" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#EBECEB" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pancreatic Cancer</p></td>
<td valign="bottom"  BGCOLOR="#EBECEB" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#EBECEB" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">95%</p></td>
<td valign="bottom"  BGCOLOR="#EBECEB" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Colorectal (CRC)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">82-89%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Small Cell Lung Cancer (SCLC)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#EBECEB" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Hepatocellular Carcinoma (HCC)</p></td>
<td valign="bottom"  BGCOLOR="#EBECEB" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#EBECEB" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79-86%</p></td>
<td valign="bottom"  BGCOLOR="#EBECEB" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#EBECEB" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#EBECEB" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ovarian Cancer</p></td>
<td valign="bottom"  BGCOLOR="#EBECEB" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#EBECEB" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91%</p></td>
<td valign="bottom"  BGCOLOR="#EBECEB" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Breast Cancer</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Renal Cell Carcinoma (RCC)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">83%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#EBECEB" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prostate Cancer</p></td>
<td valign="bottom"  BGCOLOR="#EBECEB" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#EBECEB" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90%</p></td>
<td valign="bottom"  BGCOLOR="#EBECEB" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#EBECEB" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#EBECEB" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Glioblastoma Multiforme (GBM)</p></td>
<td valign="bottom"  BGCOLOR="#EBECEB" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#EBECEB" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75%</p></td>
<td valign="bottom"  BGCOLOR="#EBECEB" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Bladder Cancer</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">92%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Neuroblastoma</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">94%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#EBECEB" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">head &amp; Neck Squamous Cell Carcinoma (HNSCC)</p></td>
<td valign="bottom"  BGCOLOR="#EBECEB" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#EBECEB" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">`86%</p></td>
<td valign="bottom"  BGCOLOR="#EBECEB" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#EBECEB" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#EBECEB" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lymphoma (high grade)</p></td>
<td valign="bottom"  BGCOLOR="#EBECEB" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#EBECEB" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100%</p></td>
<td valign="bottom"  BGCOLOR="#EBECEB" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gastric Cancer</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chronic Myeloid Leukemia (CML)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#EBECEB" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Melanoma</p></td>
<td valign="bottom"  BGCOLOR="#EBECEB" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#EBECEB" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">83-86%</p></td>
<td valign="bottom"  BGCOLOR="#EBECEB" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#EBECEB" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#EBECEB" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chronic Lymphocytic Leukemia (CLL)</p></td>
<td valign="bottom"  BGCOLOR="#EBECEB" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#EBECEB" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">`57%</p></td>
<td valign="bottom"  BGCOLOR="#EBECEB" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cervical Cancer</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Acute Myeloid Leukemia (AML)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk99444904"></a>Sources: A Survey of Telomerase Activity in Human Cancer &#8211; JW Shay, S Bacchetti &#8211; European Journ<a name="_Hlk99444904"></a>al of Cancer, 33,5,787-791, 1997. Telomerase Active in Human Liver Tissues; H Tahara, et al; Cancer Research 55, 2734-2736 1995; Highly /aggressive Metastatic Melanoma Cell Unable to Maintain Telomere Length; N Viceconte et al; Cell </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reports 2017</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">; and </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical Relevance of Telomerase Status and Telomerase Activity in Colorectal Cancer; T Femandez et al; PLOS one 2016</font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our initial development program will focus on Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Hepatocellular Carcinoma (HCC) and Small Cell Lung Cancer (SCLC) in areas of clear unmet need and/or areas with deficient immunotherapy effect within each tumor type. Each tumor type and area of unmet or undermet needs represent significant clinical and commercial opportunity. We believe that THIO offers a desirable profile with significant commercial potential.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Tumor Type</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Incidence</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020 (M)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Prevalence</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020 (M)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Mortality</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020 (M)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Annual</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Sales</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020 ($B)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Annual</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Sales</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2028 ($B)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-Small Cell Lung Cancer</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.9</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.3</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.5</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32.7</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Breast</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.3</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.8</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.7</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.0</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.0</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prostate</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.4</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.0</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.4</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.5</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.8</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Colorectal</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.9</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.2</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.9</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.0</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.7</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Liver</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.9</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.0</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.8</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.0</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.0</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Small Cell Lung Cancer</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.3</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.3</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.3</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.9</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.3</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sources: WHO; Global Data</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The table below reflects the current market for check-point inhibitors because there is no current market for THIO-like molecules. The years in the indication columns on the table below signify the timing of FDA approval in the US for the clinical indications of interest. Because the key element of our strategy is to develop THIO to work in combination with check-point inhibitors, if THIO is eventually approved by the FDA for use in conjunction with check-point inhibitors, this table provides a high-level understanding of the potential market for THIO in that combination. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Current Landscape of Checkpoint Inhibitor Franchises</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr style="height:17.2pt;">
<td rowspan="2" valign="bottom"  BGCOLOR="#1D4258" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:28.54%; border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#F7F8F9;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Drug</p></td>
<td rowspan="2" valign="bottom"  BGCOLOR="#1D4258" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:18.3%; border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#F7F8F9;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Company</p></td>
<td rowspan="2" colspan="2" valign="bottom"  BGCOLOR="#1D4258" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.52%; border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#F7F8F9;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#F7F8F9;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Sales</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#F7F8F9;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">($B)</p></td>
<td rowspan="2" valign="bottom"  BGCOLOR="#1D4258" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.22%; border-top:solid 0.75pt #000000; border-right:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#F7F8F9;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td rowspan="2" colspan="2" valign="bottom"  BGCOLOR="#1D4258" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.36%; border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#F7F8F9;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Indications</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#F7F8F9;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(tumor</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#F7F8F9;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">types)</p></td>
<td rowspan="2" valign="bottom"  BGCOLOR="#1D4258" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.22%; border-top:solid 0.75pt #000000; border-right:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#F7F8F9;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#1D4258" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#F7F8F9;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NSCLC</p></td>
<td valign="bottom"  BGCOLOR="#1D4258" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.1%; border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#F7F8F9;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SCLC</p></td>
<td valign="bottom"  BGCOLOR="#1D4258" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.04%; border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#F7F8F9;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CRC</p></td>
<td valign="bottom"  BGCOLOR="#1D4258" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:14%; border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#F7F8F9;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">HCC</p></td>
</tr>
<tr style="height:17.15pt;">
<td colspan="4" valign="bottom"  BGCOLOR="#1D4258" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#F7F8F9;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year of FDA Approval</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">KEYTRUDA <font style="font-style:italic;">(pembrolizumab)</font></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Merck</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp; 17.2</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2015</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OPDIVO <font style="font-style:italic;">(nivolumab)</font></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BMS / Ono</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 8.6</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2015</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">TECENTRIQ <font style="font-style:italic;">(atezolizumab)</font></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Genentech / Roche</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 3.5</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IMFINZI <font style="font-style:italic;">(durvalumab)</font></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AstraZeneca</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2.5</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">TYVYT <font style="font-style:italic;">(sintilimab)</font></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Eli Lilly / Innovent</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0.9</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:9pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">LIBTAYO <font style="font-style:italic;">(cemiplimab)</font></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Regeneron</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0.5</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BAVENCIO <font style="font-style:italic;">(avelumab)</font></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pfizer / Merck AG</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0.4</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">TBD <font style="font-style:italic;">(tislelizumab)</font></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Novartis / BeiGene</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0.3</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:9pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">JEMPERLI <font style="font-style:italic;">(dostarlimab)</font></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GSK</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0.1</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">TOTAL</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:9pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:9pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp; 33.9</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:9pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:9pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:9pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:9pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:9pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:9pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:9pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:9pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Source: BioMed Tracker 2022</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intellectual Property</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our goal is to obtain, maintain and enforce patent protection wherever appropriate for our product candidates, formulations, processes, methods and any other proprietary technologies, and operate without infringing on the proprietary rights of other parties, both in the United States and in other countries. Our practice is to actively seek to obtain, where appropriate, intellectual property protection for our current product candidates and any future product candidates, proprietary information, and proprietary technology through a combination of patents, protection of proprietary know-how and trade secrets, and contractual arrangements, both in the United States and abroad. However, full patent protection may not provide us with complete protection against competitors who may seek to circumvent our intellectual property. Our success will depend on the skills, knowledge, experience and know-how of </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:10pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our management research and development personnel, as well as that of our advisors, consultants, and other contractors. To help protect our proprietary know-how that is not patentable, we seek to put in place appropriate internal policies for the management of confidential information requiring all our employees, consultants, advisors, and other contractors to enter into confidentiality agreements that prohibit the disclosure of confidential information, and which will require disclosure and assignment to us of the ideas, developments, discoveries, and inventions important to our business. See &#8220;Risk Factors &#8211; Risks Related to our Intellectual Property&#8221; for additional information.</font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We file for patents, both directly and in collaboration with our licensing partners, in the United States with counterparts in certain countries in Europe and certain key market countries in the rest of the world, thereby covering the major pharmaceutical markets. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On December 8, 2020, we entered into an amended and restated agreement (of our prior November 29, 2018 agreement) with The Board of Regents of The University of Texas System on behalf of The University of Texas Southwestern Medical Center (collectively, UTSW). Pursuant to the amended and restated agreement, which we refer to as the UTSW1 Agreement, we obtained (1) an exclusive, worldwide license to develop and commercialize the following patent families, which are generally directed to methods of using THIO and are owned and/or controlled by UTSW:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:8.07%;width:69.97%;">
<tr>
<td style="width:69.97%;"></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title / PCT Application Number</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Telomerase Mediated Telomere Altering Compounds / PCT/US2014/33330 (WO2014/168947), issued in the US, MX, NZ and RU (all method of use) pending in BR, CA, CN, EP, HK and SG.</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6-Thio-2'-Deoxyguanosine (6-Thio-Dg) Results in Telomerase Dependent Telomere Dysfunction and Cell Death in Various Models of Therapy-Resistant Cancer Cells / <br />PCT/US2017/34706 (WO2017/205756), pending in the US (method of use)</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Use of 6-thio-dG to Treat Therapy-Resistant Telomerase positive Pediatric Brain Tumors / <br />PCT/US2019/023596 (WO2019/183482), pending in the US (method of use)</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Treatment of Drug Resistant Proliferative Diseases with Telomerase Mediated Telomere Altering Compounds / PCT/US2017/023858 (WO/2017/165675), pending in the US (method of use)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and (2) a non-exclusive worldwide license to develop and commercialize related technology rights. The UTSW1 Agreement includes an exclusive license to US patent no. 10,463,685 (expires April 8, 2034), and pending US patent application nos. 16/450,430 (having an earliest expiration of March 23, 2037, if a patent is granted), 16/304,538 (having an earliest expiration of May 26, 2037, if a patent is granted), and 16/982,979 (having an earliest expiration of March 22, 2039, if a patent is granted). All patents are method of use.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On December 23, 2020, we entered into a second agreement with UTSW, which set forth the agreement between the parties pursuant to the Company exercising its option rights in the UTSW1 Agreement and obtaining additional license rights. Pursuant this second license with UTSW, which we refer to as the UTSW2 Agreement, we obtained (1) an exclusive, worldwide license to develop and commercialize the following UTSW patent family:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:8.07%;width:69.97%;">
<tr>
<td style="width:69.97%;"></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title / PCT Application Number</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sequential Treatment of Cancers Using 6-Thio-dG and Checkpoint Inhibitors / PCT/US2021/022090, pending in the US and PCT (method of use)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and (2) a non-exclusive worldwide license to develop and commercialize related technology rights. The UTSW2 Agreement includes an exclusive license to pending US patent application no. 17/200,539 (having an earliest expiration of March 12, 2041, if a patent is granted). This patent is generally directed to methods of using THIO in combination with immune checkpoint inhibitors.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">82</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We continually assess and refine our intellectual property strategy as we develop new technologies and therapeutic candidates. As our business evolves, we may, among other activities, file additional patent applications in pursuit of our intellectual property acquisition and protection strategy, to adapt to competition or to seize potential opportunities. </font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Our Team</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have assembled an experienced management team with deep research, development, and commercialization experience in the areas of telomere-related science, immunotherapy, and across a vast array of oncology indications. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Key Team highlights:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">Our team is led by our Co-founder, Chief Executive Officer and President Vlad Vitoc. He is an M.D. and M.B.A. with over 22 years of experience in the Pharmaceuticals and Biotechnology industries. </font><font style="Background-color:#FEFEFE;color:#000000;font-size:10pt;font-family:Times New Roman;">He has served on leadership teams in various oncology companies and business units and has a track record of success at Bayer Pharmaceuticals, Astellas Pharma Inc., Cephalon Inc. and Incyte Corporation, including development and commercialization of major oncology brands, organizational capability building, talent recruiting and development, and functional leadership.</font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;"> </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">Our Chief Medical Officer and Head of Development, Mihail Obrocea, M.D., is a former practicing academic medical oncologist and experienced pharmaceutical physician executive that brings a successful cancer drug development track record from Juno Therapeutics Inc. (acquired by Celgene/BMS), Pharmacyclics Inc., AbbVie Bio Corp., Mannkind Corp., MedImmune, Inc. and Pfizer, Inc., among others. His experience includes clinical development of cell therapies (CAR-T), cancer vaccines, antibodies, and antibody drug conjugates (ADCs) and small molecules across a wide range of tumor types and clinical indications.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">Our Chief Scientific Officer, Sergei M. Gryaznov, is a Ph.D. who is an internationally recognized scientist and expert in the areas of modern drug discovery and development, oncology, telomerase, immune-regulatory therapeutics, nucleosides, nucleotides, DNA and RNA analogues, lipid and other conjugates, small molecules and nucleic acid based therapeutic agents. He is the co-inventor of a novel telomere-by-telomerase-targeting therapeutic approach to potential cancer treatment and responsible for leading the research team that characterized THIO&#8217;s telomere targeting activity.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">Our Chief Financial Officer, Joseph F. McGuire has served as Chief Financial Officer for several privately held and publicly traded companies in the health care, financial services, investment, and manufacturing industries. In these roles, his responsibilities included SEC financial reporting, investor relations, corporate governance, legal and audit liaison, and team building. Most recently, Mr. McGuire was the chief financial officer at Avadim Health, Inc. (&#8220;Avadim&#8221;). Mr. McGuire began his career with Price Waterhouse, where he was a certified public accountant, and later held management positions with Dean Witter Reynolds and Paine Webber, Inc. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have engaged the following advisors, who are leading, internationally recognized experts in oncology, telomeres and telomerase research, to be a part of our Scientific Advisory Board (&#8220;SAB&#8221;), which provides independent non-binding scientific advice to our management team in the roles detailed below under each member&#8217;s name:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">1.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;">Tom Gajewski, M.D., Ph.D. &#8211; Professor of Cancer Immunotherapy (University of Chicago)</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;">One of the key pioneers in cancer immunotherapies and accomplished in the field</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;">Key investigator on all phase 2 and phase 3 trials in Melanoma (with Keytruda&#174;, Opdivo&#174;, etc.)</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;">Immediate past president of the Society for Immunotherapy of Cancer (SITC)</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;">Served on the program committees for the American Society for Clinical Oncology (ASCO) and the American Association for Cancer Research (AACR)</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;">Serves as an editor for Cancer Research and Journal for Immunotherapy of Cancer</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;">On our SAB, will cover translational research for all cancers, for clinical development</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">83</a></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">2.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;">Tudor Ciuleanu, M.D., Ph.D. &#8211; Professor of Oncology (University of Medicine and Pharmacy, Cluj-Napoca, Romania)</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;">Top Key Opinion Leader (KOL) in </font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">NSCLC</font><font style="font-size:10pt;font-family:Times New Roman;"> and CRC in Europe</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;">Key investigator in more than 90 phase 3 and phase 2 clinical trials, including most immune therapy agents</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;">One of the best published clinical investigators (appears in most references in the National Comprehensive Cancer Network (NCCN) guidelines)</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;">President of Romanian Federation of Cancer Societies</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;">Editor for the Journal of Clinical Oncology (JCO), Romanian edition</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;">On our SAB, will lead clinical activities in Europe across tumor types &#8211; NSCLC, CRC, Gastric, HCC, Head and Neck, Urological cancers, and Lymphomas</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">3.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;">Jerry Shay, Ph.D. &#8211; Professor and Vice Chairman of the Department of Cell Biology (University of Texas Southwestern)</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;">One of the world leaders in the study of telomeres and telomerase</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;">Scientific co-founder of the research supporting our lead program THIO and an integral advisor to the program</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;">Highly influential biomedical researcher with over 30 issued patents and more than 500 peer reviewed publications</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;">Southland Financial Corporation Distinguished Chair in Geriatric Research and a Distinguish Professor at University of Texas Southwestern, having received the University of Texas Regent&#8217;s Outstanding Teaching Award and the Minnie Steven Piper Foundation Professor Award</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;">Awarded the Eunice Kennedy Shriver NIH Alliance Pioneer Award in 2017</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;">On our SAB, Dr. Shay will provide scientific leadership as the THIO co-inventor and a worldwide recognized expert in the science of telomeres and telomerase in cancer. Dr. Shay serves as the Chairman of the SAB.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">4.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;">David Ashley, M.D., Ph.D. &#8211; Professor of Neuro-Oncology (Duke University)</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;">Top KOL in pediatric and adult neuro-oncology</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;">Expert in translational research and clinical development</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;">Expert in immuno-oncology, having developed and clinically tested dendritic cell vaccines and other immuno-therapeutics</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;">Principal investigator of a number of important national and international studies, both clinical and pre-clinical</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;">Former Director of two major cancer centers, The Royal Children&#8217;s Hospital Melbourne and Andrew Love Cancer Centre &#8211; Barwon Health</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;">On our SAB, will assist in translational research in Brain Cancers for clinical development</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">5.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;">Gunnur Dikmen, M.D., Ph.D. &#8211; Professor at Hacettepe University Medical Faculty, Department of Medical Biochemistry, as well as the director of the Hacettepe University hospital&#8217;s emergency laboratory. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;">Broad range of experimental and clinical experience in molecular &amp; cell biology and clinical biochemistry, translating research results from bench to bedside and from academia to clinical laboratory to mentor the next generation of multidisciplinary research projects by providing new therapeutic approaches for cancer and telomere related diseases.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;">Expert in the biology of telomeres and telomerase in the treatment of cancer.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;">Under her capacity as Secretary-General of the Turkish Biochemical Society, organized various important national and international courses and congresses.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;">On our SAB, will assist in preclinical and translational research, across tumor types.</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">84</a></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">6.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;">Adam Yopp, M.D. &#8211; Occidental Chemical Chair of Cancer Research and an Associate Professor and Division Chief of Surgical Oncology and Colorectal Surgery, at Harold C. Simmons NCI-designated Comprehensive Cancer Center at UT Southwestern Medical Center in Dallas.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;">Completed a fellowship in surgical oncology at Memorial Sloan-Kettering Cancer Center focusing on upper GI and hepatopancreatobiliary malignancy and joined UT Southwestern in 2009.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;">Director of the Liver Tumor Program at UTSW and both his research and clinical interests are focused on the delivery of care in patients with primary liver cancer.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;">Much-recognized key opinion leader in liver cancer.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;">On our SAB, will assist with developing THIO for the treatment of liver cancer.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our SAB is primarily compensated by way of the grant of stock options as determined by the Company as appropriate in recognition of the specific services or areas of expertise of each member.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are also supported by a seasoned board of directors, whose members have significant entrepreneurial skills in company building and corporate financing as well as decades of collective leadership and board experience. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Our Programs</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Telomere Targeting Program</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Targeting Telomeres via Telomerase Leads to Cancer Cell Death</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:63.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Telomeres are regions of repetitive nucleotide sequences that are associated with specialized proteins at the ends of linear chromosomes, that represent a critical key therapeutic target for cancer. Telomeres are often depicted in imagery like the end of a shoelace.</p>
<p style="margin-top:10pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Maintenance of telomeres is essential for unlimited cellular proliferation and confers immortality in cancer cells. Telomeres in human cells consist of double-stranded and single-stranded repeats of the sequence TTAGGG, which terminate in a single-stranded 3&#180;- extension overhang of the G-rich strand. Their major function is to cap and protect the ends of chromosomes and thus to provide genetic stability. This capping function is mediated by a special architecture in which the 3&#180;- overhang participates with telomere-binding proteins in a large loop structure called T-loop. The image on the right reflects the general location of telomeres as the end-cap of the chromosomes, which are located in the nucleus of the cell.</p></td>
<td valign="top"  style="width:0.72%;">
<p style="text-align:center;margin-top:10pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:35.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><img src="gyowp0iggm03000009.jpg" title="" alt="" style="width:221px;height:216px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adapted from <font style="font-style:italic;">Transcendental Meditation and lifestyle modification increase telomerase</font>, December 6, 2015.</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The most successful anti-cancer drugs in the market today typically interfere with only one of the specific capabilities or &#8220;hallmarks&#8221; cancer cells use for tumor growth and progression. In contrast, our lead drug candidate, THIO, targets two major hallmark pathways:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">Targeting cancer cell </font><font style="font-style:italic;font-size:10pt;font-family:Times New Roman;color:#000000;">telomeric</font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;"> DNA structure and functional integrity; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">Activating the immune system that turns immunologically &#8220;cold&#8221; tumors into &#8220;hot&#8221; tumors that are responsive to therapy. THIO synergizes with immune activating agents, like checkpoint inhibitors, for the potential to attack and destroy tumors. </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The chart below reflects the many different methods by which successful anti-cancer drugs might prevent tumor growth and where THIO stands in relation to the other approaches.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gyowp0iggm03000010.jpg" title="" alt="" style="width:611px;height:320px;"></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:1pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:1pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#FFFFFF;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MAIA Biotech Pipeline - PLANNED STUDIES 2022 2023 2024 2025 THIOLung Cancer Colorectal Cancer Other Solid Tumors Ph 2 THIO-101 NSCLC-2L+US Accelerated approval (projected) Ph 3 TERT+ NSCLC-2L+ Ph 3 NSCLC-1LPh 2 THIO-102 TERT+ CRC-3L+ Pivotal. Ph 2 Ph 3 MSS CRC-1LPh 2 Basket TERT+ Tumors L3+Ph 3 Pivotal TBDSCLC HCC GBM Melanoma Pancreatic Ovarian Breast Prostate Ph 3 Pivotal TBD Preclinical US Potential IND</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adapted from <font style="text-decoration:underline;color:#0000FF;">Cell 2011, Volume 144, Issue 5, Pages 646-674</font> (DOI:10.1016/j.cell.2011.02.013)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Role of the Enzyme Telomerase</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Telomerase<font style="font-style:normal;"> is a ribonucleoprotein enzyme (reverse transcriptase) that synthesizes telomere repeats from the beginning, or </font>de novo<font style="font-style:normal;">. In human cells, the telomerase holoenzyme consists of a high-molecular-weight complex with a template region-containing RNA subunit, hTR, and a protein component, the catalytic subunit human telomerase reverse transcriptase (hTERT). In most normal somatic cells, telomerase activity is absent and telomere repeats are lost with cell division and with aging. Telomerase is especially important in fetal tissues, reproductive cells and other tissues where extensive cell proliferation is necessary. However, most adult normal tissues are telomerase silent. Telomere attrition, beyond a certain threshold, results in the uncapping of chromosome ends, which subsequently induces DNA damage and onset of replicative senescence. In contrast, about 73% to 100% of all cancer cells in most tumor types have detectable telomerase activity, which leads to the stabilization of telomeres and allows for unlimited growth potential along with disease progression. Successful targeting of telomerase positive (TERT+) cancers represents a significant potential for therapeutic utilization in almost all tumor types.</font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since most cancer cells are reliant on telomerase for their survival, and telomerase is undetectable or only transiently present at low levels in normal cells, telomeres of cancer cells and telomerase are attractive targets for the development of new cancer therapeutics. &#8220;Proof of Principle&#8221; for validation of telomere structural integrity-targeting as a therapeutic concept was demonstrated <font style="font-style:italic;">in vitro </font>in human tumor cells using dominant negative mutant forms of hTERT. In these experiments, telomerase activity was abolished, which was associated with continuous telomere shortening, subsequently leading to the cancer cells death. Research has also indicated that cancer cell specific anti-telomeres and anti-telomerase therapies may have fewer side effects than more traditional treatments, such as chemotherapy or radiotherapy. This has made anti-cancer therapies based on telomerase inhibition an area of interest in medicine. However, attempts to directly target telomerase in clinical trials have not yet produced an approved drug, as these efforts have encountered material limitations primarily due to increased toxicities that may result from the long lag period between initiation of anti-telomerase treatment and its therapeutic effects. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">86</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Differentiated Activity of THIO, a Telomere-Targeting Agent </font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">THIO (6-thio-2&#8217;-deoxyguanosine or 6-thio-dG) is a small molecule telomere targeting agent that uses the enzyme telomerase for DNA integration predominantly in the telomeric structure. Based on pre-clinical studies, THIO&#8217;s telomere targeting activity is believed to be primarily cancer-specific in tumor cells with active telomerase, but not in normal cells. Based on our extensive review of publicly-available information, to our knowledge THIO&#8217;s direct telomere targeting action utilizing telomerase is different from other commercially available cancer therapies and those currently in publicly disclosed clinical trials. Telomeres, along with the enzyme telomerase, play a fundamental role in the survival of cancer cells and their resistance to current therapies. The statements above are not intended to give any indication that THIO has been proven effective or that it will receive regulatory approval.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In non-clinical studies, published initially in 2014 along with subsequent studies, THIO was found to be converted, in cells, into the substrate recognized by telomerase, and then incorporated into telomeres of the cancer cells. Once incorporated, THIO compromised the cancer cell&#8217;s telomere structure and function, leading to &#8220;uncapping&#8221; of the telomeres, induction of DNA damage responses, and rapid cancer cell death. These profound structural modifications of cancer cell telomeres were irreparable. In both <font style="font-style:italic;">in vitro</font> and <font style="font-style:italic;">in vivo </font>studies, THIO showed a very prompt effect, causing telomere uncapping and leading to cancer cell death<font style="font-style:italic;">, independent</font> of the initial tumor telomere length.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;<img src="gyowp0iggm03000011.jpg" title="" alt="" style="width:594px;height:314px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#FFFFFF;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Telomeres: Key Therapeutic Targets for CancerCyclin-dependent kinase inhibitors EGFR inhibitors Aerobic glycolysis inhibitors Proapoptotic BH3 mimetics PARP inhibitors Inhibitors of VEGF signaling Inhibitors of HGF/c-Met Selective anti-inflammatory drugs Telomere Targeting Anti-PD-1 Anti-PD-L1 Sustaining proliferative signaling Deregulating cellular energetics Resisting cell death Genome instability &amp; mutation Inducing angiogenesis Inducing angiogenesis Tumor promoting inflammation Enabling replicative immortality Enabling replicative immortality Evading growth suppressors</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The above graphic represents an established method of action from previously conducted research in rodents that forms the scientific rationale for further clinical studies, but has not yet been tested in humans.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2019, further non-clinical research in syngeneic and humanized mouse models of telomerase-expressing cancers uncovered previously unknown telomere targeting activity of THIO specifically resulting from its breakdown of cancer cells. The THIO-containing DNA fragments, resulting from THIO telomere disruption, are packed into micronuclei and are released from the treated cancer cell into the blood stream, which enhances immune responses. An immune response was observed, attributed to stimulation of the cGAS/STING pathways in the host APCs (Dendritic Cells, pDCs), as well as activation of NK cells and CD 8+ and CD 4+ lymphocytes <font style="font-style:italic;">in vivo</font>. At the same time as the T-cells activation, THIO treatment reduced levels of myeloid-derived suppressor cells (MDSCs) in the tumor micro-environment (TME), which is considered important for an anticancer immune response. While THIO activated CD8+ T cells, it also increased the total number of CD8+ T cells and upregulated PD-1 expression in the CD8+ T cells on per cell basis in the mouse model. This research demonstrated how the THIO-produced telomere stress may have the potential to increase innate sensing and adaptive anti-tumor immunity. In short, this immune system stimulation and TME remodeling proceeded in a specific antigen-dependent manner and induced adaptive immune responses that eradicated remaining cancer cells <font style="font-style:italic;">in vivo</font>.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">87</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The above noted recent studies in a humanized mouse model also supported the hypothesis that sequential administration of THIO followed by an anti-PD-L1type of checkpoint inhibitor may overcome resistance to checkpoint blockade in advanced cancer models, suggesting that the combination therapy could benefit PD-L1-resistant patients.</font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Administration of low doses of THIO, aimed to activate the immune system via THIO-induced telomeric DNA modification, followed by checkpoint inhibitor therapy (anti-PD-L1 or anti-PD1), eliminated advanced tumors in preclinical models with confirmation of cancer cell type specific immune memory. This potential for THIO to induce immune memory, if confirmed in human clinical trials, would be a distinct feature of THIO&#8217;s mechanism of action, offering the possibility that the immune system may continue to be active against the cancer cells over extended periods of time, potentially reducing the need for additional treatment.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These pre-clinical results provided the basis for our new clinical therapeutic strategy for sequentially administering THIO as a telomere-targeted agent first, to activate the immune system against the specific cancer, followed by immunotherapy or other immune-activating therapy.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Limitations of Other Therapeutic Approaches</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In contrast to THIO, which targets telomeres, a challenge for the potential clinical application of pharmaceutically useful telomerase inhibitors (e.g., Imetelstat), is the therapeutic window (the range of dosage of a drug or of its concentration in a bodily system that provides safe effective therapy) and the often-observed delay between initiation of treatment and phenotypic response (called the &#8220;lag period&#8221;). Since the antiproliferative effect of any direct telomerase inhibitor is dependent on the telomere length of any given tumor cell, clinical response will be delayed until the telomeres become critically short, and thus can no longer protect the chromosomes, and as a result, the cancer cell dies. This requires a significant number of cell divisions to become apparent, and treatment may have to be given continuously for weeks to months, potentially in conjunction with other treatment modalities, to achieve an appropriate level of efficacy.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">THIO: A Telomere Targeting Agent</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Background</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">THIO (6-thio-2&#8217;-deoxyguanosine) is a synthetically-modified small molecule nucleoside that was originally designed to be an improved chemotherapy drug developed to work around purine analog resistance, which was standard-of-care therapy in the 1970s. Sponsored by the National Cancer Institute, THIO was extensively investigated in at least 19 clinical trials with over 600 cancer patient subjects (adult and pediatric) treated, both as monotherapy or in combination with other commonly used standard agents of the time. See &#8220;THIO Clinical Trials&#8221; below for more information about these trials. A traditional treatment strategy was used where patients were treated to maximum tolerated dose (MTD), a common approach for cancer therapy drug development. Although study results were promising, development was abandoned in favor of other therapies. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The previous human experience presents significant limitations as it dates to the 1970s and early 1980s when the implementation of ICH Good Clinical Practices was not yet in effect. The published studies did not disclose certain data points in line with the current ICH Good Clinical Practices, such as efficacy endpoints and serious adverse events, whether those endpoints were reached, whether the data was found to be statistically significant and serious adverse events. Further, we do not know whether those prior studies were powered for statistical significance in the way our planned studies will be powered, based generally on the results of these prior human studies, we believe that THIO has a well-established safety profile, which we intend to independently demonstrate through our own clinical studies. Moreover, all prior studies were conducted primarily in heavily pre-treated, refractory patients.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further detailed analysis of the body of prior THIO research indicates researchers were not aware of three key factors, which if they had been known at the time, may have impacted the decision to cease development. These factors have only been discovered since 2014 (with the most recent in 2019), as illustrated in the following graphic:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">1.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">THIO&#8217;s detailed telomere targeting mechanism and resulting immune activation. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">2.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">At high drug exposure (MTD), THIO can be immunosuppressive.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">3.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">Proper administration of THIO to activate the immune system followed by immunotherapy to achieve best response. </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Telomeres</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> are vital DNA-structures discovered by Jack Szostak&#8217;s laboratory, for which he received the Nobel Prize in 2009, which are present at the ends of each chromosome which protect the genome from degradation, unnecessary recombination, repair, and interchromosomal fusion. Telomeres, along with the enzyme </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">telomerase</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, are both crucial for the survival of cancer cells. Telomerase was discovered by Elizabeth Blackburn and Carol Greider, who shared the Nobel Prize with Jack Szostak in 2009. </font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">THIO is believed to selectively target telomerase positive (TERT+) cancer cells, where the enzyme is activated, versus normal cells. 73% to 100% of primary human cancers are TERT+ dependent upon tumor type, indicating a significant potential therapeutic utilization for THIO in almost all tumor types. THIO&#8217;s cancer-specific disturbance of telomeric structure by telomerase leads to disruption in the cell cycle, followed by rapid cell death. Based on extensive review of publicly-available information, THIO&#8217;s direct telomere targeting action utilizing telomerase is different from other commercially available cancer therapies and those currently in publicly disclosed clinical trials. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2019, the MAIA research team showed that in mouse models THIO-produced telomere modification and disruption induced cancer-specific innate and adaptive immune response against immunologically &#8220;cold&#8221; or unresponsive tumor types. When THIO was administered at low doses, in syngeneic and humanized mouse models of telomerase-expressing cancers, followed by a break to allow for the activation of the immune system against the specific cancer, then followed by a standard-of-care immunotherapy agent like a check point inhibitor (CPI), either PD-1 or PD-L1, complete tumor regression was observed, with no observed toxicities. These effects have been replicated in multiple preclinical models, utilizing all leading checkpoint inhibitors or radiation therapy. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based on these studies, we hypothesized that THIO, administered in advance of immune-activating therapies (e.g., checkpoint inhibitors, radiation therapy, etc.), at dose levels significantly lower than the levels evaluated in previous clinical trials, will &#8220;<font style="font-style:italic;">prime&#8221;</font> the tumor environment and initiate an overall anti-tumor immune response. This represents an entirely new therapeutic approach for THIO and forms the basis for the new clinical strategy for planned future trials. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">THIO Preclinical Development </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following summarizes the relevant preclinical studies. Extensive preclinical studies have been performed to validate THIO&#8217;s primary mechanism of action: targeting telomeres directly and causing cancer cell death via telomerase-mediated DNA damage.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To our knowledge, THIO alone has shown significant telomere targeting activity in numerous non-small cell lung cancer (NSCLC) and multiple other cancer-based cell lines <font style="font-style:italic;">in vitro</font> and <font style="font-style:italic;">in vivo</font>, including but not limited to small cell lung cancer (SCLC), melanoma, colorectal cancer (CRC), glioblastoma multiforme (GBM), diffuse intrinsic pontine glioma (DIPG), neuroblastoma, pancreatic, hepatocellular carcinoma (HCC), as well as head and neck cancer, breast cancer and prostate cancer.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">In vitro<font style="font-style:normal;">: in summary, EC<sub style="font-size:85%; vertical-align:bottom">50</sub> values (the concentrations at which half of the total number of cancer cells are dead) were approximately 0.4 &#181;M to 1.5 &#181;M. THIO was not cytotoxic in normal, untransformed telomerase-negative cells at concentrations up to 100 &#181;M.</font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">In vivo<font style="font-style:normal;">: in summary, the doses that resulted in cancer cell death were in the range of 2.5 - 5.0 mg/kg, depending on the tumor type and the schedule of the drug administration ranging from 1 to 3 days per cycle.</font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2022, the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) to THIO for the treatment of hepatocellular carcinoma, and in May 2022, the FDA granted ODD to THIO for the treatment of small cell lung cancer. The FDA&#8217;s Office of Orphan Products Development may grant orphan designation status to drugs and biologics that are intended for the treatment, diagnosis or prevention of rare diseases, or conditions that affect fewer than 200,000 people in the U.S. Orphan Drug Designation provides certain benefits, including financial incentives, to support clinical development and the potential for up to seven years of market exclusivity for the drug for the designated orphan indication in the U.S. if the drug is ultimately approved for its designated indication.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">THIO in Sequential Administration in Advance of Checkpoint Inhibitors (CPIS) Therapy</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">In vivo<font style="font-style:normal;">, THIO, at 3 mg/kg/dose, (which corresponds to a 20 mg/patient/day low-dose), administered followed by a one-day break, followed by an immune checkpoint inhibitor (either anti-programmed cell death protein 1 (PD-1) or anti-programmed death ligand 1 (PD-L1) products), resulted in complete tumor regression in NSCLC and CRC syngeneic mouse tumor models. </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At this low dose, THIO was able to transform immunologically &#8220;cold&#8217; tumors, (tumors that do not respond to the CPI treatment), into immunologically &#8220;hot&#8221; tumors, which then responded well to the following sequential treatment with a CPI. These potent anti-tumor phenotypic effects were also accompanied by the efficient induction of the tumor-specific CD8+ cells, as well as CD4+, and natural killer (NK)-cells (Mender, 2020b).</font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These responses were achieved through telomerase-dependent and cancer cell specific activation of a) DNA damage responses, and b) cGAS/STING pathways by THIO. This body of research represents the basis for the new immune-activation treatment strategy</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following represents key highlights from THIO preclinical research:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">THIO has been tested in multiple preclinical studies evaluating various tumor types </font><font style="font-style:italic;font-size:10pt;font-family:Times New Roman;color:#000000;">in vitro</font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;"> including in lung, colorectal, prostate, breast, ovarian, head and neck, brain, melanoma, and liver cancer. THIO has also been tested in </font><font style="font-style:italic;font-size:10pt;font-family:Times New Roman;color:#000000;">in vivo</font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;"> mouse models of lung, colorectal, brain, melanoma, liver and brain cancers. In the below graphic, the left panel depicts cancer cell colony formation </font><font style="font-style:italic;font-size:10pt;font-family:Times New Roman;color:#000000;">in vitro</font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;"> assay results conducted with various types of telomerase positive cancers, namely prostate, breast, ovarian, colon, brain, head and neck. In the control column, cancer cells grew. In the second column, with the telomerase inhibitor BIBR, the cancer cells also grew. In the third column, in which the telomere targeting agent THIO was administered at a concentration of 2.5&#181;M, cancer cell growth was visibly inhibited. In the fourth column, in which THIO was administered at a concentration of 5&#181;M, cancer cells were also visibly inhibited. The same concentrations of THIO were also administered&#160;</font><font style="font-style:italic;font-size:10pt;font-family:Times New Roman;color:#000000;">in vivo</font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;"> in rodent models (mice), caring tumors, derived from either brain, or liver, or melanoma, or neuroblastoma, or colorectal cancer cells were treated with THIO (at 2 mg/kg to 5 mg/kg doses), significant reduction in tumor masses resulting from the treatment with THIO was observed. Note that THIO&#8217;s activity seen in preclinical models has yet to be demonstrated in humans.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gyowp0iggm03000012.jpg" title="" alt="" style="width:168px;height:199px;"><font style="font-family:Calibri;font-size:11pt;">&nbsp;<img src="gyowp0iggm03000013.jpg" title="" alt="" style="width:446px;height:159px;"></font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">THIO demonstrated potential to </font><font style="font-style:italic;font-size:10pt;font-family:Times New Roman;color:#000000;">selectively</font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;"> cause cancer cell death with active enzyme telomerase versus normal cells</font><font style="font-style:italic;font-size:10pt;font-family:Times New Roman;color:#000000;"> in vitro</font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">. The below graphic illustrates formation of telomeric damage foci (TIFs) in telomerase activity-positive cancer cells, but not in normal non-cancerous cells, resulting from application of THIO. These data indicate molecular mechanism of THIO that targets telomeric DNA of cancer cells through their telomerase enzymatic activity. At the same time, normal cells, that are devoid of telomerase activity, are not affected by THIO. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gyowp0iggm03000014.jpg" title="" alt="" style="width:598px;height:232px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#808080;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mender I. et al., Cancer Discovery (2015)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*TIF &#8211; telomere damages induced foci</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*TRF2 &#8211; protein associated with telomeres</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">* Gamma-H2AX &#8211; protein associated with induction of DNA damage</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*CRC &#8211; colorectal cancer</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*hTERT &#8211; protein components of telomerase enzyme </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">THIO, as a single agent, showed </font><font style="font-style:italic;font-size:10pt;font-family:Times New Roman;color:#000000;">in vitro</font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;"> telomere targeting activity in cancer cells that are resistant to tyrosine kinase inhibitors (TKIs), checkpoint inhibitors, IL-2, IFN&#945;, YERVOY<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> (ipilimumab) and a host of chemotherapies. The below graphic, in NSCLC and Melanoma models respectively,</font><font style="font-family:Times New Roman;color:#000000;"> </font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">demonstrates in vivo telomere targeting activity of THIO in mice models of lung cancer, derived from PERC16 cells, and melanoma derived from WM4265 cells. Both cell lines are resistant to multiple standard-of-care drug compounds, as listed in the Figure legends.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gyowp0iggm03000015.jpg" title="" alt="" style="width:584px;height:235px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*i.p. &#8211; intraperitoneal injection</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*IL-2 &#8211; cytokine interleukin 2</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*IFN-a &#8211; interfer</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">on alfa</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">THIO was observed to penetrate the blood-brain barrier and inhibits tumor growth, inducing in-tumor telomere dysfunction and cancer cell death, in </font><font style="font-style:italic;font-size:10pt;font-family:Times New Roman;color:#000000;">in vitro</font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;"> models of difficult to treat pediatric brain cancer, where no therapy exists. In the below graphic, this is shown through presence of Caspase-3 enzyme which is associated with cell death. Sengupta, S. et al. Induced telomere damage to treat telomerase expressing therapy-resistant pediatric brain tumors. Mol Cancer Therapeutics, 17(7): 1504-1514, 2018.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gyowp0iggm03000016.jpg" title="" alt="" style="width:284px;height:218px;">&nbsp;<img src="gyowp0iggm03000017.jpg" title="" alt="" style="width:293px;height:214px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*TIF &#8211; telomere damage induced foci</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*MB004 &#8211; brain cancer cell line</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">THIO transformed &#8220;cold&#8221; tumors into &#8220;hot&#8221; tumors that were responsive to immunotherapy. THIO utilized a telomere targeting pathway that synergized with checkpoint inhibitors and other immune-activating therapies. The tumor-specific immune activation, resulting from THIO&#8217;s primary mode of action, overcame resistance to current check point inhibitor (CPI) standard-of-care therapy, as illustrated in the following Colorectal Cancer model. The below graphic demonstrates telomere targeting activity of THIO alone, and in sequential combination with immune checkpoint inhibitor (anti-PD-L1 compound, atezolizumab), in mice model of colorectal cancer, derived from MC-38 cells. Two doses of THIO are shown to control tumor growth while anti-PD-L1 agent. Sequential administration of THIO (2 days), followed by administration of the anti-PD-L1 agent, demonstrates disappearance of tumor cells.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gyowp0iggm03000018.jpg" title="" alt="" style="width:624px;height:232px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">Immunological memory was observed in mouse models, where the immune system continued to be active against the specific treated tumor cell type for 100 days post-tumor inoculation. The below graphic demonstrates that the tumor-free animals that were treated with the sequential combination of THIO and anti-PD-L1 compound were followed for 70 days, with no observed tumor recurrence. Subsequently, </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">92</a></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">animals were </font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">re-challenged with 10 </font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">times</font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;"> more </font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">MC38 cancer cells. Cancer growth was not observed in these animals, demonstrating induction of </font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">anti-</font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">tumor-prote</font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">cting memory after sequential</font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;"> administration of THIO and anti-PD-L1 agent; ref: Mender, I., et al. Telomere stress potentiates STING-dependent anti-tumor immunity. Cancer Cell, 38,3, 400-411.E6,&#160;September 14, 2020.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gyowp0iggm03000019.jpg" title="" alt="" style="width:624px;height:238px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, due to the cGAS/STING activation caused by THIO, telomere targeting activity was observed in numerous preclinical tumor models when THIO was administered followed by immune activating therapy such as immune checkpoint inhibitors (anti-PD-L1 or anti-PD-1 antibody). </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">It is therefore hypothesized that THIO, administered in advance of immune-activating therapies (e.g., checkpoint inhibitors, radiation therapy, etc.), at dose levels significantly lower than the levels evaluated in previous clinical trials, will &#8220;<font style="font-style:italic;">prime&#8221;</font> the tumor environment and initiate an overall anti-tumor immune response. If confirmed through additional clinical studies, this could represent an entirely new therapeutic approach for THIO and form the basis for the new clinical strategy for planned future trials. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">THIO Clinical Trials </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We plan to rely solely upon our self-generated clinical safety and efficacy data, if favorable, in support of our anticipated NDA filing for THIO. However, THIO, as a compound, was the subject of investigation in numerous clinical trials in the 1970s to the early-80s in a variety of solid tumors and hematological malignancies. The compound was evaluated in at least nineteen (19) Phase 1 to Phase 3 clinical trials with over 600 patients treated by major cancer institutions and cancer cooperative groups. THIO was studied in combination with common agents in use at the time, including methyl-CCNU or mitomycin, two widely used alkylating agents to treat a variety of cancers and leukemias. Studies utilizing THIO as a single agent have been published in peer-reviewed journals. As part of the existing data base of clinical experience with the drug, we expect to reference the older NCI studies in the public domain as well as reference NCI&#8217;s original IND filing in support of an IND filing, pursuant to FDA regulations.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">93</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following tables summarize the THIO single agent peer-reviewed published data available from the previous clinical trials.</font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;color:#1F497D;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Phase 1 </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:8.34%;"></td>
<td style="width:20.48%;"></td>
<td style="width:20.35%;"></td>
<td style="width:11.36%;"></td>
<td style="width:20.61%;"></td>
<td style="width:18.86%;"></td>
</tr>
<tr>
<td valign="middle" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Study</p></td>
<td valign="middle" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Tumor Type</p></td>
<td valign="middle" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Regimen/Dose Schedule</p></td>
<td valign="middle" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Evaluable Subjects</p></td>
<td valign="middle" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Observed Adverse Events</p></td>
<td valign="middle" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Responses</p></td>
</tr>
<tr style="height:88.15pt;">
<td valign="middle" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">C76-92</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:8pt;">&nbsp;</p></td>
<td valign="middle" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pediatric Acute Leukemia who received prior</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6-mercaptopurine (6-MP) or 6-thioguanine</p></td>
<td valign="middle" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">THIO 200 to 2,250 mg/m<sup style="font-size:85%;line-height:120%;vertical-align:top">2</sup> given every 12 hours for 3 doses every 2 weeks</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:8pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Maximum tolerated dose (MTD) was determined to be 1,750 mg/m<sup style="font-size:85%;line-height:120%;vertical-align:top">2</sup> given every 12 hours for 3 doses every 2 weeks</p></td>
<td valign="middle" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</p></td>
<td valign="middle" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reversible urate nephropathy, elevations of liver enzymes, nausea and vomiting, alopecia, and skin reactions</p></td>
<td valign="middle" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Therapeutic Responses observed in 6/23 (26%) patients comprised of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2 complete responses and 4 partial responses</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Source: <font style="color:#0000FF;">Higgins, G. R., Jamin, D. C., Shore, N. A., Momparler, R., Hartman, G. and Siegel, S. E. (1985). "Phase I evaluation of beta-2'-deoxythioguanosine in pediatric patients with leukemia." Cancer Treat Rep 69(6): 699-701t</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#1F497D;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Phase 2 &#8211; Single Agent Studies</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:9.1%;"></td>
<td style="width:16.32%;"></td>
<td style="width:18.02%;"></td>
<td style="width:9.63%;"></td>
<td style="width:11.15%;"></td>
<td style="width:10.16%;"></td>
<td style="width:10.26%;"></td>
<td style="width:15.35%;"></td>
</tr>
<tr style="height:22.9pt;">
<td valign="middle" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Protocol</p></td>
<td valign="middle" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Tumor Type</p></td>
<td valign="middle" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Regimen/Dose</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Schedule</p></td>
<td valign="middle" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Evaluable</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Subjects</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ORR</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Overall</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Response)</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">PR</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Partial</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Response)</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CR</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Complete</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Response)</p></td>
<td valign="middle" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Observed</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Adverse Events</p></td>
</tr>
<tr style="height:14.95pt;">
<td rowspan="7" valign="middle" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SEG-248</p></td>
<td valign="middle" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total Patients</p></td>
<td valign="middle" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:8pt;">&nbsp;</p></td>
<td valign="middle" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">117</p></td>
<td valign="middle" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">27 (23%)</p></td>
<td valign="middle" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">11 (9%)</p></td>
<td valign="middle" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">16 (14%)</p></td>
<td rowspan="7" valign="middle" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leukopenia</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thrombocytopenia</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Skin rash</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Alopecia (reversible)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nausea and vomiting</p></td>
</tr>
<tr style="height:3.7pt;">
<td rowspan="2" valign="middle" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Acute Myelocytic Leukemia (AML)</p></td>
<td valign="middle" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">300 mg/m<sup style="font-size:85%;line-height:120%;vertical-align:top">2</sup> daily for 5 days</p></td>
<td valign="middle" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</p></td>
<td valign="middle" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4 (24%)</p></td>
<td valign="middle" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1 (6%)</p></td>
<td valign="middle" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 (18%)</p></td>
</tr>
<tr style="height:3.7pt;">
<td valign="middle" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">400 mg/m<sup style="font-size:85%;line-height:120%;vertical-align:top">2</sup> daily for 5 days</p></td>
<td valign="middle" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49</p></td>
<td valign="middle" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10 (20%)</p></td>
<td valign="middle" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6 (12%)</p></td>
<td valign="middle" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4 (8%)</p></td>
</tr>
<tr style="height:13.9pt;">
<td rowspan="2" valign="middle" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Blastic transformation of chronic myelogenous leukemai (BTL)</p></td>
<td valign="middle" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">300 mg/m<sup style="font-size:85%;line-height:120%;vertical-align:top">2</sup> daily for 5 days</p></td>
<td valign="middle" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</p></td>
<td valign="middle" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 (27%)</p></td>
<td valign="middle" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 (27%)</p></td>
</tr>
<tr style="height:2.15pt;">
<td valign="middle" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">400 mg/m<sup style="font-size:85%;line-height:120%;vertical-align:top">2</sup> daily for 5 days</p></td>
<td valign="middle" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</p></td>
<td valign="middle" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6 (23%)</p></td>
<td valign="middle" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 (12%)</p></td>
<td valign="middle" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 (12%)</p></td>
</tr>
<tr style="height:3.7pt;">
<td rowspan="2" valign="middle" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Acute Lymphocytic Leukemia (ALL)</p></td>
<td valign="middle" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">300 mg/m<sup style="font-size:85%;line-height:120%;vertical-align:top">2</sup> daily for 5 days</p></td>
<td valign="middle" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
<td valign="middle" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2 (50%)</p></td>
<td valign="middle" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2 (50%)</p></td>
</tr>
<tr style="height:3.7pt;">
<td valign="middle" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">400 mg/m<sup style="font-size:85%;line-height:120%;vertical-align:top">2</sup> daily for 5 days</p></td>
<td valign="middle" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p></td>
<td valign="middle" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2 (20%)</p></td>
<td valign="middle" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1 (10%)</p></td>
<td valign="middle" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1 (10%)</p></td>
</tr>
<tr style="height:21.55pt;">
<td rowspan="2" valign="middle" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EST 4273 (ECOG)</p></td>
<td rowspan="2" valign="middle" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Colorectal</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(prior 5-FU chemotherapy)</p></td>
<td rowspan="2" valign="middle" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">THIO 100 mg/m<sup style="font-size:85%;line-height:120%;vertical-align:top">2</sup> daily for 5 days every 3 weeks</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">vs</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MeCCNU 175 mg/m<sup style="font-size:85%;line-height:120%;vertical-align:top">2 </sup></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">every 8 weeks</p></td>
<td valign="middle" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61</p></td>
<td valign="middle" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 (5%)</p></td>
<td valign="middle" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 (5%)</p></td>
<td valign="middle" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td rowspan="2" valign="middle" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leukopenia, thrombocytopenia, nausea and vomiting</p></td>
</tr>
<tr style="height:13pt;">
<td valign="middle" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55</p></td>
<td valign="middle" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5 (9%)</p></td>
<td valign="middle" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5 (9%)</p></td>
<td valign="middle" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Omura, G. A., Vogler, W. R., Smalley, R. V., Maldonado, N., Broun, G. O., Knospe, W. H., et al. (1977b). "Phase II Study of beta-2'-deoxythioguanosine in adult acute leukemia. (Study SEG-248)" Cancer Treat Rep 61(7): 1379-1381 Douglass, H. O., Jr., Lavin, P. T., Woll, J., Conroy, J. F. and Carbone, P. (1978). "Chemotherapy of advanced measurable colon and rectal carcinoma with oral 5-fluorouracil, alone or in combination with cyclophosphamide or 6-thioguanine, with intravenous 5-fluorouracil or beta-2'-deoxythioguanosine or with oral 3(4-methyl-cyclohexyl)-1(2-chlorethyl)-1-nitrosourea: A Phase II-III study of the Eastern Cooperative Oncology Group (EST 4273)." Cancer 42(6): 2538-2545</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The previous human experience presents significant limitations as it dates to the 1970s and early 1980s when the implementation of ICH Good Clinical Practices was not yet in effect. The published studies did not disclose certain data points in line with the current ICH Good Clinical Practices, such as efficacy endpoints and serious adverse events. , whether those endpoints were reached, whether the data was found to be statistically significant and serious adverse events. Further, we do not know whether those prior studies were powered for statistical significance in the way our planned studies will be powered. Based generally on the results of these prior human studies, we believe </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">94</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:10pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that THIO has a well-established safety profile, which we intend to independently demonstrate through our own clinical studies. Moreover, all prior studies were conducted primarily in heavily pre-treated, refractory patients. </font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Notwithstanding these limitations, the available data provides substantial information on the clinical experience with and clinical profile of THIO with an exposure exceeding 600 subjects (adult and pediatric) at doses significantly higher than those intended for investigation in the current program and new treatment strategy. All studies were conducted in heavily pre-treated/refractory patients, most of whom were pre-treated with other standards of care including chemotherapy. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To date, THIO has not received marketing approval in any country; therefore, there is no marketing experience to be reported. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The planned clinical trials will evaluate the new THIO immunogenic therapeutic strategy - evaluating the safety and efficacy of low potentially immunogenic doses of THIO administered to activate the immune system against the tumor to be treated, then followed by standard-of-care immunotherapy (checkpoint inhibitor) or other immune activating therapy (radiation therapy). </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">THIO Developmental Initiatives and Objectives </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based on the existing data regarding pre-clinical information on THIO, we believe it is possible to enter the next human clinical study in the near term with the new low dose immunogenic approach with THIO. We plan to approach the FDA to request a modified toxicity requirement to allow us a reduced time and expenditure to IND in the United States, however, the FDA may not grant such request. We are currently working with experts to evaluate the extent and quality of the existing data supporting THIO and expect to request a pre-IND meeting with the FDA for guidance in 2022. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Phase 2 and 3 Programs</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our primary short-term objective is to assess this approach in a Proof-of-Concept study outlined below.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This first study will be a dose-finding, Phase 2 clinical trial evaluating both safety and efficacy of THIO sequenced with cemiplimab in patients with advanced non-small lung cancer (NSCLC) who progressed or showed no clinical benefit to first line treatment containing an immune checkpoint inhibitor. This trial, designated as THIO-101 study will be our first human clinical trial to test the immune system activation demonstrated in preclinical animal models: lower doses of THIO administered prior to a checkpoint inhibitor treatment reverses drug resistance, enhance and prolong immune responses in patients with advanced lung cancer who did not respond or progressed after a prior cancer treatment which contained an immune checkpoint inhibitor. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The trial design has two primary objectives: (1) safety of THIO administered as a priming immune system agent prior to cemiplimab administration and (2) clinical efficacy of THIO using Overall Response Rate (ORR) as the primary clinical endpoint. We expect the study to start initially in Australia and Europe followed by the United States. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following chart sets forth the design of the THIO-101 trial: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gyowp0iggm03000020.jpg" title="" alt="" style="width:624px;height:165px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">95</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This &#8220;dose-finding&#8221; trial will assess the safety, mechanism of activity, and immune system activation of four THIO doses tested out in separate arms administered in parallel. Each dosing arm will be further evaluated for efficacy based on Overall Response Rate (ORR), Duration of Response (DoR) and Progression Free Survival (PFS) to determine to optimal (safe and effective) dose of THIO administered in sequence with cemiplimab. Additional patients may be recruited for further clinical evaluation in any of the THIO arms based on safety and clinical benefit. Each arm of the trial will enroll a minimum of 22 and up to 41 evaluable patients. Subsequently, we expect to target earlier lines of therapy (1<sup style="font-size:85%;line-height:120%;vertical-align:top">st</sup> line) in pivotal Phase 3 confirmatory studies in NSCLC.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In order to obtain FDA and EMEA approval of THIO in combination with other standard of care approved cancer immunotherapies, we will have to conduct head-to-head studies which will compare standard of care treatment alone to standard of care treatment combined with THIO. In such studies, we would have to show that THIO added to standard of care therapies adds a significant treatment benefit by slowing down tumor progression and increasing the overall survival of the cancer patients.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, we are actively evaluating other regulatory strategies and pathways that have the potential to accelerate and/or expand the study of THIO administered in sequence with an immune-checkpoint inhibitor in colorectal cancer (CRC) indication.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the event THIO demonstrates early clinical efficacy, we plan to expand our clinical development program in multiple tumor types and assess several regulatory approval pathways utilizing our other development programs. The clinical development plan includes the initiation of an additional &#8220;basket trial&#8221; in multiple cancer types. This study uses a special design which allows different cancer indications to be studied under the same single trial umbrella. Some of the indications considered are:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;">o</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">hepatocellular carcinomas (HCC)</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;">o</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">small-cell lung cancer (SCLC)</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;">o</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">melanoma </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;">o</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">breast cancer</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;">o</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">pancreatic cancer </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;">o</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">glioblastoma multiforme (GBM)</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;">o</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">ovarian cancer</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;">o</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">prostate cancer</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ultimately, we envision positioning THIO as the foundational priming treatment for all immune-activating agents over time based upon THIO&#8217;s tumor-specific immune-activation approach that enables key clinical strategies that could dramatically expand the immunotherapy market.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Second Generation Telomere Targeting Agents</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have initiated an early-stage research and discovery program aimed at identifying new compounds capable of acting through the same mechanism of action as THIO, such as targeting and modifying telomeric structures of cancer cells through cancer-cell intrinsic telomerase activity. The main objective for this program is to discover compositionally new compounds with potentially improved specificity towards cancer cells relative to normal cells, and to assess telomere targeting activity in comparison with THIO. This program may also allow us to strengthen our patent portfolio. Although the program is in early stages and we may not be able to identify suitable compounds, we believe we will be able to create or discover a second generation of THIO-like compounds. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Strategic Collaborations and Key Agreements</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Through our licensing agreements with The University of Texas Southwestern Medical Center (&#8220;UTSW&#8221;), we have commercial rights to certain U.S. patents, as well as their foreign counterparts, for the use of THIO in treating telomerase-expressing lung and colon cancer cells. We are currently using this technology to study a treatment regimen comprising the use of THIO treatment followed by cemiplimab (Regeneron) treatment in NSCLC. In addition, we have licensed a number of pending U.S. and foreign patent applications from UTSW directed to other indications, and we are continuing to pursue discussions with several companies to develop other treatment regimens using THIO for additional cancer indications.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">96</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><font style="font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Clinical Supply Agreement with Regeneron Pharmaceuticals, Inc.</font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2021, we entered into a Clinical Supply Agreement with Regeneron Pharmaceuticals, Inc. (REGN) to supply cemiplimab for the THIO-101 study. Regeneron will contribute the drug supply without cost, which represents a significant direct cost savings for our program. In exchange, Regeneron will receive development exclusivity for NSCLC indication during the study period, which means that MAIA cannot study THIO in NSCLC with any other PD-1 antagonist (a product sub-class of immune checkpoint inhibitors). All other tumor types remain open, and we are in discussions with other pharmaceutical companies to evaluate additional agreements that may be appropriate to support the expanded development of THIO. The supply agreement will remain in force until all of the obligations of the parties&#8217; related to the studies contemplated by the agreement are completed, or until terminated by either party. The agreement may be terminated in the event of unsafe use of cemiplimab, material breach, regulatory action or corruption.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, our management believes that strong partnership interest will develop from other pharmaceutical companies who have checkpoint inhibitor franchises or those with cancer immunotherapy interest. We expect to continue discussions with several companies that have expressed interest and plan to expand discussions to capitalize on these opportunities. The checkpoint inhibitor market is large, and our goal is to ultimately position THIO as the foundational priming treatment to be used prior to all checkpoint inhibitors.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">The University of Texas Southwestern Medical Center License Agreement 1</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On December 8, 2020, we entered into an amended and restated agreement (of our prior November 29, 2018 agreement) with The Board of Regents of The University of Texas System on behalf of The University of Texas Southwestern Medical Center (collectively, UTSW). Pursuant to the amended and restated agreement, which we refer to as the UTSW1 Agreement, we obtained (1) an exclusive, worldwide license to develop and commercialize the following UTSW patent families generally directed to methods of using THIO (below) and (2) a non-exclusive worldwide license to develop and commercialize related technology rights.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:7.64%;width:69.97%;">
<tr>
<td style="width:69.97%;"></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title / PCT Application Number</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Telomerase Mediated Telomere Altering Compounds / PCT/US2014/33330 (WO2014/168947)</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6-Thio-2'-Deoxyguanosine (6-Thio-Dg) Results in Telomerase Dependent Telomere Dysfunction and Cell Death in Various Models of Therapy-Resistant Cancer Cells / <br />PCT/US2017/34706 (WO2017/205756)</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Use of 6-thio-dG to Treat Therapy-Resistant Telomerase positive Pediatric Brain Tumors / <br />PCT/US2019/023596 (WO2019/183482)</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Treatment of Drug Resistant Proliferative Diseases with Telomerase Mediated Telomere Altering Compounds / PCT/US2017/023858 (WO/2017/165675)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the UTSW1 Agreement, we agreed to pay UTSW a minimal license fee, deferred license fees, milestone fees, and running royalties beginning on the first net sale (among others). For additional details regarding our relationship with UTSW, see the section entitled &#8220;Business &#8212; Intellectual Property &#8212;License Agreement 1 with <font style="font-style:italic;">The Board of Regents of The University of Texas System</font>/<font style="font-style:italic;">The University of Texas Southwestern Medical Center</font>.&#8221; The UTSW1 Agreement includes an exclusive license to US patent no. 10,463,685 (expires April 8, 2034), and pending US patent application nos. 16/450,430 (having an earliest expiration of March 23, 2037, if a patent is granted), 16/304,538 (having an earliest expiration of May 26, 2037, if a patent is granted), and 16/982,979 (having an earliest expiration of March 22, 2039, if a patent is granted).</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">The University of Texas Southwestern Medical Center License Agreement 2</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On December 23, 2020, we entered into a second agreement with The Board of Regents of The University of Texas System on behalf of The University of Texas Southwestern Medical Center, which set forth the agreement between the parties pursuant to the Company exercising its option rights in the UTSW1 Agreement and obtaining additional license rights. Pursuant this second license with UTSW, which we refer to as the UTSW2 Agreement, we obtained </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">97</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:8pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1) an exclusive, worldwide license to develop and commercialize the following UTSW patent family (below) and (2) a non-exclusive worldwide license to develop and commercialize related technology rights.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:7.64%;width:69.97%;">
<tr>
<td style="width:69.97%;"></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title / PCT Application Number</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sequential Treatment of Cancers Using 6-Thio-dG and Checkpoint Inhibitors / PCT/US2021/022090</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the UTSW2 Agreement, we agreed to pay UTSW a minimal license fee, deferred license fees, milestone fees, and running royalties beginning on the first net sale (among others). For additional details regarding our relationship with UTSW, see the section entitled &#8220;Business &#8212; Intellectual Property &#8212;License Agreement 2 with <font style="font-style:italic;">The Board of Regents of The University of Texas System</font> /<font style="font-style:italic;">The University of Texas Southwestern Medical Center</font>.&#8221; The UTSW2 Agreement includes an exclusive license to pending US patent application no. 17/200,539 (having an earliest expiration of March 12, 2041, if a patent is granted).</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">THIO Program</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">License Agreement 1 with The Board of Regents of The University of Texas System /The University of Texas Southwestern Medical Center </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On December 8, 2020 (the &#8220;Effective Date&#8221;), we entered into an amended and restated agreement (of our prior November 29, 2018 agreement) with The Board of Regents of The University of Texas System on behalf of The University of Texas Southwestern Medical Center, (collectively, UTSW) to develop and commercialize certain UTSW owned and/or controlled patents and related technology directed to methods of using THIO (&#8220;the UTSW1 Agreement&#8221;). The license is exclusive as to worldwide Patent Rights for all uses in the Field, which is defined as all therapeutic, prophylactic and diagnostic fields of use for all indications, including discovery and development uses. The license is sublicensable with prior UTSW written approval consistent with the terms of UTSW1 Agreement.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The UTSW1 Agreement includes an exclusive license to the &#8220;Patent Rights&#8221; of the worldwide patent families including all provisional applications and any divisionals, continuations, continuations-in-part and foreign counterpart applications that are entitled to claim priority thereto, and any patents resulting therefrom, of the following:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:7.64%;width:69.99%;">
<tr>
<td style="width:69.99%;"></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title / PCT Application Number</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Telomerase Mediated Telomere Altering Compounds / PCT/US2014/33330 (WO2014/168947)</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6-Thio-2'-Deoxyguanosine (6-Thio-Dg) Results in Telomerase Dependent Telomere Dysfunction and Cell Death in Various Models of Therapy-Resistant Cancer Cells /PCT/US2017/34706 (WO2017/205756)</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Use of 6-thio-dG to Treat Therapy-Resistant Telomerase positive Pediatric Brain Tumors /PCT/US2019/023596 (WO2019/183482)</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Treatment of Drug Resistant Proliferative Diseases with Telomerase Mediated Telomere Altering Compounds / PCT/US2017/023858 (WO/2017/165675)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The UTSW1 Agreement also grants the Company a non-exclusive worldwide license under the Technology Rights to develop, manufacture, have manufactured, distribute, have distributed, use, offer for Sale, Sell, lease, loan and/or import Licensed Products in the Field, wherein Technology Rights means Licensor&#8217;s rights in technical information, know-how, processes, procedures, compositions, devices, methods, formulas, protocols, techniques, designs, drawings or data created before the Effective Date by Inventors at UTSW which are necessary or reasonably useful for practicing Patent Rights. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">98</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The UTSW1 Agreement also grants the Company the first right to negotiate an exclusive license under any patent rights covering or claiming any improvement, which is any patentable invention and is conceived or reduced to practice solely by Dr. Jerry Shay or those under his direct supervision at UTSW within 3 years of the Effective Date, under certain conditions.</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The term of the UTSW1 Agreement begins on the Effective Date and continue until the earliest of: (i) termination pursuant to the UTSW1 Agreement, (ii) the last date of expiration or termination of the Patent Rights; or (iii) if Technology Rights are licensed and no Patent Rights are applicable, twenty (20) years after the Effective Date. The Company may terminate the UTSW1 Agreement for convenience, at any time prior by providing ninety (90) days&#8217; written notice to UTSW. UTSW may terminate the UTSW1 Agreement if the Company (i) becomes in arrears in any payments due, and fails to make the required payment within 30 days after delivery of written notice from UTSW, (ii) is in breach of any material non-payment provision, and does not cure such breach within 60 days after delivery of written notice, (iii) UTSW delivers notice to the Company of three or more actual breaches in any 12-month period, even in the event that the Company cures such breaches in the allowed period, (iv) becomes insolvent or bankrupt, then termination is immediate.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">UTSW and/or the co-owners of certain patents have reserved the right to publish the scientific findings related to the Patent Rights and use and to permit other academic institutions to use the licensed subject matter for teaching, research, education, and other education-related, non-commercial purposes. The Patent Rights are also subject to any rights of the United States federal, state and/or local Government(s), as well as nonprofit entities, if certain patents or technologies were created in the course of Government-funded or non-profit entity-funded research.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the UTSW1 Agreement, the Company paid to UTSW a nominal one-time upfront license fee. The Company is also obligated to pay all accrued patent expenses as well as ongoing patent expenses on a scheduled basis tied to Company fund-raising through Series A funding until Company has reimbursed all patent expenses. In the event that the Company assigns the agreement to a third party, the Company is obligated to pay UTSW an assignment fee in the mid-six figures within 15 days of such assignment. The agreement cannot be assigned without UTSW&#8217;s consent.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the UTSW1 Agreement, the Company is obligated to use diligent efforts to bring licensed products to market through a funded, ongoing and active research and development, manufacturing, regulatory, marketing or sales program (all as commercially reasonable) and provide semi-annual reports to UTSW on its progress. The Company is also obligated to pay agreed upon milestone payments to UTSW. Failure of the Company to fulfill these obligations may be treated as a material breach by UTSW.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The only milestones that require payments under the UTSW1 Agreement include: (i) first commercial sale in the U.S. of licensed product for treating an oncology indications ; (ii) first commercial sale in the U.S. of licensed product for treating a non-oncology indications; (iii) first time aggregate Net Sales (as defined in the UTSW1 Agreement) of licensed product for treating an oncology indications exceeds low-nine figure sales in a contract year; (iv) first time aggregate Net Sales of licensed product for treating a non-oncology indications exceeds low nine-figure sales in a contract year; (v) first time aggregate Net Sales of licensed product for treating an oncology indications exceeds low ten-figure sales in a contract year; (vi) first time aggregate Net Sales of licensed product for treating a non-oncology indications exceeds low ten-figure sales in a contract year. There are no milestone payments required on any development or regulatory milestones. The only required milestone payments under the UTSW1 Agreement related to commercial sales milestones, and the aggregate amount of milestone fees payable pursuant to the UTSW1 Agreement will not exceed $112 million.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company will also pay UTSW running royalties on a yearly basis as a percentage of Net Sales of the Company or its sublicensee. There are single digit royalty rates for licensed products and licensed services covered by a Valid Claim (as defined in UTSW1 Agreement) and dependent on whether Net Sales are greater than or less than/equal to low ten figures of sales, with Net Sales above that amount commanding a slightly higher percentage. In each case, the royalty percentage is lower before patent issuance in each jurisdiction. In the event that the licensed product or licensed service is not covered by a Valid Claim, the running royalty rates are reduced by a certain percentage. The royalty obligations continue on a country-by-country basis until the later of expiration of the last Valid Claim in each country or ten (10) years after the First Commercial Sale (as defined in UTSW1 Agreement) in each country. In the event that the Company or its sublicensee challenges the Patent Rights, then the Company will be obligated to </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">pay multiples of the applicable royalty rate of the Net Sales and, should the outcome of such challenge determine that any claim of the Patent Rights challenged is both valid and infringed then the Company will pay royalties at the rate of multiples of the applicable royalty rate of the Net Sales sold thereafter and reimburse UTSW for all fees and costs associated with defending such challenge, including attorney&#8217;s fees and expert fees. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The UTSW1 Agreement also contains an anti-stacking provision pursuant to which in the event the Company or its sublicensee pays royalties or other payments to a third party who owns or controls intellectual property deemed necessary to develop, manufacture, have manufactured, distribute, have distributed, use, lease, loan, import, offer for sale and/or sell any licensed products and licensed services, the Company may reduce payments to UTSW by a certain percentage of the royalty, milestone or other payments paid to such third party. However, such adjustment in royalty payments to UTSW may not be reduced by more than a certain percentage of the royalty obligation in any contract year. In the event that the payment to the third party who owns or controls intellectual property deemed necessary to extend or expand the franchise or exclusivity of a previously launched licensed product (e.g., such as a new formulation as a second generation product containing the same compound as the previously launched Licensed Product), then the Company may reduce payments to UTSW by a certain percentage of the royalty, milestone or other payments paid to such third party. However, such adjustment in royalty payments to UTSW may not be reduced below a certain percentage of the royalty obligation in any contract year.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">UTSW maintains direct control over the prosecution and maintenance activities of the Patent Rights, and the Company is obligated to reimburse past and ongoing patent expenses as noted above. UTSW will permit the Company to comment on submissions to government patent agencies, during prosecution and will consider the Company&#8217;s comments, but UTSW retained control over all final decisions. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The UTSW1 Agreement contains a representation that UTSW has the rights and authority to grant to Company the licensed rights and is to its knowledge unaware of any third-party infringer or any infringement of third-party intellectual property rights. The UTSW1 Agreement also requires the Company to indemnify UTSW and other related parties against any liabilities, damages, causes of action, suits, judgments, liens, penalties, fines, losses, costs and expenses arising out of any product the Company produces under the UTSW1 Agreement, and requires the Company, beginning with the earlier of the first clinical trial or commercial sale or other commercialization, to obtain liability insurance.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company will have the first and sole right but not the obligation, at its own expense, to initiate an infringement suit or other appropriate actions against third party infringers and monetary recovery received therefrom, after the Company is reimbursed for expenses in enforcing the Patent Rights, is shared between the Company and UTSW pursuant to a good faith negotiation between the parties at that time. If the Company does not file suit within six months after a written request by UTSW, then UTSW may bring suit to enforce any Patent Right and retain all recoveries from such enforcement. If UTSW pursues such infringement action, it may, as part of the resolution of such efforts, grant nonexclusive license rights to the alleged infringer notwithstanding Licensee&#8217;s exclusive license rights.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In accordance with the terms of the UTSW1 Agreement, on April 24, 2020 Company sublicensed all Company rights and obligations under the UTSW1 Agreement to Company affiliate THIO Therapeutics, Inc.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">License Agreement 2 with The Board of Regents of The University of Texas System /The University of Texas Southwestern Medical Center </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On December 23, 2020 (the &#8220;Effective Date&#8221;), we entered into a second agreement with The Board of Regents of The University of Texas System on behalf of The University of Texas Southwestern Medical Center, (collectively, UTSW), which set forth the agreement between the parties pursuant to the Company exercising its option rights in the UTSW1 Agreement and obtaining additional license rights (&#8220;the UTSW2 Agreement&#8221;). The license is exclusive as to worldwide Patent Rights for all uses in the Field, which is defined as all therapeutic, prophylactic and diagnostic fields of use for all indications, including discovery and development uses. The license is sublicensable with prior UTSW written approval consistent with the terms of UTSW2 Agreement.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The UTSW2 Agreement includes an exclusive license to the &#8220;Patent Rights&#8221; of the worldwide patent family including all provisional applications and any divisionals, continuations, continuations-in-part and foreign counterpart applications that are entitled to claim priority thereto, and any patents resulting therefrom, of the following</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:7.64%;width:69.99%;">
<tr>
<td style="width:69.99%;"></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman PS Std;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title / PCT Application Number</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman PS Std;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sequential Treatment of Cancers Using 6-Thio-dG and Checkpoint Inhibitors / PCT/US2021/022090</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The UTSW2 Agreement also grants the Company a non-exclusive worldwide license under the Technology Rights to develop, manufacture, have manufactured, distribute, have distributed, use, offer for Sale, Sell, lease, loan and/or import Licensed Products in the Field, wherein Technology Rights means UTSW&#8217;s rights in technical information, know-how, processes, procedures, compositions, devices, methods, formulas, protocols, techniques, designs, drawings or data created before the Effective Date by inventors at UTSW which are necessary or reasonably useful for practicing Patent Rights. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The terms of the UTSW2 Agreement are similar in many respects to those set forth in the UTSW1 Agreement. Pursuant to the UTSW2 Agreement, the Company paid to UTSW a nominal one-time upfront license fee. The UTSW2 Agreement recognizes the accrual of low five-figures in patent expenses relative to the Patent Rights of this agreement and provides for deferral of this fee and related ongoing patent expense fees on a schedule connected to the Company&#8217;s fundraising through Series A funding. Once the Company has raised mid seven-figures, the patent expense fees are be paid in full for all patent expenses incurred by UTSW for the Company&#8217;s licensed technologies which accrued between December 12, 2019, and the date at which the mid seven-figures has been raised. Until the Company has reimbursed all patent expenses it is obligated to report its fundraising progress to UTSW on a quarterly basis. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The milestone payments are the same as in the UTSW1 Agreement wherein the milestone fees are based solely on commercial sales milestones and are payable one time only, regardless of the number of licensed products or licensed services developed and regardless of the number of indications or patient sub-populations treated with a licensed product(s) and regardless of whether the licensed products or licensed services developed are within the rights granted by the UTSW1 Agreement or the UTSW2 Agreement. In other words, there are no milestone payments required on any development, or regulatory milestones under the UTSW1 Agreement or the UTSW2 Agreement. The only required milestone payment under the UTSW1 Agreement or the UTSW2 Agreement relate to commercial sales milestones and the aggregate amount of milestone fees payable pursuant to the UTSW1 Agreement or the UTSW2 Agreement will not exceed $112 million. In the event the Company assigns the UTSW2 Agreement to a third party, the Company is obligated to pay UTSW low six-figures within 15 days of such assignment, which is cumulative of the UTSW1 Agreement assignment fee, such that if both agreements are assigned to a third party, a total of high six-figures would be owed to UTSW. The agreement cannot be assigned without UTSW&#8217;s consent.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company will also pay UTSW running royalties on a yearly basis as a percentage of Net Sales of the Company or its sublicensee. There are mid-single digit royalty rates for licensed products and licensed services covered by a Valid Claim (as defined in UTSW2 Agreement) and dependent on whether Net Sales are greater than or less than/equal to low ten-figures in sales, with Net Sales above that amount commanding a slightly higher percentage. In each case, the royalty percentage is lower before patent issuance in each jurisdiction. In the event that the licensed product or licensed service is not covered by a Valid Claim, the running royalty rates are reduced by a certain percentage. The royalty obligations continue on a country-by-country basis until the later of expiration of the last Valid Claim in each country or ten (10) years after the First Commercial Sale (as defined in UTSW2 Agreement) in each country. In the event that the Company or its sublicensee challenges the Patent Rights, then the Company will be obligated to pay multiple times the applicable royalty rate of the Net Sales and, should the outcome of such challenge determine that any claim of the Patent Rights challenged is both valid and infringed then the Company will pay royalties at the rate of multiple times the applicable royalty rate of the Net Sales sold thereafter and reimburse UTSW for all fees and costs associated with defending such challenge, including attorney&#8217;s fees and expert fees. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The UTSW2 Agreement also contains an anti-stacking provision pursuant to which in the event the Company or its sublicensee pays royalties or other payments to a third party who owns or controls intellectual property deemed necessary to develop, manufacture, have manufactured, distribute, have distributed, use, lease, loan, import, offer for sale and/or sell any licensed products and licensed services, the Company may reduce payments to UTSW by a certain percentage of the royalty, milestone or other payments paid to such third party. However, such adjustment in royalty payments to UTSW may not be reduced by more than a minimum percentage of the royalty o</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">bligation in any contract year.</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> In the event that the payment to the third party who owns or controls intellectual property deemed necessary to extend or expand the franchise or exclusivity of a previously launched licensed product (e.g., such as a new formulation as a second-generation product containing the same compound as the previously launched Licensed Product), then the Company may reduce payments to UTSW by a certain percentage of the royalty, milestone or other payments paid to such third party. However, such adjustment in royalty payments to UTSW may not be reduced by more than a certain percentage obligation in any contract year.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has the development and reporting obligations as the UTSW1 Agreement and as with the UTSW1 Agreement, UTSW has reserved the right to publish the scientific findings related to the Patent Rights and use and to permit other academic institutions to use the licensed subject matter for teaching, research, education, and other educationally related, non-commercial purposes. The Patent Rights are also subject to any rights of the United States federal, state and/or local Government(s), as well as nonprofit entities, if certain patents or technologies were created in the course of Government-funded or non-profit entity-funded research.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The obligations and rights as to patent prosecution and defense of the Patent Rights are the same as those for the UTSW1 Agreement. The term and termination provisions of the UTSW2 Agreement is the same as the UTSW1 Agreement, however in the event that the UTSW1 Agreement is terminated for any reason, or expires, then the UTSW2 Agreement likewise is terminated or deemed to have expired.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The above description of UTSW1 Agreement and UTSW2 Agreement is just a summary and readers are referred to UTSW1 Agreement and UTSW2 Agreement, which are attached hereto as Exhibits 10.2 and 10.3 respectively, for a full and complete description of the patent expenses, milestone payments, fees and royalties payable by MAIA.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Competition </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The biotechnology industry is characterized by a rapid evolution of technologies, significant competition and strong defense of intellectual property. While we believe that our platforms, technology, knowledge, experience, and scientific resources provide us with unique competitive advantages, we expect to face competition from major pharmaceutical and biotechnology companies, academic institutions, governmental agencies, and public and private research institutions, among others. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any therapeutic candidates that we successfully develop and commercialize will compete with currently approved therapies and new therapies that may become available in the future. For example, current competitors in the non-small lung cancer indication are Merck, Regeneron, Eli Lilly and Roche. There are also many other large and small companies developing products for this indication. Key product features that, if approved, would affect our ability to effectively compete with other therapeutics include the efficacy, safety and convenience of our therapeutics, the ease of use and effectiveness of any complementary diagnostics and/or companion diagnostics, and price and levels of reimbursement. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our competitors also include large pharmaceutical and biotechnology companies, which may be developing therapeutic candidates with mechanisms similar to our compounds or targeting the same clinical indications as our therapeutic candidates. The availability of reimbursement from government and other third-party payors will also significantly affect the pricing and competitiveness of our therapeutic candidates. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many of the companies against which we may compete have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These early stage and more established competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">102</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Government Regulation</font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Government authorities in the United States, at the federal, state and local level, and in other countries, extensively regulate, among other things, the research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, post-approval monitoring and reporting, marketing and export and import of products such as those we are developing. Any pharmaceutical candidate that we develop must be approved by the United States Food and Drug Administration, or FDA, before it may be legally marketed in the United States and by the appropriate foreign regulatory agency before it may be legally marketed in foreign countries.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">United States Government Regulation </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the United States, the FDA regulates biopharmaceutical products under the Federal Food, Drug, and Cosmetic Act and the Public Health Services Act, or PHSA, and implementing regulations. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Approval Processes </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The process required by the FDA before a drug or biological product may be marketed in the United States generally involves the following:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">Completion of preclinical laboratory tests, animal studies and formulation studies according to Good Laboratory Practices or other applicable regulations;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">Submission to the FDA of an Investigational New Drug Application, or an IND, which must become effective before human clinical trials may begin;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">Performance of several phases of adequate and well-controlled human clinical trials according to the FDA&#8217;s current good clinical practices, or GCPs, to establish the safety and efficacy of the proposed drug or biologic for its intended use;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">Submission to the FDA of a New Drug Application, or an NDA, for a new drug product, or a Biologics License Application, or a BLA, for a new biological product;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">Satisfactory completion of an FDA inspection of the manufacturing facility or facilities where the drug or biologic is to be produced to assess compliance with the FDA&#8217;s current good manufacturing practice standards, or cGMP, to assure that the facilities, methods and controls are adequate to preserve the drug&#8217;s or biologic&#8217;s identity, strength, quality and purity;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">Potential FDA audit of the nonclinical and clinical trial sites that generated the data in support of the NDA or BLA; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">FDA review and approval of the NDA or BLA.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Failure to comply with the applicable U.S. requirements at any time during the product development or approval process, or after approval, may subject an applicant to administrative or judicial sanctions brought by the FDA and the Department of Justice, or DOJ, or other governmental entities, any of which could have a material adverse effect on us. These sanctions could include: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">refusal to approve pending applications; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">withdrawal of an approval; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">imposition of a clinical hold; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">warning or untitled letters; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">seizures or administrative detention of product; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">total or partial suspension of production or distribution; or </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">injunctions, fines, disgorgement, or civil or criminal penalties. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The lengthy process of seeking required approvals and the continuing need for compliance with applicable statutes and regulations require the expenditure of substantial resources. There can be no certainty that approvals will be granted.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Once a biopharmaceutical candidate is identified for development, it enters the preclinical or nonclinical testing stage. Nonclinical tests include laboratory evaluations of product chemistry, toxicity and formulation, as well as animal studies. An IND sponsor must submit the results of the nonclinical tests, together with manufacturing </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">103</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">information and analytical data, to the FDA as part of the IND. Some nonclinical testing may continue even after the IND is submitted. In addition to including the results of the nonclinical studies, the IND will also include a protocol detailing, among other things, the objectives of the clinical trial, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated if the first phase lends itself to an efficacy determination. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the 30-day time period, places the IND on clinical hold. In this case, the IND sponsor and the FDA must resolve any outstanding concerns before clinical trials can begin. A clinical hold may occur at any time during the life of an IND and may affect one or more specific studies or all studies conducted under the IND. </font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical trials involve the administration of the drug or biological candidate to healthy volunteers or patients having the disease being studied under the supervision of qualified investigators, generally physicians not employed by or under the trial sponsor&#8217;s control. Clinical trials are conducted under protocols detailing, among other things, the objectives of the clinical trial, dosing procedures, subject selection and exclusion criteria, and the parameters to be used to monitor subject safety. Each protocol must be submitted to the FDA as part of the IND. Clinical trials must be conducted in accordance with the FDA&#8217;s good clinical practices requirements. Further, each clinical trial must be reviewed and approved by an independent institutional review board, or IRB, at or servicing each institution at which the clinical trial will be conducted. An IRB is charged with protecting the welfare and rights of trial participants and considers such items as whether the risks to individuals participating in the clinical trials are minimized and are reasonable in relation to anticipated benefits. The IRB also approves the informed consent form that must be provided to each clinical trial subject or his or her legal representative and must monitor the clinical trial until it is completed.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Human clinical trials prior to approval are typically conducted in three sequential Phases that may overlap or be combined:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Phase 1. The drug or biologic is initially introduced into healthy human subjects and tested for safety, dosage tolerance, absorption, metabolism, distribution and excretion. In the case of some products for severe or life-threatening diseases, especially when the product may be too inherently toxic to ethically administer to healthy volunteers, the initial human testing is often conducted in patients having the specific disease.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Phase 2. The drug or biologic is evaluated in a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance, optimal dosage and dosing schedule for patients having the specific disease.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Phase 3. Clinical trials are undertaken to further evaluate dosage, clinical efficacy and safety in an expanded patient population at geographically dispersed clinical trial sites. These clinical trials, which usually involve more subjects than earlier trials, are intended to establish the overall risk/benefit ratio of the product and provide an adequate basis for product labeling. Generally, at least two adequate and well-controlled Phase 3 clinical trials are required by the FDA for approval of an NDA or BLA.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Post-approval studies, or Phase 4 clinical trials, may be conducted after initial marketing approval. These studies are used to gain additional experience from the treatment of patients in the intended therapeutic indication and may be required by the FDA as part of the approval process.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Progress reports detailing the results of the clinical trials must be submitted at least annually to the FDA and written IND safety reports must be submitted to the FDA by the investigators for serious and unexpected adverse events or any finding from tests in laboratory animals that suggests a significant risk for human subjects. Phase 1, Phase 2 and Phase 3 clinical trials may not be completed successfully within any specified period, if at all. The FDA or the sponsor or its data safety monitoring board may suspend a clinical trial at any time on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the drug or biologic has been associated with unexpected serious harm to patients.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Concurrent with clinical trials, companies usually complete additional animal studies and develop additional information about the chemistry and physical characteristics of the drug or biologic as well as finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the drug or biological candidate and, among other things, must include methods for testing the identity, strength, quality and purity of the final drug or biologic. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:10pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the drug or biological candidate does not undergo unacceptable deterioration over its shelf life.</font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">U.S. Review and Approval Processes</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The results of product development, preclinical studies and clinical trials, along with descriptions of the manufacturing process, analytical tests conducted on the chemistry of the drug or biologic, proposed labeling and other relevant information are submitted to the FDA as part of an NDA or BLA requesting approval to market the product. The submission of an NDA or BLA is subject to the payment of substantial user fees; a waiver of such fees may be obtained under certain limited circumstances.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA reviews for completeness all NDAs and BLAs submitted before it accepts them for filing and may request additional information rather than accepting an NDA or BLA for filing. Once the submission is accepted for filing, the FDA begins an in-depth review of the NDA or BLA.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">After the NDA or BLA submission is accepted for filing, the FDA reviews the application to determine, among other things, whether the proposed product is safe and effective for its intended use, and whether the product is being manufactured in accordance with cGMP to assure and preserve the product&#8217;s identity, strength, quality and purity. The FDA reviews a BLA to determine, among other things, whether the product is safe, pure and potent and the facility in which it is manufactured, processed, packaged or held meets standards designed to assure the product&#8217;s continued safety, purity and potency. In addition to its own review, the FDA may refer applications for novel drug or biological products or drug or biological products which present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. During the approval process, the FDA also will determine whether special marketing conditions or restrictions under a risk evaluation and mitigation strategy, or REMS, are necessary to assure the safe use of the drug or biologic. If the FDA concludes that a REMS is needed, the sponsor of the NDA or BLA must submit a proposed REMS; the FDA will not approve the NDA or BLA without a REMS, if required.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Before approving an NDA or BLA, the FDA will inspect the facilities at which the product is to be manufactured, and may also inspect facilities that provide raw materials for use in the product. The FDA will not approve the product unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving an NDA or BLA, the FDA will typically inspect one or more clinical trial sites to assure their compliance with cGCP during the conduct of studies of the subject drug. If during the review of the application the FDA identifies questions or concerns regarding the application, data, manufacturing process or manufacturing facilities, it may issue a deficiency letter which the sponsor must adequately address to the FDA&#8217;s satisfaction.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The NDA or BLA review and approval process is lengthy and difficult, and the FDA may refuse to approve an NDA or BLA if the applicable regulatory criteria are not satisfied or may require additional clinical data or other data and information. Even if such data and information is submitted, the FDA may ultimately decide that the NDA or BLA does not, in its submitted form, satisfy the criteria for approval. Data obtained from clinical trials are not always conclusive and may be susceptible to varying interpretations, which could delay, limit or prevent regulatory approval. The FDA will issue a &#8220;complete response letter&#8221; (CRL) if the agency decides not to approve the NDA or BLA. The complete response letter usually describes the specific deficiencies in the NDA or BLA identified by the FDA. The deficiencies identified may be minor, for example, requiring labeling changes, or major, for example, requiring additional clinical trials. Additionally, the complete response letter will typically include recommended actions that the applicant might take to place the application in a condition for approval. If a complete response letter is issued, the applicant may either resubmit the NDA or BLA, addressing all of the deficiencies identified in the letter, or withdraw the application.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If a product receives regulatory approval, the approval may be for more limited conditions of use than the sponsor had proposed, such as limitations to specific diseases or subsets of a disease, limited patient populations, second-line or third-line use limitations, limited dosages or other limitations which could restrict the commercial value of the product. Further, the FDA may require that certain contraindications, warnings or precautions be included in the product labeling. In addition, the FDA may require Phase 4 testing which may involve clinical trials designed to further assess a product&#8217;s safety and effectiveness and may require testing and surveillance programs to monitor the safety of approved products that have been commercialized.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">105</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><font style="font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Companion Diagnostics</font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many drugs for cancer indications involving patient-specific genetic mutations or biomarkers are approved by FDA with limitations that the specific genetic mutation must be confirmed in each patient by use of an FDA-approved diagnostic test, commonly referred to as a &#8220;companion diagnostic.&#8221; The FDA issued a final guidance document in July 2014 addressing agency policy in relation to <font style="font-style:italic;">in vitro </font>companion diagnostic tests. The guidance explains that for some drugs and therapeutic biologics, the use of a companion diagnostic test is essential for the safe and effective use of the product, such as when the use of a product is limited to a specific patient subpopulation that can be identified by using the test. According to the guidance, the FDA generally will not approve such a product if the companion diagnostic is not also approved or cleared for the appropriate indication, and accordingly the therapeutic product and the companion diagnostic should be developed and approved or cleared contemporaneously. The FDA has also issued a Guidance, <font style="font-style:italic;">Principles for Codevelopment of an In Vitro Companion Diagnostic Device with a Therapeutic Product</font> (2016), which is &#8220;is intended to be a practical guide to assist therapeutic product sponsors and IVD sponsors in developing a therapeutic product and an accompanying IVD companion diagnostic,&#8221; and a Guidance, <font style="font-style:italic;">Developing and Labeling In vitro Companion Diagnostic Devices for a Specific Group of Oncology Therapeutic Products</font> (2020), which &#8220;describes considerations for the development and labeling of in vitro companion diagnostic devices (referred to as &#8220;companion diagnostics&#8221; herein) to support the indicated uses of multiple drug or biological oncology products, when appropriate.&#8221; </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As stated in its Guidances, the FDA may decide that it is appropriate to approve such a product without an approved or cleared <font style="font-style:italic;">in vitro </font>companion diagnostic device when the drug or therapeutic biologic is intended to treat a serious or life-threatening condition for which no satisfactory alternative treatment exists and the FDA determines that the benefits from the use of a product with an unapproved or uncleared <font style="font-style:italic;">in vitro </font>companion diagnostic device are so pronounced as to outweigh the risks from the lack of an approved or cleared <font style="font-style:italic;">in vitro </font>companion diagnostic device. The FDA encourages sponsors considering developing a therapeutic product that requires a companion diagnostic to request a meeting with both relevant device and therapeutic product review divisions to ensure that the product development plan will produce sufficient data to establish the safety and effectiveness of both the therapeutic product and the companion diagnostic. To date, no product targeting TERT+ cancer patients has been approved by FDA, and the applicability to THIO of FDA&#8217;s Companion Diagnostics Guidance and policy is yet to be determined. If a companion diagnostic is required to be developed and approved in order to receive approval of THIO, the cost and length of time to fully develop and receive approval (if at all) of THIO may both be increased, as described in more detail in the section <font style="font-style:italic;">Risk Factors &#8211; Risks Relating to Government Regulation. </font>Because the FDA&#8217;s policy on companion diagnostics is set forth only in guidance, this policy is subject to change and is not legally binding. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Expedited Development and Review Programs</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA has a Fast-Track program that is intended to expedite or facilitate the process for reviewing new drug and biological products that meet certain criteria. Specifically, new drug and biological products are eligible for Fast Track designation if they are intended to treat a serious or life-threatening condition and demonstrate the potential to address unmet medical needs for the condition. Fast Track designation applies to the combination of the product and the specific indication for which it is being studied. Under a Fast Track designation, the FDA may consider for review sections of the NDA or BLA on a rolling basis before the complete application is submitted, if (i) the sponsor provides a schedule for the submission of the sections of the NDA or BLA, (ii) the FDA agrees to accept sections of the NDA or BLA and determines that the schedule is acceptable, and (iii) the sponsor pays any required user fees upon submission of the first section of the NDA or BLA.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any product submitted to the FDA for marketing approval, including those submitted under a Fast Track designation, may also be eligible for other types of FDA programs intended to expedite development and review, such as priority review and accelerated approval. Any product is eligible for priority review if it has the potential to provide safe and effective therapy where no satisfactory alternative therapy exists or the new product has the potential to offer a significant improvement in the treatment, diagnosis or prevention of a disease compared with marketed products. The FDA will attempt to direct additional resources to the evaluation of an application for a new drug or biological product designated for priority review in an effort to facilitate the review. Additionally, a product may be eligible for accelerated approval. Drug or biological products studied for their safety and effectiveness in treating serious or life-threatening illnesses and that provide meaningful therapeutic benefit over existing treatments may receive accelerated approval, which means that they may be approved on the basis of adequate and well-controlled clinical studies establishing that the product has an effect on a surrogate endpoint that is reasonably likely </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">106</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:10pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to predict a clinical benefit, or on the basis of an effect on a clinical endpoint other than survival or irreversible morbidity. As a condition of accelerated approval, the FDA generally requires that a sponsor of a drug or biological product receiving accelerated approval perform adequate and well-controlled post-marketing clinical studies to confirm the safety and efficacy for the approved indication. Failure to conduct such studies or conducting such studies that do not establish the required safety and efficacy may result in revocation of the original accelerated approval. In addition, the FDA currently requires as a condition for accelerated approval, pre-approval of promotional materials, which could adversely impact the timing of the commercial launch or subsequent marketing of the product. Fast Track designation, priority review and accelerated approval do not change the standards for approval but may expedite the </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">development or approval process, and e</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ven if granted, accelerated approval status does not guarantee an accelerated review or marketing approval by </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FDA.</font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">The Hatch-Waxman Amendments and Generic Competition</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Orange Book Listing</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Once a drug product is approved under an NDA, the product is listed in the FDA&#8217;s publication, &#8220;Approved Drug Products with Therapeutic Equivalence Evaluations,&#8221; commonly known as the Orange Book. An NDA-approved drug product will be designated in the Orange Book as a Reference Listed Drug (RLD). Sponsors of approved NDA&#8217;s are required to list with the FDA patents whose claims cover the product&#8217;s active ingredient, formulation, or an approved method of using the drug. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Patent Term Extensions</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depending upon the timing, duration and specifics of FDA approval of the use of our therapeutic candidates, some of our United States patents may be eligible for limited patent term extension under the Hatch-Waxman Act. The Hatch-Waxman Act permits a patent restoration term of up to five years as compensation for patent term lost during product development and the FDA regulatory review process. However, patent term restoration cannot extend the remaining term of a patent beyond a total of 14 years from the product or therapeutic candidate&#8217;s approval date. The patent term restoration period is generally one half of the time between the effective date of an IND and the submission date of a NDA, plus the time between the submission date of a NDA and the approval of that application, except that the review period is reduced by any time during which the applicant failed to exercise due diligence. Only one patent applicable to an approved product or therapeutic candidate is eligible for the extension and the application for extension must be made prior to expiration of the patent. The USPTO, in consultation with the FDA, reviews and approves the application for any patent term extension or restoration. In the future, we intend to apply for restorations of patent term for some of our currently owned or licensed patents to add patent life beyond their current expiration date, depending on the expected length of clinical trials and other factors involved in the submission of the relevant NDA. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">ANDA Approval Process</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Hatch-Waxman Amendments established an abbreviated FDA approval process for generic drugs that are shown to be pharmaceutically equivalent and bioequivalent to drugs previously approved by the FDA through the NDA process. Approval to market and distribute these drugs is obtained by filing an abbreviated new drug application, or ANDA, with the FDA. An ANDA provides for marketing of a drug product that has the same active ingredients in the same strengths and dosage form as the listed drug and has been shown to be bioequivalent to the listed drug. An ANDA is a comprehensive submission that contains, among other things, data and information pertaining to the active pharmaceutical ingredient, drug product formulation, specifications and stability of the generic drug, as well as analytical methods, manufacturing process validation data and quality control procedures. ANDAs are termed abbreviated because they generally do not include preclinical and clinical data to demonstrate safety and effectiveness. Instead, a generic applicant must demonstrate that its product is bioequivalent to the innovator drug. Drugs approved in this way are commonly referred to as &#8220;generic equivalents&#8221; to the listed drug and can often be substituted by pharmacists under prescriptions written for the original listed drug.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Section 505(b)(2) NDA Approval Process</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As an alternative path to FDA approval for modifications to formulations or uses of products previously approved by the FDA, an applicant may submit an NDA under Section 505(b)(2) of the FDCA. Section 505(b)(2) was enacted as part of the Hatch-Waxman Amendments to the FDCA and enables the applicant to rely, in part, on the FDA&#8217;s </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">107</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:10pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">previous approval of a similar product, and/or published literature, in support of its application. Section 505(b)(2) permits the filing of an NDA where at least some of the information required for approval comes from studies not conducted by, or for, the applicant and for which the applicant has not obtained a right of reference. If the Section 505(b)(2) applicant can establish that reliance on FDA&#8217;s previous findings of safety and effectiveness is scientifically appropriate, it may eliminate the need to conduct certain preclinical studies or clinical trials of the new product. The FDA may also require companies to perform additional studies or measurements, including clinical trials, to support the change from the approved reference drug. The FDA may then approve the new product candidate for all, or some, of the label indications for which the reference drug has been approved or for any new indication sought by the Section 505(b)(2) applicant.</font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ANDA and 505(b)(2) products may be significantly less costly to bring to market than the reference listed drug, and companies that produce generic products are generally able to offer them at lower prices. Moreover, generic versions of RLDs are often automatically substituted for the RLD by pharmacies when dispensing a prescription written for the RLD. Thus, following the introduction of a generic drug, a significant percentage of the sales of any branded product or reference listed drug is typically lost to the generic product.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">ANDA and 505(b)(2) NDA Patent Certification Requirements</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any applicant who files an ANDA seeking approval of a generic equivalent version of a drug listed in the Orange Book or a Section 505(b)(2) NDA referencing a drug listed in the Orange Book must certify to the FDA, as applicable, that (1) no patent information on the drug product that is the subject of the application has been submitted to the FDA; (2) such patent has expired; (3) the date on which such patent expires; or (4) such patent is invalid or will not be infringed upon by the manufacture, use or sale of the drug product for which the application is submitted. This last certification is known as a paragraph IV certification. If an ANDA is submitted to FDA with a Paragraph IV Certification, the generic applicant must also provide a &#8220;Paragraph IV Notification&#8221; to the holder of the NDA for the RLD and to the owner of the listed patent(s) being challenged by the ANDA applicant, providing a detailed written statement of the bases for the ANDA applicant&#8217;s position that the relevant patent(s) is invalid or would not be infringed. If the patent owner brings a patent infringement lawsuit against the ANDA applicant within 45 days of the Paragraph IV Notification, FDA approval of the ANDA will be automatically stayed for 30 months, or until 7-1/2 years after the NDA approval if the generic application was filed between 4 years and 5 years after the NDA approval. Any such stay will be terminated earlier if the court rules that the patent is invalid or would not be infringed. The applicant may, in certain circumstances, elect to submit a &#8220;section viii&#8221; statement with respect to a listed method of use patent, certifying that the proposed generic labeling does not contain (or carves out) any language that would infringe a method of use patented listed in the Orange Book for the RLD. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The ANDA or Section 505(b)(2) application also will not be approved until any applicable non-patent exclusivity listed in the Orange Book for the reference drug has expired as described in further detail below.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Regulatory Exclusivities</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">New Chemical Entity (NCE) Exclusivity</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Hatch-Waxman amendments provides a period of five years of non-patent marketing exclusivity for the first approved drug containing a new chemical entity (&#8220;NCE&#8221;) as an active ingredient. An NCE is an active moiety that has not been approved by the FDA in any other NDA. A fixed combination drug product may receive NCE exclusivity if one of its active ingredients is an NCE, but not if all of its active ingredients have previously been approved. An &#8220;active moiety&#8221; is defined as the molecule or ion responsible for the drug substance&#8217;s physiological or pharmacologic action. During the five-year exclusivity period, the FDA cannot accept for filing any ANDA or 505(b)(2) NDA seeking approval of a product that contains the same active moiety, except that the FDA may accept such an application for filing after four years if the application includes a paragraph IV certification to a listed patent. In the case of such applications accepted for filing between four and five years after approval of the reference drug, the 30-Month Stay of approval triggered by a timely patent infringement lawsuit is extended by the amount of time necessary to extend the stay until 7-1/2 years after the approval of the reference drug NDA.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">108</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><font style="font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">New Clinical Trial (3-Year) Exclusivity </font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A drug, including one approved under Section 505(b)(2), may obtain a three-year period of exclusivity for a particular indication or condition of approval, or change to a marketed product, such as a new formulation for a previously approved product, if one or more new clinical trials (other than bioavailability studies) was essential to the approval of the application or supplemental application and was conducted/sponsored by the applicant. Should this occur, the FDA would be precluded from approving any ANDA or Section 505(b)(2) application for the protected modification until after that three-year exclusivity period has run. However, unlike NCE exclusivity, the FDA can accept an application and begin the review process during the exclusivity period.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Orphan Drug Designation and Orphan Exclusivity </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Orphan Drug Act, the FDA may grant Orphan Drug Designation to a therapeutic candidate intended to treat a rare disease or condition, which is generally a disease or condition that affects either (i) fewer than 200,000 individuals in the United States, or (ii) more than 200,000 individuals in the United States and for which there is no reasonable expectation that the cost of developing and making available in the United States a product or therapeutic candidate for this type of disease or condition will be recovered from sales in the United States for that product or therapeutic candidate. Orphan Drug Designation must be requested before submitting a BLA. After the FDA grants Orphan Drug Designation, the identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. Orphan Drug Designation does not convey any advantage in or shorten the duration of the regulatory review and approval process. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If a product or therapeutic candidate that has Orphan Drug Designation subsequently receives the first FDA approval for the disease for which it has such designation, the approved product is entitled to orphan product exclusivity, which means that the FDA may not approve any other marketing applications for the same drug for the same indication, except under limited circumstances, for seven years. Orphan product exclusivity, however, could also block the approval of one of our therapeutic candidates for seven years if a competitor obtains approval of the same drug as defined by the FDA, or if our therapeutic candidate is determined to be contained within a competitor&#8217;s approved drug for the same indication or disease. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, an orphan drug credit is available for qualifying costs incurred between the date the FDA designates a drug as an orphan drug and the date the FDA approves the drug.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Pediatric Exclusivity</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pediatric exclusivity is another type of non-patent marketing exclusivity available in the United States and, if granted, it provides for the attachment of an additional six months of marketing protection to the term of any existing regulatory exclusivity or listed patents. Under the Best Pharmaceuticals for Children Act, or BPCA, certain therapeutic candidates may obtain an additional six months of exclusivity if the sponsor conducts pediatric research and submits new clinical information requested in writing by the FDA, referred to as a Written Request, relating to the use of the active moiety of the product or therapeutic candidate in children. The data do not need to support a label change for pediatric use; rather, the additional protection is granted if the pediatric clinical trial is deemed to have fairly responded to the FDA&#8217;s Written Request. Although the FDA may issue a Written Request for studies on either approved or unapproved indications, it may only do so where it determines that information relating to that use of a product or therapeutic candidate in a pediatric population, or part of the pediatric population, may produce health benefits in that population. The issuance of a Written Request does not require the sponsor to undertake the described trials. This is not a patent term extension, but it effectively extends the regulatory period during which the FDA cannot approve another application. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Post-Approval Requirements </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Following approval of a new drug or biologic product, the manufacturer and the approved product are subject to pervasive and continuing regulation by the FDA, including, among other things, continuing cGMP compliance, monitoring and recordkeeping activities, reporting of adverse experiences with the product, product sampling and distribution restrictions, complying with promotion and advertising requirements, which include restrictions on promoting drugs for unapproved uses or patient populations (i.e., &#8220;off-label use&#8221;) and limitations on industry-sponsored scientific and educational activities. Although physicians may prescribe legally available products for off-</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">109</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:10pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">label uses, manufacturers may not market or promote such uses. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability. If there are any modifications to the product, including changes in indications, labeling or manufacturing processes or facilities, the applicant may be required to submit and obtain FDA approval of a new NDA or a NDA supplement, which may require the applicant to develop additional data or conduct additional preclinical studies and clinical trials. </font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Once an NDA or BLA approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product or therapeutic reaches the market. Later discovery of previously unknown problems with a product or therapeutic candidate, including adverse events of unanticipated severity or frequency, may result in in mandatory revisions to the approved labeling to add new safety information; imposition of post-market or clinical trials to assess new safety risks; or imposition of distribution or other restrictions under a REMS program. Other potential consequences include, among other things: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">fines, warning letters or other enforcement-related letters or clinical holds on post-approval clinical trials; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">refusal of the FDA to approve pending applications or supplements to approved application, or suspension or revocation of product approvals; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">product seizure or detention, or refusal to permit the import or export of products; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">injunctions or the imposition of civil or criminal penalties; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">consent decrees, corporate integrity agreements, debarment, or exclusion from federal health care programs; or</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">mandated modification of promotional materials and labeling and the issuance of corrective information. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accordingly, a therapeutic candidate manufactured or distributed by us pursuant to FDA approvals are subject to continuing regulation by the FDA, including, among other things: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">cGMP compliance requirements;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">record-keeping requirements; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">reporting of adverse experiences with the therapeutic candidate; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">providing the FDA with updated safety and efficacy information; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">therapeutic sampling and distribution requirements; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">notifying the FDA and gaining its approval of specified manufacturing or labeling changes; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">complying with FDA promotion and advertising requirements, which include, among other things, standards for direct-to-consumer advertising, restrictions on promoting products for uses or in-patient populations that are not described in the product&#8217;s approved labeling, limitations on industry-sponsored scientific and educational activities and requirements for promotional activities involving the internet. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FDA regulations require that products be manufactured in specific approved facilities and in accordance with cGMPs. The cGMP regulations include requirements relating to organization of personnel, buildings and facilities, equipment, control of components and drug product containers and closures, production and process controls, packaging and labeling controls, holding and distribution, laboratory controls, records and reports and returned or salvaged products. Therapeutic manufacturers and other entities involved in the manufacture and distribution of approved therapeutic products are required to register their establishments with the FDA and certain state agencies and are subject to periodic unannounced inspections by the FDA, foreign regulatory agencies, and some state agencies for compliance with cGMPs and other laws. In addition, changes to the manufacturing process are strictly regulated, and, depending on the significance of the change, may require FDA approval before being implemented. FDA regulations also require investigation and correction of any noncompliance with cGMP requirements. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting and documentation requirements upon the NDA or BLA applicant and any third-party manufacturers involved in producing the approved product. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain compliance with cGMP and other aspects of quality control and quality assurance. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">110</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the distribution of prescription pharmaceutical products is subject to the Prescription Drug Marketing Act, or the PDMA, which regulates the distribution of drugs and drug samples at the federal level and sets minimum standards for the registration and regulation of drug distributors by the states. Both the PDMA and state laws limit the distribution of prescription pharmaceutical product samples and impose requirements to ensure accountability in distribution. The Drug Supply Chain Security Act, or the DSCSA, was enacted with the aim of building an electronic system to identify and trace certain prescription drugs distributed in the United States, including most biological products. The DSCSA mandates phased-in and resource-intensive obligations for pharmaceutical manufacturers, wholesale distributors, and dispensers over a 10&#8208;year period that is expected to culminate in November 2023. From time to time, new legislation and regulations may be implemented that could significantly change the statutory provisions governing the approval, manufacturing and marketing of products regulated by the FDA. It is impossible to predict whether further legislative or regulatory changes will be enacted, or FDA regulations, guidance or interpretations changed or what the impact of such changes, if any, may be. </font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Regulation Outside of the United States </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to regulations in the United States, we will be subject to regulations of other jurisdictions governing any clinical trials and commercial sales and distribution of our therapeutic candidates. Whether or not we obtain FDA approval for a product, we must obtain approval by the comparable regulatory authorities of countries outside of the United States before we can commence clinical trials in such countries and approval of the regulators of such countries or economic areas, such as the European Union, before we may market products in those countries or areas. It also is not yet clear how the United Kingdom&#8217;s recent withdrawal from the European Union will affect the approval of medicinal products in the United Kingdom. The approval process and requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary greatly from place to place, and the time may be longer or shorter than that required for FDA approval. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under European Union regulatory systems, a company can consider applying for marketing authorization in several European Union member states by submitting its marketing authorization application(s) under a centralized, decentralized or mutual recognition procedure. The centralized procedure provides for the grant of a single marketing authorization that is valid for all European Union member states. The centralized procedure is compulsory for medicines derived from biotechnology, orphan medicinal products, or those medicines with an active substance not authorized in the European Union on or before May 20, 2004 intended to treat acquired immune deficiency syndrome, cancer, neurodegenerative disorders or diabetes and optional for those medicines containing a new active substance not authorized in the European Union on or before May 20, 2004, medicines which are highly innovative, or medicines to which the granting of a marketing authorization under the centralized procedure would be in the interest of patients at the European Union-level. The decentralized procedure provides for recognition by European Union national authorities of a first assessment performed by one of the member states. Under this procedure, an identical application for marketing authorization is submitted simultaneously to the national authorities of several European Union member states, one of them being chosen as the &#8220;Reference Member State,&#8221; and the remaining being the &#8220;Concerned Member States.&#8221; The Reference Member State must prepare and send drafts of an assessment report, summary of product characteristics and the labelling and package leaflet within 120 days after receipt of a valid marketing authorization application to the Concerned Member States, which must decide within 90 days whether to recognize approval. If any Concerned Member State does not recognize the marketing authorization on the grounds of potential serious risk to public health, the disputed points are eventually referred to the European Commission, whose decision is binding on all member states. The mutual recognition procedure is similar to the decentralized procedure except that a medicine must have already received a marketing authorization in at least one of the member states, and that member state acts as the Reference Member State. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As in the United States, we may apply for designation of a therapeutic candidate as an orphan drug for the treatment of a specific indication in the European Union before the application for marketing authorization is made. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Orphan drugs in the European Union enjoy economic and marketing benefits, including up to ten years of market exclusivity for the approved indication unless another applicant can show that its product is safer, more effective or otherwise clinically superior to the orphan-designated product, the marketing authorization holder is unable to supply sufficient quantity of the medicinal product, or the marketing authorization holder has given its consent. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">111</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Coverage, Pricing and Reimbursement </font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales of our products will depend, in part, on the extent to which our products will be covered by third-party payors, such as government health programs, commercial insurance and managed healthcare organizations. There may be significant delays in obtaining coverage and reimbursement for approved products, and coverage may be more limited than the purposes for which the product is approved by the FDA or regulatory authorities in other countries. It is time consuming and expensive to seek reimbursement from third-party payors. Moreover, eligibility for reimbursement does not imply that any product will be paid for in all cases or at a rate that covers our costs, including research, development, manufacture, sale and distribution. Interim payments for new products, if applicable, may also not be sufficient to cover our costs and may not be made permanent. Payment rates may vary according to the use of the product and the clinical setting in which it is used, may be based on payments allowed for lower cost products that are already reimbursed and may be incorporated into existing payments for other services. Net prices for products may be reduced by mandatory discounts or rebates required by third-party payors and by any future relaxation of laws that presently restrict imports of products from countries where they may be sold at lower prices than in the United States. In the U.S., third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement policies, but they also have their own methods and approval process apart from Medicare coverage and reimbursement determinations. Accordingly, one third-party payor&#8217;s determination to provide coverage for a product does not assure that other payors will also provide coverage for the product. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, the containment of healthcare costs has become a priority of federal and state governments and the prices of therapeutics have been a focus in this effort. The United States government, state legislatures and foreign governments have shown significant interest in implementing cost-containment programs, including price controls, restrictions on reimbursement and requirements for substitution of generic and biosimilar products. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit our net revenue and results. If these third-party payors do not consider our products to be cost-effective compared to other therapies, they may not cover our products after approval as a benefit under their plans or, if they do, the level of payment may not be sufficient to allow us to sell our products on a profitable basis. In addition, companion diagnostic tests require coverage and reimbursement separate and apart from the coverage and reimbursement for their companion pharmaceutical or biological products. Similar challenges to obtaining coverage and reimbursement for the pharmaceutical or biological products apply to companion diagnostics. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, in some foreign countries, the proposed pricing for a product and therapeutic candidate must be approved before it may be lawfully marketed. The requirements governing therapeutic pricing vary widely from country to country. For example, the European Union provides options for its member states to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. A member state may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our therapeutic candidates. Historically, therapeutic candidates launched in the European Union do not follow price structures of the United States and generally tend to be significantly lower. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Healthcare Reform </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the United States and some foreign jurisdictions, there have been, and continue to be, several legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of product and therapeutic candidates, restrict or regulate post-approval activities, and affect the ability to profitably sell product and therapeutic candidates that obtain marketing approval. The FDA&#8217;s and other regulatory authorities&#8217; policies may change, and additional government regulations may be enacted that could prevent, limit, or delay regulatory approval of our product and therapeutic candidates. For example, in the United States, the system for FDA to collect and expend user fees paid by manufacturers of drugs, biologics, and medical devices must be reauthorized by statute every five years, and since 1992, each reauthorization legislation has included, to greater or lesser degrees, various other changes to the FDA&#8217;s regulatory systems and procedures. The current legislative authority for FDA user fees expires in September 2022, and by that time, new legislation will be required for FDA to continue collecting prescription drug user fees in future fiscal years. The expected 2022 reauthorization may include new legal provisions that could significantly impact our business in ways that cannot be predicted at this time. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">112</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:10pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we otherwise may have obtained and we may not achieve or sustain profitability, which would adversely affect our business, prospects, financial condition and results of operations. Moreover, among policy makers and payors in the United States and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of reducing drug prices, containing healthcare costs more generally, improving quality and/or expanding access. </font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For example, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively the ACA, was enacted in March 2010 and has had a significant impact on the health care industry in the U.S. The ACA expanded coverage for the uninsured while at the same time containing overall healthcare costs. It also included the BPCIA, which created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an FDA-licensed reference biological product. With regard to biopharmaceutical products, the ACA, among other things, addressed a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected, increased the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program and extended the rebate program to individuals enrolled in Medicaid managed care organizations, established annual fees on manufacturers of certain branded prescription drugs, and created a new Medicare Part D coverage gap discount program. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since its enactment, there have been executive, judicial and Congressional challenges to certain aspects of the ACA and we expect there may be additional challenges and amendments to the ACA in the future. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, other legislative changes have been proposed and adopted in the United States since the ACA that affect health care expenditures. These changes include aggregate reductions to Medicare payments to providers of up to 2% per fiscal year pursuant to the Budget Control Act of 2011, which began in 2013 and will remain in effect through 2030 unless additional Congressional action is taken. The Coronavirus Aid, Relief, and Economic Security Act, or the CARES Act, which was signed into law on March 27, 2020, and was designed to provide financial support and resources to individuals and businesses affected by the COVID-19 pandemic, suspended the 2% Medicare sequester from May 1, 2020 through December 31, 2020, and extended the sequester by one year, through 2030, in order to offset the added expense of the 2020 cancellation. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, on December 20, 2019, the Further Consolidated Appropriations Act for 2020 became law (P.L. 116-94), which includes a piece of bipartisan legislation called the Creating and Restoring Equal Access to Equivalent Samples Act of 2019 or the &#8220;CREATES Act.&#8221; The CREATES Act aims to address the concern articulated by both the FDA and others in the industry that some brand manufacturers have improperly restricted the distribution of their products, including by invoking the existence of a REMS for certain products, to deny generic and biosimilar product developers access to samples of brand products. Because generic and biosimilar product developers need samples to conduct certain comparative testing required by the FDA, some have attributed the inability to timely obtain samples as a cause of delay in the entry of generic and biosimilar products. To remedy this concern, the CREATES Act establishes a private cause of action that permits a generic or biosimilar product developer to sue the brand manufacturer to compel it to furnish the necessary samples on &#8220;commercially reasonable, market-based terms.&#8221; Whether and how generic and biosimilar product developments will use this new pathway, as well as the likely outcome of any legal challenges to provisions of the CREATES Act, remain highly uncertain and its potential effects on our future commercial products are unknown. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products. While the Trump administration put forward various proposals and executive orders aimed at reducing drug prices, the Biden administration is likely to pursue its own proposals going forward. In August 2021, President Biden announced his support for legislative proposals to grant Medicare the power to negotiate lower drug prices, for pharmaceutical companies to face penalties if they raise prices faster than inflation, and to impose a new cap on how much Medicare recipients have to spend on medications. Such proposals may be included in upcoming legislation in Congress, but the outcome of such proposals remains uncertain.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">113</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Individual states in the United States have also increasingly passed legislation and implemented regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. </font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. We expect that additional state and federal health care reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for health care products and services. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Other Healthcare Laws </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our current and future business operations are subject to healthcare regulation and enforcement by the federal government and the states and foreign governments where we research, and, if approved, market, sell and distribute our therapeutic candidates. These laws include, without limitation, state and federal anti-kickback, fraud and abuse, false claims, privacy and security, physician sunshine and drug pricing transparency laws and regulations such as: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">The federal Anti-Kickback Statute prohibits, among other things, any person from knowingly and willfully offering, soliciting, receiving or providing remuneration, directly or indirectly, to induce either the referral of an individual, for an item or service or the purchasing or ordering of a good or service, for which payment may be made under federal healthcare programs such as the Medicare and Medicaid programs. The federal Anti-Kickback Statute is subject to evolving interpretations. In the past, the government has enforced the federal Anti-Kickback Statute to reach large settlements with healthcare companies based on sham consulting and other financial arrangements with physicians. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">The federal civil and criminal false claims laws, including the civil False Claims Act, and civil monetary penalty laws, prohibit, among other things, knowingly presenting or causing the presentation of a false, fictitious or fraudulent claim for payment to the U.S. government, knowingly making, using, or causing to be made or used a false record or statement material to a false or fraudulent claim to the U.S. government, or from knowingly making a false statement to avoid, decrease or conceal an obligation to pay money to the U.S. government. Actions under these laws may be brought by the Attorney General or as a qui tam action by a private individual in the name of the government. The federal government uses these laws, and the accompanying threat of significant liability, in its investigation and prosecution of pharmaceutical and biotechnology companies throughout the U.S., for example, in connection with the promotion of products for unapproved uses and other allegedly unlawful sales and marketing practices; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">The U.S. federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, includes federal, civil and criminal provisions that prohibit among other actions, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including private third-party payors, knowingly and willfully embezzling or stealing from a healthcare benefit program, willfully obstructing a criminal investigation of a healthcare offense, and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">The Physician Payments Sunshine Act, among other things, imposes requirements on manufacturers of FDA-approved drugs, devices, biologics and medical supplies covered by Medicare or Medicaid to report, on an annual basis, to HHS information related to payments and other transfers of value to physicians (defined to include doctors, dentists, optometrists, podiatrists, chiropractors and, beginning in 2022 for payments and other transfers of value provided in the previous year, certain advanced non-physician health care practitioners), teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, and their respective implementing regulations impose specified requirements relating to the privacy, security and transmission of individually identifiable health information. Among other things, </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">114</a></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">HITECH makes HIPAA&#8217;s privacy and security standards directly applicable to &#8220;business associates,&#8221; defined as independent contractors or agents of covered entities, which include certain healthcare providers, health plans, and healthcare clearinghouses, that create, receive, maintain or transmit protected health information in connection with providing a service for or on behalf of a covered entity. HITECH also increased the civil and criminal penalties that may be imposed against covered entities, business associates and possibly other persons, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce HIPAA and seek attorney&#8217;s fees and costs associated with pursuing federal civil actions; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">Analogous state laws and regulations, such as state anti-kickback and false claims laws which may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers; state laws which require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government in addition to requiring drug and therapeutic biologics manufacturers to report information related to payments to physicians and other healthcare providers or marketing expenditures and pricing information; state and local laws which require the registration of pharmaceutical sales representatives; and state laws and non-United States laws and regulations (particularly European Union laws regarding personal data relating to individuals based in Europe) that govern the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways, thus complicating compliance efforts. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">Ensuring that our current and future business arrangements with third parties comply with applicable healthcare laws and regulations could involve substantial costs. It is possible that governmental authorities will conclude that our business practices do not comply with current or future statutes, regulations, agency guidance or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any such requirements, we may be subject to significant civil, criminal and administrative penalties, including monetary damages, fines, disgorgement, imprisonment, loss of eligibility to obtain approvals from the FDA, exclusion from participation in government contracting, healthcare reimbursement or other government programs, including Medicare and Medicaid, reputational harm, diminished profits and future earnings, additional reporting requirements if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with any of these laws, and the curtailment or restructuring of our operations. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Manufacturing </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not own or operate manufacturing facilities to produce any of our therapeutic candidates, nor do we have plans to develop our own manufacturing operations in the foreseeable future. We currently depend on third-party contract manufacturers for all our required raw materials, Active Pharmaceutical Ingredient (API), and finished products for our preclinical and clinical trials and if and when applicable, commercialization. We currently employ internal resources to manage our manufacturing relationships with these third parties. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Manufacturers of our products are required to comply with applicable FDA manufacturing requirements contained in the FDA&#8217;s current good manufacturing practices, or cGMP, regulations. cGMP regulations require, among other things, quality control and quality assurance as well as corresponding maintenance of records and documentation. Pharmaceutical product manufacturers and other entities involved in the manufacture and distribution of approved pharmaceutical products are required to register their establishments with the FDA and certain state agencies and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP and other laws. Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality control to maintain cGMP compliance. Discovery of problems with a product after approval may result in restrictions on a product, manufacturer or holder of an approved NDA, including withdrawal of the product from the market. In addition, changes to the manufacturing process generally require prior FDA approval before being implemented. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Facilities </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our headquarters is in Chicago, Illinois where we currently lease office space with approximately 124 square feet under a six month lease starting in October 2021, under which we currently pay $2,700 per month. We expect to renew this lease before it expires. We believe that this space is sufficient to meet our needs for the foreseeable future </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">115</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:10pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and that any additional space we may require will be available on commercially reasonable terms. Additionally, we intend to maintain our business model designed to leverage virtual technology to minimize brick and mortar facilities while optimizing our ability to attract top talented employees that may reside in any geography. </font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Employees </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March 28, 2022, we had a total of nine key full-time employees. We believe that we maintain a satisfactory working relationship with our employees, and we have not experienced any significant labor disputes or any difficulty in recruiting staff for our operations. None of our employees is represented by a labor union.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Human Capital Resources</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Employee Engagement, Talent Development &amp; Benefits<font style="font-weight:normal;">. We believe that our future success largely depends upon our continued ability to attract and retain highly skilled employees. We provide our employees with competitive salaries and bonuses, and opportunities for equity ownership.</font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Diversity, Inclusion, and Culture<font style="font-weight:normal;">. Much of our success is rooted in the diversity of our teams and our commitment to inclusion. We value diversity at all levels and continue to focus on extending our diversity and inclusion initiatives across our entire workforce. We believe that our business benefits from the different perspectives a diverse workforce brings, and we pride ourselves on having a strong, inclusive and positive culture based on our shared mission and values.</font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Legal Proceedings </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are not party to any material legal proceedings. From time to time, we may be involved in legal proceedings or subject to claims incident to the ordinary course of business. Regardless of the outcome, such proceedings or claims can have an adverse impact on us because of defense and settlement costs, diversion of resources and other factors, and there can be no assurances that favorable outcomes will be obtained. </p><a name="_AEIOULastRenderedPageBreakAEIOU16"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">116</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="MANAGEMENT"></a><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="MANAGEMENT"></a>MANAGE</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">MENT</font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Executive Officers and Directors </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table provides information regarding our executive officers and directors as of the date of this prospectus: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#1F497D" style="width:25%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4pt;;text-indent:0pt;;font-weight:bold;color:#FFFFFF;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name</p></td>
<td valign="middle"  BGCOLOR="#1F497D" style="width:15%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#FFFFFF;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Age</p></td>
<td valign="middle"  BGCOLOR="#1F497D" style="width:60%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4pt;;text-indent:0pt;;font-weight:bold;color:#FFFFFF;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Position</p></td>
</tr>
<tr>
<td colspan="3" valign="middle"  BGCOLOR="#F2F2F2" style="width:100%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Executive Officers</p></td>
</tr>
<tr>
<td valign="top"  style="width:25%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vlad Vitoc</p></td>
<td valign="top"  style="width:15%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52</p></td>
<td valign="middle"  style="width:60%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Co-Founder President, Chief Executive Officer, Chairman of the Board of Directors</p></td>
</tr>
<tr>
<td valign="middle"  style="width:25%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sergei M. Gryaznov</p></td>
<td valign="middle"  style="width:15%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62</p></td>
<td valign="middle"  style="width:60%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Scientific Officer</p></td>
</tr>
<tr>
<td valign="middle"  style="width:25%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mihail Obrocea</p></td>
<td valign="middle"  style="width:15%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61</p></td>
<td valign="middle"  style="width:60%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Medical Officer</p></td>
</tr>
<tr>
<td valign="middle"  style="width:25%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Joseph F. McGuire</p></td>
<td valign="middle"  style="width:15%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63</p></td>
<td valign="middle"  style="width:60%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Financial Officer</p></td>
</tr>
<tr>
<td colspan="3" valign="middle"  BGCOLOR="#F2F2F2" style="width:100%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Board of Directors (Non-Employee)</p></td>
</tr>
<tr>
<td valign="middle"  style="width:25%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Steven Chaouki</p></td>
<td valign="middle"  style="width:15%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49</p></td>
<td valign="middle"  style="width:60%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
</tr>
<tr>
<td valign="middle"  style="width:25%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ramiro Guerrero</p></td>
<td valign="middle"  style="width:15%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56</p></td>
<td valign="middle"  style="width:60%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
</tr>
<tr>
<td valign="middle"  style="width:25%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Louie Ngar Yee</p></td>
<td valign="middle"  style="width:15%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55</p></td>
<td valign="middle"  style="width:60%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
</tr>
<tr>
<td valign="middle"  style="width:25%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cristian Luput</p></td>
<td valign="middle"  style="width:15%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47</p></td>
<td valign="middle"  style="width:60%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
</tr>
<tr>
<td valign="middle"  style="width:25%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stan Smith</p></td>
<td valign="middle"  style="width:15%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75</p></td>
<td valign="middle"  style="width:60%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
</tr>
<tr>
<td valign="middle"  style="width:25%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laurentiu Vlad</p></td>
<td valign="middle"  style="width:15%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46</p></td>
<td valign="middle"  style="width:60%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Our Leadership Team</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have assembled a team with deep research, development and commercialization experience in the areas of telomere related science, immunotherapy, and across a vast array of oncology indications. Members of our team bring experience from multiple biotech and pharmaceutical companies including Pfizer Inc., Bayer Pharmaceuticals, Astellas Pharma Inc., Janssen - a Johnson &amp; Johnson pharmaceutical company, Incyte Corporation, Pharmacyclics Inc., Juno Therapeutics Inc., Cephalon Inc., Geron Corporation, Agouron Pharmaceuticals (a Pfizer Company), Novo Nordisk Pharmaceuticals Inc., among others. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Executive Officers</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Vlad Vitoc, M.D., MBA </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dr. Vitoc is our Chairman of Board, Chief Executive Officer and President. Dr. Vitoc has a broad array of experience across commercial strategic analysis and planning and medical affairs, in which he has 20 years of experience. During that time, Dr. Vitoc has managed and supported over 20 early, launch, and mature stage compounds, which have included targeted therapies and immune therapies across more than 25 tumor types, including colorectal cancer, hepatocellular carcinoma, lung cancer, breast cancer prostate cancer, and renal cell carcinoma. Vlad received an M.D. from the University of Medicine and Pharmacy &#8220;Iuliu Hatieganu&#8221;, Cluj-Napoca, Romania, and his M.B.A. from the University of South Carolina.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe Dr. Vitoc is qualified to serve on our board of directors because he is a founder of the Company and he has significant knowledge and experience in the pharmaceutical industry and in the management and support of compounds targeting various types of cancers.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Sergei M. Gryaznov, Ph.D.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dr.<font style="font-weight:bold;"> </font>Gryaznov is our Chief Scientific Officer. Dr. Gryaznov is an internationally recognized scientist and expert in the areas of modern drug discovery and development, oncology, telomerase, immune-regulatory therapeutics, nucleosides, nucleotides, DNA and RNA analogues, lipid and other conjugates, small molecules and nucleic acid based therapeutic agents. Dr. Gryaznov is the co-inventor of a novel telomere-by-telomerase-targeting therapeutic approach to potential cancer treatment and responsible for leading the research team that characterized THIO&#8217;s telomere targeting activity, our lead compound in development. Dr. Gryaznov obtained a M.S., with Honors, in Organic Chemistry and a Ph.D. in Chemistry of Natural Products from M.V. Lomonosov Moscow State University. Dr. Gryaznov also completed a post-doctoral fellowship program in Chemistry at Northwestern University in Evanston, IL.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">117</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Mihail Obrocea, M.D.</font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dr. Obrocea is our Chief Medical Officer. Dr. Obrocea is a hematologist/oncologist with over 20 years&#8217; experience in drug development in both academia and the pharmaceutical/biotechnology industry with expertise in the development of cell therapy, cancer vaccines, monoclonal antibodies, and small molecules. Dr. Obrocea&#8217;s research has been published in oncology peer-reviewed literature, he has co-authored published books related to cancer vaccines and immunology, and he holds several patents in the field of biotechnology. Dr. Obrocea received an M.D. from the Carol Davila University of Medicine &amp; Pharmacy in Bucharest, Romania.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Joseph F. McGuire </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mr. McGuire is our Chief Financial Officer, and he brings over 30 years of experience to MAIA having served as Chief Financial Officer for several privately held and publicly traded companies in the health care, financial services, investment, and manufacturing industries. In these roles, his responsibilities included SEC financial reporting, investor relations, corporate governance, legal and audit liaison, and team building. Most recently, Mr. McGuire was the chief financial officer at Avadim Health, Inc. (&#8220;Avadim&#8221;) from October 2014 to May 2021. Avadim subsequently filed a voluntary petition for protection under Chapter 11 of the U.S. Bankruptcy Code and announced on August 17, 2021, the completion of its court-approved sale of substantially all of its assets to a newly created company and emergence from the reorganization proceedings under Chapter 11. Mr. McGuire began his career with Price Waterhouse, where he was a certified public accountant, and later held management positions with Dean Witter Reynolds and Paine Webber, Inc. Joe received a Bachelor of Science in accounting from the University of Notre Dame. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The collective experience of our leadership team includes involvement in the development, approval and/or commercialization of a number of major oncology drugs, including TARCEVA<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>, NEXAVAR<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>, IMBRUVICA<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>, XTANDI<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>, NERLYNX<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>, TREANDA<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>, TRISENOX<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>, and ZOMETA<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>, as well as numerous state-of-the-art development programs, including a telomerase inhibitor (IMETELSTAT<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>), a new immune oncology platform and agent (Cavrolotimod; AST-008), and novel nucleic acid based siRNA and antisense oligonucleotide therapeutics (NP/NPS-oligos). In addition, our team was involved in the development and approval of:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">BREANZY<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>, an autologous CD19 chimeric antigen receptor (CAR T) treatment for B-cell lymphomas; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">BESPONSA<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>, a CD22-directed antibody drug conjugate (ADC) for treatment of B-cell acute lymphoblastic leukemia; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">IMBRUVICA<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>, or bruton tyrosine kinase inhibitor ibrutinib, for treatment of chronic lymphocytic leukemia and mantle cell lymphomas.</font><font style="Background-color:#FFFFFF;color:#111111;font-size:10pt;font-family:Times New Roman;"> </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Non-Employee Directors</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Louie Ngar Yee<font style="font-weight:normal;">; Director</font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ms. Louie has 30 years of service with HSBC Group in a variety of functions, principally with businesses of Global Banking and Markets including investment and securities management, asset management, and global research. She also held key leadership positions within Group Internal Audit of HSBC in Latin America, Asia Pacific, and United Kingdom.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Born and educated in Hong Kong, Ms. Louie joined HSBC as an executive trainee in Hong Kong and became an International Manager of HSBC Group in 1996. Since then, she has taken up different roles in Hong Kong, the Philippines, Indonesia, Taiwan, the United States, the United Kingdom, and Latin America, primarily in key management positions to lead, drive and execute a change agenda in a wide range of management situations including business re-engineering, business turnaround, business downsizing, and business set up.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to her current appointment with MAIA Biotechnology in April 2020, Ms. Louie was the Group Chief Operating Officer of Group Internal Audit of HSBC Group.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe Ms. Louie is qualified to serve on our board of directors because she has extensive finance, compliance, and audit experience and expertise.<sup style="font-size:85%;line-height:120%;vertical-align:top"> </sup></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">118</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Ramiro Guerrero J.D., LL.M.</font><font style="font-weight:normal;">; </font><font style="font-weight:normal;">Director</font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mr. Guerrero is the Founder and CEO of IMPERIO, Inc., a Chicago and Suburban based Real Estate Investment and Brokerage Organization with over 20 years of business experience. He has also been a Venture Capitalist for the past 10 years aiding entrepreneurs and small businesses in their startup ventures. He received his undergraduate B.S. degree in Business/Management from the University of Illinois, his J.D. at the Universidad Metropolitana de Monterrey in Monterrey, Mexico and an LL.M. (Master of Laws) in International Law from St. Mary&#8217;s University School of Law in San Antonio, Texas and the University of Innsbruck, Austria.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe Mr. Guerrero is qualified to serve on our board of directors because he has extensive entrepreneurial start-up experience and expertise.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cristian Luput<font style="font-weight:normal;">; Director</font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mr. Luput is the founder and CEO of Optimus Realty Inc, a full-service real estate company specializing in brokering, managing and developing residential properties in Chicago, with over 15 years of extensive expertise in real estate. Mr. Luput has also successfully completed multiple multimillion dollars real estate partnerships, consolidations, mergers and acquisitions.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">He is actively involved and serves in the board of directors of several charitable organizations. Mr. Luput is a graduate of Babes-Bolyai, Cluj-Napoca, in Romania with a major in accounting and Business Administration.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe Mr. Luput is qualified to serve on our board of directors because has extensive management and entrepreneurial start-up experience and expertise.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stan V. Smith Ph.D.<font style="font-weight:normal;">; Director</font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stan V. Smith, Ph.D., is president of Smith Economics Group, Ltd. in Chicago, providing economic and financial consulting nationwide. Trained at the University of Chicago and specializing in litigation economics, Dr. Smith co-authored the first textbook on the subject of economic damages. Dr. Smith has served as an adjunct professor at the University of Chicago and at DePaul University College of Law where he created the first course in the United States in forensic economics.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe Dr. Smith is qualified to serve on our board of directors because has extensive economics, financing, and management experience and expertise.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Laurentiu Vlad<font style="font-weight:normal;">; Director</font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laurentiu Vlad is a highly successful entrepreneur has started and grown two successful companies, in wholesale and retail as well as the lighting industry. His most recent company, Luminii, is the US market leader in linear lighting, having built projects including One World Trade Center, Uber HQ, Space Needle Seattle, and United Polaris Lounges.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe Mr. Vlad is qualified to serve on our board of directors because he has extensive management and entrepreneurial start-up experience and expertise.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Steven Chaouki<font style="font-weight:normal;">; Director</font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Steven M. Chaouki is President, U.S. Markets &amp; Consumer Interactive, overseeing two TransUnion business lines. U.S. Markets provides information and insights to business customers across financial services, insurance, public sector, media and diversified markets. Consumer Interactive provides credit, financial and identity protection services to consumers. He previously held the role of Executive Vice President, Financial Services, responsible for the company&#8217;s financial services business, which provides solutions to banks, credit unions, capital markets, financial services resellers, auto lenders and other customers. Before joining TransUnion, Mr. Chaouki held roles at HSBC in card/retail services and auto finance. Mr. Chaouki earned an M.B.A. from the University of Chicago Booth School of Business and a bachelor&#8217;s degree from Boston University.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">119</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe Mr. Chaouki is qualified to serve on our board of directors because he has extensive management and financial experience and expertise.</font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Family Relationships</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There are no family relationships among any of our officers or directors.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Involvement in Certain Legal Proceedings</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To the best of our knowledge, except as set forth above regarding Mr. McGuire, none of our directors or executive officers were involved in any legal proceedings described in Item 401(f) of Regulation S-K in the past ten years.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Board Composition </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our board of directors currently consists of seven members, all of whom are members pursuant to the board composition provisions of our current amended and restated certificate of incorporation and agreements with our stockholders, and who will remain members pursuant to the board composition provisions of our amended and restated certificate of incorporation, as amended. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our nominating and corporate governance committee and our board of directors may consider a broad range of factors relating to the qualifications and background of board nominees, which may include diversity, which is not only limited to race, gender or national origin. We have no formal policy regarding board diversity. Our nominating and corporate governance committee&#8217;s and our board of directors&#8217; priority in selecting board members is identification of persons who will further the interests of our stockholders through his or her established record of professional accomplishment, the ability to contribute positively to the collaborative culture among board members, knowledge of our business, understanding of the competitive landscape and professional and personal experiences and expertise relevant to our growth strategy. Our directors hold office until their successors have been elected and qualified or until the earlier of their death, resignation or removal. Our amended and restated certificate of incorporation and amended and restated bylaws, each as amended to become effective upon the completion of this offering, also provide that our directors may be removed only for cause by the affirmative vote of the holders of a majority of the votes that all our stockholders would be entitled to cast in an election of directors, and that any vacancy on our board of directors, including a vacancy resulting from an enlargement of our board of directors, may be filled only by vote of a majority of our directors then in office and not by the stockholders, unless the board determines by resolution that any such vacancies or newly created directorships shall be filled by stockholders. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Director Independence. <font style="font-style:normal;">Our board of directors has determined that all members of our board of directors are independent directors, with the exception of Vlad Vitoc, including for purposes of the rules of Nasdaq and relevant federal securities laws and regulations. </font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Staggered Board. <font style="font-style:normal;">In accordance with the terms of our amended and restated certificate of incorporation and amended and restated bylaws, our board of directors is divided into three staggered classes of directors of the same or nearly the same number and each will be assigned to one of the three classes. At each annual meeting of the stockholders, a class of directors will be elected for a three-year term to succeed the directors of the same class whose terms are then expiring. </font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The terms of the directors will expire upon the election and qualification of successor directors at the annual meeting of stockholders to be held during the years 2021 for Class II directors, 2022 for Class III directors and 2023 for Class I directors: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">our Class I directors are Louie Ngar Yee and Steven Chaouki; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">our Class II directors are Vlad Vitoc, Ramiro Guerrero and Cristian Luput; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">our Class III directors are Laurentiu Vlad and Stan Smith. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our amended and restated certificate of incorporation and amended and restated bylaws, each as amended to become effective upon the completion of this offering, provide that the number of our directors shall be fixed from time to time by a resolution of the majority of our board of directors. Any additional directorships resulting from an increase in the number of directors will be distributed among the three classes so that, as nearly as possible, each class shall consist of one third of our board of directors. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">120</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The division of our board of directors into three classes with staggered three-year terms may delay or prevent stockholder efforts to effect a change of our management or a change in control. </font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Committees of the Board of Directors </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our board of directors has an audit committee, a compensation committee and a nominating and corporate governance committee, each of which have the composition and responsibilities described below. Each of the below committees have a written charter approved by our board of directors, effective upon completion of this offering. Each of the committees will report to our board of directors as such committee deems appropriate and as our board of directors may request. Upon completion of this offering, copies of each charter will be posted on the investor relations section of our website. Members serve on these committees until their resignation or until otherwise determined by our board of directors. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Audit Committee </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our audit committee is comprised of Ms. Louie, Mr. Chaouki and Mr. Vlad, with Ms. Louie serving as chair of the committee. Our board of directors has determined that each member of the audit committee meets the independence requirements of Rule 10A-3 under the Securities Exchange Act of 1934, as amended, or the Exchange Act, and the applicable Nasdaq rules, and has sufficient knowledge in financial and auditing matters to serve on the audit committee. Each of Mr. Chaouki and Ms. Louie qualifies as an audit committee financial expert under Item 407 of Regulation S-K. We have adopted an audit committee charter, detailing the principal functions of the audit committee, including:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">assisting board oversight of&#8201;(1) the integrity of our financial statements, (2) our compliance with legal and regulatory requirements, (3) our independent auditor&#8217;s qualifications and independence, and (4) the performance of our internal audit function and independent auditors; the appointment, compensation, retention, replacement, and oversight of the work of the independent auditors and any other independent registered public accounting firm engaged by us;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">pre-approving all audit and non-audit services to be provided by the independent auditors or any other registered public accounting firm engaged by us, and establishing pre-approval policies and procedures;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">reviewing and discussing with the independent auditors all relationships the auditors have with us in order to evaluate their continued independence;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">setting clear policies for audit partner rotation in compliance with applicable laws and regulations;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">obtaining and reviewing a report, at least annually, from the independent auditors describing (1) the independent auditor&#8217;s internal quality-control procedures and (2) any material issues raised by the most recent internal quality-control review, or peer review, of the audit firm, or by any inquiry or investigation by governmental or professional authorities, within the preceding five years respecting one or more independent audits carried out by the firm and any steps taken to deal with such issues;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">meeting to review and discuss our annual audited financial statements and quarterly financial statements with management and the independent auditor, including reviewing our specific disclosures under &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221;; reviewing and approving any related party transaction required to be disclosed pursuant to Item 404 of Regulation S-K promulgated by the SEC prior to us entering into such transaction; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">reviewing with management, the independent auditors, and our legal advisors, as appropriate, any legal, regulatory or compliance matters, including any correspondence with regulators or government agencies and any employee complaints or published reports that raise material issues regarding our financial statements or accounting policies and any significant changes in accounting standards or rules promulgated by the Financial Accounting Standards Board, the SEC or other regulatory authorities.</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">121</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Compensation Committee </font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our compensation committee is comprised of Dr. Smith, Mr. Luput and Mr. Guerrero, with Dr. Smith serving as chair of the committee. Each member of this committee is a non-employee director, as defined by Rule 16b-3 promulgated under the Exchange Act. Our board of directors has determined that each member of the compensation committee is &#8220;independent&#8221; as defined in the applicable Nasdaq rules. The composition of our compensation committee meets the requirements for independence under the Nasdaq listing standards, including the applicable transition rules. We have adopted a compensation committee charter which details the principal functions of the compensation committee, including: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">reviewing and approving on an annual basis the corporate goals and objectives relevant to our Chief Executive Officer&#8217;s compensation, evaluating our Chief Executive Officer&#8217;s performance in light of such goals and objectives and determining and approving the remuneration (if any) of our Chief Executive Officer based on such evaluation;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">reviewing and making recommendations to our Board of Directors with respect to the compensation, and any incentive-compensation and equity-based plans that are subject to board approval of all of our other officers;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">reviewing our executive compensation policies and plans;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">implementing and administering our incentive compensation equity-based remuneration plans; assisting management in complying with our proxy statement and annual report disclosure requirements;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">approving all special perquisites, special cash payments and other special compensation and benefit arrangements for our officers and employees; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">producing a report on executive compensation to be included in our annual proxy statement; and reviewing, evaluating and recommending changes, if appropriate, to the remuneration for directors.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The charter also provides that the compensation committee may, in its sole discretion, retain or obtain the advice of a compensation consultant, independent legal counsel or other adviser and is directly responsible for the appointment, compensation and oversight of the work of any such adviser. However, before engaging or receiving advice from a compensation consultant, external legal counsel or any other adviser, the compensation committee will consider the independence of each such adviser, including the factors required by the Nasdaq and the SEC.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nominating and Governance Committee </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our nominating and governance committee is comprised of Ms. Louie, Mr. Luput and Dr. Smith, with Ms. Louie serving as the chair of the committee. We have adopted a nominating and corporate governance committee charter, which details the purpose and responsibilities of the nominating and corporate governance committee, including:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">identifying, screening and reviewing individuals qualified to serve as directors, consistent with criteria approved by the Board of Directors, and recommending to the Board of Directors candidates for nomination for election at the annual meeting of stockholders or to fill vacancies on the Board of Directors;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">developing and recommending to the Board of Directors and overseeing implementation of our corporate governance guidelines;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">coordinating and overseeing the annual self-evaluation of the Board of Directors, its committees, individual directors and management in the governance of the company; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">reviewing on a regular basis our overall corporate governance and recommending improvements as and when necessary.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The charter also provides that the nominating and corporate governance committee may, in its sole discretion, retain or obtain the advice of, and terminate, any search firm to be used to identify director candidates, and is directly responsible for approving the search firm&#8217;s fees and other retention terms.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have not formally established any specific, minimum qualifications that must be met or skills that are necessary for directors to possess. In general, in identifying and evaluating nominees for director, the Board of Directors considers educational background, diversity of professional experience, knowledge of our business, integrity, professional reputation, independence, wisdom, and the ability to represent the best interests of our stockholders. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">122</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Leadership Structure and Risk Oversight </font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our board of directors does not have a policy regarding the separation of the roles of Chief Executive Officer and Chairman of the board of directors, as our board of directors believes it is in the best interest of the Company to make that determination based on the position and direction of the Company and the membership of the board of directors. Our board of directors has determined that having an employee director serve as Chairman is in the best interest of our stockholders at this time because of the efficiencies achieved in having the role of Chief Executive Officer and Chairman combined, and because the detailed knowledge of our day-to-day operations and business that the Chief Executive Officer possesses greatly enhances the decision-making processes of our board of directors as a whole. Dr. Stan Smith is the lead independent director. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Chairman of the board of directors and the other members of the board of directors work in concert to provide oversight of our management and affairs. Our board of directors encourages communication among its members and between management and the board of directors to facilitate productive working relationships. Working with the other members of the board of directors, our Chairman also strives to ensure that there is an appropriate balance and focus among key board responsibilities such as strategic development, review of operations and risk oversight. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Compensation Committee Interlocks and Insider Participation </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None of the members of our compensation committee has at any time during the prior three years been one of our officers or employees. None of our executive officers currently serves, or in the past fiscal year has served, as a member of the board of directors or compensation committee of any entity that has one or more executive officers serving on our board of directors or compensation committee. For a description of transactions between us and members of our compensation committee and affiliates of such members, see the section titled &#8220;Certain Relationships and Related Party Transactions&#8221;. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Code of Business Conduct and Ethics </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have adopted a code of business conduct and ethics that applies to all our employees, officers and directors, including those officers responsible for financial reporting, which will be effective upon completion of this offering. Upon the completion of this offering, our code of business conduct and ethics will be available on the investor relations section of our website. We intend to disclose any amendments to the code, or any waivers of its requirements, on our website or in a Current Report on Form 8-K. </p><a name="_AEIOULastRenderedPageBreakAEIOU17"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">123</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="EXECUTIVE_DIRECTOR_COMPENSATION"></a><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="EXECUTIVE_DIRECTOR_COMPENSATION"></a>EXECUTIVE AND DIRE</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CTOR COMPENSATION</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc79562789"></a>Summary Compensation Table </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table shows the total compensation paid or accrued during the fiscal years ended December 31, 2021 and 2020, to our Chief Executive Officer and President and our other two most highly-compensated executive officers that were serving as executive officers as of December 31, 2021 (our &#8220;named executive officers&#8221;). </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.42%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name and Principal Position</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.2%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.2%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Salary</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.56%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Bonus<sup style="font-size:85%;line-height:120%;vertical-align:top">(1)</sup></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.56%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Option</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Awards<sup style="font-size:85%;line-height:120%;vertical-align:top">(2)</sup></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.58%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Non-Qualified</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Deferred</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Compensation</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Earnings</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.58%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">All Other</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Compensation</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.58%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.42%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vlad Vitoc, M.D. M.B.A.</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.2%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">264,583</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.56%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">172,000</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.56%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">266,068</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.58%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.58%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.58%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">702,651</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">2</sup></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Chief Executive Officer and</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; President</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">240,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">970,971</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.58%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.58%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">125,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.58%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,410,971</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Joseph F. McGuire<sup style="font-size:85%;line-height:120%;vertical-align:top">(3)</sup></p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">112,500</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,519</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">700,258</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.58%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.58%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,035</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.58%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">878,312</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Chief Financial Officer</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.58%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.58%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.58%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mihail Obrocea<sup style="font-size:85%;line-height:120%;vertical-align:top">(4)</sup></p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">162,500</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57,731</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,907,411</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.58%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.58%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,344</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.58%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,145,986</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Chief Medical&nbsp;&nbsp;Officer</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.58%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.58%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.58%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(1)</sup> All of the bonuses earned by our named executive officers in 2021 are expected to be paid in cash in 2022. The bonus earned by Vlad Vitoc in 2020 was paid out by the issuance of 219,550 stock options on April 16, 2021 to Dr. Vitoc in lieu of payment of a cash bonus.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(2)</sup> The aggregate grant date fair value of such awards were computed in accordance with Financial Accounting Standards Board ASC Topic 718, Stock Compensation (ASC Topic 718), and do not take into account estimated forfeitures related to service-based vesting conditions, if any. The valuation assumptions used in calculating these values are discussed in Note 7 of the Notes to Consolidated Financial Statements appearing elsewhere herein. These amounts do not represent actual amounts paid or to be realized. Amounts shown are not necessarily indicative of values to be achieved, which may be more or less than the amounts shown as awards may subject to time-based vesting.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(3)</sup> Mr. McGuire served as the CFO of the Company since August 16, 2021, and from July 1, 2021 through August 15, 2021, Mr. McGuire served as a consultant to the Company.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk99776993"></a><sup style="font-size:85%;line-height:120%;vertical-align:top">(4)</sup> Dr. <a name="_Hlk99776993"></a>Obrocea served as the Chief Medical Officer of the Company since July 12, 2021, and from December 1, 2020 through July 11, 2021, Dr. Obrocea served as a consultant to the Company.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Employment Agreements</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2021, we entered into executive employment agreements with each of senior executive officers in connection with their employment with us, the material terms of which are described below. Except as noted below, these executive employment agreements provide for &#8220;at will&#8221; employment. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Summary of Employment Agreement with Vlad Vitoc</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the terms of Dr. Vitoc&#8217;s employment agreement dated August 2, 2021, Dr. Vitoc is entitled to an initial annual base salary of $430,000. Dr. Vitoc may be eligible to receive an annual cash bonus of up to 40% of his then-current base salary based on the achievement of certain individual and corporate performance metrics and milestones in the previous year, as determined in the sole discretion of our board of directors. Dr. Vitoc may also be eligible for a discretionary annual performance incentive options award based on the previous year&#8217;s performance, as determined in the discretion of the board of directors. Dr. Vitoc is eligible to participate in regular health insurance and other employee benefit plans as established by the Company. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This agreement also provides for the following severance payments and benefits upon termination by us without Cause (as defined below): (i) all accrued and unpaid base salary payable and accrued and unpaid deferred compensation earned as of the date of termination; (ii) any bonus or other such compensation earned and payable pursuant to any compensation program then in effect; (iii) reimbursement for all incurred but unreimbursed reasonable and necessary business expenses for which he is entitled to reimbursement, for which proper claims are </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">124</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:10pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">made within 45 days of termination; (iv) the benefit of any options vested as of the termination date; and (v) a severance payment equal to the base salary and benefits he otherwise would have received for the one year following the termination, payable as salary continuation in accordance with the Company&#8217;s normal payroll practices. </font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, in consideration of the payments and benefits provided under his employment agreement, Dr. Vitoc has agreed to certain invention assignment, confidentiality and other restrictive covenants pursuant to an Employee Invention Assignment, Confidentiality and Non-Competition Agreement, including, among other things, non-competition and non-solicitation provisions that apply during the term of Dr. Vitoc&#8217;s employment and for one year thereafter.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;Cause&#8221; means: (i) conviction of or plea of nolo contendere to a felony or a crime involving moral turpitude; (ii) engaging in an act of gross negligence or willful misconduct in the performance of his employment obligations and duties; (iii) committing an act of fraud against, or material misconduct or willful misappropriation of property belonging to the Company or its subsidiaries or affiliates; (iv) engaging in any other misconduct that has had or will have an adverse effect on the Company&#8217;s or its subsidiaries or affiliates reputation or business; or (v) his material breach of the Employee Invention Assignment, Confidentiality and Non-Competition Agreement or other unauthorized misuse of the Company&#8217;s or any of or its subsidiaries or other affiliates&#8217; trade secrets or proprietary information. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Summary of Employment Agreement with Mihail Obrocea</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the terms of Dr. Obrocea&#8217;s employment agreement dated August 2, 2021, Dr. Obrocea is entitled to an initial annual base salary of $380,000. Dr. Obrocea may be eligible to receive an annual bonus of up to 35% of his then-current base salary based on the achievement of certain individual and corporate performance metrics and milestones in the previous year, as determined in the sole discretion of our board of directors. Dr. Obrocea may also be eligible for a discretionary annual performance incentive options award based on the previous year&#8217;s performance, as determined in the discretion of the board of directors. Dr. Obrocea is eligible to participate in regular health insurance and other employee benefit plans as established by the Company. This agreement also provides for severance payments and benefits upon termination by us without Cause (as defined above) as described above in the summary of Dr. Vitoc&#8217;s agreement.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, in consideration of the payments and benefits provided under his employment agreement, Dr. Obrocea has agreed to certain invention assignment, confidentiality and other restrictive covenants pursuant to an Employee Invention Assignment, Confidentiality and Non-Competition Agreement, including, among other things, non-competition and non-solicitation provisions that apply during the term of Dr. Obrocea&#8217;s employment and for one year thereafter.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Summary of Employment Agreement with Joseph F. McGuire</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the terms of Mr. McGuire&#8217;s employment agreement dated August 10, 2021, Mr. McGuire is entitled to an initial annual base salary of $300,000. Mr. McGuire also received a sign-on grant of 130,000 stock options, which will vest over a four year period according to the following schedule: 25% of the shares will vest as of the one-year anniversary of the vesting commencement date and 1/48th of the shares will vest monthly thereafter, so long as Mr. McGuire remains in continuous service with the Company through the applicable vesting dates. Mr. McGuire may be eligible to receive an annual bonus of up to 35% of his then-current base salary based on the achievement of certain individual and corporate performance metrics and milestones in the previous year, as determined in the sole discretion of our board of directors. Starting in 2022, Mr. McGuire may also be eligible for a discretionary annual performance incentive options award based on the previous year&#8217;s performance, as determined in the discretion of the board of directors. Mr. McGuire is eligible to participate in regular health insurance and other employee benefit plans as established by the Company. This agreement also provides for severance payments and benefits upon termination by us without Cause (as defined above) as described above in the summary of Dr. Vitoc&#8217;s agreement, with the additional requirement that prior to receiving such payments and benefits Mr. McGuire will be required to sign and not revoke a separation agreement and general release of claims in a form reasonably satisfactory to the Company by no later than the sixtieth (60th) day after his employment termination date.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">125</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, in consideration of the payments and benefits provided under his employment agreement, Mr. McGuire has agreed to certain invention assignment, confidentiality and other restrictive covenants pursuant to an Employee Invention Assignment, Confidentiality and Non-Competition Agreement, including, among other things, non-competition and non-solicitation provisions that apply during the term of Mr. McGuire&#8217;s employment and for one year thereafter.</font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc79562791"></a>Outstanding Equity Awards as of December 31, 2021</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table presents the outstanding equity incentive plan awards held by each named executive officer as of December 31, 2021.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:17.4%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="8" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.22%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Option Awards(1)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.62%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.42%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stock Awards</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Grant</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Securities</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Underlying</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unexercised</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercisable</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(#)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Securities</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Underlying</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unexercised</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unexercisable</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(#)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Option</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price Per</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Share</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">($)(2)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Option</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Expiration</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number&#160;of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares&#160;or</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Units of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stock&#160;that</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Have Not</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Vested</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Market&#160;Value</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">of&#160;Shares&#160;of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Units&#160;of&#160;Stock</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">that&#160;Have&#160;Not</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Vested(3)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vlad Vitoc</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7/1/2021</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,529</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.83</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6/30/2031  </p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4/16/2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">509,906</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.83</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4/15/2031 </p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4/1/2021</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,078</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.83</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3/31/2031 </p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11/3/2020</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">705,789</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.80</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11/2/2030 </p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4/1/2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">169,500</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.80</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3/31/2030 </p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6/17/2019</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,500</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.80</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6/16/2029</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10/1/2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">498,750</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">145,834</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.80</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9/30/2028 </p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Joseph McGuire</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8/31/2021</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,297</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.00</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8/30/2031 </p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8/16/2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">130,000</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.00</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8/15/2031 </p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7/30/2021</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">656</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.00</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7/29/2031 </p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mihail Obrocea</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7/31/2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">772</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.00</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7/30/2031 </p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7/15/2021</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">260,000</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.83</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7/14/2031 </p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6/7/2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,447</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.83</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 6/6/2031</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6/5/2021</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,476</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.83</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 6/4/2031</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4/16/2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,022</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.83</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 4/15/2031</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1/31/2021</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,131</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.80</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 1/30/2031</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1/6/2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,269</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.80</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 1/5/2031</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(1)</sup> All of the option awards were granted under the 2018 Plan or the 2020 Plan, the terms of which are described below under &#8220;&#8212;Equity Compensation Plans and Other Benefit Plans&#8212;2020 Employee, Director and Consultant Equity Incentive Plan.&#8221;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc79562792"></a>Equity Compensation Plans and Other Benefit Plans </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc79562793"></a>2020 Employee, Director and Consultant Equity Incentive Plan </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On September 14, 2018, we adopted and approved the 2018 Stock Option Plan (the &#8220;2018 Plan&#8221;), which provides for the issuance of 3,900,000 shares of our common stock for purposes of attracting, retaining, and motivating key employees, directors, and consultants. On May 29, 2020, we amended the 2018 Plan and approved it as the Amended and Restated 2020 Equity Incentive Plan (the &#8220;2020 Plan&#8221;) and reserved 1,671,000 common stock for issuance. On November 1, 2020, we approved the second amendment of the 2020 Plan to reserve a total of 3,171,000 common stock for issuance. In April and July of 2021 there were amendments to the 2020 Plan to bring the plan to a total of 4,171,000 shares reserved for issuance.<font style="font-weight:bold;"> </font>The 2020 Plan provides for the grant of incentive stock options, nonqualified stock options, restricted stock and restricted stock units. As of the date of this prospectus, we have granted an aggregate of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;  options to various key employees, directors, and consultants under the 2020 </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">126</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:10pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Plan. As of the date of this prospectus, there are </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> shares available to be granted under the 2020 Plan. On or prior to the consummation of this offering, we intend to cancel the 2020 Plan and convert these stock options to the 2021 Plan, as more fully described below.</font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021 Equity Incentive Plan</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our Board of Directors and stockholders have adopted and approved the 2021 Equity Incentive Plan (the &#8220;2021 Plan&#8221;), which has replaced the 2020 Plan. The 2021 Plan is a comprehensive incentive compensation plan under which we can grant equity<font style="color:#000000;">-based and other incentive awards to our officers, employees, directors, consultants and advisers. The purpose of the 2021 Plan is to help us attract, retain, and motivate such persons with awards under the 2021 Plan and thereby enhance shareholder value.</font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Administration<font style="font-style:normal;">. The 2021 Plan is administered by the Board, and upon consummation of this offering will be administered by the compensation committee of the Board, which shall consist of three members of the board, each of whom is a &#8220;non-employee director&#8221; within the meaning of Rule 16b-3 promulgated under the Exchange Act and &#8220;independent&#8221; for purposes of any applicable listing requirements. If a member of the compensation committee is eligible to receive an award under the 2021 Plan, such compensation committee member shall have no authority under the plan with respect to his or her own award. Among other things, the compensation committee has complete discretion, subject to the express limits of the 2021 Plan, to determine the directors, employees and nonemployee consultants to be granted an award, the type of award to be granted the terms and conditions of the award, the form of payment to be made and/or the number of shares of common stock subject to each award, the exercise price of each option and base price of each stock appreciation right (&#8220;SAR&#8221;), the term of each award, the vesting schedule for an award, whether to accelerate vesting, the value of the common stock underlying the award, and the required withholding, if any. The compensation committee may amend, modify or terminate any outstanding award, provided that the participant&#8217;s consent to such action is required if the action would impair the participant&#8217;s rights or entitlements with respect to that award. The compensation committee is also authorized to construe the award agreements, and may prescribe rules relating to the 2021 Plan. Notwithstanding the foregoing, the compensation committee does not have any authority to grant or modify an award under the 2021 Plan with terms or conditions that would cause the grant, vesting or exercise thereof to be considered nonqualified &#8220;deferred compensation&#8221; subject to Code Section 409A, unless such award is structured to be exempt from or comply with all requirements of Code Section 409A.</font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Grant of Awards; Shares Available for Awards<font style="font-style:normal;">. The 2021 Plan provides for the grant of stock options, SARs, performance share awards, performance unit awards, distribution equivalent right awards, restricted stock awards, restricted stock unit awards and unrestricted stock awards to non-employee directors, officers, employees and nonemployee consultants of MAIA or its affiliates. The aggregate number of shares of common stock reserved and available for grant and issuance under the 2021 Plan is &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;  , plus any reserved shares of common stock not issued or subject to outstanding awards granted under the 2020 Plan. The same number of shares of common stock in the aggregate may be issued under the 2021 Plan in connection with incentive stock options. Shares shall be deemed to have been issued under the 2021 Plan solely to the extent actually issued and delivered pursuant to an award. If any award granted under the 2020 Plan or the 2021 Plan expires, is cancelled, or terminates unexercised or is forfeited, the number of shares subject thereto is again available for grant under the 2021 Plan. The 2021 Plan shall continue in effect, unless sooner terminated, until the tenth (10<sup style="font-size:85%;line-height:120%;vertical-align:top">th</sup>) anniversary of the date on which it is adopted by the Board. The Board in its discretion may terminate the 2021 Plan at any time with respect to any shares for which awards have not theretofore been granted; provided, however, that the 2021 Plan&#8217;s termination shall not materially and adversely impair the rights of a holder, without the consent of the holder, with respect to any award previously granted.</font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Future new hires and additional non-employee directors and/or consultants would be eligible to participate in the 2021 Plan as well. The number of stock options and/or shares of restricted stock to be granted to executives and directors cannot be determined at this time as the grant of stock options and/or shares of restricted stock is dependent upon various factors such as hiring requirements and job performance.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Stock Options<font style="font-style:normal;">. The 2021 Plan provides for either &#8220;incentive stock options&#8221; (&#8220;ISOs&#8221;), which are intended to meet the requirements for special federal income tax treatment under Section 422 of the Code, or &#8220;nonqualified stock options&#8221; (&#8220;NQSOs&#8221;). Stock options may be granted on such terms and conditions as the compensation committee may determine, which shall be specified in the option agreement; provided, however, that the per share exercise </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">127</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:10pt;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><font style="font-style:normal;">price under a stock option may not be less than the fair market value of a share of common stock on the date of grant and the term of the stock option may not exceed 10 years (110% of such value and five years in the case of an ISO granted to an employee who owns (or is deemed to own) more than 10% of the total combined voting power of all classes of capital stock of our Company or a parent or subsidiary of our Company). ISOs may only be granted to employees. In addition, the aggregate fair market value of common stock covered by one or more ISOs (determined at the time of grant), which are exercisable for the first time by an employee during any calendar year may not exceed $100,000. Any excess is treated as a NQSO.</font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Stock Appreciation Rights<font style="font-style:normal;">. A SAR entitles the participant, upon exercise, to receive an amount, in cash or stock or a combination thereof, equal to the increase in the fair market value of the underlying common stock between the date of grant and the date of exercise. The compensation committee shall set forth in the applicable SAR award agreement the terms and conditions of the SAR, including the base value for the SAR (which shall not be less than the fair market value of a share on the date of grant), the number of shares subject to the SAR and the period during which the SAR may be exercised and any other special rules and/or requirements which the compensation committee imposes on the SAR. No SAR shall be exercisable after the expiration of ten (10) years from the date of grant. SARs may be granted in tandem with, or independently of, stock options granted under the 2021 Plan. A SAR granted in tandem with a stock option (i) is exercisable only at such times, and to the extent, that the related stock option is exercisable in accordance with the procedure for exercise of the related stock option; (ii) terminates upon termination or exercise of the related stock option (likewise, the common stock option granted in tandem with a SAR terminates upon exercise of the SAR); (iii) is transferable only with the related stock option; and (iv) if the related stock option is an ISO, may be exercised only when the value of the stock subject to the stock option exceeds the exercise price of the stock option. A SAR that is not granted in tandem with a stock option is exercisable at such times as the compensation committee may specify.</font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Performance Shares and Performance Unit Awards<font style="font-style:normal;">. Performance share and performance unit awards entitle the participant to receive cash or shares of common stock upon the attainment of specified performance goals. In the case of performance units, the right to acquire the units is denominated in cash values. The compensation committee shall set forth in the applicable award agreement the performance goals and objectives and the period of time to which such goals and objectives shall apply. If such goals and objectives are achieved, such distribution of shares, or payment in cash, as the case may be, shall be made no later than by the fifteenth (15<sup style="font-size:85%;line-height:120%;vertical-align:top">th</sup>) day of the third (3<sup style="font-size:85%;line-height:120%;vertical-align:top">rd</sup>) calendar month next following the end of the Company&#8217;s fiscal year to which such performance goals and objectives relate, unless otherwise structured to comply with Code Section 409A.</font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Distribution Equivalent Right Awards<font style="font-style:normal;">. A distribution equivalent right award entitles the participant to receive bookkeeping credits, cash payments and/or common stock distributions equal in amount to the distributions that would have been made to the participant had the participant held a specified number of shares of common stock during the period the participant held the distribution equivalent right. A distribution equivalent right may be awarded as a component of another award (but not an option or SAR award) under the 2021 Plan, where, if so awarded, such distribution equivalent right will expire or be forfeited by the participant under the same conditions as under such other award. The compensation committee shall set forth in the applicable distribution equivalent rights award agreement the terms and conditions, if any, including whether the holder is to receive credits currently in cash, is to have such credits reinvested (at fair market value determined as of the date of reinvestment) in additional ordinary shares, or is to be entitled to choose among such alternatives.</font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Restricted Stock Awards<font style="font-style:normal;">. A restricted stock award is a grant or sale of common stock to the holder, subject to such restrictions on transferability, risk of forfeiture and other restrictions, if any, as the compensation committee or the board of directors may impose, which restrictions may lapse separately or in combination at such times, under such circumstances (including based on achievement of performance goals and/or future service requirements), in such instalments or otherwise, as the compensation committee or the board of directors may determine at the date of grant or purchase or thereafter. If provided for under the restricted stock award agreement, a participant who is granted or has purchased restricted stock shall have all of the rights of a shareholder, including the right to vote the restricted stock and the right to receive dividends thereon (subject to any mandatory reinvestment or other requirement imposed by the compensation committee or the board of directors or in the award agreement). During the restricted period applicable to the restricted stock, subject to certain exceptions, the restricted stock may not be sold, transferred, pledged, exchanged, hypothecated, or otherwise disposed of by the participant.</font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Restricted Stock Unit Awards<font style="font-style:normal;">. A restricted stock unit award provides for a grant of shares or a cash payment to be made to the holder upon the satisfaction of predetermined individual service-related vesting requirements, based on the number of units awarded to the holder. The compensation committee shall set forth in the applicable restricted </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">128</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:10pt;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><font style="font-style:normal;">stock unit award agreement the individual service-based vesting requirements which the holder would be required to satisfy before the holder would become entitled to payment and the number of units awarded to the holder. The holder of a restricted stock unit shall be entitled to receive either a cash payment equal to the fair market value of a share of common stock or a distribution of one share of common stock, as determined in the sole discretion of the compensation committee and as set forth in the restricted stock unit award agreement, for each restricted stock unit subject to such restricted stock unit award, if and to the extent the holder satisfies the applicable vesting requirements. Such payment or distribution shall be made no later than by the fifteenth (15</font><font style="font-style:normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">th</sup></font><font style="font-style:normal;">) day of the third (3</font><font style="font-style:normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">rd</sup></font><font style="font-style:normal;">) calendar month next following the end of the calendar year in which the restricted stock unit first becomes vested, unless otherwise structured to comply with Code Section 409A. A restricted stock unit shall not constitute an equity interest in the Company and shall not entitle the holder to voting rights, dividends or any other rights associated with ownership of shares of our common stock prior to the time the holder shall receive a distribution of shares, if any.</font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Unrestricted Stock Awards<font style="font-style:normal;">. An unrestricted stock award is a grant or sale of shares of our common stock to the employees, non-employee directors or non-employee consultants that are not subject to transfer, forfeiture or other restrictions, in consideration for past services rendered to the Company or an affiliate or for other valid consideration.</font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Change-in-Control Provisions<font style="font-style:normal;">. The compensation committee may, in its sole discretion, at the time an award is granted or at any time prior to, coincident with or after the time of a change in control, cause any award either (i) to be cancelled in consideration of a payment in cash or other consideration in amount per share equal to the excess, if any, of the price or implied price per share of common stock in the change in control over the per share exercise, base or purchase price of such award, which may be paid immediately or over the vesting schedule of the award; (ii) to be assumed, or new rights substituted therefore, by the surviving corporation or a parent or subsidiary of such surviving corporation following such change in control; (iii) accelerate any time periods, or waive any other conditions, relating to the vesting, exercise, payment or distribution of an award so that any award to a holder whose employment has been terminated as a result of a change in control may be vested, exercised, paid or distributed in full on or before a date fixed by the compensation committee; (iv) to be purchased from a holder whose employment has been terminated as a result of a change of control, upon the holder&#8217;s request, for an amount of cash equal to the amount that could have been obtained upon the exercise, payment or distribution of such rights had such award been currently exercisable or payable; or (v) terminate any then outstanding award or make any other adjustment to the awards then outstanding as the compensation committee deems necessary or appropriate to reflect such transaction or change. The number of shares subject to any award shall be rounded to the nearest whole number.</font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Amendment and Termination<font style="font-style:normal;">. The compensation committee may adopt, amend and rescind rules relating to the administration of the 2021 Plan, and amend, suspend or terminate the 2021 Plan, but no such amendment or termination will be made that materially and adversely impairs the rights of any participant with respect to any award received thereby under the 2021 Plan without the participant&#8217;s consent, other than amendments that are necessary to permit the granting of awards in compliance with applicable laws.</font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Certain U.S. Federal Income Tax Consequences of the 2021 Equity Incentive Plan</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following is a general summary of certain U.S. federal income tax consequences under current tax law to the Company (to the extent it is subject to U.S. federal income taxation on its net income) and to participants in the 2021 Plan who are individual citizens or residents of the United States for federal income tax purposes (&#8220;U.S. Participants&#8221;) of stock options which are ISOs, or stock options which are NQSOs, unrestricted stock, restricted stock, restricted stock units, performance stock, performance units, SARs, and dividend equivalent rights. This summary does not purport to cover all of the special rules that may apply, including special rules relating to limitations on our ability to deduct certain compensation, special rules relating to deferred compensation, golden parachutes, U.S. Participants subject to Section 16(b) of the Exchange Act or the exercise of a stock option with previously acquired ordinary shares. This summary assumes that U.S. Participants will hold their shares of common stock as capital assets within the meaning of Section 1221 of the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;). In addition, this summary does not address the foreign, state or local or other tax consequences, or any U.S. federal non-income tax consequences, inherent in the acquisition, ownership, vesting, exercise, termination or disposition of an award under the 2021 Plan or shares of common stock issued pursuant thereto. Participants are urged to consult with their own tax advisors concerning the tax consequences to them of an award under the 2021 Plan or shares issued thereunder.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">129</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A U.S. Participant generally does not recognize taxable income upon the grant of a NQSO if it is structured to be exempt from or comply with Code Section 409A. Upon the exercise of a NQSO, the U.S. Participant generally recognizes ordinary compensation income in an amount equal to the excess, if any, of the fair market value of the ordinary shares acquired on the date of exercise over the exercise price thereof, and the Company generally will be entitled to a deduction for such amount at that time. If the U.S. Participant later sells ordinary shares acquired pursuant to the exercise of a NQSO, the U.S. Participant recognizes a long-term or short-term capital gain or loss, depending on the period for which the ordinary shares were held. A long-term capital gain is generally subject to more favorable tax treatment than ordinary income or a short-term capital gain. The deductibility of capital losses is subject to certain limitations.</font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A U.S. Participant generally does not recognize taxable income upon the grant or, except for purposes of the U.S. alternative minimum tax (&#8220;AMT&#8221;) the exercise, of an ISO. For purposes of the AMT, which is payable to the extent it exceeds the U.S. Participant&#8217;s regular income tax, upon the exercise of an ISO, the excess of the fair market value of the ordinary shares subject to the ISO over the exercise price is a preference item for AMT purposes. If the U.S. Participant disposes of the ordinary shares acquired pursuant to the exercise of an ISO more than two years after the date of grant and more than one year after the transfer of the ordinary shares to the U.S. Participant, the U.S. Participant generally recognizes a long-term capital gain or loss, and the Company will not be entitled to a deduction. However, if the U.S. Participant disposes of such ordinary shares prior to the end of either of the required holding periods, the U.S. Participant will have ordinary compensation income equal to the excess (if any) of the fair market value of such shares on the date of exercise (or, if less, the amount realized on the disposition of such shares) over the exercise price paid for such shares, and the Company generally will be entitled to deduct such amount.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A U.S. Participant generally does not recognize income upon the grant of a SAR. The U.S. Participant recognizes ordinary compensation income upon exercise of the SAR equal to the increase in the value of the underlying shares, and the Company generally will be entitled to a deduction for such amount.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A U.S. Participant generally does not recognize income on the receipt of a performance stock award, performance unit award, restricted stock unit award, unrestricted stock award or dividend equivalent rights award until a cash payment or a distribution of ordinary shares is received thereunder. At such time, the U.S. Participant recognizes ordinary compensation income equal to the excess, if any, of the fair market value of the ordinary shares or the amount of cash received over any amount paid therefor, and the Company generally will be entitled to deduct such amount at such time.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A U.S. Participant who receives a restricted stock award generally recognizes ordinary compensation income equal to the excess, if any, of the fair market value of such ordinary shares at the time the restriction lapses over any amount paid for the ordinary shares. Alternatively, the U.S. Participant may make an election under Section 83(b) of the Code to be taxed on the fair market value of such ordinary shares at the time of grant. The Company generally will be entitled to a deduction at the same time and in the same amount as the income that is required to be included by the U.S. Participant.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc79562794"></a>401(k) Plan</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our eligible employees will be permitted to participate in our 401(k) beginning January 1, 2022. Participation in the 401(k) plan is offered for the benefit of our employees, including our named executive officers, who remain employed with us, and who satisfy certain eligibility requirements. We plan to match employee contributions using a benchmark to industry standards. Under the 401(k) plan, eligible employees may elect to defer a portion of their compensation, within the limits prescribed by the Code, on a pre-tax or after-tax (Roth) basis, through contributions to the 401(k) plan. The 401(k) plan is intended to qualify under Sections 401(a) and 501(a) of the Code. As a tax-qualified retirement plan, pre-tax contributions to the 401(k) plan and earnings on those pre-tax contributions are not taxable to the employees until distributed from the 401(k) plan, and earnings on Roth contributions are not taxable when distributed from the 401(k) plan. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc79562795"></a>10b5-1 Plan </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our directors and executive officers may adopt written plans, known as Rule 10b5-1 plans, in which they will contract with a broker to buy or sell shares of our common stock on a periodic basis. Under a Rule 10b5-1 plan, a broker executes trades pursuant to parameters established by the director or officer when entering into the plan, </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">130</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:10pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">without further direction from the director or officer. The director or officer may amend or terminate the plan in limited circumstances. Our directors and executive officers may also buy or sell additional shares of our common stock outside of a Rule 10b5-1 plan when they are not in possession of material, nonpublic information. </font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc79562796"></a>Limitations of Liability and Indemnification Matters </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our amended and restated certificate of incorporation, which will become effective upon completion of the offering, provides that no director of our company shall be personally liable to us or our stockholders for monetary damages for any breach of fiduciary duty as a director, except for liability (i) for any breach of the director&#8217;s duty of loyalty to us or our stockholders, (ii) for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (iii) in respect of unlawful dividend payments or stock redemptions or repurchases, or (iv) for any transaction from which the director derived an improper personal benefit. In addition, our amended and restated certificate of incorporation provides that if the Delaware General Corporation Law (&#8220;DGCL&#8221;) is amended to authorize the further elimination or limitation of the liability of directors, then the liability of a director of our company shall be eliminated or limited to the fullest extent permitted by the DGCL, as so amended. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The amended and restated certificate of incorporation further provides that any repeal or modification of such article by our stockholders or amendment to the DGCL will not affect any right or protection existing at the time of such repeal or modification with respect to any acts or omissions occurring before such repeal or modification of a director serving at the time of such repeal or modification. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our amended and restated certificate of incorporation also provides that we will indemnify each person who was or is a party or threatened to be made a party to any threatened, pending or completed action, suit or proceeding whether civil, criminal, administrative or investigative (other than an action by or in the right of us) by reason of the fact that he or she is or was, or has agreed to become, our director or officer, or is or was serving, or has agreed to serve, at our request as a director, officer, partner, employee or trustee of, or in a similar capacity with, another corporation, partnership, joint venture or other enterprise (all such persons being referred to as an &#8220;Indemnitee&#8221;), or by reason of any action alleged to have been taken or omitted in such capacity, against all expenses (including attorneys&#8217; fees), judgments, fines, and amounts paid in settlement actually and reasonably incurred in connection with such action, suit or proceeding and any appeal therefrom, if such Indemnitee acted in good faith and in a manner he or she reasonably believed to be in or not opposed to our best interests, and, with respect to any criminal action or proceeding, he or she had no reasonable cause to believe his or her conduct was unlawful. Our amended and restated certificate of incorporation also provides that we will advance expenses to Indemnitees in connection with a legal proceeding, subject to limited exceptions. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our amended and restated certificate of incorporation also permits us to secure insurance on behalf of ourselves and any director, officer, employee or agent of the Company or another corporation, partnership joint venture, trust or other enterprise, against any expense, liability or loss incurred by him or her in any such capacity, or arising out of his or her status as such, whether or not the Company would have the power to indemnify such person against such expense, liability or loss under the DGCL. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have entered into separate indemnification agreements with our directors and executive officers, in addition to indemnification provided for in our amended and restated certificate of incorporation, each of which will be in effect upon the completion of this offering. These agreements, among other things, provide for indemnification of our directors and executive officers for expenses, judgments, fines and settlement amounts incurred by them in any action or proceeding arising out of their services as a director or executive officer or at our request. We believe that these provisions in our amended and restated certificate of incorporation and indemnification agreements that will be in effect upon the completion of this offering are necessary to attract and retain qualified persons as directors and executive officers. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The above description of the indemnification provisions of our amended and restated certificate of incorporation and our indemnification agreements, each of which will be in effect upon the completion of this offering is not complete and is qualified in its entirety by reference to these documents, each of which is filed as an exhibit to the registration statement of which this prospectus is a part. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">131</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The limitation of liability and indemnification provisions in our amended and restated certificate of incorporation may discourage stockholders from bringing a lawsuit against directors for breach of their fiduciary duties. They may also reduce the likelihood of derivative litigation against directors and officers, even though an action, if successful, might benefit us and our stockholders. A stockholder&#8217;s investment may be harmed to the extent we pay the costs of settlement and damage awards against directors and officers pursuant to these indemnification provisions. Insofar as indemnification for liabilities under the Securities Act may be permitted to directors, officers or persons controlling us pursuant to the foregoing provisions, we have been informed that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable. There is no pending litigation or proceeding naming any of our directors or officers as to which indemnification is being sought, nor are we aware of any pending or threatened litigation that may result in claims for indemnification by any director or officer. </font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Non-Employee Director Compensation </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our policy with respect to the compensation payable to our non-employee directors provides that each non-employee director will be eligible to receive compensation for his or her service consisting solely of equity awards, specifically 18,000 stock options per year, of which 1,500 will vest for each month of service. Non-employee directors that serve as chair of audit committee, compensation committee and nominating and corporate governance committee receive an additional 5,000 stock options per year, of which 417 will vest for each month of service.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Directors may be reimbursed for travel, food, lodging and other expenses directly related to their service as directors. Directors will also be entitled to the protection provided by their indemnification agreements and the indemnification provisions in our amended and restated certificate of incorporation and amended and restated bylaws that will be in effect upon the completion of this offering. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The employment agreements for the Director who is a full-time employee expressly provides that his service on the Board does not entitle him to any additional compensation. The following table shows the total compensation paid or accrued to sitting non-employee members of our Board of Directors for the fiscal year ended December 31, 2021.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.12%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fees</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">earned</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">or paid</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">in cash</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stock</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">awards</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Option</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">awards</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(1)</sup></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">All Other</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Compensation</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.12%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tze-Liang Chiam<sup style="font-size:85%;line-height:120%;vertical-align:top">(2)</sup>*</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,750</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(5)</sup></p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(5)</sup></p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,750</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Charlotte Tsou<sup style="font-size:85%;line-height:120%;vertical-align:top">(3)</sup>*</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(6)</sup></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,414</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(6)</sup></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,414</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Steven Chaouki<sup style="font-size:85%;line-height:120%;vertical-align:top">(4)</sup></p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(7)</sup></p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">105,645</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(7)</sup></p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">105,645</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ramiro Guerrero</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(8)</sup></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91,217</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(8)</sup></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91,217</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Louie Ngar Yee</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(9)</sup></p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">141,893</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(9)</sup></p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">141,893</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cristian Luput</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,750</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(10)</sup></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91,217</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(10)</sup></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104,967</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stan V. Smith</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(11)</sup></p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">121,763</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(11)</sup></p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">121,763</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laurentiu Vlad</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(12)</sup></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91,217</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(12)</sup></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91,217</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leigh-Ann Durant<sup style="font-size:85%;line-height:120%;vertical-align:top">(13)</sup>*</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Wayne Klohs<sup style="font-size:85%;line-height:120%;vertical-align:top">(14)</sup>*</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(1)</sup> The aggregate grant date fair value of such awards were computed in accordance with Financial Accounting Standards Board ASC Topic 718, Stock Compensation (ASC Topic 718), and do not take into account estimated forfeitures related to service-based vesting conditions, if any. The valuation assumptions used in calculating these values are discussed in Note 7 of the Notes to Consolidated Financial Statements appearing elsewhere herein. These amounts do not represent actual amounts paid or to be realized. Amounts shown are not necessarily indicative of values to be achieved, which may be more or less than the amounts shown as awards may subject to time-based vesting.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(2)</sup> Tze-Liang Chiam&#8217;s term as a director ended on September 15, 2021.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(3)</sup> Charlotte Tsou&#8217;s term as a director ended on November 15, 2021.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(4)</sup> Steven Chaouki was appointed as a director on September 15, 2021</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(5)</sup> Tze-Liang Chiam had 24,306 shares and 18,000 total options outstanding as of December 31, 2021.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">132</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(</sup></font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">6</sup></font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">)</sup></font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Charlotte Tsou had </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> shares and </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,159</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> total options outstanding as of December 31, 2021.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">7</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">)</sup> Steven Chaouki had 0 shares and 21,000 total options outstanding as of December 31, 2021.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">8</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">)</sup> Ramiro Guerrero had 33,334 shares and 36,000 total options outstanding as of December 31, 2021.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">9</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">)</sup> Louie Ngar Yee had 11,111 shares and 46,000 total options outstanding as of December 31, 2021.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">10</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">)</sup> Cristian Luput had 24,306 shares and 36,000 total options outstanding as of December 31, 2021.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(1</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">1</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">)</sup> Stan V. Smith had 33,334 shares and 97,722 total options outstanding as of December 31, 2021.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(1</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">2</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">)</sup> <font style="color:#000000;">Laurentiu Vlad</font> had 33,334 shares and 33,000 total options outstanding as of December 31, 2021.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(13)</sup> Leigh-Ann Durant&#8217;s term as a director ended on November 15, 2021.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(14)</sup> Wayne Klohs term as a director ended on January 15, 2021.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*Received compensation for service on the board in 2021 but did not sit on the Board as of December 31, 2021.</p><a name="_AEIOULastRenderedPageBreakAEIOU18"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">133</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="PRINCIPAL_STOCKHOLDERS"></a><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="PRINCIPAL_STOCKHOLDERS"></a>PRINCIPAL S</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">TOCKHOLDERS</font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based solely upon information made available to us, the following table sets forth information as of April 26, 2022 regarding the beneficial ownership of our common stock by:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:3pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:3pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:3pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">each person known by us to be the beneficial owner of more than 5% of our outstanding shares of common stock;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">each of our named executive officers and directors; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">all our executive officers and directors as a group.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The percentage ownership information shown in the table is based upon 7,951,320 shares of common stock outstanding as of April 26, 2022.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Beneficial ownership is determined in accordance with the rules of the SEC and includes voting or investment power with respect to the securities. Except as otherwise indicated, each person or entity named in the table has sole voting and investment power with respect to all shares of our capital shown as beneficially owned, subject to applicable community property laws.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In computing the number and percentage of shares beneficially owned by a person as of a particular date, shares that may be acquired by such person (for example, upon the exercise of options or warrants) within 60 days of such date are counted as outstanding, while these shares are not counted as outstanding for computing the percentage ownership of any other person.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The address of each holder listed below, except as otherwise indicated, is c/o MAIA Biotechnology, Inc., 444 West Lake Street, Suite 1700, Chicago, IL 60606. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="3" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Percentage of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Beneficial Ownership</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.06%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name and Address of Beneficial Owner</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Common</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Beneficial</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Ownership</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Prior to</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">the&#160;Offering<sup style="font-size:85%;line-height:120%;vertical-align:top">(1)</sup></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Prior to</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Offering</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">After</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Offering</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.06%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vlad Vitoc</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,138,976</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(2)</sup></p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.9%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31.70%</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.9%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Joseph F. McGuire</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,953</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(3)</sup></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sergei M. Gryaznov</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">890,992</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(4)</sup></p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.10%</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Louie Ngar Yee</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,029,208</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(5)</sup></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.75%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mihail Obrocea</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90,703</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(6)</sup></p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.13%</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ramiro Guerrero</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">291,461</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(7)</sup></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.65%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Steven Chaouki</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54,750</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(8)</sup></p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cristian Luput</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">314,631</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(9)</sup></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.94%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stan V. Smith</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">671,510</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(10)</sup></p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.17%</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laurentiu Vlad</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">406,898</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(11)</sup></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.09%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">All directors and executive officers as a group</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; (10 persons):</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,891,082</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76.54%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Five Percent Shareholders</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Frank Perabo</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">492,544</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(12)</sup></p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.21%</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Jerry Shay</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">705,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(13)</sup></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.88%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-top:0pt;margin-right:76.92%;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Less than 1%</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(1)</sup></font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Beneficial ownership is determined in accordance with the rules of the SEC and generally includes voting or investment power with respect to securities. In accordance with SEC rules, shares of common stock issuable upon the exercise of options or warrants which are currently exercisable or which become exercisable within 60 days following the date of the information in this table are deemed to be beneficially </p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">134</a></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap"></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">owned by, and outstanding with respect to, the holder of such option or warrant, however none of the persons listed hereinabove has the right to acquire beneficial ownership in any other shares of the Company. Subject to community property laws where applicable, to our knowledge, each person listed is believed to have sole voting and investment power with respect to all shares of common stock owned by such person.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Mr. Vitoc beneficially owns (i) 983,121 shares of common stock, which includes 200,000 shares of common stock owned by his spouse, and (ii) 2,155,855 shares of common stock issuable upon the conversion of options and warrants exercisable within 60 days of April 26, 2022.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Mr. McGuire beneficially owns 1,953 shares of common stock issuable upon the conversion of options exercisable within 60 days of April 26, 2022.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Mr. Gryaznov beneficially owns (i) 21,511 shares of common stock and (ii) 869,481 shares of common stock issuable upon the conversion of options exercisable within 60 days of April 26, 2022.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Ms. Louie beneficially owns (i) 908,584 shares of common and (ii) 120,624 shares of common stock issuable upon the conversion of options and warrants exercisable within 60 days of April 26, 2022.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Mr. Obrocea beneficially owns (i) 26,100 shares of common stock and (ii) 64,603 shares of common stock issuable upon the conversion of options and warrants exercisable within 60 days of April 26, 2022.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Mr. Guerrero beneficially owns (i) 259,382 shares of common stock and (ii) 32,079 shares of common stock issuable upon the conversion of options and warrants exercisable within 60 days of April 26, 2022.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Mr. Chaouki beneficially owns (i) 41,250 shares of common stock and (ii) 13,500 shares of common stock issuable upon the conversion of options exercisable within 60 days of April 26, 2022.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Mr. Luput beneficially owns (i) 277,568 shares of common stock and (ii) 37,063 shares of common stock issuable upon the conversion of options and warrants exercisable within 60 days of April 26, 2022.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Mr. Smith beneficially owns, through The Stan V. Smith Trust Dated 1993, (i) 401,128 shares of common stock and (ii) 270,382 shares of common stock issuable upon the conversion of options and warrants exercisable within 60 days of April 26, 2022.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Mr. Vlad beneficially owns (i) 371,933 shares of common stock and (ii) 34,965 shares of common stock issuable upon the conversion of options and warrants exercisable within 60 days of April 26, 2022.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Mr. Perabo beneficially owns 492,544 shares of common stock. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(13)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Mr. Shay beneficially owns (i) 700,000 shares of common stock and (ii) 5,000 shares of common stock issuable upon the conversion of options exercisable within 60 days of April 26, 2022.</p></td></tr></table></div><a name="_AEIOULastRenderedPageBreakAEIOU19"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">135</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="CERTAIN_RELATIONSHIPS_RELATED_PARTY_TRAN"></a><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="CERTAIN_RELATIONSHIPS_RELATED_PARTY_TRAN"></a>CERTAIN RELATIONSHIPS AND </font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">RELATED PARTY TRANSACTIONS</font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following includes a summary of transactions since January 1, 2020, to which we have been a party in which the amount involved exceeded or will exceed the lesser of $120,000 or one percent of the average of our total assets as of December 31, 2021 and 2020, and in which any of our directors, executive officers or, to our knowledge, beneficial owners of more than 5% of our capital stock or any member of the immediate family of any of the foregoing persons had or will have a direct or indirect material interest, other than equity and other compensation, termination, change in control and other arrangements, which are described under &#8220;Executive and Director Compensation.&#8221; </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Related Party Agreements in Effect Prior to this Offering</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Consulting Services</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Wayne Klohs is a shareholder and former member of the board of directors who also provided consulting services to the Company. During the year ended December 31, 2020, the Company incurred a total of $20,400 to Mr. Klohs for consulting services. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company did not receive consulting services from Mr. Klohs during the year ended December&#160;31, 2021.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leigh-Ann Durant, a former member of the Company&#8217;s board of directors prior to her stepping down in November 2021, provides consulting services to the Company for which the Company incurred $129,171 for services provided during the year ended December&#160;31, 2020, $53,981 of which is stock-based compensation which consist of options to purchase 47,569 shares of MAIA common stock. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company incurred $88,994 for consulting services provided by Ms. Durant during the year ended December&#160;31, 2021. The Company paid Ms. Durant $34,560 in cash, and issued her options to purchase 23,964 shares of MAIA common stock with a total fair value of $54,434 during the year ended December&#160;31, 2021.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mukesh Nyati was a minority shareholder of DGD and a consultant who received 222,500 shares of restricted stock in DGD during the year ended December 31, 2020, for his services along with cash. During 2020, the Company incurred $152,576 in research fees, $75,000 of which is stock-based compensation. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dr. Nyati is also the one of the principal researchers at the University of Michigan who was working on the specific compound licensed from the University of Michigan.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Radu Vitoc, a shareholder and brother of the CEO, provides consulting services to the Company for which the Company incurred $4,700 for services provided during the year ended December&#160;31, 2021. The Company paid Mr. Vitoc $2,350 in cash, and issued him options to purchase 184 shares of common stock with a total fair value of $1,100. The remaining $1,250 for services provided in fiscal 2021 will be settled in options for which the Company has not yet issued to Mr. Vitoc as of December 31, 2021. The Company also issued him a convertible note in the amount of $50,000 during April 2021, which was converted into 8,557 shares of common stock on September 30, 2021 at a conversion price of $6.00 per share (See Note 5), and also received 4,278 warrants to purchase shares of common stock at an exercise price of $6.00 per share.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">CEO Loan Agreement</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, Vlad Vitoc, the Company&#8217;s chief executive officer, lent the Company a total of $25,000 in August and September of 2018. Since January 1, 2019, the largest aggregate amount of principal outstanding under these loans was $25,000, and the Company has paid $3,633 of principal and no interest to Dr. Vitoc. The Company paid these loans in full on March 3, 2021, by paying principal of $367 and issuing Dr. Vitoc a convertible note in the amount of $21,000, which converted into 3,621 shares of our common stock on September 30, 2021.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Deferred Compensation Agreements </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2021 and December&#160;31, 2020, the Company had $111,271 and $661,058, respectively, of deferred compensation due to certain employees and officers of the Company pursuant to deferred compensation agreements executed during fiscal 2020 and 2019 as part of a non-qualified deferred compensation plan. Pursuant to </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">136</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:10pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the deferred compensation agreements, the employees had deferred a portion of their annual base salary to be paid upon a Qualified Fund Raising. The Qualified Fund Raising was achieved during July 2021. Upon this event, the employees' salaries were increased up to the market rates set forth in their respective agreements, and all amounts were paid to the employees. The remaining deferred compensation balance as of December 31, 2021 relates to amounts incurred for employees who were no longer with the Company as of the payout date.</font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December&#160;31, 2021, the Company accrued $193,379 in deferred compensation. The Company paid $457,749 in cash and issued 268,769 options with a total fair value of $296,264 during the year ended December&#160;31, 2021, to settle a portion of the deferred compensation balance totaling $743,167. The fair value of the options issued in excess of the deferred compensation balance settled totaling $10,846 was recorded as stock-based compensation expense which is presented within general and administrative expenses on the statement of operations for the year ended December&#160;31, 2021.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Accrued Bonus</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December 31, 2021 and 2020, the Company accrued $384,750 and $780,000, respectively, in bonus expense relating to certain key employees and officers of the Company. On April 16, 2021, the 2020 accrued bonus balance was settled by issuance of 713,536 stock options with a total fair value of $786,531. The fair value of the options issued in excess of the accrued bonus balance totaled $6,531 and was recorded as stock-based compensation expense which is presented within general and administrative expenses on the statement of operations for the for the year ended December&#160;31, 2021.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Indemnification Agreements</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We intend to enter into indemnification agreements with each of our executive officers and directors that will be in effect upon the completion of this offering. The indemnification agreements will provide the executive officers and directors with contractual rights to indemnification, expense advancement and reimbursement, to the fullest extent permitted under the DGCL, subject to certain exceptions contained in those agreements.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Policies and Procedures for Related Person Transactions </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our board of directors will adopt a written related person transaction policy, to be effective upon the closing of this offering, setting forth the policies and procedures for the review and approval or ratification by our audit committee of related person transactions. This policy will cover, with certain exceptions set forth in Item 404 of Regulation S-K under the Securities Act, any transaction, arrangement or relationship, or any series of similar transactions, arrangements or relationships, in which we were or are to be a participant, where the amount involved exceeds the lesser of $120,000 in any fiscal year or one percent of the average of our total assets as of the two previous fiscal years and a related person had, has or will have a direct or indirect material interest, including without limitation, purchases of goods or services by or from the related person or entities in which the related person has a material interest, indebtedness, guarantees of indebtedness and employment by us of a related person. In reviewing and approving any such transactions, our audit committee is tasked to consider all relevant facts and circumstances, including, but not limited to, whether the transaction is on terms comparable to those that could be obtained in an arm's length transaction and the extent of the related person's interest in the transaction. All of the transactions described in this section occurred prior to the adoption of this policy. </p><a name="_AEIOULastRenderedPageBreakAEIOU20"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">137</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="DESCRIPTION_CAPITAL_STOCK"></a><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="DESCRIPTION_CAPITAL_STOCK"></a>DESCRIPTION OF</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> CAPITAL STOCK</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following is a description of (i) the material terms of our amended and restated certificate of incorporation and amended and restated bylaws as they will be in effect upon the consummation of this offering and (ii) certain applicable provisions of Delaware law. We refer you to our amended and restated certificate of incorporation and amended and restated bylaws, copies of which will be filed as exhibits to the registration statement of which this prospectus is a part. In addition, with respect to the description of our warrants, we refer you to the forms of such warrants filed as exhibits to the registration statement of which this prospectus is a part.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Authorized Capitalization</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our authorized capital stock consists of 70 million shares of common stock, par value $0.0001 per share and 30 million shares of preferred stock, par value $0.0001 per share. Following the consummation of this offering, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock shall be issued and outstanding and no shares of preferred stock shall be issued or outstanding.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Common Stock</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Holders of our common stock are entitled to one vote for each share held on all matters submitted to a vote of stockholders and do not have cumulative voting rights. An election of directors by our stockholders shall be determined by a plurality of the votes cast by the stockholders entitled to vote in the election. Subject to the supermajority votes for some matters, other matters shall be decided by the affirmative vote of our stockholders having a majority in voting power of the votes cast by the stockholders present or represented and voting on such matter. Holders of common stock are entitled to receive proportionately any dividends as may be declared by our board of directors, subject to any preferential dividend rights of any series of preferred stock that we may designate and issue in the future. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the event of our liquidation or dissolution, the holders of common stock are entitled to receive on a pro rata basis our net assets available for distribution to stockholders after the payment of all debts and other liabilities, subject to the prior rights of any holders of outstanding preferred stock. Holders of common stock have no preemptive, subscription, redemption or conversion rights. Our outstanding shares of common stock are, and the shares offered by us in this offering will be, when issued and paid for, validly issued, fully paid and nonassessable. The rights, preferences and privileges of holders of common stock are subject to and may be adversely affected by the rights of the holders of shares of any series of preferred stock that we may designate and issue in the future. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Preferred Stock </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the terms of our amended and restated certificate of incorporation our board of directors is authorized to direct us to issue shares of preferred stock in one or more series without stockholder approval. Our board of directors has the discretion to determine the rights, preferences, privileges and restrictions, including voting rights, dividend rights, conversion rights, redemption privileges and liquidation preferences, of each series of preferred stock. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The purpose of authorizing our board of directors to issue preferred stock and determine its rights and preferences is to eliminate delays associated with a stockholder vote on specific issuances. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions, future financings and other corporate purposes, could have the effect of making it more difficult for a third party to acquire, or could discourage a third party from seeking to acquire, a majority of our outstanding voting stock. Upon the closing of this offering, there will be no shares of preferred stock outstanding, and we have no present plans to issue any shares of preferred stock. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Anti-Takeover Effects of Delaware Law and Our Certificate of Incorporation and Bylaws </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Some provisions of Delaware law, our amended and restated certificate of incorporation and our amended and restated bylaws, each as amended to become effective upon the completion of this offering, will contain provisions that delay, defer, or discourage transactions involving an actual or potential change in control of us or change in our management. It is possible that these provisions could make it more difficult to accomplish or could deter transactions that stockholders may otherwise consider to be in their best interest or in our best interests, including </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">138</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:10pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">transactions which provide for payment of a premium over the market price for our shares. These provisions, summarized below, are intended to discourage coercive takeover practices and inadequate takeover bids. These provisions are also designed to encourage persons seeking to acquire control of us to first negotiate with our board of directors. We believe that the benefits of the increased protection of our potential ability to negotiate with the proponent of an unfriendly or unsolicited proposal to acquire or restructure us outweigh the disadvantages of discouraging these proposals because negotiation of these proposals could result in an improvement of their terms. </font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Authorized but Unissued Shares </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our authorized but unissued shares of common stock and preferred stock are available for future issuance without stockholder approval. These additional shares may be utilized for a variety of corporate purposes, including future public offerings to raise additional capital and corporate acquisitions. The existence of authorized but unissued shares of common stock and preferred stock could render more difficult or discourage an attempt to obtain control of a majority of our common stock by means of a proxy contest, tender offer, merger or otherwise. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Stockholder Meetings </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any action to be taken by our stockholders must be effected at a duly called annual or special meeting of stockholders and not be taken by written consent. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Requirements for Advance Notification of Stockholder Nominations and Proposals </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stockholders seeking to present proposals before a meeting of stockholders or to nominate candidates for election as directors at a meeting of stockholders must provide advance notice in writing, and also specify requirements as to the form and content of a stockholder&#8217;s notice. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Delaware Anti-Takeover Statute </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are subject to Section 203 of the DGCL, which prohibits persons deemed to be &#8220;interested stockholders&#8221; from engaging in a &#8220;business combination&#8221; with a publicly held Delaware corporation for three years following the date these persons become interested stockholders unless the business combination is, or the transaction in which the person became an interested stockholder was, approved in a prescribed manner or another prescribed exception applies. Generally, an &#8220;interested stockholder&#8221; is a person who, together with affiliates and associates, owns, or within three years prior to the determination of interested stockholder status did own, 15% or more of a corporation&#8217;s voting stock. Generally, a &#8220;business combination&#8221; includes a merger, asset or stock sale, or other transaction resulting in a financial benefit to the interested stockholder. The existence of this provision may have an anti-takeover effect with respect to transactions not approved in advance by the board of directors. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Choice of Forum </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Court of Chancery of the State of Delaware is the exclusive forum in which we and our directors may be sued by our stockholders, to the fullest extent permitted by law, for: any derivative action or proceeding brought on our behalf&#894; any action asserting a breach of fiduciary duty&#894; any action asserting a claim against us arising pursuant to the Delaware General Corporation Law, our certificate of incorporation, or our bylaws&#894; or any action asserting a claim against us that is governed by the internal affairs doctrine. Our bylaws will not apply to suits brought to enforce a duty or liability created by the Securities Act or the Exchange Act, or any other claim for which federal courts have exclusive jurisdiction. Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all suits brought to enforce any duty or liability created by the Securities Act or the rules and regulations thereunder. These choice of forum provisions may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or any of our directors, officers, or other employees, which may discourage lawsuits with respect to such claims. Alternatively, if a court were to find either choice of forum provision contained in our bylaws to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could harm our business, results of operations, and financial condition. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">139</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><font style="font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Advance Notice Requirements </font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our amended and restated bylaws, as amended to become effective upon the completion of this offering, establish an advance notice procedure for stockholder proposals to be brought before an annual meeting of our stockholders, including proposed nominations of persons for election to the board of directors. Stockholders at an annual meeting will only be able to consider proposals or nominations specified in the notice of meeting or brought before the meeting by or at the direction of the board of directors or by a stockholder who was a stockholder of record on the record date for the meeting, who is entitled to vote at the meeting and who has given our Secretary timely written notice, in proper form, of the stockholder&#8217;s intention to bring that business before the meeting. Although our amended and restated bylaws do not give the board of directors the power to approve or disapprove stockholder nominations of candidates or proposals regarding other business to be conducted at a special or annual meeting, our bylaws may have the effect of precluding the conduct of certain business at a meeting if the proper procedures are not followed or may discourage or deter a potential acquirer from conducting a solicitation of proxies to elect its own slate of directors or otherwise attempting to obtain control of us. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Warrants</p>
<p style="margin-top:10pt;margin-bottom:8pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the sale of certain shares of our common stock to certain investors in October and November 2019, we issued to each such investors warrants as a buy-one-share, get-one-warrant arrangement. Each warrant is exercisable at an exercise price of $1.80 per share, and expire at the earlier of a change of control, or IPO or seven years from the issuance date. As of April 26, 2022, there are 442,501 of these warrants that are currently outstanding and exercisable. </p>
<p style="margin-top:10pt;margin-bottom:8pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During 2020, we issued warrants to certain consultants for services rendered during the year, 90,000 of these warrants have an exercise price of $1.80 per share and 20,520 of these warrants have an exercise price of $5.00 per share. These warrants expire at the earlier of a change of control, or an IPO, or various dates through December 2027. As of April 26, 2022, all of these warrants are currently outstanding and exercisable.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finally, in connection with the sale of certain of our outstanding convertible promissory notes in 2020 and 2021, we issued to each such lender warrants equal to that number of shares of common stock as determined by multiplying the number of shares which would be issuable upon conversion of such note by 50%, for a total of 686,489 warrants at an exercise price of $6.00 per share. As of April 26, 2022, 681,985 of these warrants are outstanding and shall expire on the earlier of the occurrence of a change of control or<font style="color:#FF0000;"> </font>September 2028.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Subsequent Event</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2022, the Company and certain warrant holders executed waivers related to the acceptance and approval of an amendment to the holders' warrant agreements originally issued between May 6, 2020 and February 26, 2021 in connection with the Company&#8217;s issuance of convertible notes. The amendment will remove the IPO expiration provision from the warrant agreements, and the warrants shall only be exercisable, in whole or in part, during the exercise period ending on earliest to occur of: (a) various dates in 2028 as stated within the warrant agreements; or (b) immediately prior to the closing of a change of control.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Crossover Round</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the First Quarter of 2022, we completed a crossover round with certain investors (the &#8220;Crossover Investors&#8221;) consisting of sales of our common stock at a price of $9.00 per share (&#8220;Crossover Price), in the aggregate amount of approximately $2.4 million (the &#8220;Crossover Round&#8221;). In connection with the Crossover Round, in the event that the price per share of common stock sold in this offering (the &#8220;IPO Share Price&#8221;) is less than the Crossover Price, then we plan to issue to the Crossover Investors, so long as such Crossover Investors continue to hold such common stock, that number of additional shares of our common stock such that the Crossover Price is equal to the IPO Share Price (the &#8220;Ratchet Shares&#8221;).</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Transfer Agent and Registrar </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The transfer agent and registrar for our common stock is Computershare Inc. The transfer agent and registrar&#8217;s address is Computershare Trust Company, N.A.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">National Securities Exchange Listing </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have applied to have our shares of common stock listed on the Nasdaq under the symbol &#8220;MAIA.&#8221; </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">140</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p><a name="_AEIOULastRenderedPageBreakAEIOU21"></a>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="SHARES_ELIGIBLE_FOR_FUTURE_SALE"></a><a name="SHARES_ELIGIBLE_FOR_FUTURE_SALE"></a>SHARES ELIGIBLE FOR FUTURE SALE</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Immediately prior to this offering, there was no public market for our common stock. Future sales of substantial amounts of common stock in the public market, or the perception that such sales may occur, could adversely affect the market price of our common stock.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;Upon the closing of this offering, we will have outstanding an aggregate of&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock, assuming the issuance of&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock offered by us in this offering, no exercise of options after&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , 2022, and&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock issuable to the Crossover Investors.&#8221; Of these shares, all shares sold in this offering will be freely tradable without restriction or further registration under the Securities Act, except for any shares purchased by our &#8220;affiliates,&#8221; as that term is defined in Rule 144 under the Securities Act, whose sales would be subject to the Rule 144 resale restrictions described below, other than the holding period requirement. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The remaining&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock will be &#8220;restricted securities,&#8221; as that term is defined in Rule 144 under the Securities Act. These restricted securities are eligible for public sale only if they are registered under the Securities Act or if they qualify for an exemption from registration under Rules 144 or 701 under the Securities Act, which are summarized below. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Lock-Up Agreements</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We, each of our officers, directors, and certain of our stockholders have agreed, subject to certain exceptions, not to offer, pledge, sell, contract to sell, grant, lend, or otherwise transfer or dispose of, directly or indirectly, or enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of any shares of our capital stock or any securities convertible into or exercisable or exchangeable for shares of our common stock, for a period of 12 months after the date of this prospectus, without the prior written consent of the representative. Certain of our other stockholders, who are not insiders, have agreed, subject to certain exceptions, not offer, pledge, sell, contract to sell, grant, lend, or otherwise transfer or dispose of, directly or indirectly, or enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of any shares of our capital stock or any securities convertible into or exercisable or exchangeable for shares of our common stock, for a period of 6 months (or in the case of options with a weighted average exercise price of $1.80 or $1.83, for a period of 12 months) after the date of this prospectus, without the prior written consent of the representative. Following the expiration of the applicable lock-up period, all of the issued and outstanding shares of our common stock will be eligible for future sale, subject to the applicable volume, manner of sale, holding period, and other limitations of Rule 144. See the section of this prospectus entitled &#8220;Underwriting&#8221; for additional information. Following the expiration of the applicable lock-up period, all of the issued and outstanding shares of our common stock will be eligible for future sale, subject to the applicable volume, manner of sale, holding period, and other limitations of Rule 144. See &#8220;Underwriting&#8221; for additional information.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Rule 144</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Affiliate Resales of Restricted Securities</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In general, beginning 90 days after the effective date of the registration statement of which this prospectus is a part, a person who is an affiliate of ours, or who was an affiliate at any time during the 90 days before a sale, who has beneficially owned shares of our common stock for at least six months would be entitled to sell in &#8220;broker&#8217;s transactions&#8221; or certain &#8220;riskless principal transactions&#8221; or to market makers, a number of shares within any three-month period that does not exceed the greater of: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">1% of the number of shares of our common stock then outstanding, which will equal approximately shares immediately after this offering&#894; or</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">the average weekly trading volume in our common stock on Nasdaq during the four calendar weeks preceding the filing of a notice on Form 144 with respect to such sale.</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">141</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Affiliate resales under Rule 144 are also subject to the availability of current public information about us. In addition, if the number of shares being sold under Rule 144 by an affiliate during any three-month period exceeds 5,000 shares or has an aggregate sale price in excess of $50,000, the seller must file a notice on Form 144 with the SEC and Nasdaq concurrently with either the placing of a sale order with the broker or the execution directly with a market maker.</font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Non-Affiliate Resales of Restricted Securities</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In general, beginning 90 days after the effective date of the registration statement of which this prospectus is a part, a person who is not an affiliate of ours at the time of sale, and has not been an affiliate at any time during the nine months preceding a sale, and who has beneficially owned shares of our common stock for at least six months but less than a year, is entitled to sell such shares subject only to the availability of current public information about us. If such person has held our shares for at least one year, such person can resell under Rule 144(b)(1) without regard to any Rule 144 restrictions, including the 90-day public company requirement and the current public information requirement. Non-affiliate resales are not subject to the manner of sale, volume limitation or notice filing provisions of Rule 144.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Rule 701</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In general, under Rule 701, any of an issuer&#8217;s employees, directors, officers, consultants or advisors who purchases shares from an issuer in connection with a compensatory stock or option plan or other written agreement before the effective date of a registration statement under the Securities Act is entitled to sell such shares 90 days after such effective date in reliance on Rule 144. An affiliate of the issuer can resell shares in reliance on Rule 144 without having to comply with the holding period requirement, and non-affiliates of the issuer can resell shares in reliance on Rule 144 without having to comply with the current public information and holding period requirements.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The SEC has indicated that Rule 701 will apply to typical stock options granted by an issuer before it becomes subject to the reporting requirements of the Exchange Act, along with the shares acquired upon exercise of such options, including exercises after an issuer becomes subject to the reporting requirements of the Exchange Act.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Equity Plans</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We intend to file one or more registration statements on Form S-8 under the Securities Act to register all shares of common stock subject to outstanding stock options and common stock issued or issuable under our stock plans. We expect to file the registration statement covering shares offered pursuant to our stock plans shortly after the date of this prospectus, permitting the resale of such shares by non-affiliates in the public market without restriction under the Securities Act and the sale by affiliates in the public market, subject to compliance with the resale provisions of Rule 144.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">142</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p><a name="_AEIOULastRenderedPageBreakAEIOU22"></a>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="MATERIAL_US_FEDERAL_INCOME_TAX_CONSEQUEN"></a><a name="MATERIAL_US_FEDERAL_INCOME_TAX_CONSEQUEN"></a>MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES FOR NON-U.S. HOLDERS</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following summary sets forth below certain material U.S. federal income tax consequences for Non-U.S. Holders (as defined below) of common stock as of the date hereof. This summary is based upon the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;), the regulations promulgated by the U.S. Treasury Department, current administrative interpretations and practices of the U.S. Internal Revenue Service (the &#8220;IRS&#8221;) and judicial decisions, all as currently in effect as of the date hereof and all of which are subject to differing interpretations or change, possibly with retroactive effect. No assurance can be given that the IRS will not assert, or that a court will not sustain a position contrary to any of the tax considerations described below. This summary does not discuss all aspects of U.S. federal income taxation that may be relevant to particular holders in light of their particular circumstances, and does not address the U.S. federal income tax consequences to holders that are subject to special tax rules, including, without limitation: financial institutions, insurance companies, mutual funds, pension plans, S corporations, controlled foreign corporations, broker-dealers, traders in securities that elect mark-to-market treatment, regulated investment companies, real estate investment trusts, partnerships and their partners, tax-exempt organizations (including private foundations), investors that hold common stock as part of a &#8220;straddle,&#8221; &#8220;hedge,&#8221; &#8220;conversion,&#8221; &#8220;synthetic security,&#8221; &#8220;constructive ownership transaction,&#8221; &#8220;constructive sale&#8221; or other integrated transaction for U.S. federal income tax purposes, holders subject to the alternative minimum tax provisions of the Code, holders who acquired common stock directly or indirectly in connection with performance of services, pursuant to an exercise of employee options, in connection with employee incentive plans or otherwise as compensation, the Sponsor and its affiliates, persons who actually or constructively own 5% or more (by vote or value) of the common stock, persons required to accelerate the recognition of any item of gross income with respect to common stock as a result of such income being recognized on an applicable financial statement, and U.S. expatriates, all of whom may be subject to tax rules that differ materially from those summarized below. In addition, this summary does not discuss any state, local, or non-United States tax considerations, any non-income tax (such as gift or estate tax) considerations, the alternative minimum tax, the Medicare tax on certain net investment income, or any tax reporting obligations in respect of the ownership of common stock. This summary is limited to holders that hold common stock as &#8220;capital assets&#8221; (generally, property held for investment) under the Code.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If a partnership (including an entity or arrangement treated as a partnership for U.S. federal income tax purposes) holds common stock, the tax treatment of a partner in such partnership will generally depend upon the status of the partner, the activities of the partnership and the partner and certain determinations made at the partner level. If you are a partner of a partnership holding common stock, you are urged to consult your tax advisor.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For purposes of this discussion, a &#8220;Non-U.S. Holder&#8221; is a beneficial owner for U.S. federal income tax purposes of common stock that is not any of the following:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">an individual who is a United States citizen or resident of the United States;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">a corporation (including an entity treated as a corporation for U.S. federal income tax purposes) created or organized in or under the laws of the United States, any state thereof or the District of Columbia;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">an estate, the income of which is includible in gross income for U.S. federal income tax purposes regardless of its source; or</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">a trust (i) the administration of which is subject to the primary supervision of a United States court and which has one or more United States persons (within the meaning of the Code) who have the authority to control all substantial decisions of the trust or (ii) that has in effect a valid election under applicable Treasury regulations to be treated as a United States person.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gain on Sale, Taxable Exchange, or Other Taxable Disposition of Common Stock </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Subject to the discussions below under &#8220;&#8212;Information Reporting and Backup Withholding&#8221; and &#8220;&#8212; FATCA,&#8221; a Non-U.S. Holder generally will not be subject to U.S. federal income or withholding tax in respect of gain recognized on a taxable disposition of its common stock, unless:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">the gain is effectively connected with the conduct of a trade or business by the Non-U.S. Holder within the United States (and, under certain income tax treaties, is attributable to a United States permanent establishment or fixed base maintained by the Non-U.S. Holder), in which case, a non&#8209;corporate Non&#8209;U.S. Holder will be subject to tax on the net gain derived from the sale under regular graduated U.S. federal </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">143</a></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">income tax rates, and a corporate Non-U.S. Holder may be subject to an additional branch profits tax at a 30% rate (or lower rate as may be specified by an applicable income tax treaty);</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">the Non-U.S. Holder is an individual who is present in the United States for 183 days or more in the taxable year in which the disposition takes place and certain other conditions are met, in which case the Non-U.S. Holder will generally be subject to a 30% tax on the individual&#8217;s net capital gain for the year; or</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">the Company or has been a &#8220;United States real property holding corporation&#8221; for U.S. federal income tax purposes at any time during the shorter of the five-year period ending on the date of disposition or the period that the Non-U.S. Holder held common stock, and, in the case where shares of common stock are regularly traded on an established securities market, the Non-U.S. Holder has owned, directly or constructively, more than 5% of the common stock at any time within the shorter of the five-year period preceding the disposition or such Non-U.S. Holder&#8217;s holding period for the shares of common stock.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">With respect to the third bullet point above (if applicable to a particular Non-U.S. Holder), gain recognized by such Non-U.S. Holder on the sale, exchange or other disposition of common stock will be subject to tax at generally applicable U.S. federal income tax rates. There can be no assurance that the common stock will be treated as regularly traded on an established securities market for this purpose. The Company does not believe that it is or has been a United States real property holding corporation for U.S. federal income tax purposes but there can be no assurance in this regard. The Company would be classified as a United States real property holding corporation if the fair market value of its &#8220;United States real property interests&#8221; equals or exceeds 50% of the sum of the fair market value of its worldwide real property interests plus its other assets used or held for use in a trade or business, as determined for U.S. federal income tax purposes.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Taxation of Distributions </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Subject to the discussions below under &#8220;&#8212;Information Reporting and Backup Withholding&#8221; and &#8220;&#8212; FATCA,&#8221; in general, any distributions the Company makes to a Non-U.S. Holder on shares of common stock, to the extent paid out of the Company&#8217;s current or accumulated earnings and profits (as determined under U.S. federal income tax principles), will constitute dividends for U.S. federal income tax purposes and, provided such dividends are not effectively connected with the Non-U.S. Holder&#8217;s conduct of a trade or business within the United States (and, under certain income tax treaties, attributable to a United States permanent establishment or fixed base maintained by the Non-U.S. Holder), the applicable withholding agent will be required to withhold tax from the gross amount of the dividend at a rate of 30%, unless such Non-U.S. Holder is eligible for a reduced rate of withholding tax under an applicable income tax treaty and provides proper certification of its eligibility for such reduced rate. Any distribution not constituting a dividend will be treated first as reducing (but not below zero) the Non-U.S. Holder&#8217;s adjusted tax basis in its shares of common stock (and, subject to the discussion below under &#8220;&#8212;Information Reporting and Backup Withholding&#8221; and &#8220;&#8212; FATCA,&#8221; and the third bullet point above under &#8220;&#8212;Gain on Sale, Taxable Exchange or Other Taxable Disposition of common stock,&#8221; to the extent such distribution does not exceed the adjusted tax basis, such amount will generally not be subject to withholding) and, to the extent such distribution exceeds the Non-U.S. Holder&#8217;s adjusted tax basis, as gain realized from the sale or other disposition of common stock, which will be treated as described above under &#8220;&#8212;Gain on Sale, Taxable Exchange or Other Taxable Disposition of Common Stock.&#8221; In addition, if the Company determines that it is classified as a United States real property holding corporation, it will withhold 15% of any distribution that exceeds the Company&#8217;s current and accumulated earnings and profits.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dividends the Company pays to a Non-U.S. Holder that are effectively connected with such Non-U.S. Holder&#8217;s conduct of a trade or business within the United States (and, under certain income tax treaties, attributable to a United States permanent establishment or fixed base maintained by the Non-U.S. Holder), generally will not be subject to U.S. federal withholding tax, provided such Non-U.S. Holder complies with certain certification and disclosure requirements. Instead, such dividends generally will be subject to U.S. federal income tax, net of certain deductions, at the same graduated individual or corporate rates applicable to United States persons as defined under the Code (subject to an exemption or reduction in such tax as may be provided by an applicable income tax treaty). If the Non-U.S. Holder is a corporation, dividends that are effectively connected income may also be subject to an additional &#8220;branch profits tax&#8221; at a rate of 30% (or such lower rate as may be specified by an applicable income tax treaty).</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">144</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Information Reporting and Backup Withholding</font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company generally must report annually to the IRS and to each Non&#8209;U.S. Holder the amount of dividends paid to such holder and the tax withheld with respect to such dividends, regardless of whether withholding was required. A Non-U.S. Holder may have to comply with certification procedures to establish that it is not a United States person in order to avoid information reporting and backup withholding requirements. The certification procedures required to claim a reduced rate of withholding under an applicable income tax treaty generally will satisfy a Non-U.S. Holder&#8217;s certification requirements necessary to avoid backup withholding as well. Backup withholding is not an additional tax. Any amounts withheld under the backup withholding rules will generally be allowed as a refund or a credit against a Non-U.S. Holders U.S. federal income tax liability provided the required information is timely furnished to the IRS. Holders should consult their tax advisors regarding the application of information reporting and backup withholding to them.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FATCA</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under sections 1471 to 1474 of the Code, commonly referred to as the Foreign Account Tax Compliance Act (&#8220;FATCA&#8221;), a 30% withholding tax generally applies with respect to certain payments on and, subject to the regulatory relief described below, gross proceeds from a sale or disposition of, common stock if paid to (i) a foreign financial institution (as the beneficial owner or as an intermediary for the beneficial owner), unless such institution (a) enters into, and is in compliance with, a withholding and information reporting agreement with the U.S. government to collect and provide to the U.S. tax authorities substantial information regarding U.S. account holders of such institution (which would include certain equity and debt holders of such institution, as well as certain account holders that are foreign entities with U.S. owners) or (b) is a resident in a country that has entered into an intergovernmental agreement with the United States in relation to such withholding and information reporting and the financial institution complies with the related information reporting requirements of such country or (ii) a foreign entity that is not a financial institution (as the beneficial owner or as an intermediary for the beneficial owner), unless such entity provides the withholding agent with a certification identifying the substantial United States owners of the entity, which generally includes any United States person who directly or indirectly owns more than 10% of the entity, or such entity otherwise qualifies for an exemption from these rules. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">An intergovernmental agreement between the United States and the applicable foreign country, or future U.S. Treasury regulations or other guidance, may modify these requirements. Under proposed U.S. Treasury regulations that may be relied upon pending finalization, the withholding tax on gross proceeds would be eliminated and, consequently, FATCA withholding on gross proceeds is not expected to apply unless such proposed U.S. Treasury regulations are modified, withdrawn or replaced in a manner that would subject gross proceeds to FATCA withholding. Non-U.S. Holders should consult their tax advisors regarding the possible implications of such withholding tax.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NON-U.S. HOLDERS OF COMMON STOCK ARE URGED TO CONSULT THEIR TAX ADVISORS CONCERNING THE U.S. FEDERAL, STATE, LOCAL, AND FOREIGN INCOME AND OTHER TAX CONSEQUENCES THEREOF.</p><a name="_AEIOULastRenderedPageBreakAEIOU23"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">145</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="UNDERWRITING"></a><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="UNDERWRITING"></a>UNDERW</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">RITING</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ThinkEquity LLC is acting as representative of the underwriters of this offering. Subject to the terms and conditions of an underwriting agreement between us and the representative, we have agreed to sell to each underwriter named below, and each underwriter named below has severally agreed to purchase, at the public offering price less the underwriting discounts set forth on the cover page of this prospectus, the number of shares of common stock listed next to its name in the following table:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Underwriter</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.82%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ThinkEquity LLC</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.82%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The underwriters are committed to purchase all shares offered by us other than those covered by the over-allotment option described below, if any are purchased. The obligations of the underwriters may be terminated upon the occurrence of certain events specified in the underwriting agreement. Furthermore, pursuant to the underwriting agreement, the underwriters&#8217; obligations are subject to customary conditions, representations and warranties contained in the underwriting agreement, such as receipt by the underwriters of officers&#8217; certificates and legal opinions.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The underwriters are offering the shares subject to prior sale, when, as and if issued to and accepted by them, subject to approval of legal matters by their counsel, and other conditions. The underwriters reserve the right to withdraw, cancel or modify offers to the public and to reject orders in whole or in part.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The underwriters propose to offer the shares offered by us to the public at the public offering price set forth on the cover of the prospectus. After the shares are released for sale to the public, the underwriters may change the offering price and other selling terms at various times.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Over-Allotment Option</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have granted the underwriters an over-allotment option. This option, which is exercisable for up to 45 days after the date of this prospectus, permits the representative to purchase a maximum of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;  additional shares of common stock (15% of the shares sold in this offering) from us to cover over-allotments, if any. If the representative exercises all or part of this option, it will purchase shares covered by the option at the initial public offering price per share that appears on the cover page of this prospectus, less the underwriting discount. If this option is exercised in full, the total offering price to the public will be $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and the total net proceeds, before expenses, to us will be $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Discount</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table shows the initial public offering price, underwriting discounts and proceeds, before expenses, to us. The information assumes either no exercise or full exercise by the underwriters of their over-allotment option.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Per Share</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total&#160;Without</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Over-&#160;Allotment</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Option</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total&#160;With</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Over-&#160;Allotment</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Option</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Initial public offering price</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Underwriting discount (7.5%)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds, before expense, to us</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have agreed to pay a non-accountable expense allowance to the underwriters equal to 1.0% of the gross proceeds received in this offering (excluding proceeds received from exercise of the underwriters&#8217; over-allotment option).</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">146</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have paid an expense deposit of $5</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,000 to the representative for out-of-pocket-accountable expenses, which will be returned to us to the extent such out-of-pocket accountable expenses are not actually incurred in accordance with FINRA Rule 5110(f)(2)(C).</font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, we have agreed to reimburse the representative for (i) fees and expenses of legal counsel to the underwriters in an amount not to exceed $125,000; (ii) fees and expenses related to the use of Ipreo&#8217;s book building, prospectus tracking and compliance software for the offering in the amount of $29,500; (iii) up to $10,000 for background checks of our officers and directors; (iv) up to $10,000 for all fees, expenses and disbursements relating to the registration, qualification or exemption of such shares under the securities laws of such foreign jurisdictions as the Representative may reasonably designate; (iv) up to $10,000 for all fees, expenses and disbursements relating to the registration, qualification or exemption of such shares under the &#8220;blue sky&#8221; securities laws of such states, if applicable, and other jurisdictions as the Representative may reasonably designate; (v) $10,000 for data services and communications expenses; (vi) $3,000 for the costs associated with bound volumes of the public offering materials as well as commemorative mementos and lucite tombstones; (vii) up to $10,000 for actual accountable &#8220;road show&#8221; expenses; and (viii) up to $30,000 for market making and trading, and clearing firm settlement expenses for the offering.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We estimate that the total expenses of the offering payable by us, excluding the total underwriting discount and non-accountable expense allowance, will be approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Representative&#8217;s Warrants</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have agreed to issue to the representative or its designees warrants to purchase up to a total of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock (5% of the aggregate number of shares of common stock sold in this offering) (the &#8220;Representative&#8217;s Warrants&#8221;). The Representative&#8217;s Warrants will be exercisable at a per share exercise price equal to 125% of the public offering price per share of the shares of common stock sold in this offering. The Representative&#8217;s Warrants are exercisable at any time, from time to time, in whole or in part, during the four and one half year period commencing six months from the effective date of the registration statement related to this offering.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Representative&#8217;s Warrants and the shares of common stock underlying the Representative&#8217;s Warrants have been deemed compensation by FINRA and are, therefore, subject to a 180-day lock-up pursuant to FINRA Rule 5110(g)(1). The Representative or permitted assignees under such rule may not sell, transfer, assign, pledge, or hypothecate the Representative&#8217;s Warrants or the securities underlying the Representative&#8217;s Warrants, nor will the representative engage in any hedging, short sale, derivative, put, or call transaction that would result in the effective economic disposition of the Representative&#8217;s Warrants or the underlying shares of common stock for a period of 180 days from the effective date of the registration statement. Additionally, the Representative&#8217;s Warrants may not be sold, transferred, assigned, pledged, or hypothecated for a 180-day period following the effective date of the registration statement, except to any underwriter and selected dealer participating in the offering and their bona fide officers or partners. The Representative&#8217;s Warrants will provide for adjustment in the number and price of the Representative&#8217;s Warrants and the shares of common stock underlying the Representative&#8217;s Warrants in the event of recapitalization, merger, stock split, or other structural transaction, or a future financing undertaken by us. The Representative&#8217;s Warrants will provide for registration rights (including a one-time demand registration right and unlimited piggyback rights) consistent with FINRA Rule 5110.05. The demand for registration may be made at any time beginning on the initial exercise date of the Representative&#8217;s Warrants and expiring on the fifth anniversary of the effective date of this registration statement in accordance with FINRA Rule 5110(g)(8)(C). In addition to the one-time demand registration right, the Representative&#8217;s Warrants shall have unlimited piggyback rights, for a period of no more than two years from the initial exercise date of the Representative&#8217;s Warrants in accordance with FINRA Rule 5110(g)(8)(D). The Representative&#8217;s Warrants will also provide for customary anti-dilution provisions (for stock dividends and splits and recapitalizations) consistent with FINRA Rule 5110, and further, the number of shares underlying the Representative&#8217;s Warrants shall be reduced if necessary to comply with FINRA rules and regulations.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Discretionary Accounts</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The underwriters do not intend to confirm sales of the securities offered hereby to any accounts over which they have discretionary authority.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">147</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Lock-Up Agreements</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We, each of our officers, directors, and certain of our stockholders have agreed, subject to certain exceptions, not to offer, pledge, sell, contract to sell, grant, lend, or otherwise transfer or dispose of, directly or indirectly, or enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of any shares of our capital stock or any securities convertible into or exercisable or exchangeable for shares of our common stock, for a period of 12 months after the date of this prospectus, without the prior written consent of the representative. Certain of our other stockholders, who are not insiders, have agreed, subject to certain exceptions, not offer, pledge, sell, contract to sell, grant, lend, or otherwise transfer or dispose of, directly or indirectly, or enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of any shares of our capital stock or any securities convertible into or exercisable or exchangeable for shares of our common stock, for a period of 6 months (or in the case of options with a weighted average exercise price of $1.80 or $1.83, for a period of 12 months) after the date of this prospectus, without the prior written consent of the representative. Following the expiration of the applicable lock-up period, all of the issued and outstanding shares of our common stock will be eligible for future sale, subject to the applicable volume, manner of sale, holding period, and other limitations of Rule 144. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Right of First Refusal</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Underwriting Agreement will provide that for a period of fifteen (15) months from the closing of the offering, we will grant the representative an irrevocable right of first refusal to act as a sole investment banker, sole book-runner, sole financial advisor, sole underwriter and/or sole placement agent, at the representative&#8217;s sole discretion, for each and every future public and private equity and debt offering, including all equity linked financings, during such fifteen (15) month period for us, or any successor to or any subsidiary of us, on terms customary to the representative. The representative has the sole right to determine whether or not any other broker dealer shall have the right to participate in any such offering and the economic terms of any such participation.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Indemnification</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To the extent permitted by law, we have agreed to indemnify the underwriters and its affiliates, stockholders, directors, officers, employees, members and controlling persons against certain liabilities, including liabilities under the Securities Act, and to contribute to payments that the underwriters may be required to make for these liabilities.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Electronic Offer, Sale and Distribution of Shares</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A prospectus in electronic format may be made available on the websites maintained by one or more underwriters or selling group members, if any, participating in this offering and one or more of the underwriters participating in this offering may distribute prospectuses electronically. The representative may agree to allocate a number of shares to underwriters and selling group members for sale to their online brokerage account holders. Internet distributions will be allocated by the underwriters and selling group members that will make internet distributions on the same basis as other allocations. Other than the prospectus in electronic format, the information on the underwriters&#8217; websites is not part of, nor incorporated by reference into, this prospectus or the registration statement of which this prospectus forms a part, has not been approved or endorsed by us or any underwriter in its capacity as underwriter, and should not be relied upon by investors.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stabilization</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with this offering, the underwriters may engage in stabilizing transactions, over-allotment transactions, syndicate-covering transactions, penalty bids and purchases to cover positions created by short sales.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stabilizing transactions permit bids to purchase securities so long as the stabilizing bids do not exceed a specified maximum and are engaged in for the purpose of preventing or retarding a decline in the market price of the securities while the offering is in progress.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Over-allotment transactions involve sales by the underwriters of securities in excess of the number of securities that underwriters are obligated to purchase. This creates a syndicate short position which may be either a covered short position or a naked short position. In a covered short position, the number of securities over-allotted by the </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">148</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:10pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">underwriters is not greater than the number of securities that they may purchase in the over-allotment option. In a naked short position, the number of securities involved is greater than the number of securities in the over-allotment option. The underwriters may close out any short position by exercising their over-allotment option and/or purchasing securities in the open market.</font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Syndicate covering transactions involve purchases of securities in the open market after the distribution has been completed in order to cover syndicate short positions. In determining the source of securities to close out the short position, the underwriters will consider, among other things, the price of securities available for purchase in the open market as compared with the price at which they may purchase securities through exercise of the over-allotment option. If the underwriters sell more securities than could be covered by exercise of the over-allotment option and, therefore, have a naked short position, the position can be closed out only by buying securities in the open market. A naked short position is more likely to be created if the underwriters are concerned that after pricing there could be downward pressure on the price of the securities in the open market that could adversely affect investors who purchase in the offering.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Penalty bids permit the representative to reclaim a selling concession from a syndicate member when the securities originally sold by that syndicate member are purchased in stabilizing or syndicate covering transactions to cover syndicate short positions.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These stabilizing transactions, syndicate covering transactions and penalty bids may have the effect of raising or maintaining the market price of our securities or preventing or retarding a decline in the market price of our securities. As a result, the price of our securities in the open market may be higher than it would otherwise be in the absence of these transactions. Neither we nor the underwriters make any representation or prediction as to the effect that the transactions described above may have on the price of our securities. These transactions may be effected on the Nasdaq, in the over-the-counter market or otherwise and, if commenced, may be discontinued at any time.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Passive Market Making</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with this offering, underwriters and selling group members may engage in passive market making transactions in our common stock on the Nasdaq or on the OTCQB in accordance with Rule 103 of Regulation M under the Exchange Act, during a period before the commencement of offers or sales of the securities and extending through the completion of the distribution. A passive market maker must display its bid at a price not in excess of the highest independent bid of that security. However, if all independent bids are lowered below the passive market maker&#8217;s bid, then that bid must then be lowered when specified purchase limits are exceeded.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Other Relationships</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain of the underwriters and their affiliates may provide in the future, various advisory, investment and commercial banking and other services to us in the ordinary course of business, for which they may receive customary fees and commissions. However, we have not yet had, and have no present arrangements with any of the underwriters for any further services.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Offer restrictions outside the United States</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other than in the United States, no action has been taken by us or the underwriters that would permit a public offering of the securities offered by this prospectus in any jurisdiction where action for that purpose is required. The securities offered by this prospectus may not be offered or sold, directly or indirectly, nor may this prospectus or any other offering material or advertisements in connection with the offer and sale of any such securities be distributed or published in any jurisdiction, except under circumstances that will result in compliance with the applicable rules and regulations of that jurisdiction. Persons into whose possession this prospectus comes are advised to inform themselves about and to observe any restrictions relating to this offering and the distribution of this prospectus. This prospectus does not constitute an offer to sell or a solicitation of an offer to buy any securities offered by this prospectus in any jurisdiction in which such an offer or a solicitation is unlawful.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Australia</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This prospectus is not a disclosure document under Chapter 6D of the Australian Corporations Act, has not been lodged with the Australian Securities and Investments Commission and does not purport to include the information </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">149</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:10pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">required of a disclosure document under Chapter 6D of the Australian Corporations Act. Accordingly, (i) the offer of the securities under this prospectus is only made to persons to whom it is lawful to offer the securities without disclosure under Chapter 6D of the Australian Corporations Act under one or more exemptions set out in section 708 of the Australian Corporations Act, (ii) this prospectus is made available in Australia only to those persons as set forth in clause (i) above, and (iii) the offeree must be sent a notice stating in substance that by accepting this offer, the offeree represents that the offeree is such a person as set forth in clause (i) above, and, unless permitted under the Australian Corporations Act, agrees not to sell or offer for sale within Australia any of the securities sold to the offeree within 12 months after its transfer to the offeree under this prospectus.</font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">China</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information in this document does not constitute a public offer of the securities, whether by way of sale or subscription, in the People&#8217;s Republic of China (excluding, for purposes of this paragraph, Hong Kong Special Administrative Region, Macau Special Administrative Region and Taiwan). The securities may not be offered or sold directly or indirectly in the PRC to legal or natural persons other than directly to &#8220;qualified domestic institutional investors.&#8221;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">European Economic Area&#8212;Belgium, Germany, Luxembourg and Netherlands</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information in this document has been prepared on the basis that all offers of securities will be made pursuant to an exemption under the Directive 2003/71/EC (&#8220;Prospectus Directive&#8221;), as implemented in Member States of the European Economic Area (each, a &#8220;Relevant Member State&#8221;), from the requirement to produce a prospectus for offers of securities.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">An offer to the public of securities has not been made, and may not be made, in a Relevant Member State except pursuant to one of the following exemptions under the Prospectus Directive as implemented in that Relevant Member State:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">to legal entities that are authorized or regulated to operate in the financial markets or, if not so authorized or regulated, whose corporate purpose is solely to invest in securities;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">to any legal entity that has two or more of (i) an average of at least 250 employees during its last fiscal year; (ii) a total balance sheet of more than &#8364;43,000,000 (as shown on its last annual unconsolidated or consolidated financial statements) and (iii) an annual net turnover of more than &#8364;50,000,000 (as shown on its last annual unconsolidated or consolidated financial statements);</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">to fewer than 100 natural or legal persons (other than qualified investors within the meaning of Article 2(1)(e) of the Prospectus Directive) subject to obtaining the prior consent of the Company or any underwriter for any such offer; or</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">in any other circumstances falling within Article 3(2) of the Prospectus Directive, provided that no such offer of securities shall result in a requirement for the publication by the Company of a prospectus pursuant to Article 3 of the Prospectus Directive.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">France</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This document is not being distributed in the context of a public offering of financial securities (offre au public de titres financiers) in France within the meaning of Article L.411-1 of the French Monetary and Financial Code (Code mon&#233;taire et financier) and Articles 211-1 et seq. of the General Regulation of the French Autorit&#233; des march&#233;s financiers (&#8220;AMF&#8221;). The securities have not been offered or sold and will not be offered or sold, directly or indirectly, to the public in France.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This document and any other offering material relating to the securities have not been, and will not be, submitted to the AMF for approval in France and, accordingly, may not be distributed or caused to distributed, directly or indirectly, to the public in France.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Such offers, sales and distributions have been and shall only be made in France to (i) qualified investors (investisseurs qualifi&#233;s) acting for their own account, as defined in and in accordance with Articles L.411-2-II-2 and </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">150</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:10pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">D.411-1 to D.411-3, D. 744-1, D.754-1 and D.764-1 of the French Monetary and Financial Code and any implementing regulation and/or (ii) a restricted number of non-qualified investors (cercle restreint d&#8217;investisseurs) acting for their own account, as defined in and in accordance with Articles L.411-2-II-2 and D.411-4, D.744-1, D.754-1 and D.764-1 of the French Monetary and Financial Code and any implementing regulation.</font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to Article 211-3 of the General Regulation of the AMF, investors in France are informed that the securities cannot be distributed (directly or indirectly) to the public by the investors otherwise than in accordance with Articles L.411-1, L.411-2, L.412-1 and L.621-8 to L.621-8-3 of the French Monetary and Financial Code.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Ireland</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information in this document does not constitute a prospectus under any Irish laws or regulations and this document has not been filed with or approved by any Irish regulatory authority as the information has not been prepared in the context of a public offering of securities in Ireland within the meaning of the Irish Prospectus (Directive 2003/71/EC) Regulations 2005 (the &#8220;Prospectus Regulations&#8221;). The securities have not been offered or sold, and will not be offered, sold or delivered directly or indirectly in Ireland by way of a public offering, except to (i) qualified investors as defined in Regulation 2(l) of the Prospectus Regulations and (ii) fewer than 100 natural or legal persons who are not qualified investors.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Israel</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The securities offered by this prospectus have not been approved or disapproved by the Israeli Securities Authority (the ISA), or ISA, nor have such securities been registered for sale in Israel. The shares may not be offered or sold, directly or indirectly, to the public in Israel, absent the publication of a prospectus. The ISA has not issued permits, approvals or licenses in connection with this offering or publishing the prospectus; nor has it authenticated the details included herein, confirmed their reliability or completeness, or rendered an opinion as to the quality of the securities being offered. Any resale in Israel, directly or indirectly, to the public of the securities offered by this prospectus is subject to restrictions on transferability and must be effected only in compliance with the Israeli securities laws and regulations.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Italy</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The offering of the securities in the Republic of Italy has not been authorized by the Italian Securities and Exchange Commission (Commissione Nazionale per le Societa e la Borsa, or CONSOB), pursuant to the Italian securities legislation and, accordingly, no offering material relating to the securities may be distributed in Italy and such securities may not be offered or sold in Italy in a public offer within the meaning of Article 1.1(t) of Legislative Decree No. 58 of 24 February 1998 (&#8220;Decree No. 58&#8221;), other than:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">to Italian qualified investors (&#8220;Qualified Investors&#8221;), as defined in Article 100 of Decree no. 58 by reference to Article 34-ter of CONSOB Regulation no. 11971 of 14 May 1999, as amended (&#8220;Regulation no. 1197l&#8221;); and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">in other circumstances that are exempt from the rules on public offer pursuant to Article 100 of Decree No. 58 and Regulation no. 1197l.</font></p></td></tr></table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any offer, sale or delivery of the securities or distribution of any offer document relating to the securities in Italy (excluding placements where a Qualified Investor solicits an offer from the issuer) under the paragraphs above must be:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">made by investment firms, banks or financial intermediaries permitted to conduct such activities in Italy in accordance with Legislative Decree No. 385 of 1 September 1993, as amended, Decree No. 58, CONSOB Regulation No. 16190 of 29 October 2007, and any other applicable laws; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">in compliance with all relevant Italian securities, tax and exchange controls and any other applicable laws.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any subsequent distribution of the securities in Italy must be made in compliance with the public offer and prospectus requirement rules provided under Decree No. 58 and the Regulation No. 11971 as amended, unless an exception from those rules applies. Failure to comply with such rules may result in the sale of such securities being </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">151</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:10pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">declared null and void and in the liability of the entity transferring the securities for any damages suffered by the investors.</font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Japan</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The securities have not been and will not be registered under Article 4, paragraph 1 of the Financial Instruments and Exchange Law of Japan (Law No. 25 of 1948), as amended (the &#8220;FIEL&#8221;) pursuant to an exemption from the registration requirements applicable to a private placement of securities to Qualified Institutional Investors (as defined in and in accordance with Article 2, paragraph 3 of the FIEL and the regulations promulgated thereunder). Accordingly, the securities may not be offered or sold, directly or indirectly, in Japan or to, or for the benefit of, any resident of Japan other than Qualified Institutional Investors. Any Qualified Institutional Investor who acquires securities may not resell them to any person in Japan that is not a Qualified Institutional Investor, and acquisition by any such person of securities is conditional upon the execution of an agreement to that effect.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Portugal</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This document is not being distributed in the context of a public offer of financial securities (oferta p&#250;blica de valores mobili&#225;rios) in Portugal, within the meaning of Article 109 of the Portuguese Securities Code (C&#243;digo dos Valores Mobili&#225;rios). The securities have not been offered or sold and will not be offered or sold, directly or indirectly, to the public in Portugal. This document and any other offering material relating to the securities have not been, and will not be, submitted to the Portuguese Securities Market Commission (Comiss&#259;o do Mercado de Valores Mobili&#225;rios) for approval in Portugal and, accordingly, may not be distributed or caused to distributed, directly or indirectly, to the public in Portugal, other than under circumstances that are deemed not to qualify as a public offer under the Portuguese Securities Code. Such offers, sales and distributions of securities in Portugal are limited to persons who are &#8220;qualified investors&#8221; (as defined in the Portuguese Securities Code). Only such investors may receive this document and they may not distribute it or the information contained in it to any other person.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Sweden</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This document has not been, and will not be, registered with or approved by Finansinspektionen (the Swedish Financial Supervisory Authority). Accordingly, this document may not be made available, nor may the securities be offered for sale in Sweden, other than under circumstances that are deemed not to require a prospectus under the Swedish Financial Instruments Trading Act (1991:980) (Sw. lag (1991:980) om handel med finansiella instrument). Any offering of securities in Sweden is limited to persons who are &#8220;qualified investors&#8221; (as defined in the Financial Instruments Trading Act). Only such investors may receive this document and they may not distribute it or the information contained in it to any other person.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Switzerland</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The securities may not be publicly offered in Switzerland and will not be listed on the SIX Swiss Exchange (&#8220;SIX&#8221;) or on any other stock exchange or regulated trading facility in Switzerland. This document has been prepared without regard to the disclosure standards for issuance prospectuses under art. 652a or art. 1156 of the Swiss Code of Obligations or the disclosure standards for listing prospectuses under art. 27 ff. of the SIX Listing Rules or the listing rules of any other stock exchange or regulated trading facility in Switzerland. Neither this document nor any other offering material relating to the securities may be publicly distributed or otherwise made publicly available in Switzerland.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Neither this document nor any other offering material relating to the securities have been or will be filed with or approved by any Swiss regulatory authority. In particular, this document will not be filed with, and the offer of securities will not be supervised by, the Swiss Financial Market Supervisory Authority (FINMA).</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This document is personal to the recipient only and not for general circulation in Switzerland.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">United Arab Emirates</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Neither this document nor the securities have been approved, disapproved or passed on in any way by the Central Bank of the United Arab Emirates or any other governmental authority in the United Arab Emirates, nor has the Company received authorization or licensing from the Central Bank of the United Arab Emirates or any other governmental authority in the United Arab Emirates to market or sell the securities within the United Arab Emirates. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">152</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:10pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This document does not constitute and may not be used for the purpose of an offer or invitation. No services relating to the securities, including the receipt of applications and/or the allotment or redemption of such shares, may be rendered within the United Arab Emirates by the Company.</font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">No offer or invitation to subscribe for securities is valid or permitted in the Dubai International Financial Centre.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">United Kingdom</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Neither the information in this document nor any other document relating to the offer has been delivered for approval to the Financial Services Authority in the United Kingdom and no prospectus (within the meaning of section 85 of the Financial Services and Markets Act 2000, as amended (&#8220;FSMA&#8221;)) has been published or is intended to be published in respect of the securities. This document is issued on a confidential basis to &#8220;qualified investors&#8221; (within the meaning of section 86(7) of FSMA) in the United Kingdom, and the securities may not be offered or sold in the United Kingdom by means of this document, any accompanying letter or any other document, except in circumstances which do not require the publication of a prospectus pursuant to section 86(1) FSMA. This document should not be distributed, published or reproduced, in whole or in part, nor may its contents be disclosed by recipients to any other person in the United Kingdom.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any invitation or inducement to engage in investment activity (within the meaning of section 21 of FSMA) received in connection with the issue or sale of the securities has only been communicated or caused to be communicated and will only be communicated or caused to be communicated in the United Kingdom in circumstances in which section 21(1) of FSMA does not apply to the Company. In the United Kingdom, this document is being distributed only to, and is directed at, persons (i) who have professional experience in matters relating to investments falling within Article 19(5) (investment professionals) of the Financial Services and Markets Act 2000 (Financial Promotions) Order 2005 (&#8220;FPO&#8221;), (ii) who fall within the categories of persons referred to in Article 49(2)(a) to (d) (high net worth companies, unincorporated associations, etc.) of the FPO or (iii) to whom it may otherwise be lawfully communicated (together &#8220;relevant persons&#8221;). The investments to which this document relates are available only to, and any invitation, offer or agreement to purchase will be engaged in only with, relevant persons. Any person who is not a relevant person should not act or rely on this document or any of its contents.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Canada</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The securities may be sold in Canada only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as defined in National Instrument 45-106 Prospectus Exemptions or subsection 73.3(1) of the Securities Act (Ontario), and are permitted clients, as defined in National Instrument 31-103 Registration Requirements, Exemptions and Ongoing Registrant Obligations. Any resale of the securities must be made in accordance with an exemption from, or in a transaction not subject to, the prospectus requirements of applicable securities laws. Securities legislation in certain provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if this prospectus (including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed by the securities legislation of the purchaser&#8217;s province or territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser&#8217;s province or territory for particulars of these rights or consult with a legal advisor. Pursuant to section 3A.3 of National Instrument 33-105 Underwriting Conflicts (NI 33-105), the underwriters are not required to comply with the disclosure requirements of NI33-105 regarding underwriter conflicts of interest in connection with this offering.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="EXPERTS"></a><a name="EXPERTS"></a>EXPERTS</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The consolidated balance sheets of MAIA Biotechnology, Inc. and Subsidiaries as of December 31, 2021 and 2020, and the related consolidated statements of operations, changes in stockholders&#8217; equity (deficit), and cash flows for each of the years then ended, have been audited by EisnerAmper LLP, independent registered public accounting firm, as stated in their report which is incorporated herein. Such financial statements have been incorporated herein in reliance on the report of such firm given upon their authority as experts in accounting and auditing.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">153</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="LEGAL_MATTERS"></a><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="LEGAL_MATTERS"></a>LEGAL M</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ATTERS</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loeb &amp; Loeb LLP, New York, New York, will pass upon the validity of the shares of common stock offered hereby. Venable, LLP, New York, New York has acted as counsel for the underwriters in connection with certain legal matters related to this offering.</p><a name="_AEIOULastRenderedPageBreakAEIOU24"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">154</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="WHERE_YOU_CAN_FIND_MORE_INFORMATION"></a><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="WHERE_YOU_CAN_FIND_MORE_INFORMATION"></a>WHERE YOU CAN FIND</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> MORE INFORMATION</font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have filed with the SEC a registration statement on Form S-1 under the Securities Act with respect to the securities offered by this prospectus. This prospectus, which constitutes a part of the registration statement, does not contain all the information set forth in the registration statement, some of which is contained in exhibits to the registration statement as permitted by the rules and regulations of the SEC. For further information with respect to us and our common stock, we refer you to the registration statement, including the exhibits filed as a part of the registration statement. Statements contained in this prospectus concerning the contents of any contract or any other document is not necessarily complete. If a contract or document has been filed as an exhibit to the registration statement, please see the copy of the contract or document that has been filed. Each statement is this prospectus relating to a contract or document filed as an exhibit is qualified in all respects by the filed exhibit. You may read and copy the registration statement, the related exhibits and other material we file with the SEC at the SEC&#8217;s public reference room in Washington, D.C. at 100 F Street, Room 1580, N.E., Washington, D.C. 20549. You can also request copies of those documents, upon payment of a duplicating fee, by writing to the SEC. Please call the SEC at 1-800-SEC-0330 for further information on the operation of the public reference rooms. The SEC also maintains an Internet website that contains reports, proxy statements and other information about issuers, like us, that file electronically with the SEC. The address of that website is <font style="text-decoration:underline;">www.sec.gov</font>.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon completion of this offering, we will become subject to the information and reporting requirements of the Securities Exchange Act of 1934, as amended, and, in accordance with this law, will be required to file periodic reports, proxy statements and other information with the SEC. These periodic reports, proxy statements and other information will be available on the website of the SEC referred to above. We also maintain a website at www.maiabiotech.com. Our website and the information contained on, or that can be accessed through, our website is not deemed to be incorporated by reference in, and is not considered part of, this prospectus. You should not rely on any such information in making your decision whether to purchase our common stock.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have not authorized anyone to give you any information or to make any representations about us or the transactions we discuss in this prospectus other than those contained in this prospectus. If you are given any information or representations about these matters that is not discussed in this prospectus, you must not rely on that information. This prospectus is not an offer to sell or a solicitation of an offer to buy securities anywhere or to anyone where or to whom we are not permitted to offer or sell securities under applicable law. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">155</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">MAIA Biotechnology, Inc. and Subsidiaries</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="INDEX_TO_FINANCIAL_STATEMENTS"></a><a name="INDEX_TO_FINANCIAL_STATEMENTS"></a>Index to Financial Statements</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="width:92.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#REPORT_INDEPENDENT_REGISTERED_PUBLIC_ACC"><font style="text-decoration:underline;">Report of Independent Registered Public Accounting Firm, EisnerAmper LLP, Iselin, New Jersey, PCAOB ID 274</font></a></p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="width:7.7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-2</p></td>
</tr>
<tr>
<td valign="top"  style="width:92.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="width:92.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial Statements:</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="width:7.7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:92.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="width:92.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_BALANCE_SHEETS1"><font style="text-decoration:none;">Consolidated Balance Sheets as of December 31, 2021 and 2020</font></a></p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="width:7.7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-3</p></td>
</tr>
<tr>
<td valign="top"  style="width:92.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_STATEMENTS_OPERATIONS"><font style="text-decoration:none;">Consolidated Statements of Operations for the years ended December 31, 2021 and 2020</font></a></p></td>
<td valign="top"  style="width:7.7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-4</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="width:92.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_STATEMENTS_CHANGES_IN_STOCK"><font style="text-decoration:none;">Consolidated Statements of Changes in Stockholders&#8217; Equity (Deficit) for the years ended December 31, 2021 and 2020</font></a></p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:7.7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-5</p></td>
</tr>
<tr>
<td valign="top"  style="width:92.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_STATEMENTS_CASH_FLOWS"><font style="text-decoration:none;">Consolidated Statements of Cash Flows for the years ended December 31, 2021 and 2020</font></a></p></td>
<td valign="top"  style="width:7.7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-7</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="width:92.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#NOTES_TO_CONSOLIDATED_FINANCIAL_STATEMEN"><font style="text-decoration:none;">Notes to Financial Statements</font></a></p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="width:7.7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-8</p></td>
</tr>
<tr>
<td valign="top"  style="width:92.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#FS_BS"><font style="text-decoration:none;">Co</font><font style="text-decoration:underline;">ndensed</font><font style="text-decoration:none;"> Consolidated Balance Sheets as of March 31, 2022 and December 31, 2021</font></a></p></td>
<td valign="top"  style="width:7.7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-28</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="width:92.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#FS_SOP"><font style="text-decoration:none;">Co</font><font style="text-decoration:underline;">ndensed </font><font style="text-decoration:none;">Consolidated Statements of Operations for the three months ended March 31, 2022 and 2021</font></a></p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="width:7.7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F<font style="font-family:Calibri;font-size:11pt;">-</font>29</p></td>
</tr>
<tr>
<td valign="top"  style="width:92.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#0563C1;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONDENSED_CONSOLIDATED_STATEMENTS_COMPRE"><font style="text-decoration:none;">Co</font><font style="text-decoration:underline;">ndensed </font><font style="text-decoration:none;">Consolidated Statements of Comprehensive Loss for the three months ended March 31, 2022 and 2021</font></a></p></td>
<td valign="top"  style="width:7.7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F<font style="font-family:Calibri;font-size:11pt;">-</font>30</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="width:92.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONDENSED_CONSOLIDATED_STATEMENTS_CHANGE"><font style="text-decoration:none;">Co</font><font style="text-decoration:underline;">ndensed </font><font style="text-decoration:none;">Consolidated Statements of Changes in Stockholders&#8217; Equity (Deficit) for the three months ended March 31, 2022 and 2021</font></a></p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:7.7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F<font style="font-family:Calibri;font-size:11pt;">-</font>31</p></td>
</tr>
<tr>
<td valign="top"  style="width:92.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONDENSED_CONSOLIDATED_STATEMENTS_CASH_F"><font style="text-decoration:none;">Co</font><font style="text-decoration:underline;">ndensed </font><font style="text-decoration:none;">Consolidated Statements of Cash Flows for the three months ended March 31, 2022 and 2021</font></a></p></td>
<td valign="top"  style="width:7.7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F<font style="font-family:Calibri;font-size:11pt;">-</font>33</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="width:92.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#NOTES_TO_UNAUDITED_CONDENSED_CONSOLIDATE"><font style="text-decoration:none;">Notes to Financial Statements</font></a></p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="width:7.7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F<font style="font-family:Calibri;font-size:11pt;">-</font>34</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-1</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p><a name="_AEIOULastRenderedPageBreakAEIOU25"></a>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="REPORT_INDEPENDENT_REGISTERED_PUBLIC_ACC"></a><a name="REPORT_INDEPENDENT_REGISTERED_PUBLIC_ACC"></a>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To the Board of Directors and Stockholders of</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MAIA Biotechnology, Inc.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Opinion on the Financial Statements </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have audited the accompanying consolidated balance sheets of MAIA Biotechnology, Inc. and Subsidiaries (the &#8220;Company&#8221;) as of December 31, 2021 and 2020, and the related consolidated statements of operations, changes in stockholders&#8217; equity (deficit), and cash flows for each of the years then ended, and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2021 and 2020, and the results of its operations and its cash flows for each of the years then ended, in conformity with accounting principles generally accepted in the United States of America. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Basis for Opinion </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ EisnerAmper LLP</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have served as the Company&#8217;s auditor since 2021.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EISNERAMPER LLP</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Iselin, New Jersey</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">April 8, 2022</p><a name="_AEIOULastRenderedPageBreakAEIOU26"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-2</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;text-align:center;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">MAIA Biotechnology, Inc. and Subsidiaries</font></p>
<p style="margin-top:0pt;text-align:center;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="CONSOLIDATED_BALANCE_SHEETS1"></a><a name="CONSOLIDATED_BALANCE_SHEETS1"></a>Consolidated Balance Sheets </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ASSETS</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current assets:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,574,292</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">663,457</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses and other current assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">98,203</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">83,048</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current assets</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,672,495</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">746,505</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred offering costs</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">651,582</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other assets</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,122</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,327,199</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">746,505</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current liabilities:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">960,401</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">154,886</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,074,324</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">838,810</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Due to related parties</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,037</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Convertible notes payable - current portion</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,586</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loan payable to officer</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,367</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred compensation</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">111,271</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">661,058</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current liabilities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,145,996</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,693,744</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Convertible notes payable, net of current portion</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">332,841</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Convertible notes payable, related parties</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">98,960</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Derivative liability for embedded conversion features on convertible notes</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; payable and convertible notes payable, related parties</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">127,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrant liability</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85,260</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Simple agreement for future equity payable</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,145,996</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,362,805</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commitments and contingencies</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stockholders' equity (deficit)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preferred stock, $0.0001 par value, 70,000,000 shares authorized, 0 shares</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; issued and outstanding</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock, $0.0001 par value, 30,000,000 shares</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; authorized, 7,584,980 and 4,433,644 shares issued and outstanding at</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; December 31, 2021 and December 31, 2020, respectively</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">758</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">443</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additional paid-in capital</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,618,438</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,599,585</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated deficit</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(28,437,993</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(15,934,113</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock subscription receivable</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,002</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total MAIA Biotechnology, Inc. stockholders' equity (deficit)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,181,203</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,336,087</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Noncontrolling interests</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,719,787</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stockholders' equity (deficit)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,181,203</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,616,300</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities and stockholders' equity (deficit)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,327,199</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">746,505</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See the accompanying notes to the consolidated financial statements.</p><a name="_AEIOULastRenderedPageBreakAEIOU27"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-3</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">MAIA Biotechnology, Inc. and Subsidiaries</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="CONSOLIDATED_STATEMENTS_OPERATIONS"></a><a name="CONSOLIDATED_STATEMENTS_OPERATIONS"></a>Consolidated Statements of Operations</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.3%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Year Ended December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,496,796</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,412,409</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,289,831</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,563,192</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating costs and expenses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,786,627</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,975,601</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7,786,627</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,975,601</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income (expense):</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest expense</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(827,539</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(32,226</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,012</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">679</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Paycheck protection program loan forgiveness</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62,500</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62,500</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Australian research and development incentives</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43,666</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.32%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value of embedded features</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(203,000</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,000</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value of warrant liability</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,546,280</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19,600</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss on extinguishment of convertible notes and convertible notes,</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; related parties</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,322,943</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income (expense), net</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,791,584</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,353</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12,578,211</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,959,248</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to noncontrolling interests</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(74,331</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(322,588</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to MAIA Biotechnology, Inc. shareholders</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12,503,880</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,636,660</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic and diluted net loss per share</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.37</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.50</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average common shares outstanding</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic and diluted</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,278,435</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.32%; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,427,242</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See the accompanying notes to the consolidated financial statements.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-4</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_______"></a>MAIA Biotechnology, Inc. and Subsidiaries</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="CONSOLIDATED_STATEMENTS_CHANGES_IN_STOCK"></a><a name="CONSOLIDATED_STATEMENTS_CHANGES_IN_STOCK"></a>Consolidated Statements of Changes in Stockholders' Equity (Deficit) </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Common Stock</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Additional</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Paid-In</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Subscription</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total MAIA</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Noncontrolling</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stockholders'</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.64%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Capital</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Deficit</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Receivable</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Equity&#160;(Deficit)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Interest</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Equity&#160;(Deficit)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2020</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,433,644</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">443</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,599,585</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(15,934,113</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,002</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,336,087</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,719,787</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,616,300</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common shares upon exercise of stock options</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,999</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common shares upon exercise of warrants</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">283,616</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">529,397</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">529,425</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">529,425</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of restricted common shares</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,278</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,498</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,500</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,500</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cancellation of restricted common shares</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,557</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense - MAIA</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,428,935</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,428,935</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,428,935</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense - DGD</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">161,460</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">161,460</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense - THIO</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104,999</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104,999</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of stock options to satisfy accrued bonus</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">786,531</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">786,531</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">786,531</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of stock options to satisfy deferred compensation</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">285,418</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">285,418</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">285,418</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common shares upon conversion of convertible notes</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,375,228</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">138</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,001,136</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,001,274</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,001,274</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common shares upon conversion of SAFE</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,208</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common shares in connection with Equity Financing</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">772,563</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,180,426</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(320,000</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,860,503</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,860,503</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Receipt of stock subscription receivable</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">322,002</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">322,002</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">322,002</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Transaction costs incurred in connection with Equity Financing</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(118,332</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(118,332</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(118,332</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reclassification of warrant liability to equity</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,952,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,952,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,952,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of restricted common shares to founder pursuant to</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;THIO Merger Agreement</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">700,000</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(70</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dissolution of DGD</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,098,110</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,098,110</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,098,110</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dissolution of THIO pursuant to Merger Agreement</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">813,805</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">813,805</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(813,805</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12,503,880</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12,503,880</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(74,331</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12,578,211</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.64%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2021</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,584,980</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">758</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,618,438</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(28,437,993</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,181,203</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,181,203</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See the accompanying notes to the consolidated financial statements.</p><a name="_AEIOULastRenderedPageBreakAEIOU28"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-5</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">MAIA Biotechnology, Inc. and Subsidiaries</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Consolidated Statements of Changes in Stockholders' Equity (Deficit)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Common Stock</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Additional</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Paid-In</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Subscription</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total MAIA</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Noncontrolling</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stockholders'</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.64%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Capital</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Deficit</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Receivable</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Equity&#160;(Deficit)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Interest</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Equity&#160;(Deficit)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2019</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,416,977</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">442</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,228,546</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9,297,453</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(104,402</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(172,867</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,497,659</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,324,792</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Receipt of stock subscription receivable - MAIA</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">102,400</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">102,400</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">102,400</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Receipt of stock subscription receivable - DGD</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,000</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,000</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of restricted common shares</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,667</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,999</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of DGD common stock</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50,000</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50,000</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense - MAIA</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,351,040</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,351,040</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,351,040</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense - DGD</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">307,928</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">307,928</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense - THIO</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">210,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">210,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Return of capital - DGD</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(58,212</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(58,212</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,636,660</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,636,660</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(322,588</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,959,248</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.64%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2020</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,433,644</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">443</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,599,585</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(15,934,113</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,002</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,336,087</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,719,787</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,616,300</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See the accompanying notes to the consolidated financial statements.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-6</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p><a name="_AEIOULastRenderedPageBreakAEIOU29"></a>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">MAIA Biotechnology, Inc. and Subsidiaries</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="CONSOLIDATED_STATEMENTS_CASH_FLOWS"></a><a name="CONSOLIDATED_STATEMENTS_CASH_FLOWS"></a>Consolidated Statements of Cash Flows</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Year Ended December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cash flows from operating activities:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss, including noncontrolling interests</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12,578,211</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,959,248</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adjustments to reconcile net loss to net cash used in operating activities:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,722,893</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,888,968</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss on extinguishment of convertible notes</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,322,943</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gain from forgiveness of Paycheck Protection Program loan</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(62,500</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(62,500</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value of embedded features</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">203,000</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,000</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value of warrant liability</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,546,280</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,600</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortization of debt discount</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">596,953</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,875</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in operating assets and liabilities:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses and other current assets</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(15,155</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(58,084</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred offering costs</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(651,582</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other assets</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,122</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">805,516</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,304</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,261,495</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">826,470</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Due to related parties</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7,037</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,938</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred compensation</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(264,369</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">483,122</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in operating activities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,122,896</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,844,163</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cash flows from financing activities:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from issuance of convertible notes, warrants, and embedded</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; conversion features</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,369,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">610,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from Paycheck Protection Program loan</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62,500</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62,500</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Collections of subscriptions receivable - MAIA</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">322,002</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">102,400</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Collections of subscriptions receivable - DGD</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,000</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from issuance of common stock, net of transaction costs - MAIA</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,742,171</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from issuance of common stock - DGD</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50,000</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from exercise of stock options</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from exercise of warrants</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">529,425</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Return of capital &#8211; DGD</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(58,212</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payment on loan payable to officer</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(367</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,633</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by financing activities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,033,731</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">798,055</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net increase (decrease) in cash</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,910,835</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,046,108</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash at beginning of year</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">663,457</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,709,565</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash at end of year</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,574,292</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">663,457</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Supplemental disclosure of cash flow information:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Conversion of convertible notes and accrued interest into MAIA common stock</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,249,587</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Conversion of SAFE into MAIA common stock</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options issued for accrued bonus</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">786,531</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options issued for deferred compensation</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">285,418</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reclassification of warrant liability to equity</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,952,000</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of convertible note for payment on loan from officer</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(21,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See the accompanying notes to the consolidated financial statements.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-7</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">MAIA Biotechnology, Inc. and Subsidiaries</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="NOTES_TO_CONSOLIDATED_FINANCIAL_STATEMEN"></a><a name="NOTES_TO_CONSOLIDATED_FINANCIAL_STATEMEN"></a>Notes to Consolidated Financial Statements</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Years Ended December 31, 2021 and 2020</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.78%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;">NATURE OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Description of Business, Organization, and Principles of Consolidation</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MAIA Biotechnology, Inc. and Subsidiaries (collectively, "the Company") is a biopharmaceutical company that develops oncology drug candidates to improve and extend the lives of people with cancer. MAIA Biotechnology, Inc. ("MAIA") was incorporated in the state of Delaware on August 3, 2018. These consolidated financial statements include the accounts of MAIA and its subsidiaries, as follows: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.51%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.51%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:10pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">THIO Therapeutics, Inc. ("THIO"), incorporated in the state of Delaware on November 26, 2018. On August 13, 2021, MAIA and THIO completed a plan of reorganization in which THIO merged with and into MAIA. Prior to the merger, MAIA owned 93.3% of the outstanding shares of THIO common stock, which were cancelled in connection with the merger. The remaining 6.7% minority stockholder of THIO received one share of MAIA common stock for each share of THIO common stock owned prior to the merger. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.51%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.51%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">DGD Pharmaceuticals Corporation ("DGD"), incorporated in the state of Delaware of April 1, 2019. In July 2020, the board of directors approved the dissolution of DGD, and shortly thereafter also approved a special dividend/return of capital to its stockholders. On August 13, 2021, DGD was officially dissolved via a filing of a Certificate of Dissolution with the state of Delaware. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.51%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.51%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">MAIA Drug Development Corporation ("MAIA DD") incorporated in the state of Texas on September 10, 2018, and was 100% owned by MAIA, until MAIA DD was legally dissolved in July 2021. The operations of MAIA DD were nominal.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.51%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.51%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">In July 2021, the Company established a wholly owned Australian subsidiary, MAIA Biotechnology Australia Pty Ltd, to conduct various pre-clinical and clinical activities for the development of the Company's product candidates.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Liquidity </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At December&#160;31, 2021, the Company had working capital of&#8201;$8,526,499, an accumulated deficit of $28,437,993, cash of $10,574,292 and current liabilities of $2,145,996. Since inception the Company has experienced net losses and negative cash flows from operations each fiscal year. The Company has no revenues and expects to continue to incur operating losses for the foreseeable future, and may never become profitable. The Company is dependent on its ability to continue to raise equity and/or debt financing to continue operations, and the attainment of profitable operations. During January and February 2022, the Company sold 263,729 shares of common stock at $9 per share for gross proceeds of $2,373,561 before transaction costs and expenses.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company believes that it currently has sufficient funds to support operations through the next twelve months from the date the consolidated financial statements are issued, including funding of the THIO-101 lead-in and preliminary efficacy of the phase 2 THIO-101. However, further significant funding will be required to perform the necessary clinical trials, and to meet the Company&#8217;s long-term development and commercialization goals. The Company cannot make any assurances that additional financings will be available to it and, if available, on acceptable terms or at all. This could negatively impact the Company&#8217;s business and operations and could also lead to the reduction of the Company&#8217;s operations.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Impact of the COVID-19 Pandemic on our Operations</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On January 30, 2020, the World Health Organization (&#8220;WHO&#8221;) announced a global health emergency because of a new strain of coronavirus originating in Wuhan, China (the &#8220;COVID-19 Outbreak&#8221;) and the risks to the international community as the virus spreads globally beyond its point of origin. In March 2020, the WHO classified the COVID-19 Outbreak as a pandemic, based on the rapid increase in exposure globally.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The full impact of the COVID-19 Outbreak continues to evolve as of the date of this report. As a result, we cannot estimate the full magnitude that the pandemic will have on our business. If the COVID-19 Outbreak continues, it may have a material adverse effect on our financial condition, liquidity, and future results of operations for the future. We are actively monitoring the impact of the global pandemic on our financial condition, liquidity, operations, industry, and workforce. Given the daily evolution of the COVID-19 Outbreak and the global responses to curb its spread, we are not able to estimate the effects of the COVID-19 Outbreak on our results of operations, financial condition, or liquidity for the future. While we have not currently experienced any potential delays or increased costs as a result of these measures, we may do so in the future.&nbsp;&nbsp;&nbsp;&nbsp; </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-8</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Basis of Presentation</font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (&#8220;GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Updates (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in its financial statements and the reported amounts of expenses during the reporting period. The most significant estimates in the Company&#8217;s financial statements relate to the valuation of common stock, stock options, warrants, the embedded features in convertible notes and the valuation allowance of deferred tax assets resulting from net operating losses. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company&#8217;s future results of operations will be affected.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Certain Risks and Uncertainties</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s activities are subject to significant risks and uncertainties including the risk of failure to secure additional funding to properly execute the Company&#8217;s business plan. The Company is subject to risks that are common to companies in the pharmaceutical industry, including, but not limited to, development by the Company or its competitors of new technological innovations, dependence on key personnel, reliance on third party manufacturers, protection of proprietary technology, and compliance with regulatory requirements</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Off-Balance Sheet Risk and Concentrations of Credit Risk</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has no significant off-balance sheet risks, such as foreign exchange contracts, option contracts, or other foreign hedging arrangements. Cash accounts are maintained at financial institutions that potentially subject the Company to concentrations of credit risk. At December&#160;31, 2021 and 2020, substantially all of the Company&#8217;s cash was deposited in accounts at one financial institution. The Company maintains its cash deposits, which at times may exceed the federally insured limits, with a reputable financial institution and, accordingly, the Company believes such funds are subject to minimal credit risk.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Cash and Cash Equivalents</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company considers all highly liquid investments purchased with maturities of three months or less to be cash equivalents. As of December 31, 2021 and 2020, cash includes cash in a depository bank account; the Company has no cash equivalents as of December 31, 2021 and 2020.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Fair Value Measurements</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ASC 820, <font style="font-style:italic;">Fair Value Measurements</font>, provides guidance on the development and disclosure of fair value measurements. Under this accounting guidance, fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. To increase the comparability of fair value measures, the following hierarchy prioritizes the inputs to valuation methodologies used to measure fair value:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.51%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:2.63%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:10pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Level&#160;1 - Valuations based on quoted prices for identical assets and liabilities in active markets.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.51%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:2.63%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:10pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Level&#160;2 - Valuations based on observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.51%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:2.63%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:10pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Level&#160;3 - Valuations based on unobservable inputs reflecting our own assumptions, consistent with reasonably available assumptions made by other market participants. These valuations require significant judgment.</p></td></tr></table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-9</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair value measurements discussed herein are based upon certain market assumptions and pertinent information available to management as of and during the year ended December&#160;31, 2021, and 2020. The carrying amount of accounts payable approximated fair value as they are short term in nature. The fair value of warrants issued for services are estimated based on the Black-Scholes model during the year ended December&#160;31, 2021. The carrying value of notes payable and convertible notes payable approximated the estimated fair values due to their recent issuances. The estimated fair value of the warrants issued with the convertible notes and embedded features, represented Level 3 measurements.</font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">General and Administrative</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses primarily consist of costs for corporate functions, including payroll and related expenses, depreciation and amortization, rent, outside legal expenses, insurance costs, and other general and administrative costs.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Research and Development</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s research and development expenses consist primarily of costs associated with the Company&#8217;s clinical trials, salaries, payroll taxes, employee benefits, and stock-based compensation charges for those individuals involved in ongoing research and development efforts. Research and development costs are expensed as incurred. Advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As part of the process of preparing the consolidated financial statements, the Company is required to estimate its accrued expenses. This process involves reviewing quotations and contracts, identifying services that have been performed on the Company&#8217;s behalf and estimating the level of service performed and the associated cost incurred for the service when the Company has not yet been invoiced or otherwise notified of the actual cost. The majority of the Company&#8217;s service providers invoice the Company monthly in arrears for services performed or when contractual milestones are met. The Company makes estimates of its accrued expenses as of each balance sheet date in our consolidated financial statements based on facts and circumstances known to the Company at that time. The Company periodically confirms the accuracy of its estimates with the service providers and makes adjustments if necessary. The significant estimates in the Company&#8217;s accrued research and development expenses are related to expenses incurred with respect to CROs, CMOs and other vendors in connection with research and development and manufacturing activities.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company bases its expense related to CROs and CMOs on its estimates of the services received and efforts expended pursuant to quotations and contracts with such vendors that conduct research and development and manufacturing activities on the Company&#8217;s behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which payments made to the Company&#8217;s vendors will exceed the level of services provided and result in a prepayment of the applicable research and development or manufacturing expense. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from its estimate, the Company adjusts the accrual or prepaid expense accordingly. Although the Company does not expect its estimates to be materially different from amounts actually incurred, the Company&#8217;s understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and could result in us reporting amounts that are too high or too low in any particular period. There have been no material changes in estimates for the periods presented.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Research and Development Incentive&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes other income from Australian research and development incentives when there is reasonable assurance that the income will be received, the relevant expenditure has been incurred, and the consideration can be reliably measured. The research and development incentive is one of the key elements of the Australian Government&#8217;s support for Australia&#8217;s innovation system and is supported by legislative law primarily in the form of the Australian Income Tax Assessment Act 1997, as long as eligibility criteria are met.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Management has assessed the Company&#8217;s research and development activities and expenditures to determine which activities and expenditures are likely to be eligible under the research and development incentive regime described above. At each period end, management estimates the refundable tax offset available to the Company based on available information at the time.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the program, a percentage of eligible research and development expenses incurred by the Company through its subsidiary in Australia are reimbursed.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-10</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Derivative Financial Instruments</font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. The Company evaluates all of its financial instruments, to determine if such instruments contain features that qualify as embedded derivatives.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Embedded derivatives must be separately measured from the host contract if all the requirements for bifurcation are met. The assessment of the conditions surrounding the bifurcation of embedded derivatives depends on the nature of the host contract. Bifurcated embedded derivatives are recognized at fair value, with changes in fair value recognized in the statement of operations each period. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Stock-Based Compensation</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company records share-based compensation for awards granted to employees, non-employees, and to members of the board of directors based on the grant date fair value of awards issued, and the expense is recorded on a straight-line basis over the requisite service period. Forfeitures are recognized when they occur. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company uses the Black-Scholes-Merton option pricing model to determine the fair value of stock options and warrants. The use of the Black-Scholes-Merton option-pricing model requires management to make assumptions with respect to the expected term of the option, the expected volatility of the common stock consistent with the expected life of the option, risk-free interest rates and expected dividend yields of the common stock. The Company has concluded that its historical share option exercise experience does not provide a reasonable basis upon which to estimate expected term. Therefore, the expected term was determined according to the simplified method, which is the average of the vesting tranche dates and the contractual term. Due to the lack of company specific historical and implied volatility data, the estimate of expected volatility is primarily based on the historical volatility of a group of similar companies that are publicly traded. For these analyses, companies with comparable characteristics are selected, including enterprise value and position within the industry, and with historical share price information sufficient to meet the expected life of the share-based awards. The Company computes the historical volatility data using the daily closing prices for the selected companies&#8217; shares during the equivalent period of the calculated expected term of its share-based awards. The risk-free interest rate is determined by reference to U.S. Treasury zero-coupon issues with remaining maturities similar to the expected term of the options. The Company has not paid, and does not anticipate paying, cash dividends on shares of its common stock.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to the initial public offering, in order to estimate the fair value of shares of the common stock, the Company's board of directors considered, among other things, sales of common stock to third party investors and valuations of common stock, business, financial condition and results of operations, including related industry trends affecting operations; the likelihood of achieving a liquidity event, such as an initial public offering, or sale, given prevailing market conditions; the lack of marketability of our common stock; the market performance of comparable publicly traded companies; and U.S. and global economic and capital market conditions. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair values of DGD and THIO common stock were based on sales of common stock to third parties for the year ended December 31, 2020. There were no issuances of common stock as it relates to DGD or THIO during the year ended December 31, 2021. The fair value of restricted stock awards is based on common stock value. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All stock-based compensation costs are recorded in general and administrative or research and development costs in the consolidated statements of operations based upon the underlying individual&#8217;s role at the Company.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Common Stock Warrants</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for common stock warrants as either equity instruments or liabilities in accordance with ASC 480, Distinguishing Liabilities from Equity ("ASC 480"), depending on the specific terms of the warrant agreement.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">When warrants are issued for services to non-employees, under ASC 718, Compensation - Stock Compensation ("ASC 718"), the warrants were classified as a liability if 1) the underlying shares are classified as liabilities or 2) the entity can be required under any circumstances to settle the warrant by transferring cash or other assets. In accordance with ASU 2018-07, Improvements to Nonemployee Share-Based Payment Accounting, the measurement of equity-classified nonemployee share-based payments is generally fixed on the grant date and are considered compensatory, as defined by ASC 718. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Income Taxes</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income taxes are recorded in accordance with ASC 740, Income Taxes (&#8220;ASC 740&#8221;), which provides for deferred taxes using an asset and liability approach. The Company recognizes deferred tax assets and liabilities for the expected future tax </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-11</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">consequences of events that have been included in the financial statements or tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Valuation allowances are provided, if based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit would more likely than not be realized assuming examination by the taxing authority. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. The Company recognizes any interest and penalties accrued related to unrecognized tax benefits as income tax expense.</font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Deferred Offering Costs</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred offering costs are included in other assets and consists of legal, accounting, underwriting fees and other costs incurred through the balance sheet date that are directly related to the planned initial public offering and that will be charged to additional paid-in capital upon the completion of the planned initial public offering. Should the planned initial public offering prove to be unsuccessful, these deferred costs, as well as additional expenses to be incurred, will be charged to operations.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Net Loss Per Share</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic loss per share of common stock is computed by dividing net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding for the period. Diluted net loss per share is calculated by adjusting the weighted-average number of shares outstanding for the dilutive effect of common stock equivalents outstanding for the period, determined using the treasury-stock method. Diluted loss per share excludes, when applicable, the potential impact of stock options, unvested shares of restricted stock awards, and common stock warrants because their effect would be anti-dilutive due to our net loss. Gains on warrant liabilities are only considered dilutive when the average market price of the common stock during the period exceeds the exercise price of the warrants. Since the Company had a net loss in each of the periods presented, basic and diluted net loss per common share are the same.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the Company&#8217;s potentially dilutive securities, in common share equivalents, which have been excluded from the calculation of dilutive loss per share as their effect would be anti-dilutive:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ending December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares issuable upon exercise of stock options</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,797,185</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,664,966</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares issuable upon exercise of warrants</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,311,117</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">908,244</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested restricted stock awards</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58,333</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">147,778</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Recent Accounting Standards</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Accounting Standards Issued, Not Yet Adopted</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2016, the FASB issued ASU No. 2016-02, as amended, Leases (&#8220;Topic 842&#8221;), which applies to all leases. Under Topic 842, a right-of-use asset and lease obligation will be recorded for all leases, whether operating or financing leases, while the statement of operations will reflect lease expense for operating leases and amortization and interest expense for financing leases. Topic 842 is effective for public entities for fiscal years beginning after December 15, 2018 and periods beginning after December 15, 2021 for all other entities. Entities are required to use a modified retrospective approach of adoption for leases that exist or are entered into after the beginning of the earliest comparative period in the financial statements. The Company currently expects that none of its operating lease commitments will be subject to the new standard as the Company's leases are short-term in nature (i.e., less than twelve months). The Company will adopt this new standard as of January 1, 2022.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2016, the FASB issued ASU No. 2016-13, Measurement of Credit Losses on Financial Instruments (ASU 2016-13), which requires a financial asset (or a group of financial assets) measured at amortized cost basis to be presented at the net amount expected to be collected. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of the financial asset(s) to present the net carrying value at the amount expected to be collected on the financial asset. The </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-12</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:10pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">new standard is effective for the Company for fiscal years beginning after December 15, 2022. The Company is currently evaluating the impact of the pending adoption of the new standard on its financial statements and intends to adopt the standard as of January 1, 2023.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.78%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">. </font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">RELATED PARTY TRANSACTIONS</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Consulting Services </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Wayne Klohs is a shareholder and former member of the board of directors who also provided consulting services to the Company. During the year ended December 31, 2020, the Company incurred a total of $20,400 to Mr. Klohs for consulting services. The Company did not receive consulting services from Mr. Klohs during the year ended December&#160;31, 2021.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leigh-Ann Durant, a former member of the Company&#8217;s board of directors prior to her stepping down in November 2021, provides consulting services to the Company for which the Company incurred $129,171 for services provided during the year ended December&#160;31, 2020, $53,981 of which is stock-based compensation which consist of options to purchase 47,569 shares of common stock. The Company incurred $88,994 for consulting services provided by Ms. Durant during the year ended December&#160;31, 2021. The Company paid Ms. Durant $34,560 in cash, and issued her options to purchase 23,964 shares of common stock with a total fair value of $54,434 during the year ended December&#160;31, 2021.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mukesh Nyati was a minority shareholder of DGD and a consultant who received 222,500 shares of restricted stock in DGD during the year ended December 31, 2020, for his services along with cash. During 2020, the Company incurred $152,576 in research fees, $75,000 of which is stock-based compensation. Dr. Nyati is also the one of the principal researchers at the University of Michigan who was working on the specific compound licensed from the University of Michigan.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Radu Vitoc, a shareholder and brother of the CEO, provides consulting services to the Company for which the Company incurred $4,700 for services provided during the year ended December&#160;31, 2021. The Company paid Mr. Vitoc $2,350 in cash, and issued him options to purchase 184 shares of common stock with a total fair value of $1,100. The remaining $1,250 for services provided in fiscal 2021 will be settled in options for which the Company has not yet issued to Mr. Vitoc as of December 31, 2021. The Company also issued him a convertible note in the amount of $50,000 during April 2021, which was converted into 8,557 shares of common stock on September 30, 2021 at a conversion price of $6.00 per share (See Note 5), and also received 4,278 warrants to purchase shares of common stock at an exercise price of $6.00 per share. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">CEO Loan Agreement</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company's chief executive officer lent the Company a total of $25,000 in August and September of 2018. These amounts, were unsecured, had no stated interest rate, and no stated repayment terms. The Company repaid $3,633 of the loan to the CEO during 2020 and $367 during 2021. The Company paid these loans in full in March 2021, by issuing the CEO a convertible note in the amount of $21,000. The convertible note issued to the CEO was converted into 3,621 shares of common stock on September 30, 2021 at a conversion price of $6.00 per share (See Note 5). </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Deferred Compensation Agreements </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2021 and December&#160;31, 2020, the Company had $111,271 and $661,058, respectively, of deferred compensation due to certain employees and officers of the Company pursuant to deferred compensation agreements executed during fiscal 2020 and 2019 as part of a non-qualified deferred compensation plan. Pursuant to the deferred compensation agreements, the employees had deferred a portion of their annual base salary to be paid upon a Qualified Fund Raising. The Qualified Fund Raising was achieved during July 2021. Upon this event, the employees' salaries were increased up to the market rates set forth in their respective agreements, and all amounts were paid to the employees. The remaining deferred compensation balance as of December 31, 2021 relates to amounts incurred for employees who were no longer with the Company as of the payout date.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December&#160;31, 2021, the Company accrued $193,379 in deferred compensation. The Company paid $457,749 in cash and issued 268,769 options with a total fair value of $296,264 during the year ended December&#160;31, 2021, to settle a portion of the deferred compensation balance totaling $743,167. The fair value of the options issued in excess of the deferred compensation balance settled totaling $10,846 was recorded as stock-based compensation expense which is presented within general and administrative expenses on the statement of operations for the year ended December&#160;31, 2021.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-13</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><font style="font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Accrued Bonus</font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December 31, 2021 and 2020, the Company accrued $384,750 and $780,000, respectively, in bonus expense relating to certain key employees and officers of the Company. On April 16, 2021, the 2020 accrued bonus balance was settled by issuance of 713,536 stock options with a total fair value of $786,531. The fair value of the options issued in excess of the accrued bonus balance totaled $6,531 and was recorded as stock-based compensation expense which is presented within general and administrative expenses on the statement of operations for the year ended December&#160;31, 2021.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.78%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">3</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">ACCRUED EXPENSES </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021 and 2020, accrued expenses consisted of the following:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Bonus</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">384,750</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">780,000</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,678</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Professional fees</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">380,277</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46,132</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development costs</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">268,140</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,157</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total accrued expenses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,074,324</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">838,810</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.78%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">4</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">. </font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">PAYCHECK PROTECTION PROGRAM </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2020, the Company applied for and received $62,500 in unsecured loan funding from the Paycheck Protection Program (the &#8220;PPP Loan&#8221;), established pursuant to the Coronavirus Aid, Relief, and Economic Security Act (the &#8220;CARES Act&#8221;) and administered by the U.S. Small Business Administration (&#8220;SBA&#8221;). The Company received full forgiveness of all outstanding principal and accrued and unpaid interest on the PPP Loan in December 2020.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On January 31, 2021, the Company received a second PPP Loan in the amount of $62,500. Under the terms of PPP Loan, interest accrues on the outstanding principal at the rate of 0.98% per annum. The term of the PPP Loan is two years. To the extent that the loan amount is not forgiven by the SBA, the Company is obligated to make equal monthly payments of principal and interest, beginning seven months from the date of the PPP Loan, until the maturity date. The loan amount may be eligible for forgiveness if used for qualifying expenses and other qualifying criteria are met. The Company used the entire PPP Loan for qualifying expenses.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company received full forgiveness of all outstanding principal and accrued and unpaid interest on the PPP Loan in November 2021. The forgiveness of the PPP Loan qualified for debt extinguishment in accordance with ASC 470-50, Debt Modifications and Extinguishments, and as a result, the outstanding principal and interest was written off in the amount of $62,500, and the Company recorded a gain on extinguishment totaling $62,500 for the year ended December 31, 2021.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.78%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">5</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">CONVERTIBLE NOTES PAYABLE </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Convertible Notes Payable</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Convertible notes payable:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Convertible note balance</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">620,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Debt discount</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(177,613</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Carrying value of convertible notes payable</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">442,387</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Convertible note payable, current portion</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,586</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Convertible notes payable, related parties</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">98,960</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Convertible notes payable, net of current portion</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">332,841</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Carrying value of convertible notes payable</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">442,387</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-14</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Convertible Notes Payable issued in 2019</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2019, the Company issued a Convertible Promissory Note totaling $10,000 to one individual (the "2019 Convertible Note"). The 2019 Convertible Note bore interest at 8% per annum, was unsecured, with a scheduled maturity date of December 31, 2021. The 2019 Convertible Note contained an automatic conversion feature, such that in the event the Company consummated an Equity Financing, as defined in the agreement, prior to the 2019 Convertible Note's scheduled maturity, the outstanding principal and interest would automatically converted into Preferred Stock (the shares of a class or series of preferred stock of the Company issued in connection with an Equity Financing) of the Company issued in connection with the Equity Financing. The Equity Financing is defined as a bona fide transaction or series of transactions with the principal purpose of raising capital, pursuant to which the Company receives gross aggregate proceeds of not less than $5,000,000 (before any transaction related expenses and costs). The conversion price will be set at 65% of the price of the preferred stock issued in the aforementioned Equity Financing.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Embedded Put Feature</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company determined that the terms related to the Equity Financing conversion, (the &#8220;Embedded Put Feature&#8221;) were not clearly and closely related to the 2019 Convertible Note host instrument and meets the definition of a derivative. Therefore, the Embedded Put Feature was bifurcated from the 2019 Convertible Note and separately measured at fair value. The derivative liability has been subsequently marked-to-market each reporting period with changes in fair value recognized in the statement of operations.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Embedded Put Feature was initially recorded as a debt discount and a related derivative liability at fair value. The debt discount is amortized using the effective interest rate over the original term of the 2019 Convertible Note.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest expense on the 2019 Convertible Note totaled $607 and $1,156 for the year ended December 31, 2021 and 2020, respectively.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The debt discount and value of the Embedded Put Feature in the 2019 Convertible Note totaled $1,000 at issuance. The balance of the debt discount was $0 and $414 as of December&#160;31, 2021 and December 31, 2020, respectively. During the year ended December&#160;31, 2021 and 2020, amortization of debt discount amounted to $310 and $586, respectively.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Convertible Notes Payable issued in 2020</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During 2020, the Company issued Convertible Promissory Notes totaling $610,000 to various investors or holders, including $110,000 of Convertible Promissory Notes to related parties (collectively, the "2020 Convertible Notes") throughout fiscal 2020. The 2020 Convertible Notes bore interest at 6% per annum, was unsecured, with a scheduled maturity date of May 31, 2022. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The 2020 Convertible Notes are automatically convertible into shares of the Company's Equity Financing Shares (shall mean the shares of any class or series of preferred stock of the Company issued in connection with an Equity Financing), upon the closing of an Equity Financing yielding gross proceeds of in excess of $5,000,000 (before any transaction related expenses and costs). The 2020 Convertible Notes also are convertible into common shares of the Company at the holders' election upon (i) a Change in Control whereby any person or group becomes a beneficial owner of more than 50% of the Company's outstanding voting securities in connection with a merger or reorganization, or (ii) at the time of maturity. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock issued on conversion shall be shares of the Company&#8217;s stock that have substantially the same rights and preferences as the shares issued in such Equity Financing. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Conversion Prices</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The conversion price is set at 75% of the price of the preferred stock issued in the aforementioned Equity Financing. The 2020 Convertible Notes also contain a clause that accelerates their maturity upon a change in control of the Company, as defined above. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Embedded Put Features</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has determined that the terms related to the Equity Financing conversion, Change in Control, and maturity conversion features (collectively, the &#8220;Embedded Put Features&#8221;) included within the 2020 Convertible Notes were not clearly and closely related to the 2020 Convertible Note host instrument and meet the definition of a derivative. Therefore, the Embedded Put Features were bifurcated from the 2020 Convertible Notes and measured at fair value. The derivative liability has been subsequently marked-to-market each reporting period with changes in fair value recognized in the statement of operations.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-15</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Embedded Put Features were initially recorded as a debt discount and a related derivative liability at fair value in the amount of $131,000 at issuance of the 2020 Convertible Notes (see Note </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">). The debt discount is amortized using the effective interest rate over the original term of the 2020 Convertible Notes.</font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Maturity Date</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The maturity date on the 2020 Convertible Notes is the earliest occurrence of (i) the closing of a Qualified Equity Financing, or (ii) the date upon which the Convertible Notes are otherwise converted into equity securities, or (iii) May 31, 2022. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest expense on the 2020 Convertible Notes totaled $27,375 and $11,523 for the year ended December&#160;31, 2021 and 2020, respectively.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Debt discounts on the 2020 Convertible Notes totaled $0 and $177,199 as of December&#160;31, 2021 and 2020, respectively. During the year ended December&#160;31, 2021 and 2020, amortization of debt discounts amounted to $83,608 and $19,461, respectively. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Warrants<font style="font-style:normal;"> </font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with each of the 2020 Convertible Notes, the Company issued each holder warrants (the 2020 Warrants) to acquire additional shares of common stock of the Company. Each holder of a 2020 Convertible Note received a warrant to purchase that number of shares of common stock as determined by multiplying the number of Equity Financing Shares which are issuable upon conversion of the holder's Convertible Note by 50%, at an exercise price equal to the conversion price per share used in the conversion of the Convertible Note. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The 2020 Warrants were initially recorded as a debt discount and a related warrant liability at fair value in the amount of $65,660 (see Note 7) at issuance of the 2020 Convertible Notes. Subsequent to issuance, the 2020 Warrants have been marked-to-market each reporting period with changes in fair value recognized in the statement of operations. The debt discount is amortized using the effective interest rate over the original term of the 2020 Convertible Notes. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Convertible Notes Payable issued in 2021</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December 31, 2021, the Company issued Convertible Promissory Notes totaling $7,390,000 to various investors or holders, including $1,863,300 of Convertible Promissory Notes to related parties (collectively, the "2021 Convertible Notes") which included a $21,000 Convertible Promissory Note to settle a loan to the Company's CEO (see Note 2) . The 2021 Convertible Notes bear interest at 6% per annum, are unsecured, and have scheduled maturity dates ranging from February 15, 2023 through June 28, 2023. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The 2021 Convertible Notes are automatically convertible into shares of the Company's Equity Financing Shares (shall mean the shares of any class or series of preferred stock of the Company issued in connection with an Equity Financing), upon the closing of an Equity Financing yielding gross proceeds of in excess of $5,000,000 (before any transaction related expenses and costs). The 2021 Convertible Notes also are convertible into common shares of the Company at the holders' election upon (i) a Change in Control whereby any person or group becomes a beneficial owner of more than 50% of the Company's outstanding voting securities in connection with a merger or reorganization, or (ii) at the time of maturity. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock issued on conversion shall be shares of the Company&#8217;s stock that have substantially the same rights and preferences as the shares issued in such Equity Financing. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Conversion Prices</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The conversion price was set at 75% of the price of the common stock issued in the aforementioned Equity Financing. The 2021 Convertible Notes also contain a clause that accelerates their maturity upon a change in control of the Company, as defined above. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Embedded Put Features</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has determined that the terms related to the Equity Financing conversion, Change in Control, and maturity conversion features (collectively, the &#8220;Embedded Put Features&#8221;) included within the 2021 Convertible Notes were not clearly and closely related to the 2021 Convertible Note host instrument and meet the definition of a derivative. Therefore, the Embedded Put Features were bifurcated from the 2021 Convertible Notes and measured at fair value. The derivative liability has been subsequently marked-to-market each reporting period with changes in fair value recognized in the statement of operations.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-16</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Embedded Put Features were initially recorded as a debt discount and a related derivative liability at fair value in the amount of $2,821,000 at issuance of the 2021 Convertible Notes (see Note </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">). The debt discount is amortized using the effective interest rate over the original term of the 2021 Convertible Notes.</font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Maturity Date</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The maturity date on the 2021 Convertible Notes is the earliest occurrence of (i) the closing of a Qualified Equity Financing, or (ii) the date upon which the Convertible Notes are otherwise converted into equity securities, or (iii) maturity dates ranging from February 15, 2023 through June 28, 2023.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest expense on the 2021 Convertible Notes totaled $199,049 and $0 for the year ended December&#160;31, 2021 and 2020, respectively.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December&#160;31, 2021 and 2020, amortization of debt discounts amounted to $513,035 and $0, respectively.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Warrants<font style="font-style:normal;"> </font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with each of the 2021 Convertible Notes, the Company issued each holder warrants (the 2021 Warrants) to acquire additional shares of common stock of the Company. Each holder of a 2021 Convertible Note received a warrant to purchase that number of shares of common stock as determined by multiplying the number of Equity Financing Shares which are issuable upon conversion of the holder's Convertible Note by 50%, at an exercise price equal to the conversion price per share used in the conversion of the Convertible Note. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The 2021 Warrants were initially recorded as a debt discount and a related warrant liability at fair value in the amount of $320,460 (see Note 7) at issuance of the 2021 Convertible Notes. Subsequent to issuance, the 2021 Warrants have been marked-to-market each reporting period with changes in fair value recognized in the statement of operations. The debt discount is amortized using the effective interest rate over the original term of the 2021 Convertible Notes. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Conversion of Convertible Notes Upon Equity Financing</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Convertible Notes </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the sale of common stock in fiscal 2021, an Equity Financing of gross proceeds in excess of $5 million, the Company converted all $8,010,000 of its outstanding principal and all accrued and unpaid interest of approximately $240,000 related to the Company&#8217;s 2019 Convertible Note, 2020 Convertible Notes, and 2021 Convertible Notes into 1,375,228 shares of the Company&#8217;s common stock on September 30, 2021 at a conversion price of $6.00 per share. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounted for the conversion of the Convertible Notes as an extinguishment. The Company recorded an approximate $2.3 million loss on extinguishment, upon conversion, year ended December&#160;31, 2021. The loss on extinguishment of the Convertible Notes included a write-off of the unamortized debt discount of approximately $3.3 million. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2021 there were no Convertible Notes outstanding. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Warrants<font style="font-style:normal;"> </font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On September 30, 2021, in connection with conversion of the 2020 and 2021 Convertible Notes, the terms of the warrants issued with the 2020 and 2021 Convertible notes became fixed such that the warrants are exercisable for a fixed number of shares of common stock at a fixed exercise price per share based on the amount of shares issuable upon conversion of the Convertible Notes and an exercise price equal to the conversion price per share used in the conversion of the Convertible Notes. The warrants are exercisable for 686,489 shares of common stock with an exercise price of $6.00 and expire at various dates throughout fiscal 2028. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2021, 4,504 of these warrants have been exercised.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.78%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">6</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">SIMPLE AGREEMENT FOR FUTURE EQUITY</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October 2019, the Company issued a simple agreement for future equity ("SAFE Agreement") for $25,000. The SAFE Agreement requires automatic conversion to preferred stock in the event of an equity financing. If the Company experiences a liquidity event, as defined, the holder may opt for either conversion or repayment in cash, with repayment based upon a valuation at the time of such event. Upon a dissolution event, as defined, the SAFE Agreement requires repayment in cash. The </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-17</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:10pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">conversion price will be set at 60% of the price of the preferred stock issued in the aforementioned equity financing. The SAFE Agreement shall terminate upon either the issuance of shares or repayment in cash as per the agreement's terms. Due to the contingencies associated with the potential conversion and conversion price as well as the valuation upon a future liquidity event should one occur, no discount associated with these features has been recorded in the accompanying consolidated financial statements.</font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the sale of common stock in 2021, an Equity Financing, the SAFE in the amount of $25,000 was converted into 5,208 shares of the Company&#8217;s common stock on September 30, 2021. The price of the common shares issued in the equity financing was $8.00. The conversion price was equal to 60% of $8.00 per share, or $4.80 per share.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.51%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">7</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">FAIR VALUE OF FINANCIAL LIABILITIES</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial liabilities consisting of embedded derivative liabilities and warrant liabilities measured at fair value on a recurring basis are summarized below. The fair values of the embedded derivative liabilities and warrant liabilities recorded are as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.51%;text-indent:-3.51%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.62%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair value at September 30, 2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Liabilities:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Derivative liability, bifurcated put contained in</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; convertible notes payable</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrant liability</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.62%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair value at December 31, 2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Liabilities:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Derivative liability, bifurcated put contained in</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; convertible notes payable</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">127,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">127,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrant liability</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85,260</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85,260</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">212,260</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">212,260</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The table below provides a summary of the changes in fair value of the derivative liabilities and warrant liabilities measured on a recurring basis using significant unobservable inputs (Level 3):</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.51%;text-indent:-3.51%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Derivative liabilities:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.04%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.04%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance, beginning of period</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">127,000</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,000</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Derivative liability on convertible notes payable</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,821,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">131,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss (Gain) on fair value of embedded features</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">203,000</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,000</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Extinguishment of derivative liability in connection with debt conversion</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,151,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.92%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance, end of period</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">127,000</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.92%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrant liabilities:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.04%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.04%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance, beginning of period</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85,260</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrant liability</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">320,460</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65,660</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss on fair value of warrant liability</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,546,280</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,600</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reclassification of warrant liability to equity</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,952,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.92%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance, end of period</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85,260</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Derivative Liability</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Embedded Put Features were separately measured at fair value, with changes in fair value recognized in current operations. The scenario-based analysis estimates the fair value of the Convertible Notes based on the probability-weighted present value of expected future investment returns, considering each of the possible outcomes available to the holders, including various </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-18</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">settlement, equity financing, and corporate transaction and dissolution scenarios. Estimating fair values of Embedded Put Features required the development of significant and subjective estimates that changed over the duration of the instrument with related changes in internal and external market factors. Because the Embedded Put Features are initially and subsequently carried at fair values, the Company&#8217;s income reflected the volatility in these estimate and assumption changes. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Immediately prior to the conversion of the convertible notes, the derivative liability was marked to fair value resulting in a loss of $203,000 for the year ended December&#160;31, 2021. The recurring Level 3 fair value measurements of the embedded derivative liability included the following significant unobservable inputs as of the conversion. The probability of the Convertible Notes outstanding at maturity was estimated to be approximately 0%; the probability of an equity financing was estimated to be approximately 100%; and the probability of default, change in control or dissolution was estimated to be approximately 0%. On September 30, 2021 the embedded derivative liability was extinguished in connection with the conversion of the convertible notes. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Convertible Note Warrants </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Warrants were separately measured at fair value, with changes in fair value recognized in current operations. The fair value of the Warrants was determined using the Black-Scholes-Merton option-pricing model utilizing inputs such as the fair value of the underlying stock, expected term, expected volatility of the underlying stock over the expected term, and the risk-free interest rate over the expected term. The Warrants were valued at each issuance date of the convertible notes and at each quarter end based on the assumptions for each of the conversion scenarios contained within each of the convertible notes. The following are the significant assumptions utilized in the Black-Scholes-Merton option-pricing model; risk-free interest rate 0.0% - 1.3%; expected term (in years) 0.46 - 6.61; expected volatility 81% - 106%; expected dividend yield 0% - 0%. Changes to these assumptions had an impact on the fair value of the Warrants and related fair value adjustments. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On September 30, 2021, in connection with conversion of the 2020 and 2021 Convertible Notes, the terms of the warrants issued with the 2020 and 2021 Convertible notes became fixed such that the warrants are exercisable for a fixed number of shares of common stock at a fixed exercise price per share based on the amount of shares issuable upon conversion of the Convertible Notes and an exercise price equal to the conversion price per share used in the conversion of the Convertible Notes. The warrants are now exercisable for 686,489 shares of common stock with an exercise price of $6.00 and expire at various dates throughout fiscal 2028. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company determined as of September 30, 2021 the warrants should be equity classified and reclassified the fair value of the warrant liability of $1,952,000 into additional paid-in capital. The change in fair value of the warrant liability of $1,546,280 for the year ended December&#160;31, 2021 is reflected in &#8220;Change in fair value of warrant liability&#8221; in the accompanying statement of operations.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.78%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">8</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">STOCKHOLDERS' EQUITY</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon incorporation, MAIA was authorized to issue 10,000,000 shares of common stock, with a par value of $0.0001 per share. In March 2020, the shareholders approved an amended and restated certificate of incorporation which authorizes MAIA to issue 100,000,000 shares of stock, as follows: 70,000,000 shares of preferred stock and 30,000,000 shares of common stock, all with a par value of $0.0001 per share. The rights, privileges, preferences, and restrictions of the classes of stock have yet to be established. As of December 31, 2021, each of the common stockholders have equal voting rights, and except in the case of restricted common shares, equal rights of participation in dividends and other distributions with other common stockholders.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Among other provisions, MAIA's shareholders agreement gives first MAIA, followed by the non-selling shareholders, the option to purchase the outstanding shares of a shareholder prior to the sale of shares to a third party. Should the non-selling shareholders decline to purchase any portion of the selling shareholders shares, MAIA shall have a final opportunity to repurchase the shares. The agreement also contains provisions for "drag-along" and "tag-along" rights, as described in the agreement.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">MAIA Equity Financing</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Between July 18, 2021 and December&#160;31, 2021, the Company sold 772,563 shares of common stock at $8.00 per share for gross proceeds of approximately $6.2 million. In connection with this sale of common stock, all of the outstanding convertible notes principal and accrued and unpaid interest were automatically converted into 1,375,228 shares of the Company&#8217;s common stock in accordance with the terms in the convertible notes (see Note 5). </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-19</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">MAIA Biotechnology, Inc. Restricted Stock Awards</font><font style="font-weight:normal;"> </font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Restricted Common Stock Awards to Founders</font> - In October 2018, the Company awarded 2,100,000 restricted common shares to four founders. Vested shares may participate in any dividends and other distributions with other common stockholders, while the unvested shares, which are subject to forfeiture in the event the holder separates from service with the Company, do not participate in such events. The share awards are subject to service conditions, with 50% of the granted shares vesting immediately upon issuance, and the remaining 1,050,000 common shares vesting in 12 equal quarterly installments over a three-year period, with the first such quarterly installment vesting on January 1, 2019.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The related compensation expense was recognized 50% upon issuance, and the remainder is recognized ratably over the service period. In November 2019, upon termination of two of the founders, 400,000 of those founders' unvested shares were forfeited.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December&#160;31, 2021 and 2020, the Company recognized $202,500 and $270,000, respectively, in general and administrative expense related to the Founders' awards. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Restricted Common Stock Awards to Directors</font> &#8212; During the year ended December 31, 2021, the Company awarded 15,278 restricted common shares to two directors. Vested shares may participate in any dividends and other distributions with other common stockholders. The share awards were subject to service conditions as defined in the agreements. The related compensation expense was recognized ratably over the service period. During the year ended December 31, 2021 the Company recognized $27,500 in general and administrative expense related to the Directors' awards, as they fully vested on December&#160;31, 2021. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December 31, 2020 the Company awarded 16,667 restricted common shares to one director. During the year ended December 31, 2020 the Company recognized $241,027 in general and administrative expense related to this Director's awards and previous Director's awards, as they fully vested by December 31, 2020.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.44%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.44%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted&#160;Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Grant Date</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested balance at January 1, 2020</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.44%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">420,848</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.44%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.80</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,667</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.80</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.44%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(289,737</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.44%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested balance at December 31, 2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.44%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">147,778</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.44%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.80</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exchanged for THIO founder restricted shares</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">87,500</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.80</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,278</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.80</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(186,666</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cancelled/forfeited</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.44%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,557</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:14.44%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.52%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested balance at December 31, 2021</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.44%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58,333</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:14.44%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.80</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On August 13, 2021, upon the dissolution of THIO and merger into MAIA (see Note 1), a founder's 612,500 fully vested THIO restricted shares were cancelled and the founder was issued 612,500 MAIA restricted shares. Additionally, in accordance with the founder's original award, the founder was also issued 87,500 MAIA restricted shares which vest ratably each quarter through June 30, 2022 to replace the equivalent number of unvested THIO restricted shares. The remaining unvested shares in the above table as of December 31, 2021 are related to the founder's unvested restricted shares only.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December&#160;31, 2021, MAIA recognized $105,000 of stock compensation expense related to the MAIA restricted shares granted to the founder. The issuance of restricted shares in MAIA as a replacement for the shares the founder held in THIO was accounted for as a modification. There was no additional incremental stock compensation recorded as related to the cancellation of the founder's THIO restricted shares and concurrent grant of MAIA restricted shares as the fair value of the original THIO award immediately before the grant of the MAIA restricted shares and the fair value of the replacement award were equal. The unrecognized stock compensation expense for the 58,333 unvested restricted shares as of December&#160;31, 2021 is approximately $52,500, which will be recognized through March 2022.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">MAIA Stock Warrants</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During 2020, the Company issued warrants to purchase 110,520 shares of common stock to certain consultants for services rendered during the year. Of these warrant grants, 90,000 have an exercise price of $1.80 and 20,520 have an exercise price of $5.00 per share. The warrants' total calculated value of $124,064 is included in operating expenses in the accompanying </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-20</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:10pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">consolidated statement of operations for the year ended December 31, 2020. As of December&#160;31, 2021, all of these warrants, which expire at various dates through December 2027, are outstanding and exercisable.</font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2020 through June 2021, the Company issued and sold convertible promissory notes with an aggregate principal amount of $8.0 million, which converted into 1,375,228 shares of its common stock on September 30, 2021, and warrants to purchase 686,489 shares of our common stock at $6.00 per share. As of December 31, 2021, 4,504 of these warrants have been exercised, and 681,985 warrants, which expire at various dates through September 2028, are outstanding and exercisable.&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Warrants</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise Price</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Term in Years</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at January 1, 2020</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">797,724</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.80</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.85</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">110,520</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.39</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.44</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2020</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">908,244</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.87</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.89</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">686,489</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.00</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.00</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(283,616</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.87</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,311,117</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.03</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.30</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The value of the warrants are calculated using the Black-Scholes-Merton option pricing model with the following assumptions for warrants granted during the years ended December&#160;31, 2021 and 2020: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.44%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.44%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.44%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.6% - 1.3%</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.44%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.41% - 1.69%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (in years)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5 - 7</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5 - 7</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81% - 106%</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75.8% - 80.5%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">MAIA Biotechnology, Inc. Stock Award Plans<font style="font-weight:normal;"> </font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2018, the Company adopted the MAIA Biotechnology, Inc. 2018 Stock Option Plan (the "MAIA 2018 Plan"). MAIA's board of directors administers the MAIA Plan, under which 3,900,000 shares of common stock are reserved for stock option issuance, for the purposes of attracting, retaining, and motivating key employees, directors, and consultants of MAIA.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2020, the Company adopted the MAIA Biotechnology, Inc. Amended and Restated 2020 Equity Incentive Plan (the "MAIA 2020 Plan"), also administered by the board of directors. The MAIA 2020 Plan reserves 1,671,000 common shares for issuance, also for the purposes of attracting, retaining, and motivating key employees, directors, and consultants of MAIA. In November 2020, the MAIA 2020 Plan was amended to reserve a total of 3,171,000 shares of common stock. The MAIA 2020 Plan permits awards to take the form of stock options, restricted stock and restricted stock units. In April and July of 2021 there were amendments to the 2020 Plan to bring the plan to a total of 4,171,000 shares reserved for issuance. As of December 31, 2021, there was a remaining 331,815 shares available for issuance.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On November 5, 2021, the Company adopted the 2021 Equity Incentive Plan (the &#8220;2021 Plan&#8221;). The 2021 Plan was adopted to enhance the Company's ability to attract, retain and motivate employees, officers, directors, consultants and advisors by providing such persons with equity ownership opportunities and performance-based incentives. The 2021 Plan is a comprehensive incentive compensation plan under which the Company can grant equity-based and other incentive awards to officers, employees, directors, consultants and advisers. The purpose of the 2021 Plan is to help the Company attract, retain, and motivate such persons with awards under the 2021 Plan and thereby enhance shareholder value. Per the terms of the 2021 Plan, it is not effective until the occurrence of an IPO. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options are to be granted with an exercise price which is at least equal to the stock's estimated fair value at the date of grant, and with a contractual term of no more than 10 years from the date of grant. In the case of an option granted to a 10% stockholder, the exercise price shall be generally no less than 110% of the fair market value per share on the date of grant, and the contractual term shall be 7 years. Outstanding options awarded under the MAIA 2020 Plan may, but need not, vest and therefore become exercisable in periodic installments that may, but need not, be equal. The option may be subject to such other terms and conditions as to the time or times when it may be exercised (which may be based on performance or other criteria) as the board of directors may deem appropriate. Unexercised options are cancelled ninety days after termination of an employee, </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-21</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:10pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">director, founder, or consultant. Unexercised options are cancelled immediately if an employee, director, founder, or consultant is terminated for cause; under certain other circumstances, the period to cancellation may differ as described in the respective plan documents. Certain clauses in the Plans also govern the Company's exercise repurchase rights and various other features of awards granted under the plans.</font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2021, only stock options have been awarded pursuant to the MAIA stock award plans.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the activity and information regarding MAIA's outstanding and exercisable options as of December&#160;31, 2021:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise Price</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Term in Years</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic Value</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at January 1, 2020</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,627,000</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.80</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.30</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,287,466</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.80</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.00</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cancelled/forfeited</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(249,500</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.80</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,664,966</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.80</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.13</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,210,787</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.92</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.38</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.80</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cancelled/forfeited</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(73,568</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.82</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,797,185</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.22</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.59</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38,784,352</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options exercisable at December 31, 2021</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,012,181</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.91</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.52</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,865,649</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the period of March 2021 through May 2021, the fair value of the Company's common stock was estimated for financial reporting purposes based on valuations of $1.83 per share in February 2021 and April 2021 due to the lack of any single specific event that would have indicated a definitive change in the value of the Company. Between June 2021 and October 2021, the fair value of the Company&#8217;s common stock, was determined based on sales of the Company&#8217;s shares at arm&#8217;s length to unrelated third parties at $8.00 per share. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During November 2021 and December 2021, the fair value of the Company&#8217;s common stock was determined to be $8.69 and $8.87, respectively. For our valuations of common stock performed, we used a hybrid method of the Option Pricing Method ("OPM&#8221;) and the Probability-Weighted Expected Return Method ("PWERM&#8221;). PWERM considers various potential liquidity outcomes. Our approach included the use of an initial public offering scenario, a scenario assuming continued operation as a private entity, and a dissolution scenario. Under the hybrid OPM and PWERM, the per share value calculated under the OPM and PWERM are weighted based on expected exit outcomes and the quality of the information specific to each allocation methodology to arrive at a final estimated fair value per share of the common stock before a discount for lack of marketability is applied. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To determine the fair value of our common stock, we first determined our enterprise value using accepted valuation approaches; adjusted these valuation approaches with relevant discounts; weighted the results appropriately; and then allocated the equity value to our common stock and common stock equivalents. Our enterprise value was estimated using two generally accepted approaches: the income approach and the market approach. The income approach estimates enterprise value based on the estimated present value of future cash flows the business is expected to generate over its remaining life. The estimated present value is calculated using a discount rate reflective of the risks associated with an investment in a similar company in a similar industry or having a similar history of revenue growth. The market approach measures the value of a business through an analysis of recent sales or offerings of comparable investments or assets, and in our case, focused on comparing us to a group of our peer companies. In applying this method, valuation multiples are derived from historical and projected operating data of the peer company group. We then apply the selected multiples to our operating data to arrive at a range of indicated enterprise values of the Company. We then subtracted the net debt to determine equity value. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Following the initial public offering, it will not be necessary to determine the fair value of our common stock, as our shares will be traded in the public market.</p><a name="_AEIOULastRenderedPageBreakAEIOU30"></a>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-22</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The value of option grants are calculated using the Black-Scholes-Merton option pricing model with the following assumptions for options granted during the year ended December 31,:</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.36% - 1.27%</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.35% - 1.39%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (in years)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5 - 6.50</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5 - 5.5</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71.40% - 81.5%</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76.5% - 80.7%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The weighted-average grant date fair values of stock options issued during the years ended December&#160;31, 2021 and 2020 were $3.55 and $1.11, respectively. At December&#160;31, 2021, the total unrecognized compensation related to unvested employee and non-employee stock option awards granted was $3,116,815, which the Company expects to recognize over a weighted average period of approximately 2.71 years.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">DGD Pharmaceuticals Corporation 2019 Stock Option Plan</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, there were options for the purchase of 805,000 shares of common stock outstanding. There were no stock options granted under the DGD plan during the year ended December 31, 2021. All options were cancelled upon the dissolution of DGD on August 13, 2021 (see Note 1). During the years ended December 31, 2021 and 2020, compensation expense associated with previously-issued options was recognized in general and administrative expenses in the amount of $5,208 and $19,802, respectively. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">THIO Therapeutics, Inc. Amended and Restated 2020 Equity Incentive Plan</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">THIO's board of directors administered the THIO Therapeutics, Inc. Amended and Restated Equity Incentive Plan (the "THIO Plan"), under which 1,000,000 shares of THIO's common stock were reserved for issuance, as authorized by the board of directors in June 2020. The terms of the THIO Plan provided for the grant of options, restricted stock, and restricted stock units to employees, directors, and consultants of THIO.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of August 13, 2021, the THIO Plan was terminated upon dissolution of THIO.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock based compensation related to the Company&#8217;s stock plans are as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Year Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,512,726</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,033,248</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">943,708</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">337,792</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stock-based compensation</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,456,434</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,371,040</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Other Equity Activity of DGD and THIO</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">DGD Pharmaceuticals Corporation </font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DGD was authorized to issue 10,000,000 shares (4,000,000 Class A and 6,000,000 Class B) of stock with a par value of $0.0001 per share. Holders of Class A common shares were entitled to one vote per share, whereas holders of Class B were entitled to two votes per share. As of December 31, 2020, 2,575,000 and 6,000,000 shares of Class A and Class B stock, respectively, were issued and outstanding. As of December 31, 2020, MAIA owned 690,000 and 6,000,000 Class A and Class B common shares, respectively. Class A common shareholders were entitled to one vote per share, whereas Class B common shareholders were entitled to two votes per share.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All shares of DGD common stock cease to exist as of August 13, 2021, when the entity was legally dissolved.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Restricted Common Stock Awards to Founders of DGD</font> &#8212; In May 2019, DGD awarded 1,550,000 restricted Class A common shares to four founders. The fair value of these shares was determined to be $1.00 based on sales of common stock to third parties, for a total fair value of $1,550,000. Vested shares participated in any dividends and other distributions with other common stockholders, while the unvested shares, which were subject to forfeiture in the event the holder separated from service with DGD, do not participate in such events. The share award was subject to service conditions, with 50% of the </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-23</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:10pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">granted shares vesting at the date of grant, and the remaining 775,000 common shares vesting in 36 equal monthly installments over a three-year period, with the first such monthly installment vesting on June 1, 2019. </font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The related compensation expense is recognized ratably over the service period. For the year ended December 31, 2021 and 2020, the Company recognized $161,460 and $206,947, respectively, in compensation expense related to these awards which was presented in general and administrative expenses.&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, in December 2019, DGD issued 62,500 shares of Class A common stock to a stockholder which vested during 2020 as certain services were provided (Note 2). During 2020, the Company recorded $75,000 to research and development expenses in connection with this agreement.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On August 13, 2021, all remaining unvested restricted shares were cancelled upon the dissolution of DGD (see Note 1).</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Grant Date</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested balance at January 1, 2020</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">686,804</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.00</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,500</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.00</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(320,836</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested balance at December 31, 2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">378,468</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.00</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cancelled</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(378,468</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested balance at August 13, 2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Other Issuances of Common Stock</font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2020, DGD issued 322,000 shares of Class B common stock to MAIA for $321,968.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2020, DGD issued 50,000 shares of Class A common stock to investors for $50,000.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2020, DGD issued 690,000 shares of Class A common stock and 10,000 shares of Class B common stock to MAIA for $699,999.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">THIO Therapeutics Inc.</font><font style="font-weight:bold;"> </font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">THIO was authorized to issue 11,000,000 shares of common stock with a par value of $0.00001 per share. All shares of THIO common stock cease to exist as of August 13, 2021, when the entity was legally dissolved.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Restricted Common Stock Award to Founder</font> &#8212; In April 2019, THIO awarded 700,000 restricted common shares to a founder. Any vested shares participated in dividends and other distributions with other common stockholders, while the unvested shares, which were subject to forfeiture in the event the founder separates from service with THIO, did not participate in such events. The share award was subject to service conditions, with 350,000 shares vesting at the date of grant, and the remaining 350,000 common shares vesting in twelve equal quarterly installments over a three-year period, with the first such quarterly installment vesting on July 1, 2019. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Grant Date</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at January 1, 2020</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">291,667</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.80</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(116,667</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2020</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">175,000</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.80</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(87,500</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cancelled</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(87,500</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at August 13, 2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-24</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The related compensation expense was recognized over the service period. For the years ended December 31, 2021 and 2020, THIO recognized $105,000 and $210,000, respectively, in compensation expense related to this award which was presented in general and administrative expenses. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On August 13, 2021, upon the dissolution of THIO and merger into MAIA, a founder's 612,500 fully vested THIO restricted shares were cancelled and the founder was issued 612,500 MAIA restricted shares. Additionally, in accordance with the founder's original award, the founder was also issued 87,500 MAIA restricted shares which vest ratably each quarter through June 30, 2022 to replace the equivalent number of unvested THIO restricted shares which were cancelled. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="OLE_LINK4"></a><font style="text-decoration:underline;">Other Issuances of Common Stock</font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During 2020, THIO issued an additional 200,000 shares of common stock to MAIA for a price of $320,000.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.78%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">9</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">COMMITMENTS AND CONTINGENCIES</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Legal</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, the Company is involved in legal actions and claims arising in the normal course of business. Management believes there are no matters which will have a material adverse effect on the Company's financial position, operations or cash flows.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Patent Licensing, Sponsored Research, and Patent &amp; Technology Agreements </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">THIO</font> - In November 2018 and as amended in December 2020, the Company entered into a Global Patent Licensing Agreement ("PLA") titled "Patent and Technology License Agreement AGT. NO. L2264 - MAIA Biotechnology" with the University of Texas Southwestern ("UTSW") to license patent families for a specific compound ("THIO") from UTSW to MAIA. The agreement, as amended, has a term of 20 years. The agreement requires MAIA to reimburse UTSW for agreed-upon expenses related to THIO. The agreement requires certain payments upon assignment of the license to a third party as well as upon reaching specific milestones, ranging between $1,000,000 and $50,000,000, not to exceed a combined milestone payment total of $112,000,000. As of December 31, 2021, no assignment has occurred and none of the defined milestones have been completed and therefore no payments are due to UTSW related to the milestones. The agreement requires royalties of 2-4% (depending on THIO reaching specified sales levels in the respective jurisdictions) royalty payments on net sales up to $1,000,000,000, and 2.5-5% on net sales above $1,000,000,000.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Also in December 2020, the Company entered into a second license agreement with UTSW titled "Patent and Technology License Agreement AGT. NO. L3648 &#8212; MAIA Biotechnology" pursuant to which UTSW is licensing an additional compound to MAIA. The agreement has a term of 20 years and requires the Company to reimburse UTSW for certain agreed-upon expenses. The agreement requires certain payments upon assignment of the license to a third party as well as upon reaching specific milestones, ranging between $1,000,000 and $50,000,000, not to exceed a combined milestone payment total of $112,000,000. As of December 31, 2020, no assignment has occurred and none of the defined milestones have been completed and therefore no payments are due to UTSW related to the milestones.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The agreement requires royalties of 2-4% (depending on THIO reaching specified sales levels in the respective jurisdictions) royalty payments on net sales up to $1,000,000, and 2.5-5% on net sales above $1,000,000,000.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company will also pay UTSW running royalties on a yearly basis as a percentage of Net Sales of the Company or its sublicensee. There are single digit royalty rates for licensed products and licensed services covered by a Valid Claim (as defined in the agreement) and dependent on whether Net Sales are greater than or less than/equal to $1,000,000,000, with Net Sales above that amount commanding a slightly higher percentage. In each case, the royalty percentage is lower before patent issuance in each jurisdiction. In the event that the licensed product or licensed service is not covered by a Valid Claim, the running royalty rates are reduced by fifty percent (50%). The royalty obligations continue on a country-by-country basis until the later of expiration of the last Valid Claim in each country or ten (10) years after the First Commercial Sale (as defined in UTSW2 Agreement) in each country. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">GMCI</font> &#8212; In November 2018, MAIA entered into a Global PLA and Sponsored Research Agreement ("SRA") for Collaborative Research and Jointly Owned Intellectual Property for the GMC1 Family of Compounds for the Treatment of Prostate Cancer with the University of Texas El Paso ("UTEP"). The SRA requires MAIA to reimburse UTEP for research program expenditures up to $46,000. The SRA for background Intellectual Property term is the last date of expiration or termination of the patent rights (2035). As amended, the SRA extended the research program to May 2020 since which point it has continued on an at-will basis.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-25</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">MJC13</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> &#8212; In January 2019, MAIA entered into a Global PLA and SRA for Collaborative Research and Jointly Owned Intellectual Property for the MJC13 Family of Compounds for the Treatment of Prostate Cancer with UTEP. The SRA requires MAIA to reimburse UTEP for research program expenditures up to $46,000. As amended, the SRA extended the research program to June 2020, since which point it has continued on an at-will basis.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.78%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">0</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">INCOME TAXES</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company's net deferred tax assets consist of the following components:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating loss carryforwards</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,013,721</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,418,873</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,800,935</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,132,473</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred compensation</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,718</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">156,717</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued bonus</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">109,673</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">222,339</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71,107</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total net deferred tax assets before valuation allowance</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,027,154</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,930,402</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation allowance</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,027,154</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,930,402</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred tax asset</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At December&#160;31, 2021, the Company has unused U.S. federal and state net operating loss (&#8220;NOL&#8221;) carryforwards of $10.6 million that may be applied against future taxable income. The state NOL carryforwards begin to expire in 2030. The U.S. federal NOL carryforwards may be carried forward indefinitely, however U.S. federal NOL carryforwards arising after January 1, 2021, are limited to 80 percent of taxable income.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The use of the Company&#8217;s NOL carryforwards may, however, be subject to limitations as a result of an ownership change. A corporation undergoes an &#8220;ownership change,&#8221; in general, if a greater than 50% change (by value) in its equity ownership by one or more five&#8209;percent stockholders (or certain groups of non&#8209;five&#8209;percent stockholders) over a three&#8209;year period occurs. After such an ownership change, the corporation&#8217;s use of its pre&#8209;change NOL carryforwards and other pre&#8209;change tax attributes to offset its post&#8209;change income is subject to an annual limitation determined by the equity value of the corporation on the date the ownership change occurs multiplied by a rate determined monthly by the Internal Revenue Service.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an ownership change occurs and if the Company earns net taxable income, the Company&#8217;s ability to use its pre&#8209;change NOLs to offset U.S. federal and taxable income would be subject to these limitations, which could potentially result in increased future tax liability compared to the tax liability the Company would incur if its use of NOL carryforwards were not so limited. In addition, for state income, franchise and similar tax purposes, there may be periods during which the use of NOL carryforwards is suspended or otherwise limited, which could accelerate or permanently increase the Company&#8217;s state income, franchise, or similar taxes. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In accordance with ASC 740, the Company recorded a valuation allowance to fully offset the gross deferred tax asset, because it is not more likely than not that the Company will realize future benefits associated with these deferred tax assets at December&#160;31, 2021 and 2020. The valuation allowance increased by approximately $2.1 million and $1.7 million during the years ended December&#160;31, 2021 and 2020, respectively, mainly due to increases in the NOL carryforward and other deferred tax assets. The Company will continue to assess the realizability of the deferred tax assets at each interim and annual balance sheet date based upon actual and forecasted operating results.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">No provision or benefit for U.S. federal or state income taxes has been recorded for the years ended December 31, 2021 and 2020, as the Company has incurred a net loss for all of the periods presented, and the Company has provided a full valuation allowance against its deferred tax assets.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-26</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The income tax expense (benefit) differs from the expense (benefit) that would result from applying federal statutory rates to loss before income taxes as follows:</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Statutory federal income tax rate</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State taxes, net of federal tax benefit</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.4</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.5</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.9</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.6</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss on extinguishment of debt</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3.9</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212; %</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other nondeductible expenses/(nontaxable income)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.8</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.2</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in valuation allowance</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16.8</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(25.1</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income tax benefit</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212; %</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212; %</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit would more likely than not be realized assuming examination by the taxing authority. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. The Company recognizes any interest and penalties accrued related to unrecognized tax benefits as income tax expense. The Company did not have any significant unrecognized tax benefits during the years ended December&#160;31, 2021 and 2020. The Company files income tax returns in the U.S. federal jurisdiction and several U.S. States, and Australia. The Company&#8217;s tax returns since inception remain open to examination by the taxing authorities.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.78%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">SUBSEQUENT EVENTS</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise of MAIA Warrants</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During January 2022, 61,111 warrants were exercised, resulting in a total of 61,111 shares of MAIA common stock issued for proceeds of approximately $110,000.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Extension of MAIA Warrant Exercise Periods</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2022, the Company and certain warrant holders executed waivers related to the acceptance and approval of an amendment to the holders' warrant agreements originally issued between May 6, 2020 and February 26, 2021 in connection with the Company's issuance of convertible notes. The amendment will remove the IPO expiration provision from the warrant agreements, and the warrants shall only be exercisable, in whole or in part, during the exercise period ending on earliest to occur of: (a) various dates in 2028 as stated within the warrant agreements; or (b) immediately prior to the closing of a change of control. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Sales of MAIA Common Stock </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During January and February 2022, the Company sold 263,729 shares of common stock at $9.00 per share for gross proceeds of $2,373,561 before transaction costs and expenses.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">MAIA Option Exercises</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2022, two employees exercised a total of 26,500 stock options, resulting in proceeds of $47,700.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">MAIA Option Grants </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During March 2022, the Company issued 102,792 stock options to employees and consultants, with a weighted average exercise price of $9.00 per share.&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-27</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p><a name="_AEIOULastRenderedPageBreakAEIOU31"></a>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">MAIA Biotechnology, Inc. and Subsidiaries</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:-0.1%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="FS_BS"></a>Condensed Consolidated Balance Sheets</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.96%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.96%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.96%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.96%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(unaudited)</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ASSETS</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current assets:</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,293,460</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,574,292</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.96%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses and other current assets</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">234,628</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">98,203</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current assets</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,528,088</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,672,495</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred offering costs</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">913,675</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">651,582</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.96%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other assets</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,800</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,122</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.96%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:25.5pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total assets</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,444,563</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,327,199</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">LLABILITIES AND STOCKHOLDERS&#8217; EQUITY</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current liabilities</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">895,108</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">960,401</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,421,452</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,074,324</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.96%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred compensation</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">114,333</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">111,271</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.96%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current liabilities</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,430,893</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,145,996</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.96%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,430,893</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,145,996</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commitments and contingencies</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stockholders' equity (deficit)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preferred stock, $0.0001 par value, 70,000,000</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; shares authorized, 0 shares issued and outstanding</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.9pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock, $0.0001 par value, 30,000,000 shares</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.9pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; authorized, 7,936,320 and 7,584,980 shares issued</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.9pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; and outstanding at March 31, 2022 and</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.9pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; December 31, 2021, respectively</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">794</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">758</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additional paid-in capital</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40,862,993</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,618,438</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated deficit</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(31,851,838</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(28,437,993</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.96%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated other comprehensive income</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,721</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.96%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stockholders' equity</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,013,670</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,181,203</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.96%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities and stockholders' equity</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,444,563</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,327,199</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0.1%;text-indent:-0.1%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See the accompanying notes to the unaudited condensed consolidated financial statements.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-28</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p><a name="_AEIOULastRenderedPageBreakAEIOU32"></a>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">MAIA Biotechnology, Inc. and Subsidiaries</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="FS_SOP"></a>Condensed Consolidated Statements of Operations</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses:</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,077,329</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">262,758</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,366,229</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">787,955</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating costs and expenses</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,443,558</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,050,713</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,443,558</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,050,713</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income (expense):</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest expense</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(62,767</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">472</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">141</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Australian research and development incentives</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,241</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value of embedded features</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(15,000</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value of warrant liability</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">106,820</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income (expense), net</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,713</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,194</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,413,845</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,021,519</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to noncontrolling interests</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(37,525</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deemed divided on warrant modification</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(450,578</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to MAIA Biotechnology, Inc. shareholders</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,864,423</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(983,994</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic and diluted</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.50</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.23</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average common shares outstanding</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic and diluted</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,752,042</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,329,088</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See the accompanying notes to the unaudited condensed consolidated financial statements.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-29</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p><a name="_AEIOULastRenderedPageBreakAEIOU33"></a>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">MAIA Biotechnology, Inc. and Subsidiaries</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="CONDENSED_CONSOLIDATED_STATEMENTS_COMPRE"></a><a name="CONDENSED_CONSOLIDATED_STATEMENTS_COMPRE"></a>Condensed Consolidated Statements of Comprehensive Loss</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:61.32%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable MAIA Biotechnology, Inc. shareholders</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.42%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,864,423</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.42%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(983,994</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:61.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign currency translation adjustment</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,720</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:61.32%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive loss to MAIA Biotechnolgy, Inc.</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,866,143</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">983,994</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See the accompanying notes to the unaudited condensed consolidated financial statements.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-30</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p><a name="_AEIOULastRenderedPageBreakAEIOU34"></a>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">MAIA Biotechnology, Inc. and Subsidiaries</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="CONDENSED_CONSOLIDATED_STATEMENTS_CHANGE"></a>Condensed Consolidated Statements o<a name="CONDENSED_CONSOLIDATED_STATEMENTS_CHANGE"></a>f Changes in Stockholders' Equity (Unaudited)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Three Months ended March 31, 2022&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.64%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Common Stock</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.46%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.46%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.46%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.46%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.46%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.46%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.64%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Additional</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Paid-In</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Capital</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Deficit</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">other</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">comprehensive</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">income</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total MAIA</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Equity</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Deficit)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Noncontrolling</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Interest</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stockholders'</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Deficit)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Equity</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2021</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,584,980</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">758</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,618,438</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(28,437,993</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,181,203</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,181,203</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common shares upon exercise of stock</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; options</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,500</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47,697</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47,700</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47,700</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common shares upon exercise of warrants</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61,111</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">109,994</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">110,000</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">110,000</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common shares in connection with Equity</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; Financing</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">263,729</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,373,534</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,373,561</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,373,561</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">713,330</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">713,330</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">713,330</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Modification of warrant in equity</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">450,478</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deemed dividend on modification of warrant</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(450,478</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign currency translation adjustment</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,721</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,721</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,721</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,413,845</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,413,845</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,413,845</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at March 31, 2022</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,936,320</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">794</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40,862,993</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(31,851,838</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,721</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,013,670</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,013,670</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See the accompanying notes to the unaudited condensed consolidated financial statements.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-31</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p><a name="_AEIOULastRenderedPageBreakAEIOU35"></a>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:1pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">MAIA Biotechnology, Inc. and Subsidiaries</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficit) (Unaudited)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Three Months ended March 31, 2021</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.64%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Common Stock</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.46%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.46%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.46%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.46%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.46%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.46%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.64%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Additional</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Paid-In</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Capital</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Deficit</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Subscription Receivable</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total MAIA</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Equity</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Deficit)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Noncontrolling</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Interest</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stockholders'</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Deficit)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Equity</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2020</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,433,644</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">443</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,599,585</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(15,934,113</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,002</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,336,087</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,719,787</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,616,300</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of restricted common shares</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,278</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,498</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,500</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,500</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cancellation of restricted common shares</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,557</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common shares upon exercise of stock</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; options</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,400</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,400</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,400</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Receipt of stock subscription receivable</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,002</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,002</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,002</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense-MAIA</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">408,608</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">408,608</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">408,608</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense-DGD</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64,584</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64,584</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense-THIO</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52,500</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52,500</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(983,994</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">983,994</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(37,525</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,021,519</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at March 31, 2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,446,365</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">444</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,041,091</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,918,107</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,876,572</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,799,346</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,077,226</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See the accompanying notes to the unaudited condensed consolidated financial statements.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-32</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p><a name="_AEIOULastRenderedPageBreakAEIOU36"></a>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">MAIA Biotechnology, Inc. and Subsidiaries</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="CONDENSED_CONSOLIDATED_STATEMENTS_CASH_F"></a><a name="CONDENSED_CONSOLIDATED_STATEMENTS_CASH_F"></a>Condensed Consolidated Statements of Cash Flows </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cash flows from operating activities:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss, including noncontrolling interests</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,413,845</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,021,519</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adjustments to reconcile net loss to net cash used in operating activities:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">713,330</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">553,192</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value of embedded features</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,000</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value of warrant liability</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(106,820</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortization of debt discount</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45,265</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in operating assets and liabilities:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses and other current assets</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(134,341</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44,307</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">322</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(68,560</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(67,120</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">119,780</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">352,874</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48,073</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Due to related parties</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7,037</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred compensation</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,062</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">125,004</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in operating activities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,545,718</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(253,315</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cash flows from financing activities:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from issuance of convertible notes, warrants, and embedded</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; conversion features</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,360,000</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred offering costs</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(262,093</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from Paycheck Protection Program loan</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62,500</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Collections of subscriptions receivable</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,002</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from issuance of common stock, net of transaction costs</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,373,561</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from exercise of stock options</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47,700</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,400</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from exercise of warrants</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">110,000</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payment on loan payable to officer</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(367</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by financing activities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,269,168</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,429,535</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cash flows from financing activities foreign currency exchange rates:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effect of foreign currency exchange on cash</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,282</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net effect of foreign currency exchange on cash</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,282</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net increase (decrease) in cash</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(280,832</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,176,220</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash at beginning of period</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,574,292</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">663,457</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash at end of period</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,293,460</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,839,677</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Supplemental disclosure of cash flow information:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of convertible note for payment on loan to officer</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,000</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See the accompanying notes to the unaudited condensed consolidated financial statements.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-33</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">MAIA Biotechnology, Inc. and Subsidiaries</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="NOTES_TO_UNAUDITED_CONDENSED_CONSOLIDATE"></a><a name="NOTES_TO_UNAUDITED_CONDENSED_CONSOLIDATE"></a>Notes to Unaudited Condensed Consolidated Financial Statements</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.78%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">NATURE OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Description of Business, Organization, and Principles of Consolidation</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MAIA Biotechnology, Inc. and Subsidiaries (collectively, "the Company") is a biopharmaceutical company that develops oncology drug candidates to improve and extend the lives of people with cancer. MAIA Biotechnology, Inc. ("MAIA") was incorporated in the state of Delaware on August 3, 2018. These consolidated financial statements include the accounts of MAIA and its subsidiaries, as follows:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.51%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.51%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">THIO Therapeutics, Inc. ("THIO"), incorporated in the state of Delaware on November 26, 2018. On August 13, 2021, MAIA and THIO completed a plan of reorganization in which THIO merged with and into MAIA. Prior to the merger, MAIA owned 93.3% of the outstanding shares of THIO common stock, which were cancelled in connection with the merger. The remaining 6.7% minority stockholder of THIO received one share of MAIA common stock for each share of THIO common stock owned prior to the merger. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.51%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.51%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">DGD Pharmaceuticals Corporation ("DGD"), incorporated in the state of Delaware of April 1, 2019. In July 2020, the board of directors approved the dissolution of DGD, and shortly thereafter also approved a special dividend/return of capital to its stockholders. On August 13, 2021, DGD was officially dissolved via a filing of a Certificate of Dissolution with the state of Delaware. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.51%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.51%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">MAIA Drug Development Corporation ("MAIA DD") incorporated in the state of Texas on September 10, 2018, and was 100% owned by MAIA, until MAIA DD was legally dissolved in July 2021. The operations of MAIA DD were nominal.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.51%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.51%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">In July 2021, the Company established a wholly owned Australian subsidiary, MAIA Biotechnology Australia Pty Ltd, to conduct various pre-clinical and clinical activities for the development of the Company's product candidates.&nbsp;&nbsp;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Liquidity </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk102667146"></a>At March&#160;31, 2022, the Company had working capital of&#8201;$8,097,195, accumulated deficit of $32,302,416, cash of $10,293,460 and current liabilities of $2,430,893. Since inception the Company has experienced net losses and negative cash flows from operations each fiscal year. The Company has no revenues and expects to continue to incur operating losses for the foreseeable future, and may never become profitable. The Company is dependent on its ability to continue to raise equity and/or debt financing to continue operations, until<a name="_Hlk102667146"></a> the attainment of profitable operations. During January and February 2022, the Company sold 263,729 shares of common stock at $9 per share for gross proceeds of $2,373,561.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company will require significant funding to perform the necessary clinical trials, and to meet the Company&#8217;s long-term development and commercialization goals. The Company believes that its cash as of March 31, 2022, subsequent cash proceeds from the exercise of warrants and planned capital raises will be sufficient to support operations through the next twelve months from the date the consolidated financial statements are issued, including funding of the THIO-101 lead-in and preliminary efficacy of the phase 2 THIO-101. The Company plans to meet its capital requirements primarily through issuances of equity securities. The Company cannot make any assurances that additional financings will be available, on acceptable terms or at all. If the Company is unable to raise the necessary funding, management will undertake cost cutting measures, as done in the past, to reduce compensation and reduce the scope of or delay its clinical programs. This could negatively impact the Company&#8217;s business and could also lead to the reduction of the Company&#8217;s operations.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Impact of the COVID-19 Pandemic on our Operations</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On January 30, 2020, the World Health Organization (&#8220;WHO&#8221;) announced a global health emergency because of a new strain of coronavirus originating in Wuhan, China (the &#8220;COVID-19 Outbreak&#8221;) and the risks to the international community as the virus spreads globally beyond its point of origin. In March 2020, the WHO classified the COVID-19 Outbreak as a pandemic, based on the rapid increase in exposure globally.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-34</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The full impact of the COVID-19 Outbreak continues to evolve as of the date of this report. As a result, we cannot estimate the full magnitude that the pandemic will have on our business. If the COVID-19 Outbreak continues, it may have a material adverse effect on our financial condition, liquidity, and future results of operations for the future. We are actively monitoring the impact of the global pandemic on our financial condition, liquidity, operations, industry, and workforce. Given the daily evolution of the COVID-19 Outbreak and the global responses to curb its spread, we are not able to estimate the effects of the COVID-19 Outbreak on our results of operations, financial condition, or liquidity for the future. One of our initial clinical studies is taking place in Australia, which has imposed one of the strictest COVID-19-related measures, including lock-downs. While we have not currently experienced any potential delays or increased costs as a result of these measures, we may do so in the future.</font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Basis of Presentation</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (&#8220;GAAP&#8221;) as determined by Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) for interim financial information. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, the unaudited interim condensed consolidated financial statements reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the balances and results of operations for the periods presented. They may not include all of the information and footnotes required by GAAP for complete financial statements. Therefore, these financial statements should be read in conjunction with the Company&#8217;s audited financial statements and notes thereto for the year ended December 31, 2021. The results of operations for any interim periods are not necessarily indicative of the results that may be expected for the entire fiscal year or any other interim period.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The unaudited interim condensed consolidated financial statements include the accounts of the Company's wholly owned subsidiaries. All transactions and accounts between and among its subsidiaries have been eliminated. All adjustments and disclosures necessary for a fair presentation of these unaudited interim condensed consolidated financial statements have been included.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of the Company&#8217;s unaudited interim condensed financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The most significant estimates in the Company&#8217;s financial statements relate to the valuation of common stock, stock options, warrants, the embedded features in convertible notes and the valuation allowance of deferred tax assets resulting from net operating losses. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company&#8217;s future results of operations will be affected.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Certain Risks and Uncertainties</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s activities are subject to significant risks and uncertainties including the risk of failure to secure additional funding to properly execute the Company&#8217;s business plan. The Company is subject to risks that are common to companies in the pharmaceutical industry, including, but not limited to, development by the Company or its competitors of new technological innovations, dependence on key personnel, reliance on third party manufacturers, protection of proprietary technology, and compliance with regulatory requirements</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Foreign Currency Translation</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The financial statements of the Company&#8217;s foreign subsidiary, where the local currency is the functional currency, are translated using exchange rates in effect as of the applicable balance sheet dates for assets and liabilities and average exchange rates during the period for results of operations. The resulting foreign currency translation adjustment, is included in shareholders&#8217; equity as accumulated other comprehensive loss.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-35</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Off-Balance Sheet Risk and Concentrations of Credit Risk</font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has no significant off-balance sheet risks, such as foreign exchange contracts, option contracts, or other foreign hedging arrangements. Cash accounts are maintained at financial institutions that potentially subject the Company to concentrations of credit risk. At March 31, 2022 and December 31, 2021, substantially all of the Company&#8217;s cash was deposited in accounts at one financial institution. The Company maintains its cash deposits, which at times may exceed the federally insured limits, with a reputable financial institution and, accordingly, the Company believes such funds are subject to minimal credit risk.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Cash and Cash Equivalents</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company considers all highly liquid investments purchased with maturities of three months or less to be cash equivalents. As of March 31, 2022 and December 31, 2021, cash includes cash in a depository bank account; the Company has no cash equivalents as of March 31, 2022 and December 31, 2021.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Fair Value Measurements</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ASC 820, <font style="font-style:italic;">Fair Value Measurements</font>, provides guidance on the development and disclosure of fair value measurements. Under this accounting guidance, fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. To increase the comparability of fair value measures, the following hierarchy prioritizes the inputs to valuation methodologies used to measure fair value:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.51%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.51%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">Level&#160;1 - Valuations based on quoted prices for identical assets and liabilities in active markets.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.51%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.51%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">Level&#160;2 - Valuations based on observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.51%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.51%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">Level&#160;3 - Valuations based on unobservable inputs reflecting our own assumptions, consistent with reasonably available assumptions made by other market participants. These valuations require significant judgment.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair value measurements discussed herein are based upon certain market assumptions and pertinent information available to management as of and during the period ended March 31, 2022, and as of and during the period ended December 31, 2021. The carrying amount of accounts payable approximated fair value as they are short term in nature. The fair value of warrants issued for services is estimated based on the Black-Scholes model during the periods ended March 31, 2022 and 2021. The carrying value of notes payable and convertible notes payable approximated the estimated fair values due to their recent issuances. The estimated fair value of the warrants issued with the convertible notes and embedded features, represented Level 3 measurements.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">General and Administrative</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses primarily consist of costs for corporate functions, including payroll and related expenses, depreciation and amortization, rent, outside legal expenses, insurance costs, and other general and administrative costs.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Research and Development</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s research and development expenses consist primarily of costs associated with the Company&#8217;s clinical trials, salaries, payroll taxes, employee benefits, and stock-based compensation charges for those individuals involved in ongoing research and development efforts. Research and development costs are expensed as incurred. Advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As part of the process of preparing the consolidated financial statements, the Company is required to estimate its accrued expenses. This process involves reviewing quotations and contracts, identifying services that have been </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-36</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:10pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">performed on the Company&#8217;s behalf and estimating the level of service performed and the associated cost incurred for the service when the Company has not yet been invoiced or otherwise notified of the actual cost. The majority of the Company&#8217;s service providers invoice the Company monthly in arrears for services performed or when contractual milestones are met. The Company makes estimates of its accrued expenses as of each balance sheet date in our consolidated financial statements based on facts and circumstances known to the Company at that time. The Company periodically confirms the accuracy of its estimates with the service providers and makes adjustments if necessary. The significant estimates in the Company&#8217;s accrued research and development expenses are related to expenses incurred with respect to CROs, CMOs and other vendors in connection with research and development and manufacturing activities.</font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company bases its expense related to CROs and CMOs on its estimates of the services received and efforts expended pursuant to quotations and contracts with such vendors that conduct research and development and manufacturing activities on the Company&#8217;s behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which payments made to the Company&#8217;s vendors will exceed the level of services provided and result in a prepayment of the applicable research and development or manufacturing expense. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from its estimate, the Company adjusts the accrual or prepaid expense accordingly. Although the Company does not expect its estimates to be materially different from amounts actually incurred, the Company&#8217;s understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and could result in us reporting amounts that are too high or too low in any particular period. There have been no material changes in estimates for the periods presented.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Research and Development Incentive&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes other income from Australian research and development incentives when there is reasonable assurance that the income will be received, the relevant expenditure has been incurred, and the consideration can be reliably measured. The research and development incentive is one of the key elements of the Australian Government&#8217;s support for Australia&#8217;s innovation system and is supported by legislative law primarily in the form of the Australian Income Tax Assessment Act 1997, as long as eligibility criteria are met.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Management has assessed the Company&#8217;s research and development activities and expenditures to determine which activities and expenditures are likely to be eligible under the research and development incentive regime described above. At each period end, management estimates the refundable tax offset available to the Company based on available information at the time and it is included in Australian research and development incentives in the condensed consolidated statements of operations.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the program, a percentage of eligible research and development expenses incurred by the Company through its subsidiary in Australia are reimbursed.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Derivative Financial Instruments</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. The Company evaluates all of its financial instruments, to determine if such instruments contain features that qualify as embedded derivatives.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Embedded derivatives must be separately measured from the host contract if all the requirements for bifurcation are met. The assessment of the conditions surrounding the bifurcation of embedded derivatives depends on the nature of the host contract. Bifurcated embedded derivatives are recognized at fair value, with changes in fair value recognized in the statement of operations each period. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Stock-Based Compensation</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company records share-based compensation for options granted to employees, non-employees, and to members of the board of directors based on the grant date fair value of awards issued, and the expense is recorded on a straight-line basis over the requisite service period. Forfeitures are recognized when they occur.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-37</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company uses the Black-Scholes-Merton option pricing model to determine the fair value of stock options and warrants. The use of the Black-Scholes-Merton option-pricing model requires management to make assumptions with respect to the expected term of the option, the expected volatility of the common stock consistent with the expected life of the option, risk-free interest rates and expected dividend yields of the common stock. The Company has concluded that its historical share option exercise experience does not provide a reasonable basis upon which to estimate expected term. Therefore, the expected term was determined according to the simplified method, which is the average of the vesting tranche dates and the contractual term. Due to the lack of company specific historical and implied volatility data, the estimate of expected volatility is primarily based on the historical volatility of a group of similar companies that are publicly traded. For these analyses, companies with comparable characteristics are selected, including enterprise value and position within the industry, and with historical share price information sufficient to meet the expected life of the share-based awards. The Company computes the historical volatility data using the daily closing prices for the selected companies&#8217; shares during the equivalent period of the calculated expected term of its share-based awards. The risk-free interest rate is determined by reference to U.S. Treasury zero-coupon issues with remaining maturities similar to the expected term of the options. The Company has not paid, and does not anticipate paying, cash dividends on shares of its common stock.</font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to the initial public offering, in order to estimate the fair value of shares of the common stock, the Company's board of directors considered, among other things, sales of common stock to third party investors and valuations of common stock, business, financial condition and results of operations, including related industry trends affecting operations; the likelihood of achieving a liquidity event, such as an initial public offering, or sale, given prevailing market conditions; the lack of marketability of our common stock; the market performance of comparable publicly traded companies; and U.S. and global economic and capital market conditions.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There were no issuances of common stock as it relates to DGD or THIO during the three months ended March 31, 2021. The fair value of restricted stock awards is based on the common stock price. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All stock-based compensation costs are recorded in general and administrative or research and development costs in the consolidated statements of operations based upon the underlying individual&#8217;s role at the Company.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Common Stock Warrants</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for common stock warrants as either equity instruments or liabilities in accordance with ASC 480, Distinguishing Liabilities from Equity ("ASC 480"), depending on the specific terms of the warrant agreement.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">When warrants are issued for services to non-employees, under ASC 718, Compensation - Stock Compensation ("ASC 718"), the warrants shall be classified as a liability if 1) the underlying shares are classified as liabilities or 2) the entity can be required under any circumstances to settle the warrant by transferring cash or other assets. In accordance with ASU 2018-07, Improvements to Nonemployee Share-Based Payment Accounting, the measurement of equity-classified nonemployee share-based payments is generally fixed on the grant date and are considered compensatory, as defined by ASC 718. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Income Taxes</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income taxes are recorded in accordance with ASC 740, Income Taxes (&#8220;ASC 740&#8221;), which provides for deferred taxes using an asset and liability approach. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Valuation allowances are provided, if based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit would more likely than not be realized assuming examination by the taxing authority. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. The Company recognizes any interest and penalties accrued related to unrecognized tax benefits as income tax expense.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-38</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Deferred Offering Costs</font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred offering costs are included in other assets and consists of legal, accounting, underwriting fees and other costs incurred through the balance sheet date that are directly related to the planned initial public offering and that will be charged to additional paid-in capital upon the completion of the planned initial public offering. Should the planned initial public offering prove to be unsuccessful, these deferred costs, as well as additional expenses to be incurred, will be charged to operations.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Leases</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2016, the FASB issued ASU No. 2016-02, as amended, Leases (&#8220;Topic 842&#8221;), which applies to all leases. Under Topic 842, a right-of-use asset and lease obligation will be recorded for all leases, whether operating or financing leases, while the statement of operations will reflect lease expense for operating leases and amortization and interest expense for financing leases. Topic 842 is effective for public entities for fiscal years beginning after December 15, 2018 and periods beginning after December 15, 2021 for all other entities. Entities are required to use a modified retrospective approach of adoption for leases that exist or are entered into after the beginning of the earliest comparative period in the financial statements. The Company adopted this new standard as of January 1, 2022. At the inception of an arrangement the Company determines whether the arrangement is or contains a lease based on the circumstances present. All leases with a term greater than one year are recognized on the condensed consolidated balance sheet as right-of-use assets, lease liabilities and, if applicable, longterm lease liabilities. The Company has elected not to recognize on the condensed consolidated balance sheet leases with terms of one-year or less when entered into. Lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. Certain adjustments to the right-of-use asset may be required for items such as initial direct costs paid or incentives received.At the inception of an arrangement the Company determines whether the arrangement is or contains a lease based on the circumstances present. Currently none of the Company&#8217;s operating lease commitments are subject to the new standard as its leases are short-term in nature (i.e., less than twelve months).</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Net Loss Per Share</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic loss per share of common stock is computed by dividing net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding for the period. Diluted net loss per share is calculated by adjusting the weighted-average number of shares outstanding for the dilutive effect of common stock equivalents outstanding for the period, determined using the treasury-stock method. Diluted loss per share excludes, when applicable, the potential impact of stock options, unvested shares of restricted stock awards, and common stock warrants because their effect would be anti-dilutive due to our net loss. Gains on warrant liabilities are only considered dilutive when the average market price of the common stock during the period exceeds the exercise price of the warrants. Since the Company had a net loss in each of the periods presented, basic and diluted net loss per common share are the same.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the Company&#8217;s potentially dilutive securities, in common share equivalents, which have been excluded from the calculation of dilutive loss per share as their effect would be anti-dilutive:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares issuable upon exercise of stock options</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,859,589</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,809,297</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares issuable upon exercise of warrants</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,250,006</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,167,375</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested restricted stock awards</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,168</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">162,500</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-39</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Recent Accounting Standards</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2016, the FASB issued ASU No. 2016-13, Measurement of Credit Losses on Financial Instruments (ASU 2016-13), which requires a financial asset (or a group of financial assets) measured at amortized cost basis to be presented at the net amount expected to be collected. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of the financial asset(s) to present the net carrying value at the amount expected to be collected on the financial asset. The new standard is effective for the Company for fiscal years beginning after December 15, 2022. The Company is currently evaluating the impact of the pending adoption of the new standard on its financial statements and intends to adopt the standard as of January 1, 2023.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.51%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2. </font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">RELATED PARTY TRANSACTIONS</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Consulting Services </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A former member of the Company&#8217;s board of directors prior to her stepping down in November 2021, provided legal consulting services to the Company during the three months ended March 31, 2021 for which the Company incurred $19,781 stock-based compensation which consist of options to purchase 17,431 shares of common stock. The Company did not incur any fees for consulting services provided by this person during the three months ended March 31, 2022.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The wife of the CEO, who was also a former member of the Company&#8217;s board of directors prior to her stepping down in November 2021 provided consulting services to the Company during the three months ended March 31, 2022 for which the Company incurred $22,208 in stock based compensation.&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The brother of the CEO, provides consulting services to the Company for which the Company incurred $15,900 in consulting services during the three months ended March 31, 2022.&nbsp;&nbsp;During the three months ended March 31, 2022, the Company paid for their services $7,950 in cash, and issued options to purchase 894 shares of common stock with a total fair value of $4,950.&nbsp;&nbsp;In addition the Company issued 226 options with a total fair value of $1,250 for December 2021 services during the three months ended March 31, 2022.&nbsp;&nbsp;The remaining $3,000 for services provided in the three months ended March 31, 2022 will be settled in options that have not yet been issued.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Deferred Compensation Agreements </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March 31, 2022 and December 31, 2021, the Company had $114,333 and $111,271 of deferred compensation due to certain&nbsp;&nbsp;former employees and officers of the Company pursuant to deferred compensation agreements executed during fiscal 2020 and 2019 as part of a non-qualified deferred compensation plan. Pursuant to the deferred compensation agreements, the employees deferred a portion of their annual base salary to be paid upon a Qualified Fund Raising. A Qualifying Fund Raising shall be defined as an inflow of funds into the Company from any source, that in aggregate over time totals $12,000,000 beginning from the date of the incorporation of the Company. Once the Company achieves a Qualified Fund Raising the employees' salary will be increased up to the market rate set forth in the deferred compensation agreements, and all amounts pursuant to the agreements will be paid to the employees.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-40</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.78%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">3</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ACCRUED EXPENSES </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March 31, 2022 and December 21, 2021, accrued expenses consisted of the following:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Bonus</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">561,873</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">384,750</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Professional&nbsp;&nbsp;fees</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">377,473</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">380,277</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development costs</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">452,592</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">268,140</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,514</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,157</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total accrued expenses</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,421,452</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,074,324</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.78%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">4</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">. </font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">STOCKHOLDERS' EQUITY</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon incorporation, MAIA was authorized to issue 10,000,000 shares of common stock, with a par value of $0.0001 per share. In March 2020, the shareholders approved an amended and restated certificate of incorporation which authorizes MAIA to issue 100,000,000 shares of stock, as follows: 70,000,000 shares of preferred stock and 30,000,000 shares of common stock, all with a par value of $0.0001 per share. The rights, privileges, preferences, and restrictions of the classes of stock have yet to be established. As of March 31, 2022, each of the common stockholders have equal voting rights, and except in the case of restricted common shares, equal rights of participation in dividends and other distributions with other common stockholders.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk102668322"></a>Among other provisions, MAIA's shareholders agreement gives first MAIA, followed by the non-selling shareholders, the option to purchase the outstanding shares of a shareholder prior to the sale of shares to a third party. Should the non-selling shareholders decline to purchase any portion of the selling shareholders shares, MAIA shall have a final opportunity to repurchase the shares. The agreement also contains provisions for "drag-along" and "tag-along" rights, as described in the agreement. MAIA&#8217;s shareholders agreement, including the aforementioned provisions, will terminate upon the closing of MAIA&#8217;s initial public offering.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Sales of MAIA Common Stock </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During January and February 2022, the Company sold 263,729 shares of common stock at $9.00 per share for gross proceeds of $2,373,561 with no transaction costs.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">MAIA Biotechnology, Inc. Restricted Stock Awards<font style="font-weight:normal;"> </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the three months ended March 31, 2021, MAIA recognized $67,500 of stock compensation expense related to 37,500 options of MAIA&#8217;s restricted shares granted to the founders.<font style="text-decoration:underline;"> </font>On August 13, 2021, upon the dissolution of THIO and merger into MAIA (see Note 1), a founder's 612,500 fully vested THIO restricted shares were cancelled and the founder was issued 612,500 MAIA restricted shares. Additionally, in accordance with the founder's original award, the founder was also issued 87,500 MAIA restricted shares which vest ratably each quarter through April 1, 2022 to replace the equivalent number of unvested THIO restricted shares. The remaining unvested shares as of March 31, 2022 are related to the founder's unvested restricted shares only.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the three months ended March 31, 2022, MAIA recognized $52,500 of stock compensation expense related to the MAIA restricted shares granted to the founder. The issuance of restricted shares in MAIA as a replacement for the shares the founder held in THIO was accounted for as a modification. There was no additional incremental stock compensation recorded as related to the cancellation of the founder's THIO restricted shares and concurrent grant of MAIA restricted shares as the fair value of the original THIO award immediately before the grant of the MAIA restricted shares and the fair value of the replacement award were equal. There was no unrecognized stock </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-41</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:10pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">compensation expense for the 29,168 unvested restricted shares as of March 31, 2022 </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">as the final shares vest on April 1, 2022</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Grant</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date Fair</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested balance at January 1, 2022</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58,333</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.80</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(29,165</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.80</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested balance at March 31, 2022</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,168</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.80</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">MAIA Stock Warrants</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2022, the Company and certain warrant holders executed waivers related to the acceptance and approval of an amendment to the holders' warrant agreements originally issued between May 6, 2020 and February 26, 2021 in connection with the Company's issuance of convertible notes. The amendment removed the IPO expiration provision from the warrant agreements, and the warrants are now only be exercisable, in whole or in part, during the exercise period ending on earliest to occur of: (a) various dates in 2028 as stated within the warrant agreements; or (b) immediately prior to the closing of a change of control. The value of the warrant modification to the 144,497 warrants was calculated using the Black-Scholes-Merton option pricing model. The incremental fair value attributable the modified awards compared to the original awards immediately prior to the modification was calculated at $450,578 was treated as a deemed dividend for the three months ended 2022 and is reflected as &#8220;Deemed dividend on warrant modification&#8221; in the accompanying statement of operations.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During January 2022, warrants were exercised, resulting in the issuance of 61,111 shares of MAIA common stock for proceeds of approximately $110,000.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Warrants</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Term in</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Balance at January 1, 2022</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,311,117</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.03</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.30</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(61,111</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.80</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Balance at March 31, 2022</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,250,006</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.14</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.02</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">MAIA Biotechnology, Inc. Stock Award Plans<font style="font-weight:normal;"> </font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2018, the Company adopted the MAIA Biotechnology, Inc. 2018 Stock Option Plan (the "MAIA 2018 Plan"). MAIA's board of directors administers the MAIA Plan, under which 3,900,000 shares of common stock are reserved for stock option issuance, for the purposes of attracting, retaining, and motivating key employees, directors, and consultants of MAIA. The 2018 plan was replaced by the Amended and Restated 2020 Equity Plan.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2020, the Company adopted the MAIA Biotechnology, Inc. Amended and Restated 2020 Equity Incentive Plan (the "MAIA 2020 Plan"), also administered by the board of directors. The MAIA 2020 Plan reserved 1,671,000 common shares for issuance, also for the purposes of attracting, retaining, and motivating key employees, directors, and consultants of MAIA. In November 2020, the MAIA 2020 Plan was amended to reserve a total of 3,171,000 shares of common stock. The MAIA 2020 Plan permits awards to take the form of stock options, restricted stock and restricted stock units. In April and July of 2021 there were amendments to the 2020 Plan to bring the plan to a total of 4,171,000 shares reserved for issuance. As of March 31, 2022 there are 242,911 shares available for future issuance under the 2020 Plan.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-42</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options are to be granted with an exercise price which is at least equal to the stock's estimated fair value at the date of grant, and with a contractual term of no more than 10 years from the date of grant. In the case of an option granted to a 10% stockholder, the exercise price shall be generally no less than 110% of the fair market value per share on the date of grant, and the contractual term shall be 7 years. Outstanding options awarded under the MAIA 2020 Plan may, but need not, vest and therefore become exercisable in periodic instalments that may, but need not, be equal. The option may be subject to such other terms and conditions as to the time or times when it may be exercised (which may be based on performance or other criteria) as the board of directors may deem appropriate. Unexercised options are cancelled ninety days after termination of an employee, director, founder, or consultant. Unexercised options are cancelled immediately if an employee, director, founder, or consultant is terminated for cause; under certain other circumstances, the period to cancellation may differ as described in the respective plan documents. Certain clauses in the Plans also govern the Company's exercise repurchase rights and various other features of awards granted under the plans.</font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March 31, 2022, only stock options have been awarded pursuant to the MAIA stock award plans.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the activity and information regarding MAIA's outstanding and exercisable options for the three months ended March 31, 2022:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Term in</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at January 1, 2022</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,797,185</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.22</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.59</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">102,792</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.00</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(26,500</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.83</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cancelled/forfeited</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(13,888</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.80</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at March 31, 2022</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,859,589</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.35</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.37</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,134,325</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options exercisable at March 31, 2022</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,116,035</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.02</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.28</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,690,410</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the three months ended March 31, 2022, the fair value of the Company's common stock was estimated for financial reporting purposes from January 1 to January 26, 2022 based on valuations of $8.87 per share as of December 31, 2021. For our valuations of common stock performed, we used a hybrid method of the Option Pricing Method ("OPM&#8221;) and the Probability-Weighted Expected Return Method ("PWERM&#8221;). PWERM considers various potential liquidity outcomes. Our approach included the use of an initial public offering scenario, a scenario assuming continued operation as a private entity, and a dissolution scenario. Under the hybrid OPM and PWERM, the per share value calculated under the OPM and PWERM are weighted based on expected exit outcomes and the quality of the information specific to each allocation methodology to arrive at a final estimated fair value per share of the common stock before a discount for lack of marketability is applied. From January 27 to March 31, 2022 the fair value of the Company&#8217;s common stock was estimated for financial reporting purposes at $9 per share based on the sale of common stock from January 27, 2022 to February 28, 2022. Due to the lack of any single specific event that would have indicated a definitive change in the value of the Company, the fair value of the Company&#8217;s common stock was determined based on sales of the Company&#8217;s shares at arm&#8217;s length to unrelated third parties at $9.00 per share through March 31, 2022.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the three months ended March 31, 2021, the fair value of the Company&#8217;s common stock was estimated for financial reporting purposes based on valuations. From January 1, 2021 to February 28, 2021 a valuation of $1.80 was used. During the period of March 2021, the fair value of the Company&#8217;s common stock was estimated for financial reporting purposes based on valuations of $1.83 per share in February 2021 due to the lack of any single specific event that would have indicated a definitive change in the value of the Company. The February 2021 valuation used the income approach and the market approach in estimating the fair value of our common stock. The market approach utilized guideline public companies in estimating fair value of our stock. The income approach estimates enterprise value based on the estimated present value of future cash flows the business is expected to generate over its remaining life. The estimated present value is calculated using a discount rate reflective of the risks </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-43</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:10pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">associated with an investment in a similar company in a similar industry or having a similar history of revenue growth. The market approach measures the value of a business through an analysis of recent sales or offerings of comparable investments or assets, and in our case, focused on comparing us to a group of our peer companies. In applying this method, valuation multiples are derived from historical and projected operating data of the peer company group. We then apply the selected multiples to our operating data to arrive at a range of indicated enterprise values of the Company. We then subtracted the net debt to determine equity value.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The value of option grants is calculated using the Black-Scholes option pricing model with the following assumptions for options granted during the three months ended March 31:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.14%</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.36% - 0.92%</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (in years)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5 - 6.25</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5 - 5.17</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72.0% - 74.2%</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74.8% - 75.9%</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;%</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The weighted-average grant date fair value of stock options issued during the three months ended March 31, 2022 and 2021 was $5.78 and $1.11, respectively. As of March 31, 2022, the total unrecognized compensation related to unvested employee and non-employee stock option awards granted was $3,152,581, which the Company expects to recognize over a weighted average period of approximately 3 years.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock based compensation related to the Company&#8217;s stock plans are as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> General and administrative</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">440,551</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">487,737</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">272,779</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65,455</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Total stock-based compensation</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">713,330</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">553,192</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.78%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">5</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">COMMITMENTS AND CONTINGENCIES</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Legal</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, the Company is involved in legal actions and claims arising in the normal course of business. Management believes there are no matters which will have a material adverse effect on the Company's financial position, operations or cash flows.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Patent Licensing, Sponsored Research, and Patent &amp; Technology Agreements </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">THIO</font> - In November 2018 and as amended in December 2020, the Company entered into a Global Patent Licensing Agreement ("PLA") titled "Patent and Technology License Agreement AGT. NO. L2264 - MAIA Biotechnology" with the University of Texas Southwestern ("UTSW") to license patent families for a specific compound ("THIO") from UTSW to MAIA. The agreement, as amended, has a term of 20 years. The agreement requires MAIA to reimburse UTSW for agreed-upon expenses related to THIO. The agreement requires certain payments upon assignment of the license to a third party as well as upon reaching specific milestones, ranging between $1,000,000 and $50,000,000, not to exceed a combined milestone payment total of $112,000,000. As of March 31, 2022, no assignment has occurred and none of the defined milestones have been completed and therefore no payments are due to UTSW related to the milestones. The agreement requires royalties of 2-4% (depending on THIO reaching specified sales levels in the respective jurisdictions) royalty payments on net sales up to $1,000,000,000, and 2.5-5% on net sales above $1,000,000,000.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Also in December 2020, the Company entered into a second license agreement with UTSW titled "Patent and Technology License Agreement AGT. NO. L3648 &#8212; MAIA Biotechnology" pursuant to which UTSW is licensing an additional compound to MAIA. The agreement has a term of 20 years and requires the Company to reimburse </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-44</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:10pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">UTSW for certain agreed-upon expenses. The agreement requires certain payments upon assignment of the license to a third party as well as upon reaching specific milestones, ranging between $1,000,000 and $50,000,000, not to exceed a combined milestone payment total of $112,000,000. As of </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2022</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, no assignment has occurred and none of the defined milestones have been completed and therefore no payments are due to UTSW related to the milestones.</font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The agreement requires royalties of 2-4% (depending on THIO reaching specified sales levels in the respective jurisdictions) royalty payments on net sales up to $1,000,000, and 2.5-5% on net sales above $1,000,000,000.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company will also pay UTSW running royalties on a yearly basis as a percentage of Net Sales of the Company or its sublicensee. There are single digit royalty rates for licensed products and licensed services covered by a Valid Claim (as defined in the agreement) and dependent on whether Net Sales are greater than or less than/equal to $1,000,000,000, with Net Sales above that amount commanding a slightly higher percentage. In each case, the royalty percentage is lower before patent issuance in each jurisdiction. In the event that the licensed product or licensed service is not covered by a Valid Claim, the running royalty rates are reduced by fifty percent (50%). The royalty obligations continue on a country-by-country basis until the later of expiration of the last Valid Claim in each country or ten (10) years after the First Commercial Sale (as defined in UTSW2 Agreement) in each country. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">MJC13</font> &#8212; In January 2019, MAIA entered into a Global PLA and SRA for Collaborative Research and Jointly Owned Intellectual Property for the MJC13 Family of Compounds for the Treatment of Prostate Cancer with UTEP. The SRA requires MAIA to reimburse UTEP for research program expenditures up to $46,000. As amended, the SRA extended the research program to June 2020, since which point it has continued on an at-will basis.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Regeneron</font> - In February 2021, the Company reached an agreement with Regeneron Pharmaceuticals, Inc. ("Regeneron") to perform one clinical trial for the treatment of patients with Non-Small Cell Lung Cancer (NSCLC) involving a Regeneron drug candidate that utilizes one of the Company's compounds/agents. The Company is responsible for all costs of the study with Regeneron supplying their drug cemiplimab representing a cost savings for the company, the first phase of which is expected to take approximately two years. The overall term of the agreement is for five years unless earlier terminated for certain reasons as defined in the agreement. Either party may terminate a study plan in the event that patient screening for the clinical study does not commence within twelve (12) months after (a) the Effective Date, with respect to the initial study, or (b) the execution of the applicable study plan, with respect to each other study. If either party terminates a study plan, the Company shall reimburse Regeneron for the Regeneron product it received in connection with such study plan based on the actual out-of-pocket cost to Regeneron of such Regeneron product. As of March 31, 2022 neither party has terminated the agreement.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.78%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">6</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">. </font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">INCOME TAXES</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">The Company provides for income taxes using the asset and liability approach. Deferred tax assets and liabilities are recorded based on the differences between the financial statement and tax bases of assets and liabilities and the tax rates in effect when these differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. As of March 31, 2022, and December 31, 2021, the Company had a full valuation allowance against its deferred tax assets.</font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">For the three months ended March 31, 2022 and 2021, the Company recorded zero income tax expense. No tax benefit has been recorded in relation to the pre-tax loss for the three months ended March 31, 2022 and 2021, due to a full valuation allowance to offset any deferred tax asset related to net operating loss carry forwards attributable to the losses.</font></p><a name="_AEIOULastRenderedPageBreakAEIOU37"></a>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-45</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.78%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">7</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SUBSEQUENT EVENTS</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Issuance of Stock Options</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During April 2022, the Company issued 23,778 options to employees and consultants to purchase MAIA common stock with an exercise price of $9.00 per share.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise of MAIA Warrants</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During April and May 2022, 153,000 warrants were exercised, resulting in a total of 153,000 shares of MAIA common stock issued for proceeds of approximately $275,400.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Romanian Subsidiary</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In April 2022, the Company established a wholly owned Romanian subsidiary, MAIA BIOTECHNOLOGY ROMANIA S.R.L. to conduct various preclinical and clinical activities for the development of the Company&#8217;s product candidates.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-46</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p><a name="_AEIOULastRenderedPageBreakAEIOU38"></a>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:14pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares of Common Stock</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:24pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gyowp0iggm03000021.jpg" title="" alt="" style="width:290px;height:110px;"></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">MAIA Biotechnology, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:37%;">
<tr>
<td style="width:37%;"></td>
</tr>
<tr>
<td valign="bottom"  style=" border-top:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">PRELIMINARY<font style="font-weight:normal;"> </font>PROSPECTUS</p></td>
</tr>
<tr>
<td valign="bottom"  style=" border-bottom:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:48pt;text-indent:0%;font-family:Times New Roman;font-size:18pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:48.82%;">
<tr>
<td style="width:48.82%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ThinkEquity</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:72pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,2022</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Through and including &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , 2022 (the 25<sup style="font-size:85%;line-height:120%;vertical-align:top">th</sup> day after the date of this offering), all dealers effecting transactions in these securities, whether or not participating in this offering, may be required to deliver a prospectus. This is in addition to a dealer&#8217;s obligation to deliver a prospectus when acting as an underwriter and with respect to an unsold allotment or subscription.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p><a name="_AEIOULastRenderedPageBreakAEIOU39"></a>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">PART II &#8211; INFORMATION NOT REQUIRED IN PROSPECTUS</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item 13.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Other Expenses of Issuance and Distribution.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table indicates the expenses to be incurred in connection with the offering described in this registration statement, other than underwriting discounts and commissions, all of which will be paid by us. All amounts are estimated except the SEC registration fee, the FINRA filing fee and the Nasdaq listing fee.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SEC registration fee</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.54%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FINRA filing fee</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.54%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Initial Nasdaq listing fee</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.54%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounting fees and expenses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.54%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Legal fees and expenses</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.54%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Transfer agent&#8217;s and registrar&#8217;s fees and expenses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.54%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Printing and engraving expenses</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.54%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-accountable expenses to underwriters</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.54%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Miscellaneous fees</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.54%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.54%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*To be filed by amendment.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item 14.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Indemnification of Directors and Officers.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Section 102 of the DGCL permits a corporation to eliminate the personal liability of directors of a corporation to the corporation or its stockholders for monetary damages for a breach of fiduciary duty as a director, except where the director breached his duty of loyalty, failed to act in good faith, engaged in intentional misconduct or knowingly violated a law, authorized the payment of a dividend or approved a stock repurchase in violation of Delaware corporate law or obtained an improper personal benefit. Our amended and restated certificate of incorporation provides that no director of the registrant shall be personally liable to it or its stockholders for monetary damages for any breach of fiduciary duty as a director, notwithstanding any provision of law imposing such liability, except to the extent that the DGCL prohibits the elimination or limitation of liability of directors for breaches of fiduciary duty.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Section 145 of the DGCL provides that a corporation has the power to indemnify a director, officer, employee, or agent of the corporation, or a person serving at the request of the corporation for another corporation, partnership, joint venture, trust or other enterprise in related capacities against expenses (including attorneys&#8217; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by the person in connection with an action, suit or proceeding to which he was or is a party or is threatened to be made a party to any threatened, ending or completed action, suit or proceeding by reason of such position, if such person acted in good faith and in a manner he reasonably believed to be in or not opposed to the best interests of the corporation, and, in any criminal action or proceeding, had no reasonable cause to believe his conduct was unlawful, except that, in the case of actions brought by or in the right of the corporation, no indemnification shall be made with respect to any claim, issue or matter as to which such person shall have been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery or other adjudicating court determines that, despite the adjudication of liability but in view of all of the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the Court of Chancery or such other court shall deem proper.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our amended and restated bylaws will authorize the indemnification of our officers and directors, consistent with Section 145 of the DGCL, as amended. Reference is made to Section 102(b)(7) of the DGCL, which enables a corporation in its original certificate of incorporation or an amendment thereto to eliminate or limit the personal liability of a director for violations of the director's fiduciary duty, except (i) for any breach of the director's duty of loyalty to the corporation or its stockholders, (ii) for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (iii) pursuant to Section 174 of the DGCL, which provides for liability of directors for unlawful payments of dividends of unlawful stock purchase or redemptions or (iv) for any transaction from which a director derived an improper personal benefit.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">II-1</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We intend to enter into indemnification agreements with each of our directors and officers</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> that will be in effect upon the completion of this offering</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. These indemnification agreements may require us, among other things, to indemnify our directors and officers for some expenses, including attorneys&#8217; fees, judgments, fines and settlement amounts incurred by a director or officer in any action or proceeding arising out of his or her service as one of our directors or officers, or any of our subsidiaries or any other company or enterprise to which the person provides services</font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We maintain a general liability insurance policy that covers certain liabilities of directors and officers of our corporation arising out of claims based on acts or omissions in their capacities as directors or officers.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In any underwriting agreement we enter into in connection with the sale of common stock being registered hereby, the underwriters will agree to indemnify, under certain conditions, us, our directors, our officers and persons who control us within the meaning of the Securities Act, against certain liabilities.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item 15.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Recent Sales of Unregistered Securities.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Set forth below is information regarding shares of capital stock issued by us within the past three years. Also included is the consideration received by us for such shares and information relating to the section of the Securities Act, or rule of the SEC, under which exemption from registration was claimed.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(a) Issuance of Common Stock</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2019 through June 2019, we issued and sold 246,668 shares of our common stock with an aggregate principal amount of $444,000.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October and November 2019, we issued and sold 873,725 shares of our common stock with an aggregate principal amount of $1.573 million.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During July through October 2021, we issued and sold 772,563 shares of our common stock with an aggregate principal amount of approximately $6.2 million.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In September 2021, we issued 1,375,228 shares of our common stock as a result of the automatic conversion of the convertible notes referenced in Item 15(b) below. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During January and February 2022, we issued and sold 263,729 shares of our common stock with an aggregate principal amount of approximately $2.4 million.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">No underwriters were involved in the foregoing issuances of securities. The securities described in this section (a) of Item 15 were issued to investors in reliance upon the exemption from the registration requirements of the Securities Act, as set forth in Section 4(a)(2) under the Securities Act relative to transactions by an issuer not involving any public offering, to the extent an exemption from such registration was required. The recipients of securities in the transactions described above represented that they were accredited investors and were acquiring the securities for their own account for investment purposes only, and not with a view to, or for sale in connection with, any distribution thereof and that they could bear the risks of the investment and could hold the securities for an indefinite period of time and appropriate legends were affixed to the instruments representing such securities issued in such transactions.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(b) Issuance of Convertible Notes &amp; Warrants</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2019, we issued and sold a convertible promissory note with a principal amount of $10,000, which converted into 2,259 shares of our common stock on September 30, 2021.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2020 through December 2020, we issued and sold convertible promissory notes with an aggregate principal amount of $610,000, which converted into 108,132 shares of our common stock on September 30, 2021, and warrants to purchase 54,066 shares of our common stock at $6.00 per share, for an aggregate purchase price of $324,396.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">II-2</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2021 through June 2021, we issued and sold convertible promissory notes with an aggregate principal amount of $7.39 million, which converted into 1,264,837 shares of our common stock on September 30, 2021,</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and warrants to purchase 632,423</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> shares of our common stock at $6.00 per share, for an aggregate purchase price of $3,794,508.</font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">No underwriters were involved in the foregoing issuances of securities. The securities described in this section (b) of Item 15 were issued to investors in reliance upon the exemption from the registration requirements of the Securities Act, as set forth in Section 4(a)(2) under the Securities Act relative to transactions by an issuer not involving any public offering, to the extent an exemption from such registration was required. The recipients of securities in the transactions described above represented that they were accredited investors and were acquiring the securities for their own account for investment purposes only, and not with a view to, or for sale in connection with, any distribution thereof and that they could bear the risks of the investment and could hold the securities for an indefinite period of time and appropriate legends were affixed to the instruments representing such securities issued in such transactions.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(c) Stock Option Grants, Option Exercises, Warrant Grants and Warrant Exercises</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Between January 1, 2019 and December 31, 2021, we have granted to our employees, officers, directors and other persons who provide services to us options to purchase up to 5,336,753&#160;shares of common stock under the 2018 Stock Option Plan and the Amended and Restated 2020 Stock Option Plan, at a weighted average exercise price of $2.26 per share. 5,000 of these options were exercised at a weighted average exercise price of $1.80. 1,749,568 of these options were terminated, expired without being exercised or were otherwise forfeited. In addition, we granted to certain of our directors and other persons who provided services to us warrants to purchase up to 1,594,733&#160;shares of our common stock at $3.65 per share, which expire at various dates through September 2030 and vested&#160;upon issuance. 283,616 of these warrants were exercised at a weighted average exercise price of $1.87.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">No underwriters were involved in the foregoing issuances of securities. The issuances of stock options described in this paragraph (c) of Item 15 were issued pursuant to written compensatory plans or arrangements with our employees, directors, consultants and advisors, in reliance on the exemption provided by Rule 701 promulgated under the Securities Act, or pursuant to Section 4(a)(2) under the Securities Act, relative to transactions by an issuer not involving any public offering, to the extent an exemption from such registration was required. All recipients either received adequate information about us or had access, through employment or other relationships, to such information.</p><a name="_AEIOULastRenderedPageBreakAEIOU40"></a>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">II-3</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item 16.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibits and Financial Statement Schedules.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a) Exhibits.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:7.6%; border-bottom:solid 1.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit<font style="font-weight:normal;"><br /></font>Number</p></td>
<td valign="bottom"  style="width:0.7%; border-bottom:solid 1.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:91.7%; border-bottom:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description of Document</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.6%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 1.1*</p></td>
<td valign="bottom"  style="width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:91.7%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> <a href="http://www.sec.gov/Archives/edgar/data/1878313/000156459022016863/maia-ex11_192.htm"><font style="font-size:10pt;font-family:Times New Roman;text-decoration:underline;">Form of Underwriting Agreement (including the form of Lock-Up Agreement). </font></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font></p></td>
</tr>
<tr>
<td valign="top"  style="width:7.6%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 3.1*</p></td>
<td valign="bottom"  style="width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:91.7%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1878313/000156459022014036/maia-ex31_19.htm"><font style="text-decoration:underline;">Amended and Restated Certificate of Incorporation of MAIA Biotechnology, Inc.</font></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font></p></td>
</tr>
<tr>
<td valign="top"  style="width:7.6%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 3.2*</p></td>
<td valign="bottom"  style="width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:91.7%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1878313/000156459022014036/maia-ex32_14.htm"><font style="text-decoration:underline;">Amended and Restated Certificate of Incorporation of MAIA Biotechnology, Inc. to be in effect upon completion of the offering.</font></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font></p></td>
</tr>
<tr>
<td valign="top"  style="width:7.6%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 3.3*</p></td>
<td valign="bottom"  style="width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:91.7%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1878313/000156459022014036/maia-ex33_9.htm"><font style="text-decoration:underline;">Amended and Restated Bylaws of MAIA Biotechnology, Inc.</font></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font></p></td>
</tr>
<tr>
<td valign="top"  style="width:7.6%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 3.4*</p></td>
<td valign="bottom"  style="width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:91.7%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1878313/000156459022014036/maia-ex34_23.htm"><font style="text-decoration:underline;">Amended and Restated Bylaws of MAIA Biotechnology, Inc. to be in effect upon completion of the offering.</font></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font></p></td>
</tr>
<tr>
<td valign="top"  style="width:7.6%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 4.1*</p></td>
<td valign="bottom"  style="width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:91.7%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1878313/000156459022014036/maia-ex41_27.htm"><font style="text-decoration:underline;">Specimen Certificate representing shares of Common Stock.</font></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font></p></td>
</tr>
<tr>
<td valign="top"  style="width:7.6%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 4.2*</p></td>
<td valign="bottom"  style="width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:91.7%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1878313/000156459022014036/maia-ex42_16.htm"><font style="text-decoration:underline;">Form of Warrant.</font></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font></p></td>
</tr>
<tr>
<td valign="top"  style="width:7.6%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 4.3</p></td>
<td valign="bottom"  style="width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:91.7%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1878313/000156459022016863/maia-ex11_192.htm"><font style="text-decoration:underline;">Form of Representative&#8217;s Warrant (included in Exhibit 1.1).</font></a></p></td>
</tr>
<tr>
<td valign="top"  style="width:7.6%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 5.1</p></td>
<td valign="bottom"  style="width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:91.7%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="maia-ex51_7.htm"><font style="text-decoration:underline;">Opinion of Loeb &amp; Loeb LLP.</font></a></p></td>
</tr>
<tr>
<td valign="top"  style="width:7.6%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1&#8224;*</p></td>
<td valign="bottom"  style="width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:91.7%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1878313/000156459022014036/maia-ex101_11.htm"><font style="text-decoration:underline;">Supply and Non-Exclusive License Agreement between the Company and Regeneron Pharmaceuticals, Inc. dated February 1, 2021.</font></a></p></td>
</tr>
<tr>
<td valign="top"  style="width:7.6%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.2&#8224;*</p></td>
<td valign="bottom"  style="width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:91.7%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1878313/000156459022014036/maia-ex102_24.htm"><font style="text-decoration:underline;">Patent &amp; Technology License Agreement between the Company and The Board of Regents of The University of Texas System on behalf of The University of Texas Southwestern Medical Center dated December 8, 2020.</font></a></p></td>
</tr>
<tr>
<td valign="top"  style="width:7.6%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.3&#8224;*</p></td>
<td valign="bottom"  style="width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:91.7%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1878313/000156459022014036/maia-ex103_13.htm"><font style="text-decoration:underline;">Patent &amp; Technology License Agreement between the Company and The Board of Regents of The University of Texas System on behalf of The University of Texas Southwestern Medical Center dated December 23, 2020.</font></a></p></td>
</tr>
<tr>
<td valign="top"  style="width:7.6%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.4+*</p></td>
<td valign="bottom"  style="width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:91.7%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1878313/000156459022014036/maia-ex104_7.htm"><font style="text-decoration:underline;">Employment Agreement between Vlad Vitoc and the Company signed August 2, 2022.</font></a></p></td>
</tr>
<tr>
<td valign="top"  style="width:7.6%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.5+*</p></td>
<td valign="bottom"  style="width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:91.7%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1878313/000156459022014036/maia-ex105_8.htm"><font style="text-decoration:underline;">Employment Agreement between Joseph F. McGuire and the Company signed August 10, 2022.</font></a></p></td>
</tr>
<tr>
<td valign="top"  style="width:7.6%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.6+*</p></td>
<td valign="bottom"  style="width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:91.7%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1878313/000156459022014036/maia-ex106_6.htm"><font style="text-decoration:underline;">Employment Agreement between Mihail Obrocea and the Company signed August 2, 2022.</font></a></p></td>
</tr>
<tr>
<td valign="top"  style="width:7.6%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.7+*</p></td>
<td valign="bottom"  style="width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:91.7%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1878313/000156459022014036/maia-ex107_21.htm"><font style="text-decoration:underline;">Form of Indemnification Agreement between the Company and each of its directors and executive officers.</font></a></p></td>
</tr>
<tr>
<td valign="top"  style="width:7.6%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.8+*</p></td>
<td valign="bottom"  style="width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:91.7%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1878313/000156459022014036/maia-ex108_15.htm"><font style="text-decoration:underline;">MAIA Biotechnology, Inc. 2018 Stock Option Plan.</font></a></p></td>
</tr>
<tr>
<td valign="top"  style="width:7.6%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.9+*</p></td>
<td valign="bottom"  style="width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:91.7%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1878313/000156459022014036/maia-ex109_22.htm"><font style="text-decoration:underline;">MAIA Biotechnology, Inc. Amended &amp; Restated 2020 Equity Incentive Plan.</font></a></p></td>
</tr>
<tr>
<td valign="top"  style="width:7.6%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.10+*</p></td>
<td valign="bottom"  style="width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:91.7%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1878313/000156459022014036/maia-ex1010_12.htm"><font style="text-decoration:underline;">MAIA Biotechnology, Inc. 2021 Equity Incentive Plan.</font></a></p></td>
</tr>
<tr>
<td valign="top"  style="width:7.6%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.1*</p></td>
<td valign="bottom"  style="width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:91.7%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1878313/000156459022014036/maia-ex141_17.htm"><font style="text-decoration:underline;">Code of Business Conduct and Ethics of MAIA Biotechnology, Inc.</font></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font></p></td>
</tr>
<tr style="height:10.35pt;">
<td valign="top"  style="width:7.6%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.1</p></td>
<td valign="bottom"  style="width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:91.7%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="maia-ex211_8.htm"><font style="text-decoration:underline;">List of Subsidiaries of the Registrant</font><font style="text-decoration:underline;font-family:Calibri;">.</font></a></p></td>
</tr>
<tr>
<td valign="top"  style="width:7.6%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23.1</p></td>
<td valign="bottom"  style="width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:91.7%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="maia-ex51_7.htm"><font style="text-decoration:underline;">Consent of Loeb &amp; Loeb LLP (included in Exhibit 5.1).</font></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font></p></td>
</tr>
<tr>
<td valign="top"  style="width:7.6%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23.2</p></td>
<td valign="bottom"  style="width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:91.7%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="maia-ex232_408.htm"><font style="text-decoration:underline;">Consent of EisnerAmper LLP, Independent Registered Public Accounting Firm.</font></a></p></td>
</tr>
<tr>
<td valign="top"  style="width:7.6%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24.1</p></td>
<td valign="bottom"  style="width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:91.7%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#PURSUANT_TO_REQUIREMENTS__SECURITIES_ACT"><font style="text-decoration:underline;">Powers of Attorney (included on signature page to this registration statement).</font></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font></p></td>
</tr>
<tr>
<td valign="top"  style="width:7.6%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">107*</p></td>
<td valign="bottom"  style="width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:91.7%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1878313/000156459022014036/maia-exfilingfees_750.htm"><font style="text-decoration:underline;">Calculation of Filing Fee Tables.</font></a></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-top:0pt;margin-right:69.23%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:10pt;margin-bottom:8pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">* Previously filed.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">+ Indicates management contract or compensatory plan.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8224; Pursuant to Item 601(b)(10) of Regulation S-K, certain portions of this exhibit have been omitted (indicated by &#8220;[***]&#8221;) because the Registrant has determined that the information is not material and is the type that the Registrant treats as private or confidential.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b) Financial Statement Schedules.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See index to financial statements on page F-1. All schedules have been omitted because they are not required or are not applicable.</p><a name="_AEIOULastRenderedPageBreakAEIOU41"></a>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">II-4</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk103247210"></a><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item 17. Undertakings</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The undersigned registrant hereby undertakes to provide to the underwriters, at the closing specified in the underwriting agreement, certificates in such denominations and registered in such names as required by the underwriters to permit prompt delivery to each purchaser.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The undersigned hereby undertakes that:</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)&#8199;For purposes of determining any liability under the Securities Act, the information omitted from the form of prospectus filed as part of this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the registrant pursuant to Rule 424(b)(1) or (4) or 497(h) under the Securities Act shall be deemed to be part of this registration statement as of the time it was declared effective.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)&#8199;For the purpose of determining any liability under the Securities Act, each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.</p><a name="_AEIOULastRenderedPageBreakAEIOU42"></a>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">II-5</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="SIGNATURES"></a><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="SIGNATURES"></a>SIGNAT</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">URES</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of the Securities Act of 1933, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Chicago, State of Illinois, on May 13, 2022.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="3" valign="top"  style="width:44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MAIA BIOTECHNOLOGY, INC.</p></td>
</tr>
<tr>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="3" valign="top"  style="width:44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:50%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:44%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Vlad Vitoc</p></td>
</tr>
<tr>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:44%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vlad Vitoc</p></td>
</tr>
<tr>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Executive Officer and Chairman</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities held on the dates indicated.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:28%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:42%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Title</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:28%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date</p></td>
</tr>
<tr>
<td valign="top"  style="width:28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:4pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:4pt;">&nbsp;</p></td>
<td valign="top"  style="width:42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:4pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:4pt;">&nbsp;</p></td>
<td valign="top"  style="width:28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:4pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:28%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Vlad Vitoc</p></td>
<td valign="top"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chairman and Chief Executive Officer</p></td>
<td valign="top"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:8pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">May 13, 2022</p></td>
</tr>
<tr>
<td valign="top"  style="width:28%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vlad Vitoc</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Principal Executive Officer)</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:4pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:4pt;">&nbsp;</p></td>
<td valign="top"  style="width:42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:4pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:4pt;">&nbsp;</p></td>
<td valign="top"  style="width:28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:4pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:28%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Joseph F. McGuire</p></td>
<td valign="top"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Financial Officer</p></td>
<td valign="top"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">May 13, 2022</p></td>
</tr>
<tr>
<td valign="top"  style="width:28%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Joseph F. McGuire</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Principal Financial Officer)</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:4pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:4pt;">&nbsp;</p></td>
<td valign="top"  style="width:42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:4pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:4pt;">&nbsp;</p></td>
<td valign="top"  style="width:28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:4pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:28%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
<td valign="top"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="top"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">May 13, 2022</p></td>
</tr>
<tr>
<td valign="top"  style="width:28%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Steven Chaouki</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:4pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:4pt;">&nbsp;</p></td>
<td valign="top"  style="width:42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:4pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:4pt;">&nbsp;</p></td>
<td valign="top"  style="width:28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:4pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:28%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
<td valign="top"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="top"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">May 13, 2022</p></td>
</tr>
<tr>
<td valign="top"  style="width:28%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ramiro Guerrero</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:4pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:4pt;">&nbsp;</p></td>
<td valign="top"  style="width:42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:4pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:4pt;">&nbsp;</p></td>
<td valign="top"  style="width:28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:4pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:28%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
<td valign="top"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="top"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">May 13, 2022</p></td>
</tr>
<tr>
<td valign="top"  style="width:28%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Louie Ngar Yee</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:4pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:4pt;">&nbsp;</p></td>
<td valign="top"  style="width:42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:4pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:4pt;">&nbsp;</p></td>
<td valign="top"  style="width:28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:4pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:28%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
<td valign="top"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="top"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">May 13, 2022</p></td>
</tr>
<tr>
<td valign="top"  style="width:28%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cristian Luput</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:4pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:4pt;">&nbsp;</p></td>
<td valign="top"  style="width:42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:4pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:4pt;">&nbsp;</p></td>
<td valign="top"  style="width:28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:4pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:28%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
<td valign="top"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="top"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">May 13, 2022</p></td>
</tr>
<tr>
<td valign="top"  style="width:28%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stan V. Smith</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:4pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:4pt;">&nbsp;</p></td>
<td valign="top"  style="width:42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:4pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:4pt;">&nbsp;</p></td>
<td valign="top"  style="width:28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:4pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:28%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
<td valign="top"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="top"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">May 13, 2022</p></td>
</tr>
<tr>
<td valign="top"  style="width:28%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laurentiu Vlad</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:50%;">
<tr>
<td style="width:6.41%;"></td>
<td style="width:0.21%;"></td>
<td style="width:43.38%;"></td>
</tr>
<tr>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*By:</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Vlad Vitoc</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vlad Vitoc</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Attorney-in-Fact</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">II-6</a></p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>2
<FILENAME>maia-ex51_7.htm
<DESCRIPTION>EX-5.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
maia-ex51_7.htm
</title>
</head>
<!-- NG Converter v5.0.2.71 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 5.1</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr style="height:108pt;">
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gzq4oqz5m4ms000001.jpg" title="" alt="" style="width:120px;height:120px;"></p></td>
<td valign="top"  style="width:25%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">345 Park Avenue</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">New York, NY 10154-1895</p></td>
<td valign="top"  style="width:25%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Main<font style="font-weight:normal;"> 212.407.4000</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fax<font style="font-weight:normal;"> 212.407.4990</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">www.loeb.com</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">May 13, 2022</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MAIA Biotechnology, Inc.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">444 West Lake Street, Suite 1700</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chicago, IL 60606</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ladies and Gentlemen:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have acted as counsel to MAIA Biotechnology, Inc., a Delaware corporation (the &#8220;<font style="text-decoration:underline;">Company</font>&#8221;), in connection with the Registration Statement on Form S-1 (File No. 333-264225), as may be amended (the &#8220;<font style="text-decoration:underline;">Registration Statement</font>&#8221;), filed by the Company with the Securities and Exchange Commission (the &#8220;<font style="text-decoration:underline;">Commission</font>&#8221;) under the Securities Act of 1933, as amended (the &#8220;<font style="text-decoration:underline;">Securities Act</font>&#8221;), relating to the (i) offer, issuance and sale by the Company of the number of shares of common stock, par value $0.0001 per share (the &#8220;<font style="text-decoration:underline;">Common Stock</font>&#8221;) of the Company (the &#8220;<font style="text-decoration:underline;">Company Shares</font>&#8221;) specified in the Registration Statement, including the number of shares of Common Stock specified in the Registration Statement issuable upon the exercise of the underwriter&#8217;s over-allotment option (the &#8220;<font style="text-decoration:underline;">Over-Allotment Shares</font>&#8221;), (ii) representative warrants to purchase up to the number of shares of Common Stock equal to five percent (5%) of the number of shares of Common Stock sold pursuant to the Registration Statement, substantially in the form filed as an exhibit to the Registration Statement (the &#8220;<font style="text-decoration:underline;">Representative Warrants</font>&#8221;), and (iii) up to the number of shares of Common Stock specified in the Registration Statement issuable upon exercise of the Representative Warrants (the &#8220;<font style="text-decoration:underline;">Warrant Shares</font>&#8221;). The Company Shares, the Over-Allotment Shares, the Representative Warrants and the Warrant Shares shall be referred to herein as the &#8220;<font style="text-decoration:underline;">Securities</font>.&#8221; We understand that (a) the Company Shares are proposed to be sold for sale to the public and (b) the Representative Warrants are proposed to be issued to the representative of the underwriters (or its permitted assignees), each as described in the Registration Statement and pursuant to an underwriting agreement, substantially in the form filed as an exhibit to the Registration Statement, to be entered into by the Company and the representative (the &#8220;<font style="text-decoration:underline;">Underwriting Agreement</font>.&#8221;)</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have examined originals or copies, certified or otherwise identified to our satisfaction, of such corporate records of the Company and other certificates and documents of officials of the Company, public officials and others as we have deemed appropriate for purposes of this letter.&nbsp;&nbsp;We have assumed the genuineness of all signatures, the authenticity of all documents submitted to us as originals, and the conformity to authentic original documents of all copies submitted to us as conformed and certified or reproduced copies. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<div align="right">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr style="height:15pt;">
<td valign="bottom"  style="width:15.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:84.72%;">
<p style="line-height:9pt;text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 2</a></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based upon the foregoing and subject to the assumptions, exceptions, qualifications and limitations set forth hereinafter, we are of the opinion that:</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.&nbsp;&nbsp;The Company Shares and the Over-Allotment Shares have been duly authorized and, when issued, delivered and paid for in accordance with the terms of the Underwriting Agreement, will be validly issued, fully paid and non-assessable.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.&nbsp;&nbsp;The Representative Warrants have been duly authorized by the Company and, when executed by the Company and delivered to the purchasers thereof against payment therefor in accordance with the terms of the Underwriting Agreement and the representative&#8217;s warrant agreement, substantially in the form filed as an exhibit to the Underwriting Agreement, will constitute valid and binding obligations of the Company, enforceable against the Company in accordance with their terms. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.&nbsp;&nbsp;The Warrant Shares have been duly authorized, and if, as, and when the Warrant Shares are issued and delivered by the Company upon exercise of the Representative Warrants in accordance with the terms thereof, including, without limitation, the payment in full of applicable consideration, the Warrant Shares will be validly issued, fully paid and non-assessable. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The opinion set forth above, is subject to (i) the effect of any applicable bankruptcy, insolvency, reorganization, moratorium or similar law relating to or affecting creditors&#8217; rights generally (including, without limitation, fraudulent conveyance laws) and (ii) the effect of general principles of equity, including, without limitation, concepts of materiality, reasonableness, good faith and fair dealing and the possible unavailability of specific performance or injunctive relief, regardless whether considered in a proceeding in equity or at law.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We express no opinion as to the enforceability of (i) provisions that relate to choice of law, forum selection or submission to jurisdiction (including, without limitation, any express or implied waiver of any objection to venue in any court or of any objection that a court is an inconvenient forum) to the extent that the validity, binding effect or enforceability of any such provision is to be determined by any court other than a state court of the State of New York or (ii) waivers by the Company of any statutory or constitutional rights or remedies.&nbsp;&nbsp;We draw your attention to the fact that, under certain circumstances, the enforceability of terms to the effect that provisions may not be waived or modified except in writing may be limited. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In rendering the foregoing opinions, we have assumed that: (i) the Registration Statement, and any amendments thereto, shall have become effective under the Securities Act and will remain effective at the time of issuance of the Company Shares, the Over-Allotment Shares and the Warrant Shares thereunder; (ii) the Company will issue and deliver the Securities in the manner contemplated by the final prospectus; and (iii) all Securities will be issued in compliance with applicable federal and state securities laws.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The opinions we express herein are limited to matters involving the internal laws of the State of New York and the Delaware General Corporation Law.&nbsp;&nbsp;<font style="color:#000000;">We express no opinion with respect to any other laws.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are furnishing this opinion in connection with the filing of the Registration Statement, and this opinion is not to be relied upon for any other purpose without our prior written consent.&nbsp;&nbsp;We hereby </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<div align="right">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr style="height:15pt;">
<td valign="bottom"  style="width:15.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:84.72%;">
<p style="line-height:9pt;text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 3</a></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">consent to the filing of this opinion as an exhibit to the Registration Statement and to the reference to our firm under the heading</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> &#8220;Legal Matters</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in the prospectus constituting part of the Registration Statement. </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In giving this consent, we do not admit that we are within the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations of the Commission thereunder.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Very truly yours, </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Loeb &amp; Loeb LLP</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loeb &amp; Loeb LLP</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>3
<FILENAME>maia-ex211_8.htm
<DESCRIPTION>EX-21.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
maia-ex211_8.htm
</title>
</head>
<!-- NG Converter v5.0.2.71 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:right;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="BigHand_Transcription"></a>Exhibit 21.1</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">SUBSIDIARIES</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MAIA Biotechnology Australia Pty Ltd., an Australian corporation.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MAIA Biotechnology Romainia S.R.L. a Romanian subsidiary.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:39.11%;"></td>
<td style="width:21.96%;"></td>
<td style="width:38.93%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21805085.1<br />238213-10001</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>4
<FILENAME>maia-ex232_408.htm
<DESCRIPTION>EX-23.2
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
maia-ex232_408.htm
</title>
</head>
<!-- NG Converter v5.0.2.71 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 23.2</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:11pt;font-family:Segoe UI;font-style:normal;text-transform:none;font-variant: normal;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;color:#auto;font-size:10pt;font-family:Segoe UI;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We consent to the inclusion in this Amendment No. 2 to the Registration Statement of MAIA Biotechnology, Inc. on Form S-1 (No. 333-264225) to be filed on or about May 13, 2022 of our reports dated April 8, 2022, on our audits of the financial statements as of December 31, 2021 and 2020 and for <font style="color:#000000;">each of the years then ended</font>. We also consent to the reference to our firm under the caption &#8220;Experts&#8221; in this Registration Statement. </p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Segoe UI;font-weight:normal;text-transform:none;font-variant: normal;">/s/ EisnerAmper LLP</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:10pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Segoe UI;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EISNERAMPER LLP</p>
<p style="text-align:justify;margin-bottom:10pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Segoe UI;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Iselin, New Jersey</p>
<p style="text-align:justify;margin-bottom:10pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Segoe UI;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">May 13, 2022</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>gyowp0iggm03000007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gyowp0iggm03000007.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" '&!&<# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HK
MD[G38]9\=:C;W=UJ2P6^F6;Q1VNHSVZAGEN0Q(B=020B\G/05<_X0W2_^?K7
M/_!]>_\ QZ@#H**Y_P#X0W2_^?K7/_!]>_\ QZC_ (0W2_\ GZUS_P 'U[_\
M>H Z"BN?_P"$-TO_ )^M<_\ !]>__'J/^$-TO_GZUS_P?7O_ ,>H Z"BN?\
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M Z"BN?\ ^$-TO_GZUS_P?7O_ ,>H_P"$-TO_ )^M<_\ !]>__'J .@HKG_\
MA#=+_P"?K7/_  ?7O_QZC_A#=+_Y^M<_\'U[_P#'J .@HKG_ /A#=+_Y^M<_
M\'U[_P#'J/\ A#=+_P"?K7/_  ?7O_QZ@#H**Y__ (0W2_\ GZUS_P 'U[_\
M>H_X0W2_^?K7/_!]>_\ QZ@#H**Y_P#X0W2_^?K7/_!]>_\ QZC_ (0W2_\
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M?7O_ ,>H Z"BN?\ ^$-TO_GZUS_P?7O_ ,>H_P"$-TO_ )^M<_\ !]>__'J
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M /A#=+_Y^M<_\'U[_P#'J/\ A#=+_P"?K7/_  ?7O_QZ@#H**Y__ (0W2_\
MGZUS_P 'U[_\>H_X0W2_^?K7/_!]>_\ QZ@#H**Y_P#X0W2_^?K7/_!]>_\
MQZC_ (0W2_\ GZUS_P 'U[_\>H Z"BN?_P"$-TO_ )^M<_\ !]>__'J/^$-T
MO_GZUS_P?7O_ ,>H Z"BN?\ ^$-TO_GZUS_P?7O_ ,>H_P"$-TO_ )^M<_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M5S_A[_D.>+/^PJG_ *16M=!7/^'O^0YXL_["J?\ I%:T =!1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MQ'&H#"WR.'?/'0Y [\<8K?\ AIK-_P"(/A[I.J:I<?:+V=',DFQ5W8=@.%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!7/^'O\ D.>+/^PJG_I%:UT%<_X>_P"0YXL_["J?^D5K0!T%%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 <_9_P#)0]9_[!5A_P"C;NN@KG[/_DH>L_\ 8*L/_1MW704 %%%%
M !1110 4444 %%%% !1110!Y_P#!+_DD.A?]O'_H^2O0*\_^"7_)(="_[>/_
M $?)7H% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MOTN:%UXC\77OB3PKI&DZE!"=3T47-S+-;JZH^ 3+@ $GT7(7)YI--OOB!?\
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M?_!+_DD.A?\ ;Q_Z/DKT"D,**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ KG_#W_ "'/%G_853_TBM:Z"N?\/?\
M(<\6?]A5/_2*UH Z"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#G[/_DH>L_]@JP_
M]&W==!7/V?\ R4/6?^P58?\ HV[KH* "F3,R02.B[F5257U.*?378I&S!2Q
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M444CG"BBB@ HHHH **** "BBN;\?>'[OQ5X)U#1;&2&.YN?+V-.Q"#;(K')
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MCNJ*Y2'Q1=R?%&X\+F&#['%I:W@D /F;R^W&<XQCV_&C0?$EYK'B7Q7I=Q%
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MUX&2!SC/%7?L?C#_ *#NA_\ @FF_^2J2VM\_Z^X.ORM_7WG045S_ -C\8?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?_@QA_\ BJZ"B@#G_P#A._!__0UZ'_X,8?\ XJC_ (3OP?\ ]#7H?_@QA_\
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MLG))8CM@52G^'.L2?#KQ#X>%S8_:]2U.2\A<N_EJC2*X#';D'"GH#]:79/\
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MJ:ZBF_\ ($%%%%(84444 <_>?\E#T;_L%7__ *-M*Z"N?O/^2AZ-_P!@J_\
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MV/QA_P!!W0__  33?_)5=!10!S_V/QA_T'=#_P#!--_\E4?8_&'_ $'=#_\
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MSN*'..BL,?,"O:5S]Y_R4/1O^P5?_P#HVTKH* "BBB@ HHHH **** .?L_\
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M*] H **** "BBB@ HHHH **** "BBB@ HHHH X" ?8_C9<G.!?:>.,]2 O\
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M>A_^#&'_ .*H Z"BN?\ ^$[\'_\ 0UZ'_P"#&'_XJC_A._!__0UZ'_X,8?\
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MG?@__H:]#_\ !C#_ /%4?\)WX/\ ^AKT/_P8P_\ Q5 !>?\ )0]&_P"P5?\
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ML%R!DA23C)'/N*COO%GAO3+R2SO_ !!I5I=1XWPSWL<;KD C*DY&00?QK/\
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M?F_V3JMC?^3CS/LEPDNS.<9VDXS@]?0UC^(_AWX5\7:C'?ZYI?VNZCB$*O\
M:)8\("2!A& ZL?SJQX9\$^'?!WVK^P-/^Q_:MGG?OI)-VW.W[['&-QZ>M %B
MQ\6>&]3O([.P\0:5=W4F=D,%['([8!)PH.3@ G\*V*X_1/A;X-\.:Q!JVDZ-
M]GOH-WER_:IGV[E*GAG(/!(Y%=A0 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 5S_ (>_Y#GBS_L*I_Z16M=!7/\
MA[_D.>+/^PJG_I%:T =!1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!S]G_P E#UG_
M +!5A_Z-NZZ"N?L_^2AZS_V"K#_T;=UT% !3)D,D$B*VTLI /IQ3Z;("8G 8
MJ2IPP[>]3+X6-;GS_P"%/B#IGPLTB?POXC\.7\>I1S2>9-!"A6Z!8X8EF&1@
MX'48KMO@]8W0M=>UJ73&TNSU:^\^TLF7;LCQUQQC.?3MZ8KA_!'QKTS0-/N=
M,\23:MJ<T5R[07K*)"R<8!#-E2,'U^M>O^#?'&D^.K"XO-)2Y6*WE\I_M"!3
MG&>,$^M:+77?3_(F6]MM?\SI:***D84444 %%%% 'G_P2_Y)#H7_ &\?^CY*
M] KS_P""7_)(="_[>/\ T?)7H% !1110 4444 %%%% !1110 4444 %%%% &
M=K\ NO#FIVY_Y:VDJ?FAK!^&,_G> =/!.3&9$/\ WVQ'Z$5USJ'1D;HPP:X+
MX2NR>&[VR<_/:WSH?IA?ZYJE\)WT_>P51=I1?YH[ZBBBI. **** "BBB@ HH
MHH **** "O+?BM^Y\7?#^\W,/*U78<>C/%G]%KU*OF[XR>.[C4?%,6E6<4EK
M'HUP661UP[S#'S#/11CCUZ]Q7JY/0G5Q2Y>B=_FFOU(J-*)](T5Q_P -_&;^
M-O#"WL]L\-W _DSD(1&[ 9W(?0CMV/X$]A7G5J4Z-1TY[HI.ZN@HHHK,8444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7/\ A[_D.>+/^PJG
M_I%:UT%<_P"'O^0YXL_["J?^D5K0!T%%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '
M/V?_ "4/6?\ L%6'_HV[KH*Y^S_Y*'K/_8*L/_1MW704 %-=UCC9W.%4$D^U
M.I'571E< J1@@^E)WMH-;ZGB&F^,O$NN^(]%U*+3=-L_"VHZDUG;IY"--. &
M^8D@X^Z>F/ZUW7PX\27FN6FJ6.JZ?!9:MI=T;>Z2  (W=6&/;^7O7!7WPM\=
M:9=6MOX5U^R?1K.[-Y81W7WK9SD?W&R/F/?'?%>B?#_P;/X1TN[.H7YO]6U"
M<W-[<XP&<]A[#G\^U5&UOZOT_P""3*_-_7G_ , Z^BBBD,**YSQ-XTT_PQ-;
MVLMKJ&H7]RI>*RTZW,TS*.K;>  /<U6M/B'HMWX9U/6U2\B72U)O+.>'R[B%
M@,[2A.,GMSCWHOI<+:V.LHKC]!^("Z]JD%DOA3Q38K,"1=7VG>5"H )Y;<<9
M[?45V%.P7//_ ()?\DAT+_MX_P#1\E>@5Y_\$O\ DD.A?]O'_H^2O0*0!111
M0 4444 %%%% !1110 4444 %%%% !7G_ (#S:>+_ !?IY/RB[$R#T#,_]"M>
M@5Y_IP-E\:=5CZ)>6*R >X"?_$M51V9WX3WJ5:']V_W-'H%%%%2< 4444 %%
M%% !1110 4444 %>0?'K0-/E\-V^N_9L7T%PD+2IP6C8'AOH<8)Z?C7K]>??
M&J'S/A?J+XSY4D+]>G[Q5_K7?EDW#&4VGNTOO)FKQ9VNE6-EINE6UIIUNMO:
M1Q@11*,;1U_/U/<U<K/T&;[1X=TR?_GI:1/USU0'K6A7'._,[[E(****@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N?\/?\ (<\6?]A5
M/_2*UKH*Y_P]_P ASQ9_V%4_](K6@#H**** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MJ?\ I%:UT%<_X>_Y#GBS_L*I_P"D5K0!T%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% '/V?\ R4/6?^P58?\ HV[KH*Y^S_Y*'K/_ &"K#_T;=UT% !1110 4444
M%%%% !116+XLU]?#'AJ\U8P^>\("Q0[L>9(S!57/;)(H8+4VJ*X#3_$OC+2]
M?TNR\7:=HZ6FJN88)M.E?,$NTL$D#]2<$97C-=_3L%SS_P""7_)(="_[>/\
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MQ)IER&*F!X9)<CU#(I&/K@^U/^SL7:_LI?<S24>6*DVM?-?BKZ?,]+HKA?\
MA<?@'_H/?^2<_P#\11_PN/P#_P!![_R3G_\ B*7U#%_\^I?^ O\ R,^:/<[J
MBN G^-'@2&!I(]7DG8=(X[24,WTW*!^9KMM/O[75=/@O[&=9[6= \<B]&!_S
MT[5G5PU:DKU(-7[JPTT]BS1116 PHHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KG_#W_(<\6?]
MA5/_ $BM:Z"N?\/?\ASQ9_V%4_\ 2*UH Z"BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MP]<:M_PGWV#R;MK;RO['MY<X1&W9^7^_C&.U>WT4 >(:=>_$._\ BAJW@O\
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MS6K5PJPTDM.OY?\ #DJFE*YY_P#\(E\0_P#HI_\ Y0+?_&C_ (1+XA_]%/\
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M5X7N)=-T>^COM(U..:""\B$1N3"X),>2<JP)P>]/HN;O^&G_  1==.WXZ_\
M ,D^%M*^'7C+PS+X?%Q:VNIW#V5Y;FY=TF)C+*Y#$_,"O;UIFOQ>(/\ A9OA
M*XU:\@%I)J$Z6MC; [458VP[L?O.0?3 [=35N#4=3\=^+-!F_P"$:U?2-/TB
M5[JXEU.'R2\FPJJ(,Y8?,3GVK5\7V-W<^-?!4\%K/+#;WDS3R1QEEB!B(!8C
M@ GCFFKWC?O^']7$]G;M^.O_  #M****0PHHHH **** "BBB@ HHHH ****
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MD G=G)^M5?WT^SN2OA:\K'B/AZVNI?BO!X*DB_T#2-7N]14$G[I4%./8X/\
MP*NO_9X79X4UE,$;=3<8/;Y%KT>W\)Z':^)[GQ)#8A=7N8_+EN/,<[EP!C:3
MM'W1R!VI^@>&-'\+V]Q!HUG]FBN)C/*OFN^YR "?F)QT' H@^6-O*WSNOT0Y
M:MOS_P _U9KT444@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH *Y_P]_P ASQ9_V%4_](K6N@KG_#W_ "'/%G_853_TBM: .@HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH Y^S_Y*'K/_8*L/_1MW705S]G_ ,E#UG_L%6'_ *-N
MZZ"@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N?\ #W_(<\6?]A5/
M_2*UKH*Y_P /?\ASQ9_V%4_](K6@#H**** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .
M?O=&UC_A(;C5M)U2QMOM%I#;217=@\_^K>5@P*S)C/FD8(/04?8_&'_0=T/_
M ,$TW_R57044 <_]C\8?]!W0_P#P33?_ "51]C\8?]!W0_\ P33?_)5=!10!
MS_V/QA_T'=#_ /!--_\ )5'V/QA_T'=#_P#!--_\E5T%% '/_8_&'_0=T/\
M\$TW_P E4?8_&'_0=T/_ ,$TW_R57044 <_]C\8?]!W0_P#P33?_ "51]C\8
M?]!W0_\ P33?_)5=!10!S_V/QA_T'=#_ /!--_\ )5'V/QA_T'=#_P#!--_\
ME5T%% '/_8_&'_0=T/\ \$TW_P E4?8_&'_0=T/_ ,$TW_R57044 <_]C\8?
M]!W0_P#P33?_ "51]C\8?]!W0_\ P33?_)5=!10!S_V/QA_T'=#_ /!--_\
M)5'V/QA_T'=#_P#!--_\E5T%% '/_8_&'_0=T/\ \$TW_P E4?8_&'_0=T/_
M ,$TW_R57044 <_]C\8?]!W0_P#P33?_ "51]C\8?]!W0_\ P33?_)5=!10!
MS_V/QA_T'=#_ /!--_\ )5'V/QA_T'=#_P#!--_\E5T%% '/_8_&'_0=T/\
M\$TW_P E4?8_&'_0=T/_ ,$TW_R57044 <_]C\8?]!W0_P#P33?_ "51]C\8
M?]!W0_\ P33?_)5=!10!S_V/QA_T'=#_ /!--_\ )5'V/QA_T'=#_P#!--_\
ME5T%% '/_8_&'_0=T/\ \$TW_P E4?8_&'_0=T/_ ,$TW_R57044 <_]C\8?
M]!W0_P#P33?_ "51]C\8?]!W0_\ P33?_)5=!10!S_V/QA_T'=#_ /!--_\
M)5'V/QA_T'=#_P#!--_\E5T%% '/_8_&'_0=T/\ \$TW_P E4?8_&'_0=T/_
M ,$TW_R57044 <_]C\8?]!W0_P#P33?_ "51]C\8?]!W0_\ P33?_)5=!10!
MS_V/QA_T'=#_ /!--_\ )5'V/QA_T'=#_P#!--_\E5T%% '/_8_&'_0=T/\
M\$TW_P E4?8_&'_0=T/_ ,$TW_R57044 <_]C\8?]!W0_P#P33?_ "51]C\8
M?]!W0_\ P33?_)5=!10!S_V/QA_T'=#_ /!--_\ )5'V/QA_T'=#_P#!--_\
ME5T%% '/_8_&'_0=T/\ \$TW_P E4?8_&'_0=T/_ ,$TW_R57044 <_]C\8?
M]!W0_P#P33?_ "51]C\8?]!W0_\ P33?_)5=!10!S_V/QA_T'=#_ /!--_\
M)5'V/QA_T'=#_P#!--_\E5T%% '/_8_&'_0=T/\ \$TW_P E4?8_&'_0=T/_
M ,$TW_R57044 <_]C\8?]!W0_P#P33?_ "51]C\8?]!W0_\ P33?_)5=!10!
MS_V/QA_T'=#_ /!--_\ )5'V/QA_T'=#_P#!--_\E5T%% '/_8_&'_0=T/\
M\$TW_P E4?8_&'_0=T/_ ,$TW_R57044 <_]C\8?]!W0_P#P33?_ "51]C\8
M?]!W0_\ P33?_)5=!10!S_V/QA_T'=#_ /!--_\ )5'V/QA_T'=#_P#!--_\
ME5T%% '/_8_&'_0=T/\ \$TW_P E4?8_&'_0=T/_ ,$TW_R57044 <_]C\8?
M]!W0_P#P33?_ "51]C\8?]!W0_\ P33?_)5=!10!S_V/QA_T'=#_ /!--_\
M)5'V/QA_T'=#_P#!--_\E5T%% '/_8_&'_0=T/\ \$TW_P E4?8_&'_0=T/_
M ,$TW_R57044 <_]C\8?]!W0_P#P33?_ "51]C\8?]!W0_\ P33?_)5=!10!
MS_V/QA_T'=#_ /!--_\ )5'V/QA_T'=#_P#!--_\E5T%% '/_8_&'_0=T/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>gzq4oqz5m4ms000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gzq4oqz5m4ms000001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #2 -,# 2(  A$! Q$!_\0
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M_()@_P"!?^A&BN*7Q,[(_"CYPUO_ )#VH_\ 7U)_Z$:HU>UO_D/:C_U]2?\
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M_P#02F_\!9/\*Y*D9<]TC>#CR69-_P *X_ZBO_DO_P#94?\ "N/^HK_Y+_\
MV50_\+J\#_\ 02F_\!9/\*/^%U>!_P#H)3?^ LG^%5[6O_2(]C1_IDW_  KC
M_J*_^2__ -E1_P *X_ZBO_DO_P#95#_PNKP/_P!!*;_P%D_PH_X75X'_ .@E
M-_X"R?X4>UK_ -(/8T?Z9-_PKC_J*_\ DO\ _94?\*X_ZBO_ )+_ /V50_\
M"ZO _P#T$IO_  %D_P */^%U>!_^@E-_X"R?X4>UK_T@]C1_IDW_  KC_J*_
M^2__ -E1_P *X_ZBO_DO_P#95#_PNKP/_P!!*;_P%D_PH_X75X'_ .@E-_X"
MR?X4>UK_ -(/8T?Z9-_PKC_J*_\ DO\ _94?\*X_ZBO_ )+_ /V50_\ "ZO
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MO#_WQ'_\74_AG_DV[6/^VW_H0KPRA<TF]1OE26A[9_PI'P__ -#O#_WQ'_\
M%UYYXR\*VGAKQ/#I-GJBZA%)&CF=0."Q(QP3TQZ]ZY:I[+_C_M_^NJ_S%6HR
M6[);3V1[9<? 72;,J+KQ=Y!;[HE@1<_3+U!_PI'P_P#]#O#_ -\1_P#Q=/\
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K0 4444 %%%% !1110 4444 %%%% 'JW@[_D5;+_@?_H;4445SRW-EL?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>gyowp0iggm03000010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gyowp0iggm03000010.jpg
M_]C_X  02D9)1@ ! 0$ JP"K  #_[@ .061O8F4 9      "_^$/BD5X:68
M $U- "H    (  @!$@ #     0 !   !&@ %     0   &X!&P %     0
M '8!*  #     0 "   !,0 "    'P   'X!,@ "    %    )X!.P "
M$@   +*':0 $     0   ,0   #P *OR;P !    J_)O  $  $%D;V)E(%!H
M;W1O<VAO<" R,BXQ("A7:6YD;W=S*0  ,C R,CHP-3HQ,R R,3HQ.3HT. !4
M:7)T:&%D978@06-H87)Y80   Z !  ,    !__\  * "  0    !   $0: #
M  0    !   ".P         & 0,  P    $ !@   1H !0    $   $^ 1L
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M^56&E];Z_<YS;9&Q\;@8WS_T?>JM^14US15>YY!:70]I!:9W,^E[7;?TC?\
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M@Z-TA&6%=H97=X=(B#F LN*SPW6EQ6=8:'C8<)#RXZ2UIK;'J,@I_\0 <Q(
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M 5"F*:A2C$P@A[2BB""-<E54?S:7_P J[P      0)    $"0    0$4 )
M              $"0         F")   ! D                   $"0
M  0 D         !)FD
M
M
M
M
M                       7*S<2IK45VP       /2I!""!(@ !ZN5%!,R@
M(UVR9(@  2( $)N"$G @
M                         =%=#Z/099M>BE6NYC1A3,2")*B,0A$D@1$(
M@D4X_FY6LR&*\_I)_.VN\VK@  VAL%JZ9WF!JBSY5B[4<VK7#,OD"443!,(1
M",RA!&1$$6XW&B9U]U&QK>(>?RMK6NQ0
M                                  "9$NC.C] L^-ZVBLTGK^!K
M     #<.[[J1L'-Z&FYBY3RRX$/55+867;M756=CZ]X,T]_:X!4Y=U%*EQ+(
M$B"-1 5&80B$C"D%VR9?0OI^>Y[^;_(=!T)"
M                                      "IHJ=>==[+8N.N4\8OH
M      %3;J=8^G^XV[E'R[QJX@N4.Z.BTNI>"^?S]M!E5-V3V?9V6ML#OVKC
MNADS=+6L:79IMV_K3:Y^N](<IB9O':56BEB<AVM<IH,1BWB>+4W,@XAOZS=<
MRY+.LS&M.^,W&Q7DO2[+8'FB
M                         !-KJ=,]S[=;N8>#\/N(1K/ICE;GGB^\Y5-S
M_34:5SG<9NP^0MKS^XND_/MWC.G_ %W6T?4OCF3KSF[OLC<&-86'9,/R,G,.
M ]AH]CA,7'1O8^IVG3O)<!=L5HUSW32[)Z;4Z>XNYK8[A#(=A+KF_O<&V;RF
M-BVKZ[N9X%N<*LQ2QKY/2EK9XI<,CHJ7 ,?491=-5S*CVF^HM>86/,O48-!R
M9LZ]G '9_6Z[37&');'<H
M                      $^JIU)V7M=LY4XOQ*YA[O&WK]_ ?.'7=,7Q[-S
MN>5D5TJYARO&)D^9;'\Y_C5XYBV1E7R-K#M]'<R9^MKV)D03%QU3W?L%JY8X
M7Q^ZR8MO=VIVQNM;J;B30;#;(5^PO/JWB;C7%#J,VCZ5VN)I[G+6W=D6S51K
M:=D:3-N@]OLYLGB^JSG2GJNIP';WF6OU_I[J(V3S?K;V5<5;_F=F0MRB.V.M
MUVIN)N2V.V0
M            )U5UVAVOK^-<C\5Y+DM!9MJ"Y9       'J";3=72U#K[T3W
MBT<3<'X'=PC7+IC=:[ K5AY-RY]PK^5^;8       !&LC<.Z>CUFI^.N4V^S
M,9FW6
M       >Z2X7\QV!W7MN.X5K^:N'/_)^>7*EII>8QP)(Q""010))A""MS:F]
M]UZ-:]A;/HJ#DS@O&\CQJO# $:CL7<X>N,BVFLL?+O(])M;$IHK?-%0@ )$
M !+VAMS?X&+="9UC!]$Z?.S/GO5W<N
M                                  "_Q<AO'K?4[3.NU0G1+W5,(57?
M<J*4BNW$A>]KL_?:'I_T39N%?&OF2[IA/U./1Z/T_!W[%<?5>@   *A+HCJ=
M5K6]U6['[R+<-K[B<8ZZ[OB-)_.[RON.E/./91BJ/FJ[";72FT5Q02MQDPUU
MQU_-M*:[(S
M                 )M-:LHI>X/4%'52E5U(55H)73%A]&?H[ZSL_P Z_GKY
M,O%I0A%3Q-IYD    !(DFS=?9/W+S[AWX[>(=UW%27:WC%"$ DF36J9O/6)9
M0JJ4-VT
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M@ C&$ A*,!$A&(C749<=9[GK9O+G>];/
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M7E_.MK;YK786)6Z]V\W;F*[KK\ !66KCM?S;R*@X<].]9KP
M                       #Z!^<X.*\"^CYV54]<(420!M*C)ILGBY3T5-C
MQL&BO#<:N7<F]3%GMZ*W0MS#RL B(#O?@+&-<.=XR78^IK\?6GYET=A^./U9
MTEUPK)M5D[96WG'J3L+8HTXJ34!.M9(DJA)O:]U-Z?[=([$PO1<*Z/\ *;6@
M]KX_48YN;KO09=AYOSN?N?:\-I7G_!Z#<F!:W-K^ ;'E&\>O?L'XTY&_/_\
M,GL/T7D6Z 5-&4]55I5-H2]1;2[T(10C,KEB77TK\:^?[9A%.TK.!O:O:9_<
MOG/FMJY([;O;EA&\R_<BS"" ;LMY=@@FON-BC&==W:,EV>NX9IBY8SWH2C)U
M+K^JUE^FZ\?,@]52A2=_^2^16_C+TOUBX89GW
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M "OHM.\O*?.[7J3J-_5<U]AU]5;9M
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MT2^BZ/H.9HNGP*5;%E[BJ:0A,O40E6<:/'GJ'H%3C&3D>@
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M7:B\)4=>.E@ JEQOBQZFYZN^4HCU5 DF$8/$UO--+S(
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MN.KT1?)VK(<7IGK)L,=BPMUS1,?IYMJRGCP
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M%1,(Q A":DU>5<R"AIH04$TID770.)Z2Y[R_-D5+RMH*Q"*D$%2(*7B9
M                                            5EG.2JK:1<Q0
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M $R<>5;KDU.'[-<*:YKF!N56VY;>(H
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M("))"F$"*))/>:\DM6=;QE)^=G] OA&9P9[9XC<-5V^24ES%
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M;\\4]TO>N.XX"?B?3ZNQ_:G\Z?L?+/-1P%[;X/3?F+_4#\YJG5-CC
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M5?,VW\PF6ZW0D39
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M3C*.UJ(W.K.A=+.='463Q[PM@
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MIUF34FON \7,=3U60   $^C*3:*U-=Q'B:0
M                                'J*U5:RWBYCJ:JR    K+.<B/U3?
MF[Z_B5)TEZP=5>Y?0'+'U;_'GF^E^ ?IS14'8/A.UG_&C]TOQAR;._H;\^,G
M_+;XS^Y]5];<;L?E]\$,GGOJ<0#ZL8NZX<LEK%O/V2Q<CX#]R=%/.'.'[:_A
M=^SW>G;^0>\*TO;>-?\ XS?T"<E?)?A^\V9VE^KGXL;E_.1^7WZ:W36O*=#,
M"7<QU/59   $156<Y$4=[!
M                     $V+B?:RDBNPE5V  "2,'<?F'0ROJ9\R]IB/QN^O
M.1N6BNIYV[=.9W?:[_6)\G?5W*GWA_ #F^Q?SG_M#\CV+Z8_NC_'=LW7NJ]#
ME:,\J^BK)Q?H_=;G9>IZ&G^=_GGWUJSZW><?7'Y*MQVLO$M:3'3/VUQ+GY7[
MOH>$J_SN?:5O]NO2GZP_A=]WN>?RD_<WGCB_XG^NZ'\ZWI?S!U;DU=+O7Z%\
M:M$RQJ;A\^/!?H.?;\,IJK(   F16J+66EU4*>YB
M                                       #TE56,Q*KMI%S&  >KQUG
MRO3:[[ \-VF1?)SZLXG(J744O-RAXHJ==97H.M_TK^2_5?)5S^H/YHNM/L#]
M'_A?LGY7>/\ ZC6.5A:UQ1XE]D47Z,?O_P# 3)_C?\,?O9RG]W/.?UZ_F;\%
M7Z/JS^>W.P?T_P#Z L'._,K]%+6L^46J^!J^@'PD[+Z$_<MPK1?SWX*=U\R=
M)>:*$:X1MWFZ>PY&'4?K/GE-\]_G7V^JD30   *FF\]V[ZFN8KQ50
M                                         ]55.F.;W6*[_P"*RIEH
MS:7NQ7<D$1"8@B1!,Q1$$R@B'I/HE0;*[AUFOZ^X<5=[I<UE40['YO?8/]./
M NHPGG/M\C-=AZ;"83M+DC5&UP?6]M=T-=E6IV6.Y/A\K4:NV/87SI/@>+Q;
MYB>ZX^>\J=WHI_W^T7T[QM]1-[^;^5;1^C/PIZ/YYP_1?/6_J/RU<>F_0/ER
MY_&?X&_H"Y2^Y^+^KG\RC .)JZI^1M_!^_7U6O;_ .,'.&G]D^RO#FR]8^V/
MYX-Y\U=Q\%YWF.V&1:=3>E\%(VAT.JA<-GH/>1ZV).C.:[VHVUTW#4]QW5?J
MR\G<];7Z[DZ?47+]E6;![[54?R]^4_?:_--QK_/1/<\'2VJ;,VDKN2T"9!"$
M8R@0@E& DFE!*=5?C:]+MO?-_&=//\6)00
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MYB3R3R7<U-/KK3Q;H) 0)("( (","2IR;S/-OJ/.].DT,CD+SCK*F%$@
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MWNASG=O)Y]##=W\IY1O:VX:WJLY. ;^]*YN3B?!["9JW!VGH
M                         ^@GD/3XSP%[+R^32+$@^E&RVG.?2?F]ZJUS
MU=6MJA7D/#V)RV\NTZ,S0.I-KW>W-A7=%:X\=F46H>PM7;&;&LO/%E_5[, +
M\RGZF_SI]-TY^<[[\X;-M![C69;*JQDJJDBI"*5YMY:-G"2\_-4V3:4.#9
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M9>^=7O\ 6?"%O6[=YJV&LR7)NKAO_.Y&GY:X;KZ@
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M>NPUVY3^F]3N=/<87-5NO";^->>V?0/+Z;D+C/3:FQX58
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M% F!( 1,$@C@G/=9[T_RW43J3%L%R$+8
M                         3(J38N)EJ^DUVTFYCH(='WN<D]$XWAL-&3[
M!(Y?K[BNE10        ^J>-MOG]\K,G4_0$ #W%Q,HO)M-PB%/>Q4N:
M
M    !Z2J;.:B/%S'2IMKG54^SN5\#T_Q4Q/O2HIYE"(        ?0;'V7&NM
MZK6:\@WL+I4)D5)]K+1B7FJ$BYC/$VP
M                                   !Z$*SI+5<-XVIB<3)M6]TU3XH
MH)N$D:JWN9+4@RFK3^<HG'H]54[RNBA[U]]=<G-H->4]UZYGR>\K:*J@ !FU
M-VQ=K6=AH'&YIR:F3L<!#H:WD<Z<]W,?HGU%7GT>HD!&3,>H(B%R1J:K,;X%
MOZWJOR@
M         $U6ZCL><6_Q@Q5<W[/TZ=0[&PBD2 I!"N"2?9H0$JJ\"HUY"DZ2
MQ/-9&68N))XRW'J-: 9K3=L?>-G9<Z_-G(U'4P        !D5-RA^C-C:<J_
M,3)T_7
M         5S(=R8'AMKX-S_:KH !UAI[6ILY[/>WS:?+[NR8QC8MTE[;64-L
MY>*W!.NLRL%LV;UT-SE_ OGYOL+=M'=H!4TR^@.@\ I_G_T/T-4>4O=FP^@>
M'LN9_GCLM7TP !N/>6+5U5INNPVOTE^95YVNH_>%CR=2Y5^JJK^//TA7BY/W
M!I]OJ'YB=9I-]V_760!M6C(Q?<M%[6'(M[!WN
M                                      !7Y=YVGS_SKYX=VOT)Z  Z
M'UEO ,DZO<9-DFFSJ/U@XEENFPHJKGRUR1J_J<3U=;4S\/TUJY<^[FSD-)<H
M!66JW7%OR*AYVQ_3:[$]CMDNS;=P8V9RCPIGZ[JX #:&]QK5O74]132]-=]S
MLO7V#+<.J?CEZ_9\&R<++:91:<THR7(.TU6:2L*  '<]C8\K<,7]=U2
M                                                        !<J[
MSN+4^!^>"]G[MZ .RK&SU]],>ARN>=0:*N[[PXRJT_-/UO5] ]E<?TF-S-M8
MT_F&AP?6F,K8;[GM/:<%M[+7WR[S>8ZC"XKCM:KPRCXCH]QK*:8(EWC9V',/
M!E_6]/  3+U3[ -?RUG>O[S(KKSU6HN;^IU_2^C,; Q7N_K.EOVY?&M)SU\W
M^\HZ1^?61I]D@ !W?8V?.7"%_6=&@
M                              76U2^@^N^>9'SHVWT5/E*0!74W4$*2
M[:+QL77W;+>)SJ;4%[6Y'ZBXR>J*39.-=P[1N1CYX%=;A]$\'YYI_F]LOH>H
M .M;6=IC"IHR3G^YB;# /5Z"85&40LRR>QD4^'V[%16YN4A<QE'KH  !W;8V
M7-'(UW#WUA=5F^@
M                !<8K?1'1_.]!I7/[Z=S1L.[J83*(   "")) ]Y=+H3F_
M-I&_==S-!P/U'N5SQ*,KV !VY9V/,]YB;?QW=P^IK1-'I("!(@    SVF[B7
M8%K.T-H.O%V/S)=P]O@
M                      76Q=; KT'G==7GM$$9@2)%(E  B$9D2D:JY#1_
M2^DS\%UVXJ9<XJCD  "X16Z>MY',=5,6LD$8@3" 2C&"$B (S#%#/N<;F+O(
M
M
M
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M !YC?J$;"%["(V 1\+T-K@;R U?Y X6$1N(@->=6"@&]>^KA5ZM7^ K_ !Y
M-K"(>=[ -JL4:^$:"U7"K!0VH!+0=-"):N6O@KX:N6AZ0H.D0'I"A$M?\84
ME&@Z*N6O@$.H@C<M"(4 D !,4* 2B "6]RC0"%[ (#TW"P"'35RW#IM<M@Z:
MN%[E&KEMU%KX+"(!0VJY0JQ;?!?X:N4!^$1^&OA"OA&CVH5!N(F&@O0#73:@
M$:$1Z1$0  &O,0]]7&KB(&$PCYW$!$/,U>?4/ON-6 *$PC1DBH4I/R:%133T
M]2I05*+ER7(@<+*9$A%-#T]EG4,+>6<2)G,NO&TR1"&!V!94#,0BS*%)D1%
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M&H0-:WD "%%((4!AH#&MUC0'\@,-A.(T)JZS6ZS" F-;J$*,8:ZC!76:A,-
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MM>PB( -_(!$*Z@H!L-P !$1"]J ;4 T(A0B T:U7#P4, EZPH.FO(:^$0^
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M7* C:KDKRJY:\A#X:N4* 2W 0L%JN4:#I + %#8! HUTF"ND: IK@ V !
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M3^(#0XWB?5]-8E7TSB-!C.(U],X@-?36(C7T_AU?3N'6^G</M].X<%!C6)
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M%1#%-<K^15>G_7QG(WN-.LCB&J8=5 :CJF4%I'K/#K.""7Q%?J2[_2CX"%O
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M6<W?ZUG:^N)V@S:;KZVG IYM#)W97DW(/A_DHC:C 0P]M.NT0:*02U\5>=A
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M5]:;AKZUW!7UKN&WUKN*OK3<%?6FX+?6NX;*Y9-1XP4_'3;?Q]_@ 7'V%?\
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MC;V55>@Y)UJ=6.,52.:+$736613-+%;';I&(<DQD4/C^/R*A(V2ZR>R[)W%
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MT]L]VX!5]X%3,<#=0AX6"AM9$W21(O6H(W]K;T6_R3&VZL:FZ(L8M*&ZQ;'
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MQL;H6Z%'SL$VJQUBU!G-+9)L5T9U/_O.>D'#I5HH#B-\"AU&,'2/M+$[8HD
MX^PZ2D<_VD*O6[H:_P >W\K<MQ[R" XDZ>S,9(R201:"2CK'8R2"48^Q:K_'
MD^9R3#7652*43GN6R2L*VA%EG2CM\?Z5D#%;YB*_37>&\M+A'J8ND#\<=DB3
M<8N3I'V2A6"NU7LGE\6>#RXG^S@ $T2BGZAO&1[9GV$Q(8JP'Z"UVTP#H)<R
M8&*V8D>-2,VPN!<(]H\2R.1))-(M13--MB#V06D2_O*J06&&E,==0^^M/3,R
MS33D0[B==Q.@43KN)UW$Z[B==Q,*[B==Q.NXG7<3HO0(Y%MC7^,)@\VIL"0A
MX=E",A6-;P$+5[O !OXD4L0.IN9V1_(.%GLD648PRZ+)Q$+.&,@60<X8@#U%
M@)3%H  ?8Z"V>,F[EVS[7R>)6;HF/%L>AVV&2,#-!RY%MV0(U0.FV;HHHQ[=
M!JH4H%+[:1N@\;E)6Z4AJ38T8BY(Z:'N%=57"KU<*O5ZZJO7575:KU"8KD<V
M+'%L*A3S,R>1.4.H?WD3&'PD?3S",UQDX[9$K]J7&F@XI<::^U+C37VI<::^
MU+C37VH\::^U+C37VI<::^U+C37VI\::^U'C37VJ\:BC"X+K_":6%V:EK=22
M(JCXB'3XW\)(H1M; .=G&(QD^LSDWLZTQJ09Y)'2"DY/_4)L;R!)WZ?*7<;B
M\ZK,MD2@!_88I*J;'P!JNCKYV+Y#!U&*ALM292>2XZ_$9"8<1I!$47!Q;]?H
MXXZAT?"_B >Q[Z:G=M%(W;VRXDH;>VA7]N;0M_;VT H=N[0"@V]L\!_M[9]_
M[>VC7]O;0M_;VT K^WMH4&WMH5_;VT+Y-FV29D?U -50*)A HD'^(V\0'I\4
ME6HE:MU"A(,6*JB8E ?U14,1?V!&U"-_&W\NO1$%'+Q&46C<@*BI7F4?U7"8
MJ)HJ=U/POX^^@"W\D*-J[AAJ=EX;&Q82F828G,4#7-0"-"-%.):!4U^L]=1P
MI-4BIEG%E;C:XC18',3F%KDC4K)<'3I1'MF]@Q@*'<4/0D7&NVM7;6KMK45!
M0@]M>NVO7;6KM+5VUJ[:]=M:NVM72X .]TC_ " X !NR*PP,5'8\F951>@E)
M *^:2%?-)"OFD@%?-9"OFLA7S"2KYA)T7YFE1@DE*^:2%?-)"C(+B1(RJ=2\
M4.4-VL\9VIXF,!2D(*@_KB "'F@;^/@43KMNE>4]B8DER/X:/%ZAB;P[^->3
M*23EDU=O9YAE<9)PJSYS&,UG"C&0B,C3E7X_]SP*/40K5O%90!B&H0M76-+@
M*J_L0K<LH^@A6DF[:9*=THJ857KL4F:CA(BKA<$Z0.!RY#(.$85[T]SQ.4#E
M1,)B?QZ/*!W6,F V(^Q*Q157D*^,R3CFB#%-Q%,CTP?JQN0L,4C(Z&DXHD^V
M7*5W(QV/M8MP/DIX#\!EVGS&/CE1427"P>^DK"]]B&>!$OX5-6(9-HA!$%$"
M@+IHDJV,V3,JX2 Y6R)4B.HU!V@O_M["?D?^/,W!4%84ZB<%XK>0*-&#;'BF
MABJ*.OG$LCW5\;8RKIP+,2F1674*F@:YE3*%*U.)S>!C)BDSDRQ2%O"U?ZN/
M83L!,673^>1I">L5:EF4%QL7K4HJ31ENK6:)H;CTF(]WV4/B#^/.3E3/*D^G
MIKV"JFHRIK](B4CA1)._6)$B)GH?<N0IR$2*0? P=:C@"2D]XJD$P)G!0OB'
M_9;&Z5V0 #@2]QJH-_!XZ%TJZ1$C'V53"-%*!0_C]J57R>*5AI**RAQZ9>O3
M+6],O7IEZ],O0-UJ],O7IUJ%NM7IEZ].M7IUZ<QX,BN,@QEJ*+M_E)C-4&B7
ML'3'J!8M 8HA<*N%7"KA5PJX5<*N%7"KA5PJX48Y"4*ICT1,"?R(I#$IT"+L
MHQV-"(QN-5\MQH:^6XU?Y=C-?+L9KY=C-?+L9KY=C0B$;C-#&XU7R[&J1Q_'
MVXH20-B>I!8J'493V1"]=E*NRE792KLI5V4:[*5=E&NRE791KLI5V4J[*-=E
M*@23 ?\ XB__V@ ( 0,  04 H!JX (B%"(!0C0C:KAU>^@&KAT^5>57&O*@&
MU -JOYWO0C>K@ #0B ^ C0T T'D'4%7N%[CU7J]"(!5ZN%7\@$>H36H1L6YJ
M P %7^&X (B%[DH! U ;X1M0" 4%K!7O&O*X"8?#JM0B(#Y4 C<MP$H>?PU>
MU (6MY@ 4'E1O,0KRN(@(6O5@H1\K"-=/EY#7G74 T;WB  %R7"P" _'0C76
M " ^7E;WU>P7"OAJ]A$0&KA>_D)KB8P5U%H#@41, UU@-=0#0B%BB- /EUT!
M@H!H37-U%N80ZCC\)A"K#>XA0F"P" !8:\_ 0KR'PL%K580&P@(%&@"@ZJM>
MNDU?#5PM< J_@(U>] 8*$;4'E755[!U (WKSO<!$3  A5RB'5X=0 :A&K^8&
MH3!?JM5[C[ZZJ$;A0B!:&UAJ]J$0$+C7G8!+1AO5_/X:#I$.J] (6OY7"XB!
MJ,:]7H;"(#Y")1$>FKWJ_F-AH#6JX6L%"'F%[ (#0>=#:KA?W#<+>0 %6M5R
MT-@H0O0"%#8:&U!8P7H*N!2@)1H34%J^"NHH#<M@$M^H!H3"-!<:Z@HOE0&\
M^OS 0H#5U6KJ ! Q1H3%KKO0F ! _GY6ZNF@M8H@-"8+"(!0@%6 :\A$>FA]
MPCY6\O.@  H;T!1N/P@/F6UJ ;B(WH1 :\J_P @!1]Q@N-PHH"=3LDH!JX4;
MH)1WLD42'?&HSMZF(M%FV2@]<ER- %G8/Y:9C*:NW#P'3Q=H#@7L:5!V[?4?
MU[,YG[N;(HX>IBJH[FTP,^C**Y>O03%Q#@:8<OZ3,O.$(LO-"=,[6E7TT(I,
ME9PI%G$F*\41P=R]DP!./6$THY7>% RCG' 9*!C/>?18%>/)*@.NR#K7=T9-
MPB99(\RGW7T?0*O9&E&YW*B@J. ]*J- V$U$%X85/5DH'[Z1 SQRP!1%-(#G
MD#F.R41.HH>7(5HDA7<DKJ)*IJ+M/G::C]^F=1=Y.)N#O%::B[2%5R_?BH=X
MY(4[EB/0O)U)KO8QS(R3UVT>/7K2FCY\[ ',FK1B$"FKM^XIT[>M:;.W#NG+
MM=G1&*D\4%EI4PQJ#<%#OPKY@^F**F[8@#M[(4'K68@;R U7"UPH3A0F"]PN
M E"A\J,-!Y 4UZ#SH+W]]  U[P_S:K#0A>@  'I&W^+&'P&XT  !BT:X5?JK
MW44H 8IA$;C0"-^JU7$HB-P$!H+UYWN->=OB$2WJXV_R(CU>5O,! H@/PU>P
MWK)'Q,4C7W,[&XT^/<H\;F4)?F%C(4/(^&?X!AV9L\APG8N?Q&K6D'S(PJ6<
M;0VI%ZT::^V%'9TRQ/DMC>;2N4\M<>QQ]K;DI ;!8L>8.-1<KJ+>N/["B7O+
M_'L?FL!Y'P&PCYGRTQ/''.$[3B-A(*NFL>7.]T1>O<LV9N*%U;%9QN5GA,>Q
MYMXDS"9Y#Q&'9;MK;D5J^"Q7(3-L43YG8PRE<%Y.PV1QFH]HQ^?*06Y(M]L+
M)>4<#%9?C')?'\X._P"8&-1HZKW#"[%3VWN*)UJGJ_8\;G6,Y#R@A\,R? .3
M6.YTYS7E-CF)2FLN143EQ=7;DC\SFI'><4SR!YRY@D5(+EQCD@HYYAXRJMLO
M=F.:X)B/*'%\N=[%RE/ X@G-3'(XVG=NL-EXZXY(0,+E^>9 3"(M/FGC$?6I
M]E1N?XY+\GL:Q6;U/MZ"SZ ?<M<;QZ?C.7&./FCKF3C #KSD#C4YB[+E[BI)
M['LPCLD;[-Y!0NNI3#^4&.YY.[,WQBV"I:VY#8QL%79')+&\"DL'Y98QF,@8
M!E2;(Y$8O@"^MM]XWL.MH;4B-;-M<[&C,^CW7(R#QW+=I;?C-7L,YR]KA3",
MY>XD1;86^(#6ZS'F'CDH[V'R2Q[ )'#.5F,Y:_ 0M>X@ 6]P^5K %>X!M<!"
MWD%#0  U8!H H;@ V&K4-[^=7O5QZA ;A<:'W6->UZM\0@(58>D M72(5<;
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M0!TT-[#8# (C7E>XA0^=!Y#U>8&M0B%[A5[T @%!:_F:KA75Y7$ N%@'PZ@
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MT-8>0NA1K[AM##7W":', <A-#@'W"Z("ON#T/7W#Z%K[A]#B'W$:&K[A="@
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M5P*K[.4^SFN3)Y;,?PL0\S  _HV :N-1L&YS')-[95'X9@4&;TM2L2I(MSN
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MS#'L:BL?5;X=J%O,I&%FWR?%_I@W'[8.%:Q=PV80>1) 8IPV_)?+,=W6)87
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MCV\/@,@S!/67&S'<5>;3W(?)*4,)C!Y4 "%)J&*;/\&P[:$9B&O,NUN/4'Z
M4H:YOX2<PG&+AEWQ3*Q#6@F$@#ZB1&AR)"AR)&P9$A7U$A7U$@%!D2 A]1(U
M]1(W^H4:^H43".1(T>6AG8.84YTBIW*:]\7NDN_(*Q'D5!@#* BE'$?#0KE2
M>BHQHF,+$"X:0,0B[F8)D&/(QK!"9@VP)+33-B5G S+W&7F,;5B\D1Y6?B7U
MEN_)MQ\+>1?&3.,8_)5-0*>_.1<AOU\^<KMY'\1DA/.<>+,QRU&<,500.DL<
MJ6;]./:'C=@"[D,7T2VRW8DGDH=0B98>M7;&,MLDQB5R.#QI!!]F<ZI#Y[E4
MABL/*R#W$V.7OES2V62#11Y/2:8Y?ETJ$4^EYM/,VN=3(Y@BEU ]R%&(2#-<
MED7+QAMM^K\GVH%?*-J6&(VF-?*-J7"(VI;Y1M2OE&T[!$;4KY1M2X0^U*^4
M;4M\HVF%(FSF/:(Y?&I+$/:A&_[U#19'IY.5%2KC0#7G[/G0W"O.WNKSKSKS
MH &FDBNP6D6C9=FK_OYD$3"-&(I?Y ^:(M8>57I6,D*- S!#D@9,&[J-?_+7
M[1ZQE.]T4>3<.! @KCW3-!A-L/,!@L)Y28AL;$]F<2>,G(-GFWX*-+S!%/P,
M[;"4X><&]J\?()IH4Y5F.A5Q,EIN+Q(JVT\!Q0V8;4R.5-WG2JB:)AI0 (8
M\BW6,Z<O71ELIQ6*/!; Q*;@5WS \(GD3!05\BCBU(YG%>I-(,W"23UDYE5(
MF.-,Y$_)$-F$:::$ZL@(%52"KDJZ=73O=.KDJY*NG5R7N2KDKJ)5R4H5?J?0
M^/R"4:NLBN W_>I @,(\?/Q.(&HHA?P 1* &Z!$*'R#VH-<BSEXP5*J):M2
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M'6/_ !\IS%,PQ+9.JT\)W1@&=O/6,*]:PKUD?7K6%>L85ZQA7K&->L8#7K6
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M8&W8$!%N-NQY=@**C:NSY=FU=H; B-"A79-0HB(]@UQ1-78&W8-7:,%=H:[
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MC0H -/@+&Q7-IVJ[V/FA1/I_C9M78.(ZZY$R\OF''CCZH\;:IV<D3,>7_,Z
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M%=@U=@1#TYA 6Y[^G/843 (H"(BW, ^G,-"@:_8\Q;^8H&L#<U>G.-=DXB"
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MC<4AH4J!&P]JU(&*BKWR4/,S0%?>9H"OO-T"-?>7H *^\S0%QYDZ O\ >;H
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M (&X*;\P35:,=RZU/'Z'G.6&&K.YW>>)[53Y1<G\'S,N9\OM1S^[4.:^*8Q
MY4M%N,C$;^)A.L;XD*.0A36*%6+5BTJ041T )E9'RKRJQ:L%6"K%HP& "@(_
MPQ/WTIYF]OH)U\2>6FN]&U_ZL];\JW/-GB1EO#7D%P?XM83PDT[Q,X]Y'D64
M&#JKG9PXP_FOI3BGM[)LKA,@RG'\'QQ;ERTU)OGD)F/.*/4D\AEY9T98XBB]
M<MU- ;=YNM)K"?S5;JT_LSC;S#T%RCQCFQR7QGBEIK\=O'6?QMBZ4,@3<VH&
M.U<:DH/'>7^G.2O'S-N+NW\=_##R!E=?YWN+@AP\QV7DE)F2L6P=O]!,]@M2
MA;#[''S_ /> AA-BNMXR9PN)T^:3Q*:X^/(Q26XZ#%3Z.ET)8D1A&&S619KA
M;G!W?\++_K0^_P!L.H3#U6X*\[,JX&9=H'=V'?E4?X=EVMMBYAL/\J.:[#VA
MPF_)=#<DH#H P_FOR;3NF^1VT]X['W7D>&Y*;"\SSG:V@]G?B(4$PFJX5^"K
M(L$7TIR\VOJW:^V<0S'*\&R+B_R.9<M^6Y3?+)7<NQ,JPU$^%\I%TY9Q(<B,
M<VCJ_2/)W5FZOS6YILO"T3-UA&W@%OT"?[4I:WL<?/\ ]ZYP-KG/X?!%4LZ4
M3P9'?\@V!QNG'E<Q6WY//74WMIO*X]F&2GRK*?X7_G]'SKW5JS!,GV[L*=U6
M7"L!_)=K\N(:,XJ&W_)\=I!6/R;\A_Y8/R>H<3,?FYN8GY7PQC:N?X1B?C$[
M!S*"P\1OX)#U&_%A^2=K )<V,MVQKF>X0<OMG\@<&U[E&M<JQO&L=?Z@Y3?E
M]XU(:IW*V$ $#B0"FZ1]]"(T!A* #81\Q$PB &,  -J"W4)C& #&* VH1O0B
M(@(@6N/AKR'PU>] 82T V$1N(F,:@,8  ;"(WHQC&#^$W&C>[]'S"OPI:':2
MF2_C]PT=A9#M'3^N]UXON;\4LI ;%V+H_4/XJ^-/&3ARO^0;9/)'1.6\:]U5
M8:80<C+KIX'F2TDZ9+,UQ 0'QC(UY(O-H_BF@M&8C^/W8[#G-K3%(#D%QN8Z
MJ4RISD7+]C!3FC]W1$3SG_'[D.I]D8C&0FIMBY/%8WA^3YH^FL%RO&)C(=3;
M#Q&+@M0[(RR+Q["LOS21G<+RC$92?U/L/$(R#U#L?+8S'<+R[,Y'(\*R_#9*
M>U/L3$8O']3[$R^,@<*RG+9?(L+R_#9*=U#L?$XN U3L3,H_C Y9L7>>8YDN
M/Y+/:AV-BD7C^IMB9C&0V#Y;D\SDN%Y7A+B<U#LC$XO'-5Y_FD=#X?D^2362
M87E>$N9O4.R,6C.DW3^[XYK38^9D'CSOZOMXW_7V\[^&OMZW]7V\[^"OMYW]
M0\>M_5]O._J^WG?UPX\[^O\ ;SOZOMXW]3W1&\(]JJV6;JT3_8*4]WZ%_,AQ
M*&3*J\)?Q0\2/S-<,%<?PO.L(V/#H=TH_FLY<*<A>3_&3\CO([BA$<S.=;7F
MYCV#X!!9!#\7/P_Z-<ZWU!Q)Q' 9C:W/'C1K?$^-LYC_ #;VMS*XS8#_ '/R
M)X?;+X[R9T^T8!$X\4]P85Q^W7NS\U/,K<D1QIWCE''/>N!9KLO;#Q_AV%I.
M]_?DZXHZ >?CRY8!MO8OY&-.):2Y?U>U>7Z( /00_F@).]AFGMJ[*5#AORYO
M]H'*J@X@\J:^T#E37V@<J1'[0.50A]H'*FOM Y4U]H/*F@X@<J1H>('*FX<1
MN5-I7C#R4@6./[(S/"$<*Q5/.'\JPDXB2"YA_<M::TR7:D\ZV+JG4HY/O7<F
M9JCFN8#7UIF%_K3,!KZTR\:^M,PKZTS :^M,PH<TS"@S3,*^M,P&OK3,*^M,
MP&H[8>?Q+MCR5R*:+F^H\;?XRG_L%']WZ"07'C;KI/;>_.8D\MEO(W.]1ZRV
MF0G"YO@F3ROY!_R@\5<.>N5W:P!<>%VL,!V9MG9_X^F,=K[BQDOVELF6HL!X
M^R,GPZU=G4UJW0\_K5I&X1E.6S4QQ\TWD.E^1'X=\F?81GVOY; I;PG<DQV%
MQ?B#R\_(#ENCW? O<6^QT[Q:T]H1[E"K2)Y*_GBUHBWR3PNF'Z*?OTAIG8^^
M,[X\_C8T1H^&4129M$FRYQ]4SMZED(>I95ZEG;U3(*%TTKU30*]4R$?5,A'U
M3.XC<;A6S./^D=TPO-7\<V1<?FV%XJELL3H&35_<63-U).]US+37$%X>ZB7Z
MC (>QT'$.@X!3#&,EE(3V-:[%R+5F6;LP&#Q>:$*4]Z*P%!9?N>-_8$! /Q'
M8BODW-S9D]]8\W%1 U -?DWR\(S3M%_VXWY8RC\KY><A8K!]E\G]=P7+*+T)
MP\+C^/\ '7GXEL5W-1*&R]P<KN3NM-<\4^.G)KBN?2OX_/R1;^Y+;$_+/A>J
MY+2V<1\ C.Z^)C;:%,;_ )/Q 9>M"<H0=#'D1!>/=\TSJ1&@/SZX0_F=!J*'
M$!$!+X0>#Z8A^+[CB9CBBN0<5=,8!B^2<:8W%57/$'&7><;ZP#&]<[0N-FQ%
M5E>%?%6%XR:'5N@UZ$6H"1%S7>$P=(B/E7^!_P"*O5 - U;D#T3=0HM$+>C;
MUW.U0*=VA 1*_8QLW&\[^.QN*?(')L9D<=8?N/&,&K+9KAPL[7\!#XM"% V[
M<VV5K+>/)31VFM3;=QN9XB:Q0XG;%XDZ.C\TQ+BWK^?R_#=.8Q!/9C0NJX'5
M.V>/VFLIWERNUT^P%?V(=U]5\6_\J>_B-B+;(-9/N.G'C(,7G^/FOL=FF7'K
MC_C,HSX_:=FIO8FHM-ZTT)X1[%>5E?Q(Z1V9IGEH@]:SG)S,)AQC.-<9-Q9!
MO35/Y4)-9UEF0<..045JC'BHH9!J/E+QLVSE7+36^M>;L?H?8^N<$EM1:GG]
MDRT1A>L\DP)SRFY#:%T_@WY".*VZ8[8&8<(,[R_>;];!41><5V"_,?\ &MJC
M7/&#(<1''L4X[\..3'*:0X"O_P"MN=.;\B>63G.,MY?9CG"3O9N5;YXC?E'>
M2NW>$VW>/NVM&,"E./C#\@MCP^O\;V_O=X^D.5_(.!DD-[[E=Q6O^1F:ZKSK
M<VR(+:NQQ* $_'E@#'97,%)N>R) =FS#/,1UC X;G6(;(@4=CXP[W&L!2#:@
M&].1ZJSS96$:FC<4R."V5!D9.24PF<7E\@F<A@L?R.*=.I6*GLKQ#!V B(C[
MA_+C@#66XQNY'(GF(?N.@@%9C[&IM$CL["MA<6\YUA%...<DRE<XTCL#"-Q;
M+U1RLRZ=UOKC?,3DL_J3;&&Q6#\*^5.?[#^W_8TVN726Y#Q/L<7LQCM<X&YY
MDZ].1;F1B(5-N]F[ODL2Q_E5F)L]E]ZK,LDQ3G!CLP2$Y)#&YFES9R/4>J>0
M:VG<>7YXY H$/SBR16;XC<B]7<GM\83&K0>Y=]<'L"R]3C+P>P[=>I=Z:O:\
M)-L:]_-1@_'?CCR)Y(YIR;V-LG(&V/[IX@9G@G,W$V&[=_8!EVY,;C92#P7,
MN+VJG">22*_%WC;HC ]HZ%SSA ZW9M[77+G//Q^.^5'Y+,NY%:HQ/C[A.]>/
MO++)837&_N-?YY8=ABVFMTY=O[G?%\NL"XN36LDY;@!EF$Y2?9FFN4.PQXQ\
M?^27Y0=;/VN6?D(E\JQ+J%,=(Y/!XKAG3QZFY27>8H:)S9KJUVRR7*M>QL>\
M7T$M%[#VUQ[U)%-?R-00.>%O,;"]W;Y"X5\-MP1LED.BMO\ 'K;N7(9)QTVR
MTP^+XRRV3;&B>)^>XE#*\1\\7U)M'AY/S>TM]8Y/9]IGE-QNVMG0;5U.:%U]
MA.M0VT[Q+C7/87F\)P_V-.ZS=Y%AC#E$'2 #:OR>RS"+X5(93'IZI_<=#YG'
MX)M79F"2.M<^\>+'(6!T_KC+.<_IH^?Y/8MG6T&O);!VW-O6O+##\5Q_,>4.
M%SNFW7._ FVT67-/6[;/V/)[3C_5L=RCTB&'>QF"8:_X_P!ANJ7RUGM# HO6
M:7-##W4\VWAKO&,NQ[D]I?!L7;\NM0R),\Y"X#*1&WLICL\VL(?%TB<WX9<H
M1Q[E[.MC,>9J'DH-QK\IF)+G@A$1&N*O'?5G(F)T_P :'7#5AN?B),;]V7I3
MC5F> ,,WW[K;?&4<MMA[UU9Q9T3^/'G=FI^ >LIQIAF:_C2UE(;QS_\ 'YO"
M$V=^,?4>^,<US^03 M#MLP^._P")/'CSW-)SCV*JR>0-&F4Q7,:5)BW#_P#/
M-FN/P?&\H"%>8T4?-UQ'VX_D,=XT;\:Y&'%S=Z*F!\2=WYE.KZ&V6T02X;Y-
M,9C/:IS[$SGZK<?-B&T_MZ*E8O(8@36HJ/47OJG,!D H3(4R9M7DN@NFK%LV
MJK!NSZT'#@L0].W^51XD4$YNW,GK(Y5^M&R3%P61#R'WF_,;N2.1B-CP41BT
M1^Y0'R_D3ATQ#RL!)?KZPUI 0<%G^=3FR,RI7W?H"  'X_\ -B:^YE<D5)#&
M^7+%FB"$]/8WB[;G!R7TUM'7QBB82^_5>?K:TSO\9>_<QW1"[]TYOS.]C1'*
MS"Y^>Y<_CVW%F.5:(X4;MXW9;J;DIROUEDN^N664:4FX73G*S6.3[JWQR0VQ
ML+#N0,RGK+,8C+,&S?-\/D,1<?CVY&:BXSY]K3;FGMK,54E$#;:@C[>SW\_F
MV74]@0^XWN*!@&:Y;EEYQCR=(P@HKE5#GQ#(>5DC.Y1#<Q8#&\0D^86)/LSV
MMMV$F=$4 ^7XT.;L4M$F<NSAZQNF *M%A!9B ]YA0K,*[S *%9C;O,!$56(4
M"L?7=86[S"NZU./_ (X4\<H'+R+Y,:YT#J_)I7).1&36.13]R 1*+/>K++6!
ML*XYSIPU/IL:_J?35?U/IRAU/INOZGTW7]4:;M_4^FZ_J?38U_4^FZ#4^FZ_
MJ?38U_4VFPH-8:-; CF?'W7=9YL+,=ESI/\ ;WT</+] P?$P>NHE[S4V2&;<
M6]=\5OS"\KIG5/\ ];[1ZL[J#@APOT%CO/#BI/\ #3E&"2@'6U_G+7$=<[-F
M]<2/"G\IZVO]<XUE.!\]LLS6/F^,'*[)L7Y)9EKV0T[S&F<7:PG%'%I?2_.7
M)(N=;;=:P/$J%Y_\/9_34NL#Z5BI.6D$..>LM10.I=C_ (Q^/F8N9+%_R-<7
MY#@ALW:_);D5^8G9A\^YAWN'^/ 1O07L)3T-Z13"QVX%+5QOZ98#\:?R?;QT
M:PQW\LW$;)2I?DFX/)5_[-N#5?\ LVX- ;_V;<&0H/R;<&:-^3;@T-#^37@U
M7_LUX,T/Y->#(U_[-N#-!^3;@V%)_DOX,%&;_*7PCA8_<7YBHE%MDV395R R
MP[UP4@B<Y_X?>U>5OQ/[!8;_ .(O'CD!S&SWA7QSC_R*\BL<XU<[-@L>6'_V
M$N (;NX]?BFRK4NN,9_+?S(-RCY*TDJ=$^O=UYWK&2?;;:9=G<=SOVY#RTES
MWR&-PV9FY;('NI=RY?I7,]*_EVQ7Z"U1R8SK27)3D_R!T-RAUQ^,SC0ML'8D
M5ED8_P E2P?*6#[;>;RN(8WQ[>.-)\+MRY]CFS,S<N]*_*,/6U@@V0<Z^#+L
MS<ZX<BJXTP,#AJVM6Z"#G /JW,W.M'"!W>E_D^'*ZV;HIN<#+EN8N=9N$5'>
MEOD^'+:V;('<X"7+<R<ZT<(>HTQ\DPU;7*%&<X 7+<P=:R<MB.M+_)\-5UVW
MIZO@?U;E[C6J[0KO2WR?#E==-P>KX".59@YU>NS3V3'L($YNH?X.G_K2ENO]
M'@5R/<<8N3$%(X=H[F)*_B2_'5D@OOQ*\/-ES?%?3F2\>>/7YE/Q>99P8VV;
M_;V>H?'J&B)F$W'/0F;<D<N8XGJGC5I#5?,S*'6U,?GD<G)FT(ER$Y ?FTY0
MF@-=IF'J R8")DQJXW\QJY:N7P$1&@"A\A1*8QS!85>@2C[P&WA<M7+X@%Z,
M%AMU (B:@"]"%A$.JA$3 (&#^$IA?P.'E^B44^Y^.'>F.\Q>,G K>^7<A^/&
M>\IN1_$28UE^2?D]NG9>,K8CRJTE^83\3J/X^L@<)*&.":HUC7XS8_5OXQQ]
M_A^+O@5@/-W3FV=6YOIG/RE$:XZZ#GM_[/T3H[!>/N#_ )0GVQH_5VU^"3G6
M/%WA/G$_IKAEKB*A>%W'+=^X\IWOM9N0JBEO.U6 1]L@6#RLI_O_ !@!L/G5
M@#]'W5^&O\=N*PB7YH>6>@N,O)+ ]C3/([!<-Q[ OR&QV]> 6_<<R/AKQ]W3
MQL@=/LLG_*SR]Y@_AUT[O)RTQ+9VJ<AW=^5K)YC1 A;QX+?D%GN'V*;@P?E-
MSNY$<-/P087A*O/;@,CMC4W&;?,-R)UA*PL+F,'E.'ZT>:YXXX6SW!F7._\
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M'(+*6' /:CB3P_B@V<0<UJ?9V-8;XZ%V0CK?9>W<+<ZVV-^\_DHCPB.21DP
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M!U#7Q4/57Q5\56-7Q!7Q5<]Q$;W-7Q5<U7-5CB%CT/4(B!Z$3WZCU_R5<UP
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M(6OGD(%?/(6OGD)7SN%KYY"T$Y"C7U'CU-9:+?*?NQC 4.TJH)4TR#^H( (
MF4@%$P!^IF>0?26'\6,9(T@6Q'*(JNTWC5*'C''CFV4?2$5C?(G&LQR#(P<S
M,=J& V1FS;8^2PV-*;3WKA"^.O-M: P7$(#)>0F?;X[PE4]A4B36024>E$\>
MY?-=V8N1YJSBV@,-$_J.7*#1%5)Z_-V&W4'8*'4A74A74@(W0JZ-71H!0JZ
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MRU@:"F^#N(\K]K[@RO;F69!%ZLT>:&5]@0 :*1RDI_%,FS"*Q<$/JN0$(&4
MWR]W88]V-?+W=?+G=!'NPH(YW0Q[NOESN_R]W0QSROE[NXQ[L:4A=C0[:$R]
M1T]\,^,Q+$&6:Q6%O"Y 12&?NY$J#?((E7"Y&:?/\A!Z# TW&*NWKV6-ED,Z
M \CDRJ,@BT<O_F$S"Q&11>4<?,TUK+XSR1AR23"<C):/-#.GU-D'B1O(0YM
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M:K?2(#,2L0>M<Y82H%]_JQ;@U/A[M6IFH\_B:]3,I9C*@W$0(C'?;A'Z7X5
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M '5KN\Y_)J_D^4CR='):/ZS?[-7_  EH_K-=_)J_X2W]IS^35_PGAM/]:?\
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M KA!L /F^ID<IUNHD>$.H\2V/_E]0_+-5^$M?\W&F_+-7^%M=\W&GC^6:O\
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M +8B2"8F3@8K:?1<1_CZ3GHNCTZB$&\%2$8Q%\$Q<#!N_P .:GB&L)-*G
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M8$.&89:B5+Y[-Y(.49>LRB8%6IJ%JLU-#G:JKB*CE:66JU0*^<@QD>09NS%
M^KXN]!#2H+)':TPP!J=B"4SY\I?JJV0AL0T7VUW"J/RC:?45J69BM,,:50HT
M9JA DBX$P 0%9A?;5FM0RM3 D$K-PDY I8N(B] W-?(!RXW<G+T'E]T*HZ[>
M\/!R6TM37.$%0A1!!@LU-5!"%RLM47UHQS>J#:IW:0CVG3!6()50.VHBNM[L
M%DI@,Y,W&\ 6J=Y$J*-+1-,&64$]K4%!(4PS#/"R%@$K,"#;(_JB/C+'(!C
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MJ3@. 5S*VGXSI>(-5TNJI"IIZA1I*DZA:E&KV:4Z:5Z)HA:U+$'*ZDJRDLC
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MTK(9[1F8SC(>+O%Y<1 FI= NY+NJW/-AR_2W3Y!8UIN5??/.=TD;'W7U8?,
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MG=[I=B=Y\1MIJE)YBK?=!'5>XCGMPZB;B*5_2:E2>B=K[  S)&'1T^2T W$
M>.(Y#B;58.\>2;%,T/R&QC&W$->-/.E"()S$CU468"_528@=:)!W\4U.@T-.
MAJ#J';J%\@IU&.2F$,0M/(P4SF<,,S38T:IRTI#*(609$&>UN&) ,P!=B(IT
M/9Z9J$0'" $7S)ZS3.> (-V5;I)L6?2^TT %D#+3*DME4G*E8Q-<93B"#,YC
ME>AKT:D[  YE:HQRE2A6&14:*0*Y&5@K921?FIZ;NX$S!CU@B!KP9!-5A,',
M '!C<1=;3#B5=FJP>T+'3,MY2<AH@'QW$1%TVIZ/4TD-%%!)24)/4 9A,*;J
M9)0J!FZ@BZS:K@^GJNZ4@]5F<0)* Y<\D!2R@3G+$D@&5 X3P;C_ !!:E:O4
M2E2=J5-#,55[)G33H AO/:=G5<U%B &<C1:E:F9JF;-O $@ "!OB_&^WMW$:
MQ33J#@"Q,L% "@&;R!@<1;BB,C ]EVD&X_)ZBG4YK^K<>6W">$_.?Q _UXUZ
MLX4FIEI@5:C+?I3[.I975GSL))&4E\SMQ;COSQ:\T>Z% JE'+&;4NQ*%OXK6
MJU54/V;@FG3J9LP@KFCYD*7 M54J<)J:G6FF7G-E8("K-F;,R+6*J0E,7D3N
MM\SE D+234<=63, )Q'4H)-^47^.;5&TU3-34Q(@@G?!!,X;[ 3?[HJ_*!UO
MZM2HH,01(#A3$79I\]@F2Z_>=YD[\>@R#@;2U.I)F\5:H)S!0QS!P3F"@-?+
M;[ HD$Y0+S%P($+,"XD7#_%$#7<.U*4Z-%*2(ZL[95I5,BJ&IZFD\J09*.*@
M;K9K4TU&LJ:FHKWN348]9X(!JU:[Y0#$/4J&!>29LU/DCRB;<:XG0)%945!N
M^^U*=/&\8/OD;CS'4/>1[\C<Q^JY#8Z2I 7X"?J1]3RV;3: T374"%>M0I9B
MS%%5>TJT2[]6>SIW<]ETVM:@*[2(IUJ%3*58*ZL-/4K97(?[W4N(Y;K4.\K5
M:9T575/0"9G[3.JTV8^J:?9DNH'RO/8A@;HW]'3Y+8;_ #\FV'AM&6[GQG;R
MGEM2*8P?>VVN>GH*=)JX(ZKUM.C,6#9%I9]13S.(D]F +O#9=/K.P[8IUEIU
MZ=<"]1D=M,]1$J7_ 'LB\&=XL X&)^J^NYCR;&;:+BNJX5J*7#]3F[*J].HM
M*MD]?(_WMQ2\XOMJ^*4]*?T=I:E-*M0%H1J_:9,_[1\;MW17I4-4E>FC0*E,
M5%1_5ZZ]L$J3?_E*1%JM'0Z&OJ'1&J-V:/4*TTS9V?(1U)N'3&^T@];86-XV
MVYC;6ZYFFCJ].)YS3K5U4XWF%8^J/6-_+0H%Q%.<HNNS-)&ZXE3!CE_PE2)^
MK\\@?0I3[,LS"1$;M]YMW,T_95,^M76E#U>K[.5SAQF@%LQRY0TM.[(6XZ5!
MS4VI @F\G,/5DP?6O-T[[+60D*1-^/A&%J=,U5#&(&:)B,-YQ! Z)MQ==65[
M!&H%BS90(*,I8W!98B+R2""+VRVT%5'!1Q4*\A ,,1?!RD@-C!-]YMWF[R\3
MXG3I<,X0^D34O*D:<ZW44M/2-<R>R1FK4\S.+D8..K)'>K0ZW6:6E2X4VG5O
MEESTSJ*5.H!J4(^0<FHN134J%T9'/9EPA S"_"_'Z&@@<J9-XZ+_ !S%A'$:
MT<N8^FQ_WA6_;-]U8!F!)NOQO.WDL]8HC5*2X",PYN4&_&XVXJFFTP76(]-:
MCC*&J,:"L)(ZYA'51F (,A)B;<;33KIAPT"D69<G9'Y20;ODR5>^6NS\ALJK
M53,PD7B_HY;4]6&^4!:#U1?$7D .1&[,1&(PL :A"Q\4CIY.;;?!K5,>7T^"
MW9BHY'.;YQW7<UA5*J6=HRF_XI,^L!NPNY^?0/$*:9(NOQ(\L6I@H,0/MA&'
M3S6[-::%8&()Y!NYO%85)"GF\/+.TBQ8L0O/>;95)CILFC<DL ;YQDAL9(-Q
M QLFMT^8ZRM4%, 2<V9<@RA>T)ZU3+E"2;@JL39:N@HK5 2&!WYEI$'*\@Q!
MF9(Q )S$/3XK15<TP9!B&$7J6/(2-^, 39JJ48ITX#DE86^YI(+9;Y]6\83#
M1IFK58ISRRV7H(471.:-TY;A+Z37T'.6FN49*9_=6-YJ+ZJD/ES$L1E16>%:
MJSZI4TC(DL%ZH"T 3<&NRF5, DDPN891:GJ--J0SIG4DB"P:FJB\S@ 1-TP&
MN S#A]/B%):J4:;4\I0%61R@AAU9 "X,3!Z(/&.(\)X3HM(:FOJU11J:;35A
M3:FH*(C5Z52M08!@@-)U=6/R92>MW2764WIU!0K$PS*P2K7:H@!R(08(%P,S
MC$670Z)E[93F&8L)BJM0]9>L# (!'6PO$ CB8J0$&FJ+A+2]5 !<"3>T"XGD
MP%NZG>_YM>,T$[B:B@:==RJ_)B@O8*H6N5K0KHRMU))!.6,M0<7X'\U'&4J]
M[>$!%*OVBD4WJ(5(]I5*509*32P8LJOUZH-6E;YD^%BK.JT3ZS,%)(5JQ%3*
MU]X5I F</!;NC7-44:%;6<;J%@I.6>,:JHN4=K3ZH:F.J,0!AOXJ^OXWQ*B,
M],H-+J'HTJ@6FRS4#/6=R)N+E+^46X=7'$=>&T]=*JS7=E8I45\K R"I*P1%
MP,6ZPM3;MG54,D*[)FZI%Y1EGF!!W0+:EN):ZH*)O)05$92:ZSUQ79C=ZG9K
M34H0+X &JH@U_:\Y&G:H69AZY,M/J[E-8R5@;@+:&IK3JC6IP&"FKV;*:3 B
MH%.1B'P*S4%3+/R>:W=HZZOJ*FLI:Q*FH-,ZI(4BIE@=O59C3;LY--R P+*E
M.FSJ0Q#M0JB#F:0A2I4,@3"YT*@1R+-]]N(:37<7U>EU51>L]-:B&FRU05[.
MH:[(91"I]GIHC*QS2]J!;YR..TT&;#4UK[M\5+XB[P\MJG'=1\X_%GX'2J4Q
M4TU2I6JZ>*BHBNR-5>3VP0W+U6=NFT1,#;R^&TS=-V['S>'S6X5Q;7U"NCI:
MS3.[0&A5ZSO\F6WM&TCN]I#Q&A3U]?BG'*VEU%2EJF2IIZO$=37= VGBO3-4
M5*5<=HM05!1-*KDJY".XNNU/#%I)2XKQ%  2I.FJT7":U*:"N !5,-0J5165
M"&ZUZ6[Z+HM$:_>9.&T6.II5\J5-1VI6AI:3/2H5KJ;/4>O5I45'J0_K#O9J
M=2:M?AE?3\*.FT^< -51 ==3IJU/)3*#/F<]@*G9J*8< 9?FIJZ6OH]1H*.O
MXO4[:E3U([.C4I:L448ZH-75@ST].]$>T(>S#T31T]&E2M13BO&**\5!K>T>
MT4M96>OBU( 4,J,2I6CV==DR%2%S86X9Q3B%04N&)K*;N\,<B"<THBM4Q;>(
MYM]OG.UFLXHJ:BOQO1U:H=*N4Z04J"(4]E7M2[=G64I7RI,!Z)I%L_S&=W^$
M\6S<+]JXT=2BS3IU:9=GH,:+!.VA7+HGWU'CY-:P[,=Q&XQKJXXF^FXG2T]7
M6T]8M=2U72U6S Z;2ZD+5IT\H=:2E<@I+VBYF/S[:?2ZWJUQPIJ8#ZJA3U#+
M2 U#(N:LP>JM.GIJC51034A%2OU%SM\VU+1<3J:?@IXIKCJ44Z@)6TTNY>I3
M"14ID./D3(&Y#!"\8K:#5FGIM5H:C*[4JXT8IJ2W:U&%$Z<ZC(G4>IJ:50!:
M-$T0%4N8)F_;QCWC:[#Z>$'86U'&Z:?(TE#$W>K^CZ]$B.J?OA7XNX<H-JO$
M;NR;3H@NWJ"3=<8PW?X290.MB,<1>+!AOV\GT%)Q31@ 9!G?R=4\^ZWS<ZT*
MBCAJ<2#$%I!U'WLTB5)RHA9)ZA[.#,L .\!:"7>B5$W8@$-=S71S3NA*3-+P
M?+, <P$ 6J*A669#?/Q2"9CF&V_C@8 A^Q@;H5%6\7[P8N-WBMW;+U$C3Z>O
M3:";R[TF!$J)49#FG*02(W@]\M#1"IJ.+ZCA54DM6;-^BM53U2*Q9F5 2A4=
MDE( L7J"J21;O[Q=2C#C=?15(( RG1Z;2Z<@F-XTRLL!<I,R38$!0;ICF,X8
M'F-QW_0O5^*HRCI-Y/@N\$^ZS@8B#S7GDYKB)'3:L4"SE:"6<WL /5]5;_6/
M)?*[N-:NJ :%6K39<K=:[3)38%2.J05NACF$"%CK<?I5=/0355AI>JE1U4=G
M6!A:BJK@0+LJR)  (!(7L8@,IC,^YLQ!DF9DWF\# 6(J 1+1!Q!)-XBXWWXQ
M;34'(+(@4D<H$<O-8 68C=Z;4V8]523?X1NZ;<)>H1GRU!=S,Q \3#HL L3\
M*78'EVPLHF^.<\GC][DM5I[[CY2/?]VE6I(HE@+YRB0JB1(,LV4"^9,29-FT
M8 5TOD2,IG,+Y2)"3<UUV%UO9.(54:D6::MP0AJ;E<T JN:5ND3-Q;?IZ.@2
MCI\SNE-)8,[*5<L YIALRTJA 4+F6C5*4YIL+/52LXHLI#@$WY@@ZQS>K&:1
M<MY)L]1*+%4,(,TW34 *DLLW"0"UPWS-GHZKB&N?7%;JBT%=231IDDYJ8N =
M5(-,S)!]56+T>#:]JB+0IM2J12 J&M1TE2F8?2,M-0A:]&(0( Z*9BAJ:>G6
MF5100OJ9FJZE0%+Y9E:.>\@DY\$!)]CK$]L,1!@0I,R ;N3K&=\1?W8U=/2:
M?1Z^OJ3VNK%%VKTUI+I & %6)05)(515^2IK382V;5:SBJM[2@I$,X(:HI:I
M#P8Q4TWF_P!8&;[QMOMQ=PT,314'G;7:<>*+:G@WS9:MU[G.R,X!I]8%LXS+
MJZ;UV)K-4G*PD7&4R@4.*_-K7([W(I'5[0%5*NN4'4J^G4&DU4D98Y1FRFW<
M#B'$J[UJ].IK'9W*,Q>HE=@SLH0?? !C?A.-OF_H:BJ&'9ZVJ3U1.?7:IP;I
M-_: D2-\",)BT@3%NL;(*SD,8F%8J,TA1.08D0LPS-=-A0U;'L'#%$[.HUR
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M:JF *3"0K7B)SA5=M/PSB6:B#?3*T"5!7,""Q,WWDE@8( D>K4I5> -3IDB
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MJ.S:%58)+9C5UFN?Y5S?=R"%N&4#U1$"-_-9J>EJQ3&%R^'$'?/TOUY'N_\
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MST>[K:5-6UV>N6 6\>JH2HI,3ZP/,K6?OE\XG'M1WJ^=:LS-6XCJ!V2JSFI
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MU335F:^HJ$PP1'J->9:9B\8FZ-;3IG,>H=UWK;R3RV[ST="D5?9Z.6^CZQ0
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M=VN ?-/W<KKWEHC4=6JY&=F%&HL-6<4E4)1J%I*Q,R>J+;IW;;76OVZ;1'6
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MH*C*Q)X9\Y' .&9NY2C*0*E,&D'TATCW5-14K5 *KFK.0F\J 0,UM1\[&JH
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M5*F8$"U;NY\TFKR]X)$&$4LIK!V4'4MDIL49V#9B1DA1F92M?N;Q?NE3KO5
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M-80?+S#;T68[XVVW]&$ 7_!T;<EL(.VW@M<3=MMYK$0=O!T^6Q)N:?-X+8$
MX\^TV,^K\&[=M%C%[#PVQVY2(BTCWO+(OM@? =O#SV.,;8[>_:X?#Y+  ;?!
M&/+81]+=?M\!N,>]:"MU@8OVVZ+ #:; E8VV^E?;F\7/;;P;>.T1=//L=M]H
M 'CY^CF\]@2+XY[YVVNL01=/O^BPCEW<FWT[2!/AZ+=4[>+;#"PW^3DOVY<+
M$?&V\>PY;&#%VW/M==:9CP[#'Z5EF/&?3>;03>=M\\V'O6!%Y//RW<FU]LHB
M/#CMX-YM>3AOVW<MC*X\G-TBQ)'EPY=K[&Z3MM=](F#Y^CE/G-]IW[ B?A^%
M8DD'GG;E^$6N%W23M[UN>-T[;3%B;K]MIL;R9/)S>&V \OIW[;[3=S>D>FVV
MV&');U9/-M?;#;#;:#<=MIYK&X7G;WX^E8$8;;>BQ,'R[=-IR\^VW1: +CAM
MMTV!@77V)"[7[<]O5ZTVN%^&VVZPN&VVV["[W[;1X[87[;MI-KA&VW)8W7W[
M;N2WJ[;_  ^BQY=MOI6N VNL1E&'/[UHB_S6%UN;;;8VD8VYMMKK2+M]A$6P
MM ,';WA;;R[K?6C;IY]C8F9-L03MMZ+2QN/O>CS6-X!V\'GL!OW^]8B1$;O@
ML,8/-\,_3L(W^7S[;K"  8Z=MQ\N%L .C;G\V(L#R;>?Z9M=NVV],6;K>?:^
MTSUMO+:\WW6//]+'Q6%UVWHBQ.'P6OY-MNBUQ@[?!;GV^&PRBZW*8]Z;1%VW
M1\-I&WP6'P6G >]:9-WIYN;HPM?<9Y/18\_HM( C;&Q$&-N7T<MF&[X/$#T6
MQ'B7TV_FLX_NGOX;MUK^%W_O@]-OYLNC]U^'DG?Z+#_=>!_=!S\^'-].T_HN
M_&.T]^<.BT_HO_2^&^\7>:^T_HS#_.#IY??\%A_NOK1^ZB=_.)Y[O";1^C(Z
M*GH/O19C^C/]+=OY_*,.6Q)X9_I!Z?).-I'"[^>J/+>/):[7G#ZCX;#^/?Z.
MT?HP3^^_#T? +7\,\':?#A-UE/Z+F_\ =1YI][#"T?HK?^ZCPX;>&P'Z,Q_S
MG-R2<)M?PK?^Z?#SVNXA>?\ -CT\]B/;S/[W\.W18_[KNG]TVZ;&.&?Z2?1S
M[8K_ +J /)VGAC'GZ.BPGAA*CDJ;K2>%Q?'WP>GX++_NC=^Z#Z1W\E_18D<1
M'1D&VQM?K_M!N\/+S6$Z^?V'P\FUUK^("0+OD_AQW_!;^;(,1]]&/[;;?:?T
M7>#^ZCTW]'0.G^:K_P!]&[P_#Y()/#+_ -\'I]ZW\X_:8WV7^/3'U@\._P!Z
MTGADB[_*"?'.$#WK&.%W_OEYYL?! %H'"KY_= ,/)OC?:!POE_R@'1OO/+X+
M ?HN'_?,?+MRQ=:[A<_]9N\?3ARFPGAEX_SHW^'X)M_-F O^4Y^F[:;S;,>&
MD?\ 6 CFOG;IBP X:03_ )P<O3OVOBRG]&DC$_*#TS[_ $Q:&X:0/WSIY3TV
MG]&7?O@CS[><#]&[L.T$>.=]VPO!_1MQWBH/3MRVG]&W?O@].TV6>&?Z0<V-
M^W-92.&''#M!XIDX>"P(X;(/^<'IZ;7\-N/^<'IL#^C-^':6G]&R!_G/AL3^
MC3$?NGPX;8V8?HV#^^;_ !VEM=?^]B_R[>2P(UO6_>QR7;[ ?HT?PD^_8_[M
M&3]\\>_PXV _1@_A/AL/]W"#/^4&_P .W-92-=?^]CT\MC_'+Y^H'I]ZP_CH
MG][&/CM^.CH[,>F;3^C1_"#QXSNY;3^CA'[YYK]O%8J.'#I[0;_#]*U_#L?\
MX/3XK3^C<3^Z?#S;;R!PW=^Z#T^*T>VW_8?#:!K!_!CTFQ_CN_\ <QXL??W7
MV,:RX_YL?=<ODY[%?T=_I1Z>FT?HT3/[H/3:?T;O_= +\.7&W\VC^$&[FGHL
M?X]?]@/38 ZRZ?J/AVPM?K8/[W\/BM/ML_\ 5CT[>?\ FV_]\$]./GL".'8_
MYSX=IZ+?S=?,_?/AME_1PD_YSX;#^.']H+O+?8_QR/V ]-OQL7?6?#8_QV[[
M >FP/MGV@]-KM9]H/3:?;)_8?#;\<O\ L!Z=]@1K?]&/3:#K!/V'PV_&Q^T'
MW4&Q_CMW[W\/PVGVS[0>F[P6/\<^T'FG&+2-7<?\V/!O/C%LOM?+\0>FWXW'
M(,@Y_KK'^.7?8#WS8?QR?V ]-OQV?V ].T6$:R[]['OG;HM^-_:#IOOY+0:F
M:+L(M=,VB\G;GV\MI.'+T[;;I@Q,>';H\)M=R[>"QOGF^G8\G//B]^P%\GI^
M ^2W6%T\IY-N?S66"?AVY393-UY@<WO8\W+:<2/2.?:,;7$0.F>?8W>.WUW3
M\ Y;_):(]$?#SV@7>:1MC)M?C?L=B+21N]_EV\]NK6RMT ^2Z/I"WXX?V@]-
MA_YC7_R#B(_^Z;8W6 'SC"#_ *AQ'P__  OFPM_>-C_^3^(_FNWDM/\ S&N_
M[OXA^:V)/SC"?Y!Q'\U]_P""3\XEW+[!Q&__ &>Q/_,<?T?Q'\UV-H'SBG'?
MH.(_FOOV,?.)?_(.(X=/LUI'SC$'^0<1_-K1_P Q1^0<1]_2S8S\XA_(.(^#
M_P"&W6$=Y;OY/Q'\VVBQGO-_H.(_FU]C_P"8N_\ _#^)?FUA_P"8PNG_ /A_
M$?S;;IPD?.((_D'$?S6W]X@G^0<1_-[&/G%']'\1_-MA=;^\8?T?Q'=_\M[]
M@/ZQ]'\7XC^;6C^L?^S\1_-MK^6PCYQ?_P W\1_-K'-\XE__ '?Q'\VM=\XO
M_P";^(_FUO[Q!'\@XC^;V)'SA7G_ %#B/)_)["?G$O\ Y!Q'\WWV$]X]\_B_
M$OS?S>"TGO'/-[/Q'D_D^^W]I+OY/Q'\V\/38C^LG^S\1_-MK[2OSA_[!Q'\
MVG#QVO\ G"$_R#B/YMMY;7?.'CO]@XCR?R>UWSB&[_4.(^?V:W]I/]GXC^;V
M)_K+_L_$?S>Q_P#,2>3^(<1_-K!A\X8G^0<1\WLUW/'@M/\ S$__ #?Q&?\
M]WM=\X1!_D'$?S>Q_P#,*?\ Y#B/YN/!;^\*!_(.(\O\GY-WBL0?G"Q/_8.(
M_F]@3\XLC?\ Q#B._P#^6^G=8Q\XW^P<1\?XOMS;[OG"/Y!Q'\WVNMF_YA#&
M?Q#B/YOMNWVC_F"8_D'$?S:W]X1_(.(_FUA'SA7Q_P!@XC^;V'_F$/R#B/YM
MRS%KOG!_V#B/3NT]KOG#./\ V#B/YO;^\(_D'$>;_5O18G_F$?R#B/YM8$_.
M&?R#B/YMMR6N^<,G_P"0XC[^GL3_ ,PC'\AXC^;V'_F$>3\0XCA^3V 'SA?[
M!Q'\WL3_ %D,_O'$?S;:;0>\EW\GXC^;V4#YP[N3V#B'YMMN%C/SA8'_ +!Q
M'\VZ?#SFU_SA7?R#B'YO8$?.'=_(.(_F]C_Q)S?B_$/S:Q']9/\ 0<1_-MKK
M?VDO_>.(_F]O[1_[/Q$?_=[.O_,,3_(.(^'_ .'M?\X?^P<1_-]O//\ S"O_
M )!Q#\W^G:/^875_D'$#_P#=[9?^84#^0<0_-[?WA7'_ %#B&X;_ .+VS?UB
MO_D_$?S?X;$_UCO_ )/Q'\WV\EK^\G^S\0_-MNFT#O'O_P"S\0'_ -VL1_S$
MO'^H<1_-K'_S!'Y!Q#='^K8V@_.%A_\ D_B/E_BVWEME_P"87^P<1_-K0>\8
M'_R_$/S:Q![QC\GXA^;6D]XL?]7XA^;6)_K'_L_$?S:Q_P#,'_8.(?FU@?\
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M\_$.)$^2N+'_ ,F]!^7\3_#V_N;T'Y?Q/\/;^YOA_P"7\3_#V_N;T'Y?Q/\
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M?T>FQG6OAS695K,U7E,$<\"0?'8&G@3<,;K]\03<21= B^3%H,SXCT']<!3
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MYD9E ZIO %X!-^H<Z/M*_; ! 6'5)<YY!4$F-Q '(+IH)0I"IGK.)+1*J5
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M-S<B#DL*NNU=2I4Y79F(PY8W >+]0!!O%E-;2I,S($-A$2"#S?#8'V-9Z?\
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M"2;A,2028MJ:%)8I" !,Q*BZ22<>7#Z&AB3?;1<5U-/+5U=?4UB-P[77:FI
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MH:OA'M>JI#K1J-0:GAIT'QO&";L,;%&[B52W/I-63BUTL@$W?56IU.(]S@E
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M5QNN@"XR021;),NK&1S1(NR7"")ZURF_$Y141&"!JD+U)G-36"P0$B6P)N$
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MD&3;14J=1,NG:KV9"LL=JV>H1UI!9KV),L9/5S$66N>%(&4Y1!*-<"N6 9B
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M3]9V)"*.KO@E3? < L3$ FZW&==W!&?1:N]EJ A"X<,U0!@Q(.>J5#92H=A
M5BMJ]'4\2>C3I%QDHE*94BY@YIT4<PJ*5+LRX5*9QG-7U+NPWLS$^]:3>!:X
MF8M3+T<P=@BDW@$QSW&(()P(GEM4H<)S:>O3=E)SO54E6B8>M( #$DYE!,P+
MHL:?LDT(D.&IY3<LWLY(OD 7DP8)BU>EWJ1AW7TXO((DYUU! ^2J4ZN;MJ:
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MTD?+58!*I5<M2G4+*3)IL0 >%]OQ\5.)ZJ@7KTQ1 [%D:$0L&8.2I#'*$@$
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MHVBP!'6G;=;='@^#GM)!RSMR>.Q48C;P^'HW6))&[EVNWV@D@;>+QFQ!4A6
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MIK23-/:U!449BV4A:0R5,XJ25RW\4J:C3]GQ!*&HI54Q5:JB00V#*U)Z;H
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M0/7"U1+*I!))F^VJKCA6DKTZ=6F4#.N<@AU;-3&D+,M\MVU0L*JTV4@ "VG
M^9W1P,V&I4;^4Z%AY[:+AG#?FYI<,KUT>*B:D/>FFJ-$#24IS!&%YND^%B#C
MS1[W@^&S CK>+R[7XVXC02.UJ4F43$$LA$E@<H!9A>;AB<+?,?IGT]9TX,.+
M!UIC3.Q]H6GV9":ESIWRE7O;,PS0I!06^;^J.XCE-/HWIU9XAIRR_+5'>DY#
M)F]II5&IEE0JDGJJ(GOEE^:^E3X;J=7P^HE ZS292M+3UZ5641S30K4J*2H]
M>";Y+#N]Q).#^SLC<0IM56IIV:G3J)772#**H9E0&GV=-0135<L(! X#P?\
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MH!^VF^/L;<1('K,C#G!I4DY]Z-O]%EF\D'HN;I&W3:5QVY[:-UP!*STA"/\
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MR;P0;TX"NGB7#1UY#"KFF36$ %FN#8"\D]:S</7AAT-=@#V1J5JLC,KCKEG
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M!4Q)$'>#!O'*#-XW\UQLR/B-O$<0>2U]M7Q#44\RH548@%F=5'657WM(Y8.
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M5X=4(@Q$P3.+8VXIKOT<NG>D*>8(S/FZVI62SZ>B%).G)N$7QN$EH=D&XGT
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MEO\ U SYMIMAA^LHDV>H"J:9?6J.80=)F"9P%^Z0 ;&%J:FI)DF*:870 "Y
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M1Z;"C6H,@452F0KFU>G[R\06OJ*>HT,U*:Z:M0#5-9E 7L-/0K4LRA/XOJJ
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MC D'GH<-TOS[!]"F8Q^@]$&+N69B["L]]Z 87+?,DVG_ /ZD7_Z:X=^%M?\
M^J1?_IKAWX6P8?\ J53H_JYP_P##CEFPJ:7N]H>]E92)RUZ7":[ F_*KKJ-,
M8!DS7I^IA+@)KNZ6LU'L_?+2"G[12<J:@[2D:J$!8HU!V0%]-F"D_*!6ZI["
M@L4AB)F=XO-X@S]"*=)"S\WO[@+?QS4$OO1()'23<"-X,<Q(OL0>'EQN)J$'
MQ#X;?S5_I6]%OYI_TK>BW\T_Z5O19>UX=FRX34/G"W_LB?+;^:?]*WHM_-/^
ME;T6_FK_ $K>BW\T_P"E;T6_FG_2MZ+?S3_I6]%OYJ_TK>BW\U?Z5O1;K:5Z
M:CZELW^-=8OHZPJ "]8AAX#B!($C$W+:#C^N"=PMI]'HM.]?B^I8)1IJ#B2H
M+N2K*$5269FN$0W4+1K];[6VN[S:UPVJUSJZ5M2XS!"4#U4I4:2,$IT5/9HH
MNEI8,*E/L=*8ZDAY@_5"\0;^>8PM/8W])M]Y\IM]Y\IM]X\IM]Y^V-OO'E-O
MO7E-C\EY3;UO(+>MY!Z+?>/*;3V/VQL)I^TKTFGM\'/8A.']B?WPOM\-J2:7
M4OH^/Z9B^EUM*_44*I90&3,Z#)"'M*5PJ#KJ4J!7&L^;SO.BT_G9X:@-2FF;
MLZM&H:CIJJ3&FFG=*E!)?*2$J$TV6E4FB/=2D@EF,#=X39M'I,?COO)Y!R 8
M>/G9OU<,C$,#B+C\%F=% UR"3 C..6!\8<W-$R GZW]&L^IG\MN_W?<ZL5=)
MJ7T^DTP (R4='3J"H5)RE@^HJU<5!4J8+*01] "P]4'?%Y@#<;KS,^",;2:M
M-LH!=5+2H8B)ZHF9N'6NN-V'>A-,$.BX=J*5..M .H#NJR8+1V;*QEH=2)BW
M<XZ837XI1U3$ FXZ4U";B;F=$;(!E!9#(%Q+5*W9+02ZN!F(&9,] [V+.PA3
M3S*"/E,JP2JUJB^U]H4U"DGY,B12#905;,%8_(E@,LN0S19M2M5#1OO&>.J.
M7*()F%DC,1OL*O:*E*0),Q)OBX' 7D[AB;=ZDU"T_:*573(I.?-?G+!?B[@>
MM RSE.8D'1?L_=JH-T>8&W<K_P!06HK5*5/@SUZ&H*ME1])Q%*&B*N!GD4M4
M=-J$'9-=2:]9[1!"[;;["18C*=KXMJ-7!SW(AY";R0=S 7J>D<WT/%-:#U=*
MH.^ ".8'IB#.'5Q'>7246'9<-KTZ4,27+5&(!&4!3.1F(F%$Q-Q.F 9%UAJU
M5()/6-,@$+>5D0<8!N,FU:I6%-'*4R&E[LS,"6 S7F, (Z)-N\ <(72K0203
MF.:_J0,L99:3E81ZP!9&XODUM,LO9!1UP'NQ4NBE1NZ^4$P,3>BBLF8TL\=8
MG+!ON4R1A DDF+P20VG$-5'U-\D@'D!\&4$8&VHK5JE-J"4W@RT9E4XP T#U
MNJ02(B1(L<L1.Z8^VOVY/H*=9,5/C')T' ]-BU,?). Z[KCS;@#( W#];]0'
MXL>46^;'C#5#4JZO15*S,8DM4U.HJ,+@HZK.1.4<]]_T(!4&1S\@^N&^^>6X
MB^_4%J:*:JJ# /Q,L1>;X@''H&%N\.=$!XC6H57NCK4>UC*-R_+/,WX7F^>[
M")E1.&4]33!60674YI#D@GJEV*%2 )),D#+5JUZ2G0$J-1"M&<*5H&5-Q6]A
ME*@D#."F::=2M34ZSM#4U!(([0XTRV4Y5RYV [$*+^OF,$'3JB1??]F (,$!
MHW9@T$QA=8*-+GH$Y[U8@9+BT@X#!B;K[Q;CK5"2:[T78GE4,MUXN@X$2<9B
MZVB_9^[0<_Y7-]J(VPM\XG=%QZ_"ZN4SO'RRB.KOI@WOOQ%D(WJ/?C=S<UIV
MW6OQW;"VD58ARY/2"%'DVN^AXKPUW95UE-5E3UERQ>LR) N@B()N)PX]K7H4
ME;B%:C5;*&C/2# E9)/6[1B9O$P+H6U&LR4P].I5<1,$UB"]W)-XY+L0)MV+
M4:;4LBJ9S PI)&#"^3NWQX>.U6I 4#4H.S!;@P!5%DMERY 3?)ZH$SCQDT]%
M35F-(J>OU#%X7.[%I-_7S"0IQ$"G4--"4IY!(. !@B&#!N=2+>UF!5$8<P Y
M22($&23RG=:K2ITD5&4@@9HZP()Q]:/5OR@?%.Y?H=!4-S9"O[0P/UOIJ:C=
M>^+OKHVNMJ/FPU]<OQWNOK]5IM<N.5-3J=1KN&@LH[,SP_4:9OD:E2 Q6MDK
M*]-/=K:1SU:R0+X&87K/AD>&W!135RG#A450A"O+]IF*D2026.8A7.0$722.
M\E-5J1J'TTAI>KE0,>M.4D%NSB0H@ =: 0_:U*@J&NLFFW9-)IO/6 <1<)&%
M\YA?;65'SNS(2"6EIE8+&5+P"9( +&# W=_*?9$+VW#A3 8W!DKO5/7$L#E6
M0UZY2%=CF5OFV_B8]DHT];VP=!3%9F-6/E$BHP3Y.!FD%8RPQ)<)3S4^T @2
M2!E5MS" ),$YL/'02I3)6G1U!OS7,"8F#,[P,3!@R+:BDE( )4IK<3,-CB2.
MC".4"2:5*E1RC,^9@L2);+UV$L8FX, V')[M76,;Z$1^S.4^;D/@MQ?AO"U6
MIWHXV]/145:0"]744J;,S>HN2@:E0$P,R  ,Y ))WFV-L;/$YJ523R!6N'AS
M7=$_0\]M.NDJ*M1E(ZR%I$@&.NNZ9Y1(%]OG$TB4J53A^HUE$UTJ$I39DU*M
M0#L$9U(J7TV58%8*55F[.WSF%:M3+6;AJ@T<M!#D&I,% &E ' 5<00"";PO#
M]-45B:F>JRDQF)D()Y\OELG;4VHL5%P&:;R">LP*\P/28$6[E&M0#54I564Q
MB6J5$6>4(P5QR&2#/K=\3JN'N]*G7TP1EOCM'KER0*B9 85<[YU!@0,;:)J5
M(99<3T,0 2"1+7G$WCJPOT6GT\=9*2AA]<9)]XC];]76U!_$Q%W3U?LO6YO)
M?;4?.ZU!*?=CO!2I:?CSP6[.II-/[/PO5E5[0YIJ^RU&I)3.5J)K=H$0TB"(
M/T&M,>ID\MM&?J\_DL+#FLQIO!J"-QD#=?B-A;3T:K_):<,$ 55 %3U\!BW*
M0=V%WN#DL'!ZP(CEW$$SRS8:<D=CFS1 %\1)RQ@.4Q[OLBFXXX7P)&P-M+\X
M2M6'<;NJ*]/2L"PIZO4ZVA[,]874V:G0"O14Y:@9JC%&7*ZM[I6J)H."K=!W
M](\<3%]LC&5(E3]4-Q]/BF(^A-F4_']ZQ9L&]ZRL[20H P%PN @= ]S11]?Y
M[:N/K/?^B.KK_>*9D?7-N7IG&X\X@R'JOZS$G;P?K@#JT,#<1<9Y;3\W'#OT
MOW"7LU30-7H4M5H%+0>PU&K=CJJ;N[N:56M2[( 4Z-1$):VLX/W<XJ*W>O2L
M%JTJE.OI]12)#/!TVHI4RP:DK8 Y0I)O! NXHGDL/]Z4Y\%OYUI^2W\ZT_):
M/THDSS6_G2GY+7\4IX\UI_2E/R6_G2GCS6_G6GY+?SHGDM?Q2GY+#VSB24_L
MB!Y#?OM0H<2[[Z8ZFHX5:=!*VJJ%KH'8Z:E6J[QBA$D"\D6%/CFAK<,[ND$/
M3-0#4ZB97K=F%[*FN20ANJDAC(O%#2<.HBGIZ:954;@">4L226))))+&223/
MT(T^L4M0W$>LO1.XC=X@8@FKIG%6D-ZXCI4W@\@O,7F+96HN&YP1;[VWB-OO
M;>(V^]MXC;[VWB-OO;>(V^]MXC;[VWB-OO;>(V^]MXC;[VWB-OO;>(V^]MXC
M::=!ST ^>+9]?5 /U"P6/O 87X$2)%E4 +17U5&[S2><C'#]<1K\1:\_Y2[K
M71ZBQEB N%^/+:II.*<+T^HI$ =A5I]J'$JT9VB I05()Q &(%O[NN&#_J_A
MYK7_ #<\,_@_AL/_ "YX9/[W\-O[N>&?P?PV_NXX9_!_#;^[GAG\'\-I_P"7
M'#/VGPVO^;GAG\'\-KOFYX9_!_#8?^7/#/X/X;7?-QPP?]7\-O[N>&?P?PVS
MZ'YON&TW&]4(.\;FYSX[)0T'#$HTQ@! C'WR3CO/+;/I$ANECOYXY#;Y4W?
M>3Z(,K$,-XL?XPYZ3-OQAO';\8:WXPWCM^,-;\8;QV_&&M^,-;\8:WXPUOQA
MK?C#6_&&\=C.I>_G(GQ7?_JC?__:  @! 0$&/P ,8#7.N>\-!$=1R/T<<N6F
M!R(<Q#/+/S\ (AG0!# B CG3&-- TY<"&"^@<F[QTQGGP&.W73(!CEC/R\#R
M =<9$?G#OP' <N[ F'0=1$<<PTX -"]F,_2 :CC'JX#0,B8,:B',,YSZA]?&
MO3C/:)@TY9#0   ,/;\G "&#@/:&>_&0 !R&0X+]4 $1'/5H&"]6.>  2AS
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M2B'/)L\@ P#H  'ZW&N=  <YS_7&Q@<>UIQ[( .,B @!B@ #D,#Z,8UX$0*
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M-,:"'L@/&A@Y>S_7:B YZC (8QZ>,#H 9YZ .N.\"A@0#@1Y9Z>\,Z@ " Y
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M,8#0.6?7QC//LTQS ->P,XXU_%V9TSQICEVAV\^-.7=C7N]>>/K&^8OZO'8
MB.0'.>0".1P&1T#D'9P("9/(8*/M#G.@"(@!<AS^3@?TSX# #J.<!KGY/7QI
MCG@1$QAQ@  !Z0TR.?U.,8 1$/ZX-!P&NIBB/3GU9Y<#@<ZB.,CVCG X 1'(
M#CT<^,XSH&<F'ZP#U#K[6G?SQP8!Z0* \L_L38  T'3 >D,Y]'!1P4 QWAG
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M<#J'(="&'0=<B.!U#/HSP.>D1U ,CD1QS  Y]O&/9#0>W&!Z== #!1[O3QG
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M8V1Q]7"@YU$?:R.!QRSW\"?(CU<M5!QH)<!DQ\9%3N[<<8$1P;0V"*C]40P
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M1Q@"E]'+)1 0$.X-/3QJ;.NFI0TP; ^V82]N?F[^ UY9'7 "4PB.0#&0''&
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MF'O'C&<B&G+Z<Y]'&,B.@CD/7IG4<?I\9R;/: 8$1Y>GO'@<&-Z<@(#@ SH
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MP%<0]?!VJK*3:4!#?#A4W#(L3H,O@>@A^GF. QGVX+<O&0'V8"#'MP.IKZ&
MP/%KW 9/)RJU:GN(UK-/+9',F2X#/&,W!O$-XRP6)Q-.C';&'I$FA=1QP6-*
MRW';%\<R /RUJ',W,D!@4!7WDMK&0QTAR]PZL]G=&6>JR*4G7Y9!9:.?HI^$
MNX8HG*DJDJ150QB*)',)1*.! 0XD*9=H:]*RL81N9T[@(JNR;(ZT@DFNOTI2
M$Q6A GAN"8'3/;C&L1M]3(O<(DU8#.RHN)*%A8ID0T3&A,I@";6]6$!P,&.=
M>0]O!H6VR4Q-S8$(9[#U6$6D5V380\,&DJ64LM:@HEQA0HB1%%00#GCEP,#4
M927A9YRL5=G#VR%<1Z\@X$0Z4H/X79;-7D%! !$ .D41QW\2E'N<9>5).(39
M*KN8.&A95H=24C$)5<.AY=Z^3IZG9!#777MP QM4C/ME7'LJ\3:,GUFAX]@S
M5>J])$H]S+15FLSA)JH8=#B3IU#.,\"53(XP(C[0=N0SCJ']D'R\'K]F>SLW
M-L%#-Y&/IL(PD$(QPF?I.A(2LA8ZY#/5"B8N?#0,4.0CGA5A27\E'3B2"BJU
M6LK,C29<,D_#\26(K[RI59]<O6;)% (IC7&,#Q7Y*]MIQU\=>RS".85]DQDW
M2:4 Z]V+,F-(SM96*<ZIR].4ND>_O:7NDB_;1[B0DH]5O-LH6/>,I6%3;K)J
M3!X$PBHDHFN @; 9R'!=I)!"SQ-K^UIZD21D(A@K64I]-X5@+M:9"Q(S)$#+
M$  S&B;O .*XPO,9:78V=Z\CV!*\VCI!5NG&'A?#3E/BT_5A45%68S@YBE H
MYSSX^T-XDO=4%USDC&"!!E)&7<I"?Q8^,ASG22:M41QU*',4A<ZCD0RSAGA[
MK6V[QP""LS9Z_'F@VQ#  @9RVCK+8%BDR :@!@#/$-&75M;I<UCKS:QQSVL,
M*_*Q@QKQ11-#PRO)BNJ&ZC)Z]0 .FGIB8&/KNZ)9&<D&<<W,M U\6OQ"7?$C
MA."9]P2D ITCX 1,4 -G. #/$I1;G%WI25ADF9W#F"A8639**RL6UEUQ!-W>
M:^7'4Z3$/:U ![<9C:G%A<JV\E7B;9B^LL5'L&2CU8Q2HQ[B4C;+9'*;90W(
MPEQD0SQK\_K]KT:^G]?@1SIR   HB.,^H QGNXY\@  QS  SR$<XQZQ_%P(B
M8>8CIC3U9[0SP.!YCG0  .?+'4.,@7N_6#7(Z: '<&NO,,^OZ.,&#LP.@!CG
MRU[N?IX#7(CH Y#/+7MTSK^&>!P.@CJ./5G&O(?HXYZZ:]F<AU9SICES[>!U
M^GTAJ(ZYR(]NG'+GCEC7M'J'0?UN,9]8"4,AKRYYT]?'8/R>GVO3@,\?6#MY
M!W>K7]3C.<^C B&F?3IRXP \AU[/DUT$=>-,#@,8Z>>--<CWAP(^R&!#40#M
MU[_2' 9Z1Y#RP.H!V8UR/'8.@:  =@YX#ZNF<^SRSCEJ.G \@S_6]HXY9XQI
MW_5#OY<NWY^ ^KKV" 9Y>OL'LXY!G':4?5RTSS'CL$1' CT\]1^G' !D/0 @
M&=>0A[0\N!'3U](!WYU$<\9#&-.9=-1'7UZ\=X=HX#3'5GGG/+C&F<]H!D.[
MOUY<\9X$VGS=^O(>7X8XQV8U#M$?7QJ <PQZ?7VAQZ,=P=FOT?I\:8Y" X$?
MP[.8\<O3G :"&.\<=G&==!#YNW7(9XP #GLSWZ!K@<Z8X#ECY\"/=V<A^GCU
M#VY'33D/K /FX >[& 'OT]K'HX#30/6&OI# X#/'K]'+GCGQH'/37GTY[!QI
MCZ,<::>K3..0>K/&@#S <Y .WN !#C  (<QY!VAIV@(<QXY"'/ :?3D>T1X
M,"  (=W(/1D<Z\M>#  =( 7(=A=!( XY]@]G+CF']E^MQD.H0QG40'( (:::
M8$ [^?JX#4?6(@(  8 HAD,]_<&>"G2$!'.NF S[P7O*H'M"?C;%4^2J"N[3
M3(/2(B8B]8.7V@*0 RH;.H<74Q@\,0I%O.4N>KJ,%=L!@+DH  "(@ #G&,\M
M.'4#4MC;EN=&'MKZ6^/UXEB(V:R*L9"(J1@&C*M-(F.BFT*90O6!A!0.0" B
MO9)^J2NW\O)S4:"]3FR37OD8FC9G; %2&F8"!2*FH"6, <X@(ZXP.-KV:#D
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M9$,E3-0$RS9 K<"<N@0+J YXKLZ_I3"?E:\*AV+]^59NW+T'4<?OTU<D-\<
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M!_8\:"&![,X#GG.@!P YY9[=!] CC/&<AW#\OJ#3]+CF//GGGV=W9QS^GF.
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MU\@X# CG AC =FF0 !P&1](<&UR(AD0]D!#&.WJ#]CV^C@1R/(39$ #VM1U
M1' "(?3P8 -C&,@7 ".F"AG(CD #/HXYX#'=Z=  P](C@.WGZ>.0@7L[<Y
M''M" 8''&<9Y9 .?>&-1'(9^GNX'D/I$ UR B C@P8$>KY^_@0 W;H(@ @(X
M <#KGES[=>,@("(YSD0'F7(!D>H>WF.. UR.-,B Y$-   $P9 1#U=O&H9#G
MGLYCVYTR(\&UP(#D!'4P@&G>/,"CZN.K(9$ '.?9 0#MR.HB'+3NX'M]/L@
M%  P.>H/U^,Y+SU#(#H(@.@9UX  ](B. #)C (#GVA'4!QSY\N!#73EG ER'
M+(#@<  <8P& Z?:[\9UR Z8#NU^GCD7/3C./1@>W&!XT$ U[M,CCF'+ B/ #
MH'+/LXQCMYZ?CXUU' AD0+V=H:=@AQIV8QH&/3H'IUX[,X[O7R[@UX[.\--
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M  ,".=/2(CCEP #RT'M[^W(]_'+LR(9QG3OSD>,<OEU'4>GD/>/ \M QVAR
M=--,_*'&,<B&'N$0Z@#'IYX'EQS+^'R<?PART_<HCC Z9U <9#/HXR60Y_\
M4H@&,:9T'.G/ \ 'Q#(:_P"E! 0$= #LT[PX']\/5AJ. ^CF&->W@"^_AGGG
MW0?5K[(#KQ@9$!QV>Z#GF&H>SW_CX_A#(CV^Z&P(<\@..7I]/9P/[X9#(<FH
ME 1#O$0[AX_A#JP7!<M, .H]VHXSQI(Y'D'[4'("(YQ@ TQGOXTD._7W3D X
MU#LZ@QW=H<?PB&HY#+01SH(?2/'[CP&F<N1[ QD1Z1]K \?N0<#_ -4F](@(
M:>CTY#@/V_W:>Z:A@1QR#.,<?N[337W3 CS[N8"'ZO _OACLR+/UCGD \@[^
M/X0 /3[H;Z1'L$?IX#]O]X8%IR](#RY\&_?#(:: T$1#.0#'<(=OHX#]J%TU
M 1<'P(B.0$/9T$>,@U#(A_TR<1$!$=1R @ #V9_'Q^[^S.?=.TN<X <\@''
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MY\9]T#D _GQT'MTZ Y?I\?N7U_MDPAGO !3#.<_I<8]UT'O<:!@ _K.8_)P
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M'_ /\?'\J.0UU^Q=OY#KR&B_)Z.,!NART#^\RW!VYQ@*( ACY<\8^W)NP?\
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M^O+C^4,,AG7[*;BB.F,\J,(<9_C?'T_WB[B8'L /\!L:<?ROC_X";AX NO\
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M;7-(;44ET8ALD!M4:L6P7%Q&'3,(B;XY'+9 -"\A_(^4_9\I1R"8+6C>USC
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M" @'VC\PG8/>.]0\N/YE7E[SD/\ MC\PFN,Y$<;UYUX_F5>7O_PC\PN<Y_\
MAUAV<!_P*_+WIV!8_,)ICESWKY<#_P "KR]?^$?F%R.FG_EKYAQD/)5Y>@[@
M&Q^870/DWK -<<%_X%GE[#&O^$?F&_$&]6.%&=S\G\;!*N5!_?[9G>;<RJ2K
M),.1DHG<I3>."6.(]ABXQPX?^47=%]>+$B0SI?8+=5A"TC>E-,F>H:PX++C1
M]S@*BF90Q(M5.1*7I#W,1,'#N-DV3QA(L'"C608OFRK1XS>)G,15H\16 BJ2
MI#$'(& !#N#^F PCS#'4/L]WKP.0#B>O^Y;IU%;0[9H,I*WK,C G-V>0E3JH
MUG;FHF,("I8+4NW/DPCT1L:B[?&R"/2=D9\1C!5B"06CJ/0H,ON54I$(=4'
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M[.YVZLOMDUDMK?,%4(Z)A=N=XZE)UJ!O.T4!--VU.M*#;;R;JDG'2/VRI9Y
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M(1\HRNMO9R<!67U'BWR-AE4GD53I9A+Q$E5(Q8KGJBZ^YBIEZB=BETHF([7
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MP"3>#EU%<X\)*/>G'Y0*F!@SP6;&COJG5G!@_OTW!^&[?TE,%% 'V;9<EX"
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MF"A _<,M3=IX:UMJZY.40 "3$I%&QV#C@>GS<[MK!_5%\I#8HCSS[)O,6&-
MX_GD;S9__$W9?_E-<?SR-YO^)NR__*;TX_GD;S=N,>3=C_\ E-\!_P ,C>;T
M_P# W8]V>?\ OF^_C^>1O+VY_P"!PQ^0?YS?&OG(WFY#_P#&;L>SGI_OG-0S
MP/\ PQ]YM.7_  -V7/\ XS?ZO'\\?>80_P#Q-V.>SL_WS?&GG(WF^7R;L0^3
M^<V/+C7SC[S?\3=D/_\ LUCZ>/YY&\WJ_P!YNQSR_P#QF^SC^>1O-_Q-V/?_
M /C-\%;;0^;_ &PD9<P&]UK>]-2MFP4H[/U=8(EGIH;9M8VQCV??[2B \M.&
M\'NC29:I+R*7OT%(NBI/:]9HLW2)96J6B*4=5ZR0YA4 06CUED_: ,Y^\$P]
MOHY:AC3D.?TN.T0Y?)KV::\8_3_#L^]$.['H[ X@4;-/TIE7:0\NTNRL4%N0
MG4=XZ(ZDXT3_  R%JDS,,BWII89INT5 L;%R*N@IFD6!>LQ("\8V:EJM*P_E
MVC6E<?V"HP;QW-0D-6X?= \W&QZ=AFJ:@%BA7Q)1_(QY"R8O ?@5ZR,/5N)5
M26S9)J:U2.TDU=/<:SY?3HUZ'1F+=!V1C7Y6GI$I-IEX&&&*D "EG!13WLV2
MD?@_ '<JYB=I8&:0JZE<(W:7'82SOWJW\9NT$RPEV [4P6W$"98U5>RH'6*Q
M-* P][8OWP$)T)V5X\0VF;K0%@\P4'#%@(>H5QL^JBU:K(;;/$8AFDBK)E++
MN9 T:\#Q94GAX%4P%*)7T>A![+BQJ^Z6[S*L/(2O;;P3%&CFJL[*0]AE8I,E
M<I5P@ZU*12#^)<S\D:+4$#,I%\TCC ;AN\DR^,S-5:XTJSQF]IKF"?5^&C4X
M7WRLL=NYVP4"$@CR\6\Z8^#>*1T<J!TB:E-G[[RYVYEM_P"5W<PNV^T%4+8Y
M6V[PPY-T(J1A=R[A-OZ'_$Z.]<"G.I#$.""<CZERPG(^, ";V>F1K%-DMG;_
M !M:ITA?8YU8);R\PWVD'<;<4KXE97W%WZHVXE#++;9;4)PP&@OALA*#+&EP
M8F 1,'&Z".STUY5HS:I;:3SAP\XM]I=H)+=UW>+6CN:&VT;3)F4E?XTY:"G:
M#*5QA%Q]>4&-U>,9 /B('$*I46$5Y;WM:NTYNG&7I^ZJVV4C,Q,,7RQ[)!52
M0]M!,9RE&_C54F1C)&/E(HHRP.NK4'@<!4J/!0C&(=-/+O9]QHFFN]IJ^[I)
M&NVJ29D=Q8>FW=7?/<C[47VXE?!(;AUN-+5Y008L!$'H".V,6C7Z.E%V>'V)
MG-XX--QLM!S4+04-W8>8N&X>[<K-W-#S&W>DVJ!,PZX%_6S42/BWK619OC D
M3)9BQ1OE?91BV[]O:^81M8JUM+472?E]C(.#84X-D88E<K-@+- D$V)7M*(6
MURDN+(\AU!T"-0EK/_% QF;M"TK=*69NGE89N:>;RV?8F$MVWTK#))&+$SOF
M3@?M1(%CQ,4LO*?#-!'V@5O$<_\ +L9Z[\F54K\-3V=*\O2S(-PQ\RNV$S<J
MM+[4,(-3'V=@P&1B8^3C#%+T.Y". !!\(;@N-OR5Q&HO9E*1C&]2.S/56P24
M5&2$C'08QAA0^#L9=5PD@4F *F0,  Y^]_Q!_'Z> [^?+3M[M,\:#G&<CD<C
MVCV=P\9YAV>C]7/W$F[9)1=PNL5%%ND4QUU3G$ *4A"@81,81P'IX2EO,#>=
MN/+#'+H%<MXW=:7D'>X3MJ)C@!TMH-O8FX[F-,F(7!I.+CDS 8! PZ<%;R/G
M6O7OQ3B*XP?E'FY&-+]80 KN9WDK;PX8U#+ HAW<?SS=VQQIIY/3>L,Y\Q&O
M&/\ ?F[M^G_@>G'3E_\ ?#^K7C'^_-W;[1Q_O/3YUQGGYB.[Z./YYV[F.8Y\
MGQ^WM_G#YY!ZN/YY^[8:Y_F?'[.6G^^(SRXT\YN[>>P/]YZ?N#F'^^'P'/C^
M>;NT&G_WGIP <\LX\P^>S3@<^<[=K_B>&[?_ )(C XX_GG;M^H?)Z;U9''F(
MX_GF[MZ#@?\ @?''L'E_PB,=O'\\W=K7_P# ]/H'/G_OA]0QP(?[\_=H-=?^
M!Z?37G_.'#Z.!8[=^=6LIROL)-F&\NS>XNUK*0=GZO9;SU;6W7K\>B4"&RI*
M+1A= [!SQ%REYJY4:A.=?V8O]<EX.Z4"TD)[)SP-PKLA.UMX*9S8$I5NL!SD
MH8_HY![<U 8]J^F"OWDA.3KTL76ZO78=FM+V&VVN5.8I(BNUJ&:*/7*Y@,4J
M:>@&,(%&6V4\H4F]K=3<,#PNX^^A8\(?=3?EX8I$Y8?C(!\=H6T2QDR_#:RR
M.F*J8 I)F75,($_1L#V?J<*;;WB#:;R["S3TBMJV7N3Q88(X&,)E)K;^9(BM
M-;6W8A%#E)+1 IK9./6!R^SQ5]U]J9UU>/+]NB,DO0;+(D3)8:O+1@!\:VIW
M-9H*%+!7^JB(9^JC+QQDY!AE)3I)GGWAIKH(!V#W\=78'9^'HSQ\FGH'_$X
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MORN*G8U0;;GU6 W-G]P*=)W0(BTVZ^5_9&"@+4W- [@O(LS4M98R L&C,/B
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MIR@F.HP=D.U;BF7JW/M<MN] U"=J%*W"MM3V];1!+7;K>?;:E+7:54DREF(
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M+WO82S5WRU69SM3.V^&W*I\+0!VTVQ0KVW5AIU]9R*AY(8V33F8N9=1[UET
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M[.-!U'TZ!R]8<?A\_'S]_P#BXXKUQKKH6$]5IJ/GH9X4 $4)*)<D=ME0 2B
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M=!SB) %0H 7WKK!.@R<O%V.3<UF%GY*0ARJHL6#B0=R:)(YL*Y2J+F+[@.3
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M/4?EV8[]<=V0SZL\#@!P(8YCW '+JP.@>C@ [N[M]&,C]/':'R:CD-.\->-
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M_J.WOY<^/K8'.GLB/&2]G;IW#\O'M8#/J'L#NSP"K@OCG'/4GU'2[, '6F4
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M /T+QKLQY2_^*ML&& T#LHG=Q_(OY2N6,_[U78/MR(_]HO;^+@1+L[Y2M?\
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M:G9%],2SU=0"E\22E)-0R[A0>D/:,(B/:.G]'OS>?\EV?(/'U/\ +!P/Y/\
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M=0CG7.O(2ESIQ)[<S'NL'<X=%Q8-K+FHQ.,A6KM% 5*&;*8, !62E)\)G#B
MBFJ4#AJ4.+3L+NXU<U_??8U^-5MT9,+"6<DX&/7+!>.58JA$2S=92(=A)A@
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M/**@X$L=$0S=O"Q292AH1,A"AV!SSJ3OSK^+MQP(]!ATY9'L'4<AZ/T#'?Z
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M7&G'5@>G.,XT^?\ HP*M-V]O-I3*.#*UJK3<\0OH$T1&K@ _+QKL=O!H&O\
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M [!]0?T34@X K%JU8,59FQV*;<@PKM2KT>43R$]898Q#)14.U*;)CB Y'
MCPO%;)5:-OM@0R1QO-NG (R)A=DZ1\7;W;.8\6OUQODH=)Y9.6DO:' I@&./
M'LNZ-ZDRIJ HDS/9Y5K&-A$<?O9#L%D(>+#I# @DD0O<'&MJL?;K\;DN8\_]
M,<^,_:JR?W;DN[T../\ "JQ^L9N2$/0'[HX_PIL?+'\-R7^N.S@/[ZK'IJ'[
M]R7=S_='/C_"JR=_\-R7/_5'/GQ_A58^X/W[DN0]W[8XQ]JK& <_X;DN> U_
M=',<<:6JQ^H)N2_%[QW\:VJR#VZSDF/?_P!48UUX_P *K)\DY)XYC_U1R'C6
MU63TYG)/T?\ 5&F<<)/HF]7",=HCA!Y'V:78O$_\8HA(IJ)ZCV"'"$7O/ P>
M^%?()&X?;%(S6Y,VP&'J+"[CPY26>+5-H.3G?IXR'ACD!X>[J;+33^T;>Q[Q
M!.SP$^4A;WMLO('$K<EI3CDB-9J$5,3I)*,0\(PCTG*0P#GYOPSV<9'Z!]&.
M.6/Q?H(AGN_%RXV?VT>$.I'7#<.GPLL4@B!O@"LLC\<.4>64X0K@WR<>67:Y
M!XNYBZK!;D;SVV"P42^_0T5&4NDS/5@# :MJ6N7$,=PYSH((-]PZ%6;*+8/V
MJ[D8OIDF8"4QA+\:*);)VY'&G"MS\O&\VZ&P]D!N8&IZM/R3QL0IP]J'17)-
M5>R$$P=II0^G9Q;XS<66JF\5)482,(UW:?$24M%6-.F6A8R6;6.&2JEH46+,
MF Q1F8^2 3ATAV95<.!$5!$!Y%#'(.S'  'I_5X6B=REW3)BVH=ZME9;N:X:
M8KDU(U*$E+')A-%+8*TN$/ P<2\D#E8'$RAFG2/3KF==R\D[K5MM4:UWKC-Z
M]PXB&H=+7KS>5G(@]0"HP,[8QVOJU]+;VIHQ[(FZG\FRC8_W%@9UCBD42P;E
M7VA4FR13ZT0-?O-XV?85M['W4G7*VL\,I0JU89F#R0O2,;+#CIR.!$6'%SJ_
MEVW0:U+9K<.4JEU?T2YL[LHBJFM#>ZFW!I-Y]]6/7YIP5N!RA)"/Q?W%F$<+
M#1^^GMW;5M$CN3.;O6F%@F=6^-7J,)%6MW!2)9^8K!JA8:T0MSW(L$?\3$\G
MT1*0'P#(H:#3MM86VR&V.SU6V@A%G5/N[:%ED86T0[IO"3U.OD83[,P<?<+_
M #D!,22EA+%BG+BU,^CQ#(]4\9Y/MMV]H-B**\:22=X&$<+OEZ15)':7=FM,
M(Q*$2@=O-X(2)3?_ !12.^%#'&D/<!*6/>'%Y8-F(Q[&EW9L%FO;&!M<G*$)
M::_N<3;O>AWMJUE65!)8WFV-[H%UA0?*2!C1A)6)C9,Q'SPSR2@UJMN3#;J-
M[VYKS218[GV9E1VE>L-A1*R!6'M,2F[M9/M2C7Q0.*I>@LS\+(!@*^$ Z6[.
M07C)5A(-/B</-0K\CV.EXTV?#DD3E-UB0W: @40$/NP]4IY@=.73)A,7>ROX
MHI'P3ZQ3&-7(XIU%2)0L2/(X 479\C[(9 P;">7R!K4A7]O7)TGNZDTE#JRU
M)@KP\2+'P*:$_,MZN2%4<Q+G)31<I)B)C"4P &.(Z5\V7FCW'W>D@\5<]7K_
M +M&UB")XQ12C8J<L2:2*#A1-$#&2-%1I2G  R; B>/?T/8NDP\S%*>,PLDZ
M,98IF+7\,_Y1.WS2065$1Z@QT$#.OIX\E^\LG(NHN+LUTMGEGMCHJ0J&E4-_
MJS;D-NR]1"HB5$+U3$E!T ,O $1P @.PF\C%%7,I79[;J4/X8E322AY,ELJI
M0()AZCN?M)*]0ZY*EC@/7KGM^33CES_#Y]>-#FSV]@\@]&F/E_0>S(Z!GD/9
MC/8/$=M[MG NYNPR)TUU!3 $&<3'ER20EIB1P1.(@FY5,K+'$"$*/:(@48Z2
MML?%[S;I.6(DDY:SQ/OE(BY ^!%O5*I9F;.MN6YD5#%,^D_BDADH&]WBSY,9
MN@V>-&C9J/P]DQ9,BC\,'V0R.@"8 Q]/ ",OV&T]P+H..?U@R. [ XSXX@&
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MA(["P5MG_,)M?28J<WOVEB]RF\LSFZO<Q/0(<9/:W<XD+)V%]'-1(8I8L@F
M.IZ41P$U?2VF>J#[<B5W[LFT=&CVM]GW]-KFW#^;/ 5F;JM<V7W+^T+M$D:4
MTP9_:*T:'B%TWY@>ER!K0XV_^TK^GCMSO["I3=F=T>WR<M<-M*A'3BP%J=CV
MEKEDVNFP^.,R*QBD;\4CNL3,)XX^T%YE%ZWN%<Z'#[9;X-(V5/N56F4K*W_;
M&(@)APJ,&KM*G/;9S9(6TLU#Q,M'2)8M8^0?OP >FK-KL6_*/[G/>4K;&ONZ
M2_VRHS"%>[S;%0MK<6B8A(O:M4MC3@IPWM)"$9)2I1-[^^!\91Z8[_\ :4IN
MI9(_:U_"2-BW CAF2DGFDU,W)K";)P:-?ME*)"C[D0D[9S2T/,QY^N-Z!.!O
MNQ\4T\/QY!TQCFXK:!XDF)$R=1@#0 ,IS[,\;D,-PJK(0!C["V-M'2)DC.X.
M7\/<;;'VXB:( MG!1]R' E-U  8$  >/.'9FX^\)2&Z=(8(.A$!#W&$V:V^'
M :Z@!#AQ9IKP,KPE>DYAJU=Z_P "PTYRQCGRYYQQ$WF?B86+E'LS8V18^+"3
M)'&+$$(H4PA,+.$\B6)U #F ._.0XVB8CCPDZ_;I(AL8_AB7BR'+Z@^$!CB*
MW\A*%)W?8^9BSS#?="AB2U5Q@C&$$LZ:T-XHQ[!2_L[*)J,ECRL?'D*HF8,A
M@<PJTA^28H2<>Y<^-G1F1^EX@B&F@AGT=O%?HW7+6Z[[FRY_+^MMB6J1AH1[
M69V6IT4EN#$W*PUHW@0%>"&>V^*C<18C9GP^_P >46@2#N,BYF'7J[_:[=?<
M;<ZS2=0=0S"66V.7K;R6E:S4HR<40KD/.J3T2SCHZ1D0+&?MKXB_#)A(*EMV
MRD8_=&T[9#.[*[]3:\@^7F3.*Y2;_;+^E(1DEM!637NUPSJHP[$']?.#.6/(
M&?/OW&[=RT[O]3O,'OY4*U!6)9!QLV_\QKA*DN4Y&K'A2RC&K'HI$HB*4P+\
M'G4;]\P=2'[;%H5F:1I.YEIOT!>K3)3EQV1E+\VF*!._$82HSTU,7"N43<X:
M[,5#=*KQ9';T[V/(D4J3=LR ?<BNBOFA-P-N*UO)$PZ5>F-R-R]I+DUL;MRP
MA99T5><^R.X]0KMEVW"MSP>YC(0$8:*!41,1^QZ2^],:C.V^.VNF#HEA6\MN
M_M#4XJXO*_*"8_L;JUN[!69&% 4V74$D&38 <#S&AU>X;P[.[K[D.%XF+L49
MN(DPW38D>SI8@#$VBE*E5F@R,]S I#$S*C[H!@*/"=$V/0KT)0*1%PLK..-O
MZ_+P,O#3R#1I 0[F5K<P8/L;(MX((L2R$:,8HG%OVWN0%9E:<;3,+[+V>_W'
M>,];AZS8+>WL%D6N=AG$[7\4)%HF3,G"06VIX]H?XG*?%!3(^<AJ(F'B\W/:
MVK6]M!HMYZT6JGM[2I9HT4XJ,GI53<*)A;!@IINMHP[/K^&2<:)H07H"7#(P
MC3)U51T@_M:ME6%BX15;>[M*[)%AVZH"<>GK.L1T4<AH),<^"M-B=HK)=6B+
MDZ$C9C)M8&DQ"J*9EE$).]6%>#K4:NFB43BD+\%!)KTXXV911EXF62+N!*T,
ML[#K_$8"2+9X2;H?Q6/4%-+WF&4)/=8&P'4G\P;G*>7K8FG[D;/;%V0]!N<F
M\=RC2_WB<@8\$[=#U=H2V'<N%:\S3&/("<7*"FDQ)U$$#!'EHL)Y+:A6=[]P
M=P*>2_SD39?":PVTM-*1*"-&6E8J]003G_CKA\P4:GF%D4TV"8%*<5 QYNF>
M\%&C]O\ =C;FB[BUV_U2+=>]M6TQ!T!2XQ$Q%)B;J2AK&_8-WRAOBTP4ZB7B
M$ 2&*(;TOHJ-E)BQV^@>5:40C(ULL]D)B2LK[8BX+?"8I IW$P ]8B D Q@
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MS>'XLVCF=MW L<CM#8X!I%Q+]@=*-M$\FWK<+#P4-+IQ1P]^.5%)3PCF 1,
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M!SUR<F)ZVE<PIY),I39-!)03MZ0/V1DPR(!KQACY-_+JV6[UZE&O@]0E&&3
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M>/Q]R,6,IUINLC8[CO G)O-JXD(;<PSRVPX1LQ$VC:M] 046GM+)WQE&MW#
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M5N8W0B8JIL8*(#@0I<;%;9O+"RK?E.A*(SD(EYLJ=U7]Y"&$ZJ$S+;T(]$;
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M+HP*/2]0F(<Q#/\ !@ZW=HW D7J;S;[?;88STT0EMA*[Z2%GKM'C:I-4R/\
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M(G;D8.#A! #@8]8>#DPZZYYCGC>>#CV!F32R7;;+:V'9@X%0(][1)ZN/E2F
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MGLTY8UXAO*]O3.MV96+OPMF;?,#AHBJY,D9Q0)R6*HCX3$$T"C$"83FZOWO
M0*+$$1BY O1X/+5(<]?[8#\P4.D! I?V0_)RX !:![(FP;WA4<Y#F @3&H_A
MSX#]K<^>%U=<ZAD0 N=2]_R\9"2#3& %FL&<?((]G'\)".<].&BY0#'+40T$
M #TCP'[Y &FN&:P:B//ZH#J \NSC^$N\1$&:XCSQS 1 0[_5V\:27,<?N-;0
M._0"X#7.._C^$0QR_<BP9QJ C[(CJ8 ].O=QI)<AU$&JN.K'8&@Y'MY\9&3-
MG3/[46Y9 ,ATAW9^?@O[Y:CCDS6[\  >SG3'R\?PCIW^Y+X$1TUTSH <>Q*>
MT8=/V@;I'!1,(>T Y$<<] X#$J(XQH#$X (Y[<"(Y$ X]ZF@ZG1?JA@_:)4L
M?M0H$_-@3LUQWYXDKKN,[*,BN0&](HL=()GG+C8@\?QHZ-53.T53JH+-2EG)
M0 ,M$J'(FD4YS%(;='?S=J9<MF3AS)OY272$P_$+4YCQ3J- JB4DJL84D?";
M) EU*!&0C4QAT(F4W>/R!GV<CZM!_HF @.!#D/#6&WVI[;=%LP;>ZQMR0D0K
M&Z40T 1 0"W-FZOVN,43>P2;1DNG7I$.!/![W6NG%$0\-AN1M:]<I-PR(B!Y
MG;^>MBRW5V8C2<?SIJ!_N<;V]GI_B][PX_G34#'HVXWLU#_<^X_G2[?YT_\
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M)G3C]3OTSW]OZ"J',/8YY >0#^ <,95@J9!XR<-'S9P3 &;/(XY1(8!QH)%
M 0]7&PWG.IM?BY2?HKW;O<%2+*Y4.*->W,KQJ?=*@4Y$A.(C8+8T*;GHS$>P
M.&L53]@D/*U7>HY)2V;I%^QTG&Q@IY!2>B=P'$Q;3%(F4>DT+6&/48=0  '$
M7=/-9YD-W?,;/MS$-(1S0BM(KK\R(=98A5VLZN5J4@1,(AUA*0A@#ZH%SI/5
M39_R];=TEG<*Q-U6SOF$.U7MUAJ-B34@;% 35Y<'-;C5SPIH!,4LR!Q NF>G
M7=?8&9<+OF-1E2.Z=./ Z/M#19V.1FZ5+@/1TG67@%R-50((E+(MU" (=..
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M#FZ)(LE'ED@,I[\4!9LV<=YC]O7QFMAB;M(67W)NS8P4=8HZ9DU3SU4DXR)
MR",+/PZSAF<I"FZ/$ Q.DQ0$-IHC;<_E:J6Z/F$VHDMU:#:?-MMK4):BKMH:
M15B)O;=6^R[IU'TW=*$F&"_A@^B)2(>J,#I"Z:G.U4,_WHL3(RU4VU<D=00(
MBF+*9N9O>B(B<062$L36"I_$%,!D#>[ &@\3%8;CF9@HJ*>NP= <0$)X)TP
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M!2PI"2:2AL&,.8Y*6\O)IIC%A[K$0$INMOR_K\!'='4>$AJ>&Z)*W7 TTT
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MQTH,A.3'@&KZ2G2G[@ " #TF >\>%WK&6;R+9F]E(9TN"*:(EDH66/!S>42
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M'ZG%.@)M[*0&TU@WHH[;>BQ0+,<Q-,2>QBA)66$"&+\$&?\ :U  ^+ T#41
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M?CEZ]>7R<<M/7QR^GCE](?J\<N.7Z_'+Z>(+<K:^R/:Q;Z\X*=N\9F.+5^Q
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MN-6AJ'7U:U5&<; 5:N(LH<9%W,+^]! 0T.K.3;N3<K*+R,@*\F^$Q0.H8"E
M,AST[0'L^0.S@0 <#C7ZO=D UP'+ABQV)N4^+B1?E,EM^<QIZJ69_(>$10BE
M07,JR/,KI$(F59J4DE@O2FH4<AQ7=F?^4G\KD3$3$E6XJVN$X./A]S(:+&<1
MEPBEY>EVYTK/4>6:MS )Q92TG)@4VH (]/#)UY0_.78MK7BRYR1]!BMT:XLQ
M6.'B=)F^TN_M<M$\ E\10 ",)' (#IC3AHU([\O>[K) @]:]J8VG:B4 ^?9Z
MD*"AN/6P Q5"YQ&Q6.D/9U'";>:\D4?84E!.'QVC^9/;LL;TI' -(>[P=<L
MY#'UA+ZN/*/O:X\IN[=;IFR%EE'UN;(3-)L4DY9/WB*8*PO1<FYIHJ)B 8V3
M%-C.,YU,ZJ'DI\QTRN!Q1(E9[5Y;J6T-Z3F-O_/3B91*;_L<(^OA$1\ONQNS
MC5<3$<FN6]EIW1L#0H"(%,\J])V[KT-U& =0":  [^(^8W^\Z3/:*'-X8N*K
MMR-$V'J<^*9CJ""-CO8VW=LBJH!@WPFSD$  .D"]KR>VKA97?;=M6+58N+Z5
M&6F;"\\,$ "*M^]VYQ5K9+H*D*4"J1Y9=/I+C.@!P]VBW"BB^72NNUI5Q!.-
MJWDH=K?($BQ/!?1VZO6F^E6"0" JI1Y8<<*%"18@<P$ ZSDQU#**"HHHH.3+
M";41$0R.1,.NH\^-0#LTT_& AKQTA\G CW8^7@ $>_ _)W<,FHB4YW3E)%-0
MR3I4H")RD_-1J*L@?JP'LID$PCRX+),MN[JZAE'YXUO.-ZU.#".G9) \2*"+
MQ:/32,K\2(*70(@?Q/8Z>K <,ZK(,#3=DD[%(59"'KD39',X\DXB+@Y<Z43$
MS$# K393(3212^X@K[75V8ZE):%H%W2GMNY!O+3 H4^4>*U5_$@$HV4GHX8M
M0D6*/@@?H>IE+T@/5DH#PM!GVROYK2JT^-KP!*C/FG1CGGMEF!BBQAG)8I0P
M^RIT 01'0<<H=F.VE[%W8??1K[7[*3I7<X$:'5(A#(A' >4%L'YSP@/X?[+'
M#N7>4NQ1T3%6V)I<_(R%?L A!STTF<46TK&Q,8YF4Q2)X0&*"(G*9XU*)>IR
M0!0L!ZC9!KKR4"$86#X))!!O90 ZPB6$L:/!HK+& N03*?Q,?L>&A+C5+)53
M238'<>WLD))0AGC(%>CQH_XFBDHNEXG[(H"'IX0JT;(PR<8R8RL7&OG-,H\C
M8(F/F571Y2.A;=*UUQ:X1-8\N[4,#)^F.70B'3D1XAZ76&?Q"<GW1&4:V <=
M:AR'$,CU  :$USV<2>T6R+XHQ2S4T3N#NBP,9*>W)>&3S*QT5)ZKQ.WRACX!
M@0X%D 3ZE1, @''U!+Z>KJ[O1QJ0#?Y(2\<L=FF<B&OX^WCY^>H!GY,]O'+Y
M-<C\N.-0Y!^'9RXUS\X_1QR_'\O';\@CQ^ED=?H[..79Z?7CY^.7TCIQR#YQ
M_4X^7T\OF]''08W4F(\\"&,%*;L$1')OQ<-++19^1@)5N4Y2.F9^GQVAQ 3L
MGZ:A#HR4:H)/:25*<@XY:!AWO3MW$L*W+1"\>QW?VYB@ (Z"D9DP!%WRIEQU
M)TNR*@":D>(]<1(^P'4D<AN/P[@']/\ HUY</+_$@+6P[^)./-YO2[ I2NY"
M->R=BV^\NE,6, &$8ZJ52$G+(EJ'4>ZZXZ R8W?C'R% .[T?= 0TSW8[.?S\
M:^O\.?W1]./HX# 9'7'9V<#\G&/OR[*7]T9/:KS35J5\NFX"*B@D9,U[^4B>
MV%R7Z<F,&V&\;:!L   ^U\,$O(P\3M6G$#,YBM34I 3K,VIF<I"OU8R01$P:
M"*3I$Q1$-!$/N@=1/QDRJ)"HD)A_+%*.H9  QU '%LV[J;G=R/LLTWK<+2G#
MJCU6G1.V^Q<)/#:&?DX7-4-V'$;N#LY4[6NG*P]B7A(N6!>+:D5C>@Q/A\/4
M_<K89TU\FVX'EZ7%N@T(Q^U]SWWNFZOQ 0^T"*IZX6&G&J*A_:'Q2#AD8OM#
MM4]N3;=Z.DMF5Y*5@4H.M5*?+?IFV^5C838^6-:)64W!KKJJ-J]>=C@D@$A)
M89>,D!2Z8\Q<F@;?(1=J)<(S9OR_4Q1S.; [+;SU^)L6Q=4;5J6A86!W6N3F
ML_!MSO<V:@652)"7J7A88,'H&U5FXQIN4$M&6;SIA#0\I3:NI%3M:\SE(GF%
M8F)B8'<X5(:?@)^29L9..+'RB1XQ,[PDBH<"1X7RX0;?<]>5WLW<L&]UQ83,
M%5FK/:*S/MIMVZ7"T_;>1:WA1:\5YO8=VA\62?!6##%P+( C>H1(38F*8)RY
M'NV6SR- G%9A0JAG,D&Y&YMQ(I#] G$D*2&N+0A -@P'(;3&!'[S=ZX6+;9J
MA)[94AU=;-OE)R:L@TI5>.600:1,9!K1#@8>8=MD7B@2$4)Y(46[H@^S[/"5
M\VYM\1:Z;(;94DL;/0QCNFHJIMGJ3U!P19-%=.715)TJ%.'4 B'9KQU&'7T^
MD,=_=P5E0]Y=TJ:RR(@RJ]^M=?9:AKEE$RS='.,=G",;'[\R[UFW7\=-2Q5:
M@VE]U@.1,>9L=.D)TX:]JVGHX63/N; O/' ,K.]MMNSG;CGFGT5M,/7D!X("
M.]2+?&H>'MOM,8,#@>;NA* /KX7)/^8K=]5!Q[+AE%W>:@(Y?.F#1$"O#,C%
MQ_T+A>0E'SR1?.3"=P]?.57;MP<<>THLN8ZAS>L1^YYF7E9J](\YT=L2C".;
MO3:A9@;J4MQ+%%-M=ZY?6D1-@T^SL2B_?FDH05 !DR>)=8=#HO!Q(44R"/Y,
M@CD0#/(1[=!^]@I=?Q10BIJ*E%@2QUB$>](L/3H; B 8#TCP_*S2LC=I);7V
MVE>[.&C(.E[.;O3VY,4 E&0$?@B,7*M4SZB;Q"#TE.7!AL,_),+&"$ENCNC;
MXM!U4:G8"MXV\55.*A)B5B)B8+7YJ?JLO'$.>+. 14D7/4)1#IXH%@9A:'+>
MLWK;JT3X)U.JU<SIE2*LA5A")AH&;- D(*2*ABLR!&I_ML0ZL9,#^J.$;!\5
M7H\C66KL#@9AX\EO7!;DF.)?B@#X!8N,<CT].?B1@_QX;E/9A"Q>XW"Y!8X!
MS)56L6WX1FM3<'[_ #51G)3[-39R"LS$6)S GTD$ ./24HGECEMI/#W!V$OS
M,K&I5F+!R.VM3+39^,&'B)QM U\2E$SZ*!@42>'U,0]R*('!6P"UMA;#(5*F
MT1Q60B(8U581U2M$%-DMT3+!-E6^-+$KX'&/-%](2+YVH#_!@ S:(8!)@NWW
M2W5N1W,@H"@'A;FWI PI#@8/;E$5X%WXH@.,'#&>P#$UP B/9S H!S_2XW/W
M"(!DK-N7*--GJ:N'M':0";;XUN=*% "FZ14AU6$64<A[$@ZYXT*4 _JL\NP0
M'N]/WD'6?+W6=V=R)67L>W]5I>],%<-K]SME]R7UL'P7IYV,J,37YWR]"DX!
MRHFQGI"RR20-?='Q&0Y5XF'^]M?+/5"R^7GS06[;J33@MW]O2EONRFW;N4 W
MPK<^E[-W0WV6F9>/D,C'K1$F4X)E%X(*IE9;A#4W+SW]/;R06JC6J;E,I2/9
M[ERD3"U!4EKG-M8#:696FYBU1Q3Q<%99.6C??,/6:?N3\S*%VKF/,5L2Y.]6
MW,A9YW3Y'<:9EJI<=MJY\;EJY(PQ]K$IR: !()D)./9/ZU*$8O$F,FH\*4AF
M5Z@%-K)*)K]'W#W!;V"KN]T@M6Z%4I^ZT7MQ+RAH>W0S>#;I5I60*^3\!A#F
M)"@8\@ OP%/B9=0S*)=*QS]&JLFT;5]W)XDM>DZQ!SDQ1EY:F;66"M4F8JZD
MVVBY5_:7]>AR2H.DROW(,GITINHU1TA&R,%%?%G1UZANW>#>%\1;18)_"MG-
MMMS+64 5< 871H\K F,&4*)@ 7%;F[SL_2[K_'5N'Y>:[2;+-W=:=N&[&V;"
MLJS=9A)&K4&S5A)";^U;(L8_DY2-CECF-U*-P$./+C:86Y[1[AS^]\5NJY/M
ME<2[RP$?"AMY#VY:9<2TY78:L*J#6QAN@P-)(I32_NX$!]&B[4" W$LNV-^K
MVWMK5(A5[W,U&R1%1L:JQ5ED20EGD8HD)-F.@P7, ,U#F$"''D40^\KDO* H
MXJLG[Q5[[%D#28HD\B,5;(H?9'\_#+* &NAL<7>A.%A=?9B>>Q+=V Z/6")^
MN,?=&H 5S%F34QGV>K^C416VQNJ-J_E;\C,9#%#JP6/<>2K8": ,B8<F,M*G
M-G^NX,4.08QGTAGO^[OEN8YVIV)W'NU/WAV1ID4KOWOI*;,0,'3[S5]Y)::/
M!*DWS\OT)8+*M-T./)T&?2ZI&HNC^XIE+[P'FF?4';J_;Q;,I[HQ'E\V6MU$
M;W>S5W:RVWJ/L,NCNW-S])7,6=H6V4U!,8HLA*B2*F(R<+(F IR%(7:Y6V;"
M;17*9?[][V4K?*6W+WEM6W=ZI^VVU$/MA,3\EM_5(G?';@MNE*#$2]C?2XQM
M?LIDTVC?K+GV#;)VB4HFR5BVPO.Y^\,1N+NSO!OA*;5;I0.VE3N</$15DH-
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M:O4]N8V'V:2W(:52EK0]AF:M)U_=>3EI2V4ZT$F+D\GYR"5+,'CRB:1(_"/
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M2GT<+BM3QG@LHT4VYP5[^,D:/\='WSX%\6"*\3/[6Z=/O-C=J57"C&*MVX4
M6W30%ZOLQM_"K#/[A7-;ZHA&TZ@Q$A*+"/L@BS,(X#C?K>TS46R>[V[^Y6Y!
M6@@!?<D;M<)JR,VP@ !CP"R $'  'L\=/8;3Y^_MX[-0#':&>[3GG'X#QV:
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M=V!"BLJ^*=13I#J$1YPVZQ$(^\WBJPC2,I,Q?WUEFPI+R&C&L-39R&+&6.!
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MW@IS=;D#0,LLT="S*4$QX3 P:EZLCWB8,ZXTS]Z2'ED=CY"X-J+0[M$6.?W
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M5(,T;U:*<R= VG)N.YH,*JR)6*Y:MRX#;^ N\V5K&0C!,X&D/"-[L  4"@4
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M_]H " $$ 08_ /\ YA#Y<?AGCD/T?J__ )A/U>WCEIZ_3^D'W.6O+37Y]-.
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MZXXT O\ 9#_F![.! P ']2(#G(=HB& P(?+QH4O+( 8X@.>X>DAP#'H$>/;
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M R(  CC40*(B "/,0 3#\_ AJ&0$,AS#/=Z>$@3!,2"H8' G,<IP1\%7 H]
M:J^/T!J(!T"8<Y /N'#Q4P$HJ";J.7V!'*H]0=08 I1R/+3[@!DPB8QL".38
M$>H_/L*'9\@?>:G HB7ZHB4- R/5@0SIGU<"(!G&-,CRR "/(W(-> $3] %,
M Y]D 'F'2/4 Z#GU\"/5U9'(<M/0& #3Z>/9 !'N$1 /G #?BX#3.O;C3O-\
MG&1SV<@$PZCCD4!'@ILX$WL8R.#8 38QR$0P/R9X''/LUQ].!_%P(?LA*(
M&U$>D1P41%,1'3O ?2'&1'&-1UTY:Y'NX$I3E,;(@( 8!$!* =0"&<@)<AGN
MR'">F<G'7N_)G'/Z7!NKZN!SSY8UY:\ON"(_\]6+_8K*%#Z ^X(%$2F'0#
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M!@'J''5V^R4=.8\(D 0*4Z@D$.0B4$%3 4@@("40$@#IV!P8A@*=,Y1(<A@
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M@E#&@E#J 0*!38 O08G3J <Q ,?)P =9BB0P&]D"Y 1(8,&!0AP !*;M#@P
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MG U_'Q^:[?\ GINSEC\KV<:_C,(>G_/<\8#ESYFU'_1> YY]1!]>?RH:_I<
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M?Z)D>/S!N_'6D.N/2J >CU<#A$?[)'^VCKKQCP#8_P <ACM[ 5[>-$3!ZC(
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M,0% !5LLFFY15 H^T0Y"G*.@@ Z< W7;$<,GS57QF[YJJ *HF\,HH.63MN
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M(?DC/# 8PY%0.?#8'Y%T7 @<YT'0F.Z0\0XG\)PJ:;L(**$,(ZE=JD H@4N
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M'Q%DT9Y-2U6")G;.N^=+J.9*/9P;=P0Y""R+X13?=.FH4ITU"F(<AP Q3D.
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M'R)5!-CH, <A'N &+5JFU;MFS;P2())HMBI_E$$T$4TP*0@-TVY0P  !2B4
M^^8;?#N=75I.;?R&WL;M2W?TYS81LL!3W.YLO>\(S!+8A#LX,AXAXW.V5(D^
M*W, ) J8Y[.K'4RJG:-$K0QIJ[Z^RC-2<LU>EIN(0C[4W2V_>&J,'*+1B1P?
MLAGETDU3B+0PID!:LWVZ0JK&1#;N?LLM'T>2M]R:IL\5Z5%O$TZ+A49BX3K]
MBD0[9)"+>2+1;Q63,R_O1S.*#,0EWWZVTK,_%3LRLMMWL#8++N6Z<LIVEQ<7
M'SFWMVV(W,M%8B3$F70N_>8!BY(02*BNDD0QA9$+N9>:&QKE&I$Y(UBLP>W!
MX6S2MBFK:20+8%;MMU<+$S,W;UA)'W>,E61D$W"G6)E!17"H5F03EWUBL];9
MSA)>KTF^3.VZ@'8.7;A0NX[2O.Z1$HN#,%3-$)"2;NUDSH !#&<(@I67R<BU
M-.RM=K3MY*JM$2H'5?-(]:6?MV319TS(X,BJLHW3!15N582 (G3R(UU*2EGD
M](I0<4E(3DBA'M7\R]38H$=RKQO$QD)%(.9!<#*G*V9M6Y3'$$T4R=) ^] 4
MUP<)N'#U\DL7ZIDI%ZX?I 4>TI$W(% >T S_ $::28JB:#EV2,+)E6=F*2.E
MT7HFKKQHT4.DU33EC2+EF\4**CE5<(XA2>&14Y/O3E<MTE@.V<,S"H0IC"U=
M@F#IOU8Z@2< D7K !P;I#/(.'$@=@U.^=(1;9RZ,B0RZ[>$>O)&'14.(9,G&
MOY!=9$/\[45,8-1X=/D6:2;M]*$FG:Y1.!UY0D,VKQ7BGMX%4(5FDWY=/AD#
M3.O"Q("/E2H'@(NK-64Q;+?9XZ%KD1$QT*WA*O&6>=F(^I1KMA$-??DHM)H6
M27;IKNP77(50)2952>K.)J&;P4HQ7F)A>O/&#8[LQ5%*JL_/6 E5TGAD5WY6
M@/G+5-%!98Z*"*:=<8M23TB%3EY"=@Y"TW*Y72?0DY-G8HYRL]LUPGIVQ3"*
M<?:WS=N@]=.$&B"I4T")D11!-.X*I2CF9034*R3>6.QO8&,76;"Q6DH>I.Y9
M:J0TVLQ450._:LD7ID'+A,51(Y<%4^]8PS!V1HBW78RMB5\+K<GB05=&9QC,
M5T%60_&G\>*3H1 YB,2+$*":JR"Q.#I*ID524(8BB:A2G34(<!*8AR& 2F(8
MHX$!# APZ7CW9I%LZ6!4(J26*@E'@1L*)$8ETW:',W:"9)/**A%"ADQBF 1$
M#,WCF.>1#ARV176BI$\>J_CE52%.=F\4B7\I&'<MS#TG%NY71$P#T',7 C^A
ME./L+$ P)KD GBI=08-T&.4Y1*8.91 2CVAP+2TV> AG8$<ODHY1^0TDK&J2
M!T$'B,20#2:Z(>*F54Z:)DR*"(=6 SPRCJ50K-9Y!TH<#MWI@B0%$H%PK&A%
MM+0YEC]1L"4B10#^JX$T30XRMI.W)5&DL$ WB7C5C@3 F[B]Q+BPE4G1M -U
M1&G<'");!NY$0+=/J\,(VV/JJY-U%$,J-JG6(DSC74!.^/C&@!Q(V.:\R\A
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MLM6&@F(4K8[-9 Z/VJ<>.H(B@R6(@4$%DUW;9;PB*F @=2BIBJ.7!B)%6=N
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M#MS![@7#;QZU^)@QW.(SL36XQ<PS052%J?=)@M?;%49)BJ)DOAKHI5DE?8R
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MF.8YS?T<<.#MB)NW34C)>0:F4929VB:AE4VX2;,Z#]-)-0XF*!5 Z1$1#F/
M%]YG\ &,A:[2!NSF<)GK$=.>>/STMW?P].=V/^R//@/RTMIWS\Z/:(ZYD1SS
MXSXTMKW3\Z'T!(X#C\]+?W>G!_'(\?GI;GG2?G0_%(AIZ./STM\L_.CW]\CZ
M>!_+2VH8_A^=^C]\=!X_/2_+'^$$]_LESXSXTMSS_#TYWB/+XCCF/S:<N/ST
MO_=^>_V2X_/2W]WYW_9'C\]+?W?G?]D>#(N6_OZ1ER./"DUEY0A%T_S:B19%
M5T")DQU+T=( /+[PL38(V+F&3ATF0L=,,&TBS6=MTC/TA]V>(K-SJHI(BH4V
M/9$N@Y#ADNNS:K+1JQW$<LJW145CW"C5=@HNR4.03-5E&3I5$3)B4PI*&)GI
M,("JV<H(N&RY#I+MUTB+(+)J (*)JI*%,FH0X".0$! >(Y^5ZZ;ECA4'W))*
M-59NNM!= GBB\CW3MH9(K@P@9HLV.? %4$Y Z>'I%8YBJ22(LG(E4:-SED$W
M#=%HN1Z4R8@Z(NT;)I'!3J R:92CD"@ */2LFA7BRB2JKLK9$'*JJ+=1HBJH
MN!/%.HDU6.D4PB(E3,)0T$0X1 XMFC=,[9JW PI((IG6.FS:-T0'H(4ZJBI4
MDR%U,8P%*&1 .&KYQ(*(-T#)(^XG2B18N7:KM$62JBSJ/5D".RNQ*5$$G"8"
M<P>R)^D0R&>9@U*)1R41*.A@ <9#0>0AJ&GW1$1   !$1$<  !J(B(Z  !PA
MMGL&P=3LXZ7PXMS9!HLP.DV)[RHG#%?*))C NPZ2J3QBF8&((HM5"G6+(,EG
MU[60O]_2!O*O6KA123K$;*OO=W97,\N[)'N[C,E>MUWZ(.TFR/A@F=%D@JFF
MN85G[E<RIND@-T_&9M$R%*< (@S0>.DA*(*#E4JJB@\NH   !,@#@ZG(,''N
MSJ!3X^OPQ?(H@PACI/"/XV3CWJ#]ROEN#-9)N^:1[AF+51$Y1,J0WCE'(%#V
M#\+RSJ C'J[%L8Z6(^,,^6\ @B@S:*O/ 3!98P 1(IE4R=9@ 1 ->!$J:+=
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MVM/RO&IC B[;*!X,C$O@3356C)=B81682#<JA1,F?F4P'()B&*8W 9#D.0]
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M-RG*1O%H(P!30HE,(I.BMT5GL0B+90O64&YEL"8!Z1$3 !<-ES]#DA.H#MP
M4SH@!G0 9P7**1E!*8! %,E$2D$.D1=*J1KHB'0P;HD\5D90Z@2<BU=NBB$F
M9'W1-IX+D,D37%$V!*=4/ 3?%+&"H9U,QSU4[QK!':G!D_BW8N$/<SM':PH@
M90R"CD#.$U6XFP/Y(%2,$T5 9(@W3",8M(11)5%!1'P$0;S+96/(@U\,#%
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M56:ZS4YVSYDN7\JS>(B9N];&*JF.!$"_<'*?BF I_"P;PCI*&153$Y'!1!5
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M"/48"=89$.60[_O3$-G!NT/K%$! 2G*.O2<A@ 2CS 0SQ@V.LHB4V- $0_9
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M+FRI-G\M$767E?VYK,_L;+[<6VCS#R-KZ5FBY8VY%4.]W&C[>J)'2<K%K$:
M5J=L86 HKM)?9&FQU=H;[R]M@F(^9<,]L-S)"T0,L0QH;:I]292D1M\JU.+
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M;0,-![ETQ*SP=RV^=3B_P]S!2D7'C'1DE)RYR_$B1Q8M>QC8;55E7*LVC0Z
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MU_HP_J<1I)*18M7+]T,3$J2;MHW=OWCHIW81; RQDE';I9%D)P13ZE#D1ZA
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M>':_9.S^94]NW@JXW:@[/65%3<B(H\?3ZIMU-VZ&V^6BW?VXLU=G:>Z1<M&
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MK87",=&WB#58K)(1"\26 F9VU2\ 9HE#H@B_&#9-6SIXHJ=8$W(+$$Z*<Q.
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MB8,?<=-TES-E5VZR*;DJ::IFZBJ9B$7*DJ!DE#)&,!@*8!*(A@=.![P'EC7
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M*) (<_05-P)B=1O P<QC= Z" @ @/>&O]-R[/:0:4ULSPJJ)9J[O9<C"$()
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M[R8C@J:!ET&JJ!SMC8!44BG,AXQ0=%R7J,4#"7VB=!M>!Z3"3(YZB= B;),
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M$NY!ZH0BRY&+-84$7"_A-U7#EP[<3EIF4F)[3:Y RYW\Z]9I*]((HN'3PD)
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M HB03I )@* #TF QU$P-V#D3%[Q'A1$O4/658 ZU5%#95$YARHKXAP#)M U
MH: &  ."& " )5!4$1( B(^$=+)3<RGP8 SSZ=.0\=(!^QZ< 8Q>S&AR^V7'
M8(:APF0  2ID53 3G.JH)1,42=2JH'54,8I<G$QA$3:CU#KP0  !2#Q#B<53
M>)XAA]E/P_#$HI=)Q'/6 E$   'F CD.D2E "].H" F$1$V=0$!#3LQZ?N$3
M,1,Z1 !93J$!,"I%"&:X3,F8HE Y#'ZNHIB'(7&<Z?>7*X[E6.L0%19-)V;:
M5:3H-KV^N>WL%M^W6;;C.;#+V"V6)GNQ$QLP*/N\["14/"K,CIKM5'Z#ELN=
M"R4>9C4U DX 7D>TMFW%Z=,XN1MJT.R<.93:VV[D5(6MH;1+KW4R4@=4B8CX
MONZI#@E8=HV=CB4Y^O2$Y#'=FN6VKPCR<JC.4?7**4JD1>)+<VL?9)*$=@\>
M3\!$1IQ2*+=RN5PU,O:I]GLINU+2=?DT&<+3&P;8QMDOL6^D4X^,LE5=V7<R
M!IL?'OP$ZXLI^6A)MDBE^W6#8ZB!%8UN9C+*J2TPG#KI%-"J)UM<:N[L?BRQ
MD)#K3:J S*U_)&=JB\<I=)?=S"L2OP%TL4+#+S<>I8';N6O.UM;;P%/.]DHZ
M,NCIK;K]7IFR0$V]BE4VQ:ZTFWQ3F3!9LB*J8&?7VS( ZBV#EJU,V&V;:4LR
MRSLQP3*2>W;O>W%*0.!4S&Z%Y5%0X /04P@(<(3<97[79*Z%9J-ZEK#%M82-
MCZ]0[<6Q.$[A*M[;/5F85804?67#J09,FKN831.F"+-94_AA8X5Q5+;76$!)
MP;1E;W2]'7A+8+].#>F+ -F5FF[&W:D6DS,7/Q.+C5^M!8S?)!;N%+'3(>W5
MB5N%.",-;JI&S\4^LE5+-L49.&-8X)J[5E(,)>-<)N&HNDDO>$#E4)U%$!'[
MJB913!00 R)E4_%(FNF(*-U3)]1>OP5BE-C(:AS#@AP P <I3 !@P8 , #@P
M=A@SK_1IVDB'20]FNKH0P(?E7URGGJXZG4^LLX,//MY!R#[M5CT;]O+M_'.(
MBTSC]_LIM&3=JR2"T',41BTCW<<ILYO4#*/42L*_65*-1<K (G36*5!3$'*W
M+=*F;<_"VBUSG4K)*U6)5M=?@ :MYNLQ<58YE!ZF\F/B@F9K-5SF0?-T43J'
M(J(*&KI]R]T*M#I43:IU4:O0=KF]OJUHO=\OFY-518;D7>2V7N$13(ZPR$1"
M1\<92U5\ISJ.3',B $<#&1M7M6]J%U"L,9"L[:4W:D]CV8NEF4^USN)A]R-X
ME/+_ 'I';R+GW]?&/?O%K) %9-!05 K95PDJXVR8DCS/2V2\/X59R6QKP@1*
M:&VVX-B"0/&) *=P*HK %:_#E<$2%R#\/;8D#BY3$C$0]'6M'EMLN[VV3JOW
M23L-J%K%T:&D+8K-L%JO1XZMO:A/72*18*LYE[\1*H98ZD>) (:T5FUP<7&2
ML!+T%[&I5BYN9<LA4;[<7U8J,U+J/(2GOX675EZX_%]%E2>LC((E31>O3*K(
MHQ$):81@C!W&][B5:ISB%GDINPKSL7,;EV9JREX M>4B8.MA2*8JHW=_'%E4
MUQ19BR0$0 ED;/*I$AMY3MG*I?(YXEN$M8]RWR\@UG!^$2L9,LTHI8ZJ=9>)
M!)N; =-99!-45UQ<N?A\DQM5$KC"Z1\C32A%5O<)2P51Q!7[<25I5?D M$U3
M:=.I2S.*BQDI)F:"!%)10&C)T_.!E2J0<_7X"NQ22$9!DDU[/-EDIS<E:N)W
M&8K]*B)FBU^/N5,BZRJ91.=9R(N5G;)\W5C&WN2Z@?>5"NHR7V:H5>A&4<]0
MC7ZR]ELZ<6VCF\2W^*B11:(AW+9 PN3IN/?E,"GU !_%!O6*-7(NLP;=0Z_N
M48W!(7;U4B9',I)NCBH]EYE]X13.7KI19VY4#K54.<1-^C/%"JN")LP)'JMC
MD,""K@4D'Q7*8J)  ]"#H"=21Q*83&*?)DP GZ#,0VVK\8/?O:BR5[?KRVV4
MA6JBL#OGM:HYEJB"24K(,*\4]H9+O8+WJ2!PTB_BOQ $3KM$!+M;O]7$4(\U
MU@1):*^@Y,Z"IWR"=+P-YJP.%")+NFL-:(YRFS<G33]_8> [(7PUR"/Z*9VP
M,#-50PG<I)D3]V?&!/PR>]$Z.LITPU*=,Q#9^MU!IP<[YNFU=@H*2J2*WO"0
M G]0R2_AI&425 _B%ZB%, 'P8 $!^]L#.6NE[M%;EHIE"PM8GI:-%*D,$*Z>
MM2!ZW<(B%B-SW\Q/-%5%G4G-STQ*$<JG.W<MP.)10A9G<&Z7.01EVLH>UV)&
MCL9YRBRL"<\UB%FE,I=2JA(U--,&!C)1B;M5E^<7.OA<+0]<W.X3]6LJ2_A[
M;V,U7E*= .Y)[+/["\B7IZNG?7R=C<3*H+,96;DHIF@1)"/:LT$R)A9JXON9
MN%-+3+V4<U^S39J0]L>WS5=05JY&5A4E)0B)E&CK@0[!U96=@DWIDBC+.I/V
MNJQ59U,S\>O86J(?:F,<1Y+)!SC%JQ3AK;7C/8Q] QMB@)*+;2+,18*,TY!$
MJAFYRB8AH&2A[/9*@UBDF\?+P=9+6THJWP#%A,M(JN31YBN3,Q"QT0YFU7:"
M]?=PLCXY$RJ.5$"^",,\CK78Z9*PS]NL$M64:LY=R,*,C&2$S5'Z%PK-LBP@
M[-\(01=JMV[>322+EH[:J#XG%HJJ<E/M8BT;8QVTQP0<QII"(K,2VMS)@XBY
MAS%.)9>8;LK@JF"S]9\F MD5/#\4SI1S(2BLK)*,)!"',>M&1A A$)N%>^]H
M6A%P2')8SS3A)NT;J$5D%6 (L413;)J"NHM]Z?/_ $Y(C\@R#H0[1[!_HU:(
MMTQ6:$AYX0C7#ATU64FHN7C(Z=^+HH(84:,D9F2>QJ952@<QHTYLB @(_=8S
MZK)!29C8V5AV$B8F7+6,G'4,]EV2)\^RA(.J\R44#M,V)W<.91-HW)(O&C)@
MZ?%2(#IPRC5I!Q'M%EP#Q%&[)>5<G2((X(9=00U,.9"/:02:,7*4.O;9.X;W
MZ3/!C1ZJG8T82";0BCT\2P3;-[8^247013=.D3IIKJ*$;MRI'5 A054(1,Z@
M '68B0J&3*8W,2D%4PAW=0\0;^18H.WE:E5IN!<*@85(N67A)BN+/FP@8 *N
MI!V!ZV$1R'AN#AC.!"/KBL$4T1%4&8VPCVX2$L5=K19]I!L9>"3D"/RR/2]:
MUIB4S@51=E%N4Q50,)A%Y,N6)SR4@A5&SQT1Z_1%9"D3LE9:PD*:#I-$A(Z:
MEW*INDH>\%5%-?Q$@*0'UBCT)<KY^N\=G:N[3:9.OLW\B^E9*1DX6J2<T\J]
M?EI%W..Q<.V+-LY737,F<YD\$!:46C'+M1W1T-N'\=(34](UV5IS9PY<(1DS
M5'\FXK,RY2,^<$!ZZ:+/_ <K(^-X2RI#GB&I)N2;*2J4T=Q:[;;+Q,&?-IL;
M$Q+]H+G-ST[\/BI<PJLF?O/NC(OY-!)-/V.&]Z5)+J3[6+/%-TC6:S#6D2*"
MH!I5.D#,?8HMI%JL=K\9^'_%P8',T!S[L84A^[)22#0TBZ:,UU6481PW:+2L
MAT"6/B6SAV=-LD[E'IDVZ(G,!154*'$?&)***I1S%HQ355Z/%43:()MR**>&
M1-/Q#E3 1Z2E+D=  /T9JB8_0XD7'N;0W08Z9%SI*'(HN)2F!)#K*4@&-@HJ
MJ)DSU'+DI $3=(  F$"@8X_LCF A2$ZCFU'  &1Y?H>[E4JU-N,MY8O.TG-[
M^,YV#KT_/U?:+S2PZ9U-VH^WS3(9)K4(G>.$23F&\I-*MT'LL5&&CBD(U21'
M]&4(;P2I'1342P.%U%2G4(Z,<O:FF040 >\P@/9]V72K@U^*F).;;HEDY*%<
M/&QE"UYF<'LFRCY:)=3SI-)D5$@BZ9_D2$3 WY(.O;J4L;K:62)3+'>PGT4J
M-)68CVVT:SR5#9VVA2LE<V*NV4Z=HD\%9JJTL*T69ZX8!(.02%VZVA&E1QK<
M,+MAM_9]R(M*KL3/$JO/PI6L/.%EIW=.DC66@KUZ55<E91UPDRHM3 G'*+>
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ML<RB8MBAU>"RCHYLDS8M$>LQC^$V;(E(7(B."ZC^@^\-C=(GZO>&YA_(N,@
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M3--;W3U23 JS(NA!\5!I& 5,KWI_IX.N4ZH  &;&2$V41,BJI^4*7)B ?)A
M1*("(:'R)0 OZ/8JQ0I \%O9M]-5_>OR[6E%1HDXK&_&U;PUDV]>IJ22A8=%
M&8>)*Q#E5X19NW:22JWAF.F3&V.^4:R2AI"V0JK2YUE)91<*?N+6GSJM;A5,
MJZQ$G#II W")>(-')R$]^9%1=$#PUR"/]-AS%(94Q2&,5(@D!102AGH(*ITT
MP,8< '48I<CJ(!KPG[JH@W-UE,K[RW.ZRGTCU)%*B[:@FKU"'M]1RA@?9'.0
MUU'MP& ^;(_H!B@8Q!,4Q>LF .7("'441 P 8N<AD!UX0CX]N1LT;@?PD4PP
M &54.LLH;M,HLNH8YS#J8YA$=1^\,#I5@Z2.L82F;MW#!1LW!$.D@D4=2)7J
MQG :FZFY2D'D(A[0D %6[HA0,LR=$\%VB'49,3&3$1*JAXI#%*LD91!02CT'
M,&OWTU;[G8H*HU.M1CN:L=HL\O'P%=@(>/1,X?RTU-RKAI&Q48R;D,HLNNJF
MDF0!,8P &>&CC9_9M]7J4Z4!-7<KS$_:7:=ZNQ>Q?CM)VD[%K5EWNU8%(:8
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M   "@=0P@4,$+U#T@ ?\P$%0H]:1RJ)*D,)%4CE,!LD4*(& #8P<OU5"")3
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M4BA(2#F276OVZ.YNZTDFX=K*+JHL9C=&W7"6BXTJBH^&S;+HM$2 4J:92E*
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JVPM;IHHP<V;;S:6@TJPN&*V/&9KS5;@(R25:*X#J3,J)#8U#_P"9&__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>gyowp0iggm03000004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gyowp0iggm03000004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %1 Q0# 2(  A$! Q$!_\0
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M7*>"?B!I/CV*]DTJ"]B6S=5?[5&J[MP)!&&/''?%=70 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!YU\0?^1^^'I_ZB$W
M_H KF?!OBO3?AQ?>)-$\5)=6E[/JTMW;R_9GD%TCA0NPJ#D\9Y_O>N:]KHH
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M[V<GYF &=P[=NM5;CX97-\=>EOO$)GNM9TV&RFF^Q!<.@ ,FT-CG&=HQCUH
M71OB;<WWB#2=/U/PQ=:3:ZQ \VGW<UPC>:$3>VY1]SCU.>1QS65IWQQL-0UJ
MT@&EJFF7ET+6"Z_M")IMQ;:&:W'SJI/<]JZ>Y\"+=:CX0NGU#Y?#L,D)C\C_
M (^=\:Q]=WR?=SWZUS.D?!C^P]8M)['6K)M/MKE9Q;W.AVTTQ4-N*_:"-X]
MW4=NE &QX<^)4GB/Q=<:/!H4D=I#-+ ;LW<;2*T>>9(1\Z*<8#'C) KOJ\^L
M/AI<0^.+;Q)J'B*2^^QM(UM$;*..0!P1MDF'S2  \9Z?GGT&@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M'4=GALM]HU";S9FR%/+8&0.@^E 'J>@_$BVU_,D?AOQ):6OV9KI;N\L1'"Z
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M7%#XM^!C'>2#7/ELR!.?LD_R9;:/X.>>.*>?BKX*#:<O]M<ZDH>T_P!%F_>
MR-'_ './G1ASCIGI0!V5%<6WQ9\$*]^AUO#6 )N1]EF_=_.(_P"YS\S <9Z^
ME#_%CP0D-C*VMX2_!-L?LLWSX<H?X./F!'.* .THHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0,J, YS)X1UO2?%?BO\ X2.;5].%W) UMI>EQW<;SQ09W-)(H.?,?:"5'W%
M!YSCT6B@ HHHH **** "BBB@ HHHH **** ,Z^AUJ2\B;3[^P@M0!YD=Q8O*
M['/.&$J <?[)_'I39/#NCRW_ -MDTZW:?# DK\K$NDA8K]TMNC0[B,@J.:TZ
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M3:WJ0N;W5+1;/S;:#R4MXER5"(68YWL6)+')QC H U;_ ,0_8?$MKH_V7?\
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MO!!!:QNDBWUEYXE9FW;QL>,J<EN,D8/3BM#PYH2>']-DM_M,EU<7$[W5U<2
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MP!!#=R,'-1:9X9O-)MK5+767$SWK7NIRM;*?MK.#N4#_ )9C.W&,D!0,GDT
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MT'P]<Z/]G@E.K/)8/:>8'CP(G+ ><WF -D;@-I.>>0#TFBBB@ HHHH ****
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MY##( SCG- M8;*Q\1+=Z'>W7A:>\C>VM[K3VEN)2W,TDD;KYL@WX(+AGP.X
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M>?D0!')/'.=HY')YQSJW<MSXPO/%D.E:HVGZ=I#VB1M9/'/=2-(LC".)PKG
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M1"IY9> 2>?8T =_13(95G@CF0.%D4,H="C $9Y5@"#[$ BGT %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %4Y]+L[G5+34I8=UY9I(D$F
MXC8LFW>,9P<[5ZCMQ5RB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MR69FY)))/X]A0!W=%<!X6TB/1OB;X@A6ZN[N233K266XNY?,DD<O,,GH ,
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M1110 4444 %%%% !1110 445GZSK%KH6G->W?F%=ZQQQ1+NDFD<A41!W9F(
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MD1;D@+JS)YC\!20C$+RV!G&.: .BHHHH **** "BBB@ HHHH **** "BBB@
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MS>1Y/EX_@QBO1_BC%)/\/-4ACLK2Z,L?E8N6P(R_RJZ_*V7#%<=/7(Q7844
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MFA_^"Z'_ .)KH** .?\ ^$$\'_\ 0J:'_P""Z'_XFC_A!/!__0J:'_X+H?\
MXFN@HH Y_P#X03P?_P!"IH?_ (+H?_B:/^$$\'_]"IH?_@NA_P#B:Z"B@#G_
M /A!/!__ $*FA_\ @NA_^)H_X03P?_T*FA_^"Z'_ .)KH** .?\ ^$$\'_\
M0J:'_P""Z'_XFC_A!/!__0J:'_X+H?\ XFN@HH Y_P#X03P?_P!"IH?_ (+H
M?_B:/^$$\'_]"IH?_@NA_P#B:Z"B@#G_ /A!/!__ $*FA_\ @NA_^)H_X03P
M?_T*FA_^"Z'_ .)KH** .?\ ^$$\'_\ 0J:'_P""Z'_XFC_A!/!__0J:'_X+
MH?\ XFN@HH Y_P#X03P?_P!"IH?_ (+H?_B:/^$$\'_]"IH?_@NA_P#B:Z"B
M@#G_ /A!/!__ $*FA_\ @NA_^)H_X03P?_T*FA_^"Z'_ .)KH** .?\ ^$$\
M'_\ 0J:'_P""Z'_XFC_A!/!__0J:'_X+H?\ XFN@HH Y_P#X03P?_P!"IH?_
M (+H?_B:/^$$\'_]"IH?_@NA_P#B:Z"B@#G_ /A!/!__ $*FA_\ @NA_^)H_
MX03P?_T*FA_^"Z'_ .)KH** .?\ ^$$\'_\ 0J:'_P""Z'_XFC_A!/!__0J:
M'_X+H?\ XFN@HH Y_P#X03P?_P!"IH?_ (+H?_B:/^$$\'_]"IH?_@NA_P#B
M:Z"B@#G_ /A!/!__ $*FA_\ @NA_^)H_X03P?_T*FA_^"Z'_ .)KH** .?\
M^$$\'_\ 0J:'_P""Z'_XFC_A!/!__0J:'_X+H?\ XFN@HH Y_P#X03P?_P!"
MIH?_ (+H?_B:/^$$\'_]"IH?_@NA_P#B:Z"B@#G_ /A!/!__ $*FA_\ @NA_
M^)H_X03P?_T*FA_^"Z'_ .)KH** .?\ ^$$\'_\ 0J:'_P""Z'_XFC_A!/!_
M_0J:'_X+H?\ XFN@HH Y_P#X03P?_P!"IH?_ (+H?_B:/^$$\'_]"IH?_@NA
M_P#B:Z"B@#G_ /A!/!__ $*FA_\ @NA_^)H_X03P?_T*FA_^"Z'_ .)KH**
M.?\ ^$$\'_\ 0J:'_P""Z'_XFC_A!/!__0J:'_X+H?\ XFN@HH Y_P#X03P?
M_P!"IH?_ (+H?_B:/^$$\'_]"IH?_@NA_P#B:Z"B@#G_ /A!/!__ $*FA_\
M@NA_^)H_X03P?_T*FA_^"Z'_ .)KH** .?\ ^$$\'_\ 0J:'_P""Z'_XFC_A
M!/!__0J:'_X+H?\ XFN@HH Y_P#X03P?_P!"IH?_ (+H?_B:/^$$\'_]"IH?
M_@NA_P#B:Z"B@#G_ /A!/!__ $*FA_\ @NA_^)H_X03P?_T*FA_^"Z'_ .)K
MH** .?\ ^$$\'_\ 0J:'_P""Z'_XFC_A!/!__0J:'_X+H?\ XFN@HH Y_P#X
M03P?_P!"IH?_ (+H?_B:/^$$\'_]"IH?_@NA_P#B:Z"B@#G_ /A!/!__ $*F
MA_\ @NA_^)H_X03P?_T*FA_^"Z'_ .)KH** .?\ ^$$\'_\ 0J:'_P""Z'_X
MFC_A!/!__0J:'_X+H?\ XFN@HH Y_P#X03P?_P!"IH?_ (+H?_B:/^$$\'_]
M"IH?_@NA_P#B:Z"B@#G_ /A!/!__ $*FA_\ @NA_^)H_X03P?_T*FA_^"Z'_
M .)KH** .?\ ^$$\'_\ 0J:'_P""Z'_XFN@HHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
+"BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>gyowp0iggm03000011.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gyowp0iggm03000011.jpg
M_]C_X  02D9)1@ ! 0$ L "P  #_[@ .061O8F4 9      !_^$3PD5X:68
M $U- "H    (  @!$@ #     0 !   !&@ %     0   &X!&P %     0
M '8!*  #     0 "   !,0 "    'P   'X!,@ "    %    )X!.P "
M$@   +*':0 $     0   ,0   #P + (K@ !    L BN  $  $%D;V)E(%!H
M;W1O<VAO<" R,2XR("A7:6YD;W=S*0  ,C R,CHP-#HR-R P.#HT.#HT,0!4
M:7)T:&%D978@06-H87)Y80   Z !  ,    !__\  * "  0    !   $0: #
M  0    !   "00         & 0,  P    $ !@   1H !0    $   $^ 1L
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M$0,1 #\ V**W7@P]K""![S U#WSN_P"MJ;\6UFV;&'<YK="=-Y !X_-W>_\
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M]NW8YM_M]+_"^MZOZNI7_L6O'TP;JK;J9I?:26;BT?K%/OKWU>H'_FW?H_\
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MZY;4'QN:YU7NCZ%GT'_1=OVO_KHZUX(TOQ:GIT!K3Z=4AQC]7MY]NK-O]?\
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M P,# P,# P,# P,# P/_P  1" )!!$$# 1$  A$! Q$!_\0 'P    8" P$
M            !P@&!00) PH" 0 +_\0 M1   @$#! $# P(# P,"!@EU 0(#
M!!$%$@8A!Q,B  @Q%$$R(Q4)44(6820S%U)Q@1ABD25#H;'P)C1R"AG!T34G
MX5,V@O&2HD14<T5&-T=C*%565QJRPM+B\F2#=).$9:.SP]/C*3AF\W4J.3I(
M24I865IG:&EJ=G=X>7J%AH>(B8J4E9:7F)F:I*6FIZBIJK2UMK>XN;K$Q<;'
MR,G*U-76U]C9VN3EYN?HZ>KT]?;W^/GZ_\0 'P$   8# 0$!
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M[?\ 5_J_;U[S7)N2./\ #_'ZD@@\G_;'WJM!PSU:E6.<==>4W;DD@"P(Y]1
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MR>/Z7]^+ 'AGK05F']&O^KAY?9U@!^GJ')'Y_%R>" 2.2??J#('5J\"3\_\
M5C'77E_J3>YL!;Z?46 )N;?X?[#GWNN> ZJ!C%2/M^7^KR_EUV1:Q%K$DVN?
MZD"][DD$?T!^OO7#[>M\2!IQ\NNE'^-KG2;D$ZA;_7Y!X]^\_EU[%*GC\O\
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MSJN.?4&Y()>XO[\. I_J_P G7B &.H_ZO\/72V !)YT_F]UN?KS<DV-N.?\
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MSI-R+G4%(_V_^W]ZIFGEULD$#U_U?ZO]6>)E^IN PN+"_-[#U?X<?\3[W7R
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M2#_B I-C?Z\>_ D\1UHT6O#AZ=<;6 M_0_FQ!^IL2/JQO_3Z^]]:TX%/\/\
MJX^N.LG^O]/]]]/=?7I_[>L?TXOS^+'Z<_UO;W[CU4#%!Q_U?ZJCK-YO\!_R
M2??M:^B]7JOJ?V?[/7__T+"1<'_@0  "#8-Z0>"!<@7]5_I]?>1>"?\ 5^?7
M)45&*?ZO]7^KCUXRFX(5[<L!I %KDCZ^GZC\_7WL''R_U?/K14@U_P!7^#UZ
M[\UB .#S]%/)/T%N00+W_P !_3WZHP?G_DZ]0YT\*>OSZB"4G^MK7 T@:KW)
M]1YL+?G_ &/O0(-<'JV@?EU[SGDW("_D:2=0!:UK!K D?X<?7WXGK06G78F:
MX!!'%K\#Z"QM<\<C_8D6_P ?>ZXX8_;UX+\O]7IUV9N;7(N3:P%BI  XN"./
MH./?M7EUX)2I]?V==^8DJ0&)(O\ 2XN+DD:OU _[[Z^_:AC'6RAJ*G'^K_5^
M>>N/F>Q'J8W)_3:QMS>][6/^W_WD:+4!X5Z\$K3&.N7F/-_TD FUCS?\WX-^
M!;_>OQX&F/+KQ6O ?ZO]7^K'4<"VL7)_-[V)!(/Z>1Q;@C_#CGWKU/EU>E/F
M>N GX/II;$ $V/!_%P1>RD#_ %C[W49]>J: U.XZ?]7^KY9Z]Y](*LK,+ 7]
M)%_3<"Q%_I]../?JU-*=;*T K7Y=1Q-8:M)6Q/'!YM8+<?0'_8_Z_O5<T_U?
MX>MZ3DD8'^JG^K/78'-CSJ%@?Z#D6])_(_V%O];WJG[/3K9IFHSZ^?7K&UQP
M3?\ 3<\W4DCBX']?]M[]CB*8ZUF@/D<?ZA3'7$SFP-R!SPQ%@2/J0;D&W^/)
M][P.'7J,06(P/]7[?\/7C,YU#CC@^E0;"X"7X(-QR;^]]5-?/_5_E_9U'\MB
M;&UR?Z!C];BP]1L.?Z_\1K'D.WJU&J#6K?ZO]7D>NSR02>'_ #:U@>!:Y'TM
M;Z_0V]Z(]./5LUJ6[?\ B_\ 5G[.HXE_3<6()-P/R.3_ &C8$<<'Z^]^O6N%
M *5'7(#B]P>2;_1N--_S:X_WKW[@2*=;H2JFIX_L_P!7\NN/F_PY)(/Y%^&/
MT(L.;_U_V/OW'R'5!04IC/\ JX?[/7+Z\_["X^O'-_Z V_U_]?WK/3@I0@^G
M[<?ZO]6.N/DO<_@GFUN0;<$_\%_P_P"-;^5!U3RK6G^7KKS6!X/ M8+^;_@<
MWY/X/^/O=?D.M$4I4X_U?*O^KTZY"9C8&_YY9;FQ/T+ 6!:Y_)Y]Z]<#JX!.
M*\0?,XKUQ$P-@H(^A:PL!SP?K]>/>ZU^SJE*X"YZ[\O /)'Y(YN+W^I-RO)O
M_L?>O6G5B* 4'YC_ %8ZY6  _!^HO?DV%^+BVJ_(^@'OP]/+KQQGS_U?X?MZ
MBM+_ +'41_J?R+ V)N1_3_#WZO&HZU3X<Y_U?ZL==B7CBXO?4#:Q(N+?1[<_
M[;WXGKP&:^?^KTZD?0"WX "_@ ?3@6YT_P"-K>_?;UO@#2M*X_+J#:_('Y((
M_P!B#:_)()_'Y_U^??O2O6\$DC@/\O[?V?Y>N TW_P!C87L !J!&DJ >"/Z?
M[W[\> _U?+JH.21]GR]<>?S_ .+ZXB4@D_0_4$6!L2?Z$"QOS]1_L;>[ 5-:
M#JM:#CC_ (O_ %>?^>8.>"#_ $/UN1<VU&_]?]>]_=3T[2M#Q_S?ZO/Y]1O*
M2?J1J(]/!%A=B?S>X)O8^[>7E3IO.K@=77O,;DW/]+7 )M;^H5;:OK_K_P"O
M[UP\L'K8()^8^?\ G^W/77E#7O<ZK\7MR!Q^2-1N;\G_ 'KWH5I7KU5)/K_J
M_P /Y]=^=A8L3_K"WTX-S>WT^I][-":4%>M L "2:?S_ -7^JE.O>4K]?H0?
MQ]+G\"XN3?\ Q]^-/(9ZV*BI/G_J^77 +8W-R; $#3;A;B_JYN?S];@^V#D$
M_P"K_+_Q76Z:3Q-:?ZO3KWFG!-[7/UY!(/U)X6X _P"(][T_/'5=5" ?\M>'
MV?ZL=<_,;LPGX*DA;  ?T%OR"/R/]C[K0GK9:C%A7A_J_P!7[:=1C+<?J/TL
M!SR/P-/TY'T_%Q^/=J_(^?6BOG7T_P!7^K'E3KWDY'# BUK+<JMR1SJX4<?T
MM[U4<,];H<8S^77C*221R ME^J_[?@"UQ_QOWO5Z#KQXG_5_J/Y]=K*;7!/"
M@K>X7Z_BS#^O/^'OU:4KD=:%:,!4&G^K_5\NL F L;@&Y'-^/Z67@\@<#_D?
MO5>..M@$<!UT)18+Z=):QX/U-OIRUO\ 6_U_?CQ^77E&*4\_]7SZ[!L38@_0
M7O8"QX'XN>3];V/O=#^0ZWZ]V>O#_"PY-[$6 %_ISSIMS^?I[UZ=>_/_ %<.
MN+ GFU_4+'Z *2;$6(Y_V'/^M[\.!'6B*FI'^;KK_ V-K?VKD@W /!_(L+_[
MQ[L:>8Z4*2!V\/3C_J\L_+KEYA<W :Q(^A'U:Q#<7L+?G_BGOU?3JA4GRKF@
M_GZ?\5UWYA>P'#"]C< V '%KL;#\7]ZR<_+IK@=/EUX@>F_(8AN.3<CCZ\VY
M_/T]ZZW04%?M_P!7^3CUCYYU6XXY'YM<VN";W'U]V]37IX'@*=W^K_#_ *CU
MB\ZB_ Y^H)L2>0"0#;Z'_'_BNA4TIQZ\2 #J.!]G^Q^SKOS @Z2 ?Q^!^/I8
M6'"V']/>JXX=,!:$@?X?]7V=<A-< 7Y (Y/-C]001]5O_A[W6GEGJH#'-#Q^
M7^Q\NNE_/(^I-K_U/'(O8!O]Z_U_=?\ !TX*#[?]7^K_ &>N^?Z_6UM0%OI>
MUK_3^EOI[V!\L]>/S./LZBFHYX M;_$6Y)N5/TL 3[WBF.JT:HQ7\_\ B_\
M5\^N_,>#QQQ<?FWYYX%[_P"\?CWJHK6F>O,",>=?E_EZ[$M[\:3SZK&XN ?R
M!] ?]?\ WOWZM,GCUZE:4%/]7^S_ )NNA]+FP-@+_2Q_K;D\\CWKC@'J^ 2Q
M'^K_ "^G7C<@?I)'/'*W)N;^]4_9UO56F16G^K_5CAUZY_!/Y-[$_DFWXO\
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MUI_2I^=>N0E;@WY%]('/ULIY*H+"PXM[T1 &*/J##T _Z"Z?\%$)J17T-?\
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MD!O;_@UKZ1>Y-QI%PQ)_'O1MUI2N.O1^ Q)!-3QQCS_SY%.L)E!^CJ;"]]1
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MU>K>OKUQ+@%Q92 ;,?H+\<#BUU/MPPR8R.O!T.HC X?ZOGQ_U'KAP0+!EYN
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M_P O\O7K\V-^ #?_  O];->Q! _U_?NMC)H?]7[<_P"JO71E'TMR02;@'@6
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MF/D7TVN!?VQ%>&H4'LZ3W_+EQ"KR^&=7J=7D13R^?7"6LIJ6CI8JFKHH*H5
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M;I*C K_J^?6AM2$4*U4_,]8XZZFF@D\#T<K25.JI$,DE5"K B_C0*DE)$/\
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MUK:0 ?\ 4.F'VN]MB=7 ')-?/RX=9$\;QB;R:B" )Y !1K;Z!#QJ(!XO:_\
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M@XY'-OI?U6N?K8?@_7_#WZI]/]7[>MBHXL?]7^;_ %#AUUY0+\"_Y N3S?2
M3R+$^_9H/7K5#FO^K_/^?7+RC_'@$  6%N/U6' ^G'^/OU30$CKU,T4_ZO\
M4?MZZMQZ3^;$&UKCT_X_4C_7X_UO?O2HZV:G@WG_ *O\'^3KWE4VXN;@WOP
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MH?XW54^Z:JF6>M62'-F&&EF,L);T0OI'-@+?[%;S%/<0:&AF92 IH/.JU/\
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M[6_KPE2YW:YFFCCN2(HR!4+Y^E<Y^1'4US\N\I<F<N6.X[ALZ/=R1EBSN:4
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MGT+_ $)X]RE"T1L3(1WT:F1UB+8R;E<;VEM<.#"63&BG$BN:>?5JM?U_U/\
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M?7NT4^8_U#_53^77?W!%K  BX4-Q?E@3^D #@?D?[ ^_5&<=;H*@@^0_U?\
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M3[J.&!7KQI6O^K_5_J^?4;S$#FH(!(%M) -OS_:U$6_UA_K>_5).#GIVBK3
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M(!!-[V:RGZ_GZ<>]DGCZ=5H.T!:^?S ]:U_S\.N;3V4FRC@AKA03P?3;@ @
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MJA(*FCR E"&*IAJT56-S5)(%HXFXT2J:DK^18^Y/@9ELR"<Z3UAI8R6_[]!
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M''F.C5?S3,[C:CO3;&VZ&>G2KPFSJF').SAI\9/4UE5D8A+$NI?\IIZI&6[
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MYY8?J/\ MK_3WOCUKX:U-/\ +^W'^SY"G7A,2%///U!MS9B&L#I(NWT'TO\
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M]Z^OOWGFE?\ 5^S_ %<>MU% H';_ *L?,=>^X-[%0">391J0,#JU GFQ%O\
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M31Y:HW'4U\=110T])54VK&K3TDL9<_<7]94W%_Z^SOFC;6W>.T^E4LZ."14
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MS:WT) 'TX-C[]BE#7K0!J*"I]?\ +_J^P]<ONU'(-B"!^+:K\F_]1_K'W[%
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MM^S_ %#KFM6  H#<CA!]/R/KJL;K?_6]^Q6N>/7BK4*AL4P.N/WB_G5<V^@
M %OZW-^?][]^KQ/5=!HM7KUW]VGXU?FWI7Z&W^U6Y/TY_/O9<>0/51!0FK8^
MW_5QKUT:T?2S6YOQ>_'XY%[7]ZKQ.>KE?*N!7\R?3KHU2:A];D_4B[<<\7X)
M _WCW[4?,&G6S&-2Y%0>N)J$-[:Q<D\+>VK_ &W-C_A[]J^76R".!Q_J\_\
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MM0+?F[:0"5('^\#W7(\JCKW:Q/D?YBOG^5?GDTQYR/.@LI]9!)NP/]01SR
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M-C]O'C^W\L_GU$60_7TJ5(TK8W%CJUDA5;Z?DW^GT]V,7'S7_5\_\'5 EL:
MX/YYSQP!\AY_9QK),S\LI&G2>+AN?KROT^JV!! _V(]Z\.IH1G_5_JIU;1;:
M2X)TGCQ^W_50C../43S$0'5<:6*^E2/58WN%L%!5?J/H![\8@3CCUX"!:$G
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M7_J.+^[>&*G^'_5\_P#5^SJH6W733XCYY\OG_FQ_/KOS7NOTX%_00; &Y]/
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M&]P>D@<]:;K!%[W!']WBIO\ B_/^Q]V&XFOQ8ZT?;>^(S;R5']'_ *'ZP_Z
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MQ%?R_P W6E]MMR H;>6G^E/_ $'_ *OLZBK\?/D#87Z([?)(_'6F[OK?Z6.
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MP!+P.;W^G)/O77J=9/X3C_\ E64< "S.+ 6(M9@?J/\ 7][KUZGSZZ_A&/\
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M(!75<@\\J /KQ_L/>_SZW7KUE^K6M;\$E0+C_!N #?\ K_L/>NM>G7?UL.+
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M.1[V012H(ZTI5OA8'[.GO[[_ )M?\G_](>ZUZM3KWWW_ #:_Y/\ ^D/?J]>
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M)^Y2I-!9A'J!#_I*_P"M[]4'SZ]UPT@@<^HD$L">% 'T++PQ_)_P]^!4>?\
MAZU7]G6)B5U&.-IX8EGDJ)81&RTJP!6D%2K.DJ,58$:5:]_?K@BV@2YD/Z;
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M]1_7\6YL+6L2/Z^]UQCAUK2"1J^('KOGZ^D6 8#DGD\FW]>/?N%>O>0 \O\
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M:KTTTM72HZQE;D^36#^GAZXYC@A0N\@I]N?R J3TGM.79[B3PDC[C^0I\R:
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M6)CS1;/;/X-@$6X"U(I2M1BA(I7^6<GC1%=1Z6E2%7+#^F0*TX9/S^SHZ?\
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M=E;IR^*J&BBG6#(XW!U]90S-#4*]/,(JF%6*.&1K68$7'M,Y*H[>@/\ @Z5
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MF51D_P"K_+T!O1GS2^)OR9R.6PW0/R&ZH[9S&#=TRF(V7N_%97*4QC$C2/\
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M>'6AY]*7W[K?7O?NO=>]^Z]T'F=YRTVJY 2+\@?5% L";  VN;?Z_OQX]>'
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MH\I)@.RMY=@]_;2V5D9LW%0FAW+D=H8*GI\8E3%2Q?W;#RU7A$C-((3/Y=8
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MN%PRJT569!D *!4"IIQ+!.%:KBM>JR,BAT5:M4*I-2<U'^"A.?MZV9P H"J
M    .  !8 "UA8#V'S4DD\>G    !0#KOW[K?7O>NO=>_P!]^?\ ?<>]]>Z]
M_OO]<_\ $^_=>Z]_OO\ ??Z_O7^#K73W%_FHO^6:?]"CW;K72<W>!_=+=_\
MCM[-D_\ GGF'YO\ T]^/ ?9UH<3TI_?NM]>]^Z]U[W[KW0=9M@<M5VM_FX0?
MJ2;1 ?D<&Z?[S_3WZF?RZ]7'Y],G%Q*>/P;!;\V N>&N+_[S?_#WKY^75OEY
M]<!8<"UK6U&W/ /TN+<G_"WO76^N7!N=9!OQ]6YM< $6/#?3_"_OW6O3KL?7
M@W( ']JZW]/I/ (L3Q_C]/>^O?*G73?1F)Y.D_D<$DW8 >GB]N?Q[]7KW @=
M=VMZOH?K9OI=N3I-Q>P'^N?>NO=>U:B3^;_4\\6X.D6-A?\ Q^O^L??NO<,#
MAU6I_-^B)_EP_*?QBG8_W%BC=C3,U1!Y<C!H*529"!8;!;C7$5%_S["VZG_=
ME!5<ZU_+M_U?Y.C;;Q^G."V-!\^.?]6/+HI?_"><(G\L+:4<-3'4Q+N;L:.5
M9JIGGDB.H3RS-YY1)$&].A*,@G^T?Q(7,NIMAVX4.8$SY<?]*?\ CPKZ>?07
MY:H-_OM5*B9R,5^SS'^QG/D:+?Y8/POVE\U?EO\ /#IS>^]^QNL^NZRLSN4W
MC0]3U6-VUD]URP]AUZ87"Y7<M?A<]!386GK*TU+TS4TRUC'Q-X;^12C;4U\K
MJ#Z/_AZ.MU(/,Y-,U3_ >LW\N;XF9;L#YJ_*?^7#_I][AV5\9\#E<]6;MQ>Q
M,RVW]U;JCV7EY<=AZ#%FLERFW=HR5"3N]?/34]7'D&]<J*Q]F=A$#M%[*X!E
M,A\OXES]G'[.'19N0"[K:J/A5!C[&_U?/H?OY;&QF^"_\\+?_P /.KMX[KK.
MHWI\C@*O%YR<Q4V;AR&"GR=#7U\=%-0XK*[BQY*I]W'1TQ55]*6 'M-RU;+-
MLN_M-1I8X$TFG#2P5:?D /GFO'I1S2YAW;8S$2JM*Q(]=2DFN3Q)K\L4I3H'
M^O\ H+$?([^>7\H.IZ[>.ZNML1NA^U%WUF^JIX<?NS-;2H9=B4E5M_";F:D+
MX9\S55*QS>2F=&2F(?4H4%)RF2+/>B!4ZY\>M5'G3_5Z=7YL_P!R=E!H!H@_
M+N/^;/2>ZG^'E7TA_-V[%_EU=*=]=K]<]/=C"IVCO/<6,R%)#O/-; S&-.4R
M&-:MHIZ3&0[NX\-/F!C@R&Q\6D6]WY:!.W;RLA#,D: &@&%( I\Z "O']O37
M,;B2^V:55TB1V8BM?B!)!/G4FO\ Q72EJNA,3_+"_G4=!]3]#[Z[ EV+ORNV
MMD-PT^ZZRDSN=W!A-ZON/&5N!W94TB;6I=Y+#F<<U2:FHITD<2:F+L3?W*\7
MUEINZKFDT_\ (#[/7_57IKFMM5YLK$ 'P;?AP^)AQXY_EZ^IB.Q*.A;_ (4^
M=?3/#CX:QMUT$UWHZ 5DJT6WI5IYZ:O4TLD\L:S-^UXZB:/61S]?=MEG2-MZ
M@7!*T ^T"O\ @'1EO-39;*36F?\ CQ^WJ5_.FH:"I_FR_ ZHK\9CYZH1=8M]
MSD*2KFE2>;L2%Z>=WFK8(EJ*@)$MRI $G,:Z6]IMHM]%]?'32OB'_C7VGIJY
MSM%O3(\5/^.CI"?SO-M3;E_G&?&+%X[)5FV=RYK:O5^)Q^[*&DH*BNV_79'*
MTM+_ !G"15U%44M5FJ*ZF&I>)XJ5U5]!=%LUL[>%S9( <%P#_O(/^0'U]?/I
MO=^[E="0"=!I_O1]/+/02_S.OA3M'^5_\L/BOVU\>NSNV\MO3M3?.6S.[=U]
MD;JQ^0W!E<W0[HVR<_0Y7=&+PF"?*X'+)6S,U'-2Q1Q2O%X]2JS*FOKAFYMM
MR>!CC_87_/R.?LZ60]O*<"F@I>D&E>(45I45XC[?\IG_ .<_W;V+\B_ES\2/
M@I!O?<77W5>]</U1FNQY-L9?)8O^/Y7M2@QU54"JKH'I%JZ3'T58S1LLDL(9
M;21N"8R>1;;#)S-:L4[0\H''RK\QGK4))0D@5X_X>B\?S#?AOMG^27V9\8N\
M?A?VGVIA3N?=AH-Y;:W'N? 1'<_\&JJ59*.IH=K[5V-@8,+5TDDA:6;%S/,T
MITS,[-<HCOI(]_NK4']%[8+Y8#.?E7S]?L/1?<]E6],_LKT93^=1V%EMQ?)3
MX(;P^2E3N_#_ ,O[?6V]AUW8\V R>4I]@/E-R4^'R>Y,9N!,*$;+-04M5,_V
MS2QU,L:72-O:RXL8HR"%R,>?V5X^?6[6[<BFNO[/2M/^+Z*1O#%?#7-?S&/A
ME-_)&HMQX^FQ&Z(,?W-G.K,7W/M[9E/1X_.3N)\OD.T*6AR5?0OAI \L\L\N
M'JD)-/-*RN MMD6,4*]I'S.#_/K<Y:1:XU5QP'#^70A_SE_D)5=U?S*<)\4^
MVMP=Z+\9NNL=@9MS=>_'O;DV[=V[\J=P0SUNX:^@VBV7H*?-VI*><>=X:VDT
M2 _;:0?89O2#?W H=.HX_(>ORZ,2M+"W\R4'^'Y>5>BD[1RF$^)WRYZ [&_E
MN=6_S%,%UI+N'!4'<NR^_NE<_MZGSAR.:>GKE;!;&VM3[8W!A_M)4D\[P4#4
MZ+H_<TEO8O)/[KF]0&^?GY^G15:*#+\.#3_B_P#5_/HZO\W?;<V__P"=%\3<
M5C,I/M/-[QH.H*6BW1145"<UM2KR>X<$M'D,6E?395<?EJ"6O:*#R4Z&.[>1
M;CV0\FKJW#<65@1XK' _X6?3AQZ67DA^ILXR**8CQ^1/'UZ"+^95\+]J?RK/
ME+\2N[?CCVGVUF]W]C;SHZS>6X^S-TTV4W!ELUC]TT^'S\U3GL)B,%2FBRM+
M60014/ATP^ V9@1[,.4+ES=;S;%OTA"IH1BK$U\O11Q].F=SAKH;SK_D'SZ,
M-_."=\[_ #AO@#524U-+69K;?6&;FAK%2N2*M_O+@YX&EIW1/30-6R_O:U6.
M.5[,-3#VURXNG>=U ;M,KX_VA\OD#^SAU3<S_P A]L L)(\G-,CS_*IZ<OYJ
MV\]Z_,G^:_U!_+XR>^MT[,Z*QM1M' Y?"8+-Y3")GI-W8F/<NY<[DJ@3T,V9
MKJFCK(*6CII/O:,)3V920+E5T?\ =DH& "O^ =&]H/\ =<[<:JQ_83U8U\:?
MY**_#/Y?[5[I^,GR3[+VKT9!05-!O7J[?&*I-U5O8&=G'DKZ/<-7AY]@[1QN
M*GA-UJ*C$9'(L;7<MR1*[ZH5#MW8)SZ^?^?H-@GQI&45X_M].CU_S294_P"&
M]OE>P8)KZMJF1)&\; -E,(%+K-I:(V(Y<+]?I[!V\4\8>I/^0=#'EH_K<MT_
MWZW^7K58_EE]]?SB.M/C)2;7^#GQ8V?VQTDN\=RU,&\,SAL)F:Q-Q"*@FR5)
M]KG.U]HU"*&=?W$IS&RM=;^Q39!19QD_%I]?Z(K_ ).@G<"D6[:<G]Z-\_Q'
M_57RZV'-F=6?(#Y[_ /L7K[^9=UC+T7V!NC^(Q97:?7<F$Q51'@=MPU.:P5?
M205&5[$Q:U-54T[>6]1H\;$>-20?87YU>2#9MKGB>DBF0UQ4,*'\_+[/GTNL
MRC[U?(R@J64'T(9:?ZCUKK?R.OY?7Q\^4/>?=F=WY+NK'UOQ:[$VWDNK:;9V
M3PN'QM?]YN'>4%5!N#'97;F<\U&$P4,QBIOMY?NI)I6D*R*BC5;^1N5%U,2S
M,*GU/A?9T6;V@EW*#_:T^P,?\G2<[I_EO?'*H_G28;X,+4[ZI>G.WLQ)N;=-
M>VX<#!O[^/;DAER^4I<1F8=J':L%"D[_ .3PU.%JYE2R^93S[)N47U6&_P#<
M1I5/GZ?9T(=\B_Q#E[MK4/C\V_9PZ%'^;CV#C>K.]/C9_+FQ^Z.Y<#\2.C^O
MMEQ;AP/7^/7>/9F^L1F:G<E37"LPN.@V/2[FR5+AXJFG\?VRTEI=11M);V@M
MZF_<5%=1_P"/5X])(5"Q@_A) _:0!7Y9S\OY%+2HV)\6?D!\?NY/Y6W7O\Q_
M:^.I,I15/:&&[ZZ0R>%H,Y2U%=%$OV=+UQ@UPV3Q\V.<".#)12:4-_*WU]GX
M4M<PJX&:_/IFX0J6K2H/E7JRK^:]V;V!\POYC'QN^"?]]=V==]0;EVIUE4;Q
MVO@:ZJQ4F0RG9V-R.[MQ09P2TDM7'D,=A,744CK-3S1PM,?*I0,/88G/^[$
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M]^_+K?78 /U8AK:FYX/J!!/U!X-_S[]U[_!UXBP)!/JY'YYN;,#?4#_3Z_\
M$^_'[>O==7-R"1?TV_H#QP#86U'C_7_V_O77NN(6Q)/%[WY/T%OH%/X_WCW[
MK?2OVC8BO(!%I$ N;W!:0_6WT6UOJ?=AP/I7JA^(#Y=+/W[KW7O?NO=>]^Z]
MU__0W^/?NO=>]^Z]U5M_.+/_ &+Q^1'/^[.K01S?_F<O5)M]#]!^?\?9YRY_
MR4+6C>3?X'Z#O,G_ "3Y\>8_PIUH_#^HN;@CZ7N.>+_B]_\ 6-O<S$U1?]7G
MU!,X_68'-/\ -UV#] +_ )U&_IYOS_L/=D^$])R148/^3KKBQ(-P3I-S_0#^
ME[?3VYCUZ]\SUVHU A1^/3_K6Y%C^>;#_7]Z/K7K0&"!_J\^N#-INO!O8 \F
MWT%_I>UO\/Q[]3UX]6^P8ZPG2+WX-N#_ +'_ &/]?I_7WIOA;TIUK H*^?7
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M5+7+72T )I))&JU"C@E;D$>P7S'L5]<L'@*\:FK?(\/V]23RMO\ 96R$3!J
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M#QDZ"7*O]OD8K: 03<?@^PORU:/8Q;K;T&J21OLKH"_LQU>;?897M_"#B-$
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MP&X&S-/%34E$VXFQY3S8^:699;0P+>WU[,&J+4A:?Q DY^SB3]@Z1R1^)(J
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MLP5;7]G0\(21D$Z:FO' \NDLXC\-C4:]1P,B@/;3\O+R/2E_FF_RS_D+V?\
M(WK'Y[?!NIP$?>?6^/Q+979&XJ]:.?=#;2J9LCM:?'><B&JRT\=56P543DK/
M _C*E6M[#TZ,;X,%)%1_Q[_8K^SK43=I#,,\/]7^K/29^-?77\\#Y,?)_K/N
MWY<;GH/A_P!1]5"3%YS8VQ#1TU;V;C9)%K*O!U6!IB(:K'9BK=P]1(9FIP05
M>UE E;PS;T5@6(SZU_U<.B^Y5B(2I(<KW4' GB!QQ\^/KTU?S</@9\T-^_+?
MI#YP?#WK_;W:V<ZKQ^WZ%=@Y"NIJ:MH,IMC<=/E<%65%%4R1QY"B+Z_(WJU1
M+<^RCE4F"&[\4:*F0#5C!88_96GKT8;JM3;*N?@K3-,9/Y?/SQTM/YA?57\T
M[Y3?R[/C_)LS:>0V=\FZS<=!N#Y'=7=?9H;7RM35>&*GPB4DT,T$<F+V\R"1
MT7C4VHBYN/7$9_>2%*F$$YXCR\_V]>32(90#BN,4)&?V>6*]7&_$3:O;&Q?B
M]T'LWOG+29ON3;'6N#Q/9&3J*LUE54;EIQ.9EK*UG?[JNIJ=HHY) 3J:._/L
MVW!D>Y+Q_ 56GY"AI^=3_/I+ "$*MQU'_/T8FX/U!"FS*0>1:YM?\GCZW%_:
M+SZ?S3'76DW!M:Q(5K$7' M]!R/K;@'GWJG7OMX]=7XMQ>^D*W/ %@"+7-N;
M7_'(][_/KU/EUZVH@B]K7OR>6!51?20;L.;?D^]<?LZ]7KD "MQ8-] 0; 7!
MMSJX+'_;\>_>77O\'7M)*W4"P(-CJM].;D-P!R 3_3Z^_=>K^WI6[2Y^^L;A
M74'T@ DL]K-S] O]?S^?=APZJWQ#[.EG[]U[KWOW7NO>_=>Z_]'?X]^Z]U[W
M[KW56O\ .)N?Y>'R(Y /EZNM<<G_ (S)U0?3:Q^O^!L?];V;\MBMY;?8W^!^
M@[S-C;IC\Q_QY.M'_@@<'Z<D@W-S<:OI;AO]MR/<QC@A'K_EZ@B2@=O3_8_U
M?D>NCI4%VL%'ZB2-*'^C&UP/Z>U<=::?/I,2NH$D4/7,J55B1I54$A/.D)<6
M<D_102+$\>W=#U^ ];#*5^(4/SZZCE2_^<4GD AEL"#:Q^@O]?\ ;^Z4/D#U
M92&)535@.H\C+<LK#^K$_0_F_P"KBP'XM[TI5B0"#\N/6W#*M64K\SCKBQL0
M";EQZ;<%A:_'T)X%Q]?>ICX:,T@TX\\=>A220@1JS_Z7/^#Y_;U$,C$.P#63
M2S,+E55CZ6:UK!K<7_U_;5NK29B0LM/+/7F!64P.*35^$_%]A''''J3==(/'
MI]1(_L_4 @W(/(]K(\-I)[OGULJ4=4E!5_0\<\/GGKLD#DF_'ZB OU^I !^O
M]"/K[HV':IQ7JKJU2@3/V=8F(O\ 6X L3>XXN;_XD7_P'NH(8BC5/7F5U!K&
M:?,?ZO\ BAUP-K\C\6(X%R.03^2?=) 5*@CB.M :JZ?6G^K&.NK@'DV)!'Y_
M/('^P(_'NNAOX#7[.M5R*M\O]7Y]8YR51N ;<  _FWX')U#\^TMS<O90M.JG
M4"!3B<_(XZ>BMA<L(V-%(X\!CYCJ&'<_6]K:6N#_ $)(-K_BW/U]F%I>M.FN
M1"HIZ #K3V\,+%$FC+5X5J>NR1>X%B5L!^ 0 "!^H?C\^TMX5D;1$I<US3/^
M#JT;,H#2,%6GV==KJ)(_-N/I^1R#8#GBWLQ@TQQ_3#"$'^?'/'I\7,_$J?3A
M_J\O]7EUW:U_H6'UN;BP YL!^?\ B?97':)'N(J?TR2:^7'KPGE)-%-:^G7K
MAAI!!?2#I'+A> S,I]5@/]A[,]YMK:'<)8K*996HN$8MQ'V^O^;JT$TKSE60
MA !DBGGPKQ_S=8HW 4FZ@?U+6O?CTD@CZ\>TXMU,5+D:&IP;M\O\^/Y=4O;L
MP$^$V?\ 9/7=T6P+ ,]]//#A3R%Y_ ^O)]E,'UEC/<.EI*8F  (4D?/)'7HU
M2^B EE4%17)I7]A_/KJ<%4!L%N[ 7%B6C)64"_%T86;GZCVL6]G8GQ+=P?F*
M?9T7RVHC?MD0CY?ZN'4,7/U_J?\ ;$\7) ^O]?:ZVG0SPEL=PJ3CHVAC"6SZ
MY5I2O^KA^?7OR >%O=A^2%*G\ 6L!Q[*MPA66\UIW"IR/],>DD5Q(DIC7^S)
M].NC<-ZOIP+$_2QM>X _K[,KC2MGH4YH?GTNO73P =8+4..NOJ&8$,C-I+ 7
M%^=0N#S;Z_7Z^TL;:U0 U8#I(.U5+X1@#_J_+KB+.GE0AHP=)D3U1*5LI&H>
MD6(^G%O;K1R*"60@?/JNM#IHX+GTX?SZCR>IE"D/;@LMK@L/\+@7'X]T#*5)
MKV_ZL=7.I2%)'[/7T_XKSZZC5WU(@+,X"@@?D!C]+$WTJ3]/H/=U4R5\-2PK
MY9_P=:-0 !_Q?^K_ %'J*"H5M/[H"K,TB>M4B)*"1C<CQ,Q(!^A(/MIU/]F%
M_4]/.G5-:T ##Y_[.>'7K6"DHVAB0C6_60 2JG_5#BX]I/$2M/$75_/JX35&
M94C)MZ5U#X0.%2> SY^O7 W TGC@BP-OQ]0/Q;W=NVA..M(*IX@4F*O'\-?3
M[>L)&D^HZ>2>3_07'U _!]ZQFG2OR!.#^7^KAUX$&Q_2!S_MK >K3]?>\5H.
MM @UQ0C_ %4ZZC82RB&)A))_QS2S2:>"2R<FP%OJ/>L=756TT530\,</^*/^
MK'6)K%W Y*\,"1>X'J!_ (_(X][\SUX*:80U^8_U?Y.HL^GT<WMJ O>WT%^1
MQ?GVT?[2.HQG^8Z>C%(IJ_+_ %?Y.K0_Y,2@_P RWXX@^GCM\G@'G_0)VMR+
M?X?GV2\X#_%_]7JG0@Y+_P!RQY?]$O\ YNM^CW%/4R=>]^Z]U[W[KW28VI_Q
MYFV_K_Q[.(^M_P#G5T_]??NO#_+U(]ZZM_@Z][]U[KWOW7CGKWOW7OLZ][UU
M[\NO>]]>Z][]UKKWOW6^O>_=:QU[_>O?NM]>]^Z]7KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=:Z]_OO]]^/?NM]>]^ZUU[W[KW7O?NM\>O?T
M_P!]_A[]U[KW^WX_WW_$^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7J=>]^Z]U
M[W[KW7O?NO=>_P"1>]=>Z]]?]]_R/WOKW3W%_FH_^6:?]"CWOJIZ8-X_\>CN
MFW_/.YK\D<?PVIOR.?I[]Z]>X\.E'[]U[KWOW7NO>_=>Z#S.6.5G4'ZK&2?Z
M>@7^O'U-O>SQ_+K0^'\^F MQP!<CDM]5(^AU-<V/T!_Q]TZO3KDK"^KD'FXX
M/!T@W^E["W]1;W[YCKU/+K* +6!(%R3P21]3S8@"Q''NWEU7@>L/ZN3ZAR+_
M $%QPIL;DFW-OZ>Z]6ZZ!*VM^FWJ_!)T_3\7_P!:W^\^_=;ZY7Y]-^;*!J%@
M;6LP/(/(M8C_  _I[WUKRZXW87!T_G\D_3ZD,23>_P#C[LA"L"1CJR@U!'7N
M""+<W!^EQS8:BI(M_K_3_'W:642.64FE!UYQW5'784#D ?D-;2. &L38 M_Q
M-OI[;!IU4Y%.NOU"XO8(+_JX "C_ &HD#W[)SUM3HJ!3/7(6!OIL  %%A<$G
MG^T0/I[]PSZ=>J37KC^T2%5!JO9>+6MR2W]!S[]75GB>FR0K+4\>NSQS_J?I
MZ?H.;:2!P>2!_B??CG!Z=",!J QUP/%P1SZK&Y_/(M<D<W^OOV2<YZTN0=/E
MQZR'U7M<$ CFVJW#68V(-]/_ !7WYCKH&-3\^J!U!(#9IUP!4?Z^HL!]2/Z<
M7'(_V_O06@H!CIW2W&G'KO3<#\W! 6QL/KZ02+"Y/U][)]>J&@J:==7N;L+D
MW8FQ^MB!<\MJN+>_>07RZTO?4I\NN1(-N/J"5-KG\@?FU[_TMQ[]Y4/#K;8J
M2>NEM8K;T7MR.!8^JZ\7 _)][U,!0,:=5!5N!Z\?VQ>ZJ3<7:+R)SP5:,LFI
M"Q^A(N/R![;D76CIZ@]7'$&GGU4]\I/Y6N)[L[U?Y9=#_(KM#XE?)ZJPU)MO
M,]C]>4&#W5B=P86BTT]-2Y/:^Y8XX"B8]WCT^5E4DV-O:6VL/#RI!(_S4ZO)
M(#@J,G_9Z S+_P F_M#NJ7%X7YI_S%.]OE=U?A-PT.Y\?U?DMA;(ZUPD^2H*
M@20)DZW UF9J*ZG$9TE3&!:_]?9U!>&W![<_X>DLD6NM*4ZN\VUM[ [,VSM_
M:&U<338?;NU\+0X# XFG8-3X[%8V+Q4U+"XB@+J@Y)"+R?H/:-YQ+)))JJ2<
M].*F@*IZ=U50.0BD7N%!/U-_RMR+CZ?CW34OKGJWF>N3$<D@$LH^MK6L;>JP
M-A?_  ][U:ADU/5E1FKI'#CUQX)NWJ/UO?@7"C4201>W%_\ #WNI\^M$:>..
MNQ9FU 7)M8V4D:2/\.#<CW21?$72?]6>J*X;X&X=>-UX()_(! *_4W(O< $W
M]J(I6B% 3U;M.<=<@-/J%A]+V^O/I%C<W!'M/,OBD'YUZW7B!PZ\M@>?U"]K
M$C20#?GZ\@<WY]WK3SZJ17'7'0@'  )_ '!M8WN;W%[<CZ?[WKK?G7KK2.%
MY/ ( !XX/(OIL?>P2*4X];_/'7=U .FXL;W '-PPL#^3Q^?K_MO?O\/7A\N'
M7( 7XMZ5LIM>U[?DBUR/QQ[T<\1UJE/+KH$6]0%[7Y%KW(6P' Y 'X][^T]>
MZ[6X(^H/%[6Y'U/-CS<_ZWNK E2//K?Y=>7U&Y'UX( '(X)!/XU#\?0^_(I
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M:^E&_P #=![F;_<":OJ/^/)UI!FY L&-[WN?Z_G_  _WU_Z^YD3_ $+/XO\
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M,) $,L1E6["Q(-_>CAM->'6JBG7<;!T1S^VVMXVA>SU$4R!R8*A(3,$G9%U
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M9G-Z;CJZ45:8/'QU8:6GHI'5A3M6$7*J5UO:]_:K8-W6QVTW,I.A%7A6O T
M^9..D.X;>+GG6:-%[C+)QI3"CCC@.C[YC^2%T3GWW/L?ISYA#=O<>UXYZK.;
M5K\AL/)QT%=(NH4&?QFW8$S6W0E7H5 Q6R-Z@;GVG'-DYG\22 HE>%6K3R-,
M>7V=+]TY4BN=QA=;E?J!H;25\AQH?4_8>J_/A)_+U/R.^2G<_P ;^\-S;LZN
MS'36V*BMR46TH]O39.3<U%N6GP63HZILO152U5$L<WDC:E41:>5(^OLVOM_D
M:UBN(E#%Z'.H"A^RO\^BE.6D;=+R*5RJASD!6_*E1_J\NC_[)_D:]0[@W!V5
ML/*_+&K'8>U:^JDP.S]N2;-JL[MS:\R*VV-P;ZP=1!/EY*?)U (E8)'$5X4\
M\!UN8)E8%8?($Y/Y@?Y/(]':<J(ZL&G H2 =(SZ$^@)X\2.D-TS_ "1=O97-
MY#87R#^2>-V-VY)79EME=;=<Y#;.2SV5VIC@ST^\<W0;A6OKV@R-$%FTPHD<
M:GBQ]NR<Q25B>)2R 9-2/R'S_ETG3E)6#QS3+'(3@:0:_,G I^9/RZKQW5_+
MY[KQ_P RY_AKMZII\GN&GR./FQV^ZFC2/#)L>LD.1_O#F*90!451QE++"4BX
M61P;<>SE-]#0B0.=)'SQ_J/'HC?EETF*,G>&I^'/S^=<$=6G#^1W\=Z?*4O6
MTGS,J(>^*O"-68[KRIJ]BK+D'*_<QU(VW4P/NZ;'VD]4L;:U0 W ]D-US'+&
M[.T)$5>)))_U?ZJ]']IRC"R(OU:M/G 7'#^+_8^5.J_NDOY:^3W3\U=W?#CO
M/=F:V+E-M83,[CP^Z=FT-'4/FL+344M30U]-%E::IQLF/:)6:22=&(('(_!]
M)S'KVT-'1B:BE6''''-:>GGPZ+(.6&CW+PY5T@&I-%/J> IQ]?3/0]_*7^57
MT1\8]C]N[CSWRH6/>6W\=!N#J+J#+5^QJ+=6YZ R4].7RE-+$F;R+U]0Y$(@
M"Q VXL;>TVT7\TUVFF.J$-J8'"D#@!@G/^JO1GN>V1Q6CU^,4H"N6!KDD8%
M:^=?+J1\??Y0&S<UTC@N\/E[\B*;XYXO=T-%EMHX3[O:V&J,:<BB^"'=]=O%
M):*MR=6CCPT-(JQ@.IT:O9??\PR))IC4L <Y(]>'[.D.T\JQSQK+<7 C#5TB
M@8\>)&/RX_ET!/S]_EAYCXA;6VWVML'?B]N])[IR%!B:#<3PJN2P=35VEQE9
M55>WQ%0Y2ARS-IC< QR_@6M[6[3OWU#A&)#^E3\NG]PY8\"/6M&BIQ  K^1%
M1ZT_/HB\?Q@^4-8AJZ7XT]R5L4U-'DHZV#8V?\60II3&T)QU1# ,:*"KA;4J
MH "OZOQ[.+O>X(962.8"3@14U&/D>B4\MRFS6Y\)BI!/ >7Y<.AFZ3^;OR]^
M)"U'4/76YSL2EC[ 6AW3M/=?7V JLG1Y!,M186K5:W*X]ZNDJ!24RQ! P TW
MMR?=I;!=[MA<D$L@QFG$5X'C^?5MF::PFEA1@ Q[JA3PX9H2#GRI\^ME+^:9
M\NN^OC7\6NBNRNE-WTFW-Y[[S>WZ'<<]9MK YR2N@K<#2UD\D-!74TU-2""K
M<RL407']/<7V5A-+N=Y Q8A ,5'&M/YCJ6/JH8K*.4TUN#Y<*?9UK^]$=<=E
M?S5ODIN'/]X]W;9VAEZ/!T==GLP^/VUAL[GL+A_)2M2[<P<4=/1U+T$"!M<L
M<D40-V'/L>6\$FW6BND3/2E *>8XD_;Q/SZCG<G3<+Z1&E1*DU+<* G^9'PC
M' "O1\\I_),Z1[!V1O/-?%/YBTG;6]-G4M0N4PN1K=A;BV_C\I0QS2RXC,S[
M$AAK,/EY#$5$<S6!'*^T<7,T\-W"MU#H4.!@L?S_ -1Z,/ZLPRV4KV<VL^&3
M0H%/V9KG^7SZ)A_+J_EQ;9^9F2[EV_V'OW?NQ,YU!58K$&DV?0[;GBS&9+9"
MCKT$F>H:F9X1545N?H6^H^OM3N?,AU*(R*U\]0 &<_;T6[?L2S,ZT([32@4D
MG%%\O/S_ )=/7R8_EH]8=%X7:>T.O?DYCNU?E#NCMW!]>5'3M)EMA/)@J?<S
MO%CUS^-*R9'$R8V, U4S:!(6]%B+^];=?27<KAE(B &:UKQ\N-/MSUZ\V%4C
MC96#2DFJT':/FQH"?6E?MZ&O</\ +*^%_P <M\=(]?\ R?\ F)OG;'<6_*G;
M];%LW9^S,;G=DUU9_&HFI9\KE:W 9:KV_A*VL1J**IK*F))+'3]?:?<M[N+Y
M5@MX (E%*DD'M_;Q%/\ !TMVW8K>Q)>YF/B-D *K  _.J^GI\ZGH7?YU=%W9
MOCL?XV_%W"=>;2R.S<]5/3=*9+:^1RE)D,B\\=!AJK [OHI91CY)L1!1+54W
MVRA566Z@:C8GVIFMI?J"QH6J?\AQT=;K&EQ$ML44:5(%!7YYK\ZFG6+#?R.>
MBMM4FTMK]]_,V397;^\($3#[1Q=1L3"KFYT@$E%3;=H-V05&4RLE*SA)33$_
M<LA%B?9S?\T32H$BM_TEH"Q8\1C@*GHMLN4T2WFDN)0&+:@ M: CU-/S\NBL
M;7_E78KISYO;3Z/^2?<D6T^O*_"1=A=;=ITE7@MNT'8FYL7GH9,5LZVX26AS
M8THM;CZ72L@9#$@O?VGL]UF,3F,$O08J1BO^JG3,6TK;78BF8!>-0M1PJ/3[
M#Z=6R?SK/CYTKV!U%M[LKLGOJ#K??G3VR-PU/5_7TV8V?BJCLO(K1QQ5-)2T
M>?3^*59DB15:3'Z9(5^I^ERK:9)'WYUC%0\<A(KPK4D_ET=;W!&-G,S#]10J
MC''RXT],]$R['ZF[DB_DPTF_JOY-]AU>R8-DX#.'I5MM;"R.*EA&[)H3A)MT
M4^&;=]3BX#4*Z^2L8(T*"P X\LABW6K#(H*YQ@8].BK;X5DY!N4%*&%C3 SX
MA%?7-//H*NI?Y,FP>W/B5U_\AJ#O_)[-S>\,'09C,T.]Y-M4W76T\='7%<M4
M5V>AIJ;+4U5%1 LGEJBNJP90/9W=;ZR2BWTCPU12#FI/H!PZ366Q>+R\A4@:
MKFIK2@H//S_8.H_RC_DV]>]=_&3.?)3XU_(JL[DPVVX:;<.23-';U;MK,[5B
MJUPV1DV]E]M4]/-)/'D&#7:1_2"0>.=1[](TC)-"4KPR37S(QZ?LZ42\OQJI
M>&<2!1G 6GD#DG_(>'KT ?QA_EI['WU\8LI\R/E7WIDNC>D7CR%;MN3:&%@S
MFZ*M(G:B-=58O(4&5CD@@E0B*FCIW,A%R/R=S;ZZ'PX(]<E*Y) 'I7Y_9U2+
M858&6=]$5:8"EF/R%0*#S)/[3U;AM3%[1^+_ /*A[ WO\&LYA?D)UON7"[MR
MV[]T]M4%=M7>63QV6AHMCY7(4M#MRAQ4ZU6#J*C[FGHZJ)?&]V0+J!(=N;N]
MFO?&8E6!Q1L T\JY& :TIT(K6TL[>P,2@.I4ZJK0T!XD D$ D8J<Y\NB+='_
M ,N[XG;T_E/YCY0[EKLG+W<NU-P[AGWW_>[+8ZDVSN"BJY)(=NS[8DR2;=G8
M*0I%5325+!QJ;^IO;7M_];%!J:A7(J3^=?*F!G'13<VEA]!)<T&M7 ^$>?E3
MS\R*>GV]:_,<LD\<$LL$],T\4508ID1ED,T2)]Y!40*L+4]<(M0B3TQ?T&HW
M%%N9_$7QOG3-?M_R=!#<!;F-?" 'KBE>'\N/5G?\EL?]C+?CA;D_\9@L5'_?
MA>V/4.!8\_X?[?VQS;_N**@T_P!E.EO)@_QL4/\ JTOUOY>XKZF+KWOW7NO>
M_=>Z2FT"#LK;! ^NU<)S_4?PFG(%[?C_ (GW[RZU7-//J9[UU?Y=:WG_  HS
M^W'7_P +&E2-IS\CLA%!YVA\!639U3YXC%-357DJ9T0+"0HT,;E@+GVIVHJ.
M8N7B^%^I7]E17IK<94BY=YD+-1OI6IQK4 \.MB?;!OMO;UF9A_ \39F*LQ'V
M$%F9DNC,?R1P3]/;FY_\E+< 1_H\G_'CZYZ1;,:[1M5#4?319_VB^?#K4%_E
M]_#7KSY<?*;^9OUGOG.;WV9UKE=[,NZ<#U358K8[;JGDW_7Y.AI<WFJ7'99L
MEC*=:$^2BJ%!DUC6"H*^TFQ7DEG:M/$H)U 9K3\1K@@^7V=&>X6ZO)#'*M#0
MGR/  '[.(SQZ,/\ SC.R<SU9NCX6?R^=HY3M/:GQU_N3L(;VAZ<6IR/<._ME
M8*LR'7>)V%MG"8O^"T>XJW'8;: GDH_-205#55_&_CCC5!>/<75Z$5"=1U$+
M@U)S2IX#R^T].Q+%#;M(SC4N!7A2G''^3A^?1$MQ]/8_XU;VZC[4_E>?$G^:
MQU1V+M3?T55V;!VG\4.XJ;9_8&Q$:.%<-546R\+#CJN25Y9!Y,CCJV,PO>50
MMV)O HMT!F%%^9!QYU"D_P"JO11<?KO^B22/.E*'R() _.ORZO!_FBO\-^U=
MG]#8'Y?;^^0FW,KNO#'<VVOB)TW59K*;Y[5K\MBXGFP^6ZQHL7/C]TY;;&18
MQ*,S U(C4\Z1QI*6="+<+9GO+9X997"DC2@7N!(HW>1IX9XDC &">C2WN-,1
M\2-49@"=5<8-148.?\E<4ZI(Z:JNL/B5_,;^**?$78GS,^,O6_864QN%[9Z9
M^3NTGZDJ]Z4V4RQQ=7F\#L^2DAH<YM^+&O&TDK@A*JQADCLH]BY(I!8?K+I&
M?GP(XY(J#7[,=%3@F9I5(** 0<5KGTR 10?['1MO^% GQ5ZHVYO'J;Y(87$U
MP[1[\[5VIUWV-D:H15N-JMK8/![7VMCXL;#!48S(8_*4V,IT\3:JR-WUL\5@
M!["UA91_UNL)@S%Y;>:H\NSP0"!3T;-3Z?F?R7*MLMS:G2)ED0J*&I'?JJ>%
M%[?3CY]'V[U^$O1GPJ_D]?-/ISIRBSLNS=T=3=H]A99=ZUN"R>1J]P[GV[CE
MJDJYL9MC#8V6AB..A"QFB,C#5=BS!@<7<Q$TJ,PTJS*,<2>T?F30?LZ)DC'@
MQOII(VBO[0:?D2>JY?B9_+9ZA^7'\JO&[R[1[ [*GIMETG=&X^JNNL?5XO$=
M0=<97!UN1^VDDZRH,104FYLG+-BV22IKZRH?Q3!H6AD 8%N[0OLT,<^\,UO%
M^FX)HW;(RA#1-1[J@>1%:D =*EI^LZHI.DFOR5:G]F>'2B_EJ_#['_S)OY?]
M!0_*'NKM[=VR>G.R^P]B]2=>T6XZBFV7@J?;N(H5Q4^_:(25B=OTF,ERT4U%
M1UU7)34D<0B#%O4@DOI1XL,:@$M2I\SP"US4T'"M?0>?17;M"\<TT9JJ D<:
M \30$4%<5IGU^:Y_DK_)#=_7'P)^8\N3SF2WCAOC+)6[@Z[QU4_\8J,?35FT
M<U,F*@D4RNM#-G]MF48Y7,6/$C0(J $>PW/<*L<[5^#_ #FGY5_U4Z,T0U[!
M\5/3SX_L'57W1W7_ ,??EILC=W=GS,Z0_F9_)[O;<V]]VY ]B_'WHO+=O=<[
M4B!2HPN QNX*F+*14E;MR63SG&T[XZ"/0H1'-W)CMJ336%I+I#!M62U"<@8^
MRO'/'AZEUR\2WUU;ER)4TB@6H!()&HGC6AQ4<#G.+MOY06[_ )2CXU_*/IGY
M*;+^0^/PO6F+K*OJ#=/R-ZV[6V5N'/[.W'MS=-//@(<WV92019N#"TV$H:AZ
M>DE9<=+DI8O5%XI&<=HC/$NK]4,*X-2*T!KPQ2GK^0KUM%E2&=67](QDBA%
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MHP.";>_:F!(TXI_EZ8(>0LR&J>7^7H0NT>Z>T-M_&/X0[YPF^:^DW/V=VO\
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M0;(Q=15]MP;".36@ZYVSUI_"Z:;)8G'Q8NE@KJNI50MJX!C=EO3R!KQZ\.)
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M?7NLIL(K ?0+P2;VT_D$V]-N1Q[MY=5''I3;1 !KK7;4R'7Q86OQ>VJ[7O\
MCZ>_#@?MZ\WQ#[.EK[]U[KWOW7NO>_=>Z__4W^/?NO=>]^Z]U5A_.+-_Y>OR
M%!^OBZH-N  3WUU\!S_6XY-['V;[$*W<./Q-_P =;H/\U8L)2#C2G_'DZTA
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MR82?^'+?C4+ _P#,X"/H>#T)VP;D7/Z=7TO]/9=S:*6P'E_LIT<<F_[E^?\
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MV]=;/J-KUW7.[=PX[%)%EH_XI1XFJIDSGV^'.TZJASM2*U8I/XC'42/*C:-
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MJ?RX_P"JAZ<KKN0VEJ+'0D@C-1CY\#D8_:.KV(O\U%_RS3_H4>V^GND[N_\
MX]/=UCS_ '?S=^!P?X1-P-/)XY_K[V> ^SK0XGI^MJ7@+<MJ _21?59F# DZ
MC?\ '^V]W!H>/35*CRZX$>D"F*@Z $U$A2$NOUTL2;'F]_H/]?WK-.[AU8TU
M=O'J4&#7M]+VO^#P#Q_4<^ZD4X]7!!X=!WFK')UI -]"CT@7;2B@@@<$"_\
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M[^GW)68N;X\9ZMS%-0PX2 KN5:W&0XPK.T>9<Q,7CU?0D@_[$5\J=)&UZ_\
M4>@H[7^'U'VEN+Y3YQNP*S##Y.]0[7ZER4$.V(G38]1MFGR6-I]W8P?QEOO9
M:F+.LIC2Y #MR ??J5J>EA/:H'I_DZ$?L/X\4W8D/QUBJ=X5.&3X^[SPVXJ>
M:EQLFK=\-+M^CQ(HZRFC:?[,.M'9V+LJWY;^NZ5'$=)7:E,5J>H.[?C#M??7
M?>_.Z=P[@R1A["^/U=\=LOM.BI(Z(X_:M=NG'[I;-X3.7R=,V3@GQ:J8:F@
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MZUU[_??[ZWO76^O>_=>Z]_OC_OO]?W[KQZ][WUZG7O?NO=/<7^:B_P"6:?\
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MII2O[:]8[&X !)O]1^3Q;Z_CVZ:@T'3 IY\.LFMUL"0+\CGZ?[#Z?3WX$I4
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M?A22. &!-CQ8#_6]^Z]Y@=>_%M((%E4@ GU?4%K@'2O(^G/O?7OEY]='5?U
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M=S'V67F;Q,!2^%1R+6 M[=%F1[>LNH%@:G!H0<"@\OVTKTWMABDCGU14;30
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M3R65PI*H+V]VF6ZNF@,H5=)[J9J " *_Y<=49+.PCG,6MF8#34\"2"<8Q2H
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M$1'A5] ,<<BI\\\?+Y] ULWN/XP_&K=G2FYOCZ>R>Y=[[7WE45W8._<_@_\
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M%#]02>/?AM_J.W_5QSU;ZZI%#W?ZN';PZDS;VR9YIXD/]FPIV//]3<VO^?\
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M_/IH'UO>W(_!_ _IQ8<_ZW/'/OW6R/V]1SI\=A<7!%[_ $LP_H;C]7U)X/\
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MNU]AM7S_ -ZH\*VX),:,-G7IFPZ,$-7%N 8MMM3RJ7 %-'6M5$7(B(!(L;<
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M_;GZW&D'ZW;\D&U[_0FXX'OVL#RZKX;$_%U[[<FWTM>_#$<VO^ 20/I_O/\
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MZ=)/!-!7RK_JX_GT:4LW U+]"?K>_P!?2"".0#<V%_\ 8\#8N5H"1_J_U?\
M%=>\#-//_5\_]7SZQ!0(343W;ZG^T38@V((NIN1];V'O45RDK:4%#^?^;I88
MVTU/#HE?RU^;?6'Q0ZLK]^[DS=(]14:\/M*EHU->-V;E9CIP>%4%_P"\&E6(
M)XPV(-SD\B!P#*"T>X)U?#_/_"*5]3D^2CJIM^!7C_J_U>G6DU\HOG9VO\FN
MQY]^]AYNJR$U+_%*':.WZ3,#^[FQ<80;X;9-S?G^" G*<#,CV!.;ON^[_N=N
M[>-Z>4?JG_+R/3_5YY$\L\U[-L,RCPN-?.3T;^@W\7[.@9VAVF:C)4\-:O\
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M_NN\+G<C#F*+.L9&HMM98X\+24[ I%5<*..4H-)36O \?\G6QW  5K7_ #=
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M%[<D_P!/I[U3@?(]:'' J*_ZO]7Y]1"UCS] /TC]&D@#_$#_ &QO[]04\O\
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M.'#('^#(/[?/H\EI-W:JFA^WC3_)_DZ<ILSE-T)/!M":?'8BIU4G]Z:BC/\
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M/LZ?:,6!AN;'@\ 6(!-_HU]0_P /^-*+%/!@,Y^+_9(]?\G1?S&PJ+:H /\
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M#Y5<:V:H*+=&:P=/7215=3#*M47CEITD6)1J^@]Z>^C3#-W$&GY"O3MOMLC
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MRHZUW3N+:V7R5!D:2'51Z:FMQ\<,JQE'!N%>4L"=3FO17)W @EJ#R!I7[?\
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M*O=G\U;.R[5IWR&9[+W8*'.MM^FCR&2Q\?Q6V@D;8"IKZ!LI)21UM3-#'X'
M+E@;W(]^ ]3TA<$4 &*#HM?6^]^L_C^?B;W=\FL3/@.H$^*M1L';>^]P[.S>
MZ-M;&WXF>K)ZO Y7;^/PF>R.#S.<IY%9)10R"8'\#40T !*20,GCU8!O"1?]
M$ _/RZM ZNS.P]R?'G<N;ZMV)F^O-E9S$[WR^V,)E]M5V!-;1Y3&5C5&[:#
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M@XD6%OX6>L\)OWZ6(!_O%VE6WMQ[RL]BY%#@D#_5]1_J_EUCY[LP,8&QG/\
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M-_1;Z _C^@M[@$\=/V]%(P">EK,PU@'U'D@  Z3:VG^I)!_-AS^/SM>!ZTW
M=:7G_"@'*S[H^:>#V[?_ "#9'06Q,.>0/]RN<WCOO>XMQ]1_&:(GD_ZY]S%[
M8VRK;SRC\;U/Y!T]?Z/0CL$'8A'E_G/5(V.VW4<?LCZ?XD&Y'(])'U^GN58B
M5E) _P!5.EL\0)H6S3[?3H<^G=K[?@W+0R[[QFXZ_:/\7QM%NZEVJ/\ ?S5V
M, %\-A!:^W[#_<9_6_\ O(>YSG:(%0?]79\O\O08VU/%/ 5_XOHY'R#^4&[>
MS*?!;87[;;FPMG@_W&V!@*NVW,#]<)_&0>?X_N$&_LCY8Y8CWAFDD6K4R?\
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MXY_K86TV4W/'^M[K]@ZMUR)#6!&FPN5L3S]2;W-S<_G_ 'OZ^ZT.NP2!S?\
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M69T5>%4D@#Z6]L5/Y=/!JGRKU'U>@HHY8Q^1BP,LIB:\;32G5+.UK*2S$M&
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M]?)M[$U=9D<?BJ):R::#%4R5U?)+)]LL9F;3Y"VA+,9\^J\/LZ6WTN>0!?U
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MODD+202.-,/"I>U_>F6&,8 /Y=66>X<DLQ KPU5_P]899JA]--_$<G404M=
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M*5\P?\'IU=;*%8XVUY8&N":$''#C7_B^A SO\O;$5FZ^C.O.M>Y<SNG>_=N
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M-^G_ '/;BX_XN?YXO[ -]=R7S%B<T_S?(>G1];E+, ?/U^W[?7JT3:-/28O
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M16[4[!VMWGF.SL;MJ?86YMRXO?.'R4.,5*.FW'3QR1[<JZ":FDD76PUZBHL
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MZ7^U -OT@< W_3_O)'^'L&> T3$@?X/\_4E27VA14_X?\Q_V.FO(9V;S04\
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M.D CJ]PKJWX(5U/''-E-^/I?Z>UJW0-,FG15=[01G3D'Y>O4(W_/TOP?]A^
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M[)V+L75_&L$57/LNW,V1;*WM?G\^SNVYE?9U5APK08%1ZU[6/$TQ7R\N#H=
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MA92>!VE?Z$_\1"7/=P/%;T_V(_ET>[&Y95J<_P"RW6QT"=-[VU>KZL "2+V
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M?07'^M[U^76QYU.>L)XOQJTL0=(%@"2/H+%F/T_I[KU;KHFS?YK4#J-R;?J
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MU[KWOW7NO>_=>Z__T]_CW[KW7O?NO=56?SD;C^79\@_J5,W4_P"H #_F>O5
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M_N^,_P!)OV53_9Z+7,; 7_(LP-KVLUSR1Q<?UXO[/>)H,CH.&@H375_J_/\
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MI!OQ^?I?\V'! ^I.D6^G]/?OLZK]O'_5Y?\ %=0[$A02>001_K_XBVK5^/\
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M 6('/X]^H*_EUH<#GI@-E N01R "#Q?\V!-M)'/YM]?=>G.N[L#]"+$6+68
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M>>>;\CGD?CW+_P"!>H*DJ78]-]^.;_7Z<\_BW'UN!_L?]C[,2<YZ3Q#N%/\
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M'^\>]>'%D^&N/D/\W7@*$J%S\_\ 5_EZCGU<GZZOJ;'CFY(O];_U_/MQ0J@
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M6_I]#_7GW8<1UK_/U-D8ZR6  93J^NH'2"PM_9MJN1S[>ICCUI#VX_U?SZE
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M.O>G78-@;DK]./4+WL=1('-[&WT_XIOB.O>=.NN!Z23I&G\AFYL0>" #IO\
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M.5*C2"6X]7((/Z^?Z<G^GL^V^W&UII!HU*5_,_,^M.H(OKB?=-^:[O\ -O\
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ME_&N,D_R5O\ 5Z=;$/\ +CR-\+E_MB3B-S;CWWN?$CZ:ML;V[+S^=P>8_M
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M-_;? @>?3(R*UP/Y<?\ 8^VOKU)_ /U(/! XY(^OU%@;#_B?Q[L,&AX?ZO\
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MJ9\B0 38\,W)-P2!Z?\ 'Z>QGLT]ALW,MMN$#UMXM0&&SJA(."&/%CY']G0
MYU@OMZY/N[29>]M-<KY3QMY:1Y#SZ$W8G1\8J*"#-8K);BW=58C^,4FR<55X
M7^*?PHDG^-9HY\?[@=OW-^3_ ,1[[8<J^[RWW)UI;Q>6O^<[GSA'IU\^?.?M
M0]CSG>3R$@'1_*!!Y3'U].A=J>L\GM?Y _$'*ULV%JMP566[APW]W\!1G^&8
M('IS.YU?X+G% W+GOZ?Q3\V_XMN/]Q!S+<"?GF(^E?\ M'7Y#K)'VZVIMN]H
M/<\D_P#1N_[3I>.3Z];#/QOZOJ-LT']XLI0?;U^3(^T6KOR+@O:Y!/TY^O\
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M_=&]7T.9@&T<I16V_5;0Q>YMQTOV=VW:,WFM^8+^#9RPL-O'^Y'^YJPOF/\
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M7V<G_5GY=-R0EJ \/^*_P]"5U+UQN?N;LW8?5>TXE&Y>PMQ8S;6)^\.97%T
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MGD'^HM_B3;G^ONO5P",=8W' /]>+6'^(X'(!_P!Y][%,^O3B4TCB1U$M^?\
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MU7D<0,=Z;$#^-WTWX ^G^Q]X\@WMM'I$*B2E*UQ^P,1Y]9EKS_;S.#Y<?/\
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MX\Q/!05F0R %6,QELKE:S^)Y'.9*X_C>8S>:SWJ.X@"!;\_T^ON>.5K-48
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MI^7F_J?GU?\ 8BBAI<90000FGIZ:E+_:,2+7-M04$GU 6'^W]AZ5JVU:\?\
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MY]01./U>&?\ 8'4<<@GFWTOR ;#G@6L1I/U]I+"B"C#_ %9ZO#5K=F#&F/\
M#_L=6)?RIJJAHOY@WQVJ,K+3T^/&6WS1TGW5M7\1'6N^QAM(OJ/^_A!%KW]A
MOF&$RB4A> S_ ,9K3_)T?\H2B&XJ6SCR^3];D_=/^AZFZWW1E^]Z7:V9ZWQ"
M2UV<@WECJ.IV_"M+*\M+734E?%44V8K$E $$I0F24 CW%,=6E45IU.;@)&Q"
MU/\ J_9U2?ON??'\T/L?J[ ;'VE#U5\,.B,XDZ=A[YFQM#4=FU0>F0T.VZ.J
MD40Q4:4@$0B%D#6XL![%%B\5N"\@9G>A &:T &!\O,]!>^625P%"@*""2: 5
MJ<YXUX>O5^F H*;%X;%8JC2JCH<;0TV/I$K6#U#TM#$*>!RQ<ETDCA#1N&L4
M(/T]DKLTNXSTT@ZJXX?"3C\_Y]+C;+'M=O*0:T\^/Q >O7SP.VLCBLEVOV;E
M-O3TM3@<IV)OJLVY54GIQ@QV;WGG_P"! FY_-^./]C[F#ENX^GC[AG_HKY=0
MUS&=4M!P_P!A>@I8\WU$^,:0?401SJ!3^TO/T8'VO ]>'154TP<_\7_Q?1X>
MOMR;9@_E^?)#:]9F\)3[FR'<O5%=CMLU&5QL67R&.HSDA4STU.U0C101&53I
M"@CZGV&Y;4FXF.GBQ.:='T-W$L< I0A:'C@X^72MV5WQO'J+X&14'5O:K;/W
M[5?*"LR68Q>W<SM-\]6;5H=J+%XZ^GSL.0CDH9ZCD?9Q2R'^USQ[=3;H78>)
M;J3PS]M?]GI6FYT/9+0$?X*>H/E45ZG]H=E;N[^^$O0&V-R=IXO?W;]3\B-[
MT<%)NO=VS\!DZ7"5.&H1AJ2HR%8FW<'BJ2.IEDM/E31QZ045S>P(N8-I\2>U
M:WB HIK2F<CU/2^UOQ*IUDD ^8X<?0#HR7=F[MF]5_/?JSL;?F\=DU'46ZNB
M,/TKG-Z[(W[L_=1PF5W#L'(;'W9438G9.<S&3H$VQ5957>:ICABG0%HV9?5[
M:V^V8 L$) / BA)%#@&GY'AT]+-X3*%9:_(U KPJ17\QQ^702_'_ *&QGQ2^
M0L?R%[0[NZ2R'3G2]5N'=&V,ULSL[9>XMQ=I15>(R$&T*?:.PMNY?*;EQ\\\
MTL?W0R4%);U,;D6]GMS^M83VZ!A(P]#ZYR<?SSY=>LKV-;R$SE7AKD'[/,<3
M^5:'CT7KX+[RPI^>W4F_]S5]%M7&[A[0W9ONJK,U6+28S"XS/T&[LA#_ !3)
M/)'%!)*:I;1EE%W((]I+6RE5#4DG\L\.'07O[LG<% >D->&:?$>.*\,8Z4^U
MMT[>IOC+_,KVU+O6@I*O?'<.Q<IC<)%N:@2OW@8<]E):FNI:<5OCK*"2%QKN
MI#!A>_MN_L9G-03J%?3%>A)-N$-O8*;1?"E(-2M030BGV]&FZD[[ZUV1V1\#
M,GNG>&V<-0?[*3V-U=59++5%)N'$=9[IWGO;?%-M[%;UAQ61;+08C[$P3+I^
MW%/C:[0)  MDWT5TP*DD'[1Z?;Y?Y.O+>V^F-S1F(!.&X^=<4SQ/V] ]W=7]
MB=<?';L;9.Z-Q_"S;&&[#[.V?AINM_CIBMOYW=._\'A<TV0B[$KLML[>V],;
M@TH8SYD_B#T^0U,=<9((]ZCM)VU,)'(K2K8_PT/5WNK:I&F('^B#_D)'0T;G
MVGU)G_G7L'L3L/.]3;BZXW=\;]F83K^4]N[7IL#E^VMF=.;4Q6)P78D.U=R0
M;^V[05&=I9TJ(<G2XRA<1W>H"MPJAM"UI<^*&:57I4BA XG3G-!PI7Y5..JF
M\@2>"BQZ2M:5)'IW4&,UJ#P\Z#/3ID8*O&_'WX^8S?%?\0]H[HZ\^9^*['WG
MM/H7>/7>#VW@=AY".CHZ3<&3Q.(WQN3%;BKZBIC\+5.'FK5B(+U)B)U>R+P+
MCQT"R2%" 1J_P' I]G1^)]N%NS&W@#AJ=M?0Y J<5\^'SZ@97;^!ZJ^6WS'^
M7.X>VNG=R]/;MV/W9C]JMM#LO:^[=T=M3]C;:KML;>V-1; PN9R6>B7$5]4O
MW%5DXX\;'#J*2$BWLSOH'_=;I;ZENNPA@*4%17N/;GA3C\J5Z)$N[<WP9M'A
MU;!)S_E('KPQ2O2.R&U,'\ANX/A7\G-F=Q].[:ZWZAV?UO2]AX;<W:N"Z_W1
MTL>L*6*#<&(PNVIJF#)9BJSK4S3>/%0U4,TLI#,I)]UV^"X5?\89GU&GKY^=
M.%/7I6US8FE(DJ%^8\OY_P"7Y]-.Z>R-E=Y?&OYMYS9^6V/MZ;=7S1VCVO@]
MM9G>.)VUEJO8V'Q>9I(\KMK![DJ<94;FA>J3S)%1K)-))(2"?P<&&&.2!62I
MT$5I@T*U)(X'T'GGTZ02W4)61E4 "F*YSJI0<3\\8Q4YZ$O?^9V7V5\M_G]1
M;;W?UEDD[*^*6%VKL?-9CL#:FW,/NG<M*^%FJMM8W=6XLCC<&/$:=R]']P_K
M73[#7T\B .P85:G#.3YT\OGP''HV-W ?$5-% *UK08#<*\3Y #)\AU"Q6=K.
MTNAOA_A>J\I\+<EG.C<#/U1VM_I[CVM#N#IC+X3=&:W++O3:#YK?NU<=N/"4
M]!.Q']W$R%?.\5@K@E?;G@S1'5KD KY>I%,T^SSQGJO[QA9?ACJ!Y@^6?V_+
MY#SZKA[4[OSU9\R,GW[4;VVQV!N#!]EX7<(WOU]BYML[6WE!M^IIX)LOMRDG
M"Y'&8W[>GMXJA%EM<D6]B/;DE^@9'<GO/&G1+?W5N]XKE0>T#%<=7+;@["^,
M+=P;?^)6V]][ H^A_EIM;?';_9FYWW%"=M8+?_;V<V7NZ/$Y:HC0?PW-X"GV
M/6P4[,]U^^E4Z+FQ++ >Y_IV#@F@JM33%1FF?+HU2YMS2,R(RFE6[J#4:FN*
M]M<^712=M;BZV[S[G^=.Y:>@Z.WWV+AL!MS9/Q=V?WMNYMO=+[DVWUU4TNV,
MGEXXJW<&W\!N"L@V]CTEI8<C5I32,3<,U@7KB&\^E01R,M6'"E1_J\SPZ]93
M[:+MM=M&:(<D&AXGS^W[>A+[BW!NC ;\^ 6X=D=S_$786\MF]8;PV1N+)X/.
M4-7TOMW<=9NG,Y/_ $?Y#:NU<EN:NV_M[,X6NCIZG()+_#15%F,RJ?9;]+?G
M6#-(,^J_RZ5W%UMZ@%((\ < W^"O^7AT3WYB;5Z?P_2^Q=P1;(ZKZI[[S_8>
MZFR75WQ][SH^U.L<EL>98ZV/>U10;>RV>VWMS=5;G)ZB..&&K>=:= 'A5@6;
M:07KE?UI-/SIY&G_ !7EZ=$]Q>6ZKVZ=>HUH32A''@ #7\^JT03?DM>XO?DW
M_(;_ &H'@_X^QEI>@[^@]6($#P^NB.;@F]P>>;_UY%^;>_:&_BZJ#%0D1BO4
M69G5].KBP ^EK<BX^OJ'/^M[4+"W@ZCQSTZ&B"X2F?R_;UA%PZ@GZCFWT^I!
ML3^?]\?:0+*7^+MKU[4E/ASUS6WE//\ 8OZ;A;_GG\&XY]JI862)"/B)Z]JC
M(X8_/K*P])7DBQ(X'Y(^O^P_']?;&AZ<3U76M=.D4ZA5*GPN;WY4,+?T90/K
MQ[\%((J<=.*P)RN1U:1_)*!/\SOXQ CC1W'<<B__ !@/MOT@#]5K$7O[*>;O
M]Q>.:?Y4Z$7*/^Y %//_ "/U]!7W%G4J=>]^Z]U[W[KW2;V=_P >CM?_ ,-[
M"C_;8ZF%OH/I[]Z=:'2D]^ZWU[W[KW7%E5E*L+@_4?[S^/\ 'WI>RE,=:(#"
MAX=$;^=?>&Y^B.D*S<.PU@_O;N?+Q;2V[DZ_^&OC\"W\%SNX<QFV\Y&IH]OX
M2L(_H0#8<>R#<]V,(%!D_P"Q\NC';]M\=R*<!_G^8_EU6?T9LWJS;6_NQ^I_
ME=N,8_?]'O=&V_V/0[GSVP-G[JQV;\FX,.<SF8]R.\VX=V+FQDDR.Y\KEVS/
MWW\.N<G0V$(CDG9+Y28Y*O7CWC_"X]"<_LKGH>WE_*Q1XJ:*9%"3P^7$>0 H
M0<ZB,= GVEMW*=4]H]M=<;^S>.PV"IJ-:/% 4N7V]D=[['S>9SHPHSF=P.X=
MI;;W_IZ\-%_N,W4,O_&/X?6XW%_[DZ"WL%;SLDVQR,MOE?R'IG+-_%T;;;O"
M1QHS<1^=#D&G;^7[>'10>_J#'=J[+K\WM!ER/8FSCMK>.T]UY7*?P_)X3>_\
M%_@(PN9.?<;FSN![3V]LK-8S-XWG,_P:NVUC<F/\AR%DVVQR0[8\;1'('F/X
MSY?833\O2G4B>T?-42Z=EW9PJL<X)K3QY,&-13.DUJ<5'G@X_P#+8[[Q7]Z=
MH[7AI\ACZ#=V&RG4W8>#W7?^\6U>RNK2N>V1_&C<%?\ B^;HQEF_XO'^1<7]
MC[V8N'VC<YC,04-*T->"3CB 3^+& 1YTS0.>]WM>-D/[YV0Z@WE33P\"/_1)
M6_B;R_,X/5\434U7&T"\WX(Y^H!M^OBW!_K>_O+ISXM0SUI\NL2HI-C!!MUH
M_P!K^GS_ #Z(-VK\--A9#.3[MV5LO96.RYJ_N_NZ;:.(&2;5^;\@#U#CZ'V7
M3;3'(P5G _U#YCH0VUSNNFMHYT?[3Y_Q?GTCL%\8-^5E=X,G3BEI_N[6!)Y
M-U!' ;@\^S6-EL1J\_\ 5]OKT@N[9=VB-]"3]8!PX>>GU5?A!.1_/H4^UM[]
M3?#+J7^^&X</4[BW3E:S^['7^R<')][O;L7>N9=#A-G;*PT>H'<#_4#BX!%_
M8?W+F,+7.?(4K4X_H_Y^ASR!R#>\_7<=MS$ EJM3KJI"@B1F_LY(S4>&M*GC
M4U !):OA?T%7_'+J_L#M'N_*XN?O7NS*UW<'R1WA4U:'%X+Q@^/"X/./_P T
M_P"J-O(,8O-Q:L/^L'>67'+NR23W+'4&#$_,R/QIKX:P1C!_;T=^[6[Q<V[O
M:V5@H6%$T*!4458H !D1FE(Z4\Q^PUC?(3MK-[]SN?W/N&NS/\8W15#[7%Y9
M5(V-L49B^R-G?P2]L#N!=O?\7H'Z9@5OX_A]N<WNQ[BK?\P3I"U2 IIP-/#A
M)I6,5X?EQ^?6=WL+[620[%#+(F#7TS22X'E+^SHBV2QE)6@U%.OATVX!M^L@
M64!PPM8'_#VUR9[\[UR/>*VU1%T'SC'X7_CMY/\ ?C?L_9-ON7[!;3O,+^$W
M?]CXS%ZW"_P]!QEFJ*'ZL. 1IL>?I<?7G_BGOJ][$_>7V[GNQ3]_R:&H?)C^
M*X_WW:Q_[[7]OVUY!_>+^[UN.RS$V\55'S0<1;#SN6_B/22\,^6K((8+U!_
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M>Z<IZ5;Y_P##^K">E/CWUS\?\,F(V+C2U;+&%S><RM\AN'+1JS!4 +, NM^
M !S?W&/,?--SS82UU=>( **,X%0?,#S!-,#SI4]2'R]RY#MHT6\"QBN0  *Y
M%>T_8//RZ':VHB_^  !_4UK:OH#;C^O'L'6RKMF7R//^?V^O0CO&TCM_G^77
M92?_ "BJ9Z:FI;>:2:JE6"GQU#C:2E2NK*@NRHM.1%)*SFPNQ/X/NAG0EO7/
M^?IR-5*K7ACAT5_K_P"9OQI[7WY7]8;![(DR&]\;%D)S09C:6[-N87++C)'%
M9+MW=F9Q--MG<C1QHQ6*@J:B5U%P/;\0#T).*=6MCXVOQ ="D\/ECYU'SZ2F
M._F"?$#,[FPFT\9VY)+7;DKZC"XO-3[/W+1[-I\OC]PYO;62Q^4WM58V+:^+
MR,64V_-3K3U-3%*\KP:0PE7WN91&*^9Z13L5F,6: _Y :'I>]T?+GX\?'C.X
MG;_;N_:C#9C-O2I3T&V=K;IWW-C5R*M)B*O<?]T<9EGV_C\M #)!4U@BI&56
M)D"B_M/$[.I+_%7_ (KI4T:H5$52M*_Y^I_:/RFZ#Z=V?M;?>^=_P_W9WLD+
M[/J=JXK([YSFYH)D#-E,=M;9L.9RU3A*%7(JJF*-XJ>1=$A#7'M[[>'5*'R!
M)Z8:OY%]<YRHZ"W!LGNG:2[*[5W/N'%4-#4;3RN8S/8E5MK;60RN:V?0STD$
ME9U]N7"+!]PRU,8DD5/"5UE5-E4FM!Y?\7UX5/\ J_U?Y>B(]#_S#,GW8ORU
MW?6=W;*Z]V+U%O#+8'9$>=^/6_(DVQL^AWE#MW;F]MVYK*T%(=R9S=5+*89\
M)&!58Z=Q)*@"W][\$L13CU;25I48/^KCT>7MGYG_ !NZ&S>U]K=K=E3X_<NY
ML?CJNGQNV]E;GWF\-+7T,4E-N+.1[3Q^4_N?A,M,_DI9,E]O&$)NVE2P\\78
MP/PD$=>56+ C)!_9U+[>^97QNZ,_N^>Q>Q&B7<E!09/''9.VMQ]E+'C\MH-!
MF,E_<G'9@8[ S*P6&LD(AF]1++H;VU&J0CM/GULO(3I48^SIAW?\@LS#\B_B
MCU]L3(;5SG5_?>T>TMW9K,+2R5V5JJ3:.S,KG]O/M[(ZXXZ%7KZ)/N59"S+J
M0@'VXSESW4Z4VR++ESC\QZ=)WXS_ "I?L+K/;>Y>Y,G@,-NO>_>O=W56RZ;!
MXJ3&X_/-UQV1O';6!P"I)-4_;YZJV]MPSRRE_P!YZ>5@-)L#,V41".K&A0$U
M/F:UI3[.'2>:,6[.4%14_9T:+$=D;*SN^-X]:8;/KD=];#IL76[LQ*T-9'%A
M(LSH.)I?O6B&/K:NH# 2)'*TL ]3+8&Q=,H2@4UKTTDKRDAR .@/'S9^+Q[1
MAZ='9IAWW4Y>AQ259VIN^38]/N O-#%M]NPAB1LVIJJRK#4JK'5,PE%FL2/;
M<-#D_%7K9@$3F5 :T_U#K/VK\P_C3TQV%C>N.R>PYMN;\K*2/)5N'Q&WMP;N
MH]K4E1;[2'?.6V_CJ[$[/IQ&PD@;(2T^J!]8.GGV\<@+@]:N!]7F6M/ECI%U
M'SIZGI?EWA?B9''DZ[*[EZS_ +\XS<^*VYO3)8VJSM350#'[>H\S18.7:TV"
MJ<--]X,L*S[?R@07N;^TEQ#&@1@23JZNI=4" 54'_4>EQU/\B>OMRS8?:U?W
M!A-_[QWGO/L?;NRWV_LFNVFF6K=B/]QF]G4]+6)'CZC-[/QZEZF?S?Y6#=+Z
M3<P@?3%6N1\_]CIAG?7I4"G^JOGT[[L^5?06Q*3L"KW7OU<4O6F<@VEN^&@V
M]N//9.BW5+0)ESAL7B<5C*JKW%DTQ,R/4P4*SM32ED/*GV7RDBXB<?A:O\OY
M]+([=9$+9UCY\:?ZOSZ!/M+^83T7LKXK;T^5>SLADNP-L[6IIH*/;T>UMX8G
M)56Y=++0[9W+BJK"INO:<M82LR3U-&D7ANQ( ]NR2-*26ZJRD4IBG'H3Z_YD
M?'S!=3;1[LW'O7)XW9F]Q6OMW&2[(W<N_<I%1QTD53/CNOH\7+N^IH<=5O(:
MB8T@TPR0D\R"]%B4=U<=)V9P2H'=]G2CB^4GQ_EZ:J/D!+V?BH.I*3_)I\[4
M8_*TF:@RZ%F&$J=G/2C=$6Z:JVF#$_:_=2B[:>#[;\"/2RYH6U?GUZ5/'55<
MG'ICH'.D_F+MGY#=[YW9_56?ILQU=B.G<+O]I,SLK<FT-Z1YW(9_/86<5-!N
MBCQN6IZ*V)71!+3H?JZ%D96-'E*O'*O$''IPIT_&[PIX*CMI3/&E:_M_GT*G
M<ORX^.OQZW%@-H=K]@56$W%N&&EJX,9BMJ;CWE68RDJUD%#5;HIMGX[,5&T\
M9E)$;[:KKA# ZQL=5@3[>C7Q(S,Y[ZD>GSQTP!1RBK@Y/Y\>DAV?\F=RTNY-
MD]9?'#K_  W?':6^-ES]CT\V0W93[8ZZV_L.&>*F;/;HW+CQ7-0BNFJ8XJ2*
M,-*\E]:@W]T1V#:13I5H71JJ>A$Z-[0[-WU_>3;_ '-T[6=0[\V@^,^_BPV3
M_O=LK=-%FP6H<GL/<%2*.7+X^C2(_=-(B2+(6 4J+^U4FH1!O.O259")&4$4
M Z#/IGY<OVS\C^TN@LCL"+:N(VL^4DZF[&BS<^7Q7<-%M/+R;8WO4T@2D6BQ
MK8S<=/*L(6:3RQ)<?CVB90Q(I0]/:R,GSZ3-=\EOD+O?L'?.%^//QZV9O_K_
M *IW%3[3["SN\^S_ .Z^^/XVI6;(0;6VK04]=29(M1@BCCJI8&FG*JW!/MR/
MCI'#%3Z=:))&2*?ZO]7ET(?;G>^Y=L= T'9&V-N2;!['[!S.QMN;"VCV'CHL
MD^)WINVNABGVQN.AH9FD23&T-!D6\B\M((]0%C[<F/A_ <CK250T'I7H-,K\
ME/D+N??W8.QNA_CYU_V=@NEJ_%;5[6S>\>SCM'-YC=U3A3EJ_#[%VU3P5YJU
MEJ*:1*=*R2(O(5 6W(U$P>FH4'GUYP),O3/3;\A/E%\I.L^MO]-W7?QHV)G^
MM:;:^W<UF\?VSVO7]?=H8+.Y[,8;;M3MG,[?QN*RU!#5X/-Y8QS3I)*DH3T_
M4'WL)I9J9R>M  "FKACI097NOYD;7Z$[$[8WCT#T%1;JVCAX=S8#:&*[QSU=
MB]Q8$4LU77R5^:."-7BJVGBA'VZK"XG:ZV%A[MJ-*4Z]Z4./S_S=!]N_YU]D
M=6]??$K?7:/0^)IX_D%4TM7V-_<+>M7N+#].]>Y3%4^4I^PVJZK'4]9GH\/'
M6TXKJ,QQE%E=B?VN6WD52*\>GH_A8!\?ZO/HUF6[UIL?WIT]U#AL-1[@P_;_
M %EO[L[&[U.6>B%#A]FU.W(:&6GIVC-%5T6<I<Z:@.\J:(D5A]3;WBOQ0"AZ
MWQ!+'AT7'%?+OY!=DT]9V=T/\6\5V+\=J.;,KBMT9GL8;=[4[(H=O5TF/S.:
MZ]V)#35%)6T$=7!*D!DE!E,14\W]V#2,.\#P_+'GTRR>18Z@?]7^HGH^&VL[
M3[LV_@MTTF.R^)H=PX2ARL&,S5(U)F<55U:1O48W-TLA26EK*)]<1 4QN5)4
MD>]XZT*B@'E_J_GT]*O'YO\ 6UP0#_3^EAP?Z#WZOKU<N:'KF6N>!<\?0<6/
M'YN>/]M[]U4 >O7$$@+P23_L.222+V('^M_M_>OMX=>]>N(YX&DJ#]3J](O]
M1ZN+_P"'^Q]^ZW_AZY$#ZW](^A!X%[<<?6UOH+<>]XZUUUQ>XL3_ +>ZD$@C
MZ"X_/]/?NO=>"V;Z-^+_ (-S:Q%K$W^G^/T]Z^76Z\3TK=H@VK6NQNR:A:PU
M,21_AP/I_KGW8<#U0\1]G2T]^Z]U[W[KW7O?NO=?_]+?X]^Z]U[W[KW56G\Y
M;G^71WY<V.KJ?GB_'?'5)])/]1_B?]C[-N5LWUI_MO\ CK]!_F?_ ))\_P"7
M_'DZT9P;$'ZDCZFS$Z03PO!^@_VQ_P!A[G*GZ:@?ZL]0-.?U,FM?\W4<WN18
M?3Z64A5LH)'!-VX_/T]I!V TX].;75K9ZC&/\)_/_5Y=/VS-W;AV%NG;6^]H
MUM3AMR[1W#C=R[<RM-I/V>3PN9.=P8L38"P_I;WX6R7 .M:@_P"#KVV3O#=4
M7A_EH3_JIUMY;'[M^.'\VOXY?Z'<]O&MV#O^MI:6H[ Z[H,W%0;MH,ACFBDK
M:O;51(C-F]BT\JEDRFET87!^H]Q#?;8UK(9!32.'\N/<3Q. *CJ=K'<Q<IH*
MFO\ Q?#'H,UZ#\_R*/CE!!0T^.[C^1-*,=E<=G*N@H]\5%%B:PO+Y?)X8Y$H
MIZ;6HN5TZOZ#VF@WAK8_#D4_U5ITKN-H%POQ>9\O7CYCK#_,,_F(; ^-_3F2
M^-W2>]8-Z]S5NUI=AU66QN23+P]88.@@-)E<ON/.QKH??T%.JA<:27LH# $:
MG$6U[<U[>23R"C,U<?Z4CUX"E?(D^7J$MUWB.WL8+6'*HE//^,-_#QS3S%/M
MQJ368<,2/U6]3"P^G]0+M>_YMQ?W)$-@(5J,_P#%GY]1E=.UW(VHG_4!]GI7
MY8ZQ2JO) )UDFY^G(^@'-AS_ *WO1&:UQTEUG\Z_['6)Y-.EP\$,]T8/5 +#
M*(@1&6E5=#M&/T!OH?;;!!4TSTH2VF8 @G2>'SZ<Y-M9JAQ>.W&^,W#1XW+O
M6T%!G)\9##@<Y5P2FGKTI\L"U#455+(#&2C:TTZ6%Q;VR9T0=I_P=5^EG'EW
M 9X],E53-(9*6GALXHQ3BAG"PT,-5'(KFJFJI%!FJ)8KG5'?D#_ >[QO!<!B
M],'^72VT$T*FI.3P/^K_ "=8:,47W54^,3[9:J.*-8J%(IXVJ::GDCK/NFJ"
M'6.KY#N!R./;;HGX<GJ\KR4)\O\ 5_DZ[I((/)$+8Z,K2+&U/2M#*M%!'*=*
M4D4X7T"_(4G2">?;<:#Q8P_P5Z+Y;B2)))$.1GKC6K#,)**IB 1Y/.L$4I<K
M.K+]M%4'6@=YXU+1.K?M("0#[5//#%BH_ET_'M\D\1N17AQSZ5_U?LZX2M%9
MZKR2$F>""LJ4I6$D4H(2"ECC$8%5'"0/6;^]Q2PS$@T^?#I*C33N(*8X>?7%
MJ:.B-255Z96G>.JJX*:DD@JZR9'B\M3#/+K4K3.(R0+*J*/Q[8:2&I%1Q^71
MB(I1P\A\_LZD8C"93)>5=O8RLF7&02563J<7CI\G1X/%T0+UN1R"X^"61Z!H
MK^0R6"W^ONOBP\!Q_+_4>MB.4#CC/K_J'3*T-*D+A:":!"C)-CW:(P2QQK''
M32R55,),A!+1LK32*PO(LUFX]U::(C2OF/YC[.J/#,K*2#6GSS7K%X:&6='B
MCAG9)8&@1:.%(%DB4NQ"'0U-13?B,C2PY^OM#X49<$]/B68)BM*'UZR4]/2^
M9?M8X?N$BCH?+*:.EI:77/YZ=B$D#M'!4@-< V_I[61E"IB(%#]GETG(F5UE
M->/S\^G'-;9RN"GPK;BVWE,!4YFBJ,[A:?<&%R&'R>=I:UF$>32.HI4I/#2L
M/+%4ZOWTMP?;4LD46%_R=>#ROJP<?;TR24J$&66D\DJ0QQPO(M+!)&T3$I5X
MZ.:4*U46)LXXY/'/MA?U<CB>G1#,^#7^?GUS^TIVC5I0DU2I5YS50I_#*F41
MZ%J7JI=$;5P')86]0][\-!4=.CQZUJ:_ZN/4(QT[/%(L40,+TR1.K1.!44KR
M,DSSL&C3RK*Z2 7#QL1^??A&F0.MDS^8]:X-.I#NPBE:#_**F"0*+K%2TZO*
MQ8TU#50%D:&7Z.EN1]?;HF2*)D^=>F#;SR3*QQ4 >9X=01# 4DAC^P9_O(WI
MIZ,B.!*V>2GJ:LT6LZ(DHV$E.P)MPX'U/M LJ.X_V.EC0W"*6H:G[?\ 5\^L
MD<%+-9EI:-J6"6H/@J BK1U@D<O-2T,3,DBLKW U:2;<'V;@1"&K4!Z0P23K
M<LVD_">NFA@IHA#3^<4L5(\:8^>&".J9M3R/61TT1?AG8N=1LQ//MFL''!I]
MG2YC,]17CGS_ -7^K/4.""FCLT;4J 48EK:N*G5*S%Q)&(Q4I$H5:C(LZEV*
M\EF8^]_HT'28PRL>.>N[O(T,<44QEG,%(NE/NE$]5?[+)U$E-K\,%4/\ZCV2
M'\GW[ZE >/3WT[XZ[#LT3RPK&ZHW,D4GGB9>;M&R>HH?QKL??OJ5(%".M?3N
M,U_9UGQ=#5[AR5)BL+15^3RM944U%1XZBI9:VMR.2JV:.CQ..IJ197JLE72&
MT4:!B;$'VK%PGT^EF]>O?3O\04U_U?ZL==Y;&9' Y:IPF=PF:P6<QU0^.R6'
MRM%+197&UL+&.J@R&/J52IHY:64%6255Y'''M"+A!)QZ]].WQ#@?]7ITVSVI
M!+,[1IXK(QFO)/4*S (U/24:SU#?N,NKBRJ2;\>U\UU'X"#SU?Y.M?3N!J%?
M\G74<B2&>)9EF,$&NJGAB>3[6HX(A2G4&>J@TW!=5.D_4>T7U*G-?\'3@MV\
MEJ*_/K!)/$\-.T8CTS7_ +50)!HYN\<J(8[Z?I[V)E<T#9/7DB*Z6(..K2OY
M)#$?S./C"> "G</U' 4=!=L\FW-K+S;_ 'GV3<WC_%A7Y_X4Z$G*)_QFO#A_
M@?KZ"GN+>I4Z][]U[KWOW7NDUM!@-I[3!)]6WL(!].3_  F!N;\_1?Q[\.'7
MCY=*7W[KW7O?NO==$@"YX'^^'^]^_#NX=>../1=?D3TWCN^>J]S;!JJP8_(5
M8^]VCG13"V!WIAV#8+,7N 6AS=KVYM].?J0;CM7CC)_/]GSZ7V.XM;&J@^8/
MS_D1C_!]O5 NX<)!L:C@Z#[/ZXBZ[W9CNS-K9FK[;Q6&RM=N/:76N;#MO=O]
MP""3MO8#C#VP^HY?##2/XGC <$;X]_N#>.6B!,_GQ[.&/1GX:L4^>3B@UMX3
M*NL&JD?9Z_/CC@:4^70B]=3=>9;L>A^*G;];C^]^M,[5Y3;?1_;FTJD'&X7*
M?W-CWQG,3A<W@-P:\%M[<NW<U0C-8L'^#8?,?9\-C+?P\:[0L&\ )<"I\CD4
M^(^5!Y?M_/HMOM4%7&">(\SP_;3A\QP\NCW;&^"'Q>V9A_L(NI=N[R$B2^/+
M]CX_#;SRE!C@WC_@^%$NWU&Q, K(0!BQ8G_#W)DGMY9Q$1A>T^I.?/'ZGK\Z
M_/H%WO,%US!<_O+;P%9&R,'! 7BZCB%.0.B\]B_RN^JH\_%W+\:\UF.F?DYM
MJJ;+[([2JJO,[DQQ5\0N 79^]=FYYUVQG]N';8_AO%\R+WOQSI^1X=H3QH</
MZUQ]N7;U^S[?*6>3O>*7< -FWQ?%@TD$4TGN+-\21*,4%16OG5>#3J/YJ=^=
M+8ZBQ7S ^*':M!7XVB^TRO;GQMI$[GZFS@L"V87#Q@=E[?5B1_N,RN';D?G\
M&L>]%!E*#U'^:G2N;V]Y5W$N-FE#2MW*K>+CSH"T@QCB02/4U'2Y/\SSXAR:
M:=-U=JQYDZ@V!_V5OY&R;E^ITC^"MTRG' N0/S[7+S0%%"3_ #_Z Z)V^[GS
MS?DOML=8_D;?[.+W()X'B.DMFOFAWUVU3UNW_BI\.NW,AN:KI5_A79_R<QG^
M@?J7!,07_C.<P>X+=FY]--[XW%X<<&_OUSN,LX.E3H'GY>7G3J]ER!#L5S'N
M%S<*(_- 1JJ5*^4K,!4\=(QZ#/2R^.GPLI]A;Q/?7R#W?-W[\K:Z@KZ2I[/R
MN.?'[>V+BLXUY-H=7;+9QMG8NW&C91?2<QEVY)-[#4.SI>ZIIVJQ-2?Y5 !&
M!BIX <:=%O./N5#N<";1RJ@BT(% %20:J^3-&!D*U!@X)J2RT&7Y;5DN.Z(W
M/!% 6&<W#UKMBJ!!/WVVL[V5L3 Y[#9H?V=6W?O?H>?K_C["ONQ.=MY:G,)P
M=/S_ -%AX5!]>/1/[8[<=XYG@\?)[O\ JU+Z%?X?\O6N;V!F*VHS51//IUM5
MDU=C==7(///J_P!C]?\ 8^^09M6W?>[PN:S/2F!Y(OV#@ORZ[9<N&'E_EVV"
M+11J\S_OQ_\ 3?Q=!#5541C:"$:R ;D%;?GC@GZ_XVL?9_;16D3AKJ'6WVL/
M+Y?E^SI_Q-PVVX"W+U'V+Z?*OKT'V2D6O_R))2;"P!-N#I) T?4VY/L9;7=[
MC"^C;$*H?P]I\B>+C[?/_)T$^?N5MMYGMU:9,_:WK'Z.O\'^KS&CI+KV+#WW
MKNG%U&2Q]/6+1XC%48"Y'=F2:_\  ]G84@:KWOQ:_P#R\O?9WV9]UI^9=GE=
MFSCT_CG_ .%)_#UP#]XO92'V]WB-5 TU/K_!!_P^7_?G'\OL/ILCI/=O8=!!
MA9ZW;M/V;G-QXO>67W#B\2-Q[)H\J 5P6&_@=@&P&UMN'^&#^OV/M'>D[OND
MS2MV#/\ Q@?Z7^'HWL42+:8Q&N3_ -!GU^WJR'9GPG_NEB\C48GM;<6-SV3P
MX%52FCRYV1_>8;S.^3F,ULO^\C:;;>_W&?PSZ?P;V4W,2,3I((!_;PX9SZ<>
M/1KIK0GT_9T[5OP]S0Q H<9\@.Q*?/';IPE3E,O5YC<6-SK#=_\ '1F<UA3N
M,@L0M'C.".*"D]^MX1'1F6N?\_"IXTS3TKZ=;TG@#4?ZO\O72_$;=4V4>;+?
M(CLB?#KN4Y<8NE_BN/\ )BO]),>_/[H9C-+N1FSJ;I>2MQ6;U!6S16CL,>M"
M* VJ. 'G_J_U4'[*=;-U@$G-./\ J'^K[>A&Z=^/E;U7NP;BF[6WYORA.R!M
MJEP.ZLMELDW\3_C'\?\ XU?^\3$C3]?SR?>VJ>'&O^K%"/\ B^J_5<<T'[/\
MG1_MN<X3'$?3[:PL#8W>]_J;&_\ C["]U^*GH/\ )T(?Q'I]'T]TC^ =>/7?
MN_6NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[I,;T'^_/W;]?\ CVL]:W/_ "ZJG\< FX_/NPXCK5./4^3U,Q)OK'%Q
M^;*+<:2?H/R/;O#\NM@G33Y_+_5_E_P]2HCRY-O^!LJ@\?32WT%AS>X_VY]M
M#S^SJI\OMZG>Z]6Z#O-D_P 6K!>Y\<(L/I;QBW'T+?C\<CWL\?RZT.'EQZ8C
MR"=1 MQSQ<$<$F_/-^/]?W3J_GURM8 !C?F[ &UB/JP#6''/!X'O?6OGUT%O
M^&%M(^OU8&S7TW8V' _K[]UO[>L8:Y/A)4#F_IMJ'Z5('%Q8BXX_/O1DA0
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M.IICOR@HLA7Y/;4NV^VL/M_<NT\+09A:A!6TLZQ2,Q)>Q]KY@M!I./\  ?\
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M,'B)MIQ2A))J1TJJPE; \^_&2=BC$C3J'RI3_"?EPZ\+:+2XH:Z33SK7U!.
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M26GE2.*DIY% "O=KA5>7DEL*QYT\:CU\@?7YBM/3I/8VT5R2D@ U?"03@^I
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MGO;[@S<_;K&\8QGT_@@_X7'P\/\ U>=LGQTZJJ-K8X;BS5"!D,D0*34;:06
M)L5'JY'^W]R/;Q6TU]+<ALXIQ_AI_D]/]F+]R2YAVR.+3Z^G\0/^7UKT;Z]R
M+TUV "CU:22+WYN=5[7_ *BWNGB-7-:=+?#4@$=<0;L?J >?K;@ZC<C@6_/O
M>NE/]6>M^&M#3/\ J_U?ZN$6/6(OWR5D06D<*AOK=PI(3]L65A]!>Q_UO:5+
M2.V0&%J'[/\ .>J[?N3VRO'O*50TTYIYFN8P?4<?R\^L,E0OA"M)91^MS']/
M6%4Z;E]))%[ ?U]N37%OI42/5_L(_P G3FW6N^[A<RR<LVWZ2TJ=4?F"/]%(
M/$-Y?Y.A:QQH$QU$U51 R-2!F(FD4,6 -B$;3R/]]]?85FNH'))?'V'_ #="
M>/9(J 1J !BF?\_ITXUE;0P4Q!FTII8^.TA$8UK:S$/RVN_^N?=8[FVDK^L,
M?(_YNFI9TVQBHA[AQR?\Q]>GI)S(?*T8&FZ'D&P9B00P35]%M];?[S[>0A^T
M'/2<2,.XC'_%]2@ ZZK@J02IYN%(%N&U 6MSQ[]\)IY].?V@!]>'6;W7JW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW28W=SM/=W/T
MP.9O8$$6Q$IL3^;C_>/=A2J]:%:FG&O4]A=CR-)_(LO^).D$_J(-_P ?X7^C
MI-/MZ\E"H(7R_P _R_U?+K)'S/"?5P""""64VN.--@/I<C@?7CVTU<8Q_J'3
M""K+TZ>Z]*.@]SW_ !=I^0?VHO\ 7'H4WO\ [3_Q/^O[]Y]:\OSZ82"!Q^>2
M+6N;$_J'T5;G_6'Y]UZO\SUUI_U7'UMQZ6L/Q>_JYY/X_/Y/OW7NNP> 1:Q(
M%S<#ZCAN3^#]+<?7\7][_P '7O\ #UX@$<.+_D6LI)-^/]58G^AX]ZXC'7O/
MK+:QU&Y %C<C^@N>!QI_P]VZU\NL*_6[#U?6UB#I(6Y%P+D?BP_'^M[KPZWU
MZQ-K<C2/KP;W( !^JD*/\1[WU[KH-"P1FJI;0>=(8)@U1"LU1^VT=/"KQ^!U
ME!=VN19CQ<<^$8E(H<TZ51Q&0G20,_Y3UW))424%-25-36Q4ICDBLJ5#_=R1
M!HVHWH/#,U+3%']4IT\<B_MQ 4([:]);9_II)01JR1]E>@XZHZTVCTCL.@ZK
MV5_%<;M'&U.[\O1T63RLV:\%1O/<NYMW[MJZBOF@2E>FCS&X*F:G1FC9%(7^
MR/=;B0Z:A?M_,\/\W5?IIKB8R+)0%N!KZ4X9_P!5.A,6JJ(()XQ-6QQ0+3+,
MM%/44KB3QA*8TJ0*]0XR"D./&LRGZ@D"_M+;$A60K3-?V]+;FW(*RB0,NFGK
MP^>.D]MS=^U]SQ3Y3:F[,3N T67GVODZW;VY:7/?P[<M \3U>*RN1Q;.E3E:
M**=5J:)HPZ$KKL1[6F,TU5QT4_51AM!4ZZ_ZO^+Z??N)=;6FRD-*=<U:\\=0
M]36TU-*L\M=7SU$$-32R0-%I@6.-U$1TVO[2OJ8Z%-"/7I6 = D\B?\ )UE%
M1,DL-0@JI9!7Q&.18*V*2LK(J?R31,L*.TY16LQ94#-P0?>BDIK1QU7'$]<(
MIZB\L:Y.KC6&N1:N2*?Q5\;U)M!'701%I&BI5)41LD19?[0/OP65>XN-(R?]
M5>KBFI1\^N(R%13)4(9ZNACDCK<A.B33R&E2LF=3!%%J*1:$'D4.-:@WM;VH
MC&L8%/MZU(K:J\1TGLOO?#X>HP='G]UT.W<WO"I7 ;:@RN5AI)\PQC!IJ'#1
MULT"9S)9 M?TG3&S<<GC3]F3Z^7_ !=.KQ3I$:.E0,_ZJYQT@^\NIMO=^[$K
M>M-X9_?^WMN9.N6IW$NPMXU&U,T^"Q,%/+4[;R$]51U]75[4W!$RP5M L :J
M20V-FM[85R6->'^K'Y=4DD$@)5""?L%>A$PN*PV"V]C=MX.CIZ#%8##XC$8K
M'1*XH:+#44:ICL6:V-%A$!B6SIZ9A)^I03[4 $X%*],1JZ.2PJ/\'7+([YPF
MWLOMS"YS>&,PV6WA63T.RL3G,O38O)9P8VBKLAE\?MS'SSP2UU;CJ"E>61FB
M+"*(BZW/ORR+X_TVDER*U\LFG[1]G3SR+@A"!3T\^G")Z_QQ)%D*JEAK)I*E
MZEGFK*>-I04/DA6)J7(454K(%IY" '-D<W(+US2W&M\BOE_J'KUY16GE7K)'
M+60,88Y)J*MJS4ND*U[P_?)2#555C*P-.M.J)Z2-**MT5F(/NB2*5#%?.@^W
MJQ6E3Y_9UW*SJT]49]#T,<Y,OFC2>GHUIS-YC1S/JF:E<%P(>)+ $'Z>TDL;
M.Q92 /GTF:)F:H;%?]7^K_-UA>2IAGDK'J1!4^&&0URI4T@^WR2EGJ9II6$$
M:REUB69OW(AI-@>/:E*!2K#O/2M)DCA=64D ?S_/]O7:R5PAIC5U]1$[U+31
MQSRS/41SQH8)L=!DFE,CM]O+YI9X@KRIZ?2.?>@32O#II66>A4'\_P#8ZG-6
MNK"<O([J@AC99FJ3+3T=351OD(ZYIBCRTM0JN6D*1GR$WL??LT^76I82",BO
M'J/IJ?*S">6JKI$(C$TRSQF1B)8TH) 4II:FO -Y/(2B_H_I[J17K?I3KC4Y
M&HJXIT2JJ*^&.$5'V+AZZ=S/6I+0B=5:&I>FTP5.EF0*!':W(NRT;O@,*].B
M&H'=CUZD153TC+]ED8HZ3P5 +Q&):*$3%&B:-$J%FA61P5=G!NZ\*;>U,,1A
MLVE8B@8_X/\ ".F"I^J6#%2H/[?+RZQ/+)!)4F&IE@JI(_MYRM:E/+]O.J"/
M(-,WVQCJ99RHC8&Y2]@WM';5G<E<?;]G'I;=E;9.\:CY4^WY]>DR%:[0ALA4
M-,BS4]-%39 S4KS/2/$DZU]0%>7(Q(LD@A(6TBAK:02%3,')A44=17\N'2*,
M%@) >TXIUBCUJYDCDJ(IA%)X%@JI)!44[OI-:[>,M(:Q@5(L=9X7VF<Z#2A_
MU?;U84_/IMK=[8C 9#!8>LW5A<;EMR5M11;1P=;GJ>CK]R9#'8JMS>:AH*:6
M?SYI\7B<?+.\4:2^.*)VDTJK$.HC4UYTC)'RZL/*@SU!79VV<?NNIW=#AJ6C
MW?E-OTN,RNY)Q)6YZKPN+J)Z:&#)K*B>+%P.78JI-YG=AQ<^V;B569NT\?\
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ME4NXAD*)@<.XYI\\T-/E3Y],.(^2-;AOE=4?*2@VLL%55=D;FWE6["_C,_\
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MOWT;$*"YH#^9^1QGYTIUOZM0'&,BGR'V=W^&O18OBUWE#\<NY<=VK+M9M[4
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M_)Q4YY'^('NP\A\QU6F3_J].G!RAD<  *"+G_7 4D&Y&D*/\>![= H!7KV7
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MVX(ZBA4[BB=Z>6I9?NHE/DC(87]JT&:'CUL0Q:Z'\O7CQ^SJKNEV7W=%U_\
MRF]O1]Z4F3["S^2@RF"[-RO6&S:$[+P%?T#42X[#8S:&.I$V[N#-;*Q)EIZ>
MOKTDERBJIJBS 'VFH/WD!7/AC_#TBNU"3C0N*5^TU/1ELE\K.VOCWTY\I?\
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M4U!60;AVY54]76?9XBKI-H=\ UV4:R_J_P!'0!N!]?I_O7M0???G[#?ZW?\
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M7O?NO=55_P Y<'_ANGY#$&_JZF%AZ2 .\^J!_06Y^OTO;@>S?EL'ZJT].[_
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MS8-(::I>:6HR&6S%1F5J0570RKI!X[6IJ&H5&:DU^61C[,="$M$VNJL 6\J
M4KBM1QX4KGHMG4&W=F;AZH^ $^\=OO2]63?.GNE<@E<U9D=L;:J"=LU^VMMY
MK<GVZ8J""++0T5'#+,T,-;$NA@B*0KPD[BOXJ<//[?7\^FJ$*'IVDT!IBHIB
MO#TP/D3TE\+G/DCNJ+^9-A?E]7]FS=%X'KK>M?3X_L2@$?7^T.Q:3/(G65+U
M7BZW$8[&[6^[IO&(Z+!5-9!/$3J;3>RB.1UC_3 J7[O6GY>?I7RZ32+&TIUD
MBB'33_5P]2,\.AYA[D[PVS\F_P"5%U7C=[[WQFQMQ_'OKV;<O7TR:MH;DQN?
MH-ZME)-U;9-)]KGTJ_#!%%1U,4T-&OJC==3'VE6V\>1UI0$Y\B309QG_ %?+
MI5)>?3QJVK*BHKD :CY' 'R_/SZ*W%V-V#W'U#_,FVMVINS.;\VSU9VILO);
M$V]N^OJ1MWKV!.RI<//3; Q@ILLFQ47 O)"8*!Z<31(3<* /9E-;BQA6Y0#6
M3I_E\J5Z9VR]CNKSZ>X8^"$)SD#S\R1GC\^CV[QWYD]F_*+%;2ZYZ&^7?9G5
ML'1>*3:>TL-W5LC!?"G=_3DFS(AF*_)8&;I?)[<@A=PLN1GJLD<U]R#:H5R_
MM )IIJ*'4-7T-:5^T^6.%*]+YH-N4LQ!T_+32M/\_E@_RZKEW7VWV?L;^5ET
M*_5>\]^=68S?WRK[:@K\9@-ZY/;<T.'HUV[#_ ),_AZ<9/+X>DDRLBE(JJGA
MG170II+ *5@#SFB]P05^RII_JI^?2BVAM!'I)[=1/X:5TY_/A6GRZL8Z]P&\
M,;W=GN@,^/F!V]''\1LWD]R;NR65V]2_$7^!9GKK(5^*IML=+TG6N1P6X%J<
MM-%34]5%F?XE_$767022?>MR>28X9/#\\'5PIQK_ ).B>V6$)7PW#^1Q0BOH
M16HSP/19/C-G.UMU]=?'#IJBIOE=\6-W08;?&UNJ]S==83&[V^//;%%N7[W*
M9[=?;VQ9*/&XK U6+^Z-#E)=P5-3(*>)"M,I4K[16:E)!J5?E7&?E7T^72B9
M0%)!;%:^8I3SI]GF1Z==;?RU;U+\0_CY3]8[;^4>YY6[L[73>F\/@SVC@^J5
MKNY\+N.CQFT,)V/B\?T[OO+Y^CSB3U,E%#6-2X"CIGG_ &)RS>W-Q,DE\[=E
M JTU G/[:?/UZ76$L4=BL;!M6IOA(^7EGYT/#JM7^8#E:K+_ "K[#J\KU&_2
M&XM.)&[]@'<&TMS)0[J%!",U7',[)VKLG;U74U]9JDG,6,I6\C-J6_LVVV5D
MB1/, #@:?S)/^'HCW-4E=W!H"3Z>OG3'[/V#HG&H<#B_^JXYM_O?U_V'L^\<
MR(%_".@T\(C=F!R<=>>UF%[6%K@VMR+7YO?W7&2>O"O#SZAS<QGU DE?Z VU
M<'FXMQ[U3JZTU9X=6C_R0R!_,]^,1_3Z>XK#Z"_^@/MG3R6](%_9-S?_ +B?
ME_E3_5_JP).4,7/YCS^3]?0;]Q;U*G7O?NO=>]^Z]TFMHC_?I[2Y'&W\+]?J
M?]Q,(LO^/-_];WX<#]G7CQ'V]*7W[KW7O?NO=0)9 (%86LUS;U%O3Q90$/JN
M?Z6]IX]-H1Y@_P"KY^O7KA3W+Z=59?S#)-U8"#K+?F,^_J-KX6+=&WMUYO$4
MKU^3V/%O/.;!CJ-Y1J[/MO![A@V%B,T,1E,IIP\>89$;_@>MXD]U=F_?=H@!
M[1_+,1_B7^' _P!1%'+K=S*>/^$=P_/RK]H'IT6:3O?KG&_!W9W2F'S>.Q7:
M6Z:7;/6>[:K=.,S="=K#>N50=I[TS>8W#MR-<RZX+-Y ') ,&S%:#>Y(!5M&
M[<M6>A3!P^<GGJ\])KQ]<>6.KM)>[J[E9#FGIY>@[0/ASC/V\1D[M[ZZ8WC1
MX;XV=?=Q]5[3ZMEVGBQV=V -\;3P"?W'2)\(W6G6#J'&9W[NH8(_QDL0N&Q)
MX]3<CI-\Y=N4TI'V_;+_ )5STB?:KVV(>0Y]*#^=#C_BOL!4^DNJ?C?+\?3F
MI^UYZ63_ $8]9_=;7_TB[2"ID?[F_P =/\(PAV[_ +@V.X\T3_R]N./^F#W+
M YZY;$D:KO=4/$^#*-/I_H=22*^6#0'B3U'5_P"WF]T!,QU4]$SP_P"&8_:3
MYYX 7Z/KGXS8[?W3V&':E1G*K%=99+#46\O[][/R6W,*N<. OA\QFF(_CVX-
MT#97Y/-O]R?_  /%U*\^[ (Y&&Z N& 4>%*"P]:^'0?837!^6I!![>;TQQ.0
M/]+'Q%?^& T_R>?'H.ZK;?QTW"=L;8A[*K]N4.2W)N;,4M7E=\;/V[N3"Y/-
M[NWW?,YG5@"5V_NG 9KC@\9RC%N;^S9/<[<D?6+D5( ^%2,4I@Q$?A&:>7S/
M2$<D[\^H+*WG2OA8R>/>*X-"!Q/V4Z7^0ZD^,XW/W36MW&E2<7MS(_[@*7M#
M: &:TX;"9TYC"XC^[X:P_@9QO_%URP/^6?[CO=Q[I;H @6ZHJY':G'A_OK/Y
M]+U]OM[(),M6)(X1G'^]X_;C^1DT_3?QHCSG2-&_>AGK?X%EZL9X=M[2R=#(
MD0P*MBLWEQMP?QLR29DZ;'$ZDH*MK_Y%8-M[K[C21!.-+TKV(!7_ )PX\N%,
MUKGK?]1=^P?'-0#FD?K_ *>I_P OX<<<<^W?C".O\YE!O_/U%/C>S<F3M>EW
M)L_^\680;P_CIWEAEN&?;[8'_<F ;"P_AQ/X]T_UT[\-XHN.\*%X+\-*4_LN
M%/YYXYZN>1=_%1X_;QIIB%34&M?$('Y_LH.D[2=:_&S-[G[:R>4[/G/V^QM[
MX;+TE)V+M #>V+-\(6PN%N"=PC;F"HN/XL "/^+=;VJG]R[=4C4;P*5!IX)[
M3YY\+)KPH/MI6H9M>3=]X^,=9\],>1GT?^9/3TG4/QO4=,(._A45<U3N2NJ\
M_1]G;1EHF9<SA-PR8;-9A-N#5;.A=-OX03B:$C^@)+-[J6X:G[^&GR_1/_6H
MT\N/K\J];N^3-ZI\9+5-<1TX"GXB?MI7TX],='US\8]L[0[HW#%V3G\A3TN[
M<GAO[ETNZ]HY/<59;>6>_P!S&#PG]WE:VZ=P9JNR1XRU\/8_3CVM'NINCLC?
M4Y7AVH/EY0^@'[.FAR;O8#'QC3TI'FGG\1 SG[,>AZ4O8VW?C;B,[X(^QQN
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M]?I[>44M"/\ 5\75Y2IN #CC^7;_ (>C*[E-OA[T4.0/]F:^4MRU])!ZU^'
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MF]NFAF\T<[F\-F<)G=O?WCSVP"Q.3.4Q0_W#_0_3V$-Q]@(YBJR_#D_MIZ7
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M&D6L+< _\C]^S3/5B17C_P 5_F^7^7KU[M8:?\> 0?S;EB+<_P"W]^KP-?\
M5_J^WK0H: #'^Q_@_9Z=1I[D6 /U(L2?J21SS>]A;FWU]^8CRZJ@U#)/G_JQ
MY?ZOGU@/^-E(L.2/ZBU[$@CT_P!+7_UC[]GB.'6R<-JX\!_J_P!7I\NO <_B
MPX' 4 W56!U:SP#>]_>QZ#]G3Y)%*_ZOE_JICKT3$_[ < GGZG2./J;\?C_8
M>]<&SQZT*G X?MP/3J-,#_@+V'^  X(]7IXO_C[3];P5'K\O]7^KY]8+6Y
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M/NK ?4C[?\G2E6/@$4_U>?5K7\DVW_#G/Q@M^8^XS]2>?] 7;5R"?S8?UO\
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MS3O5 ?J./]%/^@.O?U:VTZJQFOVM_P!!]<S_ "AOBYR/X'CKG\?P:0,3:_\
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M'M/T]FM<T_P]>-KC\WY_H1Q_K_[#WZO6R,A1Q/IU&-B+$FX)'TN?J ;\$$
M>]^?5,4-1G_5\O\ 5^?7*3CGZWM;\$_2Q^M[$_UM[\6\NK 4 -?Y_P"K]G[>
MO<'Z@'^O'IN+\$GG5]>?\?>AY=>-"#Z_R\\?ZO\ 8ZP:2+FU_H?KS8@VY%@+
M^_?/RZK2@X9'6'\?IO<<G\ ,!].;W%N/>NKUR:\1Z]=_3^NJQL/4?\?KR+_T
M^H]^IU[Y5SU&E^O^'%N/SI%K\7M8^]G(!Z4 D&AQ_J_U?X>L-_42+#5R.>0?
M]B/\;?U]^KZ]>T]U1UF^G//^%K'\<@_7GGW[T%,]:\J^77I3]+< GZWYY%S;
MG\$\>]GA\NO+0\ *]8;_ .-KG4+V X!^I(Y'(]UKZ=7I4\<_ZO\ 5_JSU-^#
M<<%0>.+&]K\@'_8?0^]^G6@: U'40_3@GD $V_LVO?D _7_?6]^^72DU!ZC@
M&UB!<7^M@" "+&U[:;G^@]^ZV3GN&.NK6_/']H6%_P#8FQ^G^/MGY=>]".NC
M>Q_PYM_K_7Z\7_K_ +'WKC7UZUZ8ZPS7'%B.#86L5"D'CU:C8^]&O^K_ %#I
M1Q&>N1OP.18?T_U)YN!P;#Z?X^]8].J@9)KCKCRQ/U!!N+#Z_DD&WY//X]^O
ML7"@_P"K ZLIU6[4'#_/U:I_)1!/\T#XQDC3^UW#?F_'^@'MKZ6(-O3_ +#G
MV5\RXM#^?^%>C+E3-WY\1_@;KZ#ON,.I9Z][]U[KWOW7NDWLT6VCM<6M_OWL
M-_[KJ?\ I[V?+[.M#_+TI/>NM]>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=5=?S+^E:C?O1%?VEM2 0]O?%O+XSY"=0U_W
M9QR/N/K<?Q?*;5RS@@G![NVW][BW%S=:ZXM;D,;];-+-#.A_62K*?L"DUS^?
MV]2K[3[ZFV<T7D%RBMMUVHBD7)+ Q3*O 5IWFO\ 18GRZ.OT]V)M_N3K;87<
M&V!,=L]I[*VCOW;HK*:V0_A.;PJYK%LPN=#^&93^D$WO]+GV((YDN;..-:ZJ
M>OSKY@>GKU&EW92[;O=[#,!5B@^5-%?*OD?R\NA-HGFD37,YE1!_M,0N=0!&
M@!KE@!_3^OM4%0+11GI'6_MS6X./]K_DKZCK!6K#D)"L/[^H<>HP@^E18EBG
M^I_/Y'NJFE*'/3D8VRX%)Q5O]M_DIZ=9X)8&E+QL-*@ZAZP"6)_)4>FWX^O^
MM[3AS$Y-.FX3;SG1'%1O6I/\L=%Z[P^4GQ^^-V!I]P=V=N;.ZTH,AJH\0VX\
MJZ9#-2"--/\ !,0%.>SK('OIQJLP_IQ<>EOXH0#+IR?7C\Z4R/G2GET+MJY+
MYBWIV3;(G8*,U"*M1Q4LSTU_T20:9I3H)_C;\_?C5\I]V;@V3U-NS.5FZL+M
M_';S?#[EV7O39N1R^Q\ZTF,Q&\MFKN; ;7DSNUIYD"C()K + <"Q"*'>8IVT
MJ<>A%/V8_P!G^?3F]\BWFS()GC4KZ@_(#(+DCC04!%<5R.CP>%GED6*6Z-H#
M*RF]$/JQ!(LP 4CD_7V<Q.A0./3]O'H&S2O<?HCXO,TSY'T^7SZ?O;75NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[I,;QN-I;LY_Y<&9(_-A_"YN".?J;_[?W8<5
MZT,D@#->NY05<A@0_I])TV"E;_T75Q_3\?7VIP?LZ\N!QSTYQA?V""-(JWXX
M')B=5NIOR&_Q!'M.1Y?ZO/IA*>7KTY^Z=*.@[S)OD:TV L$_  &D*#?ZCU6O
M_L;^_'SZT/*OKTQ7XN+\D$,U_P"U:P)6UB22;7^GNI'5^N)5+,H'/!(L>#?G
M\V!N?]X]IXP?W\WY?]6^M279>Y4#_5C[.@'^1_9\W4_3&_=]44/^Y?'8@4FV
M_NZ4 ?Q/-2_P+"D6L;%N/Q?_ %B?8IY.Y>7=.;Q&:4)4\?X8F)_%\J=$G-^Y
M?2VRD'(J/S.FGEUKA;)QV&W_ -EXMM_;L&$HMTYZ:JW;N:KK$BCIHJQ(ZBJJ
MYZHNB0PNKZ!<A;J?Z^\U+EWV38Y_IH-4B(Q51VY!P!GR_P"*ZQ5EB6[WB(2M
MV$J*D5P1DT^?GC/SZL4V5\:OB%W7+O/9O4^YM\39[:N"DKI-U2"LGVGD(:9C
M3Q34%:0:6>F^X&FZDC^GN%)>>>9;*YCEOB@A=U&E)&#+JI\Z&E<CJ2H^6]JN
MX'6)2Q5&(+1K1J?E45.5KY]$IZ"[2RO0?=U%GAD3+A:#-U.U]VQPGRKD=MTT
MS'*SECK+2>-U-^?Q[&F\Q'F+E,RRYDJ*$YH:QT;CQ%>@_M]-GYC\-!I6A^5<
M2 CA7(ZV>K\ D+R+>DBS DB_'TN/]B;_ .P.'UQ9!-Q=QPQ_QT?/K)HW1DV]
M0. K_P >X<.FS+XR?<&-R6 H\WG,#)D\;/3C<^VI?X?N3#2.)$_W&U$FE'\#
M-=7 N+ ^W?(^G3T:T1<"M//[.JEN@>U>Q>A/BS\I_D!OKL_N?Y#Y?JGLCLW'
M[>VYVEN_[J.KVUUI+@:FAIHZB 31P25-1N(JQ-RZK8\*;Z/SZU< *1I%!3_/
MT87K#Y6=S5G:76^P.^^@-O\ 4NWN[=L5&=Z=W7MG?!WH^5K8L9'E9=N[CPK?
MMXBMCH:A=2%@4<@ "Q \/,$=)XZDCT.<$]%L^07RM[][8^/G=V\NJ_CU$/CC
M2TDNV<3V+D.P#0=B9F?;O86 VUG<Y@-@P2I%4X2'*T,T,54I!\E/*FKTLOMF
M272_"HIZ^OR_V.C/PM4=-5/04XT'\7^2OSZ/5U]W0%[2ZS^/QVI)-_%>@=M=
MFQ[MR>1:"MJGJ6AQS82JH%#^-_,"/,[:BPM]#?VK$]$X?ET'Y(&#C3_$,U/I
MZ<.@CJ?G#HZKW9O^FZNJ\_NJE^06Z.@.K=BXC(3+5;MW;@]Q5& QV4S$\JK]
MIMU/$*W(2WO%!?3[1K.'F"CCGH[DC\.P:OD5J?Y<?*O\^G,?*?LOJK8'8V\?
MEMT)#U2_6F'Q^5P^6Z^W/%O;8FZJ3/5ZT%/MZDSE5,D>.S%9E9E1@YT1BY8K
M8GV_^73,  .*5S7[/4=(+I7YWY#>':.V^L.V=O\ 2VTZKM*9,'UU7]0=X;9[
MBJ*;*1^/*Q;:W_AL7E:VLVA72XY@\8$:H[B4?V!?9-32O35R* >?VX_/@/GZ
M] ]\@OE1WMVYT7WONKJ3X^4M;\<*?&;HVK%V8-^IM[M;(U>W,S3XO*9/$['B
MJ%6IQL=<&6&J)_S8/T8'WH@4X=..2 G=Y#\NCA]X[QPFRO@UNW>N\=GOV7@,
M+U1M*KW+LROKY<0^?^ZR6!IX\1-E:5Q44V7@-3$QE5M3& WY8^TSUH<8_P!7
M^K'7K<=PH?L_G_JST&NYOE/W5!V5@/C_ - _'?:>_MP#XX;9[CJZK>._7VGA
ML'MJ>3;6,H-G3UA.J?*4=/G%2.8M=Q$VK@D^U5G$9(I&8Y!4#\Q7JFY,L<T
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MVS\5)@=R9.N@R& G@4@/F*9:4FE4DZX_41;Z,0*YM^8&U A+TBA\^!X^5#P
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MDCTD< W_ $_[#CW3RZWUT"18 A3J%V*ZK ?0$VY%O];CWKKU.O<#Z\ BXL
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M?^"VY/!^A/X+6-Q< \_GW[KW^'I6;3MIKP#:QH+\G_4R?DV^HX_UO]M[LO\
MD_R=5?\ G7_+TM/?NO=>]^Z]U[W[KW7_U-_CW[KW7O?NO=55_P YSC^7)\A=
M-C=NIK ?T_TZ]3FP)-CS].+>S;ES_<RUI_2_P/T'N9/]PIZ^H_X\G6BL2#_0
M D7L?I<-8\'^H_'N8_P#U_V>H'EIX@(^''^#KL_J"M_CS^2"RW:XM;\<\^UD
M=X)5I_J_P=*TM3%;L2/Y_/[?LZ.__+=[)V[U3\Y/CKN_=%9_#L&=W93;-34U
MEU6B??.S<[L7 W:QL/\ <W;Z<#\>PYNMH\R2A/CH:?;04\_7[>C'E2Z6*Y_H
M@Y_8]?+C^S^?6Y]\C_DGMCXJ];U79^Y<'D,WC:.HD2M@Q<<TU72H:N"FGJ:E
M( /W@:]BY_I'[AR*33( S8QU.MU4)4"O'_5^76LE\E<O\2\'O_ ?)OXO_*/<
M/=W=>].Q<;GJGH;--DLOC\(,DE*]51IB*^A$%.**6Z&Y(O\ 2]K^Q?M=YJ9E
M9 $"\?7H$;M:KI0Q2EG+'4.!'YUIGC]G6T)LWLFFQW1>/[6[*:EV91X39D^[
MMY&9UI5PN/PF'?-Y>-::R>%4IU4Z1^+ ?X$E_;(^]R/%\)_Z '0BVV=_ZN0K
M(<Y_ZNFG#UZ^?3O_ '1!O3?6]]ZP0+CAN_=VZ-RTE(:O4*$YS,_QT<?7DBQ_
MQ/N7$LZV,>?7_CWV]0E<3L+Z2O  ?\='2%C*HVI(]+/'HE/EG,4P#,P9H&D,
M(*WL+*!Q?Z^W:^8'6B"PH<U'V?X/MZ-ST=W/U_L+XY_,[KG=]=6Q[N[<VILJ
MCV71T]([TU56T536ER\P8S0/!=;>!HE%^1?GVV(D:342*]&"2:88E\A_+A_J
M_P /0B?%#Y'[ VAT)W9\;>PNWNSNAY]_Y[!]@;3[PZTDW,<KM[>&%Q\6)?#9
MW&;8RF*W!E=OU,46MWBJXY%-A<@6]I+ZU!4NL8)I3(%:?(T_XOI;9W05P Y
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ML?K=V(;Z@\>R-Y@A*J&)\O\ 4,8X=#[E;E6'>6,^ZW2[=9 5+%3-3#'X58$
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MD:J45JMZR==M+CB,M0$?EC_BNFT\^.K[?\W0IX_X^T'0'S^^-FWL%V+VWO#
MY7IWY(UDN.[<WGE-_P";I:Z/<W4<"5>,W7FV?+TN-KQ3Q2+30L(X5_3;6X]F
M< 7Z61E #4/^ ?ZO]0Z61U8'SZ5_>FT,]VI\\=I]1U':/:>Q^KE^/>0WEEMJ
M]9[YRFS3F=U15IBHIWJ<2R5^*"DAI7I^9%!#?4^PPC D:2=)'[#TVQ(4XS4]
M%:[/S/R&[@[E[JHL!U3\K^P=M]&[U38O4N4Z/[YV?U3B,158+ 4IGK>T\97U
MT&7WC5UF=:2K9\BCP5%'*&3AB?:U*$-7IAJG@*&GK3UZ%',P]Y]O]F_"CJ[N
M3LC?_5V3WMT=V/G>Z]N]1[MIMOS9_)XC.S4>->;<&U9/#+D4QRTYDJZ-CXF5
MQ&;DCW7C-0_+_#TY#B($<3C_  =(?'=7]@Y78GR[S>0^2G?E=-\+-[]CX#X^
MO0[^SM.:?!;2Q=5FZ>A[;EI9?N.S)M=(L3U625I(U) (6_M:5H@P ?\ 5PZ<
M' >G0B]V]@YON'9/QHVN:#Y&]D]B=C]&;*[6W)U9\:-XXWI.JK8\KM[;V0K-
MYY3LMZJ@G\%/D<E+IQT,NJH5M3C0I]ES-ID  K_J_GTY& A?('VY'IT%5+W?
MWO'\4NC:C.[HWSM'=V"_F&=<=-9 YS<6(SF^JC8LF[]P4,W7G8.>PKS8[<D4
ME+2)#42!B\S)=K7'M;#&)!3\7^;I-,:.Q QI/[<?Y.E>_7F\^\>TOGIE<Q\B
MN^MHMTONW#GI3&[2W[D\-@MIY>DV-D\Y4MF,50.J;GH*VLITT4]?^Q;ZB_(8
MF/@CNP/]7^3I^VR5(4'_ (KY]"/1=W=D;OW+_+!W%7[QR5/+V54;XG[)H,56
M&AH-ZR8K:=?#1)E,92J*?/4J2TGE8V81NQM]![9$97234\>B=&<NI+'CZ?/_
M #=%BPFV>SLC\;NSOENOR1[Q3M[JGN++T^TX*K?=?6]7TFU/]*^$VU5;.S'7
MJ2G$9Z/^"YJ989IT,L<A1;A4(;8DTX/'I2C2%14FG0X?*O>FU=S]VIL3Y+?(
M3>/QSZ?K/CSB-Q=*OLOL*MZY3L#M?/4D#9ZA$V.:$[CR5*DSK#AF)61B- /Y
M5Q5?( K7CT\&/;7&.C;?R_-G4^R/BEU9CSL7';%KZO!4M;54E)A5Q%=N*+0(
M:/=^XU4F2;<VXJ>-:FL>7]PRRDMS[575/#!!J-7^?KP\^CGBX/(Y!Y)Y-^ /
MH#?\<?X^T%>M]>Y -_I_L2/J-0]1"WU'_7_WD'W6^N6H@DD#E/QS<W /UN/2
M5Y_Y%[]UKI6[1 M76#?KC#7^EP91>US<DW_UO]M[L.!ZJ3W#[.EG[]U[KWOW
M7NO>_=>Z_]7?X]^Z]U[W[KW55G\YMF_X;F^0@/X;J4*1]23WKU4#>S%5YY_P
M'LWY;_W+M?7N_P".OT'N9/\ <&<5\A_-DZT53>X_)]5S>_\ M('(OQ[F(U\.
MO4#24\2E>N'-KVX(LI%B+_ZQ)L&)/X^G^O[?KG/KU>M5I_J_S\?]D5ZA'D$$
M_P#$'_ <C\AO>A2M?+JQ-13Y_P#%4_S#U\Z];&/PV_G*[-@Z]H.BOG%M2JWI
MA\5BJ+;6([0AQ'][*JOQ.,B>%G[.PB/!=U4\Y''>2%B!=#]?<7;GRZWB>("0
MX^S/#Y_/J5=OYIB9?#9:H?MQQP.WY?ET<BG[<_DQ=98O;?R.V[A^M,4,_N#-
M[;P&Z-M=9=E5F8RN[-NXO9^;S&-BPSX6:7'U5/%OG'F]6M*O^61!;V<A!;V%
MY%14;Y<!_G_U>?2FXW';IA616X^1/$4SE?7^6:>754W\Q/\ FU9/Y3;>K^F>
ME\!ENONDZBJ1-V9#,Q1P[R[%1%")A%CC"+M[;JD#D DDW-SS[%NS;+,D[3S?
MVI X4\@P_B/_ !?0=WG>8&MDMHC2(5H/M*G^ >>/\_G2B2RC@$@'ZD#D_P"'
MY ]BF\CT@ &A_P"*_P O0*@&MRQ_U8\ORZ\S1*ZQO(J,_P"DOJT^FXYM?^MK
M>]1*S(M*</\ +TZH,B^(#D_Y*CK!5>.FE@^[BF>2[54$QD5T6 D+%(IC1Q'"
MCGD/I8?T][6SG61I"R!":\>GV5FA5!0$#J9"T\)CD2KF2H$U0N-T&-#75I03
MSQI4^-Y-)U:5C=%1K?J]JFCHNAF!;[>B\B=3J &D?(X_U?RZ@R,U1'!X15TY
MGEF(DI:I*2$UZ!34M6*Z3)!)2L2I46#D\>TT5@)9NUA72>)_;T[)?2K'Z&HX
M#Y#/'K-%#6U$534TV.R\V,Q*)_%JW'T-144V.GD.A7S>02EGI\6*A_\ -^8Q
MB6_'M.[P+*(CA\>G34D%X8S**%?.I/\ +K)0TF9W#4M08*@S6;S58(R^.P&*
MK,_D9Z.-GIXI&P-)335C4L;1&*1XP &'!M8^[7/A6R>++A<^GET]MMM>7#^'
M&RZ_F3Y_/J/64DN)K6ILM1U&%KJ:2KQ-9BJRAK*%L>TM.Q-#+150^ZHZ^*8*
MQBE4LFJY/T]Z@N[28+I5L@>G1A<6-Y;L?$9"0?(GJ/2RO3>E_N8IHJ2CII)8
M91'6UBLB0QT$9FBEB2JE<%@WI%C[5D1*H+ TQTG61]0!/K]G6,AJBIFI:FLD
M@CHYTI:AF;PMBHITUR&J?3_E;L"(_,A(1S:W/M-XUM(_AHK:ORZ<NI-%LIE4
ME:C XUZP^=(:>-Y'GI5,U524=+6*U1324](-0JJMXHH9HI&B]2'D7_/O3>"#
MYTZ3P3QOI"H]1TW3U,$=9/21RJN1AU2T]*DDE8T<M3!2/0U6-O#XX=49F,S%
MBJW47Y]U\2W'DU>C2+PR!AJ8Z>LE09;&54)W#C<WB$R(QU1#)GZ&JHHZTI$Y
MHZ\T<E%1MDJ.5V(B6%Q%4WN6X'MRPN;6*:0M7+?(^1Z+Y[2Y#LP9?"K4<:TZ
MA^5'@HU772UK54[R0-4:H:.K=RBI%0.A:GC>)!*D4DDH1F(U6]TO[+ZMM<)4
M+0<33SKTSXDBX<9^P_ZOSZB-+YUF25)ZMH#+!4.\\2SURK)'(LE32(D AF+I
M^P48L45S].#N.2"V@\.6I:M,4\Q3I8DSQ)(34*R$?F1_@_XOKBM4D50R)D)5
MDA52*B0?=9"G@E0F:*&HEA"FBBCX9&U-?\^T8VR19/JB5\*M>.<<?+HGE-P-
MKV_;\>+$S%C^$UK2A\^N_,D;5$ 6=6>-*FD62M25(ZAC^[.^J$1K,:<E_#]-
M/%_:R01[@@M[<4DX=V!GI>K7$PV/0PK;5U\<UK33_J\NHRMXUC $E95MK>EK
M5GMD)*21A%+)!$(Q3X^G4GC2&<'\>[BW6-%B<C4N#GTZ52/(9'->)].'^?K'
M'(K(KTK/5TI5]$\4<;UBO3M>GEC=S#.S12,X>=U*FP]/NW@H/,4^T=4#N<?Y
M#Y]8J<JS4\<E5-4FJ^Z4&1/*M2S0N\<$DB")%KVD4(C@KR;?0^VI;9)  ",9
M_EUIII(=-1Q(&/GUB2(11I0DNE911DU",YFE>&5KR4.O7Z&@7F0B0D+]/; $
M$%=8);Y4Z,0+GP!+@1T^=<=9I9))'DY5X)"E1$$C$-525?TE(K#Y9*FF\9-D
M8 ?@^U<,UE3X'.1Z=$MRUS<R%490V1FM/7K@(HVE:H9G^XG*_<SQWCD:./F-
M:8.TD=.Q Y*J/IQ[: C5V:ATUZ5_J>&J$C4!_JQU!F]<TA;ZL[VOZB/42+DV
M-E^G]/;+Y=RO"IZ4QC]- 0*T'6$?UN+\D\7')!%Q_P 3_3W3J_6(?6P-KGG_
M 'K\"_%_=:TZ?],5Z[_QL"H^GUN+\?@7X]Z\^M9SC/44S,221;Z\<$#3;DV-
MP3S_ %Y][Q7%.K< ,?['^KY=<[C\DCCBW]?QR?ZWY^AO[J/+KV:8ZC6(=K@C
M^R/S8#C5P/I<<>[,/\9!/^K'3*4\(T\OY9^75KG\D;_MYY\8F%P=/<8 &IN1
MT%VS>VD?0CC\'V6\W4^F'^KS3H\Y2_W(Q\O\#_ZO7]O7T(_<6]2KU[W[KW7O
M?NO=)C9EO[H;2/U!VU@;'^G^XJG-^2/J/Z"_O?EU7S'^KUZ4_O75NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[JJO=D,VP/YL74^9GGTX[Y#?$KLO8 C!
M4?>;EZ-[!P&^,$I-_2HVWVKG#?@<6]D:QZ2N*AE_Y^/4E6CI<\D70U4,,@('
M&@UC\_.H/RZLSJ8Z=L<T0Y)"Z;D\ 2JYL;C@+?\ U_\ >/9DD9%'KC_4.HRE
MC)M&H/TZ?\_=3*C_ ($EB?TZ.-5C;2/ZK8$%O]]^%:_VB?8?\'6[C^RA/S/^
M$=4L_P ]@@_!5QJM_P 91V,+)I))^ZO_ &;&ZG_#Z^P)[A?\D;_;#_CZ=96_
M=&S[V;5_S3N/^T2XZTI[WX/TL;?06'U(L;\?X>\8N/EUV+ICKD]D$3R3FK25
M]$,$AT"20L514+\,[-<:1S?W90S'2J]WRS_@Z9EEB@4R32JL>!4D 9\JFF3]
MO7;^6.BP]+!*FF#[T52LZ*P5W:<BQ93PJEN+\<^]A)4DG8Q-W:?(YH/\G2$1
MQ3[1RM!:[E QM?J=15XR 9'J/Q>GS/Y=2JD3O5UE34$+3IXTI:DF(1%Q"H==
M5PFL7O\ CW14\.-5,38)\B/.OIT9[G^\Y-UOKZWN$-NVBC5BH:(%P2:'->L3
M5;4$IJ89Z4M5R11$^>F"^9ETP16+26DD!(1>"UC:]KAJ,,]5,;8J>!X?L'5+
M_=)M@N'W*&^B>*8@,08R%*J %)[Z%JF@(4FAI7-/1P&&(I#)%5T]>[1O+3/!
M-$CT[ZBCS122J&]1N"0>#[5P2I*WZR%6!\ZCCY<!G_8Z<:TNK?;1'M%[%<V]
MP2-<;12+6-@U-2LZUR>+#AY]<*8?O49MQ:51?\:EU"Q_H1_MO]X]LS?[BN/L
M_P /2BR_W,VJG_#/^.GJS'^3* ?YE'QNL&'^4]O?4@@'_0+OS^M_QQSS[D7V
MX_Y*9SYC_CLO6*GWL21[,<\GY6O_ &F6G6^[[R2ZXV=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW27WCQM'=IX'^X#,_T%Q_"I;ZB#?\ V_NPXKCK0IG-.ITEO(_Y
MTE;EM2D_MVN3:[@D6_/'^QLZ!PQUY311G/\ J^?7&GN903R%J2?P>6]/ )4@
M#ZFU_;8."3QZ1QY84_BZ?/=.EO0>9R_\5GN=(TQ#\@']OB_JT\+_ +?Z\>]^
M?RIUKRK\^F$@WNI)-B;FX)7Z#2H%N5/'^O\ 3W3AU?KKC@>GG_8'_8&P)!O<
MC_>>??NM_/KOCQ0:0"W%@0VJYM>W(%R;G^A]^/!>M#BWIUT/Q<6/U)M]+V]6
MDD_11^!Q_L??NO==@E;<'\,;FQN3]3<<$<6^O(]^].O<>NOTD >L?4GDW'U
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MBWAVY@=F5%5)48G%=I[TQL=/CMS;MIHY@)IZ=!"+64!> NG>)D"H?/\ S],
M>?\ DIT::P#,;D@\7_V')+*00.>+ _U]I>M]=@AK-87_ #<&QM_K6%F^G/\
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MXL)MREV/@-DTFW:S<.=QNW-NX.BI<IE]X+44$<5(7FT.[:2OJ!]N#<Y1J)%
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M";FWUNI_) N!_B;?T^O_ !/NO==E>!SP0=7U4@'\GG\FWO?6NNB2+\7%^?\
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MZV.NK<WM^!?_ 'H&PM:Q-C^;>]=:Z]:^D6-O5QS<7N;\M>X(X_P][Z]Z]>L
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MZ7/TM8@?0B_X L#]/>L^8ZW7]O7%O\R?4+K8%B!S_4$?34!^1^?:@C_$R?\
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MMSIM;_>N?>NMU&3_ *OY==3<D?5K$CTC@<G\6MJ_WQ]^(\NK<*?,==#A";@
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MZZ(4#\!N1^1P6MQ?E05'YN.?\;^Z"?PQ4</]7RZK^]+N;&FO^\_YO]7RZXD
MZC<,+?KYM]+'@&_ %OH23[:;=M'G6G^KT/5Q-<-Q3^8_U>O7,K<%K$,1R #;
M2POQ];D _DBUO:CK5?V=>!(/!"\7%@>18GG\<W/U/]/?NO?EUV6M:_TU G_5
M?6Y _KZ3^;<_CZ>_=>ZZ/ X])%B+<&_((#>F_P#L>3>X]^\^O?;UV6!XN65B
M18B[<_4W%B5N/Q_O?OW7NN@#9KV%B 5((LI-[,;_ $TW_/X^OO?SZ]\J]>NH
MM;43];+;2;$VN%L/2/\ 7]ZZ]GKNQ-U (/\ K6!4Z0/ZD^HC_#CW[KQIUT.>
M2>+F][C@F^H "Z@6X^GUM]?KOKW7?ZK%N>#R 5]-[&PN!8*#_7\7^OO5.O?X
M>LW%C8?@"WXY! !^O];?7W8=5/E7K .> !^1:P/T&LKI !X(X_Q-OS[KU8^O
M7A#;5;FW];CC2%^B@6L./>Z=>KUG-^2/J>!_:YOZ0IN /]A_O'O?5?MX=80!
M<FQN0+CD:E^AOS<:KC_;_P"O[UU?CURY(4<_@'C3:Q&K2+6OZ;@?B_\ 3WJG
M6NN!^IYN ?I8D &]P0/Z#_7%C[]^?7L]<BQ ) # ?[38V^K \'A@.>>/]X&S
MCKU*]<3>Y OI/U NIY_VG@'D^]?EUOKO2"HY6Q:P-A_9_-[6X'^Q_'O?6ORZ
M\?H0Q(8?4J25 (^C 64W(_XU8>]5\NO>G75SS]3<#BWUL0/J;$_0?@WN?>_R
MZW3KH?4#5^0/J/K?@&S"]S<7M;GWKK5>NPVD@E00%N1]/I;ZW;D<BW^!^GO?
MSZ\?//7;<7Y/-F(# #DL#JMP ;#Z_P#&_>NO==#E2P!N-)'#&W^J//)!)Y^O
MT]^\NO>?'KUOU7)!XT@:A>Y(XM879@#_ $YY]^IQZ]^6.NQ]3J#64J.5)LH9
MK@$\<C\<BWOU.O?9UXD$7O;_ !N;@J&X8,UR>?\ BGOWV]>X==$W/GX)2QU
MD#T@A@O N>+?UY^OT]^SQZ]_1)Z\04 )_+'^EPMK DD*3?\  /O?7NNP .+@
MBQ)'U_LFP(L";.!_OA[U3KW75R.;F]EL2.+<%0+M^;<G^GOWD>O=>L?S8\$
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MA8V_Q'']![L.!^WJI^(?9TM??NO=>]^Z]U[W[KW7_]+?X]^Z]U[W[KW54_\
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M=C)8&WU]-_P ;W(!M_Q/YL%]>J%J\.N6H'218W(]2DLI-Q?U"S, 38?C^O\
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M'+"164NF@@68."+$&Q'TO[]I8?A->O AN!!Z[4*2=+7.HQMR&*N+AE9;$AE
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M'T68DLUP"+7/UO:QY_ M?V=U-/ET38)X]W_%?ZO]68\YM;G@V!M:_!86:_\
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M4R!DH"*'TKU%JWI[^H#4""9=7UMI'"BZV(_XK[7QO/%VW K7SQ_@'3?U9B-
M>'E_LD?/JO5NU=QXK>D3"NWON'M+,]I]V[6_T/T%;M>LQ]!MC9F%WO\ Z-L5
MF=I'.'<VQ<%NBGVCA=RIN=</ER7SFDL,;D*#QM?N[96;_<+'^GD_P:OE_JQT
MD6ZWG3I\7/KIC]*<>.>%>-#\LAUE^Y=R4&)Q6"V1VAO7<M=NK%]2+VMV0*/9
M^[\?U3C<QO*/"=F]AK@<#N)]R=6;@,>\7Q[8[*8H8;"C _Q$+:@R1K]C:-FH
M6^C.D_TY!Q_VW'Y_G3T7B?=9**7&,?#'3&?05X#UQBM*U6R=H1Y/=HP7]_\
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M )^C[981.%5O7_/_ )NMU3Y(?(+9?QJZMS?9.]YXJJGI%1=N;:ID:IGS69G
M;%8NEAA)FE-5/HC1OIR/<;PVAE<T&17J7Y[-XQ4I4@C_ %>>.M:C(]<]W8;Y
MV_$?M[O+.;BQN[/D=O&;?.-V_!5Y5*7 ;32J*8+;M9C1+IB:>GG+:"HNH'L1
M6=DABGDB:I0$<1@@?Y.@=>Q3++&&C(&KSKPJ/+K:SSF$QN[,1N#:VZ*&ER&
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MT?WA>W]S?U5I&":_XWD"H%0#MP+<>'G0G@">I6/W?=U44+KXF",5!-.!/CT
M)-.'"IIQ 15=N/K3,[=QVW]P0]L9[';<IMB4FSIJS=&T*+(]>Y+JW=>#WGLC
M,X1L#M^(MN ;DPF.YRRY@Z<;8CU5YKJG^\+V]21_5-B/^>H@^5,?NX\?SX_*
MO5Q]WS<3I_4 DH,4%,5K0_4"M#FM!Y5IJ'3\O9FT?XMCMUQ5_;AWU09/<F5.
M_'W)UX<I7X[-8K;^$S6U%Q#;=/7AP,D.R\*7QC8K%7- ,E<Y,%F9/]X58Y_Y
M"9\O^).<@D8.W9%>!H,&OF!U0?=^W4.6U+4&G_&O3Q_X<^8!QP!;I-S9+H^L
MV[O3%YG9N[L_G][4W[^^\]5;0R78^U:\XF/!_P 7V7F3@!_=_<29W5N2X](S
M-=6/;^Q[TW]X;89KRH2U<UN3@Y'_ $;<^1S]GS-_^![W/2Y+K_+/ \?J*CS&
M*U%#YZ0*G43_ !^&X^ITPN'RFT-[["J\K0T&Z*JGP^.W%V'#G<%/@LZ.R\O@
M:>VY?[T[@\>28,R YBAI" ND(T]^UWWKMK]R+E;9"1)7SU9Q(17_ !6.G]D<
M#ACB37H&\T>UU_M$?U#JM  2%-:96M*R9P1DG.<   V.Q4U;'=H3Z;FW$?'X
M^DC>GZ_T/O+&1FEA65!0?[-/\_EU%JPRQ.17'Y= /O+Y$]>[4W15[7S*Y66L
MQZ*U55B)EAI2ZJ5'D2/Z&_UT_7_8>\<?<K[S7(OMAOD-GNI+5)&!/6H2(X"V
MTO\ OT?B'^&@\VWD3<-ZMA+%IJ0"*D4H:^>L$</2G1;,E#2;[[VSW9&7V?/\
MANM:OIC;776P-OX-=IUN.V%GL_GMROVD,SL_?FXMN1XFJ[0VWFL)KRFLEL3@
MS0'3K R$L<M^\'(GN%LL4VT2ZR6:II/4]Y"BC01%0/#.2#J))'IT1[QL%YL+
M*)(BLI_#@TK3S#N#\7D<"E1TINO-^;_VAUA@]^Y'>^U*CJ38597[1J-N;UIL
MWDNT&ZWZNS,^Q,YO;>>^DW$),QVXL6&;<>8QR[4#6U8NPR-LBTD?9PZ)?MX]
M&2V3VM0;MR=1M>?![TVEN]\:VXZ3![[PLV!K\WM1<Q4X9<OA4CE#:%C,8F5I
M!E,6*ND_B"*7"GW7ORZ'7W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]TFMX7_N
MCNRU[G;N<MP.3_"J@"W]?]C[\>'6AQ/2E]^ZWU[W[KW7O?NO=!OFR3EZS_@D
M0M<D A-(/ /.GGZ6Y_K]?'_)UY>'YGIG6]S8*?41<'U<CB]_R3];?D>Z]6ZQ
M\'_&]S_C>UOR!^!_K>[G];CP_P!7^;IT'1CSZY7N ND<D\GD@<?@B_!N; W^
MOOWT)6I_U?X<=>$0F.1PZ9L[AL-N3'S83<6,QVX<1E"HJ\5DZ3^(XZN'#$#2
M2.0/Z_[W[2;+?;CLI!:=E8#!%!YGT!QW=()K;;KP5"?S;_*?ET%='\<NB,1D
M(LEC.I.O:;(4P(I*M=IXE'2]P;,#J7FW/U(]BR3G'<KQ"C73L/4D'_"M?+R^
M71'/RK82,'$*BG^F/I_2ST-J+#$!!! 1!ZOTD<G]1N/I8?T-^3_4>R2ZO))B
M0U?]5.C](DA&!0_G_L]>L""1I(_VD7((-B.;&]U^HO\ X>T]NE ">/\ Q?2@
M'4<=)C?];1XWK[?.9R&,BS5%A=L9G+S8LRM325Z8Z@J*EJ,52:7@6I5"FH<K
MJ]EMY,(0%)\O\O3]K )HRU.!I_+JM+:'S"W)0==?$?9'QY^,6 JZWY%;8["W
M/M[9F1WK6XK;FR)MKYW+TM:N5S=;5M-5)E9Z-I0SR7#/I'LY_"".-/3Y5Z*1
M*Q?(JIX9X9I^WJ;B/FS\JMU4/8N*VS\1=MU/8GQPR/\ #ODI@<CV!/28*C>6
M@J,KCXNH\U'5+%NR6HQ-*\CJSS>.8!!RR@^X@=W'Y=*D2IRN3_J],_RZ$OL[
MYNY'&;&^)^ZND>IW[.K/EUEWPVTL=N/-/M>GV?438*BRM%5[DJ8WA/\ #S5U
MXAG?@1JFH$7]IY5!>/4*FAZ7P6I<3-0@+3_+_FZ05!\Q_EGGLIV-U5MWXE;1
MK/D!TC!AL_VQMZK[&JJ;K^?9^>QU9786HV%N5JM#F-Q95\;5HE*\C:!2-<7O
M[4I&- J2*_+HMEE*.0HK0>M,?L_E3H:Z/YC8O,=9_'CLC ;+:I@[U[)V_P!:
M9+&5^2DI#L#(UF:I</N:KGG4@Y(8.2=GC4 F<+:US[0W,>BK')%?RZ=MRTND
M4J#_ *O]CI>[J^0QVQVGV=UF=E_Q!.N>EJCM],]_%/"<R:?&/D3@IJ0NHI*=
M].CSCU#Z^V(W-1GRK_EZW<MX-21D5^SC3HH^R/G=W[D<9TMVQV#\8MN;6^/7
M=VY\3L_#[HP'84F<W[@,KGH:T8C)9?:S54@3#UM3@J\*[1*!&D3$_N+J5J]1
M4'IN%S*!0<?G7]N/\O0V=B_)#NC-=M;RZ=^*'3^S^W<_U)+@6[:SO86\:C8^
MW\7-NNEK:C;6W]M54532?Q3<%='CIFE5BT<0B(-KCW>N2#@]+)DT(!IH:</R
M^SHO_8W>Z]Z;L_EQ[_VQ2;BV4F?^0TVW-\[/R58:>HV_EL=54<.;V9NB")HS
M45D,I98 ZW=&Y%[^_8%-/#HM&HS4.<_Y^A.W%\NN\\_F-X[F^/\ \<L#V7TA
MU%N3+X#LG=>>WA-MW>U<-M"0[PFV#@5J8(,RNU*E)*&9BCAZJBF3ZBPJ^%..
MEWQ(H;SIC_4#_AZ6&_/E_D\Q0])X/XS;'Q';79'?^ULIO_:E!NS<$VT]H;;V
M+MJM7%[FS6Z,[32T\\%72Y^>FQ-/'&X,F0JD%CP"R/*@ZIII^&GKT4+&?)3L
MG/=7;HWA\G]I;"WIG\+\K=I=4Q=!;1@.WL5T_NNERRPRY!^P,?,E;V&]'&/N
M TTTJNZ$$D'WZO::KY]5,F@TU4KY]&CWO\K^],UV5O[:?QIZ"PO;VW>D<IB\
M1W!N/=FZI]H5^1S^3Q5+G9=N]6XR"HIXMP9''XVI"RW5U6J5HN#I!\IK7MSU
M89%2>/\ J]#T]]W_ "4[IVK2[0?J?IO8M-+N' TF?R62^1O9V.ZEPF+J)[&?
M9E!-4Y'%R9+==&J2-, 3'&@1B &]J%R1_P 7U[.<?ZOV'HL_R#^0N/\ D+\8
M?BEV_LP9C9@W9\ONC]NY#%19)C4/+2=GX#"[JQ=!6TS>',8*KD=U@D)/DB<$
MW/M2)?#U*3BE.EMEDSU'X>CJ?+'Y&[@^.V!Z[K]F]7#MK<W9?9&/ZRQVWDRC
M8 T=164=/+0U\LNI8VIZ:.H7[ACR$%P>3[+YFJ149R.DLY%6_AK7HO-%\L/E
M_D-W;RZ HOBGL.K^3.TL-C-]M0Q]ESIT]6=<YZLR5%@\DN[)JU:Q-R5]=A:F
MD^U,P6.9 6 %[*HXQI#$T4?ZO]7RZU& !4&@_P!7R_R=+0?/3:,7QLV[WO7;
M0GQ^Z,_O7_1&O6&1S-/CQ0=NT^:HL#E,%6;@JWCIQMS&U%8M0]7K#?; DG\^
MZ7'F#DD=/-&4)&FM!_GZB]!_,[<.\=^9GIONC;'5.WNT?[F[@['VBO379M+V
M7L_<.UL *C[R@R&2I\CD9,1N2E>"S1.R@C40+:3[3PD:LTI\L](I9 N1@_ZO
MD.@0P7\Q/OJ?86W?D'GOB10R?'7-;NS/7E5DMJ;[FRG9>/W/C-VYO:U'DHML
MS32156VZJJQ'JD6(NI+&X&F[\Y*%:GR'6XY/$4^E?]7EP_/HQG6'RA[-_P!+
M<G5'R8ZGVQU!/N?8^?[4ZPWCM/=51NK;.7V)MN>BBS5#NYIYJB;![LQ\.0CF
M,7[:,BOQ9;^V=>:$T'3A( J/]7^KTZ#1?G+VM38"@^0V9^.U%B_AC65$E/6;
M\DW7,.X\/CFS!PE!O');$>7[0;<J:Y"SZ8M:0'R<+8GR/JIZ<.MG^?\ J\O]
MGI>[_P#E+W6?DWD?C'T;T1MC?^=PO56![7R6Z-X;XEVQBFQ&;SD^)2CH/#/"
M)I3$D<L37.KR'\#V]3K0.,^O^KR/6=_FD]%\=MT]S5.P!%V)M/L:+IZNZ<3.
M2Z&[27.XC$3XN',AS+) U#EUK$8$ZXXV_ ]^QY=:S7HQ/<6_]]]<=85&[\%L
M"@W9O1:7$K68#)[BIMN[5VYD\U$HDK]R;IK*BG2DVOMJK<C(3^0.D<>H'F_M
MEY.\BM*4^SIU!V"O^ST6OX^_,7.=BUW:.PNS-J==8KM3J_9E?V.S=0[]B[ Z
MRW+LZ")O&*'<T=76/29ZDK]%)54[R B1B5%O;Z5:E,],R2:"230=!!L+Y]=Y
MYG9W4G>^_?C'M[:/QJ[/SJ[6K-VX?L)LWOO:F2KL_E\#B\Q7;8:J<2X)ZG%@
M3,8M2-.G(N+J50BN3C_5QZ8:76HJ,'AG./E_(GH;]]_)CN[*]L[SZO\ C9T-
MB>S<?U U-3=T[OWENN;:=-15V2Q$F4&U-B4]//#_ !K<ZT!U ,'"L#<#@^T-
MP!PH/S/2Z D ,20#Z?R\CU+_ )>.5RF?^(?6^7W'_&7RV6RV[JVLBR]2:C(0
M53YZ>U-4R:I)#18T1!;G@W-O;MKD9&.F;L4)"G/1WEYM<JUR#JC-HV(MZE_J
MK'D>_4R:^O6J8'I3KBUKG^I)L/\ '2O!'-^;7]Z\^K?*O7$BQ4V)_!%R#R>/
MP#P3]0"+_P"\ZZ]Q^WKB&++?C@V/ M:W "@< Z>;?U][Z]UR'%N3R2W)%_I>
MY# 6(*C\\^]=>ZZ-S;GG4+_7ZV4W&H"]]7T_'O?SZ\.NR+$^G\6!L' %BO\
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M(;<G:NX=\;"&;P\N1R]K6S(PY*Z:$WZ+<F>\^Q\X01S\CWI:FJO8]1F10?\
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M]#QS8GCD7O<\<W(_WGWK/Y=.=I%13/\ E^?^K_+U%-A?ZG@6N>>.;#^MS?\
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M\7AE.O<;C\GBZ]-]44-=4U$M=AZILP:G<D4LD,DOBJ:ASH(U(UA[<US,B*>
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M-J!+WIUKY#UZ*#V+W_\ )&@V'\=.N,AFOD3E]S_(7$]@=J[\W)\?MFON;O\
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MI_L],F5AW5^VOV=5Q?&23LKH3X*='9G97>O:.YGWY\A-NX/7OFHI98<'M?\
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M+$^]B*(@4(_G_FZ5QW<L@(12P_+_ "GJ/3H(TAC\M4%= E88:RMCFG2[S/\
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MI9ZJLK<DU/!4(3>*GK:A:>"K:9SY)T_<*\_46]W^D7S8?S_S=4^H<@X/\O\
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M<2-&-8''B0/2OVGKGU'\6]W;.ST69[=^4':'R(H]K87)[3V+M3=&V-K]?8;
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M56_&KFUKGCZFWOW7OEU[GT@ FXO?4=5AZB2 2 +_ .\>_=>].O #^R/KSP&
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MNO5IQ_U?ZAUGY_I];"PXN00!_7DW_P /K[L:5H3T\,\ .HW-[?X?U!^ES?\
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MCUT#^FPMR"!^/P+W-B0US^./I[UU[KW-C]?\;V4 $$?[9M7TX_I[]Y'KW7?
M 7\?XBQ)]0'^OQ:Q)Y ]^/6^O V(_#&]_421;C_:@IYU?G_>O>^J^O71''];
MEK\@6((8C6;GG_&WT-O>NMU^6.O6Y$)/U!Y'^IOR18?B_P#0?3WOY=>^?7@/
MZ\BP/+6/T^A)!.FY^GTO^3;WKKW77%R>0=)N2UKEN >=)/U''T]^Z]UR%@"M
MS<6#78D6N!]&'UOS_OC[]U[KP*<B_/TL#SP26'^)_(O8W_V_OW7ORZ]>U_\
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M -!=<O\ H'-^& O_ ,9;^4+BYX_O5U%?@_0$],"QN?\  >_?UOO <D<?0?\
M0/3G]5+("@8T_/\ Z"ZP?] X_P ,/SVW\HR;FW^_IZB^FD _\T9MS[M_7"[\
MJ?L'S_H?ZOV]:_JI9YR>/S_Z#ZY_] X_PLY/^EOY/_0W/]Z^I;<7#'CID'B_
M^P]U/.%V/3]@_P W5ARG95J&/\_^@NN/_0.-\+!_S5OY0\?D;KZC %R!:W^A
MCZ#W[^N%W0C'[!_T#UK^J=D2<FI^W_H+KS?\)Q_A8!<=L_*#B_\ S%?4?U)Y
MY;IH#_??ZWOW]<+L U(_8/\ H'K?]4[+%*U_/_H+J/\ ] X/PL-O^,L_*3@<
MWW5U!;Z_V0.FR%L1?W8<X7>>&/L_Z!ZU_56SI2I_G_T'UQ'_  F\^%OY[8^4
MIY_.[.H/S_A_H;-[?[S[W_6&X_@'^K_:]:/*EE_ORO\ O7_0778_X3=?"H6!
M[9^4AN "?[U]17OS^?\ 0U<!?S_7CWK^L-Q_OM?]7Y=>_JK9'\1_XU_T'UD_
MZ!NOA3^>VOE ?Z7W5U(;?^P7Y/\ Q/O?]8[ST'_&?^@>O#E:R'XS_P :_P"@
M^N!_X3=?"NQ_XR[\I2?K;^]G4?UN+_7I<#Z>_?UCO#C _9_T#UK^JMEQU&OY
M_P#077#_ *!O/A?^>W_E->QL/[U]0\?I!/\ S)JYN /]]Q[;.]R?[Y'[?]CK
M?]4[.@_4_DW_ $%UQ;_A-Q\*+@'MGY2<GZ_WKZA_)L0#_H9O_O?'O7[[E_WR
M/V_['5OZJV9!_4/_ !K_ *"ZQ_\ 0-Q\(2>.X/E#_@!NSJ ?G\_\85YY/'MW
M^M]W_$/V#_H'I[^J]OZ']C?]!]9O^@;CX4W_ .9P?*H_7_F+^H[?0#_GRO\
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MRQ9_Q?\ 'O\ H+KW_0-A\)B>>X?E5_L=W=0\@_47_P!"?U]^_K?=T&1^P?\
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M?T_X]@\W]^QUK/RZ[_@F4_Y[#</U_P"53:?T_I_Q['U]^_;U[/J.O?P3)_\
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M\]=N+_SFVG_M^-L>_?GU[\NN/\#REC_O\=Q7_'^2;2_I_3^Z_//OV.O9Z]_
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MVQ2?F><V  MI' (/YO<D B_^/^WUCTZ]W>1ZY_W;H[\2S@<6&I38C\_I /\
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-U[KWOW7NO>_=>Z__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>gyowp0iggm03000009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gyowp0iggm03000009.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_X0""17AI9@  34T *@    @ ! $:  4
M   !    /@$;  4    !    1@$H  ,    !  (  (=I  0    !    3@
M      #<     0   -P    !  .@ 0 #     0 !  "@ @ $     0   ;:@
M P $     0   <8       #_VP!#  $! 0$! 0(! 0(" @(" @," @(" P0#
M P,# P0%! 0$! 0$!04%!04%!04&!@8&!@8'!P<'!P@(" @(" @(" C_VP!#
M 0$! 0(" @," @,(!04%" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(
M" @(" @(" @(" @(" @(" @(" C_P  1" '& ;8# 2(  A$! Q$!_\0 'P
M 04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%! 0
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M3Y?[IKGO#^IKJ.G)=*Q.>];GF#U-?ZTW1_EFHL__TO[^**** "BBB@ HHH-
M&;JYQITW_7)OY5X-&/W08=@,@=LGO_*O>-4;_0)AZ1-_*OGNZGM;6SDNM0EA
MMX((9)9;J=]L<2!=S.[$A0B@9+,<+UKW<G?NR/&S1-RC%":E?Z5H>GW.O:]<
MQV%A91M=7EY=ND4$,4:9DDD=V&$'=CP!7\<W_!3;_@O/XR^+.HZI^S?_ ,$\
MKXZ=X<4RZ9XC^*2*1=WC*2DT&B!ON1C&#<D9)^X>,U\[?\%@?^"KOBG]N'X@
M:E^S%^S3J=Y9_![1;F2TUO5K*4PS>+[R(CSHRR-DZ?%("H'_ "U(R<BOSC^$
MWP@2>.&"&W$5O&-BI'&  .-J(HP!CVK^E?"[PF^O0^OYD[4ULNK_ . ?BW'O
MB50RV+P^&UJ,\W^''P:ENKJ6X FNKBZE,]]?WCO+<7$KG+/--)\\C'J6/<\5
M]Z_#;]GMIPB10&9^.2GR#]*^I?@;^SG>Z[<Q)%;XBRH\I5P3CWQU_&OI7X@_
M$GP#^SY;OX1\'6=KKGBG:%E0$&TT]L=9G&2S\_<QQ7]!8K$4<'%4<'%**[:'
M\V5<VS#-*TG?<\JT']G73?"VC_\ "1>,+JSTBPBCW-<73+#& .R%L@D^@Y]*
M\R\1_M+_ +.OP\$MAX1T_4O$]U#]V6&,6UFQZ<RR#<^/]E:\V\4:;\0OBMJ)
MUKXCW]SJ>YB\-O*S>3!G^&.+A%5>W&:YBZ^&-A9P%0BX0#)*X&/\FOG*N+=2
M=YO0^PR_@JG!)UI7D9VO?MX?%NX5H_ WA;PSHXY6-ITEN9"O4$F0A<X] *\H
ME_;P_:RR5@OM'AV_+Y:Z7 4R#ZDYQ6AXC\+P69:554;> /QKQ#Q':6=O<"48
M&]>/J.IKJJ4\/*/O,^IP6#;:=.GL>\:;_P %#OVH=-D634H?#>HID%DFT\1Y
M'IE&!'X5[1X7_P""FFB7LB6?Q7\#1I$3^^OM!F)=5]?+F 7^=?G7=0VP);Y<
M>N:YJ\L[=SN^7! ./;.*\3%9?A)1U=C[+#4ZT5=QL?O_ /#GXA?LR?M%QK;?
M#W7+4:BR[GT;4Q]DN_P1\!C_ +K$&LOXA_LQVZ^8?)9&!SMV^U?SYMX:O9Y9
M-1T96,EG&;IIK9B&MU0@%RRD%<$C'-?=O[-W_!1_XC_"*:'PG\:?M/B[PN2B
M&:5@VJV2?=!AF;'F*.I1^H'!KX[-,L?O3H2/5A1E9<ZL=A\1OV>+NQ=Y(XR5
M&>>,<"OSV^+?AZ3PS=QZ!9VYO-7O<FUL>FV-.3<3'^")?4\-T')K^@[XI_%'
MX;>-/">BW/P"DL_%NN>+8Y'\/Z7;*!Y B^66ZU, EK2W@."^_ES\J;L\?(^K
M?LH#P+9W%_KER=9U[4/GUC6IHL>?(!D00@9$=M&?]4@Z#D\FOBJW$-5MTDK2
M6ESLA3]BO:S/P/UGX3I:6S'4LW5W.ZS7%P 482KPODXP4"=5/4'FOWR_X)<_
M\%]/B?\ LB7-C\ OVUKN_P#&'PS!2TTSQ?('N-<\/("55)V/-W:C(YP70=":
M^&/B;\+I+%Y BY').1Z]>U?$?C?P2%:5=HZ,.0,8Q]#^5;8K*\)F%%0E&TEU
M/I<KSJ56REL?ZLG@KQWX1^)GA/3O'OP_U*RUC1M7M8[W3-4TZ59K>ZAE4%7C
M9200>_<'(.,5U!WCDYK_ #D/^"17_!6;QG_P3;^)*?#?XJ7FIZM\%M;G\J^T
MD%IG\,W<S@C4;*,G(A.,7$*D YR "*_T1O!OC/PM\0/#-AXQ\%7UKJ>EZI:1
MZAIVH64@EANK>9=Z2QL.&5@>,'CIV-?EN-R^IA*DJ59;=3VJU-;K8ZU3D9I'
M^Z:<H[?RYS].M,W"7:(SG>2!CH,'OW'XUP*<;ZLY80N0EL#-17]_INC6,VL:
MW/%:V=I&TMS=7;+'!%&!RSNQ  SR2?NUYKXV^*FA^$+VV\.V4$NK>(-1BO#H
M^@VC;9;N:RC$LD)G(,,#[2"#,Z@Y&,US-C\,->\?7LFL?&RY@U*U6YO!IWAV
MU4QV*:=>6Z1M9ZI [/%>R1MN(D. "1M&*SQ-6ZM Z%!(KR_$#QI\2+JZT#X3
M12Z;9V\U]IE]XPU*$@VERD"-:W&G6TJ%-1MY"_,F?+XX)KTGP=\._#_A%[G5
MK=&N]3U&Y%]J.IW1\R:6Z,2Q321!B1;QN$4^5'A1Z5W-M$EE8PZ=:+%'#:QI
M;VMO$H2*"*(;52-1PJJ!@ =!4G.<GK6&'@]>8SJNVPD:I&,1C'.>:<0/O=LX
M_&DH\MI-PC +[24;/0@<<5TRC!7,H)MZ'\O'_!RY^T1>:/X ^'G[).BRJJ^*
M+^X\8>)40Y;[#HY1;16]%DN9-P!Z[*_CRUW4&ED+L>2Q8^Q/:OU,_P""Q?QW
MN/CW_P %%OB1JD4WFZ;X9N+?P)H^ULJL>FINN=O8;KAVSM_NXK\C[^??U'4D
MXZX_&OZ/\.<F^K9:FWK/5^A[M*+C$C24NVTGKS6E"><5E6P!/%:L/WJ^ZDW:
MR-Z"U-FW.),^U6,L/I5-5/6K]LK22;5&3V%*&FK/!SNK;J;NF6+W<J #C.?P
MKZ5\&Z9_9TVGVMMI]]JNIZK>II>D:-IL?F7=]=R_<CC7IQ]YF/RJH). *\Z\
M#>'VO;B-$0MNV\#IR< '_"OV+_X)9?!4?$7XN:G^T1<Q Z3X8CG\*>%6E!VW
M-_*!_:5]"3_<&VW1P/[V*^/XZXBA@\'.,U>^EO4^5R;+92KJN_LZKU/M+]@/
M]AKQ7X#UYOC;\9HX9?%^HVRV-CI-D_G6OAW3_O-;PR#_ %MU(X N)1P<;4R!
MFOZ2?A1X,_L;28G &"!U&#QS7F?P6^'MO:V<-W*@'IQTX^@KZVM88;6$10@<
M#^&OY?R_*L+A*/LL/%1BG?16\[^I^FX[,J^,E[;%2<GL2[BV%QST%>3?'SXS
M>#?V=/@QXE^./Q"E$.D^&M+EU"X_OR2)Q##$.C22RE8U7K\W%1?'+X\?"3]F
MWX;7_P 6OC+K5OHFAZ:F9+FXR9)I<X6WMXE^>:=S\J11@N21QCFOY6OVY_V_
M/'G[<\VE^%[?1W\(_"G2M3@U^#1]7DW:[XAN[<-]EEOX8V,5M;QEO,6 EG+!
M2^#Q7IX/!3Q<U3H1NF]6>+AL,YST/D?Q3XZ\7>,_$&O_ !L^+$HD\8^.[\ZU
MKJ9)BLX>5LM.AR3B*SAP@'][<:^<?$.L_:9GVD<GUK=\:>*'NY7"$/R?F;DD
M>OMQ@'WYKR:2X>1BYZGK7]-9!ET<-0A12V/IY0Y+,U+?)D+<]/6M&(E7SGCT
MK'M6ZL/3O5OS'QU%>Y34>:UM#XC/\S;YW?8T/M"HPY'6M6TN3<7")TVX(V_Q
M5RDDI! Q^5=5X;M)[F^62,,2& QC\J_CKZ6_T8\LXER3$9GEU%1QE*/,FDES
M6W31^C?1^^E#C>&<[P^!QE5RPM1VDGJUV:_X!]E_!O2S<S0R#(W,!CWZ@=J_
M0;_@GU;W/B/]J3XO?%B(;K:RET+X?V%P@^5VTZ.2YO,>PEEVMWR *^+?#&OZ
M9\(OAKJOQ5\2*#;Z1I\MS' PYGG*[+>%0>KR3$(H')S7[ _\$[/@%KOP@^"G
MAOPEXJ?S->N=^O>*)0<M+J>I.UQ.[$\L4+[.>RCTK_(_Z&'!%:IGN.SJK!KV
M?N*_?K]Q_H?]-#CFA+*L'EF&ES<]I/T/WS^%%S<S:"F[KL!_E[UZKNG]_P#/
MXUQ?P]T]+'14C0<[!G(Q7?8;VK_3:6Y_G$HL_]/^_BBBB@ HHHH ***:3SB@
M#*UA\:?-M YC89R!CCJ?;UK^,K_@X-_X*2ZQ8R#_ ()R_ '4C;WVHVB7GQ3U
MNP<&6STZ3_5Z3$XY66Y!W3;2&$>%/6OZ<O\ @H3^UOX5_8<_9(\9?M)>*7C9
MM"TN4Z59.<&]U28>79VZCJQDE*C'IFO\R+PQ<^+OBKX\UGXO_$>9KWQ/XOUB
MY\1^(;@9_>7]Y)YLB)G.(TSL5>R@"OW'P1X#><XUNHOW=/5^9^4>+7&4,HP'
M.G[\M%Z'HGP@^%T:BVTJV@2&"&-8@D?(1$.0HP,#\*_8G]G+X$'6KB#=!^Y4
MCRTP<<L!]>]>%?L]?"G^U+FWM$BZE6D_&OVRTBWT+]GOX.WGCRYC1KJ"$0Z?
M V 9;R7B-.W /)K^U,\Q:P-"-",$DEL?Y^4\RK9OCN7FN>$_'3X@)\%M,B^%
M'PP>-?$MQ&?[1U"-03IL+#: B\CS7!/)R1BOE'P9\)% -U<(TKL=\DDF6=V)
MY=F/)9CSFO3/ O@K4/%.J3>*?$1:XOKV8W%U,X.XNYSDD]1V'TK[%T+X>PV]
MFN(P20!S7XCG6>SC)79_4O#/#,<-1A2IQN^Y\@3>"H+.W),>.,5X!XZO&M)U
MTFWAB41RA7D 8M(CC."&XX(ZU^BWB7PQ_HTYLT,D4!42LH^YNX&2:^+?'7@O
M4[VYEUME@CMD1C&9' \\1\-Y?7Y@6^Z<<9->+2SV\ES2T/U3)N&X)MU%J?$6
MO2V4NM0P7\<,EL9OWZW$C0QE.I#21AF4>Z@FOB3Q_-K\U_*^CPMY/VF8Q*V"
M$C+<;&)RPQC&>:^R?BKI^J:=?G4GE@CA\P0^>P;"JW0NH(Z'N*\,U/3KJ.PB
M.IM")6<M+(G$9)(VGGNPZ5]O@5-5%6<KIK8]K"X&G02C[._F?,32ZD(0;F:=
M".TUMW^HR379V&@7%[X7C\07#,T,]Z]K!<+@1LL:#>A0G>&#G() 'O7I^D16
MVK6K7=D&(B=X9-ZE65D.,'/YU+XEO8_#_A]K"TB8?;TS>7[P+)]F,;J4\MOO
M /C+L <5&<8BM4=.C2IV9Z]/V-1<KA9GSQ=:%K&FZR^G7B7%DTRL[12!HVD3
M@C>F,%'&&&2<]:YW6-&?&T@E1P,CH!TS[=C7O*:_<WP1/$Q.92J1:@K&2WGV
MC:H\PDE3@8"G'%&I>'(VBS@_-G!QU _I4U:-2-G.&KW.7,*2TBX['$_LG_M(
M:_\ L;?%6X\=:) ;K3-9:&#Q1ITF&>]LH6R%CD(+1M%DE=F >AS7]0T&I>"?
MC=X!L_B%X*NHKO3-5MA=6TZD%EWC)1\?\M%;Y6'4&OY/_%7AD1@NT><\ CK7
MWW_P2[_:2O/AW\0)OV<O%=RRZ-X@D:ZT)Y#Q:ZGMY11Z3*H  'W@?6O@\_R.
M$J;J4]&>#B(?S;=C[ ^,7PM6!Y3)'P<@'%?E_P#%7P#]G:3RT/4\U_0UX\\/
M6^MVDL3(,C(&[KFORV^-7@ P7$L908() '3KVKY_*Z[4HV/&H0E3J.VQ^(7C
M/P_'&9%E564J596&<Y%?T,_\&[G_  4ZU_X5>/K;_@GS\8[]YO#^LO+<_#34
M[R0*=-O%!>72MYY\N<!C#GH_RCK7XS?$_P +_8Y'^4=#TKYP3P1K6CW,/CP7
MT_A]]'N[;5;#4(3B[%S!('A>W7@MAPH;_9S7N<2Y5''865U>:1^DY95]K#E/
M]:B^\6:!H?A^[\5^(;J*PTZPMWNKN\N6"10PQKEW=LY55QR<5Y#?ZW\2_BK=
MS67@X3>&?#N^YL;S79PIO[R.:V5[._T0C?$(U=B&-PF2!P*_,3_@EC^T_P"$
M_P!OCX$>&?VA_'E_+JVNZ-?WNF7&G2$6UOI5[]G2UGA>V1BMR)P/.0RAMID.
M*_;"!XKB,/"?E)R0O &!@;1SBOY_CA)*;CV)22DX]CC?!'@#PO\ #Z+46\.6
MB)<:U>_VGK=W(6\[4+WREA-S<'/+R(B[@NU>. !7=1G]WL/8X],C)QQV_.E\
ML#_Z]*%QZ5Z481CL<TZMU86BBBCF,@KSSXP>/M/^$GPB\4_%G5V6.V\,^'M1
MUV61NG^A6[S*I'H750.U>B=!7Y _\%U_BS<?"S_@FAX[L=.E\N]\82Z=X)M,
M'#$:G<HLVWZ0AS6<,(ZU6-.WQ-'=@X>]<_S^-:\1:GXMGG\9:X2]_KM[=:_=
M2,WS>;J$[739)[_/BO/;@F60MT)/2NZUR..W<10@>7&HA7'3:F ,?E7'K"2^
M,=Z_KG+:$:%*%-;)'KN702U0KUK4A'.:(HLCD5?BM2?NFO0<U?0T7N*[+"?=
MK>T6$FXR?:LA8&&%/<UW/AW3)995$8))V@ ?6NK#\LY69\+GF+Z(^B/!/AJ]
M\2:SX7\$6.H2Z:/%/BFQ\,W.IVL8:X@MKPMO:$=/,VY4,>5SD<U_9M^S'\#/
M"_@#PYI7PZ\#V$5CHNAPK8Z;;0]!%&>68G)+LQ)8DY)-?RG?LC>$)/'/[5WP
ML\$P@ 6>JW?B^\)_AM]*MSL<]<!I'"CWK^WGX Z="T2SA-I90Q/<[N0?QK^8
M/$*J\3CI)/1:'J8*GR48'T_X7T:/3]-BBVA<*>.E<Y\9/C!\/?V?_A7K?QD^
M*E_'IV@>'M.FU+4;M@<K'%PJ(HY9Y&(2-1RS$8KTZWBE^555F. ,@C&.O<]2
M/:OY1_\ @L'^UQIGQW^/UI^S3X%U"&\\&?#B2WUWQ3/92K-:ZMXEE :VLY&!
MVR1V"_O'7H)6P?NU\C@,#+%XB.'IO<]["T^?1'Q)^T?^TWX^_:^^)H^/GQFC
MGM+*VN7E^'W@:Y93:>';1UVQS2*H"S:C,A\R263)CW;%P!7R?XE\;75X[98_
M,Q+,3DL<8X^OX5D^+/%9NYG4/DGEB>K>F3[=J\KFNVG?=D]>:_I/(,@IX2C&
MG2C8]2--4WRHVY;^6:0G).3GFGQG<.3^E9$9.5[\5I(<=<YKZ^*C&-D>%F68
MV3C<U8R$0]P1P:193MW$UGF3ZTT,2?EY/I730I1OJ?CV?YM:,K2-6WD>YF"
M8KZ@^%7A&>_N(V"]7P.V<8_QXKQGP7X:FU.]3:N<XSFOM4W]S\(O"5K-X9L!
MJOB_7KR/0_!>A+]^^U.?A68=H8!^]E;@*HQG)%?-\59E1PV&J.MK%IGPN0X"
MKCL7"4/B3/7?AW\-?^&A/V@M(^%C1?:/"/PVGM_$_B^0',5WKI ?3--;L3!Q
M<2 9P=N>M?T^_ 7P,UW<?VC.A.Y@Y9NQSSSU.[O7YQ_L0?LM:=\$/AYI_@#3
M7:_U"6ZEU?Q+K$N3)J.L7AWW5PQ..#)P@[(H%?NU\-/"*:#I<0*X)3YAUK^
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M\_WT ;8"VT]R <?K7\5G_!QOXNFU[]NKPMX)MFS'X:^%T$CH.0)M4OYF8_\
M?$8%>WPS1=;,:%-KJ>KET.9G\X^JJ7Z8QD[?YUC0VI8GIUS767]N=P ZYYXZ
M>U16]DI/RG)K^J>6"B?0.G9VMH9]M8CEC6JEKQQQ6M;V)4<BKT=@6XQBLHR3
M=CBQ]16L8]K8F6X55YYKV[P3X<>2Z1EXP?G=^%4#N3_.N/\ #^CM-<@ ');
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MT9H76H-<R,22>U.MQD8&/QK)MMO0]2*T(<;B#Z5][&*BK(\;,LQ44[,VTE4
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MQBL76Q5=UI.[8L14E.MRQ6A^U_AB!;?3D@"E6"YY'; Y[^M?%'[?G[?'PO\
MV#/AC'XN\46\FL^)=78VWA+PE:.JW6J7"??+$[A#;1#F:4C"CH-U?A]\3/\
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MJ9=_$1ZNG7\:EJ).OXU+7PZV/I HHHI@%%%% !1110!__]+^_BBBB@ HHHH
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M^5?RUQ/BO:XRH^Q^T9;"V%IOR/T'TD,EA%_N"M"H+9-D")Z+BIZ^=-0HHHH
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MO>:[L+%V;9QUWL4ULK9CEAMX]*D_L^R]ZL8%%=*DSF*9LK./YL?B>*AF-E!
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M45HI!<4DG@\BN6\;ZM=:#X0U76;1+QY;;3KJ6!+!5ENFD1"1Y,;%5>4<%%)
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M-CC'7Z5UXB?+!/N?E6/:G4Y+GMWQA":3^R/XQD(VR7VFP:7%M[RW\Z6\:_\
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M4)WL>@ 4$L>E1_!WP"VK:G HC<@NJ (N23GCCT/<U]!?LS?#;X>?%7XJ>/\
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M7_Y!TW_7)OY5X-'_ *M?H*^@R3X9'CYK]D5>_P!:=35[_6G5[U/X4> ]PH!
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M-'<7<Q,()!/6O0_"O@:XU&3$J,=QZ@=^*]3ZW#!KVLG9H\N6%=?]W)>ZSBM
M\&WE_<&-D+?-QCWKZU\#?!"+[&^IZLT5I:Q1^9-<W3K%"BYY)=C@8[D\'M7J
MO@?X9Z!X6T&Y\;>-;NUTK1M-M&O=3U.^8)!;01C<SR%B!]T' ZL>!S6'X6\
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M(%%%%, HHHH **** /_1_OXHHHH *8[A0#[]Z9)*D;#<0,CC-? O[:7[8/\
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M)(2Q_O$CK7G\5*KG7$E')G4M1C#FE9_%KHCIR?\ X3\HEF"A^\;:5^A'=?\
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M;IT='9Z-VU/X]\:?I?8'+*,\'DDE4J:J_1'!Z#\._'7[3>K6'Q!^/NGOX?\
M!NES+?\ A3X83;3+-)$04U#7W4[96/WX;,#:A.7RU?;DIV$H,8'R@+@@+C@#
M_9_V>@X':H^2N1P#V8@D^F>!G'O6MI>D7&I3!$]<#C'-?ZY\%<'8#(\OI99E
MU-1A!+U;/\LN*^+<=G6-J8['SO*7X#=(TJXU.X\M$D//'XU]7> /@E-J<<<U
MT&4-@\BNC^#GPHGGGBNKU%[=:^\-"\/6VFVBPJB@#H<5]K1I\I\O*=CR_P &
M_"K3]&B#+&,@D9(%>X06EO:P^7",#C/MCI5I2H&T 8'I3&=/NY]/I6ADW<C4
M%V  +9X 7J?I7XS?MY_M#:E\9/%E]^Q?\(]0-KI-I!%)\8_%%DS>;8V4R!UT
M*S<;<W=\A(F=3^YAW9&]@*^F/VZ/VL]<^#&F:?\ !+X.B.Z^)OCJ">W\-HXW
MQZ-8J-MUK=Z!]R"T!+1]Y)<(!UK\@+NR\/?!?P#%\/?"\]S=")I;O4]4O6,E
MYJFHW+[KB]N93\S332;F;/"C '%>CD^!GC*BLM%O9W/9P6$D[2://OBIKNEZ
M=9Q>'O#L$-GIUE!'9V5I; )'%#"NQ$5!T  _'KW-?(%[*9KAF8=3GFN]\4Z[
M_:5XS%LGH3ZFO/Y$D9LD5_0^585481II6_ [L5BHQA*SU*C1H_RL.E9[J%;'
M:M.=2B#/K6=/C?QZ5[$8W=S\[S;'NSU,ZY4DX7H.E9+< UL2JS-67-'MSFMZ
M<Y-VL?E.>9IRP;;,R8A4 '-8$\A;[W7)K6NQN4@>]8\:[CM;Z5Z$58_%\ZQ_
M/+EOJS0T?3_M=TK*.<\8[U^B/[.GA&2XO;=2I/SKR>F2<?\ UZ^./ .@27EZ
M@BR3D'IGC@5^CVG:_IO[/?P1\2_&K7H]ZZ!I,LMO; [9)KV4^1;0I\P.]YW0
M 9]?2OE^+\QY,/*[MHSZ?P\R:=3$0TTN<K\!A)XB^//QM^*L:@VEYXRM?"NG
M.>?,A\-V:6\ISV'V@OQTXK]8?@/X<M;RZ02HQPW/>OP[_9KUKXB?LK>'/#WP
MA_:3%K<6OB6Z-]H_B^V4K%%K.L/]HNM.U@M_J9#<2D03C*R_=8J>*_H!^ &G
M^7.H._<C8;?D-TXRO4?RK^7O:N3G?N?V#[)0IPA'HC[WTK3;:SLD2+ (0?+B
MM<G)JK;AE10?[HJS3L<M0****#,**** "NL\'_\ (=_[8G^=<G76>#_^0[_V
MQ/\ .N;&_P &?H>IEW\1'JZ=?QJ6HDZ_C4M?#K8^D"BBBF 4444 %%%% '__
MTO[^*AED\M"V#U J8U4N&;RB4QN##&:F;LKA:YXE\?/CS\,OV>_AM>_%;XK:
MA_9VCV&Q698VFGN)G;;%;V\* O+-*V%2- 6)/IDU_,9\>]5U']H3Q;XQ^.'[
M1?BIOA#:^+X;7PYX=MY;R :]:>%;=3(;:,!F\B>]=WDG\M?,4%0#D5ZA\??B
MI\0OVY/V^-(^&/PKN[9+/1=7U70/!<VIQ^=I]E<Z/'_Q//$4EL<"XFB+?9;-
M3P)-SYQ7S?X4\.^-?V4/VK]9\7^.K>Y^(FO?#+Q%=Z'KL?B.&&ZU#6O!^L>7
M>P7EKE1&+FW!=X0JX(0Q#MG\ \2\9B\S_P!GIU/98:,DG46K;[6\C]*X5H4<
M+SU)1YZEM([:&U\/F_99^&OA2V\(_#KXK?&JTTRT0"VC\/OKD%JV.=R?9+4(
MY/3<<[NIKT;P;8_L_>/?B;:ZPWQ9\9>*M=TS3KBVTO3?'=W=3R6]O<[3.\$%
M[&CC+(BNZ@\=QFOZ1_@K\5?A9\;OAUIOQ(^$-[INJ:#J-N)=/N;%0J%<A61X
M\*T;QG*.C $,,8%?GK_P5@^#D]W\)M&_:/\ !FEK-JOPSUK^V-16UA3S[GP_
M<J8=4A^[E@D964+R<IP*^1XC\&L='*ZU3"9M5J:72V3796.C+N,:$\7!U\#%
M-NWF?&7P]U#X_P#[//PRD^$6H>#?!OQH^%UQ=WUU<Z:(X[36XXM0G>:8&*Z+
MVUXQ+M@ QL< <&O!?"OQ+^$W@7X@7%[^S%K.MCX5VVF3OXN\&^-[>96\,ZDT
MFR/3-/\ M*^<%()WV^7C'R!#@XKB?V<_A??^)OVD]:\,_#7XCZQX4UCQU:Q>
M+OAY>SR?;_#6L-#"HO-,NK%S\K$!)U:(HX5SM!(Q7L>M3>,_BEILNFO%HGAO
MXI^#?%*B6R8BYT/5]3T67<()3A6>"X"AD#8= 1W6OS'-<5FG]BX>GG$8U*$F
MH^T2]Z'=-;IKN?58;!X-8NI+"751)OD;T9Y'JEK\(],M/#OQ?^$@MM ^%MYK
M-Q8>/=1T72H_[;\-22-LWO:SQ[XHTN6_?9C)C0Y5-M?1/[1_P TOX/:UI'@/
MQ-?-XR^%7Q'AALM!U3Q$L5V=)\5;"UH#)"D0%I?)@PN "LH(#?,*Y3QWX]\!
M^)=2_P"&O]%TA=!35M5M_AY^TE\/KLADTZ_O$\BRU0QCY74_(HF08EA=6/*&
MN)U_X@Z[HG[/?C'_ ()O^*K>;49/#^HQ7WA_QIJ3L(-)\+,5O-,N(YNLEW:3
M1O'#&#PJ O@$9^LP60Y9EN&Q&69E4YW*"J4*N[:7;TNE;K<\/%XS$UZM+$X>
M/*EI4ATZ:GRC\"=?UGQ_\0&\,ZCJ_B*U\0?#*/7=(@^'7BN>2^M[2XG,237V
MC:F^9Y;<QHH,#O(8]X*J.M?L_P#\$R?%!7QE\9? ,@'/B+1_&=B[%E>2WUFQ
M6"1?+?!79-;,.0,YR>2:_.2YA^&&H^+=#_:3\&M'>ZEXL\/W,#>(89C;V4LV
MDK&D_G(^$B><*N9-HZ$9Q7O/P_\ B3/\(OVF/AC\=+-8(-/\:7+_  Z\8PP3
MIMN)-17S+%B5;8ZP3HP#9&T2_A7D>$_B%R\6X:M[SA./L[RONM>OF>EQAP["
MIDU6C2WB^;3L?T"EOG(!Z'/7.*1@'!'3/^?6@"6,^7-C<#@]>#],GZ?A2U_I
M33;MS7W/Y7JQU46CQ_XR?!/X7_'3P9/X&^+N@:9XDT>3!-AJL*RJC Y#1-@-
M$X/(D5@X[-7XX_$3_@GWX@^%\TC? #XE^/\ PIIRMYD6B7<\>OZ?#QC9%'J0
M>18\?P^97[W'D8KC/$WA:#7+0QLB$XQS7SF><(Y;F</9XZ@IKS1[63<08S S
MY\+6</1G\UFH_!W]J.,O:ZA\9M2A3.T-IGA;2;>8>H\Q]X7Z@&N<C_9"^&&M
MZE%K'Q>U#Q/\0[J-_-C'C;4YKRSC8?W;&/9:X)[&/CM7[0?$3X$M-))+;Q\G
MD 8KYLU+X4:Q9DA(F(4X%>+E'ACD&!ESX3 P@_)(]O'\>9QBH\N(Q4I+S;/%
M++3;#3-/@TK2+>VLK6V41VUK91K#!!&HPJ11QA548[8JVJ.S8 _'L:].M_AK
MKLL@183R:]<\+_ _4KZ0/.C;>."*^W5%*/)T/DY3NW+JSP3P_P"%K[4[A8O+
M8YZ8K[/^%?P=!:.6\C.0=V"/:O9O WP:MM(19'A''4FOHK3M-M=.39"H&%P*
MJ-)+8P<^QD:!X=L]'B3RE P.0!BNF8@GY>G:C.:2K(;N)G':O'/CW\</ ?[.
M?PGUOXQ_$9I8],T:WWL+7YKBYN966*TM(4P2TMS,RQ( ,Y;/ KV3)W!(QEBP
M'^?4D9_*OPR_:L^)4O[1O[3K>%+2='^'?P=NO^)B 1MU?QR\9:&' ^_'I<3J
M['IYS#)^6OA?$#C7#9%E>(S#$NR@F[>9]5P;PK7SC,*.!HKXW9^AX)87OCPS
MZY\??CFD47Q#\;XFU&U20/'H&D1 FPT*V89_=VZG=,<_O)BS'(V@?)7CO7KK
M49'R<DL<G.>M>T?%GQV^IWDK3/R6.3SR3D]L=Z^4M2N_M5V64G=Z]!BO\<\U
M^G+QQ_:M2IE.,5.DGHN7_AC_ &#X/^B-PQALLIPQF%YIV5W?J<I=PR1N692,
MFLUI1C# BND<7+MEB"/>LVYBB9@B@;ORS7])>%O[3SB# U(T>(L/#$0_F5U)
M(_+?$KZ">78F#GDV(E3F]E+5'.3#(SGH:S9B"U;%ZK0C:P&/:L.1@WS"O]A?
M![QVR#C?!0Q>0XA2E:\H-VE&V^A_DEXS>&F><(XN>$SK#N"O92WB^VJN59I
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M9A\NBZW(.8)D 46UXQ$<X&QR7J3X=Z'/J6JQ+\K;I%R<?K_C7Z9Z?\(?!GQ
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M7XE6S9-=^'WB5%@U2%&79)B%CBX@;)"RQ91@>O-?"/\ P5C^#GP;\,>&[/\
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M.WLE$ES;VN/^/C9.BK.J,P3."!R:^M_@!_P1XNM#O8X/CMJFB0>%+*62YL?
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MVE7&A6\4=U#I)8"ZM([W>98DSAR7VDBFL9+K$J&#A?<_H:BGANHEN;1UECE
MDCD4AD96P049201CN":Z_P &#.MACU\@_P Z^$?V"_!&I?#_ /9KTKP]?77B
M6[C_ +3U*[L#XJT]=)NXK2XN"\<<=DK,8+=<D0QL=P3 (%?=_@S_ )#8(Z>0
M?YUUUJ[GAYZ&>%ARUK(]:3K^-2U$G7\:EKXN.Q]"%%%%4 4444 %%%% '__4
M_OXJ-P>M24UER*35] /'_C3\'_ WQW^'FI?"GXDZ=#JFA:Q;&VU"SEX)&<JZ
M/G*2(P#HZ\JP!%?S1?M%? SQW^QYJ$GP]^/3-XB^'>K2#3?#_CF>+S86AE/[
MO3==7:PAG7.$N3^[E&"Q## _JY\OO_G^=<AXQ\$^'/'6BW?A?Q?96>IZ3J%L
M]G?:=?PK/;W$4@PR21N"K CU'Y5\#QGP%@LZI<E=6G'X9+=/N>[D7$%? U+T
M[-/=/8_D$O\ P%XF\(:AX:U32WU?QQX<\.:C;W5CX#U/4ALMM,$@ENX=+N9A
MR9&5&5)3C ,:L%.:_H9\#_M3_LH_MK?!OQ%HFGO8ZBEMIEPGB'P7XGMA!?VI
MCB<E+BRFR0!CAT#J<9#5\/\ QT_X)F?$?X2ZE/XJ_8XNX]3T(!II_AGXBNF5
M(L=1HU^P9K<GG$,^^'@ ,G2OS)UVT^'?Q0\2S>#_ !I8ZKX;\;:?$T5QI^I&
M30_$=F&&UXXYHRC30./ES&[QOGI@U^"PSC/>%95</F5%UZ4E;G2Z>9^A5<%@
M<WY9827LYKH_T/$6M_B#'\'D\1BUCL_!=MK2:7X"\4V3/]L\/>*+!5N+-+K)
MRL4S$10S*>,>6XPU?U1?LU_$R]^-_P"SKX(^+FJQBWNO$GAFRU:\B4 *+F6,
M"X ]0) V*_"/P-X&^,OBC2-"_9HN6T"7X7Z+XPD\=:A<PI+%JTGD,9K;3KB,
M[HY46;!68$%@NUAQFOU8_P"":.K6U_\ L8>%K6SN89H=(N-5TH()-QMTM[Z5
M4B;!/E[%Q\K ';S7Z3X'<3Y7B,PK8;+:FC7,UT4NUCX[Q"RK%4L+3Q%>.L=$
M^Z/O7G;M["C^E W#AASW&",45_5T=8IO<_&Y1Y= QQCM1116EQ.W87/ 'IQ5
M9\#)-6*A=,Y.2ONO4?2J@XI/0N#1.MK<-$9HXV89P2BYP<\=*@=!'G=D!/OD
M@C'U[_C^-?F9^W_\+GN6\)>/O#_BOQSX?OM6\?>'/"U[%H.OWEA9-87EP5F"
MVT+B-9'!(W@9SR*H?&G]N?X??L4>*D_9[TNRU#Q&_A?PO;^)M<NO$NM_\3)M
M-NYY%BAM6F626^O&2-V$;%1M &[D"N"KC91DT=U.DY+0_4.2*1$WNC <G=VZ
MXX]:&1D!)!P,9(YY]>#7Y)>'?VPO$7ACX\_$GP[X=LM5\9:MXK^(GAW0?AQX
M:N+M;*WA-QX<2_F+RR@BU@B17EE &2QP 217H%I_P4%\2:W>>'OAWX,^'.H7
MOC[5_$/B#PCJ7A^XU2WMK32=4\.Q)/<O/=A&$EJ\<BM&RQER&'RU,<Q@_B9Z
M%/#2Y=C],TY[#/!^HI&*AL'(R,C/'%?EWX)_X*/:SJ$'A_Q9\4?ASJ'A7PGX
MBLO$ M]9;5(;VXCO_"]O+<:BKVL2*3 Z0R>3-NYP-RK7GVE?\%?/ 5W\-_$?
MQ!N?"\MW%I?A&W\;Z-8Z!J<6HS7EA<W<5H;.Y.Q4M;\>?&WEL60Y.')4T_KU
M/N>2\#470_85<,VP<D_7^=("#TK\G/BM_P %0[7X.:VO@OQIX-6Q\0Z?X:A\
M6^)-$O-;@62TL;MV-G:VC+&PN[^2!#*\2[53[FXFON+Q[^U/\!OA5X-\/>/O
MBEXCL_#NF>*;:.ZT6;5Q+$TJ/$L^TH$9D=8V&Y6 P>*TCBJ;UN2\'4['T%@'
MK3%)67=@D+AL#J3V%?%!_P""D?[" .!\4/#?_DQ_\:IH_P""D7[!ZN WQ1\-
MC)ZYG&WW_P!55_7*=GJ=="C)+5'P_P#M-W'V[_@I1JPE5BFF_ >P^R,WW1]K
MU1VE91]5"FOSV^+L[O?3!AR"2<FOI3]K']L3]D&;]L+PE\7/#7Q!T*\T[7_
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M?P;AT+PEX4U);^^T_P (76O7EI9W4I:*Z7Q)%-#=QW7'S@QSN$ ' ->66O\
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MV1\/?&7)>)<)&IAL0E/JFU<_.BZ^U!C'M+'./H*HBQO;F0?(^.GT'Y5]C3?
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MHJ3FD[A1110(**** "BBB@ HHHH *ZSP?_R'?^V)_G7*#O75>#^-<S_TR/\
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MM!KY*^*7A?0?V8?V3?$'A/P8/.EO;!= TFT$,5M+>:MJF+.-E2$*K23S/N<
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M+&3I.J_$?PS8ZW(2 @M?MBS*K9X*M,J COTKQ^(<R6"R_$XNU_9PE+[DV=F
MPRK5H46_B:1\$?"31/$_BF[U+]KKX_\ DIXV\6VC7*"[.8_#NB.=UGI-N6^6
M,1JRO*<Y>1CD&H/!&F_ME?M3Z)=WO[/VBZ!;^']*GFTN\\1^++J6V?6KVW<Q
MS1620*SQQQ,-C2LH!/"CC->:_M$^#M=_:2N/B'X6U"6:T^'GPKT&'4=?M+-V
MCEUCQ'='?8V3NI5TM[5 +AU!PS%5S@&OUJ_X)4#9^QCH%P_EEKC4M7G+1=,M
M?2@?B  #7\0>&OA/#.L:\YXE3G]8O."WM%O1>1^S<0\7?V=AH8++96]GN^Y^
M8]]^QW_P4&TA'%QX%\)7P0%GFLO$Z1Q[>^5GAW8X/7G^=>"_ K0_VEOVE1??
M\*9\$Z7/+I*Q1ZV^J:REM;6MQ,T@CCBD5'\\>6@<D8"[AQS7]!/[<_Q>?X*_
MLR>+/%]A)LU":R_LG3".#]JO_P!Q'CW&2?P]J\F_X)>?"N7X8?LGZ1?ZG;^7
MJ/B2XF\17JD /LN#MMU(/0+"J "OVK$^!O#?U^G3I8?3J?(PXZS)T)593UZ'
MYT1_L'?\% KP9NM,^&.EQ$;B]QJ]]=,I]"D<"@X]FK\I_P#@I_\ #KX[? ;X
M1WOA/QOXO\$7-[JNGK-JFD^'].O/,M]-EE$0D:YFDRDLKC9 JJ23ER-JDU_7
M[^T]^T)X._9Q^$E]\1/$S!Y%'V;2K#<%DO[Z13Y-O'_O'YG)R%0%CP*_F?\
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M02?$[1-1UKQIJ/C;3$L]6O-*LXM,\=:K<EYM/D\J5GW[=H)^X2><\YJI\1_
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M2E \-R;?+S/B-0'E P!CKFKCPSP8W"^7TK=?W:_R,Z>-XH49_P"TU+]/>?\
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M@&6>VE\.R7ET;<Q7-E))EK65+QA#(0^6C;ED))'6L9\'<&NBYK+Z._\ (O\
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ML3S_ ,*X^+(_[@#TGF^#[K[D$LDQ^[C^+/L810'_ )8Q_P#? H\NW_YXQ_\
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HX>M-'C6*!5 '(*BO1XUVK7,:=U'T%=2GW:YJTFSLIJR'4445@:'_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>gyowp0iggm03000018.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gyowp0iggm03000018.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &\!*L# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110!Y/\ %O3]*G?3=#LM%TTZ]XCNA#]M
M:TC,L4:X\R3=C.0"!GTSZ53\8Z)I^G^._AIX;CMD&C0/-L@<95V 4@L.A.>>
M>I8^M>BW_A*PU'QAI?B:>6Y^V:9&\<$2LOE'>""6&,D_-V(Z"H_%_@O3?&5K
M:QWLMU;7%G+YUK=VDFR6%O53@^@_(4 ?/>O,UEX;\>Z7:?NM+7Q/''Y:'"(I
M,N0!Z I'^0]*],T>SMM'_:)N[+2K>*WM)=#5I885"H"&4 X'&< ?G746GPP\
M.6O@V\\,,EQ/:WLAFN)YI<SR2Y!#[L=1@8XQZ@Y.9O"'P]TKP==W5[;W5_?W
M]RBQO=7\PDD$:XP@( P.!^0]* .MI&W%?D(!]2,TM% $6VX_YZQ?]^S_ /%4
M;;C_ )ZQ?]^S_P#%5+10!%MN/^>L7_?L_P#Q5&VX_P">L7_?L_\ Q52T4 1;
M;C_GK%_W[/\ \51MN/\ GK%_W[/_ ,54M% $6VX_YZQ?]^S_ /%4;;C_ )ZQ
M?]^S_P#%5+10!%MN/^>L7_?L_P#Q5&VX_P">L7_?L_\ Q52T4 1;;C_GK%_W
M[/\ \51MN/\ GK%_W[/_ ,54M% $6VX_YZQ?]^S_ /%4;;C_ )ZQ?]^S_P#%
M5+10!%MN/^>L7_?L_P#Q5&VX_P">L7_?L_\ Q52T4 1;;C_GK%_W[/\ \51M
MN/\ GK%_W[/_ ,54M% $6VX_YZQ?]^S_ /%4;;C_ )ZQ?]^S_P#%5+10!%MN
M/^>L7_?L_P#Q5&VX_P">L7_?L_\ Q52T4 1;;C_GK%_W[/\ \51MN/\ GK%_
MW[/_ ,54M% $6VX_YZQ?]^S_ /%4;;C_ )ZQ?]^S_P#%5+10!%MN/^>L7_?L
M_P#Q5&VX_P">L7_?L_\ Q52T4 1;;C_GK%_W[/\ \51MN/\ GK%_W[/_ ,54
MM% $6VX_YZQ?]^S_ /%4;;C_ )ZQ?]^S_P#%5+10!%MN/^>L7_?L_P#Q5&VX
M_P">L7_?L_\ Q52T4 1;;C_GK%_W[/\ \51MN/\ GK%_W[/_ ,54M% $6VX_
MYZQ?]^S_ /%4;;C_ )ZQ?]^S_P#%5+10!%MN/^>L7_?L_P#Q5&VX_P">L7_?
ML_\ Q52T4 1;;C_GK%_W[/\ \51MN/\ GK%_W[/_ ,54M% $6VX_YZQ?]^S_
M /%4;;C_ )ZQ?]^S_P#%5+10!%MN/^>L7_?L_P#Q5*HFW#=)&1W 0C^M244
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !17)>*/B3X:\(:A'8:G=2FZ=/,,4$)D,:?WFQT'7WXJ;6/'_AW1/#UEK=Q>
MF2SO]OV3R(R[SY&0%7K]<XQTZT =/17+V?Q"\-7OA&X\3QW^W3+8E9V="'C<
M8&TKUW<C [Y%+X3\?:#XS:YCTJ:83VX#203Q&-PIZ-@]0?\ /6@#IZ*** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***XGQIXKU#0-1M
M[>S$)22'>=ZY.<D>OM0!VU%<IX)\17OB"&\:\$0,+(%\M<=<_P"%=70 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MQ_>B_(_XT8N/[T7Y'_&I:* (L7']Z+\C_C1BX_O1?D?\:EHH BQ<?WHOR/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110!F>(=3&D:#=WF<.B8C_P!\
M\#]35'P7IATWPU;[Q^^N/W\F>N6Z?IBLWQ:3K'B'2?#R',9?[1<X_NC/] WY
MBNR  & , =!0 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M]\BI:* (O+E_Y[G_ +Y%'ER_\]S_ -\BI:* (O+E_P">Y_[Y%'ER_P#/<_\
M?(J6B@"+RY?^>Y_[Y%'ER_\ /<_]\BI:* (O+E_Y[G_OD4>7+_SW/_?(J6B@
M"+RY?^>Y_P"^11Y<O_/<_P#?(J6B@"+RY?\ GN?^^11Y<O\ SW/_ 'R*EHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MSC\CR,U['X*T&7PQX-TO1IYA--:P[9'7."Q)) SV!.!["MZB@ HHHH ****
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M %ZEHH BVS_\]4_[X_\ KT;9_P#GJG_?'_UZEHH BVS_ //5/^^/_KT;9_\
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M>?\ AOXAZC=^+D\+^)_#S:+JD\!N+4+<"9)5&21D=#A6_P"^3T[T?@1/-<>
M;AYY7E;^TIAN=BQQA?6@#TZBBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M;>R $MB6*@;L =-PSUZ,/0ULR^+O'WC+Q/XAM/!LVGV5CH<AA/VA SW+@L,
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M5<XRK @C\C5FB@#QA?AU\1M/T"7PCIGB/3/^$?=F5+B176YCB8Y*\#'<]_Q
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MM.TO3]'M!::98V]G;@Y$5O$$7/K@=_>@#RSPU\./&%MJ6D+K%[H,.FZ9A?\
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M;!Z@_P">M '3T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MPM.CSU9>\MTFNY/;:9J'B.:._P!5Q%:J<PVN#@CU(S_^OZ5TZQS(BHC0JJC
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MC[=*IZ;IWCJ)?%/]H:U8RFY#_P!A;$ ^R_ZS;YG[L9QF/KO^Z?Q[&B@#Q_\
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M2Q7%C<MI6C,=S1ZBI:.0?[,7!Y]05SZU]&RPQ3*%EC210P8!U! (.0?J#3Z
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M[]O3J\[^,"JOA?3-J@9UJT)P.IW&@#?\9ZUK6D:=:IX?THW^I7ERMO&71C#
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MIZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M='17F<D>QK'!8:.T%]QEQ>&M#A&(])LA[F%2?S(K+_X5]X;_ .?)_P#O\_\
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M/3?Z_CSU^]7HUAJ%GJEG'>6%S'<6\@RLD;9!_P#K^U<>)P$J"4FDXO:2V?\
MP?)ZA'#X6>GLU?T1YA_PJK5,_P#']9X_X%_A7<V_@KPY;8V:5"V/^>A9_P#T
M(FM^BN-4XH*.78:BVXQOZZE6WTRPM,?9K&VAQT\N)5_D*M4459V**2L@HHHH
M&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_?%2T4#(MDW_ #V'_?%&R;_GL/\ OBI:* (MDW_/8?\ ?%&R;_GL/^^*EHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M='D]]\;H;3RXQX?N!<C(N(9YO+,3#L/E.?QQ]*Z?P'X['C9;\_V=]C^R&/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\D_\]I?S'^%2T4 1>2?^>TOYC_"CR3_SVE_,?X5+10!%Y)_Y[2_F/\*/)/\
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M^Z&SG*CUKN?)/_/:7\Q_A4M%8XG$SQ-5UJF[*A!0CRHB\D_\]I?S'^%*L1#
M^;(<=B1_A4E%8%A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M"-2"<^@W;3GT5JX^>V\3_#OQ[X<\2^((=)M["14TB8Z:7V"(+A2^[N  >/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M% !2!55=H4 >@%+10 @ 4    < "EHHH *0@'J <'/-+10 4444 %(%"C"@
M=>!2T4 %%%% !2%0PPP!'H12T4 %(JJ@PJA1Z 4M% " !>@ YSQ2T44 ( %
M"@ #H!0%5<X &3DX'6EHH 0J&&& (]"*6BB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
0H **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>gyowp0iggm03000006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gyowp0iggm03000006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #4 3P# 2(  A$! Q$!_\0
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M ,31X$_Y)YX9_P"P5:_^BEKH* .?_P"$$\'_ /0J:'_X+H?_ (FC_A!/!_\
MT*FA_P#@NA_^)KH** .?_P"$$\'_ /0J:'_X+H?_ (FC_A!/!_\ T*FA_P#@
MNA_^)K7N=0M+2>V@N+B..:Z<QP1LWS2, 20H[X )JI)XBTR*]N+22699($9W
M8VTNPX )"OMVNPS]U23[4 4_^$$\'_\ 0J:'_P""Z'_XFC_A!/!__0J:'_X+
MH?\ XFM>PO[?4K1;JV9S&Q(Q)&T;*0<$,K ,I![$ U9H Y__ (03P?\ ]"IH
M?_@NA_\ B:/^$$\'_P#0J:'_ ."Z'_XFN@HH Y__ (03P?\ ]"IH?_@NA_\
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MBRB:088&9R@]2$)VJ3W( )[T 9?_  @G@_\ Z%30_P#P70__ !-'_"">#_\
MH5-#_P#!=#_\37044 <__P ()X/_ .A4T/\ \%T/_P 31_P@G@__ *%30_\
MP70__$UT%% '/_\ "">#_P#H5-#_ /!=#_\ $T?\()X/_P"A4T/_ ,%T/_Q-
M=!10!S__  @G@_\ Z%30_P#P70__ !-'_"">#_\ H5-#_P#!=#_\37044 <_
M_P ()X/_ .A4T/\ \%T/_P 31_P@G@__ *%30_\ P70__$UT%% '/_\ "">#
M_P#H5-#_ /!=#_\ $T?\()X/_P"A4T/_ ,%T/_Q-=!10!S__  @G@_\ Z%30
M_P#P70__ !-'_"">#_\ H5-#_P#!=#_\37044 <__P ()X/_ .A4T/\ \%T/
M_P 31_P@G@__ *%30_\ P70__$UT%% '/_\ "">#_P#H5-#_ /!=#_\ $U\[
M_'FPL]"\<V5KH]I!IUN^FQR-%9QB%"QEE!8A<#. !GV%?5%?,'[1W_)0]/\
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MQ8FQBGMF185-[#MS$=K!<Y.WY3@XX[:FOV/BN?P3JEK9:C:/K<B_Z/-:P-;
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M!+Y.#SM&0<#'=AEECAR5W.[:U25DNNEW_7XQ+GZ'>:1K6F:]8K>Z5?07EN<
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M %%%% !1110 5AW7^A>,K"X^Y%J%M):2-U\R6,^9"OMA#='/ [$YVBMRN?\
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M5!U(]/O2_-F-\+K%M/\ AIH<+*ZEH3-AU4'$CM(/NL1CYN.<XQD*<@=?7/\
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M]<_[\V7_ ,CT44 '_"/:I_T.>N?]^;+_ .1Z/^$>U3_H<]<_[\V7_P CT44
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MM4_Z'/7/^_-E_P#(]%% !_PCVJ?]#GKG_?FR_P#D>C_A'M4_Z'/7/^_-E_\
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<_KNN:W>74<0A60M;QX0$D#"0@=6/;/-%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>gyowp0iggm03000015.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gyowp0iggm03000015.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" '8!$<# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MRVUY/!)-J]E'(\<I4NK Y4D'D'N*T!\.K:73?%EA=WSRP>(;IKAMD>PP$XP
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M;?[9Y&/OLQSLW=MW3=VKH]&T_P#LC0]/TWS?-^QVT=OYFW;OV*%SC)QG'3-
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MF^"O^2N_$7_?L/\ T4U<[XW_ .$CD^-\=KX6\E-1NO#XA-Q,<+;1F9BTGU&
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M>6,';P.!]:I?$?XB6GBGQPVCZI<7D/A73[AD>.Q56DN70X+') Y(('H.<9H
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M9_%.QDNK!=2T+6=)L]1<1V=[>P*L4C-]T$ACMSVS]>E<%J&D7NL>%OB;;:=
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M%XJU#PU;VLRI:6>G0;);M,</Y@4EB>,#WXK%TR.6?]GOQM;)%=?:(M5=GAN
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MN(T9VSM49.!FO/? /Q&B\4:EXB@NI]BVEW*]L6MWB1+5-H!9F& V3D@G/7@
M4 >B45QME\4_!^H:E#90:HP,\GE0326\B0ROG&U9"H4G/OSVJWKWQ!\->&M1
M;3M4OVBO1$LJP) [LZL2!M"@Y/!^G>@#IZ*X63XP>!X[&&[76#*LH8^7%;R-
M)&%.&+J%RH'OC/;-=!>^+M!T_P -Q^(;K4H4TN5%:.XY._=T"@#)/MC/!]*
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M;7T,W3?V:-!^U"WP,>;YP7=G&>G'6@#MR RE6 (/!![T*H50J@ #H .E>/\
MA*V\8^,X=6OQXZO+!+?5)[1($LXG 5",<G'KC\*U_&3^(O!/PEUJ[/B6XO\
M5(YHGAO7@1&C5I(U*A1D$8W<_P"U0!Z0$569E4 MRQ ZTZN*^'GC"?Q+H$]O
MJ:>1K^F'[/J$#  [QT<#T;&>.,YQQBG?"C6=0U_X;:7J6J7+7-Y,9O,E8 %L
M2NHZ #H * .Q5$3.Q57)R<#&32X&<X&?6JNI:G8Z/8R7VHW<-K:Q_?EF<*H_
M$UBP?$+PC<V(O8M?LFMS,( V_GS""0N.N2 <<=J .C5$3.Q57)R<#&33J**
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MH8#;)-O;B,G)7;G;U[XS18Z'INFZGJ.HVEMY=WJ+(]U)O8^85&%X)P,#T H
M\'LF4_"+P79WS$:*_B+R;[<Q"^4)7(5_]G/)SZ"NP\8:;H5A\5_ 36%M:V]\
M\THD2W15S$$^4D#WR!^/I70^)/"[Z7X&_L?PMH5E>VJW'F3Z9=NS">)B2X5F
M;Y7R002>,<=JY+PSX$DF\:Z/JEKX.'AG3-,,DLAGNA-/<R,NU5'S$A5Z\\4
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MWK^OZ]#!^-G_ "3"^_Z^+?\ ]&K5&XT;3M8_:$E_M&SANDMM 26))D#J'\[
M;!XR 3^=>@:WH>F^(]+?3=5MOM%I(RLT>]DR5((Y4@]0.]"Z'IJ>()->6VQJ
M<EL+5I][<Q!MVW;G;U[XS5&)XAKEK!IVC_%^PLXEAM(YK-TAC&%0O@M@#@9-
M:.OP:MJ/Q;T"UM8=(N&@T)9K.#5V?R&<DARH4'+X'3T7/85TGQ(\-7$FCZK9
M>&_#TMUJ'B1HUO;L7&$C\LKM9@QP.,CY0.G-=7K'@O0_$6G65IK-DMRUHH$,
MJNT<D9  )5E((Z#C/84 >7V=IK>B:GX_GCN=#@O&T9I)=/T5Y?W,P3Y),,@
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M=>,DGL49=N(&<[<#TX)KH#K]U=>-O%::;J^@^$XK2=8[NYN8%DNKHJ"-Y#,
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MX.NOV@],N;5K=-$R@$L*A;:2Z1#MP1P0"4''?ZU]#7^G66J6CVFH6<%W;/\
M>BGC#H?P/%47\+>'Y+>TMVT/3C#9MOMHS:IMA.<Y48XYYXH M6VK:?>ZA>6%
MM>12W=F5%S"C9:+<,KN';(%7:Q=,\.P:;XAUK65=6GU0Q;U6((%6-2 ./O'+
M,2Q]AVK:H **** "BBB@ HHHH **** "BBB@ HHKG]9\;^&_#^LVFDZIJD5M
M?7>#%$RL>"2 20,*"1CDB@#H**** "BO+/C!J7B^+0=2CT:*.QTFWMEEN=1\
M[$LA+8\J,#D=LGT/7UV/&^M3Z+\&[S48KB2.Y.GQQQRJY#AY-J9!ZY^;.: .
M[HKQCP2_A2^US3HK?XB^)[S5$VR_9;F]D$%PRC+ !T =<@\ \BO7M1O8]-TR
M[OY59H[:%YG5.I"J20/?B@"S17FB?&K13:VFHRZ/K<.C7#+&=3DM1Y*.>H."
M2<'() /(.,UJZ/\ $JRU3Q%9Z//HVKZ:]^CO8S7UN(UN HR<<Y''//;'J* .
MVHKB=2^)=E9ZK?6-CHVKZL-..+^XL( \=N<9*Y+#<P[@=.?2E_X6'8:A\--3
M\7:>DT<$$4PB$Z@%G7*KP">"V/SH [6BO(=#:X\,>-?#&GZCJ,T=O;^&7GO/
M/G.P2;]SLV3C@D\GM76VWQ'TB;PO?>)9K>]M='MVVPW$\87[7S@&)<Y()P!D
M#K[' !V-%>?I\5K2/5-,T[4/#NNZ=<:G<1PVGVJW50X<XW$[N,$C(ZC<.#7>
MSS16T$D\\BQQ1*7=V. J@9)/MB@!]%>>+\7M,,"ZB^B:W'H#R>6NKM;#R.NW
M<1G<$SQG'X5H>)_B/I_AK6;72/[-U+4KZ[MOM%M'81"3S1N(P.<YP"V<8P*
M.SHKS32]?DN/BS=W5T]W9:?_ ,(U'>-;7;;/(_> DNN2%8#KZ5.OQ?TS[.FI
M2:%KD6@O)Y:ZL]L/)ZXW$9W!<]\?A0!Z)17F7B+QGJ=G\5] TRTL]2N-->WD
M=H[94*7191AU.>53/.?P!J6W\9:+X9M?%VK2R:S<0VFK^3<I.RN(W8JN(1GB
M,9S@\T >D45PNG_%"QO-;L-/NM$UG38M28I8W5[;!(YSV YR,\8R.XZ5S/C+
M588M&^)9TV_U=+^U^R>:99@(XB<8\C:<J",[L]Z /8**\\TCXHV++I$5_I&L
M6-G?[(+74[J "&9R..<Y ;L2.>O KT.@ HKSZ?XLZ>IO+BRT/6M0TFRD:.XU
M.U@5H5*_>*Y8%E'<CZUHZ[\2=#T.ST6\*7=];ZP&^R-91>87(4$#;D'+$A0/
M4\XH ["BN0\._$"TUS6KC1KK2]1T?4H8/M(@U"((7BSC<"">G?\ ^L<94WQ?
MTJ.)[^/1M9FT*.;R7U>.W!MP=VW<.<E<\9Q0!Z)17)Z[X^L-(U"TTRRLKW6-
M3NH?M$=KIZ!B(NSL20%4U=\+^+K#Q5!=&VAN;6[LY?)N[.[CV30-VW#)X/8@
MT ;]%9GB#7M/\,Z)<ZMJ<OEVL"Y; RS$\!5'<D\"O,?$7CNYU7Q)X-L1I6N:
M))-J\4FV[3RA<0G@CY6.<$C*GID4 >PT5Q>K_$6WL=<O-'TS0]6UJ]LE5KL6
M$(9(=PR 6)'S8[ &LO5_&FA>(_!VDZPLVLVMO)J\-OLM2L4R3 GY),G&WU /
MI0!Z117ED_BJ3PY\0O'6H78O;NPT^SLI/LT+;M@889E5B .N3]*[+6_&6G:+
MHFG:H4FNX]2FAALX[< O,TO*XR0.G/6@#H:*CN+B&UMI;BXD6*&)"\DCG 50
M,DD^@%>?K\7],^SIJ4FA:Y%H+R>6NK/;#R>N-Q&=P7/?'X4 >B45QGB;XD:=
MX;UBUTD:=J.I7MY;?:;6.PB$OFC<1@<YZ MG&,"FZA\2+:TGL;&VT+6+W5KN
MT6\.GPP+YMO&>GFY;"G/&.: .UHKRCQ7X\B\1?"CQ1<:<FH:7J.G&.&X@G!B
MF@<R+Z'N,_K7IVGL6TRU9B2QA0DD\G@4 6:*XG4OB796>JWUC8Z-J^K#3CB_
MN+" /';G&2N2PW,.X'3GTIB?%70I/"5OXA2"^>&[NS9VMJD0:>>7) "J#WQW
M(_/B@#N:*XS1/B'!JGB'^P;[0]5TC4I(6GMXKV-0)U'7:02,_P"'6KVD>.-+
MU?PA=>)%2>WM;03?:8IU DB,>=RD D9P,CGN* .EHKAY_B=8)9:.UOI&JW>H
M:M;_ &JVTZ")6F$79W^;:JGUR:N^&_'VF^(%U1)K:[TJZTH!KVWU!!&T2D%@
MW4C;@$Y_Q% '5T5YM<_&73+333JTGA_7AH[9$%^;91',>V,MD ]B<9]JWM=\
M>6&BMIMM'97VH:GJ4?FVUA9QAI2F,EFR0%4>N>Q]#0!U=%<YX8\8V7B>2\M4
MM;NPU*Q8+=6-['LECS]T\$@J>Q!_F*Z.@ HHHH **** "BBB@ HHHH ****
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MOGG=0X*Q)GUY_#-4)+!=$\:>#+S3?!<_AA)=22V,TEZ&>Y1L!E:,$D<=SZT
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MDF7)\K9U P,[J\AUSP9I/ASX1:'XKT^.2/7H%LKDWWG/O9GV J><;1NP!C@
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M<8&+W#,S%=F!A@VX<_CTQ4.FZ+>:'#\(]-U.(I=17-T[QMU3<"X!]P"/RKW
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MZ@'[Y^7ECR#VP3Q6EX7\'6'A8WD\,]W>W]\X>ZOKV7S)I<= 3@  =@!7144
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M3W,%M'%-,;& ^8ZJ S9/)R03S7T?10!X+X_U2S\5S_"W4(+$QV-W?L!;3(I
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M,^"O#W@^*5-#TU+4S8\R0LSN^.Q9B3CVZ5OT44 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M%% &1JGB33='UC2=*O)'6ZU5W2U54)#% "<GM]X5KUYG\0?^2H?#?_KZNO\
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MK.IP:O;:W%/LE2U$#P21*&/"G!0@XYY]^.:/P&_Y$.[_ .PI/_): /4****
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MNL3XBTS2;&6VO3=RSPS20W*L;9XTW[649Y/3!(Q5[4M8%EJ>F:=%$LUU?RL
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M71114%A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MA;G48TUJ-TO+=+D^4Q<8+A<8W8[^]:4_A+2+OPA#X7N[<W&F16\=NJR-\VU
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MTKJ*RH[/U?YG+A/AE_BE^84445J=1S?@O_D'7W_7_-_,5TE<WX+_ .0=??\
M7_-_,5TE94/X:.7!?[O'T"BBBM3J"BBB@ HHHH **** "BBB@ HHHH ****
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M/^OB?_T<]:M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 445P'B#7KOQ)J1\-^'FRAX
MNKM3\H7N 1_#ZGOT'OI3IN;MT(J34$1ZYJ]YXPU0^']"?%FI_P!+NQ]TCN ?
M[O\ Z$?;D]IHVCVFAZ='96:;47EF/WG;NQ]ZCT+0[30--2SM%]Y)"/FD;U-:
M=54J)KDALOQ\R:<&GS2W,S7M,N]7T[[)9ZM-IK,W[R6&*.0NF""F'4@ Y!R.
M>*A\,:'-X=T2'2Y=3GU".W58X'FC1#'&JA53Y ,@8ZG)YZULT5B:A1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<_XHUK5M
M$BMY]/\ #\^L6S;A=+;2A9HAQM*H?OY^;(!R.*Z"B@#YR6S^&,8,?_"'>-(Y
M\\P>5)N)_P"_F/UKU_P3JNH7MM':#PQ>:/HMG;)#:R7\P\^3: H!C&2  .I/
M/'7G!;_$OPK=ZCJ5G;ZB97TVWDN+J18F**B%0V&QAL%ATS75PS1W$$<T+J\4
MBAT=3D,",@B@#AO'OQ)M_"%S:Z=:VQO-2FDC\R/!"01,VW<[#N3D ?Y.MXAU
MCQ);ZM;Z;X?T.*Y\R%II;V\E:.WCP<!,J"2Y_#M[XQ_BQILUYX3C%C923W#:
MA:LX@B+N55^IP,X S]*SOBKKNO>=9^&M%MM0MX+U=U_JMO92S""(D@JFQ22Y
M /IVY&<@ M1_%!K[PEH]_I^FJVKZK??V?%9RS81)02'9G Y0 9R!GD>]=#X0
M\33:^FI6M_:QVNJ:7=&UNXHG+QDXRKH2 =I![@'@UPU_H]M9:#X,OO#FF:E)
MIF@:CF>![.1+@HP^>7RV 9N>3@<YX'%:W@S0KN_F\;:O*M]I:^(+@QVK,IAG
M2-4*K* >4;+$C.#P.* (OB#_ ,E0^&__ %]77_H,=>F5X?JWA2;PQ\4/ 7F^
M(M9UC[1=7&/[2N3+Y6U4^YZ9SS]!7N% !1110 445'//%:V\EQ/(L<,2EW=C
M@*H&230!)17):/\ $;0=;U:UTZU%\LEXCR6DLUHZ1W"KG<48CD#'?'ZUNZWK
M%OH.CW&IW4<\D, !98(S(YR0.%'7K0!H45YQ'\:_"\UP]O':ZRTR8WH+!BRY
MZ9':NMT+Q3IOB*ZU2WL#*9-,N3:W'F)M&\9SCU'% &U17&R_$[P[#H4FLNUU
M]DCU Z<W[GYO.'MGI[U9\3?$+P]X3O(;'4;F5[Z9=R6MM$99"/7 Z=#U]* .
MIHKG?"_CC0/&"SC2+LO/;_ZZWE0QRQ]N5/OQQ714 %%%% !1110 4444 %%%
M% %6_P!.L]3@6&]MTFC5MX5NQP1G]37-^!M+L4TQ;Y;9!="65/,YSC<1BNNK
MG/!'_(NC_KO+_P"A&L)1BZL7;H_T..I3@\3"32O9_H='1116YV&'XQ_Y%'4O
M^N7]16AI'_(%L?\ KWC_ /016?XQ_P"11U+_ *Y?U%:&D?\ (%L?^O>/_P!!
M%9+^*_3]3E7^]/\ PK\V7**@NKRVL8#/=3QPQ#JTC "N4O/'L<TQM= L9M1N
M?[P4A![^I_3ZTYU80^)EUL32H_&]>W7[A_BK5["VUS18YKJ-7@N?,E&<[%(X
M)]*Z"?6]+MHQ)-J%LBL,@F4<BO)M3\*^)KK4)+NXTYWEN6,C>6P8*2>G7C%=
MIHWP\TN"RA;4X3<7>W,@\PA ?08]*Y*56M*<K1MZGEX?$8NI6GRT[7[W7D6;
MSXAZ';G;;M/>.> (8^,_5L?IFL^7Q/XEU:&2+2_#\L(D4J)96(*Y[@G !KL+
M/3+#3UVV=G!!Z^7& 3]3WJW6_LZLOBE;T1VNAB:G\2I;RBOU=SP6RTO66UB.
M&WM[E+Y9!@E2"C9ZD]OK7HRZ-XV.=_B"V'IM3/\ [+7:45G2P<8?:?Y'/A\I
MA137.]>S:_(XL>'O%S,2_B4#/]U3_@*S];\*>)IM,FWZU)?  $VPR-^#Z=":
M]$HK1X6#5KO[V;SRVE*+BW+7^\_\SRCP%H.JQ>(X[R6WFM[>%6$AD4KOR" N
M._.#^%>KT455"BJ,>5&F#PD<+3]G%WZA1116QUA1110 4444 %%%% !1110
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MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#B_&.BM?\
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M*J:(B(H55GG 4#  \UZUZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MHHH **** "BBB@ HHHH \8\4Z]8:?\0M<BO?&VH:"5$ 2"PLFD60>4I+.=C
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M/#:1QW-P+B91\TH39N_#M7DC>-=69=+76;2)M1TZ7=.4.T,X&""!D Y[CCT
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MS*!(N2.5)'(]:W* ,KPY_P @8?\ 7Q/_ .CGK5K*\.?\@8?]?$__ *.>M6@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M9'(]_P"*;F77=3FY=IG;8I]N<M]3^0KI+3X<^$+&\@O+70K:.X@D62)P6RK
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M&U%(H[XPH;A(3E%DVC<%]LYQ0!:HHJCK.L66@:/=:KJ,PAM+6,O(Y_0#U).
M!W)% %ZBN<N/&VCVWA>PU^1IS;:AY:VD21%I9G<95%4=6//Y5=T#Q%8>)+.6
MXL3*#!,T$\,T922&1>JLIZ'D4 <3\0?^2H?#?_KZNO\ T&.O2G;9&SX)V@G
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MOF&5(!&>0*QO4YST.3!K#.S3=GZW]#V*BBBNH\,**** "BBB@ HHHH ****
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MDWO*5DH^:2;NWTO:WF>-QW%J)(S-*1$6 8H,L!GD@5W6GZ_\.;,J?LMQ(_\
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M^_VK?TWP]X@M_$<NJ7NHZ--%<0Q03PPZ;)'\L9D*E29FPQ,IR2#P!P*ZP
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M5VKG\PA_G7=T5M[/S9YWUOM"*^7^9P!\%>);GFZ\67 SU5&<C\MPH7X9,_\
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MK9'!+$59?%)OYC4C2-=L:*J^BC IU%%48A1110!%<6MO=QB.Y@BF0'<%D0,
M?7FBWM;>TC*6T$4*$[BL:!03Z\5+10 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !7*^)_&=MX9\1Z!IM[Y$5IJOV@274TP
M18?+52.O!R6QU%=57)^*?!%MXJ\1^'[^^%O-9Z9]H\VTGAWK/YBJ!UX&"N>A
MH X<>"_@]P)-;MY4!Y1]9.UO8_-7KMB;4Z?;&Q,1LS$OD&'&SR\#;MQQC&,8
MK _X5WX,_P"A6TC_ ,!$_P *Z&VMX;.UAM;:)(8(4$<<:#"HH&  .P H EHH
MHH **** /,_B#_R5#X;_ /7U=?\ H,=>ED!E*L 01@@]Z\T^(/\ R5#X;_\
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M*B[F [GBM< *H    P .U+10!#>6D%_97%G=1B6WN(VBEC/1D88(_$&N?M?
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M;)K6HI0I*!>*Q\ZZ26GSW"BBBM3@"BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!QWC?PW
MJ&J7^@:WI"Q2W^BW32K;RR&-9HW #KNP<'@8SQUI/"'A6XM;+7YM?@MFN=>N
MY)KFU1MZ)$R[1$3@;N,Y.,<UV5% 'D'B_P"'6D)XX\&)I?A:'^S6GG_M'[/:
M9CV[4V^80, 9SC/O7;?\*U\$_P#0KZ7_ . XKG=2^)M_:S:SJ-MI=O+X>T6_
M6QO)FE83LV0KLB[<84GN>:]*!! (((/0B@#E_P#A6O@G_H5]+_\  <4?\*U\
M$_\ 0KZ7_P" XKJ:* .6_P"%:^"?^A7TO_P'%'_"M?!/_0KZ7_X#BNIJEJ]W
M<V&D75U9V3WUS%&6BMD8 RMV&3TH \S\!_#G1))?%']L^%H %UVY6R^U6NW_
M $?C9LR.4ZX(XKL/^%:^"?\ H5]+_P# <53\,^,-5OO%M[X9US3K6WO[>T2\
M#V4QDC"L0-C9 (<9^AYKM: .6_X5KX)_Z%?2_P#P'%'_  K7P3_T*^E_^ XK
MJ:* .6_X5KX)_P"A7TO_ ,!Q7.>//AQX=C\"ZP^C>%[0ZD(#]G^RVN9=V1]T
M 9S]*],KB_%WC2ZT;7++0M*M[*2_N+>2ZDFO[CR8(8UX&2 22QX'X?@ 6_\
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M60@G:![#DT <%XL^''AM++3CIOA>S\PZI9B;R+;)\DS+YF<#[NW.>V,UO_\
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M/_GP7_OX_P#C1_PB>A_\^"_]_'_QH VJ*Q?^$3T/_GP7_OX_^-'_  B>A_\
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M .$3T/\ Y\%_[^/_ (T ;5%8O_")Z'_SX+_W\?\ QH_X1/0_^?!?^_C_ .-
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MBBB@ KP"3PA>:K>VN@VVD:YIL<>MBYELI)-]A;1 Y>6.38N[<.%7MDU[_10
M4444 %%%% 'GGC'2[B7XB^!;BSL9&MX+FY>XDBB.V,LJ\L1P,G/)ZUSWQ%OM
M2\1^+%\-7EGK%KX4M]LEY/964LK7KC!" J#A1Q^()]*]DHH IZ2UL^CV9LX)
M(+7R4$,4D9C9$QP"IY! [&KE%% !39(TE0I(BNIZJPR*=10!YUX.T^^M[OX@
M&737?[3J<SV\4^8EN04X 8C[IZ;@#BN=TW2_[3\5^$9M \'W'AN;37D?5'>V
M\M%CQCR_,P/-W<X//WL\<U[/10 4444 %<;\4K":^^'&N16=J\]W) J(L4>Y
MV^<' QR>]=E10!YEXZTVYN]*\(I>:9>7^A02*VJVEJI,O$8$9*CYBJMDD#FK
M_P *+#4=.T34XKBUN+/2VU"5]*M;E2)(K<G(!!Y'7H>>M=]10 4444 -=Q'&
MSD$A020!DUXEHU]=>*/B#%X@\7:;K4"6<_EZ/IRZ?,8H<D 2R-MQGID^V>@
MKV^B@#SWXD:7<W6J^#GLK*241:[#-<-#&3M4=6;';W->A444 %%%% !1110
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M7(=6;4#.H$* HTD93[Q;,8"X!!#<D8H ]1HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH *0G )]*6D;[C?2@#RZ#XXZ5-8#4?^
M$<\1#3N=UV+0-$N.#\P..#[UZ+I>K6.M:5;:GI]RD]G<H'BE7H1_0@\$'D$8
MKQ#X?_$3PIH'P>72]2U!&OECN%-D(W9G+L^U>!CD$=^]9MHKZ=X0\$^'M8M[
M2T^UK<W0N-7FD2UB4L2H>-64.V,$!CQN'J: /HW<..1STYZT9&<9&?2OG3P[
M:W>H?"_7+VQO#<WGAW6FO;!@2%V(%+*!G(0KN.WV%=+I4P\:#QAXY:_N--L9
M++^SM.GV,S6Z!09)-J\\,>H_VJ /9@P/0@_0TM>#>"+W3M%\7:#9B'3-0NKM
M6BCO]"U&1MR@<M<PD]3G))[@^E>\T %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !17"^*/BEIOA;Q(-"ETC5[^], G L8%D^4Y[;@>WI5_P?
M\0M$\:O<P:?]IM[VU_UUG>1>7*@SC. 2",\<'COC(H ZNBBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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)%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>gyowp0iggm03000012.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gyowp0iggm03000012.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" '* 8$# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M=>%]+TV\M(+)Q%=[?/DDN'=V"G(&\G( (SC-:LFDZ2^M6NO':MY#"UO'.LI
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M7C&,CN#5O6/"=IK-XMS/<W".MA/8 (5QLE #-R/O#:,=J?\ E^G^8U:Z]?\
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M.N"RHKH;?[P3[@.5Y [>E4Z-1:\KMZ>I.FFO]:'6CI15!M9TY 2URHQUX/\
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M/^%<1-87-GEV0O&O'F(#C\?2OL\%CX5H6;U..=-Q98LV;?EPV%.>35F6Y5.
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M67PO<S*#@2+<JI/_ ([6&VI^"F;<?"=_G_K_ %_^)KGXXU48Z"EV*#WKZ6&
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M>T7^X/Y5YQJPSILN0/\ )KT>#_CWB_W!_*LY#1)1114C"BBB@ HHHH ****
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M8W $"53S^->+^+/&$:.]G92!54[693R3Z"O3OB=J$FG>#9)8_O/*L>?3(/\
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MTJ20GM4$UH]G$7L)7?:?WRXP.*SK9>G"U_Q'&H[GL'B33_#<B^;=1:\ZD?\
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MXSI>J2#38Q*D<D+@J8MFT<#&<^HJS?W]QME:9(+F)%_T=NF0#@@'O@55O?\
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MPT+[^.2!P#Z4IA()_P *HC2W\W>+F"&4_P#+2&Z09^HSS5@6VJIPFHZ;(/\
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MX)&FQ0%1F8G#<UAEN"C4E[2>PI3LK"&(3JT\R!GR/SI#:!?E$(,N<[<=JG7
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
*HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>gyowp0iggm03000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gyowp0iggm03000001.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  (! 0$! 0(! 0$" @(" @0# @("
M @4$! ,$!@4&!@8%!@8&!PD(!@<)!P8&" L("0H*"@H*!@@+# L*# D*"@K_
MVP!# 0(" @(" @4# P4*!P8'"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@K_P  1" #] IL# 2(  A$! Q$!_\0
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M0<=.2>6)))/->-O&WC?XK^-;[QQXZU^]UK7=8NO-O+ZZ<R37$K8'^ "@8
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MU1^/=%%&#C./QK[H_.3VO]AS]N/XJ?L/?%2/QKX+N&O=%O&2/Q)X;FF(@U"
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MQRXZ#S>*]]KX"I3E1J.$MT['Z=1JQK4HU([-7"BBBLS0**** "BBB@#\N?\
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M_:0^&&I?"3XN>&X]2TC4H]K*P D@D'W9HGQF.13R&'3W!(/X1_M\_L#?$_\
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MC.L-['%<ZVEK\^O^9[G#^+]O@_9O>&GRZ?Y?(L4445XY[P4444 %?BS_ ,'
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M1]?*DP,).H^\O0_>7(/'UV6YG'%1]G4TFOQ_X/=?TOA<WRB6!E[6EK3?X?\
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M:_.:ON,K_P"1?3]/U9^=9S_R,ZOJOR1^RW_!O(,_L4^)1_U5"]_]-VG5QO\
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M'=Z]JLEOX=\6?\2+71O/EJ)F'D3,.GR3!"6ZJC28ZD'Z?-,-]9PC2W6J^7_
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M?^%M?_\ QVMS_AW?^W3_ -&F>/?_  FY_P#XFC_AW?\ MT_]&F>/?_";G_\
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M7FGK!1110!^2'_!QG_R7#X<_]BI<_P#I37YS5^C/_!QF?^+X?#G_ +%2Y_\
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MMR-P5U&5R-READ9R/2Z*J$Y4Y*4=UJ34A&I!PDKIZ,_+/_B&ZU3_ *.\M_\
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MG_!R7_S1C_N8O_<97Y=U[V4?\B^'S_-DYY_R-*GR_P#24?J)_P &VG_-9_\
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MT2XL6O+?#%(YX6CWKV) ?([&@"C_ ,+S^"?_ $6'PK_X4%M_\71_PO/X)_\
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M^ZB2%F'N 17? YK\[?C'_P &_OPO?PNUW^SU\8_$5CKUNNZ&/Q5)!<6]PP'
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MKYK\L_\ @N  /VT?A/C_ * ]M_Z<7K]3* $W#UK@/%O[67[+O@+7Y/"GC?\
M:,\#Z3J<+[)M/U+Q5:0S1-Z.C2 I_P "Q7P?_P %//VQ/CI\<?VC(?\ @GS^
MRI=WMO(]U'8Z]/ILWES:A=LHD:'S%YC@B3F0Y&2'W?*O/4?#G_@WX^"=OX,V
M?%WXS^*;_P 131YDN/#[6]O:P.1T"30RO( >K%EW#LIH ^_-"\1:!XITJ'7O
M#&MV>I6-RF^WO+"Y2:*5?570E6'T-7 <U^.WQ#\%?M2?\$4OCUHOB/PCX]D\
M0>"-=E)$>UX[74XD8>;;3P%BL5PJD%9%)P&R"?G0?K5\+/B/X8^+_P .-#^*
M7@N[\_2O$&F0WUC(RX;RY$# ,.S#.".Q!% %C7_'_@3PI>PZ9XI\:Z3IMS<+
MNM[?4-2BADE&<9578%N>..]:^:_++_@N0,?MD?"G_L"V_P#Z<7K]3: "@G':
MBOB'_@L-^WWXT_9NT+2?@+\$-1:T\8>*K5KBZU*##3:?8EFB7RACB65PZJ_5
M!&Q'S%64 ^K/B-^T3\ OA!>1Z=\5?C7X4\.74J;XK76_$%O:RNOJ$D<,1[@5
MK^!OB7\.OB?I'_"0?#7Q[HWB&PW;?MNAZI%=P[O3?$S#/MFOSO\ V;_^"$]C
MXY\*P_$+]K_XI>(EU[6+=;F;1M#N(A+:,XSBXN)DE\V3!&0H ##&YJ\V_:R_
M8#^.?_!,#4[/]J+]EGXO:M=:!8WT:74T@5+JPW$!%N57$=U"Y.TG8!E@"G(-
M 'ZZ49YQ7C_["W[5&G?MA_LY:-\8(;6&UU)BUEX@L86)6VOH@/,49Y"L&210
M<D+(N2>M<C_P4W_;5E_8N^ ']O\ A;[/)XL\0W)L/#,-PFY8F"[I;EES\RQK
MCCH7>,$$$T >U?$3XQ?"7X164>I?%7XG>'_#=O,2(9M>UB&T60CLOFLNX^PR
M:K_#GX\?!+XP"3_A4_Q>\,^)6A&9DT'7+>Z:+_>6-R5ZCJ!UK\T?V._^"4_C
MO]M_0X?VI/VP?C!X@2U\2%[C3[6WF#ZC>Q$_+.TTZNL,;'.U C97!&T8KL_B
M[_P09U3PKKFG^+?V1?CUJ6GW4%]#NA\13;9[92X#3Q7-LB'* EMFP$A<!LX!
M /TFW#UK$TKXG_#;7M8_X1W0_B#H=[J&YA]AM-6ADFRN=PV*Q;C!SQQBIO!&
M@:GX6\':5X;UKQ-=:U>6&GPV]UJ]\JB:]D1 K3.$ 7<Q!8X&.:_-#_@J_P#L
MT^,_V3?V@-%_X*"?LZ0R6,-QK$<^O"UB'EV.I9_UK ?\L;@95P1@ONR3YH%
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M-?GSXF\+^(?!FNW/ACQ7HTUCJ%G)Y=Q:W";61O\  ]01P1R*^ZR_'4\;1O\
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MIQEBH/\ /S\2/B)XR^,'Q U;XF>/M7DU#6]>U"2[U"Z9>9)7;. !P .@4<
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MX?ZQ\,_&^F+>:1KNG2V6H6[ ?-'(I4D>C#.5;JK $<@5^5"_"K]O_P#X(_\
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MUN-%MH=5TQI TNFWBZ@WF6\F.XR"#@;D96P,XK]EJ_#K]HS_ ()[_&#]E?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MSR?*8[QCC>!NKZX# U_,=XO\&^-OACXNNO"/C?P[J&AZUI=QLNK&^MVAGMY
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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/ %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>gyowp0iggm03000005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gyowp0iggm03000005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #8 4(# 2(  A$! Q$!_\0
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M ,31X$_Y)YX9_P"P5:_^BEKH* .?_P"$$\'_ /0J:'_X+H?_ (FC_A!/!_\
MT*FA_P#@NA_^)KH** .?_P"$$\'_ /0J:'_X+H?_ (FC_A!/!_\ T*FA_P#@
MNA_^)K=EEC@A>::1(XD4L[NV%4#J23T%5;C6=+L[ZWL;K4K."\N/]1;RSJLD
MO;Y5)R?PH S/^$$\'_\ 0J:'_P""Z'_XFC_A!/!__0J:'_X+H?\ XFM:QU.P
MU-)'T^]MKM(I#'(UO*L@1QU4X/!'I5J@#G_^$$\'_P#0J:'_ ."Z'_XFC_A!
M/!__ $*FA_\ @NA_^)KH** .?_X03P?_ -"IH?\ X+H?_B:/^$$\'_\ 0J:'
M_P""Z'_XFN@HH Y__A!/!_\ T*FA_P#@NA_^)H_X03P?_P!"IH?_ (+H?_B:
MZ"B@#G_^$$\'_P#0J:'_ ."Z'_XFC_A!/!__ $*FA_\ @NA_^)KH** .?_X0
M3P?_ -"IH?\ X+H?_B:/^$$\'_\ 0J:'_P""Z'_XFN@HH \_O=(\*V<-TO\
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MZ4 9>@Z-K&F:GJ5U?ZI8W<=_*+AXX+!X2L@CCC&&,S_+MB'&,Y.<XXKH***
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M_<UK]S8GNCTNBBBN<84444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MC'&*S_\ A%O#W_0!TO\ \ X_\*UJ*;BGNB(UJD/ADU\S)_X1;P]_T =+_P#
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MS3/*W)SRSDL?Q-8W@3_DGGAG_L%6O_HI:Z"@ HHHH **** .?\=_\D\\3?\
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M'4=ZU: "BBB@ HHHH **** "J&J:A8Z;'#/>K(Q\S$2Q6[SR;L'[JHI;IG)
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M9A@?.:** #0IH],U:*]O;_6[M883!%$GAS4HU"<8RIW)D #YE12><YS75_\
M"9:7_P ^NN?^"&]_^,T44 '_  F6E_\ /KKG_@AO?_C-'_"9:7_SZZY_X(;W
M_P",T44 '_"9:7_SZZY_X(;W_P",T?\ "9:7_P ^NN?^"&]_^,T44 '_  F6
ME_\ /KKG_@AO?_C-'_"9:7_SZZY_X(;W_P",T44 '_"9:7_SZZY_X(;W_P",
MT?\ "9:7_P ^NN?^"&]_^,T44 '_  F6E_\ /KKG_@AO?_C-'_"9:7_SZZY_
MX(;W_P",T44 '_"9:7_SZZY_X(;W_P",T?\ "9:7_P ^NN?^"&]_^,T44 '_
M  F6E_\ /KKG_@AO?_C-'_"9:7_SZZY_X(;W_P",T44 '_"9:7_SZZY_X(;W
M_P",T?\ "9:7_P ^NN?^"&]_^,T44 '_  F6E_\ /KKG_@AO?_C-'_"9:7_S
MZZY_X(;W_P",T44 '_"9:7_SZZY_X(;W_P",T?\ "9:7_P ^NN?^"&]_^,T4
M4 '_  F6E_\ /KKG_@AO?_C-'_"9:7_SZZY_X(;W_P",T44 '_"9:7_SZZY_
MX(;W_P",T?\ "9:7_P ^NN?^"&]_^,T44 '_  F6E_\ /KKG_@AO?_C-'_"9
M:7_SZZY_X(;W_P",T44 '_"9:7_SZZY_X(;W_P",T?\ "9:7_P ^NN?^"&]_
M^,T44 '_  F6E_\ /KKG_@AO?_C-'_"9:7_SZZY_X(;W_P",T44 ?+7BSP?X
EHU/QCKFH6?AG6Y+6ZU">:%_[.F7<C2,5."H(R".#S1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>gyowp0iggm03000021.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gyowp0iggm03000021.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  (! 0$! 0(! 0$" @(" @0# @("
M @4$! ,$!@4&!@8%!@8&!PD(!@<)!P8&" L("0H*"@H*!@@+# L*# D*"@K_
MVP!# 0(" @(" @4# P4*!P8'"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@K_P  1" #] IL# 2(  A$! Q$!_\0
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M0<=.2>6)))/->-O&WC?XK^-;[QQXZU^]UK7=8NO-O+ZZ<R37$K8'^ "@8
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MU1^/=%%&#C./QK[H_.3VO]AS]N/XJ?L/?%2/QKX+N&O=%O&2/Q)X;FF(@U"
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MQRXZ#S>*]]KX"I3E1J.$MT['Z=1JQK4HU([-7"BBBLS0**** "BBB@#\N?\
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M_:0^&&I?"3XN>&X]2TC4H]K*P D@D'W9HGQF.13R&'3W!(/X1_M\_L#?$_\
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MC.L-['%<ZVEK\^O^9[G#^+]O@_9O>&GRZ?Y?(L4445XY[P4444 %?BS_ ,'
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M1]?*DP,).H^\O0_>7(/'UV6YG'%1]G4TFOQ_X/=?TOA<WRB6!E[6EK3?X?\
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M:_.:ON,K_P"1?3]/U9^=9S_R,ZOJOR1^RW_!O(,_L4^)1_U5"]_]-VG5QO\
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M'=Z]JLEOX=\6?\2+71O/EJ)F'D3,.GR3!"6ZJC28ZD'Z?-,-]9PC2W6J^7_
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M?^%M?_\ QVMS_AW?^W3_ -&F>/?_  FY_P#XFC_AW?\ MT_]&F>/?_";G_\
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M7FGK!1110!^2'_!QG_R7#X<_]BI<_P#I37YS5^C/_!QF?^+X?#G_ +%2Y_\
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MMR-P5U&5R-READ9R/2Z*J$Y4Y*4=UJ34A&I!PDKIZ,_+/_B&ZU3_ *.\M_\
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MG_!R7_S1C_N8O_<97Y=U[V4?\B^'S_-DYY_R-*GR_P#24?J)_P &VG_-9_\
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MT2XL6O+?#%(YX6CWKV) ?([&@"C_ ,+S^"?_ $6'PK_X4%M_\71_PO/X)_\
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M^ZB2%F'N 17? YK\[?C'_P &_OPO?PNUW^SU\8_$5CKUNNZ&/Q5)!<6]PP'
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MKYK\L_\ @N  /VT?A/C_ * ]M_Z<7K]3* $W#UK@/%O[67[+O@+7Y/"GC?\
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MT^,_V3?V@-%_X*"?LZ0R6,-QK$<^O"UB'EV.I9_UK ?\L;@95P1@ONR3YH%
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M-?GSXF\+^(?!FNW/ACQ7HTUCJ%G)Y=Q:W";61O\  ]01P1R*^ZR_'4\;1O\
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MIQEBH/\ /S\2/B)XR^,'Q U;XF>/M7DU#6]>U"2[U"Z9>9)7;. !P .@4<
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MX?ZQ\,_&^F+>:1KNG2V6H6[ ?-'(I4D>C#.5;JK $<@5^5"_"K]O_P#X(_\
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MUN-%MH=5TQI TNFWBZ@WF6\F.XR"#@;D96P,XK]EJ_#K]HS_ ()[_&#]E?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MSR?*8[QCC>!NKZX# U_,=XO\&^-OACXNNO"/C?P[J&AZUI=QLNK&^MVAGMY
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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/ %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>gyowp0iggm03000019.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gyowp0iggm03000019.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &X!($# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#BOBS>7UG\-M5.F)<M>
M2A(H_LZL7&7&XC;R/ESS7GO@+4-/T&^U=IIO%4&OV>D2W'V'7)08I5"ABR*
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MU_\ GWD_-?\ &I:* (O-?_GWD_-?\:/-?_GWD_-?\:EHH B\U_\ GWD_-?\
M&CS7_P"?>3\U_P :EHH B\U_^?>3\U_QH\U_^?>3\U_QJ6B@"+S7_P"?>3\U
M_P :/-?_ )]Y/S7_ !J6B@"+S7_Y]Y/S7_&CS7_Y]Y/S7_&I:* (O-?_ )]Y
M/S7_ !H\U_\ GWD_-?\ &I:* (O-?_GWD_-?\:/-?_GWD_-?\:EHH B\U_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %<=HG^F_$/7+SJMO&MN/;I_5#78$@ DG '6N/^'X,]IJ>I,/FN[Q
MF^HZ_P V- '8T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MUO\ -^ZB5.'/8 >M %VBHOL\?^W_ -]M_C1]GC_V_P#OMO\ &@"6BHOL\?\
MM_\ ?;?XT?9X_P#;_P"^V_QH EHJ+[/'_M_]]M_C1]GC_P!O_OMO\: ):*B^
MSQ_[?_?;?XT?9X_]O_OMO\: ):*B^SQ_[?\ WVW^-'V>/_;_ .^V_P : ):*
MB^SQ_P"W_P!]M_C1]GC_ -O_ +[;_&@"6BHOL\?^W_WVW^-'V>/_ &_^^V_Q
MH EHJ+[/'_M_]]M_C1]GC_V_^^V_QH EHJ+[/'_M_P#?;?XT?9X_]O\ [[;_
M !H EHJ+[/'_ +?_ 'VW^-'V>/\ V_\ OMO\: ):*B^SQ_[?_?;?XT?9X_\
M;_[[;_&@"6BHOL\?^W_WVW^-'V>/_;_[[;_&@"6BHOL\?^W_ -]M_C1]GC_V
M_P#OMO\ &@"6BHOL\?\ M_\ ?;?XT?9X_P#;_P"^V_QH EHJ+[/'_M_]]M_C
M1]GC_P!O_OMO\: ):*B^SQ_[?_?;?XT?9X_]O_OMO\: ):*B^SQ_[?\ WVW^
M-'V>/_;_ .^V_P : ):*B^SQ_P"W_P!]M_C1]GC_ -O_ +[;_&@"6BHOL\?^
MW_WVW^-'V>/_ &_^^V_QH EHJ+[/'_M_]]M_C1]GC_V_^^V_QH EHJ+[/'_M
M_P#?;?XT?9X_]O\ [[;_ !H EHJ+[/'_ +?_ 'VW^-.2)$;*[L^[$T /HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J*XN8+6$S7,T<,0Z
MO(P4#\34M>+^/[6+Q=\;_#?A/4C(^CI:/<RP*Y7>^)#U'/\  H]1SZT >S1R
M)-&LD3JZ,,JRG((]C39KB&V0//-'$I. SL%&?QKR3X*R2:9KGC3PJDKO8Z7J
M!^R*YR54O(I&?^ *?KGUJ#X\I<ZA-X6TF'3;V_MY+MIKB&U0EF"[0%! X)#/
MB@#V"&\MKDD07$,I')$;AL?E3+K4;&Q*B\O+>W+YV^=*J;L>F37D_P &CX3B
MU?5[72](U'1];BC"W5G?2ESL!ZC('0D9R!U%8?[0]C+J6N>%[. 9FECN0@]3
M\F!^- 'NT][:VL"SW%S##"Q $DD@53GIR:?!/#=0K-;RQRQ-]UXV#*?H17R]
MXP\2R^+/AMX,T:"3=/#:7%S=+W'V9&4$_54<_C7M7P9_Y)+H/^Y+_P"CGH [
MNBBB@ HHHH **** "BBB@ HHHH **** "BBN<U?Q[X6T#4&L-5UJVM;M &:*
M3.0",CM0!T=%8NB>+O#WB222/1]7M+R2-=SQQ2?,!ZXZXK:H ***1F"*68X4
M#)- "T5G:+KVE^(K$WND7L=Y;!S&9(\XW#!(Y^HK1H **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HI
MDLL<$32S2)'&HRSNP  ]R:RX?%?AVYN?LT&OZ7+.#CRDO(V;/T!S0!KT444
M%58--L+:]N+VWLK:*[N<>?/'$JO+CIN8#+8]ZM44 9MMX>T6SU.34[;2+&&_
MESON8[=%D;/7+ 9Y[^M%]X>T74[V&]O](L;JZAQY<T]NCNF.1@D9Z\UI44 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <=XT_TK5_#^F]
M1+=>8X]@1_0FNQKCKC_3?BC:IU6RM"Y'N<__ !2UV- !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 5Y?\0/"_B-/'6B^-_"]G%?W=C"UO/9R
M2A-Z'?R"2!T=AUS]W@UZA56ZU.PLG5+N^MK=V&56654)'XF@#S#P;X8\8>&/
M#_BGQ UA:R^*]9N?M"6+2*8U^8G!;<!_&YX;H!SVK2\0O\3?[.T#5M(BMC>1
MH#JNC QA7;OM=B>.HX?TQFO0+J]M+%%>[NH;=&. TL@0$^G-/2XADMQ<)-&T
M)7<)%8%2/7/3% 'F7P^\)>(AXYUKQOXGM8;"\U"(01644@?8GR<D@D=(U'7/
M7.*M^._"^L:U\0?!6J6%GYUEIMPSW<GFHOEJ60]"03P#T!KNK35M-U"1X[+4
M+2YD3[ZPS*Y7Z@'BI;B]M+0H+FZA@+G""60+N/MGK0!X#H/P@U[2]8\82/IX
M^S/IU[:Z0?/C/FM)E4_B^7Y2?O8^]7K'PST;4/#WP[TG2M4M_L][;K()8MZO
MMS(S#E20>".AKJWD2*-I)'5$499F. !]:CMKRVO8O-M;B&>,'&Z)PPS]10!-
M1110 4444 %%%% !1110 4444 %%%% !7SKXVN[2Q^/MY/>^'9-?@6Q3=9)
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MN/GNKIW)]N!_/-=?0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M;GUW?"?ASQ;K'Q1/C7Q+ID&CI#:?9X[:.97:4X(R=I/')//HO'>@#UNBBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH IZEI.G:Q;?9M3L+:]@SGR[B
M)9%SZX(ZU'I>A:1H<;QZ3I=G8J_WQ;0+'N^N!S^-:%% !1110 4444 %%%%
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M3Q)\;?"7A?42S:3Y!N7ASA9&_>$@X]1&J_B?6@#TK0_'7A?Q)=M:Z1K5K=7
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M;9;-HK&-PZ6PD1VV@CJ<;<GU% 'I%%%% !1110 4444 %%%% !1110 4444
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M!_[Z% $M%1>9+_SP/_?0H\R7_G@?^^A0!+147F2_\\#_ -]"CS)?^>!_[Z%
M$M><>)/#NGR^---M8ED#WTCS7/S]1G/'IT:O0O,E_P">!_[Z%<A$[WWQ/FD\
MLG[#:!0,C@G'_P 6: .LL;*'3K&&SMP1#$NU03DXJQ47F2_\\#_WT*/,E_YX
M'_OH4 2T5%YDO_/ _P#?0H\R7_G@?^^A0!+147F2_P#/ _\ ?0H\R7_G@?\
MOH4 2T5%YDO_ #P/_?0H\R7_ )X'_OH4 2T5%YDO_/ _]]"CS)?^>!_[Z% $
MM%1>9+_SP/\ WT*/,E_YX'_OH4 2T5%YDO\ SP/_ 'T*/,E_YX'_ +Z% $M%
M1>9+_P \#_WT*/,E_P">!_[Z% $M%1>9+_SP/_?0H\R7_G@?^^A0!+147F2_
M\\#_ -]"CS)?^>!_[Z% $M%1>9+_ ,\#_P!]"CS)?^>!_P"^A0!+147F2_\
M/ _]]"CS)?\ G@?^^A0!+147F2_\\#_WT*/,E_YX'_OH4 2T5%YDO_/ _P#?
M0H\R7_G@?^^A0!+147F2_P#/ _\ ?0H\R7_G@?\ OH4 2T5%YDO_ #P/_?0H
M\R7_ )X'_OH4 2T5%YDO_/ _]]"CS)?^>!_[Z% $M%1>9+_SP/\ WT*/,E_Y
MX'_OH4 2T5%YDO\ SP/_ 'T*/,E_YX'_ +Z% $M%1>9+_P \#_WT*/,E_P">
M!_[Z% $M%1>9+_SP/_?0H\R7_G@?^^A0!+147F2_\\#_ -]"CS)?^>!_[Z%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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ME(="77$1%9]/9L>:H8$]CT^]C':@#@_!&H?VOJ.FJ?BE-?7X1);C31'&%=L
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M#R_[2N'GV,"QZ(,=N?7H>U 'JE%5-,U"#5M*L]2M23;W<*3QDCG:P!'Z&K=
M!1110 4444 %%%% !1110 4444 %%%% !37=8XV=CA5!)/M3JR?$]U]C\,:C
M-G!\AE!]V^4?J: ,;X>HTFE7M^X^>[NW<_3C^I-=?6)X0M?LGA/3H\8+1>8?
M^!$M_6MN@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M /(] 'L%'48->/\ _"/?'/\ Z'/0_P#ORO\ \CT?\(]\<_\ H<]#_P"_*_\
MR/0!W?ASPE!H.JZE>)M(G?$ '_+./J1^?'T45TM>/_\ "/?'/_H<]#_[\K_\
MCT?\(]\<_P#H<]#_ ._*_P#R/2225D9TJ4*4>6"LCV"LW7=(BUW1Y["4[?,&
M4?&=C#H:\Q_X1[XY_P#0YZ'_ -^5_P#D>C_A'OCG_P!#GH?_ 'Y7_P"1Z;5R
MIP4XN,MF>L6-G#I]C!9VZ[8H4"*/I_6K%>/_ /"/?'/_ *'/0_\ ORO_ ,CT
M?\(]\<_^AST/_ORO_P CT#225D>P45X__P (]\<_^AST/_ORO_R/1_PCWQS_
M .AST/\ [\K_ /(] SV"BO'_ /A'OCG_ -#GH?\ WY7_ .1Z/^$>^.?_ $.>
MA_\ ?E?_ )'H ]@HKQ__ (1[XY_]#GH?_?E?_D>C_A'OCG_T.>A_]^5_^1Z
M/4=6TJ'5K=(I3C9(&##KCN/Q%7E4(H50 H& !VKR#_A'OCG_ -#GH?\ WY7_
M .1Z/^$>^.?_ $.>A_\ ?E?_ )'J%"*DYI:LMSDXJ+>B/8**\?\ ^$>^.?\
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M"/Q=J=K>W6!L\J/YT'H[\!C_ ,!_$UU5 !1110 4444 %%%% !1110 4444
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MZFC[-#_<_4U+10!%]FA_N?J:Y/X@A8_#\=O$O[RYN$C SUZG^8%=C7'>*/\
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MU/8C@\],T >T4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MAM88F.61%4GZ"N6T[X9>$-*UB/5+/2%CN(7,D*F:1HXF/5E0MM4_0<=L5UU
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M_"S6+C7?AOI%[<P1PR;&B"Q1A$*HQ0%5' &%''UKL:BM;6WLK6*UM88X;>%
MD<4:A511T  Z"I: "BBB@ KSOXP*J^%],VJ!G6K0G ZG<:]$K.UC0]-U^UBM
MM3MO/ABF2X1=[+AU.5.5(Z>G2@!^LZG'HNAW^J3#='9V\D[*#U"J6Q^E<C\)
M-)EM/!BZO>D/J6N2MJ5S)Z^9RH^FW!_$UV.J:9::SIEQIM_$9;2Y0QRQ[V7<
MIZC*D$?@:EL[2"PLH+.UC$=O;QK%$@).U5& .?84 35YO\4%AN-?\$V6H[3H
MT^J$7*2'Y'<+^Z5AT()SP:](JAK.B:;XATR33M6M([JTDP6C?/4="".0?<4
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MTZ.VU63R(+C3Y7813$9".&')/3(XKK->U&XTG0[N^M-/GU"XA3,=K "7D8D
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MJWV22QM;6>+RU"/EDSD8*CJ2 "<XS7M-M=VU[&9+6XBGC!VEHG# 'TR/K4U
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M_P#K4;YO^>(_[[_^M4M% $6^;_GB/^^__K4UO,?&Z ''^W4]% %;8W_/N/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /'_ -G'_DGFH?\
M85D_]%15[!7C_P"SC_R3S4/^PK)_Z*BKV"@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH *X7XB^+YM&M8M%TC=)KFH?)$L?+1*>-WU/0?B>U;_BOQ-:>
M%-"FU&Y^9Q\L,.<&5ST']2>P!KD_AWX8NY[J7QCX@S)JM]EX5<?ZI#WQV)'
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MGFN#&X65*JW%>X[N+6JMZFU*HI1UWZENBBBN$U"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHKFO&OC:P\"Z7#J.I6=]<6TLOE%
MK1$;8Q&1NW,N <&@#A/V<?\ DGFH?]A63_T5%7L%?/7P \;6&GVG_")-9WTV
MH7M])<))"B&)$\M 2Q+ C&P]CVKZ%H **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH *AN[NWL+.:[NI5BMX4+R.W10.M35Y1XFO[KXB^*5\)Z1*RZ1:.'U&Z3HQ
M!Z#UP> .YYZ#-=>$PWMY^\[16K?9?Y]O,SJ5.1:;O8CT2TN/B=XM;Q#J43+H
M%@Y2RMGZ2L/4?D6_!>0*];JMI]A;:7I\%C9Q+%;P($C1>P_Q]ZLT8O$^WFN5
M6BM$NR_S>[\PIT^1:[O<****Y#0**** "BBB@ HHHH **** "BBB@#G/'EI!
M=^"-66>%)1';/(FY<[6 R"/0BOFO1+F33]>T^\6WDG-O<QRB)1R^U@<#W.*^
MMZ*]K+<X^I494G#F4O.WZ,Y:^&]K)2O:QRVC?$/PSK-F9UU*&T9,>9#>.(F3
M\S@_4$UKVGB'1;^Y6VL]7L+B=L[8X;E'8X&3@ YZ5PGQ7\(65UH;ZK8:66U4
M3*"ULAW.">=P'7Z]:\S\(Q:WX8\36NKMX?U"X2W#[XUA8':5*DYP>F<_A731
MRK"XO#RKT9-/6T7;?M?MYD2Q%2G-0DK^9],T5Y/J7QPL8)8AI^DRW"-'F3SI
M?*9'R05Q@@\ '.>]==X%\9'QGIUS=FQ^R>1+Y>WS=^[C.>@KS*^5XNA2]M5A
M:/JORW-XUZ<Y<L7J=51117GFP4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !61XGT"V\4>&K_1;O'EW410-C.QNJL/<$ _A6O10!X]\#?A]<^&8-
M2U?5[?RM1EE>TB5A]R-&PQ'LS#\E![U[#110 444R6:*")I9I$CC499W8 #Z
MDT)7 ?17&ZM\4?"NE$QK?&^F' CLU\S/_ ON_K61_P );XY\0<:!X8%A W2Y
MU!L<>H!Q^@:N^&6XB4>:2Y8]Y.R_']#)UX)V6K\M1/B'\1M2\(:];V%E9VDT
M<ELLQ:8-G)9AC@CCY:V/AWXOO/&&E75U>V\$+PS>6HA!P1@'N37-7?PGUCQ'
M<K?^)?$PEN]NS$%N"JKDG /R\9)_AJ>S^$^I:*C-H?B^\M)"<E1'A&^H#8_0
MUZE2&5O"JBII5/YK2M^1SIU_:<UO=[:'J%%><?\ %T]&_P"@7K<8^B/C_P <
MY_.C_A9]]IG'B+PCJ=DHZRQ#>A_, ?J:\W^S*LOX4HS]&K_<[/\  W]O%?$F
MOD>CT5Y%XJ^,4*6MF_AB9))&9OM"7,# H.-OMZ]">E:/PS\>:QXLU:]MM1%O
MY<, D7RH]ISN ]:N>3XN&'>(FK)='OO;82Q--SY$STRBBBO+-PHHHH ****
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M7DO\C!X>FY<S6IY__P *VUQ/]3X_UE/9F=A_Z,H_X0/QA%_JOB!>-_UT@/\
M\6:] ^S0?\\D_*C[-!_SR3\J7]JXGJT_^W8_Y#^KP_IL\_\ ^$4^(47^J\;1
MM_UTMQ_@:/[$^*4?W/%.F2#TD@4?RBKT#[-!_P \D_*C[-!_SR3\J/[3J/>$
M'_VY'_(/81Z-_>SS_P"Q_%>+_F):)-_P$C_V04>=\5XO^771)OQ(_P#9A7H'
MV:#_ )Y)^5'V:#_GDGY4?VCWI0_\!_R#V/\ >?WGG_\ :_Q5C^]X<TB7_<F
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M 4444 %%%% !1110 4V21(HVDD8*B LQ/8"G5#>6XO+*XMF8JLT;1DCMD8H
MXCPM\38_$FM6EE)HUS86^HQ2S:9<RRJPNDC;#94<H>,X.>/PSWM>0^"/!_B>
MUU_PTNLZ;':6GAJUN84N5N%D%VTI(!51RH"G/S5Z]0 4444 %<=X_P#B%8^
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M]:DKYAB\+Z7J/P_\?ZY=1/)?6.JS"U?S6 A^9"2%!QDYP21V'I7T'X.GENO
M^@7$[M)-+IMN[NQR68QJ23^- &W1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MEG=6::38+:W;F2XA%L@29CU+KC#'@<GTJ[!!#:V\=O;Q)##$@2..-0JHH&
M!P !VHHH DHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
1HH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>gyowp0iggm03000003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gyowp0iggm03000003.jpg
M_]C_X  02D9)1@ ! @$ W #<  #_[@ .061O8F4 9      !_^$ 2D5X:68
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M%0%OT/,Q5ABV4U!R#25B9% KAC(,5B.&KE$1$O6353$2B)#E$IBCP,0Y1*8
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MW%&QV*%J4')62Q/B1L+$-Q=2#XZ3A<K= #%3 P(-4EW*QS*'*4I$R'.8P@
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M6S@B+=Q#,*^C+0#AZ8!2,FVN"+KR K%J*C\_5.F8$AZPI]P0RND<"**U>XM
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M/)S5AD^HJ8ZI/'QBNUX&$3!U^Z(CA%UGF_\ _G0>AB_Z&?2K?X@\J.$3F_\
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M+6]K2>\":GP!>;Q])OR%E$2CS-Z]X@(@/#R\8.X/#N&+#"40^&'<STOA??\
MW63Y/*O&/.G*P_\ 6P_UO(G])MR%_E-:^_O]]I<?#&_^ZR?)Y4^->5??8?ZW
MD40])KR&#T<S.OO[_?:7'PQO_NLGR>51\:\JC_UL/];R*/\ 2:<AOY3.OO[_
M 'VFR?A?F#W63Y/*GQMRK[[#_6^BH_TF?(=^4QK_ .)/?:7(^%]_]UD^3RI\
M;<J^^P_UOHI_29<AWY3&O_[_ 'VEQ\+[_P"ZR?)Y5'QORH/_ %T/];Z*F_I,
M>1#\I?7_ /?[[38^&-_]UD^3RI\;\J>_0_UOHI_28<B'Y2VO_B3WVFQ\,;_[
MK)\GE3XWY4'_ *Z'^M]%1#TE_(B/1S+:_P#[_?:;'POOX_\ 2R?)Y5'QQRG[
M]#_6^BH_TEW(E^4MK_\ O[]IL?#&_P#NLGR>5/CCE/WZ'^M]%/Z2WD2_*5H'
M]_?M-CX7W_W63Y/*GQQRG[]#_6^BH_TEG(H/_:4H'Q)[[38^&-_]UD^3RI\<
M<I^_0_UOHJ/])5R*_E*4#XD[]IL?"^_^ZR?)Y5'QSRE[]#_6^BHAZ2GD5'_M
M)T'^_OVFQ\+[_P"ZR?)Y4///*0SOH?ZWT5'^DIY%ORDZ#_?W[38^%]_]UD^3
MRJ/CKE'WZ'^M]% ])1R+#T<R=!_O[]IL?"^_^ZR?)Y4^.N4??H?ZWT5-_23<
MC'Y25!_O[]I\?#&_^ZR?)Y4^.^4??X?ZWT4_I)>1G\I*@_W]^T^/AC?_ '63
MY/*GQWRC[_#_ %OHJ/\ 22<C7Y2-"_O[]I\#EC?S_P"ED^3RI\=\H^_P_P!;
MZ*?TDG(T/_:1H7]_?M/CX7W_ -UD^3RJ/CSE#W^'^M]%3!Z2+D;'HYD*%_?S
M[3X^&-_]UD^3RI\>\G^_P_UOHJ/])#R.?E'T+^_GVGQ\+[^?_2R?)Y4^/.3_
M '^#^M]%1_I(.1T?^T?0O[^?:?'POO\ [K)\GE4?'O)_O\'];Z*?TCW(]^4=
M0_B3GVGQ\,;][K)\GE3X]Y/]_A_K?14?Z1[D>_*.H?Q)S[3X^%]_]UD^3RJ/
MC[D[[P@_K?14?Z1SD@_*-H?]_/M/CX7W_P!UD^3RH.?^3CEN$'];Z*C_ $C?
M)#^490_[]_:C'PQO_NLGR>51^8')OWA!_6^BH_TC7)$/_:,HG]_/M1CX8W_W
M63Y/*GY@<F_>$'];Z*C_ $C/)'^471/[^?:C(^&-^]UD^3RH?Q Y-&>X0?UO
MHJ/](OR2#_VBJ+\2;^U&2.5]_.5K)\GE5?S"Y+^\(/ZWT5'^D6Y)!_[15%_O
MW]J,GX7W_P!UD^3RI^87)?WC!_6^BG](KR2_E$T7^_?VHR/A??\ W63Y/*H_
M,3DK[Q@_K?14?Z13DF_*)HOQ)O[48^%]_P#=9/D\J?F)R3]XP?UOHJ/](GR3
M_E$47XDW]J,?#&_^ZR?)Y4/XB<DC/<8/ZWT5$/2)<E ]',11?[]_:C)^%^8/
M=9/D\JK^8W)'WC!_6^BH_P!(AR4_E#T;^_7VHR/A??\ W63Y/*I_,;D@_P#N
M,'];Z*?TB')3^4/1O[]_:C'POO\ [K)\GE4?F/R./_<H/ZWT5$/2'\E0]',-
M1A^S?VHQ\+[_ .ZR?)Y4_,?D?[R@_K?14W](;R6?E"T?^_7VIQ\,;_[K)\GE
M4?F1R-]Y6_\ 6^BG](9R6?E"T?XDU]J<?"^_^ZR?)Y4_,CD;[RM_ZWT5'^D+
MY+?RA*/_ 'Z^U./AC?\ W63Y/*H_,GD7/[2M_P"M]%1_I"N2[\H2C_WZ^U.3
M\+[_ .ZR?)Y4_,KD7[RM_P"M]%1#TA/)>/1S!TCXDU]J<CX7W_W63Y/*H_,K
MD7[RM_ZWT5'^D(Y,/R@Z1_?K[4Y/POO_ +K)\GE3\R^1/O*W_K?14?Z0;DQ_
M*"I']^?M3D?#&_\ NLGR>51^9G(GWG;_ -?Z*C_2"\F7Y0-(^)-?:G'PQO\
M[K)\GE3\S.0_O.W_ *_T4_I!>3+\H&D?$FOM3CX7W_W63Y/*GYF<A_>=O_7^
MBHAZ0/DT'HY@*3_?G[4X^%]_]UD^3RJ/S-Y#^\[?^O\ 14?Z0+DU_* I/Q)G
M[4X^&-_]UD^3RI^9O(7WG;_UOHJ/](#R:_R_TG^_/VJQ\,;_ .ZR?)Y5!_$_
MD$9[G;_U_HJ/](!R;?R_TG^_/VJP.6-_.5K)\GE4_F=R%]YV_P#7^BH_C_\
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M2%D6LN61G'93?5!T>4:+D1X>2>OUC))B;HX< Z<GX9WZE.S2?)Y5'YH?A_\
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M8HD$0'P>ME@:K,BBI&Z?!E@I&2ADJ5<)'X@!1Z0Z![XYDYM,>"FJ&]T/@]C
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MO.[S7_\ [:_QAO(OD#SB_P#J1XSX[_YUV7_DV>(=Y_\ Q/VIU?\ O=&G5_\
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MP\LW.Q;U]A"XMKW<=>@MMC(_3*'F,Q'7%&3)J;32T.S&-31=3+RDV\'P5/\
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MA<8P1:@LU&K<1$)*:"?-I73YJQ>SXN1+JO;K4S-<KJ*YH']DDVIB]5RP@)N
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MQ_4RG[%/W8-ZL882R:ZDN++JZ"&2(:JTH*R94\/E/@7.P;A/<];;6<5IN/6
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M\QNB7U"L5FH&QZWR:Z=J=XDH*3D:_9&L[(QUM;S,:_>,W"+TJSBJRC1!<IC
M(EX (<0XY3E6WAN]JN&W#626SKV1S00"*#30C_:!(71^(%[=;?S!;2V4CX;Q
MNVQ->6DM=4F2H)'\TC_XA8VVB)O0RZP,81,8W/7(B8PB(B(CJS8@B(B/=$1'
M+0?][2_] /\ QL7/?$G\+[4G/[4/_@F7RESZ]?FJG+T9(4.R"^K49M*O471_
M)12]D%7>:2W-HO=6O=M,44C.7$9%..:K:KZN;"A6W:$*:U:OM"#:98CTK%;K
M-!$$G2O'Y!]I+<7]_/:X7\$\3XSTGJ(PYA_FO;5I[X/!?I4&Y06>R;19[ACL
M]W;7,4PSH.U/+)6_SXGT>T] (XK4K)I>TZVY7MJZ7LBK$DVSY[]"P369:+%=
M0,U%S^EMVK5JWPKU,PIOZS98.2;23)<H\%F;@ANX(\ VBOX;K=HK^*NC[.E)
M'$$21:FGH<T@M(Z0N6YV:YL>7I=FN"!+]MPL#LVN:Z"70\8XM<TAPQR/2L5M
M;;5!T;N:^Z%B.7G25FU+JG8,UK*;\ZZ2VDMH7QO1)IU5;+9WFV0=)76MV&TN
MX]R\0+$NF+"/,JDF1L8B0@>]I97-_8Q[@^YN&WDT8D&E](V:QJ:WJZ:2&@@'
M4"3CCBN;<MWV_:-VFV:+;[*3:[:8Q.UQATT@C.A[C-74U[B'%NDM#:CS<%T5
M[K>B<M=<](+&'H5'VK+:3Y@M%4G6DUL>":SIX2-E)/>B9W;I%$&HO3OHB(:>
M/,.T)'/'C9$[I!=) J!N5MU<;I+MKNLDA9/;RN>&$BI B\5"30Y@$T()JNXV
M%ER]%OC>H@N9+2ZMFQ&9H?I#W39Y5\VFH5#7. +@0*+DNQV%'W%HS2>[)6 U
MWI2R3>_;YH_8E@HE-7KU&7KD37]8V^,OTAK^FM7+=B_K+.\.TG*,''D._;-T
M^J@=P'ZIV6CKBROY[%CI)XFV[)6![JOU$O:6![N#BT4+C@3G1>5N#+'=]DM-
MXDC@LYS?/MY711Z8RP-C>)#&RN+ \@A@JX#*M%RN:BJ%H.U:VV3IWF'I.Z;5
M5+K#6II'PNOMJ5E""?5.183T.^E1V+4:LUDVCJ2:$(*+8ZIQ INOU0$!'M8^
MYW&&6UO;:2"%\9;4OC=4.!! T.=0T.97D3Q;=LEQ;[CM-_%>744[7AHBF8&E
MA#@29&M!!( H,5UOR+RD\QUY<K0=OV?R];)V79U%FE?N4#$;+TZTM=ID .6.
M+?8"1K]Z@*ZYFWHII+.*_)'9('(*RBH$.IG'UF\[7; /9#<VD3<VDLDTM&>D
M@L)H,@\5.5,EZ9AY4YCOB89;JQW.YEKID:V6#K)#Z(>PMD:TN.!<PZ0<< MB
MJT4UT-RT[HE[7J76=IVYKSF_I&J?&=@U6.M@51XTU]N0+-'@@OP:3D?Y3K(E
M/'O?&8M5<J;@[<ZR"!T\Y'NW'=8(X9I664EDZ3S'%NKSX])[AH[,4=2HK0E;
M6T<>Q<N74UU:6LVZ0;LV"LK \,(BEU#^<*M/FNJRM':26BFP7;9U1K&E=#\P
MU>T!H5ML_;,YMVD7E*1UO#3>MC(ZG>U!9C,UC5$H1S1ZO,VEAL=)&35;-0(0
MT4BHQ(R,JX[7."TGEO[G;)+FY-I"V-S*/(?^\#JAT@\YP:65:"?G'4304UOM
MSL[79['?8-OL/M&[=,R2L0=%2!S:%D).ACGB0!Y ^8-(;4K'777</%\S%,D-
M8:1K%Q;7[0NMMYMM534F>,UA39W8>GXBWR\A-/I>78M&VN*9/R2C_P 7DY)L
MP*B0C=POV'$IT%T]^UR-N[AS#'</BZP"LC@R0M   )UN I5K2>(%5G>;?"SF
M2&;;+&.<7%A%<B!QTPQNDB#B7%Q ZICCJTN<UN32X"@62YB: >5Y9&>X[=6.
M7*O[&@=[5_6Y7_+38=.OZW.U&W:_N%G(A;H#2%DFZ;#3U?EJ1P:+]@T=/&[U
M4%.U!(APG:[G1NQL87W3K5UN7TG$@<'->UOFF5H<00['$@$#*JIS'9-EY8;N
MUS%MT>X,OFQ5LW0ECHWQ/?1[8'N8'M<S X$@\<UVFE__ # /1]?]"')=_P"I
M6L9PW'_;>Y_]3<_^:5[%A_WSL'_Z-LO_ +=?+/7;2)?[ HK&>!(8-[<:RTF0
M6X B,2XFF2,B"HB!@!+Q,Y^MQ >YGUMTY[;65T7]H(W$=_2:?*ORW:F0R;I;
M1W%#;NN(PZN6DO =7N4JNW\Z3N3>\WW,TI+*+J.4=Z;/8-Q<=;KDB8NWRT;
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MR.#</G < ZK0*  ++>MYL>7I=MMX-LVR6&3:;*28R0->^1SXFEY#L-!=F7-
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M8WT]:YU$KA3P9 < *+LVGY&0EM#<[,C*/GDE(.M<ZA4=/I!RL\>.5 YA-9D
MZ[IP=1=8X$* <3&$>  &>=?L9'NNW,C :P2RT % /W#^ 7T.P3SW/*7,L]R]
M\D[K>SJYQ+G'_G8AB34GPJAR0-T5^9[69E XNF*5XF(3@0BB@6F#US;IFH&0
M(?N'<EM+!F*0!\D*@%X<1X9/,9(V::F1T _T3(T._JDK'\,6M=SS95])O7.;
MQ\]MO*Z.G=UAM.ZO+Z+]\@^3E$'KM&21=D?HR*3A9-\D^36!PF]3=D.#@CLC
M@ ."@& X'#K /'NY[A8PLZL@:*4I3"F5*='<7P1GF9,+EKW"X#M0<"=0=6NH
M.SU5QK6M<5Z8Y;%3RLCO:*E'BAV%@Y;MU/)DSE1547SVL5\-@5\S@YE %1P-
MRJ[!0ISB8>T#OB.>+NX#!:O8/.;>0@=P..AU/]EQ7W')CW3R;O%.XEDNRWCG
MU).IS&"9A/2>M8T@GBO-(=_/;"_/I."K!T!ZV0KC(*8.C(6;O27JOD?_ .MM
MH'_I&AO_ -]GA<R_Z%=?\(_J7WWX6?\ ?^U_]3_\KEQ#7/\ R@4;^&-8_P -
M,L]*^_P<O_#=_P"$KY/8O]=LO^KA_P#,:O:W,-&\I*G,!O,]DNG,6UL1]P[-
M//M836.M'\*VFC76;&40B'[_ &Y&OGL6B^%0K=99LW542 ICID,(E#P=I?O_
M -EVPACLS#V>/3JDD!IH%*@1D TS )%>)7Z+SA%^')YKW,WT^]B]^T;GK!'!
M:E@?US]8877#7%@=727-!(H2 <%A>9DK O.;&%BE'BT65ORS%C5I!%%L_58!
MJ'4P,U'S=LX=MV[P[?JBJ1-50A#B(%.8  1OL^KX:=KIKI<5IE7K9:TRP\"R
MYTZL?BI&(2XPZ]MTZ@ :=FM:5 ) -,P"17B5O5-3;J>DOV HM_7#/>?,A*0O
M!,JJ@6B(+LN4J(H)F 0,Y"T,V8I=_M.KP[O#.:Y)')L5,C;6X/\ 1/5AW]4E
M=FSM8[\<[HN])NZ;BYO']XT7+HZ=WK VG=7SV(\=^,@_\:<^/^,B\\=[=7QO
MQOM16\:\9ZW;>,]M\GU^MUNMW>/'/JM+?0H-%*4X4IE3H7XV)INL[1K=U^K5
MJJ=6JM=5<ZUQK6M<5[0YDVVO5^<:W!L9[9(ZG2*]3E+V]I[",5LR$_+ZUKLM
M9SQ["0%&-%\>[.UP6*IU0 !./N@SY[9W78Y>C[&&&Y&H,#R=-!(X-J1C30!3
MP+]+YZCV1_XH7+=]?/'M3S$Z=T+6F4/=:QN?I:X::F8G54<3Q5Z$'Z/$H@(7
M[FL 0$! 0J6M@$!#N@("#_B @.3UO-O&&Q]J1:"R_!4&HOM_K_PH/HKW#S<P
MNBY?D_UW;K_/;*-M-*/%EI">V)"UYCM^Y5M-=-1NPN49#ONH^I:;1?M22+TR
M3Q #IK%[55P9-[\UR_+N;.8)8+1L/8:UF;&7&)CN)82,'U^:*@XC "K?U/\
M$FUY4G_#BSO]YFO3OK64L9+AD8O)F9ALS6D5AH:E[Z/;YKO.>ZDGQXUW^_\
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M:LIYWSQRW,'6FLC8I"QKR<RYM#GQI2M3TJ+/GC=+6UAM9H;*Z[.*1/GBUOC
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MK6UBM9K3S#[)USLVQ7A>439JL9JCO-DR$D0T(E%J(O\ SD=[$.8!(X:$9 U
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MY"BH5(13)E+>&*:^9/9M#;.!CF:@/3)H*#I:VGI<795Q71NM_?;?RY<;;O\
M,^;?MRGBG,;R2;=C:NUN&4<LVH#JP/-C J&X!91O;K7 T&[6G9TZ\DI?;5-;
MU2ETUZ8" M$D=1Y27AS#MP;,X.*AFD:*448J13.ESG,0@I@90:.MX);J*"Q:
M!'!)K>\=-#YE3BXDFKL<!3C@NANZ[G9;+>;ES%.^2ZW2T$-O ["K*M':#&*-
MC8P-I"0!K<20--7+RL7I'UQSWAP7YCQ5\E[@/#[(X/I%2KHON0\/LCE79*5]
M6^3[63FH4EY;IAJ=M+W86B[-%8@E5;UQH0YHTXE-W4S2:K@Z_#N=9'LA];X/
MF"];<7(MXS6.*M?Z1S\5*=^J_I[\)^6Y=IV=^ZW;2V[O2"T',1-KH[VLDN[K
M=*],V3YY7/X3,/VL^SY]?JQ_6MFR%*816YO=#ZX^SC@5!S"AF:LH816BJO'Y
M$O1WQS5K:8G-9.=7 9*WRRS4#= Y(S4C-4N]E^*?-4,*$PBG(3CW1Z/9RI-,
M%8#BJV45E2-[H?![&7&2+ S?NX3]W6G[7>8*A9L<L%5V:AA0J ]&9*YR5DH3
MJC_J1Z/A#ZF;-=7!45/+J#DI1Z!X#P'AW!]3X>2LU7(;K!\,.X/Q_#PS,BBT
M!J%*?I^#U,<%;@I,A0F$5(_3X/CY=N2A2Y**BK^=\/M93BH<J9O=&]<?9PJG
M-8:=_N2]_P!Z#_QA,G@H'I!97)5%XIY[.8"Y\ONI*T^UPA#CL/:FUZ1I6E2=
M@;JO86NSEX+*KA8I"/2X#($C(^$7,FD8P)BN8@G!0I12/[>Q6$-_=.;<5[/%
M$Z1P&!(;3 'A4D+PN8-RFVVTC-MI[5/.R%A<"6ASR?.(&8 !-*BJ\^EV-S4Z
M?YBJ;RP[%W; [=<\Q6J-IR6L-CHZOK6OY_7&R:56I6<2\8AXKRO6IRM(HMNN
MB#QNLJ8Y4RJ]<"J>,=YMMKO-O?N=M"Z(6\K ]FLN#V.(&9HX'IH>]3APMN]U
ML-TBVB\N&S=KBE,;Q&&.9(P:J$"K2VAJ*BN !U9GQ?<_2'<RJG*_RW3%(L!3
M;S1>;@L_,6HI5Z<H\&G:&E3Q]B8/X=:NN8:")96TLU5%5BT:KHJH& BB1 4$
M?9AY?VT;G<LF;_R)$;8<7>E**M(-:G30YD^%?/W',N[G9K.6 TW%O6ON*M94
MLMR6R C20TN)%-(!' @57K&Q\UFU;I?N=VQ:IO@--0<O7)>WN5/1:UZHR#<^
MY+IK:4VE5;:XDY2$DY%^YAX1L**L<+A2, Z0%7;F/U^OY<6UVL4%C'=1UN[B
M]TNQ</W;7ACFT! %3QI7H*]>YW>\EN-RDLI:6EIMX<WS6D=<YCI&OJ6DFC0W
MS:EN.(JN/L^8_G(U]K7DCYD;MNBJ7ZB[\OVK]:7?5"6JZW7G"25^C)%5.SH7
M&.ZC]S/BU@73M4C=*,8(/%4DB-U4"G$W6=NVB>YOMNAA?'/;QR/:_63Z!'FZ
M3A3$#$DT!-:KA^U=[MK7;-SN)XY(+N2&-\?5AO\ :MKKU ^D*$D -;C0"@JM
MGWES=;3L',UNW4-'YA8OEPJFB8FGLX]V&B)?<\GL^^62$5G73.;4;5BR$J52
MBCAXFLJB5!X?J@HW!P!E.QRLMIM8]L@NY[<W,L[G5'6B,,:TTPQ&IQS%:CII
MQZ+S=[VXWBXV^UN!:Q6K8\>I,ID>\%U#@=+ * THXG$.Z+=]SF\QVTM7\CU1
MIJ\;I/=O,_;=@5B\6B;HHRZ=1;ZF.W;V"4@ZC:"^)JJ6-O(MG[=)<%$R@84
M4+W52RW9MNM;J]FEK/96K6%H#J:NLR!<WHH0:=_N*';]NEW:;=;Q 6VYWKGA
MY<PG0(@=9:QQ^=@6AU<#X5LG)I&7J&](-SW16RK1%76YL*GR_MY6V0T"%893
MR!*)&>19$]?3=/4(J16@O%O'$D53-P> KV7!(2 %-X="_8+!UNTLA+I:-)U$
M>?B*X5%:TXTI7%7V%L[.:-U;<N#Y@VWJX#2#^[P-*FAI2N-*UI@G.7&WF8](
M+R)Q>MK-$TRYOZ?S"M8FUS<%YSL8!)6@2Q9:4+7Q>,$9>1:PHN3,T%EB-SO.
MR[;BEUP%M#H&;!?NN&E\(=#5H.DGSQ05H:"M*FE:5IBF_-G?S1M3;9P9,6W-
M'$:@/W>)I45-*T%:5I7!8%#>/-VTK'/OH9UM&+L6_.6&"IVP-=;:A=?U.,<6
MBJ34$A?7D1)TUS%2M13F'%9: T(F5H<2N7YP*J<44U<DV.T&6POQ$6V%TYS7
MQE[CI<#IJ'5#J5-<\AEBJ#<=[,.Z;6)@[=+)K'QRM8T:@YO6 %A!9JH-)PIY
MV&55O$#S;;$WCL'D%J.J+'Y +M37TINWF#!&"K\F@-0K#1.'>UI-64CI1Q%-
MYC841)Q8N&?BCA(P)"14!$0+@_:;>QM[^6[;JZJ0118D><XUK@16C"'4-1W%
MULWJXW&YVR*R=I;/$9YL&FC&M TX@TK(=-10X9K5O2V49MM")Y0M:/'JL:TV
M)S2TVC.I% A5%V#:VMEX!=ZBF?@115JE("<I1[@B7@.;<I3FU?>7+15T=HYU
M.G30_J7%SO;-O8+&S>2&2W\;"1F X.:?TKYW[BV!S!<P&BY_EDV%%34"OR34
MF_6#F)MAW#=5K>)^CM7L%I)DU=  */"220%=N#G!0)(B1GI#\2E$/H+."PV^
M^9N=N6N%[(QL+?4#B#(3T4R'1DOG=PN=TW;;)=FO YCMNAD=</X2.8#U(!XZ
MJ![L,:5"]2\SFQX..Y!>0G1$Q:&518<P=2Y;8&XS\A((1K.$U;5J?1)BZS+M
MVH/:I-V;MQ&]?J@':)&.01'CV9_-VVWD=OU_?,:7NMWS%H K5[G.#13QKT]U
MNH6<L;7MLKVL9=QV[7DNTTB:UCI#7HR!_I4[AZSZ,B[T!P?FCY7J_/5Z]:_U
M]LV>L.MEVSA";A)[4.QU71212*:O;M'T?%.&W5?$,!BBO)&(8! <Y.9(;@"U
MW.1KF7$D0#ZX$2,X]()X=Y=W*=S:DWFT0/9);03ET>FA:8I:N#0<0=)J#WUG
M/1Q5&H0NPN>^2C*Q6XEY!\W>W:C$OV$+&,',/4&TX"Z58CG3=LDK'UM!5BB<
MK)(Q&I3(D$" )"\,^8I97PV+7.<0ZSC<0235U#B>D]W-:<I0PLEW)[&-#AN,
MS00 "&U;YH/!O<R7RKN6]J%*[0N//2TV)!J;4K7.!6"4_71YQ#SDE>6^HPJE
M66.RBD% %)*R1SM%-8"<>)$EU!$0'KG^HBL+AMLS8C&[LKK-VI]/-$SCJQ/\
MTC]'>7Q]QN=DZ[DYE$T?;8]P:&LU@N-LT=6=+:U&L.+LND]U?J5C9-A-1T?,
M13I%_%RS)K)QKYN;KH/&#]!-TS=('X!UD7#=4IRCWRB&?F+FN82QPHX&A'="
M_7VN#FAS35I%0KL>G(53FF2H7PZ]+CI[9/,9MSD0TM!4S<=KTW+;A6>[[=:^
MI]NDJO6(&9LFN*G%VJPVJ/K\G5H*4@JM)V@R"[I431[=5998A452B?\ ?_P8
MWK:^6=EYAWVXGLH=\98TM!-)&V21[63R.C9&Y[7O:^1L%0T>>0UH-0:?A_XO
M[/NG,>Z\O;)#;W<^PR7^J[ZJ-[F,;KAC:^21K2(],;YZ$N% 7..0*T;TNO)5
M7(G0^KK3R?\ *PTB-P5_>];6"1Y:-.&C+M'UCS-O<BZDWB.JX!"2!A'VB(B#
MI/5B#XD[[($E$SK""G?^"_/=U-S%=VG.V[N?LDFW/&F^N=43I.MA:&CM#RVI
MC=("T'SFUJ"&X>?^,?)-O;\O6EUR5M+8]ZCW&-VJQMM,S6"*8ZJV[ \-;((R
M'?-=IH02%S/TG"6X;!S_ &C[8TY.]\<V6C.7RB,W+W7D;KG9*6M;#LRQK6&=
M=.H^XPM#M<-.,FB1JFM)I @^8/588\6Z3$H.29ZOX4'9+;\.-PLG[WMVS<P;
MG<$"9TT!G9 P,8 8G31N83_S 8:L>T2B5A] KS/Q3=O<WXB;=>1;-?[OL6VP
M!QA;!,(G7#R]Q(F;"]KP +=S@-;"8S$X ]8%WOE"WO.77F(U[677H<)7E60D
MO.SM-].-</()&B>)T>S2!>O*J<N-#(U\Z#M0A@XRS3KC(@3]5ZW8J?-\Z\N6
MUARS<W;.=V;PYG5_\H)@\S5E8WT>VS5ZNO6_V;J:*X4U#Z3D_FG<-RYBM[*;
MDZ;:HG]96Z=$YHBI$]PJ39Q :R.K_M&^G3'T3QR*;<V'HYN=KFGN<#RJ;.YG
M]#<VE_/L(MHU-6I:5M-><C/RUS6(E&U?SU(P+55]I3$09G-H1)K"JS0>M'35
M%)P@?W)G<G?B?R%M%A<;Q:;3S%LUMU/5W#VMC>-#8O2DZJO6"WCDU1&3J0YT
M;V/):X>#!'S9^&G/>ZW\.U7>Z\N;S<&;K+:-SY8SK=)30POIH,\D>F7J^NTM
MD8]H:]BT#EJU'NK;GI)=&;L<\@D9R?Z#H5%O=FB:VWU-%TEN*00EUH3&6NTL
MUJ-83D-KOMB/F[MA$NFK!\P@FS9\U;*-^,H_]'FK>=AV7\+-PV!O,;][YCN;
MB&-SS<.E-=44Q;$TR/I;B$%KY&N>U\SG1O<'?NH^/E;:-\WC\4+'?1R^S9.6
M[6WGD8SLS82X%LD ,KFQMK<.E<'MB?I+(6A[&N!ZV7RUR]6;F#U?L3F-VCN;
MT1NT^8NT<PNPE-A+(6;3-U805 >/9RY6*7CZFPM.BMDOTF\K(7$P*G%V0QD6
M38IP.8G7'ZWF>SY:WC;-KVC8^=+/:[3;+;J08[F(OF 9$QKI#'=P"K6Q8#2<
M7.(H#1?*<L[ES-LFY;INVZ<G7^X7FYW1F.N"5K(JND>6L:^TE.+I35VK$-8*
M5!)]^;,N6S=@^CEYD76K/1^W[E+VMLRWUW2\=J_6VH;+(WJ\UGM*Y-6NR6*)
MK^EJ+(,Z,\HDS8(=-^Y:KM <G6;$7377(0WYQM-AM.V?BAM3-WYDMMYV:T@?
M=.N)[F-L44GGMC8QS[J4&43-AD+&N#M(:XM+6DC]!WC==YW;\--SDV[8+K:=
MYN9FVS;>.WD?++&>K,CW-;;1D1NA?-'K<S2' AKP]S0LGS6\HFPH_P!'%RA3
MVI]=R]?YFN3Z,T5>JW5J%05+5<RW:30J33:<7&5VN)/F;F84V*Y;VJ8>&920
M.G$&L=4# NLN&7)W.FV2_BCO=OO-RR3E/>WW<3Y)INKBZIID-NYSWT(;U(-O
M$W4S2)6AM-+6J>;N3]R@_#/9Y=IMG1\U;*+25C(81+)UW[ML[6M9J!)F(N)7
M!LC7NB)<""7#QM(<M_,;K/T-4)K&E:>W#-[&YA>9-6Q[>U@?4]N?WNG5B%<R
MZ,8JG5V<-YR0<8Z>Z/J[[QUVVZIRRHI@/9N$1S[J+FCE?=OQRDW:_OK&/:]L
MVH,MI^T1B&61P:7?O"[0]P%W<,TM=AU=<VN7Q$G+7,>U?@E'M5A8WLFZ;EN6
MNY@,$CI8F-<[21&UH>QI[+ =3P0>L-,'-IN-!WE9J+1*52#^@:O5K-3JE7*J
M:TVG6,A)6>R&KT.SB!G['(CRBD%_/3 L_&'BW .U<*'-P[N<&Y<N6FX[C<;A
M^8EO#U\SY.KCG:V-FMQ=H8W[1P8VNEHX  +UMNYKW3;=N@VYG(5Y(R"%D8>^
M-[GN#&AH<]WV>*O=2KC05))HO5G,=HFQ[M]*3RGURSZ6MUTY6=7:;DT;(RD]
M>6ISR_UN['@-H3#=@G)/H%E0Y('2["H(+(HF4;NO%6S)=,PHJ-R?&<L<PVO+
M_P"$.\W5I?PV_.%Y?-T%LT8O'Q!]NTG2'F9M ZY()H6ZGO:?.#C]9S/L-[OW
MXL[1#=V4ESRE:V,A?KA<ZU;*YL^!+F]6YQ+;?S:GT6@C TQ7.+RI%USSA^CH
MV%RI\ODA2&K/<:C'<UDT!K:2KT#$T@+IJMFH?8"NO8EK!PL-(U:PV-L[</BH
ME?19W2#@ZK9(2)Z\C<XG=.1^:-LYRW-MP]UC6U9>3M>]TO57!_<B9Q>YS9&0
M.:UE=$@8YH#S4\O.W*7V;SGRSN'*.VF"-M\1<OLX"QK8C);@]<86AK6&-TS2
M7T#F%X-6U"U_FAUWS4<J'I#'?/-I'3-ZYB=<;9ID71]D42@1B;NPIN4:6RKB
M-:70BJ_>[;&P;9]K:#L03;:+20,Z3&+662*N7QGIY0W/E#G+\,A^'O,%];[7
MNEE.Z6":9U&4,I>7@N?#&YY$\T/5.D)#3US6N+3HQYKVSFKD_P#$?\P-ALKC
M<MMO(!#<0PMU2 B,,#:-CD>UE88I1(UN+VF)SF![=7.=VQ/.5Z5'9NM]4S/+
M'L_EFY2]?[!AK1L*7V>P&FW>=34+8V866*6M]60>+SZ%+!]'1L5"1\RPCY:4
M*M,.E&RK11IZO+\W(WX/;3=;S!NUINW.ES;.CA;;GK8F>@=#A%(0&&70^225
M\3WQQEL# \/#_,W^'G+\7-WMMGEVN\VODVVN6R3/N&]5*_!XUMZQE=8CUL8R
M)LK&/D#IG%I9H]+<OFK-E63TM/-US"S.J[[7]5QVMXW6M.MNP:?*UMK,6I@V
MU=5W$AKI2=:I!/P3TNNY]0DE%F5;BQ>(G4,0'Z95/E.9MWVJU_!?9>68+NWD
MWA]TZ>6.&1KRV,FXD GT$Z'CKH1HDH[4UP /5FGUO+NU;M<_C#O7,<UO<1[.
MRT9;Q/FC>P.?2 'J-;0'QZH9B7L);1[78B0$^!-5\C^V:)Z2V@:@?:OV4GRE
M:DYB-B;YUE;X&E7$^O:ZYG:'7=@TZ/<;5FX)V$N#%]K2I5Z0(\D7 */XY=!)
M0%W"BJGZ/O'X@;-N/X47.^1W=K\:7NUP6<\3Y8NN>&3/AE<+=KQIU-GN9F%K
M&T8]KB-+0!^;[1R)NNV_BG;;*ZSNCR;9[E-=P2MBE$+'20,FC!G(.K0^"WA.
MJ0ZGL<,WD']/P].?R.OZI.:ML*%25]R'RP>P.2%(S6=J59=VR=9Q+8I@2.<%
M7S@ $2M&*9@%PL8> @!NK\B0![AE#%#OYG/*V&(O.?#NE;P0NGF$8RX]P+W)
MY)C?V&C_ '.\D] _W-_8?3\Y^%TY\[K?T\:^'I7TO5LZ.%/!T+(Y573")A$P
MB81>=.:#E;U-S<:OD=6[:ASNF"IQ?5^Q1HMV]HID\1,R;:?K,DNW<E:/4RF$
MBJ9R*-W2)C)+)G3,(9Z6U[K=[1="ZM'4=D0?1<.APZ/E!Q"\C>MDL-^LC97[
M:LS:X>DQWK-.-#T\",""%^5C?OH2.;[5TZ\/JJ-A=]TDRJZD=,5J6AZU:6K(
MIN")+!4+3*1QDY _'W$6ZE4Q+\D)R"(E+^K;?SQL]TP=K+K>?B' N;7N.:#A
M_2#5^'[M^&^_V4A["UMU;<"TAK@/YS'$8_T2Y>3C>C?YZ@,(#RO[6X@(@/"#
M3,'$!X=PQ70E$/AAW,]@<R[#[U%XU\\[D[FBO^!G\7[5.'HX>>C@'_LO[6Z
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M>/\ R#["Z/K/_P#1LT^(=D]YB\:S/X8<_P!/]*NO$WZ2J?B6<UG\A&POL/\
M_1L?$6R>\Q^/]BD?AAS_ $_TJZ\3?I*J3DIYKSA\CH78AN'3PAA'V%<J>8]C
M!QNHO&J'\+OQ!)J-JNJ=YOTE<DY*.;#@ ?@$V('3TPPAWQ_W7,_B/8]5>U1>
M-6'X7?B#3_2;OQ#Z2J_B4<V'\@NP_L-_]&R?B/8J_P"*B\:R/X6?B%7_ $F[
M\3?I)^)1S7_R"[#^PW_T;+?$FQ>]1>/]BC\J_P 0_NF[\3?I*M^)7S6_R#;$
M^PP_3<GXDV+WJ+QI^5GXA_=-WXF_240Y+.:W^0;8GV%-]-R/B38O>HO&J._"
MO\0SEM-WXF_25<G)=S5@4 '0^P^__P #&]4?]UR/B38O>HO'^Q0/PJ_$2G^D
MW?B;])/Q-.:8HB!M&;  0'N@,1P$/!VN/B'9#B+F.G?/D6;_ ,*_Q#K_ *3=
M>)OTD#DTYI>/_(;?NGZTA].RXYBV2G^)C\9\BR_*K\1-5?LF[SZ&_254.3;F
MDX?\AU^^Q0?3LCXAV7WF/QGR([\*_P 0R?\ 2;OQ#Z2F#DVYI/Y#K[]B@^G9
M;XBV3WF/QGR+-WX5?B(1AM%WXF_2638\I/-C&G.K'Z=V2P55;G:K*,V:K515
MNKU>U;J'0<IF.@IU0ZQ!$2FX!Q#,G;[L3S^\GA+0:XXX].2V@_#+\3;4E]MM
ME]&\MTDMHTD',$APJ#3$9*T_$XYHOY#[Y]BR_3LU^(MD]YC\?[%S?E1^(OW1
M=^)OTE,7DXYHN/\ R(7S[%E]3_?L@\P[+[S%XU7\I_Q&U _9%W3O-^DI5^43
MF8:$3.YTM>42*KMVJ9CQA0 [ATL1NW1#]6]VLLH4I?5$<CXBV0#_ !,?C/D4
M._"?\1CEM%WXF_25Z3DZYH1X &D;V(CT $87B/=]3M^.3\1[&!C<Q^,^19'\
M)?Q(K_H]WXF_26=BN4SFPAGB;UCI*_$4)\B=,\0)D7"(B G0<)@N7KI'$H=\
M#%$ ,40, "'/)O\ L$K=#[F*G?R[V"Z[+\,/Q1L)Q/;[1>!V1!:*$<01JQ'R
M@X@@@%=AC>7CF'60[21TAL.-7(0G:)C!+NTU#B80'Q8S/ME#%   P@<A!#CP
M#K<.(^9)NVT ^9=0N']*GCJOM[7DKGF2.MUL]]%(,QHU ]XM)/C \.:RQ.7;
M>X@8/P1;!#@80'C5Y4.CN=SBV#K!\,.X.9'=]K]XB]H+K'(_.!_]LO?JG>19
MV TES&UJ683T#K79</,Q;E-W'23&ORS=VT<)B/5425(@ AQ 1*8!XE,41*8!
M 1#,Y=SV>:,Q330NC<*$%P(*[+/E+GJPN67EE87T5U&[4US8W @]PT\? C X
M+O\ LUGOK8]$KE<-I7:,!+LRL/.XL17V,=4;D_8%?CYRR,)$5*,D5+"Z5<)&
M'M7BK-'LQ[) IS"?/)LW[59W3YA<P/C-=%7$O8#3S02XC2*'( GB:8+[/F"'
MG+?MF@L/LK<(;INGKM$;&PSN;J_>N8R)CS(26G%YC;3S6 G4L3+?CC6%LJUG
M->3,D1>,"'.JZTG2#O2QQ6PLTVR$B%)"0;%0;#U4C)JD.EW!()1 !S2/X=B<
M'1RM:0:X3/I6M<M=,UQW9_%2]C,=U92R!S-!)L;<NTTTT#NHU"@P%"".%%IU
M%U[S.ZXE'LQ3]<W2,?R,2[@7RCJAMYM%Q$/U6RKUDHRGX>39=1R9H0#&!,#B
M0!)QZIC /5=7>R7C!'<31N8'!PH\MQ%:&K2#Q7C[/L?XA;#.^ZVNQNXYWQ.C
M<3;B0%CB"YNF1CVXZ17"M*BM"0<Q,T_FBL#^!EGVN+.SDZR[.^A'M=UG#5)P
MS=G49K X,I5:[#"[5258IF3%?M.R$!ZG5ZY^MG%<;%$Q\;)F%CQ1P=(YU1CZ
MSC3,Y4JNB[VO\1KZ:"YFL;AMQ;NU1NCM8X2UQ+37]S&S406BFJM,:4J:Y"7K
MG-5/S%<FY6CW55]4Y$LO %;T!E'QS"4*[;OSR PT=!M8=V[<NVB1UU%T%3..
MH *B<O<RL4VQ11/BCEB#9!1W[PDD4(I4N) H32A%."TN]O\ Q+OKJWO+FSNS
M-:R:XJ6[6M:_4':M#8VL<XN:"XN:2ZE'5"R-HB>:JZLI)A9-=3;Y*7537D7*
M.HJM%RKE=-XB^!89N*J;&835.Y1**AB+E%4O$I^L4Q@'.%^Q6S@^&9@+<OWK
MB!A3(O(R[BWW"U_$O=XI(-PL97LE(+B+.%CR0X.KUC(6O!J!4APKB#4$A9B<
M+S:VA!^A8*#,27E-@I&/7*VG*<G(G9*-18]DC*(4Y*2:'2:#U$E$54U$0 !3
M,42@(9Q_8$)!AE:-)J/WSZ5SR+Z''.HQXKIO1^)^XMDCOK*602,+'$V,&K26
MZ:!X@#VT& +7 MPH00%R0NB-S\1_^M=>.D1_>[)?2,]$;KMH_P!_%[07RWP5
MS;7_ $Z\^J=Y%G8GEWW;**D:M]:V9%0P@'7DF98=N'6$W 3.I95DV* <.Z/6
M[GA#,Y-XVQE7&9A'<Q_15=%OR%SC=/ZN/;[@._G@1CQO+1\J]F:8Y-RP;UE9
M=HK-)1VT4(Y95)AQ=1::Q.!TCSCQ1,I9'LCCQ%LD7L!,4.LHJ03$SYW<N8^N
M:8+$%K3F\X'_ &1P[YQZ #BOUOE#\)&V,[-RYE<R69A!; WSF \#(XCSZ>H!
MIJ,7.%0O>0)F   "&      *(  !T  <.X 9\K4+]MHM9LH"52M\0$.M9V!2
M\0X<3>*OQZH<>D> =&*A005L_4/^@-^E'XV*A30IU#_H#?I1^-BH2A5 R2O'
MCV9^D?SHXJ**"TDJ44U #B)# 'PRC\;,U8BF:M5>U'Y$I#<.^/ >[FC0!B<U
MB\DX#)6_8J_K9OB#EJJE"G8J_K9OB#BJ4*@**O#YV?X@Y((JI -53[!;A\[/
M^E'+:@E#2BAXNM^M'_2CDZ@HTE52LW ]T450#Y0>/L90R-X*X8[,A5O%G'ZR
MI^D-\;*:@K:7=">+./UE3](/QL:@FEW0J9FKD1']05_2#ZF7#VTS4:7="UZ=
M0634@>NF<G:3[-,G6#AUSF;/1 A>/280 >Y\+&IIXII=T+/"T<_K"OZ0WQLD
M/;TJI8ZN14/%'/['5^AF^-DZV]*C0[H*HBR=_L=;](/QLSJ.E7+74R*IG8.S
M%$/%EO5#Y >D.C+!P!K54TNZ"K 6KD.("@H AQ 0ZHYN"#B,E2AHI?%G'ZRI
M^D'XV6J%72[H42MG &#@@H/$> _(CW>/<]K*NI3O*0' Y*Y-'O1Z&J_T,WJ>
MMF>MM,PM-+J9%2>3GW[$7^ACD:V](4:7=!3R<^_8B_T,<:V](32[H*IGC7XC
M_6B_1^MF^'\++![*9A-+N@J7R:__ &&X^AF^-EM;.D)H=T%4E(R0'AP9N!X<
M?]J-\+X65U-Z0H+']!4AHN1XC_43GI'_ &HWJ^MD:V=(4&-_05@K$P>H0T@J
MLU622(B43J'()2% 52  F,/  #B.2'LZ0HT/#JT-%F?)4E^P7/T(WQL:V=(5
M.KDZ"O/O,MRS1?,QK-QKNQKV&MN6DY"V^H6^ 3($U3KK6UCN(&QQQ'!#-W"C
M0ZJB:B1^':H+*%*9,XE4+Z.V[F=MN!<1Z7 M+7-.3FNS![Z\[=-I;NEJ;:76
MTAS7-<WTFO::M<*X5!\8P7'-5\F-_@MRP^^][[KL_,#LBG524IFO7*^OJYK:
MNTZ(G!.29>H5^M+OB2-BE&9S(+/%%B@8BB@=GP[($>RZWJWDLW6-C"RWMWO#
MG^>7EQ&6)R .0^7IY++8KF.];N.XSON;MC"QGF-8U@<<2&MS<0 "XGO # <^
MUGZ-2#H.X^979C^T25CKW,' ['K3&@EJ1HMIKJ'VU+DF+VVB))6P3#20"5<(
M)%(!(]B1)-/J=4Q1$N=%SS*ZXL[:V:T-DMW,)?JJ7F,4944%*#NE<MIRJRUW
M"[O'/<^&Z#P&:32,2'5( 2X@ZR ?1:!2BCH#T<KO1O+!OCE[5V+)7&=WG!W"
MO2&S75'7C%H.*GM:M];UR/2K![?+A(,:<R2.NBGY1;BL"HH@9(A2"5?\QMOM
MT@W 1AC('-(9JK4A^LG5I%"XYX'IQ66V<J2;?LESM+IG227#7M,A92@=&(V@
M-U&H8T"@U8Y5 68MO(!*VGEYY7-#?A!=L?Q:]BZNO_G7YA'<^>GX-HRPQODG
MR'YVM_-SRUY>Z_;^./\ Q;LN'9J];B6L/,$<5_=7V@'M,<C-.KT=9!K73C2F
M5!7I"TGY9DFVZQV_K".Q2POU:/3ZH$4IJ\W57.KJ=!66V3R4[+>[JMV]M ;V
MM/+]<-FP$# ;4:(ZXK>RH"Y!5F81E<FTHFT.FC>$L41&%!%-R3M@  'Y  4<
M M2WWNU%DRQOX&7$,3B6>>6%NK$BHS!/#]E-;CE^[-^_<=MG?:W$S&MDHQKV
MOTBC31V3F@T!Q'2#C6VVGR)VK8="T)'L]W;-C-R\N\PM/TO>]@A(FY6:1DY-
M(J<Z6RPKGR2REXZ2!! @(F7 X-VR::ZCCBJ=1:[Y#;W$[C#$;.X%'1 EH &6
MDXD$=/2< ,*6O>7IKJWM@V>9M_:NU,F(:YQ)%#J% "'#,89#'.N2Y>.2Z\:4
MW7NO=ULVQ8-N63=D11F4T>8HS"M/&+^H19(]9V1U$3"\8K'NQ+U6;)%@T)'-
M")(==?J=H9N&]6]Y90644;8HX"ZE'5J'&O$5J.)J:FIPR4[9L%Q8;C=;C+,Z
M:2Y$=:L#2"QM,P:$'@ T:108YJ/,+R7W7=6[-*;OJ^UK'J:PZ3A[TRAQA*3'
MV)^_?V^*4CV[LSV9E"1:$>T.;JO&2T<\)(LSJM^N@*@*DBPWJ"SLI[*2-LL<
MY;6KB  TUR K4\""*&AQR3<]@N+_ '*UW&*5\,EL)*48'$E[:9DT '$%IU"H
MPS5KI;EE-RJQG,%NW;NQ++MJY[!1->]P[*EJ.6*3+5M?UZ24;Q\/2*R2?<I1
M\-#'==5FS%P99,J2"* =FF08O=S^U76]C:1MBAC\R-@=7SGD8ESJ8DTQ-.))
M46.TC9676Y7LKYKB7SY9"RGFQM- &-!P:VM *DY#@O%?HF^7B5B+!OS=;*%M
MY];N;'-ZHY<7]C@).!7<Z>8WJRW5\]C8F7;(2C>)F)B79J!UR$*#Q%R0W%0I
MRI^US9N+',M[)SF=I#1), 0?WA:UH!(PJ #X"%\]R5MCVONMQ8U_8W2.CMZM
M+?W(>]^ (!HYS^/$'O#Z$<QW*G-;^F^7Z:">?50=$[PIVYO%?-52>\ZO--XD
MZ\V^V\MPWD/Q_L^KXYU'G9<>/8'Z,\#;=VCV]EPS2']? Z/TJ:=7'(UIT8=]
M?3;KLDFZ/M7:C'V:Z9-Z-=6BOFYBE>G&G05G]R\M"6U=9[KHL9'!3)O=]:5@
M;-=&]<-+/E%R0J,!%R4@R!]%*2_DB,;D221%T@4" ( 8HB(CE9[D+6YAG<=;
M('AP;6@SJ0#0TJ>X5U7^U=MLKBU:.K?<1EI=IJ<6Z02*BM!PJ.^O,T?Z-QC(
M; T%9MI/XS:]+Y?^7:MZ-K^L[)JIHXKTY-0D0E#N]AS1)NQ62-67D$0,9..%
MB<&ITVYP<G.AUU/4/,A;!<1VM8IKBY,I>'X@$U#!0 X=-<<<,5X8Y3:ZXM7W
MNFXMK6S;"V-T8+2X  R&KG#$#T:&F!U8+/MO1_!1>89QOK03V(T4G):>L&L)
MF@534D6-8?2\CXXZA+PDTCIFOQ#=Y#3*<8Y79F8+)ORQH$,HD98Z@4=S )]O
M%A?UG(F#P]TAU # MQ!-"*@&HI7(T6D?+ M=T^TMM#;<&W,;HVQ@-))JU] 6
MBH-*BAJ!2HS6B:B]']O_ %;&\R$<XYD#68G,>RV++3BI=!,J^I!;2V*=LF]V
M.T58[%<.''DQB=X1")249L^V<D5$0!$$S[WF_P"W73[9XM])M] '[VM6,K1F
M+.)I5V)PIQ7/MW+6ZV#+MANM?:C(X_N-.F62GGC]X:@8T9@,<\%FH;T7.DXW
MEQ#1K[6%-EK>:AR=96WBMJFMI[!\Z))%XJ6[MY$Y',Z@YCI=T"S9J,HIV;9(
MC45C)AQ')_--Z[<NW-E>(>L#NJZQVC2/FTRQ&9TYXT5H^3=M9M0VY]O&Z;J2
MPS=4W7J(],$@D&N(&HTP%:+U-HC25VT[I[7FK)N7D;Z^H%:954EL&N+UXTK&
MQ'7:0@&B#R\^9H=A#)MVP_U6MV@H]?Y'K=0OF7U]!>7DETP"-LCB[36M"<3C
M0<:G)>UMVW7-C816<A,CHHPW5ITU#10&E74PIQ*ZP-:L'UGD/J57YG.7KHO6
M"ZS!-7T7>)/-JP?6>0^I5?F<GKHO6"CJ)O5=XE;GK-A$P\(62'H_\D5]0/\
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M/A[?/=)_8*?&_*'WE9_6M\JB'/%R>CT<RNFOO[@O?>/A_?/=)_8/D3XXY/\
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MZ')^\,?8FZ_P'_)Y5/YA\E?>,'];Z*F#F=T*/1LN"[O^Y2?O#'V)NO\  ?\
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MY@_&QI*5"=JG^B_,'XV-)2H6I6LQ3JU02B ]2VQRAN]P(5G) (]WAQX"8,D
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M_P"G4^EX[-<>H4[7;^N$_"!3/NBC_P!.I]+QV:?U2G:[;UPH#L&EAW1L4?\
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MZ?J\T&AHUSA@TDG(8KEYPY5FV'=;F&PBNG[/ (AUSVES09(8WD.D:QK*ZGD
M8&E!B<3SAE3;>[@UK*UJMD<UQL!Q<3[>#DUH1 $Q4[05I5-J9BD!.R-QZR@<
M.J/'H'.PW%NV40ND8)C\W4*^*M5\XW:=TEM#N$5M<.L&UK((WF,4SJ\#2*4-
M<>!5XSIUN>0:]E9U:QNZXU!074^V@Y->$; D8Y5!<2J34S%$$S)F W64#@)1
MX] Y1UQ;MF$+I&"8Y-+A7Q5JK1[3NDMF[<(K:X=8-K641O,8IG5X&D4H:U/
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MDC=+P"%K%(^)VJ,D%>O=?7QM=(\P*%(VF6)2!(-"C\@<#=PKQKQ$3"W5,'=
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MV]&3IC17*YN]SR R]@;<S4'L&:9UU'F:W/'+T\M!DJU'*MW,D>PO$YHTF-C
MY3$0;=D"0@(&ZW$/C[%W--]?W5BW<&M-JY@)ZF,ZM0<<!IPII[J^_P!UBY&V
MO;K+<9-KD>V]8]P:)Y06Z=&!/68UU\.A>*&>D].3/HU=G\R3.D&8;-CN<?\
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M'@@ND< !6AJ%[',FU<HV7+]EN>T-W$75^V1S!-+"YC!%,Z)X<&0L))TU;1P
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M7\_JN_6W75H(@2=I\V]A'YVBO;LG1FJ@@WD(]<2D%>.DVIDW#=00*)T%2F$
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MG[?.Q@)>87@ 8DDM- !Q)7O<K316_,VW7%PYK(&7]NYSG$-:UK96$N<30
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M(8S5G?\ 7>V]G/;1"O#D("3:4/&6N.?@D?@JHU>)J_)$.4P_/[2>JO;^V?\
MVW:NL[['QLTD=RK2.^*+[#F=IN-JVC<(@3:=A$!/ 2122:P>@D.!'2,<0K/E
M%U,=YOGE1LNSZTB746R-ZPU6CG<^9B6'MSRM3-9/,Q8Q[EP5R]ABO; P:N%3
MI>)+F7.@!SG(LF6V]7H&WW<5H_\ YV*W+B!6K0X&AKD#0$CB*5Z%EROM9=O6
MVW6Y1@;7/=!K2Z@#W,(-*$U+=1:"::23IJ34+J/*]LG;]_YNR5W;]LN<Y!WQ
MSL2"Y@J_99.3?Q'F$G6;*KL/R["2#H\>S:4F+:+O&O6(4L4X8HJ( 0Z*?#CW
M:ULK?9>MLF1MDC##"YH .O4W10C$EQH#ZP)KFO4Y;W'=[[FKLNZRROAF,S;E
MCW$LT:']8'-)T@,H:>J0*+F\O_\ +[UW_P"^)N7_ -2>A\ZX_P#N.7_HH_\
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MLATMKV.,Y#/K9<>_W<U66[NOR_B;ULFG[5E9Z1]#LT/F9^C_ #<NXNX5I/\
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M! ?4[OJ8.2J#0U5WE5NI%/<CX/9#*G-0<E;Y"JF2H.2ER516LC_<B7_L)/\
MP@QR#F/Y<"K-R=WOUA1-T>'-"H;FJ0X"EV2ADJBAA#DI<E9K\[WI%',YJCFH
MVI UA%8[KGGY<:)JN+.BW6X&OQ-I5.C/DE?%@5.Z22ULS43X<"&.H\33#W(
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M /RU42PR1;#M4LU.OGW2*9Q'$RF1X_JD!>A+ 70!_2,\U8<V!=>F@_P+ZO\
MP3AM (\S#S9&L,2W'S2"6XE\O#8#.P1\1_MCUQ5\6^2Z^<#.W?#UK]E=9JZY
M_6:*UU5\W53AIIGAE5>JX;>>:;S[9ZFG9XNIZRGH4.O37CKKECT<5XAA2S(^
MB_Y7S'+$CKA/F\;*;9&P(3;JK$J9;?9NQ/>4*^LWDU:&64%+R@5%1-P97Q<$
M3%5$@A[3]'Q1=9]I[)^[I35JT-]&N&JE:5PSJOG8.L^"K#+LG;AUNH59U?6O
M],#YFK3J\"^B/*;4:XVYO;C<J3M;E5<#):.CXZ[:GY8&4PA5WB25F;KUO8#K
MLY*5JZ,ZU((,E2(+%5(T734,B477;*_.;K-(=H9!/%=83DMDF(J,/.8, :<<
M>(..%!]9M$%N-[EN;6>T.JV:'Q0"@)U59(:.(K2K>\0>.-SSY4RL;"YM_1VT
MRYP[:P5>>LF_VLS"O3+@SDVB=:UVZ\4>%;JHG6:*JH%!5(3=FL3B0X&(8Q1G
M8II;?9]PFA);*UL-",QYS\EGS#!#=<P;3!<-#X7&XJ#D1U;#0](Z1D<C@J^V
MJS7Z9Z0KT=E4JD.PK];K]&YA8N$A(MN1K'1D<UU?/IMV;-NF $101(' I0Z,
M6<DDW+^XRRDND<^$DG,G6,2HW&*.#F;:(86AL367   H !%@ . "^<-&HR-W
MT1.:+KTWRI1KB4WA/34?S8WC;D%4]RQ[:M;(5<^6CT!W#-[_ !]GDRPG9LSG
M?()J,78 !" J#DOT,UQU%^V^E;=&D !@;&71G4RE-==);CC@<1W*+YR&T?<[
M8_;('V@)NG'M+I-,P+9B2[1H#M>% =8J#A0&J]].==478OI3IZ&V#78#8T1%
M<ET/,-&]LBHV>BGDJCL"MQ24RYBW+=6'>+G9RBXDZR)DB'5ZY"E,4AB^(R>:
MWY8#X'.C>;TCS20::":5SX+Z!UM!<\Z&.Y8V1@VP&C@"*]<!6APXKPT^K$#_
M $:'/&R+!1KA+6?.%9H;7P+L$'B]*A_P@Z+;.6=:<N$UG4,W58O7!%NP.05$
ME5 .(E,;C[;9'_$EB[4:RV;2_'TCHEQ/3D,U\W-$SX1W2)K1HAW%[8Q3T&B2
M'!O0,3EP)7J+F6INH9UKR8S>L]L<J].F*M$W*9IVN=Q-&*_+YL0KZ/A(RXO)
M1>NLG=>93L?.M#("*O4=.GPF%!0CIH/'RMLFNHS>,N8KI['EH<^.O6LH26TK
MC0CP 9X%?0;W;V<IL);.>SCECUF..6G4R5 #JZ<*M.5,:G#$+TSZ.38$'>=/
MWE"$U5K[5ZE2W!<JY.CJ$JAM4W6P-THQ9];J.LLLY4-%.T%444R%5613;(H=
MB<$C$11\[F&!\%XPOEDEUPM<.L]-H-:-=W1GWR:XXGT>5[F.YL)!'!%!U<[V
M'JO[)[A2KV=+3D,\LZ9><77XO?XZ_.U^.5^#7Q;S#U)^";\*/BWB7X,O-&7\
M\?,#ROW/*WE7Q;M/)O\ ;3RAV_BG=[;/1;V_[%LOL?K-762=9HKZ>H:=5.%.
MG"E*\%Y1^S?B+</MWJ='4P]5UM*=7I=KT:OYV=,:UHN!P32WU#D)Y'.8JV$?
M$><NV[8RQJ+.T7BCU+2=GV!)5UPW="**SE%J[8&C4F9B%,3R>* %*81)P[GF
M&;?K[;X::;B$C#+K&M#OTZJ]VJ\^ 7%ORQMNZ7-0^TN&N)(QZESRRG330YM.
MX N*3-WN&E*[9>9=WX^LKZ0#5',?#I,P3=JJPEKDKVH?7;INBD!E&RI:7+)^
M(D PI<#" E$2<3=C((KV1NVBE+"6$]]H;Y_]88KCDN9=MA?O%7:]T@N ,S1Y
M?6"G0>K=0#+#IS]C6O1=6K/,MZ,71=OKT3882M:BVG$V*$E$$9*'EIR!UHZF
M)%=\T4[1H_;.;4S,Z.D<#H*\>J8IDQ$H^1!?2R[;N=]$XM>Z6,@C @%]!3H\
MW#I7L7FWPV^[;+MTK0^*.&9I!%02V(9C(U(KT+D%I@YFGP?I@J5IF,\WF$(X
MT4^BJS56PL(Z(A)WRVZV6>(C(\J:+!!Y447HK$1(1,J*8%  (4 #LB>R9^T3
MWIU.=UH+G8DD4T5)SHZF:\V=DT WVVVT: T0EK6B@ <TF4M R):#EW%L6MJK
MK^>N_)G.4C;')C2)RNVRO+5]AIF+LS+9]VA!ANM<:5="H2T@HB_F(-!TBNM,
M)(CY15%'M.T<"DKE/+<1PWC)XKQ\;FFID(T--?-<W#@:4T\,<A4=L$-C+/8R
M6D]C'(QXTB)IUO;I.MAHZHJ*U+A@ZE<30\QF"Z0-J7TDP[G+K\>9(-U[4\WA
MM 1@WL(3LHTU \PO'?[<!&>/E?#_ &M^1\3 OC/]3]3.MG;>U;;V/K/L_J8Z
MZ:Z:U.O53"N6?'+%>>X6!LMY^T.J^U.OFTZJ:].D=5IKYU,Z4X9X+[/<JO\
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M$YN)UO;RRLEE8QTL9.EQ:"6USTDBHK05I2M%6.\N[>*2"WED9!* 'M:YS6O
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ML.S'F20C9=K!0["*@ZO5J^W>+F=O4Z_3ZG&0=4@?'W1NU<"T9HBX4X&4$Q@
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M"L6:L5"^UR/DG12E<R41!7V LL5#2+D"!VCAHDBL?A\D8<TNMHV^]EZZ>/\
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M0(\9)B<$ER J0!3/UDSG*;AAV3;[>3K8A*'@'.69PQ!!P<\C(]'=S7M7O/\
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M&UC&X#)K0..:PR??\'MYNN%5,(<BJZ7Y[P>WE2LFJL&05#\D'IR6K!V:K%Z
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M@D3 3J',8W$1$<I+++.\R3.<^0YEQ))X9G%1#!!;1B&W8R.$9-: T"IJ: 4
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M;W%!.QCPUP<W4T&CADX5!H1P(Q7:=5UM:?MC%<R0C'PJJ4F]5$!Z@'0-UV*
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M*8O3\'J9!5#Z85P3H'U_C9!X=Y#FH]_+M6;LU7RJA,EN:*J3H\/QL.S17 =
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M4=XBG;+/^+'[3?*H^=M5^Z:O_9F.]\XZF;U'>(IVVS_BQ>TWRIYV57[IJ_\
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M^VMG][MOK6?26X_A$U_]W5.^^>$]_8[)=?PI/9/D3[:V;WNU^M9])/PAZ_\
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M!79&RW+QJ:$FJK6RBH!(DJ@K+NR$ZX%!1-5'P]TCW6\FCL+(F&S<-4LS74<
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M83Z+L1WQ^S]"]29XZ]Q,(F$3")A$PB_GT<]*\FXYTN:Y26%071>87;J"7:
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M?#US72O+2UK&MK45-/.-<!X..'I['L\_(3KC?=]DB9+V=T<,37!SY'N((P'
M:1WJDF@;C\\N7/G\YH.5:DRNO=*7>+K55F;4^N4@Q>TVIV%56P2$1!PCIV5[
M/0\@\234CJZT("13@F44Q,!0,8PC]'N?+VU[M.VYOF.=*U@:"'.& ).0(XDK
MXC9><-[Y?M766VO8V!TA>:L#CJ(:TXGN-&"HZTY:N;#GOM>V=H:RHB>R[ O<
M75HV7)HV775*22M&PY&:L*JZ4?9K'5V_9R3U%VH5-DF9% "]7@0!( WN-TVC
M8(8;2ZDZJ/0&L&E[O-8 ,VM=D*9YK&TV+F'FRXN-QL(1-(92Z0AT; 'R$N-
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MZ5YFF.27=3F;?N-<0\9L75R\@HI6MNP5GK!-?O:VZ7,:+EYVPOIEJRIZX,A
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M@Z>L:W BA&'$$$<%IR1NMV_F/=-[J.WNVO<9ZD-<.L,+Y*EKPYKAJQ+7 @C
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M=F;2TD[D:]-02YUR H)1(N!4RIE*D*BOS^Z=@EL&S VK=R;)0B"H:YA&!+:
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M16UK"QHN8)8FS$ 5(D:'$N.9ID*^,8K&+>KRVGO;^>1QM+B"=\#2XZ6F!YC
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M5/UZLTZ79153E9:';U1]*.+<R%BJZLH3+!R@U2;K+%;-C-BG!-05%"C];/+
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M.@)21DR(@!4FU@1C%&%E8I@4> $C["S=(!_O?0'1GRUK:FSYA9:GYEP .]7
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M.HHP_JS=47J7$3B)VRQ4DE"E*!>H0K=<H"(B;B85NX'<'/+OXR'ME&1P\/\
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M-DCDO&;<DT=FXFD'B[ITJJ<X'5-U<]':FS=0Y\^O6Z1Q!=4$MKYI+3@RH^:
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M*#R^5>4K%$)-NAL-DD[C:K):IA>P6RVVJ8[$)&>L,TX(F=Z_<E;D >J1-/B
MFZO7.<QN6]OI[^42SZ?-:&M#11K6C( < NS;]NMMMA=#;!WGO+W%Q+G.<[-S
MB<22N6;?Y,=8[;O$KL@;5MC6EOL]=0J%WD]2WQQ30OU:;) W;1%P;>(R3:3;
MHM" @!B%24,B4I#&,!"=7IM-XN;2$6^F*2%KM31(W5I=TMRI^A<EYL=I>7!N
MM<T4[V!KS&\LUM&0=3 TKG@:85R6<N/*CI^W\N_XL 1DC6=7HQ\2PC4ZT[;)
M3T,>&G&MC0DHV4FF$VF66<RS<RCAPLBL9?MUNMQ[0<K#NEW#N'VG4.N:DFN1
MJ*4(!&%,@*4P6]QLUC<;4=GTEEEI  ::%NDAP()!QJ*U(-3GFN7;!]'WH?9&
ML-(ZFG5[JVK.A2"E5'$5*0*$O,H.4&:<VVM3AW67S-ZC95V)%WP-&[(3K<13
M%,H]0-X-_OK:ZGNX]'6S^E4&@Z-/G C36@J3X5Q77+&VW=E;6,O6=3:TTT+:
MN %"'^:00[YU VO"B[?;]"T^Y[LU+O>4DK(A;]-,+G'5B.8/(M*MOT+S!NX"
M6-/,W$.ZDW2K=F\,9N+=XU BH )P4+Q*/)#?30V4MBT-ZJ8M+B:U&DU%,:9Y
MU!71<[=!<;A!N#R\36^O2 1I/6-TG4*$F@RH1CG5:LPY4=4H6+F+GY5*<M"'
M- E6F^RZY87L>K7TFU6BY>)CT:VG&147+1@JHS*BBBBKMRL1=--1$Z0D[NKM
MTNC';QMTM-KJT$5KYQ!-:D@Y= PSJL6[/9B>ZG?J?VP-$C74TT8TM ;0 BH.
M-2<<J+2M>\E&O]=6:FV!+9>_K@RURZ5>Z]IUXVQ+3%+I:YXU:'3\BPK-K%**
M(-8MRLW32=K.4@06.D)13'J!O/O$]Q$]AC@8Z3TW-C <[&N)QXT.%,17-96V
MR6]K*R02W+VQ&K&OE<YK,-. PK@2!J+J D#!:Y>^0/3EYG=IS'G7N&HQ^YCN
M7VPZ;2K\,/2+!8'**A1M#VNN8F10=S23U47A 7,LS\;^3,@8/D<T@WV[@9$S
M3$]T/H.<VK@/5!J,.'33BJW/+MC<.G?JF8VX!ZQK'D,<XBFK30C5QZ"<2"O5
ME#I<7K>A4?7<&X?NH6A5&MTN'=2JK=>4<Q=6AF,''N))=FU8M%GZS1B0RQTD
M$4S*"(E(0O H>5<S.N)WW#Z!\CW.-,JN-33/#'I7J6MNRTMH[2,DQQ1M8"<Z
M-  K0 5H,: =Y>)'7HWM*O&URC5;[O9*"V)?I;8%[K+#8R$56K8\E'2+XD'-
M0D57F3%U!1;Q,RC4>J60(90>NZ4 J0)^N.8KUI8X1P=9'&&-<65+0.())Q/'
MAW,UX9Y7L"V5ADN.JFF=(]HDHUQ=\TAH'F@Y?.Z7$4IS7TA6GYW<D%I/E]U=
MJN]*R4?9H!XPV/$1K=OK2@4)6+G:A9(.:L*DF#E%V2+*V6%CXL(+MDT^JJ8X
M@@IT\OWC+.2:_N96:2PC02=;W5#FD"G3QK@?&.7F>PFW**#;+6*2O6-/6-H&
M,90M<":U]$^B!CT\#],*] QE6@(*L0K<&L-7(:,@8EJ'#@VC(ADA'L&X=4I2
M\$6K<A>X !W.C/GGO=*]TC\7N))[YQ*^L:QL3&QL%&-: !W!@%R2BZ#I= V/
MNW9D6[GI*9WTZJKFZ1<XXB7E?:^:,;+1+!O!,F\,R=(-7C695\:([</.T$"]
M42!Q W9-?33VT-LX-#( [216OG$$UQ[F% %Q6VV6]K>7%\PN,MUHU@TTC0"T
M:10'$'&I/@5*Z:#J=UV]J[=3R8M$5;]0Q-TB*FWAG,(G!G2O, \KTBYE6$E
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M(E+V@%$Q3<UG?S6<<L<8:Z.9FEP<#ETBA&(J:%=U[MD&X/@EE<]LMO*'M+2
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M>/MO>?>[GZU_TD^!N2_NC;?\M#]!/Q3>5O\ )QT9_-31_M'C[<WKWNY^M?\
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M_E3X"Y'^YMK_ ,K!]!/Q5^6;\GS2W\V5-^T^/MS>O>[GZQ_E4? 7(WW-M?\
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M^A#X@82@4!*4>DH?$#"4"AV9/T!?B8JHTA1ZA Z"A\3%4TA7*/9C\B<I1'I
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M7TMZ M3N""*+&),DDF03VRHI&$I0 3)JV*.35(/<[I3D,("'? <C4[I4Z6]
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M=]0[T3WE@,[ES)A$PB8199C\Y'Y<?8#.6;TO MH\E>9DM%I]U_K"'_AA3?\
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M'D2@S5ETG38[46OC0=CA%\^)W_.&O0TUF/U5)SG//08]MN>#1LE&34HNYE)
MD&YEY.$:R-YB4-;*RNIT7CR(6.@%K1A3+-.S=$ S59%90B^PM<L=?N%>@;=4
MYN*LM6M,+%V.M6."?M96#L%?FV*$G#3<-*,55V4E%2L<Z37;N$3G2614*<AA
M*(#A%\3?2,:J](;I?0W.[S=ZA]*[N*BP^G=(\PO,)KW127*KR36.H0*>M-<V
MO85?UV-PMFCIN^RL"56"39'>O7CF1,B83F4,IW<(NE<D6B.?B=K7+5S#[A]*
MGN#<55N.N=?[,NNCICE;Y,:;5++Y\4)C-N*VI<->Z7K.P(EA&2,R51%=D_;N
M#"V(!S&(90AB+OW,'Z4WD,Y7=BS&I=R[[;1.QJO%1L]>*K3-=;;V^_UG!3+4
M[^*G-LJZ>H-\9:EA9".3%TD[LJL4W.UX+ ?LA XD7FSTO_,2X_HH+MS#<KF[
M'[1I9K]R1R>O-SZ/V"]C3RU/OO.IRY5R6<5:]TF5;.%H.VU">>1SP&[GLGD>
M\7;+ 9)10@D7TYWKOS3'+'J^S[IW_LFJ:GU;3FR3BP7.X21(Z+:&<K$;,6#8
MO!1Y*S4J\4(W9,&B2[U\Y.1%NDHJ<I!(O/?*UZ2+DLYSK38Z%R\;L;6K853@
M6ULG-;VRB[.T[LI"H/':3!O<F>N]T4K7MTF*8H^<)(^5V;%Q&@JND05@,JF!
MB+2MT^EE]'[R^;#V?J/:V_RPNUM.V"IUF^ZS@M7;IO\ L!E*W;7D!M6!/7Z=
MKS7-JL-[B H=JC7S^1@6\G'1)GR+=^NV='*B)%CIWTO_ *-^ U)K[=QN:*KV
M*B;3=V9A0T=?5+9FT-@SSZDN&C2[,PT[KBDVK;\:[I;J0;)S";R";GBE'2!7
M0)"LD!R+UARW\SFA.;S5<1NSENV=7=L:SFGLE%M['7Q?-U&,U#+^+3%=L4#,
MLXNR5.S1"PE!U&2C-F_;@<@J(E Y!$B\C6CTQ7HUZ9L64UE8N::KLI: N(:]
MLMQ;U#9\KI"J7D%FK9:I6_F-B*.^Y?JE8&3QXF@Y:R5F:JM7'626 BA#E*1>
MH.8WF]Y;.4:LZ^NW,AMJNZFIFT=B1NJZ9;[$A,*U9Y=9:GW*_LV<Q88F,DHB
MI0OF=K^7?JS$NLPAFR3,06=$.HB50BTO3W/WRD[UU'LC?=!VVFUTOJ-Z^9[!
MV;LJD['TC38-..B6<X[F49K=5/U^TG*J2,?I*%F8X7<2H)A(1R8Y3% BYWH/
MTJ?(1S-;)A=0Z@WZVDMC6N*=SM$K5TUSMW4*NSH9BS"1>R>I)#<% HD1MMDT
MC.+I12M.)4I&I#K#P2(<X$7N:WVJ$HE3M%WLJSUO7*;79NU3[B-AYFPR*$)7
MHUS+RJS" KK"5L$X]28LU#),V#5R\<G $T4E%#%()%\3?1H^F/U+SH[TYHM(
M/[A<Y6SQ_-WM.F\L;(>5WF*H<6[Y?:7I/5MV;*; NUBU5%4JF7-"TK6KC'VA
M_"V!1!-H067%PS%R1>B[5Z:KT7])V#+:XLW-E5XZ1K]Q-KZPW,E(VS(:0KMV
M3D2Q#BL6'F,C* \T!!2[&6-XJY2=V9$6S@ITU>H<AP*1>RN8'FFY?^5BH4S8
M',!LR%UI1[_LW7VH*Q;9AI,O:\XONT93R/28^4EH2,E&5:A9-[Q%>9DSLX6.
M0*9=X[;H%,H!%I/+]SS\K/-%5-CW[2FT#6*@:F,4UXV!8:-L?6M"9,!BGDX>
M?A;MM"H4VKW*I-HB/6<+S,*[D(IND014<$[G$B\/6GT\/H_T%JC!:?G-R<RV
MP-E76$H&H:!J'2EUKAMU6*;<JHIIZ?VQS"M-%\NFPVC1NW4<**QUT6!9$G]3
M@NH=-,Y%[PW3SE\O_+-J:D[=YF;C^ 6-OOFW'P-+NS0TWM!Y<K(Q:O4];PU!
MUHI?IR\[ B3.#)/&%:)-@0R"JB:BK<G;"1:OH[TA'*!S(T7:NP=+[>+<8S1T
M8^F-O58]#V;6MN:\8,8=]/ I:-%6ZF0&ZXY:3BXQP>-1-7^WE3H'39$75*),
M(OGSZ-'TQ^I>='>G-%I!_<+G*V>/YN]ITWEC9#RN\Q5#BW?+[2])ZMNS938%
MVL6JHJE4RYH6E:U<8^T/X6P*()M""RXN&8N2+TCRW<R_*CRV^C<1YDY?G$W5
MS!<KNJ'.W5[/S7\PS#8E\VY+%K6^+M0;:C:(V/UG!7V;3HVP6CJML :5P"FC
MHU Z *M>HX.1;!7O2\^CCM.[:_R^PO-!5UMB7"XK:\I+QY4]E1&JK]?D7JL8
M%)U[OV7I3#0]^MKN51,T:QT/9'KMV\#L$$U%A @D7K7F$YD=&<J6M)#;_,-L
MJNZLUY'2,7"C/6!1VJM)V"<<>*0=9K4%%-9&Q6VUS;@!(SBHMH\D'0E-V2)^
MJ;@1>%=5^F$Y8N83F!JW+GRU43F1WM<9&*8V78\G%:==:;8Z#ILG8FE9CKOM
MZH\TLWH+;Q:J]?.A.FYK58L@BBD(B0#'0(J1?4&P6" J4!-VJU3<16:O68B2
ML%DLE@DF4- 5^ AF2TE,3<W,22S:.B8B)CFRB[ERNHFB@BF8YS%*41 B^<6G
M?3&^C9WUM&HZ=UES.1$E=]B/SQ6L_.37FX-=4S:LJ03E3BM3[0V/KVIZQVE)
MO#IB5LWK\Q)+.C?(HE4$0 2+USS&\T.@^4G7Q-H<Q&RH76M.=3T94X9P_;3$
MU.VRWS8.#0U-HM,J\;.72_7.73:+':Q$+'OY)PFBH=-$Q4SB4B\=Z']+!H/F
MIWVXT9RRZPYD=RMJTRJSK;>W&FLXG5E!T,YNK&TR56BMNU#F N6H>8:&D9IC
M5%54 CJ+*(G(Z;B"G YQ3(M\Y@_2F\AG*[L68U+N7?;:)V-5XJ-GKQ5:9KK;
M>WW^LX*9:G?Q4YME73U!OC+4L+(1R8NDG=E5BFYVO!8#]D('$B[1L3G+Y8-6
M<MK7F_M^XZO^+._1URZCMQ54DML*I2C+;5UJVN]>R,2KKZ-M#^5C+#<;I&M
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M?4.]$]Y8#.Y<R81,(F$668_.1^7'V SEF]+P+:/)7F9+1:?>_P![H_NY4O\
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M)X]9$7*O0_>C VQRJVCF"YXN=R\PNTO2,\[<BTG=X3%5,(T+4M1071>P6E:
M<I4R/F4(1HQ1?NB=9H 1;)DR%1LQ!Z^(O<->]&=R1U32'+CRX0&E/$-,<I7,
M!!\T?+Y3?PD;;=?@_P![5O8%RVG"WGSA>WUQ:[7XE?-@2[_R9-OI*'4\;[%1
MH9NDBDF1<NWYZ&3T9_,[?MD;-W5RNPMGN>WG%8DMDOX?8FXJ!'6ZP4V0C9&N
MW*2K6N=B5.L%V R/%)H'L*3-.<=,%%V:[M5HZ<H*D7T_PB_']_FF2SC6/+!Z
M1CDBL%S3BN;#1O/ENJ2NL%82$\Z8LDOK?5NK(6^R$')KO7SYDOL'5$N5P8X.
M$P51*50YQ6)UB+5M"\T_I?N6KT\_)-Z-OG$])/KGF^H6Z=8;>V7M&H:]Y>^7
M_7 P245HKF!M%&KUEDJKJB!O$#+EG]<Q\VD1O(-#.&1T04(=LN)52+@'(S*<
M_,[Z9[TX^P]$<NG)SO;?M/YET*/Y?YM=JW.A;&UOH-I.['K^HF6I$H.AW=T6
ME7#7D!$#**HF:$$K2.3/UR&2 "+TKH3DKYQ^7FT>GUWSN6#Y/M.ZPYE>238,
MS;.6;E3W!/; 8:PWK"Z'EEF%AEZM+U2J'J9MCP$M/6!8ZZ":KE>6+V!/%BD'
M"*P]$KRWZ M?^:B6>8LNF-93DUL#EF](-;[G.2=,@7<Y8K72=G<QD73++(S2
MS(THI/5%C1X<D6[!4J\>,8V,@9,Z)# 1?%[85IVU</0*_P";=4QS'UF_:KO/
M/O?:EL6M[;L$E6].W*1IO-7M>JZ:UMN&QQC1ZO$ZR>TXDTU?*@W<G:QC%1PF
MDHHW+A%]H_26<FOI@^<2E<L;*8Y>/14\IVQN7KF&U1=^7'=%2YE+_$6VO7&N
MNY,M1U-3#2&H*Z12,M4^\;K)0C58?&'K% R" K$(<A%LW._J;6.Z/\[;]'O3
M-N4&I;+IR?HV)>R&J5Y@H^S5AS.5BX\ZLS79%_ 2Z#J)DEH.9:HO&H.$52H.
MT$ER "J29RD7N[TG?,#R?Z*YE.03E2J?HWZ=ST\\4T_V=L;DVT5%H:PU95-6
M1A82P.M@7A]>KM&.*73XR62K\C(]EY-?)^.01I,Y4'C%BN8B^.U:L7, ;_.G
M?1KV'='(U0_1[7;9_+-S 0ENHNK=\T7>,=NFJP.E.9^6B+?<Y_75"UW$IR+*
M=KC)H5L\:.'8DA&:AEQ32;II$7K7EQH]*7_SNOG[@UZA5UH5GZ,NFRK.'5K\
M2I%M9,UAY*S&D6T>=H+1!^8SI416*0%!%0W=^2'B1;1S)_\ _8!Z/S_[%Y=/
M\8.=S"+%?YL_KJC;BJWI5-P<Q6O*'<>;:U>D[YA*7NZ1O%>A+%=6%7C:]0I&
M(I<@WFVKQY%5!C=IRT(M68%3:F.BJD!1!L4J9%XFY+FJ-+Y8/\\/TQJQC'1/
M*5K'\<@FAX*L*E5H==LLMHGFCC-G5ZF@W45CFD=#PU5JJ(-FP]DW1!$A0 O5
MPB]"<FW+?H"9_P T3V+.2VF-92,],<@'.MMN6GWE,@5Y^2V;06^[)^DWI].*
M,C2KJS5.5I40I'NSK"JT+&-DTQ*FB0@$7U\_S=B9E)[T*_("^F'JT@[0U18(
M9%=<0$Z<77-HWZO0;(HE H=C&PL6W;)AT@FD4!XCW<(O5'I8O_E9>DL_]P#G
M(_\ AUV-A%V;DK_ZF_*7_P"[-H?_ -5E5PB^"GHF)3TFRW+SMNYZ:UCZ/Z=E
M-@<Z_.]/[ILNY=S<PE1W3,;BC.9_9U2G&VS:]3-"W>"B'];KM=BXN';)2CD$
MJTSCN)43"9%,BXKS%\M^W>5[T'7/-0=KVCEYE6]B])IJ'9NMJ-RP6^U7/4^B
MJ5?_ $BO*3-3FBXQ_;JK39&+?T+;Q[2"L8FP11CTW*:/534*HDF1?3_TA**=
MD]*)Z#^@7AJTE--/MG\[.Q'4+.I).*L^YA-7\MK-]R^OG;9XBK'KVBMM)ZUR
M4%UQ*LB^:=NA^JI%$"*IZ5=$8'FA]"W?Z$U1+O(/21QNKV3]BD0UB<<NVQ.7
M7>ZW,A#B*:*CIQ4AAZU$/9 AA[!)9FW7,!3ID4(14>0JNP)/2Y^GAMI8>."S
MN=F^C[KJT_XHB,L>!9<B6LY-M#^/"07!8Y.0?JK=D!@(94_6$!$"\"+#^CKU
M[1ZEZ5_T\LC6JK!PC]]NSDF<.GD>P0;N55[;R:4/8%I4%4I>N4UBNUD?2CWJ
MB'C+UP953K& H@1><XB4N6JMB?YU,GHDKNNVBGU^E[>U?%5CM61V6\;GZ+^K
MW>1ML0DS#M4K1:]@,VSURX3#M5G@%/W3819[DSU_Z1"8]&KRX:9USH/T5MBY
M5KKRA:[KT1%3^_N9A(MUU=L/5T<O*25R;Q7+(_B7-@O<=/N'TXN1PX\9DGKE
M8RRISF4,1<0VSH"X:OY'/\W%Y?.86^ZPYC)[7?I0>4*MN]@4.6=7K5M[K52T
MAS:/]32U:FYR)B5[+$1U+CX,$7*K4"+*->N45""50Y%[=]/".P9+2_(U1Z-%
MT&Q1^R_2B\GM,O-2VY.SU=TY=(@KF^VNB5#;<A6X"U2:E!L&]*M4&[IL$<](
M[6,DB9$_7ZHD7,^>O0GI6^:74]$JFPF?HOM%2= YBN77<&J]VL.87F0<677.
MUJ!MZJ/ZL>GHV7EOA(EW9+\DNYJ:#4[DAGI9\R!"J'4*F8B_0KA%\0?1<6NN
M417TW-XN#U.-J5-]+ES66NTR*R"KE%A7*[RR\JTO-O56R"2R[A-K&,U5#$(0
MYS@7@!1$>&$7F&X[MYA-L^BHV&WY9_11Z U]Z/S87)GLJ4U5";.YNJWJZSMN
M7BV:LG+%6+U^ '7/+1M^EQ+F>J<F2?;Q2UP(^.X6+XXNV='44(1<^WHV;[$]
M#E_F\;.^H(W)I>N9/T#C:Z-;,D2;;VMO9V^KDK&A8$) KA*71G4GRQ79%P.5
MP54X' 0,/$B^M/IF-/V'?7HM.>/556OM7UG-V70UG<-[A=[3'TBG,VU968VR
M3B;3<)=VPAJS7[5%P2T2[>O5DF3=!\8[@P(@?"+Y:\R^];KZ6#E TKRA<M_(
M;SH: OU[V)REWU39&]N6^S:-TKRDU+3FU-=[7GKS5]M6A*+J]Z>L*G37,-6V
MU+5D7DDC)$X%;I&.&$79.:5SS5ROIV-6LN7VI\N-YG-;^BZL5SU=%<T.P-E4
MFK5F7OG,XZIN^+?K,->:VV4Z5ORE:@J1%2#D6[4Z4,_,B*W9N#)G(NJTCE\Y
M\K'Z4+ELYK=^/.0_4BM1Y=>873^QJ5H+<6Y+CM;?>J9Z0H=@J1%J[L73% :O
M*WI/;B;%X+HC@Q6AK&H0QBG7236(MM]$'^_?TQG_ -F8YCO_ (>N4S"+XSRW
M_P#R&\RG_P"F]_\ K.-V81?7;T_]2K5>]"OS?-*]!Q4 WU'K?7-FU<C#1[./
M2U].:SV7KY]0Y&GI-T")UYS5E(Q$C,S4$A01**9.!!$,(L1Z89V_U/O+T5?-
MZM5YS<E1Y;.;"_,['RU4)NRLFY=KR.[M$776M5N&DM7.GC9]MK86CI-R>PA#
MQ9%I=.+(\>H 1-JNH4BL*0YV-SV^E&Y4.;V@\N7,9RY:*Y/-"<S=&V#L#F=T
M_8^7FZ[\LO,*77<?3M65365Z1BMF2U0UBXI3RP.923CFL21\Y(FT%54XJ81?
M1CT@FVM Z0Y-M\[%YH-?)[:T<QJC&M7+5"E?A;2?:+G8=E@]=T_6[6#LCEE7
MGDC>[S:HR*:F?+MFB#EV1559%,AE2D7PE],1L[GUL_(([<;<Y -#<O\ K2D[
M]Y(+97M@PO.P39FV=,SL7S>Z*AZL^KNK*YRM5VG^<"IY88)<T9=P0CXZ2<+(
MKN2I^++$7L[TK\ZYTUSB^B4YKUJG;]U5S26W>9FH3O+GJ.#'8>^K8IO'1J-4
MC=U:ETPP[2T;04T :'66GDX=%=_$P,^Y>@3LTSCA%GN52*V7S+^E+V;Z05AH
MG=_+KR]1G(K4N4F&9\Q&O'^E]F[XV6KN][N!W>#:DL8-]@0-4U)70&%9/;"S
MCUWKF<=E9I*-TC*81>,?1,2GI-EN7G;=STUK'T?T[*; YU^=Z?W39=R[FYA*
MCNF8W%&<S^SJE.-MFUZF:%N\%$/ZW7:[%Q<.V2E'()5IG'<2HF$R*9%P3FCY
M6-E<OOH).?K4>\9KEQM%>OGI(]77>F:TY;+7:;SIS36M]H^D,Y37UKY?FSJX
M56FR$>M3=J.;8DYBB,$4&"+LB'5(H51),B^JGI\H6(C/1CVFQ1T8P83>H^8K
MD)N&L))FU1;.*'9X[G;Y>JJPFZL*)"$AW[.M6)\Q2.B!>HU=*)AP*80PBR?I
M?/W[^AS_ /LS'+C_ /#US9X1= YR.5'FBE^;32///R5VSE_>[SU3I#9_+S9M
M-\TA;RUUA=-4[,MM,O:\]4KIKAG/VK6&R(>U4-JW%^6%EFLE&N3MEBHE3_52
M*ZY-.;2V[&YI-Z\MW-!RD4[E9YUZ?I_56V)R7U]?8'<U*WSR^RUDN]-I-SKF
MV&E)H%Q.PJ%^C)V.& L,8@O%JN#J-3KIKK'*1?4[")A$PB81,(F$3")A%8/4
M^)04#\[W!]8?^[FL3J&G2LI!Q6,SJ62U5?\ ?O%_P5GO\+US*'T_ ?U*>!\'
MZUT5NJ"J0#W $OR(@'>X='YF<KQ1U%NPU"KY563")A$PB81,(F$3"+!N/GZG
MRV=D?H!<[_2*HY=53")A%?,/GA_E/]D7,9O1'?6D?I>!93.9;)A%I]Q^=5W^
M&%<_;H9(1;4O\['UPR69JC_15CFJQ3")A%$ON@]</9R%(S62#H#ULQ6XR4<*
M4PB81,(F$3")A$PB81,(M,N/NJI_"Z._:4GEFYJK\EG\U6"81,(HE]T'KAD'
M)2LD'0'K9BMQDHX4IA%(K\[4^4/_ *T<EOI#OJ'>B>\L!G<N9,(F$3"++,?G
M(_+C[ 9RS>EX%M'DKS,EHM/O?[W1_=RI?XV0F$6X81,(F$3")A$PBP[M3KJ\
M [I2=P/7Z#9TPMH*K!YJ[O*US944Q"B<Q2 / 3" !\;PY5QTMJE*X!9XA0(4
M"AT '#.)=(%!1384IA$PB81:?>_WNC^[E2_QLA,(MPPB81,(F$3")A$PB81,
M(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$
MPB81,(F$3")A$PB_/9S(?YN!RI\QO.'N'GC_ !L?2&:(WCNUS&JVUYRX;VUQ
MK"):-(RL5NII0\(X_ ;.6]"%<1U5:'6;N9=V4ZY1,' H$(0B]$<E'H:*%R1;
MQ9[TKW/7Z2[F!DF=9L-8+KSFEYG8;:VJ5D;$DW15EW%28ZNJ:ZD]& WXLG'C
M@ B8YA$AN/<(OL7A$PB81?$OGD] /R'\]&ZU.9>:<[UY;.8Z1:)L+3O#E)V<
MVU+>KNT08M8I +:25K%UJ\D_)$-2LSOTXU&1<M *BNX5310*D16'+7_F_/(;
MRG\QO+)S3Z?D-[L]N<LWX9WR$S9]AP5P/NZT[UHD[KFXW7?$O8*0]MUFL3&L
M3HIQA(>3@8UFHW3.+103N 7(MSYW/0<\G?.WN]+F>>6[F1Y6^9E>!:52R;]Y
M.=PGTOL:\U:/;(LF,'<UGE=N%<F$V[)J@W%V$<E)*M6S=NJY.@V;II$70N63
MT//)SRF:!YD-$ZK:[/>2'-S3K'3>8C?FP+\ML#F'V:UL-5L5.2DYJ^62,=Q"
M3^N1%I>FC6[>*1BT'2QUU&BJBJYE2+I/+7Z-O1O*UZ/-/T:FO[5M>8T4GKG>
M.L2VRXSE0D-LC ;^L>Q+/<78SL)1:]3_ "O&O]F/R1BGD'L4446X+I.#%4.J
M1<HI7H9.2.N^C8J?HJ[K7+GN[E@I2EL?5]WM>PQBFTF%@M6S+IM<EL8777E=
MUZWAK-6[->WJ4>ZCV#/^UW!JZ*Z25= X(O,.B/\ -Q^1[3^T-<;.O^W.=3FZ
M)IFQ1ENTWK7F[YB!VGJ+5]F@5.O79>L4&$IM)C7*E? "E:HR9I!J4$R]=(XA
MQPB]ZW?T;>C;[Z2#3WI09BU;7;;]TEH:3Y>*K4(V<J".GY"E2SS:3UQ*6" =
M45Y='=H(KMR2 B[:P-&@%0;<6PB145B+1?2 ^B6Y:/2)6O3VTMBVW?>CM]Z"
M4D0U'S&<K6T3ZAW92V$LJ5P_B8RTJP=FC_$CN@,JB<[$SIH=5;Q=9(%UP4(O
M,CO_ #?#D\>["Y:=X/-X\]$GS*\M.PB[ 9<T=FYG9>]<P.WT^K#-EJ!N6^7Z
MN6GRMK!Q%0YF PL$VKR";&0D44A3"1>]L1=3YHO0F\L',]SF5KGS)MKFNY>.
M8:*A:=6K?.\LNXH[6\1M^M4::AIB$KFU(Z6I-O<S4"J2NL&;QHQ<QJ+UHR0!
M8IU44U2D7H*[^C;T;??20:>]*#,6K:[;?NDM#2?+Q5:A&SE01T_(4J6>;2>N
M)2P0#JBO+H[M!%=N20$7;6!HT J#;BV$2*BL1>/^:OT 7)ES.[YO/,G7MF\W
M/*)M;;A6H[PE>3+>WX&HK=[AJ55/Q_94!(5*YQ+]^\26'QM5@E'F>*F.X7[1
MTLNNJ1>L]8>BWY1-'\AVUO1V:5J$YJ[0VZ=8;:UIL*7KDX20VC/J[LI,E0[Y
ML.0NEM864DML9W#R7%L[?LW;%IXNV03: R;I-"D5[JWT;>C=1^C?D_1?5NU;
M7>Z"EM#;AY>'%OFYRH.=P$I6[6=W96J41GV%%C:66T1Z5^>#'KFKYFB1DT>V
M;+@4X*$77^2CE&UOR'\KFHN4G4,W=['KC2\++0=6FMD24#+W9^TF;1.VQTI/
MR58K5/@G3E.1L"Q$Q;QK4H(%( E,8#',1=&YA=*57F4T%O#ETO4A8(FD[^T_
MLO2EQE*FZCF-JC:KM2ES5%L,A6GTQ%3L0SL#.(G5E&2KIB\;)N2D,J@L0#)F
M(MGU?K^&U-K37FJZXYDWM>UI1JEK^">3:S5S,NX:FP$?7(MS+.&+*-8KR:[&
M-(=P=%N@D943"1,A1 H$7SQVIZ*75USVSLC<.H.9?G5Y-IW=DT2T;RK?*/O*
M.UU0-MW+R:QAG-\L%-ME%V%%5?8$I%1C=%_.U8*_+2)DBK.G"R_%42+?;YZ,
M;E:N?(I.>CRB8NZZVT3-F@94\S0;<L7:[:]5W:,%NQEM-;8%R9W)W9=E/-L5
MUO.R$G.(2HRCT5/'$UTU#IB1;7M+D(U/O?EGHW+9O6[[HVTMK63K]OHW,-8+
MXA7.9RJ;6J2K]>J[KK.T];05&1J^TZ^>36(@^C(YFU.W4.V5;*-E5D5"+0^7
M3T:.K]$[BCN8:\[SYJ.;_>56J\W2=:;*YOMKQ>RY#3M6M162=OC]3UBITS76
MOJ9)W)K&-F\O,HPYIZ1:( W7?'0.JFH1>@M2<JFO-,[_ .;+F-J\S<W]WYQK
M-J&U[-BIZ1@W55@I'2VH:]I:K(T1C'UV+EXQD_JU:0<2!9!]*'5D#J'1.@B)
M4"D34G*IKS3._P#FRYC:O,W-_=^<:S:AM>S8J>D8-U58*1TMJ&O:6JR-$8Q]
M=BY>,9/ZM6D'$@60?2AU9 ZAT3H(B5 I%+J?E1UUI[?G-IS%5N6N,E=.<JR:
MCM&T8>POX)Y4H5]IG4%?TK6&U&CV%<C)6.82-5K:"\@21?2AUGYU#I'01$J!
M2+P(Z]"1H!!&PT2E\S//IJGE=MDO-25@Y)]7<R[FI\L*T;9WSR2M=(@8A*HN
MML4#6MF=R+D7=<K=NAX;LG"B*3=) XIX1>U=K\CVCMJP/)]4@:SFN*=R/;UU
M?OK1E0U>>NUZML9K3^N[UJ^E4B9C9&MSI#ZY8U6_NB&91XQSP%&S;LW:9"*)
MJD76^83E^U)S3Z;O>@]YU)M=M7[&BDXJR02SM_&N0,T?-)>&F86:B7+*9KMF
MK4['MI&+DV*Z#V.D6J+ENHFJD0P$7@O6OHD-4U;8FMK_ +AYH.>/G&::4LD7
M=M+ZWYMM^LMD:OUK?*^90:O?VE6K=%HBE\O-1!4PQ,M<'-D?1JW!P@H1R +
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MJ=0Q"+VWA$PB81,(F$3")A$PBD4*!R&*( /$.@?5[V2#0U4$5%%@! 0$0'I
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MW>.=,+JBG0L'MH:C(K2E_P!^\7_!6>_PO7,T^>.\?U*O ^#]:VLHB40, \!
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M#-:[,OG:RD,*JQCBE--EDQ$I/D52-G@%.' O2 &')+&BF'%8B1_3P69&4?\
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M;*Y?=N:@;Q;^]51-K#S3Q2,C+#7K'5;W5G<ND@FZ6@R6JASEEKI)Y%LJ50[
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ML?:.K!Z>I:V&H[AT8=Q>@,^J7PZD/T>'VAPBH=_!R51Z2CF:NF$6OK  V=D
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MLL).5>3LDQK\>Y75:0S.0FY%P\72;$3(J[746. J',8:-BC8]TC&M#WD%Q
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M@XL!P,SN@,QTU])X  (#BW]!Y2E(4I"%*0A"@4I2@!2E*4.!2E*'  * !P
MS^HP !08 +^)2234XDJ;"A2'Z/#[0X14._@Y*H])1S-73"+ *_OH8_N#*_X0
MALM\WPJ/G>!9E9/M""'?#NADM=I*APJ.ZL7P$!X#Q 0]7-UD,U#)53FHE$2B
M AWL@BHH@P5Z4P&+Q#U.[F9%,%H,:%2Y5:*3++-,(F$5FO[OP!FC<E1V:I9*
MA,(F$1+W8^N/MY+L@I;FKK*JZ81:Y8C"4(4 _P!LL,44?6 ZBGLDPJ'-;#DJ
M$PBHCTCZXYD<UH,E0.'=$>]Q[OPLNT\%F<U)ED3"*4<D*KE#"JF$3"*BIW_!
M[67&2#-4<*Z812&[WAR0LY."ERRS3"+$RGNXK]UD/VNZRKN'?4C]2R@].65#
MB53$HE !'I'CW/A=SX^9DU6P;3/-0RJE,(@]&2H.2ER51,(J1^GP?'RS<E"L
MS=[P^UFI4M5/,SFKJ4>G"H<TR5"J)^Y'Y8WLX**IA%BI?^YZWR[;]M(X.2JW
MT@LEDJJI#TCZXY"T&2H+'X!U0Z1Z?A!_W<D"I0X"JM,T62813%#K#P^+D'H5
MFC%,S5TPB@/1A0<E+DJBMU?=!\J'LCE@K#)4\E2F$4JGSP_RYO\ 7#EADL7>
MD>^K%]_6X_[\U_;2.% S5WA0J1^D?![6.*M\U4\J[-0F514,T4* ]&2H.2AD
MJB812F]R;UA]C)&:E6N:JRAF:E,(J9^@?@[^669S5#")A% >@?6'V,(K8W>R
M0I:I<E64,H<U*D-W_6]K)"S?Q5/+KG3")A%0S10J0](^N.56@R4F2J'-4#^Z
M'P>P&5.:*7(1,(I3='AP%(S5,<N%+LE(;H')&:J,U)EE92CTY4JIS4,*%*.
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M_P ZM&^Q<_ZO^\Y@[D6^/^_B\3O(NAOXJ;:!3LL_M-5R7T4FR@$/_KIT;N"
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MJC7^=SE=M-#O.RH#:K21JFM&S%]>U$ZO>$K!6F$F\38,9!_2W-91N@QSARH
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M \\=G<R6\ETQO[B(@/-0*%QH,":G'H!IQ6T]_:0W45E(^ES.'%@H3JT-U.Q
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M4G<YY*:LE3=>-3>)K]7@B901 !\&3;[MDL43F4?.&F,5;YP=@WCA4]-*<5]
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MTQ,7B.W7G6RPZ/WD+2Y^+?- S-:T/< ))X569W6PZF"X$E8KES6QG2XZBZI
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MNYOM+B'2VU%I$USG. TTJ2:9X A?F>S<Q;=M+K^UN"]UZ[<)W,C:QSBZND
M@4J2TC$A8&9Y<-N:I]'ARQ*3<3862](YD*[O;;58859G;)NITU\]F2M99[3Y
M5 [:=<5F+6:+/8EXB='M7:B;DH)(J"&C=RL[KF&ZT%I$EL8HW$Z07 ##4,M1
MJ X8X88E5.TW]ERM8LD:X/ANV32M:-3FLU./HT\XM!:2T@BM:X!>E-)5#5',
M_NK;MI9;SV)N]:S<N$GIV\6E71+/6FNWU<MDD?Q6+6ER05>"2V#7UB%72!5M
MVY6Q"ID6,#55)#S;R:[VRRAB=#'#IN1(T=9K>'-&=*FC#WZ5QICC[5C!M^[W
M\]RV>:?7:=2\F+1&6N)-*Z6U>WQ@&G TX1R,HVS<V]=':TOC%[V/H\:)M"O6
M,'J2AF*VS9:^35(JC1,BH"L48BEP[91N*AA!->*/V92!Q#._>S%9V,]S 1_^
M0D8YO3H#0YWC<37N'%>1R]UM]N%O9W -=IBD8[,#K"\QLPXTC;6O3DN.T4T?
M0-';6Y7N8#<VSJ)<7UNNR5FTM!\N$7>;%M-W)S*2S"TT6W.:^LI-O)U7Q8[1
MTI)M@;* D8BI$NR4'KGU3WT6YV$,3X0UNF0S%K64&+7-K@!C44-<<"5S6NBV
MVR;9MTFG;=%TFJ-L&ITNIQ\^,Z#J+J@@U\TTK047MQDA&:B](9RK1U@DY\81
M[R-U;3=3L]E@9-A(6NY1EIG02C))LDS.6,L[J/(FZ>MU>S!J97@H)>(<?&<7
M7?+]R8PW6+YTCFM((:TM&(QQ;7 'BO::P67-5J)2XQ.VT1->X8O>UY-#04U:
M1J(P7ERN72L:TY)MY<F.PJ[:'7-1.6?8,2TH2&O;+*S.P+%8K&W7K-YAI)E"
MN8B2C 2.W73>F<@8A$""3CUT.OZ4D,ESO4&\6[FC:VM8=6L ,#1YS2":@YBE
M,?&O*BF9:\OW&PW37NWEQF&GJW$R.>XEL@(%"W%IU5\WC3!=3=VR%Y<N=SEG
MD=Z/7K<U"]'31ZU<;,V@9BV!"6=E8;3!RDR^)78^8DT&KN226:F=I)'*!W92
MG,!%#&#(1/W#9;AMD!1^X.+6U#:M+00!4@94-.XNKKF[9S+;.W%Q+H]H8U[@
MTNHX/(+CI!(!-<>[W5PI_KG8=SY0=M[)H]7MD?K&>](%(;]KU09U$7,P?1B"
MCQBI,1E(>("UDH]F\=LU19"F=L)(DXG#LBF-G4+FWAW:*WF<PW+=O$1=JPZV
MF1=P)Q%<_.Z5P=DO)MDFNX&R"U=NQN T,JXP:LPPCIH[33'3W5ZOTX^HN^^9
MNA;!J7,;LO;U[HNM-B,&\ZVY?&NNZ7 ,9R&>0#>LWNRLZ]7ET95G+RQGT>V,
MFN0CA@JF*B1U"D6\F[;<6.VR6\MO%%!)(PTZW4XD&NIHU'"@H3T$9\/?LGVF
MY;M%=P7,\T\44@KU.A@#J-TO=H;YP.(;F"TUID?#<WLBA5CT7VP^5^P5NQ1/
M,'0KB"][@7E!G2J1$@??<7()7F9LYHKR,R:.ZX[0@D72SHKM=82-B$,B<IA]
M^.WFEYFCW.-S382,\TAPQ'5$:0VM:@U<12@SS7R4]Q%;\E3;/.U[=SB?YX+'
M8$W (>74I0M( =7'(+]"/_,E_P#FK_\ Y2S\]_\ 5?\ [3]:_5O_ $_^Q^I?
M""D-6K_D_P#1/,7S9N\9/.<]JU>,W2*;AJZ:N-ZWQ%PV<MUBG27;KI'$IR&
M2F*(@(" Y]W.2W>=U(P(LC_Y;%^7V@!Y<V0'$'<V_P#G2KV^_K1K/Z37=]58
M34O3W-SY"7\0I:*JY&+L<-(2MXJL$UL\1((]11"Q0:"A%&;D1$Z)T4^ @!0#
M/$;+U7+4,KFAX9?@Z78@@,)TD=!XCC5?221==SA- USH^LVHC4TT<"90T.!X
M.;\T\%-M_ERG-&<J7->^F.8/>F["V'3TTU09[>N;RTLX T>V>K*.H1)T<X,W
M+\'($6,'#KE3* ]&1:;BR^W2U#;>"'3,/[-NFM2,^FG!:W>U.VW8[\NN;JXU
MVS_[9^O31KO1P%*UQZ:!<4V6P8LM)^AV59LFC14NUN5+JJMFZ*"A?+5;JKZ9
MZITB$,'E9[^K.N[^KJ_)GZQN[G?;.<Z^W<$DCJ9_D<:>+AT+S;L!NT[ 6BA[
M3:?*P5\?'IXK2G5XJFF]=^D+Y?\ ;L!97N\=V;3W+,ZS9)ZYF9Q?:L;L> :1
MVKI.O2C&+>1[A&!L7:/P(HNF$8=01;=9P!TRZ"&6\N=OO[1S19011AYU@:"Q
MQ+P037$89>=QP6+IF6-INVUWK9#N%S/,Z(!CG=8)& 1Z2 0=)SQ\SOK<KRG,
M\M=Y]&#L[=2$TTJ>KM56;7&R+*UB'TR2H6BP:K0K45%S2<4B[<<&KN1[+M"@
MHJNFQ74(4YB"4<;<LW&#<[:RTF665KV-J!J:)"XD5[@^4+:\9+M=QLUU?AW4
MV\+XY7 %VE[H6L%:5.+L*]PE:%#O-<;AE/2M/;)&[2>:ZN+CEN?)A2Z1,+["
M!FV2L\C 65C3I5JQDBQS9Y'MY19-ZFUXQ93&5[+K< Z'BXLV;4(C$+AG7>DX
M:*X @N&%:$MPKYV2XV"UO[G>A.V8VL@MO18[K*:31P935@0'4(RS%$UEL3<6
MP;=-Z2U/NA/FIIT_RY;BIR6RY'1*FJ+)HZ46I4NVI4"YM;F/9/G[F1L[*,;+
MI.G!^N=4%#$*=(HE7-O9V\+;VZA[+,VXC=H$NL2C4-1TU- &EQ!'>XJ]I=;E
M<SNL+.Y[9 ^WE;UIAZIT#M-& NH XEU 6FCN) HN;4L],O6B-5<M%\W7M^O7
M2 L-3BE="5KEC8N;O1;>RL*A/.)M82UMJ\/%L'!EWKI_X^9TLU[8AB*JB9$W
M1-UT%_+N4$,+H7-<>M,WFN:1E35F< !3 TR&*QMNSW&V0;/<S7#+IAC!B;!Y
M['M</.KH]$$$E]<17$FH7V6YO]IN=.<N&U;O%J&+8TZXI7J@FBH8CQ:X6]PA
M5ZV+!-,0<.G3.4EDW/9I?)BF@8>)0 3!\GM5J+S<(H'?V>JKOZ+?.=\@HOLM
MYNW6.V37,?\ ;!E&=U[O-8/:(6R\N>K4M*:+U9JTJ9$W-/IT2PF.S,D=-6R.
M4ADK0Y3,B)DC)N[&]=*EX"8.!_=&]T..X71O+Z6Z.3WDCO9-\0HNG:[-NW[=
M#9-_W<8![IIYQ\)J?"O(\_\ _-9I/_N7N_\ UIV_/69_VN[_ *W_ .F%X#_^
M]1_^C?\ ZQ7CPNS:[J"$]*)IJ]LK5&[%V3;N8BZT:!:U"Q286&HWBJ6-2/LJ
M$C'QSB-90<9&+D?/G3I9!%!F;KE,<0,4/5-M)=R[9>0%IMXV0M<=0%'-<*BA
M-:DX "M2O$%PRQMMYV^Y#Q=2R7$C!I<0YCV&C@0*4'SB30*X)+L:?$>A^OUB
M.XCJ;7*_=8Z<L'B+YVPBW]FJ-'CZ^T=G8MG*B;B7>(G(@7J\3B0PAW"F$*%I
MF=O%O'C,Y[2!45(:]Q<<>@9J[3U7V!=25%NR)S7.H: OB8&@T]8X#NKL/+75
M:[L*7])'RZVLRD=8+]O/<4V$2_CGR;A"HV]VZ85VY-E%6Y&BB'CRR3EH8JG7
M,*95"AU>!LY-RED@;MVXPXQQP1BH(])N);^HKOV:WCG.Z[7<U#Y;N8D$&NB3
M!KAW#C0]Q<=Y(U+5S [7UI#W0)A@')+H^SZSD#"HH8T9M:R6>S4..=,EE"@F
MFZ::UKZ/45X=J1VP#A[@!#LWH16%K*^&A[=,'CNQAK7'^N[Q%<?+KI=RO8H[
MBH=MMNZ(YX2N<Z.H/']VS/I/<7M%ARA7VATS= 1?,MS [;G[KI+8VOZS7]K7
MQW8:]%V2R11 AK$R:NU>Q:S3)ZS*@FX$0ZB#E8./ PYY!W:&>:'7;6\4;)F.
M)C9I) .()Z".'2 O<9L5Q:PSF*\NYII('L:)9-;6N<,' 4'G C/H)Z5\_9VY
M5O8_)KICE$U[ 69OS-UZS4&*?4HU"L<;+:]LE>L2RUBNLU)NH=O$Q3 2D76.
M\!R)CE7/U^'56ZGO,ADM]XFW:X<T[:YKR':@0\.&#0*U)RPI^I?./E9=;!;[
M':M>W>&&(%NAP,;FN!<]Q(H!@3JKCPKBMPYJZS-0W-O;]&PC==.N<];?0B\V
MNU$"M&(T.Z PNRAB$40517/6H15PX,F!A5*[-\EUC#U<MLD8_:F7KR.LL3+3
MI.MM6_UCAWET;Q$Z/?'[<P'J]S$-3P_=OI*.Y6,8TSKTJTY>:M-O><&I<LLD
MT<A3^32]<P.S(4JR/8-W-9O2U94U@0P&4+V*T6^M0O$$DR]44U1,43I\>SG<
M)&-VA^Y-(ZZ\9$P]]FK7X]-#Y<Z;;&]V_,V<@B#;Y)Y!A@6R:>J'<TB1U .
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MN!S$UP?^+=^_BEE#LVYMSB/C;Y5H-ZVMV4H\3O(J@>D\Y$1Z.8>NC_Q;OO\
M%/*G:=P&<1\8\JT&Z[><I!XCY%.'I-^10W1S"5T?^+=]_BIE#MM\,XSXQY5H
M-PLSD\>(^15 ])ER,&Z.8.O#_P 7+Y_%3*&PNQFP_)Y5<7=L<G#Y?(I!])KR
M,<1#\/\ "CP'@/5JFPS!Q#U#%J E$/AAE39W(S;\H\JU$T3LG!3!Z3+D;'HW
M[##ZU3V'_%#*FVG&;2M 0<B%4#TEO(\;HWW##_Q4V$'LU'*&&09A6#''+](5
M0/24<D1NC?,/]ZNP0]FI94M<,PK]1*X8#Y1Y5,'I(^28W1O>''_BKL#^*65+
MFC-!9W)R;\H\JG#TCW)2/1O6'^]>_P#MU/*F6,9E:#;[PY,^4>550](QR7#T
M;SAQ_P"+%]_BIF9N8!F[Y#Y%H-IW Y1_*WRJ</2*<F)NC>,0/_%B^?Q5RIO+
M89N^0^17&R[F[*(^-OE4P^D/Y-#!\CN^('N_<S>_;JV4.X6@^?\ (?(M6[#N
MU?[$^TWZ2B'I">3D>C=L0/\ Q:O/\5\S.YV(SD^1WD6HY>WDY0'VF?24X>D%
MY/!Z-UQ _P#%N\?Q8RIW;;QG)\CO(KCEK>SE ?:9])5 ](!R@#T;IB?O<N_\
M6,H=ZVP9RCV7?15QRKOYRMW>TSZ2J!S]\H8]&YXG[W;M_%G*'?MI&<P]EWT5
MH.4>8CE;.]IGTE4#GVY1S=&Y8D?^+MU_BUE#S%LPSG'LO^BKCDWF8Y6KO:C^
MFIOQ\>4LX#U=QQ0_\7KH'?\ AUO*_$VQ@XSCV7_15QR1S2[*T=[<?TT#GJY4
M!Z-P18_\7[E_%S(/-6P#.X'LO^BK#D7FPY6;O;C^FJ@<\O*H/_.]%_8"X_Q=
MRIYNY=&=R/9D^BM!R#S<<!9/]N+Z:J!SP<K!NC;D6/<X_P!P;A_%[*'G+EH9
MW3?9D^@KC\/.<CE8O]N+Z:G#G<Y6QZ-MQ8__ %"M_P#%[*'G7E<9W;?8D^@K
MC\..=3E8/]N+^\54G.KROG,4I=LQ?$P@4!-"6PA>(CP#K'/ %*4.[W1$0 ,I
M\<\J^]M]B3Z"O^6G/%*_9\E/Z<7]XNW4O96O]C-#/:)<JY:T4B@=P6$EF;UT
MS P@!0?L4U1>QYQXAP*NFF;@(#PX"&>Y8;MMFZ,U[?/%, ,0UP)'?;FWP@+Y
MK<]CWC99!'NUM/;N.6MCFAW]%Q&EW?:2MV'/1"\EV2AA43")A$PB81,(I#]'
MA]H<(J'?P<E4>DHYFKIA%@%?WT,?W!E?\(0V6^;X5'SO L_E5*816BA0/UBC
MT<1]G-6FE"LB*JP,42CP'IS8&HJLS@J1NGP9!5FY*7HPK*Y25ZW<'W7LY4BF
M*@&O?5;*J4PB812&(4W2'Q.''XO#)!(0@%2=@3X?Q<G45&D*H4A2^Y  R"2<
MU-**F/2/KCEADBADHF$6 G?GD'^[K3]KO,*IS\"SN2JIA%1'I'UQS(YK09*3
M)5#FF%"81,(K?AFBB@4.'P\*-*AP'_N]S%4TJD<IA$>X'>[_ *WPLN#@@:<U
M2Z@^J&1J"E1ZGP\:D3LR]_B.-14%H)J5.  '0&023FI  R5$>D?7'+C)%B)7
MW<3^Z[?]KNL@_K4%9?)4J@K^=\/M90*'*EA53"(/1DJ#DI<E43"*D?I\'Q\L
MW)0I<LBI#TCZXY"N,E+P .@ ^)A#DH9*HF$3"+%2_P#<];Y=M^VD<')5;Z05
MPHIUNX'1[.7 XJ#A@K8>D?7S12,E*.5.:')1(7B/P@R">" <2KC"E,(K;,U*
M810'HPH.2ER516ZON@^5#V1RP5ADJ>2I3"*53YX?Y<W^N'+#)8N](]]6+[^M
MQ_WYK^VD<*!FKO"A4C](^#VL<5;YJIY5V:A,JBH9HH4!Z,E0<E#)5$PBE-[D
MWK#[&2,U*\O2/+MX_P VL%S2>>'9>1=)+:=\Q?-_M/&>UM<S9_./SF\MD['J
M^5NP\3\GGX]GU^W^2Z@>NV_IM1VS1G/UFJO\T-I2G<K6O@7E':J[X-ZZS*UZ
MG1I_GE^K57NTII[M>"]+9Y*]A,(J9^@?@[^669S5#")A% >@?6'V,(K8W>R0
MI:I<E64,H<U*D-W_ %O:R0LW\53RZYTPB81<OV5J>E;:;5)C>6#B5CZ7>J[L
M6(CTWSEFR6LU54<+0BDL@V.F67C6ZSDQSLU^NU6,!>T(;JAPZ[>ZFM2YT!HY
M["PF@/FNSIT'NC%<MS:07@8VX!<UDC7@5(\YIJTFA%0#C0U!XA=$'I'UQSF7
M:,E)DJAS5 _NA\'L!E3FBER$6#LS"8E:W8(NO3YZK/R4)*L(.T)1K&95K<P\
M8.&\9/IP\F4T;*GAWJA' -G "@N*?44#JF'+QN8R1KI&ZXPX$MJ145Q%1B*Y
M5&(6<K7OB<R-Q9(6D!P .DD8&AP-#C0X'BN#\M_+C%\O4/=C*6J4V!>MG7>6
MO^Q+Y,1[&'=6*P2JRJP]A#18FCXF/;'754(BF8X LX5, @0Q$T^_<-Q?N#V>
M:(X(HPQC02: =TXD]WN!<&T[7'MC) 'NDGFD=(][J N<[N"@ Z ,,UZ.'. +
MU79*0W0.2,U49J3+*RE'IRI53FH84*4<!5<J9^CP^T.2JJEA$PBMU?=!\J'L
MCE@K#)41R0H=FM]U=^_VN_V2Y_P>[SCN_P##N[P_2%TV7^*9W_U%>WL\%?3)
MA$PB81,(F$7YDO2K>EAM<3:[-RR\KME6KQ*XX=0.U-M0;D$YMQ.H#V$G2Z-)
M(CVL*C!KE.WD9)$2O%'A#H-S(IHG5<_IW*G*<3X6[GNC=1=C'&<J<'.'&N8:
M<*8FM:#\:YXYYGCG?LVRO+-!+996YZN+&'A3)SAC7 4 J?S5.G3E\Y</7KA=
MX\>+K.G;MTLHX<NG+A0RJ[APNJ8ZJZZZIQ,<YA$QC"(B(B.?I8 : UHHT+\>
M<YSG%SB2XFI)S)5#)4)A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3"*NC
MT_!\+*29+2'^T633Z2^N'LYPOS7N1<.^LJE[GPYQ2>DO3BR"R:/N?".<4J]6
M')7Z/NO![89QOR7J19J_2]T&<DN2]"'-9%+W0?!WLY'Y+THEDD>GP>V&<3^*
M]*+@K]+H'UP]O.1Z[H\O"LBGT>'XV<DN:]&-7Z/M![><CUZ$7!9%'\[X/9SD
MER*[8O2613Z0\.<DN1[R[H\O"K]'I'ULX7KOBR5\GTAZ^<S\EZ$>2R:?0/@]
MO.%^:]%OHA7Z/1\'J!G-(N^'-7R73X!]K.)^2]!BR"71G')FNZ+@KU+H_P#"
M]H,Y).*[8\UDD^DO@SAD\J]&/-9!/W0>OG&[)=\6:R*71\3V1SA>N^/(+((]
M'Q?:SCDS*]"+@LHET#Z_M9PR9+KCS61+TYROR7='Z2R"/2'ROQL\]^7A7HL]
M)7J?2'@SC?Q7=%^I91/W/A^-G&]>@S(+9JU89ZJRK2=K4Q)0,RP4*JSE(AZX
M8/FYP'N]FX;*)J 4P!P,7CU3!W! 0[F8Q7-Q:3MN+5[XYVXAS201WB,5O/96
M>X6KK2_BCFM7BCF/:'-/?!J/(ONCR><V(;MCU*3=SMFNS(1D+H':9$6K2XQ:
M E(M(M6R8)HMIAGURB[;)@!#%'MD0 @*$1_?^0^=OB!AVW<2!N\;:@X 2M&9
M R#Q\YHP(\YN%0W^4?Q0_#<\IRC=MI#G;!*^E#4N@><FN)Q+'8Z''$'S7&ND
MN]U9^DK\=3")A$PB81,(I#]'A]H<(J'?P<E4>DHYFKIA%KCD3%M,5PX@4\-+
MD'N=P0!U%GX<1#I 0 >YEOFJOSEL>55DPBMC>Z'UQ]G-1DLSFJ2B8'#_ %7>
M'X^6!HJD5[ZQYP$#<!Z0[GQ!RZ@*3"LI0$0'B \!^%DK-7B:H'X /<-^8/K9
MF6T[RN#7OJKD*4PB81,(F$5$>D?7'+C)%#)1,(L!._/(/]W6G[7>853GX%G<
ME53"*B/2/KCF1S6@R4F2J'-,*$PB814,T1,(F$5(_?\ ![63P4_-4F0H3")A
M$PBH#TCZXYH,E"Q$K[N)_==O^UW60?UJ"LODJ505_.^'VLH%#E2PJIA$'HR5
M!R4N2J)A%2/T^#X^6;DH4N614AZ1]<<A:#)0'HPH.2ER51,(F$6$EC]9FH >
MYZ[?P_U2CDN'FE0T4*NLT5#FJ0](^OEE89*(%$W'U X<<HXX]U2JH=S"*.$3
M"*VS-2F$4!Z,*#DI<E45NK[H/E0]D<L%89*GDJ4PBE4^>'^7-_KARPR6+O2/
M?6/?!Q23+QX=9TU*/A<)][O]W"!7N%54C](^#VL<5;YJIY5V:A,JBH9HH4!Z
M,E0<E#)5$PBE-[DWK#[&2,U*M<U5E#,U*814S] _!W\LLSFJ&$3"+Y>^DIE%
MX.7Y)IIM$24^YB.;[6LHW@H8B*LO-KQ[D':41%).%F[=22DE$@10*HH0@JG*
M!C%#B(?2\N-#VWK"0T&SD%3D*\3W!Q7R'-KBS[.> 7$;E":#,TU8"M!4\,5T
MZI<X-UEK;MO5-WY>IK7>ZM>ZID]O5*@N[]!V2.V77&8+(-$(JWP$0NS8O7DN
M*+,P(MGY453J@(F,@<@\TNTPLABNX;ALEE)*(W.#2"P\:M)QPJ<Q7#I7H6^]
MSR7$]C-;.CW&*$RL87M(D;B!1S0:>=1IP-">-%B''/A$N^7;16[:GK\+-9M\
MWZNZSKFKRW))B\:6Z5EI6&F&BD^2MOUG+2 >1"G%88U(%BJ(B8$>U+F@V-[=
MPGLI9-,<$;GE^FOF@ C"HSJ..&.=%3XCC?M5KN,$>N6ZD9&V/52CW$APU:3@
MRCJG2*TX54GI.+G<*#RC7*RT6UV6EV-K9*,@VGZE.RE<FFZ#NS,&[M%"5AW3
M-\BDZ0.)%"E4 #D$0'B \,KRU##<;PR*=C7QEK\' $>B>!P5><;B>UY>FFMG
MOCF!91S26N%7M!H00<1AWEX5V9SI;;>\J9M%Q,K/1'-U4G.Q*;MJ5CI-\PLE
M;J?+_ .K=;]DI3C91%XV<V^NQ;9%%Z!B [=+O?%S]<A!'W+79K1NZ]N>&G:'
MZ'1@@$%TITM93^:XFHX "N:^<OM_OG;([;F.<W?HQ(R4@D.:V!I<^6M!36T#
M2["KGG2:A>ME]^SNL?1CU[<4S8Y65OK[2$ QB)^8EG\A89.^7!JC PTFK).5
MEY22DF<C(E>J'%053)MSF$Y0 3!Y8L&7/,KK-C0(!.:@  !K34BF0%!3PKUC
MN4EGRFS<)'%UQV1E"223(YH#23F27$$\<S7BL+Z/^U[;I=^W1RP[[N]LO5^J
MD7K_ &K 35SGIBR2SB"N-4@T[1&-).=?/GQ8BL6!5J@1(#]F5RNN/ #&-QOO
MT5I/!#N=BQD<#R]A#0  6N.DD #%PJ>\ L^7'WEK<7&S[C*^6YC#)&N>XN):
M]H#@"23I:\$=\K#\N%1M+#GVYC*5);TYA+;4-'1>O):IUBY[<LECK\DXV7KP
MCN:1M,*^4-&2[6,>3AUHXA4D/%%4$3\3F3 1ON,L1V*VF;!;LEG+PYS8V@C0
M^@TD8BH&/3BLMJAE^)+V)]Q<OAM^J+&NE<YO[R,EU6DT(!-6BF&'0N)\YFZ=
MXN]\[,N.FKU;(G7_ "4P6H9?8-6K=DG(^!O=EM=U8R<G%6..CGK:*F6#:N*'
M0=H.$UP339."&[ACE+W;19V0L8X;QC3/>ND#'$ EH:V@()%02[*G2%Q;[?7[
MMQEN+&206VW-B=(QI($CGO#G!V(! C&.=,>\OM+6[#%6ZNP%K@G /(2SPL58
M89V < =14TQ0DH]P <1X NT<D-PXCTY\;)&Z*1T3Q1[7$'O@T*^_BD9+$V6,
MUC<T$'I!%0?$LQE4.:H']T/@]@,J<T4N0B812FZ/#@*1FJ8Y<*79*0W0.2,U
M49J3+*RE'IRI53FH84*4<!5<J9^CP^T.2JJEA$PBMU?=!\J'LCE@K#)41R0H
M=FM]U=^_VN_V2Y_P>[SCN_\ #N[P_2%TV7^*9W_U%>WL\%?3)A$PB81,(O)/
M/;O)YRX\I&\=N1+GQ2QP%//%U%R4"'4:W"X2#&G59^FB<!!QY*G)Y!V<G 0%
M) PF^1 1#U]AL1N6[P6;Q6-SZN_HM!<X>$ CPKP>9]S=M&PW-_&:3,CHT]#W
MD,:? 7 ^!?S\5UUG*RSERLJX<.%5%UUUU#JK++*G%1599503'454.81,81$1
M$>(Y_00  H,E_*Y))J<252R5"[_RXZSTYM2[RM>W?S ,^7"J,ZJ^F8^\/M>S
MFRDI6PMY>#8M*H6"@):'>-%'T;(NW@.S*F23!B*8E$RI1+Y^Y75Y:0"2QMS<
MREX!:'AE!0G54@Y$ 4[O<7K;-8V&X73H=QNVV< C+@\L+P7 M ;0.;F"36OS
M:4Q7TFNGHS.477E'UCLBY>DJB(.D[E93\CK2>6Y7+HY0M3*K.8UG/+MFS'93
MI^R+'.9=L4P.TD#'%4!(!@ PA\S#S1N]Q/+;0[8YT\) >.N;YI=6F;*8T.55
M]G<\D;):6\-U<[PQEO< F-Q@-' 4J1^]X5&?2OC7+M63&6E&4=(EEX]G(O6K
M"6(W.T)*,F[E5%K(E:J'44;%>H$*H"9C&$@&X"(B''/M&%SF!SAI<0*CH/1X
M%^=S,9',^.-VN-KB ZE-0!H#3A48T7K_ )8.3XV^JM?=LW_;-1T#H/6#V'B+
MEM6W,7M@.-@G54@CJW5ZA%.6DG9IP[94%C(E60*!#$ #")N >-NN\_9\L=I;
MPON-PE!+8VFF S+G&H \!7T6Q<MG=K>7<+NXCM-JA(:Z5XU><:4:UM14XCB,
MP!4G#(\TG)DCH:BZ]W3K3<=5YA= [,E)6N5S9U9AG]5<,[7#>-'>5NR5*5>R
M3Z#D5&K)95$IG"ACE04ZY4^!!4KM6]'<)Y+*YA?;[A$ 2QQU>::8AP !&/1Q
M'@MOO+0VFTAW*SN8[O:YG%HD:--'"OFEM7< >/ @@85ZK#<@&M*K4-:R/-!S
MA43ENV!N6GQ5[UOK)_K.];"D35>PJ*HUZ4V%/P"L?$:Y1ECI]8#.?&"I)@?K
MB"B2R:?*_F"YEFE;M=G)<V\+RU[P]K!J&88#4OIW*?*%WQ\H6=O! =ZW"*SO
M+E@<R,QN>0TY%[@6AE>[@,16H*Y+^('OC\;_ /$O\7K_ .$CQ_K><?CSSS%\
MTO(GG-Y_>5_)WCOFQYN_U1Q\6\9[7^INR\9_4LZ_B"P^Q_MKSNST]'#5JKIT
M4K357#.E,<EP?"6Z?$/P[YO:<]>.C12NNM*TIW/2\W-=:F.0#6EKIVR93E?Y
MPJ)S(W_3=2F+SLC63'6=ZUY)EK%;520L<IKZ<L"LA%[%;11U0-UVP-TUTQ+V
M9C**HIJ<C.8+F*:)NZ6<EM;S/#6/+VO&HY!X%"RO=K3P%=[^4+.X@G=LFX17
MEY;,+GQB-S"0WTBPDD/IP(%#ACB%\R<^G7PZ81>A^531D9S(;UJ&GIJ^I:PA
MK%&WR8EKZO7S6I"MQE"UU;-A/WBT"2:KQWZ2K6JG1-P=I"D"O: !^IV9_.W:
M_=MM@^\9'UKVE@#*Z:E[VL&-#3TJY=Q>OL6UMWK=8MM?+U+9 \E^G5I#&.?Z
M-6U]&F8I6O<6C;6U'<=/[2M&HK.R!>U5F=\BD"*Z[]I8$78(N*_-UU5$IC2D
M-:XIXV>QJR8#XRU=)'*'R0!F]I>0WEHR\B-(G-KCA3I!Z"T@@]!!6&X;;<[=
MN#]MF!-PQ^D4QU5]$MIF'@@M[XXKMW-;RFO^5=#3K>8O,;;Y_9%(E[!:(B+B
M19-M>VZLVZ8I%MU^M*#+2 6"3JEE@G3%ZX*BT(1XW53*0Y2@H;AVG=V[L9BR
M,LCB> TDUUM<T.:^E!0.:00*G @KU.8.77; RVZR9LLL['%P H&.8=+F5U'4
M6NJTFC<0<%Y#SV%\VO0L?J:N.^5*W;T4>S9;; <PNNM3,XXCEB%<5KENUOM*
MX23URT-&FDSS:$G2&A$%"/"(%045*9$YS$.GYSKN0;LRP ;U+K=\E<:U:]C0
M,Z4HXUPK6F*]ENW0'EYV[5=VEMXV&E1ITNC>\FE*ZJM&-:4KAQ6D;%U3/ZSB
M=3S$V^B'C?;^L6NUJ\G%+/55H^ =W6[T9)C,@[8LB(RX25$=*F(@9=$$%4A!
M43B<I-[:[CNGS,8"##*8S6F)#6NJ,3A1PSH:UP7+?;?+8,MWREI[1;B5M*X-
M<Y[0#4#'S"32HQS6$V#^#WSQF_P4^>?X/^V;>;GX0?(GGCXOXBU\<\M^;G]I
M.V\I=MV?8?(]AU.M\GULTM^T=2WM>CM''173GA2N.5,^*RO>Q=I=]G=;V/#3
MUFG7D*ZM/FYUI3A3BM,S9<J]"[WU-7-85_EPE8![-O'&X.7J&VS923#EBX18
MV.1V;M2F+,H(K*-CSMH0L71VBA4W!G2X.%%C"L)#$(GYUA=R74ERR0- AN#&
MVE<0&,=4U)QJXY4%*8+V=WVZ#;V6;H2XFXLV3.U$&CG/D:0V@%&T:* U-:XK
M@*/3\'PL[I,EY4/]HMNJ[6!?6.!96F8?5VM.YB.;6"?BX4ECD82&7=I)24JQ
MKZDK!$FW<>S,=5-H+UH#@Q )VJ?6ZP>=<%[6.=$ Z0-- 30$\ 30TKTT-.A?
M06C8GRL;,XLA+@"X#40.)TU%:=%15>K>9G0FJM$!0F5(W19]HS=WI%&V49C,
MZ@0URRBZ7L>H1MQJKH))/9MY.^F%6$HF1RT[!$K<_6X+*<.[X-E?7-Z9#-"V
M-C'N9@_75S7%KL-#<*C \>A?4[CMMGMS8A!<.FDD8QX!CT ,>-3376['N4\*
M\OH^Y\(YO*LH<E?H^Z\'MAG&_)>I%FO13K5M?:\L-3W6F\F!M4[OK8.K7<>=
MPR&OIU^J:]UI;(YXV:ECRR))A:1N;HBRAG9T#()I 5(ABG.?RI)WF\=;8:!$
MUW=J7.'BP'!>W%;L%B+JIZPS%G<H&@]%:U/3X%H=V\P_.Z7_  8^=WF+VK?S
M?\_/(WG;V'B3;QORSYO_ -I^U\H]MV?8=SL>IQ^2ZV9-ZWJQUVGK..FM/!7%
M=9ZGK#U&KJL*:J5R&=,,U@T>GP>V&<S^*[HN"OTN@?7#V\Y'KNCR\*ZA7]=3
M4]KN^[*:.8Y.#UW,4>%F6S@[LLDY=WXUC+#FCDTF:K,Z*'FLY%<55DC% Q.H
M53B;J<,S@'AG$@_(O3B:2TNX"GRJG(>8WFK4O(7G9Y[]I8?/SRMY'\U>Q\<:
M^:?FCXG_ &W[7R?V_E'QSN=MV?8_(];.5^JIK33P_75=\5*"F=%A$?SO@]G.
M:7(KLB])9%/I#PYR2Y'O+NCR\*OT>D?6SA>N^+)7R?2'KYS/R7H1Y+)I] ^#
MV\X7YKT6^B%?H]'P>H&<TB[X<U?)=/@'VLXGY+T&+()=&<<F:[HN"O4NC_PO
M:#.23BNV/-9)/I+X,X9/*O1CS603]T'KYQNR7?%FLBET?$]D<X7KOCR"R"/1
M\7VLXY,RO0BX+*)= ^O[6<,F2ZX\UD2].<K\EW1^DL@CTA\K\;//?EX5Z+/2
M5ZGTAX,XW\5W1?J643]SX?C9QO7H,R"OD>CXGMYQOS7H1>B%T36EWE-;WJJW
MF'.H5]69ME)@F0XI@\:I*E+(1JIBB ^+2; RC=4.(<4U3!EMNW&?:=R@W*W/
M[V&1KN^ <6GN.%6GN$K#>MGMM_V>YV:Z ZFXA<RM*Z21YKQW6.HX=T!?J%8O
M6TDR9R+)4J[-^U;O6BY.Z59LZ2(N@J7_ %*B2@"'PAS^R8I63Q-FB-8WM#@>
MD$5!\2_SRFADMYGP3#3*QQ:X=!!H1X"%=9=9)A$PB81,(I#]'A]H<(J'?P<E
M4>DHYFKIA%@'G[XX/]S9[_QL+EAD5!S"S^54IA%;&]T/KC[.:C)9G-0R5"MU
MTNN'$O2'=X>KD@T2GC5@("'<$! ?4'N9=%+DK-,(KI-4![AAX#ZH]_\ [N4+
M>A7!5?*J4PB81,(J(](^N.7&2*&2B818"=^>0?[NM/VN\PJG/P+.Y*JF$5$>
MD?7',CFM!DI,E4.:84)A$PBH9HB81,(J1^_X/:R>"GYJDR%"81,(F$5 >D?7
M'-!DH6(E?=Q/[KM_VNZR#^M05E\E2J"OYWP^UE H<J6%5,(@]&2H.2ER51,(
MJ1^GP?'RS<E"ERR*D/2/KCD+09* ]&%!R4N2J* B =T1X816QU1'N!W _-_[
MF6 Z46)E1$&"X@'$2BB;A\JND8?S P_T4&:O\NLSFI0(8PCPZ.[W1Z/^_DEP
M [JN,E<"4"E$ #@'<]K,AFI5/+J$PB816V9J4PB@/1A0<E+DJBMU?=!\J'LC
ME@K#)4\E2F$4JGSP_P N;_7#EADL7>D>^K%Y[A'^RVG[83PH'ZE=X4*D?I'P
M>UCBK?-5/*NS4)E45#-%"@/1DJ#DH9*HF$4IO<F]8?8R1FI5KFJLH9FI3"*F
M?H'X._EEF<U0PB81>!^>?4>X=GN>6.6TW58VTS.K.8FF;)ETIF>BH&(C8JO*
M"Y"0E5G[YJ_=1J;I,@+IQZ3M\*0F%)$YN #[FR7=I;=I;>.+62VSF"@)))X"
M@I7HK0=)7S?,5C>WO8W6+ ]\-['(ZK@T!K:U)J:TRJ&@NZ 5A=1ZQWM>N;VP
M\SVZ]<PVHXRO:<0TU0*>QO,3>I2434M+BQO[+(RL$BDQ!MVCMV5--1-LL";E
M$HI"9(YS:75S8P[2W;+.0RN=-UCW%I:!YND- ./1TY'I2PLMPGWU^\WT;86M
MMQ"QH>'DC7K+B0 !W!G0XA>+N7#4,JWY_;;I58K5QJ;E7O6T=YU)H14J[9E)
M[LA*.G3Z\H"/6*"M9:KF=M@.(&3<(.!-P$0*/L;A=L.PLO!A=W3&1.[HB+M1
M_P!K 'N47A;39R#F>7;SC86,DDS,J!UPUFEM/YH+R.[7N+WSZ0S4.Q-Y<L%K
MUWJVO>=%QDI^G/64/Y6@X3MFT5863Y^KY0L4G$1:?8-4C&ZIURF-PX% 1X!G
M@\OW=O8[HRXNG:80'5-"<P0, "?D7T?-5C=;EL<MG9,UW+BR@J!6CVDXN(&0
M/%7&YN5"KROXU&UJ+7PD-R;LY<+5JADR[:.8MW<NM4K!%ME6SU^LS9LG]J4&
M'9N5G"R2":<8D83D ZQABRW65G9;6=U+."Y;)Q-!J!X<&^<13'SCW%&Y[+#(
MV^O+9E=PN+-T7 5.EP&)I0N\T$DTHQN5"O)=]Y3]Z;2T?R,\MLQ 3-5H].)%
MRW,-88>V4A!_4W-7@BLH:,AU"2\JXF)98SU^5%9FSD&*#D[=8_7*013]:#=;
M*UO;[<6.:^=]1$"UU':CB3@*#*H)!(J%X-UL^X7NW;;M+P^.!@:9W-<T%A8R
M@ Q-275H0' $ E9R$Y([_P O'-7HW;^G+'M/<=5?HV2E[M>[5V!59:?KU5DV
MS=O$OF;IXE4G<M#,GKLSTS-ND\<)K1Y1(0W:@4*/WJWW#:Y[.[;%#*"UT88Q
MP!<,P?2H2,*F@Q[BO%L%UMF\V]_9R3W$3@YDQED:YS6$5:02&D@.Q(%3A@,2
MMET17.9N%YRMZ[DN_+5)U6B[PBJE'&D4]L:KGW%4#6="-%QZAHZ-L'C\VI<I
M2'001(5-J5D9X!UC]FFH?,[Z3;7[/!:0W(=/ 7&FAXU:W5.)%!I!).=:8+7;
M8MUBWZ[O)[5S+6YT .ZR,Z>J86X@.J=9I3#"N/%<4U?Z-6T;/J.R;OS%[!W+
MK';&X+G=[!9J11-@U-2F^)RC]T>%2M+&,B[+'6+BHNJH*24@5(K%5- I43E/
MG=<\Q16TL<.WQPRVL+&AKG,=JJ!CI)((\6=3BN"TY5FO(9KC<YKJ"[N)'N?&
MR1NBA)TAP <'8=VE*#"B]R<C=0V_KOEQINN-VUWS>N% <S-79 $W!SR<K5&C
M]1U69)N\@925;)-D8YZ#)-)4R+@A&8"=(H"43>)O<MI<;B^XLG:H9*.R(HXC
MSAB!QQZ,<U])R[!?6NTQ6FX-TW$56Y@@M!\T@@G#308T.&("]<YY2]@YJ@?W
M0^#V RIS12Y")A%*;H\. I&:ICEPI=DI#= Y(S51FI,LK*4>G*E5.:AA0I1P
M%5RIGZ/#[0Y*JJ6$3"*W5]T'RH>R.6"L,E1')"AV:WW5W[_:[_9+G_![O..[
M_P .[O#](739?XIG?_45[>SP5],F$3")A$PB^3WIK6$D\]'[LEPQ44(VBK?K
M!_,%(0QBJQJEXB(M)-4P ()IA+R34W$> =8H!TB&?6<DN:.8(@[,L>!W])/Z
M 5\-^(S'NY5F+?1;)&3WM8'Z2%^)?/VY?SBF$3"+ZV\]'_4$]%%_ 3F,_P :
M-89\CL/^O[M_Q(?T/7Z#S9_VSL7_  )?_HKB.DHOT8KC6-96YAK'SFL-PG\M
M>=[35"&HST!+JV"6+ >0#6>">S@]>KE9&==NJ;^K16ZG!/J ';?/YH%TX;<R
MS-GAI,G6:\A6NEP'I5I3A1>7MD/)3K%CMWEOV[ACK$8CT#SCIIJ83Z-*U.=5
MYPT!H/:_,C>V^L]40RTF^>)EDK#(.G(QU4JE>8J!X[;+I,*_U##U^&(J)SK*
M\3F,()HD46.1,WI[AN%IML':KMP & &;G$_-:,R3_P#'!>1L^T[CO5SV';P3
M6A>:T8UH^<\Y4'#CT E>M^<+<6J:KI'5'(OH&RFV+0]06N6V-L[;Y2G;PVS]
MS3#!W&.'5,CSF4,UI]3CI1VQ:KB<0>E.!B@8$O&G?C[-9W<M]-ONX-ZN>9@8
MR/BR,&OG'UG$ D</#0?0\R;CM]OMEORMM3^NMK9Y?)+P?*00='\T:G#CP%30
MD[KZ9(C5SSC-YF"9KH4ZRZ4T[,4 W8J)LWE26K!6L:I$E,)BF9)KM54>!!$
M53.'2 YCR94;,6//[YL\@?\ TJXU73^) U<P,>P'JG6L99W1YU*+ZL?VG_'G
M\S?)CK\)_P#0Z>9/DOQ9;S@_#!XKY4\2[/K^->7O,3]1Z.TX?(<./=SY/S_L
M'KJCLOVQJKPZO+Q:L5]_YOQAU5/^9^PM-..O77QZ5\I_0VD:MN<9Q,SK-=>G
M5K2FXIB_F[%11FSJ2-8,UDE)8I1*4K)1=TDCP.( *JA Z1#/K.<ZG9@QA_?.
MGC#/Z5<*+X#\-QIY@>]X/5-M9"_N#S:U7RCSZQ?GZ81>U/1\_P#6@A/^B'FF
M_P#A7W1GB<Q?Z4[_ (T'_GQKZCDW_N&+_A7'_P!O*NP:QYD-2HZKJ6X]AJFD
M.:SE7AAU[HN,=QA)"-V0QF?&UM1W&UN3B)#.N6!V6171!8IBOT@@V8\4T5!S
MBNMLO#=OL[;#:;MVN4@T+"/[1K?^/YHPR\\\5ZMAOFW?9T>Y7WG;_8,,< (J
M) [^R<[I[/YQ]C&JZ#0Y!T_N?H5I23>+.WKW8?E"1?O5S+.'+ISS_P![<.WC
MMRL8QU5EE3F.H<XB)C"(B.83M#8=[8P4:(Z #_I&X+:"1\CN6Y9"2]URXDG,
MDWI))[ZXURFE,7GOMA3%$IBUWG5*8I@$#%,'+QOD!*8![H" ](9V;M_H#/Z5
MM_YT2X]B_P"]9/Z=Y_Y4ZTJMNG#+T>>P7C14[=TTYV]%NFRZ8]51%PWTAS J
MHJIF[QTU" (#ZH9O* [F*-KL0;&7_P V)<4+W1\G/D8:/;NL9!Z"()"%U_GK
MYB-Y7W5W*%5KGM.YV:NW7E=J>P[9#S$RX>,+!>4=S;T@TK5)H*B)7,TG$1#5
ML"X_)]B@0O0&<>P[;8P75Y+#$QLD=TYC2!B&]7$=([E233NKT>;-YW2XL["V
MGF>Z":PCD>#2CG]9+YQPS\T>)>C[C8I"H\ZWI=;+$M8EY*0ND-HOH]*<A(NR
M12;M+?7+UV#MW!3;1_#28,%!!<B3M!=N*B9143.0!*/FPQMFV/:(GDACIV T
M)!IU4V%10BN6!!Z%[5Q,^WYIWZ>*G6,L9"*@.%0Z"AH00:9T((Z00O)U*VQL
M#FDTOS0UW?=A4V".G]'QNV]87*QLHY:T42QU[:VL:06LPMD(T0?I56UUR\.V
MRT2HL=IVJ""J"1%4NL/K3VEOM5[:R;>WJ^NG,;V@G2]KF/=J(K34TM!#L\2"
M:+P;7<KWF#;;^WW=W7"WM>NC>0W5&]CV-TAP PD#B"TGA@*KM->H-/V7N_T9
M-5OB,4[JH<E[BSR,;.MY)[!S2U"OO-??(NOS3"%1<3$C$V*7K;=BY;-$U'3A
M%P9-(IE#% >*2XFM;#=);>HE[;I!% 1K; TD$X @.)!. (J5Z45I;WV];);W
M8#H#MC7$&I!T&X> 0,2"6@$<1AQ5&(W13;>C<ZQS%<Y.N]S:IGJ)?6,5KR+T
M]N)JK0[8-9EGVNYO3K5UI>!A-9&K]W;L#.$XY9@R6BO&$'":R1Q3-66QGAT2
M[=9207;9&DO,D9UMJ \2?O"7U;6E:G50BBU@W:TNG2P;ON<5U821O C$$HT.
MH2QT7[H!FEP&1 TUK5?)Y/I+ZX>SGT3\U\C%P[Z]Q<ZO[\-$?^YGR@_^H>FY
M\WM?H3_]7/\ ^8Y?8[UZ=I_T%O\ ^ +Z%[#Y@MEK^E"G=$KR,2MI.]<U-<UI
M==5*5R!4I5N@+E:8JI6%[9HM6/4&<LKUG-N%R2CDZCYLY$AFZJ)$D2)_.Q6<
M V!MX >U,MRYKZG4"T$BAK@,!@,#QS*^OGW*Z',AL20;)UPUA9I&DAU :X8G
M&M3CX,%Y0KTO(<MVA[QLS43A&#V3.<T%ITVE??$F<A;:)0Z!5HFS1S*LRSUF
MX&M2%YEK 87+YKV#Y5*"[)-0$C+E-TRM%Y=,AN,81 'Z<@YSB0:CCI P!P\Y
M8PD[?9R3VOFSFZ,>J@)#6BH )RJ3B<S15=I[&M6T.1S6=ENKQK*V,.;/<<?(
M3J<;'Q\G/F1U!I-RG)V)Q'MFP3,YV;P$#O5@,X5012*H<PDZP\S(8X-R>R*H
M9U##2M:>>_ 5R'<76^XEN=K9),09.T.%: $^8W$TS/"O0 O26W$6E>YJ/25;
MD:L(J4O&FRGF==I3,7'SK&&L-QW!KK7SNY%AI1N]CWTC58&RNE68KH+(-G:J
M:XEZZ28AYT5765K 21&_!U,*@-<:5[I&/<7KR>9>W5P!61@&GN$EHKX O$DU
MO/=',*K5J'=2LMO7&0N\ 6GSM@BTGFQ%7K\WD)K0V=F:KQSUY5; \>-^M'N3
M*D1<()&;&;\5>UU,$-OJ?'5C TU R[].D=*HVXFN-+)*/?44)&/>KA@5]%]?
M/[5>[I<=.;>YEM(WRO+Z]WFW><M%+K.P%H.FS=6U7=;)%-M:O$M/1NI:O)Z^
MGZVW<$>1<\!#H,E4TG+LRW57\B4,8P2Q1O::M\XD5-2!CYU36O$+V8G/<\Q2
MO:0:C2 :##AA3#O_ "KA^@>8'=E#Y+^85M3-H7*LH4;8_+\QIZ<--.F05MI=
MU]VR%N;Q'8F*+).POHUNJZ G#M3HE$>Z&1<Q1NN&%P!)#J^"E%K ]PB< <J4
M\)5I!52(O>E?1^T>?=C'P5RYE]X52:?@H"(LHBQ6/ERB))V"HB )"V9O#GZW
MYWJ\<YGDMDD(S#1^@KKC]%O>/Z5OE)WKL*\\T$!R]S[>-)H:W;L::D=Z*1KL
M.WI-:ITY<24P4X2*"+*O$6:KQBQ5T)D@DE@>-@757,<3B;G>QHCU_/I6JZVF
MA/<"P5*N-DT[RH[9?T*8293,7S=:Z@HJSECXYW)QZ+;6NYNK+P#IZU<FA)==
M./ A7C;LW!$%E4R' JAN/-)B:GU5UM +P#E0_I"CL2XL;50^43?NV89O>K _
MV#LZO;1< W9QLMLZHZRL^M9UFULKUFBV+)3[J)NCV-/(+ +E5N5'M3G,GULY
M7_K79$""]C30:01W":CQ89+H6S+'>MN5K::VMN82D[AU^E&S=P6TY.TIW5[A
MKBD1,@C+J/J95K)3BU&O*U**2*1V>J3"BB;(%> '2[02X/J0:&O\OY9+IA#(
MW-UL+7UIJK@2>D@U-?YPS[J^>*?0/@]O//?FO=;Z(5^CT?!Z@9S2+OAS5\ET
M^ ?:SB?DO08L@ET9QR9KNBX*]2Z/_"]H,Y).*[8\UDD^DO@SAD\J]&/-9!/W
M0>OG&[)=\6:R*71\3V1SA>N^/(+((]'Q?:SCDS*]"+@LHET#Z_M9PR9+KCS6
M1+TYROR7='Z2R"/2'ROQL\]^7A7HL])7J?2'@SC?Q7=%^I91/W/A^-G&]>@S
M(*^1Z/B>WG&_->A%Z(5^E[?M9PR+T(\U^HO6+9TRUKKUF] X/6E'J;9V"G7[
M0'2$!'I. /V@%4ZX*E'CU@ >/3W<_LC8V/CV6SCD_M&VL0/?$;0?E7^=_,4D
M<O,%_+#3J77DQ;3*AD<1EAET+><]1>,F$3")A$PBD/T>'VAPBH=_!R51Z2CF
M:NF$6 >?OC@_W-GO_&PN6&14',+/Y52F$5L;W0^N/LYJ,EF<U#)4* ] ^L.%
M(S5LHF!PXAW#!T#ZOPAP#3O*7"N/%6 @(#P'-5BF$3"*LFKU>X;CP'AP^%_W
M\J156!5T @(<0'B&4R5E'")A%1'I'UQRXR10R43"+ 3OSR#_ '=:?M=YA5.?
M@6=R55,(J(](^N.9'-:#)29*H<TPH3")A%0S1$PB814C]_P>UD\%/S5)D*$P
MB81,(J ](^N.:#)0L1*^[B?W7;_M=UD']:@K+Y*E4%?SOA]K*!0Y4L*J81!Z
M,E0<E+DJB814C]/@^/EFY*%+ED5(>D?7'(6@R4!Z,*#DJ8F /7R514#"(@(C
MT\!Z/6R>**CEU"L)3^L'/R@?Z\N5?Z*D9J_*43#P#XO>RU:*E%6X 7N!T!QS
M-7&2@;W(^#V<D9HJ674)A$PBMLS4IA% >C"@Y*7)5%;J^Z#Y4/9'+!6&2IY*
ME,(I5/GA_ES?ZX<L,EB[TCWU8O/<(_V6T_;">% _4KO"A4C](^#VL<5;YJIY
M5V:A,JBH9HH4!Z,E0<E#)5$PBE-[DWK#[&2,U*M<U5E#,U*814S] _!W\LLS
MFJ&$3"* ] ^L/L816QN]DA2U<<T]H#3F@HR6B-/T*&H[*>>(/IKR<9\[>2CA
MHDHBS%])2KR0DG"+)-93L$C+"DB*J@D*45#B;LN[Z[OG!]W(Y[FB@KP[P% N
M.QVVPVQCH[")D3'&IH,SW3F:<.A=@SA.:[U(;O\ K>UDA9OXJGEUSIA$PBH9
MHH5(>D?7'*K09*3)5#FJ!_=#X/8#*G-%+D(F$4INCPX"D9JF.7"EV2D-T#DC
M-5&:DRRLI1Z<J54YJ&%"E' 57*F?H\/M#DJJI81,(K=7W0?*A[(Y8*PR5$<D
M*'9K?M6E$U^KH% 3#XP[-P !$>!8YX8P]SO%* B/J &<=W_AG>#](758_P"*
M9WS^@KV[G@KZ5,(F$3")A%QGF(TY$\P6C=IZ7FEDVK/8U,F:XC(*)=N6(EG#
M858"<!#N=L>"G4&SPI?SQD #.W;KQ^WWT5ZS$QO!ITCB/"*CPKSMVV^/==LG
MVZ3!LT9;7H/S7?[+J'P+^>;L*@VO5EYMFN+U$.(*WTJ>DJY88IT42J-)*+<G
M;+]F<0 KAHMU 406)Q370.10@F(8HC_0]O<174#+F AT+V@@]P_RQ' X+^4;
MNUGL;F2SN6EMQ&XM<#P(_5T'(C$+3LV7.F$7HG:_,S?-PZAY?-+6:)J+&K<M
ML3=8:C/X)A,MI^5:WM_ R,NI;'4A/2<<^7;+UY$&PLVK I"&.!RJ")1+YUIM
MEO9WEQ>Q%YEN2TN!(H-((&F@!&9K4E>QN.]W>Y6-IM\[8Q#9L<UA:"'$.TUU
M$N()\T4H&\5YVST5XZ]T\KO/UL?E4UQL3557U7H/95-VG*M92YQNYJ/.W%*6
M29L$X]M#.F<?<J[%/X)(I#*E;NV[@"K*G, AUA#/"W3E^VW:YCNY9;B*:(4:
M8W!M,:UQ:2#W00OJ-DYLO=CLI=O@AM9K:9U7B5CG5J W20'M!;09$',]*PF]
M><K\.5%-1OQ5.3'3W6F(Z7\\-%:,_!]>B^3P<!Y++8/.B7X0[[QCBX0[']5$
MA/D@ZO=O8;+V&?K^UWLV!&F676W'C32,1P*RW+F+[2M3:]AVZ"I!UPPZ'BAR
M#M1P/'#$+>==>DCW11J+3*+8]<<NF[4]8QB$+JBV;ST]%7Z\ZNBF2A5HUC3+
M*+^+<-D(E9-,S4'97@H DF0H@FF0A<+GEJRGG?/')<P=::R-BD+&O)S+FT.?
M&E*XKLM.=-SMK:*VFAL[GJ!2)\T6M\8&6EP<*4H*'$X#'!>?/QJ=]_C"?C3_
M (0I+\.?G#YR^>OBL;U_'/$/)'B/DCQ/R)Y!\A?VO\G>+^)>(?U/V?9?(YZ'
MV38?9WV5U8[#ITZ<>FM:YUKC6M:XKR?M_=?MC[=ZT_:6JNJ@IEII3+3I\VG0
MO0>Q?21[HO-%N=%KFN.7322>SHQ>%VO;-&:>BJ#>=HQ3U0RTDQN=E!_*.'*$
MLLHH9T#0K,5P54(8134.0WGVW+5E!.R>22YGZHUC;+(7M81D6MH,N%:TP7K7
M?.FYW-M+;0PV=MUXI*^&+0^0'/4XN-:U-3@<3CBOGQGT*^03"+I^G=LV/2-\
M:[#JC*$D)II7+]6$VMA;/G<69AL:@6?7,VL="-DHEV+QK"6QRJU,"X$([(F9
M0BJ8&2/RWMI'?6YMI2X,+F.PI6K'M>,P>+17#*N6:[]LW&?:KQM];AKI6M>
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M<QC4$5(J#EG59#8O,;:-EZ^@=6+T[6]-I%7OECOU<AZ%6WD"6)>V:!KT ^B
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MO/',\/*?+5QN;G 7A860#BZ9X(90<0WTW?S6E?I0  *          '   .X
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M$LBE3[;Q#_T6L7V$D_4_L7.-\C*9CQKT8F/Z#XED$:A;./[U[%T?662]4/\
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MT,DA%'/(RZ:-'S6UPQ)J22?Y3YTYSW3G/<>V7OF6K*B*$&K8VG/HU/=0:GD
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MK&_0E^/PX9=K'.[RH7@=TJQ4>*'[A?D ^%T_&S9L0!\[%9F0GN*T$1'NCFH
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4A$PB81,(F$3")A$PB81,(F$7_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>gyowp0iggm03000008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gyowp0iggm03000008.jpg
M_]C_X  02D9)1@ ! @$ W #<  #_[@ .061O8F4 9      !_^$ 2D5X:68
M $U- "H    (  ,!&@ %     0   #(!&P %     0   #H!*  #     0 "
M         -P    !    W     $  /_; $,  0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,#
M __; $,! 0$! 0$! @$! @(" 0(" P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,# P,# P,# P,# P,# P,# __  !$( BP%<@,!$0 "$0$#$0'_
MQ  ?  $   <! 0$!             0(#! 4&!P@)"@O_Q "*$   !@(  @,'
M!A,/"PT, !<! @,$!08 !Q$(,1(3(4&!%!46"5%QL<$RU/!AD=$B<M(SD].4
M59755I87&%BA0E*2(U-4M'4V=M97EQDD-'0E-:6UMM<*&F*RPD-C<T6&-T=W
M.$CA\8*S1&0FMRAXN#GC984G>:*$I$9F9X>(N8/#Q,;':)A9.O_$ !T! 0 #
M 0$! 0$!           ! @,$!08'" G_Q !=$0 ! P($ @,+" 4)!@0%  L!
M  (#$00A,1(%0091$Q1A<8&1T2(R4I)4%J%"TI,550<7L<'A(U/P8G*B,],T
ME#6"0W,D=#:RLT1%\<+#M"5U8X.C)C=DA,2U"/_:  P# 0 "$0,1 #\ _?QA
M$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F
M$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB
M81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3"
M)A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,
M(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$
MPB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$
M3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB8
M1,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")
MA$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(
MF$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$P
MB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3
M")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81
M,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A
M$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F
M$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB
M81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB812B<@=)
MRAZY@#I[H=_OADT*BH5,7"0<?DP[GJ"'Q^.3I=T%1J;TJ072(?GA^#PY(8X\
M$UMS4OCJ'JF_2Y/5/4=8U0\=1[W6'P<,=4]-;5$'J/?ZP>#CCJGIUC5$'B C
MPXF\)>Y@QO'!-;5,#I$1]WW^'$>X'K^ME2QPX)K:J@*I#PX'*/'H[N1I(X%6
MU#I4X& P<2B AZH" ^QD*00<E'")A$PB81,(F$3")A$PB81,(F$3")A$PB81
M,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A
M$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F
M$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB
M81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3"
M+!UJR0MO@HVRUU[Y0A9= 7,>]\7=M/&$04.D)_%GR#9VE^J)F#@=,H]SHX9)
M!!H<TS6 N6RJ;0'$.TM,F[9.I\LB:(;,H&PSKAX6)!F:1,5& BI11(K8L@B(
MBH!.('[G'@;@#2[)16BQ<!N*@V:79P<._G%I)^94K9-W2+Q$MS"@W5<J=I(2
MU<8Q[< 11,("HJ0##P*'$P@ R6. J4JMGN-TK- @G%FMTH2'A&JK9!9X9L]>
M&!9XN1NW23:1S9V]7.=4X=Q-,W5* F'@4HB$ %QH,U-:+/LWC:0:-7[)8CAF
M^;(/&CA,1%-=LY2*L@L01 !$BJ1P,'PAR$7+)'>FLHN5E85U,RQY"$?K1<JF
MQI=XE&[-^@5,ZS91]&5QXP,=,BI3#U53!U3 /'@.6T.I7@HJ%NU5N=6N\>:4
MJDVQFV22QF[@[10P+,W)./6;/V:Q4GC!R4 X]FLFF?AW>' 0R"",U((.2R4U
M,Q]>BGLU*J+(QT<B+AVHW9/9%<B0&*7BDQC6[M\Y/UC!P*DF<P^ID 5P3):3
M3=O4"_R+F*JDM(2+UFFZ4=$7K%KB4$!9+HMG:*CV9A(]D5V@LX*4R':=L'$?
MD> &X6+2,U (.2PSO?NK&+^5C%YV5,Z@Y20AI46M*O+YJSDHIRHTD&QY!E6G
M# _BJZ1@,<BID^ =8#"7@.-#DU!=&K=GK]OB6\[69=E-Q+H3%2>L%@53[1,0
M!5!4O<4;N41'@=)0I5"#W#% <@@@T.:G-9W(1,(F$7*IW=>N*W/2E9E9B3+-
MPIF991G'U"YS169I!BWDF95'<+7Y!B)EV+HB@ 50>''@/ P" 6#7$5X**@+8
MZ?L"GWU%\K5)M&3-&+$;R30[9]'2<<JJ4QD2OXF5:L9-EVP$-U!41*!^J;JB
M/5'A!!&: @Y+1@YAM3'[44IV:<)HK.&YUVE"V"[;=JT74;.2D=-JLJW5!%=$
MQ#"4PAUBCW<G0[^1":@NDU>V5RZQ*<Y5I=I-1:BJK?QEJ8X"BY0$ 6:NFZQ$
MG+-VEU@$R2Q"*% P"(<! 1@@C J:U7,FO,9J-Z@FZ9STX[:K%ZR+EKK_ &*X
M05* B43)K)5,Z:A0, AQ 1[H9;0[^1"C4%T^!M$)9(-*R13I8894KHX.I&/D
M8,Y",E54'2CAG-M(YZU32.@;Y)1,A1*'6 1*("-2"#3BIKQ7/4=_Z?</",D[
MLQ %7)6B4DJPF4*^HX,<4RIIV=>-3KA^L<. "#H2CZN3H=T*-0719RRPE;3B
MUIIZ#-.:G(FN1AP;NG(.IF<< TBV8>)H.!2!TX,!>T4ZJ).DYBAW<@ G)2L[
MD(N0H;VU@YL"561FI8T\LZ1:$8#2[P0>T</1CD5CN5*V5HFQ.] 2 Y,H#?N"
M/7ZH".6T.I7@HU!;BXO53:7-CKUS,)(7"3ACS\?#*-WI3NXI-9X@==!X+;R<
M=4IX]<10!;M^HD8_4Z@=;(H::N"5QIQ61LEDA:E#N)ZPO?)\2U7CVR[OQ=V[
M[-:4D6D2P)V#%!RY-V\@^23X@00+UNL80* B  DT&:G):C<MO4"@2+:*M<M(
M1SUXFU4:D0K%KED%Q>KK-FB*;V&A)!D9VNLW,4J':=L/ /D> EXR&DY*"0,U
MM3:U0#JN$MOE%-G73LC2!I.61<PJ:#,@F Z[Q&818NF($$H\06(F8/4R*&M.
M*FO%:+#[TU3.R3*)CK>W,[DERMHP[V-FXIA)N3\ 30C):5C&45(K+"/!,J*Q
MQ4'N%XCDECABHJ%UK*J5I]/O]0OR,LXJ,TC,HP<JO"2ATF[UMXM)-R$.HD!7
MS9J=PB)5 $BZ0'04X#U#FZIN$EI&:@$')91[9(6.G8*M/'O8S5E0F',*R\7=
MJ>.HP*3-:6/XRD@=HV\43?I#P543%3K_ " &$!X*&E>"E9S(10$P%#B(@ ?#
MPE0%;G=HD 1ZW7X=XG='V0RX8X\%76U<<><P6LFC^3C1EI=9W#2;^&DB-*5>
M9!%O)QCE1H^:^.1U;=,UCMW"8E$2*&*/2 B @.6$1XJIDZ%N-:O$%=8L)BK3
M#66CNW5;*+-NN51NZ2 O:LWC9PFB[9.D@.43)*D34 # /#@(#F@B:J%[E-7[
M/%V^$C[% /S/X:51%PP> @[9]NB50Z/7\7>(MG27!1(P<#IE'N>IEPQHR"J2
M>*D9V.'D9N;KK1X*TS7$(E>99B@Z)XFA.)NU8HWC"J!&K@'*;%4>"1SBGU/D
MP+Q#C:@4+%VV^5*BIQ2ULF48=.;DT8>,,JW>.?&9!<IC$2$&39R9NB!2_)K*
M@1%/B'6.'$.+!,UMHB  (B(  !Q$1[@  =\?4 ,E%R5QO75#5RLW5M[8Q&[D
MS1>0;QLV[@T7!% 2.FK86L:M!)]4X\!,+D"AW1X\ '(J$HMUG[C6JS6EK?,2
MJ2-;038+&E6B+J5142E';5C'JMDXE!\X=INW+U(I#)$. @<#>YXB!%HGX>=9
M?7.Q?S>[%_BIBH1=?*8#E*<O'JF*!@X@)1X&#B'$# !@'@/0/=R46EW78U*U
MVT;/+C/-X=)X=1-HF+=Z_>..Q)VBZB,?&-7K]1NW)P%54$^S3ZQ>L8.L'&,,
MDHMVQ0(H\3!PX&,'#O 80#(+04RR54KA8O0H/K" #Z_3E3$PJVIRKE?*![HI
M3>J/1\0.C*&$<"K"0\57(^3'W8&*/K<0#P\>.9F)PR5A(.*Y2ZW]JMH_DXQ2
M<EU7D-)OX:2*RI%[DD&TG&.5&CYIXY'5ETS6.W<)B43)J'(/2 B @(QH<K:F
MK=82_4^R5QY;(*=:R<!'IO3R#UL1R*C$8Y$7#Y!ZP,@61:NVR =<R"B15NJ(
M"!?D@XU((-#FIJ,UGH>6CY^(BIV)<>-Q4U',9:,==DNAXS'R39)XR<=@Y31<
MH]LV6*;J*$(<O'@8 'B&010T.:E6D=9(65F+# L'OC$M55XYM/-/%W:7B"TM
M'(RT>3MUD$VSKQB/7(IQ1.H!./5,(& 0R:$"O HL7:[_ %"CK0#>U32,0M:)
M5*$@R*MWJ_CLDL=(A$A,S;."-$2F6(!UUQ303ZP=8X<<!I.2@D#-;>(@ "(B
M   <1$>X  '2(CW@#(4KC[G?VHFCE9LK<VQB-G)F;B1;QDZ\@D')% 2.FK8V
MD6O )]4X\!,+D"AW1X\ '+:'="C4%O-ANE7JU86N<U+(HUA!./6-+,T74N@H
MC*O&C".5;)PZ#]R\3=NGR12&1(<! X&]SQ$( )-!FIKQ7/\ \8+5GUULG\W.
MR?XHY.AW\B%&H+LQ# <I3EXB4Y0,7B E'@8 $.)3 !@'@/0(<<JI7,+)NC65
M2E7$).6I!&59E(=^R81\Q-JQA%"]<AI482.D4XHHD^2XN!2X%$!Z!#+!KCB%
M%0%OT/,Q5ABV4U!R#25B9% KAC(,5B.&KE$1$O6353$2B)#E$IBCP,0Y1*8
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MW%&QV*%J4')62Q/B1L+$-Q=2#XZ3A<K= #%3 P(-4EW*QS*'*4I$R'.8P@
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M6S@B+=Q#,*^C+0#AZ8!2,FVN"+KR K%J*C\_5.F8$AZPI]P0RND<"**U>XM
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M/)S5AD^HJ8ZI/'QBNUX&$3!U^Z(CA%UGF_\ _G0>AB_Z&?2K?X@\J.$3F_\
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M+6]K2>\":GP!>;Q])OR%E$2CS-Z]X@(@/#R\8.X/#N&+#"40^&'<STOA??\
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M*"I']^?M3D?#&_\ NLGR>51^9G(GWG;_ -?Z*C_2"\F7Y0-(^)-?:G'PQO\
M[K)\GE3\S.0_O.W_ *_T4_I!>3+\H&D?$FOM3CX7W_W63Y/*GYF<A_>=O_7^
MBHAZ0/DT'HY@*3_?G[4X^%]_]UD^3RJ/S-Y#^\[?^O\ 14?Z0+DU_* I/Q)G
M[4X^&-_]UD^3RI^9O(7WG;_UOHJ/](#R:_R_TG^_/VJQ\,;_ .ZR?)Y5!_$_
MD$9[G;_U_HJ/](!R;?R_TG^_/VJP.6-_.5K)\GE4_F=R%]YV_P#7^BH_C_\
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M2%D6LN61G'93?5!T>4:+D1X>2>OUC))B;HX< Z<GX9WZE.S2?)Y5'YH?A_\
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M8HD$0'P>ME@:K,BBI&Z?!E@I&2ADJ5<)'X@!1Z0Z![XYDYM,>"FJ&]T/@]C
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MO.[S7_\ [:_QAO(OD#SB_P#J1XSX[_YUV7_DV>(=Y_\ Q/VIU?\ O=&G5_\
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MP\LW.Q;U]A"XMKW<=>@MMC(_3*'F,Q'7%&3)J;32T.S&-31=3+RDV\'P5/\
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MA<8P1:@LU&K<1$)*:"?-I73YJQ>SXN1+JO;K4S-<KJ*YH']DDVIB]5RP@)N
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MQ_4RG[%/W8-ZL882R:ZDN++JZ"&2(:JTH*R94\/E/@7.P;A/<];;6<5IN/6
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M\QNB7U"L5FH&QZWR:Z=J=XDH*3D:_9&L[(QUM;S,:_>,W"+TJSBJRC1!<IC
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M1W%#;NN(PZN6DO =7N4JNW\Z3N3>\WW,TI+*+J.4=Z;/8-Q<=;KDB8NWRT;
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MR.#</G < ZK0*  ++>MYL>7I=MMX-LVR6&3:;*28R0->^1SXFEY#L-!=F7-
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M8WT]:YU$KA3P9 < *+LVGY&0EM#<[,C*/GDE(.M<ZA4=/I!RL\>.5 YA-9D
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M3Q #IK%[55P9-[\UR_+N;.8)8+1L/8:UF;&7&)CN)82,'U^:*@XC "K?U/\
M$FUY4G_#BSO]YFO3OK64L9+AD8O)F9ALS6D5AH:E[Z/;YKO.>ZDGQXUW^_\
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M:LIYWSQRW,'6FLC8I"QKR<RYM#GQI2M3TJ+/GC=+6UAM9H;*Z[.*1/GBUOC
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MK6UBM9K3S#[)USLVQ7A>439JL9JCO-DR$D0T(E%J(O\ SD=[$.8!(X:$9 U
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MY"BH5(13)E+>&*:^9/9M#;.!CF:@/3)H*#I:VGI<795Q71NM_?;?RY<;;O\
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MIJ\;I/=O,_;=@5B\6B;HHRZ=1;ZF.W;V"4@ZC:"^)JJ6-O(MG[=)<%$R@84
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M3,'$!X=PQ70E$/AAW,]@<R[#[U%XU\\[D[FBO^!G\7[5.'HX>>C@'_LO[6Z
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M>/\ R#["Z/K/_P#1LT^(=D]YB\:S/X8<_P!/]*NO$WZ2J?B6<UG\A&POL/\
M_1L?$6R>\Q^/]BD?AAS_ $_TJZ\3?I*J3DIYKSA\CH78AN'3PAA'V%<J>8]C
M!QNHO&J'\+OQ!)J-JNJ=YOTE<DY*.;#@ ?@$V('3TPPAWQ_W7,_B/8]5>U1>
M-6'X7?B#3_2;OQ#Z2J_B4<V'\@NP_L-_]&R?B/8J_P"*B\:R/X6?B%7_ $F[
M\3?I)^)1S7_R"[#^PW_T;+?$FQ>]1>/]BC\J_P 0_NF[\3?I*M^)7S6_R#;$
M^PP_3<GXDV+WJ+QI^5GXA_=-WXF_240Y+.:W^0;8GV%-]-R/B38O>HO&J._"
MO\0SEM-WXF_25<G)=S5@4 '0^P^__P #&]4?]UR/B38O>HO'^Q0/PJ_$2G^D
MW?B;])/Q-.:8HB!M&;  0'N@,1P$/!VN/B'9#B+F.G?/D6;_ ,*_Q#K_ *3=
M>)OTD#DTYI>/_(;?NGZTA].RXYBV2G^)C\9\BR_*K\1-5?LF[SZ&_254.3;F
MDX?\AU^^Q0?3LCXAV7WF/QGR([\*_P 0R?\ 2;OQ#Z2F#DVYI/Y#K[]B@^G9
M;XBV3WF/QGR+-WX5?B(1AM%WXF_2638\I/-C&G.K'Z=V2P55;G:K*,V:K515
MNKU>U;J'0<IF.@IU0ZQ!$2FX!Q#,G;[L3S^\GA+0:XXX].2V@_#+\3;4E]MM
ME]&\MTDMHTD',$APJ#3$9*T_$XYHOY#[Y]BR_3LU^(MD]YC\?[%S?E1^(OW1
M=^)OTE,7DXYHN/\ R(7S[%E]3_?L@\P[+[S%XU7\I_Q&U _9%W3O-^DI5^43
MF8:$3.YTM>42*KMVJ9CQA0 [ATL1NW1#]6]VLLH4I?5$<CXBV0#_ !,?C/D4
M._"?\1CEM%WXF_25Z3DZYH1X &D;V(CT $87B/=]3M^.3\1[&!C<Q^,^19'\
M)?Q(K_H]WXF_26=BN4SFPAGB;UCI*_$4)\B=,\0)D7"(B G0<)@N7KI'$H=\
M#%$ ,40, "'/)O\ L$K=#[F*G?R[V"Z[+\,/Q1L)Q/;[1>!V1!:*$<01JQ'R
M@X@@@%=AC>7CF'60[21TAL.-7(0G:)C!+NTU#B80'Q8S/ME#%   P@<A!#CP
M#K<.(^9)NVT ^9=0N']*GCJOM[7DKGF2.MUL]]%(,QHU ]XM)/C \.:RQ.7;
M>X@8/P1;!#@80'C5Y4.CN=SBV#K!\,.X.9'=]K]XB]H+K'(_.!_]LO?JG>19
MV TES&UJ683T#K79</,Q;E-W'23&ORS=VT<)B/5425(@ AQ 1*8!XE,41*8!
M 1#,Y=SV>:,Q330NC<*$%P(*[+/E+GJPN67EE87T5U&[4US8W @]PT\? C X
M+O\ LUGOK8]$KE<-I7:,!+LRL/.XL17V,=4;D_8%?CYRR,)$5*,D5+"Z5<)&
M'M7BK-'LQ[) IS"?/)LW[59W3YA<P/C-=%7$O8#3S02XC2*'( GB:8+[/F"'
MG+?MF@L/LK<(;INGKM$;&PSN;J_>N8R)CS(26G%YC;3S6 G4L3+?CC6%LJUG
M->3,D1>,"'.JZTG2#O2QQ6PLTVR$B%)"0;%0;#U4C)JD.EW!()1 !S2/X=B<
M'1RM:0:X3/I6M<M=,UQW9_%2]C,=U92R!S-!)L;<NTTTT#NHU"@P%"".%%IU
M%U[S.ZXE'LQ3]<W2,?R,2[@7RCJAMYM%Q$/U6RKUDHRGX>39=1R9H0#&!,#B
M0!)QZIC /5=7>R7C!'<31N8'!PH\MQ%:&K2#Q7C[/L?XA;#.^ZVNQNXYWQ.C
M<3;B0%CB"YNF1CVXZ17"M*BM"0<Q,T_FBL#^!EGVN+.SDZR[.^A'M=UG#5)P
MS=G49K X,I5:[#"[5258IF3%?M.R$!ZG5ZY^MG%<;%$Q\;)F%CQ1P=(YU1CZ
MSC3,Y4JNB[VO\1KZ:"YFL;AMQ;NU1NCM8X2UQ+37]S&S406BFJM,:4J:Y"7K
MG-5/S%<FY6CW55]4Y$LO %;T!E'QS"4*[;OSR PT=!M8=V[<NVB1UU%T%3..
MH *B<O<RL4VQ11/BCEB#9!1W[PDD4(I4N) H32A%."TN]O\ Q+OKJWO+FSNS
M-:R:XJ6[6M:_4':M#8VL<XN:"XN:2ZE'5"R-HB>:JZLI)A9-=3;Y*7537D7*
M.HJM%RKE=-XB^!89N*J;&835.Y1**AB+E%4O$I^L4Q@'.%^Q6S@^&9@+<OWK
MB!A3(O(R[BWW"U_$O=XI(-PL97LE(+B+.%CR0X.KUC(6O!J!4APKB#4$A9B<
M+S:VA!^A8*#,27E-@I&/7*VG*<G(G9*-18]DC*(4Y*2:'2:#U$E$54U$0 !3
M,42@(9Q_8$)!AE:-)J/WSZ5SR+Z''.HQXKIO1^)^XMDCOK*602,+'$V,&K26
MZ:!X@#VT& +7 MPH00%R0NB-S\1_^M=>.D1_>[)?2,]$;KMH_P!_%[07RWP5
MS;7_ $Z\^J=Y%G8GEWW;**D:M]:V9%0P@'7DF98=N'6$W 3.I95DV* <.Z/6
M[GA#,Y-XVQE7&9A'<Q_15=%OR%SC=/ZN/;[@._G@1CQO+1\J]F:8Y-RP;UE9
M=HK-)1VT4(Y95)AQ=1::Q.!TCSCQ1,I9'LCCQ%LD7L!,4.LHJ03$SYW<N8^N
M:8+$%K3F\X'_ &1P[YQZ #BOUOE#\)&V,[-RYE<R69A!; WSF \#(XCSZ>H!
MIJ,7.%0O>0)F   "&      *(  !T  <.X 9\K4+]MHM9LH"52M\0$.M9V!2
M\0X<3>*OQZH<>D> =&*A005L_4/^@-^E'XV*A30IU#_H#?I1^-BH2A5 R2O'
MCV9^D?SHXJ**"TDJ44U #B)# 'PRC\;,U8BF:M5>U'Y$I#<.^/ >[FC0!B<U
MB\DX#)6_8J_K9OB#EJJE"G8J_K9OB#BJ4*@**O#YV?X@Y((JI -53[!;A\[/
M^E'+:@E#2BAXNM^M'_2CDZ@HTE52LW ]T450#Y0>/L90R-X*X8[,A5O%G'ZR
MI^D-\;*:@K:7=">+./UE3](/QL:@FEW0J9FKD1']05_2#ZF7#VTS4:7="UZ=
M0634@>NF<G:3[-,G6#AUSF;/1 A>/280 >Y\+&IIXII=T+/"T<_K"OZ0WQLD
M/;TJI8ZN14/%'/['5^AF^-DZV]*C0[H*HBR=_L=;](/QLSJ.E7+74R*IG8.S
M%$/%EO5#Y >D.C+!P!K54TNZ"K 6KD.("@H AQ 0ZHYN"#B,E2AHI?%G'ZRI
M^D'XV6J%72[H42MG &#@@H/$> _(CW>/<]K*NI3O*0' Y*Y-'O1Z&J_T,WJ>
MMF>MM,PM-+J9%2>3GW[$7^ACD:V](4:7=!3R<^_8B_T,<:V](32[H*IGC7XC
M_6B_1^MF^'\++![*9A-+N@J7R:__ &&X^AF^-EM;.D)H=T%4E(R0'AP9N!X<
M?]J-\+X65U-Z0H+']!4AHN1XC_43GI'_ &HWJ^MD:V=(4&-_05@K$P>H0T@J
MLU622(B43J'()2% 52  F,/  #B.2'LZ0HT/#JT-%F?)4E^P7/T(WQL:V=(5
M.KDZ"O/O,MRS1?,QK-QKNQKV&MN6DY"V^H6^ 3($U3KK6UCN(&QQQ'!#-W"C
M0ZJB:B1^':H+*%*9,XE4+Z.V[F=MN!<1Z7 M+7-.3FNS![Z\[=-I;NEJ;:76
MTAS7-<WTFO::M<*X5!\8P7'-5\F-_@MRP^^][[KL_,#LBG524IFO7*^OJYK:
MNTZ(G!.29>H5^M+OB2-BE&9S(+/%%B@8BB@=GP[($>RZWJWDLW6-C"RWMWO#
MG^>7EQ&6)R .0^7IY++8KF.];N.XSON;MC"QGF-8U@<<2&MS<0 "XGO # <^
MUGZ-2#H.X^979C^T25CKW,' ['K3&@EJ1HMIKJ'VU+DF+VVB))6P3#20"5<(
M)%(!(]B1)-/J=4Q1$N=%SS*ZXL[:V:T-DMW,)?JJ7F,4944%*#NE<MIRJRUW
M"[O'/<^&Z#P&:32,2'5( 2X@ZR ?1:!2BCH#T<KO1O+!OCE[5V+)7&=WG!W"
MO2&S75'7C%H.*GM:M];UR/2K![?+A(,:<R2.NBGY1;BL"HH@9(A2"5?\QMOM
MT@W 1AC('-(9JK4A^LG5I%"XYX'IQ66V<J2;?LESM+IG227#7M,A92@=&(V@
M-U&H8T"@U8Y5 68MO(!*VGEYY7-#?A!=L?Q:]BZNO_G7YA'<^>GX-HRPQODG
MR'YVM_-SRUY>Z_;^./\ Q;LN'9J];B6L/,$<5_=7V@'M,<C-.KT=9!K73C2F
M5!7I"TGY9DFVZQV_K".Q2POU:/3ZH$4IJ\W57.KJ=!66V3R4[+>[JMV]M ;V
MM/+]<-FP$# ;4:(ZXK>RH"Y!5F81E<FTHFT.FC>$L41&%!%-R3M@  'Y  4<
M M2WWNU%DRQOX&7$,3B6>>6%NK$BHS!/#]E-;CE^[-^_<=MG?:W$S&MDHQKV
MOTBC31V3F@T!Q'2#C6VVGR)VK8="T)'L]W;-C-R\N\PM/TO>]@A(FY6:1DY-
M(J<Z6RPKGR2REXZ2!! @(F7 X-VR::ZCCBJ=1:[Y#;W$[C#$;.X%'1 EH &6
MDXD$=/2< ,*6O>7IKJWM@V>9M_:NU,F(:YQ)%#J% "'#,89#'.N2Y>.2Z\:4
MW7NO=ULVQ8-N63=D11F4T>8HS"M/&+^H19(]9V1U$3"\8K'NQ+U6;)%@T)'-
M")(==?J=H9N&]6]Y90644;8HX"ZE'5J'&O$5J.)J:FIPR4[9L%Q8;C=;C+,Z
M:2Y$=:L#2"QM,P:$'@ T:108YJ/,+R7W7=6[-*;OJ^UK'J:PZ3A[TRAQA*3'
MV)^_?V^*4CV[LSV9E"1:$>T.;JO&2T<\)(LSJM^N@*@*DBPWJ"SLI[*2-LL<
MY;6KB  TUR K4\""*&AQR3<]@N+_ '*UW&*5\,EL)*48'$E[:9DT '$%IU"H
MPS5KI;EE-RJQG,%NW;NQ++MJY[!1->]P[*EJ.6*3+5M?UZ24;Q\/2*R2?<I1
M\-#'==5FS%P99,J2"* =FF08O=S^U76]C:1MBAC\R-@=7SGD8ESJ8DTQ-.))
M46.TC9676Y7LKYKB7SY9"RGFQM- &-!P:VM *DY#@O%?HF^7B5B+!OS=;*%M
MY];N;'-ZHY<7]C@).!7<Z>8WJRW5\]C8F7;(2C>)F)B79J!UR$*#Q%R0W%0I
MRI^US9N+',M[)SF=I#1), 0?WA:UH!(PJ #X"%\]R5MCVONMQ8U_8W2.CMZM
M+?W(>]^ (!HYS^/$'O#Z$<QW*G-;^F^7Z:">?50=$[PIVYO%?-52>\ZO--XD
MZ\V^V\MPWD/Q_L^KXYU'G9<>/8'Z,\#;=VCV]EPS2']? Z/TJ:=7'(UIT8=]
M?3;KLDFZ/M7:C'V:Z9-Z-=6BOFYBE>G&G05G]R\M"6U=9[KHL9'!3)O=]:5@
M;-=&]<-+/E%R0J,!%R4@R!]%*2_DB,;D221%T@4" ( 8HB(CE9[D+6YAG<=;
M('AP;6@SJ0#0TJ>X5U7^U=MLKBU:.K?<1EI=IJ<6Z02*BM!PJ.^O,T?Z-QC(
M; T%9MI/XS:]+Y?^7:MZ-K^L[)JIHXKTY-0D0E#N]AS1)NQ62-67D$0,9..%
MB<&ITVYP<G.AUU/4/,A;!<1VM8IKBY,I>'X@$U#!0 X=-<<<,5X8Y3:ZXM7W
MNFXMK6S;"V-T8+2X  R&KG#$#T:&F!U8+/MO1_!1>89QOK03V(T4G):>L&L)
MF@534D6-8?2\CXXZA+PDTCIFOQ#=Y#3*<8Y79F8+)ORQH$,HD98Z@4=S )]O
M%A?UG(F#P]TAU # MQ!-"*@&HI7(T6D?+ M=T^TMM#;<&W,;HVQ@-))JU] 6
MBH-*BAJ!2HS6B:B]']O_ %;&\R$<XYD#68G,>RV++3BI=!,J^I!;2V*=LF]V
M.T58[%<.''DQB=X1")249L^V<D5$0!$$S[WF_P"W73[9XM])M] '[VM6,K1F
M+.)I5V)PIQ7/MW+6ZV#+MANM?:C(X_N-.F62GGC]X:@8T9@,<\%FH;T7.DXW
MEQ#1K[6%-EK>:AR=96WBMJFMI[!\Z))%XJ6[MY$Y',Z@YCI=T"S9J,HIV;9(
MC45C)AQ')_--Z[<NW-E>(>L#NJZQVC2/FTRQ&9TYXT5H^3=M9M0VY]O&Z;J2
MPS=4W7J(],$@D&N(&HTP%:+U-HC25VT[I[7FK)N7D;Z^H%:954EL&N+UXTK&
MQ'7:0@&B#R\^9H=A#)MVP_U6MV@H]?Y'K=0OF7U]!>7DETP"-LCB[36M"<3C
M0<:G)>UMVW7-C816<A,CHHPW5ITU#10&E74PIQ*ZP-:L'UGD/J57YG.7KHO6
M"ZS!-7T7>)/-JP?6>0^I5?F<GKHO6"CJ)O5=XE;GK-A$P\(62'H_\D5]0/\
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M/A[?/=)_8*?&_*'WE9_6M\JB'/%R>CT<RNFOO[@O?>/A_?/=)_8/D3XXY/\
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MZ')^\,?8FZ_P'_)Y5/YA\E?>,'];Z*F#F=T*/1LN"[O^Y2?O#'V)NO\  ?\
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MY@_&QI*5"=JG^B_,'XV-)2H6I6LQ3JU02B ]2VQRAN]P(5G) (]WAQX"8,D
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M_P"G4^EX[-<>H4[7;^N$_"!3/NBC_P!.I]+QV:?U2G:[;UPH#L&EAW1L4?\
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MZ?J\T&AHUSA@TDG(8KEYPY5FV'=;F&PBNG[/ (AUSVES09(8WD.D:QK*ZGD
M8&E!B<3SAE3;>[@UK*UJMD<UQL!Q<3[>#DUH1 $Q4[05I5-J9BD!.R-QZR@<
M.J/'H'.PW%NV40ND8)C\W4*^*M5\XW:=TEM#N$5M<.L&UK((WF,4SJ\#2*4-
M<>!5XSIUN>0:]E9U:QNZXU!074^V@Y->$; D8Y5!<2J34S%$$S)F W64#@)1
MX] Y1UQ;MF$+I&"8Y-+A7Q5JK1[3NDMF[<(K:X=8-K641O,8IG5X&D4H:U/
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MDC=+P"%K%(^)VJ,D%>O=?7QM=(\P*%(VF6)2!(-"C\@<#=PKQKQ$3"W5,'=
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MV]&3IC17*YN]SR R]@;<S4'L&:9UU'F:W/'+T\M!DJU'*MW,D>PO$YHTF-C
MY3$0;=D"0@(&ZW$/C[%W--]?W5BW<&M-JY@)ZF,ZM0<<!IPII[J^_P!UBY&V
MO;K+<9-KD>V]8]P:)Y06Z=&!/68UU\.A>*&>D].3/HU=G\R3.D&8;-CN<?\
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M'@@ND< !6AJ%[',FU<HV7+]EN>T-W$75^V1S!-+"YC!%,Z)X<&0L))TU;1P
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M7\_JN_6W75H(@2=I\V]A'YVBO;LG1FJ@@WD(]<2D%>.DVIDW#=00*)T%2F$
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MG[?.Q@)>87@ 8DDM- !Q)7O<K316_,VW7%PYK(&7]NYSG$-:UK96$N<30
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M(8S5G?\ 7>V]G/;1"O#D("3:4/&6N.?@D?@JHU>)J_)$.4P_/[2>JO;^V?\
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MCW$LT:']8'-)T@,H:>J0*+F\O_\ +[UW_P"^)N7_ -2>A\ZX_P#N.7_HH_\
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MLATMKV.,Y#/K9<>_W<U66[NOR_B;ULFG[5E9Z1]#LT/F9^C_ #<NXNX5I/\
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M! ?4[OJ8.2J#0U5WE5NI%/<CX/9#*G-0<E;Y"JF2H.2ER516LC_<B7_L)/\
MP@QR#F/Y<"K-R=WOUA1-T>'-"H;FJ0X"EV2ADJBAA#DI<E9K\[WI%',YJCFH
MVI UA%8[KGGY<:)JN+.BW6X&OQ-I5.C/DE?%@5.Z22ULS43X<"&.H\33#W(
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M /RU42PR1;#M4LU.OGW2*9Q'$RF1X_JD!>A+ 70!_2,\U8<V!=>F@_P+ZO\
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MZ:Z:U.O53"N6?'+%>>X6!LMY^T.J^U.OFTZJ:].D=5IKYU,Z4X9X+[/<JO\
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M$YN)UO;RRLEE8QTL9.EQ:"6USTDBHK05I2M%6.\N[>*2"WED9!* 'M:YS6O
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ML.S'F20C9=K!0["*@ZO5J^W>+F=O4Z_3ZG&0=4@?'W1NU<"T9HBX4X&4$Q@
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M"L6:L5"^UR/DG12E<R41!7V LL5#2+D"!VCAHDBL?A\D8<TNMHV^]EZZ>/\
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M0(\9)B<$ER J0!3/UDSG*;AAV3;[>3K8A*'@'.69PQ!!P<\C(]'=S7M7O/\
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M&UC&X#)K0..:PR??\'MYNN%5,(<BJZ7Y[P>WE2LFJL&05#\D'IR6K!V:K%Z
MP<U+N'>4P9?@LSD5=A[D/6#V,R^=X53YO@4,T5%4)[7MY5RH/3*K!T9*J_-5
MR=)?6]K!R6/%9R"D?),LQD!#K$06X+ ! .86ZQ#(..H03$ 5004,).(@ &X9
MA-'UL1CXD?+P7;MUUV*]CN?FM./'S2*.IW:$T[M%Z32.15,BJ9@.FJ0BJ9RC
MQ*=-0H'3.40[ABG(8! >^ YX-",#F"OU5CFO:'M-6D5!Z0<0?"KE/H\/M!E3
MZ2U;DO86C5:TCH7F8/;F4Y(5\'FD@?MJY*,(>9.(V:S U,T?2<1.,DP(\[,5
M .W-UDNL "4W <\'<Q.=TLA;EHFI-0N!(]%M:@%IR[N:_2^4'6#>3M_.YMF?
M9:K#4(G-8_\ M9::7/9(T>=2M6FHK2A71-$;%A[5O#1-3J\&^K]-US7=HL(1
M*;E6LU/.W%@J5TGIN1EI1I%0S8PKO5@!-%- J2)2")?=" <FZ6<D&V75Q.X/
MN9GQ%VD$-&E[&M !).7$G%>UR=OEKN7-FS[9ML+X=JL8+ML8D>'R.,D,\DCG
MN:Q@Q<<&AM !AG0;GI76M>,OJ>B7VL5Z1;[(JDI/KIQ>K4)5R1B\2L!63B?V
MX_M#::J]A;*L2@#6.9G104!-)0A3G ^<VY7LU+BZM9'@PR!N,M!4::Z8@TAS
M<<W&I%34Y+U>5=@LB[;=GWFV@D9?VSY#HLP\AKA)I,EXZ4/BD!:/-C80TZ6D
M D%<<JKF-IW+@WN0TNF35F2W\^KRKNUU:-FG!8A.A1D@K$*>/H&4%J#LAQ!)
M3K$2.H<Y"E5X'#T9FON=X-OULC8>R!WF.(QZPBN'<X\:#@OD;"6WVGD,;J;.
MTFW ;VZ(F:%LAT"V8XL\X5IJ!P-0"20 [%=DN51IVNE^;E:$I]7>A2Y[2Z]4
M0L,(QG4('SI<NW4JWCB/DCB@R4.\ZO8<>R.FDF10JA"\,\ZVN+B\&WB620=8
MV;46N+2[30"M..&>>)(H5]1NNV;5L,G-$EG:6S^R36!A$L;9!'UQ)>&APP:2
M[T?1(#0X$"B.Z93%9FWS*52KS7SCY*2[2-&(Q3(8F$N<F6$*M*UQ@HB=&#51
MZ@BD+<"&2%0_4$ ,(8;<W(CCC,CSHW+JJU-2P:L''YW=KG@JS;3M+[RZNVVL
M#>OY1[9H#&Z(YWZ*OB:12,CYNFA%32E5FX2"J$A?-)ZT=46E&@[_ ,N]?EY^
M01KD<WL9IL:)8Y?RVSFTD2NF<J9[$$.=<G!183&%45/D>&4DMPRUN;ULLO6Q
M7;@T:CITZVBA;D10Y<.%%V6=GM4^];/R[+969L[[8HGRO$31+UG9Y7]8V0"K
M7ZF EPQ<2=1.%,7J=>JZ_I.O[3+Q,="KKL;Q+VMRZKTH]V!9V#T)*)J+_6EC
MC(E^M5$VPI&144%[%F Q#+B)DSD.-]PZ^[NI;>-Q<*L#0' 1M(H7B1I(U=(%
M'=&:YN5SMNQ[-8[G=11PO++B29QB>ZZE:[6R!UI*QCC"!0M<=<61?BTAQ\3"
MLLY<*N'"JJ[A=4ZRZZRAE5EEE3&.JJJJ<3'454.81,81$1$>(Y]. &M & "_
M%WO?)(9)"72.)))-22<223B23F57R%5?0#D@UTZ<2\ULQ^W,1A'M%J_ '5((
M YD78I'E';<1 !,5BS(" F#Y$PN3EZ2#P^4YGO&B-MDP^>3J=W ,AX3CX OW
M?\%^7I7W<W,D[:0,88HJ\7NH7N']%OFUR.LC,%?28>C/C%_1)R4,E43"*'1W
M1PBLUE>/R)>@._E@%FYU<!DM5G_=P'\(67[7>9*H%L.0[)%(?H\/Q\AN:*GE
ME"8152$_/#X ]O(*L!Q4YNCPY!6C<U2' 1V:ADJJL#&$PB(C_P!SULT&2H<U
M+DJ$PBH9HH5VA[@?EA]@,S=FM!DJ@].%4YK SWN(K]WHG]L84++CT9DKG)2Y
M*HF$5$WNA\'L9<9(H9**F?VO;R>"G@K1<O$H&]0?9R6YJCA@K,<T"S=DH9*H
MKE,>)0[O'AW!'O\ '*+9IJ$4]R/@]D,J<U)R5OD*J9*@Y*7)5%:R/]R)?^PD
M_P#"#'(.8_EP*LW)W>_6%$W1X<T*AN:I#@*79*&2J*&$.2ER5FM&LNMM=7&=
MK%FMU!I5JLE(>>4:98+)58*<G*C(>,,WGCU8EI-@Z?P#SQN/;J]JT42/VB"9
MN/6(40VCN;B%CHH9'LC>*. <0'#H< :',Y]*RDM+6=[)IXHWS1FK'.:"6'#%
MI(JTX#*F05*=UMKJRVBO7:QT&E3]SJ0#YJ6Z:JT%*V>L]90RIO-Z>?,%Y6%Z
MRIQ,/BRJ?$PB/3DQ7%Q'$Z&.1[87^DT.(:[O@&A\*F2UM99F7$L<;KB.NEQ:
M"YM<]+B*BO&A"K7&AT;8D0,!L"F52]00K%<#"W&NP]GB!<%(=,JXQLVS?,^V
M*FJ8H&ZG6 IA#CP$<F&>:W?UD#W,DZ6D@^,45I[>WN8S%<L9)$>#FAP\1!"Q
MDCJ[6<E2CZUD==T5_KI8B":U!>U& =4I4C.0;RS0BE57CU((Y&LJU2<I@* @
M1PF50O Y0$':;EDPN62/%QCYP<0[$4/G5KEAGDJOM+26W-I+%&ZU-/,+068&
MH\TBF! (PS%5F)BJUBPU]S4Y^N0,Y57C-*/=UF8AX^3K[I@@*0H,7,,];KQR
M[-$42=1(R8D+U"\ [@9BR66.02QN<V4&M02#7IJ,5J^**6,Q2-:Z(BA:0"".
M@@X46IR6F]0R\'6ZO+:JUO*5JFD(G4*[(T:L/8*JD3*D1,E;B7,6JP@R$*@0
M !JFD  0O#H#-FWEVQ[I6RR"5_I$.=5W?-:GPKF?96;HV0NBB,,8&ENEM&TR
MTBE!3A17\/KK7U5BIV"K%%IM<A+7)2TS:(>!K$)#Q5DF)UL@SFY6?CX]BW:3
M$E,-&Z:3I=P115PFF4JAC%* !#[BXE<U\KWN>P -)<20!D 2< . &2O#:VT+
M7LAC8QCW%S@UH <YV;G #$GB3B>*P">E].HT5?5Z6I]:):T=. =N==IT2K$H
MKEV5^C*E=+U(L4$ LX+*-DW(',W$P.$RJ<>N4!#7MMX9^U&67M(^?J=JRIZ5
M:Y89Y8*GV?8=E[#U$/8OX>ANC.OH4TYXY9XYK)S&M]=S\16Z[.T*ES5?IC^&
ME:?!RU6@Y&'JDG76JC&OR-:C'C%9E!/X)DL=%FLU(DHU2.)$Q*41#(9<7#'.
MD9(\/>"'$.(+@<PXUQ!X@Y\56:UM90V.2.-S(W-+ 6@AI:*-+01YI;P(H1P4
M+%KC7EOEH:?ME"I=HG:XH56O35BJ\'-RT"J4XJE5AI&28N7D6H54PF R!R"!
MAX].([BXB861/>UCLP'$ ]\ X^%1);V\SVR2QL=(PU:2T$M/<)%1X%;Q.L];
MURI*Z_KVOJ1 T-P1X1>DPM4@8NHK$D53K2!%JVQ8(0RA7RQQ.L HB"IA$3<1
M'#[FXDF[1)(]T^'G%Q+L,L2:X<,4BM;6"W[-#'&RVQ\QK0&XXGS0*8G/#%0I
MFM]=ZX;/&6O*%2Z&SD%4UW[2F5:#J[9\LEVHI+/$(-BQ2<JI"NIU3' PEZYN
M'2.4GN;BX=JN)'R$9:G%U/&2D%M;6K=%M&R-AX-:&CQ !7$U2J;89VMV:?J5
M9G+)2U9!>G6"8@8J3FZFO+HMV\LM6I9ZT7?P2LF@T2(X,U42%8B1 /U@* !,
M<TT<;HHWN;&^FH D!U,M0&!IPKDI?;P22LFD8QTT==#B 7-U"ATDBK:C TI4
M9J20I5-EK- 725J59D[C4TI)"K6R0@8I[9:TA,-E&4NC 3KEHI*0R4JR5.BY
M*V53!=(PD/UBB(99LTS(G0L>X0OIJ:"0'4Q%1D:'*N2S?;P23-G>QCIXZZ7$
M N;JP.DTJ*C TS&:^13KT?6Z#:_NNL)&J\F6Q7]P>7HZO,IL&J6E7F"XW6:D
MI0UD>JMZK()KV^("3/XFJE,HH-Q31+U#E3-VOU@Y@M.T,N6NO(VL#?W+'#JO
M- %!YP\TTQ&DDXXXX?&/Y8NG6TEG(RQEDDU_\P]AZX:R34@-Q<VOFD/:!04%
M OI/J#1-+U#6-?Q[:*A9J\4G5E7U2XV@Z@8U*[3E;KC./2",<SPI+S*=?5?Q
MJ;A*-%THV;B1,"@/9E-GS]S?37<DCB2V%\KGZ 3I!/&F5:&E:5*^KL=NM[**
M)K6M=<10MBZP@:RUH&!=G0D5TUI5;A'ZSUO$PEDK47KZD1M<N,E)S%N@(^J0
M+.$M4O-)((3,K9(INP38SDE+(-4B.5W2:JJY4R@<Q@*'#!]S</>V1\CS(P -
M)<26@9 &M0!P R72RTM8V/CCBC;'(XN> T .+O2+@!1Q/$FI/%8=SI73;BGQ
MVOG&I=9+T&'.\6B*0M0ZLK4(M60<N7K]6.K1XHT*Q4>O7JRRQDD2BHJJ<YN)
MC&$;B\O!,;@2R=H-*NU.U&F575KA0<>"R=86/9Q:=3%V05HS0W0*XFC:4Q))
M.'$K;H. @JQ%M8.M0L37H5B0R;&'@XUG$Q;,ACF4,1K'L$6[1N0QS"80(0 $
M1$<Q>]\CB^0ESSF2:GQE;,8R-H9& U@R % / %KUNUEK?8"L>O?-?4B[+Q(F
M-%+6ZJ0-D5C#',4YS1ZDRP>G9"8Y0$13$O$0 <TBN;B"H@D>P'/2XBO?H<5G
M-;6UQ3M$;'Z3AJ:'4[U0:*^L%4JUIK[JIV>M0%CJK]NBS?5F>AXZ7K[UHV41
M6;M7<-(-G$<Y;MU6Z9B$.F)2&(40 ! .$12RQ2=;$YS90<""01X1BM'PPSQ&
M&9K7PN%"UP!:1T$' A:Y*ZGU9.P]7KLWK2@3-?I!F)Z7!2M-KLA#U$\6W(TC
M#U>,=QRS* /'-$BI("T(D**90*3@  &6%U=1R.D9)(V1X.HAQ!=7/4:U->-<
MU1UE9R1LBDAB=%$06-+6D,+< 6BE&T& I2G!9:2IE/E;) 7&4JE:DK?54I%"
ML6I_!1;RR5Q"7;'92R,#..&JDG#I2C-4R3@K=5,%TC"4_6*(AE8YIF1.A:]P
MB?34T$T-,149&G"N2I/! ^9D[V,,[*Z7$ N;44.DYBHP-,QFJ<52Z=!3-EL4
M)4ZS#V"YJ,%;A.Q4#%Q\S;%8M%PVC%++)M&J+V=4CF[M5- 71U11(J<I. &$
M!LZ:9[&QO>XQLKI!)(;7.@R%>-,UFR"".1\T;&-FDIJ<  74P&HC$T& KEP6
M!K^I-4T^8=V2I:RU[5K$^[7QV>KE+K<)-/.W*1-?QJ4C(UJ^<=L1,I3]=0>L
M!0 >C-'W5U,T1RR2.C&0+B0/ 314CM+6%YEACC9([,AH!/?(%3X5;6'4>J+5
M*O)ZT:QUY9)R3C5H:1F9ZEUN8E9"(7:^(KQ3V1D(UP\=QJS(11.@H<R1DAZ@
MEZO<RS+JZB:&122-8#4 .( .=: Y]U2^SM)G%\T4;WENDDM:26G @DC$$9C)
M;;%Q,7 Q4=!P<;'PT+#1[2)AX>)9MXZ+BHN.;)LX^-C8]FFBT8Q[%HB1)%%(
MA$TDR 4H 4 #,GO=(XO>2Y[B22<22<R3Q)6C&,B:(H@&QM   %  ,  !@ !@
M ,ES0-&:3*L5R&GM6 X)/OK81P&OJD"Q+3)@W+)64JH1'7+/R!6B0+O 'QE4
M$B=<X]4.&G;;VE.NEII#?3=Z(R;GD. R7.+"Q::B&('67^@WTSF[+TCQ=F>E
M>=^;GEMV!S1.M?4%>=H$+HV'M-?NEU*\C)YYLR0EX0\ZT6C*ZZ3<!6VD/)PD
MMV)CJ$*Z26,8X',GQ14]#:=R@VP23ALAOBPM;0@, -,3Q)!%>CPXCS-ZVJ;=
MS%;/=&-O;(U[P6DO):3@TUH 0:$TK^@^T4TDD$DD$$TT442$2112(5-))),H
M$3333( $(F0@       ' ,\FI)J<U[YP%!DM<BZ=48&:L5C@JK7(6PW!5@O;
M9Z)@XR.FK0M%)+H1:UBE&;5%]-JQJ#I4C<SE1442*& G ##QV,TKV-C>YQC9
M72"20VN=!D*\:9K**"".1\T;&-FDIJ<  74P&HC$T& KEP5K,4:E6":B++/4
M^K3=B@&DJP@I^7K\3)34*QG6:L=-LHF5>-%GT<TF8]<Z#I-%0A'")S$4 Q1$
M,EL\T;#'&]S8W$$@$@&AJ*C(T.(KD5$MO;RR-FD8QTS =+BT$MU"CJ$BHJ,#
M3,8%5ZM4JI1X1K6J56:]3ZXQ.X490%6A8VOPC,[QPJ[=G:Q42V:,6YW3M<ZJ
M@D3 3J',8W$1$<I+++.\R3.<^0YEQ))X9G%1#!!;1B&W8R.$9-: T"IJ: 4
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M;W%!.QCPUP<W4T&CADX5!H1P(Q7:=5UM:?MC%<R0C'PJJ4F]5$!Z@'0-UV*
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M*8O3\'J9!5#Z85P3H'U_C9!X=Y#FH]_+M6;LU7RJA,EN:*J3H\/QL.S17 =
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M4=XBG;+/^+'[3?*H^=M5^Z:O_9F.]\XZF;U'>(IVVS_BQ>TWRIYV57[IJ_\
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M^VMG][MOK6?26X_A$U_]W5.^^>$]_8[)=?PI/9/D3[:V;WNU^M9])/PAZ_\
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M!79&RW+QJ:$FJK6RBH!(DJ@K+NR$ZX%!1-5'P]TCW6\FCL+(F&S<-4LS74<
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M83Z+L1WQ^S]"]29XZ]Q,(F$3")A$PB_GT<]*\FXYTN:Y26%071>87;J"7:
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M?#US72O+2UK&MK45-/.-<!X..'I['L\_(3KC?=]DB9+V=T<,37!SY'N((P'
M:1WJDF@;C\\N7/G\YH.5:DRNO=*7>+K55F;4^N4@Q>TVIV%56P2$1!PCIV5[
M/0\@\234CJZT("13@F44Q,!0,8PC]'N?+VU[M.VYOF.=*U@:"'.& ).0(XDK
MXC9><-[Y?M766VO8V!TA>:L#CJ(:TXGN-&"HZTY:N;#GOM>V=H:RHB>R[ O<
M75HV7)HV775*22M&PY&:L*JZ4?9K'5V_9R3U%VH5-DF9% "]7@0!( WN-TVC
M8(8;2ZDZJ/0&L&E[O-8 ,VM=D*9YK&TV+F'FRXN-QL(1-(92Z0AT; 'R$N-
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MZ5YFF.27=3F;?N-<0\9L75R\@HI6MNP5GK!-?O:VZ7,:+EYVPOIEJRIZX,A
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M@Z>L:W BA&'$$$<%IR1NMV_F/=-[J.WNVO<9ZD-<.L,+Y*EKPYKAJQ+7 @C
M@BJY3<>9[==[KLE4YNSQ#*NS9&R4Y%TZ@:ZUVC.MV;DCUJTG5-?U.L+S3%N\
M2(L1!T=5$%2%/U>L4!#T;?9=MM91/%&XRMR+GR/I7"HUN=0TPJ,5\YN?//-&
MZ6,EA=7#1:2@![8X8(-8!J \PQ1ES:XZ7$BO!>DMG\O6[MM:WY5[/K76-MNE
M=C^6^.A7\U!1IW<:SE66W-P/G;%RZ Q4D5VS.1054 PAU2*E$>G/&L-VVVPN
M[V&\F9'*;LD G$@QQ 'PD%?9[]RAS-S#M6QWNRV<UQ:,V:-CGLII#A/<N+22
M1B YI/?6H;$MWX$X#EZUHW+KZ\W/4B.S[9>8:9BJSLNA1-KVRK&L#T^0;NO*
M]9LLG6:Y6V*SDQ.V09RJ@E3,95N)\ZK.W^TI;N\)EBM[@QM8YI=&\MBJ=0R<
MT.<X@<2W/ T7D;]N Y8M-FV4-M+K<]N;=23QR-CN(&R71:.J<"7,D?$QC2ZE
M6LDII)+:K'Z@V2_V;S8<L<M(5775358;HU#'$9ZVH-:U]%.4PV5"N?&7T96&
M+!F]D.LN).W4(*HIE*3CU2@ 7O[-MELEZQLDT@-O*:R/<\C]V< 7$D#N+EV'
M>Y-\YYV6>2VLK8LW&U;IMH&0-/\ S##5S6  NX5.-,%C-K<K/,567M^NU@TW
M?8BI1TQ/3+ZP/H)RA&-8M24<*$?KN#!U4VQB*E'K#WAR;#>]IF9%;17$;IRU
MK0T'$F@P6?,O(?.-K=7N[7&WW#-N;++(9"!I#-1.HXUI3')=QY;>6;F \Q=^
MR_X(KQY,V+RT+,Z,]\B..PM#J:V5J&QQ3>(-PXNE7T%'+NTP#I12,;H#/,WC
M>=J-S:Q]?'KAO 7BOHAK)6FO>) [Y7TG)/)'-K=LW6X=87 AO=D>V T'[QTD
MUL]@;CFYC2X5I@#5>'[I1+CK:QO:C?:W+5.S1Z;19["3;4[*0;)/FJ3UFHJ@
MI\D4CEJN10@]\I@SZ>VNK>\B%Q:O:^$UH1EA@5^3[OM&Y['>NV[=H7P7K0"6
M.%" X5!\(6M$Z/#\;.I>4<U4R%)R*G+[H/7#V<J<EB,U=!E!DI?DILT;DLE5
M3[_@]O)4*IA#D572_/>#V\J5DU5@R"H?D@].2U8.S58O0&#FI=P[RF#+\%F<
MBKL/<AZP>QF7SO"J?-\"AFBHJA/:]O*N5!Z958.C)57YKT12RD"KP8D  ,9)
MZ940Z1/Y6D2@)OA]F4H>L&>'=U[4[P?H"_2>7P!L\-,SKK]8[]5%MH=(>N&8
MG)>RKLG1\'P\IP4\%G8.$F;%(M(:OQ$G.S#X52LHJ&8.I.2=F124<*E:L622
M[IP9)NB<Y@(0>J0HF'N (YA+)'"TR2N:V,9DD #ODX+IL[2ZOKAMK91R373Z
MZ6,:7N=05-&M!)H 2:#($K9[#KV_4]L@[MM'M]6:N5 0;N;'6IJ$;KK]0Q^Q
M16DV35-57J$$>J41'@ CF<-W:W!+;>6-[AP:X._02NV^V3>=L8)=RM+JWC<:
M RQ/C!/0"]H!/<4;73['0;))U&VQWDFPPQVZ<E'^-L7_ (L=TU;OT \;C'3Q
MBMVC1TF?]35, =;@/ 0$ B"XANXA<6YU0NR-",L,B <QT*NY[7?;-?2;9N3.
MKO8B-3=374JT.&+"YIJ"#@3XUA2]'AS4+@=FKE+W7A#(.2MQ"S<3&/9J4C8>
M,0\9DI9^SC(]MVB*/C#U^X3:M$.V<*)()=JNJ4O6.8I"\>(B <1RKWMCC,CS
M1C14]X"I6]M;S7=Q':6XU7$KVL:*@5<X@-%20!4D"I( XE7<C&/863DH>30\
M6DHE^[C)!MVB*WB[U@X5:NT.V;J*H*]DND8O6(8Q#<.("(<!RK7MD8V1AJQP
MJ.\<0ES;S6EQ):7 TW$3W,<*@T<TD.%02#0@BH)!X%42=/@]L,A55PGTAX?8
MR"KMR5VC[KX/4''$*IS5X'1A6&2[[RQF6)N^@BAU^N+R6*;J (CV)Z_+$<<0
M !^0% QNL/>+QSRM[I]ERURH/_$%]O\ AP7#G2QT5KKD\74OK\E:K[+9^<+^
MN%*?W(^#V0PBHX1,(JY2<  1Z1X"'PNYE3CAP6@%!7BL!8OGE=_A(R_:K_,U
MJMDR$3"*0_N1\'LAEFYJ#DJ&:+-2'[WA]K(*LU4QZ<*#FH9*A2*>X-ZV2W-#
MDK'-%FF$5#-%"AE79HKE#W)OE_\ 8ERJE5AZ!]8<@Y(,UKL]\[C!_P#IY%?F
MN0 /S1R@5SDLUA43"*B/2/KCF@R10PBIG]KV\G@IX*GD*$PBI*^X'X7=_,'+
M-S57"H5AFJP5 >D?7'+\$51,>D.'1P\/<Z?S,P=FKC)5,JK*7++-#_GO#[>!
MFBP<U_<Y7_?F7[>;99V2EN:O\*RERRH<TPH4H].2J'-2&Z/#@J6YK\^7-=;W
M?+-S&\_$1$=NQ4YJ.5FCV*FLF8]?RK>).SQNCCIL2%$QRS0+V67D0 W 4P[1
M3N 9,!^]VJ$;EMU@]]"+6Z<'=QNDRX]SS0/$OSC>)SM.[;FR+4);VQC<RG&3
M5U  [M7@]S$E<.VG$NN5*I<W')- E*+W<D/RE!K%%$3$:.)2SHP=/VD]%(P@
MJ[/,R<"JF"I"BH<P]=3K" AG=:O&Z36F]290F?7WFU>P> 'R+@O83LUO?\O6
MVD=H;:]4.[)2&0GI)T$USJ:FJ^CFTF=SF>9WE[Y$ZIM+8>HM35CEI"^34_JN
M31J%XM9JT\>Z_@JZVM)&[Q>%91S6 (Y53:$*(@N/$1,")TOGK4PLVR?>Y8HY
MKMUSH >-36U&LNT\2:T%>COU^IO.OEWBWY=AEE@LFV9D<Z,AKG:7"-K ZA+:
M 5.FAQ&*\I[7W=N^C<MWI'M2_A?V+-S/+'?=#,=;[C6G7$/LWS=V5L*MF<P<
ME;ZV,0\?2$6S8K-UW(=FJNB].F?@D8J1?3L[*QGW+;;OJ8VLNHY2^.E658QV
M(:ZN!P(' A>%NFY;C;;1NUB)YC+9R0".:NE^F1S#I+FZ:EN()P)#A7-;;SRZ
MRMFO/1R[$D+GN38.Y)V_W+4=R=R-Z>@LVKJK]_7B*P-1C"*K(P==35(*A&Y3
MG^3.8QC&.)C#CL5S%<<QQ-AACA9&R1M&C.@=BX\7=U=7--I+:\IW+IIY9Y))
M(GDO(HVKF#2P#!K<*@8XDDDDU7HG<C_8F[N?:"Y:F&X=I::UO1N75UN:4-JJ
M?;U2Q72S/+JUK+=LO,JQ[\%X=B@^;G[!5%PB(MG!>H JB<OGV;;>RV%VY.AB
MFN7W/5C6-0:W3JRJ,3CCAF%Z-[+=7W,S-H;/+!:QVAF/5D-<]QD# "2#@,Z<
M<:KP1KH-HU3D*YR+CKV^6N-OFH>>N\WIY.5^6?55[;6%;3UBQMK:<+774>BI
M#R<2^<O73$0.T4% I>S[A!+[UQV6;?+*&XC:8)K!C0" X-+M>FE:X@T .:^<
MM#>V_+VYW%K(_M5ONDDA();J##&7ZM-,'-U$MR/0NPN>;6[/^=>M;L1NUF:\
MHY++2>75W!A-3*=,&X7K4;W8"<_(0:"_D->:BK+*HMQ="W4=*()%(!BE!(H\
M;=J@;LKK,L:=VTNFK0:M+9-% <Z$ FE:57I2;M<NYB;?"5PV76RV+=1T:WQ&
M4/I73746LK2IRKE71U=G[S#E'Y;MRR6T=HQ]@Y@O2%5Z=4 ;W:F[ECJVQ/-@
M1C#72*2,J5%E0W"5;(Z)$(\(XQ%2&[/N% O1V:R^U+JT;%$66^W.'HM]-H82
M_+TJFFK/NK@-Y?\ V18WQEG:^[W9KJ%[JB)[I-,>>#"T Z!YO<7JN5_"ES!\
M]V^=7MM[[6U!3>7J@ZT>5&&UM*L8EC/6J\5YE8CS]L8/6#UI;(F/7DS(JL7)
M#)K D0@'2X&Z_E-[+M^QP7)@BFFN)'ZB\$T:TTHT@C232M1BO<#KO<^8[FT%
MQ-!;VD<6D,( <Z1I<7.J#J RTG#!>#-0[>V!K+T;/+=7-<2MLK<QN7F>=ZMD
MK51X]G(W"'KTU;+ ZE$*<D_<LF?GE*^)IHL"G60!0.U %4AX*%]V\L[>ZYDN
M9+@-<R&VUAKB0TD-;353'2*U.?>*^9VZ^N;/E"QBM"YDEQ>=47- +FM=(\G3
MJPU$"@KT\,U] >5 ^^:IOVR4Y\UYI[!RYS>MTIF(L'-(:+EKG5-HQTTF@[AF
M=F;2TD[D:]-02YUR H)1(N!4RIE*D*BOS^Z=@EL&S VK=R;)0B"H:YA&!+:
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M16UK"QHN8)8FS$ 5(D:'$N.9ID*^,8K&+>KRVGO;^>1QM+B"=\#2XZ6F!YC
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M5/UZLTZ79153E9:';U1]*.+<R%BJZLH3+!R@U2;K+%;-C-BG!-05%"C];/+
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M.@)21DR(@!4FU@1C%&%E8I@4> $C["S=(!_O?0'1GRUK:FSYA9:GYEP .]7
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M.HHP_JS=47J7$3B)VRQ4DE"E*!>H0K=<H"(B;B85NX'<'/+OXR'ME&1P\/\
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M-DCDO&;<DT=FXFD'B[ITJJ<X'5-U<]':FS=0Y\^O6Z1Q!=4$MKYI+3@RH^:
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M*#R^5>4K%$)-NAL-DD[C:K):IA>P6RVVJ8[$)&>L,TX(F=Z_<E;D >J1-/B
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M:10'$'&I/@5*Z:#J=UV]J[=3R8M$5;]0Q-TB*FWAG,(G!G2O, \KTBYE6$E
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M(E+V@%$Q3<UG?S6<<L<8:Z.9FEP<#ETBA&(J:%=U[MD&X/@EE<]LMO*'M+2
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M>/MO>?>[GZU_TD^!N2_NC;?\M#]!/Q3>5O\ )QT9_-31_M'C[<WKWNY^M?\
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M_E3X"Y'^YMK_ ,K!]!/Q5^6;\GS2W\V5-^T^/MS>O>[GZQ_E4? 7(WW-M?\
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M^A#X@82@4!*4>DH?$#"4"AV9/T!?B8JHTA1ZA Z"A\3%4TA7*/9C\B<I1'I
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M7TMZ M3N""*+&),DDF03VRHI&$I0 3)JV*.35(/<[I3D,("'? <C4[I4Z6]
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M=]0[T3WE@,[ES)A$PB8199C\Y'Y<?8#.6;TO MH\E>9DM%I]U_K"'_AA3?\
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M'D2@S5ETG38[46OC0=CA%\^)W_.&O0TUF/U5)SG//08]MN>#1LE&34HNYE)
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M<MK7F_M^XZO^+._1URZCMQ54DML*I2C+;5UJVN]>R,2KKZ-M#^5C+#<;I&M
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M?4.]$]Y8#.Y<R81,(F$668_.1^7'V SEF]+P+:/)7F9+1:?>_P![H_NY4O\
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M)X]9$7*O0_>C VQRJVCF"YXN=R\PNTO2,\[<BTG=X3%5,(T+4M1071>P6E:
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M=M+ZWYMM^LMD:OUK?*^90:O?VE6K=%HBE\O-1!4PQ,M<'-D?1JW!P@H1R +
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MJ=0Q"+VWA$PB81,(F$3")A$PBD4*!R&*( /$.@?5[V2#0U4$5%%@! 0$0'I
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MW>.=,+JBG0L'MH:C(K2E_P!^\7_!6>_PO7,T^>.\?U*O ^#]:VLHB40, \!
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M#-:[,OG:RD,*JQCBE--EDQ$I/D52-G@%.' O2 &')+&BF'%8B1_3P69&4?\
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M;*Y?=N:@;Q;^]51-K#S3Q2,C+#7K'5;W5G<ND@FZ6@R6JASEEKI)Y%LJ50[
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ML?:.K!Z>I:V&H[AT8=Q>@,^J7PZD/T>'VAPBH=_!R51Z2CF:NF$6OK  V=D
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MLL).5>3LDQK\>Y75:0S.0FY%P\72;$3(J[746. J',8:-BC8]TC&M#WD%Q
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M@XL!P,SN@,QTU])X  (#BW]!Y2E(4I"%*0A"@4I2@!2E*4.!2E*'  * !P
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M'P>P&5.:*7(1,(I3='AP%(S5,<N%+LE(;H')&:J,U)EE92CTY4JIS4,*%*.
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M_P ZM&^Q<_ZO^\Y@[D6^/^_B\3O(NAOXJ;:!3LL_M-5R7T4FR@$/_KIT;N"
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MJC7^=SE=M-#O.RH#:K21JFM&S%]>U$ZO>$K!6F$F\38,9!_2W-91N@QSARH
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M \\=G<R6\ETQO[B(@/-0*%QH,":G'H!IQ6T]_:0W45E(^ES.'%@H3JT-U.Q
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M4G<YY*:LE3=>-3>)K]7@B901 !\&3;[MDL43F4?.&F,5;YP=@WCA4]-*<5]
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MTQ,7B.W7G6RPZ/WD+2Y^+?- S-:T/< ))X569W6PZF"X$E8KES6QG2XZBZI
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MNYOM+B'2VU%I$USG. TTJ2:9X A?F>S<Q;=M+K^UN"]UZ[<)W,C:QSBZND
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M""D-6K_D_P#1/,7S9N\9/.<]JU>,W2*;AJZ:N-ZWQ%PV<MUBG27;KI'$IR&
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M)&-VA^Y-(ZZ\9$P]]FK7X]-#Y<Z;;&]V_,V<@B#;Y)Y!A@6R:>J'<TB1U .
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MN!S$UP?^+=^_BEE#LVYMSB/C;Y5H-ZVMV4H\3O(J@>D\Y$1Z.8>NC_Q;OO\
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MD[KZ9(C5SSC-YF"9KH4ZRZ4T[,4 W8J)LWE26K!6L:I$E,)BF9)KM54>!!$
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M0BJ8&2/RWMI'?6YMI2X,+F.PI6K'M>,P>+17#*N6:[]LW&?:KQM];AKI6M>
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M<QC4$5(J#EG59#8O,;:-EZ^@=6+T[6]-I%7OECOU<AZ%6WD"6)>V:!KT ^B
M6<3,DK)Q:2-;37(L^%U*G<+JBL\53[)-+D;9L@D,X<]TCFAI+C6M"37+/'AA
MW%Z#K^2XB$!;&R)KM0#12E12F9PXXU-3FLX]YHME2.]+[OSQ:IMK)L]S/>?-
M5&!&5U[8H:S=@,W592L6)Y-&D*V],V2/V+APJLDLDFLFJ19--0O*;2)MLVV\
M[0RE#7$$9&HIBN]E[,ZY==$-UOS%/-(-*BA.7A61L/,U;Y).!942HZWTC%U^
MWP6P6T;J&NR$.+V\5?KC6K'+S5GG+=:))>OJ.%E&391^,>U5<*G2;E,<1SC[
M,QNHO<YY((\XUP.8P &/'"J]!MT]P 8&L (/FBF(RK6N7B71(;G+M$#<DM@U
MW3F@*_<':LYYXS,71IQ,U]96AC(QMFBIEDXN#F-J["?8RBZ3GS61KRQTU#$!
M0I1$H\;[5I;H+WEG#'*F7#'PU7?'=.KK#6!Q..&?R_HHM2HO,*^I+#;D AJ_
M5,]2=PR\1-RU#L4;<W-;K$C6W5F<556GK1UYB[*S+6$;<\;M2OI&0 Z)B>,=
MNH0%,QFBU%IU.U-&>%3TUPIC1=<4A%<!0TP6IR.T[),:ZUSK-5&-9PVK[%>[
M17)./3?MY]63V$-1-+^47II!5J=%B:E-#,^P;MU$A.J)SJ<2=3F>P!Q?Q=3Y
M%VQ$D = 7<UN;N]NS/9XM(U(QVM*MWS>4WG'TI1KM1XK*MC,Y67!V68-3V-I
MDFZJG;3+6&0F#*+**@Z!8XJ9QR1@# G3T<%VQFKER=GLJ=;:JE=/$:1(UF9V
M'7ME.GQT'@SJ<[6:W:*NP:-W(/RQY8E:/MKDZR9FIUC+$3$JI"@8A^>49GN+
MLC&1X_\ P\BV1ON6XMZIJJIQX1,:EINWVZ\4Z8;,3K3 3UQ<4]T]4E0D7+Z(
M?-8]Q269FJ8-$P#KJ@KVP&*!.%^2[HV@DD\0!^GRKH4IS(33R*LC&MZUU#KF
M6NT,]KEQME!JLI$S\]!RJZ*TQ%IHR%CEZW5F<P"().B0<?%E6;B9$?U(YR&P
M><,%V10BH+BYP!J 3@#^D^$E<'3Z!\'MYP/S7KM]$*_1Z/@]0,YI%WPYJ^2Z
M? /M9Q/R7H,602Z,XY,UW1<%>I='_A>T&<DG%=L>:R2?27P9PR>5>C'FL@G[
MH/7SC=DN^+-9%+H^)[(YPO7?'D%D$>CXOM9QR9E>A%P642Z!]?VLX9,EUQYK
M(EZ<Y7Y+NC])9!'I#Y7XV>>_+PKT6>DKU/I#P9QOXKNB_4LHG[GP_&SC>O09
MD%?(]'Q/;SC?FO0B]$+T%RW:D?;FVQ6:FDV45A47J,S;G)2G[)G5XUP@K)]H
MJ4I@15D ,5H@(]SQAP3CW..>KRQL4O,.^06#03;Z@Z4^K&TC5CP)]%O\YP7S
MO/',\/*?+5QN;G 7A860#BZ9X(90<0WTW?S6E?I0  *          '   .X
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M$LBE3[;Q#_T6L7V$D_4_L7.-\C*9CQKT8F/Z#XED$:A;./[U[%T?662]4/\
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MT,DA%'/(RZ:-'S6UPQ)J22?Y3YTYSW3G/<>V7OF6K*B*$&K8VG/HU/=0:GD
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MK&_0E^/PX9=K'.[RH7@=TJQ4>*'[A?D ^%T_&S9L0!\[%9F0GN*T$1'NCFH
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4A$PB81,(F$3")A$PB81,(F$7_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>gyowp0iggm03000017.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gyowp0iggm03000017.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" *= Y4# 2(  A$! Q$!_\0
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M /2OW^U[_P"%A\9O_H)*/^(C_P#;W_Z5^_VO?_"P^,W_ -!)6K_Q#H?MW?\
M2?/]K;_PD/C%_P#1J4?\0Z'[=W_2?/\ :V_\)#XQ?_1J4![OE_Y-Y?\ !_#S
M,K_B(_\ V]_^E?O]KW_PL/C-_P#024?\1'_[>_\ TK]_M>_^%A\9O_H)*U?^
M(=#]N[_I/G^UM_X2'QB_^C4H_P"(=#]N[_I/G^UM_P"$A\8O_HU* ]WR_P#)
MO+_@_AYF2?\ @Y!_;T7[_P#P;_?M=(/5O&7QE SZ<_L2CG'/X5_5EX$^('@/
MXI>%-*\=_#+QMX1^(W@?7?MW]B>,O GB31O%_A36/[,U*\T;4O[*\1>'[W4-
M(U#^S]7T^_TJ^^R7DWV34K&\L;CR[JVFB3^*;]A+X=?M+? ?_@LC^U9^P1\7
M/VU?CE^U!H'P-_9EL/%=IXO^(_B7Q[)H^M:UXP_X9A\<6VIVWPZ\3_$WQ_9:
M!JFA6'Q1U'PQ!J<7B34KNXLX+VXC>QAUF?3;;ZP_X(M_\%>_V"_V5/\ @FA^
MS9\!/VH?VAKKP)\=/ ?_  N+_A./"M[\-?CAX[N=*_X2CX^_%/QGX9\WQ7X*
M^'/BGPSJOV[P?XB\/ZDG]FZ]??88[Q--O/LNH6=U9VX)KLNVUWNK]?ZU/ZUZ
M*_&__B( _P""1O\ T=I_Y@?]IG_YS-'_ !$ ?\$C?^CM/_,#_M,__.9H%9]G
M]Q^R%%?C3>?\'!'_  2(T^TEOKO]K?R;6#RS++_PH7]IN3;YLB11_)%\&'D;
M=(ZK\J'&<MA02/U?^&?Q&\&_&'X;_#_XN?#G6?\ A(OA[\4O!'A3XC>!/$']
MG:KI']N^#/&^@V'B;POK/]E:[8Z9K>F?VGHFIV-[_9^LZ;I^JV7G_9M0L;2[
MBFMXP+-;IKY';T444""BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MX-?^#I?_ )/I^#__ &:;\/\ _P!7!^T)7]Y5!4MH^GZ(****" HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% '\;_ /P<;_ /Q-\-_P!J#X6_\%$_
M'-[X=U?]G6[^ G@C]BRW\$Z%>ZK)\6D^-4_Q"^./QRA\4R:1<:5HWA8?#I?
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MC\>OBC_P5K^/!UCX ?M1^-/A!I^J^+=3\$?"3QM\?;6V\&_$[XT?!0_%/0M
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MXJ\+:WX GAL[_4=5U'5Y9/#>EWVC_P"@Q0#5K:WO]_S04444""BBB@ HHHH
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M%9VWP^FL/[1-G\+_ (BQ:G_PETOCB:VL_M-QX?\ L4FB2^3_ &LUVR6//?\
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M)I^K_;;7_A&K0"-KJ^>9I+IK>PF62'R0I:^6O1-ZNWY_IH>W?\&XVHWFJ_\
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MKWGQ,T_43=B4#2O''C7PE/ISZ=;6UBVH:?ITRRHMMIU[%_:%I'*Z7JJ=V/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0(**** /X-/^#I@X_;H^#Q/_ $:;\/O_ %<'[0E?WEU_#]_P<B_%;QA\'?\
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M_B?P_JFH>'KC4O"GAB_FTFXLY+SP]HMPTFFVW"_\+\_X)A_]&Z_&W_P:WO\
M\_B@KE]?N7_R7G_5F?[%=%?XZG_"_/\ @F'_ -&Z_&W_ ,&M[_\ /XK]E?\
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MD/A#6_L/B#1?MUG_ &EI]M]IAW_Y[7PC_:^_X* _![XP>.O#O[)?[4%Q\+/
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M^"7[2G_"G?\ A=?@K_A-/^% _';X>_M+_"3_ (J/Q;X<_P"$3^-OPK_M?_A
MO&O_ !2>O:%_;W]A?V]JO_%.>)?[9\):I]J_XG.@ZCY%MY/NU%% CX0_X*E_
M\HQ_^"C/_9B'[7G_ *S]\0J_CN_X(Z_\GS?\$6_^R&_&;_UB2_K^Q'_@J7_R
MC'_X*,_]F(?M>?\ K/WQ"K^.[_@CK_R?-_P1;_[(;\9O_6)+^@I;+_M__P!)
M1_H 4444$A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110!_*?\ \%R_^"H'[>?_  3P
M_:V^'DOPMTWQAIO[(/B?]G3PE'>>,[OX?^#X?A<_[2.M?$OXMM<>&%^+OB[X
M2^,+8^/F^&'@G3]5'PX@\603GP]&WB>/P]%&+G4KG\Q+_P#X*[?\%?="URQL
MKS]H/Q+J$46JZ9'J=LW[-OP)L773Y_*GN9+@I\()9;2$0.$:?*;%D642)\N?
MZY?^"DNB>,=?^!OA2S\$_P#!-KX4?\%1]5C^+&AW-Q^S_P#&'QW\#?A[X9\'
MZ>GA#QU%+\8K'6OV@/"GC#P;=:[X?N9K3P5;:7IFF0>)IM/^(.IW=G?1:59:
MS;W/\*_BGQ?\(M5^&'A?Q7\,?VE=9^*^LKXC-Z\LW@3XA>#[_P 6Z?IC>((I
M=(U#5?$\HFBM)K^TLM#9-0^TPK$D%W]FEL[=5 4E?7K=+R\G_GWN?M)_P1%_
MX*F?MZ_M>?\ !67]I/\ 9F_:/^-<OC;X+> /V2M4^)OA3P#-\+_@_P"$9=%\
M<6_C']F72K?6V\1>"_AUX6\8WW_$N^(7BZ-=-U37+O2&761*U@\MAI<MG_85
M7\3O_!NI\.?V8;C_ (*)_&OX^^'_ -K8^(/VN?''[)7B_P /_%+]B(_ ?XAZ
M6?@[X'T[XI?L^:=IOQ"_X:5O[\?#/XA?VOI_A/X=ZI_PB?A[1[35]/\ ^%H_
M89YGF\$:X]S_ &Q4"EH_NZ>6H5_&Y^W+_P $2?'_ .ROIW_!0_\ X*$?"7Q/
MX\_;$^*OQJ^.2_&?P7^RG\,O@/XGM?&]M_PMS]H/47\1>&M$USPEXV^)FL^,
M/^$+\.?%K4O$&I:Q;_"R'SM(\"7]_+I6AVNH7-YHO]D=% )_\$_AG^#'_!.K
M]H_P?_P3;^-W[5<WP@^.,/[1^I_%+0O&_AG]E2Z^!OC^T^*OV#XEW7P3M]=T
M:PTNX@D\0ZNG@:U\5^+VU35?^%72/,G@[6Y+JVT4VMT^C_'_ ,'O^")_[0'[
M1'Q L/@AXV^&_P =OV?M#_:KU'7OCE\0?CIXN_9U^)=]X;^#7BW5]'OOB->^
M#O$FDZWJO@O1+S4KO6_!MAX+62\\5>"3'J7BFRFM_#R7,%OH^H_Z+%% )VVW
M[_=_7F?P\_\ !R7X\L/AS_P4&^%6OZAX8/BV*Z_8V\#:.NF+K$^B&&2?XV_'
M6]6_^UV]E?O((UL7M_LY@5'-SYAE!B5'_IY_X)I?L$6__!.OX%>+/@G;?$__
M (6RGBCXM:[\4CXC_P"$*?P)]B?6_!W@/PD=%_LA_&/C<W/V8>"%OO[2_M6W
M$W]I?9?[/B-F;F[_ )0O^#I?_D^GX/\ _9IOP_\ _5P?M"5_>50.2LHONOT0
M4444$A1110 4444 %%%% !1110 4444 %%%% '\(_P"S3_R67_@K?_VF*_;J
M_P#4X\,5_=Q7\*7[)MI-X@_:*_X*O>$]+3[5KVJ_\%AOV\YK&PRD/GQVOBW0
M[R=OM-RT-E'LM[&ZDQ-<QLWE;4#.\:O^K\7_  68_P""G+J3+_P0_P#*;=@+
M_P /*_V?9,C ^;*_"X 9)(QUXSWH+DK\O^%=;?F?TG45_+W\0?\ @N[_ ,%!
MOA=HMMX@\:_\$6/[(TJ\U2'1K>Y_X>-?!._WZA<6E[>Q0>3I/P@U"Y7=;:?=
M2>:\*P#RMC2K(\:/_4)03:W_  ]_R"BBB@04444 %%%% !1110 4444 %%%%
M 'XR?\'!_P#RB#_:YR<#_BP?)_[.=^"U?%7_  ;S_M ? ?X/?L%ZAX<^+GQL
M^$?PL\0:E\8+OQ%IFA?$;XD>#?!&LZCX>O?@U\%+"RUZQTOQ-K.F7MWHUY?:
M9J5G:ZG;P26,]UI]];Q3O-:3I'^S?_!1']C]_P!O;]CKXP?LG)\1V^$C?%;_
M (5_CX@IX3/CEO#_ /P@OQ2\$_$HX\+#Q/X-.J?VJ/!QT0_\5)IOV(:D=1_T
MS[)]@NOY\M)_X-<_%VEZ5IFD_P##Q_Q'/#I6GV6F6W_&.VIQ1Q6MC;1VT$,$
M'_#2LBV\"+'^ZMXV\N%3L3@9(-6MJ[._9[?U<_I&_P"&V?V,_P#H[?\ 9C_\
M/U\*_P#YJZ/^&V?V,_\ H[?]F/\ \/U\*_\ YJZ_G(_XA@/%?_21CQ#_ .(\
M:E_]$C1_Q# >*_\ I(QXA_\ $>-2_P#HD:!V7\WX/^N_]/3^C?\ X;9_8S_Z
M.W_9C_\ #]?"O_YJZ/\ AMG]C/\ Z.W_ &8__#]?"O\ ^:NOYR/^(8#Q7_TD
M8\0_^(\:E_\ 1(T?\0P'BO\ Z2,>(?\ Q'C4O_HD: LOYOP?]=_Z>G[^_%']
MH[_@G[\:/AG\1/@[\2_VG?V8_$GPY^+'@7Q=\-/'_AW_ (:,\ Z/_;_@GQWX
M?U#POXJT7^U] \=:5KNE?VKH6JW]C_:6BZGIVK6/G_:=-O[.\BAN(_R>O?\
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MXK_Z2,>(?_$>-2_^B1H_XA@/%?\ TD8\0_\ B/&I?_1(T!9?S?@_Z[_T]/W
M_:E^-G[&G[2_[,?[1G[.(_;=_9C\%G]H#X$?%[X)#QB/C#\*_$G_  B?_"U?
MA_XA\"?\)-_PCO\ PL#0?[>_L'^WO[4_L7^W-&_M3[+]A_M73O/^V0_RZ_L
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 ?DG_P %)/\ @J9%^P_JGA7X5_!OX'_\-8?M1^(;#0_B!??L_?\ "RF^
M!/\ 8OP#U:X\=>'+KXQ_\+6\4_#WQ;\/-1_L[XA^$M+\%?\ "O8=1A\:7?\
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M3?\ )QO@+_LB?A;_ -3KXJ5_3)0-_HOR04444""BBB@ HHHH **** "BBB@
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MXGUU_%+Z[XGL+N&RE\-PZ2VDPWD[ZY'>1PV%P#D[J-NBU_ _4VBBB@@****
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M99A4<W7JX7VV84*6+Q.!I*$HX=1HU)Q5.A2Y:<).=KTX3A_03^T3_P %$?\
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MFW/[2O[-7PX_: \40>(+F_\ AKXHM9OA;\/])^/GAO3;S2? 7P!UOXPZ[?\
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MQ+X1T#QKX3\6^./B+K'P AN?%7PV\8?"/PWX<\=^((M/\5/\.?B7\U_L!_\
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MI37M"_MW^PO[=U7_ (ISQ+_;/A/4_M7_ !.=!U#R+;R0=]O5;>6WW:G\N_\
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M^(/^$D\4Z?I.B_V%X?O+37=8^W?V;H]U;:C<VTR=S_P5'_X*#?\ !3_]H_\
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M?3OB[XSTWX@>)OB#XS\*6UO\)?A;:? CQ[X9TNYTW0O'//\ _!*[P7_P4O\
M^"G7Q=^+WA/2?^"E7[9?P>\%?"?X9:'X@\6?$^7XZ_%KXC:?IGC#Q7XFN=,^
M&G@<?#J;]H#X=ZS-/XVTG1OBIXAG\7:/+>Z?I$/PTCT/Q!):77B7PNTGZ$_L
M_>"_VJOVA?V8/^"A=S\9_P#@BM^S3^S=K&F_L,_M5^&_V?OBS\$_V/+?]GWX
MWO\ 'W5_@1X@\%W_ ,,_!WPL\9:CXL^.WC(?&/P3\7;K3/"7C3X=:5I'A:QG
M\+>//A=J&O>._$/C%M$\)^G?\&QO[.7[0OP#\2_MWS_'7X#_ !F^"T'B_0_V
M38?"4WQ9^%_C?X<Q>*)?#E_^U$_B&+P[)XPT/1DUN304\0:"^LIIIN6TM=;T
MAKX0#4K(S<^,Q5##X3.*N#HX/#UIYIAZ4(16$Q2HQEA+8EX9VJP4*E2,TW&[
MI>UG!>SJ12AMA,'7Q6(X?P^+KXW$85X/,ISDWCL(YTXU83PE/$N3I5W[/W?9
MRG)>UC3A).=.3YOZBOA7X$_X5;\,/AQ\,O\ A,O'GQ&_X5SX#\(>!/\ A8/Q
M4\0_\)=\3_'?_"(^'M.\/_\ "9?$?Q9]CT__ (2?QYXG_L_^V_%_B'[!8_VU
MXAOM1U+[';?:?)3O***^)/T(**** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_?\ ^"4W_1U'_F#_ -H__P"=!039]G]Q^NU%?D3_ ,/W_P#@E-_T=1_Y@_\
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M#_@LM^S#\(?^"=?[/'P\_;P_:]\>ZU^U;X>_X6U_PM34_B=H'[0?QH\<7/\
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M6WNK:7^SK\5=+&KW?CF\\5Z/<Z<_C"SU 6>CZ;<MX;M[<QZIJ/XX_P#!'_\
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M6YM] L/%'C'XNZ? LOP9\(O-#X6\-W$.MWL$BWOB3Q?X#_L)_L=_%+_@IO\
M$;X':W\4?C':_P#!/;Q'X2\%^'_V3OCGI%UHUM\7?BA^T+XJ;X)Z1_P@?BG3
M[[X5WUSHFA'Q3X@^-6F6^JZ[\&O 6D0P>$?#EQ<^+GM;B&]\4?FM_P % #::
M;X/L9[:5Y%?Q]H$0,P)&&\'^(';A(XVR&3 )XQG@Y!K[,UR']B^']EWQ3JO@
M[XN^.=6_X*,:CX&^(UC^T9\ K[1M8B^%_@'X-M9>*DTOQ9X6\02_#33=!O\
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M*02N"05!]ATK[IH)N_/^O^&7W'\"7[<W[!W_  33\"? +]INV_8.^/\ \?\
MXU_MI_ OXF1?!W3_ (0?$U;'2O!$GQ&\'?%;PCX7^,WAW6];U'X"_"70[_\
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MI,>G'S(KJ>Z^+7[.<UVCA;O4VBCCD>T6(2R0-ME?+R%6:,"ST2>_2_6RO?\
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M;3_^=G7]AE%'^LV8?\^<N_\ ""AY>7E_6EC_ %2RW_G_ )I_X<<1_F?QY_\
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M=?V&44?ZS9A_SYR[_P (*'EY>7]:6/\ 5++?^?\ FG_AQQ'^9_'G_P .@/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MY\56/ANW^&"^'XOAAJRZ1;:V?'HU&[U.P/AYU_);X9?M[?\ !P%\0HK5[/\
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M3<:@/$MUOGTO^DVB@#\3/V?O^"%W[$'AK]GGPWX+_:!^!V@^./C;X_\ AO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH _BK_X2;_@Y8_Z/#_: _\ %6GP1_\
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M5:?!'_YV-'_"3?\ !RQ_T>'^T!_XJT^"/_SL:_M4HH#F_NK[OZ\_Z6O\5?\
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M (2;_@Y8_P"CP_V@/_%6GP1_^=C7]JE% <W]U?=_7G_2U_BK_P"$F_X.6/\
MH\/]H#_Q5I\$?_G8T?\ "3?\'+'_ $>'^T!_XJT^"/\ \[&O[5** YO[J^[^
MO/\ I:_Q5_\ "3?\'+'_ $>'^T!_XJT^"/\ \[&C_A)O^#EC_H\/]H#_ ,5:
M?!'_ .=C7]JE% <W]U?=_7G_ $M?XJ_^$F_X.6/^CP_V@/\ Q5I\$?\ YV-'
M_"3?\'+'_1X?[0'_ (JT^"/_ ,[&O[5** YO[J^[^O/^EK_%7_PDW_!RQ_T>
M'^T!_P"*M/@C_P#.QH_X2;_@Y8_Z/#_: _\ %6GP1_\ G8U_:I10'-_=7W?U
MY_TM?XJ_^$F_X.6/^CP_V@/_ !5I\$?_ )V-'_"3?\'+'_1X?[0'_BK3X(__
M #L:_M4HH#F_NK[OZ\_Z6O\ %7_PDW_!RQ_T>'^T!_XJT^"/_P [&C_A)O\
M@Y8_Z/#_ &@/_%6GP1_^=C7]JE% <W]U?=_7G_2U_BK_ .$F_P"#EC_H\/\
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M3_P>ANR_\%./@9M9E_XP)^%G0D?\W$_M0^E?Z:U?PR?\'-O_  1P_P""B_\
MP4._;L^%'QD_9%_9W;XM_#7PU^R/X"^&&N>)%^+OP)\ FR\<:)\9?CSXLU+1
M/['^*'Q,\&:]<_9M!\:>&;_^TK32KC1YAJ7V6WOY;VSO[>U"HO5]-':_<_SX
M)3&VH!9F&/L8(#(7&?/(!QR,XR,]?SK_ $%O^#8?XN_M:? [_@C3\7/%/[)W
M['+_ +;_ ,3M0_X*;^/= UKX4R?M$_#C]G ^'_ =W^RO\ =1U'XA#QY\3=.U
MC0-5&D^(-)\.>&_^$1M((]8OCXL.LV\RV6AWZ2^5_P#! '_@WP_:>^!'[9_Q
M*\;?\%1/V"/A'KWP#U']F'QEX6\(6?QHU/\ 96_:/\*Q_%^\^*WP:U;0+FP\
M#Z3XS^*%UI7B!/!FC_$"*U\5OH-G;V.G3:KI#:O;R:Y'9:A_<[\&?@!\"/V<
M?"]_X(_9Z^"?PD^ _@O5=?NO%6I^$/@S\-_!WPO\+ZCXHOM.TO2+WQ)?Z!X(
MT;0])O-?O-)T/1-,NM8N+234;C3M'TNREN'MM/M(H0<FKZ+\=.G_  VEC_&:
M7_@JU_P5 ECN"/\ @I#^WLDPMYF\H?MA?M#'RR!A6$@^(87/W6!&"-WL:+/_
M (*J?\%1A:O)+_P4A_;W;*,0S?MA_M",1M,F2/\ BXI/''IT&*_;']DC_@U5
M_P""@?C!OVFS^U_^SKX\^% \-?LB_&?Q;^S ?A_^T%^R??GXC_M@:+_PC0^"
MGPI\9_8?&OQ(^P^ ?& N?$Q\1:A>?\()8VQTZS^T?$CPOO3[=Z]^QC_P:>_M
M1^-/@)^W'K?[:WPD^+_P@^/7@/X11:O^PAX'^'?Q\_97U/PO\:OC#)X-^+M]
M<>%/B;=:?J'Q0M=+T!/&VD?!_1UN-1\7?": Z=XKU^7_ (21X[>?5/#8.\7;
M_@)]%]W>W;T/@']B[_@XL_;'_9D^!'[<GPE^+7C_ /::_:K\:?M3?".W^'?P
M<^,7Q&_;(^*D7BC]DCQ1'X-^+OAM_B5\-$\3:+\1=6DU^75OB)X7\4,OA?Q1
M\-=0_M'X:: #KS7+:=J&@_$FM?&C_@K5^V#^R5^U-\1_%/[3O[77QQ_9-_9[
M_P"%'M^TU9_$O]KOQGXK\$:,OQ;^)<6A_!4ZW\,?B!\4GOO'?]I?$CPS;3::
M/#GA+Q2?"^KZ38>(-8_L.*VL]2'V O\ P; ?\%PL'=^Q$RD]=O[2G[(/O_U7
ML]J_J*O_ /@W9\7_ +/G_!"W]J[X"_LS>&OB]\0/VX_VY?A#_P $^-6^.7P6
M^(7Q6^ W_"->$_C!\"/BYX(^)7Q*\*_#3Q=;:?X!\$Z9H/AJZ\3?%-7N?$7Q
M*\;0:UIWAO0;7P[XDU2^E6X\0 >ZM%9:[[]8]=?/YH\]_P"#,#X__'WXO^$/
MVY_!7Q>^-OQ>^*7@SX->&_V*_"WP=\)?$?XE>,O''ACX4>&)-+_:1TF3PY\-
M= \2ZUJFE>!-!?2O"WA?3'T?PO::5I[:?X;T&R-N;;1]/BMO[@J_D;_X-8/^
M"8?[<G_!-]?VZ8_VS?@B?@XGQ@'[,*?#,M\2_A#\1#XD7X=#]H5?%Y/_  JG
MQ_XX&CG2!XX\*Y_MT:5_:']J?\2L7OV'419_UR4$2=W]WY!1110(**** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M%OX/_P"$?@U2WU_4=5_:(O="U"UU,6&GZ3J/P(^,MQ>:HFB7WP-U?XU_T7_
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MPW>?%;QQ::'\6IO$/_"%ZQX$^'WP=O-(UO5-? _K=>7^?E^#/[LO@S_P7/\
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MK@%M>EM-4_3OZ_U8_P!<&BOP&_X?X)_TA>_X+\_^*XI__GO4?\/\$_Z0O?\
M!?G_ ,5Q3_\ SWJ M_5_Z[_U9G[\T5^ W_#_  3_ *0O?\%^?_%<4_\ \]ZC
M_A_@G_2%[_@OS_XKBG_^>]0%OZO_ %W_ *LS]^:*_ ;_ (?X)_TA>_X+\_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7^<W^R
M]<?\%5OVS/@5X%_:4_9J_P"#;'_@@-\1_@G\24\1MX)\:#]F/]G+P=_;*>$O
M%VO>!/$./#GCW]J_PMXLTT:?XK\+ZYI6-6T&P^U_8?MUB+G3;FSO+C_1DK^0
MS_@E]_P;U?';P;^PM\"_#?[2?_!0C_@KY^QG\:],C^(R^-?V:_V7_P!O;P7X
M8^!?PV:Z^+GCV]\/+X%T/P)X/^)'A6Q7Q=X4N=#\=^(_[+\::U]I\7>)]?O+
MXZ?J5Q>:58@U_ETOU]5_6G4_?K_@F!X9^.?@_P#89^!_AS]I/]E[X _L8_&K
M3A\2O^$T_9J_9>T'PAX9^!?PV^U_%_Q_?>'1X&T3P'XT^(?A2R_X3#PG=:%X
M]\2_V5XPU?[3XP\4^(+N^_L_4KB\TNR^^:\!_9>^ A_9A^!?@;X&GXT_'[]H
M<^!_^$E_XO#^U#\11\6?CIXP_P"$E\8>(/%^?'/Q 71?#PU\Z!_;_P#PB_AK
M&CV?]E>#]$\/Z+^__LW[3-[]0(**** /@7_@JW_RBX_X*3?]F"_MB?\ K/'Q
M%I__  2H_P"47G_!-W_LPC]CW_UGGX=TS_@JW_RBX_X*3?\ 9@O[8G_K/'Q%
MI_\ P2H_Y1>?\$W?^S"/V/?_ %GGX=T#Z+U?Y(^]Z***!!1110 4444 %%%%
M !1110 4444 %%%% !1110 445_/!XC_ ."&?_!*[2OVD_@E\!;#]E'38?A5
MXP_9B_:B\2^(O#;?%;X[3W=_K?PV^(?[(/A3P7>IXJN/BA+XQL/['T'XK^/K
M*2UTWQ!9V6KOKD5]KEOJ6HZ'X>N])]'+L-@\54K4\7B<3AN3#8FO1>'P=+&>
MTEAJ%7$2IU/:X[!>QC*%)J-2/MGS-)T[:GCYSCLQP%'"U<!@<%C55QV!PF(6
M,S*OEWL:>.QF'P4*U%T,KS/ZQ.%3$1E*C/ZK%PBVJU[1/Z'Z***\X]@*_$#X
M!?\ !6SXI_&WQ=\%= N/V6OAIX5TCXNZO\.+6?5+?]I_Q?XAU?PWI7CZ71C+
M?0:'+^RGX?L-<U'1['5FGBTJ3Q)HEKJ=S;K:/K.FQSF\A_;^OSC^$_\ P2__
M &?/@YJGPTUCPOXE^+5[>?"N7P;-X=.N^(O"EU'=OX'338])_MB.P\#Z9]H$
MZZ7;C4!9'3_.WS&W-H63R_S+Q$I^)U3$<,?\0[KY=1P\<PJOB=8]8%RGE_M,
M%[)8?ZY1JR4U36-O[!PGK"[;Y+?JGAK5\*J>&XJ7B7A\TKXF66T5PH\N>.4:
M>8\F.]M+$_4Z]&+CSO N'UA3I6C4TW3^"O\ @X&_X*8>+/V0_P!F[Q#^S-^R
MIJ&@^)/V[_VC_A#\<==\,>&+'Q_J/@OQ[\"_V9OAI\%?BM\1OCY^USI^H:-?
MZ#/HVN?#GP7\.?%%M\&8;OQIX.\0>)_B5;W.O?#>Q^)]_P#"?Q=\/-2VOB-\
M>_VCO#'_  ;.Z7^T1\/)?'WQ2_:-N?\ @D)\)_'.H>.Q\79_!7Q1T[6_%W[,
M7@V7XH?M&_\ "U]=NIM<O/'OPBT+6O%O[0!>'4E\<>/O$'@H^'O#NK6_C'Q'
MIFH18O\ P6/_ .#?3X!?\%7_ !3K7[0^M?$OXP>#/VGO!G[,FI_!;X&Z;I/C
MCPGX9^ ]QXF\/ZC\3O''PTOOBQ8S?!SXA?$"?0)/B%\1)(/'5UX1UJVU%_!U
MK'#H&EP:U UW>^]_LF?\$E]-_9R_X(V:[_P2ZB^)_B"W\3?%;]F#XO\ PN^*
M7Q-U+Q+XI^,'ACPI\8/VC/AQKF@_%3Q!\)_#'B6?P#;Z5\(_#7C7Q3K&K> _
MAQH&E_#*WU?3;=M?\6J?BCXR\?\ CKQ!^FGY6?F)^Q+_ ,%@_P#@J3K/P!_9
M%^ 7A+_@CE\8?VI/VA+']B/X!?'CQA\3/%/[>7P3\.^%OB1^SWXS\&^%_!7P
M2_:5\2?&;QCH/B"TLOBY^TWXU\'_ !L\1:O\!_B/J&D_%CP_IO@BX\4QZC\1
M4N_'$WP^_3OX^?\ !8KX-Z%_P1C^(7_!7C]GK3]?\:^!YO@[/KWPCT#QCX.N
M+/4;;XO^(?B#!\!/"WA3XH>%7\6^%)3H/@;X_:G:^'OBW<>#O&]S#=^%_#WB
MG6OA=XC\96TWA?4-<_.;]G3_ ()N_P#!>C]F!?A1\9?AS^T3_P $R+OXV?";
M]D+X'_\ !-^R_9^\2Z)^V3<_LM^+_P!ES]G<ZKXJ^%O[07CKQ?H7BGP]XNUS
M]KO0?%?B+Q=X)M].A^$EA\.]-^'OC;QCJOAW7="U+Q'J?AB?]5_#7_!'3]DK
M0?\ @EG<?\$AM3U'XO>,OV79O#7BO0(_$/B7QCHEK\8[2^\1?&+6/CWI/BRW
M\5>$/"'A7PLWB'P+\4M3LO$7A6WN_ UUX6O(?#VCZ+XW\->,M$GU_3M<!_U_
MGI_5S^8__@B'^UQ^V7XE_;W_ &2[7XX?\%2/VF_%>K?MP^&OB+\;?C-^PO\
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M\M]IWB+3O"OA6XTW2?"VMGX@:O\ $<&NO_!W_P"&N>__ /!$7]H?XP_M7_\
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M_MCQ#J&DZ!I/]JZ]JUA8?VEK>J:;I%C]H^U:E?V=G%-<1@'[-?MS_P#!R_\
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M$NB7'B?XF:?\'O%?C/X;)XET\:II/AKXD_8P^%+> /BE^Q;^VU^T9\-FO?\
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MG3M,^(OQMB_X:]UKQ;JOPM^+?_"H/^$>\,6$'BW0/%^I:F!]Y_3S\!?V]/\
MA?'[4GQJ_9>_X8P_;Y^#7_"F/^%A'_AHGX]?LZ_\*[_9;^+'_"OOB#H_P_\
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MA1\>OB+8?$+XPZ;:_L[^-]<\,>!/B_XF^.7PS\6>&/#OB?P6_B#QR#Z=;_\
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M\<>%M5T?1[G1VTNT^W*_(?\ X(+^'OV=/"W_  2,_8HT?]E+XB^/_BO\%4\
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MB_VK]K_LO^VM6^P^1_:-YYWOE%% !1110 4444 %%%% !1110 4444 %%%%
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M-/\ 3_\ P2I_Y1>?\$W?^S"/V/?_ %GGX=T!T7J_R1][T444""BBB@ HHHH
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MCWP-^W[^QO\ M"_L>_$.\_LC0/CE\/;[PWI_B;[-J^H?\(/XYTR\LO%/PO\
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M=X3^%G_!3<^"_BA^R%^UW\9OVP/AS\7/^&,='\1+_P )O\3/#O[(>F^%K%O
M'B']H_4- ;_A7FO?LG:=XC^T:Y>>)-'\6CQ>='U/PQ96>@S2>(@--/77TT_X
M)\7_ /!6?_@JW_P59\1?\$JK*;]H+X&?M-_\$O\ ]LWX)?\ !2/X9_"'QY\1
M?@MJ'Q<^!?P=_:!^'WB;X3?M?WMLOP-^(EEXWO\ 5_''AO1-6^&]A!\0=-T'
MX@_$SX;ZO-8_#+XI^%?'6K:;X_TKPWX'U/VF/^#P;]HGP]\5M9^)/[,'[/'[
M(/B_]AGP)\?[[X(2GQ[\;YY_VJ?CQI7AOQ%KFNO\5_ _PO\ ^$R^&OQ=^"/P
M^^)OPEC\/_\ ".>*?&W[+'Q/\#?#;XA3WV@^)?''C+Q,Q^'>G?I'\6O^#9?X
MR_'[]DOXD_L\_'/_ (*S?%[XK>-_B;^W%IO[:%YXW\5_ >W;X/>!M0_L?]HJ
M\\;^%OA#^S1I?QTT[PQ\*M;^+?Q3_:;\?_$SXG>*_!WC/3?"^O3Z7X.T6P^%
MVCSZ/>:_JO@'BO\ X-!OL_BSQ4GP0_;G^$7PG^#;?M0:S^TI\+/AAXK_ .":
M?P;^/OBKX=Q_VA,O@KX1>(OCK\6OC+J_Q2^,OPA\*>&$TO0-8^%?Q*U35?@]
M\0]0L+GQ=XR^&-_XBUC4KF8#2R_KHOUN?VFT444""BBB@ HHHH **** /Y*?
M^#GK]L_]IW]G7XC?\$N/V?\ X)?%_P#:=^&?PH_:]^+WQ(\*_M%Z#^Q9I^@Q
M?M;?$CPMX#^(_P"R=-H?AC]G/Q=)HUUXW\._%Z]M_&GBS1/!.D>#O$'A^P\>
M:WXCM?"7CFW\1>%[^YTB3T7_ ((7_P#!0KPEX4_9?_:BN/VV?^"CWAZ/P1\(
M?VV_B?\ !/X4>$/^"B7CC3/A7^W9^SCX8N=>\>:IX$^$G[;/Q*^+7B+PCI7C
M3XQ>,-)\(^*]?\.>'_#VCZ_9>$W\%?$_PEI'Q4\2VW@[4?@W^SA]L?\ !7+_
M ()#^.O^"EWQ2_84^-?PM_:]/[(OQ1_8-^('CKXH_#CQ1_PH+1_CX-1\;^)/
M$'P5\4^%M9;1/$7Q*\!Z!:CP7KWP8TZ^_LW6],\7:1XD&J&UU/3X;*RGM]4X
M#_@G_P#\$#?@G^S+'^V#XA_;/\9_#_\ X*7?$S]M3]H'1/VBOBIJWQS_ &7/
MA'H/PLL?'OAT_%._L/%'A;X*:I+\3O#^@>/+W7OCM\8KC6?%.D:SI^DKX>\3
M:5X5\*>#_"-EI>MW/BL'T_KR_KIZ]#\"_'7_  4E_P""JWQ,_P""A7_!:_0]
M"\:_#V__ &;_ (/_ + G[5_B+X=>(?A9^TG'HS? S]E1?V2_C/\ '#]BK]JK
M]F+P/\._VE;#0/B;X^^/.OZY^S=XX^)O[2ME\.?C=\1?A?\ \+$\*^"](\3?
ML\>#O$&C^"HNB_X-Y_\ @MI_P4+\5_'S]@O_ ()Z_M=>$?#_ ,5OA1^U+\&O
MVB?B3\&/VF?&WQ!\=^,OVG?%%CX)\7_M&^(I?&OQ*\9^)/B1\0[7Q9H&E^,_
M@-\7O@9HG@C6/"/PV\4Z7H.E>"O$MIKEYX8\/6%KX_\ V4^)/_!!#Q)K'[7'
M[;_QZ^"?[7'@#X ?!']N']D'4OV-O&'[-/AW]B+X7:]_P@WPOL_V+%_91^'.
M@> ?C'-\0M%\6>!? /@3Q7I7@CXSWGPR^%>B_#/P[XY'P]\&_#KQ1/<:;X;\
M/>(M&X?]B3_@W,/['/[47_!-O]I/_AL;_A8W_#O?]G_XW? L^"_^&>O^$0_X
M6[_PN3Q]^V5XX_X2G_A(O^%X>)_^$!_X1S_AK?\ LO\ L3^PO&O]K_\ "O\
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M;GQ-^$7_  4WUK]MWXP?#OX^^-+;XU_L;_#/POX4\._&'P=J'Q_U+7/'VG>
M]8\8?%GP4NO>*+C]H3Q9%:3>&]!\&P>$M.EU31]&@?2==DLK$#3IV7??2_\
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M_A4D^H^%]536_P#@U0_L_P"''_!-(?!W]O)OA)^TY_P3D_X3P:-^TN/V7_\
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MT[Q;\-_"7Q#\"Z)\5=+LO$&A^+/AGH<OCG5OBA\._B3XQ^$6@_KS_P $>_\
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MMV%S#H.EZ9XNUE/L-M+JLUQ\XZ1X2\7^(UDGT71]5U6&V7S+K^SK"XNA'&K
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *_SW?\ @K]^T5X3_8R_X+^>.?B%^P]^U]^US\-_
MVUOVA_A[\$_@7^TSX(^#_P"PA\#OVO$T4>+/AIX2G^'7@?X+:3\:/BK\+_\
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M<> *!K9^GZH[:OP7_P"#G(@?\$._VW2PRH7]F\D>H'[7/P$R/Q%?O17X-_\
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ML3D688BKAZM+#5,?@YN&(I8:K/2LJ4XVG4@[)V7D>)7^F7RS-.82/.<D#!P
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M50P&.KX*OA,*\/AJ]6GCL7S?4Z4J5)SIU<32BU-X2FH\U65/514FK:'[>?\
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MGXH\6^"?#/[ W[0&@?'?X>^'M>_9F\#>/ET.36/A!XAU36?$=YHVG:OX2O/
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M** "OX OV7/^38_V</\ L@7P:_\ 5<>&J_O]K^ +]ES_ )-C_9P_[(%\&O\
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MY_P3XU.?0_'WB&;Q-?2Z4=&TZ>4Z;J4Y-NWV>!I"NQG96$@&2. 5/3K7U7\
MOVQ_#LOQI^(_P\\1:(;RZ\2M%;^$+S1[>V,4#PO?1SF1FGB>,OYUOMV+)T;.
M#U^-XMQN'X8\5_%;-?"OC/%\85,-P[EF:K$Y=E=; Y3B*F/4HYEGN$I8CVL<
M5B*=-U*&+H1Q=&@\/SRII1/\[O%/"X3A_.>/,_\ #C@C.LP\8<GPV-XQXJ\2
MJ?$-\+B_]:L?"4*N2Y!6PM7#T993@:F*J9A4AF4X8O#>T<*5*R3_ #-^*WCK
MXL_ SQ!XE^#T'C._U+PQX?U&]T33H;B668?8].N)+2#?Y;Q1[DBC4;EC5"/X
M1D5T7ACP#X/\%? R+XS^/O$VHW_Q1^*J:E<?"CX>^&M5MK*#P_X5TS5-5\/:
MW\5?BO/]CN]0@MY]5TR_L/AMX)L;C2K_ ,07^G-XHUR[?P=';:=XB_KS_9H_
M8A_8-^'_ /P3:^+OQQ_X*9^-/AE\*C\:_P!IK4?BY\ /$7Q#GN;G4K'6OA%H
M?C/P?\- OA+3Q'XA^(^AZKK&J>-M4\2?#G21=Z;XOT%[*UU,PW,-M/9_R>?#
M*;5OC[^V5K7A#Q3XU/Q[G^(_Q ET]/B5I.DZ_I.F>,(]1OH-.T_6[31?%.D>
M'=;\/Z2MD]K;Z?H5WHFG)H=A:P:586JZ?96N?Z9X"\8<CXC\.^+\RP67T^#I
M<+T<KJ\:YWE'#48X3B>EAL)2K8NNLX]A#+9UZ>(A6AF,*E:EBL)]7IT,/'%T
M,=5Q6$_MCP\R?*,!P+EV>YGPO3SW-^*N#</F+P?#F#P%#,L]SW,<%0G@J\L)
M:-.K4Q=:K2KKF4HU9U%[T6M?@/QAK<FJZFMTLK3JA97F/5R2,D\GT)QG\J_;
M?XX?\$1?B+^SY^QA^SA_P47^)6IZOXX_9+^*7[/?@CXQ_%&U\!WFC>&?B5\/
MO$OQ3L=*A^$O@BU.O67B'3;G1_'6O^-/ ,+>-%T?4$T#2+SQ+/>Z%/?:;HUK
MKGMO[5G_  2-LOV>_A#=^,-3U71[Z]UJ^F^S:5IDTS:C9P((7DB(GLX(A.8K
M@I&5:1%D7+?+UI_MH?\ !;K_ (*!_$[X 6O[,/PXN/!O[,7[*WA?X?>&_@[H
MOPQ^&EO<7WQ U/X7^$-%LO"6B:#XS^(^M1MJ5S]L\/:=86GB&U\,VGAO3=31
M;RTDMVTN\FL7Y:7CB_%G(N&:OA%Q7D&8\$9SF6)R[CS%\2UZ>#C2R:AAH99-
MY2J="IF%#'>UQ%;$Y=B,!A)X>AB\##Z]*>%J^SK_ %%*HN$,TQ7"/&^1YEP5
MQ-EM#+)X+)<W>%6-Q-+,J,<5@\3"&$K5J-3#2]ZC4?.HTYJ5.\9Q?+_/+\5?
MBOJOQ8UOP]=3^&_"/@S1/!GA#2? 7@CP9X'TRYTWPYX6\+:3=:CJ:VMNVHWV
MK:WJVI:KKVM:[XE\0:_X@UC5=8UKQ!KFIWMQ>+#);6EKYD[L[F"*/+K@RN02
M<9P3V]?TKI8]%A;S+P7$:MD_*3@ANN#P<=1^=<N+N>&>=5VMO^20CKR0,CC_
M #Q7NYGP9B/#S+,CP^<MY;E.>8O%++JF6?5,T=;*J<76IU*;A7=2AB<;5G3E
M6K34ZJHRJRDY2NCZ:GB%BYU)4K3G3A'F4VX>_HK/2THQ6R5E=+;09<FVCEAV
M/O<LBRKD$#D ]!UP?\?6O]K3_@EIC_AV/_P3GV_=_P"&$?V1-OT_X9^^'N/T
MK_%3-C96JBXDR99QE4 Y#-TZX] ?\:_VJO\ @ED,?\$QO^"<HQC'[!_[(8QZ
M8_9]^'HQ7\9?2RP>8X/+^&WF.&R? U,9G&-Q4,ORRN\35P5"67898>6,J<JY
M*V.H\N)J4FTX5%+W4?39#.$H8GD=22C["+G-64G^_ORKM%W7IW/O"BBBOXC/
M?"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M>+X-8_LK7XM5T33?TWH$%%%% 'P+_P %6_\ E%Q_P4F_[,%_;$_]9X^(M/\
M^"5'_*+S_@F[_P!F$?L>_P#K//P[IG_!5O\ Y1<?\%)O^S!?VQ/_ %GCXBT_
M_@E1_P HO/\ @F[_ -F$?L>_^L\_#N@?1>K_ "1][T444""BBB@ HHHH ***
M* "BBB@ HHHH **** "OX OV7/\ DV/]G#_L@7P:_P#5<>&J_O\ :_@"_9<_
MY-C_ &</^R!?!K_U7'AJOZ.^CG_R..)?^Q;@O_4JH?SY]('_ )%/#O\ V,<7
M_P"HT#W6BBBOZR/Y:"IK?_CX@_Z[1?\ H:U#4UO_ ,?$'_7:+_T-::W7JOS
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M4K3]O)UIV527*K(_2.'\3*M3FY-1I48J$O=M44UUEZ)6T2_*W^W9_P $K?\
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M_%NG^+;K;>Z]<HOUW7P)_P $O?BY\=/CK^PO\#OBK^TI\//C_P#"GXU>*O\
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M_P"47G_!-W_LPC]CW_UGGX=T!T7J_P!#[WHHHH$%%%% !1110 4444 %%%%
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MD_#[P+\3M1L/[2TC2O(\"_!/XT?#3XS?$_6_M6N:AIME+_PC7PU\!>+?$?\
M9L-S)J^M?V5_8_A^PU77K[3=+O/VNK\%O^#G3'_#CG]M_=TV?LX9^G_#7'P$
MS^E=N6J^8X!>YKC<*OWBO3UKTU[ZZP_F757)E\+WV>V^W3S/\D&,6,5H)S Z
M* 3C YP3R.>Y]_RKM?"FI12I((@R+\H 8#D_-TY_SZUQ(5;NWQ(^VWCSZ $*
M3D9ZG\_I5S39)5F1;%3Y:,-S*,YQT/<>N/UK_9SPBXUQW W'W".;Y;ALO_LA
MY?0PTL)E>78>GG.<5ZU!T,1B</1PSO1P6'<W-2E)*<%=Z)H_.\?AHXK"UZ<W
M+VG.Y7G.3ITTFG%-RWF[;*^KVU/T-_9Y^.OASX6Q:E;ZSX>O]5GN;:1(FM+>
MWF)9D( 'G3QD*<888Y0D <YKY;^,GC27Q5XPO]9@M9=+L[W!@L[A$CD0"69\
M[$9T&0X& QY!SP>?7/V>IM#G\=Z/I^OVL-\-6S9PQ3MY:F=K6;8,AE^8L!C!
MZC'.<5Z;^U9\&;G2O%?AZVB\+?V-IEQ:6T[7T8F\F6.6>Z ;S78IT4<[NP]1
M7ZKXR<19QPMXQ8K(<@RO/*-;C[A>CG>"Q^79Y6H87&8/#SJ5<S6>Y90J2C6Q
MU#V/+AHTH5')<J;B>IFWTJ^/^,\%X9_11SVAE-?AC)*^(S;@VHLLRO"9@\7B
MG+#UX/,6XX[$T:<_CIV<(\_M)WY=/S;GN;L7/R@I@Y);/S>PZ_7)_E74V][<
MM%;^7$ROQG/0_,?Z8Z__ %ZO>+](BTO5+NSM,7,< _=31G>.#C[PSGUP2:JZ
M%>&XB2%DQ,FX E<'.21QCZ#I[]Z_-?"2&)GQ96P7^MF?8:EQ9AI8_*IXG+YT
M9U9X?&T8RPM*G7C%83'<JDHQI75:*O5:DVC#B++:^48K%Y=C,/AGB\IQ53!X
MM4*T*U%5:7NRE"K3;C5IW6DU>+OIH=-:7$\H2'[DK>IQCWY_SFMN2"6QMFB9
MD9Y#C<.>WN ?YG@US\;[9"7!253CICUQ^/I6W82E]QU-LH1\C.0OS$X'3&>,
M_4?05_ICX>8RABJ4\JQF+QE3.*]+$9=@<\Q5>5#+<FP3I^SQ/]KP6N&Q.)^&
M-6,9)36Z2N?G^+C)/GC&*IIJ4J<5[]22MR\FFL4NE]K',NSV4K3^>XD)'[I'
M8;CTQC(!S7VU^Q#I/A34?B#-JOB.ZM[&_P!--E/8I>!<7.7N&9$W$Y8%4_,5
M5^#?P-^%7Q,\,:[J6O\ B>PTSQ#9VFHSZ79RZHEM+/<6RSFTBCMS<1F5I6CC
M"H%;=N& 0<'Y.U&X\7?#_P 43-:QZC92:9>R"TNUMY$CEA@F^1@S1[)(V4#Y
MLL.<U_GIXTXS#<1?\1>\*\LJYCD&/X=S&%/+LWAEO]HY!FF;2K2G7S'$8BIS
M8G$4:M.FX>UP]*5"/M82;5F?!9WC<O\ $S*^-/#_ "C,L;DN?8?"0P&,Q>)P
MLL(DJUI0^I2J7CC<-.-.5&O.%W!3NM;'W=_P4#^/L?Q*UIO MKH-]I4^A316
MT%[+'#%9W,.GW*(LL)BFD=DEC@!3]V.&'3-?GGIDNJ:C+IFC:O=11Z5%/&6<
MY^6/(#9;;SD#IR/?M7I/BCXDZI\7+[2H]3L%.I$06C7\<,:RR.JJ&8B)%!=]
MI)RN<DGOBL[QE\.?$/A@6GF:3J/V2YACF%Y-;3I$6D=EVK*R!>P_BS@CIQ7X
M;X?<'<+\+\"\$X7BO!<687-L?CJKP_\ M3Q.3X/,Z--QCC>2%3W,%5O*>%JT
MH2G34G"458^D\)_#G&\*\"Y=PGE'#.,A'(L)6Q.85\%0Q6<8;+L1*"AB,QJ9
MC[.5/!PK.U2G'$2I\K;BD7_&6E>"X-0$'A_4H/)B0-(2!^\XY"A2V3G&#G&0
M<<U@W7A34[K17U:4F'3(8T>W:9I )E)4(8@5*@,"".>AZ5SWA/2--@\86MKX
MH41:6X/FS22M%&!O3&9-R@<%N"P X[CCW_Q-=S>(ICX9\*VDM_X9TR...W-A
M$;EGA@5?+8R0K)(XVQH2=Y!'))K^I/H_K-.*Z.;^&]>EB,7[6G.KA\_S+!8N
M67X:C4Q4:4*>.S>K2TI7E&O34;TU&/-)WLCHY,VPF89/D63K,<\KU*,,56QU
M3#_6'+#0?[R&&5!3E7QM3;V7+>-.\EL?*NNQ3FS18E(CV?.>1ZCI],9KAM+D
MM$OH1."45AE1@[N1P.0.>?2O:_%VGSVL<L$EO)9+"N&CFC>-\C/59 &'8<C'
M'TKPG3[.6\O5>&-FCA8.6&3P&&>WH?Q_2OYD^F/PCFO!GB]PI@LMPT^(LQQE
M"G2HX6K2J5L/B*67K#1Q$LLH4HNLL DW4E5J0C&KI+X'<_4>'JR>%K.NI8=T
M:EZD:D>6=.?-\%932:J)JSC:ZLTT?[;W_!*[_E&%_P $X<=/^&#/V0,?3_AG
MSX>8K_(M_P""KT")_P %1/\ @I!.V,M^WK^U^5'T_:#^(0_^OVY_.O\ 71_X
M)6_\HP/^"<'_ &87^Q__ .L]_#RO\B/_ (*P&:3_ (*D?\%) -Y6/]O7]K\(
M%!P"?V@OB$?3N<=?PK_.;PEQ.'PV=YNZN!ECJ\LGG'!02NJ.(CF. J2KS5]5
M3P\*RBK.]24$U:[7U>.3E3A:7(O:KF\TXSLE\[?*Y\,Q:E-YT2S95$QP3U0#
MC'/L.OO6E_:22749A)2$%0ZMQNYYP,D<COQR/QKFY$NE19I8V8+C'RXR#QZ#
M/!ZUHV4$5W)%-(XB5&&Y"VW.#D^G7./PK^R>%.,>,:N-AD5+$XB>,Q.99=F=
M&.<?[#C:F"A[*G"4L4W[*CA:2C+VM"BY?6(+WDCYVOA\.H^ULK*$X/V7OQYK
MIO3=R=])/9['K7AS4YM!O(]<TIH6F3;F&8<';DCY0",')^G\UU&\;7;_ %'4
M[K9!<:G.T\Z#A0[MO8*/3J.?UKF]\:1QK9%3M^_M;<3TQQD^Y_D:UK&WDN98
MI9%;RU8;\@JN2,<XQCDC'/\ A7^B/"N4</XKB&CB,#P]E]7/,5@:.'SC%8.>
M(EDN(CBJ<*.8YAA\7_$P]*CAG/Z["G#V=U-KN?$5L+0IUZF82BHXB5/V'MY1
M2Q'L*<HU*="?V9+VD5*%];V%D@N+:V"V1568D%CD#G W9 )SR?QK[#_9A_:*
M\/?"'^U=(\>Z/J&K:5>631VTFD6]K<R"?S86VSK=SVRB-HQ*K,I9@=O!YKYA
MU6V:U$*>7&B/&L@P^[@EAG.>.G;M^-6_#VD_\)%JMMHVDF*>_N_E2(ON'4*2
M>21@LOYU]SQSX/>&^<XBKC\YS_+\)EV2X3+I1Q;S.=+*Z=#"4W/%1RS"/EAB
M%4=J>)JP4J_)JHZGZUX!^,7B9X0^(61\7^$O)4XPJU:N6X#"5<MHYO0S2691
M>#6!Q.!JWAB54=:U.ES0:J\DHNZ2.A^*'B_3_&?CC7-=\)V]QI6FW-ZMYI_F
MA8+BVV1QX.89)-CK(A8%'..#G/3@]6\9:]J$%G'K^JW.I_V7+YMF]Q.TYCP4
M)4,YW8^1,\]!C-:?Q+\(^)OA]J\GAZZMEBO7MHKAA& ^$N(DD7!(/.V0<?UK
MQZY:ZE06]QNCE)X+#:3V]/;I^5?C7B-XBY/1P>4?ZNX7'YU4P.2/+,OSAY<X
M\+XW PHO 95E&5XBHXN3I86I+EQ%3DG-M*[;/FN-\GXAK\=\48CCW*Z.5\82
MXCS?&9_E^(P=+"8[+,YS#%U<3FM+ZM!7P*5?$5(/#4FHTH6II62/VS\"?\%+
MYO%'[.UE^SSXHT#6;F:UTJPT?2[RRAM)+4PV%H;*)7=KM)PA5@P7R2,YXR:^
M0?!WQD7]G/QY#?>(/#-S+H&H223O'%!!->&&Z_>LZ1SR11LR))N :0+D!<]Z
M^(-.\0ZCX8N[*]TV01W-IM(;9&_*X)R'5EZ@=5-:GCKXE:[\1)()_$-RMP;.
M)(H\0PP@(B! /W,<>?E ]3UY[U_!.-X%R;@B?$/#GA_F7^J62<4SQ&><:Y#]
M?Q=+"YAQ-F.'<L7B\GPJC4P^$IT54G#%U77IU;N4J,&V/Z/?AYX'_1_>>>(G
M!F3YY@?%:7'N6<9<.97+#8',_#Z>.P^(C6QF/SK!XO$1Q-3$5)Q;HX2G2J8:
M;G)S<&C]+5_:'_9_\2Z_H/C[2_#VJV^IZ7K"WE_;7UE91>>A>%\JL=]*HR8G
M)4X4;AVKZ&^-W_!3+P_\8;:/X8Z#X2N=*\-2VD.G-/:VMG%(YM(T9=PBNV)#
M-;KZ\'.!P*_ VTU*0-)%:RM @4 JIX/7U!Z?7O7KOPWM]-OEO;F[UA-.U&R_
M>61,L:/++MVMM5SER=S9XY_.OS_+_!'P7XKS;A'/>*L5Q;GTN#Z>(?#E+^W<
M9B,)//OK=.I.C@Z%.:JU,)5Q\**CA\33E"--5'M8_(?I"^&W#?C=XKY_X]^)
MF"_M#C+'YKBLZP='*J57+<FR7,LR^J15;+LDR^V&PU*C5PM&I3A!5%3;JS=V
MV>EWWQ'UCX9>,=1AT*TA>WU$"\ NU!?$KR)AL;L$"/GG&3P>#7)>+/$.B>)#
M%=S6\MM=,V^]RB",Y5LB,B3GYFS]T< ^O/NFD> /"GB'PO<:UXBU2&]\2_:&
MMK59+D1SBU58WB;[/%)&-HD>0[S&<G/)Z#YFU?3;2WU*]TBX=#]G/$@< -@X
M&"IP1S_0U_;GA+#(<^XBAGF-QU!^*$Z6(RW_ %;SO$8G 87$X')*:I83*,_I
M13IXC 3A*F\$ZL8-P]M>5SCX;ED..Q<JF&PF,H9QEE*G@\QS*%*M1_M+ZO&%
M%U:4IV6*HTN9*[A!J;1@)JL-A++'; O"X(CR!G##OSZG\/6O]I/_ ();-O\
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M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_S O\ @IS^Q_\
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M^"</_9AG[('_ *SW\/*_R>/^"NU_;>)/^"CW[>NEV%JT=WH'[</[8]G?2E5
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MT7PWXI\5^+-1\$:;XJMO!0\5^)K;P]!KM_\ LO0(**** /@7_@JW_P HN/\
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M?M:7/'%XS$N-5UJ3C&,'.JY)I,_)O$'%XO/,+F&99SGBP57'8>OE>5912R7
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MO[*,=7^]'_!Q+_P4Y^(7PX\=> OV4_V2OVG/'GPS\8^$QXL3]K3PW\-[#6_
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M?\,O%DGQ"^-^N:C\-IK+6? 5O:6L&OFU^'?PKU/XA10Z+\,]$NKS1/3OA/\
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M/ /P@^''[4>E:E\0/B?X@M?"?@?2=?\ AG\:_ 6G:UXGU"VN)M'\/MXI\?\
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M>+_ G[,GQVTOXC>,_ WA_3O%?B'PO=>$/B+X!UL>&=1U"32?[?T/3_B7X/\
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M5.G3IK:G"$%K)Z1BHK6;E-[;RE*3WDV[L****184444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !7\''_!<_6/">O_ /!53X_?#[_@I=K7PC_8X_9/
M\>_\$YY/@M_P3X_;-\2?L&:=^V)J.J>+]7^+O[,_CSXW:E;?V#X9\<>-)_B[
MX9M)/V@OA9X3GN/$/PXOOV;O"_C/2?BE\-]*\'>+_B]'X[^,7]X]?QG>,?\
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MX*TJ\U07WB;4_,UFXU&:U-G9R6]A:_IS0(_DO_X*V^$?^"J_BC_@LC^SU?\
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M<7AZ;R+ S=.AB:U*',\7F*<N6G.,>9J*3=KM)*^B/?/^&JOVFO\ HX+XS?\
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M *&M-;KU7Y@?U(_\$L?^48G_  3D_P"S#OV0O_6??A[7WC7P=_P2Q_Y1B?\
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M2A.@U3P"C'!^RK5Z%2A&-+V/+"M1JTZO*Z24)Q<VJB^-29^ 7_!/+_@AH_\
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M$4JMO:I*W/9M/^=VZ_X-TOV;_$_[$GP4_9E\>_$G5;_XX? "V^.-MX"_:O\
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M;;F**0XDW@-MP<9!(KACJ$5X]O9^4CSSR)! '48\R1@@&6&%&XCYCC 'UK?
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M_P!.YK^B+]F/X.:'\'?V=Y/$UM;:9XEOOB-%#_:JRP11OHXL(9BOSE[@MO\
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M/V6_@QX'_P"#8'XQ_M#6WA'2-?\ B]\;?CO\._BAK/CCQ/X?\)ZGXE\(:QX
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M>,+35?AY\0O MW?>'?%/CW5X_A5HW@/X8 UU7>R_%??Z']5W_!&WP?\ L<^
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M_P!G:_\ OIG[6-?@=7UW^W%_P4C\6_MJ>&?@KX#\(?\ !*W_ (+.?"M_A_\
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MB'_BNW]M;_YQE?K_ /KWP3_T5W#7_A[RW_YI/R;_ %(XR_Z)3B+_ ,,V8?\
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MAS1-2AUS2?!7Q+\$R1Z_JWCSPE\19O$7]OQ?%?Q;XH\7Z]JD<WC;Q?XYN/\
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ME_ KX;>!O"/PNUKXB^'?!OPX_99UG7-*EU7X0?"&70+#_A'-;^-4<&@V=GX
M\:_$_P"(/CCQ_P"$O".AZ%=^&HM?\3_#\#7L?W4T5^4O_!'/_@J=X4_X*[_L
ME:E^TSX=^$'B+X&:OX2^+_C+X*>//AWKGBC3_'-CIOBWPMHGA#QE;7GA;QK9
M:1X7N?$N@ZEX+^(7@^ZN+O5_!G@_4=-\4/XD\/1Z5J6E:-IGBKQ%^K5 !7R+
M\'?V+_A=\$?VK/VR?VP?"FN^/M0^)G[<*_L[K\6-$\0ZIX>N_ WA\?LS_#G5
MOACX#_X5YIFF^%M)U[2?[5T'6+J[\6_\))XF\6?;]72"XT?^P;)'L)/KJB@
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M#:LVHO9LX-V9&+GS!/\ @WA_X+L:QJ_@'4?%7[&WVV#X<^'[/PGX:M8?C_\
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MP1V_X*5ZO8^(?B'XA_8>_:_?Q'<7MSK%]IT?[,?QE@U+4=0U:[:XO7LM'MO
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M?O66EY<[OZ+4****_$#T#X\_;Z^#_P"T!\>_V2_BQ\)_V7/BC_PI?X[>*_\
MA!/^$&^)?_";>-?AU_PC7]A?$OP;XE\3?\5E\.],UCQCH_\ ;'@[1_$&@?\
M$GTVY_M#^U?[*U#R=+OKV>+^;;_AT!_P7^_Z2B?^;L_MI_\ SLZ_L,HKU<#G
M&*R^C*C0IX2<)5'5;KX:G6GS2C"+2E-74;4XVBM$VWNSQLQR/"9G7C7Q%7&P
MG"E&BEA\75H0Y8SG--P@TG.]22<MVE%;)'\>?_#H#_@O]_TE$_\ -V?VT_\
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M]_TE$_\ -V?VT_\ YV='_#H#_@O]_P!)1/\ S=G]M/\ ^=G7]AE%'^LV8?\
M/G+O_""AY>7E_6EC_5++?^?^:?\ AQQ'^9_'G_PZ _X+_?\ 243_ ,W9_;3_
M /G9T?\ #H#_ (+_ '_243_S=G]M/_YV=?V&44?ZS9A_SYR[_P (*'EY>7]:
M6/\ 5++?^?\ FG_AQQ'^9_*K^SQ_P2P_X+??#WX__ SQ_P#%C_@HY_PG'PL\
M#_&+X9>,/B7X*_X:^_:Y\3?\)A\/_#/C71-:\9>%O^$<\2_#RR\.^(/^$@\.
MV6I:3_8FOWEIHNJ_:_L&JW4%C//*G]55%%>9C\QKYA.G.O"A!TXN$50H0HII
MN_O*"7,^S>RT1Z^797A\KA4IX>>)FJLU.3Q->>(DG%<JY7-MQ5MTMWJ%%%%<
M!Z(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?Q(_
ML1?\&I7C/]GK_@K@G[7WQ%\7? &']B7X,_'OXF_'+]F'X&> O&7QR\6?%*QD
MTWQKJ.M_LO>&?&FJ>)M \$+H@^%#3^%O''B#6I/B1\6#XD\0_#JR\"^(=(\8
M^'/&WB#Q-IOR[JG_  :7_M0^"?V@/VG/$GPS^#G_  2A^,W[/_Q"^,/BW7?V
M=O!/[4?Q[_X*8Z7XJ^"?P?\ ^$R\87W@;PDES^SI??#"XU;7I/!FL^&=(\7W
M/COQE\5YUU'PI8S:'XB$ESK^I>(_]!"B@+L_AP^,_P#P;0?MR?$GQ=^VYXC\
M+>,/V(_AYHW[2W_!-_\ 87_9!^'/@70/B+^T=/X7^'7Q!_9FN_\ @FU<^-++
M[5XQ^$OCKQHGP@MK?]COXE:1\,]=UOQA\0_B5J^FZC\.I?'<$.K:MXLU/0>;
M\!?\&PG[>WA<_LFC4OB[^R'*GP)_X)??\%!/V)O&)L?'OQFE;4?BE^U>O_!3
M!?AYX@\-"?X VPO? &B_\-F?##_A,]4U1M&\1:?_ &#X]_L/PKXB_LOP]_PE
M/]V=% [O^OE_D?R6?\$^?^"<G_!Q'^Q1X,_80_9<T;]J#_@G#X&_8Q_9A^+-
MWJOQFT3X8Q?%/Q?\9/CU\'/'WQW'Q:^*/A77M<^+_P"S-K.DV/B&QTG6_'?A
MSX>77PUO?@M-'!XD"^*/$6H:C8Z1XBT;\BO!W_!H%^V%X+^'GP3O=1M?^"<G
MQF^,7@_XR?M$:Y\6]#^+GQK_ &W]+^#/Q+^#7C/X<?!+0?@)X4EG^#/@3X7?
M$/3_ !%\,?B#I7QZ\<ZC<>%=0\"2W]SXD\#6GB#Q+\0/#EO=^$- _P!$BB@+
MO^OE_D?C-_P10_X)Q^(?^"<OP"^*W@WXC? 3]B#X)_%3XD_&";Q/J=S^Q!X@
M_:=\<>$_%7P^TCP9X6TKP/!XW\<?M>>)?&'QANO$7A[Q#+\1WL?"MAKP^&GA
M[3M>_MCPQHVG^*/%WCV\U7]F:**!!1110 5_(=_P52_X-Y/VC_VBO^"GOA7_
M (*;?L9^-OV0/&7B+Q#'X6N_CC^SU_P4'\%WGCSX&:WJWP\\!>&/A/H^G:9X
M:T+X0?$^T\7^!/B!\-M%CTSQ3H?B+3_#?CCX=^+M,F\?_#7XGQ:]K_AD?"3^
MO&B@#^*S]D3_ (-&O".N?L7>$/V=/^"D7QGUX^-_A7^TY^T+\:OAQJG[$OQ)
MLX?"ESX8^/WPM_95\$:MIWC.]^.7[.3ZO<Z[INJ_LW17&GVNB:'IVGV>GZJ\
MMQJFL7-]]ET3YEL_^#8G_@J5\$OA!_P4A_8[_9E^+7[ 6H?LD_MU_$/X836>
MO?';Q_\ M$W7[1?ASX8_LW_&KQ%\3_@*MSJ'@#]G_2OAII/CS5;#5+*T^+IB
M\-^+O#]]>)=6_@T:'"(M1?\ OMHH&FT?QW?\$[/^#?+]L[]D?]M+_@DI^T9\
M2/B9^S%K?@C]@S]EK]H7X(?%_2_!'C/XJZEXJ\1^*_BS\4?^"@?C;PYJ'PVL
M=>^"WAK2-8\/66E?M6_#NWUN[\3ZYX.U*VU#1O&D5AI.I6VG:'=^(_B7]A__
M (-B_P#@J5_P3Q^*?[-W[7O[/_Q;_8#\4?M=?!CQ[^T,FNZ%\8O'W[1&L?LX
MZA\*OB+\&?#7PS^'8TG3_!7P \&?$RX^(%K?>,_C_>>-/MGB+3/#L-K!\'9]
M#-[)#XVT^\_OKHH$?R'_  6_X-BA\=_A7^VP/^"HOQ86R^-?[:/[?>G?MI^*
MU_8+\?267PL\/_\ "*>&_C='X1\/^'W_ &@?@+J?B[3?,\4?M4?'<^(=,U(>
M)_-T#2/A*-.\46^HZ;XQ/B+P&U_X-W/^"F7[&.D_\%&/V:O^"77QU_8_T_\
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MXX_$SXG>/]:^,-UX6\9^*CX ^(GA+5O#/PM3P=_8G10 4444 %%%% !1110
M5Q/A7_D._$O_ +':P_\ 5<> *[:N)\*_\AWXE_\ 8[6'_JN/ % UL_3]4=M1
M110(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M^('[:'CKQ/\ "/\ 99\'^!]:_:4@\1?L>?%/Q-KVO^!/V<[/]N&Y\;> =$\
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M-_!MOI6J?L_>%K[Q/X8\2V>N>&KSP7\1M6\(:6"TOY>5^_GY>1_0I\5?C?\
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M8?\ JN/ % EL_3]4=M1110(**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
AHH **** "BBB@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>gyowp0iggm03000013.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gyowp0iggm03000013.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" 'T!7,# 2(  A$! Q$!_\0
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M@_*C ]!^5+10 F!Z#\J,#T'Y4M% "8'H/RHP/0?E2T4 )@>@_*C ]!^5+10
MF!Z#\J,#T'Y4M% "8'H/RHP/0?E2T4 )@>@_*C ]!^5+10 F!Z#\J,#T'Y4M
M% "8'H/RHP/0?E2T4 )@>@_*C ]!^5+10 F!Z#\J,#T'Y4M% "8'H/RHP/0?
ME2T4 )@>@_*C ]!^5+10 F!Z#\J,#T'Y4M% "8'H/RHP/0?E2T4 )@>@_*C
M]!^5+10 F!Z#\J,#T'Y4M% "8'H/RHP/0?E2T4 )@>@_*C ]!^5075Y:6,#W
M-[=6]G;1C,EQ=31V\$8]7EF9(T'NS 5!I^JZ7J\1N-*U*PU.!6VM-I]Y;WL2
MM_=,EM)(@;V+9HUWMH*ZO:ZOO;K;O;<O8'H/RHP/0?E5&]U73--VG4=1L+ /
M]PWMY;VN_P#W?/DCW?AFK%O=6UY$L]I<074#_=FMY8YHF_W9(F9#^!-&N]M
MNKVNK]NOW;DV!Z#\J,#T'Y50O]7TK2A&VJ:GI^FK*VV)K^]MK,2-_=C-Q+&'
M;V7)J[%+'-&DL,B2Q2*&CEB=9(W4]&1T)5E/8J2#0%U=JZNMUU5^Z'8'H/RH
MP/0?E2YK$A\2^'+B].FV^OZ+/J(.TV$.JV,MZ&!P5-JD[3[@001LR#1KV!M*
MUVE=V5^K[+NS:P/0?E1@>@_*EK)O]?T+2I8H-4UK2=-FG($,-_J-G9RS$]!%
M'<31O(3V" Y[4:O9 VEJVDN[T_,U<#T'Y48'H/RK/O=7TG3;9;S4=3TZPLWP
M4NKV]MK6V?(R-L\\J1-D$$88Y!S4UM?V-Y;"\L[RTNK-E+K=6UQ#/;,@Y+">
M)VB*@=6#8]Z NKVNKVO:^MN]NQ:P/0?E1@>@_*LBQ\1>']4N'M-,UW1]1NHL
MF2VL=3LKNXC"G#%X;>>21-I!!W*,$8-;%&JW0*2DKQ::[IW7X"8'H/RHP/0?
ME61<^(= LKQ-/O-<T>TU"0J([&YU.R@O'+_<"6TLZ3,6_A"H2W;-;&:->P)I
MWLT[.SMT?9]F)@>@_*C ]!^5<GKOCWP3X86-O$/BWP[HPE<1QC4=7L;5G<G&
M%2297//!.W /!.:W-.U?2M7A2XTK4]/U*"1!(DUA>6]W&R'&&#V\DBD<CG/>
MG9VO9V>SL[?>)3@Y.*E%R5FXJ2<E?:ZO=7Z&A@>@_*C ]!^5+12*$P/0?E1@
M>@_*EHH 3 ]!^5&!Z#\J6B@!,#T'Y48'H/RI:* $P/0?E1@>@_*EHH 3 ]!^
M5&!Z#\J6B@!,#T'Y48'H/RI:* $P/0?E1@>@_*EHH 3 ]!^5&!Z#\J6B@!,#
MT'Y48'H/RI:* $P/0?E1@>@_*EHH 3 ]!^5&!Z#\J6B@!,#T'Y48'H/RI:*
M$P/0?E1@>@_*EHH 3 ]!^5&!Z#\J6B@!,#T'Y48'H/RI:* $P/0?E1@>@_*E
MHH 3 ]!^5&!Z#\J6B@!,#T'Y48'H/RI:* $P/0?E1@>@_*EHH 3 ]!^5&!Z#
M\J6B@!,#T'Y48'H/RI:* $P/0?E1@>@_*EHH 3 ]!^5&!Z#\J6B@!,#T'Y48
M'H/RI:* $P/0?E1@>@_*EHH 3 ]!^5&!Z#\J6B@!,#T'Y48'H/RI:* $P/0?
ME1@>@_*EHH 3 ]!^5&!Z#\J6B@!,#T'Y48'H/RI:* $P/0?E1@>@_*EHH 3
M]!^5&!Z#\J6B@!,#T'Y48'H/RI:* $P/0?E1@>@_*EHH 3 ]!^5&!Z#\J6B@
M!,#T'Y48'H/RI:* $P/0?E1@>@_*EHH 3 ]!^5&!Z#\J6B@!,#T'Y48'H/RI
M:* $P/0?E1@>@_*EHH 3 ]!^5&!Z#\J6B@!,#T'Y48'H/RI:* $P/0?E1@>@
M_*EHH 3 ]!^5&!Z#\J6B@"%OO'\/Y44/]X_A_(44 2CH/H/Y4M(.@^@_E2T
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M#'P^U[Q!!HVIZ_HGB'4;W4]'BN[Y;&"[CMI96CF0,P>;S00B G(K]T/VH/\
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M \]CXMM%L]3_ +2T6.VEFE6-,J8)([N(HP)YW \C%?H;7\AG_!H[XJM? O\
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MLAA=OO;0HXKS_P#X.&'$?[<?P:+QI*AL+)9(I!NCD1]JLCJ>&4ACD'BOCO\
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M5']?-%%%>2?;A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0(?%/@FXT?2-2O\ P_=JLEAJDMF\<\5MJ,#_ "W-FTMO"TL#_*VP5K_L-_\
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M* "BBB@ HHHH **** "BBB@#\6_^"\Y_XP!\>_\ 7Y;?RKX._P"#7+_DW_\
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MKOPV\+WB:?HDL=I*^H>,O$=[?".+5;33!NG@AMUE$?EE=QCCW-GDG]T_%/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M+_>/X?R%%#_>/X?R%% $HZ#Z#^5+2#H/H/Y4M !1110 4444 %%%% !1110
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MT[9J5A<7'DRWD!293/I*003R/9WYVI--$(1\K&2/]&/^#C;_ (*,?&'X)_\
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M;8WDDVQY=8T4,Q;[$_X*B_\ !&_]EK_@JUH?@BW^.<OBCPMXO^'<LI\)>/\
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MK$JOV*SDE!?[N[A1GN>6Z#GVH ^0_CAXLN-<\3/H,!)LM'=856,EA<7,AXD
M7J48A<\D 8]J^B?A-X+C\)>&X&N(T.JZBJ7-W, -VUU#11@]1A""PZY//2OE
M/X:Z1/XN\>V<LK^<L-T^JW9DRPE@WL^PGD<9&T$\"OOY0% 50 J@*H'0 #
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M%R/FV%2Y(..GR]CU_(?4E>+? FQ2U\$PSI&4-[,9G8C D(W+N![XSC\*]IH
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M EL'G@=:^N-$\/:1X=LX[+2+&&TA15!\M/G<JH4L[G+%FQD\XR3@"MD
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M> HO&/C3Q9;WFI'QO92W*/\ 9K30K*W?[!/NE4)B=&=@ZE0>2/YM/^".=_\
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MAU\6_P#@F+^U!I/Q'TO3M0L-!\":AXHT6:^A@:6PU_1X7N-.GLKB52]M.9E
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MZ5HKN]$D44D9M %\Z.3>RM"R.&8$$_M;_P $X_\ @JC^RO\ \%./AGJWC_\
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MS]"\%:#I:>+_  YI-S:^;ILNH^))M,OKZ*V:W.]O+DA6WB96+CDJ 9'[%_\
MP<G?!#X__M$>&?V7?VBO@9\4?V0_BUX^NXK'P%I?Q2T>ZTRSUF\N,"UM[JYO
ME@6R>]=A':%B?,?("'G'X8_\'-W_  5*\?7W[0W[.OP1\ >$?CW\))/V=/CZ
M=:\0^*;";Q#X3T7XM64<VE%-(T*YT^>UB\10O':L8;9_/@<W3!XG##;\X_\
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M 5][T4$'\JG_  :_?LY>/O#_ /P2K\;_  ;^/7PV\9?#J7QKXK^(^@ZEX?\
M&>AWWA[5[C1-?DU2PENH['4(H+E8I;:\9HGDC3=D'&"#7XP?#'PA_P %-?\
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MW#_,5[M^Q[_R!/%O_85A_P#150OC?I_D=4F_8I]>6'Z'U!_P@O@[_H6](_\
M .+_  H_X07P=_T+>D?^ <7^%=715G-=^?\ 7_#+[CE/^$%\'?\ 0MZ1_P"
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M.^()5%_&H%E=N0HND&!Y;$D NO&#U/0]J^BZ9RA1110 4444 %%%% !1110
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M?_%4?\-/_#;_ )Z:C_X#C_XJO@?_ (5K\0?^A*U__P  &H_X5K\0?^A*U_\
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MB#QY\;OBC]EL/^&B/']DOBCXC^+7E6,);:7Y=FFI:[>R2J@*R.D)E(W>:R#
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MEJVC7MOJ%A=1G^*&YMGDB?J,@-D9&1R* -RBO*O'_P <_@W\*[JSL?B3\3_
M_@>]OPILK3Q/XCTS2+FY#'"F*&\N(Y&#'[IVX(Y&1S6'\5_CSX$^&OP5\5_&
MG_A*/"MWX=T3PMJVOZ/J-QKEI%H>MW5CI\]W96$&I1RM&[7TT26Z>2S/ND'
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M+^_M-,M)[Z^G2WM;=#)++(P5551GJ<9)Z =2:LNZHK.Y"HBEF8\!54$L2?0
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MN VVIVT=M?W6G3174) *.MQ:2X]5P: /JJBBB@ HHHH **** "BBB@ HHHH
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M_P#H=1+XH_+\R(QE&$XRBXRC.SC)---<MTT]4UV9^K5%%%:',%%%% !1110
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M_B#;&U@N7%QKVN/'\0O%_FP>']%5TNM6N(_-BW16V6 =<]17]-_[*W_!QO\
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M_8R\*:9X?M-3\(V-O>ZEX?@U31G2X\3+K,%O'):V,=U GF^9?&-+@0F-'!E
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M9(H?#&OVG@*U&@:9IVN/KHTJUU[3;;3WB-K*+!B+E8BBR/(XV[&*U_1Q:_\
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M2,2NTJ 3_J/^&[B6[\.Z#=S,7FNM%TNXE=N6>6>Q@DD8GN69B2?4T ;5%%%
M!1110 4444 %%%% $+_>/X?R%%#_ 'C^'\A10!*.@^@_E2T@Z#Z#^5+0 444
M4 %%%% 'Y??M(?\ )3]1_P!P_P Q7NW['O\ R!/%O_85A_\ 15>$_M(?\E/U
M'_</\Q7NW['O_($\6_\ 85A_]%5"^-^G^1U2_@K_  P_]M/LNBN2\:>+]/\
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MR\*ZE\./#OAKP);:E=7.@KXBMC;3ZUJ236<39M$;]W9Q+)/*V\(A=55O=?\
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MQKXCU/&39VCR <]2"!^(ZCZ5\R_L[WMQJ5GXJOKN1II[C5%<NQ+':PRJ@GD
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M*CXS_L[Z-X4\!V'C?P3X_CU";Q5ISHC:G>R)#+]ALM//^M22:= @,>"2<#G
M/A'[*G_!1_\ X+)?$^Q^+7[0'[2O[+?AGP'^RSJGPCU[QY\/_#VK:?"-2T](
M8+B;3K77([A%FN(;VW\B5HKE>8W7<HSB@#]J_P#@EC_P4DT'_@IM\#O$7QG\
M/_#/Q9\,;;P]XON_"DFE>*K&ZL9KU[=KD"[M%NT262(+;[96QM61MHK].:_G
MT_X(X_\ !1_QI^U=^P!\9/VD]4^"GAO0]?\ AOXE\8V^F?#WX6Z'::6GB=M%
M;46M+>UL--0(^H7S6T<>X NS2,QZU^>6J_MQ_P#!RK^T+IGBCXU_ +]C+X>?
M!SX4Z!<ZM<67@+XAWUJGC_6=(TF60I]ATW42;RYOKZT$<R0IE@SD8 6@#^QB
MBOP>_P""'O\ P6 U;_@J!X%^+'A;XH_#?_A5?[0O[.^NQ>%_BIX7BDDELWG:
MYN+&+4(A(%\B9[NTN;>ZMT'EQ7$$J(6"[F_&GQ'_ ,'(7[:L7[:W[7_[#_P@
M_9AA^-?Q2\+_ !0UWX=? >/1HV2VTE-&U&>PGUKQ9-  JV<<"BY+W!:/. 2&
M#* #^W>BOXV?V9_^"Y7_  4*_9\_;R^%?[%/_!57X#^&O!#?'NZLX?!?CCPQ
M(D=AHAU#SY+-@]NHAU"-3%]BNU=P\<[QX!)++_9'%(DT<<T;!XY422-AR&1U
M#(P]BI!'UH ?1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M117EGQ*^)5AX(L&AA9+K7+E"+2S# ^7N&!--@Y1%ZC.,G'8T +\2OB58>![!
MH8BESKETA6SLPV3&2,"><#E47.1GJ1^!^2O#?AOQ)\4O$DTUQ--()9?,U/5)
M03';1YR88,G;N"DJJ+UZ]:/#?AOQ)\4O$<LTTTLOF3>;J>IRY:*VB+DF&$G(
M#8^41C'8_3[F\,^&=*\*:7!I6E0+%%$H\R3 \R>7'S2RMU9F.2,DX'% "^&?
M#.E^%-+@TK2K=8H8E7S'"CS)Y, -)(P&6+')P2<9P*Z"BB@ HHHH **** "B
MBB@ HHHH *CEBBG0QS11S(>J2HLB'ZJX(/Y5)10--IW5TULUHS@]3^&?@C5Y
M&EOM LY'<Y8HIB!)]HRH'^>U4K3X1_#ZR<26_AVU5P<@LTC\_1F(_P _2O2:
M*GDAOR1O_A7EY>2/1CG&;0I^RCF>/C22LJ<<7B%"W;E52UM-K%.ST^QT^-8K
M*TM[6-5VA8(4CX'J54$_B35RBBJ//E*4VY3E*4F[N4FY-ONV]6_4****"0I"
M P*L P/!!&01Z$'@TM% $4<$$1S%#%&>F8XT0X],J :EHHH *\B^-'B(:'X-
MNXHG"WFHE;:!,X+1G_7].>$/I@UZ-KFN:;X=TVXU75;A;>TMU+,Q/S.W\,<:
MY!9V/"J.M?#'CKQ;JGQ,\211Z9#-+;;E@TC3U4E@6^7[1*HY <_,Y/"B@#N_
MV>=$-SK>I:M*C>780(MM+R%:27Y74=B0.O<5]AUP7PY\(1^#?#5IIQ4"\E47
M%^W7_29%!>,-U*HV0*[V@ HJ.::*WC:6>1(8D&6DD8(BCW9B /SKPSQS\;]%
MT));+0-NKZJ&,193BT@R,&42@XD*$YV<9(P: /2?%WC31?!UA)>:I<()=I,%
MFC W-PV#@)'G=MS]YL<"OBGQ9XO\1?$[7;>VBAD:-Y/+TS28"[1KNX\^49Y.
M#F3</E&2*K6UGXO^*GB(R'S;VYF.);IPR65G"N1A<Y2)E!Z#[W<YXK[$\ _#
M;1_!-G&5C2[U9ES<:A(@,@+ 9CASG8J\C<N"U &9\,?AA9>"K-;V\5+K7[E
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M'6NN74$D]KI]Q>V2VJ7LUO&#))$C+O,:@L0<"@#^43_@W&_: T#]E3_@C/\
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MM@G# CD'D4 ;-%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MJE_&2KVEB0[1MT&]S\N,]=I/'>O$]0_:4UII&.EZ+9+%GY1=F3?CWV-UQ_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M#U_XJMI=7TZST[4/M.M>';/>MS8RW-](;F:=/+_=PL<%A7@O_!6_XZ_LH?M
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MKGB+7+V&PTK2["$9DNKN[F98XXU!&#DEB0%!) K\==)_X+Y?\$M?B7X^\1?
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M;*[9YRU?VNS!&BE61MD;1N'?=LVH5(9MYX7:N3N/W<9[4 ?CU^TY_P %Y/\
M@F-^R=XSNOA]\3/VB] OO%VF7DFG:UH_@U/^$FGT+489&BGL-7-E*%M+N!E(
MGA8LT1^5\-D#[$_9!_;W_94_;J\*WOBS]F?XM>'?B';Z2$.N:38W<2Z_H22L
MJ02:MI7F/<6D5PS*(97^1V.W(;BOYM_'GQV_X-NOV ?CS\8?AN_PD_X7S\=O
M'?BW7O%?Q%LM(^',GQYO(?$.LWTLVM0)J<RRQ:1B^:8&S@C+02F0*ZL68_F=
M_P $(OBE\(S_ ,%X_P!H5?V3/#7BSX8? 'XM>%[_ %+_ (5UXCTRZ\-S:?LG
MN=0AMV\/3[?LD$%T\LD$>T*A9"!DYH _L@\0?\%9OV"/"'COX]?#?QE\?_"/
MA+Q;^S<LO_"T=-\07D&GOI<T*L6M+,/,7OKLD!4MT17)=<X&2.*_9*_X+1?\
M$\/VU?'\WPO^!WQXT/4_'?G/!I?AW6]FBW_B"9)/+:+0HKB9CJ$G\:I& 7CY
M7)PI_D)_9P_X)X?!'_@H+_P<M?\ !3;PM\>EO]3^'WPB^(NM?$:Y\%6UP]OI
MWC6\^VZ-IMMI6MJ@*3Z?%+,;J6&0%7PP ).*]@_X+\?L:_ G]@C]M'_@G%^T
MG^RCX'TGX-^(IOB;X<\,ZQ8^#85TBPU$P:PMO:74EO:B-#.MHYAED;+2!Y,\
M.: /[F_C!\9OA=\ O 6M?$[XQ>-] ^'W@7P_ T^J>(_$E_#IVGP81W2$2SLH
MDN)A&RPPIEY&& ,9(_";XT_\%R?^"9W[4O[/7[7WP7^&_P"T7X:_X3'_ (9Y
M^+UII]MXC"Z/8>(;J;P?JEC!8:)=S221:C<W-Q=0QPP( 9 S8Z8/Y4?\'-_C
M;QO\>/C7_P $IOV#YO$^HZ)\.?VJM2\.:_\ $:VT^>6V_M.:;Q#HNBPB62,@
ME8SJ4TJCDAT4CK7Z+_\ !0O_ ((!?\$\+O\ X)W>/O#WA'X2:-\/O&/P!^#/
MB'Q7X2^(WAFVCL/$=]J_@;PO=ZM(=<NX(EFU&#69;!TN(Y3@><H)(4F@#SC_
M (,\U5?^"3.54 O^T#\5&<@ %F%QIR L1U(557)YVJ!T K^G?XD_$3PI\)O
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M?PXS7<0VMM;&0V]M! 96WRF&&.(RO_>D**N]O]ILGWJ>@#_-2_X)Q_M00?\
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MS&C%MI&*U/\ @Z>\#^//%WC7_@GK+X-\">,O&4>G?'7P]+J4GA3P[J6NIID
MUF)FN-0:P@E%G J@LTLQ5%4%B<5_8=':6D4TES%:V\=Q-_K9XX(TFE[_ +R5
M5#OSS\S&B>TM;KRS<VUO<&)@\7GPQS>6XZ/'YBML8=F7!]Z /X_?^#C;]B#]
MH_XA_#O]AW]O3]F;PMJ7C/XF?L6:;X9U#4/!VG6DESK+:+G2/$$][!81JUQ<
MR6E_80Q2V\2M*OSX1WVHWS-\;O\ @X&_;#_;L_9.\6?LS?LF?\$_OCAIG[0?
MC3X5:OHGQ6\3^._#6H6OA7P]X>&A2:;XWO-+2[L+87.HZO;RW3Z5:-/Y\8E\
ML@2 D?W1%592K*&4C!4@%2/0@\$>W2LRRT31M->>33M(TNPDN26N9++3[2U>
MX+?>,[011M*6[F0L3WH _F-_X-(?!7C+P#_P2RF\.>.O"7B7P9KUK^T!\4VE
MT?Q5HFHZ#J0C:ZT_9.MEJ=O;7+6[G<L<XC\J4HQC9U 8_LM_P4ZTW4]8_8(_
M:CTW1M,O]8U.[^$_B6*STS2[2:^U"\F:T.V&UM(%>:>9SPL<:EF/05]U06UO
M:IY=M;PV\98L8X(DA0LW5ML:JNX]SC)[U(ZJZLCJKHP*LCJ&5@>H92""#W!&
M#0!_-/\ \&K7A3Q=X0_X)GV&F>,O"7B;P;JK?$7Q-,-)\5Z+?:%J?DM>W6V4
MV5_%%.(WZJ^S:01@U\3_ ++W@7Q[9?\ !VK^UCXUO/ GC*T\%7WP5\16]EXR
MN?#FJ0>%+N9O"?AB-([;7Y+9=,N))9/,CCBBN'D:2"92J[06_LL@M[>UC$5M
M!#;Q#)$4$20QC)R<)&JJ,DDG Y)S35M+59VNEM;=;IAM:Y6",3LO]UI@OF$>
MQ;% '\(?[9OPW_:)_P""+W_!8?QQ_P %%_"?[,_B']I/]DGX_P"FSZ3XGT'P
M=HK^(M=T74]5MHUOY_LEO:WC6UQIEQ)-<03RVYBD$BM,RQH*^XO#7_!R%X"^
M*WQ'^%WPU_9X_P""9GQU\:>*/''B_P /:'JNJ:Q\/_\ A'M%\%6FI7\-K?ZM
MJ-_+X=B4'2X9#<G_ $BW7;$V&+;5;^MR>WM[J-H;F"&XA<$/%/$DT; C!#)(
MK*P(X((((XK)TSPQX;T5I7T;P]H>DM,YDF;3-)L+!I9"<EY&M;>(NY/\3$GW
MH _DO_X.9?V&_P!HOQW/^S)_P4!_99\&ZAXR^(O[+_B6UU[QSX4TF-[K6Y/#
M&GO:WT/V"U@5I[\FY#64\,*,P7<^W+(#Y);?\'1OQZ^+7A+P5\*/V??^"<7Q
M_P#^&G?%-SH/ARY_X2[PSJL/@KPUJ/VBUM]5U2^,VE1$6<L:SO MW(@@63]\
M!*$2O[1F574JRAE(P58 J1Z$'((^M8UIX;\.V%Y/J-CH&BV6H7)S<WUII5C;
MWEP?6>ZA@2>4^\CM0!_%S_P6$\ ?$SXA?\%N_P#@AWXF\1_"[Q#XAM6\'Z"O
MQ4.F^%]2UGPGH6J:KXC/_"1Z;J^H6MI-IMA!:W%Q>96]FA7R%C= PXKQ/]MW
M]FW]HW_@@9_P4GT/]O\ _8Q\&>,/'W['/[0?B26+XZ_![P;HVJ:]'H=YK5]&
M^N6_]B:=%+^]F,L^I:'J,42BR<O!)_K@T/\ >)+:6DTL4\UK;RSP_P"IFE@C
MDEBYS^ZD=2\?//RD<\TMQ:VUY&8;NV@NH203%<0QSQDCH2DJLI([''% '"_"
M?XAZ=\6_AEX"^)VD6&I:7IGCWPIHGBJSTS6;66RU73H=9L(;T6.HVDRI+;WE
MJ93!/&Z*PD0\"O0::B)$BQQHL<: *B(H1$4<!550%4 <   "G4 %%%% !111
M0 5C:YH.F>(K";3]4MH[B&:-D#,@,D1/1XV(RK*>>/IWK9HH ^$O''PM\0>!
M[LZAICSW6EHYEM[VU#>?:?-N".J\_*, OR./I77> OCK<Z;'%IOB@/>VB82/
M45.Z>$9 Q/U,A7OWY[<U]=S0Q7$3PSQI+%(I22.10R.K#!#*<@@UX/XR^!&A
MZSYEWX?=='O3DB$ FR<GDDQCD,3W)Q[\4 >PZ-XCT77X$GTK4+>Z61=X1)$\
MX+C.3#NWCC.3C P>>*VZ_/J_\(^/O 5X][%#?61@.U-2LW9DE0<L51<@*1GJ
M*[GPK\>]:TD);>((6U6 'F086] X'S;AZ>N><>] 'V917E>@?&+P7KBJK7XT
MVY<@"UO#A\DX'SJ-O7UQ7ID-W:W"JT%Q!,K@%3%*C@@C(QM8]10!8HHHH **
M** "BBB@ HHHH **** "BBB@ K^ G_@WE_Y3F_\ !1/_ +&CXE?^G74*_OVK
M^:__ ()B?\$2_C)^PQ_P4/\ VI/VQO&WQB\#^,_!_P <]6\4ZAX?\*:#I.J6
MFM:6GB*^O+R,:E<W:"W=[1+E87\DJCB)2H+%W8 _$+_@LSKFG>!/^#F7]D+Q
M7XEN(]-T&[\-_"33HM1NG6&U%S*J6JH\SD(O[Z>)!DC+, .M?UN?\%>OBK\.
M?A7_ ,$\?VE=?^(?B[1_"^E:C\-M;TW2YM0O;:&75M1O;<16MEI4$DJ/?W$K
M31MY=L'*QMO/!7/P_P#\%P/^"&FC?\%4]-\ ?$/X;?$"Q^#/[2?PKF1_"OCJ
M^M;R?2M2M8)H;JSMM933@;WSM/N+:%].N8"C6[ $.F"3^1>C?\&S'_!0G]I^
MVM/#W_!23_@HSKOQ>^&_@G1=2T_X=> M'O\ 79H['5XK%[;0]2O)92MI+I\$
MZP,]O+ONO*C8N\C% H![3_P9].LG_!,O]H^5#E)?C?XUD0XQE'\*H5..V0>E
M?&G_  :F.P_X* _\%&D!^5O''C(D8')'BN_QSC/Y&OZ%?^"'7_!*?XF?\$L?
MV3/BI^SQ\2/B7X3^(VL>._B%KWBS2M:\*Z?J%C8:=IVIZ,FE6UM=Q:@//ENE
M9/M$[(6CRQ5-JX4>$?\ !&O_ ((H_&/_ ()K_M,?M3_&_P"(OQA\#_$'1?CK
MXBUW5?#^C^&-)U.QO]*M]7UJ\U6,:E+>H(GE@BN([=A 55O+#!22S, ?"W_!
MYS%$W[$WPAF,:&5/B?IRI(5^=5:4;E5NH#9Y ZU]4?\ !5?QY\.OA_\ \&WG
MAG5?B?X;O/%>B:O^S]^SYX7TS3+.?R)5\4>(/"NE67A^]DE8X$%I>$2R[N"M
M?6'_  7A_P""4?Q1_P""K_[/O@CX1_"SXE^$/AKK'A;QE9^(KK4/&6GZEJ&G
MW=I"27A1-,Q<)*#M93N4$@ Y7(/PI_P<-?$NQ_8E_P"")O@7]G#Q7X5T3XH^
M)-5\*?"SX/1ZGJ-A)+X:MM2\*:1I^CWGB>&!U62&\CGB^UZ.'9&C;.1NZ 'X
M1_\ !,O_ (B$/@5^Q=X>^'/[&US^SKXP_9_^,6@WFN^%K_Q?XU\&W?BGP0/%
M5E-#?11#4=9MK_0[J&.7,5N+>5H)8X9,9C55_I:_X-^_^"0'C'_@GQX;^+'Q
M_P#C_P"/M*^(?[3O[1ERLWCJ^\/ZBFJ:5H6G"[35)-$DU&)I(;^_74V>XFGA
M?RU$FU512J+^)7_!/W_@V-\"_%+]C_X2_%W6/V]/'GA+QM\2/!VE>.?['^&_
MCQ[#PKX<M=>L4OK/3;RSMM0 2_L1(L=\=F4=7B?$BNH\[_X)I?&']L+_ ()Y
M_P#!<_PA_P $V8_VI]7_ &I/@9XUUZX\/>(XKC69O$.E>'[!M.U#48=924R7
M/V75+*2U2VNY&DC4B>.-U26-O, /]$"BBB@#Y@_:5TV2;3-$U15)CL9IHG;'
M ,^ H+=LX.,_UKX^K]+?'_AB/Q=X6U+1V7=+)$9K4<?\?4(9HAD_WFX^N*_-
MN\L[G3KNYL;N-HKJTE>"=&4J5=#@\'G!['O7GXF+53FZ22^])*WY,_=_#G,J
M>)R5X#F7M\OK5+POJZ%>7M(32[>T=2+>R=NK*U%%%<Y^@A1110 5];_LTZ:\
M<&OZL5/E7/DVJ/SAFA?<P^HKY/MK:>]N8+.UC:6YNI4A@C4%BTDAVJ,#)QDC
M)[5^COPW\*KX0\*:?I97;<L@N;T?]/4R@R#/?:>.371AH\T^;I%7^>Q\#XB9
ME3PN1O \R]OF-6G&,/M>PH356I.V_+SQIQ3V<G;='>4445Z!^"A1110 4444
M %%%% !7A7QO\?R>%=%32=-D":MK"NBR _-;6X'[QB.H9U)"G';WKW6OSO\
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MBCFC8$,DB!U(/7@@UYCK_P 'O!>N"5A8#3;B7.ZXLOE;)[[2<?7&,^U>IT4
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M$5:[79U)N5OE<^#8_BW\18B2=8U"3(Z26SX'N/D/-64^,OQ 08:^N'.>K02
M_P#H&*^Y'T?29#E],L&/3)M(/_B*KMX=T)B2VD:>2>O^BQ?T6F<I\61_&WQY
M'D-<&3)_CB?C'886KL/QY\;PX+Q6\^,\2QNN<^^WMU%?7?\ PB'AK_H#6/\
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MSD\!AC:C$Y:OIX'(!'(/((Y!!Z$&@ HHHH **** (7^\?P_D**'^\?P_D**
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MYEY'JEAJ=EJ*F3+1/+-&6;RPS?V(U_%%^R@ O_!WK^V&5 4M\%M?W$#!8_\
M"*>%1EL=3A5!]0HSTK^UV@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MIZ<'/I62C)NRBVWY,^DK9CE^'INK7QV#I4TK\\\314;>7ON_RO\ D>=@$D*
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M_P""</P*M_V??@+/XIN?!-OK-_KHF\7ZM_;.K->ZC-)-/NN_*B_=AI"$3:<
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M>*-*TOP]91^)=!\(78BNOM=T;749]0M7%E)N\V>W;#M&)1#G(^%O^"Y7B/\
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M82(JR,49C&G[*444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% $<TJP0RSO]R&.25_\ =C4NWZ U^>VOW#>-?B%<M9%C'J>L*MFK
MY<K#'(-ZX')Z-Q^. !7U]\6_$_\ PC7A"^>)PM[?HUI:+G!)< 2''7 C)Y'T
MKYU^ WAU]4\52:Q+%FWTB,W$4S#*FZE<J\:>C#<21Z#GUH ^S=.M8[&QM+2)
M=L=O;Q1*H&,;4 /ZYJV6"@LQ"JH)9B<  #)))X  Y)/ %+7D_P =]8U;P_\
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MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBO/?BWX_M?A3\+/B/\
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M67[+;W*QL(KA68!UVLI)%?TXJRNJNA#(ZAE93D,K#*L".""""".HH =1110
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M;]GE=%3X70VJMXH?6OLT@_LI;;.#=Y8?)GK7K/\ P;6? ;XS?LW?\$I?A/\
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M#3=9>RB748-9L;+4;?5K76-(BN[FS8Q/#>R60@E7<1$90S':N:_/[]E+X?\
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M"MKIVE>)?AEK,EMI]AXB@LHIHKF_:YNY(;6Y74+>XECN;.25/.EBM]SJ &H
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ML*Z&BB@ HHHH *K7EI!?6L]G<QK+!<1/%(C $%9%*GKW /!Z@\BK-% 'Y_\
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M:EXJD6]G7;(--3/V4'J!,.I93C(4\]\'-?1MO;P6L206T,<$,:A$CB0(BJH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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ME'P4A,/P[T4,I5F^T.V<\YE.#S_LXKU>@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M+Z>P- 'V;X6TV/2/#^DV$8VB&R@+#&,/)&KOQ[,Q%=!2    #  P .P'04M
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MW=G8I/RBNKH *X7XA^*XO"/AF^U#S52]DC:"P5L'=<R A3CT7U]<5W)( )/
M ))] .2:^&OC/XN;Q/XF.FV3O+8:2WV2(199+F=WYD"CJR.2OT ]Z ,GX:^%
M[KQWXN2:]9Y;2"X.H:G+(#(DA#;S:L3T+DX4'MTQ7WS%&D,4<,2A(XD2*- ,
M!4C4*B@=@J@ >PKS7X4^$%\)^%K1)HU74]0C2ZU"0#YF=P6B7U&R-E!'K7IM
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% &?JNJ66C6%SJ6HS+;VEK&999&(^Z.RC.68D@ #^5?%_CGXPZ[XJN38:
M%]HT[30[)&ELQ-Y><X5PR88!L9*<8!Z5UW[0GBB[-W8^&(6>*R$8N[J0942R
MY($18X#)MZCIG\J\9\'^+;;PE<S7ZZ;;:AJ! 6V>Z59(;=3SN"'/[S/1L=*
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M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5X]^T+XXU;X9?
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M($4;.24C^4<4 <S^W[_P71_:#_9TUK]GK]B7]GKX+Z?\9_\ @H=\4?#&C/\
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M1OA;HEQ+/I.EZS<K!87MTTEJ6EFE.JR[+&T=1&XVRR'R263\UO\ @V%O(O\
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M>W%?H3%%'!&D,*+'%$H2.-%"HB*,*JJ.  .E?)WQL^&]U!>MXLT2W::"<_\
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M-2,DNGZ2Z3W#2[B;J<D/$H?H<,/F'UKV/XP?$VST33YO#&A3AM5N(O+FFM9
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M%% $HZ#Z#^5+2#H/H/Y4M !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M-;W-PEK?R-J"2+<1&[CB199%DW&/*9Q7ZD?\$KO^"-O[!VA_\$U/@WX-\=?
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M9Z9XWL9K+QMK.MF6,O<WBWMO;W;P&V\QG*QB#S0?)S%M8_N_0 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !59[*SDD\U[2V>7.?,>WB:3([[RA;/XU9HH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M,_XT8^OYG_&BB@ Q]?S/^-&/K^9_QHHH ,?7\S_C1CZ_F?\ &BB@ Q]?S/\
MC1CZ_F?\:** #'U_,_XT8^OYG_&BB@ Q]?S/^-&/K^9_QHHH ,?7\S_C1CZ_
MF?\ &BB@ Q]?S/\ C1CZ_F?\:** #'U_,_XT8^OYG_&BB@ Q]?S/^-&/K^9_
MQHHH ,?7\S_C1CZ_F?\ &BB@ Q]?S/\ C1CZ_F?\:** #'U_,_XT8^OYG_&B
MB@ Q]?S/^-&/K^9_QHHH ,?7\S_C1CZ_F?\ &BB@ Q]?S/\ C1CZ_F?\:**
M#'U_,_XT8^OYG_&BB@ Q]?S/^-&/K^9_QHHH ,?7\S_C1CZ_F?\ &BB@ Q]?
MS/\ C1CZ_F?\:** #'U_,_XT8^OYG_&BB@ Q]?S/^-&/K^9_QHHH ,?7\S_C
M1CZ_F?\ &BB@ Q]?S/\ C1CZ_F?\:** #'U_,_XT8^OYG_&BB@ Q]?S/^-&/
MK^9_QHHH ,?7\S_C1CZ_F?\ &BB@ Q]?S/\ C1CZ_F?\:** #'U_,_XT8^OY
MG_&BB@ Q]?S/^-&/K^9_QHHH ,?7\S_C1CZ_F?\ &BB@ Q]?S/\ C1CZ_F?\
M:** #'U_,_XT8^OYG_&BB@ Q]?S/^-&/K^9_QHHH ,?7\S_C1CZ_F?\ &BB@
M Q]?S/\ C1CZ_F?\:** #'U_,_XT8^OYG_&BB@ Q]?S/^-&/K^9_QHHH ,?7
M\S_C1CZ_F?\ &BB@ Q]?S/\ C1CZ_F?\:** #'U_,_XT8^OYG_&BB@ Q]?S/
M^-&/K^9_QHHH ,?7\S_C1CZ_F?\ &BB@ Q]?S/\ C1CZ_F?\:** #'U_,_XT
M8^OYG_&BB@ Q]?S/^-&/K^9_QHHH ,?7\S_C1CZ_F?\ &BB@ Q]?S/\ C1CZ
M_F?\:** #'U_,_XT8^OYG_&BB@ Q]?S/^-&/K^9_QHHH ,?7\S_C1CZ_F?\
M&BB@ Q]?S/\ C1CZ_F?\:** #'U_,_XT8^OYG_&BB@ Q]?S/^-&/K^9_QHHH
M ,?7\S_C1CZ_F?\ &BB@ Q]?S/\ C1CZ_F?\:** #'U_,_XT8^OYG_&BB@ Q
M]?S/^-&/K^9_QHHH ,?7\S_C1CZ_F?\ &BB@ Q]?S/\ C1CZ_F?\:** #'U_
M,_XT8^OYG_&BB@ Q]?S/^-&/K^9_QHHH ,?7\S_C1CZ_F?\ &BB@ Q]?S/\
MC1CZ_F?\:** #'U_,_XT8^OYG_&BB@ Q]?S/^-&/K^9_QHHH ,?7\S_C1CZ_
MF?\ &BB@ Q]?S/\ C1CZ_F?\:** #'U_,_XT8^OYG_&BB@ Q]?S/^-&/K^9_
MQHHH ,?7\S_C1CZ_F?\ &BB@ Q]?S/\ C1CZ_F?\:** #'U_,_XT8^OYG_&B
MB@ Q]?S/^-&/K^9_QHHH ,?7\S_C1CZ_F?\ &BB@ Q]?S/\ C1CZ_F?\:**
M#'U_,_XT8^OYG_&BB@ Q]?S/^-&/K^9_QHHH ,?7\S_C1CZ_F?\ &BB@ P/3
*\^?U-%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>gyowp0iggm03000014.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gyowp0iggm03000014.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" '1!*D# 2(  A$! Q$!_\0
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M4** +]%4** +]%4** +]%4** +]%4** +]%4** +]%4** +]%4** +]%4**
M+]%4** +]%4** +]%4** +]%4** +]%4** +]%4** +]%4** +]%4** +]%4
M** +]%4** +]%4** +]%4** +]%4** +]%4** +]%4** +]%4** +]%4** +
M]%4** +]%4** +]%4** +]%4** +]%4** +]%1P_ZE:DH CF_P!2U5*MS?ZE
MJJ4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\6_\)OXM_P"A
MHUO_ ,&$O_Q5?:5?!] &]_PF_BW_ *&C6_\ P82__%4?\)OXM_Z&C6__  82
M_P#Q58-% &]_PF_BW_H:-;_\&$O_ ,51_P )OXM_Z&C6_P#P82__ !58-% &
M]_PF_BW_ *&C6_\ P82__%4?\)OXM_Z&C6__  82_P#Q58-% &]_PF_BW_H:
M-;_\&$O_ ,51_P )OXM_Z&C6_P#P82__ !58-% &]_PF_BW_ *&C6_\ P82_
M_%4?\)OXM_Z&C6__  82_P#Q58-% &]_PF_BW_H:-;_\&$O_ ,51_P )OXM_
MZ&C6_P#P82__ !58-% &]_PF_BW_ *&C6_\ P82__%4?\)OXM_Z&C6__  82
M_P#Q58-% &]_PF_BW_H:-;_\&$O_ ,51_P )OXM_Z&C6_P#P82__ !58-% &
M]_PF_BW_ *&C6_\ P82__%4?\)OXM_Z&C6__  82_P#Q58-% &]_PF_BW_H:
M-;_\&$O_ ,51_P )OXM_Z&C6_P#P82__ !58-% &]_PF_BW_ *&C6_\ P82_
M_%4?\)OXM_Z&C6__  82_P#Q58-% &]_PF_BW_H:-;_\&$O_ ,51_P )OXM_
MZ&C6_P#P82__ !58-% &]_PF_BW_ *&C6_\ P82__%4?\)OXM_Z&C6__  82
M_P#Q58-% 'MOP*\1ZYJ_C>]M]3UG4;V%=-=UCN;IY%#>9$,@,2,X)Y]S7T'7
MS3^SS_R/]_\ ]@N3_P!&Q5]+4 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!;A_U*U)
M4</^I6I* (YO]2U5*MS?ZEJJ4 8WBCQ/IWA'1SJFI^;]F$BQ_NDW-D]./PJ*
M[\7Z1:-H@,KRIK4@2SDB7<K9 ()/88(KE?C>BR> $1QE6OX 1[9->?-::EX8
M^(WAGP==[I;"RU876FW#'DPR'[OX$'\<]L4 >P>)?B#H7A:^BT^[:YN-0E7>
MMI9PF63;ZD=!W[U/H?C?0_$6CWFI:?<.Z608W,+H5EBP"<%3]#CZ5PUAJFG^
M&OCAXFD\0SQ69O[:%K*ZN"$1HPH!4,>!R,?5#5/1KF#6O'7Q!UO2,/H[:88#
M,@PDLPC&2/7[K<^^>] '11_&KPH\23O'JD5JYP+B2S;RQSCJ,UM^*/B%H/A&
M'3IM2DF:+4%9H'@CW@@;23UZ8<5X<L?B6V^$6C2W6IL_@ZZE,=Y!;6R>=;IY
MS<[B.06!.<CD@5V'Q/T>RUJ7P'I.F,LEG/:W<5FRG((\F/RS^BT >A:]\0-"
M\.ZWIVD7LDS75^%,(B3<,,VU23G@$_RJ[XJ\6:7X.TE=1U9Y%A>41*(UW,S$
M$\#Z U\XVMQ=>(Y='\0WJD-:ZGIFE0D\Y"(Y?\R%/_ J[_XA7EQXD^)=IH]M
MHD^MV.BP&2[M8'"9DE7 R3QP-A_.@#U>7Q!I\7AAO$/F,^GBU^U[T7),>W=T
M]<=JL:3J=MK6DVNIV98V]U$)8RZX.T],BO%_"VJ72_!_Q?X7U.-X=0T:UF7R
MI?O")U++]<'=^&*[7X>>+/#J>"_#VFMKFG+??9HH?LYN4\S>0 %VYSG/&* .
M_HHHH **** "BBB@ KX/K[PKX/H **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBK%U8W-FD+SQ%%F3?&?44KJ]A.232;W*]%%%,84444 %%%% !1110
M 4444 >M?L\_\C_?_P#8+D_]&Q5]+5\T_L\_\C_?_P#8+D_]&Q5]+4 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M /2Z*^9FMKC1)D;Q6WB71]<6ZS_;\;&XMV^;TR!C'H3].U>@_&'P]9/X/O\
MQ5%=78U"**!8WBN&6,@R*N=HXY#&@#UBBO/+7P?-H_P[U$>%[F[75=1LHW5Y
M[DL0X7/RD_=)W,,^N/2O/?"7V72/%^@PWA\0^'-8:01W O0TT&HL<#;DD8R>
MAP0,CTS0!]"U\'U]X5\'T %%%% !1110 4444 %*59<;E(R,C(ZTA!!P1@^]
M.=WD;<[%CZDYH$-IS1E$1CC#C(P??']*;5BQM'O[Z"TC95>9P@+' &:3=E=C
M<HQBW(KU)%Y6YO.W8VG&WU[59U739M(U*6RG9&DC/)0Y!JF,9YSCVI)J2NB(
MRC4BI1>C$HHI=OR[LCKC&>:HL2G-([JJN[,$&%!/04VIEN66UE@VKB5E8G'3
M&?\ &DQQ46_>(:**N&[N;NS@L-J,D)9DPOS=,GFAMHB3:V*@5BI8*2HZG' I
M*L6\]RL$UM!DI, 9%"YSMYJ *2I8#@=:+]P3=W<2BBBF4%%%% !1110!ZU^S
MS_R/]_\ ]@N3_P!&Q5]+5\T_L\_\C_?_ /8+D_\ 1L5?2U !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 6X?]2M25'#_J5J2@".;_4M52K<W^I:JE ',^.O"7_":^'?
M[)^W?8_WZ3>;Y7F?=SQC(]?6NFHHH \S_P"%2'_A6R>$!KF"MW]J%W]D]\XV
M;_US5B/X;ZM?:YIFH>)O&$^L1:;,+B"W%BENOF#!!)4G/(':O1** .6M/!D4
M'C;7/$,UTMQ%JULEN]FT/"JJJIRV?F!V],#K5+PW\/(= TO6=$EU!KW0M09S
M%9218:W#9! ?<<\8[#D9]:[:B@#RW_A4VK'31H#^-[X^&PW_ !Y?9D\S9G.S
MS<YQ^&/:MGQ1\/'U@>'?[&U?^Q6T(,+8K:B?&0@'!8#C9WSG-=S10!PV@_#^
M\LO%B>)=>\1S:UJ$,!@MR;98%C4YSPI.>I].IK-M?AMXDTF_U.?1?'36$.H7
M<EV\(TI),,QSU9^PX[=*]+HH X6Y^&\>M>(['5?$NH)J\=I8+:BVDM0BO)_%
M*<,1DG)V@<<<\4ZR^&>G:5XLN-4TN2.TTV[L6L[O3$A^24'^(-N^7MV/?UKN
M** /*?\ A3^I?V7_ ,(^?&=W_P (SYF_[!]E3?C=NV^9GUYZ8SVKM/%GA2/Q
M+X*N/#<-S]BBE2)$E\OS-@1U8#;D9^[CK7144 8>K^&+36_!\GAR]=S ]ND)
MD088%<;6'N"H.*Y&R^%VIR7VD'7_ !=<:KI^D2K+:6GV58N5^[N;)+8P.N>.
M]>E44 %?!]?>%?!] !1110 XHRHK$85ONGUIM*",C=DCT!I* %)SCC'%/MY?
M(NHIMN[RW#8/?!S5F+3)IM)N-15XQ# ZHREOF)/H*6YLDL/LTCR1W"31[]J-
MC'L:CFB]#)U(-\E[]/P)=>U8:UJLEZ+=( P V+[50F='?*1B-0 , Y_&HZL6
MUG-=K*85!\M=S9(%"C&$4ELC2A0LHTZ2VV17IZK(%,J!@$(^8=CVK7TFQT>Y
MTC4IKZ^:"\A3-O'QAS_7TK'#.(V4$["06';VH4[MI=#.-53E**6W=?EW!W:1
MR[L68]2QR35^PLI]2MKB*)H56W0S'?@,<=@:SJ<9&8*"?NC:,#'%.2;5D6^=
M1M!V&U?T6WL[K5H(;^8PVK$[W!QC@X_7%4**<E=-()Q<HN*=K]32327OKRXB
MTW-P(W(11]XIS\WTX_6LX@@D'J.M6;34;FPE,EG(8)&C,;,IY(/6H8X9KCS#
M'$\FQ2[E5)VCU/M4KF3UV)3DG[VR2];^8KV\T<$<S1L(I,[&[-CK452O<3/!
M' TC&*,DHA/"YZU%5*_4J-[:FAI&JR:-?"ZBCCD;:5VN,CFJ#-N8GIDYP*2B
MA12=^HE"*DYI:LLV36J3%[I&=%&0@.,GT-0RLKS.Z($4DD*.P]*911;6YKS/
MEY>@444 9.!WIDA15O4--N-+N%@N54.R!QM.>#52DFFKHF,HS7-%W3/6OV>?
M^1_O_P#L%R?^C8J^EJ^:?V>?^1_O_P#L%R?^C8J^EJ904444 %%%% !1110
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MP='&&7]RN ?0@8%>P4 >?^ ?B'!KO@VXU;6KM()K1G>[<PM'%&A=@@4D8;@
M<$G/7DUK:-\1O#&NZC%86=\ZW,R[H%G@>+SAZH6 #?SKR.WG@G^!6G1"1)H]
M/U=9=4MT(9T@\Y_O+U .0:[/XB:MI.N+X5L]#N[:]U-]6@FM1:N':.,9+,<?
M=7&,Y]/:@#4T+X@)JGQ,UKP^\C?9H1''9J+5P2X5FE+L1QR,#. 0!C.>;,_Q
M9\&V]R8FU-VC63RFN4MI&A5O3>%P?J,BL6TU2STOXI^/C=-&TCV5M)%;%P'N
M D!+*H[G'I7$:AK%U=_">><^(="TO39XF6'0["V5G)+_ '"6.Y3GDD#WH ]4
MFUN\;XLZ?I<-WNTR?1WN3$N"K/YF V>O3WKK;JZ@L;2:ZNIDAMX4+R2.<!5'
M))KRWPXP?XA^#V!SGPC&<_B*W_B];W-S\--36VC:0(T4DR)U:-9%+?D!GZ T
M 2P_%;P=/-'$NI2*TSJD.^UE43;B "F5Y&36GK_C;0?#5U%::A=O]LE7>EM!
M"\LFW^\54' Z\GT->?\ Q&\3>%]7TCPO;Z7>V=S.VIVTEO' P+0Q@X.0/N=0
M,''Z57G34+;XR>)C_P )1:Z!<3PP/;R7=HDJSPA "$+L ,$<@=<'TH ](_X3
MCPX?#7_"1+J:-I8<1M,J,=C$@89<94Y(ZCC.:J:5\2?"NLZQ'I=EJ1:YF)$!
M>%T2;'78Q !_KVKR34[2 _#KQG=0:RVK176JVXDG6R%O$THD&\QX9@P.1R,?
MC7HOQ&@BAU+P+Y4:H(M=@C0*,;5P>![<#\J -S7?'WAWP[J']GWUXYO GF/!
M;P/*T:_WFV@[1]:L2>,_#\?AI?$7]I1MI+,JBX168 E@H! &0<GG(X[UQW@[
M4M-T3QQXWM]9N[>SU"6_^T(]RXC\RW(RFTGJ /YUQ.HJES\+_&MW:(R:/>:^
MKV6%VJZ>8@+*/[I_I[4 >HQ?%?P7++-&=96+RHS*'EAD19%'4H2OS>P')[9K
M1T/QKH?BF*]72KU_.M5S*DD+(\8(.&VL 2*YSQO96O\ PGOP]B^SQ^7%=3JB
M[1A0J*5 'L5'Y4!0OQIUW:,;O#Z%L=SOQ_*@#4T7Q9I>E_#_ $_6-7\1?;H)
M"R"_>V:-KAM[  1 $Y&,8 _AS6IX>\9:'XHDN(=,NF:XM\>=!-$T4B ]#M8
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M^S@M+=3D101A%!^@J/4='TO6(TCU33;.^2,[D6Z@64*?4!@<5:CFBF!,4J2
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M\6>*?^$<M+&:&&.Z:YU&&Q=?,QY>_//&>1CI70RS10)OED2-?[SL * /+X/
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M==6,Q98KF%X7*'# ,"#CWYK%F\&:=/X&'A%IKH:>(%@\P.OF[5((.=N,\>E
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M&FZ=_;FMR1:==K<PN]R-[!1@1,=O,>/X?UKK* "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"W#_J5J2HX?\
M4K4E $<W^I:JE6YO]2U5* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MI4;*UR(T^5-7>KO_ %Y!1115&AZU^SS_ ,C_ '__ &"Y/_1L5?2U?-/[//\
MR/\ ?_\ 8+D_]&Q5]+4 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!;A_U*U)4</^I6
MI* (YO\ 4M52K<W^I:JE !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %?!]?>%?!]  "000<$="*.IR:** )8I$17+(QDQ^[96QM/K4;,SL68DL
M>I)ZTE%*PK*]RQ;7UQ:17$4,FU+A-D@QU%5Z*UM5.B?8+$:8LXNMG^DF0\9_
MSZ5+:B]M_P"M3-R4)I*/Q=5Z=3)ISR/(VYV+'&,FFTO'I5FI;_M*X\F2(;%2
M5%1P$ R!G'X\U5*%45CC#9QSS33CM5H68EN[>VMYEEDF*KG& K,<8S4Z1%*H
MU%1;T7X+?Y#(9S;>:%"OYL10^V?_ -50G'&,^]:-_HM[87\UB\8DE@7<YB.X
M8]:S:(N,M413E":YH.]S3TB^FT:X6^-FDT;@JOG)\I/M3;9M.N)9Y;\RQ,SE
MU$*C'/:I+_6WOM'L-.\A$CM ?F'5C6>QA^RH%#>?N.X]B.,?UK-1;U:LV9TZ
M+J*4Y>[+UZ)Z?YD;;=[;"2N>,]<5);F$7"&X5FBS\P4X)I]E9S7]W';0 &20
MX )Q4<D+Q3-%(-K*VUO0&M+KX35N+?)?421 ,,N-K9*C.2!GO3*O20VD>C12
M;G-Y)(>,?*$''YYJFVS:NT,&_B)/'X41=RE>P'9Y:XSOR=WICC']:>]O,D$<
M[1D129"-V..M1 X__54C32O$D32,8TSL4GA<]<4]>@G?2Q'2Y^7&!UZTE%,H
M**** "BBB@#UK]GG_D?[_P#[!<G_ *-BKZ6KYI_9Y_Y'^_\ ^P7)_P"C8J^E
MJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **H:SK-AX?TJ?4M
M3N%@M85W,S=3[ =R>PK//C/1(_"">*)KEH=+>,.KR(=QR< ;1SDGM0!OT5R^
ME_$+PWJNCZAJD5ZT5OIPS=B>)D>+/3*D9Y[8SGI4GACQSH7BZ6>'2[B0SP*'
M>*:)HVV'HP!Z@^ON/6@#I**** "BBB@ HHHH **** "BBB@ HHHH **H:SK-
MAX?TJ?4M3N%@M85W,S=3[ =R>PK,E\;Z%;^$8?$]Q<O#ILR@QLZ'>Q)P %'.
M>* .BHKFM-\?>'=4T*^UB&],=K8$B[$T;(\)]"I&>>V,YZ=:7PQXYT+Q=+/#
MI=Q(9X%#O%-$T;;#T8 ]0?7W'K0!TE%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110!;A_U*U)4</\ J5J2@".;_4M52K<W^I:JE !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %?!]?>%?!] !1110 4444 .
M#%0PP/F&#D>^?Z4VBB@ HHHH *56*L&4D,#D$=J2B@"W#J5W LXCF8-.,2.3
MEB/K59&9"64@'%-HI<J)4(J]EN%3VIMA-_I2N8\'[AY![5!10U=#:NK#UWQA
M9D8K\Q"L#@Y'_P"NGK,S1^3(Y\LL7Z9^;%0T46&FUL.+L4"$_*#D#TIM%%,
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M?,,YP0/P%5OA9J=[K'PWTF_U&YDN;N7SO,ED.6;$S@9_  4 =A1110 4444
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M\9U72[D[&1-@E@/W&QZ],_[PH [:BJ&M:O:Z#HMYJMZQ6WM8C(^.IQT ]R<
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MBW_H5];_ /!?+_\ $T 8-%;W_"$>+?\ H5];_P#!?+_\31_PA'BW_H5];_\
M!?+_ /$T 8-%;W_"$>+?^A7UO_P7R_\ Q-'_  A'BW_H5];_ /!?+_\ $T 8
M-%;W_"$>+?\ H5];_P#!?+_\31_PA'BW_H5];_\ !?+_ /$T 8-%;W_"$>+?
M^A7UO_P7R_\ Q-'_  A'BW_H5];_ /!?+_\ $T 8-%;W_"$>+?\ H5];_P#!
M?+_\31_PA'BW_H5];_\ !?+_ /$T 8-%;W_"$>+?^A7UO_P7R_\ Q-'_  A'
MBW_H5];_ /!?+_\ $T 8-%;W_"$>+?\ H5];_P#!?+_\31_PA'BW_H5];_\
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M^NY/+MK:)II7VD[44$L<#D\ ]*XO_A<W@#_H/_\ DG/_ /$5O>-_^1 \1_\
M8+N?_135\6T ?6G_  N;P!_T'_\ R3G_ /B*/^%S> /^@_\ ^2<__P 17R71
M0!]:?\+F\ ?]!_\ \DY__B*/^%S> /\ H/\ _DG/_P#$5\ET4 ?6G_"YO '_
M $'_ /R3G_\ B*/^%S> /^@__P"2<_\ \17R710!]:?\+F\ ?]!__P DY_\
MXBC_ (7-X _Z#_\ Y)S_ /Q%?)=% 'UI_P +F\ ?]!__ ,DY_P#XBC_A<W@#
M_H/_ /DG/_\ $5\ET4 ?6G_"YO '_0?_ /).?_XBC_A<W@#_ *#_ /Y)S_\
MQ%?)=% 'UI_PN;P!_P!!_P#\DY__ (B@?&;P 3@:]G_MSG_^(KY-^:-B",''
M<4^WF-M<QS* Q1@P!Z&ETT$]KH^M)OB[X&M]OG:T\>X9&ZRN!G_QRHO^%S>
M/^@__P"2<_\ \17S7XC\42^(4MU>UB@$(Q\G4UAGR_)7&=^>:BG*3BG-69GA
MW4G3YJJY9=KW/K#_ (7-X _Z#_\ Y)S_ /Q%'_"YO '_ $'_ /R3G_\ B*^3
M 2 0.]2VUK->3K#;QEY&Z 5;=M6:-I*[/J[_ (7-X _Z#_\ Y)S_ /Q%'_"Y
MO '_ $'_ /R3G_\ B*^4;FUGLYC#<1M'(.JFH:$TU= FFKH^M/\ A<W@#_H/
M_P#DG/\ _$4?\+F\ ?\ 0?\ _).?_P"(KY+HIC/K3_A<W@#_ *#_ /Y)S_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MZUI3VCW:ZG9M;(VUYA.I13Z%LX!Y%3S7MI;>3Y]U#%YS!(M\@7>QZ!<]3]*
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MOF[ 5#15M'/!J+O84 DX'4T$%20>HI!D'CK2Y//O3%I82BBB@04444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@,\UQ:R1QQ"0)N8CCYCP.?6MJL;Q9J5SH_A+5M2M&C6XM;5Y8S(I*[@,C(%
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M>"5/#QJ<U[]]R%"0ZG..>M:T/B*]L[>6VMVB,4@PQ:,$_@>U9J11M;O(T@#
MX5?6H>U5*$9_$KF4*TE%QB%=?I'BVUL?!L^AR:;YUU+<^:L^!]W &WU[5R%.
M4LC*XR".0:FK2C524NFIE."G!Q>S+<&F7=ZT_P!G@),(WNH/*BE2 VJK.SKN
M'(6IM)6?4=:AA,CKY[B.1D./E)JYXRT*W\.>);G3+6Z-Q'"1ACUY /\ 6H=3
M]Y[)O5JY=&M&G*TE>7Y%/4/$&I:G8VUC<W!:UMAB*,< 5ET45M&$8JT58<I2
MD^:6XH)'2DIR$!P6&1GD4.5+DJ,+GBJ%;2YL:'?Z?91W O8/,9Q\AQG%9GFQ
M?:FD\OY"20M045"@DV^YG3IJG4=1;L<S9D+*,<Y'M2R2O*VZ1RQZ9)J5X)Q9
M).8&6!FVB3;PQ],U"H4YW'''%--&K2<KC:***HDWO!'_ "/_ (<_["EM_P"C
M5K[2KXM\$?\ (_\ AS_L*6W_ *-6OM*@ K)\4:I/HGA75-4M81-/:VSRQH1P
M2!GGV[FM:LGQ1J%QI/A75-0M+=;BXMK622.)AD,0I/([CV[T >,:1\1O$$-U
M&7\36FK3RWMCBUCA4&6.56\R- HR"A(R3W ^A]]KYRTR"?PQ<Z%XKAU?PW?W
M&H7,2OI]O9PH\8DZ["H!4KG!/&.^>E?1,-Q#<Q^9!-'*F<;HV##\Q0!)7FOC
MWXB7>BZ]I^C:(B22BZA74)V7<L*R'"Q_[S#)]@/?CTJO*_$WP=%_+)<Z1K>H
MQ3W6I+>W,<]WB(<DLR!4^^,X4GIZT =CX@\=^'/"]]'9ZQ?/;SR1B556VEDR
MI)&<HI'4&L?X-?\ ))]$_P"V_P#Z/DKMK:#[-:0P>;++Y2*GF2MN=\#&6/<G
MN:XGX-?\DGT3_MO_ .CY* .[HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "HYYEM[>29\[8T+G'7 &:CO[07^GW%F9Y[<31F
M/SK=]DB9&,JW8CL:XT_#&)E*MXP\8$$8(.K'G_QV@"A+\1M1,K&&TM5CS\H<
M,3CW((IG_"Q=5_Y]K+_OAO\ XJG_ /"EM%_Z#_B3_P #A_\ $5S,7PVL7^)5
MQX=.N:_]CCTM;P,+T;]YDVXSMQC'M0!T\/Q&U 3*9[2U:+/S! P./8DFO1HY
M%EB21<[74,,^AKS@?!;10?\ D/\ B3_P.'_Q%: ^&40&!XQ\8@#_ *BQ_P#B
M: .YHJ&U@^RV<%L)99?*C6/S)FW.^!C+'N3W-34 %%%% !1110 4444 %%%%
M !7@_P"TA_S+/_;U_P"T:]XKP?\ :0_YEG_MZ_\ :--;@>$@T[-,HK52$/W4
M#GI3>IJ>-,<UK!.3 5(_6GXP>*4-@\TX$8Z5WPA&UD0VQA7Y"V>E6M*TN?6+
MT6ML!YA&1DX%4G)S4L%U+;NK0.8V'&Y3@US57+51W)J*?(^1Z]!\UG)#/+"^
M T9P?K4!.0!MP1WJPT@:3<SEV/)^M0X:0DJI)]J4?>W%!NWO#$PDJEP2N>:E
MN6BDDS"NU<=*N2VD;6=MY4@>X<X*#M4#6<EM(RW2M$P&0".M1"46R8U(2=[Z
ME4JRXW C/2I!(ZQM&$'S]\=*60LY!8YQTJ6.94B*[-[-UXYJJBE&-K%R;MJA
MMU;R6HC#%<LN<J:JXJ2>3>_0@#L:CZ5,=M1P3Y==R1>1SUIC $TY3[\]*G2.
M)=WGY!(RI%:SDG ')1(;LVS%/LZLN%^;/K54BIB!3"N#7.Z?*K%15E8CHI>]
M)65B@I:2BG<#Z6_9Z_Y$&^_["DG_ **BK=^,W_))];_[8?\ H^.L+]GK_D0;
M[_L*2?\ HJ*MWXS?\DGUO_MA_P"CXZS?Q#/DRBBEK004^.-I&VJI)]*:!FK,
M#O#('0X:JC%RV'%QNN;8$B*/M93N]*O064ERVQ%PP&>:KB9O/W2#+'J3VJQ:
MWAM[U)#F2-#DCUK9SE!62!2IJ3T;73S&0(([Y$DZ!L-7I'C*STJTT^Q?270"
M>$%]I[UYS>7D5S>R310^7&QR!Z5928E8RS[ACCGI6-2@Z\X5+VMT[G3@<7&$
M7&2MS?U^!4GC*S8.<&DGB$6WG(/>M35+JPELK=+=3]H'^M)KH--\%W&M^&Y=
M0C\N.. 9+,PR:WG7C2BI3T6QI]4C5G.$&F]+/]#BX6,;97%2J[;MN?D)Y I;
MZQ>RF\O=N]Q4"2%?K7?%QE&QYU2$Z<G3GHT22*N2,$^AI9;>94C=UV*P^5O6
MGQSE!PJM]144CRS#:[$J.@]*ET)[)'+K>RV-6UN=,@TV9;E&DN"/W;#L:RH[
MIHV!"[L=C0L!5/,;E1VH"A@QZ8K&&&C%OF9WU\5.4(Q:LDK#'W22@X&6/ K6
MM"L,AAGA!WKC JEY=NL2RF4AQVJ%;BXEO/,AR3T'M6%;W]%L:TH.E.*DKWU[
MHBO56.X9(S\H/2F(_E;7 Y%23Q2_:#YGWSR:ECM1D-(W'7&*%;EU(FFJKY59
MW]"G*WG2%O6H'3!K6FMHI(_.A(';95.:/"\C!IJFIPTZ$U83@_>ZE'%)4A%,
MKE:)/6?V>O\ D?K[_L%R?^C8J^E:^:OV>O\ D?K[_L%R?^C8J^E:REN,MP_Z
ME:DJ.'_4K4E(".;_ %+54JW-_J6JI0!FZYH&F>)+!;+5K;[1;K(LH3S&3YEZ
M'*D'O0- TP>(FU\6W_$T:W^S&?S&_P!7G.W;G;U[XS6E10!F+X>TM?$;>(!:
MXU1H/LQG\QN8\YQMSMZCKC-96O\ P[\*^*-2&H:SI?VFZ$8C\S[1*GRC.!A6
M [FNHHH Y>Q^'?A73=&O](M-*\NQU#;]IB^T2GS,=.2V1^!%7=2\(:#J^@6V
MAW^GK-IUJ$6&(R."FP;5PP.[@<=>>];=% &5J_AO2M=T4:/J=LUS8C;^[:9P
M3MZ98'<3]3SWK450B*JC"J, 4M% !1110 4444 %%%% !1110!@^-_\ D0/$
M?_8+N?\ T4U?%M?:7C?_ )$#Q'_V"[G_ -%-7Q;0 4444 &3C&:T7T6\CT1-
M781BU>3RE^<;MV,_=ZXJG;3?9[F.;RTD\M@VQQE6QV/M4EQ<RWD[$(%5FRL4
M8^5?8"HES75M@=R [L#)/M3A;S%0PB<JW0@=:?<*J$+Y31N.H85UVF_$%]*T
MX06VEV[3>4T1DDY&",'@8YJ*DZBC>G&_X&=64X2BH+F3>K71=SD);<Q1JS'Y
MCVJ&GR2O*^YSDU9FNX9+*.%;<+(O5_6M+M&M62YO<6AOZ5X;M-5\,W5W:S3-
MJ$(RT1("X[GUKE*F@N9K8LT$TD3,-I*-C([BB&UEG!*+P.IJ(1E!R<G=/8TL
MZEHP6I&A"L"1D>E.E:-L%$*GOS36&QR.N#5M6BEBW.$1EZ8JV[:CIQ<DX]?Z
MZE*BI9MC,#&.W-14T[F"9-;74UI,)8)#&XZ,.HI+BYFNYVGN)9)9G.6>1LDG
MZUK>$Y-+B\1V<FL@&P5\S C.5P>WUQ5OQS+X<GU[S?#*.MFT8W!ACYO8=AC%
M8NHE6Y.5[;]/0IP22EW.:#$*1Q@^U)4D,:ROM9PG'!-.MGCAND>5/,C5N5]:
MVN2Y?@%LL;7,:S!O++ -CKBKVO:;;Z7J;0VMRMS;D!ED4$ ^W-+J5U:7MW$;
M.'R44<DC%7?%OB&+Q!>6\D4#Q"%-AW.&ST] /2L.:;J1TTUO^@Z2YJ?M))I^
MOZ& Y0[=BD<<Y--!QG@<CO5HV\)MO,2;Y@.5-5*V33-*L)1?O=>Q8-Y.;-;1
MI':!6W+&6.U3Z@57HHII);$-MA1113$;W@C_ )'_ ,.?]A2V_P#1JU]I5\6^
M"/\ D?\ PY_V%+;_ -&K7VE0 56U#3[75=.N+"]B\VUN(S'+'N(W*>HR.1^%
M6:Q/&$6HS>#=8BTGS/M[VD@@\LX<MC^'W]/>@#G_ /A3O@ $ Z"F3T'VN;_X
MNNHT'P]I7AG3O[/T>T%M:[S)Y8=G^8XR<L2>PKP*QT;6]2U/3]573=;MYXKN
MRL-),ZL#!'&H\YY!_=P#[<GTKZ0H **** "N$^#7_))]$_[;_P#H^2N[KA/@
MU_R2?1/^V_\ Z/DH [NBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **0D*I9B  ,DGM6,_BW04<J=1CR#CA6(_,"@#BO&NH:
MI'K\D+330VZ@>2J,5!&.3QU.<UY[%>W?_">SR?:IO,.G*I;S#G&_IFO<Y/%7
MAR4 27L3@=-T3'^E<1!K>@CXR7=R9H?LAT1$!\HXW^<3TQUQ0!:\#W^IRZZL
M)GFEMBC&4.Q8+QP>>AS@5Z76#'XK\.1 B.]B0'J%B8?TJ6/Q9H4LBHNHQ[F.
M!N5@/S(H V:*.M% !1110 4444 %%%% !1110 5X/^TA_P RS_V]?^T:]XKP
M?]I#_F6?^WK_ -HTUN!X12TE**U0A\8YYJ?.TY':HU&,4X]:ZZ:M$3)=R,ZD
M\>M)*RECL^[4:*7DVCO2Y52RG)QTH]HB;),G5;5K%F9R+C=A5[8IME:2WU['
M9QX\QS@9J-PC -&N,#FFI(R2JZN48=".U8>]9M,BTN5V>OGT+6H:?-I=Z]M.
M!YB<'%*KO9[65ERX^M2+!<7\#R&3S&!SR>351!R589/3Z5I1DY>Z]7U(@W*/
M+-W:W'!VAF66%SO!SGTJ>[O;J^E5KIMS <'%-BA Y/7M4S1EADCI7HT\ W:=
MM4-J/,G;5=2IG'O4UHT2DD\2#H:9/$T!7?CYAD8J$$9R*PK14U:Y32G'0?(7
MGF+  GVJ+@DYX-.S(@W)P#WI]M:M=.P/!%<TIJ'H.ZBKO9%?-7?-%S#%!)M0
M XWU7GLYK8G< 0#R140]ZF$E(;49JZ+%R0K>2I#*O1AWJN13R01BFUHXI*R'
M%65B,BFD5(1D4RL91+0VDI325BP/I7]GK_D0;[_L*2?^BHJWOC-_R2?6_P#M
MA_Z/CK!_9Y_Y$"__ .PI)_Z*BK?^,O\ R2?6_P#MA_Z/CJ.HSY,I1UI,4X"M
M1#T&35^QE2VN5=XU<9Z,.*ALP@?Y_NFK#-;I(VT%QCBNF,$H:B=.,XZO0O:I
M&7N3+#$I#KG"#@5#IL=H(9FN&Q*!P#T-7_#GB :?+-#):QRB9=HWCI3VTF*=
M+EIY(HV'S+@UPNIR7A/3;7N)XA8:?ME2M35DM;W^6Y0TR"749C8V\,;NYX8\
M8J*ZT>\TZ5H[A&4@X!QP?H:GT>1;*;SQN)C.2 >HKIM5\3IXBL8D:%(5@7"K
MW/OFM(RJJNE%>Z]V&$H.O6G[ZBNUM;G%A HVRC:1R*NQ:]?V]JUK%<R+"W5
MW!JE=>89-SD<]*99R0Q72M<J6B[@5Z,I14=KE0YJ=2T)-7'/</(<NV<^M0DC
M.14\A@GO"$/EQ$\>U=W#\.YO^$3;76FB^S!<C+<FL,1CJ=%+VCM?8VHX65><
MES+3J^IPZ11^1YAE&[TI8BRIO9#LSC-13+&)6V?=I6:7R IW"/MZ5WT*E2G[
MR9RXB*;Y8K;<G)63 #<'M5EK)+<1N[*RL>E9(8@\5)YS, &8G'2M:E=57LD.
MBX4TW)7?3R.]OM'\/WGA?SX&:+44 PG4/7$1A[1\+PWI4T>H3 KL?YATS3%=
MC>[IR &Y)Q7ETJ,L/&7,^9/N=N)KTJE6,J"Y4MV#S.LP+*&=NYKIH!I%UX7F
M64[;U1E<"LZRTU-:G:"SR954G-8ERDUI<-"\G(."0:YYTXU+1O9K4XLR4JLU
M3A5\]/U*Y($A",0 :>2TARQSQ39D10"K9S4L<;>1YF/EKNI-=1\LE[BU*,@P
MQJ$]:GE!#'(Q4)KCJ+WF-:'K'[/7_(_W_P#V"Y/_ $;%7TK7S5^SU_R/]_\
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MKK8<^:FU?0J[=W*J3@<\4 )MR6.[TQ6AIVK'3X98_L\<GF#!+#D5156GG"J
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M9!S]>/QKT6@ HHHH **** "BBB@ KPC]I#_F6?\ MZ_]HU[O7A'[2'_,L_\
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MFV+C(%1J^P],BF]\4,/ES4VL585GX..]0FE-(:B4FRA*2EI*QD,^EOV>?^1
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M]&Q5]*UE+<9;A_U*U)4</^I6I*D".;_4M52K<W^I:JE !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 8/C?_ )$#Q'_V"[G_ -%-7Q;7VEXW_P"1
M \1_]@NY_P#135\6T %%%% &KI%_;6D<R2VBSR.,(6'2J\UC+CS %RQ^XM06
MMRUI=17"*C-&P8*XRIQZCTJ:?4KBXNWN&*J6;=L084?05DXR4KQ-*$,/'FE.
M]V6(O[0\-:G;W,EN(Y@!(BRJ""".N*JZE?RZGJ,][,%$DS;F"C _*FW5W->R
MAYG+$# R2<"F6\<LERD<*>9(3\J@9S3C&WORW(J-1;L]"9KZ<::M@R*(0_F
ME?FS]:K%\QJFU1CN!R:VM;G5X8XI[9K>\C/S*5XQ6(%8J6 X'6BFTU>UC*E-
MU8J30 X(.,TK$%L@8'I3[> W$NP,%XSDU-:K;PZG$MT=T"N-Y7TJFTC:2E&G
MSVT(F6'S,J7,8 SGKFH3UXKNO&>J>&Y](M;'2;-!<1'(GC&/E/4-ZFN%K.A4
M=2',TUZG/AZJJTXSLU?H]PHHHK8V"KEEJ+V44T:QQL)5P2PSBM3PAX9;Q3JK
M6*3+$PC+[G8*H [DUEZMIYTK5+BQ,T4QA?;YD1RI^E9>TIRFZ75:D2BIWC):
M?A]Y3ZFBBBM2PHHHH **** "BBB@ HHHH WO!'_(_P#AS_L*6W_HU:^TJ^+?
M!'_(_P#AS_L*6W_HU:^TJ "BBB@ HHHH **** "O,_A)K^C67PPT>WN]7L()
MT\[='+<HK+F9R,@G/0BO3*YP?#_P>HP/#&D_C:(?Z4 7?^$J\._]![2__ R/
M_&C_ (2KP[_T'M+_ / R/_&J?_" ^#_^A8TC_P  T_PH_P"$!\'_ /0L:1_X
M!I_A0!<_X2KP[_T'M+_\#(_\:/\ A*O#O_0>TO\ \#(_\:I_\(#X/_Z%C2/_
M  #3_"C_ (0'P?\ ]"QI'_@&G^% %S_A*O#O_0>TO_P,C_QH_P"$J\._]![2
M_P#P,C_QJG_P@/@__H6-(_\  -/\*/\ A ?!_P#T+&D?^ :?X4 7/^$J\._]
M![2__ R/_&C_ (2KP[_T'M+_ / R/_&J?_" ^#_^A8TC_P  T_PH_P"$!\'_
M /0L:1_X!I_A0!<_X2KP[_T'M+_\#(_\:/\ A*O#O_0>TO\ \#(_\:I_\(#X
M/_Z%C2/_  #3_"N;U_X;:5/XD\-S:;X;TU;""XE;4 D,: H4PNY?XOF[<T =
MA_PE7AW_ *#VE_\ @9'_ (T?\)5X=_Z#VE_^!D?^-4_^$!\'_P#0L:1_X!I_
MA1_P@/@__H6-(_\  -/\* +G_"5>'?\ H/:7_P"!D?\ C1_PE7AW_H/:7_X&
M1_XU3_X0'P?_ -"QI'_@&G^%'_" ^#_^A8TC_P  T_PH N?\)5X=_P"@]I?_
M (&1_P"-'_"5>'?^@]I?_@9'_C5/_A ?!_\ T+&D?^ :?X4?\(#X/_Z%C2/_
M  #3_"@"Y_PE7AW_ *#VE_\ @9'_ (T?\)5X=_Z#VE_^!D?^-4_^$!\'_P#0
ML:1_X!I_A1_P@/@__H6-(_\  -/\* +@\4^'CTU[2S_V^1_XTO\ PD_A_P#Z
M#FF?^!<?^-9\GP^\(.NT>'=/B_VH(A$W_?2X/ZU%_P *W\)?] G_ ,F)?_BJ
ME\W0ZZ"PCC^^<K^25OQ:-7_A)_#_ /T'-,_\"X_\:/\ A)_#_P#T'-,_\"X_
M\:RO^%;^$O\ H$_^3$O_ ,51_P *W\)?] G_ ,F)?_BJ/>-N7+OYI_='_,U?
M^$G\/_\ 0<TS_P "X_\ &C_A)_#_ /T'-,_\"X_\:RO^%;^$O^@3_P"3$O\
M\51_PK?PE_T"?_)B7_XJCW@Y<N_FG]T?\S5_X2?P_P#]!S3/_ N/_&C_ (2?
MP_\ ]!S3/_ N/_&LK_A6_A+_ *!/_DQ+_P#%5A1_#:Q_X3F8OI0_X1[^SU\L
M?:&_X^=_/\6_[OX4>\'+EW\T_NC_ )G9?\)/X?\ ^@YIG_@7'_C1_P )/X?_
M .@YIG_@7'_C65_PK?PE_P! G_R8E_\ BJ/^%;^$O^@3_P"3$O\ \51[P<N7
M?S3^Z/\ F:O_  D_A_\ Z#FF?^!<?^-'_"3^'_\ H.:9_P"!<?\ C65_PK?P
ME_T"?_)B7_XJC_A6_A+_ *!/_DQ+_P#%4>\'+EW\T_NC_F:O_"3^'_\ H.:9
M_P"!<?\ C1_PD_A__H.:9_X%Q_XUE?\ "M_"7_0)_P#)B7_XJC_A6_A+_H$_
M^3$O_P 51[P<N7?S3^Z/^9J_\)/X?'_,=TS_ ,"X_P#&D_X2KP[_ -![2_\
MP,C_ ,:S%^'/A)6#'1HWQ_#++(ZGZJS$'\14_P#P@/@__H6-(_\  -/\*:OU
M.6NJ"DO8-M>=E^39<_X2KP[_ -![2_\ P,C_ ,:/^$J\._\ 0>TO_P #(_\
M&J?_  @/@_\ Z%C2/_ -/\*/^$!\'_\ 0L:1_P" :?X4S WH9XKF!)H)4EB<
M;D=&#*P]01UJ2H;6UM[*UBM;6&.&WB4)''&H55 Z  =!4U !7A'[2'_,L_\
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M6Y2+</\ J5J2HX?]2M25($<W^I:JE6YO]2U5* "BBB@ HHHH **** "BBB@
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MM9[N9=T<:DY;C. <8SCMUKB8O#/B37/$5YK=WX?@T,1:)+I\5K'<QR&YD96
MY7@*,X&?0?@NG^"=9M;'X=)_9JI)I$TCW^)8_P!T&Y)SGYLG^[F@#>T?XK>'
M-4;6GENH[2VTR;9YKDGS8]P428 X!9@ .M:S>/O"J:0VJMK=J+$3&#SLG#2
M9*J,9;@YXS7G&K^#/%,VC>.]'M]#\Q=4U'[=9W(N8@) 9D;9@D$':"><=,>E
M=/XM\+ZE%K?AC7=#TF#4$T<2))IID6+<&0*&4GY<C'Z+0!H^(?']I8^&+/6]
M$DMM2M[F^BM-RN<#<3GW!'H:[.O%6\ >)9?#5[(=-BAO-1\01ZB=.BG0K;1
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M(/6J'_"YO '_ $'_ /R3G_\ B* .\HK@_P#A<W@#_H/_ /DG/_\ $4?\+F\
M?]!__P DY_\ XB@#O**X/_A<W@#_ *#_ /Y)S_\ Q%'_  N;P!_T'_\ R3G_
M /B* .\HK@_^%S> /^@__P"2<_\ \11_PN;P!_T'_P#R3G_^(H [RBN#_P"%
MS> /^@__ .2<_P#\11_PN;P!_P!!_P#\DY__ (B@#O**X/\ X7-X _Z#_P#Y
M)S__ !%'_"YO '_0?_\ ).?_ .(H [RBN#_X7-X _P"@_P#^2<__ ,11_P +
MF\ ?]!__ ,DY_P#XB@#O**X/_A<W@#_H/_\ DG/_ /$4?\+F\ ?]!_\ \DY_
M_B* .I\1Z=-J_AC5M,MV19KRRFMXVD)"AG0J"< G&3Z5\^?\,\^+?^@CHG_?
M^7_XW7K7_"YO '_0?_\ ).?_ .(H_P"%S> /^@__ .2<_P#\10!Y+_PSSXM_
MZ".B?]_Y?_C='_#//BW_ *".B?\ ?^7_ .-UZU_PN;P!_P!!_P#\DY__ (BC
M_A<W@#_H/_\ DG/_ /$4 >2_\,\^+?\ H(Z)_P!_Y?\ XW1_PSSXM_Z".B?]
M_P"7_P"-UZU_PN;P!_T'_P#R3G_^(H_X7-X _P"@_P#^2<__ ,10!Y+_ ,,\
M^+?^@CHG_?\ E_\ C='_  SSXM_Z".B?]_Y?_C=>M?\ "YO '_0?_P#).?\
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M_P!_Y?\ XW1_PSSXM_Z".B?]_P"7_P"-UZU_PN;P!_T'_P#R3G_^(H_X7-X
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M?\+F\ ?]!_\ \DY__B*/^%S> /\ H/\ _DG/_P#$4<\AG"_\,X?]37_Y3O\
M[;2?\,W_ /4U_P#E._\ MM=W_P +F\ ?]!__ ,DY_P#XBC_A<W@#_H/_ /DG
M/_\ $4N9@<)_PS?_ -37_P"4[_[;1_PS?_U-G_E._P#MM=W_ ,+F\ ?]!_\
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MVT?\,Y?]37_Y3O\ [;7<_P#"YO '_0?_ /).?_XBC_A<W@#_ *#_ /Y)S_\
MQ%'/(=CAO^&<O^IK_P#*=_\ ;:</V=67IXK_ /*=_P#;:[?_ (7-X _Z#_\
MY)S_ /Q%'_"YO '_ $'_ /R3G_\ B*%4FMF*R.+_ .&>I,8_X2S_ ,IW_P!M
MJ/\ X9S)_P"9K_\ *=_]MKN/^%S> /\ H/\ _DG/_P#$4?\ "YO '_0?_P#)
M.?\ ^(JI5ZDOB8**6QPW_#.7_4U_^4[_ .VTG_#./_4U_P#E._\ MM=U_P +
MF\ ?]!__ ,DY_P#XBC_A<W@#_H/_ /DG/_\ $5'/(=CA?^&<?^IK_P#*=_\
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M6<8445L^%O$EUX3UV+5[."WFFB5E"3J2AW#!Z$']:F;DHMQ5WV!&-17TI?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M2_@S_P E9T3_ +;_ /HB2OK2@"W#_J5J2HX?]2M24 1S?ZEJJ5;F_P!2U5*
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M^TJ^+?!'_(_^'/\ L*6W_HU:^TJ "BBB@ HHHH **** "BBB@ HHHH ****
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M .-T?\,\^$O^@CK?_?\ B_\ C=>P?9W]5H^SOZK0!X__ ,,\^$O^@CK?_?\
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M_P#?^+_XW1_PSSX2_P"@CK?_ '_B_P#C=>P?9W]5H^SOZK0!X_\ \,\^$O\
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MNC_AGGPE_P!!'6_^_P#%_P#&Z]@^SOZK1]G?U6@#Q_\ X9Y\)?\ 01UO_O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
D@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>gyowp0iggm03000020.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gyowp0iggm03000020.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %6!0@# 2(  A$! Q$!_\0
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M=2^ENYM?\+#\+?\ 04_\EY?_ (FC_A8?A;_H*?\ DO+_ /$UI_\ "-Z%_P!
M73O_  %3_"C_ (1O0O\ H"Z=_P" J?X4>YYC]_R,S_A8?A;_ *"G_DO+_P#$
MT?\ "P_"W_04_P#)>7_XFM/_ (1O0O\ H"Z=_P" J?X4?\(WH7_0%T[_ ,!4
M_P */<\P]_R,S_A8?A;_ *"G_DO+_P#$T?\ "P_"W_04_P#)>7_XFM/_ (1O
M0O\ H"Z=_P" J?X4?\(WH7_0%T[_ ,!4_P */<\P]_R,S_A8?A;_ *"G_DO+
M_P#$T?\ "P_"W_04_P#)>7_XFM/_ (1O0O\ H"Z=_P" J?X4?\(WH7_0%T[_
M ,!4_P */<\P]_R,S_A8?A;_ *"G_DO+_P#$T?\ "P_"W_04_P#)>7_XFM/_
M (1O0O\ H"Z=_P" J?X4?\(WH7_0%T[_ ,!4_P */<\P]_R,S_A8?A;_ *"G
M_DO+_P#$T?\ "P_"W_04_P#)>7_XFM/_ (1O0O\ H"Z=_P" J?X4?\(WH7_0
M%T[_ ,!4_P */<\P]_R,S_A8?A;_ *"G_DO+_P#$T?\ "P_"W_04_P#)>7_X
MFM/_ (1O0O\ H"Z=_P" J?X4?\(WH7_0%T[_ ,!4_P */<\P]_R,S_A8?A;_
M *"G_DO+_P#$T?\ "P_"W_04_P#)>7_XFM/_ (1O0O\ H"Z=_P" J?X4?\(W
MH7_0%T[_ ,!4_P */<\P]_R,S_A8?A;_ *"G_DO+_P#$T?\ "P_"W_04_P#)
M>7_XFM/_ (1O0O\ H"Z=_P" J?X4?\(WH7_0%T[_ ,!4_P */<\P]_R,S_A8
M?A;_ *"G_DO+_P#$UNZ=J-KJMA'>V4OFV\N=C[2N<$@\$ ]0:J_\(WH7_0%T
M[_P%3_"K]O;06<"P6T$<$*YVQQ(%49.3@#CK2?+T&N;J2UE>)=3DT?PY?7\0
M!EBC^3/0,2 #^9K5JGJVG1:OI-SI\Q*I.A0L.JGL?P.#25KZC=[:'!/H.H#P
MA_PD1U_4O[2^SB[_ -=^[QC=MV_3\/:M2\OX=5\%Z9J>J:A>V<+@>=]BR&D;
MD8. <#()JA=>'O&B^')-%CN]/FLTCV*REEE=!T3D8'I_6M+2SKY\-V$>CV<5
MA+9Y@FMM15L28 ^8$#/7)[=:U?<Q2Z6(?AM=W%U9ZENO)+BT2XQ;">0-(J\_
M>],C'XYQ4_CNXN-,FT758IY4A@NPDZ*Y"LK8/([\*1^-6?"?AJ\T>[U'4-1G
M@>[OGW,EN"$3DGC/UK1\3Z.VO>'KK3T9%ED ,;/T# @C^6/QJ6USW*47[.W4
MXFXUZ\7XH)*)Y?[-2Y6Q*[SLW%<'(Z?>.?PJQ#>WEWIOC/5UNIQ&&>&VQ(0$
M" \KZ<%>E3#P)?\ _"'-8-<P'53>_;/.W-MW=.N,],]NM:UEX7GM/ 4VA"2(
MW<L4@>3)V%V)[XSCH.G:J;CT)497U,/P*]A=W5G)_:FLS:@L)>2*:1C 3C!Z
MCGKQS64UY:S^*-;BU;5M9A"792!;.1L ;B"#P<=L5V/AS3O%&EK9V5Y)I+:=
M FP^3YAE( ..H ZXJE!H'BG2M:U:\TN;23%?S^;BY,A8#)(Z#_:]Z+J[%RNR
M*'B[79O#?B_3I1+/)#%8-^Y+G$C_ #A2P[\XR?:KUA::U;^!K[4(KR:[U:^C
M\]=K[@@/.$'3.">G? ["KVH^&)]5\46.HW?V9[2.S:WN(\G+%@P.T8Z?-ZYJ
M/1]!\0:+HE]IMM?VIVR!M/E<%BJ[LE7&. 1Z9QD^U*ZLBN5\SN97@*YT^>[4
MKJVI'4A"5N;.[D)5VXRR_0Y]Z]"KC],\.:O-XKBU_6I+!)8(C&D=FK?,2",L
M3[$_I785,VF]"Z::6H5CZMXJT70[I;;4;WR)F02*OE.V5)(SE01U!K8JG=Z1
MIM_*);S3K2YD"[0\T*N0/3)'3DU*MU*=[:&)_P +#\+?]!3_ ,EY?_B:/^%A
M^%O^@I_Y+R__ !-:?_"-Z%_T!=._\!4_PH_X1O0O^@+IW_@*G^%5[GF3[_D9
MG_"P_"W_ $%/_)>7_P")H_X6'X6_Z"G_ )+R_P#Q-:?_  C>A?\ 0%T[_P !
M4_PH_P"$;T+_ * NG?\ @*G^%'N>8>_Y&9_PL/PM_P!!3_R7E_\ B:/^%A^%
MO^@I_P"2\O\ \36G_P (WH7_ $!=._\  5/\*/\ A&]"_P"@+IW_ ("I_A1[
MGF'O^1F?\+#\+?\ 04_\EY?_ (FC_A8?A;_H*?\ DO+_ /$UI_\ "-Z%_P!
M73O_  %3_"C_ (1O0O\ H"Z=_P" J?X4>YYA[_D9G_"P_"W_ $%/_)>7_P")
MH_X6'X6_Z"G_ )+R_P#Q-:?_  C>A?\ 0%T[_P !4_PH_P"$;T+_ * NG?\
M@*G^%'N>8>_Y&9_PL/PM_P!!3_R7E_\ B:/^%A^%O^@I_P"2\O\ \36G_P (
MWH7_ $!=._\  5/\*/\ A&]"_P"@+IW_ ("I_A1[GF'O^1F?\+#\+?\ 04_\
MEY?_ (FC_A8?A;_H*?\ DO+_ /$UI_\ "-Z%_P! 73O_  %3_"C_ (1O0O\
MH"Z=_P" J?X4>YYA[_D9G_"P_"W_ $%/_)>7_P")H_X6'X6_Z"G_ )+R_P#Q
M-:?_  C>A?\ 0%T[_P !4_PH_P"$;T+_ * NG?\ @*G^%'N>8>_Y&9_PL/PM
M_P!!3_R7E_\ B:/^%A^%O^@I_P"2\O\ \36G_P (WH7_ $!=._\  5/\*/\
MA&]"_P"@+IW_ ("I_A1[GF'O^1F?\+#\+?\ 04_\EY?_ (FC_A8?A;_H*?\
MDO+_ /$UI_\ "-Z%_P! 73O_  %3_"C_ (1O0O\ H"Z=_P" J?X4>YYA[_D9
MG_"P_"W_ $%/_)>7_P")H_X6'X6_Z"G_ )+R_P#Q-:?_  C>A?\ 0%T[_P !
M4_PH_P"$;T+_ * NG?\ @*G^%'N>8>_Y&9_PL/PM_P!!3_R7E_\ B:P/#>IV
M>J?%;5;RSF\VWFLP(WVE<X$0/! /8UV7_"-Z%_T!=._\!4_PKD]#M;>T^+FL
M06T$4,*60*1QH%5<B+. .G4_G5+EL[$2YKJ_<] HHHK(V"BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M$E?_ *%_7?\ P"_^O1_PDK_]"_KO_@%_]>@#=HJGI>HPZMIT5] KK%+G:)
MW!([$^E7* "L6V\.PVWBN\U\3NTMU"(FB(&U0 G.?^ #\ZVJJ1ZG92ZG+IR7
M*->1+ODA!^95XY_\>'YTU?H)I=2W1112&%%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 9^N_\B_J7_7K+_P"@&KWA_P#Y%O2_^O.+_P!
M%4==_P"1?U+_ *]9?_0#5[P__P BWI?_ %YQ?^@"@#1HHHH **** .1\%?\
M(HV/_;3_ -&-6_6!X*_Y%&Q_[:?^C&K?H *\]M;ZTL/B]K4MY=06T9M%4/-(
M$!.V'C)[\&O0J\U.C:?KGQ9UFVU&W\^%+5)%7>RX8+$,Y4@]":N%M;F=2^EN
MYVW_  DFA?\ 0:T[_P "D_QH_P"$DT+_ *#6G?\ @4G^-9G_  KSPM_T"_\
MR8E_^*H_X5YX6_Z!?_DQ+_\ %4>YYC]_R-/_ (230O\ H-:=_P"!2?XT?\))
MH7_0:T[_ ,"D_P :S/\ A7GA;_H%_P#DQ+_\51_PKSPM_P! O_R8E_\ BJ/<
M\P]_R-/_ (230O\ H-:=_P"!2?XU8M-7TV_E,5GJ%I<R!=Q2&97('K@'IR*Q
M/^%>>%O^@7_Y,2__ !57])\*Z+H=TUSIUEY$SH8V;S7;*D@XPQ(Z@4GR] 7/
M?6QL5YWK8\2:?XATVP3Q+(4U*5PI^RH/* ([9^;K[=*]$KE_$.DWU]XI\/7E
MM!OM[21VG?<!L!VXX)R>AZ4X.S"HKK0FEUM?#7]F:?K%Q-<R7)*&_,:HF[/&
MX9XX('Z^M7M#UN#7[.2[MH9D@65HT>0 >9C^(<]*Q_&6C:AXBEL-+AB"6'F>
M;<W1*DI@$  9SGD]NX]ZM>#+74]/T%=/U.V6%[9RD;*RD2)G(/!]SUH:7+?J
M).7-;H1>-=5O;&QL[/2Y/+U&_N%AA; X'<\_@/QIOA'7+G5?"TLETY-_:M)%
M,2 #N'(./H1^1JKK/AS4M>\8QSR2SV5A:6^(+B"10YD)YP.HZXZ?PU'H7AS5
M-"U_5HE\VYTZ\@W"XDD7<9?<9SG);G'I5>[RVZBO+GOT.6@\5Z[%H]KJ:>(8
M[F[DN/+.FM$A8C/7CGGZ#KUK=\=>(-<TS7;6+3+@QHMI]HDBV*=V&.<Y'H*I
M0>"=3M?"ME<VMFL/B"TN3(-KKEUST)S@]CR>F1WKHK[1;W4O&6G7\]GBR.GO
M#<YD4[&8-E>N3][J.*IN-[F:4[6]"CXN\670TK3?[$F\NXNX6NV8 $I$J%B.
M1]?^^35?5_$NJV_@[0+D730F]*K=7HB#%!ZXZ9/)_"JVB^"M7M;/6A>1[Y19
MR6=@#(IW*VXY'/R\^N/O&MU(-;TSPMI5E'HD&HJL)2\MI95!!XQ@G*D=<]>U
M+W5HA^\[MFKX8,SZ<\CZVFKQ,^8IP@4J,#Y3COGUYK;KD? V@7NCKJ4]Y EH
M+R8/':(^\0J,]_QQ^%==6<M]#:%^74SI/$&BPRO%+J]A'(C%71KE 5(Z@C/!
MIG_"2:%_T&M._P# I/\ &J-SX$\-WEU-<SZ;OFF=I)&\^098G). V.M1?\*\
M\+?] O\ \F)?_BJ?N"]_R-/_ (230O\ H-:=_P"!2?XT?\))H7_0:T[_ ,"D
M_P :S/\ A7GA;_H%_P#DQ+_\51_PKSPM_P! O_R8E_\ BJ/<\P]_R-/_ (23
M0O\ H-:=_P"!2?XT?\))H7_0:T[_ ,"D_P :S/\ A7GA;_H%_P#DQ+_\51_P
MKSPM_P! O_R8E_\ BJ/<\P]_R.?^)NKZ;?\ ANWBL]0M+F07:L4AF5R!L?G
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MT&M._P# I/\ &C_A)-"_Z#6G?^!2?XUF?\*\\+?] O\ \F)?_BJ/^%>>%O\
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M !5'N>8>_P"1I_\ "2:%_P!!K3O_  *3_&C_ (230O\ H-:=_P"!2?XUF?\
M"O/"W_0+_P#)B7_XJC_A7GA;_H%_^3$O_P 51[GF'O\ D:?_  DFA?\ 0:T[
M_P "D_QH_P"$DT+_ *#6G?\ @4G^-9G_  KSPM_T"_\ R8E_^*H_X5YX6_Z!
M?_DQ+_\ %4>YYA[_ )&G_P ))H7_ $&M._\  I/\:/\ A)-"_P"@UIW_ (%)
M_C69_P *\\+?] O_ ,F)?_BJ/^%>>%O^@7_Y,2__ !5'N>8>_P"1I_\ "2:%
M_P!!K3O_  *3_&C_ (230O\ H-:=_P"!2?XUF?\ "O/"W_0+_P#)B7_XJC_A
M7GA;_H%_^3$O_P 51[GF'O\ D:?_  DFA?\ 0:T[_P "D_QH_P"$DT+_ *#6
MG?\ @4G^-9G_  KSPM_T"_\ R8E_^*H_X5YX6_Z!?_DQ+_\ %4>YYA[_ )&G
M_P ))H7_ $&M._\  I/\:/\ A)-"_P"@UIW_ (%)_C69_P *\\+?] O_ ,F)
M?_BJ/^%>>%O^@7_Y,2__ !5'N>8>_P"1I_\ "2:%_P!!K3O_  *3_&C_ (23
M0O\ H-:=_P"!2?XUF?\ "O/"W_0+_P#)B7_XJC_A7GA;_H%_^3$O_P 51[GF
M'O\ D:?_  DFA?\ 0:T[_P "D_QKF/A/_P BM=?]?K_^@)6I_P *\\+?] O_
M ,F)?_BJR_A/_P BM=?]?K_^@)3TY78GWN=7/2$_U:_044)_JU^@HK,U!_\
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M_P !O_KT?\)$O_0)U7_P&_\ KT?6:7</JM;^4VJ*Q?\ A(E_Z!.J_P#@-_\
M7H_X2)?^@3JO_@-_]>CZS2[A]5K?RFU16+_PD2_] G5?_ ;_ .O1_P )$O\
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M'_P(3_&C^W=(_P"@K8_^!"?XT :%%9_]NZ1_T%;'_P "$_QH_MW2/^@K8_\
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MS6Q@:W_"/Z+_ - BP_\  9/\*/\ A']%_P"@18?^ R?X5HT4 9W_  C^B_\
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M?4M\,UU%'(OD1C*E@",A<]*XFM3PW_R-.D?]?L/_ *&*3C&VPU.5]SWG7?\
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M!W_R42C['K7_ $'?_)1*.:KV_!?_ "8<E#O^+_\ D!O_  DVD?\ /W_Y"?\
MPH_X2;2/^?O_ ,A/_A3OL>M?]!W_ ,E$H^QZU_T'?_)1*.:KV_!?_)AR4._X
MO_Y S-<US3;S1KBWM[G?*^W:NQAG# ]Q[5V%<OJ9UK3M/EN_[9\SR\?+]E09
MR0.OXUU%;X5MSES;V73U\V88M15.*CM=];]O)'"?"?\ Y%:Z_P"OU_\ T!*[
MNN$^$_\ R*UU_P!?K_\ H"5W=>A4^)GFTO@13U?_ ) M]_U[R?\ H)J[HO\
MR =._P"O:/\ ]!%4M7_Y M]_U[R?^@FKNB_\@'3O^O:/_P!!%<W_ "^^7ZG5
M_P N/G^A>KS[5Y=>\1^/;WP_I_B)M#M=/M(9SY,*/-<M(6Y!;HJ[0#CN:[J\
MN&M+&XN4@EN&BB:00Q#+R$#.U?<]!7FWC Z9K\MC+JWP[\07\XMDD2>V4(\.
MX9,999%.02<@\9S6Q@;_ ('U35);_7M"U;4(]3FTBXCC6_2,(95=-VUE7@,O
M(.*[&N1^'\=A;:3/9Z;X5O\ P_;Q2;O+O5 :9B.6SN8MT R3Z5UU ',>%?\
MD6[3_@?_ *&U;%8_A7_D6[3_ ('_ .AM6Q6.&_@P]%^1OBOX\_5_F%8^@?\
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M?]!3_P EY?\ XFC_ (6'X6_Z"G_DO+_\31R2[!SQ[G3T5S'_  L/PM_T%/\
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M?]!3_P EY?\ XFC_ (6'X6_Z"G_DO+_\31R2[!SQ[G3T5S'_  L/PM_T%/\
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M2O%:V=Q/)&,ND43,5'N .*+H+,K4444""M3PW_R-.D?]?L/_ *&*RZU/#?\
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MU&_:[OXK*\ANW#1R"3(+(N!L((R,=JO?$E]3MO"%W?:=JDMC]E3>XA0;Y.5
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M^1;M/^!_^AM6Q7,>'M;TFST*V@N=4LH)EW;HY;A%898D9!.>E:?_  DFA?\
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M_(K6O_7ZG_H#U=/XD9U?@9W=%%%0:'S%1117>>8%%%% !1110 4444 %%%%
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M_P!#%;].A_%EZ+]0K_P8^K_*)PGPG_Y%:Z_Z_7_] 2N[KA/A/_R*UU_U^O\
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MN+A'ZQ/3J_S/+K'X6//J5Q+?3"VL?.;R88CN<ID[<D\#C'J:Z[P=IEII&O\
MB"RLHO+@C%MM&23]QB>3[DUT=8^@?\C=XD_[=?\ T6:WE-RW.>-.,=CIZ***
MDL**X.Z\1>*=8\6:QI'AA=)AAT98A-+J"2-Y\KKNV+L(V@#@GDYK$\2?$[4;
M+Q!J.E6EYH6GR:9#&91J DD-S,R;RD>TC"C.,GG- 'J]%>9-X^\0ZP_A*'0+
M.PAEUVRFGE^W!R+=H]N2-I!8?>P.^1TK./COQXNA:WJAL]"$7AVYDMKW_6$W
M;(1N\L9^0!64\YR?RH ];$T1G, E0S*NXQ[AN /?'I3Z\PUCQ0=/\2>(=2L=
M.LA<6_AA+Z*XDC8R-\S$(Y#<KP.!@^]3V?B[Q;9:AX;GUZVTG^S-?D6%([0/
MYML[)N3+,<-GO@#'\P#O(=5TZYC:2"^MI(UF-N6652!*#@IU^]GC'6KE>*Z=
M=I:>&XS)96MV)?'31 7*%A&6F(WK@C##L>1[&M/4/''C00>*=2L+;1O[-\/W
MTL+"99/,N$3:2HPV%(4YW=R1QP: /5Z*\]TCQ7XH7Q3H-IKEMIBV7B"":6U2
MUWF2V*('"NQ.&RIZ@#GVZYG_  L/5K'Q7I>GW>K>&;];V_6RFLM-9VEMMV0&
MWEL-@@ Y ZT >FVM]:7K3K:W,,YMY3#,(W#>7(,$JV.A&1Q[U8KQG2[[Q=IT
MOCV_T&/23966LW5Q*MX':2=E12R+M("X4 Y/4GV->K:%JJ:YX?T[5HD,:7MM
M'.$)R5W*#C\,XH T*SO$'_(MZI_UYR_^@&M&L[Q!_P BWJG_ %YR_P#H!H H
MZ%_R+^F_]>L7_H K0K/T+_D7]-_Z]8O_ $ 5H4 %%%% !15.[U2QL+FWM[NZ
MC@DN-WE"0X#8QD9Z9Y%7* ,'Q093#ID$5S/;_:-0BA=X)"C;6W \U8_X0Y/^
M@_KO_@9_]C4'B7_6:'_V%H/ZUUE '-?\(<G_ $']=_\  S_[&C_A#D_Z#^N_
M^!G_ -C72T4 <U_PAR?]!_7?_ S_ .QH_P"$.3_H/Z[_ .!G_P!C5K3?%NBZ
MMX@U'0K.\WZEI_\ Q\0E&4@=,@D8(!(!QZBK>E:U8ZR+PV,ID^QW4EG-E"NV
M5.&'/7KUH RO^$.3_H/Z[_X&?_8T?\(<G_0?UW_P,_\ L:Z6FNZQQM([!44%
MF)Z "@#G/^$.3_H/Z[_X&?\ V-'_  AR?]!_7?\ P,_^QJ#2_B/X;U?5K?3;
M:YN$FN@3:O/:R11W&!D[&90#75.Z11M)(ZHB LS,<  =230!SG_"')_T']=_
M\#/_ +&C_A#D_P"@_KO_ (&?_8TW1_'VA:]J4=EIKWDPE+"*Y^QRB"0J"2%D
M*[3P#WKIZ .:_P"$.3_H/Z[_ .!G_P!C1_PAR?\ 0?UW_P #/_L:Z6B@#DO"
MYE$.IP2W,]Q]GU"6%'GD+MM7:!S6]6%X:_UFN?\ 86G_ *5NT 4=9D>+0]0D
MC=D=+:1E93@@A3@@UFZ7X8^VZ197<FNZV))X$D8+=\ LH)QQTYK0UW_D7]2_
MZ]9?_0#5[P__ ,BWI?\ UYQ?^@"@#+_X0Y/^@_KO_@9_]C1_PAR?]!_7?_ S
M_P"QKI:* .:_X0Y/^@_KO_@9_P#8T?\ "')_T']=_P# S_[&KGB7Q5H_A'3X
M;[6KHVUM+.L"N(V?YR"1]T'C"GGVJ>\UW3K&[TRVGG_>:G(8[7:I8.0I;J.
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MDE;[2D*QJH!ZMU)[8'8Y(I>PJ_S?G_F'UBC_ "?E_D9?_"2W/_/[I7_?J?\
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MGL<L./<5G:KXOTJRM-76UO[*YU+3[2:X:S6==^44M@@<CISZ4>QJ_P WX/\
MS'[>C_)^*_R*G_"2W/\ S^Z5_P!^I_\ XFC_ (26Y_Y_=*_[]3__ !-:;>)]
M(M(;'^TM2L[*>\B62.*:=5)R.V>V>,UL4>QJ_P WX/\ S#V]'^3\5_D<I_PD
MMS_S^Z5_WZG_ /B:/^$EN?\ G]TK_OU/_P#$UU=%'LJG\_Y_YA[>E_)^*_R.
M4_X26Y_Y_=*_[]3_ /Q-'_"2W/\ S^Z5_P!^I_\ XFNKHH]E4_G_ #_S#V]+
M^3\5_D<I_P )+<_\_NE?]^I__B:/^$EN?^?W2O\ OU/_ /$UU=%'LJG\_P"?
M^8>WI?R?BO\ (Y3_ (26Y_Y_=*_[]3__ !-'_"2W/_/[I7_?J?\ ^)KJZ*/9
M5/Y_S_S#V]+^3\5_D<7?:Q+J%G):RW^FJCXR4CGSP0?[OM7>U@>)O^1>NO\
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MZ;- L+QCD;XPS(WJ00?SKI* .8\*_P#(MVG_  /_ -#:MBL?PK_R+=I_P/\
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M4_>S#Y0 ,#:G3OWJ_!/K_B+QAKUO9:^VD66BRPP0V\5M'()24#LTFX9VG.
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M*GZUJUS7@6'0(/#NWP[J,FHV9F9I+J6<RO)(<;BS'OT]*Z6@#D?!7_(HV/\
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MXTE4A:UQNE.][&1X1"Z'<>+DW7UY';:@N,EIYGS#&3[DDDGBF>-+<^(/#?\
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M5[/2SJUMI5U)+<V"NH:0,FU74,0"5/('O0!U>DZSIFNV0O-*OK>]M]Q7S()
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M<?0NI_JU^@HH3_5K]!14&H/_ *MOH:I5=?\ U;?0U2H **** "BBB@ HHHH
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M^W_$/_0K?^5"/_"@#IZ*YC^W_$/_ $*W_E0C_P */[?\0_\ 0K?^5"/_  H
MNZ?X7T_3SK6/,GCUBX:>ZCF(*Y90I4  ?+@=\]:A\'^#]-\$:/)I>ER7#V[S
MM/\ Z0X9@6 & 0!Q@"H/[?\ $/\ T*W_ )4(_P#"C^W_ !#_ -"M_P"5"/\
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M]=_Z NH_^ K_ .%%T'*S+HK4_P"$;UW_ * NH_\ @*_^%'_"-Z[_ - 74?\
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M :S_ . ;49U'_H :S_X!M1S(/J]7^5DU%0YU'_H :S_X!M1G4?\ H :S_P"
M;4<R#ZO5_E9-14.=1_Z &L_^ ;49U'_H :S_ . ;4<R#ZO5_E9UWPW_Y ^I_
M]A.7_P!!2NRKD?AY;7-MHU]]JM9[9I;^214GC*-M*I@X/^>*ZZN*I\3/HJ*:
MII,NI_JU^@HH3_5K]!14&H/_ *MOH:I5=?\ U;?0U2H **** "BBB@ HHHH
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M]\BZ>(1.9<$G80"#M W=QQC-8VD?$_P=KVJ0Z;INLB:[FW>7&;>5,X4L>64
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MYR,>_% &Y7"?%C_D5K7_ *_4_P#0'KM[>>.ZMHKB(YCE0.AQC((R*XCXL?\
M(K6O_7ZG_H#U=/XD9U?@9W=%%%0:!1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110!=3_5K]!10G^K7Z"B@ ?_5M]#5*KK_ZMOH:I4 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110!GZ[_R+^I?]>LO_ * :O>'_ /D6]+_Z
M\XO_ $ 51UW_ )%_4O\ KUE_] -7O#__ "+>E_\ 7G%_Z * -&BBB@ HHHH
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M09Y-+N7?LW#=C.,\XKS3QY87U[XXT^72W*ZA9:=)=VP'\;)(ORGUR"1^-7]
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M/H'_ "-WB3_MU_\ 19K8P.GHHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MEW;H(=Z_3(/6@">BG6<%U>VPF%G/#DD;)U"-^1-9Z:A<.ZK_ &-JPW'&6M2
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M!VC(/O7(_%C_ )%:U_Z_4_\ 0'K2G\2,JOP,[NBBBH- HHHH **** "BBB@
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MO0D* <5:HHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P# J7_XJC0+S[?C_P  MT54_LV#_GI=?^!4O_Q5']FP?\]+K_P*E_\ BJ-
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** +J?ZM?H**$_P!6OT%%
M  _^K;Z&J577_P!6WT-4J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HK-\1,R>&=6=&*LMG,00<$'8:Y;P;XKTBT\)V4&H:K&ETOF;
MQ*Q+#+L1G\,52BVKHER2=F=W16%_PF?AS_H+VWYFC_A,_#G_ $%[;\S2Y7V#
MFCW-VBL+_A,_#G_07MOS-'_"9^'/^@O;?F:.5]@YH]S=HK"_X3/PY_T%[;\S
M2'QIX; S_:]O^9_PHY7V#FCW-T]#4>]O6L>'QCX?NIX[>'5(7EE8(B@-\S$X
M Z>M:U-*VYG.79CM[>M&]O6FUF>(KJ:R\.ZA<V[[)HH&9&P#@XZ\TTB.9FKO
M;UHWMZUYI8:]K=G=^'Y)M72_CU1E66V:)0T0) SD<]_;I6OXVUC4[>>STW1I
M3'>2))<2%0"=B*3CD=\'\15\FMA>T=KG:;V]:-[>M<;<>(KFX^&K:Q;3;+L1
M*&< <.&"MQT]?SK)TG7]5CUW1K<:W'JT=]&&N(5C7,!(R<E>X_H>*7('M&>D
M;V]:-[>M>>:T/$6G^(--L4\22%-1E<*?LR#R@"/SZ^W2NWTZWN;6PBAN[LW<
MZ@[YR@3?R>PZ<<?A0XI(%-LN;V]:-[>M>?>,_$&KV^KO;:-,42PMQ<76%!SE
M@ #D=@0?H37;V%Y'J&GV]Y%_JYXUD7VR,XH<;*X*;;L6M[>M&]O6FT5-A\S[
MDB$G.:?63J7B#2]"\K^TKH0>=GR\HS;L8ST!]15#_A/_  O_ -!5?^_,G_Q-
M+E;V1K&:MJSI:*YK_A/_  O_ -!5?^_,G_Q-'_"?^%_^@JO_ 'YD_P#B:.27
M8KGCW.EHKFO^$_\ "_\ T%5_[\R?_$T?\)_X7_Z"J_\ ?F3_ .)HY)=@YX]S
MI:*YD_$+PL#SJ@_""0_^RTG_  L/PM_T%/\ R7E_^)HY)=@YX]SIZS=;UVR\
M/V27=^SK$\@C&Q=QW$$_T-97_"P_"W_04_\ )>7_ .)KD_B%XJT77- @MM.O
M?/F6Z61E\IUPH5QG+ #J13C!MZHF51*-TSU.BL+_ (3/PY_T%[;\S1_PF?AS
M_H+VWYFIY7V*YH]S=HK"_P"$S\.?]!>V_,T?\)GX<_Z"]M^9HY7V#FCW-VBL
M+_A,_#G_ $%[;\S1_P )GX<_Z"]M^9HY7V#FCW-VBL+_ (3/PY_T%[;\S1_P
MF?AS_H+VWYFCE?8.:/<W:*P&\;>&UZZO;_AD_P!*3_A./#7_ $%H?R;_  I\
MLNP<\>YT%%<__P )QX:_Z"T/Y-_A1_PG'AK_ *"T/Y-_A1RR[!SQ[G05$2=Q
MY/6L3_A./#7_ $%H?R;_  K6AGBNH([B%P\4JAT8?Q*1D'\J$FMR)R3V9)N/
MJ:-Q]3244S.[%W'U-&X^IKR/4+T?VAXEFN-=O;6ZMK@BSBCN" YRW&WTX'3&
M*ZV^UN\LOARE_=%EU":W5%.,,7;@'ZX^;\*MP)4SK]Q]31N/J:X7P3<7VGZM
MJ&@:I<22SHB7$;2,6X(&X GZC]:Y*?4\'5G;6]3CU5+QEM((I7*L-W?MZ]_P
MH4-;"Y]#V?<?4T;CZFN&\3:==R>%4UBYO[^WU&WLXQ)%#-LC+YY) '7)/0]A
M6KX0TO[+I5O?M?WUS)>6T;NMQ-O521D[1CCK2Y5:X^9WL=)N/J:-Q]37#?$&
MZ:WN=$1KNZM[:29Q.;=RK%?E].IY-)X"U&2ZU#5K=+^>YL8F7[.+M\R@<Y..
MN.E/ETN'/K8[K<?4T;CZFDHJ"KL<A.X<FI:HWNH6NEVCWM[+Y5O'C>Y!.,G
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M(UNT4<S[ARQ[&&/!OAQ>FCVOXKFE_P"$/\._] >T_P"_=;=%',^X<L>QB?\
M"'^'?^@/:?\ ?NC_ (0_P[_T![3_ +]UMT4<S[ARQ[&)_P (?X=_Z ]I_P!^
MZT8H8[>)((4"11J$15Z*!P!5JF&/)SFFI/J3*'9$=%/\OW_2CR_?]*=T1R2.
M6T;PQ]CUO6+^^BM)Q=7'FVYV[FC&6/<<'D=/2G^)_#UQXANM-A:2-=.AD,EP
MA8AW] ,#Z]^]=-Y?O^E'E^_Z4^?6XO9NUCBT\$C2_$>G:EHK+'%$2MRDTK$L
MIX^7@\X)].@J$>!YY=%UJSN7MC-=W37%LZDG8>V3CCT.,]:[KR_?]*/+]_TI
M^T8O9/L<Y=Z1J-_X*;2KB6 W[0"-I-QV$@CG.,\@>G6M32;22PT:QLY2ID@M
MTB8J>"54 X]N*O\ E^_Z4>7[_I2YA^S9R_BG0]1U6ZTJZTV2U2:QE,N+@L%)
M^7'W0?2FZ%X>U"VU^[US5KBV>[N(Q%Y=LI" <<\\Y^45U7E^_P"E'E^_Z4<^
ME@]F[W&44_R_?]*/+]_TI70^21!-:V]["UO=0QS0O]Z.10RG'(R#[BJG_"+Z
M!_T!;#_P'7_"M,)@YS3Z3?8N$=-49/\ PB^@?] 6P_\  =?\*/\ A%] _P"@
M+8?^ Z_X5K44KLOE78R?^$7T#_H"V'_@.O\ A1_PB^@?] 6P_P# =?\ "M:B
MB[#E78R?^$7T#_H"V'_@.O\ A1_PB^@?] 6P_P# =?\ "M:BB[#E78RAX8T$
M'/\ 8NG_ (VR?X4O_"-Z%_T!=._\!4_PK4HHNPY5V,O_ (1O0O\ H"Z=_P"
MJ?X4?\(WH7_0%T[_ ,!4_P *U**+L.5&7_PC>A?] 73O_ 5/\*Y;P!''#XD\
M6Q1(L<:785$48"@/+@ =A7>U##9VMM++)!;0Q23'=*T:!2YYY8CJ>3U]::EH
MT2XZIHTT_P!6OT%%"?ZM?H**DL=UJNRC<>!U]*** $VCT'Y4;1Z#\J** #:/
M0?E1M'H/RHHH -H]!^5&T>@_*BB@ VCT'Y4;1Z#\J** #:/0?E1M'H/RHHH
M-H]!^5&T>@_*BB@ VCT'Y4;1Z#\J** #:/0?E1M'H/RHHH -H]!^5&T>@_*B
MB@ VCT'Y4;1Z#\J** #:/0?E1M'H/RHHH -H]!^5&T>@_*BB@ VCT'Y4;1Z#
M\J** #:/0?E1M'H/RHHH -H]!^5&T>@_*BB@ VCT'Y4;1Z#\J** #:/0?E1M
M'H/RHHH -H]!^5&T>@_*BB@ VCT'Y4;1Z#\J** #:/0?E1M'H/RHHH -H]!^
M5&T>@_*BB@ VCT'Y4;1Z#\J** #:/0?E1M'H/RHHH -H]!^5&T>@_*BB@ VC
MT'Y4;1Z#\J** #:/0?E1M'H/RHHH -H]!^5&T>@_*BB@ VCT'Y4;1Z#\J**
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8BB@ VCT'Y4;1Z#\J** )H_NT444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>gyowp0iggm03000002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gyowp0iggm03000002.jpg
M_]C_X  02D9)1@ ! 0$ L "P  #_[@ .061O8F4 9      !_^$3PD5X:68
M $U- "H    (  @!$@ #     0 !   !&@ %     0   &X!&P %     0
M '8!*  #     0 "   !,0 "    'P   'X!,@ "    %    )X!.P "
M$@   +*':0 $     0   ,0   #P + (K@ !    L BN  $  $%D;V)E(%!H
M;W1O<VAO<" R,2XR("A7:6YD;W=S*0  ,C R,CHP-#HR-R P.#HT.#HT,0!4
M:7)T:&%D978@06-H87)Y80   Z !  ,    !__\  * "  0    !   $0: #
M  0    !   "00         & 0,  P    $ !@   1H !0    $   $^ 1L
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M$0,1 #\ V**W7@P]K""![S U#WSN_P"MJ;\6UFV;&'<YK="=-Y !X_-W>_\
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M]NW8YM_M]+_"^MZOZNI7_L6O'TP;JK;J9I?:26;BT?K%/OKWU>H'_FW?H_\
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MZY;4'QN:YU7NCZ%GT'_1=OVO_KHZUX(TOQ:GIT!K3Z=4AQC]7MY]NK-O]?\
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M P,# P,# P,# P,# P/_P  1" )!!$$# 1$  A$! Q$!_\0 'P    8" P$
M            !P@&!00) PH" 0 +_\0 M1   @$#! $# P(# P,"!@EU 0(#
M!!$%$@8A!Q,B  @Q%$$R(Q4)44(6820S%U)Q@1ABD25#H;'P)C1R"AG!T34G
MX5,V@O&2HD14<T5&-T=C*%565QJRPM+B\F2#=).$9:.SP]/C*3AF\W4J.3I(
M24I865IG:&EJ=G=X>7J%AH>(B8J4E9:7F)F:I*6FIZBIJK2UMK>XN;K$Q<;'
MR,G*U-76U]C9VN3EYN?HZ>KT]?;W^/GZ_\0 'P$   8# 0$!
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M[?\ 5_J_;U[S7)N2./\ #_'ZD@@\G_;'WJM!PSU:E6.<==>4W;DD@"P(Y]1
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MR>/Z7]^+ 'AGK05F']&O^KAY?9U@!^GJ')'Y_%R>" 2.2??J#('5J\"3\_\
M5C'77E_J3>YL!;Z?46 )N;?X?[#GWNN> ZJ!C%2/M^7^KR_EUV1:Q%K$DVN?
MZD"][DD$?T!^OO7#[>M\2!IQ\NNE'^-KG2;D$ZA;_7Y!X]^\_EU[%*GC\O\
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MSJN.?4&Y()>XO[\. I_J_P G7B &.H_ZO\/72V !)YT_F]UN?KS<DV-N.?\
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MSI-R+G4%(_V_^W]ZIFGEULD$#U_U?ZO]6>)E^IN PN+"_-[#U?X<?\3[W7R
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M2#_B I-C?Z\>_ D\1UHT6O#AZ=<;6 M_0_FQ!^IL2/JQO_3Z^]]:TX%/\/\
MJX^N.LG^O]/]]]/=?7I_[>L?TXOS^+'Z<_UO;W[CU4#%!Q_U?ZJCK-YO\!_R
M2??M:^B]7JOJ?V?[/7__T+"1<'_@0  "#8-Z0>"!<@7]5_I]?>1>"?\ 5^?7
M)45&*?ZO]7^KCUXRFX(5[<L!I %KDCZ^GZC\_7WL''R_U?/K14@U_P!7^#UZ
M[\UB .#S]%/)/T%N00+W_P !_3WZHP?G_DZ]0YT\*>OSZB"4G^MK7 T@:KW)
M]1YL+?G_ &/O0(-<'JV@?EU[SGDW("_D:2=0!:UK!K D?X<?7WXGK06G78F:
MX!!'%K\#Z"QM<\<C_8D6_P ?>ZXX8_;UX+\O]7IUV9N;7(N3:P%BI  XN"./
MH./?M7EUX)2I]?V==^8DJ0&)(O\ 2XN+DD:OU _[[Z^_:AC'6RAJ*G'^K_5^
M>>N/F>Q'J8W)_3:QMS>][6/^W_WD:+4!X5Z\$K3&.N7F/-_TD FUCS?\WX-^
M!;_>OQX&F/+KQ6O ?ZO]7^K'4<"VL7)_-[V)!(/Z>1Q;@C_#CGWKU/EU>E/F
M>N GX/II;$ $V/!_%P1>RD#_ %C[W49]>J: U.XZ?]7^KY9Z]Y](*LK,+ 7]
M)%_3<"Q%_I]../?JU-*=;*T K7Y=1Q-8:M)6Q/'!YM8+<?0'_8_Z_O5<T_U?
MX>MZ3DD8'^JG^K/78'-CSJ%@?Z#D6])_(_V%O];WJG[/3K9IFHSZ^?7K&UQP
M3?\ 3<\W4DCBX']?]M[]CB*8ZUF@/D<?ZA3'7$SFP-R!SPQ%@2/J0;D&W^/)
M][P.'7J,06(P/]7[?\/7C,YU#CC@^E0;"X"7X(-QR;^]]5-?/_5_E_9U'\MB
M;&UR?Z!C];BP]1L.?Z_\1K'D.WJU&J#6K?ZO]7D>NSR02>'_ #:U@>!:Y'TM
M;Z_0V]Z(]./5LUJ6[?\ B_\ 5G[.HXE_3<6()-P/R.3_ &C8$<<'Z^]^O6N%
M *5'7(#B]P>2;_1N--_S:X_WKW[@2*=;H2JFIX_L_P!7\NN/F_PY)(/Y%^&/
MT(L.;_U_V/OW'R'5!04IC/\ JX?[/7+Z\_["X^O'-_Z V_U_]?WK/3@I0@^G
M[<?ZO]6.N/DO<_@GFUN0;<$_\%_P_P"-;^5!U3RK6G^7KKS6!X/ M8+^;_@<
MWY/X/^/O=?D.M$4I4X_U?*O^KTZY"9C8&_YY9;FQ/T+ 6!:Y_)Y]Z]<#JX!.
M*\0?,XKUQ$P-@H(^A:PL!SP?K]>/>ZU^SJE*X"YZ[\O /)'Y(YN+W^I-RO)O
M_L?>O6G5B* 4'YC_ %8ZY6  _!^HO?DV%^+BVJ_(^@'OP]/+KQQGS_U?X?MZ
MBM+_ +'41_J?R+ V)N1_3_#WZO&HZU3X<Y_U?ZL==B7CBXO?4#:Q(N+?1[<_
M[;WXGKP&:^?^KTZD?0"WX "_@ ?3@6YT_P"-K>_?;UO@#2M*X_+J#:_('Y((
M_P!B#:_)()_'Y_U^??O2O6\$DC@/\O[?V?Y>N TW_P!C87L !J!&DJ >"/Z?
M[W[\> _U?+JH.21]GR]<>?S_ .+ZXB4@D_0_4$6!L2?Z$"QOS]1_L;>[ 5-:
M#JM:#CC_ (O_ %>?^>8.>"#_ $/UN1<VU&_]?]>]_=3T[2M#Q_S?ZO/Y]1O*
M2?J1J(]/!%A=B?S>X)O8^[>7E3IO.K@=77O,;DW/]+7 )M;^H5;:OK_K_P"O
M[UP\L'K8()^8^?\ G^W/77E#7O<ZK\7MR!Q^2-1N;\G_ 'KWH5I7KU5)/K_J
M_P /Y]=^=A8L3_K"WTX-S>WT^I][-":4%>M L "2:?S_ -7^JE.O>4K]?H0?
MQ]+G\"XN3?\ Q]^-/(9ZV*BI/G_J^77 +8W-R; $#3;A;B_JYN?S];@^V#D$
M_P"K_+_Q76Z:3Q-:?ZO3KWFG!-[7/UY!(/U)X6X _P"(][T_/'5=5" ?\M>'
MV?ZL=<_,;LPGX*DA;  ?T%OR"/R/]C[K0GK9:C%A7A_J_P!7[:=1C+<?J/TL
M!SR/P-/TY'T_%Q^/=J_(^?6BOG7T_P!7^K'E3KWDY'# BUK+<JMR1SJX4<?T
MM[U4<,];H<8S^77C*221R ME^J_[?@"UQ_QOWO5Z#KQXG_5_J/Y]=K*;7!/"
M@K>X7Z_BS#^O/^'OU:4KD=:%:,!4&G^K_5\NL F L;@&Y'-^/Z67@\@<#_D?
MO5>..M@$<!UT)18+Z=):QX/U-OIRUO\ 6_U_?CQ^77E&*4\_]7SZ[!L38@_0
M7O8"QX'XN>3];V/O=#^0ZWZ]V>O#_"PY-[$6 %_ISSIMS^?I[UZ=>_/_ %<.
MN+ GFU_4+'Z *2;$6(Y_V'/^M[\.!'6B*FI'^;KK_ V-K?VKD@W /!_(L+_[
MQ[L:>8Z4*2!V\/3C_J\L_+KEYA<W :Q(^A'U:Q#<7L+?G_BGOU?3JA4GRKF@
M_GZ?\5UWYA>P'#"]C< V '%KL;#\7]ZR<_+IK@=/EUX@>F_(8AN.3<CCZ\VY
M_/T]ZZW04%?M_P!7^3CUCYYU6XXY'YM<VN";W'U]V]37IX'@*=W^K_#_ *CU
MB\ZB_ Y^H)L2>0"0#;Z'_'_BNA4TIQZ\2 #J.!]G^Q^SKOS @Z2 ?Q^!^/I8
M6'"V']/>JXX=,!:$@?X?]7V=<A-< 7Y (Y/-C]001]5O_A[W6GEGJH#'-#Q^
M7^Q\NNE_/(^I-K_U/'(O8!O]Z_U_=?\ !TX*#[?]7^K_ &>N^?Z_6UM0%OI>
MUK_3^EOI[V!\L]>/S./LZBFHYX M;_$6Y)N5/TL 3[WBF.JT:HQ7\_\ B_\
M5\^N_,>#QQQ<?FWYYX%[_P"\?CWJHK6F>O,",>=?E_EZ[$M[\:3SZK&XN ?R
M!] ?]?\ WOWZM,GCUZE:4%/]7^S_ )NNA]+FP-@+_2Q_K;D\\CWKC@'J^ 2Q
M'^K_ "^G7C<@?I)'/'*W)N;^]4_9UO56F16G^K_5CAUZY_!/Y-[$_DFWXO\
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MUI_2I^=>N0E;@WY%]('/ULIY*H+"PXM[T1 &*/J##T _Z"Z?\%$)J17T-?\
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MD!O;_@UKZ1>Y-QI%PQ)_'O1MUI2N.O1^ Q)!-3QQCS_SY%.L)E!^CJ;"]]1
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MU>K>OKUQ+@%Q92 ;,?H+\<#BUU/MPPR8R.O!T.HC X?ZOGQ_U'KAP0+!EYN
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M_P O\O7K\V-^ #?_  O];->Q! _U_?NMC)H?]7[<_P"JO71E'TMR02;@'@6
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MF/D7TVN!?VQ%>&H4'LZ3W_+EQ"KR^&=7J=7D13R^?7"6LIJ6CI8JFKHH*H5
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M;I*C K_J^?6AM2$4*U4_,]8XZZFF@D\#T<K25.JI$,DE5"K B_C0*DE)$/\
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MUK:0 ?\ 4.F'VN]MB=7 ')-?/RX=9$\;QB;R:B" )Y !1K;Z!#QJ(!XO:_\
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M@XY'-OI?U6N?K8?@_7_#WZI]/]7[>MBHXL?]7^;_ %#AUUY0+\"_Y N3S?2
M3R+$^_9H/7K5#FO^K_/^?7+RC_'@$  6%N/U6' ^G'^/OU30$CKU,T4_ZO\
M4?MZZMQZ3^;$&UKCT_X_4C_7X_UO?O2HZV:G@WG_ *O\'^3KWE4VXN;@WOP
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MH?XW54^Z:JF6>M62'-F&&EF,L);T0OI'-@+?[%;S%/<0:&AF92 IH/.JU/\
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M[6_KPE2YW:YFFCCN2(HR!4+Y^E<Y^1'4US\N\I<F<N6.X[ALZ/=R1EBSN:4
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MGT+_ $)X]RE"T1L3(1WT:F1UB+8R;E<;VEM<.#"63&BG$BN:>?5JM?U_U/\
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M?7NT4^8_U#_53^77?W!%K  BX4-Q?E@3^D #@?D?[ ^_5&<=;H*@@^0_U?\
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M3[J.&!7KQI6O^K_5_J^?4;S$#FH(!(%M) -OS_:U$6_UA_K>_5).#GIVBK3
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M(!!-[V:RGZ_GZ<>]DGCZ=5H.T!:^?S ]:U_S\.N;3V4FRC@AKA03P?3;@ @
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MJA(*FCR E"&*IAJT56-S5)(%HXFXT2J:DK^18^Y/@9ELR"<Z3UAI8R6_[]!
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M''F.C5?S3,[C:CO3;&VZ&>G2KPFSJF').SAI\9/4UE5D8A+$NI?\IIZI&6[
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MYY8?J/\ MK_3WOCUKX:U-/\ +^W'^SY"G7A,2%///U!MS9B&L#I(NWT'TO\
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M]Z^OOWGFE?\ 5^S_ %<>MU% H';_ *L?,=>^X-[%0">391J0,#JU GFQ%O\
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M31Y:HW'4U\=110T])54VK&K3TDL9<_<7]94W%_Z^SOFC;6W>.T^E4LZ."14
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MS:WT) 'TX-C[]BE#7K0!J*"I]?\ +_J^P]<ONU'(-B"!^+:K\F_]1_K'W[%
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MM^S_ %#KFM6  H#<CA!]/R/KJL;K?_6]^Q6N>/7BK4*AL4P.N/WB_G5<V^@
M %OZW-^?][]^KQ/5=!HM7KUW]VGXU?FWI7Z&W^U6Y/TY_/O9<>0/51!0FK8^
MW_5QKUT:T?2S6YOQ>_'XY%[7]ZKQ.>KE?*N!7\R?3KHU2:A];D_4B[<<\7X)
M _WCW[4?,&G6S&-2Y%0>N)J$-[:Q<D\+>VK_ &W-C_A[]J^76R".!Q_J\_\
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MM0+?F[:0"5('^\#W7(\JCKW:Q/D?YBOG^5?GDTQYR/.@LI]9!)NP/]01SR
M/Z?CZ_GWNII7JW:6TBI('^'Y_P"H'@>N)F!/  4<?FWY!O<W4@$_X^KWNI_E
MU09R*UK_ #\Z^GY\,_ER,H](XTE3?]-B?U#\7YY-OZG_ &/OU3BG5^)-17'[
M?Y9Q4FF.L#RB]B.;CZ7L"02#8WM8D'_;?TM[UJ/IU5E4,<&F!@_;^SR_E^?$
M2@\,+$EK @"]BHO>U^;#D@7^O]/>Z_+K0! 8$Y)\R*'R\\TZZ\P)N.0QL;6N
M2!;_ %1X:W^N;V_K[\:@@@?ZN/6Q0@BE!7UR?+CC\_/YGKF99SJXO;ZE@O!%
MQ8ZAIU<_U)'M^@P.K $$D#('R_SYZ\99[#\7M]."WJ"G42  5M_M_P#6'NWV
M'/5:'%1C_5_D_P W4?RS>4-:XX )-^#>P #<7N1Q]/=?\/7O0<<_ZO\ 57\_
M3L2@_P!G4VE@6!N2?H&YNPM_3Z'WNM>)_P!7[>M:@*!14_S_ ,'^JO"O7C(?
MIP1?4?Z,K"QL!8G_ !^O^]^]"E>'3)^$H"*_Y*>7G^PDYZYM*0&*KS;\-]+B
MQL>0/2.!_P 3]?$C%*=7_BQ@C/\ /UQ3B?/^?4(RP $B1M/ O>Z@%P2!_7CG
M_C?MC%:]7; TFNG'^&OGQ/Y=<O,!]2?H20>!J](.DD791_MK?[#WK'&G7NX&
ME33_ %<*T/7!?QR+WO\ 2_JU D@BY*@GZC_;_GWOAGRZ\M&!R*_ZC^>?G^?6
M$<"P;ZG\?@\GZ$\ GCGD^_$'->M5 (S_ *J_M(SUEU4G]'_Y+E_XK[IH_IG^
M73FL_P '_'O\W7__US-B>_Y//T%["X_IJ!L;'CG_ 'CWD7X(KZ=<I/T/7%/G
M_G_R_P"Q&,Y^A  XM]&/UM:Y N;D_7_D?O" _%G_ %?/Y=:TPDDC _/KWF)!
MXLUP#;G^IO\ IYN?I] /S]#[WX0P:]>"PT(KGUH?M_U8Z\)BW^(N1>WYX%A=
M>!<  ^_>#Y?ZO\/7BL);!_P_ZOSIUV38DAP+&VJW];#BPY/ N>./?C$*9/6Z
M6YJ/YYQUWYFL;_E;WXM>Q_VG\\?\5X]^$0Q0_P"K]O\ J_/K16&F?3Y_ZL_9
M3[.N[#5P01]038<GZJ.>3S_MO?O"&,]6(MP:4\OG_AZX":YL OY'/( N>;!>
M!;WHQ"F?]7\^JA8:TJ*<//\ /U/RZ[\QN+"POZOS8 ?0W%UU _@_[?\ .S$/
M2F.MZ(>&JM3_ *N/^4_Y^N_-_@ O))XY4#@W(^I_Q'_$^]>$1J-3_/\ S];*
M6]%]!]O[?]7[/2/Y9A;D<GZ7(%['@\'_ 'W^\>\,5&>'RZ]IM\X_P_ZO]7IU
MG\UQ8@?XV^HN1:UU)X _WGWXQ"H]?]7SZJ%BJ02-)^W'^'^?6$2D_P!DZKFQ
M'!)/]/I90?Z_7VF^MN?X?\'^;\NK:(LBHX_/_5]G77^-E_/U/!Y%_P"M@1[]
M];<'&G_!_FZ]IBJ<C^?VX_P_X>NC*WT :W*AA]+'ZV_!Y_XU[]];.*U'\Q_F
MZWIC-//]O6/RG]0-R;W^G XMR03]#_C_ $]Z^MN<47'Y?YNMZ8<U;/#S_P /
M\^NA,?H">+<7MP; \^I;@M[V;RXSCA]G^;K5(>%<_G_A_P!GKORDD\GD"_ _
MISP/KQ[]];<_P_X/\W6],5#G'Y_ZO]7V==>;Z\?CB]K<<6Y'' /-_>A?7/#3
M_@_S=;TP\:CT\_\ +\^NR3QP!>_-Q;T_4"X%P0>.>?>_K)\G3_@_S=:_2J*L
M*?G_ *O]6>NW'];V^A 'TX/UL>1<#_;>]"(9 /53X!"U)I^?^K_BN'4<A6-R
M/J; FUB 1;C\V]^$0_BZN3":9_D?\O6:P^ER/P+<"S $_6_Y'T]J3&,>O50(
M1Q./S_V?LZ[-A]21J'^U6O<GT\VL1^./>_"!'V=;K"*5/'[?]7^KCUV-/()*
MF]B /ZD_TMQI/Y]^\,>O^K_5_L]> @I\^L%QSI!!/-UL?U<#G^SQ_K>]>$./
MEUX^!P4Y/V]>\IY_'%[\"Y^GT*WO;\>TWA#_ #=>*14Q3A\_Y=<N2>&X!N+D
MC_#@ 7^O^W][,-.'6Q% P-3_ (?\_P#J^SJ.!^ NG\V^G!-E-P#:P^O'^P/O
MQB%:ENG0+>E /\/6<:OR#;ZVOR"+WYXY-K>_>"M0*YZ\5A()+5 ^1_U<.L-R
M#^I0!S;E;'DW_P!?FW^M[J(ER:Y^SI'HBJ  /YBGG]G^KYYZ\K'\@ZA^;+^;
MEOH+_3_6]^\,8K_J_GU[1$:A:9_U5_R?MZZ\GT/!)Y)) ('T'UX!_K_A[WX9
M'#TZ>+0GBPI7Y\*]<[ &WJ^GX+?ZP'ZK#ZV]^\.M:GK?Z/#5Y?/KHR'BUK@$
M_FUP+K8FWI)_/'_$^_>&OR_U?GT\4A%.XT]<^OV=>\HTWL+FXMS]?J/H!_7_
M &W]?>A$,8KUXK !0G^9_+T/4;RJ;@@V6PMQ:Y&H_P!-(!)'^OQ[M]9=8JI_
M:/\ -UZMN,5%:X^7K_F\L_GUV9K?4$>H#Z:B38_ZXX(X_P!>_P#KZ^LNC3MJ
M:>H_S=6_14&IHM?G_J_U5ZZ\MV(^X /T(4?ZJQLUR+B_%K"]_>Q>70KC'Y?Y
MO\O6J0$B@XU]:?YOY5K]AZ\TP%A8'\$\&QO>S,=0'I(/U]^%]=-7M-?RZT5M
MUT\*?F>/^JO^H=1@UN .+C\AOK8'3R5^O^']>??OJ[D@U7/VC\O+JI$"DC5B
MGS_R'Y5\O2OEUXW(MI-AJYL2%(U6MP6  -A[\+RZ'EG[5_S=;*P&@\A3R)_(
MC)'R]*GYU[\A/-C_ &;&P-K\7%KG\'_8>]!#P/\ EZ8/TYJ5:H\ZCY?9\NN]
M9 Y4CD6(TL/^# :A8"_/^/\ K<ZT5/E_/JVB$ =U&^P\?]7^3TZ]8VXJ4('/
M]"=-^"/5>Y7_ %_ZCCVQ];<_P_S7S_+KU(?6E?D?+_5_DZZ\_'"@@6)*FZV*
MG]7 X#6/UL/>A?79_#@?Z7_-UK3;J"-1R?GZ?Y\_Y:==DL3ZE)']1]> 21H*
MV)'^W_VWNPO;D<4_F.K:8FI1J_:"/Y4_9_L'KH5-BP&GZ?J_IP38+SR/J;6/
MNIOKDB@4T_+_ #=>01+4DYQY'./+'D.N7+ \:@!>P<:B5"\DWTD$W^EC<_U]
M[^NN3G3_ ,=_S=/4@R!\7VG^?^H<>N F9M1M=5^H;@CB]K7"@WXOS?\ I[]]
M=< FJY^6G_-UHB*@[L?.OIY?ZO\ 9P&ZJ2%MI!(Y_(TVU<C5<D_U_5_L?:CP
MA6I-*_ZO]7SZJ1;$45O+T/RSGRX_ZL]<EF_M7X%P0;DG\7! L?2K<6L?J?Z>
M]>&:4/\ J_GUM8K4FH)X_.OY8\L_YLXX\@?ZQ8FY!4<ZN1Q9B;6YM?Z#VQ]?
M<"M%_F/\W6Z0U4U-1PX_['^KRX]>$I!4Z#J503SJN"!];VY'U/)O[]]?<5IH
M_81_FZM2+)UD5]037[1C_5_/B8^;&UPH<$\6M8WOJY8:;#\V]^^ON/-*_F/\
MW6J0FH5J8P,]1RA8 :N1<$D ->_UN&]0U7M?Z>_?73UJ(\?:/\W7CX8 !:A'
MVX_(==W:S!0 ;VUBVK2."VFY/*D\\<_[PH\,5X_\6/SZKHMZ')H//.0?MZ[&
MH$Z=7.H?46!^BD&XYU"Y_!_K[]X0_B_U?ZJ?[/5C';T(!X?;@_R^W^6,==D&
MQ_R;AA<?34+#@,O(L0.?I>_]?>@F.)Z\5MJY./L/^K.<_P"7KRSDCU F_I/T
M_5ZF'! -B2??BAR0:]:6*V.E345^1_;\_L^?[>C.W(,QU#386 _H0+K<CU6'
MX^GU^GMGZRZH:4_E_FZ\1;U'R^1%?\.?R\OEUT%X-B!86(*J+"UR+<V_Q_J?
MK?\ .C?7)_!G[1_F_EUX&(::FJ_9_F_D>N1G;DC@<D74'\K:Q(6Y-O\ ;C_;
MOE"<'_5QZWX=J,JW;^>. K_AZ\)P+E@"#P&M;26NS BQ'.JUK@<_['WX1$\>
M/6]-K7%=.,Y_U?ZL8SU& 8ZN5L 1RBJECI7^NJUP/]X]L?77/DA_:/\ -U[5
M'3-*_(4^T?/]O71E:X)@L1?22!^>!]#_ &;&PM<#_8>ZB^N3C1C[1_F_U4ZW
M2*E1(:\<@_ZJ_;G..NB3>W@Y8GTZ02JCZV')L ?H;6_WJWUMS_"/VC_-UX&*
MI[_S%?\ 8^7[:^77?C4W//X-CZ0[$6'/Z>"3]+_Z_P#7?[PN "-/;]H^7J.M
M 0GAQ^=:?RI_J/SKUW:^D^D7YL;_ (]-F.DZ[@<D_F_O7UMS_!C[1_FZ]6'A
M7@?G\N.//_+U[1<E;_CZG58G@,O'T)7_ 'D?[;QOKK/Z> ?44_P=;'A<-62.
M&:^G[:4^7GY8X\C5^^"MCZ?]:P _ !4'ZFUOQ;W[ZRXH>VA_*G^#KQ:%F\Z?
MZO+Y>7^'K$)6)5#IL/4%TBY])%A^0.!S;_#WHWUP:]IK3/P_YNO#Z<:>_MKC
MCYC[//UX==+.]P3] ?I;21]21<V)(!!_!^O^Q4&,>8SU31;@<2!3T(_8>'\O
MY]23,2;$EK$DB][$7(Y(Y)^G!^GOP0^?#KQAMCYGT\\?ZO\ )U#U6"^LFW^K
M!MS?E/SI8?ZQ]L?6W' Q_P Q_F^WJWB1=K*YT_G7C_FI_F].;3/8CCZEB0!R
MS:K W!^EK?\ %/=?KIP*Z<?:O^;JY$9) ?/'(/\ J],^?#'7O*6MP""!R=-R
M;D?JL-.G_$?7_;>]F_N1^#/Y?X*=:"V],-4?R_;CY^?VXZ]Y#9@+VOZK"]AZ
MA_4L/00+6MQ_A[U]=<$4TG^7^;K7Z'D:>9XU/^K^77?E++<VM]2%4F]M)U+Q
M<DJ./\?]Y4Z/ED=;\*V.=7:1\SP_U>?[.O>5QJ&I !>YL0/I_P @VN1>]SQQ
M]+^_>'6E1_J_;U416XU48U'^S]F/\GH*]8#.20 %(++_ &0?^26;5J'^ ''O
M7ATXGJ_AVY%0*X^><_YQ^S/EUUY6.BP"*+ VO_46XT@"^G^MO]X][\/B .J>
M':]I+\?MS_L?LZXF8W:\[$ D6L6-^?Q_KD7X//T^OO87TZW2U&2!2GS_ -7[
M?/[.L/W)N;FY!!/%C8D6X8<7U?FWT_V/O6@XI_J_F#_AZ]X=LQ8ZO\)S^>*'
MRK3AUP\I) ^K*P:UB3;AK\ABINO/^VX_&_# %0!_J_/K02W9J:C7\_\ -Z?;
M7T%<=B>Y%N;'4;JQM>Q'!)/&FW^W]U,?"HZOX5L:]YIY\<_M_9Z]>$Y(+65E
MN>2'.K3IMJ^I!4<VN>/]O[WX:BM.JB.W.>(K_2^5?]7Y>?78GX(U D$V:XU#
M4/U"R?0\?3Z_U]^,5,D?ZA^?5ECM6-%)J/MX'S_U4P>O>=K@* 20+J ?K;G3
M]0;BWU(_WL>]^$/L_EU0);D>9_:?V?[/V]=&5M5ON"1]2;"UA:]KW-^>/R?]
MC[WI'6Q':_*E,\?M\_/CP].HXG/T 2QU 7U<G6;$WU<@GCD_\5T(N(\_Y_ZO
M]7V>:.VP:C2/MI_/^6?\E??<6^I76&TMP>+_ -/J.+'C@G\^_>&30TZUHM14
M:B".(S_JQ^W'KUWYC< VU-< _P#!+ 66US8\\?FWO1C(XC/^K\NME+4C#CAQ
MS_Q?^H8ZD^?46)^@]1L/\V"M_I8V(M<$'@\6][\/R!_U>7G7KP2VR[?#YX.*
MT_U?M'IU',I(#%E)U  D$E@Q:PN/I^JPM_O'OWA_ZL]*@EL *G_#G[?EZ=1?
M*!;3/]03Q8<G5>_ M_M_\/\ 7WHS4 =:"6X!!(/[?]7EY<3U):8'TW(LQXY9
M2.2+M9P5O;Z_@7]U">=/]7RSTPT,# 48^?V?:2?]7VTZ[,K @6!OP;J0=)!]
M+\FP 'T'UY/OP2AK7/6FCM_3'YX'V>5#P\C7[>HYJ+D\6TESI%]1-S?@ :A]
M3:Y/O?A$$&O^K_5^WJNFUR*'^?H/+_53_!X2D MQ].+KQP!<-^FY6Y_V(X_(
M]^\/K82#S)X4SBOR]?\ BOMZZ:4D 7) 8>D 'TV&I;  @A#_ ,B]^$>2:>77
MBEJ//^1X>N/+Y_.F.N33$V/]KZ$$\!K>H"P%F !YM_A_A[UX5:4.:=;,=LJD
M-C]O'C^W\L_GU$60_7TJ5(TK8W%CJUDA5;Z?DW^GT]V,7'S7_5\_\'5 EL:
MX/YYSQP!\AY_9QK),S\LI&G2>+AN?KROT^JV!! _V(]Z\.IH1G_5_JIU;1;:
M2X)TGCQ^W_50C../43S$0'5<:6*^E2/58WN%L%!5?J/H![\8@3CCUX"!:$G
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M7_J.+^[>&*G^'_5\_P#5^SJH6W733XCYY\OG_FQ_/KOS7NOTX%_00; &Y]/
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M&]P>D@<]:;K!%[W!']WBIO\ B_/^Q]V&XFOQ8ZT?;>^(S;R5']'_ *'ZP_Z
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MQ%?R_P W6E]MMR H;>6G^E/_ $'_ *OLZBK\?/D#87Z([?)(_'6F[OK?Z6.
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MP!+P.;W^G)/O77J=9/X3C_\ E64< "S.+ 6(M9@?J/\ 7][KUZGSZZ_A&/\
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M(!75<@\\J /KQ_L/>_SZW7KUE^K6M;\$E0+C_!N #?\ K_L/>NM>G7?UL.+
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M.1[V012H(ZTI5OA8'[.GO[[_ )M?\G_](>ZUZM3KWWW_ #:_Y/\ ^D/?J]>
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M)^Y2I-!9A'J!#_I*_P"M[]4'SZ]UPT@@<^HD$L">% 'T++PQ_)_P]^!4>?\
MAZU7]G6)B5U&.-IX8EGDJ)81&RTJP!6D%2K.DJ,58$:5:]_?K@BV@2YD/Z;
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M]1_7\6YL+6L2/Z^]UQCAUK2"1J^('KOGZ^D6 8#DGD\FW]>/?N%>O>0 \O\
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M:KTTTM72HZQE;D^36#^GAZXYC@A0N\@I]N?R J3TGM.79[B3PDC[C^0I\R:
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M6)CS1;/;/X-@$6X"U(I2M1BA(I7^6<GC1%=1Z6E2%7+#^F0*TX9/S^SHZ?\
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M=E;IR^*J&BBG6#(XW!U]90S-#4*]/,(JF%6*.&1K68$7'M,Y*H[>@/\ @Z5
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MF51D_P"K_+T!O1GS2^)OR9R.6PW0/R&ZH[9S&#=TRF(V7N_%97*4QC$C2/\
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M>'6AY]*7W[K?7O?NO=>]^Z]T'F=YRTVJY 2+\@?5% L";  VN;?Z_OQX]>'
M^M>F(V.K2+W-SJL+@GE?4+V4_CW4<.K9Z\I_22;$VL01IY-Q?FQ;^MA_7W[[
M>O'[.NC:_P"!^ #8\@DW-@;<#\_\;]^\NO==6((/'T_U_P!(%S8< @D_T][X
M8Z]UV3<<V-K\_7A0PN1<L"2/]@/SS[UU[KW^/!NOJN #_@+"Q!N1_3W[K?77
M'TMI-E-B"3RM[F_'^' ][X]:ZIS_ )L_RS^?/Q&VQMGL+XF]*[+[#ZIQVW,G
MFNZ]X;TPU3E,=L\4V0^UQ[S?;,9(*7Q2([E8Y+7'IYN$$M]!;7(CF$F@T%56
MH!.0"> J.E7A23VVF!D\45J&- 5\Z4XGS_;T%O\ *9^??SP^<NXMU;W[MZAV
M1MWXJ2X_/4_7G;NV-NRX^;,9C#9EH*6BEK"PABF2@*&5D41![Z; CV?7T*6-
MG%>2R@JZJP4&K48T!*_;^71'8?47UY);10KJ5F!- !514@'UIG[.KH\?VWU-
MG9MP#"]H=>Y6KVO3B?>4%!O; 9%]LQ1GQ?=[BJ(:UDQL>I=-YM(U@CZ^RF(,
M;9[_ /XBD'[<<>CJ[F59X=N*,+G53(QD5'3MM[>VQ]V83^\VT-[[1W;MA/N/
MN-S[>S^.R6WZ(4A9)VJ,O3S-1(L;QD,=8M[>AK/!)<1C]-3GUX5Q^72.:407
M"6\BD2,*_+)IG\^H^U]_;#WU3"LV+O;:6]Z$9#^&3UNT,_CMQTE+DU'_ !;Z
M^;%U%0M'4D V5]/(]TL9%W"&XGMP=$2ZFK@TK3'KU:]8V%Q:VUPI\69RJT!I
M49S7@.HU-V=UGD,_D-I8[L?8>0W;AX:NMS&U:+=>'GW)AJ&@\(K*[*8=*HUU
M%0TK5$0>1T"IY!<@>[6;"^CN)(>$;,"#Q)45('Y<.O7K?N]X$N%/Z@4@CA1L
M _MX_9U)VSV%L'>XKVV/OC:&]TQ4S4N<EVIN+%9M,%5HI)@R\M#4RBC-A^IB
M%!'O5DZW\,LT+@*HJ03D_(?/K=V6L9889XVU.: @8^T^@\NN& [&ZZW?69+'
M;/[ V7N_)8665,SC-M;FQ>8R&+6&4PS3Y"EI*J2:DB2JC>)BX6TBD'Z'W:(B
M:.:6/*1D@_:HJ:=:NV-D]M%,A\65590!P5C0$]>E[&ZYI]U1[#J.P]C4V^Y9
MHX8MDR[JPZ;ND>6+RH(MN&K&5DO'SQ$>![O:(;Z-I+=25 J:C@/GZ=.7:/91
MQ2SCM8&E,\/GPZZR_8W76W,MC\#N3L#96VMPY=$DPV W!N7%8?-9I)ZQ*2E_
MAF,KZF&IJC45+A8PH)8GCVDMKF.[DECB5@Z%@:_T30_E7@?/KSJ8[=+HBL1(
M&..14?[/7L[V3UOMC/4.TMQ]B[%V_O+*-3QXS:&:W/BL7N7)R5KA*./&XJKJ
M8ZFLEJV8>-8U9G/T'MVWFCNKQ["+_<A33/#A4]4N";6U6^E4_3$5Q^SKNC[&
MZZR>Z:W8V-W]LC([RQ<<K97:E%N?#56XL8( 7E2MP\-6U? R$:"-/I8@'DB]
MR0EX+)J>,5#?*A-!U=%,EHM[0B%GTC[0,_+I19#*8W$T=3DLID*3$XZ@,S5^
M0R=33XVAHO&HD<U-55O%#$@C]5R1Q[1/N,"7\>WE',SE@"!VU45.>MK&[8Q3
MI,[8[,ZQWRD[;#[+V#OP4DBPU*[+W7AMT/3LRW19X\355+P,RZCZK<*;^UJ@
MN9@H_LTU'[/]FG5?QB.G>>%>E!F\]@-J8R?-[LW!AMK8:EC:HJ\ON+)TF(QE
M%3H#>:JJZZ2*&.,\< ^T(W&!J45Z'U'2KZ*:A.I:_(]52?.;^;1L3XJ9/JG;
M_3FQJ?Y>;_[0RX6?#=9;SILI2[+VC35,>-KLQF*O;@RDDU0]9(/!&Z)Z#K8J
M@+ R@C:Y_LB/S^VG2&8^!76IH!7A\J_ZOGU:4V[<#0[4QF\MS9+'[0P5=AL)
MDZS([ERE'C,9BI,KC*?(5%%69.ND@@$F*$Q\S,1I$9-K^TLUQ'#,\+UU*2"?
M*HXYZ>"-X4<HII85 \Z$T'4;:?86PM_QSR;"WUL[?<%&R)73[/W+B=Q04%0Z
M!S25DV,JJA(IPG)OZ2K#D^UAMY/",WX!7^7&G3*2*Y(X$>O7#(]C];X;.8O:
MV=[#V/@MT9V6*GP6V<UNC#XS<.;J9I5IX*?$X2JJH\A6235#B--*$,Y !O[8
MVV^AO3<0P*Y9&H<>@J3]@&>GY(WC=4;XB"?]1ZYT?9/7>4W)6;2Q._\ 9N3W
M;B9-64VGB=T82KW1342AQ)4'#PU;Y!8F6S@JFHH0?=(@=QEFAMC1E ))X9P!
M7RX>?2>:06WQ@_E^W_+UKR_S*]K?,W/_ ,T7XBY3I;M3^!=+RMM-<IAJ;LBG
MVE1K329ICD)-S;<KZ^F?)T5528BKC0JC%I-"_JDC#:Y<[MWE4@Z(UD5OF0IK
M0>8^?2;=H)FVE[E"-&M!D^9(IUL;;AW)B-GX3/;FWCF\9M_#8JFCJLOF,I*E
M#0T,-!1">L*Q,"[(\160%%9B'4 $D#VHN[N R&"-&#5IGAG/'IVRLIU3QI7%
M"*X^VG#I-;+[*ZY[*H:[)==[ZVIOK%8VNK,5D,EM3-T69HZ3)4-1-1U-%,:5
MRZ/Y(F,<A'AGC*R1LT;JS>%M*JAF(S_J'5GE74RT-1_/UZ!_YH=T[L^/'Q6[
MY[QV'3XNNWOUOL!\UMNEW+%-5;;FR5)D,?11"KH(2K>$T%4;VL?);^GLMN+E
M+5@D@.KAC/1C8V<NXM9+ 5'U#$)JQD5^+TSUK5='_P U#^?)\ENOXNT>B/A[
MTUV7L.HR-=BH=QX/9N8^RJ,GC/#_ !"FB:24B9X#.H-OR?\ 'VMCC:1!(&0*
M?7CP].D)=5$V&9HIVB('$E30D?T0?/JWSX,_)?Y^YC8_>6__ .97T]UU\9J#
M86,IJOKC+S0#:.'R5<U)55.1_B-=E:B.E>F6.G50TEEUFU_:7F&YM[?9+1$8
MF]</@9 -104\JCTXGIW:D9-XN6N0/HZKE:5(H:DGC@_/ KU01\':KOS^8Y\U
M>T^XNQ_Y@V>Z3/3'<NP<AM;K6MW <=B^Q=H1;JW-+_<_!43U5/BZFBEQ>"BI
MIC%&\GCR/!_2P$>RV%UMFS)>W2ZT8GX"#Q56 :OV<!GCTDYBDA?<P J:3&%&
MO5@ZC0C3^(#A7%>/0T_S1>\.T_E9_- V'\(-A?+VHZ"Z"@V[CC_?S9>[X*7;
MV*W:M&TF8J]Q9O&5T---*U7&8],\H$$GI-N3[)MHAEN)MZO48-;@H17C2@\O
M6M>C+<!%;[?LBZ2)) ]2,CB?Y4 ZVA^@=NT?3?QTZSVKNGMK%]E4_7_7V)Q^
M4[NS6<HEIMZI35>1,V;K<U4U9I4C6!=2,TK:XHI&OZ?;T=[#)*T.EM=?3 S2
ME?V](%1B=2\.A'VOV-USOL5;;"[$V-OM:$QI6-LS=>%W&:660?L1U,.,JIYH
M#)^&*A3;Z^U3J) $448CSIY=5KX;4:O'Y]*+*Y;%8'&UF:W%E,7M_$T#2)79
M/.9&DQ>.I&B0S/YZRKEBABT0@DDFR@&_'LJ:YC641$'42/+&33CTH'<*CATP
M;5[$Z[WY#5S["W_LK?:T)O7)L[<>,S[T5O4#5_PV><4Z@G@M87]K3"X3Q#33
MTS+.D6&5J_(=5&?+#^;UMSX[?,SHOXS8#%]:]@;4[7F@INSNS9M[8V.'J^ID
MR=-AZ>'+F"K-#C9:6EJ9_,KD:.+D>V-OD7=%E:W--.JNK'PFF/S..G+A?I?#
M$@-&I3YUX?EU8[W%\N/C#T#UKB^Z>X.\M@;1ZGW%5T]#@-^+F(,[@]P5=4R+
M2Q82?!R5HR4<@D5@\9:-5-R?>GD6.?Z=@=9)\L5'5E!9 X\O(X(_;PZ&C:NZ
M-O;XVQ@=Y;1R]#N+:F[,329_;>?Q<PGQV:P^0B$U'D*.0,08:A#< V(Y! -_
M;\L+0.8G^(#JJ,'4,.'3X-)'XY!XN. #];:A8L"!_O7MKJW7(W4D_0^KZ@CZ
M'\$%A^#_ +;WOAUX=90>.2#R.+ $FUK< 'G_ 'W%_>Z_+JM*>O6 Z00P^A-P
M2" 2--A;D+;FW^'NO5OMZY7!-P1:W(LI/T'/JMQ8<_D@?['WOKW77YU #Z&P
MNMR-/!#,+G3QP?\ 7]ZZ]TK=HVM76 /K3U6/'JELMR >0+D?[P/=AP/V]5;X
MA]G2S]^Z]U[W[KW7O?NO=?_7W^/?NO=>]^Z]U5I_./!_X;V^0WUTF#JH@<?G
MNCKM>!_2XO\ [X^S_EO_ '-MR,"C_P"!N@US(";&8>I7_"O6D#:P'YO?U?3^
MI^G_ !3\>YCH"G'S_P O4%SU\4BF:?Y.O:K"XO<6/(XO:XYX-R/=X\J>F&PW
MH.N/!%R?U#Z6/%KW_J?\/]C[O0U'6M0I6M.N]5CZN>;D \6_K]; CWZE3\^O
M8'#A\NNF8*I;\\7N;&QY)X Y_P!;W[KU:<>'6+R,>;#Z"_%_Q;G_ !N?]B?>
MCBI''KU:BIH/Y_ZL]8^;6.F]_P"O%_Z_0?3_ (GVVLFJM1UN@'GUV38#\<D_
M06N; \_[S^/:A5UG/6Q0<#0=>L;'^R386^IYX'TX('NK#2S+Y#KQ'GYGKNXX
M')-^+ ?XV)N/Q<>ZT/Y=5)!I4?ZO]0ZX2,5(%CI9>?QR>&%N.1_7_>_=68+0
M#K?$U(/4>^D'3ZM9 -@. 23_ +T+?GW3Q#GUZL:@C T]<]("!;W#:+BX U W
M%@;VN?Z^U=B%GN525M*D-D9X#I+>:EMZHM3J&*T^WK9M_P"$^NIM@_**(!2!
MN7:Y;RC4G[N)R['R+QJ0>,W'-P?<;\VP0172$3,P+ ' %!0]2AR:)C;2#3GP
MFI4US5>J".IZ:NK_ ):=9XJB69LME^\Z,)CZ26>!O##GI6 TIICHX:5%X86+
M#Z^SOE>YL;:&0&0&D;<0?]]]$W-5A?/(-.JOB+@$9[_G]G6SI_,?RU+)\U/Y
M8.)%+1_QNE[AQ6<KP(XY:N;#&NH\-HIIG#31@9"J4!U(/YO<>P1R/]1><C\R
M[I*-+Q),50<#IU&E>.:9/4K[E;P&2V5F[PBGYGM'#]O0-?S,G$_\S'^7-(P<
M7J]OQU"Q3R)'4(^\-V^EXU(%QJ^OU:WM9R.S7^W;[.Y\.2-F IFOZ2FIKY^7
M\^K3I'2",Y!2IQ\VZ1G\\7Y._(?IOMKJ/K/JGMK=/66R,_L'.9_,+LG)U&WL
MQF,[4YA<73T]9E<:\5:<;'1S$O#JT.1R#]?9+RS ^_7ZK-,T2=O#NSJ \_V]
M)]_GBV7:1-% LDI,F#C&FOD//AT:[HE-C=,?RI]L[AJNZZWX^8?<.PL9G]W=
MR[;VTVZL_BMQ;UHX\OFJZFHH\=DY9LPF8KY46I\32!(U!86]F7,A7:;SZ=2T
MIB  8X-3BN*?LX U/13RP6WF!YO#6(2,109%%H<UX>?#B*#H!:7YO?!>'X5;
M_P"A^T_G7O+Y/UN<VUE,;2;^WYUMO ;A?)YRFEI]M4%341;<IZ:&67)/$L)E
M*A3^?Q[*X;6\MS'>,:0S&@-?3)\NCO<?II4^A9>Z.AP!Q\OQ?Y.EQ1[ASWQ5
M_DI;>W9TYE*/9^[AUSM+-5F?H(V%5CMR;_D_BVZ,E3U":7AK(JBM)AG<ZH)%
M9+C3;VH"++<QJ]P0"ISQQB@_:3_(](HXF@MF9806U#'#U_S#/V]4A;K_ )F'
MS-W5\:MN]5;FSM34;7GRU3)5]Z9?&N=V[OR$0_B&(BQ^]*X%L9G<=462"II)
M5DT\%O9QM^V6YO[4C<)"^L"E,'Y=!K>]_N(]OO;?]U1:#&>[4:C'$>O5YO9W
M>7<.._DN;7[AP_9^],7VU5;9V=69/?\ 1[BR%#NA):G)U'W4%3N$3)4>!HD6
M.33)>1/2?K[)=YM6@W5D6M*U\L]QK_J]>A9RTJ76RK+++W%/MX1K1<_:?EUJ
M0U^0KLYDJW/YNMFSN2W!D),UE<F6#-D,C5MY,A5U,BG49&F.HWX)^ON3=EBU
MVBAFQ3_+U$MZ_P!?NYMRFA=0%14_(XKTVRF\DIU:BSN;VY>[GD 6%C;Z#V:F
MH!%:C_(.B>1%261!4T8BOF:'&/RZQA3]"0.3?GC\6_KS[UQ->J@#2!Y#UQUV
M21>Q(N.=1Y^E@!;C\^_8H/\ 5GK1)J:8QP/I_L>74=W)LMEX;\ _GZ\W_P!\
M/?@:9IUX4(.>WK'Y"MO2O( '!((_-[M;ZC_6L?=7-!4#JP)2@/V=8BUC>W^O
M8<W^G]>/I_A[;$E:5'6VD85HHZY>1N+6M;U ?@\_7Z?CW77DU'6_%.!ZG/6/
MD@GZ?7@^D'DB_P!21^G\>Z4R.G:#2?E^74=K78 6!Y%R;#\_D<GCZ^_>9-<]
M;(-  .VG#K(J!EN&-_R!^;WYY'^//^/O7IUL5--/I_J_P_ZJ]8R0C6YTV')_
M)-[@_06X]VIQ/5037\OY_/K#)8%+_0W'U_P7_6/%AQ_3VTP.N+&,]*8=(CEK
M\OV_;U9Q_)CL/YEOQQY'Z>WQQQQ_H&[7 ^C6^I]DG.'^X_\ J]4_U<>A#R;3
MZP'C_P!$OUOT>XIZF/KWOW7NO>_=>Z2FUKC9NU1S_P >WAPW)_YTL7UXNW/O
MPX'[.O>8ZF>Z]6Z][WU[KUO?NO=>]^Z]U[W[KWSZ][]U[HEW\QAE'P4^5VM-
M:_Z$=\A@'$3 -BI5\B.RNJR17U*2+:@+^TUT\D<.N-J.&2A_VP]>E%JVB=#Z
M5_P'K79_ET]"?SB=[?$'JS<GQ,^9'4O4'0F9H=P2;8Z\WQ@=JYO<V/=<S4TE
M8S9O)?'CL[,8M*Z>&610,K)X7;R)"NH$K=PEO+UDDN)RTA'&M#3( JH'SZ+[
M@RS27 A>@K0UP:Z1D&E1@C(H?3HU_P#*!W;A.C/E?\D/AKW!L"CG^8%3)N??
M_8?R'I=WG<@[42DW3+75&!BQ-7@<'5[7H5BSRYRG=$C7*"MD9H(EI8E0XDAF
M78HDCN*6<;H3&*T+%*!ZUR0M% (P-5"*FI?8QQ02BD'ZAJM?,4I53GU!-16I
M_;TS=D5?Q8^1ORF^0$_Q4_E<5/SL[2V_N23$_(OL;>7<6WNC-C;?W#!1U%#C
MTV?FM[5&8I-P5.XG@E2>*FBHI$$#2B,H&/L*K*!.X@B9CQ)K0#/'\_G_ )^C
M!?,JI*MD#AYY],9KDG[.D!_(B;<&Q_F7\\NJ1L'(].;7>IRFXJGIF7,4VYJ#
MKC/;>[*R&W,5M [HQL\V*S^7V=@*]\;555.E/$XBCNID+,QX7,EAJ<]XD6E:
M5 *FH'YTK3T^72>"4F=48D]AX_(CC@?/_4>BT=H]&=J_%?Y;_+#L#Y+_ ,LK
M>7SQVMW7VIF=Z];=F;8CWG4T=!0&JJJN";(Y?JK:O:N4V_@_[OL(I\=FJ:.8
MRT]XH]&I"'N7-ON8I'AF4_4ZOBH6KDU;YUJ":Y\CY]&>\3V\L:.1^D%(*UT^
M0Q7'I04]3\NKB?@+VM\,=^_";Y&X#XA=15O1)V[MGL'/]L=*YFEGHL_MS=^\
M-J;D1*F1JN:6HJ<)D)-NU5%CI9H:*H\6//GI*>34K'F^+*D$]7! B:E%I3M/
M$'@203Q/Y# +=J$(.E8RK%\U;57/D12H (' <>).22;^3WLKL3MC^47\P>ON
MH\I)@.RMY=@]_;2V5D9LW%0FAW+D=H8*GI\8E3%2Q?W;#RU7A$C-((3/Y=8
M]*:V_P"56Y? (,[6\I/^F+$!B>&:# X4KY].,">8]^.FD(E@H:\5"U84&?,Y
M\ZTX#JO'K^AZU^*?4D?27S;_ )+_ &;NNGV;_$<5V3\@YO[[P;?QN&W!(E3B
M30Y[;NW-U]?96:CHJA:6FFH<Y0+.*4"2$3+++-O8+1VF+.NEE8DDKJK2AH14
M8X<",>=>E.]7J11*L;U#** $+0D$5K1O2N0?F#UN&?$W>G1V_P#XZ]3;D^-U
M/34'2LVT<;1;#PU/1S8^7;^(QL?V2X'(8^JEGJZ+)XN6%HZA)7D=I 7UR!P[
M*]P^I^JE:[?5,:9' B@ I@8 %.&*4\NDUB\#VZ&W!$8)P<D&I)KD\3GCP(IU
M0Y_PH6ZGZYQ>-^/O<6-V-BINT]X=I878V>W&LE='D=Q;7Q@H5I,'71"L7'34
M]!1Y&JDC8P^9?HK@7!)MNMHK7FNQO8(],LL4FLU.64VZJ:5H"%%, 5IFM!T]
MN#:-EO9$H)UD2AQ4 K)JP<&M%X\*8XFJG_FS[)V1\./Y6=+U?\8]GXWJ39O=
MG:&P<9ON#!-5U2Y:FW51#+;BH:R7+U.1R4L^[&P<-.QBJ8FC16$;+J-UG-FX
MWMWS3M-G<2E[1[^17' %$U46@I@FA)'<=*U/36R6T,O+EY?RI6]%C&X;(/B'
M0=6#0TJU%-4!8D"M.N'R=_EF_##:O\J?+[ZV_P!+T&/[#VST)LOL/';\IZRN
MJMUQ[MK:' 92OSE7+49!<;+*:G)S22,D*-"@#PZ9(XR%HF-K)/':@)&*@ 9I
M3SJ:FIH*_P J"G58M;6\$CR$R'236F:^7#@*X\\"I.:@=WYVINWMO_A.MUIO
M'?%=/FMP05O6FW<EFLT8\A49JCVMV.^%QF1E:IA83LV/HZ=$=@7(C#%B;GV0
M[G-/-;.[.3(S]QQGCQI3\SYGYYZ,[-(C<!74% 33CZ?[)I\L=6>?RN/A_P#'
MG!_'GXS?(L]<T64[Z3K:II#VMGJC)5F[325F3W)1M2(LE>^*IJ&&@K7A@CBI
MT5(0A #@-[$^Y2O&T-O&:0BV@P /Q0QELTKEB3QIFG#H/[7!%)%)<2(/%^HF
M\S3MF=5Q6F%4>7$5XYZLW[@%^I.TK_3_ $<[WO?Z<[9R?^]CV5A59@K"JGB/
M7HXX9KUIM?%7X:5_R3_DQUW:/6%"E'\C.@>Z]^]A; W/C@U)N:?'T6R.MLCN
M/$T&2I46N_B4,%,M;C@''BJZ?1&/WF#7N--O9O:V@"PE0Y&?B 8$Y/F/VT'5
MYT2:YUW"ZN"_E7' # /Y"I)^2_WK\RL!\U^VOY/NZZ]FF[5V1V G7W=V#K10
MU-?CMY.,)1U6685,3/KR\^/-0S:(],LY5?T^Z\O2^+)!(W]LI KZYP<UKC/V
M]!WF-9(&F\-BJ^&1^RO$FOK3^?0__P Z3-[I[6_F(_$/XUUG6&7[WV#C=H;>
M[#QGQYIM[XS8T'<V\\QN[>L&4Q4&:S<;8#&O!MS9T:2UM85-+ )1#+"\K%V[
M='DW%(M0,7@%Z$T&&())QY#UX5X=".2.-]OEG52+E)PNH5)T:58@#ADGT)X<
M>'0:]R_![YEYOLOHWMOXN?RE*?X>;_Z<WO%F9]Q;$^8GQ[WK)NG!.]$D-)+1
M5^Z]F_P<X^&*83>&=VF24QVD4"YO UC&K&5P[^7:PIZC&#UJ,QBJRPZE/SI3
MY_ZN'ET>/^:I0YCISY>_RT/FI%@ZJBJ:?LW;72G9M7-51RX3:U%N'+:,13US
M13RXV6IEH^P-SPK,)& $(9/)I0H2W<X@TB-C0OI!/F#6@ICYGR_+I(UI>7)8
MVSZ2JARH"_A-22214' -,@#Y]$^_F-; W3\T?DC\V^[NM\[]Q3?RW.D.M*;K
MD8F./+4N[-Z9NFK.T\HE#/1E@3C):2?]V,R/JA4:M)5280I%;3EK^*J*!@XI
MBN:9_/RP"/1ZUGMW<EDU(QI4DTIP!!'KY>M21T-ORN[)H_GSVI_)RZ?Q64GS
MN.[*-+WYV<:-:6*2NI-L4&'R.6JY:*%3#CHZ678N>OY$59(:H*B!N :P06#I
MN%PRJT569!D *!4"IIQ+!.%:KBM>JR,BAT5:M4*I-2<U'^"A.?MZV9P H"J
M    .  !8 "UA8#V'S4DD\>G    !0#KOW[K?7O>NO=>_P!]^?\ ?<>]]>Z]
M_OO]<_\ $^_=>Z]_OO\ ??Z_O7^#K73W%_FHO^6:?]"CW;K72<W>!_=+=_\
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MVO@:ZJQ4F0RG9V-R.[MQ09P2TDM7'D,=A,744CK-3S1PM,?*I0,/88G/^[$
MX%1_Q[IR*HC[A6@_U?ZJ=6(= ?R-Z'X:_*K8O<_Q0^2'8_7G3F,H8:;L/K?>
M5-3[LF[+R,L5I,?75&(?8^UJ7&3*QTWH*R>Q%U8CV*7)^F5"06"\/E_J_P!C
MHLO"5[E[3Z\/]7^7JBKY_P#\O?H/K;^:SU;\=-OS[QDV#\D-W8;='9D60GVW
M5Y]\EV#NN*GR5/@ZNGVQBL3C:/%.2\*SXRH*J "TC ^R?DY8A%=K2JCQ#0_Z
M93\O/HUWEG<V\G!NS/V#%,GSZV+_ ))?R4^J.]/AMTW\,>MNSMX=;X#X[YVH
MR.Q-UYS 87?60K\3D0L>9QNXJ7!476R5LTRQDT4U')211@^N.2UO=;HG]ZJ=
M.:M_D\ORZK QDMI)&.6IGSKFN?.M>K-/CITG@?C;T3U;T'MFKR>1P74VTJ'9
M]#E,RJIE<JM \LE1DJVGC CII*J>=CXEN$%A<F[$WW!_$N=9(RB\,C I^?#I
M/#4)^9Z&H-]1_4D \?5?5:Y(%B!]?][]HNG3Y'KAQ_JB68@ G^TJG]5[@"_T
M]^_+K?78 /U8AK:FYX/J!!/U!X-_S[]U[_!UXBP)!/JY'YYN;,#?4#_3Z_\
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MWT%_I>UO\/Q[]3UX]6^P8ZPG2+WX-N#_ +'_ &/]?I_7WIOA;TIUK H*^?7
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M5+7+72T )I))&JU"C@E;D$>P7S'L5]<L'@*\:FK?(\/V]23RMO\ 96R$3!J
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M#QDZ"7*O]OD8K: 03<?@^PORU:/8Q;K;T&J21OLKH"_LQU>;?897M_"#B-$
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MP&X&S-/%34E$VXFQY3S8^:699;0P+>WU[,&J+4A:?Q DY^SB3]@Z1R1^)(J
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MLP5;7]G0\(21D$Z:FO' \NDLXC\-C4:]1P,B@/;3\O+R/2E_FF_RS_D+V?\
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M$C20#?GZ\@<WY]WK3SZJ17'7'0@'  )_ '!M8WN;W%[<CZ?[WKK?G7KK2.%
MY/ ( !XX/(OIL?>P2*4X];_/'7=U .FXL;W '-PPL#^3Q^?K_MO?O\/7A\N'
M7( 7XMZ5LIM>U[?DBUR/QQ[T<\1UJE/+KH$6]0%[7Y%KW(6P' Y 'X][^T]>
MZ[6X(^H/%[6Y'U/-CS<_ZWNK E2//K?Y=>7U&Y'UX( '(X)!/XU#\?0^_(I
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M:^E&_P #=![F;_<":OJ/^/)UI!FY L&-[WN?Z_G_  _WU_Z^YD3_ $+/XO\
M+U!,P[FH/+_)T8#JCXF?)GOC 5&[.F^DM]=C;4HLA4XJLS>VZ038Q\G1-IJ<
M9Y'L#5T;FT@_!]I-PW6WV^X59YU4E014TZ,-MV2YW2-G@MV=0:$A:@?+Y="A
M%_+A^? LT_Q1[7<%I%ECCHH!/]J(9)(XH9BWC75.J @_GVF_K?94I]4M/]-T
M<?U*O-(/TS5_TO\ J\NBT=J]6=G=,;H'7_;VS=P; WICL;0923;6YGB?)?89
M6(STM85A4#QE!P>;^SG9;V/<7N&1PT9A.0:\#T&]UL)-E*,Z:)O$ H10BHQQ
M^70;*@D/C:]Y?VR RQG]RZVUMP/K[;MW2.^(KBI_P=)KQI9K8.5J=/Y<>C\?
M GX)5?SIW1OG:5#V='U/+LW#XS)I5R;7.XSD16U'V_C6=YX8X@PN+ZAQ]/:#
MFG=5M;8,$UEB!0'U!ST(.2[1KF\2,R:5%6S\F44_,G[!T5#MK8!ZF[1[&ZQ?
M.)G3UYNG/;5;<T>(DPD>8.WZN.E+BEDN2"6^A%^?9IRG>H;1*MY#S^1Z+]WM
M'7G*8T.)7\OD.@V470MP!I+:?[/K^I%K?J]JG\-KLX]/\/2?>O$&[VI.36/K
MMP!&"/Q;Z 6X//)/T][NF10>F7FD-W.#7#_EUA0J;C]%SR#;D?T!M_:'LOAG
M1) =0ITHF$A3AY?['67^@(_ !OS]!P/R;W]J+J=6>"C XZ0Q>(%FXTKUP?3:
MY/T(^@_H#?Z_X^UJ2J4J#BG2)V=7TYU5_P W6"3])L/Z7N;$'\7_ -J]D=[(
MD@9">)'^'HUMS(5  P!_.G6+G018D\_T_I_A]3Q;_'V:R*D=A4'&D_X.BF&%
MY+P8).H?X>L0)MJ!^AYXL3>P)L?Z!O97M5R$N'%?,_X!T(K^P9K>(Z<@#'YU
MKUR;B_!/%@!R?Z$@?X?T]F!N46I+#ICQF< 4/IQ_*O7A^JUS<W/X&K\$?T_Q
MM_C[H95EPK @]>\61*<:CKB4\GD _:FC7RQL.6:!02_^U$*?][]TVZ,6V[2W
M&*$)_(]4>[8J%/&OK_EZ,3U%\3/D_P!\8*KW3TUT?O3L?;%+7_PR?+;:HTEI
M*+()34]6U#5,]@M5]M51RV']B5?Z^T'-F[0QO"9)0&IBIXT8]*[#:[O<FD-M
M;/(%I6BUI7(K3U\OLZ%"H_EN_P P'2U$GQ0[;7[I&"2)C()(U,0,NB:<$_;"
M6UKW%R;>T4?/4?TT5NTP 6OXO7H41<F7!0,T#!J>:]%?[2ZN[,Z9WG6=?]L[
M'RW6^[J7'4&7J]IYF2]?3IF U:M28SJ\:2A[_6Q]K(MX%\H<25KP-0?]7'H.
M;ALSV<C*\=*&G"GG_D'0="W(N+_VA_7\@?0_7V91!)2JMQ;HN>)Q!*H!H!UQ
MT\BY %OH>/I?@_ZY_P!X]V=4MP:>O5;:%L,2:4_U?ZOGURET@$_4<DF_X^GU
M_-Q_K>R^2Y#$@8ZU<PMY GJ,ITRO),[4\\@$35\8U4U##;33V@'I>HE!'%B2
M?=IG&WQK/J + ']N>E5K$^X!8..D4S\NIN1PV<QB4TN=PV<Q"5LD;T57N3 U
MN&@RT-_VJBEFECB@FCF'*$?4$>TL&_I?-X)>I^VO'I9+R\UD/&6,@4QBG4&4
M,)*@%Y/3( 490(T70K%8BH]48M?5_C[,9XTM[8\.XU_;T6A9)]3*#CM^RG4:
M*EJZR>GIZ9:Z=JRHIZ!(\<0)VGKYHX8)/ZGU(4X_XZ>_;3N"PJU308\_F>E<
M=F[BBK7/^H="1V5T]VQTHN+J^S.O]R]=-GUK:W;;9V!X8*_%T4"2K%"9(P"Z
MZA(&L0NJ_LH_?22;O*@<&L+\#Z5Z>DV%TB>700*'R]1U8OO3^5!O_97PE/S3
MJNV\-4J-H8/?>:ZRCPOF\>#W!D:'&PSTNZ _BER FR$#-&J@!2WY4CV'(]Q5
MMT6()@D4-1QTU(]>'G^71I8[:8^0KF36:F ]I!P!(17A3\JU\^JDI;LVKZ!E
M!4:K-SSI^E_U>QC<.C11>O;\^B.WB<<O,*'1]2/EY=>3BYGYM<:0+_2WX^EK
M'_>/>JJ0,CJYB8'3IR?V?+KDYL" 0PL/S<<F]OP ./\ ;^]%DX>?6_"8Y J*
M]2J+#9K)4M=+38;<>6H(*=C/4T&WJVKQ=   2M1EJ6$K3?IOZV'NZS68Q)(H
M/H3YY_U8Z5)!=A%T(]/E_J_P]-H?5!3J%T&&$1*O&D!/P&MJ:Q^M^?:R)K-N
M#KTQ(+Q*ED:O'K!,00G  -^+\ZB!ZN1^/Z?U]L72Q+) 8C7XJ_RZW&9"DYE'
MI_,_\5^P=6<?R81?^97\9Q;\=NKS]1_Q@3M?\\V_!_K[#G./^XX .?\ 93H0
M\F?[E_G_ ,^OUOX>XIZF3KWOW7NO>_=>Z2>T2#LO:]K_ /'JX,_@7!Q$-K\\
MCCZ>]_A_U?+JOX@/]7GTF>QJ[>V+Z_WODNM<)B]R=AX_:>X*S8VWLY7'&X?.
M;MI<553;?Q.3R"M']E0Y#*I%%+)J0(CDEE U"F0"1QIU9JZ33C_J_G3K6.^0
M/\T#^<W\3L1LO-?(GXG?&#8M'V1FY=L;3J*+=^=W+2MN<T;U5+@9GP^XY9%J
M:D1,8V< %0;V]TL?J)MSL;26%?#ED"T'F/D0QH>JSHJ65W=)<O6-"?A&*>="
MHZLE^&?<W\WC??=^-QGR\^,'1?6?Q^R.U]P92;>FRMYS5F[J',/!35FTL>^W
M:O/5E4AJ/+X*M7B+PMJ+ :;@UW&&WADT6[(5!-:-JX$CU/2&SGFGH6$@4BO<
MNG\Q@?ZJ]6OT^[-JU9S(I-R[?JCMPVW"*?,XV<X$Z96MF?'4-_"SIIY#^_HX
M1OZ'V7QJ92%B!8GA3-?V=+RZ*NIG 7UJ*?M_U>73O3UE)5TD.0I:JFJ:"IIH
MZRFKJ>>*:DJ*2:)9H:J&IB=H9::6%@ZR*Q5E((-O?B""5848=6!!&H'MXUZ:
ML'NK:^YA5G;>X\#N 4$@@KCA,QC\M]G,VK3%5_85%1]M*=!LKV/!_I[U0TJ1
MCK0922H8:A^WIQR.2QV'HJG)Y:OHL7C:*,SUF0R-5!14-)"" 9:FKJ9(H((P
M2+LS 7]^ZV>H.#W+MS<],];MK/X7<-'&XCDJ\'E:#+4R26N$>>@GJ(D<KS8F
M_NS(Z!2Z$ \*@BO55=&+!6!(XYZKV_F*?S!\-\%MG[!R>.V[@NQ]Z;V[#V[M
M-MCR;LH<+E\9M[*5$,64W5-2,9*K[+&15,;ZG5(R&^I_"..[B?=K7; 0TCQN
MS 'N73HI7C35J)SQH:=6FCF6UDN46@! J0:9K]E>'1]L%OS9VXMK#>>*W1MN
MNVS'2/65N=H<[C*W"X](*9*JM%9EX*AJ&G^PB>\Q=T\8Y:WM?)$T<KQT)()I
MCB!YTZ;CF5X4E) J!7/ FF"?4$T\NI3[RVA'@H-T2;KVW'MFI(6GW$^<QBX*
M=GF>F409=JH8^1FJ(VC 60W=2OU%O;7^'IS4M VH4Z<<AF</B,9+FLMEL;C,
M/3Q)/49;(5]+18V&"4HL<TM?4RQ4L<,AD4*Q<*;BQY]VT/J*:3K'$4R*<>M:
METAM0TGSKZ]3:>H@JX(:JEGAJ::IABJ*:IIY4FIZB"9%DAG@EC9HYHI8V#*R
MDAE((]U->'6QG(Z8,OO/9^WZV''9_=>VL)D:F&.IIJ#+YW%XRMJ*>6H^TBG@
MI:RJ@GEAEJAXE95*F3T@WX][".1J5"5ZJTD:8>10>.2!TI"0 2; "Y)_H!];
M_CCWKJW#CPZ35-O39U;AZ_<-'NS;57@,7--3Y/.4V=Q<^'QT],4%1!79.*J>
MBI)H#*H=9'5DU"]KCWME92 RD$_\5_AZJ)8V#.)%TCSJ*?MZ<Z;-X:MQ*YZC
MR^,J\&]+)7)F::OI9\2]%$KO+6+D8I7HVI8TC8M('T *23Q[](##J\4::"IK
MC%*@FOE3->%,]65@X!1@1\LYX?X<?;U6MTW_ #)-J]K?-_O?XHR8K9N%V?U5
MMW"Y+:7;8[%P=90]AYRM?'1Y+;^)H0T44M70&M=F6&20IX6!U<$^LE.X1W$E
MLA?PR/A[JBI%<>7G4=);FX%K<PQS.JQ,#EL4( (R<>N#2OKY&SS_ 'GWKI7U
M5G_-3^=?87PHZOZQ3H_:.V^P.^.YNR*39G7^SMTPY6IQE?CL?2G([JJ_#@ZR
MCR+5E+32TZ0@7C)E.JQ /OV20JY<G_5_L=,RN%'Q4 %21Y#\\?M]#^3M_*[^
M<.]/FOU-V-7]N[<VELCNOJ'M#+=>;_V7L_\ BYH,7!3TM.</DI1F*JLJ$J,C
MD*7)4[H)+)+0NND6NQGN-G';"UEAKX4B9R#WBFH#S &H4K4\<GI-8W+3^,LF
M2K8-*54\#Z$U!X4Q3JQ[);BV_A:K%T68SF'Q-;G*L4&$H\GDZ*AJLQ7$H%HL
M73U4\4N0JR9%M'"'?D<<^RT L6"BI J?D/4_+I?4#CQZ[.X,"N87;K9O$+N!
MX!5)@CDJ,9AZ5EF=:A,89A6M 4@<APFDA&-^#[K4$TKGK50#2N3U[-;@P.VJ
M1*_<6;Q& H9*F&CCK<UDJ/%TDE74:OMZ5*FNF@A:IGT'1&&+M8V!]^J!QZ\2
M!Q/7JS<&!Q];C<;D,WB*'(YERF(Q]9DJ.FK<JZ@%DQM+/,D]<Z@W(B5B/=J&
MI%,_YN/6@RL<,":5_(\#UFRV7Q.!QU5E\[E,=AL30H):W*9:MIL=CJ.)G6-9
M*JMK)(::GC,CA;NP&H@?4^]<33K9( R<=1X-Q[>JDPTE-G<-4)N+7_=]X,I0
MS)G?%2S5TO\ !FCG89/QT=/),W@UVBC9SZ5)#@AF*NWA-I6E30T%>%?2OEZ]
M4$T1T 2+4UID9IQIZT\Z=<LSN# [<IEK=PYO$8*CDE$,=7F<E18NF>8JSB))
MZZ:")I2JDZ0;V!/X]M@$X ZN65?B(!ZFT5;1Y*DIZ_'5E+7T-7$L]+6T51%5
M4E3"XNDU/40/)#-$XY#*Q!][92IHP(/7E(854@CIJS>Z]K;::E3<>Y<!M]ZT
M3-1KF\SCL4U6M,J/4&F6NJ(#.*=6!<I?2"+V]Z )( %3UHLJ_$P'3S3U%/5T
M\%72SPU-+4PQ5%-4T\J3T]13S(LD,\$T;-'+#+&P964E64W!M[\002&%".M@
M@@,""#TTY[<^VMJTL=;N?<.#VY12RB&*LSV6Q^(I9)C:T25&0J*>)Y3?A0;^
M]A6:NE2>O,RKEF '[.F7?N2$?7&\\OCLH:94V1N+)4&9QU2=4"K@JRJI<G0U
M=*Q:\0"RQ21M?@%3]/?@.X5]>G8%$LL*C(9E'VU(ZH;_ ) ?9F\MP](?*/-]
MM]G;AW(NW>]&HER6_P#=-3D(MNXZ'##2%KLQ4F#'4M:K1RE=2CE0>0/:RY)^
MFMBS>;\3Y=O3^XI##>SI&H6E*_M( _U>O6P=C\C09:C@R&+KJ/)8^J0O35V/
MJ8*RCJ$#,A>"IIWEAF0.I%U8BX(]HND8(85# CI3Q?YJ+_EFG_0H][ZUTG-Y
M_P#'H;L/'_'M9[C\G_<54?7Z6^GO?E_J^?5?,_ZO3I3^]=6Z][]U[KWOW7N@
M[SO.5JS8_HA ()_XXJ.?Z>H$>_</+KPS^WIA-N0"!8_0W<D7TVM]!Z3_ *_N
MOS\^K4ZY@:KEB;@);G\CTWL;\"]_Z$_GWOSZ]\NO-8CZ"R\WN!R/S^H?DG_>
MK^]?X>O=<5](8D_T%@;BP^IN/Z'FP/\ O'O?&M?3KWITB^Q^R-@=0;&W)V7V
MAN[%;&V'M*CCK]P[GSAJ_P"&XVEDG6"+6*"EK:J5Y)V"B**)W8_1;7/M@2-X
MFBGGUZOG3'3[MW<&%W=M_![LVOE:7/;7W+B,;N+;N>Q[23T&8PN6I!6T-?0%
MD%0Z24IU-&T:RQD%752ILJT]@8];%":>?3L#$(XY9I%I0Y"E9TG#1AA?S2J(
MI-,0 N3<Z;\V]I6D8,RT%!U?30<3TG$WAM>2OW#BDSE#-E=GP4E7NS&4@J<E
MD=N4U=33UN,FRM!BZ>NJ8URM)3/)3^-)6=5/ ^GM8D2F)GS4#Y4Z\5^(DGKC
ML_>&V^P-MXW=VTLE-D\!EVG3'UE7B,]MRHF:FEF@JHVQ&Z\7@LS%)!+'ZM5.
MO# BX-PUTWPICH!>Y_F?\:?CUN@[+[@[!R^UMP#%',RPT/4O=>\\11XQ5UR5
MF0W1L+KC=&U<>@7ZB:MC90.1[]6GGGK>3D<.I/3?S$^.7R#S%3@>H=_Y;=F2
MI<#3[J8U/5O<FS\5/MZKF6GAR=!N'??7FV=N9."1B&5*>KEE>/U*I!!/AGSZ
M:\10: BM:=&4\@$HA;3&05&MROC0R\#65U&$?XOI _K[]2G3JH'S2H'7$30,
M&.OR")G61H5DF6)0)=,TJ1))*8)98_&CA2K2L #IULN^MOJ4Z:XZD1H\L:R!
M-.I2"ETE=74E9(F-/)*OFB8<KK)XXN.3KJ@)&HBN>/6(L-:P1N)Y9&(2.&]B
M8Q>16E81P1/&@+,LCH;?2YX]T9E4K4Y/6J)4$J*]<#(H\2LKEY8Q4F$*#)%2
M,[I!6.BNS?9UC1MXW0../5IX/M]$+J,T'\NKYS0D_GTE=_[]VIU=LC.]B[XR
M=7B=I;9I'R&<KJ+;NZMRU]#0*RQFK&W-IX/.;FR$&ME%Z2CGTWN;*"0P[!75
M#Y]:!))!&>@XZ-^371?R5P62W/T?OK^_& PU9)C\ADVVGOW:%,M9#4U%)+!1
M-O[:VU6R[1U='+%(:-:A8Y(F#E2#[O7K=-)_U?Y.AU5E8C0-:LA?R?MI&UQJ
M5(S(T?E:0#TZ X)_/OWV]5XBG7)&5E$EI%C\GA,CT]029;PA=*")I=+236OI
MM<'_ %SZG6L>76'SPR(DBO"T;O'$A+K"3+,[(H"51@DT@"^K3HT\@GCWZORZ
MMY\>N:/%Y)55ON6D5$I8Z>.>(,YG$%_+)"ZU49D;@QBW'ZC[=56TDJ]!]O6N
M/&G7%95D,PBL_C=@^E9#X8VD9$CGB<QS>9732SV5=9( XO[:>@KJR.O T\\]
M>!*PF>4JL7B5V#J(HJ?4XCO+5RS+ SM)P$4Z_P#7]MKI)("CAZ=;)-*G]G6:
M-!(J,C>B8D4\I4I%.4+K*8]0$T8@:-@Q=42XX)]N:1UK57K'<^-92K,DA!IM
M+12K5J>&:E:&5U=$( ):UFX]^I3/6PQ!(!ITF-\[YV;UCM#<V_\ L+<.-VGL
MK9V+ES6YMQY5Y?X?B\3!I%17N*:&HJ98H'D"E8HWD9KA5)M[]UXFO7+:F\]J
M[^VKMK?>RLY1[FV;O'!XS<>T]T8E:F3%[@PN94-CZW'/-!3U&B2,ZB)$C*KS
M[]Z&N.M#2M0%H>E(9(R6(EAXD=)9I)8X8P?THT=1/)'#4"5N$\1<D\6]^(*U
M+=;^0&.D;E^RMB8# [JW1DMQ1#";(9H]VU-!B\]G:K"SQS0TLE,V,P6)R>3R
M%9%-.HDAHX:F6+]3JJ#4/ @\.M<30<>E725]'DJ.@R%'.L]%DZ:GJL?4+#4Q
MM5TM5%Y87^WE@2LI7,?)BGCBE2X#*#Q[]0UH1U[@/G^WK.CI+X(XW5Y*I)7I
MHT#/)-%$K%F"QJ?$JR(R>LI=U/XY]^IPZ]7B>H66R^&V_BJ_.YG+4.-PN)IG
MK<MEZN1H<;C,? !]Q75N19%HX(*60@. YEN/2C?7WZG7JCI-9?L;96!R6Q,3
MD<U*M?V=5?:;,&/P.YMP4F5D?%S9J)ZG)[=PV5Q6#I)\1&:B*;(STD4J%0A9
MV5#ZG#K?KCATMBR:VB9P65CY&1)&40JP3S%D1BFEVTM$X6H3ZM&%]7OU.M5Z
MX'CU$60/)"6!4K))$;E(2&M4AUY0Q:P_T!+<>_4ZW4>?71<:E7BS1QR@ :OV
MI7,8UHA>2(B13J#A0/Z6]Z]>O5Z##L/N+:76>9ZYVQFHL[EMU=J[EDVSLW;.
MU<?1Y7.U<='&\V8W57TM1D\:E#LS;L:JU?6ZW>$2+IAD]6FJLQIY5ZU4$=*'
M9&_MH]CX"/=6S,I-D<%)D<QB6K*[![DVW4)E,#738S)4L^,W1A\)EH1'54SB
M*H>#[2H13)'*\?K]NJH8_/K9) -:]*Y)H6NXDTHC0:Y662.F1:@D)4"?QD5%
M,) $,L1E6["Q(-_>CAM->'6JBG7<;!T1S^VVMXVA>SU$4R!R8*A(3,$G9%U
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M9G-Z;CJZ45:8/'QU8:6GHI'5A3M6$7*J5UO:]_:K8-W6QVTW,I.A%7A6O T
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M"Q VXL;>TVT7\TUVFF.J$-J8'"D#@!@G/^JO1GN>V1Q6CU^,4H"N6!KDD8%
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M>DE9<=+DI8O5%XI&<=HC/$NK]4,*X-2*T!KPQ2GK^0KUM%E2&=67](QDBA%
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MHP.";>_:F!(TXI_EZ8(>0LR&J>7^7H0NT>Z>T-M_&/X0[YPF^:^DW/V=VO\
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M0;(Q=15]MP;".36@ZYVSUI_"Z:;)8G'Q8NE@KJNI50MJX!C=EO3R!KQZ\.)
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M?7NLIL(K ?0+P2;VT_D$V]-N1Q[MY=5''I3;1 !KK7;4R'7Q86OQ>VJ[7O\
MCZ>_#@?MZ\WQ#[.EK[]U[KWOW7NO>_=>Z__4W^/?NO=>]^Z]U5A_.+-_Y>OR
M%!^OBZH-N  3WUU\!S_6XY-['V;[$*W<./Q-_P =;H/\U8L)2#C2G_'DZTA
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MR82?^'+?C4+ _P#,X"/H>#T)VP;D7/Z=7TO]/9=S:*6P'E_LIT<<F_[E^?\
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MV]=;/J-KUW7.[=PX[%)%EH_XI1XFJIDSGV^'.TZJASM2*U8I/XC'42/*C:-
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MJ?RX_P"JAZ<KKN0VEJ+'0D@C-1CY\#D8_:.KV(O\U%_RS3_H4>V^GND[N_\
MX]/=UCS_ '?S=^!P?X1-P-/)XY_K[V> ^SK0XGI^MJ7@+<MJ _21?59F# DZ
MC?\ '^V]W!H>/35*CRZX$>D"F*@Z $U$A2$NOUTL2;'F]_H/]?WK-.[AU8TU
M=O'J4&#7M]+VO^#P#Q_4<^ZD4X]7!!X=!WFK')UI -]"CT@7;2B@@@<$"_\
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M[^GW)68N;X\9ZMS%-0PX2 KN5:W&0XPK.T>9<Q,7CU?0D@_[$5\J=)&UZ_\
M4>@H[7^'U'VEN+Y3YQNP*S##Y.]0[7ZER4$.V(G38]1MFGR6-I]W8P?QEOO9
M:F+.LIC2Y #MR ??J5J>EA/:H'I_DZ$?L/X\4W8D/QUBJ=X5.&3X^[SPVXJ>
M:EQLFK=\-+M^CQ(HZRFC:?[,.M'9V+LJWY;^NZ5'$=)7:E,5J>H.[?C#M??7
M?>_.Z=P[@R1A["^/U=\=LOM.BI(Z(X_:M=NG'[I;-X3.7R=,V3@GQ:J8:F@
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MZUU[_??[ZWO76^O>_=>Z]_OC_OO]?W[KQZ][WUZG7O?NO=/<7^:B_P"6:?\
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MII2O[:]8[&X !)O]1^3Q;Z_CVZ:@T'3 IY\.LFMUL"0+\CGZ?[#Z?3WX$I4
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M?A22. &!-CQ8#_6]^Z]Y@=>_%M((%E4@ GU?4%K@'2O(^G/O?7OEY]='5?U
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M=S'V67F;Q,!2^%1R+6 M[=%F1[>LNH%@:G!H0<"@\OVTKTWMABDCGU14;30
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M3R65PI*H+V]VF6ZNF@,H5=)[J9J " *_Y<=49+.PCG,6MF8#34\"2"<8Q2H
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M$1'A5] ,<<BI\\\?+Y] ULWN/XP_&K=G2FYOCZ>R>Y=[[7WE45W8._<_@_\
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M%#]02>/?AM_J.W_5QSU;ZZI%#W?ZN';PZDS;VR9YIXD/]FPIV//]3<VO^?\
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M_/IH'UO>W(_!_ _IQ8<_ZW/'/OW6R/V]1SI\=A<7!%[_ $LP_H;C]7U)X/\
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MNU]AM7S_ -ZH\*VX),:,-G7IFPZ,$-7%N 8MMM3RJ7 %-'6M5$7(B(!(L;<
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M_;GZW&D'ZW;\D&U[_0FXX'OVL#RZKX;$_%U[[<FWTM>_#$<VO^ 20/I_O/\
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MZ=)/!-!7RK_JX_GT:4LW U+]"?K>_P!?2"".0#<V%_\ 8\#8N5H"1_J_U?\
M%=>\#-//_5\_]7SZQ!0(343W;ZG^T38@V((NIN1];V'O45RDK:4%#^?^;I88
MVTU/#HE?RU^;?6'Q0ZLK]^[DS=(]14:\/M*EHU->-V;E9CIP>%4%_P"\&E6(
M)XPV(-SD\B!P#*"T>X)U?#_/_"*5]3D^2CJIM^!7C_J_U>G6DU\HOG9VO\FN
MQY]^]AYNJR$U+_%*':.WZ3,#^[FQ<80;X;9-S?G^" G*<#,CV!.;ON^[_N=N
M[>-Z>4?JG_+R/3_5YY$\L\U[-L,RCPN-?.3T;^@W\7[.@9VAVF:C)4\-:O\
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M_NN\+G<C#F*+.L9&HMM98X\+24[ I%5<*..4H-)36O \?\G6QW  5K7_ #=
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M%[<D_P!/I[U3@?(]:'' J*_ZO]7Y]1"UCS] /TC]&D@#_$#_ &QO[]04\O\
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M.'#('^#(/[?/H\EI-W:JFA^WC3_)_DZ<ILSE-T)/!M":?'8BIU4G]Z:BC/\
M4'5A<+G3ISVH'_BYV_@Y^O\ N0]V%:Z2#4Y_U'A\Z<3UXG%0>W[/V_ZN%>E+
MBL'B\1'>&"<5%2<9]WE:FL_B.2K?\,WFR=1-CQS_ (^_%B*9'\_\'^SG[.O4
M!J<TQ^S[?]C_ "]53_SO^Z)NH_Y?/9>/HJ\4VX>YMP;9Z=Q%0#8J,]F?XUO0
MD&]E;KW!Y!A]!_EWL0<C6GU.Y6RE>U5<_M# #CYY/VCIF'@6.03_ )Z_Y*]?
M/Y:HFJJ@SSV'^(']"1:U@?I^/R/\/>6.W.EG$HI_A]3]OKTL7/<2:?ZOS_R<
M/LZ?:,6!AN;'@\ 6(!-_HU]0_P /^-*+%/!@,Y^+_9(]?\G1?S&PJ+:H /\
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M#Y5<:V:H*+=&:P=/7215=3#*M47CEITD6)1J^@]Z>^C3#-W$&GY"O3MOMLC
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MRHZUW3N+:V7R5!D:2'51Z:FMQ\<,JQE'!N%>4L"=3FO17)W @EJ#R!I7[?\
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M*O=G\U;.R[5IWR&9[+W8*'.MM^FCR&2Q\?Q6V@D;8"IKZ!LI)21UM3-#'X'
M+E@;W(]^ ]3TA<$4 &*#HM?6^]^L_C^?B;W=\FL3/@.H$^*M1L';>^]P[.S>
MZ-M;&WXF>K)ZO Y7;^/PF>R.#S.<IY%9)10R"8'\#40T !*20,GCU8!O"1?]
M$ _/RZM ZNS.P]R?'G<N;ZMV)F^O-E9S$[WR^V,)E]M5V!-;1Y3&5C5&[:#
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M@XD6%OX6>L\)OWZ6(!_O%VE6WMQ[RL]BY%#@D#_5]1_J_EUCY[LP,8&QG/\
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M-_1;Z _C^@M[@$\=/V]%(P">EK,PU@'U'D@  Z3:VG^I)!_-AS^/SM>!ZTW
M=:7G_"@'*S[H^:>#V[?_ "#9'06Q,.>0/]RN<WCOO>XMQ]1_&:(GD_ZY]S%[
M8VRK;SRC\;U/Y!T]?Z/0CL$'8A'E_G/5(V.VW4<?LCZ?XD&Y'(])'U^GN58B
M5E) _P!5.EL\0)H6S3[?3H<^G=K[?@W+0R[[QFXZ_:/\7QM%NZEVJ/\ ?S5V
M, %\-A!:^W[#_<9_6_\ O(>YSG:(%0?]79\O\O08VU/%/ 5_XOHY'R#^4&[>
MS*?!;87[;;FPMG@_W&V!@*NVW,#]<)_&0>?X_N$&_LCY8Y8CWAFDD6K4R?\
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MXY_K86TV4W/'^M[K]@ZMUR)#6!&FPN5L3S]2;W-S<_G_ 'OZ^ZT.NP2!S?\
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M69T5>%4D@#Z6]L5/Y=/!JGRKU'U>@HHY8Q^1BP,LIB:\;32G5+.UK*2S$M&
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M]?)M[$U=9D<?BJ):R::#%4R5U?)+)]LL9F;3Y"VA+,9\^J\/LZ6WTN>0!?U
MW'-N3;5:^OCZ?X\>_=;Z5FT; 5HY/J0W_%B7X/)L>/\ &X'U][' ]5:NH?9T
MM/?NO=>]^Z]U[W[KW7__U]_CW[KW7O?NO=5:_P Y%C_PW=W^2& 4]2FQ)^O^
MG7JLFQOQI_(X_'^M[/>7/]S[7AG5_P =;_5^7IT'>932QN*<,?\ 'DZT;@-4
MW/U"J.>?P"W! M:_'TN?<S-_9BG^K/4$2@^,?4T_P>G^#'^?KNH.D7M<<GZJ
M6'T-B+#Z6Y_-OS[O;CPL'_5QZ:N(P0?]7IT_;7W3N'9>YL#N_:U?4X7<NT-P
MXW<VW<M36(H<E@\R<]A .!J7V7[A23&?]5/\W1A8R>$/3_4?\_\ J\MOOH;Y
M;_$W^9=TG_H5[KAP]/O'<45#'O?I_*[AR&VI=P9?'5#5,.<V+54$T<V:P"M*
M2'3]Z+ZU[1D ^X@N;.\M"',(/YC_ "'J<;3<K&Y[/&(;[#\_5>A(Q'\I'^7A
MMJNP.XL/T)+CZO:59'F*&>7?V\32Q5$$BRQ5U6M=DIJ"=49>& N+6_P.[?<]
MP2H6) ?GY>6,C^=>E$UCM\M=4QX^0'_0/[?3HI'\R;^9?UAU7UIN'X__ !LW
M31[G['SFU_[AUV<VSEJG/;<ZJVW_  NDPE52)GL2TDHWW!0T*?J+/BG)D<ZR
M2QSM&T7$EU+<3-4NQ/EY@UX-0#B?SKT%.8.8;1[&"SMUHB+0X.<J<]E:THIX
M86F<=:HAL!;\&Q=2M_J1P;_D6_/N38+#PT%?]7'Y]14!XKECP\_]7Y?ZN/6)
M:H/&J1M&*ORF+Q2E] 8:=0+@$ @_[#Z^WRQ& .'^?JI.D"OKUD%</(*)*OP0
MK4U-:\-963+B?XDD"B6KIZ168>;Q6"$J-3"UQ[:CMXB0?$/GY=+9;@JJLJ@X
M'GUP8ZX*95F9J:"2NJDQ,TT]13O4S0QFLJ8_W108V5H]);RLB:1P23[].T=N
M"5740/,=(#)<S$KH/[1_@ZQ"HAB_A..%;,E/3U'W>$AIZK,4M.F:J8S)+4[>
MF:2"5*M6-I62RM<A2R^T\?@WJO)(BKI-,9KY^?ITK@FN;6JT)9C7)IY?+Y=<
MY)S6I+2U5=D<G#J$BT^6RV4RB?<QN6JYL94Y>I,,"BHNSB)EF5_I<>TC)"K:
M00!]G1I'-,RU9"?3/E^?74GWM4JHU9E,K31M.RX^LS.9JJ51.(?/YH:_)24$
MK1+$Q#, !J('T'M\;?!,A#3D CR X=)9-TN(@2L(-,Y8_LI_J\NN(U 5$E ]
M4LU*4GIJK&/44LU/!$ 8IDFIT8QOCY?4OCN"1^/9_9QP6\'@@@KC-,\.BV2!
M[P?4N[(_\/EG/V]<:BH%,XDKJNJ=ZS&J:JLI:NN@J\Y1ZQ.&R/EE2KR]3)4H
MKM&Z6!7Z^R>XAAAD\6M3Z4Z4V<TUU)].U5!\ZU.<<.L3U J:6.JDEJZ[$S2-
M2F%#4R89(:8:]=#BZI4@HH:1F_REQJ9FO?W431RD.4 KT\PEVZ[N(HV+Z/7&
M?RK3K@\E=64AA%=D*V DRT\=3GLK68JG5:IYHC3135LM E((VM'$R*0C#_#W
MLQ0OI8D#UQU2Y,UU\3$*. K7Y]8*F9RKHS5XQLLRHU!_$\BU'%]Q)#&\.-C^
M\CQ/DU L%:)BM]0/I]M2Q0P@,F2V.'^7IY)ITB6.G8#6M>/Y==QY/(SP0UD&
M=W1D!5,I6<9K<VJ62HIYZ>2;^)2U"XV66GCX%/&R1^G_ &'M,+:*8DM)0'Y=
M*$O[E!VI6GJ:4ZQ1R9")2*?+;@2FDIZ"F-70YS<=)4R?8!5_RUY:VGI7E8\L
MR@J/Z'V8PV-NJ_&3]H_U?MZ32WUR]:II'G1CQ_S?RZC0^:"3RT+Y"FK/M%HZ
M*NQM?5TLL5)'*TS- ]'4T=15 LY)D<C3_2_NLME;&.R6HI!-XG#XCZ'-*=-B
M[N%92./V_P"4?Y.L@^XTU57!69*:K9X6J\U35>:%5:!@0*K+R6KJFH,;21M-
M'( $<K;T\I)88';>FU?[FNK$ 86G #U_EU[ZZ[6E(@?F3GS_ -6>HJRS2) J
MY/*UC0^5*)*#+;@.0IA*VHS25\E7$H:.2VMF/FG7TD@<^ZI96\@5GDRHT\/3
MSZN-UNE&@0T\_B_V.LU565]13&DJ\]GJR-EB2KIJS-YZNQS"J_<SP-'/755,
MODD+202.-,/"I>U_>F6&,8 /Y=66>X<DLQ KPU5_P]899JA]--_$<G404M=
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M*5\P?\'IU=;*%8XVUY8&N":$''#C7_B^A SO\O;$5FZ^C.O.M>Y<SNG>_=N
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M-^G_ '/;BX_XN?YXO[ -]=R7S%B<T_S?(>G1];E+, ?/U^W[?7JT3:-/28O
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M16[4[!VMWGF.SL;MJ?86YMRXO?.'R4.,5*.FW'3QR1[<JZ":FDD76PUZBHL
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MZ7^U -OT@< W_3_O)'^'L&> T3$@?X/\_4E27VA14_X?\Q_V.FO(9V;S04\
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M.D CJ]PKJWX(5U/''-E-^/I?Z>UJW0-,FG15=[01G3D'Y>O4(W_/TOP?]A^
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M[)V+L75_&L$57/LNW,V1;*WM?G\^SNVYE?9U5APK08%1ZU[6/$TQ7R\N#H=
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MA92>!VE?Z$_\1"7/=P/%;T_V(_ET>[&Y95J<_P"RW6QT"=-[VU>KZL "2+V
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M?07'^M[U^76QYU.>L)XOQJTL0=(%@"2/H+%F/T_I[KU;KHFS?YK4#J-R;?J
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MU[KWOW7NO>_=>Z__T]_CW[KW7O?NO=56?SD;C^79\@_J5,W4_P"H #_F>O5
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M_N^,_P!)OV53_9Z+7,; 7_(LP-KVLUSR1Q<?UXO[/>)H,CH.&@H375_J_/\
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MI!OQ^?I?\V'! ^I.D6^G]/?OLZK]O'_5Y?\ %=0[$A02>001_K_XBVK5^/\
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M 6('/X]^H*_EUH<#GI@-E N01R "#Q?\V!-M)'/YM]?=>G.N[L#]"+$6+68
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M>>>;\CGD?CW+_P"!>H*DJ78]-]^.;_7Z<\_BW'UN!_L?]C[,2<YZ3Q#N%/\
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M'^\>]>'%D^&N/D/\W7@*$J%S\_\ 5_EZCGU<GZZOJ;'CFY(O];_U_/MQ0J@
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M6_I]#_7GW8<1UK_/U-D8ZR6  93J^NH'2"PM_9MJN1S[>ICCUI#VX_U?SZE
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M.O>G78-@;DK]./4+WL=1('-[&WT_XIOB.O>=.NN!Z23I&G\AFYL0>" #IO\
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M.5*C2"6X]7((/Z^?Z<G^GL^V^W&UII!HU*5_,_,^M.H(OKB?=-^:[O\ -O\
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ME_&N,D_R5O\ 5Z=;$/\ +CR-\+E_MB3B-S;CWWN?$CZ:ML;V[+S^=P>8_M
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M-_;? @>?3(R*UP/Y<?\ 8^VOKU)_ /U(/! XY(^OU%@;#_B?Q[L,&AX?ZO\
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MJ9\B0 38\,W)-P2!Z?\ 'Z>QGLT]ALW,MMN$#UMXM0&&SJA(."&/%CY']G0
MYU@OMZY/N[29>]M-<KY3QMY:1Y#SZ$W8G1\8J*"#-8K);BW=58C^,4FR<55X
M7^*?PHDG^-9HY\?[@=OW-^3_ ,1[[8<J^[RWW)UI;Q>6O^<[GSA'IU\^?.?M
M0]CSG>3R$@'1_*!!Y3'U].A=J>L\GM?Y _$'*ULV%JMP566[APW]W\!1G^&8
M('IS.YU?X+G% W+GOZ?Q3\V_XMN/]Q!S+<"?GF(^E?\ M'7Y#K)'VZVIMN]H
M/<\D_P#1N_[3I>.3Z];#/QOZOJ-LT']XLI0?;U^3(^T6KOR+@O:Y!/TY^O\
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M_=&]7T.9@&T<I16V_5;0Q>YMQTOV=VW:,WFM^8+^#9RPL-O'^Y'^YJPOF/\
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M7V<G_5GY=-R0EJ \/^*_P]"5U+UQN?N;LW8?5>TXE&Y>PMQ8S;6)^\.97%T
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MGD'^HM_B3;G^ONO5P",=8W' /]>+6'^(X'(!_P!Y][%,^O3B4TCB1U$M^?\
M>AP0/SQ_AS[UZCIZ@P>N:CU&WTL>;W_K_O%A_O/O?6O7%,]<V/!'YY!_PY%P
M/J ;_P"P]Z(-?GU[YU/'J._Z6%R/IJ_K^H "[<6_Q][I\^O5H:D=6A_R2^?Y
MG?QI!X&CN$A?Z'_0%VT2/Q?2!QR+'V3<W8M@:>O^%.A%RC_N6*_ZL/Y_ZL]?
M04]Q9U+77O?NO=>]^Z]TF-GG_?H[1Y(OM[!@?7G_ '$0&QY'%A[\.!Z\?+I3
M^_=>Z][]U[KWOW7NO>_=>ZJ]^0'SE_N'O[_0_P!7X_;.Y-\T7[V]*K=F4W>M
M+MV2:/7B,5A]O['VONG<V=8L3:OD3$X51Z?XE_$#XQ%/,O-TE@NI0*C_ *$'
M\)Q_J^?0GV_E\S"I) /#[,^I%#\J=$_WK\Z?DIO7^ 0[#R_5F(P;;BR6&R^X
ML9M+=V.RG\1N5;#X,[[0;7SVX"S77%8G^,9C^$-_$A86 CR+W4F5B#0#_B_^
M%?ZAT92\K(>)-?\ BOZ0/ET!OQN^6./ZS^=O;>#[]W-@,=4_)7K'J3,;>WGB
MJEVV3_??JM-[[(S>&3-:0V$MMS.T=SD\1M,XC["V3QN/:X]C_EWG"6WMS([C
M(%.%/B<?P$>G&GSQGJ7^8.7TW7VQ]K7$;%4.YB@#$_[E(21W+JH!P0,<$"K]
MO1I>M.N]O_+#NOMC?/;U9D=Q[/Z]W7E]N;(V=2YF3^[0QZ;TWOL?!YA05DW'
M@%;;NSJ+**,6^&.7S.=K!D@0*"Q]L-P><KMT=NT?] L?()_!_J\\<IX#RY;6
MV/-O\/G\5?BX^?GGHL?RF^,$W6T^<JL=B*ANLFK/O-H[VHPHQ^"QV6+*VS-Z
M@ /@&VG(H&'R>6MAAAA1@Y(9/C(8@>\GLQ-RU+]3;$4!] ?]\ C,[$?$01@\
M0>LV?N^^^@OU^GGK6E?,'_B00<0"H- 01C@1@]5W5G2.=,1R=:]+3[?(^[_B
MU7D<0,=Z;$#^-WTWX ^G^Q]X\@WMM'I$*B2E*UQ^P,1Y]9EKS_;S.#Y<?/\
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MX\Q/!05F0R %6,QELKE:S^)Y'.9*X_C>8S>:SWJ.X@"!;\_T^ON>.5K-48
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MI^7F_J?GU?\ 8BBAI<90000FGIZ:E+_:,2+7-M04$GU 6'^W]AZ5JVU:\?\
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MY]01./U>&?\ 8'4<<@GFWTOR ;#G@6L1I/U]I+"B"C#_ %9ZO#5K=F#&F/\
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M3;3'(P5G _U#YCH0VUSNNFMHYT?[3Y_Q?GTCL%\8-^5E=X,G3BEI_N[6!)Y
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M*X_WW:Q_[[7]OVUY!_>+^[UN.RS$V\55'S0<1;#SN6_B/22\,^6K((8+U!_
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M>Z<IZ5;Y_P##^K">E/CWUS\?\,F(V+C2U;+&%S><RM\AN'+1JS!4 +, NM^
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M^&%M(^OU8&S7TW8V' _K[]UO[>L8:Y/A)4#F_IMJ'Z5('%Q8BXX_/O1DA0
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M.IICOR@HLA7Y/;4NV^VL/M_<NT\+09A:A!6TLZQ2,Q)>Q]KY@M!I./\  ?\
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M,'B)MIQ2A))J1TJJPE; \^_&2=BC$C3J'RI3_"?EPZ\+:+2XH:Z33SK7U!.
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M26GE2.*DIY% "O=KA5>7DEL*QYT\:CU\@?7YBM/3I/8VT5R2D@ U?"03@^I
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MGO;[@S<_;K&\8QGT_@@_X7'P\/\ U>=LGQTZJJ-K8X;BS5"!D,D0*34;:06
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MW?E-OTN,RNY)Q)6YZKPN+J)Z:&#)K*B>+%P.78JI-YG=AQ<^V;B569NT\?\
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ME4NXAD*)@<.XYI\\T-/E3Y],.(^2-;AOE=4?*2@VLL%55=D;FWE6["_C,_\
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MOWT;$*"YH#^9^1QGYTIUOZM0'&,BGR'V=W^&O18OBUWE#\<NY<=VK+M9M[4
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M_)Q4YY'^('NP\A\QU6F3_J].G!RAD<  *"+G_7 4D&Y&D*/\>![= H!7KV7
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MVX(ZBA4[BB=Z>6I9?NHE/DC(87]JT&:'CUL0Q:Z'\O7CQ^SJKNEV7W=%U_\
MRF]O1]Z4F3["S^2@RF"[-RO6&S:$[+P%?T#42X[#8S:&.I$V[N#-;*Q)EIZ>
MOKTDERBJIJBS 'VFH/WD!7/AC_#TBNU"3C0N*5^TU/1ELE\K.VOCWTY\I?\
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M4U!60;AVY54]76?9XBKI-H=\ UV4:R_J_P!'0!N!]?I_O7M0???G[#?ZW?\
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M7O?NO=55_P Y<'_ANGY#$&_JZF%AZ2 .\^J!_06Y^OTO;@>S?EL'ZJT].[_
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MS8-(::I>:6HR&6S%1F5J0570RKI!X[6IJ&H5&:DU^61C[,="$M$VNJL 6\J
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M4Y7AVH/EY0^@'[.FAR;O8#'QC3TI'FGG\1 SG[,>AZ4O8VW?C;B,[X(^QQN
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M]?I[>44M"/\ 5\75Y2IN #CC^7;_ (>C*[E-OA[T4.0/]F:^4MRU])!ZU^'
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MF]NFAF\T<[F\-F<)G=O?WCSVP"Q.3.4Q0_W#_0_3V$-Q]@(YBJR_#D_MIZ7
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M&D6L+< _\C]^S3/5B17C_P 5_F^7^7KU[M8:?\> 0?S;EB+<_P"W]^KP-?\
M5_J^WK0H: #'^Q_@_9Z=1I[D6 /U(L2?J21SS>]A;FWU]^8CRZJ@U#)/G_JQ
MY?ZOGU@/^-E(L.2/ZBU[$@CT_P!+7_UC[]GB.'6R<-JX\!_J_P!7I\NO <_B
MPX' 4 W56!U:SP#>]_>QZ#]G3Y)%*_ZOE_JICKT3$_[ < GGZG2./J;\?C_8
M>]<&SQZT*G X?MP/3J-,#_@+V'^  X(]7IXO_C[3];P5'K\O]7^KY]8+6Y
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M/NK ?4C[?\G2E6/@$4_U>?5K7\DVW_#G/Q@M^8^XS]2>?] 7;5R"?S8?UO\
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MS3O5 ?J./]%/^@.O?U:VTZJQFOVM_P!!]<S_ "AOBYR/X'CKG\?P:0,3:_\
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M'M/T]FM<T_P]>-KC\WY_H1Q_K_[#WZO6R,A1Q/IU&-B+$FX)'TN?J ;\$$
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ML'MJ>3;6,H-G3UA.J?*4=/G%2.8M=Q$VK@D^U5G$9(I&8Y!4#\Q7JFY,L<T
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MVS\5)@=R9.N@R& G@4@/F*9:4FE4DZX_41;Z,0*YM^8&U A+TBA\^!X^5#P
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MDCTD< W_ $_[#CW3RZWUT"18 A3J%V*ZK ?0$VY%O];CWKKU.O<#Z\ BXL
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M?^"VY/!^A/X+6-Q< \_GW[KW^'I6;3MIKP#:QH+\G_4R?DV^HX_UO]M[LO\
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MW&;8RF*W!E=OU,46MWBJXY%-A<@6]I+ZU!4NL8)I3(%:?(T_XOI;9W05P Y
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ML?K=V(;Z@\>R-Y@A*J&)\O\ 4,8X=#[E;E6'>6,^ZW2[=9 5+%3-3#'X58$
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MD:J45JMZR==M+CB,M0$?EC_BNFT\^.K[?\W0IX_X^T'0'S^^-FWL%V+VWO#
MY7IWY(UDN.[<WGE-_P";I:Z/<W4<"5>,W7FV?+TN-KQ3Q2+30L(X5_3;6X]F
M< 7Z61E #4/^ ?ZO]0Z61U8'SZ5_>FT,]VI\\=I]1U':/:>Q^KE^/>0WEEMJ
M]9[YRFS3F=U15IBHIWJ<2R5^*"DAI7I^9%!#?4^PPC D:2=)'[#TVQ(4XS4]
M%:[/S/R&[@[E[JHL!U3\K^P=M]&[U38O4N4Z/[YV?U3B,158+ 4IGK>T\97U
MT&7WC5UF=:2K9\BCP5%'*&3AB?:U*$-7IAJG@*&GK3UZ%',P]Y]O]F_"CJ[N
M3LC?_5V3WMT=V/G>Z]N]1[MIMOS9_)XC.S4>->;<&U9/#+D4QRTYDJZ-CXF5
MQ&;DCW7C-0_+_#TY#B($<3C_  =(?'=7]@Y78GR[S>0^2G?E=-\+-[]CX#X^
MO0[^SM.:?!;2Q=5FZ>A[;EI9?N.S)M=(L3U625I(U) (6_M:5H@P ?\ 5PZ<
M' >G0B]V]@YON'9/QHVN:#Y&]D]B=C]&;*[6W)U9\:-XXWI.JK8\KM[;V0K-
MYY3LMZJ@G\%/D<E+IQT,NJH5M3C0I]ES-ID  K_J_GTY& A?('VY'IT%5+W?
MWO'\4NC:C.[HWSM'=V"_F&=<=-9 YS<6(SF^JC8LF[]P4,W7G8.>PKS8[<D4
ME+2)#42!B\S)=K7'M;#&)!3\7^;I-,:.Q QI/[<?Y.E>_7F\^\>TOGIE<Q\B
MN^MHMTONW#GI3&[2W[D\-@MIY>DV-D\Y4MF,50.J;GH*VLITT4]?^Q;ZB_(8
MF/@CNP/]7^3I^VR5(4'_ (KY]"/1=W=D;OW+_+!W%7[QR5/+V54;XG[)H,56
M&AH-ZR8K:=?#1)E,92J*?/4J2TGE8V81NQM]![9$97234\>B=&<NI+'CZ?/_
M #=%BPFV>SLC\;NSOENOR1[Q3M[JGN++T^TX*K?=?6]7TFU/]*^$VU5;.S'7
MJ2G$9Z/^"YJ989IT,L<A1;A4(;8DTX/'I2C2%14FG0X?*O>FU=S]VIL3Y+?(
M3>/QSZ?K/CSB-Q=*OLOL*MZY3L#M?/4D#9ZA$V.:$[CR5*DSK#AF)61B- /Y
M5Q5?( K7CT\&/;7&.C;?R_-G4^R/BEU9CSL7';%KZO!4M;54E)A5Q%=N*+0(
M:/=^XU4F2;<VXJ>-:FL>7]PRRDMS[575/#!!J-7^?KP\^CGBX/(Y!Y)Y-^ /
MH#?\<?X^T%>M]>Y -_I_L2/J-0]1"WU'_7_WD'W6^N6H@DD#E/QS<W /UN/2
M5Y_Y%[]UKI6[1 M76#?KC#7^EP91>US<DW_UO]M[L.!ZJ3W#[.EG[]U[KWOW
M7NO>_=>Z_]7?X]^Z]U[W[KW55G\YMF_X;F^0@/X;J4*1]23WKU4#>S%5YY_P
M'LWY;_W+M?7N_P".OT'N9/\ <&<5\A_-DZT53>X_)]5S>_\ M('(OQ[F(U\.
MO4#24\2E>N'-KVX(LI%B+_ZQ)L&)/X^G^O[?KG/KU>M5I_J_S\?]D5ZA'D$$
M_P#$'_ <C\AO>A2M?+JQ-13Y_P#%4_S#U\Z];&/PV_G*[-@Z]H.BOG%M2JWI
MA\5BJ+;6([0AQ'][*JOQ.,B>%G[.PB/!=U4\Y''>2%B!=#]?<7;GRZWB>("0
MX^S/#Y_/J5=OYIB9?#9:H?MQQP.WY?ET<BG[<_DQ=98O;?R.V[A^M,4,_N#-
M[;P&Z-M=9=E5F8RN[-NXO9^;S&-BPSX6:7'U5/%OG'F]6M*O^61!;V<A!;V%
MY%14;Y<!_G_U>?2FXW';IA616X^1/$4SE?7^6:>754W\Q/\ FU9/Y3;>K^F>
ME\!ENONDZBJ1-V9#,Q1P[R[%1%")A%CC"+M[;JD#D DDW-SS[%NS;+,D[3S?
MVI X4\@P_B/_ !?0=WG>8&MDMHC2(5H/M*G^ >>/\_G2B2RC@$@'ZD#D_P"'
MY ]BF\CT@ &A_P"*_P O0*@&MRQ_U8\ORZ\S1*ZQO(J,_P"DOJT^FXYM?^MK
M>]1*S(M*</\ +TZH,B^(#D_Y*CK!5>.FE@^[BF>2[54$QD5T6 D+%(IC1Q'"
MCGD/I8?T][6SG61I"R!":\>GV5FA5!0$#J9"T\)CD2KF2H$U0N-T&-#75I03
MSQI4^-Y-)U:5C=%1K?J]JFCHNAF!;[>B\B=3J &D?(X_U?RZ@R,U1'!X15TY
MGEF(DI:I*2$UZ!34M6*Z3)!)2L2I46#D\>TT5@)9NUA72>)_;T[)?2K'Z&HX
M#Y#/'K-%#6U$534TV.R\V,Q*)_%JW'T-144V.GD.A7S>02EGI\6*A_\ -^8Q
MB6_'M.[P+*(CA\>G34D%X8S**%?.I/\ +K)0TF9W#4M08*@S6;S58(R^.P&*
MK,_D9Z.-GIXI&P-)335C4L;1&*1XP &'!M8^[7/A6R>++A<^GET]MMM>7#^'
M&RZ_F3Y_/J/64DN)K6ILM1U&%KJ:2KQ-9BJRAK*%L>TM.Q-#+150^ZHZ^*8*
MQBE4LFJY/T]Z@N[28+I5L@>G1A<6-Y;L?$9"0?(GJ/2RO3>E_N8IHJ2CII)8
M91'6UBLB0QT$9FBEB2JE<%@WI%C[5D1*H+ TQTG61]0!/K]G6,AJBIFI:FLD
M@CHYTI:AF;PMBHITUR&J?3_E;L"(_,A(1S:W/M-XUM(_AHK:ORZ<NI-%LIE4
ME:C XUZP^=(:>-Y'GI5,U524=+6*U1324](-0JJMXHH9HI&B]2'D7_/O3>"#
MYTZ3P3QOI"H]1TW3U,$=9/21RJN1AU2T]*DDE8T<M3!2/0U6-O#XX=49F,S%
MBJW47Y]U\2W'DU>C2+PR!AJ8Z>LE09;&54)W#C<WB$R(QU1#)GZ&JHHZTI$Y
MHZ\T<E%1MDJ.5V(B6%Q%4WN6X'MRPN;6*:0M7+?(^1Z+Y[2Y#LP9?"K4<:TZ
MA^5'@HU772UK54[R0-4:H:.K=RBI%0.A:GC>)!*D4DDH1F(U6]TO[+ZMM<)4
M+0<33SKTSXDBX<9^P_ZOSZB-+YUF25)ZMH#+!4.\\2SURK)'(LE32(D AF+I
M^P48L45S].#N.2"V@\.6I:M,4\Q3I8DSQ)(34*R$?F1_@_XOKBM4D50R)D)5
MDA52*B0?=9"G@E0F:*&HEA"FBBCX9&U-?\^T8VR19/JB5\*M>.<<?+HGE-P-
MKV_;\>+$S%C^$UK2A\^N_,D;5$ 6=6>-*FD62M25(ZAC^[.^J$1K,:<E_#]-
M/%_:R01[@@M[<4DX=V!GI>K7$PV/0PK;5U\<UK33_J\NHRMXUC $E95MK>EK
M5GMD)*21A%+)!$(Q3X^G4GC2&<'\>[BW6-%B<C4N#GTZ52/(9'->)].'^?K'
M'(K(KTK/5TI5]$\4<;UBO3M>GEC=S#.S12,X>=U*FP]/NW@H/,4^T=4#N<?Y
M#Y]8J<JS4\<E5-4FJ^Z4&1/*M2S0N\<$DB")%KVD4(C@KR;?0^VI;9)  ",9
M_EUIII(=-1Q(&/GUB2(11I0DNE911DU",YFE>&5KR4.O7Z&@7F0B0D+]/; $
M$%=8);Y4Z,0+GP!+@1T^=<=9I9))'DY5X)"E1$$C$-525?TE(K#Y9*FF\9-D
M8 ?@^U<,UE3X'.1Z=$MRUS<R%490V1FM/7K@(HVE:H9G^XG*_<SQWCD:./F-
M:8.TD=.Q Y*J/IQ[: C5V:ATUZ5_J>&J$C4!_JQU!F]<TA;ZL[VOZB/42+DV
M-E^G]/;+Y=RO"IZ4QC]- 0*T'6$?UN+\D\7')!%Q_P 3_3W3J_6(?6P-KGG_
M 'K\"_%_=:TZ?],5Z[_QL"H^GUN+\?@7X]Z\^M9SC/44S,221;Z\<$#3;DV-
MP3S_ %Y][Q7%.K< ,?['^KY=<[C\DCCBW]?QR?ZWY^AO[J/+KV:8ZC6(=K@C
M^R/S8#C5P/I<<>[,/\9!/^K'3*4\(T\OY9^75KG\D;_MYY\8F%P=/<8 &IN1
MT%VS>VD?0CC\'V6\W4^F'^KS3H\Y2_W(Q\O\#_ZO7]O7T(_<6]2KU[W[KW7O
M?NO=)C9EO[H;2/U!VU@;'^G^XJG-^2/J/Z"_O?EU7S'^KUZ4_O75NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[JJO=D,VP/YL74^9GGTX[Y#?$KLO8 C!
M4?>;EZ-[!P&^,$I-_2HVWVKG#?@<6]D:QZ2N*AE_Y^/4E6CI<\D70U4,,@('
M&@UC\_.H/RZLSJ8Z=L<T0Y)"Z;D\ 2JYL;C@+?\ U_\ >/9DD9%'KC_4.HRE
MC)M&H/TZ?\_=3*C_ ($EB?TZ.-5C;2/ZK8$%O]]^%:_VB?8?\'6[C^RA/S/^
M$=4L_P ]@@_!5QJM_P 91V,+)I))^ZO_ &;&ZG_#Z^P)[A?\D;_;#_CZ=96_
M=&S[V;5_S3N/^T2XZTI[WX/TL;?06'U(L;\?X>\8N/EUV+ICKD]D$3R3FK25
M]$,$AT"20L514+\,[-<:1S?W90S'2J]WRS_@Z9EEB@4R32JL>!4D 9\JFF3]
MO7;^6.BP]+!*FF#[T52LZ*P5W:<BQ93PJEN+\<^]A)4DG8Q-W:?(YH/\G2$1
MQ3[1RM!:[E QM?J=15XR 9'J/Q>GS/Y=2JD3O5UE34$+3IXTI:DF(1%Q"H==
M5PFL7O\ CW14\.-5,38)\B/.OIT9[G^\Y-UOKZWN$-NVBC5BH:(%P2:'->L3
M5;4$IJ89Z4M5R11$^>F"^9ETP16+26DD!(1>"UC:]KAJ,,]5,;8J>!X?L'5+
M_=)M@N'W*&^B>*8@,08R%*J %)[Z%JF@(4FAI7-/1P&&(I#)%5T]>[1O+3/!
M-$CT[ZBCS122J&]1N"0>#[5P2I*WZR%6!\ZCCY<!G_8Z<:TNK?;1'M%[%<V]
MP2-<;12+6-@U-2LZUR>+#AY]<*8?O49MQ:51?\:EU"Q_H1_MO]X]LS?[BN/L
M_P /2BR_W,VJG_#/^.GJS'^3* ?YE'QNL&'^4]O?4@@'_0+OS^M_QQSS[D7V
MX_Y*9SYC_CLO6*GWL21[,<\GY6O_ &F6G6^[[R2ZXV=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW27WCQM'=IX'^X#,_T%Q_"I;ZB#?\ V_NPXKCK0IG-.ITEO(_Y
MTE;EM2D_MVN3:[@D6_/'^QLZ!PQUY311G/\ J^?7&GN903R%J2?P>6]/ )4@
M#ZFU_;8."3QZ1QY84_BZ?/=.EO0>9R_\5GN=(TQ#\@']OB_JT\+_ +?Z\>]^
M?RIUKRK\^F$@WNI)-B;FX)7Z#2H%N5/'^O\ 3W3AU?KKC@>GG_8'_8&P)!O<
MC_>>??NM_/KOCQ0:0"W%@0VJYM>W(%R;G^A]^/!>M#BWIUT/Q<6/U)M]+V]6
MDD_11^!Q_L??NO==@E;<'\,;FQN3]3<<$<6^O(]^].O<>NOTD >L?4GDW'U
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MBWAVY@=F5%5)48G%=I[TQL=/CMS;MIHY@)IZ=!"+64!> NG>)D"H?/\ S],
M>?\ DIT::P#,;D@\7_V')+*00.>+ _U]I>M]=@AK-87_ #<&QM_K6%F^G/\
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MXL)MREV/@-DTFW:S<.=QNW-NX.BI<IE]X+44$<5(7FT.[:2OJ!]N#<Y1J)%
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M";FWUNI_) N!_B;?T^O_ !/NO==E>!SP0=7U4@'\GG\FWO?6NNB2+\7%^?\
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MZV.NK<WM^!?_ 'H&PM:Q-C^;>]=:Z]:^D6-O5QS<7N;\M>X(X_P][Z]Z]>L
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MZ7/TM8@?0B_X L#]/>L^8ZW7]O7%O\R?4+K8%B!S_4$?34!^1^?:@C_$R?\
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MMSIM;_>N?>NMU&3_ *OY==3<D?5K$CTC@<G\6MJ_WQ]^(\NK<*?,==#A";@
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MZZ(4#\!N1^1P6MQ?E05'YN.?\;^Z"?PQ4</]7RZK^]+N;&FO^\_YO]7RZXD
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MK@$\<C\<BWOU.O?9UXD$7O;_ !N;@J&X8,UR>?\ BGOWV]>X==$W/GX)2QU
MD#T@A@O N>+?UY^OT]^SQZ]_1)Z\04 )_+'^EPMK DD*3?\  /O?7NNP .+@
MBQ)'U_LFP(L";.!_OA[U3KW75R.;F]EL2.+<%0+M^;<G^GOWD>O=>L?S8\$
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MA8V_Q'']![L.!^WJI^(?9TM??NO=>]^Z]U[W[KW7_]+?X]^Z]U[W[KW54_\
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M=C)8&WU]-_P ;W(!M_Q/YL%]>J%J\.N6H'218W(]2DLI-Q?U"S, 38?C^O\
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M'+"164NF@@68."+$&Q'TO[]I8?A->O AN!!Z[4*2=+7.HQMR&*N+AE9;$AE
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M'T68DLUP"+7/UO:QY_ M?V=U-/ET38)X]W_%?ZO]68\YM;G@V!M:_!86:_\
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M4R!DH"*'TKU%JWI[^H#4""9=7UMI'"BZV(_XK[7QO/%VW K7SQ_@'3?U9B-
M>'E_LD?/JO5NU=QXK>D3"NWON'M+,]I]V[6_T/T%;M>LQ]!MC9F%WO\ Z-L5
MF=I'.'<VQ<%NBGVCA=RIN=</ER7SFDL,;D*#QM?N[96;_<+'^GD_P:OE_JQT
MD6ZWG3I\7/KIC]*<>.>%>-#\LAUE^Y=R4&)Q6"V1VAO7<M=NK%]2+VMV0*/9
M^[\?U3C<QO*/"=F]AK@<#N)]R=6;@,>\7Q[8[*8H8;"C _Q$+:@R1K]C:-FH
M6^C.D_TY!Q_VW'Y_G3T7B?=9**7&,?#'3&?05X#UQBM*U6R=H1Y/=HP7]_\
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M )^C[981.%5O7_/_ )NMU3Y(?(+9?QJZMS?9.]YXJJGI%1=N;:ID:IGS69G
M;%8NEAA)FE-5/HC1OIR/<;PVAE<T&17J7Y[-XQ4I4@C_ %>>.M:C(]<]W8;Y
MV_$?M[O+.;BQN[/D=O&;?.-V_!5Y5*7 ;32J*8+;M9C1+IB:>GG+:"HNH'L1
M6=DABGDB:I0$<1@@?Y.@=>Q3++&&C(&KSKPJ/+K:SSF$QN[,1N#:VZ*&ER&
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MT?WA>W]S?U5I&":_XWD"H%0#MP+<>'G0G@">I6/W?=U44+KXF",5!-.!/CT
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MY# 6(*C\\^]=>ZZ-S;GG4+_7ZV4W&H"]]7T_'O?SZ\.NR+$^G\6!L' %BO\
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M(;<G:NX=\;"&;P\N1R]K6S(PY*Z:$WZ+<F>\^Q\X01S\CWI:FJO8]1F10?\
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M]#QS8GCD7O<\<W(_WGWK/Y=.=I%13/\ E^?^K_+U%-A?ZG@6N>>.;#^MS?\
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M\7AE.O<;C\GBZ]-]44-=4U$M=AZILP:G<D4LD,DOBJ:ASH(U(UA[<US,B*>
MIGAQ% #_ + Z8N?IR1H.=1KP_D?M/GU7_P!N56YMG_ '^7YBQD<AM[.8/MGL
M6>KQ<.0I:.3:^XZ3*;7CHT..H*IA;'S4Q=6JTE6P=$95!'NZ1S M44'VGK:3
MV^A14U'R'R_U9_+I0?.;H+M/O[YR_+'(=;+MO)T>P-G8+L3=DE5N[;6#:KPF
M$V=@Y<QD]NAX:K#Y6HJY9'<T\423RE2%;5[4QLT;1*0>YP!QX_/Y?.O1=*GB
MU,8KI4DU(X ^5>)SP_S=5%%XYCY$)T/RE@0=+ ,MP;D<CZ<^Q.?GT3$@FJDT
M/7(?FWI8?V>;@BX/%A8-86'Y]U:OU-?]7#KT?]C\Z_Y?]7[?7JU[^2$5/\T7
MXOW-O3W"I)X MT#VR/J/Z_X6^OLMYO\ ]Q:A?7_GSH[Y0(-R!7S'_/\ _J_/
MKZ%7N+>I5Z][]U[KWOW7NDOM/_CU-G_C_<#A>"!S_N&CX_P/OPX=>Z5'OW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[HL.\_CKUANX"63%1
MX"M!_P"!6"@%%(> #=XY$0W/)](O?WBUSU]T?VZYYE2:]C\.1?\ GH8<(P<"
M[0?@&#C]G0\V/W)W+9*HLJM'\QG\7F$/\1_/I3=;]7X#JR@KZ3!Y3)95LC5?
M=M/DPRLC7%R68#7PQY_Q]B_VM]H>4_9R,P[.=0]?UA_OT_CFG_W^WV_X"CF?
MFN]YJ(:5-)K6F#_#_13^'H>/<[=!KKWOW7NO>_=>Z][]U[I,;O\ ^/2W=]?^
M/>S=^!_SJ)OI:Q;_ &//OQX=:'$]*?W[K?7O?NO=>]^Z]T'6: &6J['DI"Q!
M&D Z ;VO;G^OY][/'\NM#A^?3'P T''T(M=;?0@$ D6%R/Q_7W6OEU;T/78O
MZ?H+, "21P+W^C7'T_J?Z^]>G6_6O7OU&Q )N2;^JY+!>;#CD7^@XM[]UX8'
M7BS#3?@\J+:;7'IL;@W^G]3]??NO?+KKTFPX-Q_MR+7NRJ!=B1_7^OOW7N'7
M=['G_6%R5%^3_6X(!^G^P]^ZW\NO$6^G!&DCEKW8\'F_'_$CZW][ZUTBNR<E
M6XCKKL;.XRI%)DL1L?<-?C)F%PN1@H)I(26L;JDB(Q'-Q_K^PQ<EK:-(ZT/'
M_C1Z660_2H145-?V=4Z;8W-\H]K_ !8ZR^=&5^4W:&[]YQ/LR#>/268IJ=>I
M,[@]P]LUG7M1/0X1(TF6MCQE?$YJO6FN _DBP[:*-"J"(:2HS6IKI!SZ'HK@
M+O2LF:^@]?+S_P!7KT8.NJ>Z.YOFSVIL2A^0W9_473/675G6G:6#V7U_#!B*
MC,YFJR.+JLU19+-UD<GEV_F5J)*=Z>W*-KX /LJGJI-3P'1B]=&0-9]?S_S=
M$\J?DQ\J.S*O-=O;(PGSR&YL)O'>6W>N>MNK^H:S)?%S(8C;&:DQF(PN\*Y*
M>1,E!/14OAGRK2JJR!CZC<^VH6+:ZFN>DU<$#C^7_%]'^D[Y[!ZB[BHL[W!6
MU])U_P!G?%]>VZ/K[+01KCNN.U.L,+22[^V=B921)456Y:[<U/3P0LQ)>C8@
M-J!+WIUKY#UZ*#V+W_\ )&@V'\=.N,AFOD3E]S_(7$]@=J[\W)\?MFON;O\
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MI_L],F5AW5^VOV=5Q?&23LKH3X*='9G97>O:.YGWY\A-NX/7OFHI98<'M?\
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M+$^]B*(@4(_G_FZ5QW<L@(12P_+_ "GJ/3H(TAC\M4%= E88:RMCFG2[S/\
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MI9ZJLK<DU/!4(3>*GK:A:>"K:9SY)T_<*\_46]W^D7S8?S_S=4^H<@X/\O\
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M<2-&-8''B0/2OVGKGU'\6]W;.ST69[=^4':'R(H]K87)[3V+M3=&V-K]?8;
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M56_&KFUKGCZFWOW7OEU[GT@ FXO?4=5AZB2 2 +_ .\>_=>].O #^R/KSP&
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MNO5IQ_U?ZAUGY_I];"PXN00!_7DW_P /K[L:5H3T\,\ .HW-[?X?U!^ES?\
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MCUT#^FPMR"!^/P+W-B0US^./I[UU[KW-C]?\;V4 $$?[9M7TX_I[]Y'KW7?
M 7\?XBQ)]0'^OQ:Q)Y ]^/6^O V(_#&]_421;C_:@IYU?G_>O>^J^O71''];
MEK\@6((8C6;GG_&WT-O>NMU^6.O6Y$)/U!Y'^IOR18?B_P#0?3WOY=>^?7@/
MZ\BP/+6/T^A)!.FY^GTO^3;WKKW77%R>0=)N2UKEN >=)/U''T]^Z]UR%@"M
MS<6#78D6N!]&'UOS_OC[]U[KP*<B_/TL#SP26'^)_(O8W_V_OW7ORZ]>U_\
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M -!=<O\ H'-^& O_ ,9;^4+BYX_O5U%?@_0$],"QN?\  >_?UOO <D<?0?\
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M^M]W_$/V#_H'I[^J]OZ']C?]!]9O^@;CX4W_ .9P?*H_7_F+^H[?0#_GRO\
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MRQ9_Q?\ 'O\ H+KW_0-A\)B>>X?E5_L=W=0\@_47_P!"?U]^_K?=T&1^P?\
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M?T_X]@\W]^QUK/RZ[_@F4_Y[#</U_P"53:?T_I_Q['U]^_;U[/J.O?P3)_\
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M\]=N+_SFVG_M^-L>_?GU[\NN/\#REC_O\=Q7_'^2;2_I_3^Z_//OV.O9Z]_
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MVQ2?F><V  MI' (/YO<D B_^/^WUCTZ]W>1ZY_W;H[\2S@<6&I38C\_I /\
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-U[KWOW7NO>_=>Z__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>gyowp0iggm03000016.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gyowp0iggm03000016.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %_ ?$# 2(  A$! Q$!_\0
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M^U7>GGPMJ?\ :EL-[6@()$>,EF/;@CL>HKK?#/B&V\4:%!JMHCQQRY!C?JK
MX(H<6MQJ:>B->BBBI*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** (;NUBOK*>TG7=#/&T<B^JL,']#7EOP[\ ZUHOBA[W6X\6]A"\%@QE5
M@=S$D@ D@8+'G'WZ]8HJE)I6)<4VF>)ZYX)\5ZG=ZTMWH_\ :5Q/*7L[^34
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M/J_Y2?\ QZO3**.>0>SB>9_\*S\3?]%'U?\ *3_X]1_PK/Q-_P!%'U?\I/\
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MVM-+@F5I(8T+2,QRQV@=NW2N2OO&7BIM N'L-35;YO&;Z1 [P(RK 20J$8Y
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M0ORAG,NTMCID+_(5U.MZ)X?NM:T;5=3>*WU"TGVV4IF$3.[#_5]M^?[OU]Z
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M2[+<_,CX$2R?,65NF.!CIS[UH2P6UW+N+!"R\G>""3PI*_R]:S%\Z98FD5L
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MTFFT^&&\NP9IVM\8* X#$\Y*@C(]R!5*$PQ6Z+,7210T/VN,,7A?@[5./FP
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MV)+&S#JH8$T\L 0"0">@SUH 6BD+ $ D GH,]:&8*,L0!G&2: %HI&947<Q
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MFM;F.W9@8T)#(ZJ-RLO0G:<AO4#W-5U3)78O2(\.R*-C&S;K@JT4F.!C++G
MR,\*0?3-5IKY[F:X33'"1-BTG^1E *H=VS(R4YP"<#OFKGVCS;R>."?>EO"!
M D2YP-FT D G=RP/IC%8UU>2+9@M9Q[[B789!O<HYP.0<9!Z9 XSFJZ78):V
M1;T&V?3IYS)=QS,ZK)B8[22<*4'^QD#"Y.#V&!72Z+':W%S9W%M+C:J_*QY
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M3WJ0EQ\I&U64[B#@C'<#VKTBUP;. C=CRUQN.3T[F@":N;'_ "4L_P#8(_\
M:M=)7-C_ )*6?^P1_P"U: .DHHHH ***BN(/M$1C,DL>3G=&VT_G0!+16=_9
M*_\ /]?_ /@0:/[)7_G^O_\ P(- &C6=KNIG1M$NM06!IV@3<(E/+\XP/?FC
M^R5_Y_K_ /\  @T?V0O>^O\ _O\ F@"IX3UY_$GA^#4I;1K5W #1/U!P#T[9
MSQUXQ6Y6:NCHJA5O;Y5 P )R !2_V2O_ #_7_P#X$&@#1HK._LE?^?Z__P#
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M6Y<;8Q$D.<H"3D[O7C%6T#PE\KYH9RX!/R@'\.HY_2JUP]QND4O%(J*?,C"
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M5!<2VLT>RPG$7F0DKO5B2 1@9Q['U%=SIL,=OIEK#%)+)&D2A'F.7(QQGWH
MM5S8_P"2EG_L$?\ M6NDS7-C_DI9_P"P1_[5H Z2BBB@ HHHH **** "BBB@
M HHHH ***H:CK-CI31K>22(9 2NV%WZ?[H.*3:6Y4(2G+E@KOR/.?A/SK_B5
MI/\ 7;X__0GS_2O5:\8\-ZU9>'?B?JHEFE6PO@QC8P.,DD,ORXS_ 'ATZUZ7
M_P )?HO_ #WG_P# 27_XFHC**6K/6S+"UYU5.,&TXQZ/LE;\#;) !)Z#DUD:
M3XHT?7+J2VTZ\$TT2[G78PP,X[BN='Q.TN37FTHVMR(RY3[1M/IUV8W?I47A
M^'PCX:OY[RQNK]I)DV,)8)",9SV0>E3[5-KE:MU%'+)TZ4O;PDIM)QLKKYG?
MUYEXZPOQ-\(M'_K3*@;_ '?,'^+5V/\ PE^B_P#/>?\ \!)?_B:\[NM<L-;^
M+MM?&23^S]-BV[UB<DL 3]W&1\[8Z?PU4I1:W*RW"UX5G.4&DHRZ/LU;\3V"
MBJUC?V^HVPN+5F:,DC+(R'(]F -6:TO<\>47%\LE9A1110(**** "BBB@#R[
M2W6'XDRI%9K&\E_,)+1&N1)&,$_:6);RBK<<;?XA@D@UN^);MK;5XW9)I=C<
M10GEP1V'\3#&<>F:QM&-T?B!<_:8;W/]H3['F2\QLYVX/^IVXZ<=/4\UTNN-
M%:W<T[[5387=V;@;1G/X54=P*R+$GR;1ME;.1\IR:BGFMK>'R(9UCD5LNB@%
MQG., _0_D:AA\NXMTDA9';AA,^2"&'W@1@'(_"LFY:> 74MF9C(K*K$A2)!G
M<V"Y^;Y21G.!VJTA&S=%BPQ($P5</C)(!Y7'N,\^]1VY3S57EEE1@27;*E3P
M/3IW/-1I'+#J:X2/)A4,=VY@<G P.PQ]*(C)<VMQ;AL7!4Y*DEDR3SDCZX^H
MIVT L1A_-4J6\R,$X+@; W&WIR,@\U$LICBDESM4L(Y$\X;4QR"!V)SW[4[[
M+#;Z8D,4,:R2.7=.^X#J>>H..?6F62+%;26D@C>X7EVW+N; &"P'3N.?3BC0
M!3(PE6.%EVMB1  =HX')(/3%+<1Q?;(4S&8U8L59.=W!SSQU[U'+!'_:8*R)
MF5 2A7/ YR3Z#H/K4]M"&A7S?O*QV[EZCJ#UQT[],T  DE#, "@AW'@8#'L,
MG^8I8]3=;"-;FU40RQL9%WY(!Y.>G3/-,MEN[FU\VYLTBDE&\H'#!0.@+ 8Y
MX_,U, Y$N%\R,I@A6'WSU!X]"#FBR$9BR>6D<D%O]HMY(T,04L1@G@\C('OD
MGCM6BJJS;'@V*(CM&_@C@9SVIC3/%I[-(N^./.1)T&#Z^@]O2DM+A+FW2<PR
MPJR@;,@8&>HQZ\<>E# 8P.&4F-9", .< <\XX'Y_2FVXCN;G#3(4,1;<4*L6
M (X[ \'GKBK40>:4$/NC7CRP@(!]<]<>@_&D:-85/G.D;,^Q<M@L3P.IY-%P
M-;3]]QX+7S(GC,L7$;Q?.H/0,N3EO7UZUS<<<,-KYP,CLJ;4&X$ X.2-O4Y)
MR>]==LG3PYY<4DIE"J%>,C<>1SG%<YY]JD#7+1?:6BW+)):)N;>#SG:>/I21
M13B9D@6YAMF3R6,3/*A58\=3MSTXZ].1C-:=Q;O-=K)%).D:H7&#B(],@\=A
MTJ7[0%@MUBB&]V^5>JX)/))JCKNI6NEVMU<WQN5ME WM"<\#'Y=?TI-I:L:N
MW9$MP)[SRK6.9I;6<,I,1VA8C&>6;OSTQR,^U8 TN]TRZFABNKUHX_WR0N3,
MK1$@;0Y&5*GC@GBMK2=5MKFV:XM)O,C^XB@EEZ#MC@Y/3':K+W$US)=6C0B)
ME7"AU&)?E^8KR> 2.HX[U"BI.Y?-*.AFZ!J-KJVDPW<44T=X0R212J<AD^7Y
M@3GOG/<5IV\A20H"=K?+E5SN;/KG@#M[5C6[2BZN$:W\R&2(L9H[@++)P 2-
MO*C@'MCH*U].CG@L 9UC0P99S"FT2 ]\>@Z<UIK;4AVOH9=_>WUAJUI]DTL2
M6ER["\F+;#;[5X[X![Y[]*W0\30J=ROGYX#M^8 ]_KWS6;IT[7L*W0MKB/SA
MM$=R@#KC/('(Y ZY]*EC>?RFM98U2;:8PZD)(>HWKVZ8_&I2>Z8W;:Q+&YA2
M1"\LF3_K"/DSWSSTQCGI5:VM9XI[@S70GMYF#BV)_=P'H0".6&0.#T-7(XPL
M!ADV.D-N(PTG#C 'WB>N?YT]@8XML)(D$F\A"&"'&<'_ #Z4TA7($FF'F--;
MAE$GF0,C[3)\O(P.X/!ZY'-0+>7%WJ]Q"VF21V[QB-;M9%;<5^\K#MCD ]ZM
MR&<RR*@_T<[5C\L;-JD$-D]\=>*S[:.:W\036V_?9-#'LWLV[*_*5ST)Z'UY
MJ)*S33+C9IW70TKF+RK) 524YR6_U>.IR0.N/3O1H+0QM"]O)MAN;AGVH6;Y
MF&<-G..GL/SJ1I'4*B1LVQ]N/0@9&X^G;-.L6BL;JPM9)V9G;"%W^9V.3C/\
M6 #Q[5H[6U,T=37 :5X4N]-\?RW\&F6L%FTDC>9'# $\LKP%P/,$F[.23MP:
M[^O,O^$FNK#XDSQWVKSKI;W @56@D\H/MP$!\O:.64EMQ_PR ;XVBNXM<$MW
M<31V\C$6OF:A:QK@*-^Q9(6(''/->D-%]HL#"[R+YD6UG1\,,C&0P[^XK@OB
M9%;/-8F>QNY9!#+Y+VS2CSWRN+9O+4\.">3C&.O6O0( %MX@(_* 0#R_[O'3
M\* /+)/"FN+IVAVZ:?.\MO%Y<,GV@9LY!<AS(Q+9.8QC(R>W>NFT^/4H_B;=
M?VA<VTRMII-N((3&43SN V6.X^XQ]*[&N;'_ "4L_P#8(_\ :M '24444 %%
M%% !1110 4444 %%%% !1110!QGQ!\)SZ_80WVF'9JUB=\)!P77J5SZYY'O]
M:G\%^-+?Q':"VN3]GU>#Y)[=QM)(ZL!_,=JZRN2\3^ -.\0S_;H9'L-44@K=
M0#DD=-PXS]<@\#FI::=T>C0KTJE+ZOB-$OAEO:^ZMU3-X:'I:ZC_ &@+"W%Y
MN+>?L&_)&,YJ_7G7D?$[2/W4$^GZO$OW6EPK$>AR5Y_$_6H9K'XG:YF&XN[/
M28''SF%@&Q[%=S9^A%)-+9%RP3G9RKQ:77FZ>F_RL:OCKQS%H,#:9IS&?6IQ
MLCCC&XQ$\ D?WN>!].W6?X?^%7\-Z,TMYEM3O2);@L<E?1<]\9.?<FCPK\/=
M+\-2"[=FOM2Y)N91]TG.=H[=>I)/OVKKZ:3;NR*]>E3I?5\/JG\4MK]DET2"
MBBBJ/."BBB@ HHHH *AO+E;.RN+IU9EAC:0JO4@#/'Y5-3)H8[B"2"9 \<BE
M'4]"",$4 >7:%+I.M^+;#5K.^TJ"2>8W0BB>8W$@9#\C@MLSSDX'5>*Z37XC
M%J;7"/*\C';Y:C<",="O0CJ?6NIMK2WL[:&WMX4CAA01QJH^ZH& /RKG=4$1
MUQR@<R@ ,ZJ?EXX&?3O51W QH[L1Z''/%#<1X7)BDX*]>""/QQ4US#'<01VP
MVAG4J5<#G*\C']*F;S(BS,&+MP4=OOXZ8[#/K56_2WM3;74\B#9("TSM@G/;
MT)/ ]:TN(C;3=AL8%A@9(8PH3!!C08Y'.<\8(&>HSQ5NSD(U"3S)7+$XD5N<
M.>57IV'.>E+Y_F7,,Q906&V,,A#[3UR.H_\ K52U"2;[.UA-)(+@ONB$;_/+
M&""YSV&TG@]A1OH!9U!X4C>Z=$VK^['R9X+#/Y]STQS5E88[</>,&9V7=EE!
M;;C.WUJI<K*]DS2K$'BN"08B?NY^7/\ M8QQTJTX+JC%G7:%; 8;6'?G\>OT
MJ0*D-TEU:V]YLFCC=/,5)1AXP>FX'N/3WIT<[6TT=M($!G=E^8@< 9Q@GN"<
M8]*CN8/M3*/+78LGS!CG<WM@]N1^%3[7EO\ R9HHSB'][F( D'/.[/\ +UJE
MMJ#\AT:(GEQNK1RJQ$?EAO+4 #MG'3IFI5+QP9<Y1!SN^\WI39?,%R2C#(7#
M8Y!'MZ'WJ&&0/ 77.#@=ST/_ ->@">,;[>5))8I6.!(63"GT&W\JACE(N$M[
MB-F62,GS8QA=XX*]<Y_PJSY:2J/,4(P # ')/IS6+;6U\NK K>(MJ=H,83+$
M\Y /09YY _6D!IQD"7<<>9(!N' <XX'_ .JF7RVLT:W%S$)8H668>8IRN ?F
M/IC'3VJ7<S.5<,IC.4## P/?TZ=:2XW7#+Y;.K XR3Q]#G\J?41N2RW$?A:2
M:V^:81[EW<XZ=<>@KS*/7;RULRHD>YN)6.U-A'!&[+'/W0H+9)SV[UZK;B,:
M'PIBC9<X(P1GVKCKO38%=9)(GDB=@5'(DB;KD =0#C@]*4;6:+3L4EUFSW>3
M+&)HU*NLD9)C9C@JV[&%R,$CM4T.JVNL6ES/8,LICD?[1"'*OM[':><G'L.O
M6L>\\/ZA<S_9[P1>7'YB+,9,*P)7@J!G /S9S21>&[*X>XNGG@NT#N!.&951
ML%&8[.I'3'/7H#S0DDK)E/5W-C1Y-7>S6;5],2#4 WFB.TE^65@V-K$\!B,$
M+G!YZ5KN\IN6MT)5T(D8[2ZLCG##J,-D'N<8KE;*PU[0WACCNTG@:<&X.YF=
M,8 P'&<8&,D^_O31XIU.SMI9(-,BO(B=J;Y&A*8R1O)7 Z9R#C)I<K0;G52'
M$[3170N70HC0JPPN#\V0HZX/2B2:>SN)I;E=\2J&+PI@CJ>3TVX'.:YK3O$.
MF274:+&;36FBQO=<*[8Z9'WE)Q@G&< UU"2QSPR!69IV!20. Q<8QD+TQSG\
MZ$V[H3C;<D@Q*D=ZLQE\^)1    5(SG Z]:KW*&[L6BBMGE+GRYANPR@G))P
M>:?;VCVEK!:H5GDBCVF.%PNS/4_[(&.,8^E-M;J.^R]LS2,A(F"O]Q@2,@'G
M) X[472"U]2VRI919@6/YLEXLEMQ)Y;'<G/--DBD2YCD\QEFE;RU4H"".IXX
MYP,9IDD1D*RM:R23Q@QPLR#=@@!CG/&>,_2I(H)8)!%YNU7<D&.,\'C.22??
MVZ4U<D)KNWMY49W9H]I#'  /.,8 R3D@>G-)MDE.YB47=M1?*X7IAA[CU^M,
ME2":=2F#(@*!F/8__7&?PI@F6XEE54E5T*HS&3:'&,[AZ@X_0TKM/4=E;0=Y
MA2]DDDMOW<APK+@LV#Z=>>N>G%6[")+FZL]\B>=:R,=J-@=",<]1@BJ4H!AM
MYA")+<.4=MK;PN"!@=\GN>U:>E +>QPD*_EQX5@/N8.,?E_*F]A(Z&O+DT>3
M5_B7---IUO/IJ73>8RD[8Y$4$%@7QN)V=$YY!/'/J->;:=:2CXN7T@BTD(#O
M,@\M9_N= N Y)R,MDC ]ZR WO%OB^3PY(D<-G]H:6%S&1ELS KMC(4';N!/S
M' &*ZB-B\2,R[6902N<X]LUY9\3XS::S;W >V,=Q ^Z.6TMR?EV@E'D4EI2,
M!4]J]1M\"VB # ;!@.,'IW'8T 2US8_Y*6?^P1_[5J/Q-XEO-#U73XDM?^)?
M)@W=XT;.L(+JJ@[3QG)YYQ5>PU2SU'XFW2VLI=K;3/*E!C9=K";IR!GZB@#L
M**** "BBB@ HKE-<^(.BZ!XGL=!O//-U=;?G1,I'N.%W'.>3Z UU=:U*%2G&
M,IQLI:KS$FGL%%%%9#"BBB@ HHHH **** "BN4\=V&O:AIEM'H$DJ3K-F0QS
M>6=N#WR.]:_AR"^MO#MC#J3,UZD0$Q=]Y)]SWJ5)\W+8ZI8>,</&MSIMNW+U
M7F:E%%%4<H4444 %%%% !1110 4444 %<CK^9-9CC\[:$ D!/ #>GOD5UU<I
MKLR6>I&9XS<M,5C"9 $0QR2?QJHO4"C/ 7G>6*63YVV,BN>N.?H>E1SR1PA7
M6([E!(##:J\X ]\9-,,\-K<S-+=^7$ZB.%&!WJW.<G)!]N*F6![B)E?#0>5T
MX*YS^><58B33[HIJL$%RLLCN,!F0!4(&?S]_<TR"Y%MJ$]I;12R.8_-$DT@V
MELXQZCCGI40261X-Q*Q*XV&*7 0 =3ZYZ4EYYMQ<EVBD5@BJ2ISM).>G?\/Q
MHT 73HK2[#)<1QK>1R%R$!"JQZ[0>HZ\GZU+,$>_41$I,8VBRPSP,'!/8?SJ
M** S7:2R3.-@W@;1M"GL6]?\!5F*:65+L9RH!VOC!/X_UIO<!RVJ6),9=I9_
M+!W."  3G (__73&E>Y$,H*CY@6PFW(_'D8.>#42OO@$JR[&F4%<L2-_4#_]
M76I-FU)7E=7^?>@SM(7 SFD!$C36ETPDF0)R3N.TL.HP,?A3Y&,=D&8D2R-G
M"+CYB>,'\_K3IUD,.V!(YV<8*S,02,XZC..*J+.@T^8W+Y%ME&<\''('TXXS
MUI^8%EX'93"H1<G*,F04?'S-SP?8XIK0A;XSJ0S!"!C//3(STYP.:%E18[.(
MV\KQ2H,/"04'!)W'T]QUS4D\;B,"-!L4D_OCC.>?EQ_GBEU :\)CO6=I6169
M<DN#G_9]0,BI+@AG11LVG#QAFX/OGL*A8IYJR^?N/!.#@QKM_P :25(+HNR[
M9&*G.1PV.G'3I]*8'4Q[AHK'Y'(Y (R#S7*V]PES+)%]MF,@;)$@ ,9[*<=
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M*%%<]2O!PY=%%23L[7V[==.IE!O1)W.A_P"$S\,?]#!IG_@4G^-'_"9^&/\
MH8-,_P# I/\ &M7[':_\^T/_ '[%'V.U_P"?:'_OV*\6^'[2^]?Y&OO$RLKH
MKHP96&00>"*6@<# HKG*"BBB@ HHHH Q_$7B6P\,6D5S?B8QROL7RD#'.,^H
MJ[I>HP:OIEOJ%L'$,Z;TWC!Q[U!K.@Z=K]O'!J5OYT<;;U&XC!QCM5JQL;?3
M;&&SM(_+@A7:BY)P/QJ5S<WD=4GAOJ\5%/VE]>UO\RQ1115'*%%%% !1110
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MU<_>QU(IH\3:;.ZLULI=6VKF3D8Z_EGH*->P7,^PCC^SK%AA#&[( Z[22",
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M%<5V6DVUPEQ'*S ,QS+NC )Z_+QZ>M5-,U31[G4)9$TM[>ZN%$<\DBX9@
M3UXZ<XZ9Z5JVVL65[J*6ZHP=>8RY*DG'.%],8Y]Q4)23;*D[I*VQLT445)!P
M7Q%\'7WBF2SDM(K646T;@)*J [F*X^9D;C&3@8Z?EV>G64.G:=;V=O#%#%#&
M%6.%=J+]!Z5:HH I7FKZ=I]S:VUY?6]O/=/L@CED"F1O10>O;\ZR!_R4L_\
M8(_]JU3\6>%K_6]3AEM6M1#+$EO<-,3NB59EEW( .2=N,<=CGBIY_!?GZO+J
M:^(M;BN)%,8\N:,!4+;M@!3H#0!U-%<S_P (E<_]#9X@_P"_T7_QNC_A$KG_
M *&SQ!_W^B_^-T =-17,_P#")7/_ $-GB#_O]%_\;H_X1*Y_Z&SQ!_W^B_\
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M1*Y_Z&SQ!_W^B_\ C='_  B5S_T-GB#_ +_1?_&Z .FHKF?^$2N?^AL\0?\
M?Z+_ .-T?\(E<_\ 0V>(/^_T7_QN@#IJ*C@B,%O'$97E**%,DA!9L=SCO4E
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M Q@#WQTKM-.F0^%%<QH5(VJJ+P<M@<?7K7E5Q9KK?Q&-FBR)96>ZUE;>1#L
MRY(!''#?CBBFE9FBUW+NI.T>JZ3>V<,<U\D9MYA.VUFAZLY8#YATQQSS3=2C
MN+6<VUJT,D3!K<D*?OC;)NC !ZAOPQ6E+*MWJ\HMMT\J9A6-0!Y,>#M(!((X
M.<]>G4U7-G-'JME;&?[3)#9 SNK<%I"?GXZ'  .?O>E;*-F*^A/>6MLUB9S<
M1Q6RPA4CWG#LRD#=CJ 2.E8MGJO_ !+8;J6V\CSIA8/YHV,[]%*IS\F1@#/O
MGK5+69'UN>/1]/%RD5M*!!):MY*+B/[C2'(& 2>0/US4ESI"MJNIW@O8_M#7
M*&(#/R;1@^HY&#QZ<UDYRO=&B@MF4DNI;CQ)/>I;K$(5#')+#8  <L><X/3C
M]:[2_L/[)%QJ\:S.RQM/%:HV5<E0-N,?>ST^M9UD+._\U5E9U$BPW$97RW#;
M@9!_M C)XXZ#VJ;6DLI-<2PB;9(D4DUM90H?F0,""SGI@Y.WH<U"BHWDNI<I
M.5H]C5L=3_M/PT8WG>*6S@1I8983&8B<#8PQ@@LK<]>*+**8S3%X(RH5F90B
MA6<H"?3(('Y=:HQZM)HG@3R[Y6N=0DD^T3QQ1-,0&D  5,@9^8'!P.^*N/J-
M^8X#9S1!E#B:2:(9,APH&!TZ]/J*N#;T,I*VP[PV;=[^.6>6,0W,TDD05E"N
M@'\0QSR"?< 'M39C:ZUXMNM2CA(BM8XI-A^0.QR0Q(X<X"G';:,U5\M-(T:_
MU&+=]HBMF=GF1B(&;Y'V@';N (^4>_O4L>VQT\:0\Z33^9E7B@\M5<84DJ>"
M"022>.H'2JM[UD3YB:+,+*WE6&)Y[BS+8C08*-@[#GE7)5LCL,5?BO;O0O#4
ME_XAECDO;V4,JAB47YOED"^V4R!Z5#96NHSW4'[Q8;46S1,I&)$ 8Y?_ +Y/
M''&??-5_$.L:9J.LQ'4QLTO3XI&B0@'S9!QD#'S#&.1P#]:SJ/6Y4%=V,KPI
M<;?L]O<P!M5N;EDN9T/,DG?YB>@ SZ\8KL-(TB6X\727\T06"$$P+Y81HR#L
M!+$;F9@#GM@ UR^EF.]+:M-&EH+@AK>UAE+*@D958E2  Y!."1QNKM;&\MU\
M2>38PK$NP0S"0$,Q3@!?7;W.>_?.:34K%2:N['4T445B9A1110 4444 %%%%
M !6!XD\2IH'D[8TN'(,DT*/F9(0.95C'+A3C(';.*A\5^(QHPALVTZYN#?@P
MQ2)*(H_,/ 1I,_NR1D@]R, YKFM!\-7>NWW]IWEU?V]N/*0J<1RSK$Y98IE(
MRK1L,;U.'4_C0!J_#Z;Q-/;W,NN3+<VTN)+>X$D;!\]?+V#_ %9&"-V",XQQ
MFNUI%544*BA5'0 8 I: "BBB@ HHHH **** "H[B86]M+.RNRQH7*H,L<#.
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M=Q^)M1GC>"ZC,-Y9S6[ EE&QT /_ "S8JKC(RO;J37J:*L:*BC"J, >@I:*
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M\91>&;)8[@^=(9KE4VB-E!+H2.&;<0..*4[K<:3:T/2:***Q("BBB@ HHHH
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MFI#92SRLT91#PS+TY_NYZ?7%=]_9]D7+FTM]YZMY0R?TIILK")53[);JK'
MB&"3^%'.%CSV.*>,M*8PS*&W['_B( P 1D=.W%1F5 A)B#S%F(01AAG&,;NQ
M'K7I/V&T(P;6# _Z9BA;&S10JVL"J.@$8&*?.%CS=X_-AWK^\;@;FPV& Y.0
M?EQC'L:C=0(U> 1'C:P7!';<Q..3GL>M>DC2M."%!86H4G)40K@G.<]/6E_L
MRP+[S8VV[&,^4N<?E3]H%CS@1QR6KQ-)^\67#*S9#,>0#2E8[J2&0Q^7N<'
MQNV^_.<@^E>CC3K$=+.W'_;)?\*0Z98,P9K&V+#H3$O'?TI>T"QC:;YS^"@L
M,D<TGE,J.!M5N< \UQ.@E]0M(TD>XM&A2<F&XER..<N03E>,<\@-QFO5C#$8
MO*,2>7_=VC'Y5772]/1F9+"U4NAC8B%1N0YRIXZ<GCWIQFD/I8\CLK6'5].@
MU>#(^S7+I!%;Y*9*A'X!&1P.>O'YZZ"YM-4DCA\A0R"4E!U9CCD8QG Q]%Y-
M>AVVGZ;%;"WMK*UC@C)41I"JJOK@8Q0VG::S"%K&U8C+A3"I'IGIUY_6K]LE
MT!ZGF>FO%:6-]>SS1F6XN?-995P6/!&#_= YQ]:ECU_7-/U.QBM;:-H!AYS(
MJEWB&1LW#D-DCU_G7HG]@Z/Y:Q_V38[%<2*OV9,!QT8#'7GK3CHNE&3S#IED
M7/\ %]G7/7/7'KS2=5-6:&K7.8UMFO9;&]$@2.6(2B()O).UNOL,]1DUCQ6L
M,]FMM/:P2PK*)(O.CW8PPPV%YR5YS]*]%^PVAA\DVL'E<_)Y8V\]>/>C[!9B
M/RQ:0;,8V^6,?E255)6L(\SEBBU2'3[074UM'$^^*-2R^8@'(==Q)7YLG)R-
MOO3[.>YE@CNKF 6X;<PB#"0B,8"]/O%NN,^G%>B2:1IDTIEETZT>0QF(LT"D
ME#U7..AP./:G0V.GZ?;X@L[>WAC7A8H@H4#T %-54GL-['%&\338[S6[J&0K
M&6Q#$@=G11C "YVEB1CVS5A+N.PL8%DAG\VX"QK'$V_RD=N"3C'R^G8"NL6Q
MTZ2.2%;.V*%@73R1@GJ"1CFGO:V2GY[:',C8/[L?,<=^/2DZB8CD+.V?3M/"
MHY:UD,EU)N8*44\")>< <* <^OK6'<6T6F:<+>>5VN-3DD\XK$"T<CGYMHQE
M00 O<<9]Z],DL+.6-HY+2!T9=A5HP05SG'TSS1)96;2+/):P-)'DJYC!*^N#
M2]HNHT['GT.G+;:']ALK6*-(6D"P2%PL2<@,3G);@'KWR,<5HZ);*==@N9)'
MW0KY?V4,6CB=NX)^\P4'+9_B]ZZ_[+9R1$_9H6C<;CF,8/'T]*CL?[/E3S+.
M*( #JD>WN?;U!J7)-6L/F9=HHJ-IXU+ M@J0#QZ]*@DDHHHH **** "BJ\5[
M;S2^7')E_3::F=UC0NYPHY)H =1110 44U'5\[3G!*GZBG4 %%-+J'5"?F;.
M!]*#(HD5"?F8$@?2@!U%%% !1110 44U75F95.2IP?:G4 %%%% !1110 444
,4 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
